PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Choowongkomon, K; Carlin, CR; Sonnichsen, FD				Choowongkomon, K; Carlin, CR; Sonnichsen, FD			A structural model for the membrane-bound form of the juxtamembrane domain of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOMATED NOE ASSIGNMENT; HUMAN EGF RECEPTOR; PROTEIN-KINASE-C; CRYSTAL-STRUCTURE; EXTRACELLULAR REGION; CHEMICAL-SHIFT; NMR; C-13; LOCALIZATION; TRAFFICKING	The epidermal growth factor receptor ( EGFR) is a member of the receptor tyrosine kinase family involved in the regulation of cellular proliferation and differentiation. Its juxtamembrane domain (JX), the region located between the transmembrane and kinase domains, plays important roles in receptor trafficking. Two sorting signals, a PXXP motif and a (LL659)-L-658 motif, are responsible for basolateral sorting in polarized epithelial cells, and a (LL680)-L-679 motif targets the ligand-activated receptor for lysosomal degradation. To understand the regulation of these signals, we characterized the structural properties of recombinant JX domain in aqueous solution and in dodecylphosphocholine (DPC) detergent. JX is inherently unstructured in aqueous solution, albeit a nascent helix encompasses the lysosomal sorting signal. In DPC micelles, structures derived from NMR data showed three amphipathic, helical segments. A large, internally inconsistent group of long range nuclear Overhauser effects suggest a close proximity of the helices, and the presence of significant conformational averaging. Models were determined for the average JX conformation using restraints representing the translational restriction due to micelle-surface adsorption, and the helix orientations were determined from residual dipolar couplings. Two equivalent average structural models were obtained that differ only in the relative orientation between first and second helices. In these models, the 658LL659 and 679LL680 motifs are located in the first and second helices and face the micelle surface, whereas the PXXP motif is located in a flexible helix-connecting region. The data suggest that the activity of these signals may be regulated by their membrane association and restricted accessibility in the intact receptor.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Rainbow Babies & Childrens Hosp, Rainbow Ctr Childhood PKD, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Canc, Cleveland, OH 44106 USA; Cleveland Ctr Struct Biol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University	Sonnichsen, FD (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	fds@case.edu	choowongkomon, kiattawee/M-6528-2014; Sönnichsen, Frank D/D-8408-2011	choowongkomon, kiattawee/0000-0002-2421-7859; Sönnichsen, Frank D/0000-0002-4539-3755	NIDDK NIH HHS [DK54178] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK054178] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aifa S, 2005, EXP CELL RES, V302, P108, DOI 10.1016/j.yexcr.2004.08.032; Aifa S, 2002, CELL SIGNAL, V14, P1005, DOI 10.1016/S0898-6568(02)00034-7; Arora A, 2001, CURR OPIN STRUC BIOL, V11, P540, DOI 10.1016/S0959-440X(00)00246-3; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; BRANDLI AW, 1991, J BIOL CHEM, V266, P8560; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Choowongkomon K, 2004, J BIOMOL STRUCT DYN, V21, P813, DOI 10.1080/07391102.2004.10506971; Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594; COCHET C, 1991, J BIOL CHEM, V266, P637; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dillon C, 2002, MOL CELL BIOL, V22, P6553, DOI 10.1128/MCB.22.18.6553-6563.2002; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Fischer MWF, 1999, BIOCHEMISTRY-US, V38, P9013, DOI 10.1021/bi9905213; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; He C, 2002, J BIOL CHEM, V277, P38284, DOI 10.1074/jbc.M104646200; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; HOBERT M, 1995, J CELL PHYSIOL, V162, P434, DOI 10.1002/jcp.1041620316; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Houliston RS, 2004, J BIOL CHEM, V279, P24073, DOI 10.1074/jbc.M401919200; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 2004, NAT REV MOL CELL BIO, V5, P464, DOI 10.1038/nrm1399; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kaplan W, 2001, Brief Bioinform, V2, P195, DOI 10.1093/bib/2.2.195; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Kil SJ, 2000, J CELL PHYSIOL, V185, P47, DOI 10.1002/1097-4652(200010)185:1<47::AID-JCP4>3.3.CO;2-F; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lindberg M, 2001, FEBS LETT, V497, P39, DOI 10.1016/S0014-5793(01)02433-4; Linge JP, 2003, BIOINFORMATICS, V19, P315, DOI 10.1093/bioinformatics/19.2.315; Martin-Nieto J, 1998, BIOCHEMISTRY-US, V37, P227, DOI 10.1021/bi971765v; Mesleh MF, 2003, J AM CHEM SOC, V125, P8928, DOI 10.1021/ja034211q; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; MONTELIONE GT, 1992, J AM CHEM SOC, V114, P10974, DOI 10.1021/ja00053a051; MORRISON P, 1993, J BIOL CHEM, V268, P15536; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Oxenoid K, 2002, BIOCHEMISTRY-US, V41, P12876, DOI 10.1021/bi020335o; Poppleton HM, 2000, ARCH BIOCHEM BIOPHYS, V383, P309, DOI 10.1006/abbi.2000.2095; Rigby AC, 1998, BBA-BIOMEMBRANES, V1371, P241, DOI 10.1016/S0005-2736(98)00020-0; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Skrynnikov NR, 2000, J MOL BIOL, V295, P1265, DOI 10.1006/jmbi.1999.3430; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Vinogradova O, 1998, J BIOMOL NMR, V11, P381, DOI 10.1023/A:1008289624496; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Weigelt J, 1998, J AM CHEM SOC, V120, P10778, DOI 10.1021/ja982649y; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; Zdunek J, 2003, BIOCHEMISTRY-US, V42, P1872, DOI 10.1021/bi0267184; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	67	42	43	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24043	24052		10.1074/jbc.M502698200	http://dx.doi.org/10.1074/jbc.M502698200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15840573	hybrid			2022-12-25	WOS:000229880000078
J	Gibbons, IR; Garbarino, JE; Tan, CE; Reck-Peterson, SL; Vale, RD; Carter, AP				Gibbons, IR; Garbarino, JE; Tan, CE; Reck-Peterson, SL; Vale, RD; Carter, AP			The affinity of the dynein microtubule-binding domain is modulated by the conformation of its coiled-coil stalk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DYNEIN; NUCLEOTIDE-BINDING; MOTOR; SITES; PROTEINS; ATPASES; FAMILY; AAA(+); ATP	The microtubule-binding domain ( MTBD) of dynein is separated from the AAA ( ATPase with any other activity) core of the motor by an similar to 15-nm stalk that is predicted to consist of an antiparallel coiled coil. However, the structure of this coiled coil and the mechanism it uses to mediate communication between the MTBD and ATP-binding core are unknown. Here, we sought to identify the optimal alignment between the hydrophobic heptad repeats in the two strands of the stalk coiled coil. To do this, we fused the MTBD of mouse cytoplasmic dynein, together with 12-36 residues of its stalk, onto a stable coiled-coil base provided by Thermus thermophilus seryl-tRNA synthetase and tested these chimeric constructs for microtubule binding in vitro. The results identified one alignment that yielded a protein displaying high affinity for microtubules ( 2.2 mu M). The effects of mutations applied to the MTBD of this construct paralleled those previously reported (Koonce, M. P., and Tikhonenko, I. (2000) Mol. Biol. Cell 11, 523-529) for an intact dynein motor unit in the absence of ATP, suggesting that it resembles the tight binding state of native intact dynein. All other alignments showed at least 10-fold lower affinity for microtubules with the exception of one, which had an intermediate affinity. Based on these results and on amino acid sequence analysis, we hypothesize that dynein utilizes small amounts of sliding displacement between the two strands of its coiled-coil stalk as a means of communication between the AAA core of the motor and the MTBD during the mechanochemical cycle.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94107 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94107 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gibbons, IR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 335 LSA-3200, Berkeley, CA 94720 USA.	igibbons@berkeley.edu		Reck-Peterson, Samara/0000-0002-1553-465X; Carter, Andrew/0000-0001-7292-5430	NIAMS NIH HHS [P01-AR42895-10, P01 AR042895] Funding Source: Medline; NIGMS NIH HHS [F32 GM067403, R01 GM030401, R37 GM030401, GM30401, GM67403-01, R01 GM038499] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030401, F32GM067403, R01GM030401, R01GM038499] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; Burgess SA, 2004, J STRUCT BIOL, V146, P205, DOI 10.1016/j.jsb.2003.10.005; Gee M, 1998, EUR BIOPHYS J BIOPHY, V27, P466, DOI 10.1007/s002490050157; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GIBBONS IR, 1995, CELL MOTIL CYTOSKEL, V32, P136, DOI 10.1002/cm.970320214; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; Kamiya R, 2002, INT REV CYTOL, V219, P115; Kon T, 2004, BIOCHEMISTRY-US, V43, P11266, DOI 10.1021/bi048985a; Koonce MP, 2000, MOL BIOL CELL, V11, P523, DOI 10.1091/mbc.11.2.523; Koonce MP, 1997, J BIOL CHEM, V272, P19714, DOI 10.1074/jbc.272.32.19714; Koonce MP, 1996, MOL BIOL CELL, V7, P935, DOI 10.1091/mbc.7.6.935; KORADI R, 1996, J MOL GRAPHICS, V51, P25; Mizuno N, 2004, EMBO J, V23, P2459, DOI 10.1038/sj.emboj.7600240; Mocz G, 2001, STRUCTURE, V9, P93, DOI 10.1016/S0969-2126(00)00557-8; Neuwald AF, 1999, GENOME RES, V9, P27; Nishiura M, 2004, J BIOL CHEM, V279, P22799, DOI 10.1074/jbc.M313362200; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; PORTER ME, 1989, ANNU REV CELL BIOL, V5, P119; Porter ME, 2000, J CELL BIOL, V151, pF37, DOI 10.1083/jcb.151.5.F37; Reck-Peterson SL, 2004, P NATL ACAD SCI USA, V101, P1491, DOI 10.1073/pnas.2637011100; Samso M, 2004, J MOL BIOL, V340, P1059, DOI 10.1016/j.jmb.2004.05.063; Takahashi Y, 2004, P NATL ACAD SCI USA, V101, P12865, DOI 10.1073/pnas.0403429101; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314	27	125	126	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23960	23965		10.1074/jbc.M501636200	http://dx.doi.org/10.1074/jbc.M501636200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15826937	Green Accepted, hybrid			2022-12-25	WOS:000229880000070
J	Molnar, J; Ujfaludi, Z; Fong, SFT; Bollinger, JA; Waro, G; Fogelgren, B; Dooley, DM; Mink, M; Csiszar, K				Molnar, J; Ujfaludi, Z; Fong, SFT; Bollinger, JA; Waro, G; Fogelgren, B; Dooley, DM; Mink, M; Csiszar, K			Drosophila lysyl Oxidases Dmloxl-1 and Dmloxl-2 are differentially expressed and the active DmLOXL-1 influences gene expression and development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION-EFFECT VARIEGATION; X-CHROMOSOME; HISTONE ACETYLATION; GROWTH-FACTOR; PROTEIN; MOUSE; LOX; TRANSFORMATION; LOCALIZATION; PROCOLLAGEN	Mammalian lysyl oxidase (LOX) is essential for the catalysis of lysyl-derived cross-links in fibrillar collagens and elastin in the extracellular matrix and has also been implicated in cell motility, differentiation, and tumor cell invasion. The active LOX has been shown to translocate to the nuclei of smooth muscle cells and regulate chromatin structure and transcription. It is difficult to interpret the role of the LOX protein as it is co-expressed with other members of the LOX amine oxidase family in most mammalian cells. To investigate the function of the LOX proteins, we have characterized the Drosophila lysyl oxidases Dmloxl-1 and Dmloxl-2. We present the gene, domain structure, and expression pattern of Dmloxl-1 and Dmloxl-2 during development. In early development, only Dmloxl-1 was expressed, which allowed functional studies. We have expressed Dmloxl-1 in S2 cells and determined that it is a catalytically active enzyme, inhibited by beta-amino-proprionitrile (BAPN), a specific LOX inhibitor. We localized DmLOXL-1 in the nuclei in embryos and in adult salivary gland cells in the nuclei, cytoplasm, and cell surface, using immunostaining and a DmLOXL-1 antibody. To address the biological function of Dmloxl-1, we raised larvae under BAPN inhibitory conditions and over-expressed Dmloxl1 in transgenic Drosophila. DmLOXL-1 inhibition resulted in developmental delay and a shift in sex ratio; over-expression in the w(m4) variegating strain increased drosopterin production, demonstrating euchromatinization. Our previous data on the transcriptional down-regulation of seven ribosomal genes and the glue gene under inhibitory conditions and the current results collectively support a nuclear role for Dmloxl-1 in euchromatinization and gene regulation.	Univ Hawaii, John A Burns Sch Med, Cardiovasc Res Ctr, Honolulu, HI USA; Univ Szeged, Dept Genet & Mol Biol, H-6726 Szeged, Hungary; Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA	University of Hawaii System; Szeged University; Montana State University System; Montana State University Bozeman	Csiszar, K (corresponding author), 1960 East West Rd, Honolulu, HI 96822 USA.	kcsiszar@aol.com	molnar, joseph/D-4375-2013; Ujfaludi, Zsuzsanna/AAC-7657-2020	Ujfaludi Dr., Zsuzsanna/0000-0003-4738-0963	NCRR NIH HHS [RR03061] Funding Source: Medline; NIAMS NIH HHS [AR47713] Funding Source: Medline; NIGMS NIH HHS [GM27659] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [S11AR047713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027659] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler DA, 1997, P NATL ACAD SCI USA, V94, P9244, DOI 10.1073/pnas.94.17.9244; ASHBURNER M, 1989, DROSOPHILA LAB MANUA, P28; Asuncion L, 2001, MATRIX BIOL, V20, P487, DOI 10.1016/S0945-053X(01)00161-5; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bhadra U, 2000, GENETICS, V155, P753; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; Borel A, 2001, J BIOL CHEM, V276, P48944, DOI 10.1074/jbc.M109499200; BUTLER E, 1987, EXP CELL RES, V173, P174, DOI 10.1016/0014-4827(87)90343-0; CHVAPIL M, 1981, J SURG RES, V31, P151, DOI 10.1016/0022-4804(81)90043-3; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; Contente S, 1999, MOL CELL BIOCHEM, V194, P79, DOI 10.1023/A:1006913122261; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; Di Donato A, 1997, FEBS LETT, V419, P63, DOI 10.1016/S0014-5793(97)01420-8; Eberl DF, 1997, GENETICS, V146, P951; Giampuzzi M, 2003, BBA-PROTEINS PROTEOM, V1647, P245, DOI 10.1016/S1570-9639(03)00059-1; Gilad GM, 2001, EUR J PHARMACOL, V430, P69, DOI 10.1016/S0014-2999(01)01354-1; Gu WG, 1998, DEV GENET, V22, P56, DOI 10.1002/(SICI)1520-6408(1998)22:1<56::AID-DVG6>3.0.CO;2-6; Hayashi K, 2004, J MOL HISTOL, V35, P845, DOI 10.1007/s10735-004-2340-1; Hein S, 2001, PLACENTA, V22, P49, DOI 10.1053/plac.2000.0580; Hornstra IK, 2003, J BIOL CHEM, V278, P14387, DOI 10.1074/jbc.M210144200; Hynes RO, 2000, J CELL BIOL, V150, pF89, DOI 10.1083/jcb.150.2.F89; Ito H, 2001, J BIOL CHEM, V276, P24023, DOI 10.1074/jbc.M100861200; Jourdan-Le Saux C, 2000, MATRIX BIOL, V19, P179, DOI 10.1016/S0945-053X(00)00061-5; Jourdan-Le Saux C, 2001, GENOMICS, V74, P211, DOI 10.1006/geno.2001.6545; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; KAGAN HM, 1983, BIOCHEM BIOPH RES CO, V115, P186, DOI 10.1016/0006-291X(83)90987-7; KENYON K, 1993, J BIOL CHEM, V268, P18435; Kim MS, 2003, J BIOL CHEM, V278, P52071, DOI 10.1074/jbc.M308856200; Kim YH, 1999, J CELL BIOCHEM, V72, P181, DOI 10.1002/(SICI)1097-4644(19990201)72:2<181::AID-JCB3>3.0.CO;2-D; Kirschmann DA, 2002, CANCER RES, V62, P4478; Klapper M, 1997, J CELL SCI, V110, P2519; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; Lazarus HM, 1995, MATRIX BIOL, V14, P727, DOI 10.1016/S0945-053X(05)80015-0; Li WD, 2000, J CELL BIOCHEM, V78, P550, DOI 10.1002/1097-4644(20000915)78:4<550::AID-JCB4>3.3.CO;2-#; Li WD, 2003, J CELL BIOCHEM, V88, P152, DOI 10.1002/jcb.10304; Li WD, 1997, P NATL ACAD SCI USA, V94, P12817, DOI 10.1073/pnas.94.24.12817; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lucchesi JC, 1998, CURR OPIN GENET DEV, V8, P179, DOI 10.1016/S0959-437X(98)80139-1; Maki JM, 2002, CIRCULATION, V106, P2503, DOI 10.1161/01.CIR.0000038109.84500.1E; Maki JM, 2001, BIOCHEM J, V355, P381, DOI 10.1042/0264-6021:3550381; MELLO MLS, 1995, EXP CELL RES, V220, P374, DOI 10.1006/excr.1995.1328; Mink M, 2001, GENOMICS, V74, P234, DOI 10.1006/geno.2001.6548; Molnar J, 2003, BBA-PROTEINS PROTEOM, V1647, P220, DOI 10.1016/S1570-9639(03)00053-0; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nellaiappan K, 2000, J CELL BIOCHEM, V79, P576, DOI 10.1002/1097-4644(20001215)79:4<576::AID-JCB60>3.0.CO;2-A; Noblesse E, 2004, J INVEST DERMATOL, V122, P621, DOI 10.1111/j.0022-202X.2004.22330.x; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; Paro R., 2000, DROSOPHILA PROTOCOLS, P131; Real MD, 1985, DROS INF SERV, V61, P198; RIEMER D, 1995, J CELL SCI, V108, P3189; ROBERTS DB, 1998, DROSOPHILA PRACTICAL, P219; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1; Schotta G, 2003, SEMIN CELL DEV BIOL, V14, P67, DOI 10.1016/S1084-9521(02)00138-6; Slee RB, 2001, ENDOCRINOLOGY, V142, P1082, DOI 10.1210/en.142.3.1082; Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; Stuurman N, 1996, J STRUCT BIOL, V117, P1, DOI 10.1006/jsbi.1996.0064; TANG SS, 1983, J BIOL CHEM, V258, P4331; Tchaparian EH, 2000, ARCH BIOCHEM BIOPHYS, V379, P71, DOI 10.1006/abbi.2000.1842; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122	61	19	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22977	22985		10.1074/jbc.M503006200	http://dx.doi.org/10.1074/jbc.M503006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15811848	hybrid			2022-12-25	WOS:000229741800052
J	Gleenberg, IO; Avidan, O; Goldgur, Y; Herschhorn, A; Hizi, A				Gleenberg, IO; Avidan, O; Goldgur, Y; Herschhorn, A; Hizi, A			Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN ANTIBODY; DNA-BINDING DOMAIN; HIV-1 INTEGRASE; IN-VITRO; CATALYTIC DOMAIN; ACTIVE-SITE; PREINTEGRATION COMPLEXES; ESCHERICHIA-COLI; RETROVIRAL INTEGRASE; MONOCLONAL-ANTIBODY	Recent studies have shown that the integrase ( IN) of HIV-1 is inhibited in vitro by HIV-1 reverse transcriptase (RT). We further investigated the specific protein sequences of RT that were involved in this inhibition by screening a complete library of RT-derived peptides for their inhibition of IN activities. Two 20-residue peptides, peptide 4286, derived from the RT DNA polymerase domain, and the one designated 4321, from the RT ribonuclease H domain, inhibit the enzymatic activities of IN in vitro. The former peptide inhibits all three IN-associated activities (3'-end processing, strand transfer, and disintegration), whereas the latter one inhibits primarily the first two functions. We showed the importance of the sequences and peptide length for the effective inhibition of IN activities. Binding assays of the peptides to IN ( with no DNA substrate present) indicated that the two inhibitory peptides ( as well as several non-inhibitory peptides) interact directly with IN. Moreover, the isolated catalytic core domain of IN also interacted directly with the two inhibitory peptides. Nevertheless, only peptide 4286 can inhibit the disintegration activity associated with the IN core domain, because this activity is the only one exhibited by this domain. This result was expected from the lack of inhibition of disintegration of full-length IN by peptide 4321. The data and the three-dimensional models presented suggested that the inhibition resulted from steric hindrance of the catalytic domain of IN. This information can substantially facilitate the development of novel drugs against HIV INs and thus contribute to the fight against AIDS.	Tel Aviv Univ, Sackler Sch Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel; Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel	Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University	Hizi, A (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel.	ahizy@post.tau.ac.il						AIGAR A, 1996, J VIROL, V70, P3571; Barsov EV, 1996, J VIROL, V70, P4484, DOI 10.1128/JVI.70.7.4484-4494.1996; Brodin P, 2002, BIOCHEMISTRY-US, V41, P1529, DOI 10.1021/bi015732y; Bujacz G, 1996, FEBS LETT, V398, P175, DOI 10.1016/S0014-5793(96)01236-7; BURKINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; Chow SA, 1997, METHODS, V12, P306, DOI 10.1006/meth.1997.0484; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; Coffin J, 1997, RETROVIRUSES; CRAIGIE R, 2002, RETROVIRAL DNA INTEG, P613; de Soultrait VR, 2003, CURR MED CHEM, V10, P1765; de Soultrait VR, 2002, J MOL BIOL, V318, P45, DOI 10.1016/S0022-2836(02)00033-5; de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1; de Soultrait VR, 2002, BBA-GENE STRUCT EXPR, V1575, P40, DOI 10.1016/S0167-4781(02)00241-5; Desjobert C, 2004, BIOCHEMISTRY-US, V43, P13097, DOI 10.1021/bi049385e; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Fouchier RAM, 1999, ADV VIRUS RES, V52, P275, DOI 10.1016/S0065-3527(08)60302-4; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Grobler JA, 2002, P NATL ACAD SCI USA, V99, P6661, DOI 10.1073/pnas.092056199; Harris D, 2000, J BIOL CHEM, V275, P39671, DOI 10.1074/jbc.M002626200; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Hehl EA, 2004, J VIROL, V78, P5056, DOI 10.1128/JVI.78.10.5056-5067.2004; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; Hindmarsh P, 1999, J VIROL, V73, P2994, DOI 10.1128/JVI.73.4.2994-3003.1999; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HU SC, 1986, J VIROL, V60, P267, DOI 10.1128/JVI.60.1.267-274.1986; Ishikawa T, 1999, J VIROL, V73, P4475, DOI 10.1128/JVI.73.5.4475-4480.1999; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kitamura Y, 1999, J ACQ IMMUN DEF SYND, V20, P105, DOI 10.1097/00042560-199902010-00001; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; LEEHUANG S, 1995, P NATL ACAD SCI USA, V92, P8818, DOI 10.1073/pnas.92.19.8818; LevyMintz P, 1996, J VIROL, V70, P8821, DOI 10.1128/JVI.70.12.8821-8832.1996; Lubkowski J, 1998, P NATL ACAD SCI USA, V95, P4831, DOI 10.1073/pnas.95.9.4831; LUTZKE RAP, 1995, P NATL ACAD SCI USA, V92, P11456, DOI 10.1073/pnas.92.25.11456; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Marchand C, 2002, J BIOL CHEM, V277, P12596, DOI 10.1074/jbc.M110758200; Maroun RG, 2001, BIOCHEMISTRY-US, V40, P13840, DOI 10.1021/bi011328n; Maurin C, 2003, CURR MED CHEM, V10, P1795, DOI 10.2174/0929867033456981; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Okui N, 1998, J VIROL, V72, P6960, DOI 10.1128/JVI.72.8.6960-6964.1998; Oz I, 2002, BIOCHEM J, V361, P557, DOI 10.1042/0264-6021:3610557; Ren J, 2000, STRUCTURE, V8, P1089, DOI 10.1016/S0969-2126(00)00513-X; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; Sevilya Z, 2001, J MOL BIOL, V311, P957, DOI 10.1006/jmbi.2001.4904; SHALKA AM, 1993, REVERSE TRANSCRIPTAS; Sourgen F, 1996, EUR J BIOCHEM, V240, P765, DOI 10.1111/j.1432-1033.1996.0765h.x; Tasara T, 2001, FEBS LETT, V507, P39, DOI 10.1016/S0014-5793(01)02945-3; THANG KC, 2004, CURR TOP MED CHEM, V4, P965; VANGENT DC, 1993, NUCLEIC ACIDS RES, V21, P3373, DOI 10.1093/nar/21.15.3373; VASU N, 2002, REV MED VIROL, V12, P179; Wu XY, 1999, J VIROL, V73, P2126, DOI 10.1128/JVI.73.3.2126-2135.1999; Yang F, 2003, BIOCHEMISTRY-US, V42, P6249, DOI 10.1021/bi034177s; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; Yi JZ, 2002, J BIOL CHEM, V277, P12164, DOI 10.1074/jbc.M105072200; Yung E, 2001, NAT MED, V7, P920, DOI 10.1038/90959; Zhao L, 2003, BIOORG MED CHEM LETT, V13, P1175, DOI 10.1016/S0960-894X(03)00040-4	66	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21987	21996		10.1074/jbc.M414679200	http://dx.doi.org/10.1074/jbc.M414679200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15790559	hybrid			2022-12-25	WOS:000229557900041
J	Kim, IM; Ramakrishna, S; Gusarova, GA; Yoder, HM; Costa, RH; Kalinichenko, VV				Kim, IM; Ramakrishna, S; Gusarova, GA; Yoder, HM; Costa, RH; Kalinichenko, VV			The forkhead box M1 transcription factor is essential for embryonic development of pulmonary vasculature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG BRANCHING MORPHOGENESIS; DNA-BINDING-DOMAIN; GROWTH-FACTOR-BETA; MOUSE LUNG; CELL-DIFFERENTIATION; GENE-EXPRESSION; SONIC HEDGEHOG; LIVER-REGENERATION; MESENCHYMAL CELLS; FACTOR TRIDENT	Transgenic and gene knock-out studies demonstrated that the mouse Forkhead Box m1 (Foxm1 or Foxm1b) transcription factor (previously called HFH-11B, Trident, Win, or MPP2) is essential for hepatocyte entry into mitosis during liver development, regeneration, and liver cancer. Targeted deletion of Foxm1 gene in mice produces an embryonic lethal phenotype due to severe abnormalities in the development of liver and heart. In this study, we show for the first time that Foxm1(-/-) lungs exhibit severe hypertrophy of arteriolar smooth muscle cells and defects in the formation of peripheral pulmonary capillaries as evidenced by significant reduction in platelet endothelial cell adhesion molecule 1 staining of the distal lung. Consistent with these findings, significant reduction in proliferation of the embryonic Foxm1(-/-) lung mesenchyme was found, yet proliferation levels were normal in the Foxm1-deficient epithelial cells. Severe abnormalities of the lung vasculature in Foxm1(-/-) embryos were associated with diminished expression of the transforming growth factor beta receptor II, a disintegrin and metalloprotease domain 17 (ADAM-17), vascular endothelial growth factor receptors, Polo-like kinase 1, Aurora B kinase, laminin alpha 4 (Lama4), and the Forkhead Box f1 transcription factor. Cotransfection studies demonstrated that Foxm1 stimulates transcription of the Lama4 promoter, and this stimulation requires the Foxm1 binding sites located between -1174 and -1145 bp of the mouse Lama4 promoter. In summary, development of mouse lungs depends on the Foxm1 transcription factor, which regulates expression of genes essential for mesenchyme proliferation, extracellular matrix remodeling, and vasculogenesis.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Dev Biol, Chicago, IL 60637 USA; Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kalinichenko, VV (corresponding author), Univ Chicago, Dept Math, 5841 S Maryland Ave,MC 6076, Chicago, IL 60637 USA.	vkalin@medicine.bsd.uchicago.edu		Kim, Il-man/0000-0002-9268-8337; Ramakrishna, Sneha/0000-0001-7445-3190	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054687] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 54687-06] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Bellusci S, 1996, DEVELOPMENT, V122, P1693; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; BREIER G, 1992, DEVELOPMENT, V114, P521; Brody SL, 2000, AM J RESP CELL MOL, V23, P45, DOI 10.1165/ajrcmb.23.1.4070; Calonge MJ, 2004, J BIOL CHEM, V279, P23759, DOI 10.1074/jbc.M402178200; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen JC, 1998, J CLIN INVEST, V102, P1077, DOI 10.1172/JCI4786; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; Drissi MH, 2003, J CELL BIOCHEM, V90, P1287, DOI 10.1002/jcb.10677; Evans PC, 2001, TRANSPLANTATION, V71, P457, DOI 10.1097/00007890-200102150-00020; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Getsios S, 1998, J REPROD FERTIL, V114, P357; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Golan T, 2004, J BIOL CHEM, V279, P14879, DOI 10.1074/jbc.M306421200; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; Kalinichenko VV, 2004, AM J PHYSIOL-LUNG C, V286, pL521, DOI 10.1152/ajplung.00212.2003; Kalinichenko VV, 2003, J BIOL CHEM, V278, P37888, DOI 10.1074/jbc.M305555200; Kalinichenko VV, 2003, HEPATOLOGY, V37, P107, DOI 10.1053/jhep.2003.50005; Kalinichenko VV, 2002, J BIOL CHEM, V277, P12369, DOI 10.1074/jbc.M112162200; Kalinichenko VV, 2002, AM J PHYSIOL-LUNG C, V282, pL1253, DOI 10.1152/ajplung.00463.2001; Kalinichenko VV, 2001, DEV BIOL, V235, P489, DOI 10.1006/dbio.2001.0322; Kalinichenko VV, 2001, AM J PHYSIOL-LUNG C, V280, pL695, DOI 10.1152/ajplung.2001.280.4.L695; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kawabata M, 1999, ANN NY ACAD SCI, V886, P73, DOI 10.1111/j.1749-6632.1999.tb09402.x; Korver W, 1998, CURR BIOL, V8, P1327, DOI 10.1016/S0960-9822(07)00563-5; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Krupczak-Hollis K, 2004, DEV BIOL, V276, P74, DOI 10.1016/j.ydbio.2004.08.022; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Lu Min Min, 2002, Gene Expression Patterns, V2, P223, DOI 10.1016/S1567-133X(02)00058-3; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Mahlapuu M, 2001, DEVELOPMENT, V128, P2397; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; Muller WA, 1999, J LEUKOCYTE BIOL, V66, P698, DOI 10.1002/jlb.66.5.698; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Ohmichi H, 1998, DEVELOPMENT, V125, P1315; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; Peterson RS, 1997, MECH DEVELOP, V69, P53, DOI 10.1016/S0925-4773(97)00153-6; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; Rausa FM, 2003, MOL CELL BIOL, V23, P437, DOI 10.1128/MCB.23.2.437-449.2003; Relan NK, 1999, J CELL BIOL, V147, P1341, DOI 10.1083/jcb.147.6.1341; Reynolds PR, 2004, J BIOL CHEM, V279, P37124, DOI 10.1074/jbc.M405254200; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Samadani U, 1996, GENE EXPRESSION, V6, P23; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shannon JM, 2004, ANNU REV PHYSIOL, V66, P625, DOI 10.1146/annurev.physiol.66.032102.135749; Shu WG, 2001, J BIOL CHEM, V276, P27488, DOI 10.1074/jbc.M100636200; Shu WG, 2002, DEVELOPMENT, V129, P4831; Tan YJ, 2001, GENE EXPRESSION, V9, P237, DOI 10.3727/000000001783992542; Thyboll J, 2002, MOL CELL BIOL, V22, P1194, DOI 10.1128/MCB.22.4.1194-1202.2002; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; Wan HJ, 2004, DEVELOPMENT, V131, P953, DOI 10.1242/dev.00966; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Weaver M, 1999, DEVELOPMENT, V126, P4005; Wells NJ, 1999, J CELL SCI, V112, P3361; Whitsett JA, 1999, AM J RESP CELL MOL, V21, P153, DOI 10.1165/ajrcmb.21.2.f159; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zeng X, 1998, DEV DYNAM, V211, P215, DOI 10.1002/(SICI)1097-0177(199803)211:3<215::AID-AJA3>3.0.CO;2-K; Zhao JS, 1998, MECH DEVELOP, V72, P89, DOI 10.1016/S0925-4773(98)00019-7; Zhao JS, 1998, DEV BIOL, V194, P182, DOI 10.1006/dbio.1997.8825; Zhao JS, 2001, DEV BIOL, V232, P204, DOI 10.1006/dbio.2001.0176; Zhao JS, 1996, DEV BIOL, V180, P242, DOI 10.1006/dbio.1996.0298	79	124	132	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22278	22286		10.1074/jbc.M500936200	http://dx.doi.org/10.1074/jbc.M500936200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817462	hybrid			2022-12-25	WOS:000229557900073
J	Oberwinkler, J; Lis, A; Giehl, KM; Flockerzi, V; Philipp, SE				Oberwinkler, J; Lis, A; Giehl, KM; Flockerzi, V; Philipp, SE			Alternative splicing switches the divalent cation selectivity of TRPM3 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY HYPOCALCEMIA; EXPRESSION; HYPOMAGNESEMIA; PERMEATION; ACTIVATION; MUTATIONS; CELLS; PORE; CA2+	TRPM3 is a poorly understood member of the large family of transient receptor potential ( TRP) ion channels. Here we describe five novel splice variants of TRPM3, TRPM3a1-5. These variants are characterized by a previously unknown amino terminus of 61 residues. The differences between the five variants arise through splice events at three different sites. One of these splice sites might be located in the pore region of the channel as indicated by sequence alignment with other, better-characterized TRP channels. We selected two splice variants, TRPM3a1 and TRPM3a2, that differ only in this presumed pore region and analyzed their biophysical characteristics after heterologous expression in human embryonic kidney 293 cells. TRPM3a1 as well as TRPM3a2 induced a novel, outwardly rectifying cationic conductance that was tightly regulated by intracellular Mg2+. However, these two variants are highly different in their ionic selectivity. Whereas TRPM3a1 encoded channels are poorly permeable for divalent cations, TRPM3a2- encoded channels are well permeated by Ca2+ and Mg2+. Additionally, we found that currents through TRPM3a2 are blocked by extracellular monovalent cations, whereas currents through TRPM3a1 are not. These differences unambiguously show that TRPM3 proteins constitute a pore-forming channel subunit and localize the position of the ion-conducting pore within the TRPM3 protein. Although the ionic selectivity of ion channels has traditionally been regarded as rather constant for a given channel-encoding gene, our results show that alternative splicing can be a mechanism to produce channels with very different selectivity profiles.	Univ Saarland, Inst Expt & Klin Pharmacol & Toxicol, D-66421 Homburg, Germany; Univ Saarland, Inst Anat, D-66421 Homburg, Germany	Saarland University; Saarland University	Philipp, SE (corresponding author), Univ Saarland, Inst Expt & Klin Pharmacol & Toxicol, Gebaude 46, D-66421 Homburg, Germany.	stephan.philipp@uniklinik-saarland.de	Philipp, Stephan/AAR-7519-2020	Oberwinkler, Johannes/0000-0002-8541-3626; Philipp, Stephan/0000-0003-1959-9167				Brown PD, 2004, NEUROSCIENCE, V129, P957, DOI 10.1016/j.neuroscience.2004.07.003; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; GIEHL K, 1995, EXP BRAIN RES, V103, P344; Grabowski PJ, 2001, PROG NEUROBIOL, V65, P289, DOI 10.1016/S0301-0082(01)00007-7; Grimm C, 2005, MOL PHARMACOL, V67, P798, DOI 10.1124/mol.104.006734; Grimm C, 2003, J BIOL CHEM, V278, P21493, DOI 10.1074/jbc.M300945200; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; Launay P, 2004, SCIENCE, V306, P1374, DOI 10.1126/science.1098845; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Lee N, 2003, J BIOL CHEM, V278, P20890, DOI 10.1074/jbc.M211232200; LIS A, 2005, IN PRESS NAUNYNSCHMI; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; MONTELL C, 2005, SCI STKE 2005; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Nilius B, 2003, J BIOL CHEM, V278, P30813, DOI 10.1074/jbc.M305127200; Numaguchi H, 2000, NAT NEUROSCI, V3, P429, DOI 10.1038/74793; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Romani AMP, 2000, FRONT BIOSCI, V5, pD720, DOI 10.2741/Romani; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Seeburg PH, 2003, CURR OPIN NEUROBIOL, V13, P279, DOI 10.1016/S0959-4388(03)00062-X; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Voets T, 2004, J BIOL CHEM, V279, P15223, DOI 10.1074/jbc.M312076200; Voets T, 2004, J BIOL CHEM, V279, P19, DOI 10.1074/jbc.M311201200; Voets T, 2003, CELL CALCIUM, V33, P299, DOI 10.1016/S0143-4160(03)00044-7; Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901; Warnat J, 1999, J PHYSIOL-LONDON, V518, P631, DOI 10.1111/j.1469-7793.1999.0631p.x; WISCHMEYER E, 1995, PFLUG ARCH EUR J PHY, V429, P809, DOI 10.1007/BF00374805; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200	32	156	166	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22540	22548		10.1074/jbc.M503092200	http://dx.doi.org/10.1074/jbc.M503092200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824111	hybrid			2022-12-25	WOS:000229557900102
J	Bubikat, A; De Windt, LJ; Zetsche, B; Fabritz, L; Sickler, H; Eckardt, D; Godecke, A; Baba, HA; Kuhn, M				Bubikat, A; De Windt, LJ; Zetsche, B; Fabritz, L; Sickler, H; Eckardt, D; Godecke, A; Baba, HA; Kuhn, M			Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLYL CYCLASE-A; ACTIVATED PROTEIN-KINASES; ANGIOTENSIN-II; CALCINEURIN-NFAT; GENE-EXPRESSION; RECEPTOR; LACKING; FIBROBLASTS; MYOCYTES; INHIBIT	The crucial functions of atrial natriuretic peptide (ANP) and endothelial nitric oxide/NO in the regulation of arterial blood pressure have been emphasized by the hypertensive phenotype of mice with systemic inactivation of either the guanylyl cyclase-A receptor for ANP (GC-A-/-) or endothelial nitric-oxide synthase (eNOS-/-). Intriguingly, similar levels of arterial hypertension are accompanied by marked cardiac hypertrophy in GC-A-/-, but not in eNOS-/-, mice, suggesting that changes in local pathways regulating cardiac growth accelerate cardiac hypertrophy in the former and protect the heart of the latter. Our recent observations in mice with conditional, cardiomyocyte-restricted GC-A deletion demonstrated that ANP locally inhibits cardiomyocyte growth. Abolition of these local, protective effects may enhance the cardiac hypertrophic response of GC-A-/- mice to persistent increases in hemodynamic load. Notably, eNOS-/- mice exhibit markedly increased cardiac ANP levels, suggesting that increased activation of cardiac GC-A can prevent hypertensive heart disease. To test this hypothesis, we generated mice with systemic inactivation of eNOS and cardiomyocyte-restricted deletion of GC-A by crossing eNOS-/- and cardiomyocyte-restricted GC-A-deficient mice. Cardiac deletion of GC-A did not affect arterial hypertension but significantly exacerbated cardiac hypertrophy and fibrosis in eNOS-/- mice. This was accompanied by marked cardiac activation of both the mitogen-activated protein kinase ( MAPK) ERK 1/2 and the phosphatase calcineurin. Our observations suggest that local ANP/GC-A/cyclic GMP signaling counter-regulates MAPK/ERK- and calcineurin/nuclear factor of activated T cells-dependent pathways of cardiac myocyte growth in hypertensive eNOS-/- mice.	Univ Wurzburg, Inst Physiol, D-97070 Wurzburg, Germany; Univ Klinikum Munster, Dept Pharmacol & Toxicol, D-48129 Munster, Germany; Univ Klinikum Munster, Dept Cardiol & Angiol, D-48129 Munster, Germany; Univ Klinikum Munster, Interdisciplinary Ctr Clin Res, D-48129 Munster, Germany; Royal Netherlands Acad Sci, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Royal Netherlands Acad Sci, Interuniv Cardiol Inst Netherlands, NL-3584 CT Utrecht, Netherlands; Univ Dusseldorf, Inst Herz & Kreislaufphysiol, D-40001 Dusseldorf, Germany; Univ Duisburg Essen, Inst Pathol, D-45147 Essen, Germany	University of Wurzburg; University of Munster; University of Munster; University of Munster; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Interuniversity Cardiology Institute of the Netherlands; Utrecht University; Heinrich Heine University Dusseldorf; University of Duisburg Essen	Kuhn, M (corresponding author), Univ Wurzburg, Inst Physiol, Rontgenring 9, D-97070 Wurzburg, Germany.	kuhn@mail.uni-wuerzburg.de	de Windt, Leon/AAO-6395-2020	de Windt, Leon/0000-0002-7793-2856; Fabritz, Larissa/0000-0002-9241-1733				Airhart N, 2003, J BIOL CHEM, V278, P38693, DOI 10.1074/jbc.M304098200; Balligand JL, 1997, ARTERIOSCL THROM VAS, V17, P1846, DOI 10.1161/01.ATV.17.10.1846; Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; Bueno OF, 2002, CIRC RES, V91, P776, DOI 10.1161/01.RES.0000038488.38975.1A; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; de Bold AJ, 2001, CAN J PHYSIOL PHARM, V79, P705, DOI 10.1139/cjpp-79-8-705; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; Fiedler B, 2002, P NATL ACAD SCI USA, V99, P11363, DOI 10.1073/pnas.162100799; Friddle CJ, 2000, P NATL ACAD SCI USA, V97, P6745, DOI 10.1073/pnas.100127897; FUJISAKI H, 1995, J CLIN INVEST, V96, P1059, DOI 10.1172/JCI118092; Godecke A, 1998, CIRC RES, V82, P186; Gyurko R, 2000, AM J PHYSIOL-HEART C, V278, pH971, DOI 10.1152/ajpheart.2000.278.3.H971; Holtwick R, 2003, J CLIN INVEST, V111, P1399, DOI 10.1172/JCI200317061; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Ichinose F, 2004, AM J PHYSIOL-HEART C, V286, pH1070, DOI 10.1152/ajpheart.00940.2003; Ito T, 2003, CIRCULATION, V107, P807, DOI 10.1161/01.CIR.0000057794.29667.08; Kirchhefer U, 2001, J BIOL CHEM, V276, P4142, DOI 10.1074/jbc.M006443200; Kishimoto I, 2001, P NATL ACAD SCI USA, V98, P2703, DOI 10.1073/pnas.051625598; Knowles JW, 2001, J CLIN INVEST, V107, P975, DOI 10.1172/JCI11273; Kuhn M, 2003, CIRC RES, V93, P700, DOI 10.1161/01.RES.0000094745.28948.4D; Kuhn M, 2002, HEART, V87, P368, DOI 10.1136/heart.87.4.368; Li YH, 2002, CIRCULATION, V106, P1722, DOI 10.1161/01.CIR.0000029923.57048.61; Liang QR, 2003, J MOL CELL CARDIOL, V35, P1385, DOI 10.1016/j.yjmcc.2003.10.001; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; Molkentin JD, 2004, CARDIOVASC RES, V63, P467, DOI 10.1016/j.cardiores.2004.01.021; Ritchie RH, 1998, AM J PHYSIOL-HEART C, V275, pH1370, DOI 10.1152/ajpheart.1998.275.4.H1370; Rosenkranz S, 2004, CARDIOVASC RES, V63, P423, DOI 10.1016/j.cardiores.2004.04.030; Sanna B, 2005, MOL CELL BIOL, V25, P865, DOI 10.1128/MCB.25.3.865-878.2005; Sharma GD, 2002, MOL CELL BIOCHEM, V233, P165, DOI 10.1023/A:1015882302796; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; Tamura N, 2000, P NATL ACAD SCI USA, V97, P4239, DOI 10.1073/pnas.070371497; van Rooij E, 2004, CIRC RES, V94, pE18, DOI 10.1161/01.RES.0000118597.54416.00; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; Zolle O, 2000, J BIOL CHEM, V275, P25892, DOI 10.1074/jbc.M000786200; Zou YZ, 2001, CIRCULATION, V104, P97, DOI 10.1161/01.CIR.104.1.97	37	49	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21594	21599		10.1074/jbc.m501103200	http://dx.doi.org/10.1074/jbc.m501103200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15793309	hybrid			2022-12-25	WOS:000229438800083
J	Domingo, E; Niessen, RC; Oliveira, C; Alhopuro, P; Moutinho, C; Espin, E; Armengol, M; Sijmons, RH; Kleibeuker, JH; Seruca, R; Aaltonen, LA; Imai, K; Yamamoto, H; Schwartz, S; Hofstra, RMW				Domingo, E; Niessen, RC; Oliveira, C; Alhopuro, P; Moutinho, C; Espin, E; Armengol, M; Sijmons, RH; Kleibeuker, JH; Seruca, R; Aaltonen, LA; Imai, K; Yamamoto, H; Schwartz, S; Hofstra, RMW			RRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes	ONCOGENE			English	Article						HNPCC; BRAF; MSH6	MISMATCH REPAIR DEFICIENCY; BETHESDA GUIDELINES; BRAF MUTATIONS; CANCER; COLON; HMLH1	Recently, it was shown that the oncogenic activation of BRAF, a member of the RAS/RAF family of kinases, by the V600E mutation is characteristic for sporadic colon tumors with microsatellite instability. Further, it was shown to associate with the silencing of the mismatch repair (MMR) gene MLH1 by hypermethylation. Moreover, BRAF mutations proved to be absent in tumors from hereditary nonpolyposis colorectal cancer syndrome (HNPCC) families with germline mutations in the MMR genes MLH1 and MSH2. These data suggest that the oncogenic activation of BRAF is involved only in sporadic colorectal tumorigenesis. In order to further support this hypothesis, we have extended the analysis of the BRAF gene to a different subset of HNPCC families without germline mutations in MLH1 and MSH2. BRAF-V600E mutations were analysed by automatic sequencing in 38 tumors from HNPCC families with germline mutations in the MSH6 gene and also in HNPCC (suspected) families that do not have mutations in the MMR genes MLH1, MSH2 and MSH6. All patients belong to different families. No mutations were detected in 14 tumors from HNPCC patients with germline mutations in MSH6. Further, no mutations of BRAF were found in tumors from 23 MMR-negative families, from which 13 fulfilled the Amsterdam criteria (HNPCC) and 10 were suspected for HNPCC as they were positive for the Bethesda criteria. Overall, our data reinforce the concept that BRAF is not involved in the colorectal tumorigenesis of HNPCC. The detection of a positive BRAF-V600E mutation in a colorectal cancer suggests a sporadic origin of the disease and the absence of germline alterations of MLH1, MSH2 and also of MSH6. These findings have a potential impact in the genetic testing for HNPCC diagnostics and suggest a potential use of BRAF as exclusion criteria for HNPCC or as a molecular marker of sporadic cancer.	Hosp Univ Vall Hebron, CIBBIM, Barcelona 08035, Spain; Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands; Univ Porto, Inst Patol & Imunol Mol, P-4200465 Oporto, Portugal; Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Groningen Hosp, Dept Clin Genet, Groningen, Netherlands; Univ Groningen Hosp, Dept Gastroenterol, Groningen, Netherlands; Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	Hospital Universitari Vall d'Hebron; University of Groningen; Universidade do Porto; University of Helsinki; University of Groningen; University of Groningen; Sapporo Medical University	Schwartz, S (corresponding author), Hosp Univ Vall Hebron, CIBBIM, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	sschwartz@vhebron.net	Domingo, Enric/A-9099-2018; Oliveira, Carla/F-8188-2011; seruca, raquel/F-8187-2011; Aaltonen, Lauri/A-5375-2010; Sijmons, Rolf/E-5829-2012; Schwartz, Simo/H-7776-2012	Domingo, Enric/0000-0003-4390-8767; Oliveira, Carla/0000-0001-8340-2264; Aaltonen, Lauri/0000-0001-6839-4286; Sijmons, Rolf/0000-0001-8446-2779; Schwartz, Simo/0000-0001-8297-7971; Hofstra, Robert/0000-0001-7498-3829; Espin-Basany, Eloy/0000-0002-9139-4548; Armengol, Manuel/0000-0002-3211-3195; Seruca, Raquel/0000-0002-8851-4166				Berends MJW, 2002, AM J HUM GENET, V70, P26, DOI 10.1086/337944; Boland CR, 1998, CANCER RES, V58, P5248; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; Di Fiore F, 2004, J MED GENET, V41, P18, DOI 10.1136/jmg.2003.012062; Domingo E, 2004, J MED GENET, V41, P664, DOI 10.1136/jmg.2004.020651; Domingo E, 2004, GENE CHROMOSOME CANC, V39, P138, DOI 10.1002/gcc.10310; Gille JJP, 2002, BRIT J CANCER, V87, P892, DOI 10.1038/sj.bjc.6600565; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Oliveira C, 2003, ONCOGENE, V22, P9192, DOI 10.1038/sj.onc.1207061; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Wahlberg S, 1999, GENET TEST, V3, P259, DOI 10.1089/109065799316563; Wang L, 2003, CANCER RES, V63, P5209; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773	19	129	135	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3995	3998		10.1038/sj.onc.1208569	http://dx.doi.org/10.1038/sj.onc.1208569			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782118				2022-12-25	WOS:000229435300015
J	Mukherjee, K; Syed, V; Ho, SM				Mukherjee, K; Syed, V; Ho, SM			Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial	ONCOGENE			English	Article						ICI 182,780; hormonal carcinogenesis; ovarian; surface epithelial cells; apoptosis; RU486; 17 beta hydroxysteroid dehydrogenase	STEROID-HORMONE RECEPTORS; BREAST-CANCER CELLS; NUCLEAR EXPORT SIGNAL; B-ISOFORM; TRANSCRIPTIONAL ACTIVITY; MONOCLONAL-ANTIBODY; ANDROGEN RECEPTOR; INDUCED APOPTOSIS; GENE-EXPRESSION; MESSENGER-RNA	While estrogens are suspected risk factors for epithelial ovarian cancer (OCa), progesterone (P4) has been shown to exert protective effects. The biological actions of P4 in target cells are mediated by progesterone receptors (PRs) that exist principally as A- and B-isoforms. We observed overexpression of PR-A and PR-B protein in two lines of OCa cells when compared to two lines of nontumorigenic, normal human ovarian surface epithelial (HOSE) cells. Treatment of HOSE or OCa cells with estrone or 17 beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of PR-A and PR-B mRNA and protein expression, with the regulation primarily controlled at the transcriptional level. In contrast, breast cancer cells (line MCF-7) exposed to estrogens upregulated PR-A and PR-B expression. Of significance, both the inhibitory and stimulatory actions of estrogens were blocked by the specific ER-antagonist ICI 182,780 (ICI, 10(-5) M), con. firming estrogen speci. city. Cotreatment of estrogen-exposed HOSE, OCa, and MCF-7 cell lines with inhibitors of type 1- and type 2-17 beta hydroxysteroid dehydrogenase did not affect the previously observed changes in PR expression, suggesting that the action of each estrogen is direct and not mediated via conversion to its metabolic counterpart. Green fluorescence protein (GFP)-PR-A and GFP-PR-B were localized in the cytoplasmic compartment of untreated HOSE cells and translocated to the nucleus after P4 treatment, while both chimera PRs resided in the nuclei of OCa cells in a ligand-independent manner. In OCa cell cultures, P4 (10(-6) M), but not RU486 (10(-5) M), induced apoptosis that was blocked by cotreatment with the antiprogestin but enhanced by cotreatment with ICI. In sharp contrast, P4 induced proliferation, while ICI and RU486 caused cell death in MCF-7 cells. In conclusion, this study is first to demonstrate estrogens as negative regulators of PR expression in HOSE/OCa cells and to provide a mechanistic basis upon which to explain the antagonism of estrogens on the anti-OCa action of progestins. It also raises the possibility of using progestin and ICI as a combinational therapy for OCa treatment.	Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ho, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, 364 Plantat St,Room 504,Lazare Res Bldg, Worcester, MA 01605 USA.	Shuk-mei.Ho@umassmed.edu			NCI NIH HHS [CA94221, CA091250] Funding Source: Medline; NIDDK NIH HHS [DK61084] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA091250, R01CA094221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061084] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akahira J, 2000, BRIT J CANCER, V83, P1488, DOI 10.1054/bjoc.2000.1463; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BELL DA, 1991, HUM PATHOL, V22, P750, DOI 10.1016/0046-8177(91)90205-4; Bu SZ, 1997, CANCER, V79, P1944, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1944::AID-CNCR15>3.0.CO;2-V; Clarke RB, 2004, TRENDS ENDOCRIN MET, V15, P316, DOI 10.1016/j.tem.2004.07.004; Clemm DL, 2000, MOL ENDOCRINOL, V14, P52, DOI 10.1210/me.14.1.52; DANDLIKER WB, 1978, CANCER RES, V38, P4212; Davis M, 1996, CANCER RES, V56, P741; Elbi C, 2004, P NATL ACAD SCI USA, V101, P2876, DOI 10.1073/pnas.0400116101; Flototto T, 2004, J STEROID BIOCHEM, V88, P131, DOI 10.1016/j.jsbmb.2003.11.004; Fujimura M, 2001, AM J SURG PATHOL, V25, P667, DOI 10.1097/00000478-200105000-00016; Gabra H, 1996, CANCER RES, V56, P950; GABRA H, 1995, BRIT J CANCER, V72, P367, DOI 10.1038/bjc.1995.340; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; Graham JD, 2002, BREAST CANCER RES, V4, P187, DOI 10.1186/bcr450; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; GuiochonMantel A, 1996, J STEROID BIOCHEM, V56, P3, DOI 10.1016/0960-0760(95)00268-5; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HEINONEN PK, 1982, BRIT J OBSTET GYNAEC, V89, P84, DOI 10.1111/j.1471-0528.1982.tb04643.x; Hempling RE, 1998, AM J CLIN ONCOL-CANC, V21, P447, DOI 10.1097/00000421-199810000-00005; Hewitt SC, 2000, STEROIDS, V65, P551, DOI 10.1016/S0039-128X(00)00113-6; HO SM, 2003, REPROD BIOL ENDOCRIN, V73, P1; Hopp TA, 2004, CLIN CANCER RES, V10, P2751, DOI 10.1158/1078-0432.CCR-03-0141; Hornung R, 2004, CANCER LETT, V206, P97, DOI 10.1016/j.canlet.2003.10.034; Hu Z, 2000, Zhonghua Fu Chan Ke Za Zhi, V35, P423; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; Knotts TA, 2001, J BIOL CHEM, V276, P8475, DOI 10.1074/jbc.M009805200; KONTULA K, 1975, ACTA ENDOCRINOL-COP, V78, P574, DOI 10.1530/acta.0.0780574; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; KREITMANN B, 1979, J STEROID BIOCHEM, V11, P1253, DOI 10.1016/0022-4731(79)90193-6; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Langdon SP, 1998, CLIN CANCER RES, V4, P2245; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Leslie KK, 2005, GYNECOL ONCOL, V96, P32, DOI 10.1016/j.ygyno.2004.09.057; Li AJ, 2003, AM J OBSTET GYNECOL, V189, P22, DOI 10.1067/mob.2003.328; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; Lindgren PR, 2004, MOL CELL ENDOCRINOL, V221, P97, DOI 10.1016/j.mce.2004.02.020; Luce Therese L, 2003, Nurse Pract, V28, P41, DOI 10.1097/00006205-200312000-00007; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MISRAHI M, 1988, NUCLEIC ACIDS RES, V16, P5459, DOI 10.1093/nar/16.12.5459; Modan B, 1998, AM J EPIDEMIOL, V147, P1038; Munstedt K, 2000, CANCER, V89, P1783, DOI 10.1002/1097-0142(20001015)89:8<1783::AID-CNCR19>3.0.CO;2-D; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935; Passinen S, 2001, EUR J BIOCHEM, V268, P5337, DOI 10.1046/j.0014-2956.2001.02467.x; Petz LN, 2002, ENDOCRINOLOGY, V143, P4583, DOI 10.1210/en.2002-220369; Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972; Poirier D, 2001, MOL CELL ENDOCRINOL, V171, P119, DOI 10.1016/S0303-7207(00)00427-5; Qiu M, 2003, J STEROID BIOCHEM, V85, P147, DOI 10.1016/S0960-0760(03)00221-8; Qiu M, 2003, MOL ENDOCRINOL, V17, P628, DOI 10.1210/me.2002-0378; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Rickard DJ, 2002, J BONE MINER RES, V17, P580, DOI 10.1359/jbmr.2002.17.4.580; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Rodriguez GC, 1998, J SOC GYNECOL INVEST, V5, P271, DOI 10.1016/S1071-5576(98)00017-3; Rodriguez GC, 2002, JNCI-J NATL CANCER I, V94, P50; Ross G.T., 1981, TXB ENDOCRINOLOGY, P355; Saegusa M, 2000, JPN J CANCER RES, V91, P510, DOI 10.1111/j.1349-7006.2000.tb00975.x; Saporita AJ, 2003, J BIOL CHEM, V278, P41998, DOI 10.1074/jbc.M302460200; Sartorius CA, 2003, BREAST CANCER RES TR, V79, P287, DOI 10.1023/A:1024031731269; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; Schultz JR, 2003, MOL CELL ENDOCRINOL, V201, P165, DOI 10.1016/S0303-7207(02)00415-X; Scully RE, 1995, J CELL BIOCHEM, P208; SHAFIE S, 1979, J LAB CLIN MED, V94, P784; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696; Simpson ET, 1981, TXB ENDOCRINOLOGY, P412; Smid-Koopman E, 2003, J SOC GYNECOL INVEST, V10, P49, DOI 10.1016/S1071-5576(02)00217-4; Smith CL, 2000, MOL ENDOCRINOL, V14, P956, DOI 10.1210/me.14.7.956; Syed V, 2001, CANCER RES, V61, P6768; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; Syed V, 2003, ONCOGENE, V22, P6883, DOI 10.1038/sj.onc.1206828; Takimoto GS, 1996, J BIOL CHEM, V271, P13308, DOI 10.1074/jbc.271.23.13308; Tang YT, 1996, MOL CELL BIOL, V16, P1989; Taube M, 2002, INT J ONCOL, V20, P589; Taube M, 2003, INT J ONCOL, V22, P1257; Tibbetts TA, 1998, BIOL REPROD, V59, P1143, DOI 10.1095/biolreprod59.5.1143; Tremblay MR, 1998, J STEROID BIOCHEM, V66, P179, DOI 10.1016/S0960-0760(98)00043-0; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Tyagi RK, 1998, MOL ENDOCRINOL, V12, P1684, DOI 10.1210/me.12.11.1684; VAUGHN CB, 1976, J CLIN ENDOCR METAB, V43, P387, DOI 10.1210/jcem-43-2-387; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Vienonen A, 2002, J STEROID BIOCHEM, V80, P307, DOI 10.1016/S0960-0760(02)00027-4; Wang Gang, 2004, Ai Zheng, V23, P406; WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WEN DX, 1994, MOL CELL BIOL, V14, P8356, DOI 10.1128/MCB.14.12.8356; Yu S, 2001, J CELL BIOCHEM, V82, P445, DOI 10.1002/jcb.1171	92	26	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4388	4400		10.1038/sj.onc.1208623	http://dx.doi.org/10.1038/sj.onc.1208623			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806153				2022-12-25	WOS:000229976900008
J	Zhang, Y; Baranov, PV; Atkins, JF; Gladyshev, VN				Zhang, Y; Baranov, PV; Atkins, JF; Gladyshev, VN			Pyrrolysine and selenocysteine use dissimilar decoding strategies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMATE DEHYDROGENASE H; GENETIC-CODE; ESCHERICHIA-COLI; TRANSFER-RNA; TRANSLATIONAL TERMINATION; SELENOPROTEIN SYNTHESIS; RELEASE FACTOR; STOP CODON; CRYSTAL-STRUCTURE; MESSENGER-RNA	Selenocysteine (Sec) and pyrrolysine (Pyl) are known as the 21st and 22nd amino acids in protein. Both are encoded by codons that normally function as stop signals. Sec specification by UGA codons requires the presence of a cis-acting selenocysteine insertion sequence ( SECIS) element. Similarly, it is thought that Pyl is inserted by UAG codons with the help of a putative pyrrolysine insertion sequence (PYLIS) element. Herein, we analyzed the occurrence of Pyl-utilizing organisms, Pyl-associated genes, and Pyl-containing proteins. The Pyl trait is restricted to several microbes, and only one organism has both Pyl and Sec. We found that methanogenic archaea that utilize Pyl have few genes that contain in-frame UAG codons, and many of these are followed with nearby UAA or UGA codons. In addition, unambiguous UAG stop signals could not be identified. This bias was not observed in Sec-utilizing organisms and non-Pyl-utilizing archaea, as well as with other stop codons. These observations as well as analyses of the coding potential of UAG codons, overlapping genes, and release factor sequences suggest that UAG is not a typical stop signal in Pyl-utilizing archaea. On the other hand, searches for conserved Pyl-containing proteins revealed only four protein families, including methylamine methyltransferases and transposases. Only methylamine methyltransferases matched the Pyl trait and had conserved Pyl, suggesting that this amino acid is used primarily by these enzymes. These findings are best explained by a model wherein UAG codons may have ambiguous meaning and Pyl insertion can effectively compete with translation termination for UAG codons obviating the need for a specific PYLIS structure. Thus, Sec and Pyl follow dissimilar decoding and evolutionary strategies.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Natl Univ Ireland Univ Coll Cork, Biosci Inst, Cork, Ireland	University of Nebraska System; University of Nebraska Lincoln; Utah System of Higher Education; University of Utah; University College Cork	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	Baranov, Pavel/A-2782-2011; Gladyshev, Vadim N/A-9894-2013; Gladyshev, Vadim N/J-6187-2013	Baranov, Pavel/0000-0001-9017-0270; Atkins, John/0000-0001-7933-0165; Gladyshev, Vadim/0000-0002-0372-7016	NIGMS NIH HHS [GM061603, GM48152] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603, R01GM048152] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Atkins JF, 2002, SCIENCE, V296, P1409, DOI 10.1126/science.1073339; Barrett G.C, 1999, AMINO ACID DERIVATIV; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; Bjornsson A, 1996, EMBO J, V15, P1696, DOI 10.1002/j.1460-2075.1996.tb00515.x; Blight SK, 2004, NATURE, V431, P333, DOI 10.1038/nature02895; Bock A, 2000, Biofactors, V11, P77; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BOCK A, 1991, TRENDS BIOCHEM SCI, V16, P463, DOI 10.1016/0968-0004(91)90180-4; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; Buczek O, 2005, J BIOL CHEM, V280, P4247, DOI 10.1074/jbc.M405835200; Carlson BA, 2002, METHOD ENZYMOL, V347, P24; Castellano S, 2004, EMBO REP, V5, P71, DOI 10.1038/sj.embor.7400036; Commans S, 1999, FEMS MICROBIOL REV, V23, P335, DOI 10.1111/j.1574-6976.1999.tb00403.x; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; Copeland PR, 2001, MOL CELL BIOL, V21, P1491, DOI 10.1128/MCB.21.5.1491-1498.2001; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; EHRENREICH A, 1992, EUR J BIOCHEM, V206, P767, DOI 10.1111/j.1432-1033.1992.tb16983.x; Fenske C, 2003, ANGEW CHEM INT EDIT, V42, P606, DOI 10.1002/anie.200390174; Fourmy D, 2002, J MOL BIOL, V324, P137, DOI 10.1016/S0022-2836(02)01030-6; Frolova L, 2002, RNA, V8, P129, DOI 10.1017/S1355838202013262; Fukuda Y, 2003, GENE, V323, P181, DOI 10.1016/j.gene.2003.09.021; Goodchild A, 2004, MOL MICROBIOL, V53, P309, DOI 10.1111/j.1365-2958.2004.04130.x; Hao B, 2002, SCIENCE, V296, P1462, DOI 10.1126/science.1069556; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; Ibba M, 2004, GENE DEV, V18, P731, DOI 10.1101/gad.1187404; Ibba M, 2002, CURR BIOL, V12, pR464, DOI 10.1016/S0960-9822(02)00947-8; Inagaki Y, 2001, NUCLEIC ACIDS RES, V29, P921, DOI 10.1093/nar/29.4.921; Kervestin S, 2001, EMBO REP, V2, P680, DOI 10.1093/embo-reports/kve156; Khangulov SV, 1998, BIOCHEMISTRY-US, V37, P3518, DOI 10.1021/bi972177k; Kisselev LL, 2000, TRENDS BIOCHEM SCI, V25, P561, DOI 10.1016/S0968-0004(00)01669-8; Knight RD, 2000, CELL, V101, P569, DOI 10.1016/S0092-8674(00)80866-1; Knight RD, 2001, NAT REV GENET, V2, P49, DOI 10.1038/35047500; Kryukov GV, 2004, EMBO REP, V5, P538, DOI 10.1038/sj.embor.7400126; Kryukov GV, 1999, J BIOL CHEM, V274, P33888, DOI 10.1074/jbc.274.48.33888; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Krzycki JA, 2004, CURR OPIN CHEM BIOL, V8, P484, DOI 10.1016/j.cbpa.2004.08.012; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; Lozupone CA, 2001, CURR BIOL, V11, P65, DOI 10.1016/S0960-9822(01)00028-8; Medzihradszky KF, 2004, MOL CELL PROTEOMICS, V3, P429, DOI 10.1074/mcp.M300140-MCP200; Mottagui-Tabar S, 1998, GENE, V212, P189, DOI 10.1016/S0378-1119(98)00176-0; Nakamura Y, 2000, CELL, V101, P349, DOI 10.1016/S0092-8674(00)80845-4; Namy O, 2004, MOL CELL, V13, P157, DOI 10.1016/S1097-2765(04)00031-0; OSAWA S, 1992, MICROBIOL REV, V56, P229, DOI 10.1128/MMBR.56.1.229-264.1992; OW SC, 1996, TRENDS BIOCHEM SCI, V21, P203; Pezo V, 2004, P NATL ACAD SCI USA, V101, P8593, DOI 10.1073/pnas.0402893101; Polycarpo C, 2004, P NATL ACAD SCI USA, V101, P12450, DOI 10.1073/pnas.0405362101; Polycarpo C, 2003, MOL CELL, V12, P287, DOI 10.1016/S1097-2765(03)00280-6; Poole E, 2000, BBA-GENE STRUCT EXPR, V1493, P1, DOI 10.1016/S0167-4781(00)00162-7; Poole ES, 1997, RNA, V3, P974; Poole ES, 1998, NUCLEIC ACIDS RES, V26, P954, DOI 10.1093/nar/26.4.954; Rogozin IB, 2002, TRENDS GENET, V18, P228, DOI 10.1016/S0168-9525(02)02649-5; Rother M, 2001, BIOFACTORS, V14, P75, DOI 10.1002/biof.5520140111; Santos MAS, 2004, TRENDS GENET, V20, P95, DOI 10.1016/j.tig.2003.12.009; Santos MAS, 1997, MOL MICROBIOL, V26, P423, DOI 10.1046/j.1365-2958.1997.5891961.x; Schimmel P, 2004, NATURE, V431, P257, DOI 10.1038/431257a; Silva Raquel M., 2004, Briefings in Functional Genomics & Proteomics, V3, P35, DOI 10.1093/bfgp/3.1.35; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; Srinivasan G, 2002, SCIENCE, V296, P1459, DOI 10.1126/science.1069588; Tate WP, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1342; Thanbichler M, 2002, METHOD ENZYMOL, V347, P3; Thanbichler M, 2001, BIOFACTORS, V14, P53, DOI 10.1002/biof.5520140108; Theobald-Dietrich A, 2004, NUCLEIC ACIDS RES, V32, P1091, DOI 10.1093/nar/gkh266; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tormay P, 1996, MOL MICROBIOL, V21, P1253, DOI 10.1046/j.1365-2958.1996.881450.x; TOURANCHEAU AB, 1995, EMBO J, V14, P3262, DOI 10.1002/j.1460-2075.1995.tb07329.x; VERES Z, 1994, J BIOL CHEM, V269, P10597	68	82	88	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20740	20751		10.1074/jbc.M501458200	http://dx.doi.org/10.1074/jbc.M501458200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788401	Green Published, hybrid			2022-12-25	WOS:000229242000072
J	Levesque, AA; Kohn, EA; Bresnick, E; Eastman, A				Levesque, AA; Kohn, EA; Bresnick, E; Eastman, A			Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G(2) cell cycle checkpoints	ONCOGENE			English	Article						p53 tumor suppressor; topoisomerase I inhibitors; cell cycle checkpoints; UCN-01; cyclin B	CHK2 PROTEIN-KINASE; TRANSCRIPTIONAL REPRESSION; IONIZING-RADIATION; CANCER-CELLS; PHOSPHORYLATION; ACTIVATION; PATHWAY; 7-HYDROXYSTAUROSPORINE; REPLICATION; INHIBITOR	The topoisomerase I inhibitor SN38 arrests cell cycle progression primarilyin S or G(2) phases of the cell cycle in a p53-independent manner. The Chk1 inhibitor, 7-hydroxystaurosporine (UCN-01), overcomes both S and G(2) arrest preferentiallyin cells mutated for p53, driving cells through a lethal mitosis and thereby enhancing cytotoxicity. The mechanism by which p53 maintains S and G(2) arrest was investigated here. The p53 wild-type MCF10A cells were arrested in S phase by incubation with SN38 for 24 h. Subsequent incubation with UCN-01 failed to abrogate arrest. To examine the impact of p53, MCF10A cells were developed, which express the tetramerization domain of p53 to inhibit endogenous p53 function. These cells were attenuated in SN38-mediated induction of p21(WAF1), and UCN-01 induced S, but not G(2) progression. In contrast, MCF10A cells expressing short hairpin RNA to ablate p53 expression underwent both S and G(2) phase progression with UCN-01. The difference in G(2) progression was attributed to p53-mediated gene repression; the MCF10A cells expressing the tetramerization domain retained p53 protein and repressed both cyclin B and Chk1, while cells ablated for p53 did not repress these proteins. Hence, inhibition of p53 activator function permits S phase abrogation, while additional inhibition of p53 repressor function is required for abrogation of G(2) arrest. These studies provide a mechanistic explanation for how this therapeutic strategy can selectively target tumor cells.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA; Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	Dartmouth College; Norris Cotton Cancer Center	Eastman, A (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA.	alan.eastman@dartmouth.edu	Levesque, Aime/GNM-9708-2022	Levesque, Aime/0000-0002-2907-229X	NATIONAL CANCER INSTITUTE [P30CA023108, R01CA082220] Funding Source: NIH RePORTER; NCI NIH HHS [CA82220, CA23108] Funding Source: Medline; PHS HHS [T3209658] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; Damia G, 2001, J BIOL CHEM, V276, P10641, DOI 10.1074/jbc.M007178200; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FAN SJ, 1995, CANCER RES, V55, P1649; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Gorczyca W, 1997, MODERN PATHOL, V10, P457; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirose Y, 2001, CANCER RES, V61, P5843; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Husain A, 1997, CLIN CANCER RES, V3, P2089; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Kohn EA, 2003, CANCER RES, V63, P31; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Park M, 2000, CANCER RES, V60, P542; POWELL SN, 1995, CANCER RES, V55, P1643; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sagata N, 2002, SCIENCE, V298, P1905, DOI 10.1126/science.1079225; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shao RG, 1997, CANCER RES, V57, P4029; Shieh SY, 2000, GENE DEV, V14, P289; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	42	52	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3786	3796		10.1038/sj.onc.1208451	http://dx.doi.org/10.1038/sj.onc.1208451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782134				2022-12-25	WOS:000229346300009
J	Radke, S; Pirkmaier, A; Germain, D				Radke, S; Pirkmaier, A; Germain, D			Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer	ONCOGENE			English	Article						ubiquitin; F-box protein; breast cancer; Skp2; p27	UBIQUITIN LIGASE SUBUNIT; S-PHASE; DEGRADATION; PROTEOLYSIS; P27(KIP1); P27; P45(SKP2); CARCINOMA	Skp2 is an F-box protein involved in the ubiquitination and subsequent degradation of the cyclin-dependent kinase (Cdk) inhibitor p27. Skp2 has been reported to be overexpressed in a variety of cancer types and to correlate with poor prognosis. We have identified a novel isoform of Skp2 we named Skp2B, which differs from Skp2 only in the C-terminal domain and unlike Skp2 localizes to the cytoplasm. Here, we describe the relative expression of both Skp2 and Skp2B in breast cancer cell lines and in primary breast cancers using quantitative real time RT-PCR. We show that Skp2B mRNA is expressed 10-fold less than Skp2 mRNA in the immortalized but non-transformed breast cell line, 184B5. However, Skp2B is overexpressed as frequently as Skp2, and to higher levels than Skp2 in breast cancer cell lines and primary cancers. Further, we show that cytoplasmic staining is frequent in primary breast cancers. In addition, we found that xenografts expressing Skp2B grow faster than xenografts expressing low levels of Skp2B, and that this effect is independent of p27 degradation. These findings therefore suggest that Skp2B overexpression is also observed in breast cancers and identify Skp2B as a putative oncogene.	CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA; Peter MacCallum Canc Ctr, Trescowthick Res Labs, Melbourne, Vic 3002, Australia	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Peter Maccallum Cancer Center	Germain, D (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	doris.germain@mssm.edu						Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Dowen SE, 2003, INT J CANCER, V105, P326, DOI 10.1002/ijc.11066; Drobnjak M, 2003, CLIN CANCER RES, V9, P2613; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Ganiatsas S, 2001, ONCOGENE, V20, P3641, DOI 10.1038/sj.onc.1204501; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Masuda T, 2003, CLIN CANCER RES, V9, P5693; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Penin RM, 2002, MODERN PATHOL, V15, P1227, DOI 10.1097/01.MP.0000036589.99516.D6; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Shapira M, 2004, CANCER-AM CANCER SOC, V100, P1615, DOI 10.1002/cncr.20172; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	24	74	79	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3448	3458		10.1038/sj.onc.1208328	http://dx.doi.org/10.1038/sj.onc.1208328			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15782142				2022-12-25	WOS:000229038800007
J	Premkumar, L; Sawkar, AR; Boldin-Adamsky, S; Toker, L; Silman, I; Kelly, JW; Futerman, AH; Sussman, JL				Premkumar, L; Sawkar, AR; Boldin-Adamsky, S; Toker, L; Silman, I; Kelly, JW; Futerman, AH; Sussman, JL			X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide - Implications for Gaucher disease.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL STORAGE DISORDERS; N-GLYCOSIDASE-F; CONFORMATIONAL-CHANGES; ENZYME-ACTIVITY; MUTATIONS; GLUCOCEREBROSIDASE; PEPTIDE; SITE; CRYSTALLOGRAPHY; IDENTIFICATION	Gaucher disease is an inherited metabolic disorder caused by mutations in the lysosomal enzyme acid-beta-glucosidase (GlcCerase). We recently determined the x-ray structure of GlcCerase to 2.0 angstrom resolution (Dvir, H., Harel, M., McCarthy, A. A., Toker, L., Silman, I., Futerman, A. H., and Sussman, J. L. ( 2003) EMBO Rep. 4, 704-709) and have now solved the structure of GlcCerase conjugated with an irreversible inhibitor, conduritol-B- epoxide ( CBE). The crystal structure reveals that binding of CBE to the active site does not induce a global conformational change in GlcCerase and confirms that Glu(340) is the catalytic nucleophile. However, only one of two alternative conformations of a pair of flexible loops ( residues 345-349 and 394-399) located at the entrance to the active site in native GlcCerase is observed in the GlcCerase-CBE structure, a conformation in which the active site is accessible to CBE. Analysis of the dynamics of these two alternative conformations suggests that the two loops act as a lid at the entrance to the active site. This possibility is supported by a cluster of mutations in loop 394-399 that cause Gaucher disease by reducing catalytic activity. Moreover, in silico mutational analysis demonstrates that all these mutations stabilize the conformation that limits access to the active site, thus providing a mechanistic explanation of how mutations in this loop result in Gaucher disease.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Scripps Research Institute; Scripps Research Institute	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tony.futerman@weizmann.ac.il		Sussman, Joel/0000-0003-0306-3878; Futerman, Anthony/0000-0003-0013-0115				Amaral O, 1996, HUM MUTAT, V8, P280, DOI 10.1002/(SICI)1098-1004(1996)8:3<280::AID-HUMU15>3.3.CO;2-6; Amaral O, 2000, EUR J HUM GENET, V8, P95, DOI 10.1038/sj.ejhg.5200422; BEUTLER E, 1994, HUM GENET, V93, P209; BEUTLER E, 2001, METABOLIC MOL BASES, P3635; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHU FK, 1986, J BIOL CHEM, V261, P172; DINUR T, 1986, P NATL ACAD SCI USA, V83, P1660, DOI 10.1073/pnas.83.6.1660; Fan JQ, 2003, TRENDS PHARMACOL SCI, V24, P355, DOI 10.1016/S0165-6147(03)00158-5; Futerman AH, 2004, TRENDS PHARMACOL SCI, V25, P147, DOI 10.1016/j.tips.2004.01.004; Futerman AH, 2004, NAT REV MOL CELL BIO, V5, P554, DOI 10.1038/nrm1423; GRACE ME, 1994, J BIOL CHEM, V269, P2283; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Hrmova M, 2001, STRUCTURE, V9, P1005, DOI 10.1016/S0969-2126(01)00673-6; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MEIVARLEVY I, 1994, BIOCHEM J, V303, P377, DOI 10.1042/bj3030377; MIAO SC, 1994, J BIOL CHEM, V269, P10975; Qasba PK, 2005, TRENDS BIOCHEM SCI, V30, P53, DOI 10.1016/j.tibs.2004.11.005; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Seeman PJV, 1996, NEUROLOGY, V46, P1102, DOI 10.1212/WNL.46.4.1102; Stone DL, 1999, EUR J HUM GENET, V7, P505, DOI 10.1038/sj.ejhg.5200315; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Zeev-Ben-Mordehai T, 2003, BIOPOLYMERS, V68, P395, DOI 10.1002/bip.10287	28	81	83	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23815	23819		10.1074/jbc.M502799200	http://dx.doi.org/10.1074/jbc.M502799200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15817452	hybrid, Green Submitted			2022-12-25	WOS:000229880000053
J	Bozonet, SM; Findlay, VJ; Day, AM; Cameron, J; Veal, EA; Morgan, BA				Bozonet, SM; Findlay, VJ; Day, AM; Cameron, J; Veal, EA; Morgan, BA			Oxidation of a eukaryotic 2-Cys peroxiredoxin is a molecular switch controlling the transcriptional response to increasing levels of hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; ACTIVATED MAP KINASE; CYSTEINE-SULFINIC ACID; FISSION YEAST; BUDDING YEAST; FACTOR PAP1; THIOREDOXIN PEROXIDASE; STRESS-RESPONSE; H2O2; REDUCTION	dAlthough activation of the AP-1-like transcription factor Pap1 in Schizosaccharomyces pombe is important for oxidative stress-induced gene expression, this activation is delayed at higher concentrations of peroxide. Here, we reveal that the 2-Cys peroxiredoxin ( 2-Cys Prx) Tpx1 is required for the peroxide-induced activation of Pap1. Tpx1, like other eukaryotic 2-Cys Prxs, is highly sensitive to oxidation, which inactivates its thioredoxin peroxidase activity. Our data suggest that the reduced thioredoxin peroxidase-active form of Tpx1 is required for the peroxide-induced oxidation and nuclear accumulation of Pap1. Indeed, in contrast to the previously described role for Tpx1 in the activation of the Sty1 stress-activated protein kinase by peroxide, we find that both catalytic cysteines of Tpx1 are required for Pap1 activation. Moreover, overexpression of the conserved sulfiredoxin Srx1, which interacts with and reduces Tpx1, allows rapid activation of Pap1 at higher concentrations of H2O2. Conversely, loss of Srx1 prevents the reduction of oxidized Tpx1 and prolongs the inhibition of Pap1 activation. Collectively, these data suggest that redox regulation of the thioredoxin peroxidase activity of Tpx1 acts as a molecular switch controlling the transcriptional response to H2O2. Furthermore, they reveal that a single eukaryotic 2-Cys Prx regulates peroxide signaling by multiple independent mechanisms.	Newcastle Univ, Fac Med Sci, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Veal, EA (corresponding author), Newcastle Univ, Fac Med Sci, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	e.a.veal@ncl.ac.uk; b.a.morgan@ncl.ac.uk	Bozonet, Stephanie/AAM-8574-2020	Bozonet, Stephanie/0000-0002-6375-4999; Findlay, Victoria/0000-0002-9994-6319; Veal, Elizabeth/0000-0002-1152-5473	MRC [G120/817] Funding Source: UKRI; Medical Research Council [G120/817] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		An JH, 2003, GENE DEV, V17, P1882, DOI 10.1101/gad.1107803; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Castillo EA, 2002, MOL MICROBIOL, V45, P243, DOI 10.1046/j.1365-2958.2002.03020.x; Chang TS, 2004, J BIOL CHEM, V279, P50994, DOI 10.1074/jbc.M409482200; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Desaint S, 2004, J BIOL CHEM, V279, P31157, DOI 10.1074/jbc.M401888200; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Jang HH, 2004, CELL, V117, P625, DOI 10.1016/j.cell.2004.05.002; Koo KH, 2002, ARCH BIOCHEM BIOPHYS, V397, P312, DOI 10.1006/abbi.2001.2700; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; NAKAGAWA CW, 1995, J BIOCHEM-TOKYO, V118, P109, DOI 10.1093/oxfordjournals.jbchem.a124864; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Okazaki S, 2005, ANTIOXID REDOX SIGN, V7, P327, DOI 10.1089/ars.2005.7.327; Quinn J, 2002, MOL BIOL CELL, V13, P805, DOI 10.1091/mbc.01-06-0288; Ross SJ, 2000, MOL BIOL CELL, V11, P2631, DOI 10.1091/mbc.11.8.2631; Sambrook I, 1989, MOL CLONING LAB MANU; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Veal EA, 2002, J BIOL CHEM, V277, P35523, DOI 10.1074/jbc.M111548200; Veal EA, 2004, MOL CELL, V15, P129, DOI 10.1016/j.molcel.2004.06.021; Veal EA, 2003, J BIOL CHEM, V278, P30896, DOI 10.1074/jbc.M303542200; Vivancos AP, 2004, MOL MICROBIOL, V52, P1427, DOI 10.1111/j.1365-2958.2004.04065.x; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; Wong CM, 2002, J BIOL CHEM, V277, P5385, DOI 10.1074/jbc.M106846200; Woo HA, 2005, J BIOL CHEM, V280, P3125, DOI 10.1074/jbc.C400496200; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; ZHU Y, 1994, GENE DEV, V8, P885, DOI 10.1101/gad.8.8.885	39	124	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23319	23327		10.1074/jbc.M502757200	http://dx.doi.org/10.1074/jbc.M502757200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824112	hybrid			2022-12-25	WOS:000229741800091
J	Pullmann, R; Juhaszova, M; de Silanes, IL; Kawai, T; Mazan-Mamczarz, K; Halushka, MK; Gorospe, M				Pullmann, R; Juhaszova, M; de Silanes, IL; Kawai, T; Mazan-Mamczarz, K; Halushka, MK; Gorospe, M			Enhanced proliferation of cultured human vascular smooth muscle cells linked to increased function of RNA-binding protein HuR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; GROWTH-FACTOR; GENE-EXPRESSION; GLOBAL ANALYSIS; DOWN-REGULATION; ANGIOTENSIN-II; ALPHA-ACTIN; TNF-ALPHA; CYCLIN-A; KINASE	In dividing cells, the RNA-binding protein HuR associates with and stabilizes labile mRNAs encoding proliferative proteins, events that are linked to the increased cytoplasmic presence of HuR. Here, assessment of HuR levels in various vascular pathologies (intimal hyperplasia, atherosclerosis and neointimal proliferation, sclerosis of arterialized saphenous venous graft, and fibromuscular dysplasia) revealed a distinct increase in HuR expression and cytoplasmic abundance within the intima and neointima layers. On the basis of these observations, we postulated a role for HuR in promoting the proliferation of vascular smooth muscle cells. To test this hypothesis directly, we investigated the expression, subcellular localization, and proliferative influence of HuR in human vascular smooth muscle cells (hVSMCs). Treatment of hVSMCs with platelet-derived growth factor increased HuR levels in the cytoplasm, thereby influencing the expression of metabolic, proliferative, and structural genes. Importantly, knockdown of HuR expression by using RNA interference caused a reduction of hVSMC proliferation, both basally and following platelet-derived growth factor treatment. We propose that HuR contributes to regulating hVSMC growth and homeostasis in pathologies associated with vascular smooth muscle proliferation.	NIA IRP, LCMB, NIH, Baltimore, MD 21224 USA; NIA IRP, Cardiovasc Sci Lab, NIH, Baltimore, MD 21224 USA; Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21231 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University	Gorospe, M (corresponding author), NIA IRP, LCMB, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	myriam-gorospe@nih.gov	; Lopez de Silanes, Isabel/K-4962-2015	Halushka, Marc/0000-0002-7112-7389; Kawai, Tomoko/0000-0001-8137-0334; Lopez de Silanes, Isabel/0000-0001-6762-9792	NATIONAL INSTITUTE ON AGING [Z01AG000511, ZIAAG000511] Funding Source: NIH RePORTER; NIA NIH HHS [Z01 AG000511-08] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akool ES, 2003, MOL CELL BIOL, V23, P4901, DOI 10.1128/MCB.23.14.4901-4916.2003; Atasoy U, 2003, J IMMUNOL, V171, P4369, DOI 10.4049/jimmunol.171.8.4369; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Blaschke F, 2004, CIRCULATION, V110, P579, DOI 10.1161/01.CIR.0000136999.77584.A2; BOEHM M, 2003, PROG CELL CYCLE RES, V23, P555; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Campos AH, 2003, CIRC RES, V92, P111, DOI 10.1161/01.RES.0000049100.22673.F6; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; CORJAY MH, 1989, J BIOL CHEM, V264, P10501; CORJAY MH, 1990, J CELL PHYSIOL, V145, P391, DOI 10.1002/jcp.1041450302; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Dzau VJ, 2002, NAT MED, V8, P1249, DOI 10.1038/nm1102-1249; Esnault S, 2003, J IMMUNOL, V171, P6780, DOI 10.4049/jimmunol.171.12.6780; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HOLYCROSS BJ, 1992, CIRC RES, V71, P1525, DOI 10.1161/01.RES.71.6.1525; Kawai T, 2004, MOL CELL BIOL, V24, P6773, DOI 10.1128/MCB.24.15.6773-6787.2004; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Kirigiti P, 2001, MOL PHARMACOL, V60, P1308, DOI 10.1124/mol.60.6.1308; Kloss S, 2003, J BIOL CHEM, V278, P2377, DOI 10.1074/jbc.M206453200; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Moon SK, 2003, FEBS LETT, V552, P130, DOI 10.1016/S0014-5793(03)00935-9; Nagata D, 2004, CIRCULATION, V110, P444, DOI 10.1161/01.CIR.0000136025.96811.76; Ohnaka K, 2000, HYPERTENSION, V35, P68, DOI 10.1161/01.HYP.35.1.68; PHILLIPS PD, 1984, J GERONTOL, V39, P11, DOI 10.1093/geronj/39.1.11; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Rubin LJ, 2005, J APPL PHYSIOL, V98, P296, DOI 10.1152/japplphysiol.00075.2004; Skalweit A, 2003, CIRC RES, V92, P419, DOI 10.1161/01.RES.0000059300.67152.4E; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Sukhanov S, 2003, BIOCHEM BIOPH RES CO, V306, P443, DOI 10.1016/S0006-291X(03)00990-2; van der Giessen K, 2003, J BIOL CHEM, V278, P47119, DOI 10.1074/jbc.M308889200; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2004, J BIOL CHEM, V279, P48376, DOI 10.1074/jbc.M409014200; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang WG, 2003, J BIOL CHEM, V278, P27016, DOI 10.1074/jbc.M300318200; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Zhang QJ, 2002, ARTERIOSCL THROM VAS, V22, P2030, DOI 10.1161/01.ATV.0000042206.98651.15; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	46	59	59	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22819	22826		10.1074/jbc.M501106200	http://dx.doi.org/10.1074/jbc.M501106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824116	Green Accepted, hybrid			2022-12-25	WOS:000229741800033
J	Burr, KLA; Smith, AG; Dubrova, YE				Burr, KLA; Smith, AG; Dubrova, YE			p53 deficiency does not affect mutation rate in the mouse germline	ONCOGENE			English	Article						p53; mutagenesis; mouse; germlines	HOMOLOGOUS RECOMBINATION; DNA-REPAIR; MICE; RADIATION; INSTABILITY; CELLS; HETEROZYGOSITY; FREQUENCY	Although the influence of p53 deficiency on somatic genetic stability is well established, its effect in the germline is poorly understood. Mutation rates at two expanded simple tandem repeat ( ESTR) loci were studied in the germline of nonexposed and irradiated p53-deficient mice. Spontaneous mutation rates in the homozygous and heterozygous p53-deficient males did not significantly differ from that in the isogenic wild-type mice. Acute exposure to 1 Gy of X rays resulted in a similar increase in mutation rates across males with different p53 genotypes. ESTR mutation spectra did not significantly differ across males with different p53 genotypes. Taken together, these results suggest that p53-deficiency does not affect spontaneous and radiation-induced mutation in the mouse germline.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester; University of Leicester	Dubrova, YE (corresponding author), Univ Leicester, Dept Genet, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	yed2@le.ac.uk	Dubrova, Yuri/ABA-7148-2020	Dubrova, Yuri/0000-0001-5281-7539	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barber RC, 2004, MUTAT RES-FUND MOL M, V554, P287, DOI 10.1016/j.mrfmmm.2004.05.003; Beumer TL, 1998, CELL DEATH DIFFER, V5, P669, DOI 10.1038/sj.cdd.4400396; Bishop AJR, 2003, CANCER RES, V63, P5335; BOUE A, 1985, ADV HUM GENET, V14, P1; Chang PY, 2001, MUTAGENESIS, V16, P7, DOI 10.1093/mutage/16.1.7; Chuang YYE, 1999, CANCER RES, V59, P3073; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dubrova YE, 1998, P NATL ACAD SCI USA, V95, P6251, DOI 10.1073/pnas.95.11.6251; Liang L, 2002, MUTAT RES-FUND MOL M, V502, P69, DOI 10.1016/S0027-5107(02)00029-5; Lu XB, 2003, MUTAT RES-FUND MOL M, V522, P69, DOI 10.1016/S0027-5107(02)00261-0; Morris SM, 2002, MUTAT RES-REV MUTAT, V511, P45, DOI 10.1016/S1383-5742(01)00075-8; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SEARLE AG, 1974, ADV RADIAT BIOL, V4, P131; Shao CS, 2000, P NATL ACAD SCI USA, V97, P7405, DOI 10.1073/pnas.97.13.7405; SOUTHERN EM, 1979, ANAL BIOCHEM, V100, P319, DOI 10.1016/0003-2697(79)90235-5; van Buul PPW, 2002, MUTAT RES-FUND MOL M, V508, P29, DOI 10.1016/S0027-5107(02)00137-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yatagai F, 2004, MUTAT RES-GEN TOX EN, V560, P133, DOI 10.1016/j.mrgentox.2004.02.012; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443	20	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4315	4318		10.1038/sj.onc.1208604	http://dx.doi.org/10.1038/sj.onc.1208604			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806156				2022-12-25	WOS:000229815300015
J	Chen, LL; Sabripour, M; Wu, EF; Prieto, VG; Fuller, G; Frazier, ML				Chen, LL; Sabripour, M; Wu, EF; Prieto, VG; Fuller, G; Frazier, ML			A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors	ONCOGENE			English	Article						intra-exonic pre-mRNA splicing; aberrant pre-mRNA splicing; KIT mutation; KIT; gastrointestinal stromal tumor	RECEPTOR TYROSINE KINASE; OF-FUNCTION MUTATIONS; C-KIT; MISSENSE MUTATIONS; GENE; MECHANISM; NONSENSE; AUTOINHIBITION; INHIBITION; EXPRESSION	We report a new mechanism of aberrant pre-mRNA splicing resulting in constitutive activation of a mis-spliced oncoprotein (KIT) leading to malignancy(gastrointestinal stromal tumor) in contrast to loss of function of mis-spliced proteins resulting in diverse human diseases in the literature. The mechanisms of three consecutive molecular events, deletion of noncoding and coding regions encompassing the 30 authentic splice site, creation of a novel intra-exonic pre-mRNA 30 splice acceptor site leading to in-frame loss of 27 nucleotides ( nine amino acids; Lys550-Lys558), and the mechanism of constitutive activation of the mis-spliced KIT are elucidated. Loss of a peptide in a critical location unleashed the protein from autoinhibition ( as evidenced by three-dimensional structural analysis), causing KIT to become constitutively activated and resulting in the GIST phenotype. We also demonstrated that only one of the following two exonic splicing enhancers is sufficient for inclusion of the KIT exon 11 in vivo: AACCCATGT ( nucleotides 2 - 10 from the 50 end, which are recognized by SC35, SRp55, and SF2/ASF) or GGTTGTTGAGG ( nucleotides 27 - 37 from the 50 end, which are recognized by SC35 and SRp55), suggestive of exonic enhancer redundancy.	Univ Texas, MD Anderson Canc Ctr, Dept Sarcoma, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Human & Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Chen, LL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Sarcoma, 1515 Holcombe Blvd, Houston, TX 77030 USA.	llchen@mdanderson.org	Pillay, Nischalan/F-9536-2012	Fuller, Gregory/0000-0001-9447-2647	NATIONAL CANCER INSTITUTE [R25CA057730, U01CA070172, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [U01-CA70172-01, R25 CA57730, CA16672, N0-CM-17003] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allander SV, 2001, CANCER RES, V61, P8624; Aznarez I, 2003, HUM MOL GENET, V12, P2031, DOI 10.1093/hmg/ddg215; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Buratti E, 2003, TRENDS MOL MED, V9, P229, DOI 10.1016/S1471-4914(03)00072-8; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Chang PM, 2003, MOL CELL BIOL, V23, P3067, DOI 10.1128/MCB.23.9.3067-3078.2003; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; Colapietro P, 2003, HUM GENET, V113, P551, DOI 10.1007/s00439-003-1009-2; Corless CL, 2004, J MOL DIAGN, V6, P366, DOI 10.1016/S1525-1578(10)60533-8; CROSIER PS, 1993, BLOOD, V82, P1151; Di Blasi C, 2001, BRAIN, V124, P698, DOI 10.1093/brain/124.4.698; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; Gorlov IP, 2003, AM J HUM GENET, V73, P1157, DOI 10.1086/378819; Graveley BR, 2002, CELL, V109, P409, DOI 10.1016/S0092-8674(02)00750-X; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Harland M, 2001, HUM MOL GENET, V10, P2679, DOI 10.1093/hmg/10.23.2679; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Isozaki K, 2000, AM J PATHOL, V157, P1581, DOI 10.1016/S0002-9440(10)64795-5; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kinoshita K, 2003, J GASTROEN HEPATOL, V18, P147, DOI 10.1046/j.1440-1746.2003.02911.x; Koh JS, 2004, HISTOL HISTOPATHOL, V19, P565, DOI 10.14670/HH-19.565; Ladd AN, 2002, GENOME BIOL, V3; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Namour F, 2003, BRIT J HAEMATOL, V123, P915, DOI 10.1046/j.1365-2141.2003.04685.x; NELSON KK, 1990, P NATL ACAD SCI USA, V87, P6253, DOI 10.1073/pnas.87.16.6253; Pagani F, 2002, NAT GENET, V30, P426, DOI 10.1038/ng858; Pagani F, 2004, NAT REV GENET, V5, P389, DOI 10.1038/nrg1327; Roca X, 2003, NUCLEIC ACIDS RES, V31, P6321, DOI 10.1093/nar/gkg830; Sandberg AA, 2002, CANCER GENET CYTOGEN, V135, P1, DOI 10.1016/S0165-4608(02)00546-0; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; Syrris P, 2002, HUM MUTAT, V20, DOI 10.1002/humu.9057; Taniguchi M, 1999, CANCER RES, V59, P4297; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; ZHU WM, 1994, LEUKEMIA LYMPHOMA, V12, P441, DOI 10.3109/10428199409073786	43	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4271	4280		10.1038/sj.onc.1208587	http://dx.doi.org/10.1038/sj.onc.1208587			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15824741				2022-12-25	WOS:000229815300010
J	Camandola, S; Cutler, RG; Gary, DS; Milhavet, O; Mattson, MP				Camandola, S; Cutler, RG; Gary, DS; Milhavet, O; Mattson, MP			Suppression of calcium release from inositol 1,4,5-trisphosphate-sensitive stores mediates the anti-apoptotic function of nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INTRACELLULAR CA2+ STORES; ENDOPLASMIC-RETICULUM; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; BCL-2 EXPRESSION; IP3 RECEPTOR; CELL-DEATH; NEURODEGENERATIVE DISORDERS; PRESENILIN-1 MUTATIONS	The activation of the transcription factor nuclear factor-kappa B (NF-kappa B) by growth factors, cytokines, and cellular stress can prevent apoptosis, but the underlying mechanism is unknown. Here we provide evidence for an action of NF-kappa B on calcium signaling that accounts for its anti-apoptotic function. Embryonic fibroblasts lacking the transactivating subunit of NF-kappa B RelA (p65) exhibit enhanced inositol 1,4,5- trisphosphate (IP3) receptor-mediated calcium release and increased sensitivity to apoptosis, which are restored upon re-expression of RelA. The size of the endoplasmic reticulum (ER) calcium pool and the number of IP3 receptors per cell are decreased in response to stimuli that activate NF-kappa B and are increased when NF-kappa B activity is suppressed. The selective antagonism of IP3 receptors blocks apoptosis in RelA-deficient cells, whereas activation of NF-kappa B in normal cells leads to decreased levels of the type 1 IP3 receptor and decreased calcium release. Overexpression of Bcl-2 normalizes ER calcium homeostasis and prevents calcium-mediated apoptosis in RelA-deficient cells. These findings establish an ER calcium channel as a pivotal target for NF-kappa B-mediated cell survival signaling.	NIA, Neurosci Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University	Camandola, S (corresponding author), NIA, Neurosci Lab, Gerontol Res Ctr, GRC 4F01,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	camandolasi@grc.nia.nih.gov	Mattson, Mark P/F-6038-2012; Cutler, Roy G./L-5572-2013	Milhavet, Ollivier/0000-0001-6236-0499	NATIONAL INSTITUTE ON AGING [ZIAAG000314, Z01AG000314, ZIAAG000313, Z01AG000313] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AnandApte B, 1997, STEM CELLS, V15, P259, DOI 10.1002/stem.150259; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERRIDGE MJ, 1985, J CELL SCI, P187; BYRON KL, 1992, J BIOL CHEM, V267, P108; Camandola S, 2000, J NEUROSCI RES, V61, P134, DOI 10.1002/1097-4547(20000715)61:2<134::AID-JNR3>3.0.CO;2-P; Camandola S, 2000, MOL BRAIN RES, V85, P53, DOI 10.1016/S0169-328X(00)00234-5; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Cutler RG, 2002, ANN NEUROL, V52, P448, DOI 10.1002/ana.10312; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Diaz F, 2000, CELL CALCIUM, V27, P315, DOI 10.1054/ceca.2000.0126; Esser MT, 1998, J EXP MED, V187, P1057, DOI 10.1084/jem.187.7.1057; Fisher TE, 2001, PROG BIOPHYS MOL BIO, V77, P269, DOI 10.1016/S0079-6107(01)00017-7; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; Glazner GW, 2001, J BIOL CHEM, V276, P22461, DOI 10.1074/jbc.M101315200; GONZALEZ FA, 1989, P NATL ACAD SCI USA, V86, P4530, DOI 10.1073/pnas.86.12.4530; Granville DJ, 2001, CELL CALCIUM, V30, P343, DOI 10.1054/ceca.2001.0243; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Guo Q, 1999, J NEUROSCI RES, V56, P457, DOI 10.1002/(SICI)1097-4547(19990601)56:5<457::AID-JNR2>3.0.CO;2-P; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; Hogan B, 1994, MANIPULATING MOUSE E; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; Kass GEN, 1999, ENVIRON HEALTH PERSP, V107, P25, DOI 10.2307/3434469; Kim BC, 2002, J BIOL CHEM, V277, P31381, DOI 10.1074/jbc.M203465200; Kirkwood KL, 1997, J BIOL CHEM, V272, P22425, DOI 10.1074/jbc.272.36.22425; Kobrinsky E, 1999, AM J PHYSIOL-CELL PH, V277, pC665, DOI 10.1152/ajpcell.1999.277.4.C665; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kumasaka S, 1999, ANTIOXID REDOX SIGN, V1, P55, DOI 10.1089/ars.1999.1.1-55; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Magnusson C, 1999, IMMUNOL CELL BIOL, V77, P41, DOI 10.1046/j.1440-1711.1999.00800.x; MARKS AR, 1997, AM J PHYSIOL, V272, pH587; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Mattson MP, 2001, BIOESSAYS, V23, P733, DOI 10.1002/bies.1103; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; METCALFE JC, 1986, BRIT MED BULL, V42, P405, DOI 10.1093/oxfordjournals.bmb.a072159; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pollock J, 2002, NEUROPHARMACOLOGY, V42, P93, DOI 10.1016/S0028-3908(01)00163-0; Reyes M, 1996, J NEUROSCI, V16, P5951; Rosemblit N, 1999, DEV BIOL, V206, P163, DOI 10.1006/dbio.1998.9120; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; VAN AD, 1996, SCIENCE, V274, P787; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yoshiyama Y, 2001, NEUROREPORT, V12, P2641, DOI 10.1097/00001756-200108280-00011; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999; ZACCHETTI D, 1991, J BIOL CHEM, V266, P20152; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200	71	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22287	22296		10.1074/jbc.M410923200	http://dx.doi.org/10.1074/jbc.M410923200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15814613	hybrid			2022-12-25	WOS:000229557900074
J	Iordanidou, P; Aggelidou, E; Demetriades, C; Hadzopoulou-Cladaras, M				Iordanidou, P; Aggelidou, E; Demetriades, C; Hadzopoulou-Cladaras, M			Distinct amino acid residues may be involved in coactivator and ligand interactions in hepatocyte nuclear factor-4 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATOR; CRYSTAL-STRUCTURE; HORMONE RECEPTOR; GENE-EXPRESSION; BINDING DOMAIN; NATURAL LIGAND; PGC-1; HNF-4-ALPHA; HNF4-ALPHA; MODULATION	Hepatocyte nuclear factor-4 (HNF-4) is a transcription factor of the nuclear hormone receptor superfamily that is constitutively active without the addition of exogenous ligand. Crystallographic analysis of the HNF-4 alpha and HNF-4 gamma ligand binding domains (LBDs) demonstrated the presence of endogenous ligands that may act as structural cofactors for HNF-4. It was also proposed by crystallographic studies that a combination of ligand and coactivator might be required to lock the receptor in its active state. We previously showed that mutations in amino acid residues Ser-181 and Met-182 in H3, Leu-219 and Leu-220 and Arg-226 in H5, Ileu-338 in H10, and Ileu-346 in H11, which line the LBD pocket in HNF-4 alpha and come in contact with the ligand, impair its transactivation potential. In the present study, physical and functional interaction assays were utilized with two different coactivators, PGC-1 and SRC-3, to address the role of coactivators in HNF-4 function. We show that the integrity of the hinge (D) domain of HNF-4 alpha and the activation function (AF)-2 activation domain region are critical for coactivation. Surprisingly, a different mode of coactivation is observed among the LBD point mutants that lack transcriptional activity. In particular, coactivation is maintained in mutants Ser-181, Arg-226, and Ile-346 but is abolished in mutants Met-182, Leu-219, and Ile-338. Physical interactions confirm this pattern of activation, implying that distinct amino acid residues may be involved in coactivator and ligand interactions, although some residues may be critical for both functions. Our results provide evidence and expand predictions based on the crystallographic data as to the role of coactivators in HNF-4 alpha constitutive transcriptional activity.	Aristotle Univ Thessaloniki, Dev Biol Lab, Dept Genet Dev & Mol Biol, Thessaloniki 54124, Greece	Aristotle University of Thessaloniki	Hadzopoulou-Cladaras, M (corresponding author), Aristotle Univ Thessaloniki, Dev Biol Lab, Dept Genet Dev & Mol Biol, Thessaloniki 54124, Greece.	cladaras@bio.auth.gr	Aggelidou, Eleni/GQZ-2215-2022; Demetriades, Constantinos/AAD-3600-2021; Demetriades, Constantinos/E-7444-2015	Demetriades, Constantinos/0000-0001-7813-7726; Demetriades, Constantinos/0000-0001-7813-7726				Aggelidou E, 2004, J BIOL CHEM, V279, P30680, DOI 10.1074/jbc.M401120200; [Anonymous], 2001, NUCL RECEPTORS GENET; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100; Delerive P, 2002, J BIOL CHEM, V277, P3913, DOI 10.1074/jbc.M109409200; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Duda K, 2004, J BIOL CHEM, V279, P23311, DOI 10.1074/jbc.M400864200; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; HADZOPOULOUCLADARA, 1993, BIOCHEMISTRY-US, V32, P9657; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Li JX, 2000, GENE DEV, V14, P464; OGAMI K, 1990, J BIOL CHEM, V265, P9808; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	28	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21810	21819		10.1074/jbc.M501221200	http://dx.doi.org/10.1074/jbc.M501221200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15826954	hybrid			2022-12-25	WOS:000229557900020
J	Strassmaier, T; Bond, CT; Sailer, CA; Knaus, HG; Maylie, J; Adelman, JP				Strassmaier, T; Bond, CT; Sailer, CA; Knaus, HG; Maylie, J; Adelman, JP			A novel isoform of SK2 assembles with other SK subunits in mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNELS; ACTIVATED POTASSIUM CHANNELS; SMALL-CONDUCTANCE; EXPRESSION; AFTERHYPERPOLARIZATION; CALMODULIN; CURRENTS; NEURONS; APAMIN; SYSTEM	The SK2 subtype of small conductance Ca2+-activated K+ channels is widely distributed throughout the central nervous system and modulates neuronal excitability by contributing to the afterhyperpolarization that follows an action potential. Western blots of brain membrane proteins prepared from wild type and SK2-null mice reveal two isoforms of SK2, a 49-kDa band corresponding to the previously reported SK2 protein (SK2-S) and a novel 78-kDa form. Complementary DNA clones from brain and Western blots probed with an antibody specific for the longer form, SK2-L, identified the larger molecular weight isoform as an N-terminally extended SK2 protein. The N-terminal extension of SK2-L is cysteinerich and mediates disulfide bond formation between SK2-L subunits or with heterologous proteins. Immunohistochemistry revealed that in brain SK2-L and SK2-S are expressed in similar but not identical patterns. Heterologous expression of SK2-L results in functional homomeric channels with Ca2+ sensitivity similar to that of SK2-S, consistent with their shared core and intracellular C-terminal domains. In contrast to the diffuse, uniform surface distribution of SK2-S, SK2-L channels cluster into sharply defined, distinct puncta suggesting that the extended cysteine-rich N-terminal domain mediates this process. Immunoprecipitations from transfected cells and mouse brain demonstrate that SK2-L co-assembles with the other SK subunits. Taken together, the results show that the SK2 gene encodes two subunit proteins and suggest that native SK2-L subunits may preferentially partition into heteromeric channel complexes with other SK subunits.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97239 USA; Univ Innsbruck, Inst Biochem Pharmacol, A-6020 Innsbruck, Austria	Oregon Health & Science University; Oregon Health & Science University; University of Innsbruck	Adelman, JP (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	adelman@ohsu.edu						ABACIOGLU YH, 1994, AIDS RES HUM RETROV, V10, P371, DOI 10.1089/aid.1994.10.371; Benton DCH, 2003, J PHYSIOL-LONDON, V553, P13, DOI 10.1113/jphysiol.2003.054551; Bildl W, 2004, NEURON, V43, P847, DOI 10.1016/j.neuron.2004.08.033; Bond CT, 2000, SCIENCE, V289, P1942, DOI 10.1126/science.289.5486.1942; Bond CT, 2004, J NEUROSCI, V24, P5301, DOI 10.1523/JNEUROSCI.0182-04.2004; Bond CT, 1999, ANN NY ACAD SCI, V868, P370, DOI 10.1111/j.1749-6632.1999.tb11298.x; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jager H, 2000, FEBS LETT, V469, P196, DOI 10.1016/S0014-5793(00)01236-9; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Kramar EA, 2004, J NEUROSCI, V24, P5151, DOI 10.1523/JNEUROSCI.0800-04.2004; Lee WS, 2003, J BIOL CHEM, V278, P25940, DOI 10.1074/jbc.M302091200; Maylie J, 2004, J PHYSIOL-LONDON, V554, P255, DOI 10.1113/jphysiol.2003.049072; Monaghan AS, 2004, J BIOL CHEM, V279, P1003, DOI 10.1074/jbc.M308070200; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; SAH P, 1991, NEURON, V7, P257, DOI 10.1016/0896-6273(91)90264-Z; Sailer CA, 2004, MOL CELL NEUROSCI, V26, P458, DOI 10.1016/j.mcn.2004.03.002; Sailer CA, 2002, J NEUROSCI, V22, P9698; Stackman RW, 2002, J NEUROSCI, V22, P10163; Stocker M, 1999, P NATL ACAD SCI USA, V96, P4662, DOI 10.1073/pnas.96.8.4662; Stocker M, 2000, MOL CELL NEUROSCI, V15, P476, DOI 10.1006/mcne.2000.0842; ZHANG L, 1995, J PHYSIOL-LONDON, V488, P661, DOI 10.1113/jphysiol.1995.sp020998	24	63	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21231	21236		10.1074/jbc.M413125200	http://dx.doi.org/10.1074/jbc.M413125200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797870	hybrid			2022-12-25	WOS:000229438800041
J	Hansen, IA; Attardo, GM; Roy, SG; Raikhel, AS				Hansen, IA; Attardo, GM; Roy, SG; Raikhel, AS			Target of rapamycin-dependent activation of S6 kinase is a central step in the transduction of nutritional signals during egg development in a mosquito	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA FAT-BODY; AEDES-AEGYPTI; VITELLOGENIN SYNTHESIS; MAMMALIAN TARGET; CELLULAR GROWTH; PROTEIN; GENE; EXPRESSION; ECDYSONE; TRANSLATION	Female mosquitoes are effective disease vectors, because they take blood from vertebrate hosts to obtain nutrients for egg development. Amino acid signaling via the target of rapamycin ( TOR) pathway has been identified as a key requirement for the activation of egg development after a blood meal. We report the characterization of the TOR kinase and one of its major downstream targets, S6 kinase, of the yellow fever mosquito Aedes aegypti during egg development in adult females. Both TOR and S6K mRNA are expressed at high levels in the ovaries and in lower levels in fat body and other tissues. After a blood meal, the subcellular localization of TOR shifts from the cytoplasm to the plasma membrane of fat body cells. By detecting phosphothreonine 388 of mosquito S6 kinase, we show that TOR activity strongly increases in fat body and ovaries after a blood meal in vivo. Furthermore, phosphorylation of S6 kinase increases in in vitro cultured fat bodies after stimulation with amino acids. This increase is sensitive to the TOR inhibitor rapamycin in a concentration-dependent manner but not to the phosphatidylinositol 3-kinase/phosphatidylinositol 3-kinase-related kinase inhibitor LY294002, the MAPK inhibitor PD98059, or the translational inhibitor cycloheximide. RNA interference-mediated reduction of S6 kinase strongly inhibits the amino acid-induced up-regulation of the major yolk protein vitellogenin in vitro and effectively disrupts egg development after a blood meal in vivo. Our data show that TOR-dependent activation of S6 kinase is a central step in the transduction of nutritional information during egg development in mosquitoes.	Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA; Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Raikhel, AS (corresponding author), Univ Calif Riverside, Dept Entomol, 3401 Watkins Dr, Riverside, CA 92521 USA.	raikhel@ucr.edu	Attardo, Geoffrey Michael/I-3320-2019	Attardo, Geoffrey Michael/0000-0001-6265-2969	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024716] Funding Source: NIH RePORTER; NIAID NIH HHS [5 R37 AI024716, R01 AI024716] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Clements AN., 1992, BIOL MOSQUITOES DEV; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; FALLON AM, 1974, J INSECT PHYSIOL, V20, P1815, DOI 10.1016/0022-1910(74)90211-X; Hansen IA, 2004, P NATL ACAD SCI USA, V101, P10626, DOI 10.1073/pnas.0403460101; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; Hennig KM, 2002, GENESIS, V34, P107, DOI 10.1002/gene.10139; HOTCHKIN PG, 1987, BIOCHIM BIOPHYS ACTA, V924, P352, DOI 10.1016/0304-4165(87)90033-X; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kokoza VA, 2001, GENE, V274, P47, DOI 10.1016/S0378-1119(01)00602-3; Martin D, 2001, MOL CELL BIOL, V21, P164, DOI 10.1128/MCB.21.1.164-174.2001; Martin D, 2001, MOL CELL ENDOCRINOL, V173, P75, DOI 10.1016/S0303-7207(00)00413-5; Menand B, 2002, P NATL ACAD SCI USA, V99, P6422, DOI 10.1073/pnas.092141899; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Pierceall WE, 1999, MOL CELL ENDOCRINOL, V150, P73, DOI 10.1016/S0303-7207(99)00022-2; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Raikhel A. S., 1997, The molecular biology of insect disease vectors: a methods manual., P507; RAIKHEL AS, 1983, TISSUE CELL, V15, P281, DOI 10.1016/0040-8166(83)90023-X; RAIKHEL AS, 1992, ANNU REV ENTOMOL, V37, P217, DOI 10.1146/annurev.en.37.010192.001245; Rusten TE, 2004, DEV CELL, V7, P179, DOI 10.1016/j.devcel.2004.07.005; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Sun GQ, 2004, MOL CELL ENDOCRINOL, V218, P95, DOI 10.1016/j.mce.2003.12.014; Thomas G., 2004, TOR TARGET RAPAMYCIN; Uchida K, 2003, J MED ENTOMOL, V40, P441, DOI 10.1603/0022-2585-40.4.441; Withers DJ, 1997, BIOCHEM BIOPH RES CO, V241, P704, DOI 10.1006/bbrc.1997.7878; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	35	116	119	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20565	20572		10.1074/jbc.M500712200	http://dx.doi.org/10.1074/jbc.M500712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788394	hybrid			2022-12-25	WOS:000229242000051
J	Kim, HS; Skurk, C; Maatz, H; Shiojima, I; Ivashchenko, Y; Yoon, SW; Park, YB; Walsh, K				Kim, HS; Skurk, C; Maatz, H; Shiojima, I; Ivashchenko, Y; Yoon, SW; Park, YB; Walsh, K			Akt/FOXO3a signaling modulates the endothelial stress response through regulation of heat shock protein 70 expression	FASEB JOURNAL			English	Article						endothelial cells; apoptosis	TRANSCRIPTION FACTOR FOXO3A; ACTIVATED PROTEIN-KINASE; HEAT-SHOCK; CELL-SURVIVAL; AKT; ANGIOGENESIS; PHOSPHORYLATION; APOPTOSIS; FKHR-L1	To identify new antiapoptotic targets of the PI3K-Akt signaling pathway in endothelial cells, adenovirus-mediated Akt1 gene transfer and oligonucleotide microarrays were used to examine Akt-regulated transcripts. DNA microarray analysis revealed that HSP70 expression underwent the greatest fold activation of 12,532 transcripts examined in human umbilical vein endothelial cells (HUVEC) transduced with constitutively active Akt1. Akt1 gene transfer increased HSP70 transcript expression by 24.8-fold as determined by quantitative PCR and promoted a dose-dependent up-regulation of HSP70 protein as determined by Western immunoblot analysis. Gene transfer of FOXO3a, a downstream target of Akt in endothelial cells, significantly suppressed both basal and stress-induced HSP70 protein expression. FOX03a induced caspase-9-dependent apoptosis in HUVEC, and cotransduction with Ad-HSP70 rescued endothelial cells from FOXO3a-induced apoptosis under basal and stress conditions. Our results identify HSP70 as a new antiapoptotic target of Akt-FOXO3a signaling in endothelial cells that controls viability through modulation of the stress-induced intrinsic cell death pathway.	Boston Univ, Sch Med, Mol Cardiol Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea; AVENTIS Pharma, Cardiovasc Dis Grp, Frankfurt, Germany	Boston University; Seoul National University (SNU); Sanofi-Aventis	Walsh, K (corresponding author), Boston Univ, Sch Med, Mol Cardiol Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.	kxwalsh@bu.edu	Kim, Hyo Soo/J-2753-2012	Youn, Seock-Won/0000-0003-3275-2170	NIAMS NIH HHS [AR40197] Funding Source: Medline; NIA NIH HHS [AG17241, AG15052] Funding Source: Medline; NICHD NIH HHS [HD23681] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017241, R37AG015052, R01AG015052] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abid R, 2004, ARTERIOSCL THROM VAS, V24, P294, DOI 10.1161/01.ATV.0000110502.10593.06; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bijur GN, 2000, J NEUROCHEM, V75, P2401, DOI 10.1046/j.1471-4159.2000.0752401.x; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Esposito F, 2003, J BIOL CHEM, V278, P20828, DOI 10.1074/jbc.M211841200; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nollen EAA, 2002, J CELL SCI, V115, P2809; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Semenza GL, 2000, GENE DEV, V14, P1983; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200	33	48	52	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					1042	+		10.1096/fj.04-2841fje	http://dx.doi.org/10.1096/fj.04-2841fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15784720				2022-12-25	WOS:000227901300008
J	Fernandes, AP; Fladvad, M; Berndt, C; Andresen, C; Lillig, CH; Neubauer, P; Sunnerhagen, M; Holmgren, A; Vlamis-Gardikas, A				Fernandes, AP; Fladvad, M; Berndt, C; Andresen, C; Lillig, CH; Neubauer, P; Sunnerhagen, M; Holmgren, A; Vlamis-Gardikas, A			A novel monothiol glutaredoxin (Grx4) from Escherichia coli can serve as a substrate for thioredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-DEPENDENT SYNTHESIS; SENSITIVE SANDWICH ELISA; MIXED DISULFIDE; HYDROGEN DONOR; GROWTH-PHASE; ENZYMATIC MECHANISM; HOMOLOGY DOMAIN; NMR STRUCTURE; NULL MUTANTS; HUMAN SERUM	Glutaredoxins are ubiquitous proteins that catalyze the reduction of disulfides via reduced glutathione ( GSH). Escherichia coli has three glutaredoxins ( Grx1, Grx2, and Grx3), all containing the classic dithiol active site CPYC. We report the cloning, expression, and characterization of a novel monothiol E. coli glutaredoxin, which we name glutaredoxin 4 ( Grx4). The protein consists of 115 amino acids ( 12.7 kDa), has a monothiol ( CGFS) potential active site and shows high sequence homology to the other monothiol glutaredoxins and especially to yeast Grx5. Experiments with gene knock-out techniques showed that the reading frame encoding Grx4 was essential. Grx4 was inactive as a GSH-disulfide oxidoreductase in a standard glutaredoxin assay with GSH and hydroxyethyl disulfide in a complete system with NADPH and glutathione reductase. An engineered CGFC active site mutant did not gain activity either. Grx4 in reduced form contained three thiols, and treatment with oxidized GSH resulted in glutathionylation and formation of a disulfide. Remarkably, this disulfide of Grx4 was a direct substrate for NADPH and E. coli thioredoxin reductase, whereas the mixed disulfide was reduced by Grx1. Reduced Grx4 showed the potential to transfer electrons to oxidized E. coli Grx1 and Grx3. Grx4 is highly abundant ( 750 - 2000 ng/mg of total soluble protein), as determined by a specific enzyme-link immunosorbent assay, and most likely regulated by guanosine 3',5'-tetraphosphate upon entry to stationary phase. Grx4 was highly elevated upon iron depletion, suggesting an iron-related function for the protein.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden; Linkoping Univ, Dept Phys & Measurement Technol, S-58183 Linkoping, Sweden; Univ Oulu, Dept Proc & Environm Engn, Bioproc Engn Lab, FIN-90014 Oulu, Finland; Univ Oulu, Dept Proc & Environm Engn, Bioctr, FIN-90014 Oulu, Finland	Karolinska Institutet; Linkoping University; University of Oulu; University of Oulu	Vlamis-Gardikas, A (corresponding author), Acad Athens, Fdn Biomed Res, Soranou Efessiou 4, GR-11527 Athens, Greece.	alexios.vlamis@mbb.ki.se	Berndt, Carsten/X-6260-2018; Lillig, Christopher Horst/AAD-7098-2019; Neubauer, Peter/W-4518-2019; Neubauer, Peter/N-8146-2013; Vlamis, Alexios/AAF-5152-2020; Fernandes, Aristi/D-2507-2015	Berndt, Carsten/0000-0001-8583-7966; Lillig, Christopher Horst/0000-0003-2509-5117; Neubauer, Peter/0000-0002-1214-9713; Vlamis, Alexios/0000-0001-5068-6459; Fernandes, Aristi/0000-0002-4145-0222				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Aslund F, 1996, J BIOL CHEM, V271, P6736, DOI 10.1074/jbc.271.12.6736; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Belli G, 2002, J BIOL CHEM, V277, P37590, DOI 10.1074/jbc.M201688200; Bjornberg O, 1991, Protein Expr Purif, V2, P287, DOI 10.1016/1046-5928(91)90085-W; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun V, 2003, FRONT BIOSCI-LANDMRK, V8, pS1409, DOI 10.2741/1232; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Das KC, 1998, J IMMUNOL METHODS, V211, P9, DOI 10.1016/S0022-1759(97)00163-4; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Farewell A, 1996, J BACTERIOL, V178, P6443, DOI 10.1128/jb.178.22.6443-6450.1996; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Fladvad M, 2005, J BIOL CHEM, V280, P24553, DOI 10.1074/jbc.M500679200; Gerdes SY, 2003, J BACTERIOL, V185, P5673, DOI 10.1128/JB.185.19.5673-5684.2003; Greenfield NJ, 2004, METHOD ENZYMOL, V383, P282; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HENGGEARONIS R, 1996, ESCHERICHIA COLI SAL, V2, P1497; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200; Krauth-Siegel RL, 2002, METHOD ENZYMOL, V347, P259; KULAKAUSKAS S, 1991, J BACTERIOL, V173, P2633, DOI 10.1128/jb.173.8.2633-2638.1991; Kvint K, 2000, J BIOL CHEM, V275, P14795, DOI 10.1074/jbc.C000128200; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Lim CJ, 2000, BBA-GENE STRUCT EXPR, V1491, P1, DOI 10.1016/S0167-4781(00)00026-9; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MILLER HJ, 1992, SHORT COURSE BACTERI; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; Newton GL, 2002, ARCH MICROBIOL, V178, P388, DOI 10.1007/s00203-002-0469-4; NOE G, 1992, BRIT J HAEMATOL, V80, P285; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; Potamitou A, 2002, J BIOL CHEM, V277, P18561, DOI 10.1074/jbc.M201225200; Potamitou A, 2002, J BIOL CHEM, V277, P17775, DOI 10.1074/jbc.M201306200; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; Rahlfs S, 2001, J BIOL CHEM, V276, P37133, DOI 10.1074/jbc.M105524200; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; SODANO P, 1991, J MOL BIOL, V221, P1311; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Tamarit J, 2003, J BIOL CHEM, V278, P25745, DOI 10.1074/jbc.M303477200; Teich A, 1999, BIOTECHNOL PROGR, V15, P123, DOI 10.1021/bp980102h; Vlamis-Gardikas A, 2002, J BIOL CHEM, V277, P10861, DOI 10.1074/jbc.M111024200; Vlamis-Gardikas A, 2002, METHOD ENZYMOL, V347, P286; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; Walker J, 1997, INT J PARASITOL, V27, P883, DOI 10.1016/S0020-7519(97)00039-8; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902; Xia B, 2001, J MOL BIOL, V310, P907, DOI 10.1006/jmbi.2001.4721; XIA TH, 1992, PROTEIN SCI, V1, P310	59	113	119	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24544	24552		10.1074/jbc.M500678200	http://dx.doi.org/10.1074/jbc.M500678200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15833738	hybrid			2022-12-25	WOS:000230114000032
J	Ishino, T; Urbina, C; Bhattacharya, M; Panarello, D; Chaiken, I				Ishino, T; Urbina, C; Bhattacharya, M; Panarello, D; Chaiken, I			Receptor epitope usage by an interleukin-5 mimetic peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GM-CSF; MACROMOLECULAR INTERACTIONS; BETA-SUBUNIT; ALPHA-CHAIN; BINDING; EXPRESSION; REVEALS; IL-5; IDENTIFICATION	The cyclic peptide AF17121 is a library-derived antagonist for human interleukin-5 (IL5) receptor alpha (IL5R alpha) and inhibits IL5 activity. Our previous results have demonstrated that the sixth arginine residue of the peptide is crucial for the inhibitory effect and that several acidic residues in the N- and C-terminal regions also make a contribution, although to a lesser extent (Ruchala, P., Varadi, G., Ishino, T., Scibek, J., Bhattacharya, M., Urbina, C., Van Ryk, D., Uings, I., and Chaiken, I. ( 2004) Biopolymers 73, 556-568). However, the recognition mechanism of the receptor has remained unresolved. In this study, AF17121 was fused to thioredoxin by recombinant DNA techniques and examined for IL5R alpha interaction using a surface plasmon resonance biosensor method. Kinetic analysis revealed that the dissociation rate of the peptide (.) receptor complex is comparable with that of the cytokine (.) receptor complex. The fusion peptide competed with IL5 for both biological function and interaction with IL5R alpha, indicating that the binding sites on the receptor are shared by AF17121 and IL5. To define the epitope residues for AF17121, we defined its binding footprint on IL5R alpha by alanine substitution of Asp(55), Asp(56), Glu(58), Lys(186), Arg(188), and Arg(297) of the receptor. Marked effects on the interaction were observed in all three fibronectin type III domains of IL5R alpha, in particular Asp(55), Arg(188), and Arg(297) in the D1, D2, and D3 domains, respectively. This footprint represents a significant subset of that for IL5 binding. The fact that AF17121 mimics the receptor binding capability of IL5 but antagonizes biological function evokes several models for how IL5 induces activation of the multisubunit receptor system.	Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA; Drexel Univ, Coll Med, AJ Drexel Inst Basic & Appl Prot Sci, Philadelphia, PA 19102 USA	Drexel University; Drexel University	Chaiken, I (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 11102 New Coll Bldg,245 N 15th St, Philadelphia, PA 19102 USA.	imc23@drexel.edu		Bhattacharya, Madhushree/0000-0001-8549-7092	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055648] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40462] Funding Source: Medline; NIGMS NIH HHS [GM55648] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGLEY CJ, 1999, IL 5 MOL DRUG TARGET, P189; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Chung KF, 2002, THORAX, V57, P751, DOI 10.1136/thorax.57.8.751; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; Elkins PA, 2000, NAT STRUCT BIOL, V7, P808, DOI 10.1038/79047; England BP, 2000, P NATL ACAD SCI USA, V97, P6862, DOI 10.1073/pnas.110053997; FATTAH D, 1990, Cytokine, V2, P112, DOI 10.1016/1043-4666(90)90005-E; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; HITOSHI Y, 1991, INT IMMUNOL, V3, P135, DOI 10.1093/intimm/3.2.135; Ishino T, 2004, J BIOL CHEM, V279, P9547, DOI 10.1074/jbc.M309327200; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; LYNE PD, 1995, PROTEIN SCI, V4, P2223, DOI 10.1002/pro.5560041027; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MORTON T, 1995, P NATL ACAD SCI USA, V92, P10879, DOI 10.1073/pnas.92.24.10879; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Murphy JM, 2003, J BIOL CHEM, V278, P10572, DOI 10.1074/jbc.M211664200; Myszka DG, 2000, METHOD ENZYMOL, V323, P325; Nakamura Y, 2000, NUCLEIC ACIDS RES, V28, P292, DOI 10.1093/nar/28.1.292; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; Plugariu CG, 2000, BIOCHEMISTRY-US, V39, P14939, DOI 10.1021/bi001467p; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Ruchala P, 2004, BIOPOLYMERS, V73, P556, DOI 10.1002/bip.20001; Sanderson C J, 2000, Curr Opin Investig Drugs, V1, P435; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Scibek JJ, 2002, ANAL BIOCHEM, V307, P258, DOI 10.1016/S0003-2697(02)00043-X; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Tavernier J, 2000, BLOOD, V95, P1600, DOI 10.1182/blood.V95.5.1600.005k22_1600_1607; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wu SJ, 2000, J BIOL CHEM, V275, P7351, DOI 10.1074/jbc.275.10.7351	40	10	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22951	22961		10.1074/jbc.M502341200	http://dx.doi.org/10.1074/jbc.M502341200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15826943	hybrid			2022-12-25	WOS:000229741800049
J	Jain, M; Evans, MS; King, J; Clark, PL				Jain, M; Evans, MS; King, J; Clark, PL			Monoclonal antibody epitope mapping describes tailspike beta-helix folding and aggregation intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAIL SPIKE ENDORHAMNOSIDASE; P22 TAILSPIKE; PHAGE-P22 TAILSPIKE; IN-VITRO; MOLECULAR CHAPERONES; CRYSTAL-STRUCTURE; MUTANT PROTEINS; ANTIGEN COMPLEX; AMINO-ACID; PATHWAY	There is growing interest in understanding how the cellular environment affects protein folding mechanisms, but most spectroscopic methods for monitoring folding in vitro are unsuitable for experiments in vivo or in other complex mixtures. Monoclonal antibody binding represents a sensitive structural probe that can be detected against the background of other cellular components. A panel of antibodies has been raised against Salmonella typhimurium phage P22 tailspike. In this report, nine alpha-tailspike antibody binding epitopes were characterized by measuring the binding of these monoclonal antibodies to tailspike variants bearing surface point mutations. These results reveal that the antibody epitopes are distributed throughout the tailspike structure, with several clustered in the central parallel beta-helix domain. The ability of each antibody to distinguish between tailspike conformational states was assessed by measuring antibody binding to tailspike in vitro refolding intermediates. Interestingly, the binding of all but one of the nine antibodies is sensitive to the tailspike conformational state. Whereas several antibodies bind preferentially to the tailspike native structure, the structural features that comprise the binding epitopes form with different rates. In addition, two antibodies preferentially recognize early refolding intermediates. Combined with the epitope mapping, these results indicate portions of the beta-helix form early during refolding, perhaps serving as a scaffold for the formation of additional structure. Finally, three of the antibodies show enhanced binding to non-native, potentially aggregation-prone tailspike conformations. The refolding results indicate these non-native conformations form early during the refolding reaction, long before the appearance of native tailspike.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	University of Notre Dame; Massachusetts Institute of Technology (MIT)	Clark, PL (corresponding author), Univ Notre Dame, Dept Chem & Biochem, 251 Nieuwland Sci Hall, Notre Dame, IN 46556 USA.	pclark1@nd.edu	Clark, Patricia/C-9850-2009	Clark, Patricia/0000-0001-5462-8248	NIGMS NIH HHS [GM17980] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017980, R01GM017980] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benton CB, 2002, BIOCHEMISTRY-US, V41, P5093, DOI 10.1021/bi0115582; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; Betts SD, 1998, PROTEIN SCI, V7, P1516, DOI 10.1002/pro.5560070704; BLONDELGUINDI S, 1990, RES IMMUNOL, V141, P879; Bradley P, 2001, P NATL ACAD SCI USA, V98, P14819, DOI 10.1073/pnas.251267298; Clark PL, 2004, TRENDS BIOCHEM SCI, V29, P527, DOI 10.1016/j.tibs.2004.08.008; Clark PL, 1998, FOLD DES, V3, P401, DOI 10.1016/S1359-0278(98)00053-4; Clark PL, 2001, J BIOL CHEM, V276, P25411, DOI 10.1074/jbc.M008490200; COLLAWN JF, 1988, J BIOL CHEM, V263, P8625; Danks MK, 1998, CELL DEATH DIFFER, V5, P678, DOI 10.1038/sj.cdd.4400408; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; Dedmon MM, 2002, P NATL ACAD SCI USA, V99, P12681, DOI 10.1073/pnas.202331299; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Evans MS, 2005, PROTEIN PEPTIDE LETT, V12, P189, DOI 10.2174/0929866053005908; FRIGUET B, 1994, J BIOL CHEM, V269, P15945; FRIGUET B, 1990, J BIOL CHEM, V265, P10347; FRIGUET B, 1984, MOL IMMUNOL, V21, P673, DOI 10.1016/0161-5890(84)90053-1; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; FRIGUET B, 1989, PROTEIN STRUCTURE PR, P287; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; Haase-Pettingell C, 2001, PROTEIN SCI, V10, P397, DOI 10.1110/ps.34701; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Jenkins J, 1998, J STRUCT BIOL, V122, P236, DOI 10.1006/jsbi.1998.3985; King J, 1986, Methods Enzymol, V131, P250; Kosinski-Collins MS, 2004, PROTEIN SCI, V13, P2223, DOI 10.1110/ps.04627004; Kreisberg JF, 2002, PROTEIN SCI, V11, P820, DOI 10.1110/ps.3440102; Kreisberg JF, 2000, PROTEIN SCI, V9, P2338, DOI 10.1110/ps.9.12.2338; MAURIDES PA, 1990, GENETICS, V125, P673; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; Pearce KH, 1997, J BIOL CHEM, V272, P20595, DOI 10.1074/jbc.272.33.20595; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5591, DOI 10.1073/pnas.042681399; Plaxco KW, 1998, J MOL BIOL, V277, P985, DOI 10.1006/jmbi.1998.1645; SATHER SK, 1994, J BIOL CHEM, V269, P25268; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; Schuler B, 2000, PROTEINS, V39, P89; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; Sidhu SS, 2003, CHEMBIOCHEM, V4, P14, DOI 10.1002/cbic.200390008; Speed MA, 1997, PROTEIN SCI, V6, P99; SPEED MA, 1995, PROTEIN SCI, V4, P900; Steinbacher S, 1997, J MOL BIOL, V267, P865, DOI 10.1006/jmbi.1997.0922; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; Tribbick G, 2002, J IMMUNOL METHODS, V267, P27, DOI 10.1016/S0022-1759(02)00138-2; Vendruscolo M, 2003, CURR OPIN STRUC BIOL, V13, P82, DOI 10.1016/S0959-440X(03)00007-1; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008; Zhu A, 1999, J BIOL CHEM, V274, P5731, DOI 10.1074/jbc.274.9.5731	55	10	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23032	23040		10.1074/jbc.M501963200	http://dx.doi.org/10.1074/jbc.M501963200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15833745	hybrid			2022-12-25	WOS:000229741800059
J	Raghavan, SC; Chastain, P; Lee, JS; Hegde, BG; Houston, S; Langen, R; Hsieh, CL; Haworth, IS; Lieber, MR				Raghavan, SC; Chastain, P; Lee, JS; Hegde, BG; Houston, S; Langen, R; Hsieh, CL; Haworth, IS; Lieber, MR			Evidence for a triplex DNA conformation at the bcl-2 major breakpoint region of the t(14;18) translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN V(D)J RECOMBINATION; DOT-TTC REPEATS; HELIX FORMATION; CHROMOSOMAL TRANSLOCATION; FOLLICULAR LYMPHOMA; FRIEDREICHS-ATAXIA; STICKY DNA; 3RD STRAND; SEQUENCE; COMPLEXES	The most common chromosomal translocation in cancer, t(14; 18), occurs at the bcl-2 major breakpoint region (Mbr) in follicular lymphomas. The 150-bp bcl-2 Mbr, which contains three breakage hotspots (peaks), has a single-stranded character and, hence, a non-B DNA conformation both in vivo and in vitro. Here, we use gel assays and electron microscopy to show that a triplex-specific antibody binds to the bcl-2 Mbr in vitro. Bisulfite reactivity shows that the non-B DNA structure is favored by, but not dependent upon, supercoiling and suggests a possible triplex conformation at one portion of the Mbr (peak I). We have used circular dichroism to test whether the predicted third strand of that suggested structure can indeed form a triplex with the duplex at peak I, and it does so with 1: 1 stoichiometry. Using an intracellular minichromosomal assay, we show that the non-B DNA structure formation is critical for the breakage at the bcl-2 Mbr, because a 3-bp mutation that disrupts the putative peak I triplex also markedly reduces the recombination of the Mbr. A three-dimensional model of such a triplex is consistent with bond length, bond angle, and energetic restrictions (stacking and hydrogen bonding). We infer that an imperfect purine/purine/pyrimidine (R.R.Y) triplex likely forms at the bcl-2 Mbr in vitro, and in vivo recombination data favor this as the major DNA conformation in vivo as well.	Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Sci Biol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Zilka Neurogenet Inst, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pharmaceut Sci, Los Angeles, CA 90033 USA; Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Saskatchewan	Lieber, MR (corresponding author), Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Pathol, Rm 5428,1441 Eastlake Ave,MC9176, Los Angeles, CA 90033 USA.	lieber@usc.edu	Hegde, Balachandra/GPS-6028-2022; Chastain, Paul/AAN-2692-2020	Chastain, Paul/0000-0001-6782-6788; Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909				AGAZIE YM, 1994, J BIOL CHEM, V269, P7019; ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BELOTSERKOVSKII BP, 1990, NUCLEIC ACIDS RES, V18, P6621, DOI 10.1093/nar/18.22.6621; BERGETHON PR, 1998, PHYSICAL BASIS BIOCH, P249; BLOOMFIELD DA, 1974, PHYSICAL CHEM NUCL A, P322; Buchonnet G, 2002, LEUKEMIA, V16, P1852, DOI 10.1038/sj.leu.2402568; CASE DA, 1999, AMBERG 6; CHAMBERL.MJ, 1965, J MOL BIOL, V12, P410, DOI 10.1016/S0022-2836(65)80264-9; Chambers EJ, 2003, J BIOMOL STRUCT DYN, V21, P111, DOI 10.1080/07391102.2003.10506909; CLEARY ML, 1986, CELL, V44, P97, DOI 10.1016/0092-8674(86)90488-5; COTTER F, 1990, BLOOD, V76, P131; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; Faucon B, 1996, NUCLEIC ACIDS RES, V24, P3181, DOI 10.1093/nar/24.16.3181; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; Gacy AM, 1998, MOL CELL, V1, P583, DOI 10.1016/S1097-2765(00)80058-1; GAUSS GH, 1993, MOL CELL BIOL, V13, P3900, DOI 10.1128/MCB.13.7.3900; Gauss GH, 1996, MOL CELL BIOL, V16, P258; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; Gauss GH, 1998, EUR J IMMUNOL, V28, P351, DOI 10.1002/(SICI)1521-4141(199801)28:01<351::AID-IMMU351>3.0.CO;2-#; Gilbert DE, 1999, CURR OPIN STRUC BIOL, V9, P305, DOI 10.1016/S0959-440X(99)80041-4; Goobes R, 2002, NUCLEIC ACIDS RES, V30, P2154, DOI 10.1093/nar/30.10.2154; Gowers DM, 1999, NUCLEIC ACIDS RES, V27, P1569, DOI 10.1093/nar/27.7.1569; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; Jager U, 2000, BLOOD, V95, P3520, DOI 10.1182/blood.V95.11.3520.011k12_3520_3529; KLYSIK J, 1995, J MOL BIOL, V245, P499, DOI 10.1006/jmbi.1994.0041; Kramer PR, 1997, BIOCHEMISTRY-US, V36, P3151, DOI 10.1021/bi962396q; LEE JS, 1979, NUCLEIC ACIDS RES, V6, P3073, DOI 10.1093/nar/6.9.3073; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1046; Lewis SM, 1997, MOL CELL BIOL, V17, P3125, DOI 10.1128/MCB.17.6.3125; MACAYA RF, 1991, SCIENCE, V254, P270, DOI 10.1126/science.1925581; Marculescu R, 2002, J EXP MED, V195, P85, DOI 10.1084/jem.20011578; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; Polak M, 2002, NUCLEIC ACIDS RES, V30, P983, DOI 10.1093/nar/30.4.983; Raghavan SC, 2004, CELL CYCLE, V3, P762; Raghavan SC, 2004, J BIOL CHEM, V279, P46213, DOI 10.1074/jbc.M406280200; Raghavan SC, 2004, NATURE, V428, P88, DOI 10.1038/nature02355; Raghavan SC, 2001, J BIOL CHEM, V276, P29126, DOI 10.1074/jbc.M103797200; RAGHAVAN SC, 2005, IN PRESS MOL CELL BI; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27178, DOI 10.1074/jbc.M101852200; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SINGLETON SF, 1993, BIOCHEMISTRY-US, V32, P13171, DOI 10.1021/bi00211a028; Soyfer V.N., 1996, TRIPLE HELICAL NUCL; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; Wu P, 2002, J INORG BIOCHEM, V91, P277, DOI 10.1016/S0162-0134(02)00444-0; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919	54	79	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22749	22760		10.1074/jbc.M502952200	http://dx.doi.org/10.1074/jbc.M502952200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15840562	hybrid			2022-12-25	WOS:000229741800025
J	Sher, D; Fishman, Y; Zhang, ML; Lebendiker, M; Gaathon, A; Mancheno, JM; Zlotkin, E				Sher, D; Fishman, Y; Zhang, ML; Lebendiker, M; Gaathon, A; Mancheno, JM; Zlotkin, E			Hydralysins, a new category of beta-pore-forming toxins in Cnidaria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; CYTOLYSIN EQUINATOXIN-II; PROTEIN TOXINS; FLAMMULINA-VELUTIPES; LIPID RAFTS; AEROLYSIN; BINDING; RECEPTOR; SPHINGOMYELIN; PROAEROLYSIN	Cnidaria are venomous animals that produce diverse protein and polypeptide toxins, stored and delivered into the prey through the stinging cells, the nematocytes. These include pore-forming cytolytic toxins such as well studied actinoporins. In this work, we have shown that the non-nematocystic paralytic toxins, hydralysins, from the green hydra Chlorohydra viridissima comprise a highly diverse group of beta-pore-forming proteins, distinct from other cnidarian toxins but similar in activity and structure to bacterial and fungal toxins. Functional characterization of hydralysins reveals that as soluble monomers they are rich in beta-structure, as revealed by far UV circular dichroism and computational analysis. Hydralysins bind erythrocyte membranes and form discrete pores with an internal diameter of similar to 1.2 nm. The cytolytic effect of hydralysin is cell type-selective, suggesting a specific receptor that is not a phospholipid or carbohydrate. Multiple sequence alignment reveals that hydralysins share a set of conserved sequence motifs with known pore-forming toxins such as aerolysin, epsilon-toxin, alpha-toxin, and LSL and that these sequence motifs are found in and around the pore-forming domains of the toxins. The importance of these sequence motifs is revealed by the cloning, expression, and mutagenesis of three hydralysin isoforms that strongly differ in their hemolytic and paralytic activities. The correlation between the paralytic and cytolytic activities of hydralysin suggests that both are a consequence of receptor-mediated pore formation. Hydralysins and their homologues exemplify the wide distribution of beta-pore formers in biology and provide a useful model for the study of their molecular mode of action.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Bletterman Lab Macromol, IL-91120 Jerusalem, Israel; CSIC, Inst Quim Fis Rocasolano, Dept Cristalog, E-28006 Madrid, Spain	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Zlotkin, E (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel.	zlotkin@vms.huji.ac.il	Mancheno, Jose/K-4984-2014	Mancheno, Jose/0000-0001-6943-3291				Abrami L, 2000, TRENDS MICROBIOL, V8, P168, DOI 10.1016/S0966-842X(00)01722-4; Abrami L, 2002, FEBS LETT, V512, P249, DOI 10.1016/S0014-5793(02)02274-3; Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderluh G, 2005, J MOL BIOL, V347, P27, DOI 10.1016/j.jmb.2004.12.058; Anderluh G, 1999, TOXICON, V37, P1391, DOI 10.1016/S0041-0101(99)00082-3; Anderluh G, 2002, TOXICON, V40, P111, DOI 10.1016/S0041-0101(01)00191-X; Athanasiadis A, 2001, STRUCTURE, V9, P341, DOI 10.1016/S0969-2126(01)00592-5; BALLARD J, 1993, MOL MICROBIOL, V10, P627, DOI 10.1111/j.1365-2958.1993.tb00934.x; Bashford CL, 1996, J MEMBRANE BIOL, V150, P37, DOI 10.1007/s002329900028; Ben-Zimra M, 2002, MOL ENDOCRINOL, V16, P1864, DOI 10.1210/me.2002-0056; BERNIER F, 1987, GENE, V59, P265, DOI 10.1016/0378-1119(87)90334-9; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cole AR, 2004, NAT STRUCT MOL BIOL, V11, P797, DOI 10.1038/nsmb804; Cole DS, 2003, CLIN SCI, V104, P455, DOI 10.1042/CS20020362; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cromer BA, 2002, EUR BIOPHYS J BIOPHY, V31, P356, DOI 10.1007/s00249-002-0219-1; de Maagd RA, 2001, TRENDS GENET, V17, P193, DOI 10.1016/S0168-9525(01)02237-5; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Edwards L, 2000, TOXICON, V38, P1015, DOI 10.1016/S0041-0101(99)00213-5; EITAN M, 1990, BIOCHEMISTRY-US, V29, P5941, DOI 10.1021/bi00477a009; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gilbert RJC, 2002, CELL MOL LIFE SCI, V59, P832, DOI 10.1007/s00018-002-8471-1; Gouaux E, 1997, CURR OPIN STRUC BIOL, V7, P566, DOI 10.1016/S0959-440X(97)80123-6; Hinds MG, 2002, J MOL BIOL, V315, P1219, DOI 10.1006/jmbi.2001.5321; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; Kiyokawa E, 2004, BIOCHEMISTRY-US, V43, P9766, DOI 10.1021/bi049561j; KUGA S, 1981, J CHROMATOGR, V206, P449, DOI 10.1016/S0021-9673(00)88914-1; Lazebnik Y, 2001, CURR BIOL, V11, pR767, DOI 10.1016/S0960-9822(01)00465-1; Lenhoff H.M., 1983, P29; Mancheno JM, 2003, STRUCTURE, V11, P1319, DOI 10.1016/j.str.2003.09.019; MANCHENO JM, 2005, J BIOL CHEM; MEINARDI E, 1995, BIOCHEM BIOPH RES CO, V216, P348, DOI 10.1006/bbrc.1995.2630; MEINARDI E, 1994, COMP BIOCHEM PHYS B, V109, P153, DOI 10.1016/0305-0491(94)90152-X; Melton JA, 2004, J BIOL CHEM, V279, P14315, DOI 10.1074/jbc.M313758200; Nagai H, 2000, BIOCHEM BIOPH RES CO, V275, P589, DOI 10.1006/bbrc.2000.3352; Nagai H, 2000, BIOCHEM BIOPH RES CO, V275, P582, DOI 10.1006/bbrc.2000.3353; Parker MW, 2005, PROG BIOPHYS MOL BIO, V88, P91, DOI 10.1016/j.pbiomolbio.2004.01.009; Parker MW, 2003, TOXICON, V42, P1, DOI 10.1016/S0041-0101(03)00106-5; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Parry-Smith DJ, 1998, GENE, V221, pGC57, DOI 10.1016/S0378-1119(97)00650-1; Perera OP, 1999, ARCH INSECT BIOCHEM, V40, P157, DOI 10.1002/(SICI)1520-6327(1999)40:3&lt;157::AID-ARCH5&gt;3.0.CO;2-W; PRIMOR N, 1975, TOXICON, V13, P227, DOI 10.1016/0041-0101(75)90128-2; REED L. J., 1938, AMER JOUR HYG, V27, P493; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Rossjohn J, 1997, EMBO J, V16, P3426, DOI 10.1093/emboj/16.12.3426; Rossjohn J, 1998, J STRUCT BIOL, V121, P92, DOI 10.1006/jsbi.1997.3947; Rossjohn J, 1998, BIOCHEMISTRY-US, V37, P741, DOI 10.1021/bi9721039; Sekiya K, 1998, J ELECTRON MICROSC, V47, P543, DOI 10.1093/oxfordjournals.jmicro.a023627; SHER D, 2005, IN PRESS TOXICON; Sollod BL, 2005, PEPTIDES, V26, P131, DOI 10.1016/j.peptides.2004.07.016; Sreerama N, 1999, PROTEIN SCI, V8, P370; TARDENT P, 1995, BIOESSAYS, V17, P351, DOI 10.1002/bies.950170411; Tateno H, 2003, J BIOL CHEM, V278, P40455, DOI 10.1074/jbc.M306836200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tomita T, 2004, J BIOL CHEM, V279, P54161, DOI 10.1074/jbc.M408783200; Tomita T, 1998, BIOCHEM J, V333, P129, DOI 10.1042/bj3330129; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yamaji-Hasegawa A, 2003, J BIOL CHEM, V278, P22762, DOI 10.1074/jbc.M213209200; Zhang ML, 2003, BIOCHEMISTRY-US, V42, P8939, DOI 10.1021/bi0343929; Zhuang MB, 2002, J BIOL CHEM, V277, P13863, DOI 10.1074/jbc.M110057200	64	65	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22847	22855		10.1074/jbc.M503242200	http://dx.doi.org/10.1074/jbc.M503242200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824108	hybrid			2022-12-25	WOS:000229741800037
J	Kinoshita, T; Wang, YT; Hasegawa, M; Imamura, R; Suda, T				Kinoshita, T; Wang, YT; Hasegawa, M; Imamura, R; Suda, T			PYPAF3, a PYRIN-containing APAF-1-like protein, is a feedback regulator of caspase-1-dependent interleukin-1 beta secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CONTAINING APAF1-LIKE PROTEIN; CASPASE-1 ACTIVATION; INFLAMMATION; APOPTOSIS; INHIBITOR; VECTOR; BETA; ASC	PYPAF3 is a member of the PYRIN-containing apoptotic protease-activating factor-1-like proteins (PYPAFs, also called NALPs). Among the members of this family, PYPAF1, PYPAF5, PYPAF7, and NALP1 have been shown to induce caspase-1-dependent interleukin-1 beta secretion and NF-kappa B activation in the presence of the adaptor molecule ASC. On the other hand, we recently discovered that PYNOD, another member of this family, is a suppressor of these responses. Here, we show that PYPAF3 is the second member that inhibits caspase-1-dependent interleukin-1 beta secretion. In contrast, PYPAF2/NALP2 does not inhibit this response but rather inhibits the NF-kappa B activation that is induced by the combined expression of PYPAF1 and ASC. Both PYPAF2 and PYPAF3 mRNAs are broadly expressed in a variety of tissues; however, neither is expressed in skeletal muscle, and only PYPAF2 mRNA is expressed in heart and brain. They are also expressed in many cell lines of both hematopoietic and non-hematopoietic lineages. Stimulation of monocytic THP-1 cells with lipopolysaccharide or interleukin-1 beta induced PYPAF3 mRNA expression. Furthermore, the stable expression of PYPAF3 in THP-1 cells abrogated the ability of the cells to produce interleukin-1 beta in response to lipopolysaccharide. These results suggest that PYPAF3 is a feedback regulator of interleukin-1 beta secretion. Thus, PYPAF2 and PYPAF3, together with PYNOD, constitute an anti-inflammatory subgroup of PYPAFs.	Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan	Kanazawa University	Suda, T (corresponding author), Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.	sudat@kenroku.kanazawa-u.ac.jp	KINOSHITA, Takeshi/D-8436-2015; IMAMURA, Ryu/D-8433-2015					Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; DINARELLO CA, 1992, INT J TISSUE REACT, V14, P65; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; Fiorentino L, 2002, J BIOL CHEM, V277, P35333, DOI 10.1074/jbc.M200446200; Fukui M, 2003, J IMMUNOL, V171, P1868, DOI 10.4049/jimmunol.171.4.1868; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Lee SH, 2001, J BIOL CHEM, V276, P34495, DOI 10.1074/jbc.M101415200; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Razmara M, 2002, J BIOL CHEM, V277, P13952, DOI 10.1074/jbc.M107811200; Reed JC, 2003, GENOME RES, V13, P1376, DOI 10.1101/gr.1053803; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Wang YT, 2004, INT IMMUNOL, V16, P777, DOI 10.1093/intimm/dxh081	19	111	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21720	21725		10.1074/jbc.M410057200	http://dx.doi.org/10.1074/jbc.M410057200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817483	hybrid, Green Submitted			2022-12-25	WOS:000229557900007
J	Lee, YI; Seo, M; Kim, Y; Kim, SY; Kang, UG; Kim, YS; Juhnn, YS				Lee, YI; Seo, M; Kim, Y; Kim, SY; Kang, UG; Kim, YS; Juhnn, YS			Membrane depolarization induces the undulating phosphorylation/dephosphorylation of glycogen synthase kinase 3 beta and this dephosphorylation involves protein phosphatases 2A and 2B in SH-SY5Y human neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; POTASSIUM DEPOLARIZATION; KINASE; PHOSPHORYLATION; CALCINEURIN; SURVIVAL; INSULIN; BINDING	Changes in plasma membrane electrical potential evoke signals that regulate the expressions of various genes in the nervous system. However, the role of glycogen synthase kinase 3 beta (GSK-3 beta) in this process has not been elucidated. Thus, this study was performed to examine whether membrane depolarization can regulate the phosphorylation of GSK-3 beta and to identify the molecular mechanisms involved in this regulation. The depolarization by treating with 100 mM KCl for 5 min resulted in the undulating phosphorylation of GSK-3 beta at Ser-9 in SH-SY5Y human neuroblastoma cells, in H19-7/ IGF-IR rat embryonic hippocampal cells, and in PC12 rat pheochromocytoma cells, but not in A172 human glioblastoma cells. Cellular beta-catenin contents showed a temporal pattern similar to that of the Ser-9 phosphorylation of GSK-3 beta. Treatment with wortmannin or calphostin C or the expression of dominant negative Akt inhibited phosphorylation of GSK-3 beta at Ser-9 following the KCl-induced depolarization of SH-SY5Y cells. Moreover, pretreatment with okadaic acid or cyclosporin A blocked the dephosphorylation of GSK-3 beta at Ser-9 at 0, 15, and 30 min after KCl-induced depolarization, and the activity of protein phosphatases (PP) 2A and 2B increased at these times. Treatment with nifedipine or calcium-free medium inhibited GSK-3 beta dephosphorylation following membrane depolarization, and the amounts of co-immunoprecipitated GSK-3 beta and PP2A changed in parallel with GSK-3 beta dephosphorylation. Our study demonstrated that KCl-induced depolarization caused undulating GSK-3 beta phosphorylation/dephosphorylation, which was regulated for the most part by phosphatidylinositol 3-kinase and Akt (phosphorylation) and PP2A and PP2B (dephosphorylation), respectively.	Seoul Natl Univ, Coll Med, Dept Biochem, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Juhnn, YS (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, 28 Yongon Dong, Seoul 110799, South Korea.	juhnn@snu.ac.kr	Kang, Ung Gu/J-2729-2012; Juhnn, Yong-Sung/J-2790-2012					Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cedazo-Minguez A, 2003, J NEUROCHEM, V87, P1152, DOI 10.1046/j.1471-4159.2003.02088.x; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Crowder RJ, 1999, J NEUROCHEM, V73, P466, DOI 10.1046/j.1471-4159.1999.0730466.x; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Koivisto L, 2003, J CELL SCI, V116, P3749, DOI 10.1242/jcs.00693; Lewis RS, 2003, BIOCHEM SOC T, V31, P925; Miller TM, 1997, J BIOL CHEM, V272, P9847; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Roh MS, 2003, PROG NEURO-PSYCHOPH, V27, P1, DOI 10.1016/S0278-5846(02)00307-X; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Schaffer B, 2003, GENE, V302, P73, DOI 10.1016/S0378-1119(02)01092-2; Schmidt J, 1996, REV PHYSIOL BIOCH P, V127, P251, DOI 10.1007/BFb0048269; Seo MR, 2004, J BIOL CHEM, V279, P17366, DOI 10.1074/jbc.M312442200; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; WOODGETT JR, 2001, SCI STKE, pRE12	35	52	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22044	22052		10.1074/jbc.M413987200	http://dx.doi.org/10.1074/jbc.M413987200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15799972	hybrid			2022-12-25	WOS:000229557900048
J	Park, KH; Hernandez, L; Cai, SQ; Wang, Y; Sesti, F				Park, KH; Hernandez, L; Cai, SQ; Wang, Y; Sesti, F			A family of K+ channel ancillary subunits regulate taste sensitivity in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINK-RELATED PEPTIDES; C-ELEGANS; POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; NEURONS; GENE; KCNQ1; IDENTIFICATION; CHEMOTAXIS; K(V)LQT1	We have identified a family of ancillary subunits of K+ channels in Caenorhabditis elegans. MPS-1 and its related members MPS-2, MPS-3, and MPS-4 are detected in the nervous system of the nematode. Electrophysiological analysis in ASE neurons and mammalian cells and epigenetic inactivation by double-stranded RNA interference (RNAi) in vivo show that each MPS can associate with and functionally endow the voltage-gated K+ channel KVS-1. In the chemosensory neuron ADF, three different MPS subunits combine with KVS-1 to form both binary (MPS-1 center dot KVS-1) and ternary (MPS-2 center dot MPS-3 center dot KVS-1) complexes. RNAi of mps-2, mps-3, or both, enhance the taste of the animal for sodium without altering the susceptibility to other attractants. When sodium is introduced in the test plate as background or as antagonist attractant, the nematode loses the ability to recognize a second attractant. Thus, it appears that the chemosensory apparatus of C. elegans uses sensory thresholds and that a voltage-gated K+ channel is specifically required for this mechanism.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Sesti, F (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 683 Hoes Lane, Piscataway, NJ 08854 USA.	sestife@umdnj.edu	Hernandez, Leonardo H/A-5363-2013; Park, Ki Ho/E-8921-2011; wang, yi/C-4312-2012; Park, Ki Ho/N-8153-2017	Hernandez, Leonardo H/0000-0002-8570-5848; Park, Ki Ho/0000-0002-6193-9826	NIGMS NIH HHS [R01 GM 68581] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068581] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Anantharam A, 2003, J BIOL CHEM, V278, P11739, DOI 10.1074/jbc.M212751200; Angelo K, 2002, BIOPHYS J, V83, P1997, DOI 10.1016/S0006-3495(02)73961-1; BARGMANN C, 1997, C ELEGANS 2, V1, P717; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bianchi L, 2003, J BIOL CHEM, V278, P12415, DOI 10.1074/jbc.M212788200; Christensen M, 2002, NEURON, V33, P503, DOI 10.1016/S0896-6273(02)00591-3; de Bono M, 2002, NATURE, V419, P899, DOI 10.1038/nature01169; Goodman MB, 1998, NEURON, V20, P763, DOI 10.1016/S0896-6273(00)81014-4; Grunnet M, 2003, BIOPHYS J, V85, P1525, DOI 10.1016/S0006-3495(03)74585-8; Lundquist Andrew L, 2005, J Mol Cell Cardiol, V38, P277, DOI 10.1016/j.yjmcc.2004.11.012; McCrossan ZA, 2004, NEUROPHARMACOLOGY, V47, P787, DOI 10.1016/j.neuropharm.2004.06.018; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Piccini M, 1999, GENOMICS, V60, P251, DOI 10.1006/geno.1999.5904; Pierce-Shimomura JT, 2001, NATURE, V410, P694, DOI 10.1038/35070575; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; WARD S, 1973, P NATL ACAD SCI USA, V70, P817, DOI 10.1073/pnas.70.3.817; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384	24	23	29	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21893	21899		10.1074/jbc.M502732200	http://dx.doi.org/10.1074/jbc.M502732200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15799965	hybrid			2022-12-25	WOS:000229557900029
J	Perez, GJ				Perez, GJ			Dual effect of tamoxifen on arterial KCa channels does not depend on the presence of the beta 1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNEL; CA2+-ACTIVATED K+ CHANNELS; MUSCLE BK CHANNELS; BETA-SUBUNIT; LARGE-CONDUCTANCE; SMOOTH-MUSCLE; ANTIESTROGEN; INACTIVATION; SENSITIVITY; MODULATION	Tamoxifen has been reported to directly activate large conductance calcium-activated potassium (KCa) channels through the KCa beta 1 subunit, suggesting a cardio-protective role of this compound. The present study using knock-out (KO) mice for the KCa channel beta 1 subunit was aimed at understanding the molecular mechanisms of the effects of tamoxifen on arterial smooth muscle KCa channels. Single channel studies were conducted in excised patches from cerebral artery myocytes from both wild-type and KO animals. The present data demonstrated that tamoxifen can inhibit arterial KCa channels due to a major decrease in channel open probability (P-o), a mechanism different from the reduction in single channel amplitude reported previously and also observed in the present work. A tamoxifen-induced decrease in P-o was present in arterial KCa channels from both wild-type and beta 1 KO animals. This inhibition was concentration-dependent and partially reversible with a half-maximal concentration constant IC50 of 2.6 mu M. The effect of tamoxifen was actually dual in nature. Single channel kinetic analysis showed that tamoxifen shortens both mean closed time and mean open time; the latter is probably due to an intermediate duration voltage-independent blocking mechanism. Thus, tamoxifen block would predominate when KCa channel P-o is > 0.1-0.2, limiting the maximum P-o, whereas a leftward shift in voltage or Ca2+ activation curves can be observed for P-o values lower than those values. This dual effect of tamoxifen appears to be independent of the beta 1 subunit. The molecular specificity of tamoxifen, or eventually other xenoestrogen derivatives, for the KCa channel beta 1 subunit is uncertain.	Masonic Med Res Lab, Dept Expt Cardiol, Utica, NY 13501 USA	Masonic Medical Research Laboratory	Perez, GJ (corresponding author), Masonic Med Res Lab, Dept Expt Cardiol, 2150 Bleecker St, Utica, NY 13501 USA.	gperez@mmrl.edu	Perez, Guillermo J/D-5932-2013	Perez, Guillermo J/0000-0003-0237-2150	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL073161] Funding Source: NIH RePORTER; NHLBI NIH HHS [K01 HL 073161-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amberg GC, 2003, J CLIN INVEST, V112, P717, DOI 10.1172/JC1200318684; Amberg GC, 2003, CIRC RES, V93, P965, DOI 10.1161/01.RES.0000100068.43006.36; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; Cox DH, 2000, J GEN PHYSIOL, V116, P411, DOI 10.1085/jgp.116.3.411; Dick GM, 2002, BRIT J PHARMACOL, V136, P961, DOI 10.1038/sj.bjp.0704807; Dick GM, 2002, MOL PHARMACOL, V61, P1105, DOI 10.1124/mol.61.5.1105; Dick GM, 2001, J BIOL CHEM, V276, P44835, DOI 10.1074/jbc.M106851200; Dick GM, 2001, J BIOL CHEM, V276, P34594, DOI 10.1074/jbc.M104689200; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; Fernandez-Fernandez JM, 2004, J CLIN INVEST, V113, P1032, DOI 10.1172/JCI200420347; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; Hanner M, 1998, J BIOL CHEM, V273, P16289, DOI 10.1074/jbc.273.26.16289; Hanner M, 1997, P NATL ACAD SCI USA, V94, P2853, DOI 10.1073/pnas.94.7.2853; He JY, 2003, AM J PHYSIOL-HEART C, V285, pH661, DOI 10.1152/ajpheart.00686.2002; Kaczorowski GJ, 1996, J BIOENERG BIOMEMBR, V28, P255, DOI 10.1007/BF02110699; MCMANUS OB, 1993, BIOCHEMISTRY-US, V32, P6128, DOI 10.1021/bi00075a002; Meera P, 1996, FEBS LETT, V385, P127; Orio P, 2002, NEWS PHYSIOL SCI, V17, P156, DOI 10.1152/nips.01387.2002; Pluger S, 2000, CIRC RES, V87, pE53, DOI 10.1161/01.RES.87.11.e53; Thomas D, 2003, N-S ARCH PHARMACOL, V368, P41, DOI 10.1007/s00210-003-0766-8; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185	25	16	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21739	21747		10.1074/jbc.M413953200	http://dx.doi.org/10.1074/jbc.M413953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15826942	hybrid			2022-12-25	WOS:000229557900010
J	Luna-Medina, R; Cortes-Canteli, M; Alonso, M; Santos, A; Martinez, A; Perez-Castillo, A				Luna-Medina, R; Cortes-Canteli, M; Alonso, M; Santos, A; Martinez, A; Perez-Castillo, A			Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); ALZHEIMERS-DISEASE; MICROGLIA; EXPRESSION; ASTROCYTES; NEUROTOXICITY; INDUCTION; APOPTOSIS	In most neurodegenerative disorders, including multiple sclerosis, Parkinson disease, and Alzheimer disease, a massive neuronal cell death occurs as a consequence of an uncontrolled inflammatory response, where activated astrocytes and microglia and their cytotoxic agents play a crucial pathological role. Current treatments for these diseases are not effective. In the present study we investigate the effect of thiadiazolidinone derivatives, which have been recently suggested to play a role in neurodegenerative disorders. We have found that thiadiazolidinones are potent neuroprotector compounds. Thiadiazolidinones inhibited inflammatory activation of cultured brain astrocytes and microglia by diminishing lipopolysaccharide-induced interleukin 6, tumor necrosis factor alpha, inducible nitric-oxide synthase, and inducible cyclooxygenase type 2 expression. In addition, thiadiazolidinones inhibited tumor necrosis factor-alpha and nitric oxide production and, concomitantly, protected cortical neurons from cell death induced by the cell-free supernatant from activated microglia. The neuroprotective effects of thiadiazolidinones are completely inhibited by the peroxisome proliferator-activated receptor gamma antagonist GW9662. In contrast the glycogen synthase kinase 3 beta inhibitor LiCl did not show any effect. These findings suggest that thiadiazolidinones potently attenuate lipopolysaccharide-induced neuroinflammation and reduces neuronal death by a mechanism dependent of peroxisome proliferator-activated receptor gamma activation.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed, E-28049 Madrid, Spain; Neuropharma SA, Madrid 28760, Spain; Univ Complutense Madrid, Fac Med, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Complutense University of Madrid	Perez-Castillo, A (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28049 Madrid, Spain.	aperez@iib.uam.es	Cortes-Canteli, Marta/L-5449-2014; Martinez, Ana/L-6414-2014; Santos, Angel/K-3744-2014; Perez-Castillo, Ana/A-9505-2015	Cortes-Canteli, Marta/0000-0001-8802-4338; Martinez, Ana/0000-0002-2707-8110; Santos, Angel/0000-0002-7551-8483; Perez-Castillo, Ana/0000-0002-2632-5853				ALONSO M, 2004, 8 INT MONTR SPRINGF; ALONSO M, 2004, 18 INT S MED CHEM CO, P337; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Aschner M, 1998, NEUROTOXICOLOGY, V19, P269; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; CHOWEN JA, 1992, NEUROENDOCRINOLOGY, V56, P895, DOI 10.1159/000126321; CollacoMoraes Y, 1996, J CEREBR BLOOD F MET, V16, P1366, DOI 10.1097/00004647-199611000-00035; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; Diab A, 2002, J IMMUNOL, V168, P2508, DOI 10.4049/jimmunol.168.5.2508; Dorronsoro I, 2002, EXPERT OPIN THER PAT, V12, P1527, DOI 10.1517/13543776.12.10.1527; Feinstein DL, 2002, ANN NEUROL, V51, P694, DOI 10.1002/ana.10206; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; Giri S, 2004, J IMMUNOL, V173, P5196, DOI 10.4049/jimmunol.173.8.5196; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Han KH, 2000, J CLIN INVEST, V106, P793, DOI 10.1172/JCI10052; Heneka MT, 1998, J NEUROCHEM, V71, P88; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kielian T, 2003, J NEUROSCI RES, V71, P315, DOI 10.1002/jnr.10501; Klappacher GW, 2002, CURR OPIN LIPIDOL, V13, P305, DOI 10.1097/00041433-200206000-00011; LASSMANN H, 1994, NEUROPATH APPL NEURO, V20, P195; Lee P, 2001, BRAIN RES, V892, P380, DOI 10.1016/S0006-8993(00)03257-1; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Maggi LB, 2000, DIABETES, V49, P346, DOI 10.2337/diabetes.49.3.346; Martinez A, 2002, MED RES REV, V22, P373, DOI 10.1002/med.10011; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; Marx N, 2000, J IMMUNOL, V164, P6503, DOI 10.4049/jimmunol.164.12.6503; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MincGolomb D, 1996, J NEUROCHEM, V66, P1504; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; OTTMANN G, 1966, ANGEW CHEM INT EDIT, V5, P672, DOI 10.1002/anie.196606722; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Ricote M, 1999, J LEUKOCYTE BIOL, V66, P733, DOI 10.1002/jlb.66.5.733; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; SATO I, 1995, NEUROSCI LETT, V184, P145, DOI 10.1016/0304-3940(94)11191-K; Schoderbock P, 1996, APPL SURF SCI, V93, P109, DOI 10.1016/0169-4332(95)00327-4; Sheng JG, 1997, ACTA NEUROPATHOL, V94, P1, DOI 10.1007/s004010050664; SKAPER SD, 1995, J NEUROCHEM, V64, P266; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Uryu S, 2002, BRAIN RES, V924, P229, DOI 10.1016/S0006-8993(01)03242-5; Varley CL, 2004, J CELL SCI, V117, P2029, DOI 10.1242/jcs.01042; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619	50	170	177	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21453	21462		10.1074/jbc.M414390200	http://dx.doi.org/10.1074/jbc.M414390200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15817469	hybrid, Green Submitted			2022-12-25	WOS:000229438800066
J	Seemann, S; Hainaut, P				Seemann, S; Hainaut, P			Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity	ONCOGENE			English	Article						p53; thioredoxin; APE/Ref-1; redox regulation; base excision repair	DNA-BINDING ACTIVITY; REPORTER GENE TRANSACTIVATION; NF-KAPPA-B; EXCISION-REPAIR; GENOTOXIC STRESS; REDOX REGULATION; TRANSCRIPTION FACTOR; DIRECT ASSOCIATION; METAL-IONS; IN-VITRO	The p53 protein is redox-sensitive in vitro but in vivo effectors of this sensitivity are not known. In yeasts deficient for thioredoxin (Trx) reductase (TRR), p53 accumulates in an inactive, oxidized form, suggesting a role for TRR-Trx in controlling p53. In mammalian cells, p53 binds to redox factor-1 (APE/Ref-1), an enzyme containing an abasic endonuclease domain involved in base excision repair, and a thiol reductase domain recycled by Trx and involved in regulating the transcription factor AP-1. To evaluate the role of TRR and APE/Ref-1 in p53 regulation, we have abrogated their expression using RNA interference in cell lines expressing wild-type p53. Inhibition of TRR resulted in accumulation of oxidized Trx and increased levels and DNA-binding activity of p53, with no phosphorylation of Ser15 or Ser20. In contrast, inhibition of APE/Ref-1 accelerated p53 protein turnover, resulting in a decrease in p53 levels and activity. However, inhibition of either TRR or APE/Ref-1 did not prevent activation and accumulation of p53 in response to DNA-damage by doxorubicin. When both factors were inhibited, basal levels of p53 were restored. These results suggest that TRR-Trx and APE/Ref-1 cooperate in the control of basal p53 activity, but not in its induction by DNA-damage.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC)	Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				Achanta G, 2004, CANCER RES, V64, P6233, DOI 10.1158/0008-5472.CAN-04-0494; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bersani NA, 2002, METHOD ENZYMOL, V347, P317; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Freemerman AJ, 1999, CANCER RES, V59, P4090; Fritz G, 2003, TOXICOLOGY, V193, P67, DOI 10.1016/S0300-483X(03)00290-7; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; HAINAUT P, 1993, CANCER RES, V53, P1739; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hainaut P, 2001, ANTIOXID REDOX SIGN, V3, P611, DOI 10.1089/15230860152542961; HAINAUT P, 1993, CANCER RES, V53, P4469; Hirota K, 2001, FEBS LETT, V489, P134, DOI 10.1016/S0014-5793(01)02094-4; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kelley MR, 2003, CANCER RES, V63, P549; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Meplan C, 2000, ONCOGENE, V19, P5227, DOI 10.1038/sj.onc.1203907; Merrill GF, 1999, CANCER RES, V59, P3175; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; Offer H, 2001, CANCER RES, V61, P88; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wei SJ, 2000, CANCER RES, V60, P6688; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zurer I, 2004, CARCINOGENESIS, V25, P11, DOI 10.1093/carcin/bgg186	43	100	100	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3853	3863		10.1038/sj.onc.1208549	http://dx.doi.org/10.1038/sj.onc.1208549			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15824742				2022-12-25	WOS:000229435300001
J	Navarro, C; Nola, S; Audebert, S; Santoni, MJ; Arsanto, JP; Ginestier, C; Marchetto, S; Jacquemier, J; Isnardon, D; Le Bivic, A; Birnbaum, D; Borg, JP				Navarro, C; Nola, S; Audebert, S; Santoni, MJ; Arsanto, JP; Ginestier, C; Marchetto, S; Jacquemier, J; Isnardon, D; Le Bivic, A; Birnbaum, D; Borg, JP			Junctional recruitment of mammalian Scribble relies on E-cadherin engagement	ONCOGENE			English	Article						carcinoma; scribble; breast; PDZ domain; E-cadherin	TUMOR-SUPPRESSOR SCRIBBLE; BASOLATERAL PDZ PROTEIN; EPITHELIAL-CELLS; ADHERENS JUNCTIONS; GENE-EXPRESSION; POLARITY; LOCALIZATION; COMPLEX; BREAST; DOMAIN	Members of the LAP protein family, LET-413 in Caenorhabditis elegans, Scribble in Drosophila melanogaster, and Erbin, Lano, Densin-180 and hScrib in mammals, have conserved structural features. LET-413 and Scribble are junctional proteins involved in establishing and maintaining epithelial cell polarity. scribble also behaves as a neoplastic tumor suppressor gene. We show here that, in epithelial cells, hScrib is recruited at cell-cell junctions in an E-cadherin-dependent manner as shown by calcium switch assays in MDCK cells, re-expression of E-cadherin in MDA-231 cells treated by 5-Aza-2'-deoxycytidine (5Aza), and siRNA experiments. hScrib is restricted at the basolateral membrane of epithelial cells by its LRR domain, and is enriched in Triton X-100-insoluble fractions. In breast cancers, most lobular tumors did not express hScrib and E-cadherin while ductal tumors had a less frequent downregulation of hScrib. Our data provide additional insights on the modalities of recruitment of hScrib at the cell-cell junctions, and establish a potential link between the E-cadherin and hScrib tumor suppressors.	Inst J Paoli I Calmettes, INSERM, UMR 599, Marseille Canc Inst, F-13009 Marseille, France; Fac Sci Luminy, NMDA, F-13288 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Borg, JP (corresponding author), Inst J Paoli I Calmettes, INSERM, UMR 599, Marseille Canc Inst, 27 Blvd Lei Roure, F-13009 Marseille, France.	borg@marseille.inserm.fr	Borg, Jean-Paul/AAX-8096-2020; Ginestier, Christophe/M-8828-2017; Nola, Sebastien/D-6518-2017	Borg, Jean-Paul/0000-0001-8418-3382; Ginestier, Christophe/0000-0002-7477-3837; Nola, Sebastien/0000-0002-6485-9856; Audebert, Stephane/0000-0002-9409-2588; Santoni, Marie-Josee/0000-0002-2619-7257				Albertson R, 2004, J CELL SCI, V117, P6061, DOI 10.1242/jcs.01525; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Benton R, 2003, CURR BIOL, V13, P1330, DOI 10.1016/S0960-9822(03)00508-6; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; GRAFF JR, 1995, CANCER RES, V55, P5195; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Huang YZ, 2001, J BIOL CHEM, V276, P19318, DOI 10.1074/jbc.M100494200; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Laprise P, 2004, J BIOL CHEM, V279, P10157, DOI 10.1074/jbc.M309843200; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Mantovani F, 2001, J CELL SCI, V114, P4285; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; Mizuno K, 2003, J BIOL CHEM, V278, P31240, DOI 10.1074/jbc.M303593200; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Nourry Claire, 2003, Sci STKE, V2003, pRE7; Ohno H, 2002, ONCOGENE, V21, P7042, DOI 10.1038/sj.onc.1205852; Roche JP, 2002, J NEUROSCI, V22, P6471, DOI 10.1523/jneurosci.22-15-06471.2002; Santoni MJ, 2002, TRENDS GENET, V18, P494, DOI 10.1016/S0168-9525(02)02738-5; Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Walikonis RS, 2001, J NEUROSCI, V21, P423, DOI 10.1523/JNEUROSCI.21-02-00423.2001; Zeitler J, 2004, J CELL BIOL, V167, P1137, DOI 10.1083/jcb.200407158	36	156	163	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4330	4339		10.1038/sj.onc.1208632	http://dx.doi.org/10.1038/sj.onc.1208632			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806148				2022-12-25	WOS:000229976900002
J	Komarova, EA; Krivokrysenko, V; Wang, KH; Neznanov, N; Chernov, MV; Komarov, PG; Brennan, ML; Golovkina, TV; Rokhlin, O; Kuprash, DV; Nedospasov, SA; Hazen, SR; Feinstein, E; Gudkov, AV				Komarova, EA; Krivokrysenko, V; Wang, KH; Neznanov, N; Chernov, MV; Komarov, PG; Brennan, ML; Golovkina, TV; Rokhlin, O; Kuprash, DV; Nedospasov, SA; Hazen, SR; Feinstein, E; Gudkov, AV			p53 is a suppressor of inflammatory response in mice	FASEB JOURNAL			English	Article						inflammation; nuclear factor kappa B; cytokines	NF-KAPPA-B; RHEUMATOID-ARTHRITIS SYNOVIUM; AGE-ASSOCIATED DIFFERENCES; OXIDE SYNTHASE EXPRESSION; NITRIC-OXIDE; INDUCED APOPTOSIS; HELICOBACTER-PYLORI; GENE-EXPRESSION; BLADDER-CANCER; TNF-ALPHA	Chronic inflammation is known to promote cancer, suggesting that negative regulation of inflammation is likely to be tumor suppressive. We found that p53 is a general inhibitor of inflammation that acts as an antagonist of nuclear factor kappa B (NF kappa B). We first observed striking similarities in global gene expression profiles in human prostate cancer cells LNCaP transduced with p53 inhibitory genetic element or treated with TNF, suggesting that p53 inhibits transcription of TNF-inducible genes that are largely regulated by NF kappa B. Consistently, ectopically expressed p53 acts as an inhibitor of transcription of NF kappa B-dependent promoters. Furthermore, suppression of inflammatory response by p53 was observed in vivo in mice by comparing wild-type and p53 null animals at molecular (inhibition of transcription of genes encoding cytokines and chemokines, reducing accumulation of reactive oxygen species and protein oxidation products), cellular (activation of macrophages and neutrophil clearance) and organismal (high levels of metabolic markers of inflammation in tissues of p53-deficient mice and their hypersensitivity to LPS) levels. These observations indicate that p53, acting through suppression of NF kappa B, plays the role of a general "buffer" of innate immune response in vivo that is well consistent with its tumor suppressor function and frequent constitutive activation of NF kappa B in tumors.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Quark Biotech Inc, Fremont, CA USA; Cleveland BioLabs Inc, Cleveland, OH USA; Jackson Lab, Bar Harbor, ME 04609 USA; Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Lab Mol Immunol, Moscow, Russia; NCI, Mol Immunoregulat Lab, Ctr Canc Res, Frederick, MD 21701 USA; SAIC Frederick Inc, Frederick, MD 21701 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Jackson Laboratory; University of Iowa; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Gudkov, AV (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	gudkov@ccf.org	Nedospasov, Sergei/Q-7319-2016; Nedospasov, Sergei/J-5936-2013; Nedospasov, Sergei/C-3043-2018; Nedospasov, Sergei/L-1990-2015; Kuprash, Dmitry/O-4899-2015	Kuprash, Dmitry/0000-0002-1488-4148; Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [N01-CO-12400, CA75179, CA88071] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC010601] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA088071, R01CA075179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambs S, 1998, P NATL ACAD SCI USA, V95, P8823, DOI 10.1073/pnas.95.15.8823; Badawi AF, 1996, CANCER LETT, V105, P123, DOI 10.1016/0304-3835(96)04284-X; Celli A, 1998, SEMIN LIVER DIS, V18, P177, DOI 10.1055/s-2007-1007153; Chompret A, 2002, BIOCHIMIE, V84, P75, DOI 10.1016/S0300-9084(01)01361-X; Chorinchath BB, 1996, J IMMUNOL, V156, P1525; Coleman WB, 2003, CURR MOL MED, V3, P573, DOI 10.2174/1566524033479546; CORREA P, 1992, CANCER RES, V52, P6735; Davis DW, 2000, J EXP MED, V192, P857, DOI 10.1084/jem.192.6.857; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Drane P, 2002, CELL DEATH DIFFER, V9, P527, DOI 10.1038/sj.cdd.4400983; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Firestein GS, 1997, P NATL ACAD SCI USA, V94, P10895, DOI 10.1073/pnas.94.20.10895; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Ghosh S, 2002, AM J RESP CRIT CARE, V166, P890, DOI 10.1164/rccm.2109094; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gu LB, 2004, J BIOL CHEM, V279, P52141, DOI 10.1074/jbc.M407915200; Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; Hibi K, 1997, AM J CLIN PATHOL, V108, P26; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; KOMAROVA EA, 2005, IN PRESS ONCOGENE; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kuwano K, 1996, AM J RESP CRIT CARE, V154, P477, DOI 10.1164/ajrccm.154.2.8756825; Lang SM, 1997, AM J GASTROENTEROL, V92, P2166; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Lu T, 2004, ONCOGENE, V23, P2138, DOI 10.1038/sj.onc.1207332; Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101; Merched AJ, 2003, ARTERIOSCL THROM VAS, V23, P1608, DOI 10.1161/01.ATV.0000084825.88022.53; Neznanov N, 2001, J VIROL, V75, P10409, DOI 10.1128/JVI.75.21.10409-10420.2001; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; Ohkusu-Tsukada K, 1999, J IMMUNOL, V163, P1966; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Okuda Y, 2003, J NEUROIMMUNOL, V135, P29, DOI 10.1016/S0165-5728(02)00428-9; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rokhlin OW, 2000, ONCOGENE, V19, P1959, DOI 10.1038/sj.onc.1203453; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P248; Saito H, 2001, J BIOL CHEM, V276, P29307, DOI 10.1074/jbc.M103740200; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Shanahan F, 2003, ALIMENT PHARM THER, V18, P6, DOI 10.1046/j.1365-2036.18.s2.5.x; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Tateda K, 1996, INFECT IMMUN, V64, P769, DOI 10.1128/IAI.64.3.769-774.1996; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; van Vlijmen BJM, 2001, CIRC RES, V88, P780, DOI 10.1161/hh0801.089261; von der Thusen JH, 2002, CIRCULATION, V105, P2064, DOI 10.1161/01.CIR.0000015502.97828.93; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; WANG L, 1995, J BIOL CHEM, V270, P23159, DOI 10.1074/jbc.270.39.23159; WARREN W, 1995, CARCINOGENESIS, V16, P1181, DOI 10.1093/carcin/16.5.1181; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wichmann MW, 1996, J SURG RES, V65, P109, DOI 10.1006/jsre.1996.0351; Winterbourn CC, 2000, CURR OPIN HEMATOL, V7, P53, DOI 10.1097/00062752-200001000-00010; WU CQ, 1994, J INTERFERON RES, V14, P357, DOI 10.1089/jir.1994.14.357; Yamanishi Y, 2002, P NATL ACAD SCI USA, V99, P10025, DOI 10.1073/pnas.152333199; Yamanishi Y, 2002, AM J PATHOL, V160, P123, DOI 10.1016/S0002-9440(10)64356-8; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	62	180	193	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					1030	+		10.1096/fj.04-3213fje	http://dx.doi.org/10.1096/fj.04-3213fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15811878				2022-12-25	WOS:000228865300027
J	Wooldridge, L; van den Berg, HA; Glick, M; Gostick, E; Laugel, B; Hutchinson, SL; Milicic, A; Brenchley, JM; Douek, DC; Price, DA; Sewell, AK				Wooldridge, L; van den Berg, HA; Glick, M; Gostick, E; Laugel, B; Hutchinson, SL; Milicic, A; Brenchley, JM; Douek, DC; Price, DA; Sewell, AK			Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; ALPHA-3 DOMAIN MUTANTS; SIGNAL-TRANSDUCTION; LIGAND INTERACTIONS; TCR AFFINITY; PEPTIDE; BINDING; ACTIVATION; SPECIFICITY; ASSOCIATION	The off-rate (k(off)) of the T cell receptor (TCR)/peptide-major histocompatibility complex class I (pMHCI) interaction, and hence its half-life, is the principal kinetic feature that determines the biological outcome of TCR ligation. However, it is unclear whether the CD8 coreceptor, which binds pMHCI at a distinct site, influences this parameter. Although biophysical studies with soluble proteins show that TCR and CD8 do not bind cooperatively to pMHCI, accumulating evidence suggests that TCR associates with CD8 on the T cell surface. Here, we titrated and quantified the contribution of CD8 to TCR/pMHCI dissociation in membrane-constrained interactions using a panel of engineered pMHCI mutants that retain faithful TCR interactions but exhibit a spectrum of affinities for CD8 of > 1,000-fold. Data modeling generates a "stabilization factor" that preferentially increases the predicted TCR triggering rate for low affinity pMHCI ligands, thereby suggesting an important role for CD8 in the phenomenon of T cell cross-reactivity.	Univ Oxford, Nuffield Dept Med, T Cell Modulat Grp, Oxford OX1 3SY, England; Univ Kent, Inst Math Stat & Actuarial Sci, Canterbury CT2 7NF, Kent, England; Novartis Inst Biomed Res, Cambridge, MA 02139 USA; NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA	University of Oxford; University of Kent; Novartis; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Sewell, AK (corresponding author), Univ Oxford, Nuffield Dept Med, T Cell Modulat Grp, Peter Medawar Bldg Pathogen Res,S Parks Rd, Oxford OX1 3SY, England.	andy.sewell@ndm.ox.ac.uk	Sewell, Andrew/GPT-4220-2022; Brenchley, Jason/AAC-5085-2019; Price, David A/C-7876-2013; Milicic, Anita/B-7693-2011	Sewell, Andrew/0000-0003-3194-3135; Price, David A/0000-0001-9416-2737; Milicic, Anita/0000-0002-7984-1317; Brenchley, Jason/0000-0001-8357-2984; Wooldridge, Linda/0000-0002-6213-347X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005033, Z01AI005066] Funding Source: NIH RePORTER; MRC [G108/441] Funding Source: UKRI; Intramural NIH HHS [ZIA AI001029-02, Z01 AI001029-01, Z99 AI999999] Funding Source: Medline; Medical Research Council [G108/441] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Arcaro A, 2000, J IMMUNOL, V165, P2068, DOI 10.4049/jimmunol.165.4.2068; Arcaro A, 2001, J EXP MED, V194, P1485, DOI 10.1084/jem.194.10.1485; Bodinier M, 2000, NAT MED, V6, P707, DOI 10.1038/76292; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; Bosselut R, 1999, J EXP MED, V190, P1517, DOI 10.1084/jem.190.10.1517; Buslepp J, 2003, J IMMUNOL, V170, P373, DOI 10.4049/jimmunol.170.1.373; Campanelli R, 2002, INT IMMUNOL, V14, P39, DOI 10.1093/intimm/14.1.39; Cawthon AG, 2002, J IMMUNOL, V169, P3492, DOI 10.4049/jimmunol.169.7.3492; CHALUPNY NJ, 1991, EMBO J, V10, P1201, DOI 10.1002/j.1460-2075.1991.tb08061.x; Cho BK, 2001, P NATL ACAD SCI USA, V98, P1723, DOI 10.1073/pnas.98.4.1723; Choi EM, 2002, J IMMUNOL METHODS, V268, P35, DOI 10.1016/S0022-1759(02)00198-9; Choi EML, 2003, J IMMUNOL, V171, P5116, DOI 10.4049/jimmunol.171.10.5116; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Daniels MA, 2000, J EXP MED, V191, P335, DOI 10.1084/jem.191.2.335; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Denkberg G, 2001, J IMMUNOL, V167, P270, DOI 10.4049/jimmunol.167.1.270; Diamond DJ, 1997, BLOOD, V90, P1751, DOI 10.1182/blood.V90.5.1751; Doucey MA, 2003, J BIOL CHEM, V278, P3257, DOI 10.1074/jbc.M208119200; Dutoit V, 2003, J IMMUNOL, V170, P5110, DOI 10.4049/jimmunol.170.10.5110; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; Gao GF, 1998, PROTEIN SCI, V7, P1245, DOI 10.1002/pro.5560070520; Gao GF, 2000, J BIOL CHEM, V275, P15232, DOI 10.1074/jbc.275.20.15232; Gao GF, 2002, TRENDS IMMUNOL, V23, P408, DOI 10.1016/S1471-4906(02)02282-2; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; Glick M, 2002, J MED CHEM, V45, P4639, DOI 10.1021/jm020830i; Glick M, 2002, J AM CHEM SOC, V124, P2337, DOI 10.1021/ja016490s; Glick M, 2002, J BIOL CHEM, V277, P20840, DOI 10.1074/jbc.M201819200; Goulder PJR, 1997, J EXP MED, V185, P1423, DOI 10.1084/jem.185.8.1423; Guillaume P, 2003, J BIOL CHEM, V278, P4500, DOI 10.1074/jbc.M208863200; Hamad ARA, 1998, J EXP MED, V188, P1633, DOI 10.1084/jem.188.9.1633; Holler PD, 2003, IMMUNITY, V18, P255, DOI 10.1016/S1074-7613(03)00019-0; Hutchinson SL, 2003, J BIOL CHEM, V278, P24285, DOI 10.1074/jbc.M300633200; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JOHNSON RP, 1991, J IMMUNOL, V147, P1512; Kalergis AM, 2001, NAT IMMUNOL, V2, P229, DOI 10.1038/85286; Kelleher AD, 2000, CURR OPIN IMMUNOL, V12, P370, DOI 10.1016/S0952-7915(00)00102-3; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Kerry SE, 2003, J IMMUNOL, V171, P4493, DOI 10.4049/jimmunol.171.9.4493; Klenerman P, 2002, NAT REV IMMUNOL, V2, P263, DOI 10.1038/nri777; Krogsgaard M, 2003, MOL CELL, V12, P1367, DOI 10.1016/S1097-2765(03)00474-X; KWANLIM GE, 1993, INT IMMUNOL, V5, P1219, DOI 10.1093/intimm/5.10.1219; Laugel B, 2005, J BIOL CHEM, V280, P1882, DOI 10.1074/jbc.M409427200; Lim GEK, 1998, EUR J IMMUNOL, V28, P745, DOI 10.1002/(SICI)1521-4141(199802)28:02<745::AID-IMMU745>3.0.CO;2-6; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Naeher D, 2002, J IMMUNOL, V169, P2964, DOI 10.4049/jimmunol.169.6.2964; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; O'Callaghan CA, 1999, ANAL BIOCHEM, V266, P9, DOI 10.1006/abio.1998.2930; Osono E, 1997, SCAND J IMMUNOL, V45, P487, DOI 10.1046/j.1365-3083.1997.d01-427.x; Pittet MJ, 2003, J IMMUNOL, V171, P1844, DOI 10.4049/jimmunol.171.4.1844; Purbhoo MA, 2001, J BIOL CHEM, V276, P32786, DOI 10.1074/jbc.M102498200; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; Rosette C, 2001, IMMUNITY, V15, P59, DOI 10.1016/S1074-7613(01)00173-X; Rudolph MG, 2002, CURR OPIN IMMUNOL, V14, P52, DOI 10.1016/S0952-7915(01)00298-9; Savage PA, 1999, IMMUNITY, V10, P485, DOI 10.1016/S1074-7613(00)80048-5; Schott E, 2002, P NATL ACAD SCI USA, V99, P13735, DOI 10.1073/pnas.212515399; Schott E, 2002, EUR J IMMUNOL, V32, P3425, DOI 10.1002/1521-4141(2002012)32:12<3425::AID-IMMU3425>3.0.CO;2-Q; Scotet E, 1996, J EXP MED, V184, P1791, DOI 10.1084/jem.184.5.1791; Sewell AK, 1997, EUR J IMMUNOL, V27, P2323, DOI 10.1002/eji.1830270929; Sewell AK, 2001, TRENDS IMMUNOL, V22, P173, DOI 10.1016/S1471-4906(01)01866-X; SUZUKI S, 1992, EUR J IMMUNOL, V22, P2475, DOI 10.1002/eji.1830221002; TOMONARI K, 1990, INT IMMUNOL, V2, P1189, DOI 10.1093/intimm/2.12.1189; UTZ U, 1992, J IMMUNOL, V149, P214; Van Den Berg HA, 2002, B MATH BIOL, V64, P781, DOI 10.1006/bulm.2002.0302; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Whelan JA, 1999, J IMMUNOL, V163, P4342; Willcox BE, 1999, PROTEIN SCI, V8, P2418; Wilson JDK, 1998, J EXP MED, V188, P785, DOI 10.1084/jem.188.4.785; Wooldridge L, 2003, J IMMUNOL, V171, P6650, DOI 10.4049/jimmunol.171.12.6650; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9; Xiong Y, 2001, J BIOL CHEM, V276, P5659, DOI 10.1074/jbc.M009580200; Xu XN, 2001, IMMUNITY, V14, P591, DOI 10.1016/S1074-7613(01)00133-9	80	125	131	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27491	27501		10.1074/jbc.M500555200	http://dx.doi.org/10.1074/jbc.M500555200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15837791	hybrid, Green Accepted			2022-12-25	WOS:000230678600004
J	Lotan, R; Rotem, A; Gonen, H; Finberg, JPM; Kemeny, S; Steller, H; Ciechanover, A; Larisch, S				Lotan, R; Rotem, A; Gonen, H; Finberg, JPM; Kemeny, S; Steller, H; Ciechanover, A; Larisch, S			Regulation of the proapoptotic ARTS protein by ubiquitin-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES APOPTOSIS; CASPASE ACTIVATION; MITOCHONDRIAL; MECHANISMS; BCL-2; PROTEASOME; IDENTIFICATION; INHIBITOR; SURVIVAL; PATHWAY	ARTS is a mitochondrial protein that promotes apoptosis induced by a variety of proapoptotic stimulators. ARTS induces apoptosis, at least in part, through binding to and antagonizing IAPs ( inhibitors of apoptosis proteins). As a result of ARTS binding to IAPs, caspase inhibition is removed and apoptosis can be executed. Here we show that high cellular levels of ARTS protein sensitize cells toward apoptosis. Accordingly, in healthy cells ARTS levels are kept low through constant ubiquitin-mediated degradation. Upon proapoptotic stimuli, the ubiquitination process is inhibited, resulting in increased levels of ARTS. Increased ARTS in turn leads to a decrease of Bcl-2 and Bcl-x(L) protein levels, cytochrome c release from mitochondria and apoptosis.	Rambam Med Ctr, Apoptosis & Canc Res Lab, Dept Pathol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Fac Med, Pharmacol Unit, IL-31096 Haifa, Israel; Bruce Rappaport Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Bruce Rappaport Fac Med, Rappaport Inst Res Med Sci, IL-31096 Haifa, Israel; Rockefeller Univ, Howard Hughes Med Inst, Strang Lab Canc Res, New York, NY 10021 USA	Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Howard Hughes Medical Institute; Rockefeller University	Larisch, S (corresponding author), Rambam Med Ctr, Apoptosis & Canc Res Lab, Dept Pathol, IL-31096 Haifa, Israel.	s_larisch@rambam.health.gov.il	Kemény, Sándor/H-4592-2012; Ciechanover, Aaron J/C-9166-2017	Kemeny, Stav/0000-0002-5292-215X				Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chandra D, 2002, J BIOL CHEM, V277, P50842, DOI 10.1074/jbc.M207622200; Ciechanover A, 2004, IUBMB LIFE, V56, P193, DOI 10.1080/1521654042000223616; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elhasid R, 2004, ONCOGENE, V23, P9450, DOI 10.1038/sj.onc.1208363; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gottfried Y, 2004, CANCER-AM CANCER SOC, V101, P2614, DOI 10.1002/cncr.20675; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hall PA, 2004, J PATHOL, V204, P489, DOI 10.1002/path.1654; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Hoff Henry, 2004, Methods Mol Biol, V285, P79; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Kissel H, 2005, DEV CELL, V8, P353, DOI 10.1016/j.devcel.2005.01.021; Kluck RM, 1997, APOPTOSIS, V2, P337; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Larisch S, 2004, CELL CYCLE, V3, P1021; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Nelson DA, 2004, GENE DEV, V18, P1223, DOI 10.1101/gad.1212404; Olson MR, 2003, J BIOL CHEM, V278, P4028, DOI 10.1074/jbc.M209734200; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; SCHWARTZ AL, 1992, AM J RESP CELL MOL, V7, P463, DOI 10.1165/ajrcmb/7.5.463; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Shi Y, 2002, CELL DEATH DIFFER, V9, P93, DOI 10.1038/sj/cdd/4400957; Simoes-Wust AP, 2000, INT J CANCER, V87, P582, DOI 10.1002/1097-0215(20000815)87:4<582::AID-IJC19>3.0.CO;2-P; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wojcik C, 2002, J CELL MOL MED, V6, P25, DOI 10.1111/j.1582-4934.2002.tb00309.x; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yang YL, 2003, FASEB J, V17, P790, DOI 10.1096/fj.02-0654rev	47	27	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25802	25810		10.1074/jbc.M501955200	http://dx.doi.org/10.1074/jbc.M501955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15837787	hybrid			2022-12-25	WOS:000230207900061
J	Genolet, R; Kersten, S; Braissant, O; Mandard, S; Tan, NS; Bucher, P; Desvergne, B; Michalik, L; Wahli, W				Genolet, R; Kersten, S; Braissant, O; Mandard, S; Tan, NS; Bucher, P; Desvergne, B; Michalik, L; Wahli, W			Promoter rearrangements cause species-specific hepatic regulation of the glyoxylate reductase/hydroxypyruvate reductase gene by the peroxisome proliferator-activated receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY OXALATE; ALPHA; HYPEROXALURIA; DEHYDROGENASE; METABOLISM; COMPLEX; PROTEIN; RATS	In liver, the glyoxylate cycle contributes to two metabolic functions, urea and glucose synthesis. One of the key enzymes in this pathway is glyoxylate reductase/ hydroxypyruvate reductase (GRHPR) whose dysfunction in human causes primary hyperoxaluria type 2, a disease resulting in oxalate accumulation and formation of kidney stones. In this study, we provide evidence for a transcriptional regulation by the peroxisome proliferator-activated receptor alpha (PPAR alpha) of the mouse GRHPR gene in liver. Mice fed with a PPAR alpha ligand or in which PPAR alpha activity is enhanced by fasting increase their GRHPR gene expression via a peroxisome proliferator response element located in the promoter region of the gene. Consistent with these observations, mice deficient in PPAR alpha present higher plasma levels of oxalate in comparison with their wild type counterparts. As expected, the administration of a PPAR alpha ligand (Wy-14,643) reduces the plasma oxalate levels. Surprisingly, this effect is also observed in null mice, suggesting a PPAR alpha-independent action of the compound. Despite a high degree of similarity between the transcribed region of the human and mouse GRHPR gene, the human promoter has been dramatically reorganized, which has resulted in a loss of PPAR alpha regulation. Overall, these data indicate a species-specific regulation by PPAR alpha of GRHPR, a key gene of the glyoxylate cycle.	Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland; Univ Lausanne, Natl Ctr Competence Res Frontiers Genet, CH-1015 Lausanne, Switzerland; Univ Lausanne Hosp, Clin Chem Lab, CH-1011 Lausanne, Switzerland; Swiss Inst Expt Canc Res, Swiss Inst Bioinformat, CH-1066 Epalinges, Switzerland	University of Lausanne; University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Institute Experimental Cancer Research; Swiss Institute of Bioinformatics	Wahli, W (corresponding author), Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland.	walter.wahli@unil.ch	Mandard, Stéphane/J-4800-2019; Wahli, Walter/B-1398-2009; Kersten, Sander/A-1116-2011; Wahli, Walter/I-3194-2019; Tan, Nguan Soon/A-2220-2011; Desvergne, Beatrice/C-8892-2016	Mandard, Stéphane/0000-0002-7298-821X; Wahli, Walter/0000-0002-5966-9089; Kersten, Sander/0000-0003-4488-7734; Tan, Nguan Soon/0000-0003-0136-7341; Desvergne, Beatrice/0000-0001-5483-288X; Michalik, Liliane/0000-0003-2963-2100				Cramer SD, 1999, HUM MOL GENET, V8, P2063, DOI 10.1093/hmg/8.11.2063; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Giafi CF, 1998, ANN CLIN BIOCHEM, V35, P104, DOI 10.1177/000456329803500114; Gould SJ, 2002, NAT REV MOL CELL BIO, V3, P382, DOI 10.1038/nrm807; Holmes RP, 1998, J UROLOGY, V160, P1617, DOI 10.1016/S0022-5347(01)62363-2; Holmes RP, 2001, KIDNEY INT, V59, P270, DOI 10.1046/j.1523-1755.2001.00488.x; Huang TS, 2000, BIOCHEM BIOPH RES CO, V268, P298, DOI 10.1006/bbrc.2000.2122; Kersten S, 2001, FASEB J, V15, P1971, DOI 10.1096/fj.01-0147com; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Lambe KG, 1999, TOXICOL LETT, V110, P119, DOI 10.1016/S0378-4274(99)00151-4; Lavery DJ, 1997, P NATL ACAD SCI USA, V94, P6831, DOI 10.1073/pnas.94.13.6831; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leumann E, 2001, J AM SOC NEPHROL, V12, P1986, DOI 10.1681/ASN.V1291986; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Mandard S, 2004, J BIOL CHEM, V279, P34411, DOI 10.1074/jbc.M403058200; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Ogawa Y, 2000, WORLD J SURG, V24, P1154, DOI 10.1007/s002680010193; Ogawa Y, 2000, MOL UROL, V4, P341; Patsouris D, 2004, J CLIN INVEST, V114, P94, DOI 10.1172/JC1200420468; Peters JM, 2000, CARCINOGENESIS, V21, P823, DOI 10.1093/carcin/21.4.823; Podvinec M, 2002, MOL ENDOCRINOL, V16, P1269, DOI 10.1210/me.16.6.1269; Sambrook J., 2002, MOL CLONING LAB MANU; Sharma V, 1997, METABOLISM, V46, P135, DOI 10.1016/S0026-0495(97)90290-0; Shearer BG, 2003, CURR MED CHEM, V10, P267, DOI 10.2174/0929867033368295; TAGLE DA, 1988, J MOL BIOL, V203, P439, DOI 10.1016/0022-2836(88)90011-3; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wu PF, 2001, BIOCHEM BIOPH RES CO, V287, P391, DOI 10.1006/bbrc.2001.5608; Xu J, 2002, J BIOL CHEM, V277, P50237, DOI 10.1074/jbc.M201208200	30	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24143	24152		10.1074/jbc.M502649200	http://dx.doi.org/10.1074/jbc.M502649200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15840574	hybrid			2022-12-25	WOS:000229880000088
J	Sanders, MA; Basson, MD				Sanders, MA; Basson, MD			p130(cas) but not paxillin is essential for caco-2 intestinal epithelial cell spreading and migration on collagen IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CRK-ASSOCIATED SUBSTRATE; ADAPTER PROTEIN CAS; C-SRC ACTIVITY; TYROSINE PHOSPHORYLATION; IN-VITRO; V-CRK; ACTIN CYTOSKELETON; DEPENDENT MANNER; ERK ACTIVATION	We have previously observed that collagen IV regulates Caco-2 intestinal epithelial cell spreading and migration via Src kinase and stimulates Src-dependent tyrosine phosphorylation of p130(cas). We observed that collagen IV also stimulated Src-dependent phosphorylation of both paxillin Tyr(31) and paxillin Tyr(118). Caco-2 transfection with paxillin or p130(cas) siRNAs inhibited expression of these proteins by more than 90% for at least 5 days after transfection. Although p130(cas) siRNA inhibited cell spreading on collagen IV by 33%, three different paxillin siRNAs did not inhibit cell spreading. p130cas siRNA did not affect Src Tyr(416) or Src Tyr(527) phosphorylation, FAK Tyr(397) phosphorylation, or Src-dependent phosphorylation of FAK Tyr(925), suggesting that p130cas did not inhibit cell spreading by altering FAK or Src activity. Rat p130(cas) expression after siRNA knock-out of endogenous human p130(cas) in Caco-2 cells reduced cell spreading inhibition by 71%. In contrast, expression of rat p130(cas) from which the Src-phosphorylated substrate domain was deleted did not rescue siRNA inhibition of cell spreading. Combined treatment with siRNAs to Crk and CrkL, which bind to the p130cas substrate domain, inhibited cell spreading by 54%. Both p130(cas) siRNA and the combined Crk/CrkL siRNAs strongly inhibited ( 52 and 46% inhibition, respectively) Caco-2 sheet migration on collagen IV and noticeably inhibited lamellipodial extension, whereas paxillin siRNA only inhibited migration by 18% and did not noticeably affect lamellipodial extension. These results suggest that Src may regulate Caco-2 migration on collagen IV via both p130cas and paxillin but that Src phosphorylation of p130cas is more important for this process.	Wayne State Univ, Dept Surg, Detroit, MI 48202 USA; Dept Vet Affairs Med Ctr, Surg Serv, Detroit, MI 48201 USA	Wayne State University	Sanders, MA (corresponding author), Wayne State Univ, Dept Surg, Detroit, MI 48202 USA.	aj2198@wayne.edu			NIDDK NIH HHS [R01DK60771] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060771] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abassi YA, 2003, J BIOL CHEM, V278, P35636, DOI 10.1074/jbc.M306438200; Basson MD, 1998, CLIN EXP PHARMACOL P, V25, P280, DOI 10.1111/j.1440-1681.1998.t01-10-.x; BASSON MD, 1992, J CLIN INVEST, V90, P15, DOI 10.1172/JCI115828; Basson MD, 2001, LIFE SCI, V69, P3005, DOI 10.1016/S0024-3205(01)01408-4; Beaulieu JF, 1997, PROG HISTOCHEM CYTOC, V31, P1; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; De Arcangelis A, 1996, J CELL BIOL, V133, P417, DOI 10.1083/jcb.133.2.417; Di Stefano P, 2004, MOL BIOL CELL, V15, P787, DOI 10.1091/mbc.E03-09-0689; Dignass AU, 2001, INFLAMM BOWEL DIS, V7, P68, DOI 10.1097/00054725-200102000-00014; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Huang C, 2004, J CELL BIOL, V164, P593, DOI 10.1083/jcb.200307081; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Ku H, 2000, J BIOL CHEM, V275, P11333, DOI 10.1074/jbc.275.15.11333; Lamorte L, 2003, MOL BIOL CELL, V14, P2818, DOI 10.1091/mbc.E02-08-0497; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Lotz MM, 2000, AM J PATHOL, V156, P985, DOI 10.1016/S0002-9440(10)64966-8; Lotz MM, 1997, AM J PATHOL, V150, P747; Lussier C, 2000, MICROSC RES TECHNIQ, V51, P169; MADRI JA, 1988, AM J PATHOL, V132, P18; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; PETERSON MD, 1993, J CELL SCI, V105, P461; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Podolsky DK, 1999, AM J PHYSIOL-GASTR L, V277, pG495, DOI 10.1152/ajpgi.1999.277.3.G495; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Sanders MA, 2000, J BIOL CHEM, V275, P38040, DOI 10.1074/jbc.M003871200; Sanders MA, 2004, AM J PHYSIOL-GASTR L, V286, pG547, DOI 10.1152/ajpgi.00262.2003; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Stupack DG, 2000, IMMUNOL RES, V21, P83, DOI 10.1385/IR:21:2-3:83; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; VACHON PH, 1995, AM J PHYSIOL, V268, P857; Wolpert S, 1996, AM J SURG, V171, P109, DOI 10.1016/S0002-9610(99)80083-X; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Yano H, 2004, J CELL BIOL, V166, P283, DOI 10.1083/jcb.200312013; Yu CF, 2000, AM J PHYSIOL-GASTR L, V278, pG952, DOI 10.1152/ajpgi.2000.278.6.G952; ZHANG J, 2003, FASEB J	45	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23516	23522		10.1074/jbc.M413165200	http://dx.doi.org/10.1074/jbc.M413165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15817476	hybrid			2022-12-25	WOS:000229880000015
J	Schuurman-Wolters, GK; Poolman, B				Schuurman-Wolters, GK; Poolman, B			Substrate specificity and ionic regulation of GlnPQ from Lactococcus lactis - An ATP-binding cassette transporter with four extracytoplasmic substrate-binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; GLUTAMINE; SYSTEM; MECHANISM	We report on the functional characterization of GlnPQ, an ATP-binding cassette transporter with four extracytoplasmic substrate-binding domains. The first predicted transmembrane helix of GlnP was cleaved off in the mature protein and most likely serves as the signal sequence for the extracytoplasmic substrate-binding domains. Deletion analysis showed that the substrate-binding domain, in the primary sequence of GlnP nearest to the translocator domain, is used as the receptor that delivers the substrate to the translocator. Membrane reconstitution of the detergent-solubilized and purified GlnPQ complex yielded proteoliposomes that transported glutamine and glutamic acid at the expense of ATP. The transport activity of GlnPQ increased with lumenal salt concentration and internal pH, but the mechanism of ionic activation of the transporter is distinct from that of other osmoregulatory ATP-binding cassette transporters and does not depend on the presence of anionic lipids. The regulation of GlnPQ conforms to an electrostatic switch in which protein domain(s) and low molecular weight electrolytes participate.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	University of Groningen	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	b.poolman@rug.nl	Poolman, Bert/D-1882-2012					Biemans-Oldehinkel E, 2003, EMBO J, V22, P5983, DOI 10.1093/emboj/cdg581; HAGTING A, 1994, J BIOL CHEM, V269, P11391; Holland I. B., 2003, ABC PROTEINS BACTERI; Hsiao CD, 1996, J MOL BIOL, V262, P225, DOI 10.1006/jmbi.1996.0509; Khademi S, 2004, SCIENCE, V305, P1587, DOI 10.1126/science.1101952; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; Kunji ERS, 2003, BBA-BIOMEMBRANES, V1610, P97, DOI 10.1016/S0005-2736(02)00712-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOLENAAR D, 1993, J BACTERIOL, V175, P5438, DOI 10.1128/JB.175.17.5438-5444.1993; POOLMAN B, 1987, J BACTERIOL, V169, P2755, DOI 10.1128/jb.169.6.2755-2761.1987; Poolman B, 2004, BBA-BIOMEMBRANES, V1666, P88, DOI 10.1016/j.bbamem.2004.06.013; POOLMAN B, 1987, J BACTERIOL, V169, P2272, DOI 10.1128/jb.169.5.2272-2276.1987; Racher KI, 2001, BIOCHEMISTRY-US, V40, P7324, DOI 10.1021/bi002331u; Rubenhagen R, 2001, EMBO J, V20, P5412, DOI 10.1093/emboj/20.19.5412; Sun YJ, 1998, J MOL BIOL, V278, P219, DOI 10.1006/jmbi.1998.1675; Tamura GS, 2002, INFECT IMMUN, V70, P2877, DOI 10.1128/IAI.70.6.2877-2885.2002; van der Heide T, 2000, P NATL ACAD SCI USA, V97, P7102, DOI 10.1073/pnas.97.13.7102; van der Heide T, 2002, EMBO REP, V3, P938, DOI 10.1093/embo-reports/kvf201; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022	19	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23785	23790		10.1074/jbc.M500522200	http://dx.doi.org/10.1074/jbc.M500522200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15795228	hybrid, Green Published			2022-12-25	WOS:000229880000049
J	Huddleson, JP; Ahmad, N; Srinivasan, S; Lingrel, JB				Huddleson, JP; Ahmad, N; Srinivasan, S; Lingrel, JB			Induction of KLF2 by fluid shear stress requires a novel promoter element activated by a phosphatidylinositol 3-kinase-dependent chromatin-remodeling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; KRUPPEL-LIKE FACTOR; HUMAN ENDOTHELIAL-CELLS; GENE-EXPRESSION; MESSENGER-RNA; STIMULATES PHOSPHORYLATION; TRANSCRIPTIONAL REGULATOR; SMOOTH-MUSCLE; IN-VITRO; AKT	Fluid shear stress maintains vascular homeostasis by influencing endothelial gene expression. One mechanism by which shear stress achieves this is through the induction of transcription factors including Kruppel-like factor 2 (KLF2). We have previously reported that a 62-bp region of the KLF2 promoter is responsible for its shear stress-induced expression via the binding of nuclear factors. In this study, we find that the 62-bp shear stress response region contains a 30-bp tripartite palindrome motif. Electrophoretic mobility supershift and chromatin immunoprecipitation assays demonstrate that PCAF (P-300/cAMP-response element-binding protein-binding protein-associated factor)) and heterogeneous nuclear ribonucleoprotein D bind this region as components of the shear stress regulatory complex. We have also characterized a PI3K-dependent/Akt-independent pathway responsible for shear stress-induced KLF2 nuclear binding, promoter activation, and mRNA expression. Furthermore, the shear stress response region of the KLF2 promoter was specifically immunoprecipitated by antibodies against acetylated histones H3 and H4 in shear-stressed but not static hemangioendothelioma cells. The acetylation of these histones was blocked by PI3K inhibition. Finally, we have found that KLF2 increases endothelial nitric-oxide synthase expression in murine endothelial cultures, an effect that is also blocked by PI3K inhibition. These results define the DNA regulatory element, signal transduction pathway, and molecular mechanism activating the flow-dependent expression of a vital endothelial transcription factor.	Univ Cincinnati, Ctr Med, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Lingrel, JB (corresponding author), Univ Cincinnati, Ctr Med, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	jerrylingrel@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057281] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL57281] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD N, 2005, IN PRESS BIOCHEMISTR; Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Barakat AI, 2003, CELL BIOCHEM BIOPHYS, V38, P323, DOI 10.1385/CBB:38:3:323; Berk BC, 2001, ANN NY ACAD SCI, V947, P93; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Carty SM, 2002, MOL CELL PROTEOMICS, V1, P598, DOI 10.1074/mcp.M200029-MCP200; Chen BPC, 2001, PHYSIOL GENOMICS, V7, P55, DOI 10.1152/physiolgenomics.2001.7.1.55; Cowan PJ, 1998, J BIOL CHEM, V273, P11737, DOI 10.1074/jbc.273.19.11737; Davis ME, 2001, CIRC RES, V89, P1073, DOI 10.1161/hh2301.100806; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; Deng WG, 2004, BLOOD, V103, P2135, DOI 10.1182/blood-2003-09-3131; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Dostanic I, 2004, J BIOL CHEM, V279, P54053, DOI 10.1074/jbc.M410737200; Dostanic I, 2003, J BIOL CHEM, V278, P53026, DOI 10.1074/jbc.M308547200; Fisslthaler B, 2000, ACTA PHYSIOL SCAND, V168, P81; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Huang A, 2004, CIRC RES, V94, P245, DOI 10.1161/01.RES.0000111525.96232.46; Huddleson JP, 2004, BIOL CHEM, V385, P723, DOI 10.1515/BC.2004.088; Illi B, 2003, CIRC RES, V93, P155, DOI 10.1161/01.RES.0000080933.82105.29; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Inoue H, 2002, ARTERIOSCL THROM VAS, V22, P1415, DOI 10.1161/01.ATV.0000028816.13582.13; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; Kaiser D, 1997, BIOCHEM BIOPH RES CO, V231, P586, DOI 10.1006/bbrc.1997.6146; Katahira M, 2001, J MOL BIOL, V311, P973, DOI 10.1006/jmbi.2001.4862; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Lin K, 2000, P NATL ACAD SCI USA, V97, P9385, DOI 10.1073/pnas.170282597; Lin Y, 2003, MOL CELL BIOL, V23, P5849, DOI 10.1128/MCB.23.16.5849-5856.2003; Lin ZY, 2005, CIRC RES, V96, pE48, DOI 10.1161/01.RES.0000159707.05637.a1; Liu ZJ, 2003, FASEB J, V17, P1931, DOI 10.1096/fj.02-1171fje; Malek AM, 1999, BIOCHEM BIOPH RES CO, V254, P231, DOI 10.1006/bbrc.1998.9921; Malek AM, 1995, J BIOMECH, V28, P1515, DOI 10.1016/0021-9290(95)00099-2; OBESO J, 1990, LAB INVEST, V63, P259; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; REDMOND EM, 1995, IN VITRO CELL DEV-AN, V31, P601; Rossig L, 2000, J BIOL CHEM, V275, P25502, DOI 10.1074/jbc.M002283200; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Schrick JJ, 1999, GENE, V236, P185, DOI 10.1016/S0378-1119(99)00235-8; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Topper JN, 1999, MOL MED TODAY, V5, P40, DOI 10.1016/S1357-4310(98)01372-0; Tsai JC, 2002, J VASC RES, V39, P148, DOI 10.1159/000057763; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Wani MA, 1999, GENOMICS, V60, P78, DOI 10.1006/geno.1999.5888; Wasserman SM, 2002, PHYSIOL GENOMICS, V12, P13, DOI 10.1152/physiolgenomics.00102.2002; Wong DS, 2004, J BIOL CHEM, V279, P55667, DOI 10.1074/jbc.M408174200; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Xu NH, 2001, MOL CELL BIOL, V21, P6960, DOI 10.1128/MCB.21.20.6960-6971.2001; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yoshizumi M, 2003, J PHARMACOL SCI, V91, P172; Ziegler T, 1998, HYPERTENSION, V32, P351, DOI 10.1161/01.HYP.32.2.351	63	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23371	23379		10.1074/jbc.M413839200	http://dx.doi.org/10.1074/jbc.M413839200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15834135	hybrid			2022-12-25	WOS:000229741800097
J	Qiao, ZS; Kim, MK; Reinhold, B; Montefiori, D; Wang, JH; Reinherz, EL				Qiao, ZS; Kim, MK; Reinhold, B; Montefiori, D; Wang, JH; Reinherz, EL			Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL MEMBRANE-FUSION; TYPE-1 GP41; TRANSMEMBRANE GLYCOPROTEIN; NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODIES; POTENT INHIBITORS; ATOMIC-STRUCTURE; FAB FRAGMENTS; GP120	The human immunodeficiency virus-1 (HIV-1) envelope glycoprotein (Env) is comprised of non-covalently associated gp120/gp41 subunits that form trimeric spikes on the virion surface. Upon binding to host cells, Env undergoes a series of structural transitions, leading to gp41 rearrangement necessary for fusion of viral and host membranes. Until now, the prefusion state of gp41 ectodomain (e-gp41) has eluded molecular and structural analysis, and thus assessment of the potential of such an e-gp41 conformer to elicit neutralizing antibodies has not been possible. Considering the importance of gp120 amino (C1) and carboxyl (C5) segments in the association with e-gp41, we hypothesize that these regions are sufficient to maintain e- gp41 in a prefusion state. Based on the available gp120 atomic structure, we designed several truncated gp140 variants by including the C1 and C5 regions of gp120 in a gp41 ectodomain fragment. After iterative cycles of protein design, expression and characterization, we obtained a variant truncated at Lys(665) that stably folds as an elongated trimer under physiologic conditions. Several independent biochemical/biophysical analyses strongly suggest that this mini-Env adopts a prefusion e- gp41 configuration that is strikingly distinct from the postfusion trimer-of-hairpin structure. Interestingly, this prefusion mini-Env, lacking the fragment containing the 2F5/4E10 neutralizing monoclonal antibody binding sites, displays no detectable HIV-neutralizing epitopes when employed as an immunogen in rabbits. The result of this immunogenicity study has important implications for HIV-1 vaccine design efforts. Moreover, this engineered mini-Env protein should facilitate three-dimensional structural studies of the prefusion e- gp41 and serve to guide future attempts at pharmacologic and immunologic intervention of HIV-1.	Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Dept Med, Sch Med, Boston, MA 02115 USA; Harvard Univ, Dept Pediat, Sch Med, Boston, MA 02115 USA; Harvard Univ, Dept Biol Chem & Mol Pharmacol, Sch Med, Boston, MA 02115 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Duke University	Reinherz, EL (corresponding author), Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.	ellis_reinherz@dfci.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI043649, R01AI143649] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43649] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004; Brandt SM, 2002, J BIOL CHEM, V277, P17291, DOI 10.1074/jbc.M108232200; Bures R, 2000, AIDS RES HUM RETROV, V16, P2019, DOI 10.1089/088922200750054756; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Caffrey M, 2000, J BIOL CHEM, V275, P19877, DOI 10.1074/jbc.M001036200; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011; Center RJ, 2004, J VIROL, V78, P2265, DOI 10.1128/JVI.78.5.2265-2276.2004; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327; Chen B, 2004, J VIROL, V78, P4508, DOI 10.1128/JVI.78.9.4508-4516.2004; Chen B, 2000, J BIOL CHEM, V275, P34946, DOI 10.1074/jbc.M004905200; Chong JM, 2001, J BIOL CHEM, V276, P5804, DOI 10.1074/jbc.M008839200; Coeffier E, 2000, VACCINE, V19, P684, DOI 10.1016/S0264-410X(00)00267-X; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; Dacheux L, 2004, J VIROL, V78, P12625, DOI 10.1128/JVI.78.22.12625-12637.2004; de Rosny E, 2004, J VIROL, V78, P2627, DOI 10.1128/JVI.78.5.2627-2631.2004; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gorny MK, 2000, J VIROL, V74, P6186, DOI 10.1128/JVI.74.13.6186-6192.2000; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; Ho J, 2002, VACCINE, V20, P1169, DOI 10.1016/S0264-410X(01)00441-8; Hovanessian AG, 2004, IMMUNITY, V21, P617, DOI 10.1016/j.immuni.2004.08.015; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; Kim M, 2005, AIDS RES HUM RETROV, V21, P58, DOI 10.1089/aid.2005.21.58; Kim M, 2001, J BIOL CHEM, V276, P42667, DOI 10.1074/jbc.M104166200; Kwong PD, 2000, STRUCTURE, V8, P1329, DOI 10.1016/S0969-2126(00)00547-5; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; Li J, 1998, EMBO J, V17, P7320, DOI 10.1093/emboj/17.24.7320; Liang XP, 1999, VACCINE, V17, P2862, DOI 10.1016/S0264-410X(99)00125-5; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Maerz AL, 2001, J VIROL, V75, P6635, DOI 10.1128/JVI.75.14.6635-6644.2001; MONTEFIORI D, 2004, CURRENT PROTOCOLS IM; MONTEFIORI DC, 1988, J CLIN MICROBIOL, V26, P231, DOI 10.1128/JCM.26.2.231-235.1988; Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Srivastava IK, 2003, J VIROL, V77, P11244, DOI 10.1128/JVI.77.20.11244-11259.2003; Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Verrier F, 2001, J VIROL, V75, P9177, DOI 10.1128/JVI.75.19.9177-9186.2001; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Wyatt R, 1997, J VIROL, V71, P9722, DOI 10.1128/JVI.71.12.9722-9731.1997; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Zhang CWH, 2001, J BIOL CHEM, V276, P39577, DOI 10.1074/jbc.M107147200	51	22	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23138	23146		10.1074/jbc.M414515200	http://dx.doi.org/10.1074/jbc.M414515200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15833740	hybrid, Green Published			2022-12-25	WOS:000229741800071
J	Staniszewska, MM; Nagaraj, RH				Staniszewska, MM; Nagaraj, RH			3-Hydroxykynurenine-mediated modification of human lens proteins - Structure determination of a major modification using a monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CRYSTALLIN; INDOLEAMINE 2,3-DIOXYGENASE; CATARACTOUS LENSES; OXIDATION-PRODUCTS; BOUND KYNURENINE; NUCLEAR CATARACT; GLUTATHIONE; GLUCOSIDE; GLYCATION; CONSEQUENCES	Tryptophan can be oxidized in the eye lens by both enzymatic and non-enzymatic mechanisms. Oxidation products, such as kynurenines, react with proteins to form yellow-brown pigments and cause covalent cross-linking. We generated a monoclonal antibody against 3-hydroxykynurenine (30HKYN)-modified keyhole limpet hemocyanin and characterized it using 30HKYN-modified amino acids and proteins. This monoclonal antibody reacted with 30HKYN-modified N-alpha-acetyl lysine, N-alpha-acetyl histidine, N-alpha-acetyl arginine, and N-alpha-acetyl cysteine. Among the several tryptophan oxidation products tested, 30HKYN produced the highest concentration of antigen when reacted with human lens proteins. A major antigen from the reaction of 30HKYN and N-alpha-acetyl lysine was purified by reversed phase high pressure liquid chromatography, which was characterized by spectroscopy and identified as 2-amino-3-hydroxyl-alpha-((5S)-5-acetamino-5-carboxypentyl amino)-gamma-oxo-benzene butanoic acid. Enzyme-digested cataractous lens proteins displayed 30HKYN-derived modifications. Immunohistochemistry revealed 3-HKYN modifications in proteins associated with the lens fiber cell plasma membrane. The low molecular products (< 10,000 Da) isolated from normal lenses after reaction with glucosidase followed by incubation with proteins generated 30HKYN-derived products. Human lens epithelial cells incubated with 30HKYN showed intense immunoreactivity. We also investigated the effect of glycation on tryptophan oxidation and kynurenine-mediated modification of lens proteins. The results showed that glycation products failed to oxidize tryptophan or generate kynurenine modifications in proteins. Our studies indicate that 30HKYN modifies lens proteins independent of glycation to form products that may contribute to protein aggregation and browning during cataract formation.	Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Nagaraj, RH (corresponding author), Case Western Reserve Univ, Dept Ophthalmol, Wearn Bldg,Rm 643, Cleveland, OH 44106 USA.	ram.nagaraj@case.edu	Staniszewska, PhD, DSc, Associate Professor, Magdalena/AAE-9903-2019	Staniszewska, Magdalena/0000-0003-1119-2397	NEI NIH HHS [P30 EY 11373, R01 EY 09912] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009912, P30EY011373] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aquilina JA, 1999, BIOCHEMISTRY-US, V38, P11455, DOI 10.1021/bi990458h; Aquilina JA, 1997, EXP EYE RES, V64, P727, DOI 10.1006/exer.1996.0258; Aquilina JA, 2001, BIOCHEM BIOPH RES CO, V285, P1107, DOI 10.1006/bbrc.2001.5288; Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3; Bova LM, 2001, INVEST OPHTH VIS SCI, V42, P200; Bron AJ, 2000, OPHTHALMOLOGICA, V214, P86, DOI 10.1159/000027475; Brownlee M, 2000, METABOLISM, V49, P9, DOI 10.1016/S0026-0495(00)80078-5; Cheng RZ, 2004, J BIOL CHEM, V279, P45441, DOI 10.1074/jbc.M405664200; Cobb BA, 2000, J BIOL CHEM, V275, P6664, DOI 10.1074/jbc.275.9.6664; Daubener W, 1999, ADV EXP MED BIOL, V467, P517; de Jong W.W., 1988, Advances in Experimental Medicine and Biology, V231, P95; Dillon J, 1999, PHOTOCHEM PHOTOBIOL, V69, P248, DOI 10.1562/0031-8655(1999)069<0248:TPAOTG>2.3.CO;2; DYER DG, 1991, Z ERNAHRUNGSWISS, V30, P29, DOI 10.1007/BF01910730; Garner B, 2000, BBA-PROTEIN STRUCT M, V1476, P265, DOI 10.1016/S0167-4838(99)00234-4; Garner B, 1999, J BIOL CHEM, V274, P20847, DOI 10.1074/jbc.274.30.20847; Goda K, 2003, ADV EXP MED BIOL, V527, P687; Goldstein LE, 2000, BIOCHEMISTRY-US, V39, P7266, DOI 10.1021/bi992997s; Grant RS, 2000, J VIROL, V74, P4110, DOI 10.1128/JVI.74.9.4110-4115.2000; Hood BD, 1999, J BIOL CHEM, V274, P32547, DOI 10.1074/jbc.274.46.32547; Kamei A, 1998, BIOL PHARM BULL, V21, P982; LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; Ortwerth BJ, 1997, PHOTOCHEM PHOTOBIOL, V65, P666, DOI 10.1111/j.1751-1097.1997.tb01909.x; Oya T, 1999, J BIOL CHEM, V274, P18492, DOI 10.1074/jbc.274.26.18492; Padayatti PS, 2001, INVEST OPHTH VIS SCI, V42, P1299; Parker NR, 2004, FREE RADICAL BIO MED, V37, P1479, DOI 10.1016/j.freeradbiomed.2004.07.015; PAU H, 1990, EXP EYE RES, V50, P17, DOI 10.1016/0014-4835(90)90005-F; PEARSON SJ, 1992, NEUROSCI LETT, V144, P199, DOI 10.1016/0304-3940(92)90749-W; REDDY VN, 1971, EXP EYE RES, V11, P310, DOI 10.1016/S0014-4835(71)80043-X; Sala A, 2004, J BIOL CHEM, V279, P51033, DOI 10.1074/jbc.M408242200; Shamsi FA, 1998, INVEST OPHTH VIS SCI, V39, P2355; Shirao Y, 2000, JPN J OPHTHALMOL, V44, P198, DOI 10.1016/S0021-5155(00)00151-9; Simat TJ, 1998, J AGR FOOD CHEM, V46, P490, DOI 10.1021/jf970818c; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; SPECTOR A, 1972, ISRAEL J MED SCI, V8, P1577; Streete IM, 2004, INVEST OPHTH VIS SCI, V45, P4091, DOI 10.1167/iovs.04-0178; Taylor LM, 2002, EXP EYE RES, V75, P165, DOI 10.1006/exer.2002.2012; Vazquez S, 2000, FREE RADICAL RES, V32, P11, DOI 10.1080/10715760000300021; Vazquez S, 2004, INVEST OPHTH VIS SCI, V45, P879, DOI 10.1167/iovs.03-0558; Vazquez S, 2002, J BIOL CHEM, V277, P4867, DOI 10.1074/jbc.M107529200; Wolf AM, 2004, CLIN IMMUNOL, V113, P47, DOI 10.1016/j.clim.2004.05.004; XIE PY, 1991, OPHTHALMIC RES, V23, P133, DOI 10.1159/000267112; Zampighi GA, 2000, EXP EYE RES, V71, P415, DOI 10.1006/exer.2000.0895; Zhang H, 2004, FREE RADICAL BIO MED, V36, P1355, DOI 10.1016/j.freeradbiomed.2004.02.038	44	22	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22154	22164		10.1074/jbc.M501419200	http://dx.doi.org/10.1074/jbc.M501419200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817458	hybrid			2022-12-25	WOS:000229557900060
J	van Doorn-Khosrovani, SBV; Spensberger, D; de Knegt, Y; Tang, M; Lowenberg, B; Delwel, R				van Doorn-Khosrovani, SBV; Spensberger, D; de Knegt, Y; Tang, M; Lowenberg, B; Delwel, R			Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia	ONCOGENE			English	Article						ETV6; TEL; AML	CHRONIC MYELOMONOCYTIC LEUKEMIA; MESSENGER-RNA DECAY; GENE; FUSION; EXPRESSION; BETA; DIFFERENTIATION; OLIGOMERIZATION; CLASSIFICATION; IDENTIFICATION	ETV6 (ets translocation variant gene 6) TEL ( translocation ets leukemia), encoding a transcriptional repressor, is involved in various translocations associated with human malignancies. Strikingly, the nonrearranged ETV6 allele is often deleted or inactivated in cells harboring these translocations. Although ETV6 translocations are infrequent in acute myeloid leukemia (AML), mutations or deregulated expression of ETV6 may contribute to leukemogenesis. To investigate the involvement of ETV6 in AML, we analysed 300 newly diagnosed patients for mutations in the coding region of the gene. Furthermore, we studied protein expression in 77 patients using two ETV6-specific antibodies. Five somatic heterozygous mutations were detected, which affected either the homodimerization- or the DNA-binding domain of ETV6. The proteins translated from the cDNAs of these mutants were unable to repress transcription and showed dominant-negative effects. In addition, we demonstrate that one-third of AML patients have deficient ETV6 protein expression, which is not related to ETV6 mRNA expression levels. In conclusion, we demonstrate that ETV6 abnormalities are not restricted to translocations and occur more frequently in AML than previously thought. Additional comprehensive studies are required to de. ne the clinical consequence of ETV6 loss of function in AML.	Erasmus MC, Dept Hematol, NL-3015 GE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Delwel, R (corresponding author), Erasmus MC, Dept Hematol, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.	h.delwel@erasmusmc.nl		Spensberger, Dominik/0000-0002-9798-2949; Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar/0000-0003-1239-9867				Agape P, 1997, BRIT J HAEMATOL, V98, P234, DOI 10.1046/j.1365-2141.1997.1973014.x; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Alexander FE, 2001, CANCER RES, V61, P2542; Andreasson P, 2001, CANCER GENET CYTOGEN, V130, P93, DOI 10.1016/S0165-4608(01)00518-0; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; BUIJS A, 1995, ONCOGENE, V10, P1511; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Goseki-Sone M, 2001, J BONE MINER METAB, V19, P263, DOI 10.1007/s007740170030; Hermans MHA, 2003, BLOOD, V101, P2584, DOI 10.1182/blood-2002-07-2062; Hernandez JM, 2000, HAEMATOLOGICA, V85, P31; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Iwase S, 1998, INT J HEMATOL, V67, P361; Joosten M, 2004, J BIOL CHEM, V279, P38169, DOI 10.1074/jbc.M401283200; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kibel AS, 1999, GENE CHROMOSOME CANC, V25, P270, DOI 10.1002/(SICI)1098-2264(199907)25:3<270::AID-GCC9>3.3.CO;2-Q; Kibel AS, 2002, PROSTATE, V52, P305, DOI 10.1002/pros.10112; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lamba JK, 2003, HUM MOL GENET, V12, P99, DOI 10.1093/hmg/ddg011; Liu TC, 2000, AM J HEMATOL, V63, P170, DOI 10.1002/(SICI)1096-8652(200004)63:4<170::AID-AJH2>3.0.CO;2-0; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; LOWENBERG B, 1985, BLOOD, V66, P1225; Odero MD, 2001, GENE CHROMOSOME CANC, V31, P134, DOI 10.1002/gcc.1127; Patel N, 2003, BRIT J HAEMATOL, V122, P94, DOI 10.1046/j.1365-2141.2003.04399.x; Perrin-Vidoz L, 2002, HUM MOL GENET, V11, P2805, DOI 10.1093/hmg/11.23.2805; Plaschke Jens, 2004, Hum Mutat, V23, P285, DOI 10.1002/humu.9217; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Poirel H, 1998, ONCOGENE, V16, P2895, DOI 10.1038/sj.onc.1201817; Romana SP, 1996, LEUKEMIA, V10, P167; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Schell T, 2002, GENOME BIOL, V3; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459; Waga K, 2003, ONCOGENE, V22, P59, DOI 10.1038/sj.onc.1206072; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wlodarska I, 1996, LEUKEMIA LYMPHOMA, V23, P287, DOI 10.3109/10428199609054831; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100	48	53	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4129	4137		10.1038/sj.onc.1208588	http://dx.doi.org/10.1038/sj.onc.1208588			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806161				2022-12-25	WOS:000229680300011
J	Beischlag, TV; Perdew, GH				Beischlag, TV; Perdew, GH			ER alpha-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; ESTROGEN-RECEPTOR; GLUCOCORTICOID-RECEPTOR; NUCLEAR TRANSLOCATOR; DNA-BINDING; TESTICULAR CANCER; CROSS-TALK; IN-VIVO; KAPPA-B; C-JUN	The aryl hydrocarbon receptor (AHR) and the aryl hydrocarbon receptor nuclear translocator (ARNT) form a heterodimeric transcription factor upon binding a wide variety of environmental pollutants, including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). AHR target gene activation can be repressed by estrogen and estrogen-like compounds. In this study, we demonstrate that a significant component of TCDD-inducible Cyp1a1 transcription is the result of recruitment of estrogen receptor (ER)-alpha by AHR/ARNT as a transcriptional corepressor. Both AHR and ARNT were capable of interacting directly with ER alpha, as ascertained by glutathione S-transferase pull-down. 17 beta-estradiol repressed TCDD-activated Cyp1a1 and Cyp1b1 gene transcription in MCF-7 cells in the presence of cycloheximide, as determined by reverse transcription/real-time PCR. Furthermore, chromatin immunoprecipitation (ChIP) assays have shown that ER alpha is present at the Cyp1a1 enhancer only after co-treatment with E2 and TCDD, in MCF-7 cells. Sequential two-step ChIP assays were performed which demonstrate that AHR and ER alpha are present together at the same time on the Cyp1a1 enhancer during transrepression. Taken together these data support a role for ER-mediated transrepression of AHR-dependent gene regulation.	Penn State Univ, Dept Vet Sci, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Perdew, GH (corresponding author), Penn State Univ, Dept Vet Sci, Ctr Mol Toxicol & Carcinogenesis, Life Sci Bldg,Rm 309A, University Pk, PA 16802 USA.	ghp2@psu.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004869, R29ES004869] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04869] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexander DL, 1998, J CELL SCI, V111, P3311; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Beischlag TV, 2004, J BIOL CHEM, V279, P54620, DOI 10.1074/jbc.M410456200; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Brunnberg S, 2003, P NATL ACAD SCI USA, V100, P6517, DOI 10.1073/pnas.1136688100; Carlson DB, 2002, J BIOCHEM MOL TOXIC, V16, P317, DOI 10.1002/jbt.10051; Carver LA, 1997, J BIOL CHEM, V272, P11452; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; Elizondo G, 2000, MOL PHARMACOL, V57, P1056; FERNANDEZSALGUE.P, 1995, SCIENCE NEW YORK N Y, V0268; FERNANDEZSALGUERO, 1996, TOXICOL APPL PHARM, V140, P173; FOLEY S, 1995, BRIT J UROL, V76, P495, DOI 10.1111/j.1464-410X.1995.tb07755.x; Glass CK, 2000, GENE DEV, V14, P121; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Imaida K, 2000, Nihon Rinsho, V58, P2527; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kazerouni N, 2000, AM J IND MED, V38, P410, DOI 10.1002/1097-0274(200010)38:4<410::AID-AJIM6>3.0.CO;2-5; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kharat I, 1996, J BIOL CHEM, V271, P10533, DOI 10.1074/jbc.271.18.10533; Klinge CM, 2000, ARCH BIOCHEM BIOPHYS, V373, P163, DOI 10.1006/abbi.1999.1552; Kobayashi A, 1997, J BIOCHEM, V122, P703; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; Kumar MB, 1999, GENE EXPRESSION, V8, P273; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Ma Q, 1997, J BIOL CHEM, V272, P8878; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Moline JM, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3434987; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Ohlson CG, 2000, CHEMOSPHERE, V40, P1277, DOI 10.1016/S0045-6535(99)00380-X; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Peters JM, 1999, TOXICOL SCI, V47, P86, DOI 10.1093/toxsci/47.1.86; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; Reen RK, 2002, ARCH BIOCHEM BIOPHYS, V408, P93, DOI 10.1016/S0003-9861(02)00518-0; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Ricci MS, 1999, IN VITRO CELL DEV-AN, V35, P183, DOI 10.1007/s11626-999-0025-5; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Safe S, 2003, CHEM RES TOXICOL, V16, P807, DOI 10.1021/tx034036r; Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Tsuchiya Y, 2004, CANCER RES, V64, P3119, DOI 10.1158/0008-5472.CAN-04-0166; Tyree CM, 2002, J STEROID BIOCHEM, V80, P291, DOI 10.1016/S0960-0760(02)00022-5; Wang S, 2004, J BIOL CHEM, V279, P13593, DOI 10.1074/jbc.M312274200; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	51	150	157	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21607	21611		10.1074/jbc.C500090200	http://dx.doi.org/10.1074/jbc.C500090200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15837795	hybrid			2022-12-25	WOS:000229438800085
J	Gianakopoulos, PJ; Skerjanc, IS				Gianakopoulos, PJ; Skerjanc, IS			Hedgehog signaling induces cardiomyogenesis in P19 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR 2C; CENTRAL-NERVOUS-SYSTEM; HEART TUBE FORMATION; LEFT-RIGHT ASYMMETRY; SONIC-HEDGEHOG; TRANSCRIPTION FACTOR; MUSCLE DEVELOPMENT; SKELETAL-MUSCLE; MUTANT MICE; GLI PROTEINS	Sonic Hedgehog (Shh) is a critical signaling factor for a variety of developmental pathways during embryogenesis, including the specification of left-right asymmetry in the heart. Mice that lack Hedgehog signaling show a delay in the induction of cardiomyogenesis, as indicated by a delayed expression of Nkx2-5. To further examine a role for Shh in cardiomyogenesis, clonal populations of P19 cells that stably express Shh, termed P19( Shh) cells, were isolated. In monolayer P19( Shh) cultures the Shh pathway was functional as shown by the up-regulation of Ptc1 and Gli1 expression, but no cardiac muscle markers were activated. However, Shh expression induced cardiomyogenesis following cellular aggregation, resulting in the expression of factors expressed in cardiac muscle including GATA-4, MEF2C, and Nkx2-5. Furthermore, aggregated P19 cell lines expressing Gli2 or Meox1 also up-regulated the expression of cardiac muscle factors, leading to cardiomyogenesis. Meox1 up-regulated the expression of Gli1 and Gli2 and, thus, can modify the Shh signaling pathway. Finally, Shh, Gli2, and Meox1 all up-regulated BMP-4 expression, implying that activation of the Hedgehog pathway can regulate bone morphogenetic protein signals. Taken together, we propose a model in which Shh, functioning via Gli1/2, can specify mesodermal cells into the cardiac muscle lineage.	Univ Ottawa, Dep Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	University of Ottawa; Western University (University of Western Ontario)	Skerjanc, IS (corresponding author), Univ Ottawa, Dep Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	iskerjan@uottawa.ca	Skerjanc, Ilona/AAN-3318-2020					ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Alsan BH, 2002, DEVELOPMENT, V129, P1935; Andree B, 1998, MECH DEVELOP, V70, P119, DOI 10.1016/S0925-4773(97)00186-X; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Borycki AG, 2000, DEVELOPMENT, V127, P2075; Cai J, 2000, GENESIS, V27, P6, DOI 10.1002/1526-968X(200005)27:1<6::AID-GENE20>3.3.CO;2-F; Candia AF, 1996, INT J DEV BIOL, V40, P1179; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Craven SE, 2004, DEVELOPMENT, V131, P1165, DOI 10.1242/dev.01024; Ding Q, 1998, DEVELOPMENT, V125, P2533; Dodou E, 2004, DEVELOPMENT, V131, P3931, DOI 10.1242/dev.01256; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Eisenberg CA, 1999, DEV DYNAM, V216, P45, DOI 10.1002/(SICI)1097-0177(199909)216:1<45::AID-DVDY7>3.0.CO;2-L; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Grepin C, 1997, DEVELOPMENT, V124, P2387; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jamali M, 2001, J BIOL CHEM, V276, P42252, DOI 10.1074/jbc.M107814200; Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756-3282(01)00470-7; Kim JH, 2001, CLIN GENET, V59, P306, DOI 10.1034/j.1399-0004.2001.590503.x; Kos L, 1998, MECH DEVELOP, V70, P25, DOI 10.1016/S0925-4773(97)00168-8; Koyabu Y, 2001, J BIOL CHEM, V276, P6889, DOI 10.1074/jbc.C000773200; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lee J, 1997, DEVELOPMENT, V124, P2537; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Mankoo BS, 2003, DEVELOPMENT, V130, P4655, DOI 10.1242/dev.00687; Mankoo BS, 1999, NATURE, V400, P69, DOI 10.1038/21892; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Matise MP, 1998, DEVELOPMENT, V125, P2759; Ming JE, 1998, MOL MED TODAY, V4, P343, DOI 10.1016/S1357-4310(98)01299-4; Mizugishi K, 2001, J BIOL CHEM, V276, P2180, DOI 10.1074/jbc.M004430200; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Nakamura T, 2003, P NATL ACAD SCI USA, V100, P5834, DOI 10.1073/pnas.0935626100; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; Ogura H, 2001, BEHAV GENET, V31, P317, DOI 10.1023/A:1012235510600; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Petropoulos H, 2004, J BIOL CHEM, V279, P23874, DOI 10.1074/jbc.M312612200; Petropoulos H, 2002, J BIOL CHEM, V277, P15393, DOI 10.1074/jbc.M112141200; Platt KA, 1997, MECH DEVELOP, V62, P121, DOI 10.1016/S0925-4773(96)00648-X; Purandare SM, 2002, DEVELOPMENT, V129, P2293; Reecy JM, 1999, DEVELOPMENT, V126, P839; Reifers F, 2000, DEVELOPMENT, V127, P225; Ridgeway AG, 2000, J BIOL CHEM, V275, P41, DOI 10.1074/jbc.275.1.41; Ridgeway AG, 2001, J BIOL CHEM, V276, P19033, DOI 10.1074/jbc.M011491200; Ridgeway AG, 2000, J BIOL CHEM, V275, P32398, DOI 10.1074/jbc.M004349200; Rodrigo I, 2004, MOL CELL BIOL, V24, P2757, DOI 10.1128/MCB.24.7.2757-2766.2004; Rogerson PJ, 2002, FEBS LETT, V524, P134, DOI 10.1016/S0014-5793(02)03024-7; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Schilling TF, 1999, DEV BIOL, V210, P277, DOI 10.1006/dbio.1999.9214; Schultheiss TM, 1997, COLD SPRING HARB SYM, V62, P413; Searcy RD, 1998, DEVELOPMENT, V125, P4461; SKERJANC IS, 1994, MOL CELL BIOL, V14, P8451, DOI 10.1128/MCB.14.12.8451; Skerjanc IS, 2000, FEBS LETT, V472, P53, DOI 10.1016/S0014-5793(00)01438-1; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; Skopicki HA, 1997, CIRC RES, V80, P452, DOI 10.1161/01.RES.80.4.452; Tsukui T, 1999, P NATL ACAD SCI USA, V96, P11376, DOI 10.1073/pnas.96.20.11376; Wilton S, 1999, IN VITRO CELL DEV-AN, V35, P175; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3	72	55	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21022	21028		10.1074/jbc.M502977200	http://dx.doi.org/10.1074/jbc.M502977200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15793308	hybrid			2022-12-25	WOS:000229438800016
J	Gravielle, MC; Faris, R; Russek, SJ; Farb, DH				Gravielle, MC; Faris, R; Russek, SJ; Farb, DH			GABA induces activity dependent delayed-onset uncoupling of GABA/benzodiazepine site interactions in neocortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT MESSENGER-RNAS; CHRONIC BENZODIAZEPINE TREATMENT; AMINOBUTYRIC ACID(A) RECEPTORS; NEONATAL-RAT HIPPOCAMPUS; CHRONIC AGONIST EXPOSURE; A RECEPTOR; DOWN-REGULATION; CORTICAL-NEURONS; ALLOSTERIC INTERACTIONS; INHIBITORY SYNAPSES	Changes in the function of type A gamma-aminobutyric acid receptors ( GABAARs) are associated with neuronal development and tolerance to the sedative-hypnotic effects of GABA(A)R positive modulators. Persistent activation of GABAARs by millimolar concentrations of GABA occurs under physiological conditions as GABAergic fast-spiking neurons in neocortex and cerebellum exhibit basal firing rates of 5 to 50 Hz and intermittent rates up to 250 Hz, leaving a substantial fraction of synaptic receptors occupied persistently by GABA. Persistent exposure of neurons to GABA has been shown to cause a down-regulation of receptor number and an uncoupling of GABA/benzodiazepine (BZD) site interactions with a half-life of similar to 24 h. Here, we report that a single brief exposure of neocortical neurons in primary culture to GABA for 5 - 10 min (t(1/ 2) = 3.2 +/- 0.2 min) initiates a process that results in uncoupling hours later (t(1/ 2) = 12.1 +/- 2.2 h). Initiation of delayed-onset uncoupling is blocked by co-incubation with picrotoxin or alpha-amanitin but is insensitive to nifedipine, indicating that uncoupling is contingent upon receptor activation and transcription but is not dependent on voltage-gated Ca2+ influx. Delayed-onset uncoupling occurs without a change in receptor number or a change in the proportion of alpha 1 subunit pharmacology, as zolpidem binding affinity is unaltered. Such activity dependent latent modulation of GABAAR function that manifests as delayed-onset uncoupling may be relevant to physiological, pathophysiological, and pharmacological conditions where synaptic receptors are transiently exposed to GABA agonists for several minutes.	Boston Univ, Sch Med, Dept Pharmacol, Mol Neurobiol Lab, Boston, MA 02118 USA	Boston University	Farb, DH (corresponding author), Boston Univ, Sch Med, Dept Pharmacol, Mol Neurobiol Lab, Boston, MA 02118 USA.	dfarb@bu.edu	Farb, david H/C-7089-2014	Farb, david H/0000-0002-9050-6480; Russek, Shelley/0000-0001-7547-3089; Gravielle, Maria/0000-0003-4353-5526				Ali NJ, 2001, J NEUROCHEM, V79, P1100, DOI 10.1046/j.1471-4159.2001.00664.x; BAUMGARTNER BJ, 1994, MOL BRAIN RES, V26, P9, DOI 10.1016/0169-328X(94)90068-X; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; Benes FM, 1996, NEUROSCIENCE, V75, P1021, DOI 10.1016/0306-4522(96)00328-4; Benke D, 2004, J BIOL CHEM, V279, P43654, DOI 10.1074/jbc.M407154200; Bianchi MT, 2001, J NEUROSCI, V21, P9083, DOI 10.1523/JNEUROSCI.21-23-09083.2001; BORDEN LA, 1988, MOL PHARMACOL, V34, P354; BORDEN LA, 1984, SCIENCE, V226, P857, DOI 10.1126/science.6093257; Brandon NJ, 2002, PHARMACOL THERAPEUT, V94, P113, DOI 10.1016/S0163-7258(02)00175-4; Caillard O, 1999, J NEUROSCI, V19, P7568, DOI 10.1523/JNEUROSCI.19-17-07568.1999; Caillard O, 1999, J PHYSIOL-LONDON, V518, P109, DOI 10.1111/j.1469-7793.1999.0109r.x; Chen S, 1999, NEUROSCIENCE, V93, P33, DOI 10.1016/S0306-4522(99)00118-9; Cheron G, 2004, J NEUROSCI, V24, P434, DOI 10.1523/JNEUROSCI.3197-03.2004; CHOI DW, 1977, NATURE, V269, P342, DOI 10.1038/269342a0; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; Cohen I, 2002, SCIENCE, V298, P1418, DOI 10.1126/science.1076510; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; Czurko A, 1999, EUR J NEUROSCI, V11, P344, DOI 10.1046/j.1460-9568.1999.00446.x; Follesa P, 2000, MOL PHARMACOL, V57, P1262; FRIEDMAN L, 1993, MOL PHARMACOL, V44, P191; Friedman LK, 1996, BRAIN RES, V707, P100, DOI 10.1016/0006-8993(95)01226-5; Fujiwara-Tsukamoto Y, 2004, J PHYSIOL-LONDON, V557, P961, DOI 10.1113/jphysiol.2003.059915; Gaiarsa JL, 2002, TRENDS NEUROSCI, V25, P564, DOI 10.1016/S0166-2236(02)02269-5; GALLAGER DW, 1984, NATURE, V308, P74, DOI 10.1038/308074a0; GYENES M, 1994, MOL PHARMACOL, V46, P542; HAIGH JRM, 1988, TRENDS PHARMACOL SCI, V9, P361, DOI 10.1016/0165-6147(88)90255-6; Hajos N, 2004, J NEUROSCI, V24, P9127, DOI 10.1523/JNEUROSCI.2113-04.2004; Holt RA, 1999, J NEUROCHEM, V72, P2219, DOI 10.1046/j.1471-4159.1999.0722219.x; HU XJ, 1994, MOL PHARMACOL, V45, P618; HU XJ, 1994, J PHARMACOL EXP THER, V270, P485; Hutchinson PJ, 2002, J NEUROL NEUROSUR PS, V72, P99, DOI 10.1136/jnnp.72.1.99; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Kanematsu T, 2002, EMBO J, V21, P1004, DOI 10.1093/emboj/21.5.1004; Khaliq ZM, 2005, J NEUROSCI, V25, P454, DOI 10.1523/JNEUROSCI.3045-04.2005; KLEIN RL, 1994, J NEUROCHEM, V63, P2349; Luscher B, 2004, PHARMACOL THERAPEUT, V102, P195, DOI 10.1016/j.pharmthera.2004.04.003; Lyons HR, 2001, J NEUROCHEM, V78, P1114, DOI 10.1046/j.1471-4159.2001.00501.x; Lyons HR, 2000, J NEUROCHEM, V74, P1041, DOI 10.1046/j.1471-4159.2000.0741041.x; Mehta AK, 1999, MOL BRAIN RES, V67, P194, DOI 10.1016/S0169-328X(99)00020-0; Miranda JD, 1997, J BIOL CHEM, V272, P16288, DOI 10.1074/jbc.272.26.16288; MONTPIED P, 1991, J BIOL CHEM, V266, P6011; MOUNTCASTLE VB, 1969, J NEUROPHYSIOL, V32, P452, DOI 10.1152/jn.1969.32.3.452; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; Poulter MO, 1997, J NEUROCHEM, V68, P631; PRASAD A, 1992, BRAIN RES, V591, P327, DOI 10.1016/0006-8993(92)91714-P; PUIA G, 1991, MOL PHARMACOL, V39, P691; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; ROCA DJ, 1990, MOL PHARMACOL, V37, P710; ROCA DJ, 1990, MOL PHARMACOL, V37, P37; ROCA DJ, 1988, MOL PHARMACOL, V33, P481; Russek SJ, 2000, P NATL ACAD SCI USA, V97, P8600, DOI 10.1073/pnas.97.15.8600; SEIDEL WF, 1985, PSYCHOPHARMACOLOGY, V87, P194, DOI 10.1007/BF00431806; Smith AJ, 2001, MOL PHARMACOL, V59, P1108, DOI 10.1124/mol.59.5.1108; Smith SS, 1998, J NEUROSCI, V18, P5275, DOI 10.1523/JNEUROSCI.18-14-05275.1998; Sun MK, 2001, J NEUROPHYSIOL, V85, P269, DOI 10.1152/jn.2001.85.1.269; SWIFT CG, 1984, AGE AGEING, V13, P335, DOI 10.1093/ageing/13.6.335; Takayama C, 2004, NEUROSCI RES, V50, P447, DOI 10.1016/j.neures.2004.08.012; Tietz EI, 1999, NEUROSCIENCE, V91, P327, DOI 10.1016/S0306-4522(98)00516-8; Tietz EI, 1999, J PHARMACOL EXP THER, V291, P932; Timofeev I, 2002, NEUROSCIENCE, V114, P1115, DOI 10.1016/S0306-4522(02)00300-7; WAFFORD KA, 1993, MOL PHARMACOL, V43, P240; Walsh LA, 1999, J PHARMACOL EXP THER, V289, P1626; West AE, 2002, NAT REV NEUROSCI, V3, P921, DOI 10.1038/nrn987; WONG G, 1994, MOL PHARMACOL, V46, P1056	65	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20954	20960		10.1074/jbc.M500131200	http://dx.doi.org/10.1074/jbc.M500131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15805111	hybrid, Green Published			2022-12-25	WOS:000229438800008
J	Hu, XY; Kohler, K; Falick, AM; Moore, AMF; Jones, PR; Sparkman, OD; Vierra, C				Hu, XY; Kohler, K; Falick, AM; Moore, AMF; Jones, PR; Sparkman, OD; Vierra, C			Egg case protein-1 - A new class of silk proteins with fibroin-like properties from the spider Latrodectus hesperus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR AMPULLATE SILK; MECHANICAL-PROPERTIES; DRAGLINE SILK; GENE FAMILY; BLACK-WIDOW; SEQUENCE; CONSERVATION; ARANEIDAE; FIBER; CDNA	Spiders produce multiple types of silk that exhibit diverse mechanical properties and biological functions. Most molecular studies of spider silk have focused on fibroins from dragline silk and capture silk, two important silk types involved in the survival of the spider. In our studies we have focused on the characterization of egg case silk, a third silk fiber produced by the black widow spider, Latrodectus hesperus. Analysis of the physical structure of egg case silk using scanning electron microscopy demonstrates the presence of small and large diameter fibers. By using the strong protein denaturant 8 M guanidine hydrochloride to solubilize the fibers, we demonstrated by SDS-PAGE and protein silver staining that an abundant component of egg case silk is a 100-kDa protein doublet. Combining matrix-assisted laser desorption ionization tandem time-of-flight mass spectrometry and reverse genetics, we have isolated a novel gene called ecp-1, which encodes for one of the protein components of the 100-kDa species. BLAST searches of the NCBInr protein data base using the primary sequence of ECP-1 revealed similarity to fibroins from spiders and silkworms, which mapped to two distinct regions within the ECP-1. These regions contained the conserved repetitive fibroin motifs poly( Ala) and poly(Gly-Ala), but surprisingly, no larger ensemble repeats could be identified within the primary sequence of ECP-1. Consistent with silk gland-restricted patterns of expression for fibroins, ECP-1 was demonstrated to be predominantly produced in the tubuliform gland, with lower levels detected in the major and minor ampullate glands. ECP-1 monomeric units were also shown to assemble into higher aggregate structures through the formation of disulfide bonds via a unique cysteine-rich N-terminal region. Collectively, our findings provide new insight into the components of egg case silk and identify a new class of silk proteins with distinctive molecular features relative to traditional members of the spider silk gene family.	Univ Pacific, Dept Sci Biol, Stockton, CA 95211 USA; Univ Pacific, Dept Chem, Stockton, CA 95211 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of the Pacific; University of the Pacific; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Vierra, C (corresponding author), Univ Pacific, Dept Sci Biol, 3601 Pacific Ave, Stockton, CA 95211 USA.	cvierra@pacific.edu		Kohler, Kristin/0000-0001-7753-843X				Altman GH, 2002, BIOMATERIALS, V23, P4131, DOI 10.1016/S0142-9612(02)00156-4; Arcidiacono S, 1998, APPL MICROBIOL BIOT, V49, P31, DOI 10.1007/s002530051133; BECKWITT R, 1994, J BIOL CHEM, V269, P6661; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; CANDELAS G, 1983, BIOCHEM BIOPH RES CO, V116, P1033, DOI 10.1016/S0006-291X(83)80246-0; Casem ML, 1999, INT J BIOL MACROMOL, V24, P103, DOI 10.1016/S0141-8130(98)00078-6; Colgin MA, 1998, PROTEIN SCI, V7, P667, DOI 10.1002/pro.5560070315; Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214; Foradori MJ, 2002, J MORPHOL, V252, P218, DOI 10.1002/jmor.1100; FORLIX RF, 1996, BIOL SPIDERS, P1; Gatesy J, 2001, SCIENCE, V291, P2603, DOI 10.1126/science.1057561; Gosline JM, 1999, J EXP BIOL, V202, P3295; Guerette PA, 1996, SCIENCE, V272, P112, DOI 10.1126/science.272.5258.112; Hayashi CY, 1999, INT J BIOL MACROMOL, V24, P271, DOI 10.1016/S0141-8130(98)00089-0; Hayashi CY, 2004, MOL BIOL EVOL, V21, P1950, DOI 10.1093/molbev/msh204; Hayashi CY, 2000, SCIENCE, V287, P1477, DOI 10.1126/science.287.5457.1477; Hayashi CY, 1998, J MOL BIOL, V275, P773, DOI 10.1006/jmbi.1997.1478; HINMAN MB, 1992, J BIOL CHEM, V267, P19320; Hoffman RT, 1996, J BIOL CHEM, V271, P9809, DOI 10.1074/jbc.271.16.9809; JIMENEZ CR, 1998, CURRENT PROTOCOLS PR; Jin HJ, 2003, NATURE, V424, P1057, DOI 10.1038/nature01809; Lawrence BA, 2004, BIOMACROMOLECULES, V5, P689, DOI 10.1021/bm0342640; MELLO CM, 1994, ACS SYM SER, V544, P67; Mitchell B, 2000, BBA-GENE STRUCT EXPR, V1492, P320, DOI 10.1016/S0167-4781(00)00109-3; Nguyen L, 2001, NUCLEIC ACIDS RES, V29, P4423, DOI 10.1093/nar/29.21.4423; Parkhe AD, 1997, J MOL RECOGNIT, V10, P1, DOI 10.1002/(SICI)1099-1352(199701/02)10:1<1::AID-JMR338>3.0.CO;2-7; Sambrook J., 2002, MOL CLONING LAB MANU; Sekiguchi K., 1955, Science Reports Tokyo Kyoiku Daigaku, V8B, P23; Tian MZ, 2004, BIOMACROMOLECULES, V5, P657, DOI 10.1021/bm034391w; TILLINGHAST EK, 1981, NATURWISSENSCHAFTEN, V68, P526, DOI 10.1007/BF00365384; Vollrath F, 2001, NATURE, V410, P541, DOI 10.1038/35069000; XU M, 1990, P NATL ACAD SCI USA, V87, P7120, DOI 10.1073/pnas.87.18.7120	32	45	48	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21220	21230		10.1074/jbc.M412316200	http://dx.doi.org/10.1074/jbc.M412316200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797873	hybrid			2022-12-25	WOS:000229438800040
J	Park, EH; Lee, JM; Blais, JD; Bell, JC; Pelletier, J				Park, EH; Lee, JM; Blais, JD; Bell, JC; Pelletier, J			Internal translation initiation mediated by the angiogenic factor Tie2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; RIBOSOME ENTRY SITE; FACTOR MESSENGER-RNA; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; GROWTH-FACTOR GENE; C-MYC; EFFICIENT TRANSLATION; ENDOTHELIAL-CELLS; ORNITHINE DECARBOXYLASE; SECONDARY STRUCTURE	Tie2 is an endothelium-specific receptor tyrosine kinase required for normal blood vessel maturation. We report that Tie2 mRNA translation is maintained under hypoxic conditions. To identify the mechanism responsible for this, we undertook structure/function analysis of the Tie2 5'-untranslated region (UTR). Transcription start site mapping indicates the existence of a several mRNA isoforms containing unusually long 5'-UTRs (> 350 nucleotides) with five upstream open reading frames. We find internal ribosome binding activity that allows the Tie2 mRNA to initiate in a cap-independent fashion. Our data provide a framework for understanding how Tie2 mRNA is translated despite a cumbersome structured 5'-UTR and how its production is secured under unfavorable environmental conditions.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Ottawa Reg Canc Ctr, Res Labs, Ottawa, ON K1H 8L6, Canada	McGill University; McGill University; University of Ottawa; Ottawa Hospital Research Institute	Park, EH (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,Rom 810,3655 Promenade Sir, Montreal, PQ H3G 1Y6, Canada.	jerry.pelletier@mcgill.ca						Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Christensen RA, 2002, J CELL BIOCHEM, V85, P505, DOI 10.1002/jcb.10148; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Fadel BM, 1998, BIOCHEM J, V330, P335; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GEHRKE L, 1983, BIOCHEMISTRY-US, V22, P5157, DOI 10.1021/bi00291a015; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gorlach A, 2000, BBA-GENE STRUCT EXPR, V1493, P125, DOI 10.1016/S0167-4781(00)00172-X; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hewett PW, 1998, BIOCHEM BIOPH RES CO, V252, P546, DOI 10.1006/bbrc.1998.9690; HOFMANN GE, 1994, P NATL ACAD SCI USA, V91, P8492, DOI 10.1073/pnas.91.18.8492; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Jones N, 2001, EMBO REP, V2, P438, DOI 10.1093/embo-reports/kve093; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Lin SK, 2002, BIOCHEM BIOPH RES CO, V296, P710, DOI 10.1016/S0006-291X(02)00924-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Nanbru C, 2001, ONCOGENE, V20, P4270, DOI 10.1038/sj.onc.1204548; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Park YS, 2003, MICROVASC RES, V65, P125, DOI 10.1016/S0026-2862(02)00035-3; PARKIN NT, 1988, EMBO J, V7, P2831, DOI 10.1002/j.1460-2075.1988.tb03139.x; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Seidel ER, 1997, BRIT J PHARMACOL, V120, P571, DOI 10.1038/sj.bjp.0700936; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Svitkin YV, 2001, RNA, V7, P1743; Tinton SA, 1999, FEBS LETT, V446, P55, DOI 10.1016/S0014-5793(99)00185-4; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Willam C, 2000, CIRC RES, V87, P370; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3	50	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20945	20953		10.1074/jbc.M412744200	http://dx.doi.org/10.1074/jbc.M412744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802272	hybrid			2022-12-25	WOS:000229438800007
J	Sakamoto, A; Chen, M; Nakamura, T; Xie, T; Karsenty, G; Weinstein, LS				Sakamoto, A; Chen, M; Nakamura, T; Xie, T; Karsenty, G; Weinstein, LS			Deficiency of the G-protein alpha-subunit G(s)alpha in osteoblasts leads to differential effects on trabecular and cortical bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE; IN-VITRO; ALPHA-SUBUNIT; GROWTH-PLATE; OSTEOPROGENITOR CELLS; PTH/PTHRP RECEPTOR; PROSTAGLANDIN E-2; MC3T3-E1 CELLS; KNOCKOUT MICE; EXPRESSION	The G-protein alpha-subunit G(s)alpha is required for the intracellular cAMP responses to hormones and other agonists. G(s)alpha is known to mediate the cAMP response to parathyroid hormone and other hormones and cytokines in bone and cartilage. To analyze the in vivo role of G(s)alpha signaling in osteoblasts, we developed mice with osteoblast/osteocyte-specific G(s)alpha deficiency (BGsKO) by mating G(s)alpha-floxed mice with collagen I alpha 1 promoter-Cre recombinase transgenic mice. Early skeletal development was normal in BGsKO mice, because formation of the initial cartilage template and bone collar was unaffected. The chondrocytic zones of the growth plates also appeared normal in BGsKO mice. BGsKO mice had a defect in the formation of the primary spongiosa with reduced immature osteoid (new bone formation) and overall length, which led to reduced trabecular bone volume. In contrast, cortical bone was thickened with narrowing of the bone marrow cavity. This was probably due to decreased cortical bone resorption, because osteoclasts were markedly reduced on the endosteal surface of cortical bone. In addition, the expression of alkaline phosphatase, an early osteoblastic differentiation marker, was normal, whereas the expression of the late osteoblast differentiation markers osteopontin and osteocalcin was reduced, suggesting that the number of mature osteoblasts in bone is reduced. Expression of the osteoclast- stimulating factor receptor activator of NF-kappa B ligand was also reduced. Overall, our findings have similarities to parathyroid hormone null mice and confirm that the differential effects of parathyroid hormone on trabecular and cortical bone are primarily mediated via G(s)alpha in osteoblasts. Osteoblast-specific G(s)alpha deficiency leads to reduced bone turnover.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Baylor College of Medicine	Weinstein, LS (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 8C101, Bethesda, MD 20892 USA.	leew@amb.niddk.nih.gov	Nakamura, Takashi/P-7796-2016; Nakamura, Takashi/A-8931-2012; Weinstein, Lee S/I-5575-2015	Nakamura, Takashi/0000-0001-9904-1037; Nakamura, Takashi/0000-0001-9904-1037; Weinstein, Lee/0000-0002-1899-5152	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK043302, Z01DK043302] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bastepe M, 2004, P NATL ACAD SCI USA, V101, P14794, DOI 10.1073/pnas.0405091101; BELLOWS CG, 1990, ENDOCRINOLOGY, V127, P3111, DOI 10.1210/endo-127-6-3111; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296; Cao J, 2003, J BONE MINER RES, V18, P270, DOI 10.1359/jbmr.2003.18.2.270; Choi JY, 1996, J CELL BIOCHEM, V61, P609, DOI 10.1002/(SICI)1097-4644(19960616)61:4<609::AID-JCB15>3.3.CO;2-Q; Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226; Ishii-Suzuki M, 1999, ANAT REC, V255, P452, DOI 10.1002/(SICI)1097-0185(19990801)255:4<452::AID-AR10>3.0.CO;2-E; Ishizeki K, 2003, ANN ANAT, V185, P403, DOI 10.1016/S0940-9602(03)80097-3; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Kanematsu M, 2000, J BONE MINER RES, V15, P1321, DOI 10.1359/jbmr.2000.15.7.1321; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Lanske B, 1999, J CLIN INVEST, V104, P399, DOI 10.1172/JCI6629; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552; Li X, 2002, BONE, V30, P567, DOI 10.1016/S8756-3282(02)00683-X; Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054; Liu J, 2005, P NATL ACAD SCI USA, V102, P5513, DOI 10.1073/pnas.0408262102; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817; NISHIDA S, 1994, BONE, V15, P717, DOI 10.1016/8756-3282(94)90322-0; NODA M, 1988, J BIOL CHEM, V263, P18574; Okahashi N, 2004, INFECT IMMUN, V72, P1706, DOI 10.1128/IAI.72.3.1706-1714.2004; PARISIEN M, 1990, J CLIN ENDOCR METAB, V70, P930, DOI 10.1210/jcem-70-4-930; QUARLES LD, 1992, J BONE MINER RES, V7, P683; Rosen CJ, 2004, TRENDS ENDOCRIN MET, V15, P229, DOI 10.1016/j.tem.2004.05.005; Sakamoto A, 2005, J BONE MINER RES, V20, P663, DOI 10.1359/JBMR.041210; Sakamoto A, 2004, HUM MOL GENET, V13, P819, DOI 10.1093/hmg/ddh098; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; Skinner JA, 2002, GENOMICS, V80, P373, DOI 10.1006/geno.2002.6842; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Suda M, 1996, ENDOCRINOLOGY, V137, P1698, DOI 10.1210/en.137.5.1698; TURKSEN K, 1990, J CELL PHYSIOL, V142, P61, DOI 10.1002/jcp.1041420109; Weinstein LS, 2001, ENDOCR REV, V22, P675, DOI 10.1210/er.22.5.675; WEINSTEIN LS, 2002, PRINCIPLES BONE BIOL, P1165; Yu SH, 1998, P NATL ACAD SCI USA, V95, P8715, DOI 10.1073/pnas.95.15.8715; zur Nieden NI, 2003, DIFFERENTIATION, V71, P18, DOI 10.1046/j.1432-0436.2003.700602.x	40	68	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21369	21375		10.1074/jbc.M500346200	http://dx.doi.org/10.1074/jbc.M500346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797856	hybrid			2022-12-25	WOS:000229438800056
J	Zhang, R; Luo, DH; Miao, R; Bai, LF; Ge, QY; Sessa, WC; Min, W				Zhang, R; Luo, DH; Miao, R; Bai, LF; Ge, QY; Sessa, WC; Min, W			Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis	ONCOGENE			English	Article						Hsp90; Akt; ASK1; hydrogen peroxide; 17-allyamino-17-demethoxygeldanamycin (17-AAG); apoptosis	REGULATING KINASE 1; NITRIC-OXIDE SYNTHASE; KAPPA-B; ACTIVATION; STRESS; DISSOCIATION; SURVIVAL; NECROSIS; DOMAIN; TRANSCRIPTION	Hsp90 client protein Akt has been shown to inhibit cell apoptosis in part by inhibiting proapoptotic kinase ASK1 (apoptosis signal-regulating kinase 1) activity. In the present study, we show that Hsp90 inhibits hydrogen peroxide (H2O2)-induced ASK1-p38 activation in endothelial cells (EC). The inhibitory effect of Hsp90 on ASK1-p38 activities is diminished when the Akt phosphorylation site on ASK1 (pSer83) is absent or when Akt is genetically deleted in cells, suggesting that Hsp90 and Akt function together to inhibit ASK1-p38 signaling. Thus, inhibition of Hsp90 by 17-allyamino-17-demethoxy-geldanamycin (17-AAG) or phosphatidylinositol 3-kinase (PI3K) LY294002 induced and synergized ASK1 activation and ASK1-mediated EC apoptosis. Furthermore, we show that in resting EC Hsp90, Akt and ASK1 form a ternary complex in which both Akt and ASK1 bind to the middle domain of Hsp90, suggesting that Hsp90 may hold Akt and ASK1 in close proximity. The N-terminal domain of ASK1 containing the Akt phosphorylation site (pSer83) associates with Akt in resting state. However, Akt is released from the N-terminal domain concomitant with binding to the C-terminal domain of ASK1 in response to ASK1 activator H2O2, inhibitor of Hsp90 17-AAG and Akt inhibitor LY294002, leading to a more stable Hsp90Akt-ASK1 complex. We conclude that Hsp90-Akt forms a complex with ASK1 and protect EC from stress-induced apoptosis.	Yale Univ, Sch Med, Interdepartmental Program Vasc Biol & Transplanta, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06510 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA	Yale University; Yale University; Yale University	Min, W (corresponding author), Yale Univ, Sch Med, Interdepartmental Program Vasc Biol & Transplanta, 295 Congress Ave, New Haven, CT 06510 USA.	wang.min@yale.edu	Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL061371, R01HL061371, R01HL057665, P01HL070295, R01HL065978] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 57665, HL 65978, HL 67793, P01 HL 70295, HL 61371] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Min W, 1997, J IMMUNOL, V159, P3508; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Zhang BM, 1999, SMART MATER STRUCT, V8, P515, DOI 10.1088/0964-1726/8/4/310; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790	41	139	147	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3954	3963		10.1038/sj.onc.1208548	http://dx.doi.org/10.1038/sj.onc.1208548			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782121				2022-12-25	WOS:000229435300011
J	Basso, E; Fante, L; Fowlkes, J; Petronilli, V; Forte, MA; Bernardi, P				Basso, E; Fante, L; Fowlkes, J; Petronilli, V; Forte, MA; Bernardi, P			Properties of the permeability transition pore in mitochondria devoid of cyclophilin D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; INNER MEMBRANE; CULTURED-HEPATOCYTES; INORGANIC-PHOSPHATE; RAT HIPPOCAMPUS; CELL-DEATH; DAMAGE; MODULATION; REPERFUSION; PROTECTION	We have studied the properties of the permeability transition pore (PTP) in mitochondria from the liver of mice where the Ppif gene encoding for mitochondrial Cyclophilin D (CyP-D) had been inactivated. Mitochondria from Ppif(-/-) mice had no CyP-D and displayed a striking desensitization of the PTP to Ca2+, in that pore opening required about twice the Ca2+ load necessary to open the pore in strain-matched, wild-type mitochondria. Mitochondria lacking CyP-D were insensitive to Cyclosporin A (CsA), which increased the Ca2+ retention capacity only in mitochondria from wild-type mice. The PTP response to ubiquinone 0, depolarization, pH, adenine nucleotides, and thiol oxidants was similar in mitochondria from wild-type and Ppif(-/-) mice. These experiments demonstrate that (i) the PTP can form and open in the absence of CyP-D, (ii) that CyP-D represents the target for PTP inhibition by CsA, and (iii) that CyP-D modulates the sensitivity of the PTP to Ca2+ but not its regulation by the proton electrochemical gradient, adenine nucleotides, and oxidative stress. These results have major implications for our current understanding of the PTP and its modulation in vitro and in vivo.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Inst Neurosci, CNR, I-35121 Padua, Italy	Oregon Health & Science University; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Forte, MA (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, L474,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	forte@ohsu.edu; bernardi@bio.unipd.it	Basso, Emy/F-7687-2015; Petronilli, Valeria/C-3558-2015; Bernardi, Paolo/C-3656-2008	Basso, Emy/0000-0003-2962-7213; Petronilli, Valeria/0000-0003-4026-6404; Bernardi, Paolo/0000-0001-9187-3736	NIGMS NIH HHS [GM69883] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069883] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basso E, 2004, BIOPHYS J, V86, p357A; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BROEKEMEIER KM, 1992, FEBS LETT, V304, P192, DOI 10.1016/0014-5793(92)80616-O; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; CROMPTON M, 1988, BIOCHEM J, V255, P357; Crouser ED, 2002, CRIT CARE MED, V30, P276, DOI 10.1097/00003246-200202000-00002; DAVIDSON AM, 1990, BIOCHEM J, V268, P147, DOI 10.1042/bj2680147; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; Feldmann G, 2000, HEPATOLOGY, V31, P674, DOI 10.1002/hep.510310318; Ferrand-Drake M, 1999, NEUROSCIENCE, V90, P1325, DOI 10.1016/S0306-4522(98)00559-4; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; GRIFFITHS EJ, 1993, J MOL CELL CARDIOL, V25, P1461, DOI 10.1006/jmcc.1993.1162; HALESTRAP AP, 1991, BIOCHEM J, V278, P715, DOI 10.1042/bj2780715; Haouzi D, 2002, APOPTOSIS, V7, P395, DOI 10.1023/A:1020026923038; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P10014, DOI 10.1073/pnas.1633614100; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; LENARTOWICZ E, 1991, J BIOENERG BIOMEMBR, V23, P679, DOI 10.1007/BF00785817; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Lin DT, 2002, J BIOL CHEM, V277, P31134, DOI 10.1074/jbc.M112035200; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; SELWYN MJ, 1970, FEBS LETT, V10, P1, DOI 10.1016/0014-5793(70)80402-1; SNYDER JW, 1992, BIOCHEM PHARMACOL, V44, P833, DOI 10.1016/0006-2952(92)90425-I; Soriano ME, 2004, J BIOL CHEM, V279, P36803, DOI 10.1074/jbc.M405297200; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; ZOETEWEIJ JP, 1993, J BIOL CHEM, V268, P3384	44	646	672	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18558	18561		10.1074/jbc.C500089200	http://dx.doi.org/10.1074/jbc.C500089200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15792954	hybrid			2022-12-25	WOS:000228932300002
J	Abaan, OD; Levenson, A; Khan, O; Furth, PA; Uren, A; Toretsky, JA				Abaan, OD; Levenson, A; Khan, O; Furth, PA; Uren, A; Toretsky, JA			PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis	ONCOGENE			English	Article						PTPL1; phosphatase; EWS-FLI1; Ewing's sarcoma	PROTEIN-TYROSINE-PHOSPHATASE; FAS-ASSOCIATED PHOSPHATASE-1; KAPPA-B-ALPHA; PRIMITIVE NEUROECTODERMAL TUMOR; GTPASE-ACTIVATING PROTEIN; BREAST-CANCER CELLS; FACTOR-I RECEPTOR; GROWTH-FACTOR; MEDIATED APOPTOSIS; GENE-EXPRESSION	Ewing's Sarcoma family tumors (ESFT) are characterized by a translocation t(11: 22) forming an aberrant transcription factor EWS-FLI1. Protein tyrosine phosphatase L1 (PTPL1) was identified as a gene upregulated by EWS-FLI1 in transfected cells by microarray. Our results show that PTPL1 is a transcriptional target of EWS-FLI1 both by chromatin immunoprecipitation and promoter activation studies. We demonstrate that PTPL1 is highly expressed in ESFT cells and patient tumors compared with normal tissues, witha trend towards higher expression in metastatic versus primary tumors. Reduction of PTPL1 protein in ESFT cells correlated witha significant reduction in both monolayer and soft-agar cell growth. In addition, these PTPL1-reduced cells were more sensitive to etoposide-induced apoptosis than the controls. We therefore report a novel transcriptional activation of a phosphatase involved in the oncogenesis of ESFT. Increasing interest in specific phosphatase inhibitors would allow PTPL1 to be evaluated as a therapeutic target in ESFT.	Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA	Georgetown University	Toretsky, JA (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Res Bldg,Room W311,3970 Reservoir Rd,NW Box 57146, Washington, DC 20057 USA.	jat42@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA088004] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA088004, R01 CA88004] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baer C, 2004, INT J CANCER, V110, P687, DOI 10.1002/ijc.20171; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; Bompard G, 2003, J CELL SCI, V116, P2519, DOI 10.1242/jcs.00448; Bompard G, 2002, J BIOL CHEM, V277, P47861, DOI 10.1074/jbc.M208950200; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; Deneen B, 2003, CANCER RES, V63, P4268; Deneen B, 2003, MOL CELL BIOL, V23, P3897, DOI 10.1128/MCB.23.11.3897-3908.2003; Erdmann KS, 2003, EUR J BIOCHEM, V270, P4789, DOI 10.1046/j.1432-1033.2003.03895.x; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fan CG, 2002, J CELL SCI, V115, P4843, DOI 10.1242/jcs.00151; Freiss G, 1998, MOL ENDOCRINOL, V12, P568, DOI 10.1210/me.12.4.568; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Gil-Henn H, 2003, J BIOL CHEM, V278, P15579, DOI 10.1074/jbc.M210273200; Grier HE, 2003, NEW ENGL J MED, V348, P694, DOI 10.1056/NEJMoa020890; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Houghton JA, 1997, CLIN CANCER RES, V3, P2205; Irie S, 2001, DNA SEQUENCE, V11, P519, DOI 10.3109/10425170109041336; Ivanov VN, 2003, MOL CELL BIOL, V23, P3623, DOI 10.1128/MCB.23.10.3623-3635.2003; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Komada Y, 1997, BRIT J HAEMATOL, V99, P325, DOI 10.1046/j.1365-2141.1997.3903204.x; Kontny HU, 1998, CANCER RES, V58, P5842; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Lee SH, 1999, J PATHOL, V188, P207; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Maekawa K, 1999, BIOCHEM J, V337, P179, DOI 10.1042/0264-6021:3370179; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Mitsiades N, 1999, J NATL CANCER I, V91, P1678, DOI 10.1093/jnci/91.19.1678; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Myc A, 1999, ENDOCRINOLOGY, V140, P5431, DOI 10.1210/en.140.11.5431; Nakai Y, 2000, EUR J BIOCHEM, V267, P7170, DOI 10.1046/j.1432-1327.2000.01818.x; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; Saras J, 1997, J BIOL CHEM, V272, P24333, DOI 10.1074/jbc.272.39.24333; Saras J, 1997, J BIOL CHEM, V272, P20979, DOI 10.1074/jbc.272.34.20979; SARAS J, 1994, J BIOL CHEM, V269, P24082; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Thompson AD, 1996, ONCOGENE, V13, P2649; Toretsky JA, 1999, CANCER RES, V59, P5745; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Ungefroren H, 1998, CANCER RES, V58, P1741; Uren A, 2003, ONCOGENE, V22, P2334, DOI 10.1038/sj.onc.1206330; Uslu R, 1997, CLIN CANCER RES, V3, P963; Watanabe G, 2003, GENE CHROMOSOME CANC, V36, P224, DOI 10.1002/gcc.10153; XIAO S, 1994, J BIOL CHEM, V269, P21244; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	49	60	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2715	2722		10.1038/sj.onc.1208247	http://dx.doi.org/10.1038/sj.onc.1208247			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15782144				2022-12-25	WOS:000228356700013
J	Clarkson, AN; Liu, HZ; Rahman, R; Jackson, DM; Appleton, I; Kerr, DS				Clarkson, AN; Liu, HZ; Rahman, R; Jackson, DM; Appleton, I; Kerr, DS			Clomethiazole: mechanisms underlying lasting neuroprotection after hypoxia-ischemia	FASEB JOURNAL			English	Article						hippocampus; NOS; diaschisis; electrophysiology; arginase	NITRIC-OXIDE SYNTHASE; ORNITHINE-DECARBOXYLASE ACTIVITY; GAMMA-AMINOBUTYRIC-ACID; FOCAL CEREBRAL-ISCHEMIA; BRAIN-DAMAGE; TRANSHEMISPHERIC DIASCHISIS; MESSENGER-RNA; C-FOS; POLYAMINE LEVELS; NEURONAL DEATH	Damage after hypoxia-ischemia (HI) is observed in both cortical and subcortical regions. In this study. we employed a "Levine" rat model of HI (left carotid ligation + 1 h global hypoxia on PND-26) and used histological and electrophysiological paradigms to assess the long-term neuroprotective properties of clomethiazole (CMZ; a GABA(A) receptor modulator). Key enzymes involved in inflammation, namely nitric oxide synthase (NOS) and arginase, were also examined to assess potential CMZ mechanisms not involving GABA-R activation. Assessments were carried out 3 and 90 days post-HI. Extensive CNS lesions were evident after HI ipsilaterally at both short- and long-term intervals. CMZ significantly decreased the lesion size at 3 and 90 days (P < 0.01; P < 0.05). Evoked field potential analysis were used to assess hippocampal CA1 neuronal acitivity ex vivo. Electrophysiological measurements contralateral to the occlusion revealed impaired neuronal function after HI relative to short- long-term controls (P < 0.01, 3 and 14 days; P < 0.01, 90 days), with CMZ treatment providing near complete protection (P < 0.001 at 3 and 14 days; P < 0.01 at 90 days). Both NOS and arginase activities were significantly increased at 3 days (P < 0.01), with arginase remaining elevated at 90 days post-HI (P < 0.05) ipsilaterally. CMZ suppressed the HI-induced increase in iNOS and arginase activities (P 0.001; P < 0.05). These data provide evidence of long-term functional neuroprotection by CMZ in a model of HI. We further conclude that under conditions of HI, functional deficits are not restricted to the ipsilateral hemisphere and are due, at least in part, to changes in the activity of NOS and arginase.	Univ Otago, Sch Med Sci, Dept Pharmacol & Toxicol, Dunedin, New Zealand	University of Otago	Kerr, DS (corresponding author), Univ Otago, Sch Med Sci, Dept Pharmacol & Toxicol, POB, Dunedin, New Zealand.	steve.kerr@stonebow.otago.ac.nz		Clarkson, Andrew/0000-0003-3804-3834				ANDREWS RJ, 1991, STROKE, V22, P943, DOI 10.1161/01.STR.22.7.943; Baskaya MK, 1997, BRAIN RES, V744, P302; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHAN A, 1990, J NEUROSCI, V10, P311; BuchkremerRatzmann I, 1997, EUR J PHARMACOL, V320, P103, DOI 10.1016/S0014-2999(96)00891-6; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Butefisch CM, 2003, BRAIN, V126, P470, DOI 10.1093/brain/awg044; Chaulk D, 2003, EXP NEUROL, V182, P476, DOI 10.1016/S0014-4886(03)00121-3; Clarkson AN, 2004, FASEB J, V18, P1114, DOI 10.1096/fj.03-1203fje; Congar P, 2000, J NEUROPHYSIOL, V83, P2040, DOI 10.1152/jn.2000.83.4.2040; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; CROSS AJ, 1989, BRIT J PHARMACOL, V98, P284, DOI 10.1111/j.1476-5381.1989.tb16893.x; CROSS AJ, 1995, BRIT J PHARMACOL, V114, P1625, DOI 10.1111/j.1476-5381.1995.tb14949.x; CROSS AJ, 1991, BRIT J PHARMACOL, V104, P406, DOI 10.1111/j.1476-5381.1991.tb12443.x; DOBKIN JA, 1989, ARCH NEUROL-CHICAGO, V46, P1333, DOI 10.1001/archneur.1989.00520480077023; Dogan A, 1999, J NEUROCHEM, V72, P765, DOI 10.1046/j.1471-4159.1999.0720765.x; DOMANN R, 1993, NEUROSCI LETT, V155, P69, DOI 10.1016/0304-3940(93)90675-B; Empson RM, 2000, BRAIN RES, V884, P31, DOI 10.1016/S0006-8993(00)02875-4; Escott KJ, 1998, J CEREBR BLOOD F MET, V18, P281, DOI 10.1097/00004647-199803000-00006; Fedele E, 1999, PROG NEUROBIOL, V58, P89, DOI 10.1016/S0301-0082(98)00077-X; Ferriero DM, 1996, NEUROBIOL DIS, V3, P64, DOI 10.1006/nbdi.1996.0006; Forman LJ, 1998, NEUROCHEM RES, V23, P141, DOI 10.1023/A:1022468522564; Galvin KA, 1998, PEDIATR RES, V44, P740, DOI 10.1203/00006450-199811000-00017; Gilby KL, 1997, MOL BRAIN RES, V48, P87, DOI 10.1016/S0169-328X(97)00085-5; Green AR, 2000, NEUROPHARMACOLOGY, V39, P1483, DOI 10.1016/S0028-3908(99)00233-6; Green AR, 1998, PHARMACOL THERAPEUT, V80, P123, DOI 10.1016/S0163-7258(98)00024-2; Green AR, 1996, NEUROPHARMACOLOGY, V35, P1243, DOI 10.1016/S0028-3908(96)00060-3; GUBITS RM, 1993, MOL BRAIN RES, V18, P228, DOI 10.1016/0169-328X(93)90194-T; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; Hagberg H, 1996, PEDIATR RES, V40, P603, DOI 10.1203/00006450-199610000-00015; HALES TG, 1992, EUR J PHARMACOL, V210, P239, DOI 10.1016/0014-2999(92)90410-6; HALLMAYER J, 1985, ACTA NEUROPATHOL, V68, P27, DOI 10.1007/BF00688952; Harmon D, 2003, ANESTH ANALG, V97, P13, DOI 10.1213/01.ANE.0000063821; HEISS WD, 1993, STROKE, V24, P1784, DOI 10.1161/01.STR.24.12.1784; Henley CM, 1997, J NEUROCHEM, V69, P259; Hodges H, 1996, NEUROSCIENCE, V72, P959, DOI 10.1016/0306-4522(96)00004-8; HU JG, 1994, NEUROSCI LETT, V175, P41, DOI 10.1016/0304-3940(94)91073-1; HUANG Z, 1996, J CEREB BLOOD FLOW M, V15, P378; Iadecola C, 1997, J NEUROSCI, V17, P9157; Jensen FE, 1998, J NEUROPHYSIOL, V79, P73, DOI 10.1152/jn.1998.79.1.73; JOHANSEN FF, 1993, ACTA NEUROL SCAND, V88, P1; JOHANSEN FF, 1983, ACTA NEUROPATHOL, V61, P135, DOI 10.1007/BF00697393; Jude EB, 1999, DIABETOLOGIA, V42, P748, DOI 10.1007/s001250051224; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; Kapoor M, 2004, AM J PATHOL, V165, P299, DOI 10.1016/S0002-9440(10)63297-X; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KIRINO T, 1986, STROKE, V17, P455, DOI 10.1161/01.STR.17.3.455; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KLEIHUES P, 1975, BRAIN RES, V95, P61, DOI 10.1016/0006-8993(75)90207-3; KLEMPT ND, 1992, MOL BRAIN RES, V13, P93, DOI 10.1016/0169-328X(92)90048-G; LAGREZE HL, 1987, STROKE, V18, P882, DOI 10.1161/01.STR.18.5.882; LEVINE S, 1960, AM J PATHOL, V36, P1; Liu P, 2003, NEUROSCIENCE, V117, P965, DOI 10.1016/S0306-4522(02)00878-3; Marshall JWB, 2000, BRAIN RES BULL, V52, P21, DOI 10.1016/S0361-9230(99)00275-0; MOODY EJ, 1989, EUR J PHARMACOL, V164, P153, DOI 10.1016/0014-2999(89)90242-2; MUNELL F, 1994, DEV BRAIN RES, V77, P111, DOI 10.1016/0165-3806(94)90218-6; NATHAN T, 1991, J NEUROPHYSIOL, V66, P1704, DOI 10.1152/jn.1991.66.5.1704; NATHAN T, 1990, BRAIN RES, V531, P55, DOI 10.1016/0006-8993(90)90757-3; Nelson RM, 2000, BRIT J PHARMACOL, V130, P1124, DOI 10.1038/sj.bjp.0703398; Nelson RM, 2002, EUR J PHARMACOL, V452, P255, DOI 10.1016/S0014-2999(02)02233-1; NITSCH C, 1989, NEUROSCI LETT, V105, P263, DOI 10.1016/0304-3940(89)90631-9; Nurse S, 1996, J CEREBR BLOOD F MET, V16, P474, DOI 10.1097/00004647-199605000-00014; Palmer GC, 2001, CURR DRUG TARGETS, V2, P241, DOI 10.2174/1389450013348335; PASCHEN W, 1991, J CEREB BLOOD FLO S2, V11, P59; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; Pepicelli O, 2004, NEUROPHARMACOLOGY, V46, P480, DOI 10.1016/j.neuropharm.2003.10.010; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; PULSINELLI WA, 1982, ANN NEUROL, V11, P725; Que M, 1999, NEUROSCIENCE, V93, P1233, DOI 10.1016/S0306-4522(99)00197-9; Rao AM, 2000, J NEUROCHEM, V74, P1106; RAO AM, 1995, J NEUROCHEM, V65, P2639; Rao VLR, 1998, BRAIN RES, V783, P163, DOI 10.1016/S0006-8993(97)01301-2; Reinecke S, 1999, NEUROSCI LETT, V261, P85, DOI 10.1016/S0304-3940(99)00014-2; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Robello M, 1996, NEUROSCIENCE, V74, P99, DOI 10.1016/0306-4522(96)00110-8; Sari P, 2001, EPILEPSY RES, V47, P65, DOI 10.1016/S0920-1211(01)00295-9; SILVERSTEIN FS, 1986, J NEUROCHEM, V47, P1614, DOI 10.1111/j.1471-4159.1986.tb00803.x; Simi A, 2000, J CEREBR BLOOD F MET, V20, P1077, DOI 10.1097/00004647-200007000-00007; Simi A, 2002, J NEUROCHEM, V83, P727, DOI 10.1046/j.1471-4159.2002.01178.x; Sutherland BA, 2004, FASEB J, V18, P258, DOI 10.1096/fj.04-2806fje; Sydserff SG, 2000, BRAIN RES, V862, P59, DOI 10.1016/S0006-8993(00)02071-0; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TADOLINI B, 1988, BIOCHEM J, V249, P33, DOI 10.1042/bj2490033; TOWFIGHI J, 1994, BIOL NEONATE, V65, P108; TOWFIGHI J, 1995, ACTA NEUROPATHOL, V90, P375, DOI 10.1007/BF00315011; van den Tweel ERW, 2002, DEV NEUROSCI-BASEL, V24, P389, DOI 10.1159/000069044; Vannucci RC, 2001, PEDIATR RES, V49, P799, DOI 10.1203/00006450-200106000-00015; Wall MJ, 2003, EUR J NEUROSCI, V18, P869, DOI 10.1046/j.1460-9568.2003.02822.x; WATANABE H, 1990, FREE RADICAL BIO MED, V8, P507, DOI 10.1016/0891-5849(90)90150-H; WISE R, 1986, STROKE, V17, P853, DOI 10.1161/01.STR.17.5.853; Zheng YW, 2003, HIPPOCAMPUS, V13, P873, DOI 10.1002/hipo.10174; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306	93	36	40	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1036	+		10.1096/fj.04-3367fje	http://dx.doi.org/10.1096/fj.04-3367fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15809357				2022-12-25	WOS:000228865300030
J	Watanabe, Y; Takano, M; Yoshida, M				Watanabe, Y; Takano, M; Yoshida, M			ATP binding to nucleotide binding domain (NBD)1 of the ClpB chaperone induces motion of the long coiled-coil, stabilizes the hexamer, and activates NBD2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE HSP104; HEAT-INACTIVATED PROTEINS; THERMUS-THERMOPHILUS; AGGREGATED PROTEINS; MITOCHONDRIAL HSP78; FLUORESCENT-PROBE; ESCHERICHIA-COLI; SITES; DNAK; MECHANISM	The molecular chaperone ClpB can rescue the heat-damaged proteins from an aggregated state in cooperation with other chaperones. It has two nucleotide binding domains (NBD1 and NBD2) and forms a hexamer ring in a manner dependent on ATP binding to NBD1. In the crystal structure of ClpB with both NBDs filled by nucleotides, the linker between two NBDs forms an 85-angstrom-long coiled-coil that extends on the outside of the hexamer and leans to NBD1. To probe the possible motion of the coiled-coil, we tested the accessibility of a labeling reagent, fluorescence change of a labeled dye, and cross-linking between the coiled-coil and NBD1 by using the mutants with defective NBD1 or NBD2. The results suggest that the coiled-coil is more or less parallel to the main body of ClpB in the absence of nucleotide and that ATP binding to NBD1 brings it to the leaning position as seen in the crystal structure. This motion results in stabilization of the hexamer form of ClpB and promotion of ATP hydrolysis at NBD2.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Nagatsuta 4259,R-1, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp						Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Hattendorf DA, 2002, P NATL ACAD SCI USA, V99, P2732, DOI 10.1073/pnas.261693199; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIRATSUKA T, 1993, J BIOL CHEM, V268, P24742; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Krzewska J, 2001, J MOL BIOL, V314, P901, DOI 10.1006/jmbi.2001.5190; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Neuwald AF, 1999, GENOME RES, V9, P27; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; Stiggall D L, 1979, Methods Enzymol, V55, P308; TOYOOKA T, 1985, ANAL CHEM, V57, P1931, DOI 10.1021/ac00286a032; Watanabe Y, 2004, J BIOL CHEM, V279, P15723, DOI 10.1074/jbc.M308782200; Watanabe YH, 2000, J BIOL CHEM, V275, P12388, DOI 10.1074/jbc.275.17.12388; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	28	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24562	24567		10.1074/jbc.M414623200	http://dx.doi.org/10.1074/jbc.M414623200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15809298	hybrid			2022-12-25	WOS:000230114000034
J	Bomberger, JM; Spielman, WS; Hall, CS; Weinman, EJ; Parameswaran, N				Bomberger, JM; Spielman, WS; Hall, CS; Weinman, EJ; Parameswaran, N			Receptor activity-modifying protein (RAMP) isoform-specific regulation of adrenomedullin receptor trafficking by NHERF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED INHIBITION; PARATHYROID-HORMONE; BINDING; INTERNALIZATION; EXCHANGE; COMPLEX; FAMILY; DOMAIN	Receptor activity-modifying proteins (RAMPs 1-3) are single transmembrane accessory proteins critical to various G-protein coupled receptors for plasma membrane expression and receptor phenotype. A functional receptor for the vasodilatory ligand, adrenomedullin (AM), is comprised of RAMP2 or RAMP3 and calcitonin receptor-like receptor (CRLR). It is now known that RAMP3 protein-protein interactions regulate the recycling of the AM2 receptor. The major aim of this study was to identify other interaction partners of RAMP3 and determine their role in CRLR-RAMP3 trafficking. Trafficking of G-protein-coupled receptors has been shown to be regulated by the Na+/H+ exchanger regulatory factor-1 (NHERF-1), an adaptor protein containing two tandem PSD-95/Discs-large/ZO-1 homology (PDZ) domains. In HEK 293T cells expressing the AM2 receptor, the complex undergoes agonist-induced desensitization and internalization. However, in the presence of NHERF-1, although the AM receptor (CRLR/RAMP3) undergoes desensitization, the internalization of the receptor complex is blocked. Overlay assays and mutational analysis indicated that RAMP3 and NHERF-1 interact via a PDZ type I domain on NHERF-1. The internalization of the CRLR-RAMP complex was not affected by NHERF-1 when CRLR was co-expressed with RAMP1 or RAMP2. Mutation of the ezrin/radixin/moesin (ERM) domain on NHERF-1 indicated that NHERF-1 inhibits CRLR/RAMP3 complex internalization by tethering the complex to the actin cytoskeleton. When examined in a primary culture of human proximal tubule cells endogenously expressing the CRLR-RAMP3 complex and NHERF-1, the CRLR-RAMP complex desensitizes but is unable to internalize upon agonist stimulation. Knock-down of either RAMP3 or NHERF-1 by RNA interference technology enabled agonist-induced internalization of the CRLR-RAMP complex. These results, using both endogenous and overexpressed cellular models, indicate a novel function for NHERF-1 and RAMP3 in the internalization of the AM receptor and suggest additional regulatory mechanisms for receptor trafficking.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA	Michigan State University; University System of Maryland; University of Maryland Baltimore	Spielman, WS (corresponding author), Michigan State Univ, Dept Physiol, 2201 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	spielman@msu.edu	Parameswaran, Narayanan/V-1969-2019	Parameswaran, Narayanan/0000-0002-8894-5564				Aiyar N, 2002, BIOCHEM PHARMACOL, V63, P1949, DOI 10.1016/S0006-2952(02)00990-5; AIYAR N, 1987, MOL PHARMACOL, V31, P180; Bomberger JM, 2005, J BIOL CHEM, V280, P9297, DOI 10.1074/jbc.M413786200; Brain SD, 2004, PHYSIOL REV, V84, P903, DOI 10.1152/physrev.00037.2003; Buhlmann N, 1999, ENDOCRINOLOGY, V140, P2883, DOI 10.1210/en.140.6.2883; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; Kurihara H, 2003, HYPERTENS RES, V26, pS105, DOI 10.1291/hypres.26.S105; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; Mahon MJ, 2004, J BIOL CHEM, V279, P23550, DOI 10.1074/jbc.M313229200; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nowak W, 2002, AM J PHYSIOL-CELL PH, V282, pC1322, DOI 10.1152/ajpcell.00561.2001; Parameswaran N, 2000, EUR J PHARMACOL, V407, P205, DOI 10.1016/S0014-2999(00)00656-7; Roh J, 2004, J BIOL CHEM, V279, P7264, DOI 10.1074/jbc.M305332200; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Sneddon WB, 2003, J BIOL CHEM, V278, P43787, DOI 10.1074/jbc.M306019200; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Weinman EJ, 2001, AM J PHYSIOL-RENAL, V281, pF374, DOI 10.1152/ajprenal.2001.281.2.F374; Xia ZQ, 2003, J BIOL CHEM, V278, P21901, DOI 10.1074/jbc.M301905200	28	54	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23926	23935		10.1074/jbc.M501751200	http://dx.doi.org/10.1074/jbc.M501751200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15805108	hybrid			2022-12-25	WOS:000229880000067
J	Cebecauer, M; Guillaume, P; Mark, S; Michielin, O; Boucheron, N; Bezard, M; Meyer, BH; Segura, JM; Vogel, H; Luescher, IF				Cebecauer, M; Guillaume, P; Mark, S; Michielin, O; Boucheron, N; Bezard, M; Meyer, BH; Segura, JM; Vogel, H; Luescher, IF			CD8+ cytotoxic T lymphocyte activation by soluble major histocompatibility complex-peptide dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; LIGAND-SPECIFIC OLIGOMERIZATION; MHC-PEPTIDE; SIGNAL-TRANSDUCTION; CORECEPTOR FUNCTION; STRUCTURAL BASIS; BINDING; TCR; RECOGNITION; MOLECULES	CD8+ cytotoxic T lymphocyte (CTL) can recognize and kill target cells that express only a few cognate major histocompatibility complex class I-peptide (pMHC) complexes. To better understand the molecular basis of this sensitive recognition process, we studied dimeric pMHC complexes containing linkers of different lengths. Although dimers containing short (10-30-angstrom) linkers efficiently bound to and triggered intracellular calcium mobilization and phosphorylation in cloned CTL, dimers containing long linkers (>= 80 angstrom) did not. Based on this and on fluorescence resonance energy transfer experiments, we describe a dimeric binding mode in which two T cell receptors engage in an anti-parallel fashion two pMHC complexes facing each other with their constant domains. This binding mode allows integration of diverse low affinity interactions, which increases the overall binding and, hence, the sensitivity of antigen recognition. In proof of this, we demonstrated that pMHC dimers containing one agonist and one null ligand efficiently activate CTL, corroborating the importance of endogenous pMHC complexes in antigen recognition.	Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; Swiss Fed Inst Technol, Inst Chem Sci & Engn, Lab Phys Chem Polymers & Membranes, CH-1015 Lausanne, Switzerland	Ludwig Institute for Cancer Research; University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Luescher, IF (corresponding author), Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland.	immanuel.luescher@isrec.unil.ch	Cebecauer, Marek/F-5169-2014; Michielin, Olivier/ABE-7924-2020	Cebecauer, Marek/0000-0002-4606-1218; Boucheron, Nicole/0000-0002-4979-8311				Alam SM, 1999, IMMUNITY, V10, P227, DOI 10.1016/S1074-7613(00)80023-0; Alarcon B, 2003, IMMUNOL REV, V191, P38, DOI 10.1034/j.1600-065X.2003.00017.x; Arcaro A, 2001, J EXP MED, V194, P1485, DOI 10.1084/jem.194.10.1485; Arora PS, 2002, J AM CHEM SOC, V124, P13067, DOI 10.1021/ja0208355; Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; Baker BM, 2001, IMMUNITY, V14, P681, DOI 10.1016/S1074-7613(01)00160-1; Bhatnagar A, 2003, MOL IMMUNOL, V39, P953, DOI 10.1016/S0161-5890(03)00027-0; Bodnar A, 2003, INT IMMUNOL, V15, P331, DOI 10.1093/intimm/dxg042; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Buslepp J, 2003, IMMUNITY, V19, P595, DOI 10.1016/S1074-7613(03)00269-3; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Call ME, 2004, EMBO J, V23, P2348, DOI 10.1038/sj.emboj.7600245; Capps GG, 2004, BIOPHYS J, V86, P2896, DOI 10.1016/S0006-3495(04)74341-6; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Cochran JR, 2000, IMMUNITY, V12, P241, DOI 10.1016/S1074-7613(00)80177-6; Cochran JR, 2001, J BIOL CHEM, V276, P28068, DOI 10.1074/jbc.M103280200; Dick TP, 1998, EUR J IMMUNOL, V28, P2478, DOI 10.1002/(SICI)1521-4141(199808)28:08<2478::AID-IMMU2478>3.3.CO;2-L; Doucey MA, 2003, J BIOL CHEM, V278, P26983, DOI 10.1074/jbc.M302709200; Doucey MA, 2003, J BIOL CHEM, V278, P3257, DOI 10.1074/jbc.M208119200; Doucey MA, 2001, EUR J IMMUNOL, V31, P1561, DOI 10.1002/1521-4141(200105)31:5&lt;1561::AID-IMMU1561&gt;3.0.CO;2-W; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Fernandez-Miguel G, 1999, P NATL ACAD SCI USA, V96, P1547, DOI 10.1073/pnas.96.4.1547; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Frank SJ, 2002, ENDOCRINOLOGY, V143, P2, DOI 10.1210/en.143.1.2; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Gaspar R, 2001, J IMMUNOL, V166, P5078, DOI 10.4049/jimmunol.166.8.5078; Ge Q, 2002, P NATL ACAD SCI USA, V99, P13729, DOI 10.1073/pnas.212515299; Guillaume P, 2003, J BIOL CHEM, V278, P4500, DOI 10.1074/jbc.M208863200; HARPUR AG, 1993, IMMUNOL LETT, V35, P235, DOI 10.1016/0165-2478(93)90188-8; Hudrisier D, 1998, J IMMUNOL, V161, P553; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Kessler BM, 1997, J EXP MED, V185, P629, DOI 10.1084/jem.185.4.629; Kjer-Nielsen L, 2002, J IMMUNOL, V169, P5153, DOI 10.4049/jimmunol.169.9.5153; La Gruta NL, 2004, J IMMUNOL, V172, P3662, DOI 10.4049/jimmunol.172.6.3662; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; LUESCHER IF, 1995, IMMUNITY, V3, P51, DOI 10.1016/1074-7613(95)90158-2; LUESCHER IF, 1991, NATURE, V351, P72, DOI 10.1038/351072a0; O'Herrin SM, 2001, J IMMUNOL, V167, P2555, DOI 10.4049/jimmunol.167.5.2555; Purbhoo MA, 2004, NAT IMMUNOL, V5, P524, DOI 10.1038/ni1058; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; Sasada T, 2001, J EXP MED, V194, P883, DOI 10.1084/jem.194.7.883; SCHAMEL WW, 2004, CELL, V109, P901; SCHNECK J, 1989, P NATL ACAD SCI USA, V86, P8516, DOI 10.1073/pnas.86.21.8516; SCHWEITZERSTENNER R, 1987, BIOCHEMISTRY-US, V26, P3602, DOI 10.1021/bi00386a053; Stanasila L, 2003, J BIOL CHEM, V278, P40239, DOI 10.1074/jbc.M306085200; STREYER L, 1967, BIOCHEMISTRY-US, V6, P719; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; Velloso LM, 2004, J IMMUNOL, V172, P5504, DOI 10.4049/jimmunol.172.9.5504; WATTS JD, 1993, J BIOL CHEM, V268, P23275; Wulfing C, 2002, NAT IMMUNOL, V3, P42, DOI 10.1038/ni741; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	54	46	50	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23820	23828		10.1074/jbc.M500654200	http://dx.doi.org/10.1074/jbc.M500654200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15805102	hybrid			2022-12-25	WOS:000229880000054
J	Dobrzyn, A; Dobrzyn, P; Miyazaki, M; Sampath, H; Chu, K; Ntambi, JM				Dobrzyn, A; Dobrzyn, P; Miyazaki, M; Sampath, H; Chu, K; Ntambi, JM			Stearoyl-CoA desaturase 1 deficiency increases CTP : choline cytidylyltransferase translocation into the membrane and enhances phosphatidylcholine synthesis in liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; LOW-DENSITY LIPOPROTEINS; FATTY-ACID OXIDATION; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; TRIACYLGLYCEROL SYNTHESIS; PROTEIN-KINASE; RAT-LIVER; TRIGLYCERIDE SYNTHESIS; MICE; CHOLESTEROL	Stearoyl-CoA desaturase (SCD) is the rate-limiting enzyme in monounsaturated fatty acid synthesis. Previously, we showed that Scd1 deficiency reduces liver triglyceride accumulation and considerably decreases synthesis of very low density lipoprotein and its secretion in both lean and obese mice. In the present study, we found that Scd1 deficiency significantly modulates hepatic glycerophospholipid profile. The content of phosphatidylcholine (PC) was increased by 40% and the activities of CTP:choline cytidylyltransferase (CCT), the rate-limiting enzyme in de novo PC synthesis, and choline phosphotransferase were increased by 64 and 53%, respectively, in liver of Scd1-/- mice. In contrast, the protein level of phosphatidylethanolamine N-methyltransferase, an enzyme involved in PC synthesis via methylation of phosphatidylethanolamine, was decreased by 80% in the liver of Scd1-/- mice. Membrane translocation of CCT is required for its activation. Immunoblot analyses demonstrated that twice as much CCT alpha was associated with plasma membrane in livers of Scd1-/- compared with wild type mice, suggesting that Scd1 mutation leads to an increase in CCT membrane affinity. The incorporation of [H-3] glycerol into PC was increased by 2.5-fold in Scd1-/- primary hepatocytes compared with those of wild type mice. Furthermore, mitochondrial glycerol-3-phosphate acyltransferase activity was reduced by 42% in liver of Scd1-/- mice; however, the activities of microsomal glycerol-3-phosphate acyltransferase, diacylglycerol acyltransferase, and ethanolamine phosphotransferase were not affected by Scd1 mutation. Our study revealed that SCD1 deficiency specifically increases CCT activity by promoting its translocation into membrane and enhances PC biosynthesis in liver.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ntambi, JM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	ntambi@biochem.wisc.edu	Dobrzyn, Agnieszka/R-4073-2016; Dobrzyn, Pawel/R-4076-2016	Dobrzyn, Agnieszka/0000-0002-6331-9460; Dobrzyn, Pawel/0000-0002-2433-1897	NIDDK NIH HHS [R01-DK62388] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062388] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agellon LB, 1999, HEPATOLOGY, V30, P725, DOI 10.1002/hep.510300305; Attie AD, 2002, J LIPID RES, V43, P1899, DOI 10.1194/jlr.M200189-JLR200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Davies SMA, 2001, BIOCHEMISTRY-US, V40, P10522, DOI 10.1021/bi010904c; Dobrzyn A, 2005, AM J PHYSIOL-ENDOC M, V288, pE599, DOI 10.1152/ajpendo.00439.2004; Dobrzyn A, 2004, TRENDS CARDIOVAS MED, V14, P77, DOI 10.1016/j.tcm.2003.12.005; Dobrzyn A, 2002, AM J PHYSIOL-ENDOC M, V282, pE277, DOI 10.1152/ajpendo.00151.2001; Dobrzyn P, 2004, P NATL ACAD SCI USA, V101, P6409, DOI 10.1073/pnas.0401627101; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Drobnies AE, 2002, BBA-BIOMEMBRANES, V1564, P82, DOI 10.1016/S0005-2736(02)00404-2; Drobnies AE, 1999, BIOCHEMISTRY-US, V38, P15606, DOI 10.1021/bi991573v; ERICKSON SK, 1980, J LIPID RES, V21, P930; Giorgione JR, 1998, BIOCHEMISTRY-US, V37, P10956, DOI 10.1021/bi980185a; Howe AG, 2001, BBA-MOL CELL BIOL L, V1534, P65, DOI 10.1016/S1388-1981(01)00181-0; Igal RA, 2001, J BIOL CHEM, V276, P42205, DOI 10.1074/jbc.M103386200; Igal RA, 1996, J BIOL CHEM, V271, P16644, DOI 10.1074/jbc.271.28.16644; Johnson JE, 2003, J BIOL CHEM, V278, P514, DOI 10.1074/jbc.M206072200; MALLAMPALLI RK, 1994, AM J PHYSIOL-LUNG C, V267, pL641, DOI 10.1152/ajplung.1994.267.6.L641; Miyazaki M, 2004, J BIOL CHEM, V279, P35017, DOI 10.1074/jbc.M405327200; Miyazaki M, 2001, J LIPID RES, V42, P1018; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; Noga AA, 2003, J BIOL CHEM, V278, P21851, DOI 10.1074/jbc.M301982200; Noga AA, 2002, J BIOL CHEM, V277, P42358, DOI 10.1074/jbc.M204542200; Ntambi JM, 2004, LIPIDS, V39, P1061, DOI 10.1007/s11745-004-1331-2; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Rahman SM, 2005, AM J PHYSIOL-ENDOC M, V288, pE381, DOI 10.1152/ajpendo.00314.2004; Rahman SM, 2003, P NATL ACAD SCI USA, V100, P11110, DOI 10.1073/pnas.1934571100; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; STALS HK, 1992, BIOCHEM J, V283, P719, DOI 10.1042/bj2830719; Sun Y, 2003, J BIOL CHEM, V278, P5813, DOI 10.1074/jbc.M208687200; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; VANCE DE, 1989, PHOSPHATIDYLCHOLINE; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; VANCE JE, 1988, J BIOL CHEM, V263, P5898; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; White AL, 1997, CLIN GENET, V52, P326	44	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23356	23362		10.1074/jbc.M502436200	http://dx.doi.org/10.1074/jbc.M502436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15829484	hybrid			2022-12-25	WOS:000229741800095
J	Garneau, D; Revil, T; Fisette, JF; Chabot, B				Garneau, D; Revil, T; Fisette, JF; Chabot, B			Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; TRACT-BINDING-PROTEIN; HNRNP-H; CANCER-CELLS; 5'-SPLICE SITES; BREAST-CANCER; GENE; EXPRESSION; EXON; REGULATOR	x is a member of the Bcl-2 family of proteins that are key regulators of apoptosis. The Bcl-x pre-mRNA is alternatively spliced to yield Bcl-x(S) and Bcl-x(L), two isoforms that have been associated, respectively, with the promotion and the prevention of apoptosis. We have investigated some of the elements and factors involved in the production of these two splice variants. Deletion mutagenesis using a human Bcl-x minigene identifies two regions in exon 2 that modulate Bcl-x 5'-splice site selection in human HeLa cells. One region (B3) is located upstream of the Bcl-x(L) 5'-splice site and enforces Bcl-x(L) production in cells and splicing extracts. The other region (B2) is located immediately downstream of the 5'-splice site of Bcl-x(S) and favors Bcl-x(S) production in vivo and in vitro. A 30-nucleotide G-rich element (B2G) is responsible for the activity of the B2 element. We show that recombinant heterogeneous nuclear ribonucleoprotein (hnRNP) F and H proteins bind to B2G, and mutating the G stretches abolishes binding. Moreover, the addition of hnRNP F to a HeLa extract improved the production of the Bcl-x(S) variant in a manner that was dependent on the integrity of the G stretches in B2G. Consistent with the in vitro results, small interfering RNA-mediated RNA interference targeting hnRNP F and H decreased the Bcl-x(S)/Bcl-x(L) ratio of plasmid-derived and endogenously produced Bcl- x transcripts. Our results document a positive role for the hnRNP F/H proteins in the production of the proapoptotic regulator Bcl-x(S).	Univ Sherbrooke, Fac Med & Sci Sante, Dept Microbiol & Infectiol, RNA RNP Grp, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Chabot, B (corresponding author), Univ Sherbrooke, Fac Med & Sci Sante, Dept Microbiol & Infectiol, RNA RNP Grp, 3001,12E Ave N, Sherbrooke, PQ J1H 5N4, Canada.	Chabot@USherbrooke.ca		Chabot, Benoit/0000-0003-0994-0042				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Buratti E, 2004, NUCLEIC ACIDS RES, V32, P4224, DOI 10.1093/nar/gkh752; Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; Caputi M, 2001, J BIOL CHEM, V276, P43850, DOI 10.1074/jbc.M102861200; Chabot B., 1994, RNA PROCESSING PRACT, VI, P1; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ealovega MW, 1996, CANCER RES, V56, P1965; Fogel BL, 2000, J BIOL CHEM, V275, P32371, DOI 10.1074/jbc.M005000200; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Forch P, 2002, EMBO J, V21, P6882, DOI 10.1093/emboj/cdf668; Forch P, 2001, APOPTOSIS, V6, P463, DOI 10.1023/A:1012441824719; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Honore B, 2004, EXP CELL RES, V294, P199, DOI 10.1016/j.yexcr.2003.11.011; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; Jin W, 1999, J BIOL CHEM, V274, P28035, DOI 10.1074/jbc.274.39.28035; Jin W, 2000, CANCER RES, V60, P1221; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; Krajewska M, 1996, AM J PATHOL, V148, P1567; Le Guienr C, 2001, J BIOL CHEM, V276, P40638, DOI 10.1074/jbc.M105642200; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; Massiello A, 2004, J BIOL CHEM, V279, P15799, DOI 10.1074/jbc.M313950200; Mercatante DR, 2002, J BIOL CHEM, V277, P49374, DOI 10.1074/jbc.M209236200; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Navakauskiene R, 2004, PROTEOMICS, V4, P1029, DOI 10.1002/pmic.200300671; Nissim-Rafinia M, 2002, TRENDS GENET, V18, P123, DOI 10.1016/S0168-9525(01)02619-1; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Patry C, 2003, CANCER RES, V63, P7679; Pecci A, 2001, J BIOL CHEM, V276, P21062, DOI 10.1074/jbc.M008665200; Philips AV, 2000, CELL MOL LIFE SCI, V57, P235, DOI 10.1007/PL00000687; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; Romano M, 2002, J BIOL CHEM, V277, P43821, DOI 10.1074/jbc.M208107200; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; Tu YP, 1998, CANCER RES, V58, P256; Villemaire J, 2003, J BIOL CHEM, V278, P50031, DOI 10.1074/jbc.M308897200; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; Wu J Y, 2003, Prog Mol Subcell Biol, V31, P153; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2	48	160	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22641	22650		10.1074/jbc.M501070200	http://dx.doi.org/10.1074/jbc.M501070200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15837790	hybrid			2022-12-25	WOS:000229741800013
J	Jhandier, MN; Kruglov, EA; Lavoie, EG; Sevigny, J; Dranoff, JA				Jhandier, MN; Kruglov, EA; Lavoie, EG; Sevigny, J; Dranoff, JA			Portal fibroblasts regulate the proliferation of bile duct epithelia via expression of NTPDase2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLANGIOCYTE GROWTH; BILIARY; CELLS; RECEPTORS; CLONING; LIVER; URSODEOXYCHOLATE; MODULATION; ACTIVATION; SECRETION	Bile duct epithelia are the target of a number of "cholangiopathies" characterized by disordered bile ductular proliferation. Although mechanisms for bile ductular proliferation are unknown, recent evidence suggests that extracellular nucleotides regulate cell proliferation via activation of P2Y receptors. Portal fibroblasts may regulate bile duct epithelial P2Y receptors via expression of the ecto-nucleotidase NTPDase2. Thus, we tested the hypothesis that portal fibroblasts regulate bile duct epithelial proliferation via expression of NTPDase2. We generated a novel co-culture model of MzChA-1 human cholangiocarcinoma cells and primary portal fibroblasts. Cell proliferation was measured by bromodeoxyuridine uptake. NTPDase2 expression was assessed by immunofluorescence and quantitative real-time reverse transcription PCR. NTPDase2 expression in portal fibroblasts was blocked using short interfering RNA. NTPDase2 overexpression in portal myofibroblasts isolated from bile duct-ligated rats was achieved by cDNA transfection. Co-culture of Mz-ChA-1 cells with portal fibroblasts decreased their proliferation to 26% of control. Similar decreases in Mz-ChA-1 proliferation were induced by the soluble ecto-nucleotidase apyrase and the P2 receptor inhibitor suramin. The proliferation of Mz-ChA-1 cells returned to baseline when NTPDase2 expression in portal fibroblasts was inhibited using NT-PDase2-specific short interfering RNA. Untransfected portal myofibroblasts lacking NTPDase2 had no effect on Mz-ChA-1 proliferation, yet portal myofibroblasts transfected with NTPDase2 cDNA inhibited Mz-ChA-1 proliferation. We conclude that portal fibroblasts inhibit bile ductular proliferation via expression of NTPDase2 and blockade of P2Y activation. Loss of NTPDase2 may mediate the bile ductular proliferation typical of obstructive cholestasis. This novel cross-talk signaling pathway may mediate pathologic alterations in bile ductular proliferation in other cholangiopathic conditions.	Yale Univ, Sch Med, Sect Digest Dis, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale Liver Ctr, New Haven, CT 06520 USA; Univ Laval, Ctr Rech Rheumatol & Immunol, Ste Foy, PQ G1K 7P4, Canada	Yale University; Yale University; Laval University	Dranoff, JA (corresponding author), Yale Univ, Sch Med, Sect Digest Dis, 333 Cedar St,LMP 1080, New Haven, CT 06520 USA.	jonathan.dranoff@yale.edu	Sévigny, Jean/AGH-9323-2022; Sevigny, Jean/E-8039-2012	Sévigny, Jean/0000-0003-2922-1600; Sevigny, Jean/0000-0003-2922-1600	Canadian Institutes of Health Research [49460] Funding Source: Medline; NIDDK NIH HHS [DK066287, DK02379] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK066287] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpini G, 2002, HEPATOLOGY, V35, P1256, DOI 10.1053/jhep.2002.33541; Alpini G, 2002, HEPATOLOGY, V35, P1041, DOI 10.1053/jhep.2002.32712; Aoki S, 2004, MOL BIOL CELL, V15, P4647, DOI 10.1091/mbc.E04-01-0038; Bigonnesse F, 2004, BIOCHEMISTRY-US, V43, P5511, DOI 10.1021/bi0362222; Braun N, 2000, BIOCHEM J, V351, P639, DOI 10.1042/0264-6021:3510639; Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360; Chadwick BP, 1998, GENOMICS, V50, P357, DOI 10.1006/geno.1998.5317; Dranoff JA, 2004, J INVEST MED, V52, P475, DOI 10.1136/jim-52-07-42; Dranoff JA, 2004, AM J PHYSIOL-GASTR L, V287, pG417, DOI 10.1152/ajpgi.00294.2003; Dranoff JA, 2004, MED INTELL UNIT, P96; Dranoff JA, 2002, HEPATOLOGY, V36, P1135, DOI 10.1053/jhep.2002.36823; Dranoff JA, 2001, AM J PHYSIOL-GASTR L, V281, pG1059, DOI 10.1152/ajpgi.2001.281.4.G1059; Eichhorst ST, 2004, NAT MED, V10, P602, DOI 10.1038/nm1049; Elghazi L, 2002, P NATL ACAD SCI USA, V99, P3884, DOI 10.1073/pnas.062321799; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Everson GT, 2004, HEPATOLOGY, V40, P774, DOI 10.1002/hep.20431; Fitz JG, 2002, SEMIN LIVER DIS, V22, P211, DOI 10.1055/s-2002-34510; Friedman SL, 1999, GASTROENTEROLOGY, V117, P1244, DOI 10.1016/S0016-5085(99)70413-0; Fuster D, 2004, P NATL ACAD SCI USA, V101, P10482, DOI 10.1073/pnas.0403930101; Gerasimovskaya EV, 2002, J BIOL CHEM, V277, P44638, DOI 10.1074/jbc.M203012200; Glaser S, 2000, HEPATOLOGY, V32, P17; Grzmil M, 2003, AM J PATHOL, V163, P543, DOI 10.1016/S0002-9440(10)63682-6; ISHII M, 1989, GASTROENTEROLOGY, V97, P1236, DOI 10.1016/0016-5085(89)91695-8; Kanno N, 2002, HEPATOLOGY, V35, P1329, DOI 10.1053/jhep.2002.33330; KARPEN SJ, 2001, LIVER DIS CHILDREN, P3; KELLER BB, 2004, HURSTS HEART, P155; Kittel A, 2004, J HISTOCHEM CYTOCHEM, V52, P861, DOI 10.1369/jhc.3A6167.2004; Kruglov EA, 2002, J INVEST MED, V50, P179, DOI 10.2310/6650.2002.33431; Kuehn EW, 2002, AM J PHYSIOL-RENAL, V283, pF1326, DOI 10.1152/ajprenal.00166.2002; Kukulski F, 2005, Purinergic Signal, V1, P193, DOI 10.1007/s11302-005-6217-x; Lavoie EG, 2004, BIOCHEM PHARMACOL, V67, P1917, DOI 10.1016/j.bcp.2004.02.012; Lazaridis KN, 2004, GASTROENTEROLOGY, V127, P1565, DOI 10.1053/j.gastro.2004.08.006; LeSage G, 2001, LIVER, V21, P73, DOI 10.1034/j.1600-0676.2001.021002073.x; Libbrecht L, 2002, LIVER, V22, P252, DOI 10.1046/j.0106-9543.2002.01674.x; MCGILL JM, 1994, GASTROENTEROLOGY, V107, P236, DOI 10.1016/0016-5085(94)90082-5; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Okada H, 2000, KIDNEY INT, V58, P587, DOI 10.1046/j.1523-1755.2000.00205.x; Park JM, 2002, CAMPBELLS UROLOGY, P1737; Ramadori G, 2002, LIVER, V22, P283, DOI 10.1034/j.1600-0676.2002.01726.x; ROMAN J, 1998, FISHMANS PULM DIS DI, P73; Roman RM, 1996, AM J PHYSIOL-GASTR L, V271, pG239, DOI 10.1152/ajpgi.1996.271.2.G239; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; Selman M, 2001, RESP RES, V3, DOI 10.1186/rr175; Shigetani Y, 2002, SCIENCE, V296, P1316, DOI 10.1126/science.1068310; SHIMOKURA GH, 1995, GASTROENTEROLOGY, V109, P965, DOI 10.1016/0016-5085(95)90407-7; Smyth I, 2004, P NATL ACAD SCI USA, V101, P13560, DOI 10.1073/pnas.0402760101; Sneddon P, 1999, PROG BRAIN RES, V120, P11; Soares-Da-Silva P, 2004, FASEB J, V18, P1489, DOI 10.1096/fj.04-1787com; Somasiri A, 2001, J CELL SCI, V114, P1125; Strazzabosco M, 2000, J GASTROEN HEPATOL, V15, P244, DOI 10.1046/j.1440-1746.2000.02091.x; Tadlock L, 2003, AM J PHYSIOL-GASTR L, V284, pG924, DOI 10.1152/ajpgi.00355.2002	51	86	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22986	22992		10.1074/jbc.M412371200	http://dx.doi.org/10.1074/jbc.M412371200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15799977	hybrid			2022-12-25	WOS:000229741800053
J	Wang, J; Liu, H; Lin, CM; Aladjem, MI; Epner, EM				Wang, J; Liu, H; Lin, CM; Aladjem, MI; Epner, EM			Targeted deletion of the chicken beta-globin regulatory elements reveals a cooperative gene silencing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; RNA-POLYMERASE-II; OPEN CHROMATIN-STRUCTURE; DEVELOPMENTAL REGULATION; HYPERSENSITIVE SITES; HISTONE ACETYLATION; DNA METHYLATION; DELTA-GLOBIN; EXPRESSION; TRANSCRIPTION	The chicken beta-globin locus represents a well characterized system to study the role of both proximal and distal regulatory elements in a eukaryotic multigene domain. The function of the chicken beta(A)/epsilon-intergenic enhancer and upstream regulatory elements 5'-HS1 and 5'-HS2 were studied using a gene targeting approach in chicken DT40 cells followed by microcell-mediated chromosome transfer into human erythroleukemia cells ( K562). These regulatory elements all repressed expression of the rho- and beta(H)-chicken globin genes in the chromosome transfer assay. No rho- or beta(H)-globin gene expression was detected in K562 cells containing the chicken chromosome without deletions, whereas rho- and beta(H)-mRNA was activated in K562 cells containing chicken chromosomes with deletions of the intergenic enhancers, 5'-HS1 and 5'-HS2. Transcriptional activation of the rho- and beta(H)-globin genes correlated with hyperacetylation of histones H3 and H4, loss of histone H3 lysine 9 methylation, and binding of RNA polymerase II to the gene promoters. Surprisingly, the status of CpG dinucleotide methylation at the promoters did not correlate with the transcriptional status of the genes. Our results using a chromosomal transfer assay demonstrate an identical silencing function for these regulatory elements, which suggests they function as part of a common silencing pathway or complex.	Oregon Hlth & Sci Univ, Dept Med, Oregon Canc Inst, Ctr Hematol Malignancies, Portland, OR 97239 USA; NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA	Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Epner, EM (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Oregon Canc Inst, Ctr Hematol Malignancies, Portland, OR 97239 USA.	epnere@ohsu.edu	Aladjem, Mirit/G-2169-2010	Aladjem, Mirit/0000-0002-1875-3110	NATIONAL CANCER INSTITUTE [ZIABC010411, Z01BC010411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056798] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRUZZO LV, 1994, J BIOL CHEM, V269, P32565; Bender MA, 1998, BLOOD, V92, P4394, DOI 10.1182/blood.V92.11.4394.423k48_4394_4403; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Bender MA, 2001, BLOOD, V98, P2022, DOI 10.1182/blood.V98.7.2022; Brand M, 2004, NAT STRUCT MOL BIOL, V11, P73, DOI 10.1038/nsmb713; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Bulger M, 2002, CURR OPIN GENET DEV, V12, P170, DOI 10.1016/S0959-437X(02)00283-6; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; Dieken ES, 1996, NAT GENET, V12, P174, DOI 10.1038/ng0296-174; Donda A, 1996, EUR J IMMUNOL, V26, P493, DOI 10.1002/eji.1830260232; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; FOLEY KP, 1994, P NATL ACAD SCI USA, V91, P7252, DOI 10.1073/pnas.91.15.7252; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GLAUBER JG, 1991, MOL CELL BIOL, V11, P4690, DOI 10.1128/MCB.11.9.4690; GROUDINE M, 1981, CELL, V24, P393, DOI 10.1016/0092-8674(81)90329-9; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Jackson DA, 2003, NUCLEIC ACIDS RES, V31, P1180, DOI 10.1093/nar/gkg217; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Johnson KD, 2001, MOL CELL, V8, P465, DOI 10.1016/S1097-2765(01)00309-4; Klebe RJ, 1996, BIOTECHNIQUES, V21, P1094; Kyrylenko S, 2003, CELL MOL LIFE SCI, V60, P1990, DOI 10.1007/s00018-003-3090-z; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Liu H, 2004, BLOOD, V104, P2505, DOI 10.1182/blood-2004-02-0483; MASON MM, 1995, MOL CELL BIOL, V15, P407, DOI 10.1128/MCB.15.1.407; MCGHEE JD, 1979, NATURE, V280, P419, DOI 10.1038/280419a0; MOOKERJEE B, 1992, BLOOD, V79, P820; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Mutskov VJ, 2002, GENE DEV, V16, P1540, DOI 10.1101/gad.988502; Nahlik KW, 2003, ACTA BIOCHIM POL, V50, P667; Oberley MJ, 2003, J BIOL CHEM, V278, P42466, DOI 10.1074/jbc.M307733200; Peterson KR, 1996, P NATL ACAD SCI USA, V93, P6605, DOI 10.1073/pnas.93.13.6605; Poddie D, 2003, HEMOGLOBIN, V27, P219, DOI 10.1081/HEM-120026046; Prioleau MN, 1999, EMBO J, V18, P4035, DOI 10.1093/emboj/18.14.4035; Prioleau MN, 2003, MOL CELL BIOL, V23, P3536, DOI 10.1128/MCB.23.10.3536-3549.2003; RAICH N, 1992, BLOOD, V79, P861; Recillas-Targa F, 2001, CRIT REV EUKAR GENE, V11, P227; Reik A, 1998, MOL CELL BIOL, V18, P5992, DOI 10.1128/MCB.18.10.5992; REITMAN M, 1990, NATURE, V348, P749, DOI 10.1038/348749a0; REITMAN M, 1995, NUCLEIC ACIDS RES, V23, P1790, DOI 10.1093/nar/23.10.1790; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; Singal R, 2002, BLOOD, V100, P4217, DOI 10.1182/blood-2002-02-0457; Taniuchi I, 2002, MOL CELL, V10, P1083, DOI 10.1016/S1097-2765(02)00735-9; Wandersee NJ, 1996, MOL CELL BIOL, V16, P236; WANG J, 1991, MOL CELL BIOL, V11, P75, DOI 10.1128/MCB.11.1.75; WEINTRAUB H, 1994, GENE DEV, V8, P2203, DOI 10.1101/gad.8.18.2203; YOUNG K, 1985, NUCLEIC ACIDS RES, V13, P5203, DOI 10.1093/nar/13.14.5203; Zou YR, 2001, NAT GENET, V29, P332, DOI 10.1038/ng750	58	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23340	23348		10.1074/jbc.M501161200	http://dx.doi.org/10.1074/jbc.M501161200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824098	hybrid			2022-12-25	WOS:000229741800093
J	Blumenschein, TMA; Stone, DB; Fletterick, RJ; Mendelson, RA; Sykes, BD				Blumenschein, TMA; Stone, DB; Fletterick, RJ; Mendelson, RA; Sykes, BD			Calcium-dependent changes in the flexibility of the regulatory domain of troponin C in the troponin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CARDIAC TROPONIN; SKELETAL-MUSCLE; STRUCTURAL-CHANGES; BACKBONE DYNAMICS; CROSS-CORRELATION; CRYSTAL-STRUCTURE; NMR RELAXATION; BINDING-SITE; N-DOMAIN; MACROMOLECULES	With the recent advances in structure determination of the troponin complex, it becomes even more important to understand the dynamics of its components and how they are affected by the presence or absence of Ca2(+). We used NMR techniques to study the backbone dynamics of skeletal troponin C (TnC) in the complex. Transverse relaxation-optimized spectroscopy pulse sequences and deuteration of TnC were essential to assign most of the TnC residues in the complex. Backbone amide N-15 relaxation times were measured in the presence of Ca2+ or EGTA/Mg2+. T-1 relaxation times could not be interpreted precisely, because for a molecule of this size, the longitudinal backbone amide 15N relaxation rate due to chemical shift anisotropy and dipole-dipole interactions becomes too small, and other relaxation mechanisms become relevant. T-2 relaxation times were of the expected magnitude for a complex of this size, and most of the variation of T-2 times in the presence of Ca2+ could be explained by the anisotropy of the complex, suggesting a relatively rigid molecule. The only exception was EF-hand site III and helix F immediately after, which are more flexible than the rest of the molecule. In the presence of EGTA/Mg2+, relaxation times for residues in the C-domain of TnC are very similar to values in the presence of Ca2+, whereas the N-domain becomes more flexible. Taken together with the high flexibility of the linker between the two domains, we concluded that in the absence of Ca2+, the N-domain of TnC moves independently from the rest of the complex.	Univ Alberta, Canadian Inst Hlth Res Grp Struct & Funct, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA	University of Alberta; University of Alberta; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Sykes, BD (corresponding author), Univ Alberta, Canadian Inst Hlth Res Grp Struct & Funct, Edmonton, AB T6G 2H7, Canada.	Brian.Sykes@ualberta.ca	Blumenschein, Tharin/C-5984-2009	Blumenschein, Tharin/0000-0002-4932-5178	NIAMS NIH HHS [AR 45659] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045659] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baber JL, 2001, J AM CHEM SOC, V123, P3953, DOI 10.1021/ja0041876; Blumenschein TMA, 2001, J BIOL CHEM, V276, P36606, DOI 10.1074/jbc.M105130200; Cantor CR, 1980, BIOPHYSICAL CHEM 2, P461; Dargis R, 2002, J BIOL CHEM, V277, P34662, DOI 10.1074/jbc.C200419200; de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Forman-Kay JD, 1999, NAT STRUCT BIOL, V6, P1086, DOI 10.1038/70008; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; Gagne SM, 1998, J MOL BIOL, V278, P667, DOI 10.1006/jmbi.1998.1723; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kay LE, 1998, BIOCHEM CELL BIOL, V76, P145, DOI 10.1139/bcb-76-2-3-145; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; King WA, 2005, J MOL BIOL, V345, P797, DOI 10.1016/j.jmb.2004.10.090; Kontaxis G, 2000, J MAGN RESON, V143, P184, DOI 10.1006/jmre.1999.1979; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Lindhout DA, 2003, J BIOL CHEM, V278, P27024, DOI 10.1074/jbc.M302497200; LINDHOUT DA, 2005, THESIS U ALBERTA ED; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; Mercier P, 2003, BIOCHEMISTRY-US, V42, P4333, DOI 10.1021/bi027041n; Mercier P, 2000, BIOCHEMISTRY-US, V39, P2902, DOI 10.1021/bi992579n; Mercier P, 2001, BIOCHEMISTRY-US, V40, P10063, DOI 10.1021/bi010748+; Oliveira DCSG, 2003, EUR J BIOCHEM, V270, P2937, DOI 10.1046/j.1432-1033.2003.03659.x; Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; POTTER JD, 1975, J BIOL CHEM, V250, P4628; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; Salzmann M, 1998, P NATL ACAD SCI USA, V95, P13585, DOI 10.1073/pnas.95.23.13585; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; SLUPSKY CM, 1995, BIOCHEMISTRY-US, V34, P7365, DOI 10.1021/bi00022a009; SLUPSKY CM, 1995, PROTEIN SCI, V4, P1279, DOI 10.1002/pro.5560040704; Stone DB, 1998, J MOL BIOL, V281, P689, DOI 10.1006/jmbi.1998.1965; Sykes BD, 2003, NAT STRUCT BIOL, V10, P588, DOI 10.1038/nsb0803-588; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; Vinogradova MV, 2005, P NATL ACAD SCI USA, V102, P5038, DOI 10.1073/pnas.0408882102; Wang X, 2002, J BIOL CHEM, V277, P31124, DOI 10.1074/jbc.M203896200	51	31	34	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21924	21932		10.1074/jbc.M500574200	http://dx.doi.org/10.1074/jbc.M500574200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15826946	hybrid			2022-12-25	WOS:000229557900033
J	Chen, B; Colgrave, ML; Daly, NL; Rosengren, KJ; Gustafson, KR; Craik, DJ				Chen, B; Colgrave, ML; Daly, NL; Rosengren, KJ; Gustafson, KR; Craik, DJ			Isolation and characterization of novel cyclotides from Viola hederaceae - Solution structure and anti-HIV activity of vhl-1, a leaf-specific expressed cyclotide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE SULFOXIDE REDUCTASE; NMR STRUCTURE CALCULATION; SPIN COUPLING-CONSTANTS; CYSTINE KNOT MOTIF; KALATA B1; MACROCYCLIC PEPTIDES; PLANT CYCLOTIDES; CIRCULAR PROTEINS; DRUG DESIGN; SPECTROSCOPY	Based on a newly established sequencing strategy featured by its efficiency, simplicity, and easy manipulation, the sequences of four novel cyclotides (macrocyclic knotted proteins) isolated from an Australian plant Viola hederaceae were determined. The three-dimensional solution structure of V. hederaceae leaf cyclotide-1 ( vhl-1), a leaf-specific expressed 31-residue cyclotide, has been determined using two-dimensional H-1 NMR spectroscopy. vhl-1 adopts a compact and well defined structure including a distorted triple-stranded beta- sheet, a short 310 helical segment and several turns. It is stabilized by three disulfide bonds, which, together with backbone segments, form a cyclic cystine knot motif. The three-disulfide bonds are almost completely buried into the protein core, and the six cysteines contribute only 3.8% to the molecular surface. A pH titration experiment revealed that the folding of vhl-1 shows little pH dependence and allowed the pK(a) of 3.0 for Glu(3) and similar to 5.0 for Glu(14) to be determined. Met(7) was found to be oxidized in the native form, consistent with the fact that its side chain protrudes into the solvent, occupying 7.5% of the molecular surface. vhl-1 shows anti-HIV activity with an EC50 value of 0.87 mu m.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Chinese Acad Sci, Chengdu Inst Biol, Ctr Nat Prod, Chengdu 610041, Peoples R China; NCI, Mol Targets Dev Program, Ctr Canc Res, NIH, Ft Detrick, MD 21702 USA	University of Queensland; Chinese Academy of Sciences; Chengdu Institute of Biology, CAS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Chen, B (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Craik, David/B-1695-2010; Colgrave, Michelle/A-5710-2012; Rosengren, K. Johan/P-4450-2016; Daly, Norelle L/D-4302-2013	Craik, David/0000-0003-0007-6796; Colgrave, Michelle/0000-0001-8463-805X; Rosengren, K. Johan/0000-0002-5007-8434; Daly, Norelle L/0000-0002-4697-6602	NATIONAL CANCER INSTITUTE [Z01BC010469, ZICBC010469] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barry DG, 2004, STRUCTURE, V12, P85, DOI 10.1016/j.str.2003.11.019; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bokesch HR, 2001, J NAT PROD, V64, P249, DOI 10.1021/np000372l; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; Ciorba MA, 1997, P NATL ACAD SCI USA, V94, P9932, DOI 10.1073/pnas.94.18.9932; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2001, TOXICON, V39, P1809, DOI 10.1016/S0041-0101(01)00129-5; Craik DJ, 2004, CURR PROTEIN PEPT SC, V5, P297, DOI 10.2174/1389203043379512; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Craik DJ, 2002, CURR OPIN DRUG DI DE, V5, P251; Daly NL, 2004, FEBS LETT, V574, P69, DOI 10.1016/j.febslet.2004.08.007; Daly NL, 1999, J MOL BIOL, V285, P333, DOI 10.1006/jmbi.1998.2276; DAVOODI J, 1995, EUR J BIOCHEM, V232, P839, DOI 10.1111/j.1432-1033.1995.tb20881.x; Dutton JL, 2004, J BIOL CHEM, V279, P46858, DOI 10.1074/jbc.M407421200; El Hassouni M, 1999, P NATL ACAD SCI USA, V96, P887, DOI 10.1073/pnas.96.3.887; Goransson U, 2003, J BIOL CHEM, V278, P48188, DOI 10.1074/jbc.M308771200; Goransson U, 2003, ANAL BIOCHEM, V318, P107, DOI 10.1016/S0003-2697(03)00114-3; Goransson U, 1999, J NAT PROD, V62, P283, DOI 10.1021/np9803878; GRAN L, 1973, LLOYDIA, V36, P207; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Gustafson KR, 2004, CURR PROTEIN PEPT SC, V5, P331, DOI 10.2174/1389203043379468; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Hallock YF, 2000, J ORG CHEM, V65, P124, DOI 10.1021/jo990952r; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; Jennings CV, 2005, BIOCHEMISTRY-US, V44, P851, DOI 10.1021/bi047837h; Koltay A, 2005, INT J PEPT RES THER, V11, P99, DOI 10.1007/s10989-004-1722-2; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Li H, 2004, PROTEINS, V55, P689, DOI 10.1002/prot.20032; Lindholm P, 2002, MOL CANCER THER, V1, P365; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rosengren KJ, 2003, J BIOL CHEM, V278, P8606, DOI 10.1074/jbc.M211147200; SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002; Schoepke T., 1993, SCI PHARM, V61, P145; SHRAGER RI, 1972, BIOCHEMISTRY-US, V11, P541, DOI 10.1021/bi00754a010; Skjeldal L, 2002, ARCH BIOCHEM BIOPHYS, V399, P142, DOI 10.1006/abbi.2002.2769; Svangard E, 2004, J NAT PROD, V67, P144, DOI 10.1021/np030101l; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; Trabi M, 2004, PLANT CELL, V16, P2204, DOI 10.1105/tpc.104.021790; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002	53	105	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22395	22405		10.1074/jbc.M501737200	http://dx.doi.org/10.1074/jbc.M501737200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824119	hybrid			2022-12-25	WOS:000229557900085
J	Gersdorff, N; Kohfeldt, E; Sasaki, T; Timpl, R; Miosge, N				Gersdorff, N; Kohfeldt, E; Sasaki, T; Timpl, R; Miosge, N			Laminin gamma 3 chain binds to nidogen and is located in murine basement membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-LIKE MOTIF; N-TERMINAL DOMAINS; COLLAGEN TYPE-IV; EXPRESSION; COMPLEX; ARM; AFFINITY; MODULES; ADULT; SITE	Recently a novel laminin gamma 3 chain was identified in mouse and human and shown to have the same modular structure as the laminin gamma 1 chain. We expressed two fragments of the gamma 3 chain in mammalian cells recombinantly. The first, domain VI/V, consisting of laminin N-terminal (domain VI) and four laminin-type epidermal growth factor-like (domain V) and laminin N-terminal modules, was shown to be essential for self-assembly of laminins. The other was domain III3-5, which consists of three laminin-type epidermal growth factor-like modules and is predicted to bind to nidogens. The gamma 3 VI/V fragment was a poor inhibitor for laminin-1 polymerization as was the gamma 2 VI/ V fragment. The gamma 3 III3-5 fragment bound to nidogen-1 and nidogen-2 with lower affinity than the gamma 1 III3-5 fragment. These data suggested that laminins containing the gamma 3 chain may assemble networks independent of other laminins. Polyclonal antibodies raised against gamma 3 VI/V and gamma 3 III3-5 showed no cross-reaction with homologous fragments from the gamma 1 and gamma 2 chains of laminin and allowed the establishment of gamma chain-specific radioimmunoassays and light and electron microscopic immunostaining of tissues. This demonstrated a 20-100-fold lower content of the gamma 3 chain compared with the gamma 1 chain in various tissue extracts of adult mice. The expression of gamma 3 chain was highly tissue-specific. In contrast to earlier assumptions, the antibodies against the gamma 3 chain showed light microscopic staining exclusively in basement membrane zones of adult and embryonic tissues, such as the brain, kidney, skin, muscle, and testis. Ultrastructural immunogold staining localized the gamma 3 chain to basement membranes of these tissues.	Univ Gottingen, Dept Histol, D-37075 Gottingen, Germany; Univ Gottingen, Dept Prosthodont, D-37075 Gottingen, Germany; Max Planck Inst Biochem, Dept Prot Chem, D-82152 Martinsried, Germany	University of Gottingen; University of Gottingen; Max Planck Society	Miosge, N (corresponding author), Univ Gottingen, Dept Histol, D-37075 Gottingen, Germany.	nmiosge@gwdg.de	Miosge, Nicolai/E-3244-2010					AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; BRUCH M, 1989, EUR J BIOCHEM, V185, P271, DOI 10.1111/j.1432-1033.1989.tb15112.x; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Ettner N, 1998, FEBS LETT, V430, P217, DOI 10.1016/S0014-5793(98)00601-2; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; Garbe JHO, 2002, BIOCHEM J, V362, P213, DOI 10.1042/0264-6021:3620213; Iivanainen A, 1999, J BIOL CHEM, V274, P14107, DOI 10.1074/jbc.274.20.14107; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; KOHFELDT E, 1997, FEBS LETT, V414, P217; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; MAYER U, 1995, EUR J BIOCHEM, V227, P681, DOI 10.1111/j.1432-1033.1995.tb20188.x; MAYER U, 1995, FEBS LETT, V365, P129, DOI 10.1016/0014-5793(95)00438-F; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; Miosge N, 2002, MATRIX BIOL, V21, P611, DOI 10.1016/S0945-053X(02)00070-7; Miosge N, 2000, HISTOCHEM CELL BIOL, V113, P115, DOI 10.1007/s004180050014; Miosge N, 1999, FASEB J, V13, P1743, DOI 10.1096/fasebj.13.13.1743; Odenthal U, 2004, J BIOL CHEM, V279, P44504, DOI 10.1074/jbc.M402455200; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAULSSON M, 1988, J BIOL CHEM, V263, P5425; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x; Poschl E, 1996, EMBO J, V15, P5154, DOI 10.1002/j.1460-2075.1996.tb00899.x; Salmivirta K, 2002, EXP CELL RES, V279, P188, DOI 10.1006/excr.2002.5611; Sasaki T, 1996, J CELL SCI, V109, P2895; Sasaki T, 2001, J MOL BIOL, V314, P751, DOI 10.1006/jmbi.2001.5176; Sasaki T, 1999, GUIDEBOOK EXTRACELLU, P434; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Stetefeld J, 1996, J MOL BIOL, V257, P644, DOI 10.1006/jmbi.1996.0191; Takagi J, 2003, NATURE, V424, P969, DOI 10.1038/nature01873; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; Yurchenco PD., 1994, EXTRACELLULAR MATRIX, P351	39	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22146	22153		10.1074/jbc.M501875200	http://dx.doi.org/10.1074/jbc.M501875200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824114	hybrid			2022-12-25	WOS:000229557900059
J	Hong, SP; Momcilovic, M; Carlson, M				Hong, SP; Momcilovic, M; Carlson, M			Function of mammalian LKB1 and Ca2+/calmodulin-dependent protein kinase kinase a as Snf1-activating kinases in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; SACCHAROMYCES-CEREVISIAE; SNF1 KINASE; AMP-KINASE; HYPERTROPHIC CARDIOMYOPATHY; GLUCOSE REPRESSION; UPSTREAM KINASES; BUDDING YEAST; FOOD-INTAKE; ACTIVATION	The Snf1/AMP-activated protein kinase (AMPK) family is important for metabolic regulation in response to stress. In the yeast Saccharomyces cerevisiae, the Snf1 kinase cascade comprises three Snf1-activating kinases, Pak1, Tos3, and Elm1. The only established mammalian AMPK kinase is LKB1. We show that LKB1 functions heterologously in yeast. In pak1D tos3D elm1D cells, LKB1 activated Snf1 catalytic activity and conferred a Snf+ growth phenotype. Coexpression of STRADa and MO25a, which form a complex with LKB1, enhanced LKB1 function. Thus, the Snf1/AMPK kinase cascade is functionally conserved between yeast and mammals. Ca2+/calmodulin-dependent kinase kinase (CaMKK) shows more sequence similarity to Pak1, Tos3, and Elm1 than does LKB1. When expressed in pak1D tos3D elm1D cells, CaMKKa activated Snf1 catalytic activity, restored the Snf+ phenotype, and also phosphorylated the activation loop threonine of Snf1 in vitro. These findings indicate that CaMKKa is a functional member of the Snf1/AMPK kinase family and support CaMKKa as a likely candidate for an AMPK kinase in mammalian cells. Analysis of the function of these heterologous kinases in yeast provided insight into the regulation of Snf1. When activated by LKB1 or CaMKKa, Snf1 activity was significantly inhibited by glucose, suggesting that a mechanism independent of the activating kinases can mediate glucose signaling in yeast. Finally, this analysis provided evidence that Pak1 functions in another capacity, besides activating Snf1, to regulate the nuclear enrichment of Snf1 protein kinase in response to carbon stress.	Columbia Univ, Dept Genet & Dev & Microbiol, New York, NY 10032 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Columbia University	Carlson, M (corresponding author), 701 W 168th St,HSC922, New York, NY 10032 USA.	mbc1@columbia.edu			NIGMS NIH HHS [GM 34095] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034095, R01GM034095] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; BLACKETER MJ, 1993, MOL CELL BIOL, V13, P5567, DOI 10.1128/MCB.13.9.5567; Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Bouquin N, 2000, J CELL SCI, V113, P1435; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; Cullen PJ, 2000, P NATL ACAD SCI USA, V97, P13619, DOI 10.1073/pnas.240345197; Cyert MS, 2001, ANNU REV GENET, V35, P647, DOI 10.1146/annurev.genet.35.102401.091302; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hedbacker K, 2004, MOL CELL BIOL, V24, P8255, DOI 10.1128/MCB.24.18.8255-8263.2004; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kraus PR, 2003, BIOCHEM BIOPH RES CO, V311, P1151, DOI 10.1016/S0006-291X(03)01528-6; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Ludin K, 1998, P NATL ACAD SCI USA, V95, P6245, DOI 10.1073/pnas.95.11.6245; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Nath N, 2003, MOL CELL BIOL, V23, P3909, DOI 10.1128/MCB.23.11.3909-3917.2003; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Ruderman N, 2004, NAT REV DRUG DISCOV, V3, P340, DOI 10.1038/nrd1344; Sakamoto K, 2004, AM J PHYSIOL-ENDOC M, V287, pE310, DOI 10.1152/ajpendo.00074.2004; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Song WJ, 1998, EMBO J, V17, P5757, DOI 10.1093/emboj/17.19.5757; Sreenivasan A, 2003, MOL CELL BIOL, V23, P6327, DOI 10.1128/MCB.23.17.6327-6337.2003; Sreenivasan A, 1999, MOL CELL BIOL, V19, P7983; Sutherland CM, 2003, CURR BIOL, V13, P1299, DOI 10.1016/S0960-9822(03)00459-7; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Vincent O, 1999, EMBO J, V18, P6672, DOI 10.1093/emboj/18.23.6672; Vincent O, 1998, EMBO J, V17, P7002, DOI 10.1093/emboj/17.23.7002; Vincent O, 2001, GENE DEV, V15, P1104, DOI 10.1101/gad.879301; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; WOODS A, 1994, J BIOL CHEM, V269, P19509; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	54	101	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21804	21809		10.1074/jbc.M501887200	http://dx.doi.org/10.1074/jbc.M501887200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15831494	hybrid			2022-12-25	WOS:000229557900019
J	Kim, H; Ki, H; Park, HS; Kim, K				Kim, H; Ki, H; Park, HS; Kim, K			Presenilin-1 D257A and D385A mutants fail to cleave notch in their endoproteolyzed forms, but only presenilin-1 D385A mutant can restore its gamma-secretase activity with the compensatory overexpression of normal C-terminal fragment gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; INTRAMEMBRANE PROTEOLYSIS; ALZHEIMERS-DISEASE; COMPLEX; PEN-2; NICASTRIN; LOCALIZATION; APH-1; APP	The enzyme gamma-secretase is involved in the cleavage of several type I membrane proteins, such as Notch 1 and amyloid precursor protein. Presenilin-1 (PS-1) is one of the critical integral membrane protein components of the gamma-secretase complex and is processed endoproteolytically, generating N- and C-terminal fragments (NTF and CTF, respectively). PS-1 is also known to incorporate into a high molecular weight complex by binding to other gamma- secretase components such as Nicastrin, Aph-1, and Pen-2. Mutations on PS-1 can alter the effects of gamma- secretase on its many substrates to different extents. Here, we showed that PS-1 mutants have a different activity for Notch cleavage, which depended on the PS-1 mutation site. We demonstrated that defective PS-1 mutants located in CTF, i. e. D385A and C410Y, could restore their gamma- secretase activities with the compensatory overexpression of wild type CTF or of minimal deleted CTF ( amino acids 349 - 467). However, the defective PS-1 D257A mutant could not restore their gamma- secretase activities with the compensatory overexpression of wild type NTF. In comparison, both D257A NTF and D385A CTF could abolish the gamma- secretase activity of wild type and pathogenic PS-1 mutants. We also showed that PS-1 NTF but not CTF forms strong high molecular weight aggregates in SDS-PAGE. Taken together, results have shown that NTF and CTF integrate differently into high molecular weight aggregates and that PS-1 Asp-257 and Asp385 have different accessibilities in their unendoproteolyzed conformation.	Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Chonnam Natl Univ, Sch Biol Sci & Technol, Kwangju 500757, South Korea	Chonnam National University; Chonnam National University	Kim, H (corresponding author), Chonnam Natl Univ, Coll Pharm, Bldg 1-211,300 Yongbong Dong, Kwangju 500757, South Korea.	koskim@chonnam.ac.kr						Bergman A, 2004, J BIOL CHEM, V279, P45564, DOI 10.1074/jbc.M407717200; Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M; Crystal AS, 2004, BIOCHEMISTRY-US, V43, P3555, DOI 10.1021/bi0361214; Czech C, 2000, PROG NEUROBIOL, V60, P363, DOI 10.1016/S0301-0082(99)00033-7; da Costa CA, 2003, J BIOL CHEM, V278, P12064, DOI 10.1074/jbc.M212379200; DE SB, 1999, NATURE, V398, P518; De Strooper B, 2001, J CELL BIOL, V152, pF17, DOI 10.1083/jcb.152.4.F17; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Fluhrer R, 2004, J BIOL CHEM, V279, P1585, DOI 10.1074/jbc.M306653200; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Gu YJ, 2004, J BIOL CHEM, V279, P31329, DOI 10.1074/jbc.M401548200; Hebert SS, 2003, FEBS LETT, V550, P30, DOI 10.1016/S0014-5793(03)00813-5; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Knappenberger KS, 2004, BIOCHEMISTRY-US, V43, P6208, DOI 10.1021/bi036072v; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Laudon H, 2004, J BIOL CHEM, V279, P23925, DOI 10.1074/jbc.M401277200; Laudon H, 2004, J NEUROCHEM, V89, P44, DOI 10.1046/j.1471-4159.2003.02298.x; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Levitan D, 2001, P NATL ACAD SCI USA, V98, P12186, DOI 10.1073/pnas.211321898; Lleo A, 2003, J BIOL CHEM, V278, P47370, DOI 10.1074/jbc.M308480200; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Rogaeva EA, 2001, NEUROLOGY, V57, P621, DOI 10.1212/WNL.57.4.621; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Rubinsztein DC, 1997, PROG NEUROBIOL, V52, P447, DOI 10.1016/S0301-0082(97)00014-2; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Six E, 2003, P NATL ACAD SCI USA, V100, P7638, DOI 10.1073/pnas.1230693100; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Xia XF, 2002, P NATL ACAD SCI USA, V99, P8760, DOI 10.1073/pnas.132045399; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	53	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22462	22472		10.1074/jbc.M502769200	http://dx.doi.org/10.1074/jbc.M502769200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15797863	hybrid			2022-12-25	WOS:000229557900092
J	Koo, BK; Yoon, KJ; Yoo, KW; Lim, HS; Song, R; So, JH; Kim, CH; Kong, YY				Koo, BK; Yoon, KJ; Yoo, KW; Lim, HS; Song, R; So, JH; Kim, CH; Kong, YY			Mind bomb-2 is an E3 ligase for notch ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE; EMBRYONIC LETHALITY; DOWN-REGULATION; DEFECTS; PROTEIN; ACTIVATION; HOMOLOG; DIFFERENTIATION; INTERNALIZATION; DEGRADATION	The zebrafish gene, mind bomb (mib), encodes a protein that positively regulates of the Delta-mediated Notch signaling. It interacts with the intracellular domain of Delta to promote its ubiquitination and endocytosis. In our search for the mouse homologue of zebrafish mind bomb, we cloned two homologues in the mouse genome: a mouse orthologue (mouse mib1) and a paralogue, named mind bomb-2 (mib2), which is evolutionarily conserved from Drosophila to human. Both Mib1 and Mib2 have an E3 ubiquitin ligase activity in their C-terminal RING domain and interact with Xenopus Delta (XD) via their N-terminal region. Mib2 is also able to ligate ubiquitin to XD and shift the membrane localization of Delta to intracellular vesicles. Importantly, Mib2 rescues both the neuronal and vascular defects in the zebrafish mib(ta52b) mutants. In contrast to the functional similarities between Mib1 and Mib2, mib2 is highly expressed in adult tissues, but almost not at all in embryos, whereas mib1 is abundantly expressed in both embryos and adult tissues. These data suggest that Mib2 has functional similarities to Mib1, but might have distinct roles in Notch signaling as an E3 ubiquitin ligase.	Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, Kyungbuk, South Korea	Chungnam National University; Pohang University of Science & Technology (POSTECH)	Kim, CH (corresponding author), Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea.	zebrakim@cnu.ac.kr; ykong@postech.ac.kr	Koo, Bon-Kyoung/V-5219-2017; Yoon, Ki-Jun/S-8170-2018	Koo, Bon-Kyoung/0000-0002-4134-8033; Yoon, Ki-Jun/0000-0003-2985-2541; Lim, Hyoung Soo/0000-0001-6268-8208; Kim, Cheol-Hee/0000-0002-3019-0699				Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Annaert W, 1999, TRENDS NEUROSCI, V22, P439, DOI 10.1016/S0166-2236(99)01455-1; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Deblandre GA, 2001, DEV CELL, V1, P795, DOI 10.1016/S1534-5807(01)00091-0; Duarte A, 2004, GENE DEV, V18, P2474, DOI 10.1101/gad.1239004; Dunwoodie SL, 2002, DEVELOPMENT, V129, P1795; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101; Haddon C, 1998, DEVELOPMENT, V125, P4637; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Kim CH, 1996, NEUROSCI LETT, V216, P109, DOI 10.1016/0304-3940(96)13021-4; KRAMER H, 2000, SCI STKE; KREBS LT, 2000, GENE DEV, V18, P2469; Kusumi K, 1998, NAT GENET, V19, P274, DOI 10.1038/961; Lai EC, 2001, DEV CELL, V1, P783, DOI 10.1016/S1534-5807(01)00092-2; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; Lawson ND, 2001, DEVELOPMENT, V128, P3675; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Moore KA, 2004, CURR OPIN HEMATOL, V11, P107, DOI 10.1097/01.moh.0000133652.06863.47; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nam Y, 2003, J BIOL CHEM, V278, P21232, DOI 10.1074/jbc.M301567200; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Pavlopoulos E, 2001, DEV CELL, V1, P807, DOI 10.1016/S1534-5807(01)00093-4; Pfeffer S, 2003, CELL, V112, P507, DOI 10.1016/S0092-8674(03)00118-1; Sidow A, 1997, NATURE, V389, P722, DOI 10.1038/39587; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Takeuchi T, 2003, AM J PATHOL, V163, P1395, DOI 10.1016/S0002-9440(10)63497-9; Thelu Jacques, 2002, BMC Dermatol, V2, P7, DOI 10.1186/1471-5945-2-7; THOMAS JB, 1990, FASEB J, V4, P2476, DOI 10.1096/fasebj.4.8.2185974; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723	40	76	79	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22335	22342		10.1074/jbc.M501631200	http://dx.doi.org/10.1074/jbc.M501631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824097	hybrid			2022-12-25	WOS:000229557900079
J	Lu, G; Seta, KA; Millhorn, DE				Lu, G; Seta, KA; Millhorn, DE			Novel role for cyclin-dependent kinase 2 in neuregulin-induced acetylcholine receptor epsilon subunit expression in differentiated myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; ACTIVATED PROTEIN-KINASE; MOLECULAR-WEIGHT FORMS; HUMAN-MELANOMA CELLS; LARGE T-ANTIGEN; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; CDK COMPLEXES; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE	Cyclin-dependent kinases (CDKs) are a family of evolutionarily conserved serine/threonine kinases. CDK2 acts as a checkpoint for the G(1)/S transition in the cell cycle. Despite a down-regulation of CDK2 activity in postmitotic cells, many cell types, including muscle cells, maintain abundant levels of CDK2 protein. This led us to hypothesize that CDK2 may have a function in postmitotic cells. We show here for the first time that CDK2 can be activated by neuregulin (NRG) in differentiated C2C12 myotubes. In addition, this activity is required for expression of the acetylcholine receptor (AChR) epsilon subunit. The switch from the fetal AChR gamma subunit to the adult-type AChR epsilon is required for synapse maturation and the neuromuscular junction. Inhibition of CDK2 activity with either the specific CDK2 inhibitory peptide Tat-LFG or by RNA interference abolished neuregulin-induced AChR epsilon expression. Neuregulin-induced activation of CDK2 also depended on the ErbB receptor, MAPK, and PI3K, all of which have previously been shown to be required for AChR epsilon expression. Neuregulin regulated CDK2 activity through coordinating phosphorylation of CDK2 on Thr-160, accumulation of CDK2 in the nucleus, and down-regulation of the CDK2 inhibitory protein p27 in the nucleus. In addition, we also observed a novel mechanism of regulation of CDK2 activity by a low molecular weight variant of cyclin E in response to NRG. These findings establish CDK2 as an intermediate molecule that integrates NRG-activated signals from both the MAPK and PI3K pathways to AChR epsilon expression and reveal an undiscovered physiological role for CDK2 in postmitotic cells.	Univ Cincinnati, Genome Res Inst, Dept Genome Sci, Cincinnati, OH 45237 USA	University of Cincinnati	Millhorn, DE (corresponding author), Univ Cincinnati, Genome Res Inst, Dept Genome Sci, 2180 E Galbraith Rd, Cincinnati, OH 45237 USA.	david.millhorn@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059945, R37HL033831, R01HL033831, R01HL066312] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 66312, HL 33831, HL 59945] Funding Source: Medline; NIDDK NIH HHS [DK 58811] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMCZEWSKI JP, 1993, J VIROL, V67, P6551, DOI 10.1128/JVI.67.11.6551-6557.1993; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Akli S, 2004, BREAST CANCER RES, V6, P188, DOI 10.1186/bcr905; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Bales E, 2005, CANCER RES, V65, P692; Baliga RR, 1999, AM J PHYSIOL-HEART C, V277, pH2026, DOI 10.1152/ajpheart.1999.277.5.H2026; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Blanchard DA, 2000, ONCOGENE, V19, P4184, DOI 10.1038/sj.onc.1203761; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Chu CY, 2000, BBA-MOL CELL RES, V1497, P175, DOI 10.1016/S0167-4889(00)00064-1; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; Ding QM, 1998, AM J PHYSIOL-CELL PH, V275, pC1193, DOI 10.1152/ajpcell.1998.275.5.C1193; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; Gladden AB, 2003, CANCER CELL, V4, P160, DOI 10.1016/S1535-6108(03)00217-4; Grim JE, 2003, TRENDS CELL BIOL, V13, P396, DOI 10.1016/S0962-8924(03)00148-X; GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; GUO K, 1995, MOL CELL BIOL, V15, P3823; Hamburger AW, 1997, ANTICANCER RES, V17, P2197; HARPER JW, 1993, CELL, V75, P805; Harwell RM, 2000, CANCER RES, V60, P481; Hauck L, 2002, CIRC RES, V91, P782, DOI 10.1161/01.RES.0000041030.98642.41; Hinds PW, 2003, CANCER CELL, V3, P305, DOI 10.1016/S1535-6108(03)00084-9; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Jackman M, 2002, MOL BIOL CELL, V13, P1030, DOI 10.1091/mbc.01-07-0361; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Lazaro JB, 1997, J CELL SCI, V110, P1251; Le XF, 2000, CLIN CANCER RES, V6, P260; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Love S, 2003, NEUROSCI LETT, V353, P29, DOI 10.1016/j.neulet.2003.09.004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MARTE BM, 1995, ONCOGENE, V10, P167; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Missias AC, 1997, DEVELOPMENT, V124, P5075; MORGAN DO, 1991, ANNU REV CELL DEV BI, V19, P261; Mumberg D, 1997, NUCLEIC ACIDS RES, V25, P2098, DOI 10.1093/nar/25.11.2098; Ng YP, 1997, MOL CELL NEUROSCI, V9, P132, DOI 10.1006/mcne.1997.0613; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pagano M, 2004, CELL, V118, P535, DOI 10.1016/j.cell.2004.08.013; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter DC, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.23.e101; Puricelli L, 2002, INT J CANCER, V100, P642, DOI 10.1002/ijc.10533; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; SEWING A, 1994, J CELL SCI, V107, P581; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; Si JT, 1999, MOL BRAIN RES, V67, P18, DOI 10.1016/S0169-328X(99)00028-5; Suzuki JI, 1997, NAT MED, V3, P900, DOI 10.1038/nm0897-900; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tedesco D, 1997, J VIROL, V71, P2217, DOI 10.1128/JVI.71.3.2217-2224.1997; USDIN TB, 1986, J CELL BIOL, V103, P493, DOI 10.1083/jcb.103.2.493; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Wang XD, 2003, ONCOGENE, V22, P769, DOI 10.1038/sj.onc.1206166; Watanabe Y, 1999, BRAIN RES, V842, P342, DOI 10.1016/S0006-8993(99)01844-2; Witzemann V, 1996, P NATL ACAD SCI USA, V93, P13286, DOI 10.1073/pnas.93.23.13286; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	86	8	8	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21731	21738		10.1074/jbc.M412498200	http://dx.doi.org/10.1074/jbc.M412498200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824106	hybrid			2022-12-25	WOS:000229557900009
J	Mendillo, ML; Mazur, DJ; Kolodner, RD				Mendillo, ML; Mazur, DJ; Kolodner, RD			Analysis of the interaction between the Saccharomyces cerevisiae MSH2-MSH6 and MLH1-PMS1 complexes with DNA using a reversible DNA end-blocking system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MISMATCH REPAIR; ESCHERICHIA-COLI MUTS; COLORECTAL-CANCER; SLIDING-CLAMP; TRANSLOCATION MECHANISM; MISPAIR-BINDING; YEAST MSH2-MSH6; GENE-PRODUCT; HMUTS-ALPHA; HUMAN-CELLS	The Lac repressor-operator interaction was used as a reversible DNA end-blocking system in conjunction with an IAsys biosensor instrument ( Thermo Affinity Sensors), which detects total internal reflectance and allows monitoring of binding and dissociation in real time, in order to develop a system for studying the ability of mismatch repair proteins to move along the DNA. The MSH2-MSH6 complex bound to a mispaired base was found to be converted by ATP binding to a form that showed rapid sliding along the DNA and dissociation via the DNA ends and also showed slow, direct dissociation from the DNA. In contrast, the MSH2-MSH6 complex bound to a base pair containing DNA only showed direct dissociation from the DNA. The MLH1-PMS1 complex formed both mispair-dependent and mispair-independent ternary complexes with the MSH2-MSH6 complex on DNA. The mispair-independent ternary complexes were formed most efficiently on DNA molecules with free ends under conditions where ATP hydrolysis did not occur, and only exhibited direct dissociation from the DNA. The mispair-dependent ternary complexes were formed in the highest yield on DNA molecules with blocked ends, required ATP and magnesium for formation, and showed both dissociation via the DNA ends and direct dissociation from the DNA.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Canc, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	rkolodner@ucsd.edu	Classen, Scott/AAY-8176-2020	Mendillo, Marc/0000-0001-8128-0128	NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER; NCI NIH HHS [CA 92584, F32 CA210407] Funding Source: Medline; NIGMS NIH HHS [R01 GM050006, GM 50006, F32 GM106598] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Antony E, 2003, BIOCHEMISTRY-US, V42, P7682, DOI 10.1021/bi034602h; AU KG, 1992, J BIOL CHEM, V267, P12142; Baitinger C, 2003, J BIOL CHEM, V278, P49505, DOI 10.1074/jbc.M308738200; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Blackwell LJ, 2001, J BIOL CHEM, V276, P34339, DOI 10.1074/jbc.M104256200; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 2000, J MOL BIOL, V302, P327, DOI 10.1006/jmbi.2000.4081; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Fu TJ, 1996, EMBO J, V15, P4414, DOI 10.1002/j.1460-2075.1996.tb00814.x; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hess MT, 2002, J BIOL CHEM, V277, P25545, DOI 10.1074/jbc.M202282200; Joshi A, 2000, NUCLEIC ACIDS RES, V28, P853, DOI 10.1093/nar/28.4.853; Kijas AW, 2003, J MOL BIOL, V331, P123, DOI 10.1016/S0022-2836(03)00694-6; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Lynch HT, 1999, J MED GENET, V36, P801; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Matthews KS, 1998, PROG NUCLEIC ACID RE, V58, P127; Mazurek A, 2002, J BIOL CHEM, V277, P8260, DOI 10.1074/jbc.M111269200; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Peltomaki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060; Plotz G, 2002, NUCLEIC ACIDS RES, V30, P711, DOI 10.1093/nar/30.3.711; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Raschle M, 2002, J BIOL CHEM, V277, P21810, DOI 10.1074/jbc.M108787200; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; Saenko EL, 1998, J BIOL CHEM, V273, P27918, DOI 10.1074/jbc.273.43.27918; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Selmane T, 2003, J MOL BIOL, V334, P949, DOI 10.1016/j.jmb.2003.10.010; SU SS, 1988, J BIOL CHEM, V263, P6829; Tran PT, 2000, MOL CELL BIOL, V20, P6390, DOI 10.1128/MCB.20.17.6390-6398.2000; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; WELSH KM, 1987, J BIOL CHEM, V262, P15624; Wheeler JMD, 2000, GUT, V47, P148, DOI 10.1136/gut.47.1.148	56	104	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22245	22257		10.1074/jbc.M407545200	http://dx.doi.org/10.1074/jbc.M407545200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15811858	hybrid			2022-12-25	WOS:000229557900070
J	Sossey-Alaoui, K; Li, XR; Ranalli, TA; Cowell, JK				Sossey-Alaoui, K; Li, XR; Ranalli, TA; Cowell, JK			WAVE3-mediated cell migration and lamellipodia formation are regulated downstream of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; GROWTH-FACTOR; N-WASP; ARP2/3 COMPLEX; ACTIN-POLYMERIZATION; BINDING-PROTEIN; WAVE; ACTIVATION; RAC; NUCLEATION	WAVE3 is a member of the WASP/WAVE family of protein effectors of actin reorganization and cell movement. The precise role of WAVE3 in cell migration and its regulation, however, have not been elucidated. Here we show that endogenous WAVE3 was found to be concentrated in the lamellipodia at the leading edge of migrating MDA-MB-231 cells. Platelet-derived growth factor (PDGF) treatment induced lamellipodia formation as well as two-dimensional migration of cells in the wound-closure assay and chemotactic migration toward PDGF in three-dimensional migration chambers. Knockdown of WAVE3 expression by RNA interference prevented the PDGF-induced lamellipodia formation and cell migration. Treatment of cells with LY294002, an inhibitor of phosphatidylinositol 3-kinase (PI3K), also abrogated the PDGF-induced lamellipodia formation and cell migration, suggesting that PI3K may be required for WAVE3 activity. WAVE3 and the PI3K regulatory subunit, p85, were found to interact in a yeast two-hybrid screen, which was confirmed through co-immunoprecipitation. The WAVE3-p85 interaction was mediated by the N-terminal region of WAVE3 and the C-terminal SH2 domain of p85. These results imply that the WAVE3-mediated migration in MDA-MB-231 cells via lamellipodia formation is activated downstream of PI3K and induced by PDGF. The findings of the WAVE3-p85 partnership also suggest a potential regulatory role for p85 in WAVE3-dependent actin-cytoskeleton reorganization and cell migration.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Sossey-Alaoui, K (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton Sts, Buffalo, NY 14263 USA.	Khalid.Sossey-Alaoui@RoswellPark.org		Cowell, John/0000-0002-2079-5950	NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035791] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056] Funding Source: Medline; NINDS NIH HHS [NS 35791-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Betsholtz Christer, 2003, Birth Defects Research, V69, P272, DOI 10.1002/bdrc.10030; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; Cao RH, 2004, CANCER CELL, V6, P333, DOI 10.1016/j.ccr.2004.08.034; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Echarri A, 2004, MOL CELL BIOL, V24, P4979, DOI 10.1128/MCB.24.11.4979-4993.2004; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Funa K, 2003, ACTA BIOCHIM POL, V50, P647; Gautreau A, 2004, P NATL ACAD SCI USA, V101, P4379, DOI 10.1073/pnas.0400628101; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Innocenti M, 2004, NAT CELL BIOL, V6, P319, DOI 10.1038/ncb1105; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; Kawamura K, 2004, J BIOL CHEM, V279, P54862, DOI 10.1074/jbc.M408057200; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leng Y, 2005, P NATL ACAD SCI USA, V102, P1098, DOI 10.1073/pnas.0409120102; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; MEAD RS, 1995, CANCER GENET CYTOGEN, V81, P151; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1999, J BIOL CHEM, V274, P27605, DOI 10.1074/jbc.274.39.27605; MIKI H, 1994, J BIOL CHEM, V269, P5489; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Millard TH, 2004, BIOCHEM J, V380, P1, DOI 10.1042/BJ20040176; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Nozumi M, 2003, J CELL SCI, V116, P239, DOI 10.1242/jcs.00233; Oda A, 2005, BLOOD, V105, P3141, DOI 10.1182/blood-2003-04-1319; Oikawa T, 2004, NAT CELL BIOL, V6, P420, DOI 10.1038/ncb1125; OKKENHAUG K, 2001, SCI STKE, pE1; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Sossey-Alaoui K, 2003, MAMM GENOME, V14, P314, DOI 10.1007/s00335-002-2247-7; Sossey-Alaoui K, 2002, ONCOGENE, V21, P5967, DOI 10.1038/sj.onc.1205734; Suetsugu S, 2003, INT REV CYTOL, V229, P245, DOI 10.1016/S0074-7696(03)29006-9; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Takenawa T, 2001, J CELL SCI, V114, P1801; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Weaver AM, 2003, CURR OPIN CELL BIOL, V15, P23, DOI 10.1016/S0955-0674(02)00015-7; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Yamaguchi H, 2002, CANCER RES, V62, P2503; Yamazaki D, 2003, NATURE, V424, P452, DOI 10.1038/nature01770; Yan C, 2003, EMBO J, V22, P3602, DOI 10.1093/emboj/cdg350	52	79	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21748	21755		10.1074/jbc.M500503200	http://dx.doi.org/10.1074/jbc.M500503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15826941	hybrid			2022-12-25	WOS:000229557900011
J	Stallings, JD; Tall, EG; Pentyala, S; Rebecchi, MJ				Stallings, JD; Tall, EG; Pentyala, S; Rebecchi, MJ			Nuclear translocation of phospholipase C-delta(1) is linked to the cell cycle and nuclear phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MESSENGER-RNA EXPORT; BASIC-AMINO-ACIDS; INOSITOL LIPIDS; C ISOZYMES; S-PHASE; BINDING; PHOSPHOINOSITIDES; C-DELTA-1; MEMBRANE	Nuclear phosphoinositides, especially phosphatidylinositol 4,5-bisphosphate, fluctuate throughout the cell cycle and are linked to proliferation and differentiation. Here we report that phospholipase C-delta(1) accumulates in the nucleus at the G1/S boundary and in G(0) phases of the cell cycle. Furthermore, as wild-type protein accumulated in the nucleus, nuclear phosphatidylinositol 4,5-bisphosphate levels were elevated 3-5-fold, whereas total levels were decreased compared with asynchronous cultures. To test whether phosphatidylinositol 4,5-bisphosphate binding is important during this process, we introduced a R40D point mutation within the pleckstrin homology domain of phospholipase C-delta(1), which disables high affinity phosphatidylinositol 4,5-bisphosphate binding, and found that nuclear translocation was significantly reduced at G(1)/S and in G(0). These results demonstrate a cell cycle-dependent compartmentalization of phospholipase C-delta(1) and support the idea that relative levels of phosphoinositides modulate the portioning of phosphoinositide-binding proteins between the nucleus and other compartments.	SUNY Stony Brook, Hlth Sci Ctr, Dept Anesthesiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Rebecchi, MJ (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Anesthesiol, Level 4,Rm 076, Stony Brook, NY 11794 USA.	mrebecchi@notes.cc.sunysb.edu	Stallings, Jonathan D/H-7779-2013	Stallings, Jonathan D/0000-0002-6430-5888				ASANO M, 1994, J BIOL CHEM, V269, P12360; Auger K. R., 1990, METHODS INOSITIDE RE, P159; Baek KJ, 2001, J BIOL CHEM, V276, P5591, DOI 10.1074/jbc.M008252200; Balla Tamas, 2002, Sci STKE, V2002, ppl3, DOI 10.1126/stke.2002.125.pl3; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Clarke JH, 2001, BIOCHEM J, V357, P905, DOI 10.1042/0264-6021:3570905; Cocco L, 2001, MARC MALPIG SYMP SER, V7, P31; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; DeLillo N, 2003, MOL GENET GENOMICS, V269, P261, DOI 10.1007/s00438-003-0832-4; Divecha N, 1997, BIOCHEM SOC T, V25, P571, DOI 10.1042/bst0250571; Flygare J, 2001, EXP CELL RES, V268, P61, DOI 10.1006/excr.2001.5265; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Gillooly DJ, 2001, J CELL BIOL, V155, P15, DOI 10.1083/jcb.200109001; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Hammond G, 2004, CURR TOP MICROBIOL, V282, P177; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Kobayashi M, 2004, BIOCHEMISTRY-US, V43, P7522, DOI 10.1021/bi035966c; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; Lomasney JW, 1999, J BIOL CHEM, V274, P21995, DOI 10.1074/jbc.274.31.21995; Martelli AM, 2004, PHARMACOL THERAPEUT, V101, P47, DOI 10.1016/j.pharmthera.2003.10.003; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nakamura Y, 2003, EMBO J, V22, P2981, DOI 10.1093/emboj/cdg302; Okada M, 2002, GENES CELLS, V7, P985, DOI 10.1046/j.1365-2443.2002.00577.x; Osborne SL, 2001, J CELL SCI, V114, P2501; Pagon Z, 2003, J CELL BIOCHEM, V89, P733, DOI 10.1002/jcb.10549; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Percival JM, 2000, CELL MOTIL CYTOSKEL, V47, P189, DOI 10.1002/1097-0169(200011)47:3<189::AID-CM3>3.0.CO;2-C; Rando OJ, 2002, P NATL ACAD SCI USA, V99, P2824, DOI 10.1073/pnas.032662899; REBECCHI MJ, 1984, BASIC MED SCI PROGRA, P168; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Santagata S, 2001, SCIENCE, V292, P2041, DOI 10.1126/science.1061233; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shimohama S, 1998, BIOCHEM BIOPH RES CO, V243, P210, DOI 10.1006/bbrc.1998.8090; Tabellini G, 2003, EXP CELL RES, V287, P143, DOI 10.1016/S0014-4827(03)00115-0; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; Tall EG, 2000, CURR BIOL, V10, P743, DOI 10.1016/S0960-9822(00)00541-8; TALL EG, 2002, PHYSL BIOPHYSICS, P224; Vann LR, 1997, BIOCHEM J, V327, P569; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Williams RL, 1996, STRUCTURE, V4, P1387, DOI 10.1016/S0969-2126(96)00146-3; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; Yamaga M, 1999, J BIOL CHEM, V274, P28537, DOI 10.1074/jbc.274.40.28537; Yamaga M, 2004, GENES CELLS, V9, P25, DOI 10.1111/j.1356-9597.2004.00698.x; Yashiroda Y, 2003, CURR MED CHEM, V10, P741, DOI 10.2174/0929867033457791; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; YORK JD, 1994, J BIOL CHEM, V269, P7847; Yu HY, 1998, EUR J BIOCHEM, V251, P281, DOI 10.1046/j.1432-1327.1998.2510281.x; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	56	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22060	22069		10.1074/jbc.M413813200	http://dx.doi.org/10.1074/jbc.M413813200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15809301	hybrid			2022-12-25	WOS:000229557900050
J	Thiruchelvam, M; Prokopenko, O; Cory-Slechta, DA; Richfield, EK; Buckley, B; Mirochnitchenko, O				Thiruchelvam, M; Prokopenko, O; Cory-Slechta, DA; Richfield, EK; Buckley, B; Mirochnitchenko, O			Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat plus maneb-induced Parkinson disease phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLENE-BIS-DITHIOCARBAMATE; ENVIRONMENTAL RISK-FACTORS; CELL-DEATH; HERBICIDE PARAQUAT; DOPAMINERGIC NEURODEGENERATION; MITOCHONDRIAL DYSFUNCTION; CHRONIC EXPOSURE; FUNGICIDE MANEB; TRAUMATIC BRAIN; REACTIVE OXYGEN	Oxidative stress has been implicated in the pathogenesis of Parkinson disease based on its role in the cascade of biochemical changes that lead to dopaminergic neuronal death. This study analyzed the role of oxidative stress as a mechanism of the dopaminergic neurotoxicity produced by the combined paraquat and maneb model of the Parkinson disease phenotype. Transgenic mice overexpressing either Cu, Zn superoxide dismutase or intracellular glutathione peroxidase and non-transgenic mice were exposed to saline, paraquat, or the combination of paraquat + maneb twice a week for 9 weeks. Non-transgenic mice chronically exposed to paraquat + maneb exhibited significant reductions in locomotor activity, levels of striatal dopamine and metabolites, and dopaminergic neurons in the substantia nigra pars compacta. In contrast, no corresponding effects were observed in either Cu, Zn superoxide dismutase or glutathione peroxidase transgenic mice. Similarly, the increase in levels of lipid hydroperoxides in the midbrain and striatum of paraquat + maneb- treated non-transgenic mice was not detected in either Cu, Zn superoxide dismutase or glutathione peroxidase transgenic mice. To begin to determine critical pathways of paraquat + maneb neurotoxicity, the functions of cell death- inducing and protective mechanisms were analyzed. Even a single injection of paraquat + maneb in the non-transgenic treated group modulated several key pro- and antiapoptotic proteins, including Bax, Bad, Bcl-xL, and upstream stress-induced cascade. Collectively, these findings support the assertion that protective mechanisms against paraquat + maneb- induced neurodegeneration could involve modulation of the level of reactive oxygen species and alterations of the functions of specific signaling cascades.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Environm & Occupat Med, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Mirochnitchenko, O (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Environm & Occupat Med, Environm & Occupat Hlth Sci Inst, 170 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	mirochol@umdnj.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005022] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES005022, ES 05022] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akhtar RS, 2004, BBA-MOL CELL RES, V1644, P189, DOI 10.1016/j.bbamcr.2003.10.013; Barlow BK, 2004, DEV NEUROSCI-BASEL, V26, P11, DOI 10.1159/000080707; Barlow BK, 2003, J NEUROCHEM, V85, P1075, DOI 10.1046/j.1471-4159.2003.01773.x; Barzilai A, 2003, TRENDS MOL MED, V9, P126, DOI 10.1016/S1471-4914(03)00020-0; Cheng WH, 2003, FREE RADICAL BIO MED, V34, P918, DOI 10.1016/S0891-5849(03)00021-2; Chu CT, 2004, EUR J BIOCHEM, V271, P2060, DOI 10.1111/j.1432-1033.2004.04132.x; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; Cotteret S, 2003, MOL CELL BIOL, V23, P5526, DOI 10.1128/MCB.23.16.5526-5539.2003; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Day BJ, 1999, P NATL ACAD SCI USA, V96, P12760, DOI 10.1073/pnas.96.22.12760; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; FERRAZ HB, 1988, NEUROLOGY, V38, P550, DOI 10.1212/WNL.38.4.550; Fitsanakis VA, 2002, FREE RADICAL BIO MED, V33, P1714, DOI 10.1016/S0891-5849(02)01169-3; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hartmann A, 2002, NEUROBIOL DIS, V10, P28, DOI 10.1006/nbdi.2002.0494; Hildeman DA, 2003, P NATL ACAD SCI USA, V100, P15035, DOI 10.1073/pnas.1936213100; Ishibashi N, 2002, J IMMUNOL, V168, P1926, DOI 10.4049/jimmunol.168.4.1926; Ishibashi N, 2002, MOL BRAIN RES, V109, P34, DOI 10.1016/S0169-328X(02)00459-X; ISRAELI R, 1983, SCAND J WORK ENV HEA, V9, P47, DOI 10.5271/sjweh.2443; Jin ZH, 2004, J BIOL CHEM, V279, P23837, DOI 10.1074/jbc.M402566200; Jones GM, 2000, J TOXICOL-CLIN TOXIC, V38, P123, DOI 10.1081/CLT-100100926; Jordan J, 2004, J NEUROCHEM, V89, P124, DOI 10.1046/j.1471-4159.2003.02299.x; Kirkland RA, 2003, ANTIOXID REDOX SIGN, V5, P589, DOI 10.1089/152308603770310257; Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; McCormack AL, 2002, NEUROBIOL DIS, V10, P119, DOI 10.1006/nbdi.2002.0507; McGrew DM, 2000, NEUROTOXICOLOGY, V21, P309; MECO G, 1994, SCAND J WORK ENV HEA, V20, P301, DOI 10.5271/sjweh.1394; Melchiorri D, 1998, LIFE SCI, V62, P1927, DOI 10.1016/S0024-3205(98)00161-1; MIROCHNITCHENKO O, 1995, P NATL ACAD SCI USA, V92, P8120, DOI 10.1073/pnas.92.18.8120; Mollace V, 2003, NEUROSCI LETT, V335, P163, DOI 10.1016/S0304-3940(02)01168-0; Moulding DA, 2001, J LEUKOCYTE BIOL, V70, P783; Nicotra A, 2002, NEUROTOXICOL TERATOL, V24, P599, DOI 10.1016/S0892-0362(02)00213-1; Peng J, 2004, J BIOL CHEM, V279, P32626, DOI 10.1074/jbc.M404596200; Priyadarshi A, 2000, NEUROTOXICOLOGY, V21, P435; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Schelman WR, 2004, MOL BRAIN RES, V128, P160, DOI 10.1016/j.molbrainres.2004.06.011; SEMCHUK KM, 1992, NEUROLOGY, V42, P1328, DOI 10.1212/WNL.42.7.1328; Serrano F, 2003, BRAIN RES, V988, P193, DOI 10.1016/S0006-8993(03)03364-X; Shimizu K, 2003, BRAIN RES, V976, P243, DOI 10.1016/S0006-8993(03)02750-1; Suntres ZE, 2002, TOXICOLOGY, V180, P65, DOI 10.1016/S0300-483X(02)00382-7; TANNER CM, 1989, TRENDS NEUROSCI, V12, P49, DOI 10.1016/0166-2236(89)90135-5; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Tatton WG, 2003, ANN NEUROL, V53, pS61, DOI 10.1002/ana.10489; Thiruchelvam M, 2000, BRAIN RES, V873, P225, DOI 10.1016/S0006-8993(00)02496-3; Thiruchelvam M, 2003, EUR J NEUROSCI, V18, P589, DOI 10.1046/j.1460-9568.2003.02781.x; Thiruchelvam M, 2002, NEUROTOXICOLOGY, V23, P621, DOI 10.1016/S0161-813X(02)00092-X; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; Thiruchelvam MJ, 2004, EUR J NEUROSCI, V19, P845, DOI 10.1111/j.0953-816X.2004.03139.x; Valks DM, 2003, J BIOL CHEM, V278, P25542, DOI 10.1074/jbc.M303760200; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; Voehringer DW, 2000, ANTIOXID REDOX SIGN, V2, P537, DOI 10.1089/15230860050192314; Widdowson PS, 1996, HUM EXP TOXICOL, V15, P583, DOI 10.1177/096032719601500706; Zhang J, 2003, J NEUROCHEM, V84, P336, DOI 10.1046/j.1471-4159.2003.01525.x; Zhou Y, 2004, NEUROSCIENCE, V128, P281, DOI 10.1016/j.neuroscience.2004.06.048	57	118	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22530	22539		10.1074/jbc.M500417200	http://dx.doi.org/10.1074/jbc.M500417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824117	hybrid, Green Published			2022-12-25	WOS:000229557900101
J	Joyce, JA; Freeman, C; Meyer-Morse, N; Parish, CR; Hanahan, D				Joyce, JA; Freeman, C; Meyer-Morse, N; Parish, CR; Hanahan, D			A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer	ONCOGENE			English	Article						heparanase; heparan sulfate-binding proteins; invasion; angiogenesis; pancreatic neuroendocrine cancer; mouse model	FIBROBLAST GROWTH-FACTORS; MAMMALIAN HEPARANASE; CELL-SURFACE; ENDOTHELIAL-CELLS; GENE-EXPRESSION; BINDING; SEQUESTRATION; PROTEOGLYCANS; DEGRADATION; INVOLVEMENT	Heparan sulfate proteoglycans are integral components of the extracellular matrix that surrounds all mammalian cells. In addition to providing structural integrity, they act as a storage depot for a variety of heparan sulfate (HS)binding proteins, including growth factors and chemokines. Heparanase is a matrix-degrading enzyme that cleaves heparan sulfate side chains from the core proteoglycans, thus liberating such HS-binding proteins, as well as potentially contributing to extracellular matrix degradation. Here, we report that heparanase mRNA and protein expression are increased in the neoplastic stages progressively unfolding in a mouse model of multistage pancreatic islet carcinogenesis. Notably, heparanase is delivered to the neoplastic lesions in large part by infiltrating Gr1+/ Mac1+ innate immune cells. A sulfated oligosaccharide mimetic of heparan sulfate, PI-88, was used to inhibit simultaneously both heparanase activity and HS effector functions. PI-88 had significant effects at distinct stages of tumorigenesis, producing a reduction in the number of early progenitor lesions and an impairment of tumor growth at later stages. These responses were associated with decreased cell proliferation, increased apoptosis, impaired angiogenesis, and a substantive reduction in the number of invasive carcinomas. In addition, we show that the reduction in tumor angiogenesis is correlated with a reduced association of VEGF-A with its receptor VEGF-R2 on the tumor endothelium, implicating heparanase in the mobilization of matrix-associated VEGF. These data encourage clinical applications of inhibitors such as PI-88 for the many human cancers where heparanase expression is elevated or mobilization of HS-binding regulatory factors is implicated.	Univ Calif San Francisco, Dept Biochem & Biophys, Diabet & Comprehens Canc Ctr, San Francisco, CA 94143 USA; Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canberra, ACT 2601, Australia	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Australian National University; John Curtin School of Medical Research	Joyce, JA (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave,Box 372, New York, NY 10021 USA.	joycej@mskcc.org; dh@biochem.ucsf.edu		Parish, Christopher/0000-0001-7740-0430				BARTLETT MR, 1995, J LEUKOCYTE BIOL, V57, P207, DOI 10.1002/jlb.57.2.207; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brekken RA, 1998, CANCER RES, V58, P1952; Cochran S, 2003, J MED CHEM, V46, P4601, DOI 10.1021/jm030180y; Compagni A, 2000, CANCER RES, V60, P7163; DAMORE MA, 1988, BIOCHEMISTRY-US, V27, P7131, DOI 10.1021/bi00418a070; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Ferro V, 2001, CARBOHYD RES, V332, P183, DOI 10.1016/S0008-6215(01)00061-1; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Francis DJ, 2003, CIRC RES, V92, pE70, DOI 10.1161/01.RES.0000071345.76095.07; Freeman C, 1997, BIOCHEM J, V325, P229, DOI 10.1042/bj3250229; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Haimov-Kochman R, 2002, MOL HUM REPROD, V8, P566, DOI 10.1093/molehr/8.6.566; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kelly T, 2003, CANCER RES, V63, P8749; Khachigian LM, 2004, CARDIOVASC DRUG REV, V22, P1; Kim AW, 2002, J GASTROINTEST SURG, V6, P167, DOI 10.1016/S1091-255X(01)00087-7; Koliopanos A, 2001, CANCER RES, V61, P4655; Levidiotis V, 2004, J AM SOC NEPHROL, V15, P68, DOI 10.1097/01.ASN.0000103229.25389.40; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Marchetti D, 1997, ADV ENZYME REGUL, V37, P111, DOI 10.1016/S0065-2571(96)00019-2; Marchetti D, 2000, CANCER RES, V60, P4767; Maxhimer JB, 2002, SURGERY, V132, P326, DOI 10.1067/msy.2002.125719; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; PARANGI S, 1995, CANCER RES, V55, P6071; Parish CR, 1999, CANCER RES, V59, P3433; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SOKER S, 1994, BIOCHEM BIOPH RES CO, V203, P1339, DOI 10.1006/bbrc.1994.2329; Tang WH, 2002, MODERN PATHOL, V15, P593, DOI 10.1038/modpathol.3880571; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Uno F, 2001, CANCER RES, V61, P7855; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; Zcharia E, 2001, J MAMMARY GLAND BIOL, V6, P311, DOI 10.1023/A:1011375624902; Zetser A, 2003, CANCER RES, V63, P7733	56	140	155	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4037	4051		10.1038/sj.onc.1208602	http://dx.doi.org/10.1038/sj.onc.1208602			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806157				2022-12-25	WOS:000229680300004
J	Carpaneto, A; Geiger, D; Bamberg, E; Sauer, N; Fromm, J; Hedrich, R				Carpaneto, A; Geiger, D; Bamberg, E; Sauer, N; Fromm, J; Hedrich, R			Phloem-localized, proton-coupled sucrose carrier ZmSUT1 mediates sucrose efflux under the control of the sucrose gradient and the proton motive force	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER; EXPRESSION; POTATO; GENE; COTRANSPORT; VOLTAGE; CLONING; HEXOSE; H+	The phloem network is as essential for plants as the vascular system is for humans. This network, assembled by nucleus- and vacuole- free interconnected living cells, represents a long distance transport pathway for nutrients and information. According to the Munch hypothesis, osmolytes such as sucrose generate the hydrostatic pressure that drives nutrient and water flow between the source and the sink phloem (Munch, E. (1930) Die Stoffbewegungen in der Pflanze, Gustav Fischer, Jena, Germany). Although proton-coupled sucrose carriers have been localized to the sieve tube and the companion cell plasma membrane of both source and sink tissues, knowledge of the molecular representatives and the mechanism of the sucrose phloem efflux is still scant. We expressed ZmSUT1, a maize sucrose/ proton symporter, in Xenopus oocytes and studied the transport characteristics of the carrier by electrophysiological methods. Using the patch clamp techniques in the giant inside-out patch mode, we altered the chemical and electrochemical gradient across the sucrose carrier and analyzed the currents generated by the proton flux. Thereby we could show that ZmSUT1 is capable of mediating both the sucrose uptake into the phloem in mature leaves ( source) as well as the desorption of sugar from the phloem vessels into heterotrophic tissues ( sink). As predicted from a perfect molecular machine, the ZmSUT1-mediated sucrose-coupled proton current was reversible and depended on the direction of the sucrose and pH gradient as well as the membrane potential across the transporter.	Julius Von Sachs Inst Biosci Mol Plant Physiol &, D-97082 Wurzburg, Germany; CNR, Ist Biofis, I-16149 Genoa, Italy; Max Planck Inst Biophys, D-60439 Frankfurt, Germany; Univ Erlangen Nurnberg, D-91058 Erlangen, Germany; Tech Univ Munich, Holzforsch, D-80797 Munich, Germany	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Max Planck Society; University of Erlangen Nuremberg; Technical University of Munich	Hedrich, R (corresponding author), Julius Von Sachs Inst Biosci Mol Plant Physiol &, Julius Von Sachs Pl 2, D-97082 Wurzburg, Germany.	hedrich@botanik.uni-wuerzburg.de	Carpaneto, Armando/F-7754-2013; Geiger, Dietmar/AAH-8140-2019; Geiger, Dietmar/D-6914-2014; Hedrich, Rainer/G-8771-2011	Geiger, Dietmar/0000-0003-0715-5710; Geiger, Dietmar/0000-0003-0715-5710; Hedrich, Rainer/0000-0003-3224-1362; Carpaneto, Armando/0000-0002-5060-3657				Ache P, 2001, PLANT J, V27, P571, DOI 10.1046/j.1365-313X.2001.t01-1-01116.x; Aoki N, 1999, PLANT CELL PHYSIOL, V40, P1072, DOI 10.1093/oxfordjournals.pcp.a029489; Becker D, 1996, P NATL ACAD SCI USA, V93, P8123, DOI 10.1073/pnas.93.15.8123; Bel A. J. E. van, 1993, Progress in Botany, V54, P134; Boorer KJ, 1996, J BIOL CHEM, V271, P25139, DOI 10.1074/jbc.271.41.25139; Deeken R, 2002, PLANTA, V216, P334, DOI 10.1007/s00425-002-0895-1; EVERT RF, 1993, AM J BOT, V80, P1310, DOI 10.2307/2445716; Gottwald JR, 2000, P NATL ACAD SCI USA, V97, P13979, DOI 10.1073/pnas.250473797; Hilgemann Donald W., 1995, P307; Hirose T, 1997, PLANT CELL PHYSIOL, V38, P1389, DOI 10.1093/oxfordjournals.pcp.a029134; KOMOR E, 1974, J GEN PHYSIOL, V64, P568, DOI 10.1085/jgp.64.5.568; KOMOR E, 1974, NATURE, V248, P511, DOI 10.1038/248511a0; Kuhn C, 2003, PLANT BIOLOGY, V5, P215, DOI 10.1055/s-2003-40798; Kuhn C, 2003, PLANT PHYSIOL, V131, P102, DOI 10.1104/pp.011676; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; Lalonde S, 2003, PLANT CELL ENVIRON, V26, P37, DOI 10.1046/j.1365-3040.2003.00847.x; Lemoine R, 1999, FEBS LETT, V454, P325, DOI 10.1016/S0014-5793(99)00843-1; Lohaus G, 2000, J EXP BOT, V51, P1721, DOI 10.1093/jexbot/51.351.1721; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Munch E., 1930, STOFFBEWEGUNGEN PFLA; Quick M, 2003, BIOCHEMISTRY-US, V42, P9147, DOI 10.1021/bi034842x; Roitsch T, 2003, J EXP BOT, V54, P513, DOI 10.1093/jxb/erg050; Saier M H Jr, 1999, J Mol Microbiol Biotechnol, V1, P257; Sauer GA, 2000, FEBS LETT, V469, P98, DOI 10.1016/S0014-5793(00)01255-2; Tegeder M, 1999, PLANT J, V18, P151, DOI 10.1046/j.1365-313X.1999.00439.x; TRUERNIT E, 1995, PLANTA, V196, P564, DOI 10.1007/BF00203657; van Bel AJE, 2000, EXPTL BIOL REV, P85; Viola R, 2001, PLANT CELL, V13, P385, DOI 10.1105/tpc.13.2.385; Weber H, 1997, PLANT CELL, V9, P895, DOI 10.1105/tpc.9.6.895; WRIGHT JP, 1981, PLANT PHYSIOL, V67, P845, DOI 10.1104/pp.67.4.845; Zeuthen T, 1996, J PHYSIOL-LONDON, V497, P3, DOI 10.1113/jphysiol.1996.sp021745; Zhou JJ, 1997, J MEMBRANE BIOL, V159, P113, DOI 10.1007/s002329900275	32	158	166	2	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21437	21443		10.1074/jbc.M501785200	http://dx.doi.org/10.1074/jbc.M501785200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15805107	hybrid			2022-12-25	WOS:000229438800064
J	Giangrossi, M; Zattoni, S; Tramonti, A; De Biase, D; Falconi, M				Giangrossi, M; Zattoni, S; Tramonti, A; De Biase, D; Falconi, M			Antagonistic role of H-NS and GadX in the regulation of the glutamate decarboxylase-dependent acid resistance system in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CURVED DNA; GENE-EXPRESSION; STRESS CONDITIONS; VIRF PROMOTER; PROTEIN; SHIGELLA; OPERON; REPRESSION; ACTIVATOR; THERMOREGULATION	One of the most efficient systems of acid resistance in Escherichia coli, the gad system, is based on the coordinated action of two isoforms of glutamate decarboxylase (GadA and GadB) and of a specific glutamate/gamma-aminobutyrate antiporter (GadC). The gadA/BC genes, activated in response to acid stress and in stationary phase cells, are subjected to complex circuits of regulation involving sigma(70), sigma(S), cAMP receptor protein, H-NS, EvgAS, TorRS, GadE, GadX, GadW, and YdeO. Herein, we provide evidence that the nucleoid-associated protein H-NS directly functions as repressor of gadA, one of the structural genes, and gadX, a regulatory gene encoding one of the primary activators of the gad system. Band shift and DNase I footprints reveal that H-NS indeed binds to specific sites in the promoter regions of gadA and gadX and represses the transcription of these genes both in an in vitro system and in vivo. Moreover, we show that a maltose-binding protein MalE-GadX fusion is able to stimulate the promoter activity of gadA/BC, thus indicating that GadX is by itself able to up-regulate the gad genes and that a functional competition between H-NS and GadX takes place at the gadA promoter. Altogether, our results indicate that H-NS directly inhibits gadA and gadX transcription and, by controlling the intracellular level of the activator GadX, indirectly affects the expression of the whole gad system.	Univ Camerino, Dipartimento Biol MCA, Genet Lab, I-62032 Camerino, MC, Italy; Univ Roma La Sapienza, CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy; Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy	University of Camerino; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Sapienza University Rome	Falconi, M (corresponding author), Univ Camerino, Dipartimento Biol MCA, Genet Lab, I-62032 Camerino, MC, Italy.	maurizio.falconi@unicam.it	De Biase, Daniela/H-3678-2019; Falconi, Maurizio/AAW-2929-2020; Tramonti, Angela/K-5325-2019; Messier, Claude/A-2322-2008	De Biase, Daniela/0000-0003-3536-9927; Falconi, Maurizio/0000-0002-4646-6741; Tramonti, Angela/0000-0002-5625-1170; Messier, Claude/0000-0002-4791-1763; Giangrossi, Mara/0000-0003-3065-9327				Atlung T, 1997, MOL MICROBIOL, V24, P7, DOI 10.1046/j.1365-2958.1997.3151679.x; Brandi A, 1999, EMBO J, V18, P1653, DOI 10.1093/emboj/18.6.1653; Dame RT, 2000, NUCLEIC ACIDS RES, V28, P3504, DOI 10.1093/nar/28.18.3504; De Biase D, 1999, MOL MICROBIOL, V32, P1198, DOI 10.1046/j.1365-2958.1999.01430.x; DeBiase D, 1996, PROTEIN EXPRES PURIF, V8, P430; Dorman CJ, 2004, NAT REV MICROBIOL, V2, P391, DOI 10.1038/nrmicro883; FALCONI M, 1993, MOL MICROBIOL, V10, P273, DOI 10.1111/j.1365-2958.1993.tb01953.x; FALCONI M, 1988, MOL MICROBIOL, V2, P323, DOI 10.1111/j.1365-2958.1988.tb00035.x; Falconi M, 1998, EMBO J, V17, P7033, DOI 10.1093/emboj/17.23.7033; Falconi M, 2001, MOL MICROBIOL, V42, P439, DOI 10.1046/j.1365-2958.2001.02646.x; Foster JW, 1999, CURR OPIN MICROBIOL, V2, P170, DOI 10.1016/S1369-5274(99)80030-7; Foster JW, 2004, NAT REV MICROBIOL, V2, P898, DOI 10.1038/nrmicro1021; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; Haack KR, 2003, INFECT IMMUN, V71, P384, DOI 10.1128/IAI.71.1.384-392.2003; Hommais F, 2004, MICROBIOL-SGM, V150, P61, DOI 10.1099/mic.0.26659-0; Hommais F, 2001, MOL MICROBIOL, V40, P20, DOI 10.1046/j.1365-2958.2001.02358.x; JORDI BJAM, 1992, EMBO J, V11, P2627, DOI 10.1002/j.1460-2075.1992.tb05328.x; Lin JS, 1996, APPL ENVIRON MICROB, V62, P3094, DOI 10.1128/AEM.62.9.3094-3100.1996; LIN JS, 1995, J BACTERIOL, V177, P4097, DOI 10.1128/jb.177.14.4097-4104.1995; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; Ma Z, 2004, J BACTERIOL, V186, P7378, DOI 10.1128/JB.186.21.7378-7389.2004; Ma Z, 2003, MOL MICROBIOL, V49, P1309, DOI 10.1046/j.1365-2958.2003.03633.x; Ma Z, 2002, J BACTERIOL, V184, P7001, DOI 10.1128/JB.184.24.7001-7012.2002; Masuda N, 2003, MOL MICROBIOL, V48, P699, DOI 10.1046/j.1365-2958.2003.03477.x; Merrell DS, 2002, CURR OPIN MICROBIOL, V5, P51, DOI 10.1016/S1369-5274(02)00285-0; Miller J.H., 1972, EXPT MOL GENETICS; Prosseda G, 2004, MOL MICROBIOL, V51, P523, DOI 10.1046/j.1365-2958.2003.03848.x; Rimsky S, 2001, MOL MICROBIOL, V42, P1311, DOI 10.1046/j.1365-2958.2001.02706.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schroder O, 2002, BIOL CHEM, V383, P945, DOI 10.1515/BC.2002.101; Shin S, 2001, MOL MICROBIOL, V41, P1133, DOI 10.1046/j.1365-2958.2001.02570.x; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Spurio R, 1997, EMBO J, V16, P1795, DOI 10.1093/emboj/16.7.1795; TANAKA K, 1991, MOL GEN GENET, V226, P367, DOI 10.1007/BF00260648; TIPPNER D, 1994, MOL MICROBIOL, V11, P589, DOI 10.1111/j.1365-2958.1994.tb00339.x; Tramonti A, 2003, BBA-PROTEINS PROTEOM, V1647, P376, DOI 10.1016/S1570-9639(03)00098-0; Tramonti A, 2002, J BACTERIOL, V184, P2603, DOI 10.1128/JB.184.10.2603-2613.2002; Tucker DL, 2003, J BACTERIOL, V185, P3190, DOI 10.1128/JB.185.10.3190-3201.2003; TUPPER AE, 1994, EMBO J, V13, P258, DOI 10.1002/j.1460-2075.1994.tb06256.x; Waterman SR, 2003, J BACTERIOL, V185, P4644, DOI 10.1128/JB.185.15.4644-4647.2003; YAMADA H, 1990, J BIOCHEM-TOKYO, V108, P420, DOI 10.1093/oxfordjournals.jbchem.a123216; YAMASHINO T, 1995, EMBO J, V14, P594, DOI 10.1002/j.1460-2075.1995.tb07035.x; YOSHIDA T, 1993, BIOSCI BIOTECH BIOCH, V57, P1568, DOI 10.1271/bbb.57.1568	43	44	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21498	21505		10.1074/jbc.M413255200	http://dx.doi.org/10.1074/jbc.M413255200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15795232	Green Published, hybrid			2022-12-25	WOS:000229438800071
J	Hong, JW; Ryu, MS; Lim, IK				Hong, JW; Ryu, MS; Lim, IK			Phosphorylation of serine 147 of tis21/BTG2/pc3 by p-Erk1/2 induces Pin-1 binding in cytoplasm and cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL ISOMERASE PIN1; DEPENDENT PROLINE ISOMERIZATION; GROWTH-FACTOR; PROTEIN-KINASE; BREAST-CANCER; TIS21 PROTEIN; CYCLIN D1; TUMOR PROMOTERS; MESSENGER-RNA; BETA-CATENIN	Treatment of U937 cells with epidermal growth factor (EGF) induces phosphorylation of tis21 and subsequent interaction of tis21 with Pin-1, resulting in the increased cell death with mitochondrial depolarization. Ser(147) and Ser(149) residues of tis21 were strongly phosphorylated by p-Erk1/2 and p-p38(MAPK), respectively, but not by JNK. To investigate the significance of phosphorylation of the Ser147 residue, Pin-1, one of the mitotic regulators that binds to the Ser(P)/Thr(P)-Pro region, was employed. Wild type tis21 phosphorylated by p-Erk1/2 clearly increased its binding to Pin-1, but not the P148A mutant, indicating that Pin-1 was bound to the Ser(P)(147)-Pro(148) region of tis21. Transfection of tis21 significantly enhanced EGF-induced Pin-1 diffusion to cytoplasm, compared with that in the vector-transfected cells. Knockdown of tis21 expression by using shRNAi significantly inhibited EGF-induced Pin-1 diffusion, and analysis by flow cytometry after JC-1 stain and confocal microscope revealed that EGF aggravated tis21-induced mitochondrial depolarization and cell death. Furthermore, tis21 was bound to cyclin B1 and Cdc2 and inhibited its activity in vivo and in vitro. In summary, treatment of U937 cells with EGF activates Erk1/2, which in turn phosphorylates Ser147 of tis21 and induces tis21 and Pin-1 binding and mitochondrial depolarization. These data suggest, for the first time, a mechanism of how EGF can be antiproliferative in human tumor cells: binding of tis21/ BTG2/pc3 to Pin-1 or cyclin B1-Cdc2 complex and induction of mitochondrial depolarization.	Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 443721, South Korea	Ajou University	Lim, IK (corresponding author), Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 443721, South Korea.	iklim@ajou.ac.kr		Lim, In Kyoung/0000-0002-2399-607X				Ayala G, 2003, CANCER RES, V63, P6244; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; CHURCH JG, 1988, J BIOL CHEM, V263, P4242; Duriez C, 2002, GENE, V282, P207, DOI 10.1016/S0378-1119(01)00825-3; Eales-Reynolds LJ, 2001, CYTOKINE, V16, P169, DOI 10.1006/cyto.2001.0966; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Harding A, 2003, J BIOL CHEM, V278, P16747, DOI 10.1074/jbc.M301015200; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Jakus J, 1996, ONCOGENE, V12, P2369; Joseph James D, 2003, Prog Cell Cycle Res, V5, P477; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; Lim IK, 1998, BIOCHEM MOL BIOL INT, V45, P871; Lim IK, 1998, MOL CARCINOGEN, V23, P25, DOI 10.1002/(SICI)1098-2744(199809)23:1<25::AID-MC4>3.0.CO;2-G; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Lin WJ, 2001, BIOCHEM J, V354, P635, DOI 10.1042/0264-6021:3540635; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 2002, J BIOL CHEM, V277, P2381, DOI 10.1074/jbc.C100228200; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Miyashita H, 2003, ONCOL REP, V10, P1045; Miyashita H, 2003, ONCOL REP, V10, P455; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Pang R, 2004, ONCOGENE, V23, P4182, DOI 10.1038/sj.onc.1207493; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Ryo A, 2002, MOL CELL BIOL, V22, P5281, DOI 10.1128/MCB.22.15.5281-5295.2002; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Ryu MS, 2004, EXP CELL RES, V299, P159, DOI 10.1016/j.yexcr.2004.05.014; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; Walter SA, 1997, MOL BIOL CELL, V8, P2157, DOI 10.1091/mbc.8.11.2157; Wang WL, 2003, J BIOL CHEM, V278, P37705, DOI 10.1074/jbc.M304619200; Wei L, 2004, J CELL BIOCHEM, V91, P325, DOI 10.1002/jcb.10760; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120	47	45	48	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21256	21263		10.1074/jbc.M500318200	http://dx.doi.org/10.1074/jbc.M500318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15788397	hybrid			2022-12-25	WOS:000229438800044
J	Kauppinen, KP; Duan, FP; Wels, JI; Manor, D				Kauppinen, KP; Duan, FP; Wels, JI; Manor, D			Regulation of the Dbl proto-oncogene by heat shock cognate protein 70 (Hsc70)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE FACTOR; DNA-BINDING; RHO; ONCOGENE; RAC; ACTIVATION; EXPRESSION; CDC42; ATP; AUTOINHIBITION	The dbl oncogene product is the defining member of a family of onco-proteins known as Dbl guanine nucleotide exchange factors ( GEFs) that facilitate the activation of the small GTP-binding proteins Cdc42, Rac, and Rho. Oncogenic activation of proto-Dbl occurs through loss of the amino-terminal 497 residues, rendering the protein constitutively active. Because both onco- and proto-Dbl contain the structural elements required for GEF activity (i.e. the Dbl homology (DH) and pleckstrin homology (PH) domains), it is thought that the amino terminus of proto-Dbl somehow inhibits the biochemical activity of the protein. To better understand the molecular basis of this regulation, we set forth to identify cellular proteins that preferentially bind the proto-oncogenic form of Dbl. We identified the molecular chaperone heat shock cognate protein (Hsc70) as a binding partner that preferentially interacts with the proto-oncogenic form of Dbl. Dbl is complexed with Hsc70 in transfected cells, as well as in native mouse brain extracts. The interaction between Hsc70 and proto-Dbl is mediated by at least two regions in Dbl, the amino-terminal spectrin homology domain (residues 224-417) and the pleckstrin homology domain (residues 711-808). Overexpression of a dominant negative Hsc70 mutant leads to activation of proto-Dbl GEF activity, indicating that the chaperone negatively regulates proto-Dbl function in vivo. We propose that Hsc70 attenuates Dbl activity by maintaining an inactive conformation in which the amino terminus is "folded over" the catalytic DH-PH domain.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Manor, D (corresponding author), Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA.	dm43@cornell.edu			NATIONAL CANCER INSTITUTE [R01CA082391, R24CA088336, R55CA082391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007158] Funding Source: NIH RePORTER; NCI NIH HHS [CA82391, CA88336] Funding Source: Medline; NIDDK NIH HHS [T32DK-007158-30] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Arbeitman MN, 2000, CELL, V101, P67, DOI 10.1016/S0092-8674(00)80624-8; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chang HC, 2002, J CELL BIOL, V159, P477, DOI 10.1083/jcb.200205086; Diehl JA, 2003, MOL CELL BIOL, V23, P1764, DOI 10.1128/MCB.23.5.1764-1774.2003; Elefant F, 1999, MOL BIOL CELL, V10, P2101, DOI 10.1091/mbc.10.7.2101; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; Hannan LA, 1998, MOL BIOL CELL, V9, P2217, DOI 10.1091/mbc.9.8.2217; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; HONING S, 1994, J CELL SCI, V107, P1185; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Johnson ER, 1999, BIOCHEMISTRY-US, V38, P10823, DOI 10.1021/bi990816g; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Lagaudriere-Gesbert C, 2002, P NATL ACAD SCI USA, V99, P1515, DOI 10.1073/pnas.042688099; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; Niyaz Y, 2003, NUCLEIC ACIDS RES, V31, P2209, DOI 10.1093/nar/gkg303; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RON D, 1989, ONCOGENE, V4, P1067; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schneikert J, 2000, EMBO J, V19, P6508, DOI 10.1093/emboj/19.23.6508; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; VAN AL, 1997, GENE DEV, V11, P2295; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	46	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21638	21644		10.1074/jbc.M413984200	http://dx.doi.org/10.1074/jbc.M413984200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802271	hybrid			2022-12-25	WOS:000229438800089
J	Kouchi, Z; Shikano, T; Nakamura, Y; Shirakawa, H; Fukami, K; Miyazaki, S				Kouchi, Z; Shikano, T; Nakamura, Y; Shirakawa, H; Fukami, K; Miyazaki, S			The role of EF-hand domains and C2 domain in regulation of enzymatic activity of phospholipase C xi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; CA2+ OSCILLATIONS; MOUSE EGGS; LIVING CELLS; TROPONIN-C; PLC-ZETA; ACTIVATION; CALCIUM; BINDING; PROTEIN	Sperm-specific phospholipase C-xi(PLC xi) induces Ca2+ oscillations and egg activation when injected into mouse eggs. PLC xi has such a high Ca2+ sensitivity of PLC activity that the enzyme can be active in resting cells at similar to 100 nM Ca2+, suitable for a putative sperm factor to be introduced into the egg at fertilization (Kouchi, Z., Fukami, K., Shikano, T., Oda, S., Nakamura, Y., Takenawa, T., and Miyazaki, S. (2004) J. Biol. Chem. 279, 10408 - 10412). In the present structure-function analysis, deletion of EF1 and EF2 of the N-terminal four EF-hand domains caused marked reduction of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2)- hydrolyzing activity in vitro and loss of Ca2+ oscillation-inducing activity in mouse eggs after injection of RNA encoding the mutant. However, deletion of EF1 and EF2 or mutation of EF1 or EF2 at the x and z positions of the putative Ca2+-binding loop little affected the Ca2+ sensitivity of the PLC activity, whereas deletion of EF1 to EF3 caused 12-fold elevation of the EC50 of Ca2+ concentration. Thus, EF1 and EF2 are important for the PLC xi activity, and EF3 is responsible for its high Ca2+ sensitivity. Deletion of four EF-hand domains or the C-terminal C2 domain caused complete loss of PLC activity, indicating that both regions are prerequisites for PLC xi activity. Screening of interactions between the C2 domain and phosphoinositides revealed that C2 has substantial affinity to PI(3) P and, to the lesser extent, to PI(5) P but not to PI(4,5)P-2 or acidic phospholipids. PI(3) P and PI(5) P reduced PLC xi activity in vitro, suggesting that the interaction could play a role for negative regulation of PLC xi.	Tokyo Womens Med Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1628666, Japan; Tokyo Univ Pharm & Life Sci, Lab Genome & Biosignal, Hachioji, Tokyo 1920392, Japan	Tokyo Women's Medical University; Tokyo University of Pharmacy & Life Sciences	Miyazaki, S (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Physiol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	shunm@research.twmu.ac.jp		Nakamura, Yoshikazu/0000-0001-8355-1091				Aida T, 2001, MOL HUM REPROD, V7, P1039, DOI 10.1093/molehr/7.11.1039; Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; BABU A, 1992, J BIOL CHEM, V267, P15469; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Catz SD, 2002, P NATL ACAD SCI USA, V99, P11652, DOI 10.1073/pnas.172382799; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fukami K, 2002, J BIOCHEM, V131, P293, DOI 10.1093/oxfordjournals.jbchem.a003102; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Jones KT, 1998, INT J DEV BIOL, V42, P1; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Kouchi Z, 2004, J BIOL CHEM, V279, P10408, DOI 10.1074/jbc.M313801200; Larman MG, 2004, J CELL SCI, V117, P2513, DOI 10.1242/jcs.01109; Lomasney JW, 1999, J BIOL CHEM, V274, P21995, DOI 10.1074/jbc.274.31.21995; MIYAZAKI S, 1993, JPN J PHYSIOL, V43, P409, DOI 10.2170/jjphysiol.43.409; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; Nagano K, 1999, J BIOL CHEM, V274, P2872, DOI 10.1074/jbc.274.5.2872; NAKASHIMA S, 1995, BIOCHEM BIOPH RES CO, V211, P364, DOI 10.1006/bbrc.1995.1822; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oda S, 1999, DEV BIOL, V209, P172, DOI 10.1006/dbio.1999.9233; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Saunders CM, 2002, DEVELOPMENT, V129, P3533; SHIAVO G, 1996, P NATL ACAD SCI USA, V93, P13327; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Swann K, 1996, Rev Reprod, V1, P33, DOI 10.1530/ror.0.0010033; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Wang T, 1999, P NATL ACAD SCI USA, V96, P7843, DOI 10.1073/pnas.96.14.7843; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Yoda A, 2004, DEV BIOL, V268, P245, DOI 10.1016/j.ydbio.2003.12.028	40	92	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21015	21021		10.1074/jbc.M412123200	http://dx.doi.org/10.1074/jbc.M412123200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15790568	hybrid			2022-12-25	WOS:000229438800015
J	Ledee, DR; Gao, CY; Seth, R; Fariss, RN; Tripathi, BK; Zelenka, PS				Ledee, DR; Gao, CY; Seth, R; Fariss, RN; Tripathi, BK; Zelenka, PS			A specific interaction between muskelin and the cyclin-dependent kinase 5 activator p39 promotes peripheral localization of muskelin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KELCH-REPEAT SUPERFAMILY; DIRECTED PROTEIN-KINASE; LENS FIBER CELLS; NEURONAL DIFFERENTIATION; EPITHELIAL-CELLS; P35/CDK5 KINASE; BOVINE BRAIN; CDK5; PHOSPHORYLATION; EXPRESSION	Previous studies implicate cyclin-dependent kinase 5 in cell adhesion and migration of epithelial cells of the cornea and lens. To explore molecular interactions underlying these functions, we performed yeast two-hybrid screening of an embryonic rat lens library for proteins that interact with cyclin-dependent kinase 5 and its regulators, p35 and p39. This screen identified a specific interaction between p39 and muskelin, an intracellular protein known to affect cytoskeletal organization in adherent cells. Immunohistochemistry detected muskelin in the developing lens and in other tissues, including brain and muscle. Glutathione S-transferase pull-down experiments and co-immunoprecipitations confirmed the specificity of the p39-muskelin interaction. Deletion analysis of p39 showed that muskelin binds to the p39 C terminus, which contains a short insertion ( amino acids 329-366) absent from p35. Similar analysis of muskelin mapped the interaction with p39 to the fifth kelch repeat. Co-expression of p39 and muskelin in COS1 cells or lens epithelial cells altered the intracellular localization of muskelin, recruiting it to the cell periphery. These findings demonstrate a novel interaction between muskelin and the cyclin-dependent kinase 5 activator p39 and suggest that p39 may regulate the subcellular localization of muskelin.	NEI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Zelenka, PS (corresponding author), NEI, NIH, Bldg 7,Rm 102,7 Mem Dr,MSC 0704, Bethesda, MD 20892 USA.	zelenkap@nei.nih.gov	Fariss, Robert/ABI-1771-2020	Fariss, Robert/0000-0003-3227-7170; Ledee, Dolena/0000-0003-1041-4795	NATIONAL EYE INSTITUTE [ZIAEY000238, Z01EY000238] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Adams JC, 1998, EMBO J, V17, P4964, DOI 10.1093/emboj/17.17.4964; Alexander K, 2004, MOL CELL BIOL, V24, P2808, DOI 10.1128/MCB.24.7.2808-2819.2004; AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, V2; Bassnett S, 1999, J CELL SCI, V112, P2155; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chen F, 2001, BLOOD, V97, P3763, DOI 10.1182/blood.V97.12.3763; Dhavan R, 2002, J NEUROSCI, V22, P7879; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Gao C, 2002, MOL CANCER RES, V1, P12; GAO CY, 1995, DEV BIOL, V169, P185, DOI 10.1006/dbio.1995.1136; Gao CY, 2004, J CELL SCI, V117, P4089, DOI 10.1242/jcs.01271; Gao CY, 1997, DEV GENET, V20, P267; Gilmore EC, 1998, J NEUROSCI, V18, P6370; Hasegawa H, 2000, BIOCHEM BIOPH RES CO, V276, P350, DOI 10.1006/bbrc.2000.3467; He HY, 1998, DEV DYNAM, V211, P26, DOI 10.1002/(SICI)1097-0177(199801)211:1<26::AID-AJA3>3.0.CO;2-9; Honjyo Y, 1999, NEUROREPORT, V10, P3375, DOI 10.1097/00001756-199911080-00022; Humbert S, 2000, J CELL SCI, V113, P975; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; Kato G, 1999, J BIOCHEM-TOKYO, V126, P957, DOI 10.1093/oxfordjournals.jbchem.a022540; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; Lilja L, 2004, J BIOL CHEM, V279, P29534, DOI 10.1074/jbc.M312711200; Negash S, 2002, J CELL SCI, V115, P2109; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Prag S, 2004, BIOCHEM J, V381, P547, DOI 10.1042/BJ20040253; Prag S, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-42; Rashid T, 2001, J BIOL CHEM, V276, P49043, DOI 10.1074/jbc.M105599200; Takahashi S, 2003, J BIOL CHEM, V278, P10506, DOI 10.1074/jbc.M211964200; Tanaka T, 2001, J NEUROSCI, V21, P550, DOI 10.1523/JNEUROSCI.21-02-00550.2001; Tarricone C, 2001, MOL CELL, V8, P657, DOI 10.1016/S1097-2765(01)00343-4; Umeda M, 2003, GENE, V303, P47, DOI 10.1016/S0378-1119(02)01153-8; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6; Xiong W, 1997, MOL CELL BIOL, V17, P6585, DOI 10.1128/MCB.17.11.6585; Zhang Q, 1997, DEV BIOL, V183, P222, DOI 10.1006/dbio.1996.8494; Zheng M, 1998, J NEUROBIOL, V35, P141, DOI 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4	38	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21376	21383		10.1074/jbc.M501215200	http://dx.doi.org/10.1074/jbc.M501215200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797862	hybrid			2022-12-25	WOS:000229438800057
J	Paumet, F; Rahimian, V; Di Liberto, M; Rothman, JE				Paumet, F; Rahimian, V; Di Liberto, M; Rothman, JE			Concerted auto-regulation in yeast endosomal t-SNAREs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; MEMBRANE-FUSION; CRYSTAL-STRUCTURE; SYNTAXIN 7; 3-DIMENSIONAL STRUCTURE; GOLGI TRANSPORT; COMPLEX; SPECIFICITY; HOMOLOG; TRAFFICKING	In yeast, the assembly of the target (t)-SNAREs [Tlg2p/Tlg1p, Vti1p] and [Pep12p/Tlg1p, Vti1p] with the vesicular (v)- SNARE Snc2p promotes endocytic fusion. Here, selected mutations and truncations of SNARE proteins were tested in an in vitro fusion assay to identify potential regulatory regions in these proteins, and two distinct regions were found. The first is represented by the combined effect of the three t-SNARE N-terminal regions and the second is located within the Tlg1p SNARE motif. These internal controls provide a potential mechanism to enable SNARE-dependent fusion to be regulated.	Columbia Univ, Ctr Med, Dept Physiol & Biophys, New York, NY 10032 USA	Columbia University	Rothman, JE (corresponding author), Columbia Univ, Ctr Med, Dept Physiol & Biophys, Russ Berrie Pavil,1150 St Nicholas Av, New York, NY 10032 USA.	jr2269@columbia.edu		Paumet, Fabienne/0000-0003-4466-6966	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027044] Funding Source: NIH RePORTER; NIDDK NIH HHS [5R01DK27044-27] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonin W, 2002, J BIOL CHEM, V277, P36449, DOI 10.1074/jbc.M204369200; Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Conibear E, 2003, MOL BIOL CELL, V14, P1610, DOI 10.1091/mbc.E02-10-0654; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Dulubova I, 2001, NAT STRUCT BIOL, V8, P258, DOI 10.1038/85012; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; Gonzalez LC, 2001, J BIOL CHEM, V276, P24203, DOI 10.1074/jbc.M101584200; Gurunathan S, 2000, MOL BIOL CELL, V11, P3629, DOI 10.1091/mbc.11.10.3629; Laage R, 2001, MOL BIOL CELL, V12, P3375, DOI 10.1091/mbc.12.11.3375; McNew JA, 1998, FEBS LETT, V435, P89, DOI 10.1016/S0014-5793(98)01044-8; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Melia TJ, 2002, J CELL BIOL, V158, P929, DOI 10.1083/jcb.200112081; Misura KMS, 2002, P NATL ACAD SCI USA, V99, P9184, DOI 10.1073/pnas.132274599; Mullock BM, 2000, MOL BIOL CELL, V11, P3137, DOI 10.1091/mbc.11.9.3137; Munson M, 2000, NAT STRUCT BIOL, V7, P894; Nakamura N, 2000, J BIOL CHEM, V275, P6523, DOI 10.1074/jbc.275.9.6523; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Parlati F, 2002, P NATL ACAD SCI USA, V99, P5424, DOI 10.1073/pnas.082100899; Paumet F, 2004, P NATL ACAD SCI USA, V101, P3376, DOI 10.1073/pnas.0400271101; Paumet F, 2001, J CELL BIOL, V155, P961, DOI 10.1083/jcb.200104092; Pelham HRB, 2001, TRENDS CELL BIOL, V11, P99, DOI 10.1016/S0962-8924(01)01929-8; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Siniossoglou S, 2001, EMBO J, V20, P5991, DOI 10.1093/emboj/20.21.5991; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Wang H, 1997, GENE, V199, P39, DOI 10.1016/S0378-1119(97)00343-0; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X	33	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21137	21143		10.1074/jbc.M500841200	http://dx.doi.org/10.1074/jbc.M500841200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799968	hybrid			2022-12-25	WOS:000229438800030
J	Vives, RR; Imberty, A; Sattentau, QJ; Lortat-Jacob, H				Vives, RR; Imberty, A; Sattentau, QJ; Lortat-Jacob, H			Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RECEPTOR-BINDING; CONFORMATIONAL-CHANGES; TYPE-1 ATTACHMENT; PROTEOGLYCANS; MECHANISM; CELLS; GLYCOSAMINOGLYCANS; CHEMOKINES; INFECTION	Human immunodeficiency virus (HIV) attachment to host cells is a multi-step process that involves interaction of the viral envelope gp120 with the primary receptor CD4 and coreceptors. HIV gp120 also binds to other cell surface components, including heparan sulfate (HS), a sulfated polysaccharide whose wide interactive properties are exploited by many pathogens for attachment and concentration at the cell surface. To analyze the structural features of gp120 binding to HS, we used soluble CD4 to constrain gp120 in a specific conformation. We first found that CD4 induced conformational change of gp120, dramatically increasing binding to HS. We then showed that HS binding interface on gp120 comprised, in addition to the well characterized V3 loop, a CD4-induced epitope. This epitope is efficiently targeted by nanomolar concentrations of size-defined heparin/ HS- derived oligosaccharides. Because this domain of the protein also constitutes the binding site for the viral coreceptors, these results support an implication of HS at late stages of the virus- cell attachment process and suggest potential therapeutic applications.	Univ Grenoble 1, CNRS, Commissariat Energie Atom, Inst Biol Struct, F-38027 Grenoble, France; CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Oxford	Lortat-Jacob, H (corresponding author), Univ Grenoble 1, CNRS, Commissariat Energie Atom, Inst Biol Struct, 41 Rue Horowitz, F-38027 Grenoble, France.	Hugues.Lortat-Jacob@ibs.fr	Vives, Romain/I-9372-2012; Imberty, Anne/P-6451-2018	Imberty, Anne/0000-0001-6825-9527				Argyris EG, 2003, J VIROL, V77, P12140, DOI 10.1128/JVI.77.22.12140-12151.2003; Basmaciogullari S, 2002, J VIROL, V76, P10791, DOI 10.1128/JVI.76.21.10791-10800.2002; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bobardt MD, 2003, IMMUNITY, V18, P27, DOI 10.1016/S1074-7613(02)00504-6; Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327; Choe H, 2003, CELL, V114, P161, DOI 10.1016/S0092-8674(03)00508-7; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Cros S, 1997, BIOORGAN MED CHEM, V5, P1301, DOI 10.1016/S0968-0896(97)00087-4; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Hsu STD, 2004, PROTEINS, V55, P582, DOI 10.1002/prot.20061; IMBERTY A, 1999, PERSPECTIVES STRUCTU, P392; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 2000, STRUCTURE, V8, P1329, DOI 10.1016/S0969-2126(00)00547-5; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; Mikhailov D, 1997, BIOCHEM J, V328, P51, DOI 10.1042/bj3280051; Mondor I, 1998, J VIROL, V72, P3623, DOI 10.1128/JVI.72.5.3623-3634.1998; Moore JP, 2000, NAT REV MOL CELL BIO, V1, P40, DOI 10.1038/35036060; Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000; Mulloy B, 2001, CURR OPIN STRUC BIOL, V11, P623, DOI 10.1016/S0959-440X(00)00257-8; Ohshiro Y, 1996, MICROBIOL IMMUNOL, V40, P827, DOI 10.1111/j.1348-0421.1996.tb01148.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; RODERIQUEZ G, 1995, J VIROL, V69, P2233, DOI 10.1128/JVI.69.4.2233-2239.1995; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; Sharon M, 2003, STRUCTURE, V11, P225, DOI 10.1016/S0969-2126(03)00011-X; Spillmann D, 2001, BIOCHIMIE, V83, P811, DOI 10.1016/S0300-9084(01)01290-1; Stanfield RL, 2004, STRUCTURE, V12, P193, DOI 10.1016/j.str.2004.01.003; Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959; *TRIP INC, 1997, SYBYL VERS 6 4; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; Vives RR, 2004, J BIOL CHEM, V279, P54327, DOI 10.1074/jbc.M409760200; Vives RR, 2002, BIOCHEMISTRY-US, V41, P14779, DOI 10.1021/bi026459i; Waldherr-Teschner M., 1992, Advances in Scientific Visualization, P58; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Zhang YJ, 2002, J VIROL, V76, P6332, DOI 10.1128/JVI.76.12.6332-6343.2002	42	101	103	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21353	21357		10.1074/jbc.M500911200	http://dx.doi.org/10.1074/jbc.M500911200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797855	hybrid			2022-12-25	WOS:000229438800054
J	Hesson, LB; Wilson, R; Morton, D; Adams, C; Walker, M; Maher, ER; Latif, F				Hesson, LB; Wilson, R; Morton, D; Adams, C; Walker, M; Maher, ER; Latif, F			CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations	ONCOGENE			English	Article						RASSF2; colorectal cancer; epigenetic inactivation; K-ras	TUMOR-SUPPRESSOR GENE; HUMAN-CHROMOSOME 3P21.3; COLORECTAL-CANCER; LUNG-CANCER; EPIGENETIC INACTIVATION; IDENTIFICATION; METHYLATION; NORE1; REGION; TUMORIGENESIS	We report in silico identification and characterisation of a novel member of the ras association domain family 1 (RASSF1)/NORE1 family, namely, RASSF2, located at chromosomal region 20p13. It has three isoforms, all contain a ras association domain in the C-terminus. The longest isoform RASSF2A contains a 5' CpG island. RASSF2A was cloned from a brain cDNA library and directly sequenced, confirming the genomic gene structure. In previous reports, we and others have demonstrated that RASSF1A is epigenetically inactivated in a variety of cancers, including sporadic colorectal cancer (CRC). In the present report, we analysed the methylation status of RASSF2A promoter region CpG island in sporadic CRC and compared it to K-ras mutation status. RASSF2A promoter region CpG island was hypermethylated in a majority of colorectal tumour cell lines (89%) and in primary colorectal tumours (70%), while DNA from matched normal mucosa was found to be unmethylated (tumour-specific methylation). RASSF2A expression was reactivated in methylated tumour cell lines after treatment with 5-aza 2-deoxycytidine. RASSF2A methylation is an early event, detectable in 7/8 colon adenomas. Furthermore, 75% of colorectal tumours with RASSF2A methylation had no K-ras mutations (codons, 12 and 13) (P = 0.048), Fisher's exact test). Our data demonstrate that RASSF2A is frequently inactivated in CRCs by CpG island promoter hypermethylation, and that epigenetic (RASSF2A) and genetic (K-ras) changes are mutually exclusive and provide alternative pathways for affecting Ras signalling.	Univ Birmingham, Inst Biomed Res, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Surg, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Inst Biomed Res, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	flatif@hgmp.mrc.ac.uk	Hesson, Luke/HDM-0311-2022; MAHER, EAMONN R/A-9507-2008	MAHER, EAMONN R/0000-0002-6226-6918				Agathanggelou A, 2003, CANCER RES, V63, P5344; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; AGATHANGGELOU A, 2005, IN PRESS CANC RES; Behn M, 1998, CLIN CANCER RES, V4, P361; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Herman JG, 2002, GASTROENTEROL CLIN N, V31, P945, DOI 10.1016/S0889-8553(02)00058-4; Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Irimia M, 2004, ONCOGENE, V23, P8695, DOI 10.1038/sj.onc.1207914; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782; Lerman MI, 2000, CANCER RES, V60, P6116; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Muller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922	30	76	95	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3987	3994		10.1038/sj.onc.1208566	http://dx.doi.org/10.1038/sj.onc.1208566			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15806169				2022-12-25	WOS:000229435300014
J	Tikhomirov, O; Dikov, M; Carpenter, G				Tikhomirov, O; Dikov, M; Carpenter, G			Identification of proteolytic fragments from ErbB-2 that induce apoptosis	ONCOGENE			English	Article						ErbB-2; apoptosis; proteolytic fragmentation; kinase domain	CASPASE-MEDIATED ACTIVATION; KINASE DOMAIN; KAPPA-B; CLEAVAGE; GELDANAMYCIN; SENSITIVITY; MECHANISM; MEMBRANE; PROTEASE; CELLS	The receptor tyrosine kinase ErbB-2 plays an important role in cell proliferation and differentiation as well as oncogenesis. We have found that ErbB-2 kinase domain fragmentation is important for the induction of apoptosis. Exogenous expression of peptides derived from the ErbB-2 kinase domain induces cells death with the hallmarks of apoptosis. In contrast, transfection of the ErbB-2 carboxy-terminal domain did not induce apoptosis. We have identified a 37-residue segment from the ErbB-2 kinase N-terminal lobe that can strongly induce apoptosis in transfected cells. Cell death was not blocked by the pan-caspase inhibitor z-VAD-FMK. Similar fragments derived from several other receptor tyrosine kinases also induce cell death. These data imply that proteolytic fragmentation of tyrosine kinases liberates apoptotic fragments that can accelerate cell death.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Hematol Oncol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 647 Light Hall,23rd Ave & Garland, Nashville, TN 37232 USA.	graham.carpenter@vanderbilt.edu	Dikov, Mikhail/E-5593-2010		NCI NIH HHS [P30 CA 68485] Funding Source: Medline; NIDDK NIH HHS [P30 DK 20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Bonvin C, 2002, CELL SIGNAL, V14, P123, DOI 10.1016/S0898-6568(01)00219-4; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Cuello M, 2001, CANCER RES, V61, P4892; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Inbal B, 2000, MOL CELL BIOL, V20, P1044, DOI 10.1128/MCB.20.3.1044-1054.2000; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; MUNSTER P, 2002, CANCER RES, V61, P2945; Neve RM, 2001, ANN ONCOL, V12, P9, DOI 10.1023/A:1011199404516; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Smith V, 2002, ANTICANCER RES, V22, P1993; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Tikhomirov O, 2003, CANCER RES, V63, P39; Tikhomirov O, 2001, J BIOL CHEM, V276, P33675, DOI 10.1074/jbc.M101394200; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; Wu YM, 2001, J BIOL CHEM, V276, P17672, DOI 10.1074/jbc.M010964200; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	27	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3906	3913		10.1038/sj.onc.1208534	http://dx.doi.org/10.1038/sj.onc.1208534			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782126				2022-12-25	WOS:000229435300006
J	Benini, S; Perbal, B; Zambelli, D; Colombo, MP; Manara, MC; Serra, M; Parenza, M; Martinez, V; Picci, P; Scotlandi, K				Benini, S; Perbal, B; Zambelli, D; Colombo, MP; Manara, MC; Serra, M; Parenza, M; Martinez, V; Picci, P; Scotlandi, K			In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type	ONCOGENE			English	Article						Ewing's sarcoma; CCN3; migration; tumorigenicity	TISSUE GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; CCN FAMILY; PROGNOSTIC IMPACT; GENE NOV; EXPRESSION; TUMORS; MATRIX-METALLOPROTEINASE-9; SURFACE; OVEREXPRESSION	Altered expression of CCN3 has been observed in a variety of musculoskeletal tumours, including Ewing's sarcoma (ES). Despite its widespread distribution, very little is known about its biological functions and molecular mechanisms of action. We transfected CCN3 gene into a CCN3-negative ES cell line and analysed the in vitro and in vivo behaviours of stably transfected clones. Forced expression of CCN3 significantly reduced cell proliferation in vitro, growth in anchorage-independent conditions, and tumorigenicity in nude mice. Despite the antiproliferative effect, CCN3-transfected ES cells displayed increased migration and invasion of Matrigel. The decreased expression of alpha 2 beta 1 integrin receptor and the increased amount of cell surface-associated matrix metalloproteinase (MMP)-9 following the expression of CCN3 may be the basis for the increased migratory abilities of transfected cells. Cells lacking a2b1 are less facilitated to have stable anchorage since the predominant collagen extracted from ES tissue is indeed type I collagen, and proMMP-9 was recently found to provide a cellular switch between stationary and migratory ES cell phase. Our findings are in line with those recently obtained in glioblastoma. However, the underlying molecular mechanisms appear to be different, further highlighting the importance of the cellular context in the regulation of function of CCN proteins.	Ist Otroped Rizzoli, Lab Ric Oncol, I-40136 Bologna, Italy; Univ Paris 07, Lab Oncol Virale & Mol, UFR Biochem, F-75005 Paris, France; Ist Nazl Studio & Cura Tumori, Immunotherapy & Gene Therapy Unit, I-20133 Milan, Italy	UDICE-French Research Universities; Universite Paris Cite; Fondazione IRCCS Istituto Nazionale Tumori Milan	Scotlandi, K (corresponding author), Ist Otroped Rizzoli, Lab Ric Oncol, Via Barbiano 1-10, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Manara, Maria Cristina/K-3366-2018; Serra, Massimo/J-4878-2016; Colombo, Mario P./V-7166-2017; Scotlandi, Katia/J-9009-2016; BENINI, STEFANIA/D-1804-2019; Picci, Piero/J-5979-2016	Manara, Maria Cristina/0000-0001-5686-720X; Serra, Massimo/0000-0003-0742-1177; Colombo, Mario P./0000-0003-0042-7955; Scotlandi, Katia/0000-0001-6114-9499; BENINI, STEFANIA/0000-0003-0958-9088; Picci, Piero/0000-0002-8519-4101				AARONSON SA, 1968, SCIENCE, V162, P1024, DOI 10.1126/science.162.3857.1024; Bacci G, 2000, J CLIN ONCOL, V18, P4, DOI 10.1200/JCO.2000.18.1.4; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Chevalier G, 1998, AM J PATHOL, V152, P1563; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellis PD, 2000, ARTERIOSCL THROM VAS, V20, P1912, DOI 10.1161/01.ATV.20.8.1912; Fan WH, 2002, J BIOL CHEM, V277, P9800, DOI 10.1074/jbc.M111213200; Fridman R, 2003, CANCER METAST REV, V22, P153, DOI 10.1023/A:1023091214123; Glukhova L, 2001, CANCER GENET CYTOGEN, V130, P105, DOI 10.1016/S0165-4608(01)00477-0; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; HARVEY W, 1982, BRIT J CANCER, V46, P848, DOI 10.1038/bjc.1982.294; Hattinger CM, 2002, BRIT J CANCER, V86, P1763, DOI 10.1038/sj.bjc.6600332; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Lake A. C., 2003, CELL COMMUN SIGNAL, V1, P1, DOI DOI 10.1186/1478-811X-1-5; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Laurent M, 2003, FASEB J, V17, P1919, DOI 10.1096/fj.02-1023fje; Lin CG, 2003, J BIOL CHEM, V278, P24200, DOI 10.1074/jbc.M302028200; Liu CL, 1999, GENE, V238, P471, DOI 10.1016/S0378-1119(99)00364-9; Lopez-Guerrero JA, 2001, LAB INVEST, V81, P803, DOI 10.1038/labinvest.3780290; Maillard M, 2001, J CLIN PATHOL-MOL PA, V54, P275, DOI 10.1136/mp.54.4.275; Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002-9440(10)64908-5; Ohali A, 2003, J CLIN ONCOL, V21, P3836, DOI 10.1200/JCO.2003.05.059; Ozaki T, 2001, GENE CHROMOSOME CANC, V32, P164, DOI 10.1002/gcc.1178; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Perbal B., 1988, PRACTICAL GUIDE MOL; Perri T, 2001, PEDIATR HEMAT ONCOL, V18, P325, DOI 10.1080/088800101300312591; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Sanceau J, 2003, J BIOL CHEM, V278, P36537, DOI 10.1074/jbc.M304300200; Scholz G, 1996, MOL CELL BIOL, V16, P481; Scotlandi K, 2000, J ORTHOPAED RES, V18, P959, DOI 10.1002/jor.1100180616; Soon LL, 2003, J BIOL CHEM, V278, P11465, DOI 10.1074/jbc.M210945200; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; VANVALEN F, 1994, EUR J CANCER, V30A, P2119, DOI 10.1016/0959-8049(94)00346-7; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; Yabe H, 2002, BIOCHEM BIOPH RES CO, V293, P61, DOI 10.1016/S0006-291X(02)00129-8; Yu CY, 2003, J PATHOL, V201, P609, DOI 10.1002/path.1468; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zielenska M, 2001, CANCER, V91, P2156, DOI 10.1002/1097-0142(20010601)91:11<2156::AID-CNCR1244>3.0.CO;2-I	45	84	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4349	4361		10.1038/sj.onc.1208620	http://dx.doi.org/10.1038/sj.onc.1208620			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15824736				2022-12-25	WOS:000229976900004
J	Brand, LA; Strauss, E				Brand, LA; Strauss, E			Characterization of a new pantothenate kinase isoform from Helicobacter pylori.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-DISULFIDE REDUCTASE; COENZYME-A; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; FEEDBACK-REGULATION; COMPARATIVE GENOMICS; GENE; EXPRESSION; BIOSYNTHESIS; CLONING	Pantothenate kinase (PanK) catalyzes the first step in the biosynthesis of the essential and ubiquitous cofactor coenzyme A (CoA) in all organisms. Two well characterized isoforms of the enzyme are known: a prokaryotic PanK that predominates in eubacteria and a eukaryotic isoform that has primarily been characterized from mammalian and plant sources. Curiously, the genomes of certain pathogenic bacteria, including Helicobacter pylori and Pseudomonas aeruginosa, do not contain a PanK similar to either isoform, although these organisms possess all the other biosynthetic machinery required for CoA production. In this study we cloned, overexpressed and characterized an enzyme from Bacillus subtilis and its homologue from H. pylori and show that they catalyze the ATP-dependent phosphorylation of pantothenate. These enzymes do not share sequence homology with any known PanK, and unlike the bacterial and eukaryotic PanK isoforms their activity is not regulated by either CoA or acetyl-CoA. They also do not accept the pantothenic acid antimetabolite N-pentylpantothenamide as a substrate or are inhibited by it. Taken together, these results point to the identification of a third distinct isoform of PanK that accounts for the only known activity of the enzyme in pathogens such as H. pylori and P. aeruginosa.	Univ Stellenbosch, Dept Chem, ZA-7602 Matieland, South Africa	Stellenbosch University	Strauss, E (corresponding author), Univ Stellenbosch, Dept Chem, Private Bag X1, ZA-7602 Matieland, South Africa.	estrauss@sun.ac.za	Strauss, Erick/G-1783-2010	Strauss, Erick/0000-0002-9898-8226				Allen KN, 2004, TRENDS BIOCHEM SCI, V29, P495, DOI 10.1016/j.tibs.2004.07.008; Begley TP, 2001, VITAM HORM, V61, P157; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; Cheek S, 2002, J MOL BIOL, V320, P855, DOI 10.1016/S0022-2836(02)00538-7; Choudhry AE, 2003, ANTIMICROB AGENTS CH, V47, P2051, DOI 10.1128/AAC.47.6.2051-2055.2003; delCardayre SB, 1998, J BIOL CHEM, V273, P5744, DOI 10.1074/jbc.273.10.5744; DESHAZER D, 1995, J BACTERIOL, V177, P3801, DOI 10.1128/jb.177.13.3801-3807.1995; Genschel U, 2004, MOL BIOL EVOL, V21, P1242, DOI 10.1093/molbev/msh119; Jackowski S., 1996, ESCHERICHIA COLI SAL, P687; Leonardi R, 2005, J BIOL CHEM, V280, P3314, DOI 10.1074/jbc.M411608200; Luba J, 1999, BIOCHEMISTRY-US, V38, P2725, DOI 10.1021/bi9825899; Osterman A, 2003, CURR OPIN CHEM BIOL, V7, P238, DOI 10.1016/S1367-5931(03)00027-9; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; Ramaswamy G, 2004, J LIPID RES, V45, P17, DOI 10.1194/jlr.M300279-JLR200; Rock CO, 2003, J BACTERIOL, V185, P3410, DOI 10.1128/JB.185.11.3410-3415.2003; Rock CO, 2002, GENE, V291, P35, DOI 10.1016/S0378-1119(02)00564-4; Rock CO, 2000, J BIOL CHEM, V275, P1377, DOI 10.1074/jbc.275.2.1377; Rudolph F B, 1979, Methods Enzymol, V63, P138; Singh SK, 2004, J BIOL CHEM, V279, P13166, DOI 10.1074/jbc.M311393200; SONG WJ, 1994, J BIOL CHEM, V269, P27051; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; Strauss E, 2002, J BIOL CHEM, V277, P48205, DOI 10.1074/jbc.M204560200; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; Wood GE, 2000, FEMS MICROBIOL LETT, V193, P25, DOI 10.1016/S0378-1097(00)00448-1; Yocum RR., 2004, US Patent, Patent No. [6830898, 6,830,898]; Yun M, 2000, J BIOL CHEM, V275, P28093; Zhang YM, 2004, J BIOL CHEM, V279, P50969, DOI 10.1074/jbc.M409607200	27	59	62	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20185	20188		10.1074/jbc.C500044200	http://dx.doi.org/10.1074/jbc.C500044200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15795230	hybrid			2022-12-25	WOS:000229242000004
J	Dateki, M; Horii, T; Kasuya, Y; Mochizuki, R; Nagao, Y; Ishida, J; Sugiyama, F; Tanimoto, K; Yagami, K; Imai, H; Fukamizu, A				Dateki, M; Horii, T; Kasuya, Y; Mochizuki, R; Nagao, Y; Ishida, J; Sugiyama, F; Tanimoto, K; Yagami, K; Imai, H; Fukamizu, A			Neurochondrin negatively regulates CaMKII phosphorylation, and nervous system-specific gene disruption results in epileptic seizure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTGROWTH-RELATED PROTEIN; II MUTANT MICE; KINASE-II; NEURITE-OUTGROWTH; ADULT-RAT; DEFICIENT; BRAIN; NEUROGENESIS; HIPPOCAMPUS; ASTROCYTES	Neurochondrin is a novel cytoplasmic protein and possibly involved in neurite outgrowth, chondrocyte differentiation, and bone metabolism. Our previous trial in disclosing its role by the loss of function in mice failed because of the lethality in utero. In this study, we eliminated the neurochondrin gene expression preferentially in the nervous system by the conditional knockout strategy. Our results showed that neurochondrin is a negative regulator of Ca2+/calmodulin-dependent protein kinase II phosphorylation and essential for the spatial learning process but not for the differentiation or neurite outgrowth of the neuron. In addition, the nervous system-specific homozygous gene disruption resulted in epileptic seizure.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Kyoto Univ, Grad Sch Agr, Reprod Physiol Lab, Kyoto 6068502, Japan; Chiba Univ, Grad Sch Med, Dept Mol Pharmacol & Biochem, Chiba 2608670, Japan; Univ Tsukuba, Lab Anim Source Ctr, Tsukuba, Ibaraki 3058577, Japan	University of Tsukuba; Kyoto University; Chiba University; University of Tsukuba	Fukamizu, A (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan.	akif@tara.tsukuba.ac.jp	fukamizu, akiyoshi/J-5350-2012; Tanimoto, Keiji/B-2600-2014	fukamizu, akiyoshi/0000-0002-8786-6020; Tanimoto, Keiji/0000-0003-1971-6546; Kasuya, Yoshitoshi/0000-0003-0614-5836				Armon C, 2000, J CLIN NEUROPHYSIOL, V17, P511, DOI 10.1097/00004691-200009000-00011; Asada S, 1999, BIOCHEM BIOPH RES CO, V260, P441, DOI 10.1006/bbrc.1999.0917; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; Bendotti C, 2000, EXP NEUROL, V161, P317, DOI 10.1006/exnr.1999.7262; Bodian D, 1936, ANAT REC, V65, P89, DOI 10.1002/ar.1090650110; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; BUTLER LS, 1995, P NATL ACAD SCI USA, V92, P6852, DOI 10.1073/pnas.92.15.6852; Coussens CM, 1996, SYNAPSE, V24, P97, DOI 10.1002/(SICI)1098-2396(199610)24:2<97::AID-SYN1>3.0.CO;2-9; CRAWLEY JN, 2000, WHATS WRONG MY MOUSE, P83; Dateki M, 2004, NEUROSCI LETT, V356, P107, DOI 10.1016/j.neulet.2003.11.026; Elgersma Y, 2002, NEURON, V36, P493, DOI 10.1016/S0896-6273(02)01007-3; Freitag S, 2003, BEHAV BRAIN RES, V145, P189, DOI 10.1016/S0166-4328(03)00109-8; FUKUNAGA K, 1993, J BIOL CHEM, V268, P133; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; Ishizuka Y, 1999, BBA-MOL CELL RES, V1450, P92, DOI 10.1016/S0167-4889(99)00039-7; KHURGEL M, 1995, NEUROBIOL DIS, V2, P23, DOI 10.1006/nbdi.1995.0003; Ktistakis NT, 2003, BIOCHEM SOC T, V31, P94, DOI 10.1042/bst0310094; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mochizuki R, 2003, BIOCHEM BIOPH RES CO, V310, P1219, DOI 10.1016/j.bbrc.2003.09.153; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morimoto K, 2004, PROG NEUROBIOL, V73, P1, DOI 10.1016/j.pneurobio.2004.03.009; Ohoka Y, 2001, BIOCHEM BIOPH RES CO, V280, P237, DOI 10.1006/bbrc.2000.4080; Osada T, 1999, J NEUROSCI, V19, P6068, DOI 10.1523/JNEUROSCI.19-14-06068.1999; Parent JM, 1997, J NEUROSCI, V17, P3727; Reisel D, 2002, NAT NEUROSCI, V5, P868, DOI 10.1038/nn910; Shinozaki K, 1999, MOL BRAIN RES, V71, P364, DOI 10.1016/S0169-328X(99)00181-3; Shinozaki K, 1997, BIOCHEM BIOPH RES CO, V240, P766, DOI 10.1006/bbrc.1997.7660; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703	30	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20503	20508		10.1074/jbc.M414033200	http://dx.doi.org/10.1074/jbc.M414033200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15790563	hybrid			2022-12-25	WOS:000229242000043
J	Pan, L; Glenn, ST; Jones, CA; Gross, KW				Pan, L; Glenn, ST; Jones, CA; Gross, KW			Activation of the rat renin promoter by HOXD10 center dot PBX1b center dot PREP1, ets-1, and the intracellular domain of notch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RBP-J-KAPPA; BINDING-PROTEIN; TRANSCRIPTION FACTORS; RESPONSIVE ELEMENT; PROXIMAL PROMOTER; DEVELOPING KIDNEY; GENE-EXPRESSION; MOUSE; REGION; CELLS	Renin gene expression is subject to complex developmental and tissue-specific regulation. A comparison of the promoter sequences of the human, rat, and mouse renin genes has revealed a highly conserved sequence homologous to the DNA recognition sequence for CBF1 (CSL/RBP-J kappa/Su(H)/LAG1/RBPSUH). Electrophoretic mobility shift assays document that As4.1 cell nuclear protein complex binding to the putative rat renin CBF1-binding ;site (-175 to - 168 bp) contains CBF1. Transient transfection analyses in COS-7 cells further document that a CBF1-VP16 fusion protein and the intracellular domain of Notch1 robustly activate a promoter containing multiple copies of the rat renin CBF1-binding site. An Ets-binding site (-143 to -138 bp) has also been identified in the rat renin promoter by sequence comparisons and electrophoretic mobility shift assays. Transcription factor Ets-1 is capable of activating the rat renin promoter through the Ets-binding site. Mutation of the CBF-binding site significantly increases transcriptional activity of the rat renin promoter in Calu-6 and COS-7 cells but not in As4.1 cells, whereas mutation of the Ets-binding site reduces promoter activity of the rat renin gene in all three cell lines. Finally, we show that the intracellular domain of Notch1, Ets-1, and HOXD10 (.) PBX1b (.) PREP1 activate the rat renin promoter cooperatively in COS-7 cells. These results strongly suggest that the renin gene is a downstream target of the Notch signaling pathway.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Gross, KW (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton Sts, Buffalo, NY 14263 USA.	gross@acsu.buffalo.edu			NCI NIH HHS [CA-16056] Funding Source: Medline; NHLBI NIH HHS [HL48459] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048459] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beatus P, 1999, DEVELOPMENT, V126, P3925; BORENSZTEIN P, 1994, CIRC RES, V74, P764, DOI 10.1161/01.RES.74.5.764; Chen HW, 2000, BIOCHEMISTRY-US, V39, P1675, DOI 10.1021/bi991786k; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; Florence B, 1998, GENETICS, V150, P1497; Furriols M, 2001, CURR BIOL, V11, P60, DOI 10.1016/S0960-9822(00)00044-0; Ghosh D, 2005, MOL ENDOCRINOL, V19, P1049, DOI 10.1210/me.2004-0320; Gomez RA, 1999, J HISTOCHEM CYTOCHEM, V47, P1643; GOMEZ RA, 1989, AM J PHYSIOL, V257, pF850, DOI 10.1152/ajprenal.1989.257.5.F850; HAMAGUCHI Y, 1992, J BIOCHEM-TOKYO, V112, P314, DOI 10.1093/oxfordjournals.jbchem.a123898; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Jones CA, 2000, PHYSIOL GENOMICS, V4, P75, DOI 10.1152/physiolgenomics.2000.4.1.75; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Konoshita T, 2004, J CELL BIOCHEM, V93, P327, DOI 10.1002/jcb.20151; Konoshita T, 1996, KIDNEY INT, V50, P1515, DOI 10.1038/ki.1996.466; Kopan R, 2002, J CELL SCI, V115, P1095; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Krebs LT, 2003, GENESIS, V37, P139, DOI 10.1002/gene.10241; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; LANG JA, 1995, HYPERTENSION, V25, P704, DOI 10.1161/01.HYP.25.4.704; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Palmieri M, 1999, NUCLEIC ACIDS RES, V27, P2785, DOI 10.1093/nar/27.13.2785; Pan L, 2005, HYPERTENSION, V45, P3, DOI 10.1161/01.HYP.0000149717.55920.45; Pan L, 2004, AM J PHYSIOL-RENAL, V286, pF1107, DOI 10.1152/ajprenal.00319.2003; Pan L, 2001, J BIOL CHEM, V276, P45530, DOI 10.1074/jbc.M103010200; Pan L, 2001, J BIOL CHEM, V276, P32489, DOI 10.1074/jbc.M011541200; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; Reddi V, 1998, J AM SOC NEPHROL, V9, P63; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Sato Y, 2001, CELL STRUCT FUNCT, V26, P19, DOI 10.1247/csf.26.19; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shawber CJ, 2004, BIOESSAYS, V26, P225, DOI 10.1002/bies.20004; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; Wang JH, 2001, J IMMUNOL, V167, P289, DOI 10.4049/jimmunol.167.1.289; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644	38	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20860	20866		10.1074/jbc.M414618200	http://dx.doi.org/10.1074/jbc.M414618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15792957	hybrid			2022-12-25	WOS:000229242000084
J	Yonezawa, N; Kudo, K; Terauchi, H; Kanai, S; Yoda, N; Tanokura, M; Ito, K; Miura, K; Katsumata, T; Nakano, M				Yonezawa, N; Kudo, K; Terauchi, H; Kanai, S; Yoda, N; Tanokura, M; Ito, K; Miura, K; Katsumata, T; Nakano, M			Recombinant porcine zona pellucida glycoproteins expressed in Sf9 cells bind to bovine sperm but not to porcine sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARBOHYDRATE CHAINS; MOUSE SPERM; STRUCTURAL-CHARACTERIZATION; ALPHA-GLYCOPROTEIN; EGG-COAT; ZP3; RECEPTOR; OLIGOSACCHARIDES; FERTILIZATION; SPERMATOZOA	The zona pellucida, which surrounds the mammalian oocyte, consists of the ZPA, ZPB, and ZPC glycoproteins and plays roles in species-selective sperm-egg interactions via its carbohydrate moieties. In the pig, this activity is conferred by tri- and tetraantennary complex type chains; in cattle, it is conferred by a chain of 5 mannose residues. In this study, porcine zona glycoproteins were expressed as secreted forms, using the baculovirus-Sf9 insect cell system. The sperm binding activities of the recombinant proteins were examined in three different assays. The assays clearly demonstrated that recombinant ZPB bound bovine sperm weakly but did not bind porcine sperm; when recombinant ZPC was also present, bovine sperm binding activity was greatly increased, but porcine sperm still was not bound. The major sugar chains of ZPB were pauci and high mannose type chains that were similar in structure to the major neutral N-linked chain of the bovine zona. In fact, the nonreducing terminal alpha-mannose residues were necessary for the sperm binding activity. These results show that the carbohydrate moieties of zona glycoproteins, but not the polypeptide moieties, play an essential role in species-selective recognition of porcine and bovine sperm. Moreover, Asn to Asp mutations at either of two of the N-glycosylation sites of ZPB, residue 203 or 220, significantly reduced the sperm binding activity of the ZPB/ZPC mixture, whereas a similar mutation at the third N-glycosylation site, Asn-333, had no effect on binding. These results suggest that the N-glycans located in the N-terminal half of the ZP domain of porcine ZPB are involved in sperm-zona binding.	Chiba Univ, Fac Sci, Dept Chem, Inage Ku, Chiba 2638522, Japan; Chiba Univ, Grad Sch Sci & Technol, Inage Ku, Chiba 2638522, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Gakushuin Univ, Inst Biomol Sci, Tokyo 1718588, Japan; Tokyo Med & Dent Univ, Coll Liberal Arts & Sci, Ichikawa, Chiba 2720827, Japan	Chiba University; Chiba University; University of Tokyo; Gakushuin University; Tokyo Medical & Dental University (TMDU)	Nakano, M (corresponding author), Chiba Univ, Fac Sci, Dept Chem, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.	mnakano@faculty.chiba-u.jp	Yonezawa, Naoto/F-8300-2011	Tanokura, Masaru/0000-0001-5072-2480				Amari S, 2001, MOL REPROD DEV, V59, P221, DOI 10.1002/mrd.1026; BERGER T, 1989, J REPROD FERTIL, V86, P559, DOI 10.1530/jrf.0.0860559; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; Boja ES, 2003, J BIOL CHEM, V278, P34189, DOI 10.1074/jbc.M304026200; BRACKETT BG, 1975, BIOL REPROD, V12, P260, DOI 10.1095/biolreprod12.2.260; Butters TD, 1998, GLYCOCONJUGATE J, V15, P83, DOI 10.1023/A:1006999718552; Chapman NR, 1998, BIOCHEM J, V330, P839; Chen J, 1998, P NATL ACAD SCI USA, V95, P6193, DOI 10.1073/pnas.95.11.6193; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNWALL GA, 1991, BIOL REPROD, V44, P913, DOI 10.1095/biolreprod44.5.913; Dell A, 2003, P NATL ACAD SCI USA, V100, P15631, DOI 10.1073/pnas.2635507100; Easton RL, 2000, J BIOL CHEM, V275, P7731, DOI 10.1074/jbc.275.11.7731; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; Gahlay GK, 2002, J REPROD IMMUNOL, V53, P67, DOI 10.1016/S0165-0378(01)00083-3; Granovsky M, 2000, NAT MED, V6, P306; GUPTA SK, 1995, MOL REPROD DEV, V42, P220, DOI 10.1002/mrd.1080420211; Harris JD, 1999, PROTEIN EXPRES PURIF, V16, P298, DOI 10.1006/prep.1999.1060; HARRIS JD, 1994, DNA SEQUENCE, V4, P361, DOI 10.3109/10425179409010186; HEDRICK JL, 1987, DEV BIOL, V121, P478, DOI 10.1016/0012-1606(87)90184-9; Hoodbhoy T, 2004, REPRODUCTION, V127, P417, DOI 10.1530/rep.1.00181; Johnston DS, 1998, J BIOL CHEM, V273, P1888, DOI 10.1074/jbc.273.4.1888; Jungnickel MK, 2003, CELL, V114, P401, DOI 10.1016/S0092-8674(03)00648-2; Katsumata T, 1996, EUR J BIOCHEM, V240, P448, DOI 10.1111/j.1432-1033.1996.0448h.x; Kiefer SM, 2002, BIOL REPROD, V66, P407, DOI 10.1095/biolreprod66.2.407; Kudo K, 1998, EUR J BIOCHEM, V252, P492, DOI 10.1046/j.1432-1327.1998.2520492.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITSCHER ES, 1995, BIOCHEMISTRY-US, V34, P4662, DOI 10.1021/bi00014a020; LITSCHER ES, 1993, TRENDS GLYCOSCI GLYC, V5, P369; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; Lu QX, 1997, DEVELOPMENT, V124, P4121; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; Mori E, 1997, BIOCHEM BIOPH RES CO, V238, P95, DOI 10.1006/bbrc.1997.7249; NOGUCHI S, 1993, BIOCHIM BIOPHYS ACTA, V1158, P217, DOI 10.1016/0304-4165(93)90018-4; NOGUCHI S, 1992, EUR J BIOCHEM, V204, P1089, DOI 10.1111/j.1432-1033.1992.tb16733.x; NOGUCHI S, 1994, BBA-GEN SUBJECTS, V1201, P7, DOI 10.1016/0304-4165(94)90143-0; PRASAD SV, 1995, BIOL REPROD, V52, P1167, DOI 10.1095/biolreprod52.5.1167; Rankin TL, 2003, DEV CELL, V5, P33, DOI 10.1016/S1534-5807(03)00195-3; SACCO AG, 1989, BIOL REPROD, V41, P523, DOI 10.1095/biolreprod41.3.523; Shi SL, 2004, MOL CELL BIOL, V24, P9920, DOI 10.1128/MCB.24.22.9920-9929.2004; Thaler CD, 1996, J BIOL CHEM, V271, P23289, DOI 10.1074/jbc.271.38.23289; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; Topfer-Petersen E, 1999, HUM REPROD UPDATE, V5, P314, DOI 10.1093/humupd/5.4.314; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYODA Y, 1974, J REPROD FERTIL, V36, P9, DOI 10.1530/jrf.0.0360009; Tsubamoto H, 1999, PROTEIN EXPRES PURIF, V17, P8, DOI 10.1006/prep.1999.1091; Tsubamoto H, 1999, BIOL REPROD, V61, P1649, DOI 10.1095/biolreprod61.6.1649; VANDUIN M, 1994, BIOL REPROD, V51, P607, DOI 10.1095/biolreprod51.4.607; VOSS T, 1993, EUR J BIOCHEM, V217, P913, DOI 10.1111/j.1432-1033.1993.tb18321.x; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Williams Z, 2001, BIOCHEMISTRY-US, V40, P929, DOI 10.1021/bi002275x; Yonezawa N, 1997, EUR J BIOCHEM, V248, P86, DOI 10.1111/j.1432-1033.1997.00086.x; Yonezawa N, 2003, BIOCHEM BIOPH RES CO, V307, P877, DOI 10.1016/S0006-291X(03)01297-X; YONEZAWA N, 1995, EUR J BIOCHEM, V233, P35, DOI 10.1111/j.1432-1033.1995.035_1.x; Yonezawa N, 2001, EUR J BIOCHEM, V268, P3587, DOI 10.1046/j.1432-1327.2001.02269.x; YUREWICZ EC, 1987, J BIOL CHEM, V262, P564; YUREWICZ EC, 1991, MOL REPROD DEV, V30, P126, DOI 10.1002/mrd.1080300209; YUREWICZ EC, 1993, MOL REPROD DEV, V36, P382, DOI 10.1002/mrd.1080360315; Yurewicz EC, 1998, J BIOL CHEM, V273, P7488, DOI 10.1074/jbc.273.13.7488; Zhao M, 2002, MOL CELL BIOL, V22, P3111, DOI 10.1128/MCB.22.9.3111-3120.2002	59	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20189	20196		10.1074/jbc.M414242200	http://dx.doi.org/10.1074/jbc.M414242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788399	hybrid			2022-12-25	WOS:000229242000005
J	Zhang, XY; Zajac, A; Zhang, J; Wang, PY; Li, M; Murray, J; TerBush, D; Guo, W				Zhang, XY; Zajac, A; Zhang, J; Wang, PY; Li, M; Murray, J; TerBush, D; Guo, W			The critical role of exo84p in the organization and polarized localization of the exocyst complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; SECRETORY VESICLES; SPATIAL REGULATION; PROTEIN-TRANSPORT; SEC6/8 COMPLEX; EXOCYTOSIS; SEC3P; DELIVERY	The exocyst complex plays an essential role in tethering secretory vesicles to specific domains of the plasma membrane for exocytosis. However, how the exocyst complex is assembled and targeted to sites of secretion is unclear. Here, we have investigated the role of the exocyst component Exo84p in these processes. We have generated an array of temperature-sensitive yeast exo84 mutants. Electron microscopy and cargo protein traffic analyses of these mutants indicated that Exo84p is specifically involved in the post-Golgi stage of secretion. Using various yeast mutants, we systematically studied the localization of Exo84p and other exocyst proteins by fluorescence microscopy. We found that pre-Golgi traffic and polarized actin organization are required for Exo84p localization. However, none of the exocyst proteins controls Exo84p polarization. In addition, Sec3p is not responsible for the polarization of Exo84p or any other exocyst component to the daughter cell. On the other hand, several exocyst members, including Sec10p, Sec15p, and Exo70p, clearly require Exo84p for their polarization. Biochemical analyses of the exocyst composition indicated that the assembly of Sec10p, Sec15p, and Exo70p with the rest of the complex requires Exo84p. We propose that there are at least two distinct regulatory mechanisms for exocyst polarization, one for Sec3p and one for the other members, including Exo84p. Exo84p plays a critical role in both the assembly of the exocyst and its targeting to sites of secretion.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Uniformed Serv Univ Hlth Sci, Dept Biochem, Bethesda, MD 20814 USA	University of Pennsylvania; University of Pennsylvania; Uniformed Services University of the Health Sciences - USA	Guo, W (corresponding author), Univ Penn, Dept Biol, 415 S Univ Ave, Philadelphia, PA 19104 USA.	guowei@sas.upenn.edu			NIGMS NIH HHS [R01-GM64690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064690] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; Boyd C, 2004, J CELL BIOL, V167, P889, DOI 10.1083/jcb.200408124; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Chu S, 2004, TOP CURR GENET, V10, P89; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Grote E, 2000, MOL BIOL CELL, V11, P4051, DOI 10.1091/mbc.11.12.4051; Guo W, 2004, TRENDS CELL BIOL, V14, P61, DOI 10.1016/j.tcb.2003.12.008; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Guthrie C, 1991, METHODS ENZYMOL, V194; Haarer BK, 1996, GENETICS, V144, P495; HARSAY E, 1995, J CELL BIOL, V131, P297, DOI 10.1083/jcb.131.2.297; Hsu SC, 2004, INT REV CYTOL, V233, P243, DOI 10.1016/S0074-7696(04)33006-8; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; Lipschutz JH, 2002, CURR BIOL, V12, pR212, DOI 10.1016/S0960-9822(02)00753-4; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Novick P, 2002, TRENDS CELL BIOL, V12, P247, DOI 10.1016/S0962-8924(02)02293-6; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Pruyne DW, 1998, J CELL BIOL, V143, P1931, DOI 10.1083/jcb.143.7.1931; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Scott BL, 2004, J CELL BIOL, V167, P75, DOI 10.1083/jcb.200405018; Spiliotis ET, 2003, CURR OPIN CELL BIOL, V15, P430, DOI 10.1016/S0955-0674(03)00074-7; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; Wiederkehr A, 2003, MOL BIOL CELL, V14, P4770, DOI 10.1091/mbc.E03-04-0229; Yeaman C, 2001, J CELL BIOL, V155, P593, DOI 10.1083/jcb.200107088; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2; Zajac A, 2005, MOL BIOL CELL, V16, P1500, DOI 10.1091/mbc.E04-10-0896; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200	44	34	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20356	20364		10.1074/jbc.M500511200	http://dx.doi.org/10.1074/jbc.M500511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788396	hybrid			2022-12-25	WOS:000229242000026
J	Pedigo, NG; Zhang, HX; Bruno, MEC; Kaetzel, CS; Dugan, AR; Shanehsaz, P; Hennigan, RF; Xing, ZL; Koszewski, NJ; Kaetzel, DM				Pedigo, NG; Zhang, HX; Bruno, MEC; Kaetzel, CS; Dugan, AR; Shanehsaz, P; Hennigan, RF; Xing, ZL; Koszewski, NJ; Kaetzel, DM			A 5 '-distal enhanceosome in the PDGF-A gene is activated in choriocarcinoma cells via ligand-independent binding of vitamin D receptor and constitutive jun kinase signaling	ONCOGENE			English	Article						platelet-derived growth factor; transcription; enhancer; vitamin D receptor; jun kinase; enhanceosome	GROWTH-FACTOR; CHAIN GENE; DNA-BINDING; C-JUN; TRANSCRIPTION; PROMOTER; EXPRESSION; INDUCTION; PROTEIN; REQUIRES	Overexpression of platelet-derived growth factor A-chain ( PDGF-A) is clearly linked to autocrine and paracrine stimulation of malignant growth in many human cancers. We have shown previously that PDGF-A overexpression in choriocarcinoma, hepatoma and lung carcinoma cell lines is driven by the activity of a 66 bp enhancer element (ACE66) located approximately 7kb upstream of the PDGF-A transcription start site. In this study, the ACE66 element is shown to be activated in JEG-3 choriocarcinoma cells through synergistic interactions between consensus DNA motifs for binding of vitamin D receptor, AP1 and ELK1. Binding of the vitamin D/retinoid-X receptor (VDR/RXR alpha) heterodimer to the ACE66 element was reconstituted in vitro with recombinant VDR/RXR alpha and with JEG-3 nuclear extract, and was verified in living JEG-3 cells by chromatin immunoprecipitation analysis. Transcriptional activity of the ACE66 element, as well as occupancy of the element by VDR/RXRa, was shown to be independent of stimulation with the hormonal VDR ligand, 1,25-dihydroxyvitamin D-3. The jun kinase pathway of mitogen-activated protein kinase (MAPK) signaling was shown to activate the ACE66 enhancer, most likely through activation of factors binding to the AP1 element. These results identify a novel mechanism of transcriptional enhancement involving ligand-independent activity of the VDR/RXR heterodimer and MAPK signaling pathways that appears to play an important role in the overexpression of PDGF in many different settings of human malignancy.	Univ Kentucky, Coll Med, Chandler Med Ctr, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Microbiol Mol Genet & Immunol, Lexington, KY 40536 USA; Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Kentucky, Coll Med, Dept Internal Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University System of Ohio; University of Cincinnati; University of Kentucky	Kaetzel, DM (corresponding author), Univ Kentucky, Coll Med, Chandler Med Ctr, Dept Mol & Biomed Pharmacol, MS-305, Lexington, KY 40536 USA.	dmkaetz@uky.edu		Kaetzel, Charlotte/0000-0001-7546-0085	NATIONAL CANCER INSTITUTE [R01CA083237] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045518] Funding Source: NIH RePORTER; NCI NIH HHS [CA83237] Funding Source: Medline; NHLBI NIH HHS [HL62877] Funding Source: Medline; NIDDK NIH HHS [DK45518] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHANDARI B, 1995, J BIOL CHEM, V270, P5541, DOI 10.1074/jbc.270.10.5541; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Brown AJ, 1999, AM J PHYSIOL-RENAL, V277, pF157, DOI 10.1152/ajprenal.1999.277.2.F157; BROWN PH, 1993, ONCOGENE, V8, P877; BUNING H, 1995, NUCLEIC ACIDS RES, V23, P1443, DOI 10.1093/nar/23.8.1443; Day FL, 1999, J BIOL CHEM, V274, P23726, DOI 10.1074/jbc.274.34.23726; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Hakim I, 2003, J CELL BIOCHEM, V88, P986, DOI 10.1002/jcb.10453; Hart LL, 2002, BIOCHEM CELL BIOL, V80, P335, DOI 10.1139/O02-038; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hennigan RF, 2001, MOL BIOL CELL, V12, P2352, DOI 10.1091/mbc.12.8.2352; Kaetzel DM, 2003, CYTOKINE GROWTH F R, V14, P427, DOI 10.1016/S1359-6101(03)00051-0; KAETZEL DM, 1994, BIOCHEM J, V301, P321, DOI 10.1042/bj3010321; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; Khachigian LM, 1999, CIRC RES, V84, P1258, DOI 10.1161/01.RES.84.11.1258; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Koszewski NJ, 1998, ARCH BIOCHEM BIOPHYS, V349, P388, DOI 10.1006/abbi.1997.0481; Koszewski NJ, 1996, J STEROID BIOCHEM, V59, P377, DOI 10.1016/S0960-0760(96)00127-6; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; LIN XH, 1992, J BIOL CHEM, V267, P25614; Liu SM, 1996, MOL ENDOCRINOL, V10, P206, DOI 10.1210/me.10.2.206; Ma DQ, 2002, J BIOL CHEM, V277, P1560, DOI 10.1074/jbc.M108359200; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Maul RS, 1998, J BIOL CHEM, V273, P33239, DOI 10.1074/jbc.273.50.33239; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; MULKINS MA, 1983, J BIOL CHEM, V258, P6219; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Pedigo N, 2003, GROWTH FACTORS, V21, P151, DOI 10.1080/08977190310001636595; Pietras K, 2003, CANCER CELL, V3, P439, DOI 10.1016/S1535-6108(03)00089-8; PIKE JW, 1980, LIFE SCI, V26, P407, DOI 10.1016/0024-3205(80)90158-7; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rafty LA, 2002, EMBO J, V21, P334, DOI 10.1093/emboj/21.3.334; Silverman ES, 1999, AM J PATHOL, V155, P1311, DOI 10.1016/S0002-9440(10)65233-9; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH CL, 1991, MOL ENDOCRINOL, V5, P867, DOI 10.1210/mend-5-6-867; Sun TJ, 1998, ENDOCRINOLOGY, V139, P1684, DOI 10.1210/en.139.4.1684; Tanamura A, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P631; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tolon RM, 2000, MOL CELL BIOL, V20, P8793, DOI 10.1128/MCB.20.23.8793-8802.2000; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG ZY, 1992, J BIOL CHEM, V267, P21999; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	53	5	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2654	2666		10.1038/sj.onc.1208336	http://dx.doi.org/10.1038/sj.onc.1208336			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829977				2022-12-25	WOS:000228356700007
J	White, PS; Thompson, PM; Gotoh, T; Okawa, ER; Igarashi, J; Kok, M; Winter, C; Gregory, SG; Hogarty, MD; Maris, JM; Brodeur, GM				White, PS; Thompson, PM; Gotoh, T; Okawa, ER; Igarashi, J; Kok, M; Winter, C; Gregory, SG; Hogarty, MD; Maris, JM; Brodeur, GM			Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; chromosome; human; pair 1; genes; suppressor; tumor; loss of heterozygosity; deletion mapping	TUMOR-SUPPRESSOR-GENE; CHROMOSOME 1P DELETIONS; SHORT ARM; MOLECULAR ANALYSIS; CELL-LINE; DROSOPHILA-HAIRY; BAND 1P36; DISTAL 1P; TRANSLOCATION; HETEROZYGOSITY	Substantial genomic and functional evidence from primary tumors and cell lines indicates that a consistent region of distal chromosome 1p is deleted in a sizable proportion of human neuroblastomas, suggesting that this region contains one or more tumor suppressor genes. To determine systematically and precisely the location and extent of 1p deletion in neuroblastomas, we performed allelic loss studies of 737 primary neuroblastomas and genotype analysis of 46 neuroblastoma cell lines. Together, the results defined a single region within 1p36.3 that was consistently deleted in 25% of tumors and 87% of cell lines. Two neuroblastoma patients had constitutional deletions of distal 1p36 that overlapped the tumor-defined region. The tumor- and constitutionally-derived deletions together defined a smallest region of consistent deletion (SRD) between D1S2795 and D1S253. The 1p36.3 SRD was deleted in all but one of the 184 tumors with 1p deletion. Physical mapping and DNA sequencing determined that the SRD minimally spans an estimated 729 kb. Genomic content and sequence analysis of the SRD identified 15 characterized, nine uncharacterized, and six predicted genes in the region. The RNA expression profiles of 21 of the genes were investigated in a variety of normal tissues. The SHREW1 and KCNAB2 genes both had tissue-restricted expression patterns, including expression in the nervous system. In addition, a novel gene (CHD5) with strong homology to proteins involved in chromatin remodeling was expressed mainly in neural tissues. Together, these results suggest that one or more genes involved in neuroblastoma tumorigenesis or tumor progression are likely contained within this region.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Duke Univ, Sch Med, Ctr Human Genet, Durham, NC 27710 USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Duke University; University of Pennsylvania; Pennsylvania Medicine	White, PS (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Rm 1407 CHOP N,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	white@genome.chop.edu		Gregory, Simon/0000-0002-7805-1743	NCI NIH HHS [CA039771, CA087847] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039771, R01CA087847] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abel F, 2002, BRIT J CANCER, V86, P596, DOI 10.1038/sj.bjc.6600111; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMLER LC, 1995, ONCOGENE, V10, P1095; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BARKER PE, 1993, ONCOGENE, V8, P3353; Bauer A, 2001, GENE CHROMOSOME CANC, V31, P228, DOI 10.1002/gcc.1139; Bentley DR, 2001, NATURE, V409, P942, DOI 10.1038/35057165; Bharti S, 2004, MOL BIOL CELL, V15, P397, DOI 10.1091/mbc.E03-05-0281; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; Birney E, 2004, GENOME RES, V14, P925, DOI 10.1101/gr.1860604; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Casciano I, 1996, ONCOGENE, V12, P2101; Cerignoli F, 2002, CANCER RES, V62, P1196; De Toledo M, 2001, ONCOGENE, V20, P7307, DOI 10.1038/sj.onc.1204921; DRACOPOLI NC, 1988, AM J HUM GENET, V43, P462; Eggert A, 2000, BIOTECHNIQUES, V28, P681, DOI 10.2144/00284st04; Ejeskar K, 2000, CYTOGENET CELL GENET, V89, P62, DOI 10.1159/000015566; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; Godfried MB, 2002, EUR J CANCER, V38, P1513, DOI 10.1016/S0959-8049(02)00137-5; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Heilstedt HA, 2003, AM J HUM GENET, V72, P1200, DOI 10.1086/375179; Heilstedt HA, 2001, EPILEPSIA, V42, P1103, DOI 10.1046/j.1528-1157.2001.08801.x; Hogarty MD, 2002, CANCER RES, V62, P6481; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P512, DOI 10.1002/1096-911X(20001201)35:6<512::AID-MPO2>3.0.CO;2-D; Huang S, 2001, EUR J CLIN INVEST, V31, P907, DOI 10.1046/j.1365-2362.2001.00892.x; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; Janoueix-Lerosey I, 2004, ONCOGENE, V23, P5912, DOI 10.1038/sj.onc.1207784; Jensen SJ, 1997, GENOMICS, V42, P126, DOI 10.1006/geno.1997.4714; Judson H, 2000, HUM GENET, V106, P406, DOI 10.1007/s004390000257; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Katoh M, 2004, INT J ONCOL, V25, P529; Katoh M, 2003, INT J ONCOL, V23, P1219; Krona C, 2003, ONCOGENE, V22, P2343, DOI 10.1038/sj.onc.1206324; Letovsky SI, 1998, NUCLEIC ACIDS RES, V26, P94, DOI 10.1093/nar/26.1.94; Maris JM, 1997, EUR J CANCER, V33, P1991, DOI 10.1016/S0959-8049(97)00279-7; Maris JM, 2000, J CLIN ONCOL, V18, P1888, DOI 10.1200/JCO.2000.18.9.1888; MARIS JM, 1995, CANCER RES, V55, P4664; Maris JM, 2001, MED PEDIATR ONCOL, V36, P32, DOI 10.1002/1096-911X(20010101)36:1<32::AID-MPO1009>3.0.CO;2-0; Maris JM, 1996, CANCER RES, V56, P3421; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; Mathysen D, 2004, EUR J CANCER, V40, P1255, DOI 10.1016/j.ejca.2004.01.013; McCormack K, 2002, J BIOL CHEM, V277, P13219, DOI 10.1074/jbc.M111465200; Mollet G, 2002, NAT GENET, V32, P300, DOI 10.1038/ng996; Mora J, 2000, J MOL DIAGN, V2, P37, DOI 10.1016/S1525-1578(10)60613-7; Murphy K, 2004, BIOINFORMATICS, V20, P588, DOI 10.1093/bioinformatics/btg466; Nakatani K, 2004, INT J ONCOL, V24, P1407; Nishimura M, 1998, GENOMICS, V49, P69, DOI 10.1006/geno.1998.5213; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Satge D, 2003, CANCER GENET CYTOGEN, V147, P89, DOI 10.1016/S0165-4608(03)00203-6; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Shapria SK, 1997, AM J HUM GENET, V61, P642, DOI 10.1086/515520; Spieker N, 2001, GENE CHROMOSOME CANC, V31, P172, DOI 10.1002/gcc.1130.abs; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; Thompson PM, 2001, CANCER RES, V61, P679; Van Roy N, 2002, GENE CHROMOSOME CANC, V35, P113, DOI 10.1002/gcc.10034; VANDERDRIFT P, 1995, GENE CHROMOSOME CANC, V14, P35, DOI 10.1002/gcc.2870140107; Wheeler DL, 2004, NUCLEIC ACIDS RES, V32, pD35, DOI 10.1093/nar/gkh073; White PS, 1997, EUR J CANCER, V33, P1957, DOI 10.1016/S0959-8049(97)00311-0; White PS, 2001, MED PEDIATR ONCOL, V36, P37, DOI 10.1002/1096-911X(20010101)36:1<37::AID-MPO1010>3.0.CO;2-L; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; White PS, 1999, GENOME RES, V9, P978, DOI 10.1101/gr.9.10.978; White PS, 2000, NEUROBLASTOMA, P57; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472	69	125	133	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2684	2694		10.1038/sj.onc.1208306	http://dx.doi.org/10.1038/sj.onc.1208306			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829979				2022-12-25	WOS:000228356700010
J	Merx, MW; Godecke, A; Flogel, U; Schrader, J				Merx, MW; Godecke, A; Flogel, U; Schrader, J			Oxygen supply and nitric oxide scavenging by myoglobin contribute to exercise endurance and cardiac function	FASEB JOURNAL			English	Article						genetically altered mice; contractile function; echocardiography; cardiac pathophysiology	IN-VIVO; SYNTHASE; HEART; MICE; DIFFUSION; TRANSPORT; MODELS	Recent studies of myoglobin (Mb) knockout (myo(-/-)) mice have extended our understanding of Mb's diverse functions and have demonstrated a complex array of compensatory mechanisms. The present study was aimed at detailed analysis of cardiac function and exercise endurance in myo(-/-) mice and at providing evidence for Mb's functional relevance. Myo(-/-) isolated working hearts display decreased contractility (dP/dtmax 3883 +/- 351 vs. 4618 +/- 268 mmHg/sec, myo(-/-) vs. WT, P < 0.005). Due to a shift in sympathetic/parasympathetic tone, heart rate is reduced in conscious myo mice(-/-) (615 +/- 33 vs. 645 +/- 27 bpm, myo(-/-) vs. WT, P < 0.001). Oxygen consumption (VO2) under resting conditions (3082 +/- 413 vs. 4452 +/- 552 ml*kg(-1)*h(-1), myo(-/-) vs. WT, P < 0.001) and exercise endurance, as determined by spiroergometry, are decreased (466 +/- 113 vs. 585 +/- 153 m, myo(-/-) vs. WT, P < 0.01). Conscious myo(-/-) mice evaluated by echocardiography display lowered cardiac output (0.64 +/- 0.06 vs. 0.75 +/- 0.09 ml*min(-1)*g(-1), myo(-/-) vs. WT, P < 0.001), impaired systolic shortening (60 +/- 3.5 vs. 65 +/- 4%, myo(-/-) vs. WT, P < 0.001) and fail to respond to beta(1)-stimulation. Strikingly, the latter cardiac effects of Mb deficiency can be partially attenuated by NOS inhibition. Loss of Mb results in a distinct phenotype, even under resting conditions, and the importance of oxygen supply and nitric oxide scavenging by Mb is clearly demonstrated at the conscious animal level.	Rhein Westfal TH Aachen, Med Klin 1, Aachen, Germany; Univ Dusseldorf, Inst Herz & Kreislaufphysiol, D-4000 Dusseldorf, Germany	RWTH Aachen University; Heinrich Heine University Dusseldorf	Merx, MW (corresponding author), Univ Klinikum Aachen, Med Klin 1, Pauwelsstr 30, D-52057 Aachen, Germany.	mmerx@oukaachen.de						Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Desai KH, 1997, AM J PHYSIOL-HEART C, V272, pH1053, DOI 10.1152/ajpheart.1997.272.2.H1053; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Flogel U, 2004, FASEB J, V18, P1156, DOI 10.1096/fj.03-1382fje; Garry DJ, 1998, NATURE, V395, P905, DOI 10.1038/27681; Godecke A, 1999, P NATL ACAD SCI USA, V96, P10495, DOI 10.1073/pnas.96.18.10495; Godecke A, 2003, J BIOL CHEM, V278, P21761, DOI 10.1074/jbc.M302573200; Haywood GA, 1996, CIRCULATION, V93, P1087, DOI 10.1161/01.CIR.93.6.1087; Heger J, 2002, CIRC RES, V90, P93, DOI 10.1161/hh0102.102757; Lewis NP, 1996, CIRCULATION, V93, P720, DOI 10.1161/01.CIR.93.4.720; Meeson AP, 2001, CIRC RES, V88, P713, DOI 10.1161/hh0701.089753; Merx Marc W., 2001, FASEB Journal, V15, P1077; Merx MW, 2004, CIRCULATION, V109, P2560, DOI 10.1161/01.CIR.0000129774.09737.5B; Millikan GA, 1937, PROC R SOC SER B-BIO, V123, P218, DOI 10.1098/rspb.1937.0052; OBRIEN PJ, 1992, J MOL CELL CARDIOL, V24, P721, DOI 10.1016/0022-2828(92)93386-X; Papadopoulos S, 2001, P NATL ACAD SCI USA, V98, P5904, DOI 10.1073/pnas.101109798; Paulus WJ, 1997, CIRCULATION, V96, P3436; Rohrer DK, 1998, AM J PHYSIOL-HEART C, V274, pH1184, DOI 10.1152/ajpheart.1998.274.4.H1184; Schenkman KA, 1999, APPL SPECTROSC, V53, P332, DOI 10.1366/0003702991946541; Takahashi E, 2000, BIOPHYS J, V78, P3252, DOI 10.1016/S0006-3495(00)76861-5; Takahashi E, 1998, AM J PHYSIOL-HEART C, V275, pH225, DOI 10.1152/ajpheart.1998.275.1.H225; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; WITTENBERG JB, 1959, BIOL BULL, V117, P402; WITTENBERG JB, 1970, PHYSIOL REV, V50, P559, DOI 10.1152/physrev.1970.50.4.559; Wunderlich C, 2003, CIRC RES, V92, P1352, DOI 10.1161/01.RES.0000079026.70629.E5	25	36	36	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1015	+		10.1096/fj.04-2886fje	http://dx.doi.org/10.1096/fj.04-2886fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15817640				2022-12-25	WOS:000228865300023
J	Lee, KS; Park, SJ; Hwang, PH; Yi, HK; Song, CH; Chai, OH; Kim, JS; Lee, MK; Lee, YC				Lee, KS; Park, SJ; Hwang, PH; Yi, HK; Song, CH; Chai, OH; Kim, JS; Lee, MK; Lee, YC			PPAR-gamma modulates allergic inflammation through upregulation of PTEN	FASEB JOURNAL			English	Article						asthma; eosinophils; phosphatidylinositol 3-kinase; signal transduction	ACTIVATED-RECEPTOR-GAMMA; NF-KAPPA-B; AIRWAY HYPERRESPONSIVENESS; TRANSCRIPTION FACTOR; HUMAN EOSINOPHILS; TUMOR-SUPPRESSOR; IN-VITRO; ASTHMA; MECHANISMS; APOPTOSIS	The ligand-activated nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR gamma) has been shown to regulate cell activation, differentiation, proliferation, and/or apoptosis. PPAR gamma is also associated with anti-inflammatory responses. However, the signaling mechanism remains elusive. We have used a mouse model for asthma to determine the effect of PPAR gamma agonists, rosiglitazone or pioglitazone, and PPAR gamma on allergen-induced bronchial inflammation and airway hyperresponsiveness. Administration of PPAR gamma agonists or adenovirus carrying PPAR gamma cDNA (AdPPAR gamma) reduced bronchial inflammation and airway hyperresponsiveness. Expression of PPAR gamma was increased by ovalbumin (OVA) inhalation, and the increase was further enhanced by the administration of the PPAR gamma agonists or AdPPAR gamma. Levels of IL-4, IL-5, IL-13, and eosinophil cationic protein were increased after OVA inhalation, and the increased levels were significantly reduced by the administration of PPAR gamma agonists or AdPPAR gamma. The results also showed that the administration of PPAR gamma agonists or AdPPAR gamma up-regulated phosphatase and tensin homologue deleted on chromosome ten (PTEN) expression in allergen-induced asthmatic lungs. This up-regulation correlated with decreased phosphatidylinositol 3-kinase activity as measured by reduced phosphorylation of Akt. These findings demonstrate a protective role of PPAR gamma in the pathogenesis of the asthma phenotype through regulation of PTEN expression.	Chonbuk Natl Univ, Sch Med, Dept Internal Med, Jeonju 561712, South Korea; Chonbuk Natl Univ, Sch Med, Res Ctr Allerg Immune Dis, Jeonju 561712, South Korea; Chonbuk Natl Univ, Sch Med, Dept Pediat, Jeonju 561712, South Korea; Chonbuk Natl Univ, Sch Med, Dept Anat, Jeonju 561712, South Korea; Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju 561712, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr,Dept Med, Div Endocrinol & Metab, Seoul, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Sungkyunkwan University (SKKU); Samsung Medical Center	Lee, YC (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Internal Med, 634-18 Keumamdong, Jeonju 561712, South Korea.	leeyc@chonbuk.ac.kr						Alves AC, 1996, EUR J PHARMACOL, V312, P89, DOI 10.1016/0014-2999(96)00357-3; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Barnes PJ, 1997, TRENDS PHARMACOL SCI, V18, P46, DOI 10.1016/S0165-6147(97)89796-9; Benayoun L, 2001, AM J RESP CRIT CARE, V164, P1487, DOI 10.1164/ajrccm.164.8.2101070; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dunzendorfer S, 1998, J LEUKOCYTE BIOL, V64, P828, DOI 10.1002/jlb.64.6.828; Ezeamuzie CI, 2001, AM J RESP CRIT CARE, V164, P1633, DOI 10.1164/ajrccm.164.9.2101104; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; Gelman L, 1999, CELL MOL LIFE SCI, V55, P932, DOI 10.1007/s000180050345; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hammad H, 2004, AM J PATHOL, V164, P263, DOI 10.1016/S0002-9440(10)63116-1; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Honda K, 2004, J ALLERGY CLIN IMMUN, V113, P882, DOI 10.1016/j.jaci.2004.02.036; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; Rahman I, 1998, THORAX, V53, P601, DOI 10.1136/thx.53.7.601; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Tigani B, 2001, EUR J PHARMACOL, V433, P217, DOI 10.1016/S0014-2999(01)01515-1; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384; Yamada KM, 2001, J CELL SCI, V114, P2375; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739; Zhu XD, 2000, J IMMUNOL METHODS, V240, P157, DOI 10.1016/S0022-1759(00)00192-7	37	113	120	2	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					1033	+		10.1096/fj.04-3309fje	http://dx.doi.org/10.1096/fj.04-3309fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15788448				2022-12-25	WOS:000227901300002
J	McGill, A; Frank, A; Emmett, N; Leech, SN; Turnbull, DM; Birch-Machin, MA; Reynolds, NJ				McGill, A; Frank, A; Emmett, N; Leech, SN; Turnbull, DM; Birch-Machin, MA; Reynolds, NJ			The antipsoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria	FASEB JOURNAL			English	Article						rho zero cells; psoriasis; ubiquinone pool; cytochrome c	CYTOCHROME-C RELEASE; ANTIPROLIFERATIVE ACTIVITY; ULTRASTRUCTURAL CHANGES; PSORIATIC EPIDERMIS; CYCLOSPORINE-A; HUMAN-CELLS; DITHRANOL; SKIN; INHIBITION; CHAIN	Anthralin is a potent topical drug, inducing clearance of psoriatic plaques. Anthralin disrupts mitochondrial function and structure, but its mechanism of action remains undefined. This study aimed to determine whether anthralin induced keratinocyte apoptosis as well as to investigate molecular mechanisms and the role of mitochondria. We studied human keratinocytes and human 143B rho(0) cells, which lack mitochondrial DNA and a functional respiratory chain. We show that anthralin disrupts mitochondrial membrane potential (Delta Psi(m)) and causes endogenous cytochrome c release, resulting in the activation of caspase-3 and characteristic morphological changes of apoptosis. Disruption of Delta Psi(m) and cytochrome c release were independent of mitochondrial permeability transition or caspase activation. Human 143B rho(0) cells were resistant to anthralin-induced cell death, disruption of Delta Psi(m), and cytochrome c release compared with the isogenic 143B rho(+) cell line. Using the intrinsic fluorescence of anthralin, rapid accumulation within mitochondria was observed independent of Delta Psi(m). Using assays that measure individual respiratory chain complexes, we show that anthralin specifically interacts with ubiquinone pool. These data indicate that anthralin induces apoptosis through a novel mitochondrial pathway dependent on oxidative respiration and involving electron transfer with the ubiquinone pool. These studies identify keratinocyte apoptosis as a potentially important mechanism involved in the clearance of psoriasis.	Univ Newcastle Upon Tyne, Sch Clin & Lab Sci, Skin & Environm Interact Res Grp, Newcastle Upon Tyne, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Reynolds, NJ (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Framington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	N.J.Reynolds@ncl.ac.uk		Reynolds, Nick/0000-0002-6484-825X	Wellcome Trust [061178] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Al-Daraji WI, 2002, J INVEST DERMATOL, V118, P779, DOI 10.1046/j.1523-1747.2002.01709.x; Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631; BAXTER DL, 1970, J INVEST DERMATOL, V54, P410, DOI 10.1111/1523-1747.ep12259209; Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4; Birch-Machin Mark A., 1993, V2, P324; BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Cossarizza A, 1996, EXP CELL RES, V222, P84, DOI 10.1006/excr.1996.0011; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; Dedov VN, 2001, MICRON, V32, P653, DOI 10.1016/S0968-4328(00)00065-2; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dominguez I, 2000, DEVELOPMENT, V127, P861; Duan S, 2003, J BIOL CHEM, V278, P1346, DOI 10.1074/jbc.M209269200; Fantin VR, 2002, CANCER CELL, V2, P29, DOI 10.1016/S1535-6108(02)00082-X; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1; FUCHS J, 1990, J INVEST DERMATOL, V94, P71, DOI 10.1111/1523-1747.ep12873369; Gao WH, 2001, J CELL SCI, V114, P2855; GILLBERG BO, 1967, NATURE, V214, P415, DOI 10.1038/214415a0; GOTTLIEB AB, 1992, J INVEST DERMATOL, V98, P680, DOI 10.1111/1523-1747.ep12499901; Hail N, 2002, JNCI-J NATL CANCER I, V94, P1281, DOI 10.1093/jnci/94.17.1281; Hajek P, 2001, J BIOL CHEM, V276, P606, DOI 10.1074/jbc.M007871200; HAYDEN PJ, 1994, MOL PHARMACOL, V46, P186; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KAMMERAU B, 1975, J INVEST DERMATOL, V64, P145, DOI 10.1111/1523-1747.ep12533307; KANERVA L, 1990, J CUTAN PATHOL, V17, P37, DOI 10.1111/j.1600-0560.1990.tb01676.x; KANERVA L, 1990, AM J DERMATOPATH, V12, P51, DOI 10.1097/00000372-199002000-00008; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KLUG H, 1987, J CUTAN PATHOL, V14, P212, DOI 10.1111/j.1600-0560.1987.tb01335.x; KOHEN E, 1986, CELL BIOCHEM FUNCT, V4, P157, DOI 10.1002/cbf.290040302; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lew W, 2004, TRENDS IMMUNOL, V25, P295, DOI 10.1016/j.it.2004.03.006; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Marchetti P, 1996, CANCER RES, V56, P2033; MARSDEN JR, 1983, BRIT J DERMATOL, V109, P209, DOI 10.1111/j.1365-2133.1983.tb07083.x; Muller K, 1997, J MED CHEM, V40, P3773, DOI 10.1021/jm970292n; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; REICHERT U, 1985, J INVEST DERMATOL, V84, P130, DOI 10.1111/1523-1747.ep12275369; Rivas MV, 1997, J INVEST DERMATOL, V108, P188, DOI 10.1111/1523-1747.ep12334217; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Salvioli S, 2000, FEBS LETT, V469, P186, DOI 10.1016/S0014-5793(00)01266-7; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMETS LA, 1994, BLOOD, V84, P1613; SWANBECK G, 1972, ACTA DERM-VENEREOL, V52, P94; TAYLOR RW, 1993, BIOCHIM BIOPHYS ACTA, V1181, P261, DOI 10.1016/0925-4439(93)90030-5; Todd C, 1998, AM J PATHOL, V153, P39, DOI 10.1016/S0002-9440(10)65543-5; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; WILBORN WH, 1974, J CUTAN PATHOL, V1, P132, DOI 10.1111/j.1600-0560.1974.tb00205.x; Yamada K, 2003, BIOCHEM PHARMACOL, V65, P339, DOI 10.1016/S0006-2952(02)01518-6	52	73	77	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					1012	+		10.1096/fj.04-2664fje	http://dx.doi.org/10.1096/fj.04-2664fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15802490				2022-12-25	WOS:000227901300043
J	Kalant, D; MacLaren, R; Cui, W; Samanta, R; Monk, PN; Laporte, SA; Cianflone, K				Kalant, D; MacLaren, R; Cui, W; Samanta, R; Monk, PN; Laporte, SA; Cianflone, K			C5L2 is a functional receptor for acylation-stimulating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED SKIN FIBROBLASTS; DRY MOTIF; GLUCOSE-TRANSPORT; COUPLED RECEPTORS; BETA-ARRESTIN; CHEMOATTRACTANT RECEPTOR; MOLECULAR DETERMINANTS; ASP; C3A; CELLS	C5L2 binds acylation-stimulating protein ( ASP) with high affinity and is expressed in ASP-responsive cells. Functionality of C5L2 has not yet been demonstrated. Here we show that C5L2 is expressed in human subcutaneous and omental adipose tissue in both preadipocytes and adipocytes. In mice, C5L2 is expressed in all adipose tissues, at levels comparable with other tissues. Stable transfection of human C5L2 cDNA into HEK293 cells results in ASP stimulation of triglyceride synthesis (TGS) (193 +/- 33%, 5 mu M ASP, p < 0.001, where basal = 100%) and glucose transport (168 +/- 21%, 10 mu M ASP, p < 0.001). C3a similarly stimulates TGS (163 +/- 12%, p < 0.001), but C5a and C5a des-Arg have no effect. The ASP mechanism is to increase V-max of glucose transport (149%) and triglyceride (TG) synthesis activity (165%) through increased diacylglycerolacyltransferase activity (200%). Antisense oligonucleotide down-regulation of C5L2 in human skin fibroblasts decreases cell surface C5L2 ( down to 54 +/- 4% of control, p < 0.001, comparable with nonimmune background). ASP response is coordinately lost ( basal TGS = 14.6 +/- 1.6, with ASP = 21.0 +/- 1.4 (144%), with ASP + oligonucleotides = 11.0 +/- 0.8 pmol of TG/mg of cell protein, p < 0.001). In mouse 3T3-L1 preadipocytes, antisense oligonucleotides decrease C5L2 expression to 69.5 +/- 0.5% of control, p < 0.001 ( comparable with nonimmune) with a loss of ASP stimulation (basal TGS = 22.4 +/- 2.9, with ASP = 39.6 +/- 8.8 ( 177%), with ASP + oligonucleotides = 25.3 +/- 3.0 pmol of TG/mg of cell protein, p < 0.001). C5L2 down-regulation and decreased ASP response correlate (r = 0.761, p < 0.0001 for HSF and r = 0.451, p < 0.05 for 3T3-L1). In HEK-hC5L2 expressing fluorescently tagged beta-arrestin, ASP induced beta-arrestin translocation to the plasma membrane and formation of endocytic complexes concurrently with increased phosphorylation of C5L2. This is the first demonstration that C5L2 is a functional receptor, mediating ASP triglyceride stimulation.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Mike Rosenbloom Lab Cardiovasc Res,Div Cardiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Med, Hormones & Canc Res Unit, Montreal, PQ H3A 1A1, Canada; Concordia Univ, Dept Chem Biochem, Montreal, PQ H4B 1R6, Canada; Univ Sheffield, Sch Med, Dept Neurol, Sheffield S10 2RX, S Yorkshire, England	McGill University; Royal Victoria Hospital; McGill University; Concordia University - Canada; University of Sheffield	Cianflone, K (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Mike Rosenbloom Lab Cardiovasc Res,Div Cardiol, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	katherine.cianflone@mcgill.ca	Laporte, Stephane/ABC-4228-2021; Laporte, Stephane A/F-3282-2012; Monk, Peter/C-6155-2008	Laporte, Stephane/0000-0002-0633-543X; Monk, Peter/0000-0003-4637-3059				Ahren B, 2003, INT J OBESITY, V27, P1037, DOI 10.1038/sj.ijo.0802369; Barak LS, 1999, METHOD ENZYMOL, V302, P153, DOI 10.1016/S0076-6879(99)02016-9; Chung DA, 2002, BIOCHEM BIOPH RES CO, V293, P1233, DOI 10.1016/S0006-291X(02)00357-1; Cianflone K, 1997, CLIN BIOCHEM, V30, P301, DOI 10.1016/S0009-9120(97)00011-8; CIANFLONE K, 1987, BIOCHEM BIOPH RES CO, V144, P94, DOI 10.1016/S0006-291X(87)80480-1; CIANFLONE K, 1994, BIOCHEMISTRY-US, V33, P9489, DOI 10.1021/bi00198a014; CIANFLONE K, 1988, CLIN INVEST MED, V11, P99; Cianflone K, 1999, SEMIN CELL DEV BIOL, V10, P31, DOI 10.1006/scdb.1998.0272; CIANFLONE KM, 1990, J CLIN INVEST, V85, P722, DOI 10.1172/JCI114497; CIANFLONE KM, 1989, J BIOL CHEM, V264, P426; Cidad P, 2004, BIOCHEM J, V384, P629, DOI 10.1042/BJ20040886; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Ferguson Stephen S. G., 2003, V237, P121; Fernandes R, 2004, MOL VIS, V10, P618; Fischer WH, 1997, J IMMUNOL, V159, P4279; Fischer WH, 1999, J IMMUNOL, V162, P453; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; Francis K, 2003, FASEB J, V17, P2266, DOI 10.1096/fj.02-1103fje; GERMINARIO R, 1993, METABOLISM, V42, P574, DOI 10.1016/0026-0495(93)90215-A; Igal RA, 2001, J BIOL CHEM, V276, P42205, DOI 10.1074/jbc.M103386200; Ikonomov OC, 2002, ENDOCRINOLOGY, V143, P4742, DOI 10.1210/en.2002-220615; Johnson EC, 2003, J BIOL CHEM, V278, P52172, DOI 10.1074/jbc.M306756200; Kalant D, 2003, J BIOL CHEM, V278, P11123, DOI 10.1074/jbc.M206169200; KALANT D, 2003, CAN J DIABETES, V27, P154; KLOS A, 1992, BIOCHEMISTRY-US, V31, P11274, DOI 10.1021/bi00161a003; Lee DK, 2001, MOL BRAIN RES, V86, P13, DOI 10.1016/S0169-328X(00)00242-4; Levine KB, 2002, BIOCHEMISTRY-US, V41, P12629, DOI 10.1021/bi0258997; Luttrell LM, 2002, J CELL SCI, V115, P455; Maslowska M, 1997, INT J OBESITY, V21, P261, DOI 10.1038/sj.ijo.0800396; MASLOWSKA M, 2004, VITAM HORM, V70, P309; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Murray I, 1999, BIOCHEM J, V342, P41, DOI 10.1042/0264-6021:3420041; Murray I, 1997, J LIPID RES, V38, P2492; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; Ohyama K, 2002, BIOCHEM BIOPH RES CO, V292, P362, DOI 10.1006/bbrc.2002.6670; Okinaga S, 2003, BIOCHEMISTRY-US, V42, P9406, DOI 10.1021/bi034489v; Otto M, 2004, J BIOL CHEM, V279, P142, DOI 10.1074/jbc.M310078200; Paczkowski NJ, 1999, BRIT J PHARMACOL, V128, P1461, DOI 10.1038/sj.bjp.0702938; Puschel GP, 1996, HEPATOLOGY, V24, P685, DOI 10.1053/jhep.1996.v24.pm0008781343; Rhee MH, 2000, FEBS LETT, V466, P300, DOI 10.1016/S0014-5793(00)01094-2; Saleh J, 1999, AM J PHYSIOL-ENDOC M, V276, pE815, DOI 10.1152/ajpendo.1999.276.5.E815; Seibold A, 1998, RECEPTOR CHANNEL, V5, P375; Tams JW, 2001, J MOL NEUROSCI, V17, P325, DOI 10.1385/JMN:17:3:325; Tao YH, 1997, BBA-LIPID LIPID MET, V1344, P221, DOI 10.1016/S0005-2760(96)00144-0; Van Hermelen V, 1999, J BIOL CHEM, V274, P18243, DOI 10.1074/jbc.274.26.18243; Van Oekelen D, 2003, BRAIN RES REV, V42, P123, DOI 10.1016/S0165-0173(03)00153-X; WALSH MJ, 1989, J SURG RES, V46, P470, DOI 10.1016/0022-4804(89)90162-5; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Wong SKF, 2003, NEUROSIGNALS, V12, P1, DOI 10.1159/000068914; YASRUEL Z, 1991, LIPIDS, V26, P495, DOI 10.1007/BF02536592; Zhang XJ, 1998, EUR J CLIN INVEST, V28, P730	55	139	156	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23936	23944		10.1074/jbc.M406921200	http://dx.doi.org/10.1074/jbc.M406921200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15833747	hybrid			2022-12-25	WOS:000229880000068
J	Mathai, JP; Germain, M; Shore, GC				Mathai, JP; Germain, M; Shore, GC			BH3-only BIK regulates BAX, BAK-dependent release of Ca2+ from endoplasmic reticulum stores and mitochondrial apoptosis during stress-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; PROTEIN; INDUCTION; FISSION; BAP31; ASSOCIATION; SUPPRESSION; ADENOVIRUS; INTERACTS	BIK, a pro-apoptotic BH3-only member of the BCL-2 family, targets the membrane of the endoplasmic reticulum (ER). It is induced in human cells in response to several stress stimuli, including genotoxic stress ( radiation, doxorubicin) and overexpression of E1A or p53 but not by ER stress pathways resulting from protein malfolding. BIK initiates an early release of Ca2+ from ER upstream of the activation of effector caspases. Release of the mobile ER Ca2+ stores in baby mouse kidney cells doubly deficient in BAX and BAK, on the other hand, is resistant to BIK but is sensitive to ectopic BAK. Over-expression of p53 stimulates recruitment of BAK to the ER, and both its recruitment and assembly into higher order structures is inhibited by BIK small interfering RNA. Employing small interfering RNA knockdowns, we also demonstrated that release of ER Ca2+ and mitochondrial apoptosis in human epithelial cells requires BIK and that a Ca2+-regulated target, the dynamin-related GTPase DRP1, is involved in p53-induced mitochondrial fission and release of cytochrome c to the cytosol. Endogenous cellular BIK, therefore, regulates a BAX, BAK-dependent ER pathway that contributes to mitochondrial apoptosis.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg, Montreal, PQ H3G 1Y6, Canada.	gordon.shore@mcgill.ca						Amanna IJ, 2001, J IMMUNOL, V167, P6069, DOI 10.4049/jimmunol.167.11.6069; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Boatright KM, 2003, BIOCHEM SOC SYMP, V70, P233, DOI 10.1042/bss0700233; Bouillet P, 2002, J CELL SCI, V115, P1567; BOYD JM, 1995, ONCOGENE, V11, P1921; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Castells A, 2000, CANCER RES, V60, P2836; Coultas L, 2004, MOL CELL BIOL, V24, P1570, DOI 10.1128/MCB.24.4.1570-1581.2004; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; GERMAIN M, 2003, SCI STKE; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Han J, 1996, MOL CELL BIOL, V16, P5857; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Jiang AM, 2001, J IMMUNOL, V166, P6025, DOI 10.4049/jimmunol.166.10.6025; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Oakes SA, 2003, BIOCHEM PHARMACOL, V66, P1335, DOI 10.1016/S0006-2952(03)00482-9; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Thomenius MJ, 2003, J CELL SCI, V116, P4493, DOI 10.1242/jcs.00829; TOLLOCZKO B, 1995, AM J PHYSIOL-LUNG C, V269, pL234, DOI 10.1152/ajplung.1995.269.2.L234; Verma S, 2000, GENE, V254, P157, DOI 10.1016/S0378-1119(00)00276-6; Wang B, 2003, J BIOL CHEM, V278, P14461, DOI 10.1074/jbc.M209684200; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084; Zuppini A, 2002, BIOCHEMISTRY-US, V41, P2850, DOI 10.1021/bi015967+	41	146	167	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23829	23836		10.1074/jbc.M500800200	http://dx.doi.org/10.1074/jbc.M500800200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15809295	hybrid			2022-12-25	WOS:000229880000055
J	Jee, YK; Gilmour, J; Kelly, A; Bowen, H; Richards, D; Soh, C; Smith, P; Hawrylowicz, C; Cousins, D; Lee, T; Lavender, P				Jee, YK; Gilmour, J; Kelly, A; Bowen, H; Richards, D; Soh, C; Smith, P; Hawrylowicz, C; Cousins, D; Lee, T; Lavender, P			Repression of interleukin-5 transcription by the glucocorticoid receptor targets GATA3 signaling and involves histone deacetylase recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIFFERENTIATION; REGULATORY COMPLEXES; ENHANCER FUNCTION; GENE-EXPRESSION; DNA-BINDING; INHIBITION; PROTEIN; AP-1; ACETYLATION; COFACTOR	Glucocorticoids are the mainstay of asthma therapy and mediate the repression of a number of cytokine genes, such as Interleukin (IL)-4, -5, -13, and granulocyte macrophage colony-stimulating factor (GM-CSF), which are central to the pathogenesis of asthmatic airway inflammation. The glucocorticoid receptor (GR) mediates repression by a number of diverse mechanisms. We have previously suggested that one such repressive activity is by direct binding of GR to elements within the GM-CSF enhancer that are recognized by the nuclear factor of activated T cells(.)activator protein 1 (NF-AT(.)AP-1) complex. We reasoned that, because many cytokine genes activated in asthma are transcriptionally regulated by the recruitment of this complex to DNA, their binding sites might provide a target for GR to mediate its repressive effects. Here, we show that transcriptional repression of the Interleukin-5 gene involves recruitment of GR to a DNA region located within the IL-5 proximal promoter, which is bound by NF-AT and AP-1 proteins. GR recruitment had a profound effect upon the activation capacity of GATA3, which has a binding site close to the NF-AT(.)AP-1 domain in both IL-5 and IL-13 promoters. Repression by GR involves co-repressor recruitment, because treatment of transfected cells with the deacetylase inhibitor trichostatin A caused a partial relief of repression. Additionally, repression could be augmented by co-transfection of cells with a histone deacetylase (HDAC1). These data suggest that the local recruitment of GR causes repression by inhibiting transcriptional activation by GATA3, a key tissue-specific determinant of expression of Th2 cytokines.	Kings Coll London, Dept Asthma Allergy & Resp Sci, Guys Hosp, London SE1 9RT, England; Dankook Univ, Coll Med, Div Pulm Med & Allergy, Cheonan 330715, South Korea; St Bartholomews Hosp, Dept Endocrinol, London EC1A 7BE, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Dankook University; University of London; Queen Mary University London	Lavender, P (corresponding author), Kings Coll London, Dept Asthma Allergy & Resp Sci, Guys Hosp, 5th Floor,Thomas Guy House, London SE1 9RT, England.	paul.lavender@kcl.ac.uk	Lee, Tak/AAA-9526-2020; Hawrylowicz, Catherine/Q-8483-2017	Lee, Tak/0000-0002-7554-4059; Cousins, David/0000-0003-3821-9596; Jee, Young-Koo/0000-0001-5800-8038; Hawrylowicz, Catherine/0000-0002-2337-7463; Lavender, Paul/0000-0001-8710-0263	Asthma UK [MRC-Asthma UK Centre] Funding Source: researchfish	Asthma UK		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Ausubel F., 1999, CURRENT PROTOCOLS MO; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; Cockerill PN, 1999, P NATL ACAD SCI USA, V96, P15097, DOI 10.1073/pnas.96.26.15097; Cousins DJ, 2002, J IMMUNOL, V169, P2498, DOI 10.4049/jimmunol.169.5.2498; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Frazer KA, 1997, GENOME RES, V7, P495, DOI 10.1101/gr.7.5.495; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Garlisi CG, 2001, AM J RESP CELL MOL, V24, P90, DOI 10.1165/ajrcmb.24.1.4224; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kishikawa H, 2001, J IMMUNOL, V167, P4414, DOI 10.4049/jimmunol.167.8.4414; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; McBride' K, 2003, ONCOGENE, V22, P8403, DOI 10.1038/sj.onc.1206877; Nagaich AK, 2004, MOL CELL, V14, P163, DOI 10.1016/S1097-2765(04)00178-9; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Smith PJ, 2001, J IMMUNOL, V167, P2502, DOI 10.4049/jimmunol.167.5.2502; Valapour M, 2002, J ALLERGY CLIN IMMUN, V109, P238, DOI 10.1067/mai.2002.121145; Yamamoto KR, 1998, COLD SPRING HARB SYM, V63, P587, DOI 10.1101/sqb.1998.63.587; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; Zhang DH, 1998, J IMMUNOL, V161, P3817; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	36	55	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23243	23250		10.1074/jbc.M503659200	http://dx.doi.org/10.1074/jbc.M503659200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15826950	hybrid			2022-12-25	WOS:000229741800082
J	Lan, DB; Silver, DL				Lan, DB; Silver, DL			Fenofibrate induces a novel degradation pathway for scavenger receptor B-I independent of PDZK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; E-DEFICIENT MICE; ATHEROSCLEROTIC LESION DEVELOPMENT; CORONARY-ARTERY DISEASE; HDL PARTICLE UPTAKE; SR-BI; CHOLESTEROL 7-ALPHA-HYDROXYLASE; HEPATIC CHOLESTEROL; TARGETED DISRUPTION; PROTEIN	Fibrate drugs improve cardiovascular health by lowering plasma triglycerides, normalize low density lipoprotein levels, and raise high density lipoprotein (HDL) levels in patients with dyslipidemias. The HDL-raising effect of fibrates has been shown to be due in part to an increase in human apolipoprotein AI gene expression. However, it has recently been shown that fibrates can affect HDL metabolism in mouse by significantly decreasing hepatic levels of the HDL receptor scavenger receptor B-I (SR-BI) and the PDZ domain containing protein PDZK1. PDZK1 is essential for maintaining hepatic SR-BI levels. Therefore, decreased SR-BI might be secondary to decreased PDZK1, but the mechanism by which fibrates lower SR-BI has not been elucidated. Here we show that feeding PDZK1-deficient mice fenofibrate resulted in the near absence of SR-BI in liver, definitively demonstrating that the effect of fenofibrate on SR-BI is PDZK1-independent. Metabolic labeling experiments in primary hepatocytes from fenofibratefed mice demonstrated that fenofibrate enhanced the degradation of SR-BI in a post-endoplasmic reticulum compartment. Moreover, fenofibrate-induced degradation of SR-BI was independent of the proteasome, calpain protease, or the lysosome, and antioxidants did not inhibit fenofibrate-induced degradation of SR-BI. Using metabolic labeling coupled with cell surface biotinylation assays, fenofibrate did not inhibit SR-BI trafficking to the plasma membrane. Together, the data support a model in which fenofibrate enhances the degradation of SR-BI in a post-ER, post-plasma membrane compartment. The further elucidation of this novel degradation pathway may provide new insights into the physiological and pathophysiological regulation of hepatic SR-BI.	Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Silver, DL (corresponding author), Columbia Univ, Coll Phys & Surg, Room 8-401, New York, NY 10032 USA.	dls51@columbia.edu		Silver, David/0000-0002-7289-9890				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; BERTOLOTTI M, 1995, ARTERIOSCL THROM VAS, V15, P1064, DOI 10.1161/01.ATV.15.8.1064; BOCOS C, 1993, BIOCHIM BIOPHYS ACTA, V1168, P340, DOI 10.1016/0005-2760(93)90191-B; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; Connelly MA, 2001, BIOCHEMISTRY-US, V40, P5249, DOI 10.1021/bi002825r; Duez H, 2005, ARTERIOSCL THROM VAS, V25, P585, DOI 10.1161/01.ATV.0000154140.73570.00; Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4; Frick MH, 1997, CIRCULATION, V96, P2137; FRUCHART JC, 1987, AM J MED, V83, P71, DOI 10.1016/0002-9343(87)90874-6; Fu T, 2003, J BIOL CHEM, V278, P52559, DOI 10.1074/jbc.M310892200; GOLDBERG AC, 1989, CLIN THER, V11, P69; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Huszar D, 2000, ARTERIOSCL THROM VAS, V20, P1068, DOI 10.1161/01.ATV.20.4.1068; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Kocher O, 2003, J BIOL CHEM, V278, P52820, DOI 10.1074/jbc.M310482200; Kocher O, 2003, MOL CELL BIOL, V23, P1175, DOI 10.1128/MCB.23.4.1175-1180.2003; Mardones P, 2003, J BIOL CHEM, V278, P7884, DOI 10.1074/jbc.M211627200; Mardones P, 2001, J LIPID RES, V42, P170; Maxwell KN, 2005, P NATL ACAD SCI USA, V102, P2069, DOI 10.1073/pnas.0409736102; Pan MH, 2004, J CLIN INVEST, V113, P1277, DOI 10.1172/JCI200419197; Post SM, 2001, ARTERIOSCL THROM VAS, V21, P1840, DOI 10.1161/hq1101.098228; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Robins SJ, 2001, J CARDIOVASC RISK, V8, P195, DOI 10.1097/00043798-200108000-00003; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 2003, J BIOL CHEM, V278, P28528, DOI 10.1074/jbc.M304109200; Silver DL, 2002, J BIOL CHEM, V277, P34042, DOI 10.1074/jbc.M206584200; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; STAHLBERG D, 1995, HEPATOLOGY, V21, P1025, DOI 10.1016/0270-9139(95)90250-3; STAHLBERG D, 1989, J LIPID RES, V30, P953; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Van Eck M, 2004, AM J PATHOL, V165, P785, DOI 10.1016/S0002-9440(10)63341-X; Xian-Cheng J, 2005, J BIOL CHEM, V280, P18336, DOI 10.1074/jbc.M500007200; Zhang WW, 2003, CIRCULATION, V108, P2258, DOI 10.1161/01.CIR.0000093189.97429.9D	39	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23390	23396		10.1074/jbc.M502777200	http://dx.doi.org/10.1074/jbc.M502777200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15837786	hybrid			2022-12-25	WOS:000229741800099
J	Snijders, AM; Schmidt, BL; Fridlyand, J; Dekker, N; Pinkel, D; Jordan, RCK; Albertson, DG				Snijders, AM; Schmidt, BL; Fridlyand, J; Dekker, N; Pinkel, D; Jordan, RCK; Albertson, DG			Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma	ONCOGENE			English	Article						array CGH; hedgehog; notch; oral SCC; amplicon	COMPARATIVE GENOMIC HYBRIDIZATION; HEDGEHOG-BINDING PROTEIN; NECK-CANCER; TUMOR-SUPPRESSOR; HEAD; GENE; EXPRESSION; PROGRESSION; GROWTH; NOTCH	Genomes of solid tumors are characterized by gains and losses of regions, which may contribute to tumorigenesis by altering gene expression. Often the aberrations are extensive, encompassing whole chromosome arms, which makes identification of candidate genes in these regions difficult. Here, we focused on narrow regions of gene amplification to facilitate identification of genetic pathways important in oral squamous cell carcinoma (SCC) development. We used array comparative genomic hybridization ( array CGH) to define minimum common amplified regions and then used expression analysis to identify candidate driver genes in amplicons that spanned <3 Mb. We found genes involved in integrin signaling (TLN1), survival ( YAP1, BIRC2), and adhesion and migration ( TLN1, LAMA3, MMP7), as well as members of the hedgehog (GLI2) and notch (JAG1, RBPSUH, FJX1) pathways to be amplified and overexpressed. Deregulation of these and other members of the hedgehog and notch pathways (HHIP, SMO, DLL1, NOTCH4) implicates deregulation of developmental and differentiation pathways, cell fate misspecification, in oral SCC development.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Albertson, DG (corresponding author), Univ Calif San Francisco, Canc Res Inst, Box 0808, San Francisco, CA 94143 USA.	albertson@cc.ucsf.edu		Schmidt, Brian/0000-0002-2409-8984	NATIONAL CANCER INSTITUTE [R33CA094407, R01CA090421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F31DE019604, K12DE014609] Funding Source: NIH RePORTER; NCI NIH HHS [CA92531, CA90421, CA94407] Funding Source: Medline; NIDCR NIH HHS [K12 DE14609, DE19604] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; Aho S, 2004, J CELL BIOCHEM, V92, P1271, DOI 10.1002/jcb.20125; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Buckles GR, 2001, DEVELOPMENT, V128, P3533; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Chuang PT, 2003, GENE DEV, V17, P342, DOI 10.1101/gad.1026303; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Fridlyand J, 2004, J MULTIVARIATE ANAL, V90, P132, DOI 10.1016/j.jmva.2004.02.008; Garnis C, 2004, ONCOGENE, V23, P2582, DOI 10.1038/sj.onc.1207367; Ha PK, 2003, CLIN CANCER RES, V9, P3058; Hansson EM, 2004, SEMIN CANCER BIOL, V14, P320, DOI 10.1016/j.semcancer.2004.04.011; Huang Q, 2002, GENE CHROMOSOME CANC, V34, P224, DOI 10.1002/gcc.10062; HUME WJ, 1979, J ORAL PATHOL MED, V8, P3, DOI 10.1111/j.1600-0714.1979.tb01618.x; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kim MM, 2004, INT J CANCER, V112, P545, DOI 10.1002/ijc.20379; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Lefort K, 2004, SEMIN CANCER BIOL, V14, P374, DOI 10.1016/j.semcancer.2004.04.017; Lohi J, 2001, INT J CANCER, V94, P763, DOI 10.1002/ijc.1539; Macabeo-Ong M, 2003, ORAL ONCOL, V39, P638, DOI 10.1016/S1368-8375(03)00034-4; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; MIELE M, 1989, MUTAT RES, V219, P171, DOI 10.1016/0921-8734(89)90012-X; Mineta H, 1997, ORAL ONCOL, V33B, P42, DOI 10.1016/S0964-1955(96)00039-5; Moore L, 2000, BIOTECHNIQUES, V28, P986, DOI 10.2144/00285rr04; Murnane JP, 2004, BIOESSAYS, V26, P1164, DOI 10.1002/bies.20125; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; Neve RM, 2002, ONCOGENE, V21, P3934, DOI 10.1038/sj.onc.1205503; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nishimaki H, 2004, BIOCHEM BIOPH RES CO, V314, P313, DOI 10.1016/j.bbrc.2003.12.097; Ohki K, 2004, INT J ORAL MAX SURG, V33, P584, DOI 10.1016/j.ijom.2004.01.013; Parkhurst HB, 1999, J CREATIVE BEHAV, V33, P1, DOI 10.1002/j.2162-6057.1999.tb01035.x; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Redon R, 2002, CANCER RES, V62, P6211; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Roth JR, 2004, RES MICROBIOL, V155, P342, DOI 10.1016/j.resmic.2004.01.016; Shimizu N, 2005, EXP CELL RES, V302, P233, DOI 10.1016/j.yexcr.2004.09.001; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Watkins DN, 2004, BIOCHEM PHARMACOL, V68, P1055, DOI 10.1016/j.bcp.2004.04.025; Weng AP, 2004, CURR OPIN GENET DEV, V14, P48, DOI 10.1016/j.gde.2003.11.004; Westfall P.H., 1993, RESAMPLING BASED MUL, V279; Wolff E, 1998, ORAL ONCOL, V34, P186, DOI 10.1016/S1368-8375(97)00079-1; Zeidler MP, 1999, CURR BIOL, V9, P1363, DOI 10.1016/S0960-9822(00)80081-0	48	216	230	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4232	4242		10.1038/sj.onc.1208601	http://dx.doi.org/10.1038/sj.onc.1208601			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15824737				2022-12-25	WOS:000229815300007
J	Aroca-Aguilar, JD; Sanchez-Sanchez, F; Ghosh, S; Coca-Prados, M; Escribano, J				Aroca-Aguilar, JD; Sanchez-Sanchez, F; Ghosh, S; Coca-Prados, M; Escribano, J			Myocilin mutations causing glaucoma inhibit the intracellular endoproteolytic cleavage of myocilin between amino acids Arg(226) and Ile(227)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRABECULAR MESHWORK CELLS; OLFACTOMEDIN DOMAIN; NON-SECRETION; CILIARY BODY; GENE; MUTANT; PROTEIN; TIGR; LOCALIZATION; EXPRESSION	Myocilin is a secreted glycoprotein of unknown function that is ubiquitously expressed in many human organs, including the eye. Mutations in this protein produce glaucoma, a leading cause of blindness worldwide. To explore the biological role of myocilin and the pathogenesis of glaucoma, we have analyzed the expression of recombinant wild type and four representative pathogenic myocilin mutations (E323K, Q368X, P370L, and D380A) in transiently transfected cell lines derived from ocular and nonocular tissues. We found that wild type myocilin undergoes an intracellular endoproteolytic processing at the C terminus of Arg(226). This cleavage predicts the production of two fragments, one of 35 kDa containing the C-terminal olfactomedin-like domain, and another of 20 kDa containing the N-terminal leucine zipper-like domain. Here we have analyzed the 35-kDa processed fragment, and we have found that it is co-secreted with the nonprocessed protein. Western immunoblot analyses showed that human aqueous humor and some ocular tissues also contain the processed 35-kDa myocilin, indicating that the endoproteolytic cleavage occurs in vivo. Mutant myocilins accumulated in the endoplasmic reticulum of transfected cells as insoluble aggregates. Interestingly, the four pathogenic myocilins inhibited the endoproteolytic processing with varying efficiency. Furthermore, the mutation P370L, which produces the most severe glaucoma phenotype, also elicited the most potent endoproteolytic cleavage inhibition. We propose that the endoproteolytic processing might regulate the activity of myocilin and that the inhibition of the processing by pathogenic mutations impairs the normal role of myocilin.	Univ Castilla La Mancha, Fac Med, Ctr Reg Invest Biomed, Area Genet, Albacete 02006, Spain; Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06510 USA	Universidad de Castilla-La Mancha; Yale University	Escribano, J (corresponding author), Univ Castilla La Mancha, Fac Med, Ctr Reg Invest Biomed, Area Genet, Avda Almansa Sn, Albacete 02006, Spain.	julio.escribano@uclm.es	Escribano, Julio/D-9742-2015; Aroca-Aguilar, Jose Daniel/R-5513-2019; Aroca-Aguilar, J.Daniel/B-7842-2008	Escribano, Julio/0000-0002-8919-8134; Aroca-Aguilar, Jose Daniel/0000-0001-6487-1612; Aroca-Aguilar, J.Daniel/0000-0001-6487-1612	NEI NIH HHS [EY04873] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004873] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adam MF, 1997, HUM MOL GENET, V6, P2091, DOI 10.1093/hmg/6.12.2091; BAL RS, 1993, BIOCHEMISTRY-US, V32, P1047, DOI 10.1021/bi00055a008; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Caballero M, 2001, BIOCHEM BIOPH RES CO, V282, P662, DOI 10.1006/bbrc.2001.4624; Caballero M, 2000, BBA-MOL BASIS DIS, V1502, P447, DOI 10.1016/S0925-4439(00)00068-5; Coca-Prados M, 1999, PROG RETIN EYE RES, V18, P403, DOI 10.1016/S1350-9462(98)00026-3; COCAPRADOS M, 1986, P NATL ACAD SCI USA, V83, P8754, DOI 10.1073/pnas.83.22.8754; ESCRIBANO J, 1995, J BIOCHEM-TOKYO, V118, P921, DOI 10.1093/jb/118.5.921; Fautsch MP, 2001, INVEST OPHTH VIS SCI, V42, P2324; Goldwich A, 2003, INVEST OPHTH VIS SCI, V44, P1953, DOI 10.1167/iovs.02-0863; Huang W, 2000, Ophthalmic Genet, V21, P155, DOI 10.1076/1381-6810(200009)21:3;1-Z;FT155; Jacobson N, 2001, HUM MOL GENET, V10, P117, DOI 10.1093/hmg/10.2.117; Joe MK, 2003, BIOCHEM BIOPH RES CO, V312, P592, DOI 10.1016/j.bbrc.2003.10.162; Karali A, 2000, INVEST OPHTH VIS SCI, V41, P729; Kennan AM, 1998, J MED GENET, V35, P957, DOI 10.1136/jmg.35.11.957; Kim BS, 2001, MOL CELL BIOL, V21, P7707, DOI 10.1128/MCB.21.22.7707-7713.2001; Kubota R, 1997, GENOMICS, V41, P360, DOI 10.1006/geno.1997.4682; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam DSC, 2000, INVEST OPHTH VIS SCI, V41, P1386; Li G, 1997, ELECTROPHORESIS, V18, P391, DOI 10.1002/elps.1150180313; Liu YH, 2004, HUM MOL GENET, V13, P1193, DOI 10.1093/hmg/ddh128; Mertts M, 1999, LAB INVEST, V79, P1237; Morissette J, 1998, NAT GENET, V19, P319, DOI 10.1038/1203; Mukhopadhyay A, 2002, MOL VIS, V8, P271; Nagy I, 2003, BIOCHEM BIOPH RES CO, V302, P554, DOI 10.1016/S0006-291X(03)00198-0; Nguyen TD, 1998, J BIOL CHEM, V273, P6341, DOI 10.1074/jbc.273.11.6341; O'Brien ET, 2000, INVEST OPHTH VIS SCI, V41, P3842; Ortego J, 1997, FEBS LETT, V413, P349, DOI 10.1016/S0014-5793(97)00934-4; Polansky JR, 1997, OPHTHALMOLOGICA, V211, P126, DOI 10.1159/000310780; Polansky JR, 1993, BASIC ASPECTS GLAUCO, P307; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; QUIGLEY HA, 1992, OPHTHALMOLOGY, V99, P19; Rao PV, 2000, EXP EYE RES, V71, P637, DOI 10.1006/exer.2000.0920; Rozsa F W, 1998, Mol Vis, V4, P20; Russell P, 2001, INVEST OPHTH VIS SCI, V42, P983; Sarfarazi M, 1997, HUM MOL GENET, V6, P1667, DOI 10.1093/hmg/6.10.1667; Shimizu S, 2000, AM J OPHTHALMOL, V130, P165, DOI 10.1016/S0002-9394(00)00536-5; Sohn S, 2002, INVEST OPHTH VIS SCI, V43, P3680; Stamer WD, 1998, INVEST OPHTH VIS SCI, V39, P1804; Stoilova D, 1998, J MED GENET, V35, P989, DOI 10.1136/jmg.35.12.989; Suyama M, 2003, BIOINFORMATICS, V19, P673, DOI 10.1093/bioinformatics/btg031; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Ueda J, 2000, J HISTOCHEM CYTOCHEM, V48, P1321, DOI 10.1177/002215540004801003; Wentz-Hunter K, 2003, MOL VIS, V9, P308; WILSON CM, 1983, METHOD ENZYMOL, V91, P236; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; Zhou ZH, 1999, HUM MOL GENET, V8, P2221, DOI 10.1093/hmg/8.12.2221; Zimmerman CC, 1999, MOL VIS, V5	49	65	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21043	21051		10.1074/jbc.M501340200	http://dx.doi.org/10.1074/jbc.M501340200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15795224	hybrid			2022-12-25	WOS:000229438800019
J	Fiedor, L; Scheer, H				Fiedor, L; Scheer, H			Trapping of an assembly intermediate of photosynthetic LH1 antenna beyond B820 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; RHODOSPIRILLUM-RUBRUM; CRYSTAL-STRUCTURE; RHODOBACTER-SPHAEROIDES; SPECTROSCOPIC CHARACTERIZATION; PERIDININ-CHLOROPHYLL; CIRCULAR-DICHROISM; PURPLE BACTERIA; CORE COMPLEX; BACTERIOCHLOROPHYLL	Most photosynthetic LH1 antennae undergo dissociation into B820 subunits, suggesting their universal character as structural modules. However, dissociation into subunits seems to occur reversibly only in the absence of carotenoids and the subunits were never found to bind carotenoids. The interactions of carotenoids with B820 have been studied in a newly developed reconstitution assay of the LH1 antenna from Rhodospirillum rubrum (Fiedor, L., Akahane, J., and Koyama, Y. ( 2004) Biochemistry 43, 16487 - 16496). These model studies show that B820 subunits strongly interact with carotenoids and spontaneously form stable LH1-like complexes with substoichiometric carotenoid content. This is the first experimental evidence that B820 may occur as a short-lived intermediate in the assembly of LH1 in vivo. The resulting complex of B820 subunits with carotenoid, termed iB873, is homogeneous, according to ion exchange chromatography and reproducible pigment composition. The iB873-bound carotenoid is as efficient in energy transfer to bacteriochlorophyll as the one in native antenna. To our knowledge, iB873 is the first complex binding functional carotenoid, with the spectral and biochemical properties intermediate between that of B820 and the fully assembled LH1.	Jagiellonian Univ, Fac Biotechnol, PL-30387 Krakow, Poland; Univ Munich, Dept Biol 1, D-80638 Munich, Germany	Jagiellonian University; University of Munich	Fiedor, L (corresponding author), Jagiellonian Univ, Fac Biotechnol, Gronostajowa 7, PL-30387 Krakow, Poland.	lfiedor@mol.uj.edu.pl						Arluison V, 2002, BIOCHEMISTRY-US, V41, P11812, DOI 10.1021/bi0202124; Bahatyrova S, 2004, NATURE, V430, P1058, DOI 10.1038/nature02823; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; CHANG MC, 1990, BIOCHEMISTRY-US, V29, P421, DOI 10.1021/bi00454a017; Cogdell R. J., 1995, ANOXYGENIC PHOTOSYNT, P315; COGDELL RJ, 1985, PHOTOCHEM PHOTOBIOL, V42, P669, DOI 10.1111/j.1751-1097.1985.tb01629.x; DAVIS CM, 1995, J BIOL CHEM, V270, P5793, DOI 10.1074/jbc.270.11.5793; DEISENHOFER J, 1993, PHOTOSYNTHETIC REACT, V1, P541; Drews G, 1996, ARCH MICROBIOL, V166, P151, DOI 10.1007/s002030050370; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Fiedor L, 2004, BIOCHEMISTRY-US, V43, P16487, DOI 10.1021/bi0481287; Fiedor L, 2000, CHEM PHYS LETT, V319, P145, DOI 10.1016/S0009-2614(00)00112-3; Fiedor L, 2001, BIOCHEMISTRY-US, V40, P3737, DOI 10.1021/bi002257f; Fujii R, 2001, J PHYS CHEM A, V105, P5348, DOI 10.1021/jp010150b; GHOSH R, 1988, BIOCHEMISTRY-US, V27, P1004, DOI 10.1021/bi00403a025; Hofmann E, 1996, SCIENCE, V272, P1788, DOI 10.1126/science.272.5269.1788; KARRASCH S, 1995, EMBO J, V14, P631, DOI 10.1002/j.1460-2075.1995.tb07041.x; Koepke J, 1996, STRUCTURE, V4, P581, DOI 10.1016/S0969-2126(96)00063-9; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Loach P. A., 1995, ANOXYGENIC PHOTOSYNT, P437; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; Meyer M, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL I, P919; MILLER JF, 1987, BIOCHEMISTRY-US, V26, P5055, DOI 10.1021/bi00390a026; Moskalenko A, 1996, Z NATURFORSCH C, V51, P309; NOGUCHI T, 1990, BIOCHIM BIOPHYS ACTA, V1017, P280, DOI 10.1016/0005-2728(90)90194-9; Pandit A, 2003, PHOTOSYNTH RES, V75, P235, DOI 10.1023/A:1023988722299; PICOREL R, 1983, BIOCHEMISTRY-US, V22, P2491, DOI 10.1021/bi00279a028; Pilch M, 1998, J CHEM SOC FARADAY T, V94, P227, DOI 10.1039/a705173e; Prince SM, 2003, J MOL BIOL, V326, P307, DOI 10.1016/S0022-2836(02)01361-X; Pugh RJ, 1998, BBA-BIOENERGETICS, V1366, P301, DOI 10.1016/S0005-2728(98)00131-5; Roszak AW, 2003, SCIENCE, V302, P1969, DOI 10.1126/science.1088892; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scheuring S, 2004, P NATL ACAD SCI USA, V101, P11293, DOI 10.1073/pnas.0404350101; SMITH JRL, 1966, J AM CHEM SOC, V88, P4500, DOI 10.1021/ja00971a036; STURGIS JN, 1994, J MOL BIOL, V238, P445, DOI 10.1006/jmbi.1994.1303; Sundstrom V, 1999, J PHYS CHEM B, V103, P2327, DOI 10.1021/jp983722+; SUNDSTROM V, 1995, ADV PHOTOSYNTHESIS R, P00349; van Amerongen H., 2000, PHOTOSYNTHETIC EXCIT; van Oijen AM, 1999, SCIENCE, V285, P400, DOI 10.1126/science.285.5426.400; Vegh AP, 2002, FEBS LETT, V528, P222, DOI 10.1016/S0014-5793(02)03314-8; Wang YL, 2002, J AM CHEM SOC, V124, P8445, DOI 10.1021/ja025618i; Wang ZY, 2002, J AM CHEM SOC, V124, P1072, DOI 10.1021/ja0112994; WESTERHUIS WHJ, 1992, PHOTOSYNTH RES, V34, P112; Zhang JP, 2001, J PHYS CHEM B, V105, P7312, DOI 10.1021/jp004360k; Zhang JP, 1998, J PHYS CHEM B, V102, P1632, DOI 10.1021/jp9728058	45	16	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20921	20926		10.1074/jbc.M501212200	http://dx.doi.org/10.1074/jbc.M501212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15788392	hybrid			2022-12-25	WOS:000229438800003
J	Wu, HY; Yuen, EY; Lu, YF; Matsushita, M; Matsui, H; Yan, Z; Tomizawa, K				Wu, HY; Yuen, EY; Lu, YF; Matsushita, M; Matsui, H; Yan, Z; Tomizawa, K			Regulation of N-methyl-D-aspartate receptors by calpain in cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MOLECULAR DIVERSITY; HIPPOCAMPAL-NEURONS; MEDIATED CLEAVAGE; NMDA RECEPTORS; PROTEOLYSIS; INACTIVATION; ACTIVATION; CHANNELS; PHOSPHORYLATION	The N-methyl-D-aspartate (NMDA) receptor is a cation channel highly permeable to calcium and plays critical roles in governing normal and pathologic functions in neurons. Calcium entry through NMDA receptors (NMDARs) can lead to the activation of the Ca2+-dependent protease, calpain. Here we investigated the involvement of calpain in regulation of NMDAR channel function. After prolonged (5-min) treatment with NMDA or glutamate, the whole-cell NMDAR-mediated current was significantly reduced in both acutely dissociated and cultured cortical pyramidal neurons. The down-regulation of NMDAR current was blocked by bath application of selective calpain inhibitors. Intracellular injection of a specific calpain inhibitory peptide also eliminated the down-regulation of NMDAR current induced by prolonged NMDA treatment. In contrast, dynamin inhibitory peptide had no effect on the depression of NMDAR current, suggesting the lack of involvement of dynamin/clathrin-mediated NMDAR internalization in this process. Immunoblotting analysis showed that the NR2A and NR2B subunits of NMDARs were markedly degraded in cultured cortical neurons treated with glutamate, and the degradation of NR2 subunits was prevented by calpain inhibitors. Taken together, our results suggest that prolonged activation of NMDARs in neurons activates calpain, and activated calpain in turn down-regulates the function of NMDARs, which provides a neuroprotective mechanism against NMDAR overstimulation accompanying ischemia and stroke.	Okayama Univ, Grad Sch Med & Dent, Dept Physiol, Okayama 7008558, Japan; SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, Buffalo, NY 14214 USA; Japan Sci & Technol Corp, Prot Therapy, New Technoventure Oriented R&D, Okayama 7008558, Japan	Okayama University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Japan Science & Technology Agency (JST)	Tomizawa, K (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Physiol, 2-5-1 Shikata, Okayama 7008558, Japan.	tomikt@md.okayama-u.ac.jp	Tomizawa, Kazuhito/F-2405-2015	Tomizawa, Kazuhito/0000-0002-5663-2627	NIMH NIH HHS [MH63128] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063128] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adamec R, 1998, NEUROSCI BIOBEHAV R, V23, P301, DOI 10.1016/S0149-7634(98)00032-3; Bi RF, 2000, J BIOL CHEM, V275, P26477, DOI 10.1074/jbc.M003763200; Bi XN, 1998, BRAIN RES, V790, P245, DOI 10.1016/S0006-8993(98)00067-5; Chen GJ, 2004, P NATL ACAD SCI USA, V101, P2596, DOI 10.1073/pnas.0308618100; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Dingledine R, 1999, PHARMACOL REV, V51, P7; Feng J, 2001, J NEUROSCI, V21, P6502, DOI 10.1523/JNEUROSCI.21-17-06502.2001; Garcia JH, 1997, STROKE, V28, P2303, DOI 10.1161/01.STR.28.11.2303; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Guttmann RP, 2002, J PHARMACOL EXP THER, V302, P1023, DOI 10.1124/jpet.102.036962; Guttmann RP, 2001, J NEUROCHEM, V78, P1083, DOI 10.1046/j.1471-4159.2001.00493.x; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; KAWASAKI H, 1989, J BIOCHEM, V106, P274, DOI 10.1093/oxfordjournals.jbchem.a122844; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P9870, DOI 10.1073/pnas.152336999; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; Kittler JT, 2000, J NEUROSCI, V20, P7972; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; Lissin DV, 1998, P NATL ACAD SCI USA, V95, P7097, DOI 10.1073/pnas.95.12.7097; Lynch DR, 2002, J PHARMACOL EXP THER, V300, P717, DOI 10.1124/jpet.300.3.717; MAKI M, 1989, J BIOL CHEM, V264, P18866; Medina I, 1996, J PHYSIOL-LONDON, V495, P411, DOI 10.1113/jphysiol.1996.sp021603; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Nong Y, 2003, NATURE, V422, P302, DOI 10.1038/nature01497; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patzke H, 2002, J BIOL CHEM, V277, P8054, DOI 10.1074/jbc.M109645200; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Simpkins KL, 2003, J NEUROSCI, V23, P11322; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Tomizawa K, 2002, J NEUROSCI, V22, P2590, DOI 10.1523/JNEUROSCI.22-07-02590.2002; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; VYKLICKY L, 1993, J PHYSIOL-LONDON, V470, P575, DOI 10.1113/jphysiol.1993.sp019876; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang X, 2003, J NEUROSCI, V23, P9852; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Wu HY, 2003, NEUROSCI RES, V47, P131, DOI 10.1016/S0168-0102(03)00195-0; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	48	86	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21588	21593		10.1074/jbc.M501603200	http://dx.doi.org/10.1074/jbc.M501603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15790561	hybrid			2022-12-25	WOS:000229438800082
J	Hoegy, FO; Celia, H; Mislin, GL; Vincent, M; Gallay, J; Schalk, IJ				Hoegy, FO; Celia, H; Mislin, GL; Vincent, M; Gallay, J; Schalk, IJ			Binding of iron-free siderophore, a common feature of siderophore outer membrane transporters of Escherichia coli and Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR FPVA; PYOVERDIN RECEPTOR; CRYSTAL-STRUCTURE; TONB; PROTEIN; FHUA; MECHANISM; PYOCHELIN; ACQUISITION; INHIBITION	TonB-dependent iron transporters present in the outer membranes of Gram-negative bacteria transport ferric-siderophore complexes into the periplasm. This requires proton motive force and an integral inner membrane complex, TonB-ExbB-ExbD. Recognition of iron-free siderophores by TonB-dependent outer membrane transporters (OMT) has only been described for a subfamily called OMTN. These OMT(N)s have an additional domain at the N terminus, which interacts with an inner membrane regulatory protein to activate a cytoplasmic sigma factor. This induces transcription of iron transport genes. Here we showed that the ability to bind aposiderophores is not specific to the OMTN subfamily but may be a more general feature of OMTs. FhuA, the ferrichrome OMT in Escherichia coli, and FptA, the pyochelin (Pch) OMT in Pseudomonas aeruginosa, were both able to bind in vitro and in vivo the apo-forms and the ferric forms of their corresponding siderophore at a common binding site. FptA produced in P. aeruginosa cells grown in an iron-deficient medium copurifies with a ligand that, as characterized by fluorescence, is iron-free Pch. As described previously for the FpvA transporter ( pyoverdine OMT in P. aeruginosa), it appears that in conditions of iron limitation all the FptA receptors at the cell surface are loaded with apoPch. This FptA-Pch complex is less stable in vitro than the previously described copurified FpvA-Pvd complex and can be loaded with iron in vitro in the presence of Pch-Fe, citrate-Fe, or ferrichrome-Fe. These findings improved our understanding of the iron uptake mechanism via siderophores in Gram-negative bacteria.	ESBS, CNRS, UPR 9050, Dept Recepteurs & Prot Membranaires, F-67413 Illkirch Graffenstaden, France; Univ Paris 11, CNRS, UMR 8619, IBBMC, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Schalk, IJ (corresponding author), ESBS, CNRS, UPR 9050, Dept Recepteurs & Prot Membranaires, Bld Sebastien Brant,BP 10412, F-67413 Illkirch Graffenstaden, France.	schalk@esbs.u-strasbg.fr						ALBRECHTGARY AM, 1994, INORG CHEM, V33, P6391, DOI 10.1021/ic00104a059; ANKENBAUER R, 1986, J BACTERIOL, V167, P7, DOI 10.1128/jb.167.1.7-11.1986; ANKENBAUER RG, 1994, J BACTERIOL, V176, P307, DOI 10.1128/JB.176.2.307-319.1994; Bonhivers M, 2001, BIOCHEMISTRY-US, V40, P2606, DOI 10.1021/bi001725i; Boukhalfa H, 2002, BIOMETALS, V15, P325, DOI 10.1023/A:1020218608266; Braun V, 1997, ARCH MICROBIOL, V167, P325, DOI 10.1007/s002030050451; Braun V, 2003, FRONT BIOSCI-LANDMRK, V8, pS1409, DOI 10.2741/1232; Braun V, 2002, FEBS LETT, V529, P78, DOI 10.1016/S0014-5793(02)03185-X; Braun V, 2001, INT J MED MICROBIOL, V291, P67, DOI 10.1078/1438-4221-00103; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clement E, 2004, BIOCHEMISTRY-US, V43, P7954, DOI 10.1021/bi049768c; Cobessi D, 2005, J MOL BIOL, V347, P121, DOI 10.1016/j.jmb.2005.01.021; COX CD, 1981, P NATL ACAD SCI-BIOL, V78, P4256, DOI 10.1073/pnas.78.7.4256; DEMANGE P, 1990, BIOL MET, V3, P155; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Folschweiller N, 2000, MOL MEMBR BIOL, V17, P123; Folschweiller N, 2002, BIOCHEMISTRY-US, V41, P14591, DOI 10.1021/bi0259711; Hantke K, 2001, CURR OPIN MICROBIOL, V4, P172, DOI 10.1016/S1369-5274(00)00184-3; KADNER RJ, 1995, J BACTERIOL, V177, P4829, DOI 10.1128/jb.177.17.4829-4835.1995; Letoffe S, 2004, J BACTERIOL, V186, P4067, DOI 10.1128/JB.186.13.4067-4074.2004; Letoffe S, 2001, MOL MICROBIOL, V41, P439, DOI 10.1046/j.1365-2958.2001.02530.x; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Moeck GS, 1998, MOL MICROBIOL, V28, P675, DOI 10.1046/j.1365-2958.1998.00817.x; Moeck GS, 2001, J BACTERIOL, V183, P2755, DOI 10.1128/JB.183.9.2755-2764.2001; Namiranian S, 1997, PHOTOCHEM PHOTOBIOL, V65, P777, DOI 10.1111/j.1751-1097.1997.tb01924.x; Newton SMC, 1999, MOL MICROBIOL, V32, P1153, DOI 10.1046/j.1365-2958.1999.01424.x; POOLE K, 1993, J BACTERIOL, V175, P4597, DOI 10.1128/JB.175.15.4597-4604.1993; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; ROYLE PL, 1981, J BACTERIOL, V145, P145, DOI 10.1128/JB.145.1.145-155.1981; Schalk IJ, 1999, BIOCHEMISTRY-US, V38, P9357, DOI 10.1021/bi990421x; Schalk IJ, 2004, MOL MICROBIOL, V54, P14, DOI 10.1111/j.1365-2958.2004.04241.x; Schalk IJ, 2002, BIOCHEMISTRY-US, V41, P1663, DOI 10.1021/bi0157767; Schalk IJ, 2001, MOL MICROBIOL, V39, P351, DOI 10.1046/j.1365-2958.2001.02207.x; SCHALK IJ, 2005, PSEUDOMONAS MOL BIOL, V4; Shouldice SR, 2005, J BIOL CHEM, V280, P5820, DOI 10.1074/jbc.M411238200; Stintzi A, 2000, P NATL ACAD SCI USA, V97, P10691, DOI 10.1073/pnas.200318797; Stojiljkovic I, 1997, J BACTERIOL, V179, P805, DOI 10.1128/jb.179.3.805-812.1997; Takase H, 2000, INFECT IMMUN, V68, P1834, DOI 10.1128/IAI.68.4.1834-1839.2000; Vasil ML, 1999, MOL MICROBIOL, V34, P399, DOI 10.1046/j.1365-2958.1999.01586.x; Vincent M, 2000, J PHYS CHEM B, V104, P11286, DOI 10.1021/jp000638x; Visca P, 2002, MOL MICROBIOL, V45, P1177, DOI 10.1046/j.1365-2958.2002.03088.x; Winkelmann G, 2002, BIOCHEM SOC T, V30, P691, DOI 10.1042/BST0300691; Xiao R, 1997, MICROBIOL-UK, V143, P2509, DOI 10.1099/00221287-143-7-2509; Yue WW, 2003, J MOL BIOL, V332, P353, DOI 10.1016/S0022-2836(03)00855-6; Zamri A, 2000, TETRAHEDRON, V56, P249, DOI 10.1016/S0040-4020(99)00946-1	48	47	49	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20222	20230		10.1074/jbc.M500776200	http://dx.doi.org/10.1074/jbc.M500776200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15784620	hybrid			2022-12-25	WOS:000229242000009
J	Misra, S; Ghatak, S; Toole, BP				Misra, S; Ghatak, S; Toole, BP			Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-CARCINOMA CELLS; MULTIDRUG-RESISTANCE; CD44 INTERACTION; SURFACE CD44; CANCER-CELLS; TUMOR-CELLS; IN-VIVO; GROWTH; ACTIVATION; PHOSPHORYLATION	Multidrug resistance is a potent barrier to effective, long term therapy in cancer patients. It is frequently attributed to enhanced expression of multidrug transporters or to the action of receptor kinases, such as ErbB2, and downstream anti-apoptotic signaling pathways, such as the phosphoinositide 3-kinase/Akt pathway. However, very few connections have been made between receptor kinases or anti-apoptotic pathways and multidrug transporter expression or function. Data presented herein show that constitutive interaction of the pericellular polysaccharide, hyaluronan, with its receptor, CD44, regulates assembly and activation of an ErbB2-containing signaling complex, which in turn stimulates phosphoinositide 3-kinase activity in multi-drug-resistant MCF-7/Adr human breast carcinoma cells. Phosphoinositide 3-kinase activates Akt and downstream anti-apoptotic events, which contribute to drug resistance. However, hyaluronan and phosphoinositide 3-kinase stimulate expression of the multidrug transporter, MDR1 (P-glycoprotein), in an interdependent, but Akt-independent, manner. Furthermore, constitutively active phosphoinositide 3-kinase, but not Akt, stimulates hyaluronan production. These Akt-independent effects are dominant over the effects of Akt on doxorubicin resistance in MCF-7/Adr cells. Thus hyaluronan, phosphoinositide 3-kinase, and ErbB2 form a positive feedback loop that strongly amplifies MDR1 expression and regulates drug resistance in these cells. This pathway may also be important in progression of other malignant characteristics. These results illustrate the potential importance of hyaluronan as a therapeutic target in multidrug-resistant carcinomas.	Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA	Medical University of South Carolina	Misra, S (corresponding author), Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA.	misra@musc.edu; toolebp@musc.edu			NATIONAL CANCER INSTITUTE [R01CA082867, R01CA073839] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017698] Funding Source: NIH RePORTER; NCI NIH HHS [CA73839, CA82867] Funding Source: Medline; NCRR NIH HHS [RR-17698] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Chen JS, 2003, DRUG RESIST UPDATE, V6, P129, DOI 10.1016/S1368-7646(03)00040-2; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Gordon LB, 2003, HUM GENET, V113, P178, DOI 10.1007/s00439-003-0958-9; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Itano N, 2004, J BIOL CHEM, V279, P18679, DOI 10.1074/jbc.M313178200; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Lee JT, 2004, CANCER RES, V64, P8397, DOI 10.1158/0008-5472.CAN-04-1612; Lesley J, 2000, J BIOL CHEM, V275, P26967; Li RS, 2001, J CELL PHYSIOL, V186, P371, DOI 10.1002/1097-4652(2000)9999:999<000::AID-JCP1042>3.0.CO;2-8; Misra S, 2003, J BIOL CHEM, V278, P25285, DOI 10.1074/jbc.C300173200; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Ouskova G, 2004, GLYCOBIOLOGY, V14, P931, DOI 10.1093/glycob/cwh115; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Prehm P, 2004, BIOCHEM PHARMACOL, V68, P1401, DOI 10.1016/j.bcp.2004.06.017; Schroeder JA, 2003, J MOL MED-JMM, V81, P392, DOI 10.1007/s00109-003-0456-5; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Tsatas D, 2002, J CLIN NEUROSCI, V9, P282, DOI 10.1054/jocn.2001.1063; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; Ward JA, 2003, AM J PATHOL, V162, P1403, DOI 10.1016/S0002-9440(10)64273-3; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wobus M, 2002, APPL IMMUNOHISTO M M, V10, P34, DOI 10.1097/00022744-200203000-00006; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Zeng CX, 1998, INT J CANCER, V77, P396; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	38	206	213	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20310	20315		10.1074/jbc.M500737200	http://dx.doi.org/10.1074/jbc.M500737200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15784621	hybrid			2022-12-25	WOS:000229242000020
J	Huang, YP; Wernyj, RP; Norton, DD; Precht, P; Seminario, MC; Wange, RL				Huang, YP; Wernyj, RP; Norton, DD; Precht, P; Seminario, MC; Wange, RL			Modulation of specific protein expression levels by PTEN: identification of AKAP121, DHFR, G3BP, Rap1, and RCC1 as potential targets of PTEN	ONCOGENE			English	Article						PTEN; RCC1; G3BP; proteomics; leukemia; tumor suppressor	GTPASE-ACTIVATING PROTEIN; TUMOR-SUPPRESSOR GENE; JURKAT T-CELLS; PHOSPHATASE-ACTIVITY; BINDING-PROTEIN; GROWTH; RAS; DEGRADATION; INHIBITOR; MECHANISM	The tumor suppressor PTEN is mutated in a high percentage of human cancers, and is implicated in pathways regulating cell growth, proliferation, survival, and migration. Despite significant advances, our understanding of its mechanisms of action remains incomplete. We have used a high-throughput proteomic immunoblotting approach to identify proteins whose expression levels are modulated by PTEN. Out of over 800 proteins screened, 22 proteins showed significant changes in expression. Five proteins that exhibited two-fold or greater changes in expression level were further characterized. AKAP121 and G3BP expression was reduced, while dihydrofolate reductase ( DHFR), Rap1 and RCC1 expression was elevated in response to PTEN expression in a PTEN-null T-cell leukemia line. The phosphatase activity of PTEN was required for these effects. However, direct inhibition of PI-3 Kinase could mimic PTEN in modulating expression of DHFR, G3BP, Rap1 and RCC1, but not AKAP121. Real-time PCR showed that the effects of PTEN were primarily post-transcriptional, and would not have been revealed by mRNA-based screens. We conclude from these data that PTEN can modulate the expression level of a number of different proteins. The identified proteins have the potential to serve as previously unrecognized effectors of PTEN, and suggest the existence of additional complexity in the modes by which PTEN can regulate cellular biology.	NIA, Cellular & Mol Biol Lab, IRP NIH DHHS, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Wange, RL (corresponding author), NIA, Cellular & Mol Biol Lab, IRP NIH DHHS, 5600 Nathan Shock Dr,MSC-12, Baltimore, MD 21224 USA.	wanger@grc.nia.nih.gov	Wange, Ronald/AAI-2505-2021	Wange, Ronald/0000-0001-9593-3572				Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Furnari FB, 1998, CANCER RES, V58, P5002; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Guitard E, 2001, CANCER LETT, V162, P213, DOI 10.1016/S0304-3835(00)00638-8; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kociok N, 1999, J CELL BIOCHEM, V74, P194, DOI 10.1002/(SICI)1097-4644(19990801)74:2<194::AID-JCB5>3.0.CO;2-M; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu K, 2001, J IMMUNOL, V166, P7335, DOI 10.4049/jimmunol.166.12.7335; LIVAK KJ, 2004, USER B PE APPL BIOSY, V2; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Moore JD, 2001, BIOESSAYS, V23, P77, DOI 10.1002/1521-1878(200101)23:1<77::AID-BIES1010>3.3.CO;2-5; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Parker F, 1996, MOL CELL BIOL, V16, P2561; Pazman C, 2000, DEVELOPMENT, V127, P1715; Pilarski R, 2004, J MED GENET, V41, P323, DOI 10.1136/jmg.2004.018036; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; POWIS G, 1994, CANCER RES, V54, P2419; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Seminario MC, 2003, ONCOGENE, V22, P8195, DOI 10.1038/sj.onc.1206872; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; Xu Z, 2002, CELL GROWTH DIFFER, V13, P285; Yamaguchi R, 2003, CELL, V113, P115, DOI 10.1016/S0092-8674(03)00200-9	43	19	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3819	3829		10.1038/sj.onc.1208527	http://dx.doi.org/10.1038/sj.onc.1208527			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782128				2022-12-25	WOS:000229346300012
J	Chun, KH; Pfahl, M; Lotan, R				Chun, KH; Pfahl, M; Lotan, R			Induction of apoptosis by the synthetic retinoid MX3350-1 through extrinsic and intrinsic pathways in head and neck squamous carcinoma cells	ONCOGENE			English	Article						retinoid; apoptosis; mitochondrial pathway; death receptor-related pathway; HNSCC	BCL-2 FAMILY PROTEINS; RECEPTOR-INDEPENDENT INDUCTION; STRESS-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; LUNG-CANCER CELLS; MEDIATED APOPTOSIS; SIGNAL-TRANSDUCTION; CHEMOPREVENTIVE AGENTS; SELECTIVE RETINOIDS; CARBOXYLIC-ACID	Retinoids have shown promise in cancer prevention and therapy. As some retinoids exhibit undesirable side effects, new retinoid analogs have been synthesized. In this study, we examined the effects of the retinoid MX3350-1 on human head and neck squamous cell carcinoma (HNSCC) cell lines. MX3350-1 suppressed the growth of 7/8 HNSCC cell lines by >65%. This inhibition appeared to be due to induction of apoptosis as revealed by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay. Studies with cell line UMSCC17B indicated that apoptosis was induced within 1-2 days and involved activation of caspase-8, -9, and -3. Inhibitors of these caspases suppressed MX3350-1-induced apoptosis. MX3350-1 decreased the levels of antiapoptotic Bcl-2 and Bcl-XL, increased proapoptotic Bax, induced mitochondrial membrane permeabilization (MMP), and cytochrome c release from mitochondria to cytosol. The antioxidant butylated hydroxyanisol and the MMP inhibitor cyclosporin A (Cs A) blocked apoptosis induced by MX3350-1. In contrast, retinoid receptor antagonists failed to inhibit apoptosis. MX3350-1 increased the levels of Fas-ligand, Fas, and Fas-associated death domain, and enhanced activation of procaspase-8 and cleavage of its substrate Bid. Soluble Fas rescued the cells from MX3350-1-induced apoptosis. These results demonstrate that MX3350-1 induces apoptosis by activating both extrinsic and intrinsic apoptosis pathways and suggest that further studies on the potential of this retinoid for prevention and therapy of HNSCCs are warranted.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Unit 432, Houston, TX 77030 USA; Maxocore Pharmaceut Inc, San Diego, CA USA	University of Texas System; UTMD Anderson Cancer Center	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Unit 432, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rlotan@mdanderson.org			NCI NIH HHS [P30 CA16672-30, P50 CA907007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bang S, 2000, J BIOL CHEM, V275, P36217, DOI 10.1074/jbc.M006620200; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; CHAKRAVARTI N, 2003, INT J CANCER, V91, P27; Chun KH, 2003, CANCER RES, V63, P4796; Chun KH, 2003, CANCER RES, V63, P3826; D'Ambrosio SM, 2000, ANTICANCER RES, V20, P2273; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; DiSepio D, 1999, Mol Cell Biol Res Commun, V1, P7, DOI 10.1006/mcbr.1999.0101; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Garattini E, 2004, CURR PHARM DESIGN, V10, P433, DOI 10.2174/1381612043453351; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guruswamy S, 2001, JNCI-J NATL CANCER I, V93, P516, DOI 10.1093/jnci/93.7.516; HSU CK, 1997, EXP CELL RES, V232, P7; Krilleke D, 2003, INT J CANCER, V107, P520, DOI 10.1002/ijc.11331; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee JJ, 2000, CLIN CANCER RES, V6, P1702; Lippman SC, 2000, J NUTR, V130, p479S, DOI 10.1093/jn/130.2.479S; Lotan R, 2003, J BIOL REG HOMEOS AG, V17, P13; LOTAN R, 1995, CANCER RES, V55, P232; Lotan R, 1996, ANTICANCER RES, V16, P2415; Lu XP, 1997, NAT MED, V3, P686, DOI 10.1038/nm0697-686; Marchetti P, 1999, CANCER RES, V59, P6257; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Ortiz MA, 2001, CANCER RES, V61, P8504; Pfahl M, 2003, ONCOGENE, V22, P9058, DOI 10.1038/sj.onc.1207109; Schmitz I, 2000, INT J BIOCHEM CELL B, V32, P1123, DOI 10.1016/S1357-2725(00)00048-0; Shi Y, 2003, BIOCHEM BIOPH RES CO, V305, P989, DOI 10.1016/S0006-291X(03)00871-4; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Sun SY, 2000, CANCER RES, V60, P6537; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 2000, MOL PHARMACOL, V58, P508, DOI 10.1124/mol.58.3.508; Sun SY, 2000, CLIN CANCER RES, V6, P1563; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Ulukaya E, 1999, CANCER TREAT REV, V25, P229, DOI 10.1053/ctrv.1999.0127; Yanase N, 2000, J INTERF CYTOK RES, V20, P1121, DOI 10.1089/107999000750053799; Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045	40	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3669	3677		10.1038/sj.onc.1208339	http://dx.doi.org/10.1038/sj.onc.1208339			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782141				2022-12-25	WOS:000229221800014
J	Ji, P; Agrawal, S; Diederichs, S; Baumer, N; Becker, A; Cauvet, T; Kowski, S; Beger, C; Welte, K; Berdel, WE; Serve, H; Muller-Tidow, C				Ji, P; Agrawal, S; Diederichs, S; Baumer, N; Becker, A; Cauvet, T; Kowski, S; Beger, C; Welte, K; Berdel, WE; Serve, H; Muller-Tidow, C			Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells	ONCOGENE			English	Article						cyclin A1; leukemia; cell cycle; siRNA	ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC-CELLS; MICE; PROTEINS; MOUSE; EXPRESSION; MEIOSIS; FAMILY; E2F	Cyclin A1 is an alternative A-type cyclin that is essential for spermatogenesis, but it is also expressed in hematopoietic progenitor cells and in acute myeloid leukemia. Its functions during cell cycle progression of somatic cells are incompletely understood. Here, we have analysed the cell cycle functions of cyclin A1 in transformed and non-transformed cells. Murine embryonic fibroblasts derived from cyclin A1-deficient mice were significantly impaired in their proliferative capacity. In accordance, cyclin A1(-/-) cells accumulated in G1 and G2/M phase while the percentage of S phase cells decreased. Also, lectin stimulated splenic lymphocytes from cyclin A1(-/-) mice proliferated slower than their wild-type counterparts. Forced cyclin A1 overexpression in NIH3T3 cells and in U937 leukemic cells either by transient transfection or by retroviral infection enhanced S phase entry. Consequently, siRNA mediated silencing of cyclin A1 in highly cyclin A1 expressing ML1 leukemic cells significantly slowed S phase entry, decreased proliferation and inhibited colony formation. Taken together, these analyses demonstrate that cyclin A1 contributes to G1 to S cell cycle progression in somatic cells. Cyclin A1 overexpression enhances S phase entry consistent with an oncogenic function. Finally, cyclin A1 might be a therapeutic target since its silencing inhibited leukemia cell growth.	Univ Munster, Dept Med, D-48149 Munster, Germany; MHH Hannover, Dept Pediat Hematol & Oncol, D-30625 Hannover, Germany	University of Munster; Hannover Medical School	Muller-Tidow, C (corresponding author), Univ Munster, Dept Med, Domagkstr 3, D-48149 Munster, Germany.	muellerc@uni-muenster.de	Müller-Tidow, Carsten CMT/B-5257-2014; Müller-Tidow, Carsten/O-7207-2018; Diederichs, Sven/J-6237-2012	Müller-Tidow, Carsten/0000-0002-7166-5232; Diederichs, Sven/0000-0001-7901-4752				Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Diederichs S, 2004, J BIOL CHEM, V279, P33727, DOI 10.1074/jbc.M401708200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Knudson AG, 2002, AM J MED GENET, V111, P96, DOI 10.1002/ajmg.10320; Lania L, 1999, J CELL PHYSIOL, V179, P134, DOI 10.1002/(SICI)1097-4652(199905)179:2<134::AID-JCP3>3.0.CO;2-O; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sweeney C, 1996, DEVELOPMENT, V122, P53; van der Meer T, 2004, REPRODUCTION, V127, P503, DOI 10.1530/rep.1.00131; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yang R, 1999, MOL CELL BIOL, V19, P2400; Yang R, 1997, CANCER RES, V57, P913; Yang R, 1999, BLOOD, V93, P2067	22	69	74	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2739	2744		10.1038/sj.onc.1208356	http://dx.doi.org/10.1038/sj.onc.1208356			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829981				2022-12-25	WOS:000228356700016
J	Zeini, M; Hortelano, S; Traves, PG; Gomez-Valdes, AG; Pujol, A; Perales, JC; Bartrons, R; Bosca, L				Zeini, M; Hortelano, S; Traves, PG; Gomez-Valdes, AG; Pujol, A; Perales, JC; Bartrons, R; Bosca, L			Assessment of a dual regulatory role for NO in liver regeneration after partial hepatectomy: protection against apoptosis and retardation of hepatocyte proliferation	FASEB JOURNAL			English	Article						nitric oxide synthase; transgenic; gene therapy	NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; RAPID ACTIVATION; INJURY; MICE; INTERLEUKIN-6; CYTOKINE; ANIMALS; ENZYMES; GROWTH	The role of hepatic nitric oxide (NO) in liver regeneration after partial hepatectomy (PH) was studied in animals carrying a nitric oxide synthase-2 transgene under the control of the phospho(enol)pyruvate carboxykinase promoter. These mice expressed NOS-2 in liver cells under fasting conditions. Liver mass recovery and molecular parameters related to cell proliferation were determined after PH. Preexisting hepatic NO synthesis, as well as NO delivery by NO-donors, impaired early signaling (for example, attenuated NF-kappa B activation and TNF-alpha. and IL-6 release). The regenerative process was also impaired as a result of an insufficient proliferative response, but mouse survival after surgery was not compromised. However, NO exerted a protective role against apoptosis in transgenic hepatectomized mice. Local production of NO in liver cells, achieved by hydrodynamic-based transfection with a NOS-2-encoding plasmid, also resulted in delayed liver recovery after PH and also protected against Fas-mediated apoptosis. These data show that sustained presence of NO after PH exerts a dual role: attenuating liver regeneration while efficiently protecting against liver apoptosis.	Univ Complutense, Fac Farm, Inst Bioquim, CSIC,Ctr Mixto, E-28040 Madrid, Spain; Univ Complutense, Fac Farm, Ctr Nacl Invest Cardiovasc, E-28040 Madrid, Spain; Univ Barcelona, Dept Ciencies Fisiol 2, Barcelona, Spain; Univ Autonoma Barcelona, Ctr Biotecnol Anim & Terapia Genica, Unidad Anim Transgen, E-08193 Barcelona, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Complutense University of Madrid; University of Barcelona; Autonomous University of Barcelona	Bosca, L (corresponding author), Univ Complutense, Fac Farm, Inst Bioquim, CSIC,Ctr Mixto, E-28040 Madrid, Spain.	lbosca@cnic.es	Hortelano, Sonsoles/A-7954-2010; PERALES, JOSE C. C/D-5586-2012; Pujol, Anna/J-7939-2017; PERALES, JOSE C./AAC-3156-2019; G. Traves, Paqui/L-5693-2014; PERALES, JOSE C/J-7457-2017; Bosca, Lisardo/A-2059-2008	Hortelano, Sonsoles/0000-0003-2528-0072; PERALES, JOSE C. C/0000-0001-7363-2226; Pujol, Anna/0000-0002-3484-598X; PERALES, JOSE C./0000-0001-7363-2226; G. Traves, Paqui/0000-0001-5749-8426; PERALES, JOSE C/0000-0001-7363-2226; Bosca, Lisardo/0000-0002-0253-5469; G. Gomez-Valades, Alicia/0000-0002-4088-1338; Bartrons, Ramon/0000-0001-9349-5847				Blindenbacher A, 2003, HEPATOLOGY, V38, P674, DOI 10.1053/jhep.2003.50378; Bohlinger I, 1995, HEPATOLOGY, V22, P1829, DOI 10.1016/0270-9139(95)90212-0; Clavien PA, 1997, HEPATOLOGY, V25, P1294, DOI 10.1002/hep.510250544; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DINARELLO CA, 1995, CURR BIOL, V5, P587, DOI 10.1016/S0960-9822(95)00116-3; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P2652, DOI 10.1073/pnas.041603898; Higgins GM, 1931, ARCH PATHOL, V12, P186; HORTELANO S, 1995, HEPATOLOGY, V21, P776; Hortelano S, 1999, FASEB J, V13, P2311, DOI 10.1096/fasebj.13.15.2311; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Laszlo F, 1997, EUR J PHARMACOL, V334, P99, DOI 10.1016/S0014-2999(97)01163-1; Leu JI, 2003, MOL CELL BIOL, V23, P1251, DOI 10.1128/MCB.23.4.1251-1259.2003; Leu JI, 2003, J CLIN INVEST, V111, P129, DOI 10.1172/JCI200316712; LI J, 1999, AM J PHYSIOL, V276, P1069; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Mojena M, 2001, FASEB J, V15, P583; Morio LA, 2001, TOXICOL APPL PHARM, V172, P44, DOI 10.1006/taap.2000.9133; Nakamura K, 2004, HEPATOLOGY, V39, P635, DOI 10.1002/hep.20086; Navarro-Lerida I, 2004, J CELL SCI, V117, P1687, DOI 10.1242/jcs.01002; OBOLENSKAYA M, 1994, BIOCHEM BIOPH RES CO, V204, P1305, DOI 10.1006/bbrc.1994.2605; OBOLENSKAYA MY, 1994, BIOCHEM BIOPH RES CO, V202, P571, DOI 10.1006/bbrc.1994.1966; Pinkoski MJ, 2000, AM J PHYSIOL-GASTR L, V278, pG354, DOI 10.1152/ajpgi.2000.278.3.G354; Rai RM, 1996, AM J PHYSIOL-GASTR L, V270, pG909, DOI 10.1152/ajpgi.1996.270.6.G909; Rai RM, 1998, P NATL ACAD SCI USA, V95, P13829, DOI 10.1073/pnas.95.23.13829; Russo MW, 2004, GASTROENTEROLOGY, V126, P1448, DOI 10.1053/j.gastro.2004.01.025; Sakamoto T, 1999, HEPATOLOGY, V29, P403, DOI 10.1002/hep.510290244; Taub R, 2003, J CLIN INVEST, V112, P978, DOI 10.1172/JCI20031200319974; Togo S, 2004, J HEPATOL, V40, P464, DOI 10.1016/j.jhep.2003.11.005; Webber EM, 1998, HEPATOLOGY, V28, P1226, DOI 10.1002/hep.510280509; Wustefeld T, 2000, HEPATOLOGY, V32, P514, DOI 10.1053/jhep.2000.16604; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Zhu W, 2000, FREE RADICAL BIO MED, V29, P870, DOI 10.1016/S0891-5849(00)00396-8	37	24	30	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					995	+		10.1096/fj.04-3233fje	http://dx.doi.org/10.1096/fj.04-3233fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15788446				2022-12-25	WOS:000227901300005
J	Sundararajan, R; Chen, GH; Mukherjee, C; White, E				Sundararajan, R; Chen, GH; Mukherjee, C; White, E			Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling	ONCOGENE			English	Article						apoptosis; TNF-alpha; mitochondria; DBC-1; caspase; proapoptotic	SCAFFOLD ATTACHMENT FACTOR; CYTOCHROME-C; CHROMOSOME 8P; HEPATOCELLULAR-CARCINOMA; MITOCHONDRIAL FUSION; SUPPRESSOR GENES; CELL-DEATH; TNF-ALPHA; KAPPA-B; SAF-A	Deleted in breast cancer-1 (DBC-1) was initially cloned from a homozygously deleted region in breast and other cancers on human chromosome 8p21, although no function is known for the protein product it encodes. We identified the generation of amino-terminally truncated versions of DBC-1 during tumor necrosis factor (TNF)-alpha-mediated apoptosis. Full-length 150 kDa DBC-1 underwent caspase-dependent processing during TNF-alpha-mediated death signaling, to produce p120 DBC-1 and p66 DBC-1 carboxy-terminal fragments. Endogenous DBC-1 localized to the nucleus in healthy cells, but localized to the cytoplasm during TNF-alpha-mediated apoptosis, consistent with the loss of the amino-terminus containing the nuclear localization signal. Overexpression of an amino-terminal truncated DBC-1, resembling p120 DBC-1, caused mitochondrial clustering, mitochondrial matrix condensation, and sensitized cells to TNF-alpha-mediated apoptosis. The carboxy-terminal coiled-coil domain of DBC-1 was responsible for the cytoplasmic and mitochondrial localization, and for the death-promoting activity of DBC-1. Thus, caspase-dependent processing of DBC-1 may act as a feed-forward mechanism to promote apoptosis and possibly also tumor suppression. DBC-1, like its homolog cell cycle and apoptosis regulatory protein-1 (CARP-1), may function in the regulation of apoptosis.	Rutgers State Univ, CABM, Piscataway, NJ 08854 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick	White, E (corresponding author), Rutgers State Univ, CABM, 679 Hoes Lane,Room 140, Piscataway, NJ 08854 USA.	ewhite@cabm.rutgers.edu	White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA53370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053370, R37CA053370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Baffa R, 2000, CLIN CANCER RES, V6, P1372; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chiu R, 2002, J CELL BIOL, V159, P637, DOI 10.1083/jcb.200208013; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; De Vos K, 2000, J CELL BIOL, V149, P1207, DOI 10.1083/jcb.149.6.1207; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; Hamaguchi M, 2002, P NATL ACAD SCI USA, V99, P13647, DOI 10.1073/pnas.212516099; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Kahng YS, 2003, J GASTROEN HEPATOL, V18, P430, DOI 10.1046/j.1440-1746.2003.02997.x; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Kim KW, 2002, J CELL BIOCHEM, V85, P334, DOI 10.1002/jcb.10139; Kipp M, 2000, J BIOL CHEM, V275, P5031, DOI 10.1074/jbc.275.7.5031; Knosel T, 2002, VIRCHOWS ARCH, V440, P187, DOI 10.1007/s004280100493; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kurimoto F, 2001, INT J MOL MED, V8, P89; Lai J, 2003, BRIT J CANCER, V88, P270, DOI 10.1038/sj.bjc.6600674; Lassus H, 2001, LAB INVEST, V81, P517, DOI 10.1038/labinvest.3780260; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Martinez-Climent JA, 2001, BLOOD, V98, P3479, DOI 10.1182/blood.V98.12.3479; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Nachmias B, 2003, CANCER RES, V63, P6340; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z; Rishi AK, 2003, J BIOL CHEM, V278, P33422, DOI 10.1074/jbc.M303173200; Rojo M, 2002, J CELL SCI, V115, P1663; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Santel A, 2001, J CELL SCI, V114, P867; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; Swalwell JI, 2002, GENE CHROMOSOME CANC, V33, P201, DOI 10.1002/gcc.10015; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; Thor AD, 2002, HUM PATHOL, V33, P628, DOI 10.1053/hupa.2002.124034; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; Xu ZH, 2003, BIOCHEM BIOPH RES CO, V311, P1057, DOI 10.1016/j.bbrc.2003.10.109; Zamzami N, 1999, NATURE, V401, P127, DOI 10.1038/43591; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440	57	59	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4908	4920		10.1038/sj.onc.1208681	http://dx.doi.org/10.1038/sj.onc.1208681			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15824730				2022-12-25	WOS:000230646500004
J	Jacquiau, HR; van Waardenburg, RCAM; Reid, RJD; Woo, MH; Guo, H; Johnson, ES; Bjornsti, MA				Jacquiau, HR; van Waardenburg, RCAM; Reid, RJD; Woo, MH; Guo, H; Johnson, ES; Bjornsti, MA			Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOA4 DEUBIQUITINATING ENZYME; ACTIVE-SITE; PROTEIN SUMOYLATION; YEAST; CAMPTOTHECIN; MECHANISM; ISOPEPTIDASE; RESISTANCE; COMPLEX; BINDING	Eukaryotic DNA topoisomerase I (Top1p) has important functions in DNA replication, transcription, and recombination. This enzyme also constitutes the cellular target of camptothecin (CPT), which induces S-phase-dependent cytotoxicity. To define cellular pathways that regulate cell sensitivity to Top1p-induced DNA lesions, we described a yeast genetic screen for conditional tah ( top1T722A-hypersensitive) mutants with enhanced sensitivity to low levels of the CPT mimetic mutant top1T722A (Reid, R. J., Fiorani, P., Sugawara, M., and Bjornsti, M. A. ( 1999) Proc. Natl. Acad. Sci. U. S. A. 96, 11440 - 11445; Fiorani, P., Reid, R. J., Schepis, A., Jacquiau, H. R., Guo, H., Thimmaiah, P., Benedetti, P., and Bjornsti, M. A. (2004) J. Biol. Chem. 279, 21271 - 21281). Here we report that tah mutant ubc9-10 harbors a hypomorphic allele of UBC9, which encodes the essential SUMO ( small ubiquitin-related modifier) E2-conjugating enzyme. The same conditional ubc9P123L mutant was also isolated in an independent screen for enhanced sensitivity to a distinct Top1p poison, Top1N726Hp. The ubc9-10 mutant exhibited a decrease in global protein sumoylation and increased sensitivity to a wide range of DNA-damaging agents independent of Top1p. Deletion of the Ulp2 SUMO protease failed to restore ubc9-10 cell resistance to Top1p poisons or hydroxyurea yet adversely affected wild-type TOP1 cell genetic stability and sensitivity to hydroxyurea. Moreover, although mutation of different consensus SUMO sites in the N terminus and linker region of yeast Top1p failed to recapitulate ubc9-10 mutant phenotypes, they revealed distinct and subtle effects on cell sensitivity to CPT. These results provide insights into the complexities of SUMO conjugation and the confounding effects of SUMO modification on Top1p function and cell sensitivity to genotoxic agents.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	St Jude Children's Research Hospital; Jefferson University	Bjornsti, MA (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale, Memphis, TN 38105 USA.	Mary-Ann.Bjornsti@stjude.org	Reid, Robert/AAR-1560-2020	Reid, Robert/0000-0002-7424-3537	NATIONAL CANCER INSTITUTE [P01CA023099, P30CA021765, R01CA058755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062268] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA23099, CA58755] Funding Source: Medline; NIGMS NIH HHS [GM62268] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; Bastin-Shanower SA, 2003, MOL CELL BIOL, V23, P3487, DOI 10.1128/MCB.23.10.3487-3496.2003; Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bylebyl GR, 2003, J BIOL CHEM, V278, P44113, DOI 10.1074/jbc.M308357200; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Christensen MO, 2004, J BIOL CHEM, V279, P21873, DOI 10.1074/jbc.M400498200; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Colley WC, 2004, J BIOL CHEM, V279, P54069, DOI 10.1074/jbc.M409764200; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Denison C, 2005, MOL CELL PROTEOMICS, V4, P246, DOI 10.1074/mcp.M400154-MCP200; Desai SD, 2001, CANCER RES, V61, P5926; ENG WK, 1988, MOL PHARMACOL, V34, P755; Fertala J, 2000, J BIOL CHEM, V275, P15246, DOI 10.1074/jbc.275.20.15246; Fiorani P, 1999, MOL PHARMACOL, V56, P1105, DOI 10.1124/mol.56.6.1105; Fiorani P, 2004, J BIOL CHEM, V279, P21271, DOI 10.1074/jbc.M312338200; Fiorani P, 2000, ANN NY ACAD SCI, V922, P65; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Haluska P, 1998, ADV ENZYME REGUL, V38, P253, DOI 10.1016/S0065-2571(97)00008-3; Hann CL, 1998, J BIOL CHEM, V273, P31519, DOI 10.1074/jbc.273.47.31519; Harlow E, 1987, ANTIBODIES LAB MANUA; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Horie K, 2002, ONCOGENE, V21, P7913, DOI 10.1038/sj.onc.1205917; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 2003, J CELL BIOL, V160, P1069, DOI 10.1083/jcb.200212052; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Li TK, 2003, CANCER RES, V63, P8400; Lisby M, 2001, J BIOL CHEM, V276, P20220, DOI 10.1074/jbc.M010991200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Mo YY, 2004, CANCER RES, V64, P2793, DOI 10.1158/0008-5472.CAN-03-2410; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Panse VG, 2004, J BIOL CHEM, V279, P41346, DOI 10.1074/jbc.M407950200; Panse VG, 2003, NAT CELL BIOL, V5, P21, DOI 10.1038/ncb893; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Rallabhandi P, 2002, J BIOL CHEM, V277, P40020, DOI 10.1074/jbc.M200388200; Redon C, 2003, EMBO REP, V4, P678, DOI 10.1038/sj.embor.embor871; Reid RJD, 1998, BBA-GENE STRUCT EXPR, V1400, P289, DOI 10.1016/S0167-4781(98)00142-0; Reid RJD, 1999, P NATL ACAD SCI USA, V96, P11440, DOI 10.1073/pnas.96.20.11440; Rodriguez-Galindo C, 2000, MED PEDIATR ONCOL, V35, P385, DOI 10.1002/1096-911X(20001001)35:4<385::AID-MPO1>3.0.CO;2-E; Ruchelman AL, 2002, BIOORG MED CHEM LETT, V12, P3333, DOI 10.1016/S0960-894X(02)00737-0; SIKORSKI RS, 1989, GENETICS, V122, P19; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wohlschlegel JA, 2004, J BIOL CHEM, V279, P45662, DOI 10.1074/jbc.M409203200; Woo MH, 2002, J BIOL CHEM, V277, P3813, DOI 10.1074/jbc.M110484200; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	61	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23566	23575		10.1074/jbc.M500947200	http://dx.doi.org/10.1074/jbc.M500947200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15817450	hybrid			2022-12-25	WOS:000229880000021
J	Morinaga, N; Iwamaru, Y; Yahiro, K; Tagashira, M; Moss, J; Noda, M				Morinaga, N; Iwamaru, Y; Yahiro, K; Tagashira, M; Moss, J; Noda, M			Differential activities of plant polyphenols on the binding and internalization of cholera toxin in vero cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLTRANSFERASE ACTIVITY; INDUCED FLUID ACCUMULATION; ENDOPLASMIC-RETICULUM; ADENYLATE-CYCLASE; MEMBRANE; IDENTIFICATION; GANGLIOSIDES; INHIBITION; ACTIVATION; MECHANISM	Plant polyphenols, RG-tannin, and applephenon had been reported to inhibit cholera toxin (CT) ADP-ribosyltransferase activity and CT-induced fluid accumulation in mouse ileal loops. A high molecular weight fraction of hop bract extract (HBT) also inhibited CT ADP-ribosyltransferase activity. We report here the effect of those polyphenols on the binding and entry of CT into Vero cells. Binding of CT to Vero cells or to ganglioside GM1, a CT receptor, was inhibited in a concentration-dependent manner by HBT and applephenon but not RG-tannin. These observations were confirmed by fluorescence microscopy using Cy3-labeled CT. Following toxin binding to cells, applephenon, HBT, and RG-tannin suppressed its internalization. HBT or applephenon precipitated CT, CTA, and CTB from solution, creating aggregates larger than 250 kDa. In contrast, RG-tannin precipitated CT poorly; it formed complexes with CT, CTA, or CTB, which were demonstrated with sucrose density gradient centrifugation and molecular weight exclusion filters. In agreement, CTA blocked the inhibition of CT internalization by RG-tannin. These data suggest that some plant polyphenols, similar to applephenon and HBT, bind CT, forming large aggregates in solution or, perhaps, on the cell surface and thereby suppress CT binding and internalization. In contrast, RG-tannin binding to CT did not interfere with its binding to Vero cells or GM1, but it did inhibit internalization.	Chiba Univ, Grad Sch Med, Dept Mol Infectiol, Chuo Ku, Chiba 2608670, Japan; Asahi Brewery Co Ltd, Fundamental Res Labs, Moriya, Ibaraki 3020106, Japan; NHLBI, NIH, Pulm Crit Care Med Branch, Bethesda, MD 20892 USA	Chiba University; Asahi Group Holdings Ltd.; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Morinaga, N (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Infectiol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	nmorinaga@faculty.chiba-u.jp		Yahiro, Kinnosuke/0000-0002-9813-0780	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; Charlton AJ, 2002, J AGR FOOD CHEM, V50, P1593, DOI 10.1021/jf010897z; CUATRECASAS P, 1973, BIOCHEMISTRY-US, V12, P3558, DOI 10.1021/bi00742a032; FIELD M, 1972, J CLIN INVEST, V51, P796, DOI 10.1172/JCI106874; Fujinaga Y, 2003, MOL BIOL CELL, V14, P4783, DOI 10.1091/mbc.E03-06-0354; GILL DM, 1978, P NATL ACAD SCI USA, V75, P3050, DOI 10.1073/pnas.75.7.3050; Haslam E, 1996, J NAT PROD, V59, P205, DOI 10.1021/np960040+; HOLMGREN J, 1975, P NATL ACAD SCI USA, V72, P2520, DOI 10.1073/pnas.72.7.2520; Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOSS J, 1977, J BIOL CHEM, V252, P2455; Oi H, 2002, P NATL ACAD SCI USA, V99, P3042, DOI 10.1073/pnas.052709499; Saito T, 2002, MICROBIOL IMMUNOL, V46, P249, DOI 10.1111/j.1348-0421.2002.tb02693.x; Schmitz A, 2000, J CELL BIOL, V148, P1203, DOI 10.1083/jcb.148.6.1203; TAGASHIRA M, 2003, US JAP CHOL OTH BACT, P45; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Teter K, 2002, INFECT IMMUN, V70, P6166, DOI 10.1128/IAI.70.11.6166-6171.2002; Torgersen ML, 2001, J CELL SCI, V114, P3737; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917; Yanagida A, 2000, J CHROMATOGR A, V890, P251, DOI 10.1016/S0021-9673(00)00614-2	24	52	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23303	23309		10.1074/JBC.M502093200	http://dx.doi.org/10.1074/JBC.M502093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15814610	hybrid			2022-12-25	WOS:000229741800089
J	Tatematsu, K; Yoshimoto, N; Koyanagi, T; Tokunaga, C; Tachibana, T; Yoneda, Y; Yoshida, M; Okajima, T; Tanizawa, K; Kuroda, S				Tatematsu, K; Yoshimoto, N; Koyanagi, T; Tokunaga, C; Tachibana, T; Yoneda, Y; Yoshida, M; Okajima, T; Tanizawa, K; Kuroda, S			Nuclear-cytoplasmic shuttling of a RING-IBR protein RBCK1 and its functional interaction with nuclear body proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOIMMUNE REGULATOR PROTEIN; CREB BINDING-PROTEIN; FINGER PROTEIN; SUBCELLULAR-LOCALIZATION; TRANSACTIVATION DOMAIN; EXPORT; PML; TRANSCRIPTION; SEQUENCE; BODIES	The intracellular localization of a RING-IBR protein, RBCK1, possessing DNA binding and transcriptional activities, has been investigated. The endogenous RBCK1 was found in both the cytoplasm and nucleus. Particularly in the nucleus, it was localized in the granular structures, most likely nuclear bodies. In contrast, the over-expressed RBCK1 was detected exclusively in the cytoplasm. When the cells were treated with leptomycin B, the over-expressed RBCK1 accumulated in the nuclear bodies. These results suggest that RBCK1 possesses the signal sequences responsible for the nuclear-cytoplasmic translocation. Mutational analysis of RBCK1 has indicated that an N-terminal region containing Leu-142 and Leu-145 and a C-terminal one containing the RING-IBR domain serve as the nuclear export and localization signals, respectively. Thus, RBCK1 is a transcription factor dynamically shuttling between cytoplasm and nucleus. Furthermore, RBCK1 was found to interact with nuclear body proteins, CREB-binding protein (CBP), and promyelocytic leukemia protein (PML). Coexpression of RBCK1 with CBP significantly enhanced the transcriptional activity of RBCK1. Although PML per se showed no effect on the transcriptional activity of RBCK1, the CBP-enhanced activity was repressed by coexpression with PML, presumably through the interaction of PML and CBP. Taken together, our data demonstrate that RBCK1 is involved in transcriptional machinery in the nuclear bodies, and its transcriptional activity is regulated by nucleocytoplasmic shuttling.	Osaka Univ, Inst Sci & Ind Res, Dept Struct Mol Biol, Ibaraki, Osaka 5670047, Japan; Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan; Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; RIKEN, Chem Genet Lab, Wako, Saitama 3510198, Japan	Osaka University; Kobe University; Osaka University; RIKEN	Tatematsu, K (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Struct Mol Biol, 8-1 Mihogaoka, Ibaraki, Osaka 5670047, Japan.	kenji44@sanken.osaka-u.ac.jp	Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674; Okajima, Toshihide/0000-0003-1733-9580				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Akiyoshi H, 2004, J BIOL CHEM, V279, P33984, DOI 10.1074/jbc.M400702200; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Asamitsu K, 2003, J BIOL CHEM, V278, P26879, DOI 10.1074/jbc.M211831200; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Chan HM, 2001, J CELL SCI, V114, P2363; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chu D, 2001, J BIOL CHEM, V276, P14004, DOI 10.1074/jbc.M010262200; Cong YS, 1997, J BIOL CHEM, V272, P16482, DOI 10.1074/jbc.272.26.16482; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kiesslich A, 2002, J STRUCT BIOL, V140, P167, DOI 10.1016/S1047-8477(02)00571-3; Kumar PG, 2001, J BIOL CHEM, V276, P41357, DOI 10.1074/jbc.M104898200; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Marin I, 2002, MOL BIOL EVOL, V19, P2039, DOI 10.1093/oxfordjournals.molbev.a004029; Martinez-Noel G, 1999, FEBS LETT, V454, P257, DOI 10.1016/S0014-5793(99)00823-6; Maul GG, 1998, CELL GROWTH DIFFER, V9, P743; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; MINATO N, 2003, NAT CELL BIOL, V5, P336; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Ostendorff HP, 2002, NATURE, V416, P99, DOI 10.1038/416099a; Palmeri D, 1996, J VIROL, V70, P6442, DOI 10.1128/JVI.70.9.6442-6445.1996; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pitkanen J, 2001, J BIOL CHEM, V276, P19597, DOI 10.1074/jbc.M008322200; Pitkanen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Tatematsu K, 1998, BIOCHEM BIOPH RES CO, V247, P392, DOI 10.1006/bbrc.1998.8795; Thomas D, 2000, CURR BIOL, V10, pR341, DOI 10.1016/S0960-9822(00)00462-0; Tokunaga C, 1998, BIOCHEM BIOPH RES CO, V244, P353, DOI 10.1006/bbrc.1998.8270; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	61	20	20	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22937	22944		10.1074/jbc.M413476200	http://dx.doi.org/10.1074/jbc.M413476200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15833741	hybrid			2022-12-25	WOS:000229741800047
J	Zabeau, L; Defeau, D; Iserentant, H; Vandekerckhove, J; Peelman, F; Tavernier, J				Zabeau, L; Defeau, D; Iserentant, H; Vandekerckhove, J; Peelman, F; Tavernier, J			Leptin receptor activation depends on critical cysteine residues in its fibronectin type III subdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; ERYTHROPOIETIN RECEPTOR; EXTRACELLULAR DOMAIN; BINDING-SITES; BETA-CHAIN; IDENTIFICATION; EXPRESSION; WEIGHT; OBESE; GENE	The leptin receptor (LR) complex is composed of a single subunit belonging to the class I cytokine receptor family and exists as a preformed complex. The extracellular portion contains two cytokine receptor homology (CRH) domains, separated by an Ig-like domain and followed by two membrane-proximal fibronectin type III (FNIII) domains. The mechanisms underlying ligand-induced receptor activation are still poorly understood. LRs can exist as disulfide-linked dimers at the cell surface, even in the absence of leptin. We evaluated the role of the two unpaired cysteine residues (Cys-672 and Cys-751) in the FNIII domains in receptor clustering, leptin binding, and biological activity. Although mutation of cysteine on position 751 to serine has hardly any effect on ligand binding and receptor activation, the C672S mutant exhibits a marked reduction in STAT3-dependent signaling. The double mutant was completely devoid of biological activity, although leptin binding remained unaffected. Mutation of both residues resulted in complete loss of disulfide bridge formation of FNIII domains in solution. In contrast, no difference was observed in ligand-independent oligomerization of the membrane-bound receptor, suggesting a role for cysteines in the CRH2 domain in formation of the preformed LR complex. We propose a model wherein leptin-induced clustering of two preformed dimers forms the activated LR complex. Disulfide bridge formation involving Cys-672 and Cys-751 may be necessary for JAK activation and hence signaling.	State Univ Ghent VIB, Fac Med & Hlth Sci, Dept Med Prot Res, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University	Tavernier, J (corresponding author), State Univ Ghent VIB, Fac Med & Hlth Sci, Dept Med Prot Res, A Baertsoenkaai 3, B-9000 Ghent, Belgium.	Jan.Tavernier@UGent.be	Tavernier, Jan/AAG-3636-2019					Baile CA, 2000, ANNU REV NUTR, V20, P105, DOI 10.1146/annurev.nutr.20.1.105; Belouzard S, 2004, J BIOL CHEM, V279, P28499, DOI 10.1074/jbc.M400508200; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Broekaert D, 2002, EUR CYTOKINE NETW, V13, P78; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Carr PD, 2001, CELL, V104, P291, DOI 10.1016/S0092-8674(01)00213-6; Chehab FF, 2002, NUTR REV, V60, pS39, DOI 10.1301/002966402320634823; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; Couturier C, 2003, J BIOL CHEM, V278, P26604, DOI 10.1074/jbc.M302002200; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; Fantuzzi G, 2000, J LEUKOCYTE BIOL, V68, P437; Fong TM, 1998, MOL PHARMACOL, V53, P234, DOI 10.1124/mol.53.2.234; Frank SJ, 2002, ENDOCRINOLOGY, V143, P2, DOI 10.1210/en.143.1.2; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Haniu M, 1998, J BIOL CHEM, V273, P28691, DOI 10.1074/jbc.273.44.28691; Krause CD, 2002, MOL CELL PROTEOMICS, V1, P805, DOI 10.1074/mcp.M200065-MCP200; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Matarese G, 2002, TRENDS IMMUNOL, V23, P182, DOI 10.1016/S1471-4906(02)02188-9; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Peelman F, 2004, J BIOL CHEM, V279, P41038, DOI 10.1074/jbc.M404962200; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pflanz S, 2001, BIOCHEM J, V356, P605, DOI 10.1042/0264-6021:3560605; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Sandowski Y, 2002, J BIOL CHEM, V277, P46304, DOI 10.1074/jbc.M207556200; Schuster B, 2003, FEBS LETT, V538, P113, DOI 10.1016/S0014-5793(03)00154-6; Stomski FC, 1998, J BIOL CHEM, V273, P1192, DOI 10.1074/jbc.273.2.1192; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; White DW, 1999, J CELL BIOCHEM, V73, P278, DOI 10.1002/(SICI)1097-4644(19990501)73:2<278::AID-JCB13>3.0.CO;2-W; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; Zabeau L, 2004, MOL ENDOCRINOL, V18, P150, DOI 10.1210/me.2003-0078	37	41	43	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22632	22640		10.1074/jbc.M413308200	http://dx.doi.org/10.1074/jbc.M413308200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15840566	hybrid			2022-12-25	WOS:000229741800012
J	Chubykin, AA; Liu, XR; Comoletti, D; Tsigelny, I; Taylor, P; Sudhof, TC				Chubykin, AA; Liu, XR; Comoletti, D; Tsigelny, I; Taylor, P; Sudhof, TC			Dissection of synapse induction by neuroligins - Effect of a neuroligin mutation associated with autism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LATROTOXIN RECEPTORS; CELL-SURFACE PROTEINS; NEUREXIN I-ALPHA; EXCITATORY SYNAPSES; ADHESION MOLECULES; QUALITY-CONTROL; BETA-NEUREXINS; F-ACTIN; BINDING; GENES	To study synapse formation by neuroligins, we cocultured hippocampal neurons with COS cells expressing wild type and mutant neuroligins. The large size of COS cells makes it possible to test the effect of neuroligins presented over an extended surface area. We found that a uniform lawn of wild type neuroligins displayed on the cell surface triggers the formation of hundreds of uniformly sized, individual synaptic contacts that are labeled with neurexin antibodies. Electron microscopy revealed that these artificial synapses contain a presynaptic active zone with docked vesicles and often feature a postsynaptic density. Neuroligins 1, 2, and 3 were active in this assay. Mutations in two surface loops of neuroligin 1 abolished neuroligin binding to neurexin 1 beta, a presumptive presynaptic binding partner for postsynaptic neuroligins, and blocked synapse formation. An analysis of mutant neuroligins with an amino acid substitution that corresponds to a mutation described in patients with an autistic syndrome confirmed previous reports that these mutant neuroligins have a compromised capacity to be transported to the cell surface. Nevertheless, the small percentage of mutant neuroligins that reached the cell surface still induced synapse formation. Viewed together, our data suggest that neuroligins generally promote artificial synapse formation in a manner that is associated with beta-neurexin binding and results in morphologically well differentiated synapses and that a neuroligin mutation found in autism spectrum disorders impairs cell-surface transport but does not completely abolish synapse formation activity.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Diego	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, NA4-118,6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Thomas.Sudhof@UTSouthwestern.edu		Chubykin, Alexander/0000-0001-8224-9296	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH052804] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM 18360-29] Funding Source: Medline; NIMH NIH HHS [R37 MH 52804-08] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Biederer T, 2001, J BIOL CHEM, V276, P47869, DOI 10.1074/jbc.M105287200; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Bolliger MF, 2001, BIOCHEM J, V356, P581, DOI 10.1042/0264-6021:3560581; Cantallops I, 2000, CURR BIOL, V10, pR620, DOI 10.1016/S0960-9822(00)00663-1; Chih B, 2005, SCIENCE, V307, P1324, DOI 10.1126/science.1107470; Comoletti D, 2003, J BIOL CHEM, V278, P50497, DOI 10.1074/jbc.M306803200; Comoletti D, 2004, J NEUROSCI, V24, P4889, DOI 10.1523/JNEUROSCI.0468-04.2004; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; Eaton BA, 2002, NEURON, V34, P729, DOI 10.1016/S0896-6273(02)00721-3; Fu ZY, 2003, J NEUROPHYSIOL, V90, P3950, DOI 10.1152/jn.00647.2003; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; Gilbert M, 2001, GLIA, V34, P151, DOI 10.1002/glia.1050; Goda Y, 2003, NEURON, V40, P243, DOI 10.1016/S0896-6273(03)00608-1; Goslin K., 1998, CULTURING NERVE CELL, P339; Helenius A, 2001, PHILOS T ROY SOC B, V356, P147, DOI 10.1098/rstb.2000.0759; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; Laumonnier F, 2004, AM J HUM GENET, V74, P552, DOI 10.1086/382137; Marchot P, 1996, PROTEIN SCI, V5, P672; Missler M, 2003, NATURE, V423, P939, DOI 10.1038/nature01755; Morales M, 2000, NEURON, V27, P539, DOI 10.1016/S0896-6273(00)00064-7; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Rao A, 2000, NAT NEUROSCI, V3, P747, DOI 10.1038/77636; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Rowen L, 2002, GENOMICS, V79, P587, DOI 10.1006/geno.2002.6734; Sara Y, 2005, J NEUROSCI, V25, P260, DOI 10.1523/JNEUROSCI.3165-04.2005; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Sudhof TC, 2001, ANNU REV NEUROSCI, V24, P933, DOI 10.1146/annurev.neuro.24.1.933; Sugita S, 1999, NEURON, V22, P489, DOI 10.1016/S0896-6273(00)80704-7; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Tabuchi K, 2002, GENOMICS, V79, P849, DOI 10.1006/geno.2002.6780; Tobaben S, 2002, J BIOL CHEM, V277, P6359, DOI 10.1074/jbc.M111231200; Tsigelny I, 2000, PROTEIN SCI, V9, P180; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; Yamagata M, 2003, CURR OPIN CELL BIOL, V15, P621, DOI 10.1016/S0955-0674(03)00107-8; Zhang WD, 2001, J NEUROSCI, V21, P5169, DOI 10.1523/JNEUROSCI.21-14-05169.2001; Zoghbi HY, 2003, SCIENCE, V302, P826, DOI 10.1126/science.1089071	43	143	147	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22365	22374		10.1074/jbc.M410723200	http://dx.doi.org/10.1074/jbc.M410723200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15797875	hybrid			2022-12-25	WOS:000229557900082
J	Lyu, J; Joo, CK				Lyu, J; Joo, CK			Wnt-7a up-regulates matrix metalloproteinase-12 expression and promotes cell proliferation in corneal epithelial cells during wound healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; VERTEBRATE GASTRULATION; SIGNALING PATHWAY; ACTIVATION; KINASE; GENE; RHO; DIFFERENTIATION; METALLOELASTASE; MECHANISMS	Corneal wound repair involves the rapid coverage of a denuded area by residual epithelial cells. During wound healing, there are different cell behaviors in different regions of the epithelium: cell proliferation in the peripheral epithelium and cell migration in the central epithelium. We found that Wnt-7a was rapidly induced in the wounded cornea, promoted the proliferation of corneal epithelial cells, and enhanced wound closure. Matrix metalloproteinase-12 (MMP-12) was detected in the peripheral epithelium, where cell proliferation was enhanced, but was diminished in the migrating central epithelium. Wnt-7a induced the accumulation of b-catenin and the activation of Rac and b-catenin, and Rac synergistically induced the transcription of MMP-12. Blocking the function of MMP-12 delayed wound closure induced by Wnt-7a. Our results also suggest that, in addition to the b-catenin pathway, Wnt-7a might induce a b-catenin-independent pathway. By regulating the proliferation of corneal epithelial cells, Wnt-7a and MMP-12 appear to contribute to corneal wound healing.	Catholic Univ Korea, Coll Med, Dept Ophthalmol & Visual Sci, Seoul 137040, South Korea	Catholic University of Korea	Joo, CK (corresponding author), Catholic Univ Korea, Coll Med, Dept Ophthalmol & Visual Sci, 505 Banpo Dong, Seoul 137040, South Korea.	ckjoo@catholic.ac.kr						Block ER, 2004, J BIOL CHEM, V279, P24307, DOI 10.1074/jbc.M401058200; Bonniaud P, 2004, J IMMUNOL, V173, P2099, DOI 10.4049/jimmunol.173.3.2099; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Daniels JT, 2003, EXP EYE RES, V77, P653, DOI 10.1016/j.exer.2003.08.010; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200; Jormsjo S, 2000, CIRC RES, V86, P998, DOI 10.1161/01.RES.86.9.998; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Kilian B, 2003, MECH DEVELOP, V120, P467, DOI 10.1016/S0925-4773(03)00004-2; Kishida S, 2004, MOL CELL BIOL, V24, P4487, DOI 10.1128/MCB.24.10.4487-4501.2004; KRUSE FE, 1994, INVEST OPHTH VIS SCI, V35, P2405; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Larsen PH, 2004, J NEUROSCI, V24, P7597, DOI 10.1523/JNEUROSCI.2092-04.2004; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Nawrocki-Raby B, 2003, AM J PATHOL, V163, P653, DOI 10.1016/S0002-9440(10)63692-9; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Poon R, 2001, ONCOGENE, V20, P451, DOI 10.1038/sj.onc.1204107; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Viti J, 2003, J NEUROSCI, V23, P5919; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Watanabe H, 2004, J BIOL CHEM, V279, P1676, DOI 10.1074/jbc.M303650200; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu LH, 2003, GENES CELLS, V8, P225, DOI 10.1046/j.1365-2443.2003.00628.x; Xu KP, 2004, INVEST OPHTH VIS SCI, V45, P813, DOI 10.1167/iovs.03-0851; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Ye HQQ, 2000, INVEST OPHTH VIS SCI, V41, P2894; Zieske JD, 2000, PROG RETIN EYE RES, V19, P257, DOI 10.1016/S1350-9462(99)00018-X	40	61	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21653	21660		10.1074/jbc.m500374200	http://dx.doi.org/10.1074/jbc.m500374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802269	hybrid			2022-12-25	WOS:000229438800091
J	Sengupta, P; Xu, Y; Wang, L; Widom, R; Smith, BD				Sengupta, P; Xu, Y; Wang, L; Widom, R; Smith, BD			Collagen alpha 1(I) gene (COL1A1) is repressed by RFX family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II TRANSACTIVATOR; BARE LYMPHOCYTE SYNDROME; DNA-BINDING PROTEIN; CHICK-EMBRYO FIBROBLASTS; ALPHA-2(I) COLLAGEN GENE; MESSENGER-RNA LEVELS; REGULATORY FACTOR-X; CANCER-CELL-LINES; INTERFERON-GAMMA; IN-VITRO	Collagen type I is composed of three polypeptide chains transcribed from two separate genes (COL1A1 and COL1A2) with different promoters requiring coordinate regulation. Our recent publications, centering on COL1A2 regulation, demonstrate that methylation in the first exon of COL1A2 at a regulatory factor for X box (RFX) site (at -1 to +20) occurs in human cancer cells and correlates with increased RFX1 binding and decreased collagen transcription (Sengupta, P. K., Erhlich, M., and Smith, B. D. ( 1999) J. Biol. Chem. 274, 36649 36655; Sengupta, S., Smith, E. M., Kim, K., Murnane, M. J., and Smith, B. D. ( 2003) Cancer Res. 63, 1789 - 1797). In normal cells, RFX5 complex along with major histocompatibility class II transactivator ( CIITA) is induced by interferon-gamma to occupy this site and repress collagen transcription (Xu, Y., Wang, L., Buttice, G., Sengupta, P. K., and Smith, B. D. ( 2004) J. Biol. Chem. 279, 41319 41332). In this paper, we demonstrate that COL1A1 has an RFX consensus binding site surrounding the transcription start site (- 11 to +10) that contains three methylation sites rather than one in the COL1A2 gene RFX binding site. RFX1 interacts weakly with the unmethylated COL1A1 site, and binds with higher affinity to the methylated site. RFX1 represses the unmethylated COL1A1 less efficiently than COL1A2. COL1A1 promoter activity is sensitive to DNA methylation and the COL1A1 gene is methylated in human cancer cells with coordinately decreased collagen expression. The DNA methylation inhibitor, 5- aza-2'-deoxycytidine (aza- dC) increases collagen gene expression with time in human cancer cells. On the other hand, RFX5 interacts with both collagen type I genes with a similar binding affinity and represses both promoters equally in transient transfections. Two dominant negative forms of RFX5 activate both collagen genes coordinately. Finally, CIITA RNA interference experiments indicate that CIITA induction is required for interferon gamma-mediated repression of both collagen type I genes.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Ctr Arthritis, Boston, MA 02118 USA; Vet Affairs Boston Healthcare Syst, Boston, MA 02118 USA	Boston University; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Sengupta, P (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	smith@biochem.bumc.bu.edu		Smith, Barbara/0000-0002-5375-7627	NHLBI NIH HHS [R01 HL068094, P01 HL013262] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, R01HL068094] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; BARKER DD, 1991, MOL CELL BIOL, V11, P5154, DOI 10.1128/MCB.11.10.5154; CHAN H, 1991, MOL CELL BIOL, V11, P47, DOI 10.1128/MCB.11.1.47; Chen M, 2002, NAT GENET, V32, P670, DOI 10.1038/ng1041; Chen M, 2003, CLIN EXP DERMATOL, V28, P193, DOI 10.1046/j.1365-2230.2003.01191.x; DeSandro AM, 2000, MOL CELL BIOL, V20, P6587, DOI 10.1128/MCB.20.17.6587-6599.2000; Di Natale P, 2002, EUR J BIOCHEM, V269, P2764, DOI 10.1046/j.1432-1033.2002.02951.x; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Dishart KL, 2003, J MOL CELL CARDIOL, V35, P739, DOI 10.1016/S0022-2828(03)00136-6; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; El-Osta A, 2004, CANCER BIOL THER, V3, P816, DOI 10.4161/cbt.3.9.1100; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; Esteller M, 2003, ADV EXP MED BIOL, V532, P39; Gerolami R, 2000, CANCER GENE THER, V7, P1286, DOI 10.1038/sj.cgt.7700225; Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529; Gourley T, 1999, IMMUNITY, V10, P377, DOI 10.1016/S1074-7613(00)80037-0; Gourley TS, 2001, J IMMUNOL, V166, P2917, DOI 10.4049/jimmunol.166.5.2917; Gouze E, 2003, MOL THER, V7, P460, DOI 10.1016/S1525-0016(03)00024-8; GUENETTE DK, 1992, BIOCHEM J, V283, P699, DOI 10.1042/bj2830699; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; HARTUNG S, 1986, NATURE, V320, P365, DOI 10.1038/320365a0; Hirtenlehner K, 2002, EUR CYTOKINE NETW, V13, P234; HUANG LH, 1984, NATURE, V308, P293, DOI 10.1038/308293a0; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jorgensen HF, 2002, MENT RETARD DEV D R, V8, P87, DOI 10.1002/mrdd.10021; Katan-Khaykovich Y, 1998, J BIOL CHEM, V273, P24504, DOI 10.1074/jbc.273.38.24504; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Moreno CS, 1997, J IMMUNOL, V158, P5841; Nagarajan UM, 2002, J IMMUNOL, V169, P5078, DOI 10.4049/jimmunol.169.9.5078; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nekrep N, 2000, MOL CELL BIOL, V20, P4455, DOI 10.1128/MCB.20.12.4455-4461.2000; Ravot E, 2002, J GENE MED, V4, P161, DOI 10.1002/jgm.256; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; RHODES K, 1994, MOL CELL BIOL, V14, P5950, DOI 10.1128/MCB.14.9.5950; Rhodes Katherine, 1992, Gene Expression, V2, P59; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; SANDMEYER S, 1981, CANCER RES, V41, P830; Santos AN, 1997, IMMUNOL LETT, V58, P53, DOI 10.1016/S0165-2478(97)02712-0; Sengupta PK, 2003, CANCER RES, V63, P1789; Sengupta PK, 2002, J BIOL CHEM, V277, P24926, DOI 10.1074/jbc.M111712200; Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; SILACCI P, 1994, J EXP MED, V180, P1329, DOI 10.1084/jem.180.4.1329; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; SMITH BD, 1990, ANN NY ACAD SCI, V580, P459, DOI 10.1111/j.1749-6632.1990.tb17960.x; SMITH BD, 1980, BIOCHEMISTRY-US, V19, P1820, DOI 10.1021/bi00550a014; SMITH BD, 1988, BIOCHEM J, V253, P269, DOI 10.1042/bj2530269; Stathopulos PB, 2003, BIOTECHNOL ADV, V21, P513, DOI 10.1016/S0734-9750(03)00102-2; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Takatsu M, 1999, MECH AGEING DEV, V110, P37, DOI 10.1016/S0047-6374(99)00041-X; Taxman DJ, 2000, J IMMUNOL, V165, P1410, DOI 10.4049/jimmunol.165.3.1410; THOMPSON JP, 1991, J BIOL CHEM, V266, P2549; Villani GRD, 2002, BIOCHEM J, V364, P747, DOI 10.1042/BJ20011872; Villard J, 2001, MEDICINE, V80, P405, DOI 10.1097/00005792-200111000-00006; Westerheide SD, 1997, J IMMUNOL, V158, P4812; Widom RL, 2001, MATRIX BIOL, V20, P451, DOI 10.1016/S0945-053X(01)00167-6; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Xu Y, 2004, J BIOL CHEM, V279, P41319, DOI 10.1074/jbc.M404174200; Xu Y, 2003, J BIOL CHEM, V278, P49134, DOI 10.1074/jbc.M309003200; Yamane K, 2005, J CELL PHYSIOL, V202, P822, DOI 10.1002/jcp.20205; Yee CSK, 2004, J IMMUNOL, V172, P5528, DOI 10.4049/jimmunol.172.9.5528; Yuan WH, 1999, J CELL PHYSIOL, V179, P97, DOI 10.1002/(SICI)1097-4652(199904)179:1<97::AID-JCP12>3.3.CO;2-5; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253; Zhu XS, 2001, MOL CELL BIOL, V21, P7078, DOI 10.1128/MCB.21.20.7078-7088.2001	69	52	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21004	21014		10.1074/jbc.M413191200	http://dx.doi.org/10.1074/jbc.M413191200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15788405	hybrid, Green Accepted			2022-12-25	WOS:000229438800014
J	Thomas, M; Yu, ZG; Dadgar, N; Varambally, S; Yu, JJ; Chinnaiyan, AM; Lieberman, AP				Thomas, M; Yu, ZG; Dadgar, N; Varambally, S; Yu, JJ; Chinnaiyan, AM; Lieberman, AP			The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MOUSE MODEL; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; ER STRESS; TRANSLATIONAL CONTROL; ATF6; DEGRADATION; IRE1; EXPRESSION; SITE	Kennedy disease, a degenerative disorder caused by an expanded glutamine tract, is mediated by misfolding of the mutant androgen receptor (AR) protein, a process that may disrupt proteasome function. We hypothesized that this might lead to endoplasmic reticulum ( ER) stress and induction of the unfolded protein response (UPR), a complex physiologic pathway that regulates cell survival. To test this hypothesis, we used amino-terminal fragments of wild type (AR16Q) or mutant (AR112Q) AR that triggered glutamine length-dependent cell death and activated an ER stress-inducible promoter. To evaluate the role of the UPR, we examined the contributions of three proximal sensors of ER stress: activating transcription factor 6 (ATF6), inositol requiring 1 (IRE1), and PKR-like endoplasmic reticulum kinase ( PERK). AR112Q toxicity was significantly increased by a dominant negative ATF6 mutant and significantly decreased by a constitutively active ATF6 mutant, indicating that ATF6 promoted cell survival. In contrast, co-transfection with three separate IRE1 alpha dominant negative mutants failed to alter glutamine length-dependent toxicity, suggesting that this arm of the UPR did not significantly affect AR112Q induced cell death. Activation of PERK, an ER transmembrane protein that functions as the third proximal UPR sensor, promoted glutamine length-dependent toxicity. Although nuclear localization sequence-and nuclear export sequence-targeted proteins both activated the UPR, this pathway more potently influenced toxicity when proteins were targeted to the cytoplasm. Taken together, our data demonstrate that the UPR is activated in cells expressing long glutamine tracts and that this pathway modulates polyglutamine toxicity.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Lieberman, AP (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine,4233 Med Sci 1, Ann Arbor, MI 48109 USA.	liebermn@umich.edu	Longo, Kenneth A/A-5631-2010; Yu, Zhigang/A-6893-2009	Varambally, Sooryanarayana/0000-0002-2277-1127	NATIONAL INSTITUTE ON AGING [P50AG008671, K08AG024758] Funding Source: NIH RePORTER; NIA NIH HHS [K08 AG024758, P50 AG08671] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adachi H, 2003, J NEUROSCI, V23, P2203; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chevalier-Larsen ES, 2004, J NEUROSCI, V24, P4778, DOI 10.1523/JNEUROSCI.0808-04.2004; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Forman MS, 2003, TRENDS NEUROSCI, V26, P407, DOI 10.1016/S0166-2236(03)00197-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Kanuka H, 2003, P NATL ACAD SCI USA, V100, P11723, DOI 10.1073/pnas.1934748100; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lieberman AP, 2002, HUM MOL GENET, V11, P1967, DOI 10.1093/hmg/11.17.1967; Lieberman AP, 2000, MUSCLE NERVE, V23, P843, DOI 10.1002/(SICI)1097-4598(200006)23:6<843::AID-MUS2>3.0.CO;2-8; McCampbell A, 2001, P NATL ACAD SCI USA, V98, P15179, DOI 10.1073/pnas.261400698; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; McManamny P, 2002, HUM MOL GENET, V11, P2103, DOI 10.1093/hmg/11.18.2103; Merry DE, 1998, HUM MOL GENET, V7, P693, DOI 10.1093/hmg/7.4.693; Miranda E, 2004, J BIOL CHEM, V279, P28283, DOI 10.1074/jbc.M313166200; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Southwood CM, 2002, NEURON, V36, P585, DOI 10.1016/S0896-6273(02)01045-0; Szebenyi G, 2003, NEURON, V40, P41, DOI 10.1016/S0896-6273(03)00569-5; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Thomas M, 2004, J BIOL CHEM, V279, P8389, DOI 10.1074/jbc.M311761200; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang Y, 2000, J BIOL CHEM, V275, P27013; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	47	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21264	21271		10.1074/jbc.M500144200	http://dx.doi.org/10.1074/jbc.M500144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799970	hybrid			2022-12-25	WOS:000229438800045
J	Wang, ZL; Mandell, KJ; Parkos, CA; Mrsny, RJ; Nusrat, A				Wang, ZL; Mandell, KJ; Parkos, CA; Mrsny, RJ; Nusrat, A			The second loop of occludin is required for suppression of Raf1-induced tumor growth	ONCOGENE			English	Article						tight junction; occludin; raf	TIGHT JUNCTION STRUCTURE; EXPRESSION DECREASES; POSSIBLE INVOLVEMENT; EPITHELIAL-CELLS; MEMBRANE-PROTEIN; BARRIER FUNCTION; PERMEABILITY; CANCER; DOMAIN; LOCALIZATION	Tight junctions (TJs) regulate epithelial cell polarity and paracellular permeability. Loss of functional TJs is commonly associated with epithelial cell-derived cancers. Raf1-mediated transformation of rat salivary gland epithelial cells (Pa4-Raf1) induces transcriptional down-regulation of the TJ protein occludin and forced reexpression of occludin rescues polarized phenotype of epithelial cells. In the present study, we used this model to examine how specific structural modi. cations in the occludin protein affect its function in vitro and influence tumor growth in vivo. Our results revealed that neither the C-terminal nor the N-terminal half of occludin alone were sufficient to rescue cells from transformation by Raf1. However, forced expression of an occludin mutant lacking the first extracellular loop was sufficient to rescue cells from Raf1-mediated transformation. Interestingly, forced expression of an occludin mutant lacking the second extracellular loop did not rescue the epithelial phenotype in vitro nor did it prevent tumor growth in vivo. These results demonstrate that the TJ protein occludin has a potent inhibitory effect on the Raf1-mediated tumorigenesis, and the second extracellular loop of occludin appears to be critical for this function.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; Unity Pharmaceut, Los Altos Hills, CA 94022 USA	Emory University	Nusrat, A (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, 615 Michael St,Room 105E, Atlanta, GA 30322 USA.	anusrat@emory.edu	Nusrat, Asma/B-3887-2009; Parkos, Charles a/B-3896-2009		NIDDK NIH HHS [DK61379, DK72564, DK 59888, DK64399] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK072564, R24DK064399, R01DK061379, R01DK059888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Bamforth SD, 1999, J CELL SCI, V112, P1879; Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; deVries JE, 1996, PATHOL RES PRACT, V192, P658, DOI 10.1016/S0344-0338(96)80087-2; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; Hopkins AM, 2003, J CELL SCI, V116, P725, DOI 10.1242/jcs.00300; Kimura Y, 1997, AM J PATHOL, V151, P45; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Lacaz-Vieira F, 1999, J MEMBRANE BIOL, V168, P289, DOI 10.1007/s002329900518; Lan MD, 2004, CARCINOGENESIS, V25, P2385, DOI 10.1093/carcin/bgh248; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Li DX, 1997, J BIOL CHEM, V272, P25062, DOI 10.1074/jbc.272.40.25062; Li DX, 2000, J CELL BIOL, V148, P791, DOI 10.1083/jcb.148.4.791; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Matter K, 1998, J CELL SCI, V111, P511; McCarthy KM, 1996, J CELL SCI, V109, P2287; Medina R, 2000, J MEMBRANE BIOL, V178, P235, DOI 10.1007/s002320010031; Michl P, 2003, CANCER RES, V63, P6265; Mitic LL, 1999, J CELL BIOL, V146, P683, DOI 10.1083/jcb.146.3.683; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Nakamura T, 2000, P NATL ACAD SCI USA, V97, P7284, DOI 10.1073/pnas.97.13.7284; Nottage M, 2002, CURR PHARM DESIGN, V8, P2231, DOI 10.2174/1381612023393107; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Sanders SE, 1995, EPITHELIAL CELL BIOL, V4, P25; Tobioka H, 2004, HUM PATHOL, V35, P159, DOI 10.1016/j.humpath.2003.09.013; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; VanItallie CM, 1997, J CELL SCI, V110, P1113; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399	35	56	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4412	4420		10.1038/sj.onc.1208634	http://dx.doi.org/10.1038/sj.onc.1208634			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806147				2022-12-25	WOS:000229976900010
J	Provost, E; McCabe, A; Stern, J; Lizardi, I; D'Aquila, TG; Rimm, DL				Provost, E; McCabe, A; Stern, J; Lizardi, I; D'Aquila, TG; Rimm, DL			Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin	ONCOGENE			English	Article						adhesion; signaling; wnt; armadillo; ubiquitination; MDCK	PATHWAY; PHOSPHORYLATION; DEGRADATION; PROTEIN; UBIQUITINATION; SIAH-1; P53	beta-catenin is a multifunctional protein involved in both cadherin-mediated adhesion and the wnt signaling cascade. Mutations in exon 3 of beta-catenin have been identified in many cancers. In addition to disruption of key serine and threonine residues, mutations are frequently reported in other residues in exon 3 that are not kinase substrates. The most frequently mutated nonserine/threonine residues are D32 and G34. Since D32 and G34 are part of the ubiquitination destruction motif, DSG phi XS, we hypothesize that this motif may contribute to disruption of beta-catenin homeostasis and lead to cellular transformation. We demonstrate that the mutants D32A and G34A exhibit no change in phosphorylation by GSK3 beta, but display reduced ubiquitination compared to wild- type and S33A mutant beta-catenin. To assess the functional implications of these mutations, we created stable MDCK cell lines expressing these constructs. We found that stable cell lines harboring D32A- mutated beta-catenin were highly transformed, while S33A and G34 demonstrated only weak transforming properties in our assays. Despite altered ubiquitination status and increased transformation, the D32A mutant cell line does not display transcriptional activation of standard target genes. Therefore, D32A mutation may mediate transformation by an alternative beta-catenin-mediated signaling pathway.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Rimm, DL (corresponding author), Yale Univ, Sch Med, Dept Pathol, 333 Cedar St,POB 208023, New Haven, CT 06520 USA.	david.rimm@yale.edu		Rimm, David/0000-0001-5820-4397				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Al-Fageeh M, 2004, ONCOGENE, V23, P4839, DOI 10.1038/sj.onc.1207634; Besnard-Guerin C, 2004, J BIOL CHEM, V279, P788, DOI 10.1074/jbc.M308068200; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hattori K, 1999, J BIOL CHEM, V274, P29641, DOI 10.1074/jbc.274.42.29641; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Provost E, 2003, J BIOL CHEM, V278, P31781, DOI 10.1074/jbc.M304953200; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Zou JX, 2002, J BIOL CHEM, V277, P1824, DOI 10.1074/jbc.M103133200	15	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2667	2676		10.1038/sj.onc.1208346	http://dx.doi.org/10.1038/sj.onc.1208346			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829978				2022-12-25	WOS:000228356700008
J	Bogdanovich, S; Perkins, KJ; Krag, TOB; Whittemore, SA; Khurana, TS				Bogdanovich, S; Perkins, KJ; Krag, TOB; Whittemore, SA; Khurana, TS			Myostatin propeptide-mediated amelioration of dystrophic pathophysiology	FASEB JOURNAL			English	Article						DAM; dystroglycan complex; neuromuscular disease; dystrophin; extracellular matrix	DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE MASS; MDX MOUSE; MICE; GENE; ACTIVATION; EXPRESSION; PROTEIN; ORGANIZATION; HYPERTROPHY	Mutations in myostatin (GDF8) cause marked increases in muscle mass, suggesting that this transforming growth factor-beta (TGF-beta) superfamily member negatively regulates muscle growth. Myostatin blockade therefore offers a strategy for reversing muscle wasting in Duchenne's muscular dystrophy (DMD) without resorting to genetic manipulation. Here, we demonstrate that pharmacological blockade using a myostatin propeptide stabilized by fusion to IgG-Fc improved pathophysiology of the mdx mouse model of DMD. Functional benefits evidenced by specific force improvement, exceeded those reported previously using myostatin antibody-mediated blockade. More importantly, use of a propeptide blockade strategy obviates possibilities of anti-idiotypic responses that could potentially limit the effectiveness of antibody-mediated myostatin blockade strategies over time. This study provides a novel pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD and since it uses an endogenous inhibitor of myostatin should help circumvent technical hurdles and toxicity associated with conventional gene or cell based therapies.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penns Muscle Inst, Philadelphia, PA 19104 USA; Glostrup Cty Hosp, Dept Expt Med, Glostrup, Denmark; Wyeth Res, Cardiovasc & Metab Dis Dept, Cambridge, MA USA	University of Pennsylvania; University of Pennsylvania; University of Copenhagen; Pfizer	Khurana, TS (corresponding author), Univ Penn, Sch Med, Dept Physiol, A-601 Richards Bldg,3700 Hamilton Walk, Philadelphia, PA 19104 USA.	tsk@mail.med.upenn.edu	Krag, Thomas/AAD-3307-2021	Krag, Thomas/0000-0001-9330-668X				Amthor H, 2002, DEV BIOL, V251, P241, DOI 10.1006/dbio.2002.0812; Bachrach E, 2004, P NATL ACAD SCI USA, V101, P3581, DOI 10.1073/pnas.0400373101; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Bogdanovich S, 2004, J MOL MED, V82, P102, DOI 10.1007/s00109-003-0484-1; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P299, DOI 10.1111/j.1365-2990.1988.tb00890.x; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; Hill JJ, 2002, J BIOL CHEM, V277, P40735, DOI 10.1074/jbc.M206379200; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1987, SCIENCE, V238, P347, DOI 10.1126/science.3659917; Kapsa R, 2003, LANCET NEUROL, V2, P299, DOI 10.1016/S1474-4422(03)00382-X; Khurana TS, 2003, NAT REV DRUG DISCOV, V2, P379, DOI 10.1038/nrd1085; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Krag TOB, 2004, P NATL ACAD SCI USA, V101, P13856, DOI 10.1073/pnas.0405972101; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Lynch GS, 2001, NEUROMUSCULAR DISORD, V11, P260, DOI 10.1016/S0960-8966(00)00192-9; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; MUNTONI F, 1993, J NEUROL SCI, V120, P71, DOI 10.1016/0022-510X(93)90027-V; Nishino I, 2002, CURR OPIN NEUROL, V15, P539, DOI 10.1097/00019052-200210000-00004; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Sohn RL, 2004, EXPERT OPIN BIOL TH, V4, P1, DOI 10.1517/14712598.4.1.1; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Szabo G, 1998, MAMM GENOME, V9, P671, DOI 10.1007/s003359900843; Thies RS, 2001, GROWTH FACTORS, V18, P251; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; van Deutekom JCT, 2003, NAT REV GENET, V4, P774, DOI 10.1038/nrg1180; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; Whittemore LA, 2003, BIOCHEM BIOPH RES CO, V300, P965, DOI 10.1016/S0006-291X(02)02953-4; Wolfman NM, 2003, P NATL ACAD SCI USA, V100, P15842, DOI 10.1073/pnas.2534946100; Zammit PS, 2002, NAT MED, V8, P1355, DOI 10.1038/nm1202-1355; Zhu XL, 2000, FEBS LETT, V474, P71, DOI 10.1016/S0014-5793(00)01570-2	45	189	210	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					543	549		10.1096/fj.04-2796com	http://dx.doi.org/10.1096/fj.04-2796com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791004				2022-12-25	WOS:000228865300038
J	Brabant, G; Muller, G; Horn, R; Roden, M; Nave, H				Brabant, G; Muller, G; Horn, R; Roden, M; Nave, H			Hepatic leptin signaling in obesity	FASEB JOURNAL			English	Article						leptin receptor; AMPK; PEPCK	DIET-INDUCED OBESITY; BOUND LEPTIN; FOOD-INTAKE; IN-VIVO; INSULIN; PROTEIN; RECEPTOR; GLUCOSE; RAT; METABOLISM	Obesity, a state of apparent "leptin resistance," is well known to be associated with insulin resistance. In diet-induced obesity (DIO), hepatic insulin signaling is impaired but the link between leptin and insulin signaling pathways is only incompletely defined. The aim of the present study was to evaluate the effects of DIO on leptin and insulin cross-signaling in the liver. Leptin receptor expression was measured by in situ hybridization with pan-leptin receptor probes and by immunoblotting. Furthermore, intracellular signaling was investigated in vivo under basal conditions and at 45 and 360 min after stimulation with a bolus of human recombinant leptin (hrec-leptin; 1 mg/kg body wt) or saline. At baseline, all forms of the leptin receptor were markedly to completely down-regulated in DIO rats. Hrec-leptin bolus injection stimulated leptin-dependent signaling with a fivefold increase in JAK-2pY in lean but not in DIO rats. Basal IRpY, IRS-1pY, IRS-1p85, IRS-2pY, IRSp85, and PKBpT308 levels were reduced (P<0.01) in DIO rats as compared with lean controls. Basal GSK-3 beta serine phosphorylation (S9) was higher (P<0.01) in lean animals along with lower basal PEPCK activity compared with DIO rats consistent with the insulin and leptin resistance of the latter. Only in lean animals phosphorylation of PKB (T308) and GSK-3 beta (S9) was acutely stimulated by leptin at 45 min followed by inhibition at 6 h after application. AMPK alpha. protein levels as well as basal and leptin-stimulated total and alpha-specific AMPK activity were comparable in both groups. These data show that in a model of dietary-induced obesity 1) leptin receptors and subsequent signaling events are down-regulated, 2) basal insulin signaling is impaired, and 3) the cross-talk between leptin and insulin signaling is differentially regulated by the nutritional status, which is sensed by AMPK in rat liver. Thus, the liver seems to play a major role in the modulation of the leptin signal and insulin resistance in obesity.	Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany; Aventis Pharma, Frankfurt, Germany; Hanusch Hosp, Dept Med, Vienna, Austria; Hannover Med Sch, Dept Funct & Appl Anat, D-3000 Hannover, Germany	Hannover Medical School; Sanofi-Aventis; WGKK - Hanusch Hospital; Hannover Medical School	Brabant, G (corresponding author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neubergstr 1, D-30625 Hannover, Germany.	brabant.georg@mh-hannover.de	Roden, Michael/AAD-3843-2019; Kielstein, Heike/GNW-4839-2022; Anderwald, Christian Heinz/AAG-2271-2021	Anderwald, Christian Heinz/0000-0001-7485-0815; Muller, Gunter/0000-0001-6178-8215				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Anderwald C, 2002, MOL ENDOCRINOL, V16, P1612, DOI 10.1210/me.16.7.1612; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Bjorbaek C, 2004, RECENT PROG HORM RES, V59, P305, DOI 10.1210/rp.59.1.305; Brabant G, 2000, DIABETOLOGIA, V43, P438, DOI 10.1007/s001250051326; Brabant G, 2004, EUR J CLIN INVEST, V34, P831, DOI 10.1111/j.1365-2362.2004.01427.x; Bryson JM, 1999, AM J PHYSIOL-ENDOC M, V277, pE417, DOI 10.1152/ajpendo.1999.277.3.E417; Ceddia RB, 2002, FASEB J, V16, DOI 10.1096/fj.02-0158rev; Ceddia RB, 1999, INT J OBESITY, V23, P1207, DOI 10.1038/sj.ijo.0801095; Chan JL, 2002, DIABETES, V51, P2105, DOI 10.2337/diabetes.51.7.2105; Gupta G, 2000, AM J PHYSIOL-ENDOC M, V278, pE985, DOI 10.1152/ajpendo.2000.278.6.E985; Hidaka S, 2002, FASEB J, V16, P509, DOI 10.1096/fj.01-0164com; Huang W, 2004, J BIOL CHEM, V279, P21695, DOI 10.1074/jbc.M401546200; Inoue H, 2004, NAT MED, V10, P168, DOI 10.1038/nm980; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Lam NT, 2004, MOL ENDOCRINOL, V18, P1333, DOI 10.1210/me.2002-0193; Lee Y, 2001, J BIOL CHEM, V276, P5629, DOI 10.1074/jbc.M008553200; Lin S, 2000, BRAIN RES, V875, P89, DOI 10.1016/S0006-8993(00)02580-4; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Nave H, 1998, J EXP ANIM SCI, V39, P67; Nemecz M, 1999, HEPATOLOGY, V29, P166, DOI 10.1002/hep.510290110; Roden M, 2000, HEPATOLOGY, V32, P1045, DOI 10.1053/jhep.2000.18712; Sinha MK, 1996, J CLIN INVEST, V98, P1277, DOI 10.1172/JCI118913; Surwit RS, 2000, DIABETES, V49, P1203, DOI 10.2337/diabetes.49.7.1203; Sweeney G, 2002, CELL SIGNAL, V14, P655, DOI 10.1016/S0898-6568(02)00006-2; Szanto I, 2000, P NATL ACAD SCI USA, V97, P2355, DOI 10.1073/pnas.050580497; Wilsey J, 2004, J ENDOCRINOL, V181, P297, DOI 10.1677/joe.0.1810297; Yang GQ, 2004, MOL ENDOCRINOL, V18, P1354, DOI 10.1210/me.2004-0027; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao AZ, 2000, J BIOL CHEM, V275, P11348, DOI 10.1074/jbc.275.15.11348	33	81	89	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					1048	+		10.1096/fj.04-2846fje	http://dx.doi.org/10.1096/fj.04-2846fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15788447				2022-12-25	WOS:000227901300001
J	Oshima, Y; Oshima, S; Nambu, H; Kachi, S; Takahashi, K; Umeda, N; Shen, J; Dong, A; Apte, RS; Duh, E; Hackett, SF; Okaye, G; Ishibashi, K; Handa, J; Melia, M; Weigand, S; Yancopoulos, G; Zack, DJ; Campochiaro, PA				Oshima, Y; Oshima, S; Nambu, H; Kachi, S; Takahashi, K; Umeda, N; Shen, J; Dong, A; Apte, RS; Duh, E; Hackett, SF; Okaye, G; Ishibashi, K; Handa, J; Melia, M; Weigand, S; Yancopoulos, G; Zack, DJ; Campochiaro, PA			Different effects of angiopoietin-2 in different vascular beds in the eye: new vessels are most sensitive	FASEB JOURNAL			English	Article						angiogenesis; neovascularization; Tie2; vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; INCREASED EXPRESSION; RETINAL NEOVASCULARIZATION; OCULAR NEOVASCULARIZATION; GENE-EXPRESSION; TIE2 RECEPTOR; ANGIOGENESIS; MICE; MODEL	In this study, we used double transgenic mice with inducible expression of angiopoietin-2 (Ang2) to investigate the role of Ang2 in the retinal and choroidal circulations and in three models of ocular neovascularization (NV). Mice with induced expression of Ang2 ubiquitously, or specifically in the retina, survived and appeared grossly normal. They also had normal-appearing retinal and choroidal circulations, demonstrating that high levels of Ang2 did not induce regression of mature retinal or choroidal vessels. When Ang2 expression was induced soon after birth, there was increased density of the deep capillary bed on postnatal day (P) 11 that returned to normal by P18, the time that retinal vascular development is usually completed. In mice with ischemic retinopathy, induction of Ang2 during the ischemic period resulted in a significant increase in retinal NV, but induction of Ang2 at a later time point when ischemia (and vascular endothelial growth factor [VEGF]) was less, hastened regression of NV. In triple transgenic mice that coexpressed VEGF and Ang2, the increased expression of Ang2 inhibited VEGF-induced NV in the retina. Increased expression of Ang2 also resulted in regression of choroidal neovascularization. These data suggest that ocular neovascularization, but not mature retinal or choroidal vessels, is sensitive to Ang2; a high Ang2/VEGF ratio promotes regression, while high Ang2 in the setting of hypoxia and/or concomitantly high Ang2 and VEGF stimulate neovascularization.	Johns Hopkins Univ, Sch Med, Dept Ophthalmol & Neurosci, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21287 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Johns Hopkins University; Johns Hopkins University; Regeneron	Campochiaro, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol & Neurosci, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.	pcampo@jhmi.edu		Zack, Don/0000-0002-7966-1973; Umeda, Naoyasu/0000-0001-5814-8356	NEI NIH HHS [EY05951, P30EY1765, EY12609] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001765, R01EY012609] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Beck H, 2000, AM J PATHOL, V157, P1473, DOI 10.1016/S0002-9440(10)64786-4; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chang MA, 2000, INVEST OPHTH VIS SCI, V41, P4281; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.3.CO;2-Z; Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128; Hazzard TM, 2000, MOL HUM REPROD, V6, P993, DOI 10.1093/molehr/6.11.993; Kim I, 2000, ONCOGENE, V19, P4549, DOI 10.1038/sj.onc.1203800; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Miquerol L, 2000, DEVELOPMENT, V127, P3941; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428; Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230; Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985; Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2; Okamoto N, 1997, AM J PATHOL, V151, P281; Okoye G, 2003, J NEUROSCI, V23, P4164; Ozaki H, 1998, AM J PATHOL, V153, P757, DOI 10.1016/S0002-9440(10)65619-2; Pichiule P, 2002, J APPL PHYSIOL, V93, P1131, DOI 10.1152/japplphysiol.00318.2002; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Shih SC, 2002, AM J PATHOL, V161, P35, DOI 10.1016/S0002-9440(10)64154-5; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Teichert-Kuliszewska K, 2001, CARDIOVASC RES, V49, P659, DOI 10.1016/S0008-6363(00)00231-5; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180; Visconti RP, 2002, P NATL ACAD SCI USA, V99, P8219, DOI 10.1073/pnas.122109599; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; YI X, 1997, LAB INVEST, V235, P313	36	86	91	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					963	+		10.1096/fj.04-2209fje	http://dx.doi.org/10.1096/fj.04-2209fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15802489				2022-12-25	WOS:000227901300040
J	Lin, CF; Chen, CL; Chang, WT; Jan, MS; Hsu, LJ; Wu, RH; Fang, YT; Tang, MJ; Chang, WC; Lin, YS				Lin, CF; Chen, CL; Chang, WT; Jan, MS; Hsu, LJ; Wu, RH; Fang, YT; Tang, MJ; Chang, WC; Lin, YS			Bcl-2 rescues ceramide- and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CELL-DEATH; NEURONAL APOPTOSIS; TUMOR-CELLS; INTRACELLULAR ACIDIFICATION; SIGNAL-TRANSDUCTION; CANCER CELLS; PROTEIN; STRESS; DEPHOSPHORYLATION	Recent studies indicate that caspase-2 is involved in the early stage of apoptosis before mitochondrial damage. Although the activation of caspase-2 has been shown to occur in a large protein complex, the mechanisms of caspase-2 activation remain unclear. Here we report a regulatory role of Bcl-2 on caspase-2 upstream of mitochondria. Stress stimuli, including ceramide and etoposide, caused caspase-2 activation, mitochondrial damage followed by downstream caspase-9 and -3 activation, and cell apoptosis in human lung epithelial cell line A549. When A549 cells were pretreated with the caspase-2 inhibitor benzyloxycarbonyl-Val-Asp(-OMe)Val-Ala-Asp(-OMe)-fluoromethyl ketone or transfected with caspase-2 short interfering RNA, both ceramide- and etoposide-induced mitochondrial damage and apoptosis were blocked. Overexpression of Bcl-2 prevented ceramide- and etoposide-induced caspase-2 activation and mitochondrial apoptosis. Furthermore, caspase-2 was activated when A549 cells were introduced with Bcl-2 short interfering RNA or were treated with Bcl-2 inhibitor, which provided direct evidence of a negative regulatory effect of Bcl-2 on caspase-2. Cell survival was observed when caspase-2 was inhibited in Bcl-2-silencing cells. Blockage of the mitochondrial permeability transition pore and caspase-9 demonstrated that Bcl-2-modulated caspase-2 activity occurred upstream of mitochondria. Further studies showed that Bcl-2 was dephosphorylated at serine 70 after ceramide and etoposide treatment. A protein phosphatase inhibitor, okadaic acid, rescued Bcl-2 dephosphorylation and blocked caspase-2 activation, mitochondrial damage, and cell death. Taken together, ceramide and etoposide induced mitochondria-mediated apoptosis by initiating caspase-2 activation, which was, at least in part, regulated by Bcl-2.	Natl Cheng Kung Univ, Dept Microbiol & Immunol, Coll Med, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Dept Biochem, Coll Med, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Dept Physiol, Coll Med, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Dept Pharmacol, Coll Med, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan 70101, Taiwan; Chung Shan Med Univ, Dept Microbiol & Immunol, Taichung 402, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Chung Shan Medical University	Lin, YS (corresponding author), Natl Cheng Kung Univ, Dept Microbiol & Immunol, Coll Med, Tainan 70101, Taiwan.	yslin1@mail.ncku.edu.tw	Hsu, Li-Jin/G-7822-2011	Tang, Ming-Jer/0000-0002-0883-4363				An J, 2004, J BIOL CHEM, V279, P19133, DOI 10.1074/jbc.M400295200; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eliseev RA, 2003, EXP CELL RES, V289, P275, DOI 10.1016/S0014-4827(03)00278-7; Elliott MJ, 1999, CANCER CHEMOTH PHARM, V44, P1, DOI 10.1007/s002800050938; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Haviv R, 1998, J NEUROSCI RES, V52, P491, DOI 10.1002/(SICI)1097-4547(19980601)52:5<491::AID-JNR1>3.0.CO;2-7; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JAFFREZOU JP, 2004, B CANC PARIS, V91, P133; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Johnson VL, 1999, EXP CELL RES, V251, P175, DOI 10.1006/excr.1999.4557; Kawahara A, 1998, ONCOGENE, V17, P2549, DOI 10.1038/sj.onc.1202192; Kim PK, 2004, MOL CELL, V14, P523, DOI 10.1016/S1097-2765(04)00263-1; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lin CF, 2004, J BIOL CHEM, V279, P40755, DOI 10.1074/jbc.M404726200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Raffo A, 2004, CLIN CANCER RES, V10, P3195, DOI 10.1158/1078-0432.CCR-03-0287; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Schweizer A, 2003, J BIOL CHEM, V278, P42441, DOI 10.1074/jbc.M304895200; SMITH MJ, 1996, BIOCHEM J, V316, P25; Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3; Swanton E, 1999, ONCOGENE, V18, P1781, DOI 10.1038/sj.onc.1202490; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Toman RE, 2002, J NEUROSCI RES, V68, P323, DOI 10.1002/jnr.10190; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wolf CM, 1997, EXP CELL RES, V230, P22, DOI 10.1006/excr.1996.3401; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang JD, 1999, J CELL BIOL, V145, P99, DOI 10.1083/jcb.145.1.99; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	54	51	56	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23758	23765		10.1074/jbc.M412292200	http://dx.doi.org/10.1074/jbc.M412292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15817479	hybrid			2022-12-25	WOS:000229880000045
J	Han, XJ; Chae, JK; Lee, MJ; You, KR; Lee, BH; Kim, DG				Han, XJ; Chae, JK; Lee, MJ; You, KR; Lee, BH; Kim, DG			Involvement of GADD153 and cardiac ankyrin repeat protein in hypoxia-induced apoptosis of H9c2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; MESSENGER-RNA; GENE-EXPRESSION; CHOP GADD153; MEDIATED APOPTOSIS; GROWTH ARREST; CARP GENE; ACTIVATION; TRANSCRIPTION; C/EBP	Oxidative stress is the main cause of cardiac injury during ischemia/reperfusion but the molecular mechanism for this process is unclear. In this study, it was found that hypoxia induces apoptosis in rat embryonic heart-derived H9c2 cells leading to the induction of GADD153, which is an apoptosis-related gene. Therefore, this study addressed the molecular role of GADD153 in hypoxia-induced apoptosis. The stable or inducible overexpression of GADD153 sensitized the H9c2 cells to apoptotic cell death. The results suggest that the transactivation domain of the GADD153 might be responsible for this cell execution and play a role in the nucleoplasmic localization of GADD153. The cells transiently transfected with the antisense GADD153 were more resistant to hypoxia-induced apoptosis than the vector control cells. Furthermore, GADD153 transcriptionally down-regulated the expression of the cardiac ankyrin repeat protein gene (CARP), which is a nuclear transcriptional co-factor that negatively regulates the expression of the cardiac gene. The ectopic expression of CARP in H9c2 cells increased the resistance to hypoxia-induced apoptosis. These results suggest that GADD153 overexpression and the concomitant down-regulation of CARP might have a causative role in the apoptotic cell injury of hypoxic H9c2 cells.	Chonbuk Natl Univ, Med Sch & Hosp, Res Inst Clin Med, Dept Internal Med,Div Hepatol, Jeonju 561172, Jeonbuk, South Korea; Chonbuk Natl Univ, Med Sch & Hosp, Res Inst Clin Med, Dept Internal Med,Div Cardiol, Jeonju 561172, Jeonbuk, South Korea; Korea Res Inst Chem Technol, Taejon 305600, South Korea	Jeonbuk National University; Jeonbuk National University; Korea Research Institute of Chemical Technology (KRICT)	Kim, DG (corresponding author), Chonbuk Natl Univ, Med Sch & Hosp, Res Inst Clin Med, Dept Internal Med,Div Gastroenterol & Hepatol, 634-18 Keumam Dong, Jeonju 561172, Jeonbuk, South Korea.	daeghon@chonbuk.ac.kr						Adachi S, 2001, CIRC RES, V88, P408, DOI 10.1161/01.res.88.4.408; Aihara Y, 2000, J MOL CELL CARDIOL, V32, P1401, DOI 10.1006/jmcc.2000.1173; Aihara Y, 2000, HYPERTENSION, V36, P48, DOI 10.1161/01.HYP.36.1.48; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chen RH, 2000, RES COMMUN MOL PATH, V108, P3; Eastman HB, 1996, SHOCK, V6, P286, DOI 10.1097/00024382-199610000-00011; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Halleck MM, 1997, CELL STRESS CHAPERON, V2, P31, DOI 10.1379/1466-1268(1997)002<0031:TMRTRS>2.3.CO;2; Imhof A, 1996, J CLIN MICROBIOL, V34, P1646, DOI 10.1128/JCM.34.7.1646-1648.1996; Jeyaseelan R, 1997, J BIOL CHEM, V272, P22800, DOI 10.1074/jbc.272.36.22800; Kajstura J, 1998, AM J CARDIOL, V82, p30K, DOI 10.1016/S0002-9149(98)00535-9; Kajstura J, 1996, LAB INVEST, V74, P86; Kanai H, 2001, CIRC RES, V88, P30, DOI 10.1161/01.RES.88.1.30; Kim DG, 1996, CANCER LETT, V107, P149, DOI 10.1016/0304-3835(96)04407-2; Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; PRICE BD, 1992, J CELL PHYSIOL, V152, P545, DOI 10.1002/jcp.1041520314; PRICE BD, 1992, CANCER RES, V52, P3814; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Suzuki YJ, 2003, ANTIOXID REDOX SIGN, V5, P741, DOI 10.1089/152308603770380043; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; Tang JR, 2002, BIOCHEM BIOPH RES CO, V290, P1255, DOI 10.1006/bbrc.2002.6336; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wen J, 2002, J BIOL CHEM, V277, P38954, DOI 10.1074/jbc.M203842200; Yoshisue H, 2002, ATHEROSCLEROSIS, V162, P323, DOI 10.1016/S0021-9150(01)00735-3; Zhou SY, 2001, TOXICOL LETT, V121, P151, DOI 10.1016/S0378-4274(01)00329-0; Zhu WZ, 2003, J CLIN INVEST, V111, P617, DOI 10.1172/JCI200316326; Zolk O, 2002, BIOCHEM BIOPH RES CO, V293, P1377, DOI 10.1016/S0006-291X(02)00387-X	44	39	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23122	23129		10.1074/jbc.M501095200	http://dx.doi.org/10.1074/jbc.M501095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15826945	hybrid			2022-12-25	WOS:000229741800069
J	Lisal, J; Tuma, R				Lisal, J; Tuma, R			Cooperative mechanism of RNA packaging motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; BACTERIOPHAGE PHI-6; ATP SYNTHASE; PROTEIN P4; TRANSCRIPTION; HELICASE; TRANSLOCATION; F-1-ATPASE; RHO	P4 is a hexameric ATPase that serves as the RNA packaging motor in double-stranded RNA bacteriophages from the Cystoviridae family. P4 shares sequence and structural similarities with hexameric helicases. A structure-based mechanism for mechano-chemical coupling has recently been proposed for P4 from bacteriophage phi 12. However, coordination of ATP hydrolysis among the subunits and coupling with RNA translocation remains elusive. Here we present detailed kinetic study of nucleotide binding, hydrolysis, and product release by phi 12 P4 in the presence of different RNA and DNA substrates. Whereas binding affinities for ATP and ADP are not affected by RNA binding, the hydrolysis step is accelerated and the apparent cooperativity is increased. No nucleotide binding cooperativity is observed. We propose a stochastic-sequential cooperativity model to describe the coordination of ATP hydrolysis within the hexamer. In this model the apparent cooperativity is a result of hydrolysis stimulation by ATP and RNA binding to neighboring subunits rather than cooperative nucleotide binding. The translocation step appears coupled to hydrolysis, which is coordinated among three neighboring subunits. Simultaneous interaction of neighboring subunits with RNA makes the otherwise random hydrolysis sequential and processive.	Univ Helsinki, Viikki Bioctr, Dept Biol & Environm Sci, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Tuma, R (corresponding author), Univ Helsinki, Viikki Bioctr, Dept Biol & Environm Sci, POB 65,Viikinkaari 1, FIN-00014 Helsinki, Finland.	roman.tuma@helsinki.fi	Tuma, Roman/AAL-4436-2020	Tuma, Roman/0000-0003-0047-0013				Antes I, 2003, BIOPHYS J, V85, P695, DOI 10.1016/S0006-3495(03)74513-5; Cornish-Bowden A, 2012, FUNDAMENTALS ENZYME, V4th; Gai' DH, 2004, CELL, V119, P47, DOI 10.1016/j.cell.2004.09.017; Jeong YJ, 2004, P NATL ACAD SCI USA, V101, P7264, DOI 10.1073/pnas.0400372101; Jeong YJ, 2004, J BIOL CHEM, V279, P18370, DOI 10.1074/jbc.M309162200; Juuti JT, 1998, J MOL BIOL, V279, P347, DOI 10.1006/jmbi.1998.1772; Kainov DE, 2004, NUCLEIC ACIDS RES, V32, P3515, DOI 10.1093/nar/gkh680; Kainov DE, 2003, J BIOL CHEM, V278, P48084, DOI 10.1074/jbc.M306928200; Lisal J, 2005, NAT STRUCT MOL BIOL, V12, P460, DOI 10.1038/nsmb927; Lisal J, 2004, J BIOL CHEM, V279, P1343, DOI 10.1074/jbc.M309587200; Mancini EJ, 2004, CELL, V118, P743, DOI 10.1016/j.cell.2004.09.007; Mancini EJ, 2004, ACTA CRYSTALLOGR D, V60, P588, DOI 10.1107/S0907444904001052; Mindich L, 1999, MICROBIOL MOL BIOL R, V63, P149, DOI 10.1128/MMBR.63.1.149-160.1999; Oster G, 2000, BBA-BIOENERGETICS, V1458, P482, DOI 10.1016/S0005-2728(00)00096-7; OSTER G, 2003, MOL MOTORS, P207; PAATERO AO, 1995, J VIROL, V69, P6729, DOI 10.1128/JVI.69.11.6729-6734.1995; RICARD J, 1985, J THEOR BIOL, V117, P633, DOI 10.1016/S0022-5193(85)80244-7; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; Sun S, 2003, EUR BIOPHYS J BIOPHY, V32, P676, DOI 10.1007/s00249-003-0335-6; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; Zhang WQ, 1997, ANAL BIOCHEM, V251, P246, DOI 10.1006/abio.1997.2238	22	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23157	23164		10.1074/jbc.M502658200	http://dx.doi.org/10.1074/jbc.M502658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15840563	hybrid			2022-12-25	WOS:000229741800073
J	Saifudeen, Z; Diavolitsis, V; Stefkova, J; Dipp, S; Fan, H; El-Dahr, SS				Saifudeen, Z; Diavolitsis, V; Stefkova, J; Dipp, S; Fan, H; El-Dahr, SS			Spatiotemporal switch from Delta Np73 to TAp73 Isoforms during nephrogenesis - Impact on differentiation gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; FAMILY-MEMBER; P73; P63; TARGET; ZEBRAFISH; STABILITY; RECEPTOR; TRANSACTIVATION; OVEREXPRESSION	p73 is a member of the p53 gene family, which also includes p53 and p63. These proteins share sequence similarity and target genes but also have divergent roles in cancer and development. Unlike p53, transcription of the p73 gene yields multiple full-length (transactivation (TA) domain) and amino terminus-truncated (Delta N) isoforms. Delta Np73 acts in a dominant negative fashion to inhibit the actions of TAp73 and p53 on their target genes, promoting cell survival and proliferation and suppressing apoptosis. The balance between TAp73 and its negative regulator, Delta Np73, may therefore represent an important determinant of developmental cell fate. There is little if anything known regarding the developmental regulation of the p73 gene. In this study, we showed that TAp73 and Delta Np73 exhibit reciprocal spatiotemporal expression and functions during nephrogenesis. TAp73 was predominantly expressed in the differentiation domain of the renal cortex in an overlapping manner with the vasopressin-sensitive water channel aquaporin-2 (AQP-2). Chromatin immunoprecipitation assays demonstrated that the endogenous AQP-2 promoter was occupied by TAp73 in a developmentally regulated manner. Furthermore TAp73 stimulated AQP-2 promoter-driven reporter expression. TAp73 also activated the bradykinin B2 receptor (B2R) promoter, a developmentally regulated gene involved in regulation of sodium excretion. The transcriptional effects of TAp73 on AQP-2 and B2R were independent of p53. In marked contrast to TAp73, Delta Np73 isoforms were induced early in development and were preferentially expressed in proliferating nephron precursors. Moreover Delta Np73 was a potent repressor of B2R gene transcription. We conclude that the p73 gene is developmentally regulated during kidney organogenesis. The spatiotemporal switch from Delta Np73 to TAp73 may play an important role in the terminal differentiation program of the developing nephron.	Tulane Univ, Hlth Sci Ctr, Dept Pediat, Sect Pediat Nephrol, New Orleans, LA 70112 USA	Tulane University	El-Dahr, SS (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Pediat, Sect Pediat Nephrol, Sl-37,1430 Tulane Ave, New Orleans, LA 70112 USA.	seldahr@tulane.edu						ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Amariglio F, 1997, ONCOGENE, V15, P2191, DOI 10.1038/sj.onc.1201395; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Barrera FN, 2003, J BIOL CHEM, V278, P46878, DOI 10.1074/jbc.M307846200; Billon N, 2004, DEVELOPMENT, V131, P1211, DOI 10.1242/dev.01035; Bonilla-Felix M, 2004, AM J PHYSIOL-RENAL, V287, pF1093, DOI 10.1152/ajprenal.00119.2004; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ElDahr SS, 1997, KIDNEY INT, V51, P739, DOI 10.1038/ki.1997.105; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; HOEVER M, 1994, ONCOGENE, V9, P109; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kartasheva NN, 2003, ONCOGENE, V22, P8246, DOI 10.1038/sj.onc.1207138; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lain S, 2003, BIOCHEM SOC T, V31, P482, DOI 10.1042/BST0310482; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; Levine EM, 2004, DEVELOPMENT, V131, P2241, DOI 10.1242/dev.01180; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Levrero M, 2000, J CELL SCI, V113, P1661; Li ZR, 1998, CANCER RES, V58, P4282; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Maisse C, 2003, BIOCHEM PHARMACOL, V66, P1555, DOI 10.1016/S0006-2952(03)00511-2; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; Marks J, 2003, J BIOL CHEM, V278, P34158, DOI 10.1074/jbc.M304543200; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Miro-Mur F, 2003, ONCOGENE, V22, P5451, DOI 10.1038/sj.onc.1206538; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Nadasdy T, 1998, PEDIATR DEVEL PATHOL, V1, P49, DOI 10.1007/s100249900006; Nakagawa T, 2003, CANCER LETT, V197, P105, DOI 10.1016/S0304-3835(03)00090-9; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Rentzsch F, 2003, GENE, V323, P19, DOI 10.1016/j.gene.2003.10.002; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Saifudeen Z, 2002, AM J PHYSIOL-RENAL, V283, pF727, DOI 10.1152/ajprenal.00114.2002; Saifudeen Z, 2002, J CLIN INVEST, V109, P1021, DOI 10.1172/JCI200213972; Saifudeen Z, 2000, J BIOL CHEM, V275, P15557, DOI 10.1074/jbc.M909810199; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; SCHMID P, 1991, DEVELOPMENT, V113, P857; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Tchang F, 1999, EXP CELL RES, V251, P46, DOI 10.1006/excr.1999.4570; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; Thisse C, 2000, DIFFERENTIATION, V66, P61, DOI 10.1046/j.1432-0436.2000.660201.x; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; Ueda Y, 2001, BIOCHEM J, V356, P859, DOI 10.1042/0264-6021:3560859; Ueda Y, 2001, BIOCHEM BIOPH RES CO, V283, P327, DOI 10.1006/bbrc.2001.4788; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; White JD, 2002, INT J DEV BIOL, V46, P577; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yosipiv IV, 2001, AM J PHYSIOL-RENAL, V281, pF795, DOI 10.1152/ajprenal.0020.2001; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zheng XJ, 2001, FEBS LETT, V489, P4, DOI 10.1016/S0014-5793(00)02437-6	70	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23094	23102		10.1074/jbc.M414575200	http://dx.doi.org/10.1074/jbc.M414575200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15805112	hybrid			2022-12-25	WOS:000229741800066
J	Chen, DQ; Texada, DE; Duggan, C; Liang, CP; Reden, TB; Kooragayala, LM; Langford, MP				Chen, DQ; Texada, DE; Duggan, C; Liang, CP; Reden, TB; Kooragayala, LM; Langford, MP			Surface calreticulin mediates muramyl dipeptide-induced apoptosis in RK13 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; ENDOPLASMIC-RETICULUM; BINDING; INDUCTION; RECEPTOR; PEPTIDOGLYCAN; PROTEIN; EXPRESSION; PEPTIDES; PATHWAYS	Calreticulin (CRT) is a binding protein for apoptotic N-acetylmuramyl-L-alanyl-D-isoglutamine (L,D-MDP) or peptidoglycan in RK13 cells. CRT on RK13 cell surface (srCRT) forms complex(es) with tumor necrosis factor receptor 1 (TNFR1) and TNFR-associated death domain ( TRADD) protein of the cell membrane. CRT polyclonal or monoclonal antibody binding to RK13 srCRT dose-dependently inhibited L,D-MDP- induced apoptosis. In RK13 cells, L,D-MDP up-regulated the TNFR1.TRADD complex of the plasma membrane and subsequently induced cytosolic TRADD-Fas-associated death domain protein complex. Biotinylated srCRT was capable of calcium-dependent binding of Sepharose-immobilized L, D-MDP or peptidoglycan. However, Toll-like receptors TLR-2 and TLR-4, Nod2, and CD14 of RK13 cells did not specifically bind Sepharose-immobilized L, D-MDP. High concentrations (5-40 mM) of EGTA dose- dependently inhibited free L,D-MDP binding to purified RK13 cell CRT and promoted free L,D-MDP dissociation from RK13 cell CRT.MDP complex. Different concentrations of EGTA (0-40mM) added to Dulbecco's modified essential medium with 1.8 mM calcium or phosphate-buffered saline with 0.18 mM calcium have different effects on medium free calcium concentrations but have identical inhibiting effects on L, D-MDP induced apoptosis. More inhibition of theL,D-MDP-induced apoptotic DNA ladders and caspase-3 activity in RK13 cells was obtained with EGTA pretreatment ( 83%) than just EGTA + L,D-MDP ( 47%). The knocking down of srCRT by antisense oligonucleotide CRTAS121 ( 250 nmol/ ml) and stealth small interfering RNA CRT_siR479 (150 pM/ ml) for 2 days ( 44 and 66%, respectively), resulted in the inhibition of L,D-MDP-induced caspase-3 activity ( 47 and 65%, respectively). The results suggest that (a) the binding of L, D-MDP to srCRT is calcium-dependent, i.e. on srCRT- bound calcium, and ( b) it is srCRT, not TLR-2, TLR-4, Nod2 or CD14, that mediates L,D-MDP-induced RK13 cell apoptosis through activating the TNFR1.TRADD-Fas-associated death domain protein apoptotic pathway.	Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Chen, DQ (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, 1501 Kingshighway, Shreveport, LA 71130 USA.	dchen@lsuhsc.edu						Barnhart BC, 2003, CELL, V114, P148, DOI 10.1016/S0092-8674(03)00561-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; BURROUGHS M, 1993, J CLIN INVEST, V92, P297, DOI 10.1172/JCI116565; Chen D.-Y., UNPUB; Chen DQ, 2004, BIOCHEMISTRY-US, V43, P11796, DOI 10.1021/bi0490789; Cottagnoud P, 2003, INFECT IMMUN, V71, P3663, DOI 10.1128/IAI.71.6.3663-3666.2003; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; DEWHIRST FE, 1982, INFECT IMMUN, V35, P133, DOI 10.1128/IAI.35.1.133-137.1982; DOUGHERTY PM, 1987, EUR J PHARMACOL, V141, P253, DOI 10.1016/0014-2999(87)90270-6; Drummer HE, 2003, FEBS LETT, V546, P385, DOI 10.1016/S0014-5793(03)00635-5; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Fulda S, 2004, BBA-REV CANCER, V1705, P27, DOI 10.1016/j.bbcan.2004.09.003; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HURLEY WL, 1990, METHOD ENZYMOL, V184, P429; IKEBE T, 1990, ARTHRITIS RHEUM, V33, P1801, DOI 10.1002/art.1780331207; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; Kaisho T, 2002, BBA-MOL CELL RES, V1589, P1, DOI 10.1016/S0167-4889(01)00182-3; KOGA T, 1986, MICROBIOL IMMUNOL, V30, P717, DOI 10.1111/j.1348-0421.1986.tb02997.x; KOTANI S, 1986, FASEB J, V45, P2534; Langford MP, 2002, MOL CELL BIOCHEM, V236, P63, DOI 10.1023/A:1016110429204; LIU NG, 1994, J BIOL CHEM, V269, P28635; McDonnell JM, 1996, J BIOL CHEM, V271, P7891, DOI 10.1074/jbc.271.14.7891; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; Natoli G, 1998, BIOCHEM PHARMACOL, V56, P915, DOI 10.1016/S0006-2952(98)00154-3; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Patil AR, 2000, J BIOL CHEM, V275, P24348, DOI 10.1074/jbc.M003102200; RIVAS RJ, 1989, J CELL BIOL, V109, P51, DOI 10.1083/jcb.109.1.51; ROOTBERNSTEIN RS, 1990, BRAIN RES BULL, V25, P827, DOI 10.1016/0361-9230(90)90178-3; Sambrook J, 1989, MOL CLONING; Shakibaei M, 2005, ANTIOXID REDOX SIGN, V7, P482, DOI 10.1089/ars.2005.7.482; Sheikh MS, 2003, CELL CYCLE, V2, P550, DOI 10.4161/cc.2.6.566; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; WATERS RV, 1986, INFECT IMMUN, V51, P816, DOI 10.1128/IAI.51.3.816-825.1986; Weidemann B, 1997, INFECT IMMUN, V65, P858, DOI 10.1128/IAI.65.3.858-864.1997; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; Xiao GQ, 1999, J NEUROSCI RES, V58, P652, DOI 10.1002/(SICI)1097-4547(19991201)58:5<652::AID-JNR6>3.0.CO;2-H; Yoshimura A, 2000, J ENDOTOXIN RES, V6, P407, DOI 10.1177/09680519000060050201	42	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22425	22436		10.1074/jbc.M413380200	http://dx.doi.org/10.1074/jbc.M413380200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817475	hybrid			2022-12-25	WOS:000229557900088
J	Chen, LY; Doerner, A; Lehmann, PF; Huang, S; Zhong, GM; Pan, ZXK				Chen, LY; Doerner, A; Lehmann, PF; Huang, S; Zhong, GM; Pan, ZXK			A novel protein kinase C (PKEe) is required for fMET-Leu-Phe-induced activation of NF-kB in human peripheral blood monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; WEIGHT GTPASE RHOA; GENE-EXPRESSION; HUMAN NEUTROPHILS; BETA; EPSILON; CELLS; TRANSCRIPTION; PHOSPHORYLATION; INVOLVEMENT	We have reported that the chemoattractant, fMet-LeuPhe ( fMLP), induces the activation of NF-kB in human peripheral blood monocytes and that this requires the activity of small GTPase, RhoA ( Huang, S., Chen, L.-Y., Zuraw, B. L., Ye, R. D., and Pan, Z. K. (2001) J. Biol. Chem. 276, 40977-40981). Here we showed that the novel protein kinase C isozyme, PKCe, associates functionally with RhoA in fMLP-stimulated monocytes and that PKCe acted as a signaling component downstream of the GTPase RhoA during fMLP-induced activation of NF-kB. Stimulation of monocytes with fMLP resulted in activation of both PKCe and NF-kB. This latter activation was largely blocked by specific inhibitors of PKCe by transient expression of a dominant-negative form of PKCe and by PKCe- specific short interfering RNA. These findings demonstrate, for the first time, that fMLP- induced activation of NF-kB utilizes a signaling pathway, which requires activity of PKCe, and that PKCe acts as a signaling component downstream of RhoA in cytokine gene transcription stimulated by a chemoattractant. The specificity of this response suggests an important role for the Rho GTPase- PKCe- NF-kB pathway in host defense and represents a novel and potentially important mechanism through which fMLP not only attracts leukocytes but may also contribute directly to inflammation.	Med Coll Ohio, Dept Med Microbiol & Immunol, Toledo, OH 43614 USA; Med Coll Ohio, Dept Med, Toledo, OH 43699 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol & Immunol, San Antonio, TX 78229 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of Texas System; University of Texas Health San Antonio; Scripps Research Institute; Scripps Research Institute	Pan, ZXK (corresponding author), Med Coll Ohio, Dept Med Microbiol & Immunol, 3055 Arlington Ave, Toledo, OH 43614 USA.	zkpan@mco.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007469, R01AI043524, R56AI043524] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR 00833] Funding Source: Medline; NIAID NIH HHS [R01 AI043524-11, T32 AI 07469, R01 AI043524, AI 43524] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aksoy E, 2002, EUR J IMMUNOL, V32, P3040, DOI 10.1002/1521-4141(200211)32:11<3040::AID-IMMU3040>3.0.CO;2-M; Aktories K, 1997, J CLIN INVEST, V99, P827, DOI 10.1172/JCI119245; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Chen LY, 2004, J BIOL CHEM, V279, P7208, DOI 10.1074/jbc.M309542200; Chen LY, 2002, J IMMUNOL, V169, P3934, DOI 10.4049/jimmunol.169.7.3934; Dang PMC, 2001, J IMMUNOL, V166, P1206, DOI 10.4049/jimmunol.166.2.1206; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Foryst-Ludwig A, 2000, J BIOL CHEM, V275, P39779, DOI 10.1074/jbc.M007617200; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; GOMEZCAMBRONERO J, 1987, BIOCHEM BIOPH RES CO, V148, P38, DOI 10.1016/0006-291X(87)91073-4; Huang S, 2001, J BIOL CHEM, V276, P40977, DOI 10.1074/jbc.M105242200; Ivaska J, 2003, NAT CELL BIOL, V5, P363, DOI 10.1038/ncb957; Kempiak SJ, 1999, J IMMUNOL, V162, P3176; Korchak HM, 1998, J BIOL CHEM, V273, P27292, DOI 10.1074/jbc.273.42.27292; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MAJUMDAR S, 1993, BIOCHIM BIOPHYS ACTA, V1176, P276, DOI 10.1016/0167-4889(93)90056-U; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MERRITT JE, 1991, CELL SIGNAL, V3, P73, DOI 10.1016/0898-6568(91)90010-R; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; PAN ZX, 1995, J BIOL CHEM, V270, P7787, DOI 10.1074/jbc.270.14.7787; Pan ZXK, 2000, J IMMUNOL, V164, P404, DOI 10.4049/jimmunol.164.1.404; Pan ZXK, 1998, BBA-GENE STRUCT EXPR, V1443, P90, DOI 10.1016/S0167-4781(98)00198-5; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; Valledor AF, 2000, J IMMUNOL, V164, P29, DOI 10.4049/jimmunol.164.1.29	35	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22497	22501		10.1074/jbc.M413033200	http://dx.doi.org/10.1074/jbc.M413033200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15809302	hybrid			2022-12-25	WOS:000229557900096
J	Komyod, W; Bauer, UM; Heinrich, PC; Haan, S; Behrmann, I				Komyod, W; Bauer, UM; Heinrich, PC; Haan, S; Behrmann, I			Are STATS arginine-methylated?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL NUCLEOSIDE N-6-METHYLDEOXYADENOSINE; TRANSCRIPTIONAL ACTIVATION; MELANOMA-CELLS; UP-REGULATION; INTERLEUKIN-6; EXPRESSION; RNA; PHOSPHORYLATION; DIFFERENTIATION; REASSESSMENT	Transcription factors of the STAT (signal transducer and activator of transcription) family are important in signal transduction of cytokines. They are subject to post-translational modification by phosphorylation on tyrosine and serine residues. Recent evidence suggested that STATs are methylated on a conserved arginine residue within the N-terminal region. STAT arginine methylation has been described to be important for STAT function and loss of arginine methylation was discussed to be involved in interferon resistance of cancer cells. Here we provide several independent lines of evidence indicating that the issue of arginine methylation of STATs has to be reassessed. First, we show that treatment of melanoma and fibrosarcoma cells with inhibitors used to suppress methylation (N-methyl-2-deoxyadenosine, adenosine, DL-homocysteine) had profound and rapid effects on phosphorylation of STAT1 and STAT3 but also on p38 and Erk signaling cascades which are known to cross-talk with the Jak/STAT pathway. Second, we show that anti-methylarginine antibodies did not precipitate specifically STAT1 or STAT3. Third, we show that mutation of Arg31 to Lys led to destabilization of STAT1 and STAT3, implicating an important structural role of Arg31. Finally, purified catalytically active protein arginine methyltransferases (PRMT1, -2, -3, -4, and -6) did not methylate STAT proteins, and co-transfection with PRMT1 did not affect STAT1-controlled reporter gene activity. Taken together, our data suggest the absence of arginine methylation of STAT1 and STAT3.	Univ Klinikum Aachen, Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany; Univ Marburg, Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany; Univ Luxembourg, Fac Sci Technol & Commun, Lab Biol & Physiol Integree, L-1511 Luxembourg, Luxembourg	RWTH Aachen University; RWTH Aachen University Hospital; Philipps University Marburg; University of Luxembourg	Behrmann, I (corresponding author), Univ Klinikum Aachen, Rhein Westfal TH Aachen, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.	iris.behrmann@uni.lu	Komyod, Waraporn/CAG-9665-2022	Komyod, Waraporn/0000-0001-8020-0026; Behrmann, Iris/0000-0003-3688-3645				ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Behrmann I, 2003, AM J PATHOL, V163, P683, DOI 10.1016/S0002-9440(10)63695-4; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Charles MP, 2004, BIOCHEM BIOPH RES CO, V314, P476, DOI 10.1016/j.bbrc.2003.12.132; Charles MP, 2003, BIOCHEM BIOPH RES CO, V304, P795, DOI 10.1016/S0006-291X(03)00666-1; Chen WG, 2004, J IMMUNOL, V172, P6744, DOI 10.4049/jimmunol.172.11.6744; Duong FHT, 2004, GASTROENTEROLOGY, V126, P263, DOI 10.1053/j.gastro.2003.10.076; Fischer P, 2004, BIOCHEM J, V378, P449, DOI 10.1042/BJ20030893; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Haq R, 2002, J BIOL CHEM, V277, P17359, DOI 10.1074/jbc.M201842200; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Kortylewski M, 2004, J INVEST DERMATOL, V122, P414, DOI 10.1046/j.0022-202X.2004.22237.x; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Meissner T, 2004, CELL, V119, P587, DOI 10.1016/S0092-8674(04)01090-6; Mowen K, 2004, CELL, V119, P589, DOI 10.1016/j.cell.2004.11.019; Mowen KA, 2004, MOL CELL, V15, P559, DOI 10.1016/j.molcel.2004.06.042; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; Ratel D, 2001, BIOCHEM BIOPH RES CO, V285, P800, DOI 10.1006/bbrc.2001.5240; Rho J, 2001, J VIROL, V75, P8031, DOI 10.1128/JVI.75.17.8031-8044.2001; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Smith WA, 2004, J BIOL CHEM, V279, P22795, DOI 10.1074/jbc.C300512200; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vriend G, 1990, J MOL GRAPHICS, V8, P29; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Zauberman A, 1999, ONCOGENE, V18, P3886, DOI 10.1038/sj.onc.1202738; Zhu W, 2002, J BIOL CHEM, V277, P35787, DOI 10.1074/jbc.C200346200	32	60	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21700	21705		10.1074/jbc.C400606200	http://dx.doi.org/10.1074/jbc.C400606200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15826948	hybrid			2022-12-25	WOS:000229557900004
J	Puri, N; Lai-Zhang, J; Meier, S; Mueller, DM				Puri, N; Lai-Zhang, J; Meier, S; Mueller, DM			Expression of bovine F-1-ATPase with functional complementation in yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; ATP SYNTHASE; UNCOUPLING PROTEINS; NUCLEAR GENE; MITOCHONDRIAL ATPASE; BETA-SUBUNIT; ROTATION; COMPLEX; F1-ATPASE; MEMBRANE	The mitochondrial F1F0- ATP synthase is a multimeric enzyme complex composed of at least 16 unique peptides with an overall molecular mass of similar to 600 kDa. F-1-ATPase is composed of alpha(3)beta(3)gamma delta epsilon with an overall molecular mass of 370 kDa. The genes encoding bovine F-1-ATPase have been expressed in a quintuple yeast Saccharomyces cerevisiae deletion mutant (Delta alpha Delta beta Delta gamma Delta delta Delta epsilon). This strain expressing bovine F-1 is unable to grow on medium containing a non-fermentable carbon source (YPG), indicating that the enzyme is non-functional. However, daughter strains were easily selected for growth on YPG medium and these were evolved for improved growth on YPG medium. The evolution of the strains was presumably due to mutations, but mutations in the genes encoding the subunits of the bovine F-1-ATPase were not required for the ability of the cell to grow on YPG medium. The bovine enzyme expressed in yeast was partially purified to a specific activity of about half of that of the enzyme purified from bovine heart mitochondria. These results indicate that the molecular machinery required for the assembly of the mitochondrial ATP synthase is conserved from bovine and yeast and suggest that yeast may be useful for the expression, mutagenesis, and analysis of the mammalian F-1- or F1F0-ATP synthase.	Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, Abbott Pk, IL 60064 USA	Rosalind Franklin University Medical & Science	Mueller, DM (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, Abbott Pk, IL 60064 USA.	david.mueller@RosalindFranklin.edu			NIGMS NIH HHS [R01 GM 066223, R01 GM 067091] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067091, R01GM066223] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ackerman SH, 2002, BBA-BIOENERGETICS, V1555, P101, DOI 10.1016/S0005-2728(02)00262-1; ACKERMAN SH, 1991, FEBS LETT, V278, P234, DOI 10.1016/0014-5793(91)80124-L; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; AVISE JC, 1991, ANNU REV GENET, V25, P45, DOI 10.1146/annurev.ge.25.120191.000401; Bonnefoy N, 2002, METHOD ENZYMOL, V350, P97, DOI 10.1016/S0076-6879(02)50958-7; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CLARKWALKER GD, 1991, CURR GENET, V20, P195, DOI 10.1007/BF00326232; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 2000, BBA-BIOENERGETICS, V1459, P383, DOI 10.1016/S0005-2728(00)00175-4; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; Hoogenraad NJ, 2001, IUBMB LIFE, V51, P345; Jie LZ, 1999, EMBO J, V18, P58, DOI 10.1093/emboj/18.1.58; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; KNOWLES AF, 1972, J BIOL CHEM, V247, P6617; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai-Zhang J, 2000, EUR J BIOCHEM, V267, P2409, DOI 10.1046/j.1432-1327.2000.01253.x; Mabuchi T, 2000, J BIOL CHEM, V275, P10492, DOI 10.1074/jbc.275.14.10492; Maniatis T., 1982, MOL CLONING LAB MANU; Mihara K, 2000, BIOESSAYS, V22, P364, DOI 10.1002/(SICI)1521-1878(200004)22:4<364::AID-BIES6>3.0.CO;2-N; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Mueller DM, 2004, ACTA CRYSTALLOGR D, V60, P1441, DOI 10.1107/S0907444904012661; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; PRESCOTT M, 1995, BIOCHEM BIOPH RES CO, V207, P943, DOI 10.1006/bbrc.1995.1276; Rassow J, 2000, TRAFFIC, V1, P457, DOI 10.1034/j.1600-0854.2000.010603.x; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; Rial E, 2001, BBA-BIOENERGETICS, V1504, P70, DOI 10.1016/S0005-2728(00)00240-1; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Tanabe M, 2001, J BIOL CHEM, V276, P15269, DOI 10.1074/jbc.M100289200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; Velours J, 2001, J BIOL CHEM, V276, P8602, DOI 10.1074/jbc.M008123200; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WALKER JE, 1994, CURR OPIN STRUC BIOL, V4, P912, DOI 10.1016/0959-440X(94)90274-7; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; Wang ZG, 2001, J BIOL CHEM, V276, P30773, DOI 10.1074/jbc.M104133200; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	57	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22418	22424		10.1074/jbc.M411113200	http://dx.doi.org/10.1074/jbc.M411113200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817482	hybrid			2022-12-25	WOS:000229557900087
J	Thoden, JB; Holden, HM				Thoden, JB; Holden, HM			The molecular architecture of galactose mutarotase/UDP-galactose 4-epimerase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-STRUCTURE; UDP-GALACTOSE; GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; 3-DIMENSIONAL STRUCTURE; LACTOCOCCUS-LACTIS; ESCHERICHIA-COLI; II GALACTOSEMIA; SUGAR BINDING; GALACTOKINASE; MECHANISM	The metabolic pathway by which beta-D-galactose is converted to glucose 1-phosphate is known as the Leloir pathway and consists of four enzymes. In most organisms, these enzymes appear to exist as soluble entities in the cytoplasm. In yeast such as Saccharomyces cerevisiae, however, the first and last enzymes of the pathway, galactose mutarotase and UDP-galactose 4-epimerase, are contained within a single polypeptide chain referred to as Gal10p. Here we report the three-dimensional structure of Gal10p in complex with NAD(+), UDP-glucose, and beta-D-galactose determined to 1.85-angstrom resolution. The enzyme is dimeric with dimensions of similar to 91 angstrom x 135 angstrom x 108 angstrom and assumes an almost V-shaped appearance. The overall architecture of the individual subunits can be described in terms of two separate N-and C-terminal domains connected by a Type II turn formed by Leu-357 to Val-360. The first 356 residues of Gal10p fold into the classical bilobal topology observed for all other UDP-galactose 4-epimerases studied thus far. This N-terminal domain contains the binding sites for NAD(+) and UDP-glucose. The polypeptide chain extending from Glu-361 to Ser-699 adopts a beta-sandwich motif and harbors the binding site for beta-D-galactose. The two active sites of Gal10p are separated by over 50 angstrom. This investigation represents the first structural analysis of a dual function enzyme in the Leloir pathway.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	Hazel_Holden@biochem.wisc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK047814, R01DK047814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brahma A, 2004, EUR J BIOCHEM, V271, P58, DOI 10.1046/j.1432-1033.2003.03902.x; Christacos NC, 2000, MOL GENET METAB, V70, P272, DOI 10.1006/mgme.2000.3019; Duax WL, 2000, VITAM HORM, V58, P121, DOI 10.1016/S0083-6729(00)58023-6; Hartley A, 2004, J MOL BIOL, V337, P387, DOI 10.1016/j.jmb.2004.01.043; Holden HM, 2004, CELL MOL LIFE SCI, V61, P2471, DOI 10.1007/s00018-004-4160-6; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; KIM JM, 1990, BIOCHEMISTRY-US, V29, P10590, DOI 10.1021/bi00499a003; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Majumdar S, 2004, EUR J BIOCHEM, V271, P753, DOI 10.1111/j.1432-1033.2003.03974.x; Novelli G, 2000, MOL GENET METAB, V71, P62, DOI 10.1006/mgme.2000.3073; Petry KG, 1998, TRENDS GENET, V14, P98, DOI 10.1016/S0168-9525(97)01379-6; Segal S, 1995, METABOLIC MOL BASIS, P967; Thoden JB, 2005, J BIOL CHEM, V280, P9662, DOI 10.1074/jbc.M412916200; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P1212, DOI 10.1021/bi9626517; Thoden JB, 2004, J BIOL CHEM, V279, P23431, DOI 10.1074/jbc.M402347200; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; Thoden JB, 2003, J BIOL CHEM, V278, P33305, DOI 10.1074/jbc.M304789200; Thoden JB, 2003, PROTEIN SCI, V12, P1051, DOI 10.1110/ps.0243203; Thoden JB, 2002, J BIOL CHEM, V277, P20854, DOI 10.1074/jbc.M201415200; Thoden JB, 2002, J BIOL CHEM, V277, P45458, DOI 10.1074/jbc.M208395200; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677	25	42	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21900	21907		10.1074/jbc.M502411200	http://dx.doi.org/10.1074/jbc.M502411200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15795221	hybrid			2022-12-25	WOS:000229557900030
J	Kim, YJ; Nakatomi, R; Akagi, T; Hashikawa, T; Takahashi, R				Kim, YJ; Nakatomi, R; Akagi, T; Hashikawa, T; Takahashi, R			Unsaturated fatty acids induce cytotoxic aggregate formation of amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASTROCYTIC HYALINE INCLUSIONS; PROTEIN MISFOLDING DISEASES; MOLECULAR-WEIGHT COMPLEXES; SOLUBLE AMYLOID OLIGOMERS; FIBRILLIZATION IN-VITRO; SUPEROXIDE-DISMUTASE; ALPHA-SYNUCLEIN; COMMON MECHANISM; TRANSGENIC MICE; SPINAL-CORDS	Formation of misfolded protein aggregates is a remarkable hallmark of various neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, prion encephalopathies, and amyotrophic lateral sclerosis (ALS). Superoxide dismutase 1 (SOD1) immunoreactive inclusions have been found in the spinal cord of ALS animal models and patients, implicating the close involvement of SOD1 aggregates in ALS pathogenesis. Here we examined the molecular mechanism of aggregate formation of ALS-related SOD1 mutants in vitro. We found that long-chain unsaturated fatty acids (FAs) promoted aggregate formation of SOD1 mutants in both dose- and time-dependent manners. Metal-deficient SOD1s, wild-type, and mutants were highly oligomerized compared with holo-SOD1s by incubation in the presence of unsaturated FAs. Oligomerization of SOD1 is closely associated with its structural instability. Heat-treated holo-SOD1 mutants were readily oligomerized by the addition of unsaturated FAs, whereas wild-type SOD1 was not. The monounsaturated FA, oleic acid, directly bound to SOD1 and was characterized by a solid-phase FA binding assay using oleate-Sepharose. The FA binding characteristics were closely correlated with the oligomerization propensity of SOD1 proteins, which indicates that FA binding may change SOD1 conformation in a way that favors the formation of aggregates. High molecular mass aggregates of SOD1 induced by FAs have a granular morphology and show significant cytotoxicity. These findings suggest that SOD1 mutants gain FA binding abilities based on their structural instability and form cytotoxic granular aggregates.	Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Takahashi, R (corresponding author), Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	ryosuket@kuhp.kyoto-u.ac.jp	Kim, Yeon-Jeong/X-5633-2018	Kim, Yeon-Jeong/0000-0003-1482-7319				Bartnikas TB, 2003, J BIOL CHEM, V278, P33602, DOI 10.1074/jbc.M305435200; Boissinot M, 1997, EMBO J, V16, P2171, DOI 10.1093/emboj/16.9.2171; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chirita CN, 2003, J BIOL CHEM, V278, P25644, DOI 10.1074/jbc.M301663200; Crow JP, 1997, J NEUROCHEM, V69, P1936; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DiDonato M, 2003, J MOL BIOL, V332, P601, DOI 10.1016/S0022-2836(03)00889-1; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; FRIED R, 1975, BIOCHIMIE, V57, P657, DOI 10.1016/S0300-9084(75)80147-7; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P14203, DOI 10.1021/bi001876l; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kato S, 1999, HISTOL HISTOPATHOL, V14, P973, DOI 10.14670/HH-14.973; Kato S, 1997, AM J PATHOL, V151, P611; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Lindberg MJ, 2002, P NATL ACAD SCI USA, V99, P16607, DOI 10.1073/pnas.262527099; Necula M, 2003, J BIOL CHEM, V278, P46674, DOI 10.1074/jbc.M308231200; PETERS T, 1973, J BIOL CHEM, V248, P2447; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Shibata N, 1996, DEV NEUROSCI-BASEL, V18, P492, DOI 10.1159/000111445; Shibata N, 1998, ACTA NEUROPATHOL, V95, P136, DOI 10.1007/s004010050777; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; Strange RW, 2003, J MOL BIOL, V328, P877, DOI 10.1016/S0022-2836(03)00355-3; Tateno M, 2004, HUM MOL GENET, V13, P2183, DOI 10.1093/hmg/ddh246; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Urushitani M, 2004, J NEUROCHEM, V90, P231, DOI 10.1111/j.1471-4159.2004.02486.x; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; Wilson DM, 1997, AM J PATHOL, V150, P2181	39	160	168	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21515	21521		10.1074/jbc.M502230200	http://dx.doi.org/10.1074/jbc.M502230200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799963	hybrid			2022-12-25	WOS:000229438800073
J	Whittaker, J; Whittaker, L				Whittaker, J; Whittaker, L			Characterization of the functional insulin binding epitopes of the full-length insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE-SCANNING MUTAGENESIS; FACTOR-I RECEPTOR; STRUCTURAL BASIS; NEGATIVE COOPERATIVITY; AFFINITY; DOMAIN; SITE; DETERMINANTS; ISOFORM; REGION	Mutational analyses of the secreted recombinant insulin receptor extracellular domain have identified a ligand binding site composed of residues located in the L1 domain (amino acids 1 - 470) and at the C terminus of the alpha subunit (amino acids 705 - 715). To evaluate the physiological significance of this ligand binding site, we have transiently expressed cDNAs encoding full-length receptors with alanine mutations of the residues forming the functional epitopes of this binding site and determined their insulin binding properties. Insulin bound to wild-type receptors with complex kinetics, which were fitted to a two-component sequential model; the K-d of the high affinity component was 0.03 nM and that of the low affinity component was 0.4 nM. Mutations of Arg(14), Phe(64), Phe(705), Glu(706), Tyr(708), Asn(711), and Val(715) inactivated the receptor. Alanine mutation of Asn(15) resulted in a 20-fold decrease in affinity, whereas mutations of Asp(12), Gln(34), Leu(36), Leu(37), Leu(87), Phe(89), Tyr(91), Lys(121), Leu(709), and Phe(714) all resulted in 4-10-fold decreases. When the effects of the mutations were compared with those of the same mutations of the secreted recombinant receptor, significant differences were observed for Asn(15), Leu(37), Asp(707), Leu(709), Tyr(708), Asn(711), Phe714, and Val715, suggesting that the molecular basis for the interaction of each form of the receptor with insulin differs. We also examined the effects of alanine mutations of Asn(15), Gln(34), and Phe(89) on insulin-induced receptor autophosphorylation. They had no effect on the maximal response to insulin but produced an increase in the EC50 commensurate with their effect on the affinity of the receptor for insulin.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Whittaker, J (corresponding author), Case Western Reserve Univ, Dept Nutr, Dent Bldg,2123 Abington Rd,Rm 201, Cleveland, OH 44106 USA.	Jonathan.Whittaker@case.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065890] Funding Source: NIH RePORTER; NIDDK NIH HHS [5 R01 DK065890] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; Chen JW, 2003, AM J PHYSIOL-ENDOC M, V284, pE1149, DOI 10.1152/ajpendo.00410.2002; CHOTHIA C, 1983, NATURE, V302, P500, DOI 10.1038/302500a0; CHRISTOFFERSEN CT, 1994, ENDOCRINOLOGY, V135, P472, DOI 10.1210/en.135.1.472; CUTFIELD JF, 1979, J MOL BIOL, V132, P85, DOI 10.1016/0022-2836(79)90497-2; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; DEGER A, 1986, BIOCHEM BIOPH RES CO, V135, P458; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; Denley A, 2004, MOL ENDOCRINOL, V18, P2502, DOI 10.1210/me.2004-0183; EMDIN SO, 1980, DIABETES, V29, P301, DOI 10.2337/diabetes.29.4.301; FABRY M, 1992, J BIOL CHEM, V267, P8950; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; HEDO JA, 1981, BIOCHEMISTRY-US, V20, P3385, DOI 10.1021/bi00515a013; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Marino-Buslje C, 1998, FEBS LETT, V441, P331, DOI 10.1016/S0014-5793(98)01509-9; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; Sambrook J, 2001, MOL CLONING LAB MANU; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; VOLUND A, 1991, DIABETIC MED, V8, P839, DOI 10.1111/j.1464-5491.1991.tb02122.x; Ward CW, 1999, GROWTH FACTORS, V16, P315, DOI 10.3109/08977199909069149; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; Whittaker J, 2002, J BIOL CHEM, V277, P47380, DOI 10.1074/jbc.M208371200; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; Whittaker J, 2001, J BIOL CHEM, V276, P43980, DOI 10.1074/jbc.M102863200; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	35	35	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20932	20936		10.1074/jbc.M411320200	http://dx.doi.org/10.1074/jbc.M411320200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799978	hybrid			2022-12-25	WOS:000229438800005
J	Patnaik, SK; Stanley, P				Patnaik, SK; Stanley, P			Mouse large can modify complex N- and mucin O-glycans on alpha-dystroglycan to induce laminin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARY GLYCOSYLATION MUTANTS; DYSTROPHIN-GLYCOPROTEIN COMPLEX; CONGENITAL MUSCULAR-DYSTROPHY; UDP-GLUCOSE-GLYCOPROTEIN; HUMAN LARGE GENE; MOLECULAR-CLONING; MENTAL-RETARDATION; EPIMERASE DOMAIN; CELL MUTANTS; GDP-MANNOSE	The human LARGE gene encodes a protein with two putative glycosyltransferase domains and is required for the generation of functional alpha-dystroglycan (alpha-DG). Monoclonal antibodies IIH6 and VIA4-1 recognize the functional glycan epitopes of alpha-DG that are necessary for binding to laminin and other ligands. Overexpression of full-length mouse Large generated functionally glycosylated alpha-DG in Pro(-)5 Chinese hamster ovary (CHO) cells, and the amount was increased by co-expression of protein: O-mannosyl N-acetylglucosaminyltransferase 1. However, functional alpha-DG represented only a small fraction of the alpha-DG synthesized by CHO cells or expressed from an alpha-DG construct. To identify features of the glycan epitopes induced by Large, the production of functionally glycosylated alpha-DG was investigated in several CHO glycosylation mutants. Mutants with defective transfer of sialic acid (Lec2), galactose (Lec8), or fucose (Lec13) to glycoconjugates, and the Lec15 mutant that cannot synthesize O-mannose glycans, all produced functionally glycosylated alpha-DG upon overexpression of Large. Laminin binding and the alpha-DG glycan epitopes were enhanced in Lec2 and Lec8 cells. In Lec15 cells, functional alpha-DG was increased by co-expression of core 2 N- acetylglucosaminyltransferase 1 with Large. Treatment with N- glycanase markedly reduced functionally glycosylated alpha-DG in Lec2 and Lec8 cells. The combined data provide evidence that Large does not transfer to Gal, Fuc, or sialic acid on alpha-DG nor induce the transfer of these sugars to alpha-DG. In addition, the data suggest that human LARGE may restore functional alpha-DG to muscle cells from patients with defective synthesis of O-mannose glycans via the modification of N- glycans and/or mucin O-glycans on alpha-DG.	Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Stanley, P (corresponding author), 1300 Morris Pk Ave, Bronx, NY 10461 USA.	stanley@aecom.yu.edu		Stanley, Pamela/0000-0001-5704-3747	PHS HHS [R01 36434, P01 13330] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akasaka-Manya K, 2004, BIOCHEM BIOPH RES CO, V325, P75, DOI 10.1016/j.bbrc.2004.10.001; Aravind L, 1999, CURR BIOL, V9, pR836, DOI 10.1016/S0960-9822(00)80039-1; Arnold SM, 2000, BIOCHEMISTRY-US, V39, P2149, DOI 10.1021/bi9916473; Barresi R, 2004, NAT MED, V10, P696, DOI 10.1038/nm1059; Brancaccio Andrea, 2003, Ital J Biochem, V52, P68; Brennan PA, 2004, EJSO, V30, P589, DOI 10.1016/j.ejso.2004.03.014; Breton C, 2002, BIOCHEM SOC SYMP, V69, P23; Broccolini A, 2005, NEUROMUSCULAR DISORD, V15, P177, DOI 10.1016/j.nmd.2004.10.001; Brockington M, 2005, HUM MOL GENET, V14, P657, DOI 10.1093/hmg/ddi062; Brown SC, 1999, J CELL SCI, V112, P209; Chai WG, 1999, EUR J BIOCHEM, V263, P879, DOI 10.1046/j.1432-1327.1999.00572.x; CHANEY W, 1989, J CELL BIOL, V109, P2089, DOI 10.1083/jcb.109.5.2089; Chen W, 2003, GLYCOBIOLOGY, V13, P43, DOI 10.1093/glycob/cwg003; Chiba A, 1997, J BIOL CHEM, V272, P2156; de Bernabe DBV, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.013870; de Bernabe DBV, 2003, J MED GENET, V40, P845; Dejgaard S, 2004, CURR ISSUES MOL BIOL, V6, P29; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Doucey MA, 1998, MOL BIOL CELL, V9, P291, DOI 10.1091/mbc.9.2.291; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Ervasti JM, 1993, CURR OPIN CELL BIOL, V5, P82, DOI 10.1016/S0955-0674(05)80012-2; Ervasti JM, 1997, J BIOL CHEM, V272, P22315, DOI 10.1074/jbc.272.35.22315; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; Harel T, 2004, EUR J HUM GENET, V12, P38, DOI 10.1038/sj.ejhg.5201087; Holzfeind PJ, 2002, HUM MOL GENET, V11, P2673, DOI 10.1093/hmg/11.21.2673; Hong YJ, 2003, J BIOL CHEM, V278, P53045, DOI 10.1074/jbc.M309967200; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Inamori K, 2004, J BIOL CHEM, V279, P2337, DOI 10.1074/jbc.C300480200; Inamori K, 2003, J BIOL CHEM, V278, P43102, DOI 10.1074/jbc.M308255200; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Kanagawa M, 2004, CELL, V117, P953, DOI 10.1016/j.cell.2004.06.003; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; KOSTROMINOVA TY, 1995, J CELL BIOCHEM, V58, P527, DOI 10.1002/jcb.240580416; Kovach MJ, 2001, MOL GENET METAB, V74, P458, DOI 10.1006/mgme.2001.3256; Kunz S, 2001, J CELL BIOL, V155, P301, DOI 10.1083/jcb.200104103; Longman C, 2003, HUM MOL GENET, V12, P2853, DOI 10.1093/hmg/ddg307; Louhichi N, 2004, NEUROGENETICS, V5, P27, DOI 10.1007/s10048-003-0165-9; Manya H, 2004, P NATL ACAD SCI USA, V101, P500, DOI 10.1073/pnas.0307228101; Manya H, 2003, BIOCHEM BIOPH RES CO, V306, P93, DOI 10.1016/S0006-291X(03)00924-0; Marchler-Bauer A, 2002, NUCLEIC ACIDS RES, V30, P281, DOI 10.1093/nar/30.1.281; McDearmon EL, 2003, J BIOL CHEM, V278, P44868, DOI 10.1074/jbc.M307026200; Mercuri E, 2003, ANN NEUROL, V53, P537, DOI 10.1002/ana.10559; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Muntoni F, 2004, CURR OPIN NEUROL, V17, P205, DOI 10.1097/00019052-200404000-00020; Muschler J, 2002, CANCER RES, V62, P7102; Oelmann S, 2001, J BIOL CHEM, V276, P26291, DOI 10.1074/jbc.M011124200; Ohyama C, 1998, J BIOL CHEM, V273, P14582, DOI 10.1074/jbc.273.23.14582; Patnaik SK, 2000, ARCH BIOCHEM BIOPHYS, V375, P322, DOI 10.1006/abbi.1999.1693; Peng HB, 1998, CELL ADHES COMMUN, V5, P475, DOI 10.3109/15419069809005605; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; Pu LX, 2003, BIOCHEM BIOPH RES CO, V312, P555, DOI 10.1016/j.bbrc.2003.10.152; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Rando TA, 2001, MUSCLE NERVE, V24, P1575, DOI 10.1002/mus.1192; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; RUTTLEDGE MH, 1994, GENE CHROMOSOME CANC, V10, P122, DOI 10.1002/gcc.2870100207; Saito F, 2004, NEUROMUSCULAR DISORD, V14, P158, DOI 10.1016/j.nmd.2003.09.006; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Sasaki T, 1998, BBA-GEN SUBJECTS, V1425, P599, DOI 10.1016/S0304-4165(98)00114-7; Schachter H, 2003, GLYCOCONJUGATE J, V20, P291, DOI 10.1023/B:GLYC.0000033626.65127.e4; Sherman DL, 2001, NEURON, V30, P677, DOI 10.1016/S0896-6273(01)00327-0; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; Smalheiser NR, 1998, J BIOL CHEM, V273, P23698, DOI 10.1074/jbc.273.37.23698; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; STANLEY P, 1980, J CELL BIOL, V85, P60, DOI 10.1083/jcb.85.1.60; STANLEY P, 1980, ACS SYM SER, V128, P213; STOLL J, 1982, P NATL ACAD SCI-BIOL, V79, P2296, DOI 10.1073/pnas.79.7.2296; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; Tessier DC, 2000, GLYCOBIOLOGY, V10, P403, DOI 10.1093/glycob/10.4.403; Yamada H, 1996, J NEUROCHEM, V66, P1518; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Yudate HT, 2001, NUCLEIC ACIDS RES, V29, P185, DOI 10.1093/nar/29.1.185	86	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20851	20859		10.1074/jbc.M500069200	http://dx.doi.org/10.1074/jbc.M500069200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788414	hybrid			2022-12-25	WOS:000229242000083
J	Zhao, L; Tong, TJ; Zhang, ZY				Zhao, L; Tong, TJ; Zhang, ZY			Expression of the Leo1-like domain of replicative senescence down-regulated Leo1-like (RDL) protein promotes senescence of 2BS fibroblasts	FASEB JOURNAL			English	Article						replicative senescence; subtractive hybridization; RDL; Leo1-like domain	GENE-EXPRESSION; CAENORHABDITIS-ELEGANS; REPLICATIVE SENESCENCE; MICROARRAY ANALYSIS; ELONGATION-FACTORS; GROWTH-FACTOR; IN-VITRO; CELLS; IDENTIFICATION; FIBROBLASTS	Replicative senescence is thought to relate to aging in vivo and tumor suppression. In this report, we isolated a gene and designated it as RDL (replicative senescence down-regulated Leol-like gene). RDEs expression decreased upon replicative senescence of human diploid 2BS fibroblasts. Overexpression of RDL slightly delayed 2BS fibroblast senescence, whereas suppression of RDL expression imposed no obvious effects on senescence. However, introduction of cDNA fragment encoding the Leol-like domain of RDLp (Leo) alone shortened the replicative life span of 2BS fibroblasts and promoted several senescent features; the introduction of truncated RDL cDNA fragment resulting from deletion of Leo (RDILeo(-)) significantly prolonged 2BS life span and caused a noticeable delay of these senescent features. We demonstrated that introduction of Leo obviously increased the expression of p16(INK4a), p21(WAF1), and PTEN, whereas introduction of RDL-Leo(-) distinctly decreased p16(INK4a) expression. Taken together, our results suggest that the Leol-like domain of RDLp is a senescence-associated domain that accelerates the senescence of 2BS fibroblasts and that there should be another counteractive domain in the remaining part of RDLp.	Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; Peking Univ, Hlth Sci Ctr, Peking Univ Res Ctr Aging, Beijing 100083, Peoples R China	Peking University; Peking University	Tong, TJ (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xueyuan Rd, Beijing 100083, Peoples R China.	tj@bjmu.edu.cn	Zhao, Liang/K-1484-2014	Zhao, Liang/0000-0002-3489-7421				BAYREUTHER K, 1988, P NATL ACAD SCI USA, V85, P5112, DOI 10.1073/pnas.85.14.5112; BELL GI, 1983, NATURE, V304, P368, DOI 10.1038/304368a0; Betz JL, 2002, MOL GENET GENOMICS, V268, P272, DOI 10.1007/s00438-002-0752-8; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Bucher MH, 2002, ACTA CRYSTALLOGR D, V58, P392, DOI 10.1107/S0907444901021187; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Campisi J, 2001, EXP GERONTOL, V36, P607, DOI 10.1016/S0531-5565(00)00230-8; Coates PJ, 2002, J PATHOL, V196, P371, DOI 10.1002/path.1073; Derventzi A, 1996, ANTICANCER RES, V16, P2901; Dierick JF, 2002, FEBS LETT, V531, P499, DOI 10.1016/S0014-5793(02)03604-9; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DIPAOLO BR, 1995, EXP CELL RES, V220, P178, DOI 10.1006/excr.1995.1304; DOLE MG, 1995, CANCER RES, V55, P2576; Duan JM, 2001, J BIOL CHEM, V276, P48325, DOI 10.1074/jbc.M104814200; Endege WO, 1999, BIOTECHNIQUES, V26, P542, DOI 10.2144/99263cr04; Fan WW, 2004, CANCER RES, V64, P5132, DOI 10.1158/0008-5472.CAN-04-0615; Garbarino JE, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-18; Gonos ES, 1998, EXP CELL RES, V240, P66, DOI 10.1006/excr.1998.3948; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; LeckaCzernik B, 1996, EXP GERONTOL, V31, P159, DOI 10.1016/0531-5565(95)02014-4; LI JH, 1995, MECH AGEING DEV, V80, P25, DOI 10.1016/0047-6374(94)01557-3; LINSKENS MHK, 1995, NUCLEIC ACIDS RES, V23, P3244, DOI 10.1093/nar/23.16.3244; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; MAGDOLEN V, 1994, BBA-GENE STRUCT EXPR, V1218, P205, DOI 10.1016/0167-4781(94)90013-2; Mueller CL, 2002, MOL CELL BIOL, V22, P1971, DOI 10.1128/MCB.22.7.1971-1980.2002; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; Nauck MA, 1999, DIABETOLOGIA, V42, P373, DOI 10.1007/s001250051165; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Semov A, 2002, ANAL BIOCHEM, V302, P38, DOI 10.1006/abio.2001.5515; Severino J, 2000, EXP CELL RES, V257, P162, DOI 10.1006/excr.2000.4875; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Spector D. L., 1998, CELLS LAB MANUAL; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; TANG ZQ, 1994, MECH AGEING DEV, V73, P57, DOI 10.1016/0047-6374(94)90038-8; Walhout AJM, 2002, CURR BIOL, V12, P1952, DOI 10.1016/S0960-9822(02)01279-4; Wang W, 2001, J BIOL CHEM, V276, P48655, DOI 10.1074/jbc.M108278200; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682	45	5	10	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					521	532		10.1096/fj.04-2689com	http://dx.doi.org/10.1096/fj.04-2689com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791002				2022-12-25	WOS:000228865300036
J	Barrett, CF; Cao, YQ; Tsien, RW				Barrett, CF; Cao, YQ; Tsien, RW			Gating deficiency in a familial hemiplegic migraine type 1 mutant P/Q-type calcium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC KIDNEY-CELLS; CA2+ CHANNEL; TRANSMITTER RELEASE; CURRENT-DENSITY; MUTATIONS; CURRENTS; ALPHA(1A); NEURONS; INACTIVATION; MODULATION	Familial hemiplegic migraine type 1 (FHM1) arises from missense mutations in the gene encoding alpha(1A), the pore-forming subunit of P/Q-type calcium channels. The nature of the channel disorder is fundamental to the disease, yet is not well understood. We studied how the most prevalent FHM1 mutation, a threonine to methionine substitution at position 666 (TM), affects both ionic current and gating current associated with channel activation, a previously unexplored feature of P/Q channels. Whole-cell currents were measured in HEK293 cells expressing channels containing either wild-type (WT) or TM alpha(1A). Calcium currents were significantly smaller in cells expressing TM channels, consistent with previous reports. In contrast, surface expression of TM channels, measured by immunostaining against an extracellular epitope, was not decreased, and Western blots demonstrated that TM alpha(1A) subunits were expressed as full-length proteins. WT and TM gating currents were isolated by replacing Ca2+ with the nonpermeant cation La3+. The gating currents generated by the mutant channels were one-third that of WT, a deficiency sufficient to account for the observed attenuation in calcium current; the remaining gating current was no different in kinetics or voltage dependence. Thus, the decreased calcium influx seen with TM channels can be attributed to a reduced number of channels available to undergo the voltage-dependent conformational changes needed for channel opening, not to fewer channel proteins expressed on the cell surface. This identification of an intrinsic defect in FHM1 mutant channels helps explain their impact on neurotransmission when they occupy type-specific slots for P/Q channels at central nerve terminals.	Stanford Univ, Sch Med, Beckman Ctr, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	Stanford University	Tsien, RW (corresponding author), Stanford Univ, Sch Med, Beckman Ctr, Dept Mol & Cellular Physiol, Rm B105, Stanford, CA 94305 USA.	rwtsien@stanford.edu			NINDS NIH HHS [NS24067] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024067] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altier C, 2002, J BIOL CHEM, V277, P33598, DOI 10.1074/jbc.M202476200; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BEAN BP, 1989, J GEN PHYSIOL, V94, P65, DOI 10.1085/jgp.94.1.65; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; Cao YQ, 2005, P NATL ACAD SCI USA, V102, P2590, DOI 10.1073/pnas.0409896102; Cao YQ, 2004, NEURON, V43, P387, DOI 10.1016/j.neuron.2004.07.014; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ELMSLIE KS, 1992, J PHYSIOL-LONDON, V451, P229, DOI 10.1113/jphysiol.1992.sp019162; Ferrari MD, 1998, LANCET, V351, P1043, DOI 10.1016/S0140-6736(97)11370-8; Flagg TP, 1999, J GEN PHYSIOL, V114, P685, DOI 10.1085/jgp.114.5.685; Frindt G, 2001, AM J PHYSIOL-RENAL, V280, pF112, DOI 10.1152/ajprenal.2001.280.1.F112; Goadsby PJ, 2002, NEW ENGL J MED, V346, P257, DOI 10.1056/NEJMra010917; HADLEY RW, 1991, J GEN PHYSIOL, V98, P265, DOI 10.1085/jgp.98.2.265; Hans M, 1999, J NEUROSCI, V19, P1610; HONG SJ, 1995, J PHYSIOL-LONDON, V482, P283, DOI 10.1113/jphysiol.1995.sp020517; Jones LP, 1999, BIOPHYS J, V76, P2530, DOI 10.1016/S0006-3495(99)77407-2; Jones LP, 1997, J PHYSIOL-LONDON, V498, P601, DOI 10.1113/jphysiol.1997.sp021886; Jones LP, 1998, J GEN PHYSIOL, V112, P125, DOI 10.1085/jgp.112.2.125; Josephson IR, 1997, PFLUG ARCH EUR J PHY, V433, P321; Josephson IR, 1996, BIOPHYS J, V70, P1285, DOI 10.1016/S0006-3495(96)79685-6; Kors EE, 2003, ARCH NEUROL-CHICAGO, V60, P684, DOI 10.1001/archneur.60.5.684; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; Kraus RL, 2000, J BIOL CHEM, V275, P9239, DOI 10.1074/jbc.275.13.9239; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; Liu L, 2003, J BIOENERG BIOMEMBR, V35, P671, DOI 10.1023/B:JOBB.0000008031.12485.ee; McDonough SI, 2005, BIOPHYS J, V88, P211, DOI 10.1529/biophysj.104.051714; Melliti K, 2003, J PHYSIOL-LONDON, V546, P337, DOI 10.1113/jphysiol.2002.026716; Meza U, 1998, J NEUROSCI, V18, P5240, DOI 10.1523/JNEUROSCI.18-14-05240.1998; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; Mullner C, 2004, J BIOL CHEM, V279, P51844, DOI 10.1074/jbc.M408756200; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PEROZO E, 1993, NEURON, V11, P353, DOI 10.1016/0896-6273(93)90190-3; Piedras-Renteria ES, 2001, J NEUROSCI, V21, P9185, DOI 10.1523/JNEUROSCI.21-23-09185.2001; Pietrobon D, 2002, MOL NEUROBIOL, V25, P31, DOI 10.1385/MN:25:1:031; Pietrobon D, 2003, NAT REV NEUROSCI, V4, P386, DOI 10.1038/nrn1102; Pineda JC, 1998, J NEUROPHYSIOL, V79, P2522, DOI 10.1152/jn.1998.79.5.2522; Protti DA, 1996, NEUROLOGY, V46, P1391, DOI 10.1212/WNL.46.5.1391; Soong TW, 2002, J NEUROSCI, V22, P10142; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; Tottene A, 2002, P NATL ACAD SCI USA, V99, P13284, DOI 10.1073/pnas.192242399; Tsien RW, 1999, CALCIUM AS A CELLULAR REGULATOR, P171; van den Maagdenberg AMJM, 2004, NEURON, V41, P701, DOI 10.1016/S0896-6273(04)00085-6; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	46	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24064	24071		10.1074/jbc.M502223200	http://dx.doi.org/10.1074/jbc.M502223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15795222	hybrid			2022-12-25	WOS:000229880000080
J	Shlyonsky, V; Goolaerts, A; Van Beneden, R; Sariban-Sohraby, S				Shlyonsky, V; Goolaerts, A; Van Beneden, R; Sariban-Sohraby, S			Differentiation of epithelial Na+ channel function - An in vitro model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY CELL-LINE; DOME FORMATION; II CELLS; LUNG; EXPRESSION; TRANSPORT; CONDUCTANCE; CURRENTS; ATPASE; GENE	Confluent monolayers of epithelial cells grown on nonporous support form fluid-filled hemicysts called domes, which reflect active ion transport across the epithelium. Clara-like H441 lung adenocarcinoma cells grown on glass supports and exposed to 50 nM dexamethasone developed domes in a time-dependent fashion. Uplifting of small groups of cells occurred within 6-12 h, well formed domes appeared between 24 and 48 h, and after 7 days, individual domes started to merge. Cells inside of domes compared with those outside domes, or with monolayers not exposed to dexamethasone, differed by higher surfactant production, an increased cytokeratin expression, and the localization of claudin-4 proteins to the plasma membrane. In patch clamp studies, amiloride-blockable sodium currents were detected exclusively in cells inside domes, whereas in cells outside of domes, sodium crossed the membrane through La3+-sensitive nonspecific cation channels. Cells grown on permeable support without dexamethasone expressed amiloride-sensitive currents only after tight electrical coupling was achieved (transepithelial electrical resistance (R-t) > 1 kilohm). In real-time quantitative PCR experiments, the addition of dexamethasone increased the content of claudin-4, occludin, and Na+ channel gamma-subunit (gamma-ENaC) mRNAs by 1.34-, 1.32-, and 1.80-fold, respectively, after 1 h and was followed by an increase at 6 h in the content of mRNA of alpha- and beta-ENaC and of alpha 1- and beta 1-Na, K-ATPase. In the absence of dexamethasone, neither change in gene expression nor cell uplifting was observed. Our data suggest that during epithelial differentiation, coordinated expression of tight junction proteins precedes the development of vectorial transport of sodium, which in turn leads to the fluid accumulation in basolateral spaces that is responsible for dome formation.	Univ Libre Bruxelles, Lab Physiol & Physiopathol, B-1070 Brussels, Belgium	Universite Libre de Bruxelles	Sariban-Sohraby, S (corresponding author), Univ Libre Bruxelles, Lab Physiol & Physiopathol, Campus Erasme,CP 604,808 Route Lennik, B-1070 Brussels, Belgium.	sohraby@ulb.ac.be		Shlyonsky, Vadim/0000-0003-2999-6553				Abraham V, 2001, AM J PHYSIOL-LUNG C, V280, pL1085, DOI 10.1152/ajplung.2001.280.6.L1085; AKAIKE N, 1994, JPN J PHYSIOL, V44, P433, DOI 10.2170/jjphysiol.44.433; Awayda MS, 2004, AM J PHYSIOL-CELL PH, V287, pC395, DOI 10.1152/ajpcell.00412.2003; Barquin N, 1997, AM J PHYSIOL-LUNG C, V273, pL825, DOI 10.1152/ajplung.1997.273.4.L825; BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; Chalaka S, 1999, AM J PHYSIOL-LUNG C, V277, pL197, DOI 10.1152/ajplung.1999.277.1.L197; CHANDER A, 1986, J BIOL CHEM, V261, P6126; Clunes MT, 2004, J PHYSIOL-LONDON, V557, P809, DOI 10.1113/jphysiol.2004.061143; CUTZ E, 1971, AM J PATHOL, V62, P127; GAZDAR AF, 1990, CANCER RES, V50, P5481; Gonzales LW, 2002, AM J PHYSIOL-LUNG C, V283, pL940, DOI 10.1152/ajplung.00127.2002; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; Hao H, 2003, AM J PHYSIOL-LUNG C, V285, pL593, DOI 10.1152/ajplung.00037.2003; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Inagaki A, 2004, AM J PHYSIOL-CELL PH, V286, pC380, DOI 10.1152/ajpcell.00373.2003; Itani OA, 2002, AM J PHYSIOL-LUNG C, V282, pL631, DOI 10.1152/ajplung.00085.2001; Kemp PJ, 2001, J PHYSIOL-LONDON, V536, P693, DOI 10.1111/j.1469-7793.2001.t01-1-00693.x; Kunzelmann K, 1996, PFLUG ARCH EUR J PHY, V431, P578, DOI 10.1007/BF02191906; Lazrak A, 2003, AM J PHYSIOL-LUNG C, V285, pL443, DOI 10.1152/ajplung.00412.2002; LEVER JE, 1979, P NATL ACAD SCI USA, V76, P1323, DOI 10.1073/pnas.76.3.1323; MASON RJ, 1982, P NATL ACAD SCI-BIOL, V79, P6033, DOI 10.1073/pnas.79.19.6033; Mauro T, 2002, J INVEST DERMATOL, V118, P589, DOI 10.1046/j.1523-1747.2002.01721.x; Nakahari T, 1996, J MEMBRANE BIOL, V154, P35, DOI 10.1007/s002329900130; RABITO CA, 1980, IN VITRO CELL DEV B, V16, P461, DOI 10.1007/BF02626458; Ramminger SJ, 2004, AM J PHYSIOL-LUNG C, V287, pL411, DOI 10.1152/ajplung.00407.2003; RANNELS SR, 1989, J MOL CELL CARDIOL, V21, P151, DOI 10.1016/0022-2828(89)90851-1; Rothen-Rutishauser B, 1998, PHARMACEUT RES, V15, P964, DOI 10.1023/A:1011953405272; SARIBANSOHRABY S, 1983, AM J PHYSIOL, V245, pC167, DOI 10.1152/ajpcell.1983.245.3.C167; Sayegh R, 1999, J BIOL CHEM, V274, P12431, DOI 10.1074/jbc.274.18.12431; SCHNEEBERGER EL, 1997, LUNG SCI FDN, P505; SHEN SS, 1976, J MEMBRANE BIOL, V29, P373, DOI 10.1007/BF01868971; SUGAHARA K, 1984, J CELL BIOL, V99, P1541, DOI 10.1083/jcb.99.4.1541; Thomas CP, 2004, AM J PHYSIOL-LUNG C, V287, pL843, DOI 10.1152/ajplung.00340.2003; Tonoli H, 2000, ENDOCRINOLOGY, V141, P1403, DOI 10.1210/en.141.4.1403; Wadsworth SJ, 1997, AM J PHYSIOL-LUNG C, V273, pL427, DOI 10.1152/ajplung.1997.273.2.L427; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Xu W, 1999, J MEMBRANE BIOL, V171, P117, DOI 10.1007/s002329900564; Zucchi I, 1999, P NATL ACAD SCI USA, V96, P13766, DOI 10.1073/pnas.96.24.13766; Zucchi I, 2001, P NATL ACAD SCI USA, V98, P5608, DOI 10.1073/pnas.091101898	39	48	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24181	24187		10.1074/jbc.M413823200	http://dx.doi.org/10.1074/jbc.M413823200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15817472	hybrid			2022-12-25	WOS:000229880000093
J	Howard, MJ; Smales, CM				Howard, MJ; Smales, CM			NMR analysis of synthetic human serum albumin alpha-helix 28 identifies structural distortion upon amadori modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN MODIFICATION; ADVANCED GLYCATION; NONENZYMATIC GLYCATION; EMPIRICAL PARAMETERS; FOLDING PROBLEM; GLUCOSE; MOBILITY; MODEL; PEPTIDES; FRUCTOSE	The non-enzymatic reaction between reducing sugars and long-lived proteins in vivo results in the formation of glycation and advanced glycation end products, which alter the properties of proteins including charge, helicity, and their tendency to aggregate. Such protein modifications are linked with various pathologies associated with the general aging process such as Alzheimer disease and the long-term complications of diabetes. Although it has been suggested that glycation and advanced glycation end products altered protein structure and helicity, little structural data and information currently exist on whether or not glycation does indeed influence or change local protein secondary structure. We have addressed this problem using a model helical peptide system containing a di-lysine motif derived from human serum albumin. We have shown that, in the presence of 50 mM glucose and at 37 degrees C, one of the lysine residues in the di-lysine motif within this peptide is preferentially glycated. Using NMR analysis, we have confirmed that the synthetic peptide constituting this helix does indeed form a alpha-helix in solution in the presence of 30% trifluoroethanol. Glycation of the model peptide resulted in the distortion of the alpha-helix, forcing the region of the helix around the site of glycation to adopt a 3(10) helical structure. This is the first reported evidence that glycation can influence or change local protein secondary structure. The implications and biological significance of such structural changes on protein function are discussed.	Univ Kent, Dept Biosci, Prot Sci Grp, Canterbury CT2 7NJ, Kent, England	University of Kent	Smales, CM (corresponding author), Univ Kent, Dept Biosci, Prot Sci Grp, Canterbury CT2 7NJ, Kent, England.	c.m.smales@kent.ac.uk		Smales, Christopher Mark/0000-0002-2762-4724; Howard, Mark/0000-0002-0762-2887	Biotechnology and Biological Sciences Research Council [BB/C504600/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Ahmed N, 2005, J BIOL CHEM, V280, P5724, DOI 10.1074/jbc.M410973200; Alikhani ZB, 2005, J BIOL CHEM, V280, P12087, DOI 10.1074/jbc.M406313200; Arumugam S, 2003, J MOL BIOL, V327, P719, DOI 10.1016/S0022-2836(03)00180-3; Biemel KM, 2002, J BIOL CHEM, V277, P24907, DOI 10.1074/jbc.M202681200; Blakytny R, 1997, BBA-PROTEIN STRUCT M, V1343, P299, DOI 10.1016/S0167-4838(97)00145-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUCALA R, 1996, DIAGN ENDOCRIN METAB, V14, P99; Bunk DH, 1997, ANAL CHEM, V69, P2457, DOI 10.1021/ac961205m; CAVANAGH J, 1996, PROTEIN MNR SPECTROS; Choi YG, 2004, J BIOL CHEM, V279, P30402, DOI 10.1074/jbc.M400854200; Coussons PJ, 1997, FREE RADICAL BIO MED, V22, P1217, DOI 10.1016/S0891-5849(96)00557-6; Davis PJ, 2001, ALLERGY, V56, P56, DOI 10.1034/j.1398-9995.2001.00918.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hanford LE, 2004, J BIOL CHEM, V279, P50019, DOI 10.1074/jbc.M409782200; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lapolla A, 1999, CLIN CHEM, V45, P288; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; MUNOZ V, 1995, J MOL BIOL, V245, P275, DOI 10.1006/jmbi.1994.0023; NEGLIA CI, 1985, J BIOL CHEM, V260, P5406; Rohovec J, 2003, CHEM-EUR J, V9, P2193, DOI 10.1002/chem.200204632; Sell DR, 2004, J BIOL CHEM, V279, P54173, DOI 10.1074/jbc.M408946200; SHAKLAI N, 1984, J BIOL CHEM, V259, P3812; Smales CM, 2000, BIOTECHNOL APPL BIOC, V32, P109, DOI 10.1042/BA20000032; Smales CM, 2002, BIOTECHNOL BIOENG, V77, P37, DOI 10.1002/bit.10161; Smales CM, 2000, BIOTECHNOL BIOENG, V67, P177, DOI 10.1002/(SICI)1097-0290(20000120)67:2<177::AID-BIT7>3.0.CO;2-3; SUAREZ G, 1989, J BIOL CHEM, V264, P3674; VANGUNSTEREN WF, 1994, METHOD ENZYMOL, V239, P619; Wada Y, 1996, J MASS SPECTROM, V31, P263, DOI 10.1002/(SICI)1096-9888(199603)31:3<263::AID-JMS292>3.0.CO;2-2; Williamson RA, 1999, J BIOL CHEM, V274, P37226, DOI 10.1074/jbc.274.52.37226; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yoon MS, 2004, BIOCHEM BIOPH RES CO, V323, P377, DOI 10.1016/j.bbrc.2004.08.118; Zhao HR, 1996, BIOCHEM BIOPH RES CO, V229, P128, DOI 10.1006/bbrc.1996.1768; Zigrovic I, 1998, GLYCOCONJUGATE J, V15, P563, DOI 10.1023/A:1006907724915	37	33	34	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22582	22589		10.1074/jbc.M501480200	http://dx.doi.org/10.1074/jbc.M501480200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15837789	Green Accepted, hybrid			2022-12-25	WOS:000229741800006
J	Skacel, N; Menon, LG; Mishra, PJ; Peters, R; Banerjees, D; Bertino, JR; Abali, EE				Skacel, N; Menon, LG; Mishra, PJ; Peters, R; Banerjees, D; Bertino, JR; Abali, EE			Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDYLATE SYNTHASE INHIBITOR; MESSENGER-RNA; IN-VITRO; ESCHERICHIA-COLI; POTENT INHIBITOR; BINDING; METHOTREXATE; ENZYME; CELLS; DEHYDROGENASE	Human dihydrofolate reductase ( DHFR) protein levels rapidly increase upon exposure to methotrexate, a potent inhibitor of this enzyme. A model to explain this increase proposes that DHFR inhibits its own translation by binding to its cognate mRNA and that methotrexate disrupts the DHFR protein-mRNA complex allowing its translation to resume. In the present study, Chinese hamster ovary cells lacking DHFR were transfected with wild type and mutants of human DHFR to identify amino acids that are essential for increases in DHFR in response to methotrexate. Glu-30, Leu-22, and Ser-118 were involved in the up-regulation of DHFR protein levels by methotrexate and certain other antifolates. Cells transfected with E30A, L22R, and S118A mutants that did not respond to methotrexate up-regulation had higher basal levels of DHFR, consistent with the model, i.e. lack of feedback regulation of these enzymes. Although cells containing the S118A mutant enzyme had higher levels of DHFR and had catalytic activity similar to that of wild type DHFR, they had the same sensitivity to the cytotoxicity of methotrexate, as were cells with wild type DHFR. This finding provides evidence that the adaptive up-regulation of DHFR by methotrexate contributes to the decreased sensitivity to this drug. Based on these observations, a new model is proposed whereby DHFR exists in two conformations, one bound to DHFR mRNA and the other bound to NADPH. The mutants that are not up-regulated by methotrexate are unable to bind their cognate mRNA.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ 08903 USA; Weill Cornell Grad Sch Med Sci, New York, NY 10021 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar	Bertino, JR (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Rm 3030,195 Little Albany St, New Brunswick, NJ 08903 USA.	abaliem@umdnj.edu; bertinoj@umdnj.edu			NCI NIH HHS [CA 08010] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008010, R37CA008010] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABALI E, 2003, P AM ASSOC CANC RES, V114, P601; APPLEMAN JR, 1988, J BIOL CHEM, V263, P10304; APPLEMAN JR, 1990, J BIOL CHEM, V265, P5579; APPLEMAN JR, 1988, J BIOL CHEM, V263, P9187; BASTOW KF, 1984, ADV ENZYME REGUL, V22, P15, DOI 10.1016/0065-2571(84)90006-2; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BERTINO JR, 1965, CLIN PHARMACOL THER, V6, P763; BERTINO JR, 1963, J CLIN INVEST, V42, P1899, DOI 10.1172/JCI104875; BERTINO JR, 1970, CANCER RES, V30, P2372; BERTINO JR, 1962, NATURE, V193, P140, DOI 10.1038/193140a0; BERTINO JR, 1997, CANC MED, V2, P907; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; Blakley RL, 1998, HUM MUTAT, V11, P259, DOI 10.1002/(SICI)1098-1004(1998)11:4<259::AID-HUMU1>3.3.CO;2-N; BYSTROFF C, 1991, BIOCHEMISTRY-US, V30, P2227, DOI 10.1021/bi00222a028; CAREY J, 1983, BIOCHEMISTRY-US, V22, P4723, DOI 10.1021/bi00289a017; CHU E, 1994, J BIOL CHEM, V269, P20289; CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009; Chu E., 1996, CANC CHEMOTHERAPY BI, P109; COWAN KH, 1986, MOL PHARMACOL, V30, P69; DOMIN BA, 1982, MOL PHARMACOL, V21, P478; Ercikan E, 1993, Adv Exp Med Biol, V338, P537; Ercikan-Abali E. A., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P163; ErcikanAbali EA, 1997, BIOCHEMISTRY-US, V36, P12317, DOI 10.1021/bi971026e; ErcikanAbali EA, 1996, CANCER RES, V56, P4142; ErcikanAbali EA, 1996, MOL PHARMACOL, V49, P430; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; HILLCOAT BL, 1967, P NATL ACAD SCI USA, V58, P1632, DOI 10.1073/pnas.58.4.1632; HOWELL EE, 1986, SCIENCE, V231, P1123, DOI 10.1126/science.3511529; JACKMAN AL, 1991, CANCER RES, V51, P5579; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LEWIS WS, 1995, J BIOL CHEM, V270, P5057, DOI 10.1074/jbc.270.10.5057; Mayer-Kuckuk P, 2002, P NATL ACAD SCI USA, V99, P3400, DOI 10.1073/pnas.062036899; McGuire JJ, 2003, CURR PHARM DESIGN, V9, P2593, DOI 10.2174/1381612033453712; McPherson J. P., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P676; Nagy E, 2000, BIOCHEM BIOPH RES CO, V275, P253, DOI 10.1006/bbrc.2000.3246; Nowak W, 2001, ACTA BIOCHIM POL, V48, P903; Pioli PA, 2002, J BIOL CHEM, V277, P35738, DOI 10.1074/jbc.M204002200; ROMANIUK PJ, 1985, BIOCHEMISTRY-US, V24, P4239, DOI 10.1021/bi00336a064; Rouault TA, 2000, COLD SPRING HARBOR M, V39, P655; SCHWEITZER BI, 1989, J BIOL CHEM, V264, P20786; Shih C, 1997, CANCER RES, V57, P1116; Tai NW, 2002, NUCLEIC ACIDS RES, V30, P4481, DOI 10.1093/nar/gkf562; THEIL EC, 1990, J BIOL CHEM, V265, P4771; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; Webber S, 1996, CANCER CHEMOTH PHARM, V37, P509, DOI 10.1007/s002800050422	45	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22721	22731		10.1074/jbc.M500277200	http://dx.doi.org/10.1074/jbc.M500277200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817466	hybrid			2022-12-25	WOS:000229741800022
J	Wang, TY; Leventis, R; Silvius, JR				Wang, TY; Leventis, R; Silvius, JR			Artificially lipid-anchored proteins can elicit clustering-induced intracellular signaling events in Jurkat T-lymphocytes independent of lipid raft association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-RECEPTOR; IMMUNOLOGICAL SYNAPSE; MEMBRANE DOMAINS; FUNCTIONAL RAFTS; MICRODOMAINS; ACCUMULATION; TRANSDUCTION; RECRUITMENT; ACTIVATION; LIPOSOMES	We have incorporated artificial lipid-anchored streptavidin conjugates with fully saturated or polyunsaturated lipid anchors into the plasma membranes of Jurkat T-lymphocytes to assess previous conclusions that the activation of signaling processes induced in these cells by clustering of endogenous glycosylphosphatidylinositol-anchored proteins or ganglioside GM1 depends specifically on the association of these membrane components with lipid rafts. Lipid-anchored streptavidin conjugates could be incorporated into Jurkat or other mammalian cell surfaces by inserting biotinylated phosphatidylethanolamine-polyethyleneglycols (PE-PEGs) and subsequently binding streptavidin to the cell-incorporated PE-PEGs. Saturated dipalmitoyl-PE-PEG-streptavidin conjugates prepared in this manner partitioned substantially into the detergentin-soluble membrane fraction isolated from Jurkat or fibroblast cells, whereas polyunsaturated dilinoleoyl-PE-PEG-anchored conjugates were wholly excluded from this fraction, consistent with the differences in the affinities of the two types of lipid anchors for liquid-ordered membrane domains. Remarkably, however, antibody-mediated cross-linking of either dipalmitoyl- or dilinoleoyl-PE-PEG-anchored streptavidin conjugates in Jurkat cells induced elevation of cytoplasmic calcium levels and tyrosine phosphorylation of the scaffolding protein linker of T-cell activation in a manner similar to that observed upon cross-linking of endogenous CD59 or ganglioside GM1. The amplitude of the cross-linking-stimulated elevation of cytoplasmic calcium moreover showed an essentially identical dependence on the level of incorporated streptavidin conjugate for either type of lipid anchor. Confocal fluorescence microscopy revealed that PE-PEG-streptavidin conjugates with saturated versus polyunsaturated anchors showed very similar surface distributions vis a vis GM1 or CD59 under conditions where one or both species were cross-linked. These results indicate that cross-linking of diverse proteins anchored only to the outer leaflet of the plasma membrane can induce activation of Jurkat T-cell-signaling responses, but they appear to contradict previous suggestions that this phenomenon rests specifically on the association of such species with lipid rafts.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Silvius, JR (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	john.silvius@mcgill.ca						BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Brunschwig EB, 1999, J IMMUNOTHER, V22, P390, DOI 10.1097/00002371-199909000-00002; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Burack WR, 2002, J IMMUNOL, V169, P2837, DOI 10.4049/jimmunol.169.6.2837; CINEK T, 1992, J IMMUNOL, V149, P2262; Civenni G, 1998, BLOOD, V91, P1784, DOI 10.1182/blood.V91.5.1784.1784_1784_1792; Comiskey M, 2003, HUM IMMUNOL, V64, P999, DOI 10.1016/j.humimm.2003.08.352; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Fenske DB, 2001, BBA-BIOMEMBRANES, V1512, P259, DOI 10.1016/S0005-2736(01)00327-3; FRA AM, 1994, J BIOL CHEM, V269, P30745; Giurisato E, 2003, J BIOL CHEM, V278, P6771, DOI 10.1074/jbc.M210758200; Glebov OO, 2004, NAT CELL BIOL, V6, P238, DOI 10.1038/ncb1103; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Ilangumaran S, 1997, BBA-BIOMEMBRANES, V1328, P227, DOI 10.1016/S0005-2736(97)00099-0; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Johnsson M, 2003, BIOPHYS J, V85, P3839, DOI 10.1016/S0006-3495(03)74798-5; Jordan S, 2003, J IMMUNOL, V171, P78, DOI 10.4049/jimmunol.171.1.78; Kato K, 2004, BIOTECHNOL PROGR, V20, P897, DOI 10.1021/bp0342093; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Loertscher R, 2002, TRANSPL IMMUNOL, V9, P93, DOI 10.1016/S0966-3274(02)00013-8; LOWRY RR, 1974, LIPIDS, V9, P491, DOI 10.1007/BF02534277; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Palmer LR, 2003, BBA-BIOMEMBRANES, V1611, P204, DOI 10.1016/S0005-2736(03)00058-0; Parmryd I, 2003, EXP CELL RES, V285, P27, DOI 10.1016/S0014-4827(02)00048-4; Pizzo P, 2004, MICROBES INFECT, V6, P686, DOI 10.1016/j.micinf.2004.02.017; Pizzo P, 2004, IMMUNOL LETT, V91, P3, DOI 10.1016/j.imlet.2003.09.008; Pizzo P, 2002, EUR J IMMUNOL, V32, P3082, DOI 10.1002/1521-4141(200211)32:11<3082::AID-IMMU3082>3.0.CO;2-2; Premkumar DRD, 2001, J CELL BIOCHEM, V82, P234, DOI 10.1002/jcb.1154; Rodgers W, 2001, EXP CELL RES, V267, P173, DOI 10.1006/excr.2001.5253; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SILVIUS JR, 1993, BIOCHEMISTRY-US, V32, P3153, DOI 10.1021/bi00063a030; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Tavano R, 2004, J IMMUNOL, V173, P5392, DOI 10.4049/jimmunol.173.9.5392; Tuosto L, 2001, EUR J IMMUNOL, V31, P345, DOI 10.1002/1521-4141(200102)31:2<345::AID-IMMU345>3.3.CO;2-C; VANDENBERG CW, 1995, J CELL BIOL, V131, P669, DOI 10.1083/jcb.131.3.669; Wang TY, 2000, BIOPHYS J, V79, P919, DOI 10.1016/S0006-3495(00)76347-8; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	51	46	46	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22839	22846		10.1074/jbc.M502920200	http://dx.doi.org/10.1074/jbc.M502920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817446	hybrid			2022-12-25	WOS:000229741800036
J	Carmichael, JA; Lawrence, MC; Graham, LD; Pilling, PA; Epa, VC; Noyce, L; Lovrecz, G; Winkler, DA; Pawlak-Skrzecz, A; Eaton, RE; Hannan, GN; Hill, RJ				Carmichael, JA; Lawrence, MC; Graham, LD; Pilling, PA; Epa, VC; Noyce, L; Lovrecz, G; Winkler, DA; Pawlak-Skrzecz, A; Eaton, RE; Hannan, GN; Hill, RJ			The X-ray structure of a hemipteran ecdysone receptor ligand-binding domain - Comparison with a Lepidopteran ecdysone receptor ligand-binding domain and implications for insecticide design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ECDYSTEROID RECEPTOR; PROTEIN; CAVITIES; SEQUENCE; POCKET; ECR; ACTIVATION; REVEALS; PROGRAM	The ecdysone receptor is a hormone-dependent transcription factor that plays a central role in regulating the expression of vast networks of genes during development and reproduction in the phylum Arthropoda. The functional receptor is a heterodimer of the two nuclear receptor proteins ecdysone receptor (EcR) and ultraspiracle protein. The receptor is the target of the environmentally friendly bisacylhydrazine insecticides, which are effective against Lepidoptera but not against Hemiptera or several other insect orders. Here we present evidence indicating that much of the selectivity of the bisacylhydrazine insecticides can be studied at the level of their binding to purified ecdysone receptor ligand-binding domain (LBD) heterodimers. We report the crystal structure of the ecdysone receptor LBD heterodimer of the hemipteran Bemisia tabaci (Bt, sweet potato whitefly) in complex with the ecdysone analogue ponasterone A. Although comparison with the corresponding known LBD structure from the lepidopteran Heliothis virescens (Hv) ecdysone receptor revealed the overall mode of ponasterone A binding to be very similar in the two cases, we observed that the BtEcR ecdysteroid-binding pocket is structured differently to that of HvEcR in those parts that are not in contact with ponasterone A. We suggest that these differences in the ligand-binding pocket may provide a molecular basis for the taxonomic order selectivity of bisacylhydrazine insecticides.	CSIRO, Hlth Sci & Nutr, Parkville, Vic 3052, Australia; Commonwealth Sci & Ind Org, N Ryde, NSW 1670, Australia; Commonwealth Sci & Ind Org, Clayton S MDC, Vic 3169, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Commonwealth Scientific & Industrial Research Organisation (CSIRO); Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Lawrence, MC (corresponding author), CSIRO, Hlth Sci & Nutr, 343 Royal Parade, Parkville, Vic 3052, Australia.	mike.lawrence@csiro.au; ron.hill@csiro.au	Lawrence, Michael C/A-5357-2009; Winkler, David A/A-3774-2008; Pilling, Patricia/AAT-7845-2021; Graham, Lloyd/A-1461-2008	Winkler, David A/0000-0002-7301-6076; Graham, Lloyd/0000-0002-9778-1688; Lawrence, Michael/0000-0003-1999-0801				Bahadur RP, 2004, J MOL BIOL, V336, P943, DOI 10.1016/j.jmb.2003.12.073; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bergman T, 2004, BIOCHEM J, V378, P779, DOI 10.1042/BJ20031302; Billas IML, 2003, NATURE, V426, P91, DOI 10.1038/nature02112; Billas IML, 2001, J BIOL CHEM, V276, P7465, DOI 10.1074/jbc.M008926200; Bonneton F, 2003, MOL BIOL EVOL, V20, P541, DOI 10.1093/molbev/msg054; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clayton GM, 2001, P NATL ACAD SCI USA, V98, P1549, DOI 10.1073/pnas.041611298; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Dhadialla TS, 1998, ANNU REV ENTOMOL, V43, P545, DOI 10.1146/annurev.ento.43.1.545; Downes M, 2003, MOL CELL, V11, P1079, DOI 10.1016/S1097-2765(03)00104-7; Egea PF, 2002, MOL ENDOCRINOL, V16, P987, DOI 10.1210/me.16.5.987; Elzen GW, 2001, J ECON ENTOMOL, V94, P55, DOI 10.1603/0022-0493-94.1.55; Enmark E, 2001, TRENDS PHARMACOL SCI, V22, P611, DOI 10.1016/S0165-6147(00)01859-9; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Farnegardh M, 2003, J BIOL CHEM, V278, P38821, DOI 10.1074/jbc.M304842200; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Hannan GN, 1997, INSECT BIOCHEM MOLEC, V27, P479, DOI 10.1016/S0965-1748(97)00019-2; Hannan GN, 2001, INSECT BIOCHEM MOLEC, V31, P771, DOI 10.1016/S0965-1748(00)00182-X; Harmatha J, 1997, ARCH INSECT BIOCHEM, V35, P219, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<219::AID-ARCH20>3.3.CO;2-Z; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; Hoerer S, 2003, J MOL BIOL, V334, P853, DOI 10.1016/j.jmb.2003.10.033; Hubbard SJ, 1995, PROTEIN ENG, V8, P1011, DOI 10.1093/protein/8.10.1011; HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613; Hubbard SJ, 1996, J MOL BIOL, V261, P289, DOI 10.1006/jmbi.1996.0460; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; Kumar MB, 2004, J BIOL CHEM, V279, P27211, DOI 10.1074/jbc.M403839200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; Lezzi M, 2002, EUR J BIOCHEM, V269, P3237, DOI 10.1046/j.1432-1033.2002.03001.x; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mi LZ, 2003, MOL CELL, V11, P1093, DOI 10.1016/S1097-2765(03)00112-6; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; Riddiford L M, 2000, Vitam Horm, V60, P1, DOI 10.1016/S0083-6729(00)60016-X; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; Smagghe G, 2002, INSECT BIOCHEM MOLEC, V32, P187, DOI 10.1016/S0965-1748(01)00109-6; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Williams S, 2003, J BIOL CHEM, V278, P27138, DOI 10.1074/jbc.M302260200; WING KD, 1988, SCIENCE, V241, P470, DOI 10.1126/science.241.4864.470; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YUND MA, 1978, P NATL ACAD SCI USA, V75, P6039, DOI 10.1073/pnas.75.12.6039	57	90	97	5	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22258	22269		10.1074/jbc.M500661200	http://dx.doi.org/10.1074/jbc.M500661200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15809296	hybrid			2022-12-25	WOS:000229557900071
J	Chen, H; Tu, SW; Hsieh, JT				Chen, H; Tu, SW; Hsieh, JT			Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABERRANT PROMOTER METHYLATION; H3 LYSINE-27 METHYLATION; PROTEIN HDAB2IP GENE; METHYLTRANSFERASE ACTIVITY; PROLIFERATION; ESTABLISHMENT; REPRESSION; ENHANCER; STATES; SUZ12	Human DAB2IP ( hDAB2IP), a novel GTPase-activating protein modulating the Ras-mediated signaling and tumor necrosis factor-mediated apoptosis, is a potent growth inhibitor in human prostate cancer (PCa). Loss of hDAB2IP expression in PCa is due to altered epigenetic regulation (i.e. DNA methylation and histone modification) of its promoter region. The elevated polycomb Ezh2, a histone methyltransferase, has been associated with PCa progression. In this study, we have demonstrated that an increased Ezh2 expression in normal prostatic epithelial cells can suppress hDAB2IP gene expression. In contrast, knocking down the endogenous Ezh2 levels in PCa by a specific small interfering RNA can increase hDAB2IP expression. The association of Ezh2 complex (including Eed and Suz12) with hDAB2IP gene promoter is also detected in PCa cells but not in normal prostatic epithelial cells. Increased Ezh2 expression in normal prostatic epithelial cells by cDNA transfection facilitates the recruitment of other components of Ezh2 complex to the hDAB2IP promoter region accompanied with the increased levels of methyl histone H3 (H3) and histone deacetylase (HDAC1). Consistently, data from PCa cells transfected with Ezh2 small interfering RNA demonstrated that reduced Ezh2 levels resulted in the dissociation of Ezh2 complex accompanied with decreased levels of both methyl H3 and HDAC1 from hDAB2IP gene promoter. We further unveiled that the methylation status of Lys-27 but not Lys-9 of H3 in hDAB2IP promoter region is consistent with the hDAB2IP levels in both normal prostatic epithelial cells and PCa cells. Together, we conclude that hDAB2IP gene is a target gene of Ezh2 in prostatic epithelium, which provides an underlying mechanism of the down-regulation of hDAB2IP gene in PCa.	Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hsieh, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75390 USA.	JT.Hsieh@UTSouthwestern.edu						Bloyer S, 2003, DEV BIOL, V261, P426, DOI 10.1016/S0012-1606(03)00314-2; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200; Chen H, 2002, GENOMICS, V79, P573, DOI 10.1006/geno.2002.6739; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236; Fong YY, 2002, SCIENCE, V296, P2235, DOI 10.1126/science.1070790; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Kelly WG, 2002, DEVELOPMENT, V129, P479; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Korenchuk S, 2001, IN VIVO, V15, P163; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Navone NM, 1997, CLIN CANCER RES, V3, P2493; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; PAIK WK, 1971, SCIENCE, V174, P114, DOI 10.1126/science.174.4005.114; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Pirrotta V, 2003, GENETICA, V117, P191, DOI 10.1023/A:1022992011833; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5; Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Rossant J, 2001, Harvey Lect, V97, P17; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Sengupta AK, 2004, DEVELOPMENT, V131, P1959, DOI 10.1242/dev.01084; Sewalt RGAB, 2002, MOL CELL BIOL, V22, P5539, DOI 10.1128/MCB.22.15.5539-5553.2002; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; Weijerman PC, 1998, UROLOGY, V51, P657, DOI 10.1016/S0090-4295(97)00696-1; Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200	45	177	188	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22437	22444		10.1074/jbc.M501379200	http://dx.doi.org/10.1074/jbc.M501379200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817459	hybrid			2022-12-25	WOS:000229557900089
J	Yoon, HS; Ghaleb, AM; Nandan, MO; Hisamuddin, IM; Dalton, WB; Yang, VW				Yoon, HS; Ghaleb, AM; Nandan, MO; Hisamuddin, IM; Dalton, WB; Yang, VW			Kruppel-like factor 4 prevents centrosome amplification following gamma-irradiation-induced DNA damage	ONCOGENE			English	Article						cell cycle; GKLF; p53; cyclin E; Cdk2; small hairpin RNA (shRNA)	CYCLIN-E OVEREXPRESSION; HUMAN BREAST-TUMORS; CHROMOSOME INSTABILITY; GENOMIC INSTABILITY; CANCER-CELLS; COLORECTAL-CANCER; P53 MUTATION; E GENE; ABNORMALITIES; ARREST	Centrosome duplication is a carefully controlled process in the cell cycle. Previous studies indicate that the tumor suppressor, p53, regulates centrosome duplication. Here, we present evidence for the involvement of the mammalian Kruppel-like transcription factor, KLF4, in preventing centrosome amplification following DNA damage caused by gamma-irradiation. The colon cancer cell line HCT116, which contains wild-type p53 alleles ( HCT116 p53 +/+), displayed stable centrosome numbers following gamma-irradiation. In contrast, HCT116 cells null for the p53 alleles (HCT116 p53-/-) exhibited centrosome amplification after irradiation. In the latter cell line, KLF4 was not activated following gamma-irradiation due to the absence of p53. However, centrosome amplification could be suppressed in irradiated HCT116 p53 -/- cells by conditional induction of exogenous KLF4. Conversely, in a HCT116 p53+/+ cell line stably transfected with small hairpin RNA (shRNA) designed to specifically inhibit KLF4, gamma-irradiation induced centrosome amplification. In these cells, the inability of KLF4 to become activated in response to DNA damage was directly associated with an increase in cyclin E level and Cdk2 activity, both essential for regulating centrosome duplication. Cotransfection experiments showed that KLF4 overexpression suppressed the promoter activity of the cyclin E gene. The results of this study demonstrated that KLF4 is both necessary and sufficient in preventing centrosome amplification following gamma-radiation-induced DNA damage and does so by transcriptionally suppressing cyclin E expression.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Oncol, Atlanta, GA 30322 USA	Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu	; Dalton, William/M-7944-2017	Mandayam, Nandan/0000-0002-4061-9348; Dalton, William/0000-0002-1314-0534	NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230, R24DK064399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER; NCI NIH HHS [CA84197, R01 CA084197] Funding Source: Medline; NIDDK NIH HHS [R24 DK064399, DK64399, DK52230, R01 DK052230] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Romaih K, 2003, CANCER GENET CYTOGEN, V144, P91, DOI 10.1016/S0165-4608(02)00929-9; Bennett RA, 2004, ONCOGENE, V23, P6823, DOI 10.1038/sj.onc.1207561; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; CARDER P, 1993, ONCOGENE, V8, P1397; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Donehower LA, 1996, PROG CLIN BIOL RES, V395, P1; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geng Y, 1996, ONCOGENE, V12, P1173; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; HARVEY M, 1993, ONCOGENE, V8, P2457; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; KELLOGG DR, 1989, NATURE, V340, P99, DOI 10.1038/340099a0; KIRSCHNER MW, 1986, NATURE, V324, P621, DOI 10.1038/324621a0; Kuo KK, 2000, HEPATOLOGY, V31, P59, DOI 10.1002/hep.510310112; LEE JM, 1994, ONCOGENE, V9, P3731; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Mayer F, 2003, ONCOGENE, V22, P3859, DOI 10.1038/sj.onc.1206469; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 2003, CANCER RES, V63, P1398; Pihan GA, 1998, CANCER RES, V58, P3974; Sato N, 1999, CLIN CANCER RES, V5, P963; Sato N, 2001, CANCER GENET CYTOGEN, V126, P13, DOI 10.1016/S0165-4608(00)00384-8; Schatten H, 2000, BIOL CELL, V92, P331, DOI 10.1016/S0248-4900(00)01079-0; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Sluder G, 1997, J CELL SCI, V110, P421; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2002, CELL CYCLE, V1, P75, DOI 10.4161/cc.1.1.103; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	58	65	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4017	4025		10.1038/sj.onc.1208576	http://dx.doi.org/10.1038/sj.onc.1208576			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806166	Green Accepted			2022-12-25	WOS:000229680300002
J	Conner, SD; Schmid, SL				Conner, SD; Schmid, SL			CVAK104 is a novel poly-L-lysine-stimulated kinase that targets the beta 2-subunit of AP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; ENDOCYTOSIS IN-VITRO; PROTEIN-KINASES; PHOSPHORYLATION; BETA-2-ADAPTIN; IDENTIFICATION; APPENDAGE; REVEALS; COMPLEX; CDK5	Isolated clathrin adaptor protein (AP) preparations are known to co-fractionate with endogenous kinase activities, including poly-L-lysine-stimulated kinases that target various constituents of the clathrin coat. We have identified CVAK104 (a coated vesicle-associated kinase of 104 kDa) using a mass spectroscopic analysis of adaptor protein preparations. CVAK104 is a novel serine/threonine kinase that belongs to the SCY1-like family of protein kinases, previously thought to be catalytically inactive. We found that CVAK104 co-fractionates with adaptor protein preparations extracted from clathrin-coated vesicles and directly binds to both clathrin and the plasma membrane adaptor, AP2. CVAK104 binds ATP, and kinase assays indicate that it functions in vitro as a poly-L-lysine-stimulated kinase that is capable of autophosphorylation and phosphorylating the beta 2-adaptin subunit of AP2.	Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Minnesota System; University of Minnesota Twin Cities; Scripps Research Institute	Conner, SD (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, 6-160 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	sdconner@umn.edu		Schmid, Sandra/0000-0002-1690-7024	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH061345] Funding Source: NIH RePORTER; NIMH NIH HHS [R37-MH61345] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BALL CL, 1995, J CELL SCI, V108, P2865; BARZVI D, 1986, J BIOL CHEM, V261, P9614; Blondeau F, 2004, P NATL ACAD SCI USA, V101, P3833, DOI 10.1073/pnas.0308186101; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cousin MA, 2001, TRENDS NEUROSCI, V24, P659, DOI 10.1016/S0166-2236(00)01930-5; GEORGIEVAHANSON V, 1988, J NEUROCHEM, V50, P307, DOI 10.1111/j.1471-4159.1988.tb13265.x; Greener T, 2000, J BIOL CHEM, V275, P1365, DOI 10.1074/jbc.275.2.1365; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; Harlow E., 1988, ANTIBODIES LAB MANUA; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; Korolchuk VI, 2002, TRAFFIC, V3, P428, DOI 10.1034/j.1600-0854.2002.30606.x; Lauritsen JPH, 2000, BBA-MOL CELL RES, V1497, P297, DOI 10.1016/S0167-4889(00)00065-3; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Morgan JR, 2000, J NEUROSCI, V20, P8667; Olusanya O, 2001, CURR BIOL, V11, P896, DOI 10.1016/S0960-9822(01)00240-8; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; ROBINSON PJ, 1994, TRENDS NEUROSCI, V17, P348, DOI 10.1016/0166-2236(94)90179-1; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635	35	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21539	21544		10.1074/jbc.M502462200	http://dx.doi.org/10.1074/jbc.M502462200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15809293	hybrid			2022-12-25	WOS:000229438800076
J	Yamazaki, T; Sasaki, E; Kakinuma, C; Yano, T; Miura, S; Ezaki, O				Yamazaki, T; Sasaki, E; Kakinuma, C; Yano, T; Miura, S; Ezaki, O			Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA-CHOLESTEROL ACYLTRANSFERASE; B-CONTAINING LIPOPROTEINS; DIACYLGLYCEROL ACYLTRANSFERASE; ACYL-COENZYME; STIMULATES SECRETION; PLASMA-LIPOPROTEINS; OBESITY RESISTANCE; LEPTIN SENSITIVITY; ADIPOSE-TISSUE; INSULIN	Acyl-CoA:diacylglycerol acyltransferases (DGATs) catalyze the last step in triglyceride (TG) synthesis. The genes for two DGAT enzymes, DGAT1 and DGAT2, have been identified. To examine the roles of liver DGAT1 and DGAT2 in TG synthesis and very low density lipoprotein (VLDL) secretion, liver DGAT1- and DGAT2-overexpressing mice were created by adenovirus-mediated gene transfection. DGAT1-overexpressing mice had markedly increased DGAT activity in the presence of the permeabilizing agent alamethicin. This suggests that DGAT1 possesses latent DGAT activity on the lumen of the endoplasmic reticulum. DGAT1-overexpressing mice showed increased VLDL secretion, resulting in increased gonadal ( epididymal or parametrial) fat mass but not subcutaneous fat mass. The VLDL-mediated increase in gonadal fat mass might be due to the 4-fold greater expression of the VLDL receptor protein in gonadal fat than in subcutaneous fat. DGAT2-overexpressing mice had increased liver TG content, but VLDL secretion was not affected. These results indicate that DGAT1 but not DGAT2 has a role in VLDL synthesis and that increased plasma VLDL concentrations may promote obesity, whereas increased DGAT2 activity has a role in steatosis.	Natl Inst Hlth & Nutr, Div Clin Nutr, Shinjuku Ku, Tokyo 1628636, Japan; Mochida Pharmaceut Co Ltd, Shizuoka 4128524, Japan	National Institute of Health & Nutrition - Japan; Mochida Pharmaceutical Co Ltd	Ezaki, O (corresponding author), Natl Inst Hlth & Nutr, Div Clin Nutr, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628636, Japan.	ezaki@nih.go.jp	Miura, Shinji/K-6516-2013	Miura, Shinji/0000-0001-8806-9763				ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; Arion W J, 1976, J Biol Chem, V251, P4891; Buhman KK, 2001, J BIOL CHEM, V276, P40369, DOI 10.1074/jbc.R100050200; Cao JS, 2003, J BIOL CHEM, V278, P25657, DOI 10.1074/jbc.M302835200; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2003, J CLIN INVEST, V111, P1715, DOI [10.1172/JCI15859, 10.1172/JCI200315859]; Chen HC, 2003, AM J PHYSIOL-ENDOC M, V284, pE213, DOI 10.1152/ajpendo.00248.2002; Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI [10.1172/JCI200214672, 10.1172/JCI0214672]; Chen HC, 2002, ENDOCRINOLOGY, V143, P2893, DOI 10.1210/en.143.8.2893; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fried SK, 2003, AM J CLIN NUTR, V78, p873S, DOI 10.1093/ajcn/78.4.873S; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; Ganji SH, 2004, J LIPID RES, V45, P1835, DOI 10.1194/jlr.M300403-JLR200; GIBBONS GF, 1995, ADV ENZYME REGUL, V35, P179, DOI 10.1016/0065-2571(94)00006-O; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; Goudriaan JR, 2001, ARTERIOSCL THROM VAS, V21, P1488, DOI 10.1161/hq0901.095147; HAMILTON RL, 1967, LAB INVEST, V16, P305; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; JONES AL, 1966, P SOC EXP BIOL MED, V123, P4; Joyce CW, 2000, MOL BIOL CELL, V11, P3675, DOI 10.1091/mbc.11.11.3675; KONO T, 1982, J BIOL CHEM, V257, P942; Liang JJ, 2004, J BIOL CHEM, V279, P44938, DOI 10.1074/jbc.M408507200; Lin S, 2003, MOL BIOL CELL, V14, P2447, DOI 10.1091/mbc.E02-11-0725; Meegalla RL, 2002, BIOCHEM BIOPH RES CO, V298, P317, DOI 10.1016/S0006-291X(02)02466-X; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; SAMBROOK J, 1989, MOL CLONING LAB MANU, P187; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Siri P, 2001, J BIOL CHEM, V276, P46064, DOI 10.1074/jbc.M108909200; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; Usui S, 2002, J LIPID RES, V43, P805; Waterman IJ, 2002, DIABETES, V51, P1708, DOI 10.2337/diabetes.51.6.1708; Waterman IJ, 2002, J LIPID RES, V43, P1555, DOI 10.1194/jlr.M200051-JLR200; Wiggins D, 1996, BIOCHEM J, V320, P673, DOI 10.1042/bj3200673; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899; Zammit VA, 1996, BIOCHEM J, V314, P1, DOI 10.1042/bj3140001	44	114	126	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21506	21514		10.1074/jbc.M412989200	http://dx.doi.org/10.1074/jbc.M412989200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797871	hybrid			2022-12-25	WOS:000229438800072
J	Zhang, N; Ahsan, MH; Zhu, L; Sambucetti, LC; Purchio, AF; West, DB				Zhang, N; Ahsan, MH; Zhu, L; Sambucetti, LC; Purchio, AF; West, DB			NF-kB and not the MAPK signaling pathway regulates GADD45b expression during acute inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B; KINASE; PROTEIN; MYD118; JNK; SUPPRESSION; INHIBITION; ACTIVATION; INDUCTION; INTERACTS	The GADD45 ( growth arrest and DNA damage-inducible) family of genes is involved in the regulation of cell cycle progression and apoptosis. To study signaling pathways affecting GADD45b expression and to examine systematically in vivo the GADD45b expression in tissues following various toxic stresses, we created a transgenic mouse by fusing the GADD45b promoter to firefly luciferase (Gadd45b-luc). In vivo GADD45b expression was assessed by measuring the luciferase activity in the Gadd45b-luc transgenic mouse using a noninvasive imaging system (IVIS Imaging System, Xenogen Corporation). We found that a number of agents that induce oxidative stress, such as sodium arsenite, CC14, lipopolysaccharide (LPS), or tumor necrosis factor-a, are able to induce luciferase expression throughout the entire animal. In liver, spleen, lung, intestine, kidney, and heart, we observed an induction of luciferase activity after LPS treatment, which correlates with an increase of GADD45b mRNA in these tissues. Processes that induce DNA damage activate the NF-kB signaling pathway. Several inhibitors of the NF-kB signaling pathway, including dexamethasone, thalidomide, and a proteasome inhibitor, bortezomib, showed inhibitory effects on LPS-induced GADD45b expression as indicated by a decrease of the luciferase activity. Northern blot analysis confirmed a broad inhibitory effect of bortezomib on LPS-induced GADD45b mRNA expression in spleen, lung, and intestine. In liver of bortezomib-treated mice, we observed a reverse correlation between the luciferase activity and the GADD45b mRNA level. We speculate that such a discrepancy could be due to severe liver toxicity caused by bortezomib and LPS co-treatment. MAPK inhibitors had transient and inconsistent effects on LPS-induced luciferase expression. Our data are consistent with the notion that NF-kB, but not the MAPK signaling pathways, is involved in the in vivo regulation of GADD45b expression. Thus, NF-kB signaling involves induction of GADD45b expression, which supports the proposed role of GADD45b in protecting cells against DNA damaged under various stress conditions.	Xenogen Corp, Alameda, CA 94501 USA; Telik Inc, Palo Alto, CA 94304 USA		Zhang, N (corresponding author), Xenogen Corp, 860 Atlantic Ave, Alameda, CA 94501 USA.	ning.zhang@xenogen.com						ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Balliet AG, 2001, DNA CELL BIOL, V20, P239, DOI 10.1089/104454901750219125; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; Gebel T, 2000, TOXICOLOGY, V144, P155, DOI 10.1016/S0300-483X(99)00202-4; Jin RG, 2002, DNA CELL BIOL, V21, P491, DOI 10.1089/104454902320219059; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Keifer JA, 2001, J BIOL CHEM, V276, P22382, DOI 10.1074/jbc.M100938200; Lee EC, 2001, GENOMICS, V73, P56, DOI 10.1006/geno.2000.6451; Li QT, 2002, NAT REV IMMUNOL, V2, P975, DOI 10.1038/nri968; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Spiecker M, 2000, J IMMUNOL, V164, P3316, DOI 10.4049/jimmunol.164.6.3316; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Tan C, 2002, CANCER RES, V62, P1083; Tong T, 2001, EXP CELL RES, V269, P64, DOI 10.1006/excr.2001.5312; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Vairapandi M, 1996, ONCOGENE, V12, P2579; Weber LWD, 2003, CRIT REV TOXICOL, V33, P105, DOI 10.1080/713611034; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	29	58	60	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21400	21408		10.1074/jbc.M411952200	http://dx.doi.org/10.1074/jbc.M411952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797874	hybrid			2022-12-25	WOS:000229438800060
J	Hsieh, TS; Capp, C				Hsieh, TS; Capp, C			Nucleotide- and stoichiometry-dependent DNA supercoiling by reverse gyrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-I; SUPERHELICAL TURNS; MECHANISM; SUBSTRATE; HELICASE; ENZYME; LATCH	Reverse gyrase is a unique type IA topoisomerase that can introduce positive supercoils into DNA. We have investigated some of the biochemical properties of Archaeoglobus fulgidus reverse gyrase. It can mediate three distinct supercoiling reactions depending on the adenine nucleotide cofactor that is present in the reaction. Besides the ATP-driven positive supercoiling reaction, the enzyme can introduce negative supercoils with a nonhydrolyzable analog, adenylyl imidodiphosphate. In the presence of ADP the plasmid DNA is relaxed almost completely, leaving a very low level of positive supercoiling. Surprisingly, the final supercoiling extent for all three distinct reactions depends on the stoichiometry of enzyme to DNA. This dependence is not due to the difference of reaction rate, suggesting that the amount of enzyme bound to DNA is an important determinant for the final supercoiling state of the reaction product. Reverse gyrase also displays exquisite sensitivity toward temperature. Raising the reaction temperatures from 80 to 85 degrees C, both of which are within the optimal growth temperature of A. fulgidus, greatly increases enzyme activity for all the supercoiling reactions. For the reaction with AMPPNP, the product is a hypernegatively supercoiled DNA. This dramatic enhancement of the reverse gyrase activity is also correlated with the appearance of DNA in a pre-melting state at 85 degrees C, likely due to the presence of extensively unwound regions in the plasmid. The possible mechanistic insights from these findings will be presented here.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hsieh, TS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	hsieh@biochem.duke.edu	Hsieh, Tao-shih/G-9305-2012; Wu, Wan-lin/G-8937-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029006] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM029006, GM29006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atomi H, 2004, J BACTERIOL, V186, P4829, DOI 10.1128/JB.186.14.4829-4833.2004; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; Declais AC, 2000, J BIOL CHEM, V275, P19498, DOI 10.1074/jbc.M910091199; Dekker NH, 2002, P NATL ACAD SCI USA, V99, P12126, DOI 10.1073/pnas.132378799; DELATOUR CB, 1990, J BACTERIOL, V172, P6803, DOI 10.1128/jb.172.12.6803-6808.1990; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; DUGUET M, 1993, NUCLEIC ACIDS RES, V21, P463, DOI 10.1093/nar/21.3.463; Duguet M, 2000, METH MOL B, V95, P35; Forterre P, 2002, TRENDS GENET, V18, P236, DOI 10.1016/S0168-9525(02)02650-1; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; HSIEH TS, 1975, BIOCHEMISTRY-US, V14, P527, DOI 10.1021/bi00674a011; HSIEH TS, 1992, NUCLEIC ACIDS RES, V20, P6177, DOI 10.1093/nar/20.23.6177; JAXEL C, 1989, EMBO J, V8, P3135, DOI 10.1002/j.1460-2075.1989.tb08466.x; Kampmann M, 2004, NUCLEIC ACIDS RES, V32, P3537, DOI 10.1093/nar/gkh683; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KIM RA, 1992, J BIOL CHEM, V267, P17178; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Krah R, 1996, P NATL ACAD SCI USA, V93, P106, DOI 10.1073/pnas.93.1.106; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; Plank JL, 2005, J BIOL CHEM, V280, P3564, DOI 10.1074/jbc.M411337200; Rodriguez AC, 2003, BIOCHEMISTRY-US, V42, P5993, DOI 10.1021/bi034188l; Rodriguez AC, 2002, J BIOL CHEM, V277, P29865, DOI 10.1074/jbc.M202853200; Rodriguez AC, 2002, EMBO J, V21, P418, DOI 10.1093/emboj/21.3.418; SHIBATA T, 1987, J BIOL CHEM, V262, P10419; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Viard T, 2001, J BIOL CHEM, V276, P46495, DOI 10.1074/jbc.M107714200; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831	30	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20467	20475		10.1074/jbc.M502739200	http://dx.doi.org/10.1074/jbc.M502739200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788400	hybrid			2022-12-25	WOS:000229242000039
J	Naryzhny, SN; Zhao, H; Lee, H				Naryzhny, SN; Zhao, H; Lee, H			Proliferating cell nuclear antigen (PCNA) may function as a double homotrimer complex in the mammalian cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-C; DNA-REPLICATION; CHROMATIN; PROTEINS; IDENTIFICATION; INHERITANCE; INTERACT; PARTNERS; REPAIR; CLAMP	The diverse function of proliferating cell nuclear antigen (PCNA) may be regulated by interactions with different protein partners. Interestingly, the binding sites for all known PCNA-associating proteins are on the outer surface or the C termini ("front") sides of the PCNA trimer. Using cell extracts and purified human PCNA protein, we show here that two PCNA homotrimers form a back-to-back doublet. Mutation analysis suggests that the Arg-5 and Lys-110 residues on the PCNA back side are the contact points of the two homotrimers in the doublet. Furthermore, short synthetic peptides encompassing either Arg-5 or Lys-110 inhibit double trimer formation. We also found that a PCNA double trimer, but not a homotrimer alone, can simultaneously accommodate chromatin assembly factor-1 and polymerase delta. Together, our data supports a model that chromatin remodeling by chromatin assembly factor-1 (and, possibly, many other cellular activities) are tightly coupled with DNA replication (and repair) through a PCNA double trimer complex.	NE Ontario Reg Canc Ctr, Dept Res, Sudbury, ON P3E 5J1, Canada		Lee, H (corresponding author), NE Ontario Reg Canc Ctr, Dept Res, 41 Ramsey Lake Rd, Sudbury, ON P3E 5J1, Canada.	hlee@hrsrh.on.ca	Naryzhny, Stanislav/D-1683-2012	Naryzhny, Stanislav/0000-0002-4102-3423				Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Henderson DS, 2000, GENETICS, V154, P1721; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Matsumiya S, 2002, GENES CELLS, V7, P911, DOI 10.1046/j.1365-2443.2002.00572.x; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; Naryzhny SN, 1996, ANAL BIOCHEM, V238, P50, DOI 10.1006/abio.1996.0249; Naryzhny SN, 2001, ELECTROPHORESIS, V22, P1764, DOI 10.1002/1522-2683(200105)22:9&lt;1764::AID-ELPS1764&gt;3.0.CO;2-V; Naryzhny SN, 2003, PROTEOMICS, V3, P930, DOI 10.1002/pmic.200300400; Naryzhny SN, 2004, J BIOL CHEM, V279, P20194, DOI 10.1074/jbc.M312850200; Ohta S, 2002, J BIOL CHEM, V277, P40362, DOI 10.1074/jbc.M206194200; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Schurtenberger P, 1998, J MOL BIOL, V275, P123, DOI 10.1006/jmbi.1997.1435; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Stucki M, 2001, PROG NUCLEIC ACID RE, V65, P261; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	31	46	53	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13888	13894		10.1074/jbc.M500304200	http://dx.doi.org/10.1074/jbc.M500304200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15805117	hybrid			2022-12-25	WOS:000228095500088
J	Tuxworth, RI; Stephens, S; Ryan, ZC; Titus, MA				Tuxworth, RI; Stephens, S; Ryan, ZC; Titus, MA			Identification of a myosin VII-Talin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONVENTIONAL MYOSIN; DICTYOSTELIUM; ADHESION; MORPHOGENESIS; RECRUITMENT; MUTANTS; HOMOLOG; PROTEIN; DYNEIN; CELLS	Myosin VII ( M7) plays a role in adhesion in both Dictyostelium and mammalian cells where it is a component of a complex of proteins that serve to link membrane receptors to the underlying actin cytoskeleton. The nature of this complex is not fully known, prompting a search for M7-binding proteins. Co-immunoprecipitation experiments reveal that Dictyostelium M7 ( DdM7) interacts with talinA, an actin-binding protein with a known role in cell-substrate adhesion. No additional proteins are observed in the immunoprecipitate, indicating that the interaction is direct. The N-terminal region of the DdM7 tail that lies between the region of predicted coil and the first MyTH4 domain is found to harbor the talinA binding site. Localization experiments reveal that talinA does not serve as a membrane receptor for DdM7 and vice versa. These findings reveal that talinA is a major DdM7 binding partner and suggest that their interaction induces a conformational change in each that, in combination with membrane receptor binding, promotes the assembly of a high avidity receptor complex essential for adhesion of the cell to substrata.	Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Titus, MA (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, 6-160 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	titus@lenti.med.umn.edu		Tuxworth, Richard/0000-0001-5697-6254	NIGMS NIH HHS [GM046486] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046486] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boeda B, 2002, EMBO J, V21, P6689, DOI 10.1093/emboj/cdf689; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; CRITCHLEY DR, 1999, GUIDEBOOK CYTOSKELET, P141; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Ernest S, 2000, HUM MOL GENET, V9, P2189, DOI 10.1093/hmg/9.14.2189; Gebbie L, 2004, MOL BIOL CELL, V15, P3915, DOI 10.1091/mbc.E03-12-0908; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Han YH, 2002, J BIOL CHEM, V277, P49877, DOI 10.1074/jbc.M209107200; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; Hibi M, 2004, J MUSCLE RES CELL M, V25, P127, DOI 10.1023/B:JURE.0000035842.71415.f3; Inoue A, 2003, J BIOL CHEM, V278, P5478, DOI 10.1074/jbc.M210489200; KIEKE MC, 2003, MOL MOTORS, P3; KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P51, DOI 10.1002/cm.970150108; KREITMEIER M, 1995, J CELL BIOL, V129, P179, DOI 10.1083/jcb.129.1.179; Kussel-Andermann P, 2000, EMBO J, V19, P6020, DOI 10.1093/emboj/19.22.6020; Kussel-Andermann P, 2000, J BIOL CHEM, V275, P29654, DOI 10.1074/jbc.M004393200; Larochelle DA, 1997, MOL BIOL CELL, V8, P935, DOI 10.1091/mbc.8.5.935; Levi S, 2000, PLASMID, V44, P231, DOI 10.1006/plas.2000.1487; Ma S, 1999, J CELL BIOL, V147, P1261, DOI 10.1083/jcb.147.6.1261; Mburu Philomena, 1997, Genes and Function, V1, P191; Niewohner J, 1997, J CELL BIOL, V138, P349, DOI 10.1083/jcb.138.2.349; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; PATTERSON B, 1995, GENETICS, V140, P505; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; Self T, 1998, DEVELOPMENT, V125, P557; Senda S, 2001, J BIOL CHEM, V276, P2898, DOI 10.1074/jbc.M008059200; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; Titus MA, 1999, CURR BIOL, V9, P1297, DOI 10.1016/S0960-9822(00)80051-2; Todorov PT, 2001, BIOCHEM J, V354, P267, DOI 10.1042/0264-6021:3540267; Tsujioka M, 1999, CURR BIOL, V9, P389, DOI 10.1016/S0960-9822(99)80169-9; Tuxworth RI, 2001, CURR BIOL, V11, P318, DOI 10.1016/S0960-9822(01)00097-5; WIEL D, 1995, NATURE, V374, P60	32	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26557	26564		10.1074/jbc.M503699200	http://dx.doi.org/10.1074/jbc.M503699200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15826949	hybrid			2022-12-25	WOS:000230386800072
J	Pruitt, K; Ulku, AS; Frantz, K; Rojas, RJ; Muniz-Medina, VM; Rangnekar, VM; Der, CJ; Shields, JM				Pruitt, K; Ulku, AS; Frantz, K; Rojas, RJ; Muniz-Medina, VM; Rangnekar, VM; Der, CJ; Shields, JM			Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLON-CANCER; ONCOGENIC RAS; K-RAS; PHOSPHOINOSITIDE 3-KINASE; GUANOSINE TRIPHOSPHATASES; CELLULAR-TRANSFORMATION; FAMILY PROTEINS; DOWN-REGULATION; KINASE CASCADE; ACTIVATION	The apoptosis-promoting protein Par-4 has been shown to be down-regulated in Ras-transformed NIH 3T3 fibroblasts through the Raf/MEK/ERK MAPK pathway. Because mutations of the ras gene are most often found in tumors of epithelial origin, we explored the signaling pathways utilized by oncogenic Ras to down-regulate Par-4 in RIE-1 and rat ovarian surface epithelial ( ROSE) cells. We determined that constitutive activation of the Raf,phosphatidylinositol 3-kinase, or Ral guanine nucleotide exchange factor effector pathway alone was not sufficient to down-regulate Par-4 in RIE-1 or ROSE cells. However, treatment of Ras-transformed RIE-1 or ROSE cells with the MEK inhibitors U0126 and PD98059 increased Par-4 protein expression. Thus, although oncogenic Ras utilizes the Raf/MEK/ERK pathway to down-regulate Par-4 in both fibroblasts and epithelial cells, Ras activation of an additional signaling pathway(s) is required to achieve the same outcome in epithelial cells. Methylation-specific PCR showed that the par-4 promoter is methylated in Ras-transformed cells through a MEK-dependent pathway and that treatment with the DNA methyltransferase inhibitor azadeoxycytidine restored Par-4 mRNA transcript and protein levels, suggesting that the mechanism for Ras-mediated down-regulation of Par-4 is by promoter methylation. Support for this possibility is provided by our observation that Ras transformation was associated with up-regulation of Dnmt1 and Dnmt3 DNA methyltransferase expression. Finally, ectopic Par-4 expression significantly reduced Ras-mediated growth in soft agar, but not morphological transformation, highlighting the importance of Par-4 down-regulation in specific aspects of Ras-mediated transformation of epithelial cells.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Tumor Biol, Baltimore, MD 21231 USA; Univ Kentucky, Div Urol Microbiol & Immunol, Dept Radiat Med, Lexington, KY 40536 USA; Univ N Carolina, Markey Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; Johns Hopkins University; Johns Hopkins Medicine; University of Kentucky; University of North Carolina; University of North Carolina Chapel Hill	Shields, JM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.	shieldsj@med.unc.edu		Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA63071, CA84511] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084511, R01CA063071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Bonfils C, 2000, J BIOL CHEM, V275, P10754, DOI 10.1074/jbc.275.15.10754; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CAPELLA G, 1991, ENVIRON HEALTH PERSP, V93, P125, DOI 10.2307/3431180; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Contente S, 1999, MOL CELL BIOCHEM, V194, P79, DOI 10.1023/A:1006913122261; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Esteller M, 2000, CANCER RES, V60, P2368; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Feig LA, 2002, CURR BIOL, V12, pR259, DOI 10.1016/S0960-9822(02)00787-X; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Guan RJ, 1999, GASTROENTEROLOGY, V116, P1063, DOI 10.1016/S0016-5085(99)70009-0; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Joneson T, 1999, MOL CELL BIOL, V19, P5892; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Olson AL, 2001, AMBUL PEDIATR, V1, P91, DOI 10.1367/1539-4409(2001)001<0091:PCPRAP>2.0.CO;2; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Qiu SG, 1999, ONCOGENE, V18, P7115, DOI 10.1038/sj.onc.1203199; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Tamm I, 2001, LANCET ONCOL, V2, P33, DOI 10.1016/S1470-2045(00)00193-5; Ulku AS, 2003, MOL CANCER RES, V1, P1077; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092; Zhang JH, 2002, TRENDS CELL BIOL, V12, P84, DOI 10.1016/S0962-8924(01)02206-1; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	58	77	83	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23363	23370		10.1074/jbc.M503083200	http://dx.doi.org/10.1074/jbc.M503083200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15831492	hybrid, Green Published			2022-12-25	WOS:000229741800096
J	Thomas, EK; Nakamura, M; Wienke, D; Isacke, CM; Pozzio, A; Liang, P				Thomas, EK; Nakamura, M; Wienke, D; Isacke, CM; Pozzio, A; Liang, P			Endo180 binds to the C-terminal region of type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; MACROPHAGE MANNOSE RECEPTOR; GENE-EXPRESSION; DIFFERENTIAL DISPLAY; MESSENGER-RNA; TRANSMEMBRANE GLYCOPROTEIN; CELLULAR-TRANSFORMATION; TYROSINE KINASE; RAS; CELLS	Type I collagen is a fibril-forming heterotrimer composed of two alpha 1 and one alpha 2 chains and plays a crucial role in cell-matrix adhesion and cell differentiation. Through a comprehensive differential display screening of oncogenic ras target genes, we have shown that the alpha 1 chain of type I collagen (col1a1) is markedly down-regulated by the ras oncogene through the mitogen-activated protein kinase pathway. Although ras-transformed cells are no longer able to produce and secrete endogenous collagen, they can still adhere to exogenous collagen, suggesting that the cells express a collagen binding factor(s) on the cell surface. When the region of col1a1 encompassing the C-terminal glycine repeat and C-prodomain (amino acids 1000 - 1453) was affinity-labeled with human placental alkaline phosphatase, the secreted trimeric fusion protein could bind to the surface of Ras-transformed cells. Using biochemical purification followed by matrix-assisted laser desorption/ionization mass spectrometry analysis, we identified this collagen binding factor as Endo180 (uPARAP, CD280), a member of the mannose receptor family. Ectopic expression of Endo180 in CosE5 cells followed by in situ staining and quantitative binding assays confirmed that Endo180 indeed recognizes and binds to placental alkaline phosphatase. The interaction between Endo180 and the C-terminal region of type I collagen appears to play an important role in cell-matrix adhesion.	Vanderbilt Univ, Sch Med, Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Hypertens & Nephrol, Nashville, TN 37232 USA; Inst Canc Res, Chester Beatty Labs, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England	Vanderbilt University; Vanderbilt University; Vanderbilt University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Liang, P (corresponding author), Vanderbilt Univ, Sch Med, Ingram Canc Ctr, 658 Preston Res Bldg, Nashville, TN 37232 USA.	peng.liang@vanderbilt.edu		Isacke, Clare/0000-0002-9222-3345	NATIONAL CANCER INSTITUTE [R01CA094849] Funding Source: NIH RePORTER; NCI NIH HHS [R01 T32CA09592, R01 CA94849-01] Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Now		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993; Bernocco S, 2001, J BIOL CHEM, V276, P48930, DOI 10.1074/jbc.M108611200; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; COHEN RL, 1989, J BIOL CHEM, V264, P8375; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; East L, 2003, EMBO REP, V4, P710, DOI 10.1038/sj.embor.embor882; East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EIZENBERG O, 1991, BIOCHIM BIOPHYS ACTA, V1129, P34, DOI 10.1016/0167-4781(91)90209-5; Engelholm LH, 2003, J CELL BIOL, V160, P1009, DOI 10.1083/jcb.200211091; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISACKE CM, 1990, MOL CELL BIOL, V10, P2606, DOI 10.1128/MCB.10.6.2606; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kadler KE, 1996, BIOCHEM J, V316, P1; KIARIS H, 1995, BIOCHEM BIOPH RES CO, V214, P788, DOI 10.1006/bbrc.1995.2355; Kjoller L, 2004, EXP CELL RES, V293, P106, DOI 10.1016/j.yexcr.2003.10.008; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEVINE EM, 1965, P NATL ACAD SCI USA, V53, P350, DOI 10.1073/pnas.53.2.350; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, P NATL ACAD SCI USA, V91, P12515, DOI 10.1073/pnas.91.26.12515; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Mousavi SA, 2005, BIOCHEM J, V387, P39, DOI 10.1042/BJ20040966; Myllyharju J, 1997, J BIOL CHEM, V272, P21824, DOI 10.1074/jbc.272.35.21824; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pozzi M, 1998, J CELL BIOL, V142, P587; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; Sheikh H, 2000, J CELL SCI, V113, P1021; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; Stein S, 2002, CELL MOL LIFE SCI, V59, P1274, DOI 10.1007/s00018-002-8506-7; TAN JC, 1995, J BIOL CHEM, V270, P12906, DOI 10.1074/jbc.270.21.12906; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Wienke D, 2003, MOL BIOL CELL, V14, P3592, DOI 10.1091/mbc.E02-12-0814; Wu K, 1996, J BIOL CHEM, V271, P21323, DOI 10.1074/jbc.271.35.21323; Yang ST, 2004, MOL BIOTECHNOL, V27, P197, DOI 10.1385/MB:27:3:197; Zhang R, 1997, ONCOGENE, V14, P1607, DOI 10.1038/sj.onc.1200957; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	56	30	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22596	22605		10.1074/jbc.M501155200	http://dx.doi.org/10.1074/jbc.M501155200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817460	hybrid			2022-12-25	WOS:000229741800008
J	Yoshimura, S; Yoshioka, K; Barr, FA; Lowe, M; Nakayama, K; Ohkuma, S; Nakamura, N				Yoshimura, S; Yoshioka, K; Barr, FA; Lowe, M; Nakayama, K; Ohkuma, S; Nakamura, N			Convergence of cell cycle regulation and growth factor signals on GRASP65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI MATRIX PROTEIN; POLO-LIKE KINASE; STACKING FACTOR; CDC2 KINASE; FREE SYSTEM; GM130; FRAGMENTATION; APPARATUS; MITOSIS; SUBSTRATE	Together with other Golgi matrix components, GRASP65 contributes to the stacking of Golgi cisternae in interphase cells. During mitosis, GRASP65 is heavily phosphorylated, and in turn, cisternal stacking is inhibited leading to the breakdown of the Golgi apparatus. Here we show that GRASP65 is phosphorylated on serine 277 in interphase cells, and this is strongly enhanced in response to the addition of serum or epidermal growth factor. This is directly mediated by ERK suggesting that GRASP65 has some role in growth factor signal transduction. Phosphorylation of Ser-277 is also dramatically increased during mitosis, however this is mediated by Cdk1 and not by ERK. The microinjection of recombinant GRASP65 without N-terminal myristoylation or a peptide fragment containing Ser-277 into the cytosol of normal rat kidney cells inhibits passage through mitosis. This effect is abolished when Ser-277 is replaced with alanine suggesting the phosphorylation of Ser-277 plays an important role in cell cycle regulation. The convergence of cell cycle regulation and growth factor signals on GRASP65 Ser-277 suggests that GRASP65 may function as a signal integrator controlling the cell growth.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Life Sci, Kanazawa, Ishikawa 9201192, Japan; Japan Soc Promot Sci, Chiyoda Ku, Tokyo 1028471, Japan; Kanazawa Univ, Inst Canc Res, Div Cell Cycle Regulat, Kanazawa, Ishikawa 9200934, Japan; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Kyoto 6068501, Japan	Kanazawa University; Japan Society for the Promotion of Science; Kanazawa University; Max Planck Society; University of Manchester; Kyoto University	Nakamura, N (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Life Sci, Kanazawa, Ishikawa 9201192, Japan.	osaru3@kenroku.kanazawa-u.ac.jp	Nakamura, Nobuhiro/F-7811-2011; Nakayama, Kazuhisa/ABF-2924-2020	Nakamura, Nobuhiro/0000-0002-8836-6714; Barr, Francis/0000-0001-7518-253X; Nakayama, Kazuhisa/0000-0001-7701-7183				Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; Aebersold DM, 2004, MOL CELL BIOL, V24, P10000, DOI 10.1128/MCB.24.22.10000-10015.2004; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Barr FA, 2001, J CELL BIOL, V155, P885, DOI 10.1083/jcb.200108102; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Cha HJ, 2001, J CELL BIOL, V153, P1355, DOI 10.1083/jcb.153.7.1355; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Inoue D, 2005, EMBO J, V24, P1057, DOI 10.1038/sj.emboj.7600567; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kano F, 2000, J CELL BIOL, V149, P357, DOI 10.1083/jcb.149.2.357; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Lowe M, 2000, J CELL BIOL, V149, P341, DOI 10.1083/jcb.149.2.341; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Pelham HRB, 2001, J CELL BIOL, V155, P1099, DOI 10.1083/jcb.200110160; Preisinger C, 2005, EMBO J, V24, P753, DOI 10.1038/sj.emboj.7600569; Preisinger C, 2004, J CELL BIOL, V164, P1009, DOI 10.1083/jcb.200310061; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; Seemann J, 2002, SCIENCE, V295, P848, DOI 10.1126/science.1068064; Shorter J, 1999, EMBO J, V18, P4949, DOI 10.1093/emboj/18.18.4949; Shorter J, 2002, ANNU REV CELL DEV BI, V18, P379, DOI 10.1146/annurev.cellbio.18.030602.133733; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Sudo T, 2000, BIOCHEM BIOPH RES CO, V269, P521, DOI 10.1006/bbrc.2000.2333; Sutterlin C, 2002, CELL, V109, P359, DOI 10.1016/S0092-8674(02)00720-1; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Wang YZ, 2005, J BIOL CHEM, V280, P4921, DOI 10.1074/jbc.M412407200; Wang YZ, 2003, EMBO J, V22, P3279, DOI 10.1093/emboj/cdg317; Yoshimura S, 2004, J BIOCHEM, V135, P201, DOI 10.1093/jb/mvh024; Yoshimura S, 2001, J CELL SCI, V114, P4105; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	40	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23048	23056		10.1074/jbc.M502442200	http://dx.doi.org/10.1074/jbc.M502442200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15834132	hybrid			2022-12-25	WOS:000229741800061
J	McMullen, ME; Bryant, PW; Glembotski, CC; Vincent, PA; Pumiglia, KM				McMullen, ME; Bryant, PW; Glembotski, CC; Vincent, PA; Pumiglia, KM			Activation of p38 has opposing effects on the proliferation and migration of endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PHOSPHATASE-1; N-TERMINAL KINASE; MAP KINASE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; C-JUN; SMOOTH-MUSCLE; TNF-ALPHA; FOCAL ADHESION; POTENTIAL ROLE	Pathological conditions such as hypertension and hyper-glycemia as well as abrasions following balloon angioplasty all lead to endothelial dysfunction that impacts disease morbidity. These conditions are associated with the elaboration of a variety of cytokines and increases in p38 activity in endothelial cells. However, the relationship between enhanced p38 activity and endothelial cell function remains poorly understood. To investigate the effect of enhanced p38 MAPK activity on endothelial cell function, we expressed an activated mutant of MEK6 (MEK6E), an upstream regulator of p38. Expression of MEK6E activated p38 and resulted in phosphorylation of its downstream substrate, heat shock protein 27 (Hsp27). Activation of p38 was not sufficient to induce apoptosis; however, it did induce p38-dependent cell cycle arrest. MEK6E expression was sufficient to inhibit ERK phosphorylation triggered by growth factors and integrin engagement. MAPK phosphatase-1 (MKP-1) expression was increased upon p38 activation, and expression of a "substrate-trapping" MKP-1 was sufficient to restore ERK activity. Activation of p38 was sufficient to induce cell migration, which was accompanied by alterations in actin architecture characterized by enhanced lamellipodia. Co-expression of a mutant form of Hsp27, lacking all three phosphorylation sites, reversed MEK6E-induced cell migration and altered the cytoskeletal changes induced by p38 activation. Collectively, these results suggest that cellular decisions regarding migration and proliferation are influenced by p38 activity and that prolonged activation of p38 may result in an anti-angiogenic phenotype that contributes to endothelial dysfunction.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; San Diego State Univ, Inst Heart, San Diego, CA 92182 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	Albany Medical College; Albany Medical College; California State University System; San Diego State University; California State University System; San Diego State University	Pumiglia, KM (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave,MC 165, Albany, NY 12208 USA.	pumiglk@mail.amc.edu		Pumiglia, Kevin/0000-0003-4655-0334	NCI NIH HHS [CA-90653, R01-CA-81419, R01 CA081419, R01 CA081419-06] Funding Source: Medline; NHLBI NIH HHS [HL075573, T32-HL-07194] Funding Source: Medline; NINDS NIH HHS [NS/HL20537] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081419, R01CA090653] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075573, T32HL007194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Avdi NJ, 2002, J BIOL CHEM, V277, P40687, DOI 10.1074/jbc.M204455200; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garcia JGN, 2002, FASEB J, V16, P1064, DOI 10.1096/fj.01-0895com; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; Goldberg PL, 2002, AM J PHYSIOL-LUNG C, V282, pL146, DOI 10.1152/ajplung.2002.282.1.L146; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Guo YL, 2001, J CELL BIOCHEM, V82, P556, DOI 10.1002/jcb.1180; Harnois C, 2004, J CELL PHYSIOL, V198, P209, DOI 10.1002/jcp.10399; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Hoover HE, 2000, J BIOL CHEM, V275, P23825, DOI 10.1074/jbc.M003864200; Horowitz JC, 2004, J BIOL CHEM, V279, P1359, DOI 10.1074/jbc.M306248200; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Issbrucker K, 2002, FASEB J, V16, P262, DOI 10.1096/fj.02-0329fje; Ju HS, 2003, J PHARMACOL EXP THER, V307, P932, DOI 10.1124/jpet.103.057422; Kevil CG, 2001, ENDOTHELIUM-J ENDOTH, V8, P107, DOI 10.3109/10623320109165320; Kim MS, 2003, CANCER RES, V63, P5454; Kishore R, 2003, CIRC RES, V93, P932, DOI 10.1161/01.RES.0000102400.22370.20; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096; McGinn S, 2003, AM J PHYSIOL-ENDOC M, V285, pE708, DOI 10.1152/ajpendo.00572.2002; McMullen M, 2004, ONCOGENE, V23, P1275, DOI 10.1038/sj.onc.1207243; Meadows KN, 2004, ONCOGENE, V23, P192, DOI 10.1038/sj.onc.1206921; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; Nakagami H, 2001, DIABETES, V50, P1472, DOI 10.2337/diabetes.50.6.1472; Pervin S, 2003, CANCER RES, V63, P8853; Pichon S, 2004, J CELL SCI, V117, P2569, DOI 10.1242/jcs.01110; Piotrowicz RS, 1998, FASEB J, V12, P1481, DOI 10.1096/fasebj.12.14.1481; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Pratt PF, 2003, J BIOL CHEM, V278, P51928, DOI 10.1074/jbc.M309256200; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Reddy ST, 2004, ARTERIOSCL THROM VAS, V24, P1676, DOI 10.1161/01.ATV.0000138342.94314.64; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sandberg EM, 2004, J BIOL CHEM, V279, P1956, DOI 10.1074/jbc.M303540200; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 2001, J CELL SCI, V114, P2553; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sheetz MJ, 2002, JAMA-J AM MED ASSOC, V288, P2579, DOI 10.1001/jama.288.20.2579; Song C, 2002, J NEUROCHEM, V83, P828, DOI 10.1046/j.1471-4159.2002.01182.x; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Uddin S, 2004, P NATL ACAD SCI USA, V101, P147, DOI 10.1073/pnas.0307075101; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yashima R, 2001, J CELL PHYSIOL, V188, P201, DOI 10.1002/jcp.1107; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200; Zhu WH, 2002, AM J PATHOL, V161, P823, DOI 10.1016/S0002-9440(10)64242-3	63	117	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20995	21003		10.1074/jbc.M407060200	http://dx.doi.org/10.1074/jbc.M407060200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15790570	hybrid			2022-12-25	WOS:000229438800013
J	Minami, M; Daimon, Y; Mori, K; Takashima, H; Nakajima, T; Itoh, Y; Okanoue, T				Minami, M; Daimon, Y; Mori, K; Takashima, H; Nakajima, T; Itoh, Y; Okanoue, T			Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis	ONCOGENE			English	Article						viral integration; Alu repeat; viral carcinogenesis; DNA tumor virus; liver cancer	COMMON FRAGILE SITES; HEPATOCELLULAR-CARCINOMA; HEPADNAVIRUS INSERTION; DELTA-CATENIN; C-MYC; INTEGRATION; ACTIVATION; CANCER; DNA; IDENTIFICATION	Growing evidence demonstrates that hepatitis B virus (HBV) integration and resulting insertional mutagenesis play an important role in cell growth or maintenance in hepatocellular carcinomas (HCCs). To determine if HBV integration occurs and affects cellular genes at such a stage of infection, we analysed viral-host junctions in chronic hepatitis tissues without HCC using PCR amplification with primers specific to human Alu-repeat and HBV. We obtained 42 independent viral-host junctions from six patients examined and identified chromosomal locations for 20 of the 42 junctions. In six clones, each integration apparently affected a single gene. These six candidate genes included one known tumor suppressor gene, three human homologs of drosophila genes that are critical for organ development, one putative oncogene and one recently found chemokine. Our data, together with previously reported HBV integrants in HCCs, suggested preferential HBV integration into chromosome 3 (P = 0.022). Our virus-tagging approach provided (a) firm evidence of HBV integration in hepatocytes at an early stage of chronic infection and (b) revealed cellular genes possibly affected by HBV integration and potentially involved in early steps of the process leading to carcinogenesis.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kamigyo Ku, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine	Minami, M (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kamigyo Ku, Kyoto 6028566, Japan.	minami@koto.kpu-m.ac.jp						Bagutti C, 2003, J CELL SCI, V116, P2957, DOI 10.1242/jcs.00603; BEASLEY RP, 1981, LANCET, V2, P1129; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Burger MJ, 2002, INT J CANCER, V100, P228, DOI 10.1002/ijc.10468; Daub H, 2002, J VIROL, V76, P8124, DOI 10.1128/JVI.76.16.8124-8137.2002; Ferber MJ, 2003, ONCOGENE, V22, P7233, DOI 10.1038/sj.onc.1207006; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; Lettice LA, 2002, P NATL ACAD SCI USA, V99, P7548, DOI 10.1073/pnas.112212199; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Luo LY, 2001, BIOCHEM BIOPH RES CO, V280, P401, DOI 10.1006/bbrc.2000.4126; Maleszka R, 1998, P NATL ACAD SCI USA, V95, P3731, DOI 10.1073/pnas.95.7.3731; MINAMI M, 1995, GENOMICS, V29, P403, DOI 10.1006/geno.1995.9004; Murakami Y, 2004, J MED VIROL, V72, P203, DOI 10.1002/jmv.10547; NEVINS JR, 1996, FIELDS VIROLOGY, P301; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Paterlini-Brechot P, 2003, ONCOGENE, V22, P3911, DOI 10.1038/sj.onc.1206492; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shen HF, 2003, J VIROL, V77, P1584, DOI 10.1128/JVI.77.2.1584-1588.2003; Smith DI, 1998, INT J ONCOL, V12, P187; TAKADA S, 1990, J VIROL, V64, P822, DOI 10.1128/JVI.64.2.822-828.1990; Tang YT, 2004, GENOMICS, V83, P727, DOI 10.1016/j.ygeno.2003.10.006; Thorland EC, 2003, ONCOGENE, V22, P1225, DOI 10.1038/sj.onc.1206170; TOKINO T, 1991, J VIROL, V65, P6761, DOI 10.1128/JVI.65.12.6761-6764.1991; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang Y, 2004, ONCOGENE, V23, P142, DOI 10.1038/sj.onc.1206889; YAGINUMA K, 1987, J VIROL, V61, P1808, DOI 10.1128/JVI.61.6.1808-1813.1987; Yu MW, 2000, J NATL CANCER I, V92, P1159, DOI 10.1093/jnci/92.14.1159; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	36	65	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2005	24	27					4340	4348		10.1038/sj.onc.1208628	http://dx.doi.org/10.1038/sj.onc.1208628			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806150				2022-12-25	WOS:000229976900003
J	Hasan, UA; Trinchieri, G; Vlach, J				Hasan, UA; Trinchieri, G; Vlach, J			Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27(KIP1); LAMINA PROPRIA FIBROBLASTS; KAPPA-B ACTIVATION; GROWTH ARREST; PHOSPHORYLATION; P27; LOCALIZATION; DEGRADATION; INDUCTION; LIPOPOLYSACCHARIDE	Toll-like receptors (TLRs) are proteins involved in recognition of foreign pathogen-associated molecular patterns and activation of processes leading to innate immune recognition. We show that stimulation of fibroblasts with a TLR5 ligand, flagellin, can induce proliferation of serum-starved cells or prevent cell cycle exit upon serum withdrawal independently of autologous growth factor secretion. Other TLR ligands, such as poly(I:C) and lipopolysaccharide, can have a similar effect only if the action of type I interferons is blocked. Flagellin stimulation can prevent cell cycle arrest induced by overexpression of exogenous cyclin-dependent kinase inhibitor p27. Stimulation of TLR5 and overexpression of MyD88, but not TRIF, TIRAP, or TRAM, result in p27 degradation, which can be suppressed by dominant negative Akt and mutation of the p27 C-terminal Thr(187) site. These data provide evidence for a nonimmune and cell autonomous role of TLR signaling, whereby TLR stimulation provides a positive signal for cell division.	Schering Plough Lab Immunol Res, F-69571 Dardilly, France	Merck & Company	Hasan, UA (corresponding author), Int Agcy Res Canc, Infect & Canc Biol Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	Hasan@iarc.fr	hasan, uzma A/G-3247-2013; Trinchieri, Giorgio/F-9369-2015	Trinchieri, Giorgio/0000-0001-5892-7464; Hasan, Uzma/0000-0002-1770-5539				Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chakravortty D, 1997, BIOCHEM BIOPH RES CO, V240, P458, DOI 10.1006/bbrc.1997.7680; Chakravortty D, 1999, MICROBIOL IMMUNOL, V43, P527, DOI 10.1111/j.1348-0421.1999.tb02438.x; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Gewirtz AT, 2003, CURR PHARM DESIGN, V9, P1, DOI 10.2174/1381612033392422; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hasan UA, 2004, BIOCHEM BIOPH RES CO, V321, P124, DOI 10.1016/j.bbrc.2004.06.134; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; MaasSzabowski N, 1996, J INVEST DERMATOL, V107, P849, DOI 10.1111/1523-1747.ep12331158; Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376; Pagano M, 2004, MOL CELL, V14, P414, DOI 10.1016/S1097-2765(04)00268-0; Piazuelo E, 2000, EUR SURG RES, V32, P191, DOI 10.1159/000008762; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Srivastava SK, 2004, CARCINOGENESIS, V25, P1701, DOI 10.1093/carcin/bgh179; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Ulevitch RJ, 2004, NAT REV IMMUNOL, V4, P512, DOI 10.1038/nri1396; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vivarelli MS, 2004, J EXP MED, V200, P399, DOI 10.1084/jem.20040446; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x	35	69	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20620	20627		10.1074/jbc.M500877200	http://dx.doi.org/10.1074/jbc.M500877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788393	hybrid			2022-12-25	WOS:000229242000058
J	Nehring, LC; Miyamoto, A; Hein, PW; Weinmaster, G; Shipley, JM				Nehring, LC; Miyamoto, A; Hein, PW; Weinmaster, G; Shipley, JM			The extracellular matrix protein MAGP-2 interacts with Jagged1 and induces its shedding from the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROFIBRIL-ASSOCIATED GLYCOPROTEIN-2; ELASTIN-ASSOCIATED MICROFIBRILS; NOTCH LIGAND; MOLECULAR-CLONING; DEVELOPMENTAL EXPRESSION; FIBRILLIN GENES; GAMMA-SECRETASE; DELTA; IDENTIFICATION; TISSUE	Elastic fibers are composed of the protein elastin and a network of 10-12-nm microfibrils, which are composed of several glycoproteins, including fibrillin-1, fibrillin-2, and MAGP1/2 (microfibril-associated glycoproteins-1 and -2). Although fibrillins and MAGPs covalently associate, we find that the DSL (Delta/Serrate/LAG2) protein Jagged1, an activating ligand for Notch receptor signaling, also interacts with MAGP-2 in both yeast two-hybrid and coimmunoprecipitation studies. Interaction between Jagged1 and MAGP-2 requires the epidermal growth factor-like repeats of Jagged1. MAGP-2 was found complexed with the Jagged1 extracellular domain shed from 293T cells and COS-7 cells coexpressing full-length Jagged1 and MAGP-2. MAGP- 2 shedding of the Jagged1 extracellular domain was decreased by the metalloproteinase hydroxamate inhibitor BB3103 implicating proteolysis in its release. Although MAGP- 2 also interacted with the other DSL ligands, Jagged2 and Delta1, they were not found associated with MAGP-2 in the conditioned media, identifying differential effects of MAGP- 2 on DSL ligand shedding. The related microfibrillar protein MAGP- 1 was also found to interact with DSL ligands but, unlike MAGP-2, was unable to facilitate the shedding of Jagged1. Our findings suggest that in addition to its role in microfibrils, MAGP-2 may also affect cellular differentiation through modulating the Notch signaling pathway either by binding to cell surface DSL ligands or by facilitating release and/or stabilization of a soluble extracellular form of Jagged1.	Washington Univ, Div Pulm & Crit Care Med, Dept Med, St Louis, MO 63110 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	Washington University (WUSTL); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Shipley, JM (corresponding author), Washington Univ, Div Pulm & Crit Care Med, Dept Med, Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	mshipley@im.wustl.edu	Hein, Patrick/F-1180-2015		NHLBI NIH HHS [HL67353] Funding Source: Medline; NINDS NIH HHS [NS31885] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031885, R37NS031885] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMS WR, 1995, GENOMICS, V26, P47, DOI 10.1016/0888-7543(95)80081-V; Aho S, 2004, J CELL BIOCHEM, V92, P1271, DOI 10.1002/jcb.20125; Bland CE, 2003, J BIOL CHEM, V278, P13607, DOI 10.1074/jbc.C300016200; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; Chen N, 2004, DEV CELL, V6, P183, DOI 10.1016/S1534-5807(04)00021-8; Crosnier C, 2000, HEPATOLOGY, V32, P574, DOI 10.1053/jhep.2000.16600; Duan ZJ, 2004, MOL CELL BIOL, V24, P58, DOI 10.1128/MCB.24.1.58-70.2004; FAHRENBACH WH, 1966, ANAT RECORD, V155, P563, DOI 10.1002/ar.1091550409; Ge WH, 2002, J NEUROSCI RES, V69, P848, DOI 10.1002/jnr.10364; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GODFREY M, 1990, AM J HUM GENET, V46, P652; GREENLEE TK, 1966, J CELL BIOL, V30, P59, DOI 10.1083/jcb.30.1.59; Hicks C, 2002, J NEUROSCI RES, V68, P655, DOI 10.1002/jnr.10263; HORRIGAN SK, 1992, J BIOL CHEM, V267, P10087; Hukriede NA, 1997, GENETICS, V145, P359; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; KAGAN HM, 1986, REGULATION MATRIX AC, P322; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; Kiyota T, 2004, MECH DEVELOP, V121, P573, DOI 10.1016/j.mod.2004.03.034; KOBAYASHI R, 1989, J BIOL CHEM, V264, P17347; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; Lemaire R, 2004, ARTHRITIS RHEUM-US, V50, P915, DOI 10.1002/art.20053; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; Lillie MA, 1998, CONNECT TISSUE RES, V37, P121, DOI 10.3109/03008209809028905; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MARIENCHECK MC, 1995, CONNECT TISSUE RES, V31, P87, DOI 10.3109/03008209509028396; Mishra-Gorur K, 2002, J CELL BIOL, V159, P313, DOI 10.1083/jcb.200203117; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Penner AS, 2002, J BIOL CHEM, V277, P35044, DOI 10.1074/jbc.M206363200; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Ross JM, 1998, THROMB HAEMOSTASIS, V79, P155; Sakamoto H, 1996, J BIOL CHEM, V271, P4916; Segade F, 2002, J BIOL CHEM, V277, P11050, DOI 10.1074/jbc.M110347200; Six E, 2003, P NATL ACAD SCI USA, V100, P7638, DOI 10.1073/pnas.1230693100; STREETEN BW, 1988, CURR EYE RES, V7, P139, DOI 10.3109/02713688808995743; Sun X, 1997, DEVELOPMENT, V124, P3439; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	48	44	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20349	20355		10.1074/jbc.M500273200	http://dx.doi.org/10.1074/jbc.M500273200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788413	hybrid			2022-12-25	WOS:000229242000025
J	Raja, SM; Metkar, SS; Honing, S; Wang, BK; Russin, WA; Pipalia, NH; Menaa, C; Belting, M; Cao, XF; Dressel, R; Froelich, CJ				Raja, SM; Metkar, SS; Honing, S; Wang, BK; Russin, WA; Pipalia, NH; Menaa, C; Belting, M; Cao, XF; Dressel, R; Froelich, CJ			A novel mechanism for protein delivery - Granzyme B undergoes electrostatic exchange from serglycin to target cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; GRANULE-MEDIATED APOPTOSIS; MANNOSE 6-PHOSPHATE RECEPTORS; CASPASE ACTIVATION; MEMBRANE; REQUIRES; BIOSYNTHESIS; CYTOTOXICITY; COMPLEX; DEATH	The molecular interaction of secreted granzyme B-serglycin complexes with target cells remains undefined. Targets exposed to double-labeled granzyme B-serglycin complexes show solely the uptake of granzyme B. An in vitro model demonstrates the exchange of the granzyme from serglycin to immobilized, sulfated glycosaminoglycans. Using a combination of cell binding and internalization assays, granzyme B was found to exchange to sulfated glycosaminoglycans and, depending on the cell type, to higher affinity sites. Apoptosis induced by purified granzyme B and cytotoxic T-cells was diminished in targets with reduced cell surface glycosaminoglycan content. A mechanism of delivery is proposed entailing electrostatic transfer of granzyme B from serglycin to cell surface proteins.	Evanston Northwestern Healthcare Res Inst, Dept Med, Evanston, IL 60201 USA; Northwestern Univ, Bioimaging Facil, Dept Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ Gottingen, Dept Biochem 2, D-37073 Gottingen, Germany; Univ Gottingen, Dept Immunogenet, D-37073 Gottingen, Germany; Washington Univ, Sch Med, Siteman Canc Ctr, Dept Med,Div Oncol, St Louis, MO 63110 USA; Cornell Univ, Dept Biochem, New York, NY 10021 USA; Scripps Res Inst, Dept Immunol & Vasc Biol, La Jolla, CA 92037 USA	Northwestern University; University of Gottingen; University of Gottingen; Siteman Cancer Center; Washington University (WUSTL); Cornell University; Scripps Research Institute	Raja, SM (corresponding author), Evanston Northwestern Healthcare Res Inst, Dept Med, 2650 Ridge Ave, Evanston, IL 60201 USA.	s-raja@northwestern.edu; c-froelich@northwestern.edu	Dressel, Ralf/R-7065-2016	Dressel, Ralf/0000-0002-1651-1214; Belting, Mattias/0000-0003-1585-5434	NIAID NIH HHS [5R01AI04494-03] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADRIAN C, 2005, J BIOL CHEM, V280, P4663; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAI XM, 1994, J HISTOCHEM CYTOCHEM, V42, P1043, DOI 10.1177/42.8.8027524; Beerens A. M. J., 2003, Current Gene Therapy, V3, P486, DOI 10.2174/1566523034578258; Beresford PJ, 2001, J BIOL CHEM, V276, P43285, DOI 10.1074/jbc.M108137200; Bossi G, 2002, IMMUNOL REV, V189, P152, DOI 10.1034/j.1600-065X.2002.18913.x; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Dehio C, 1998, EXP CELL RES, V242, P528, DOI 10.1006/excr.1998.4116; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Dressel R, 2004, TRANSPLANTATION, V78, P758, DOI 10.1097/01.TP.0000131815.43399.58; Dressel R, 2004, J BIOL CHEM, V279, P20200, DOI 10.1074/jbc.M313108200; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; Froelich CJ, 2004, CELL DEATH DIFFER, V11, P369, DOI 10.1038/sj.cdd.4401381; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Goping IS, 2003, IMMUNITY, V18, P355, DOI 10.1016/S1074-7613(03)00032-3; Griffiths GM, 2003, J CELL BIOL, V160, P155, DOI 10.1083/jcb.200212143; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; Kett WC, 2003, BBA-GEN SUBJECTS, V1620, P225, DOI 10.1016/S0304-4165(02)00539-1; Kurschus FC, 2005, BLOOD, V105, P2049, DOI 10.1182/blood-2004-06-2180; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Lin SX, 2004, MOL BIOL CELL, V15, P721, DOI 10.1091/mbc.E03-07-0497; Metkar SS, 2005, J IMMUNOL METHODS, V299, P117, DOI 10.1016/j.jim.2005.02.003; Metkar SS, 2003, J CELL BIOL, V160, P875, DOI 10.1083/jcb.200210158; Metkar SS, 2002, IMMUNITY, V16, P417, DOI 10.1016/S1074-7613(02)00286-8; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Osmond RIW, 2002, ANAL BIOCHEM, V310, P199, DOI 10.1016/S0003-2697(02)00396-2; Pardo J, 2004, J CELL BIOL, V167, P457, DOI 10.1083/jcb.200406115; Pinkoski MJ, 1998, BLOOD, V92, P1044; Raja SM, 2003, CURR OPIN IMMUNOL, V15, P528, DOI 10.1016/S0952-7915(03)00111-0; Raja SM, 2002, J BIOL CHEM, V277, P49523, DOI 10.1074/jbc.M209607200; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; Trapani JA, 2003, J CELL BIOL, V160, P223, DOI 10.1083/jcb.200210150; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Veugelers K, 2004, BLOOD, V103, P3845, DOI 10.1182/blood-2003-06-2156; Vongchan P, 2005, BBA-GEN SUBJECTS, V1721, P1, DOI 10.1016/j.bbagen.2004.09.007	42	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20752	20761		10.1074/jbc.M501181200	http://dx.doi.org/10.1074/jbc.M501181200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788411	hybrid			2022-12-25	WOS:000229242000073
J	Williams, DC; Cao, ML; Suh, JY; Peterkofsky, A; Clore, GM				Williams, DC; Cao, ML; Suh, JY; Peterkofsky, A; Clore, GM			Solution NMR structure of the 48-kDa IIA(Mannose)-HPr complex of the Escherichia coli mannose phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYL TRANSFER COMPLEX; MACROMOLECULAR STRUCTURE DETERMINATION; PHOSPHOCARRIER PROTEIN HPR; SIGNAL-TRANSDUCING PROTEIN; N-TERMINAL DOMAIN; BACTERIAL PHOSPHOENOLPYRUVATE; CARBOHYDRATE TRANSPORTERS; STEREOCHEMICAL COURSE; STRUCTURE REFINEMENT; ANGSTROM RESOLUTION	The solution structure of the 48-kDa IIA(Man)-HPr complex of the mannose branch of the Escherichia coli phosphotransferase system has been solved by NMR using conjoined rigid body/torsion angle-simulated annealing on the basis of intermolecular nuclear Overhauser enhancement data and residual dipolar couplings. IIA(Man) is dimeric and has two symmetrically related binding sites per dimer for HPr. A convex surface on HPr, formed primarily by helices 1 and 2, interacts with a deep groove at the interface of the two subunits of IIAMan. The interaction surface on IIAMan is predominantly helical, comprising helix 3 from the subunit that bears the active site His-10 and helices 1, 4, and 5 from the other subunit. The total buried accessible surface area at the protein-protein interface is 1450 angstrom(2). The binding sites on the two proteins are complementary in terms of shape and distribution of hydrophobic, hydrophilic, and charged residues. The active site histidines, His-10 of IIAMan and His-15 ( italics indicate HPr residues) of HPr, are in close proximity. An associative transition state involving a pentacoordinate phosphoryl group with trigonal bipyramidal geometry bonded to the N-is an element of 2 atom of His-10 and the N-delta 1 atom of His-15 can be readily formed with negligible displacement in the backbone coordinates of the residues immediately adjacent to the active site histidines. Comparing the structures of complexes of HPr with three other structurally unrelated phosphotransferase system proteins, enzymes I, IIA(glucose), and IIA(mannitol), reveals a number of common features that provide a molecular basis for understanding how HPr specifically recognizes a wide range of diverse proteins.	NIDDK, Phys Chem Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Cell Biol Labs, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Clore, GM (corresponding author), NIDDK, Phys Chem Lab, NIH, Bldg 5,Rm B1-301, Bethesda, MD 20892 USA.	mariusc@intra.niddk.nih.gov	Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027	NIDDK NIH HHS [Z01 DK029023-15] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029023] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; BAX A, 1994, METHOD ENZYMOL, V239, P79; BEGLEY GS, 1982, BIOCHEMISTRY-US, V21, P5552, DOI 10.1021/bi00265a026; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Clore GM, 2000, P NATL ACAD SCI USA, V97, P9021, DOI 10.1073/pnas.97.16.9021; Clore GM, 2004, J AM CHEM SOC, V126, P2923, DOI 10.1021/ja0386804; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Clore GM, 2002, J AM CHEM SOC, V124, P2866, DOI 10.1021/ja017712p; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; Clore GM, 1998, P NATL ACAD SCI USA, V95, P5891, DOI 10.1073/pnas.95.11.5891; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; Cornilescu G, 2002, J BIOL CHEM, V277, P42289, DOI 10.1074/jbc.M207314200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; ERNI B, 1985, J BIOL CHEM, V260, P5495; ERNI B, 1989, J BIOL CHEM, V264, P18733; ERNI B, 1987, J BIOL CHEM, V262, P5238; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; Goto NK, 1999, J BIOMOL NMR, V13, P369, DOI 10.1023/A:1008393201236; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; JIA ZC, 1993, J BIOL CHEM, V268, P22490; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; Kuszewski J, 1999, J AM CHEM SOC, V121, P2337, DOI 10.1021/ja9843730; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARKOVICHOUSLEY Z, 1994, BIOCHEMISTRY-US, V33, P10977, DOI 10.1021/bi00202a017; MARTINVERSTRAETE I, 1990, J MOL BIOL, V214, P657, DOI 10.1016/0022-2836(90)90284-S; MUELLER EG, 1990, BIOCHEMISTRY-US, V29, P6892, DOI 10.1021/bi00481a019; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nunn RS, 1996, J MOL BIOL, V259, P502, DOI 10.1006/jmbi.1996.0335; Orriss GL, 2003, J MOL BIOL, V327, P1111, DOI 10.1016/S0022-2836(03)00215-8; PELTON JG, 1993, PROTEIN SCI, V2, P543; PERUVSHIN K, 1997, P NATL ACAD SCI USA, V94, P12366; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Schauder S, 1998, J MOL BIOL, V276, P591, DOI 10.1006/jmbi.1997.1544; Schwieters CD, 2002, J BIOMOL NMR, V23, P221, DOI 10.1023/A:1019875223132; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Schwieters CD, 2001, J MAGN RESON, V152, P288, DOI 10.1006/jmre.2001.2413; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Siebold C, 2001, FEBS LETT, V504, P104, DOI 10.1016/S0014-5793(01)02705-3; STOLZ B, 1993, J BIOL CHEM, V268, P27094; Tugarinov V, 2002, J AM CHEM SOC, V124, P10025, DOI 10.1021/ja0205636; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; WEHMEIER UF, 1994, BBA-PROTEIN STRUCT M, V1208, P348, DOI 10.1016/0167-4838(94)90124-4; Williams DC, 2004, J BIOL CHEM, V279, P1449, DOI 10.1074/jbc.M309790200; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	50	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20775	20784		10.1074/jbc.M501986200	http://dx.doi.org/10.1074/jbc.M501986200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788390	Green Accepted, hybrid			2022-12-25	WOS:000229242000075
J	Tsai, TC; Lee, YL; Hsiao, WC; Tsao, YP; Chen, SL				Tsai, TC; Lee, YL; Hsiao, WC; Tsao, YP; Chen, SL			NRIP, a novel nuclear receptor interaction protein, enhances the transcriptional activity of nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; ANDROGEN RECEPTOR; GLUCOCORTICOID HORMONES; STEROID-RECEPTORS; CERVICAL-CANCER; BINDING PROTEIN; GENE-EXPRESSION; WD-REPEAT; COACTIVATOR; COREGULATOR	Transcriptional regulation by members of the nuclear hormone receptor superfamily is a modular process requiring the mediation of distinct subclasses of coregulators. In this study, we isolated a novel WD40 repeat-containing gene, human nuclear receptor interaction protein (NRIP). We found NRIP interacts with either androgen or glucocorticoid receptors from in vitro and in vivo pulldown assays. Subsequently, transient transfection and luciferase activity assays suggested that NRIP was a ligand-dependent coactivator of steroid receptors (androgen and glucocorticoid) in distinct promoters. To further clarify the function of NRIP, we found an RNA interference-3-targeted NRIP gene sequence (5'-GATGATACAGCACGAGAAC-3') that could efficiently and specifically knock down endogenous and exogenous NRIP gene expression and that significantly diminished cell proliferation in prostate (LNCaP) and cervical (C33A) cells. Therefore, NRIP may play a role in enhancing the transcriptional activity of nuclear receptors and may be a critical target for developing therapeutic agents against nuclear receptor-mediated progression of prostate and cervical cancers.	Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan; Natl Def Med Ctr, Dept Microbiol & Immunol, Taipei 114, Taiwan; Mackay Mem Hosp, Dept Ophthalmol, Taipei 104, Taiwan	National Defense Medical Center; National Defense Medical Center; Mackay Memorial Hospital	Chen, SL (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan.	sltsao@mail.ndmctsgh.edu.tw						Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Ahmad A, 1999, J BIOL CHEM, V274, P16646, DOI 10.1074/jbc.274.23.16646; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; BRINTON LA, 1993, GYNECOL ONCOL, V51, P301, DOI 10.1006/gyno.1993.1294; BRINTON LA, 1991, CONTRACEPTION, V43, P581, DOI 10.1016/0010-7824(91)90005-Z; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; Dixon SC, 2001, PHARMACOL REV, V53, P73; FERENCZY A, 1989, CLIN OBSTET GYNECOL, V32, P191, DOI 10.1097/00003081-198903000-00023; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Khare S, 1997, EXP CELL RES, V232, P353, DOI 10.1006/excr.1997.3529; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2001, BBA-REV CANCER, V1551, pM1, DOI 10.1016/S0304-419X(01)00021-X; KLOCK G, 1988, CANCER DETECT PREV, V12, P23; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Mitsuzawa H, 2001, J BIOL CHEM, V276, P17117, DOI 10.1074/jbc.M100248200; MITTAL R, 1993, OBSTET GYNECOL, V81, P5; Mittal V, 2004, NAT REV GENET, V5, P355, DOI 10.1038/nrg1323; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Moodley M, 2003, INT J GYNECOL CANCER, V13, P103, DOI 10.1136/ijgc-00009577-200303000-00001; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Neely KE, 2002, BBA-REV CANCER, V1603, P19, DOI 10.1016/S0304-419X(02)00067-7; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEGRINI BP, 1990, CANCER RES, V50, P4670; ONATE SA, 1995, SCIENCE, V270, P1354; OREDER RG, 1998, COLD SPRING HARB SYM, V63, P201; PATTILLO R A, 1977, Science (Washington D C), V196, P1456, DOI 10.1126/science.867042; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Rochette-Egly C, 2003, CELL SIGNAL, V15, P355, DOI 10.1016/S0898-6568(02)00115-8; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Savkur RS, 2004, VITAM HORM, V68, P145; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Stallcup MR, 2000, BIOCHEM SOC T, V28, P415, DOI 10.1042/0300-5127:0280415; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang X, 2001, J BIOL CHEM, V276, P40417, DOI 10.1074/jbc.M104765200; Wen Y, 2000, CANCER RES, V60, P6841; Wiseman H, 2001, BIOCHEM SOC T, V29, P205, DOI 10.1042/BST0290205; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	54	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20000	20009		10.1074/jbc.M412169200	http://dx.doi.org/10.1074/jbc.M412169200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15784617	hybrid			2022-12-25	WOS:000229113700070
J	Ma, H; Nguyen, C; Lee, KS; Kahn, M				Ma, H; Nguyen, C; Lee, KS; Kahn, M			Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression	ONCOGENE			English	Article						survivin; CBP; p300; TCF/catenin	BETA-CATENIN; C-MYC; CYCLIN D1; TRANSCRIPTIONAL REPRESSION; CARCINOMA-CELLS; BINDING PROTEIN; DISTINCT ROLES; APOPTOSIS; CANCER; SUPPRESSION	The inhibitor of apoptosis (IAP) protein survivin is highly expressed in cancers, but not in normal differentiated tissues. TCF/beta-catenin signaling has been reported to participate in the regulation of survivin transcription in colon cancer. We have recently characterized ICG-001, a small molecule specific inhibitor of the beta-catenin/Creb-binding protein (CBP) interaction. Inhibition of the beta-catenin/CBP interaction represses a subset of TCF/beta-catenin-mediated transcription. ICG-001 potently inhibits survivin gene transcription and expression. ICG-001-mediated downregulation of survivin expression enhanced caspase-3 activity and apoptosis, which was rescued by overexpression of wild type but not mutant (C84A) survivin. Small interfering RNA and genetic reduction of CBP also decreased survivin expression. Chromatin immunoprecipitation assay confirmed that CBP is the crucial coactivator for TCF/beta-catenin-mediated survivin transcription. Furthermore, ICG-001-induced recruitment of p300 to the survivin promoter led to concomitant recruitment of SUMO-1, HDAC6 and PML proteins, which have been associated with transcriptional repression. These findings demonstrate that CBP and p300 play very distinct roles in survivin gene transcription.	Inst Chem Genom, Dept Mol Cell Biol, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kahn, M (corresponding author), Inst Chem Genom, Dept Mol Cell Biol, 600 Broadway,Suite 580, Seattle, WA 98122 USA.	mkahn@ichemgen.org						ABARZUA P, 1995, CANCER RES, V55, P3490; Adida C, 2000, BLOOD, V96, P1921; Altieri Dario C, 2003, Methods Mol Biol, V223, P533; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Baluchamy S, 2003, P NATL ACAD SCI USA, V100, P9524, DOI 10.1073/pnas.1633700100; Chesire DR, 2003, ENDOCR-RELAT CANCER, V10, P537, DOI 10.1677/erc.0.0100537; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goodman RH, 2000, GENE DEV, V14, P1553; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jiang MC, 1996, ONCOGENE, V13, P609; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kim JS, 2002, CANCER RES, V62, P2744; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; Kung AL, 2000, GENE DEV, V14, P272; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lee YJ, 2004, MOL CELLS, V17, P217; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Maeda O, 2004, ONCOGENE, V23, P964, DOI 10.1038/sj.onc.1207254; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; OMURA S, 1977, J ANTIBIOT, V30, P275, DOI 10.7164/antibiotics.30.275; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Roth JF, 2003, EMBO J, V22, P5186, DOI 10.1093/emboj/cdg473; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Suganuma T, 2002, P NATL ACAD SCI USA, V99, P13073, DOI 10.1073/pnas.192586699; Tamm I, 1998, CANCER RES, V58, P5315; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tu SP, 2003, CANCER RES, V63, P7724; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Xu ZX, 2004, J BIOL CHEM, V279, P1838, DOI 10.1074/jbc.M310987200; Yamauchi T, 2002, NAT GENET, V30, P221, DOI 10.1038/ng829; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang T, 2001, CANCER RES, V61, P8664	52	273	291	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3619	3631		10.1038/sj.onc.1208433	http://dx.doi.org/10.1038/sj.onc.1208433			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782138				2022-12-25	WOS:000229221800009
J	Li, GR; Cui, G; Tzeng, NS; Wei, SJ; Wang, TG; Block, ML; Hong, JS				Li, GR; Cui, G; Tzeng, NS; Wei, SJ; Wang, TG; Block, ML; Hong, JS			Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage	FASEB JOURNAL			English	Article						DM; femtomolar; inflammation; microglia; neuroprotection; Parkinson's disease	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; INJURY FOLLOWING TRANSIENT; NEURODEGENERATIVE DISEASES; MICROGLIAL ACTIVATION; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; OPIOID PEPTIDE; FOCAL ISCHEMIA; NADPH OXIDASE; RAT	Inflammation in the brain has increasingly been recognized to play an important role in the pathogenesis of several neuro degenerative disorders, including Parkinson's disease (PD). Progress in the search for effective therapeutic strategies that can halt this degenerative process remains limited. We previously showed that micromolar concentrations of dextromethorphan (DM), a major ingredient of widely used antitussive remedies, reduced the inflammation-mediated degeneration of dopaminergic neurons through the inhibition of microglial activation. In this study, we report that femto- and micromolar concentrations of DM (both pre- and post-treatment) showed equal efficacy in protecting lipopolysaccharide (LPS)-induced dopaminergic neuron death in midbrain neuron-glia cultures. Both concentrations of DM decreased LPS-induced release of nitric oxide, tumor necrosis factor-alpha, prostaglandin E-2 and superoxide from microglia in comparable degrees. The important role of superoxide was demonstrated by DM's failure to show a neuroprotective effect in neuron-glia cultures from NADPH oxidase-deficient mice. These results suggest that the neuroprotective effect elicited by femtomolar concentrations of DM is mediated through the inhibition of LPS-induced proinflammatory factors, especially superoxide. These findings suggest a novel therapeutic concept of using "ultra-low" drug concentrations for the intervention of inflammation-related neurodegenerative diseases.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Natl Ctr Toxicogenom, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Chapel Hill, NC USA; Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Psychiat, Taipei, Taiwan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; National Defense Medical Center; Tri-Service General Hospital	Li, GR (corresponding author), NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, POB 12233,MD-F1-01 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	guorongl@med.unc.edu; hong3@niehs.nih.gov	Tzeng, Nian-Sheng/AAU-4945-2021; Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Wei, Sung Jen/0000-0002-9810-9041; Block, Michelle/0000-0001-8303-7914	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101411] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BASKIN DS, 1984, NATURE, V312, P551, DOI 10.1038/312551a0; Britton P, 1997, LIFE SCI, V60, P1729, DOI 10.1016/S0024-3205(97)00132-X; Christensen ST, 1996, CELL BIOL INT, V20, P437, DOI 10.1006/cbir.1996.0055; Crain SM, 2001, BRAIN RES, V888, P75, DOI 10.1016/S0006-8993(00)03010-9; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; EFANOV AM, 1994, FEBS LETT, V355, P114, DOI 10.1016/0014-5793(94)01109-5; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; GATLEY SJ, 1976, BIOCHEM J, V158, P307, DOI 10.1042/bj1580307; GEORGE CP, 1988, BRAIN RES, V440, P375, DOI 10.1016/0006-8993(88)91011-6; Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; Hayashi T, 2002, SYNAPSE, V43, P86, DOI 10.1002/syn.10019; Jenner P, 1996, PATHOL BIOL, V44, P57; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; KUTTAN SC, 1991, J CARDIOVASC PHARM, V17, P929, DOI 10.1097/00005344-199106000-00011; Leker RR, 2002, STROKE, V33, P1085, DOI 10.1161/01.STR.0000014207.05597.D7; Liu B, 2000, NEUROSCIENCE, V97, P749, DOI 10.1016/S0306-4522(00)00057-9; Liu B, 2003, METH MOLEC MED, V79, P387; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu B, 2001, J PHARMACOL EXP THER, V298, P1133; Liu J, 2001, LIFE SCI, V69, P1833, DOI 10.1016/S0024-3205(01)01267-X; Liu YX, 2003, J PHARMACOL EXP THER, V305, P212, DOI 10.1124/jpet.102.043166; Liu YX, 2002, J PHARMACOL EXP THER, V302, P1212, DOI 10.1124/jpet.102.035956; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MONYER H, 1988, BRAIN RES, V446, P144, DOI 10.1016/0006-8993(88)91304-2; PRINCE DA, 1988, NEUROSCI LETT, V85, P291, DOI 10.1016/0304-3940(88)90581-2; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; RAMESHWAR P, 1993, J IMMUNOL, V151, P2484; Reglodi D, 2000, STROKE, V31, P1411, DOI 10.1161/01.STR.31.6.1411; Sharp BM, 1998, BIOCHEM PHARMACOL, V56, P289, DOI 10.1016/S0006-2952(98)00155-5; Souza HP, 2001, AM J PHYSIOL-HEART C, V280, pH658, DOI 10.1152/ajpheart.2001.280.2.H658; STEINBERG GK, 1988, STROKE, V19, P1112, DOI 10.1161/01.STR.19.9.1112; Tortella FC, 1999, J PHARMACOL EXP THER, V291, P399; Yoshida LS, 1998, J BIOL CHEM, V273, P27879, DOI 10.1074/jbc.273.43.27879	37	65	72	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					489	496		10.1096/fj.04-2555com	http://dx.doi.org/10.1096/fj.04-2555com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15790998				2022-12-25	WOS:000228865300032
J	Zhang, W; Wang, TG; Pei, Z; Miller, DS; Wu, XF; Block, ML; Wilson, B; Zhang, WQ; Zhou, Y; Hong, JS; Zhang, J				Zhang, W; Wang, TG; Pei, Z; Miller, DS; Wu, XF; Block, ML; Wilson, B; Zhang, WQ; Zhou, Y; Hong, JS; Zhang, J			Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease	FASEB JOURNAL			English	Article						microglia; phagocytosis; innate immunity; aging; oxidative stress; protein aggregation; inflammation	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; ROTENONE-INDUCED DEGENERATION; NIGRAL DOPAMINERGIC-NEURONS; NADPH OXIDASE; NEURODEGENERATIVE DISEASES; MESENCEPHALIC NEURONS; NEUROTROPHIC FACTOR; ALZHEIMERS-DISEASE; MOUSE MODEL; MUTATION	A growing body of evidence indicates that an inflammatory process in the substantia nigra, characterized by activation of resident microglia, likely either initiates or aggravates nigral neurodegeneration in Parkinson's disease (PD). To study the mechanisms by which nigral microglia are activated in PD, the potential role of alpha-synuclein (a major component of Lewy bodies that can cause neurodegeneration when aggregated) in microglial activation was investigated. The results demonstrated that in a primary mesencephalic neuron-glia culture system, extracellular aggregated human alpha-synuclein indeed activated microglia; microglial activation enhanced dopaminergic neurodegeneration induced by aggregated alpha-synuclein. Furthermore, microglial enhancement of alpha-synuclein-mediated neurotoxicity depended on phagocytosis of alpha-synuclein and activation of NADPH oxidase with production of reactive oxygen species. These results suggest that nigral neuronal damage, regardless of etiology, may release aggregated alpha-synuclein into substantia nigra, which activates microglia with production of proinflammatory mediators, thereby leading to persistent and progressive nigral neuro degeneration in PD. Finally, NADPH oxidase could be an ideal target for potential pharmaceutical intervention, given that it plays a critical role in alpha-synuclein-mediated microglial activation and associated neurotoxicity.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; Dalian Med Univ, Dept Physiol, Dalian, Peoples R China; Dalian Med Univ, Clin Hosp 1, Dept Neurol, Dalian, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Dalian Medical University; Dalian Medical University	Zhang, J (corresponding author), Univ Washington, Sch Med, Harborview Med Ctr, Div Neuropathol, 703C Res & Training Bldg,Campus Box 359635,325 9t, Seattle, WA 98104 USA.	zhangj@u.washington.edu	Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Block, Michelle/0000-0001-8303-7914	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080048, ZIAES090082, Z01ES080048, Z01ES090082] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Aimi Y, 1996, Parkinsonism Relat Disord, V2, P69, DOI 10.1016/1353-8020(96)00004-1; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; BLOCK ML, 2004, IN PRESS FASEB J; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cunningham LA, 2002, EXP NEUROL, V174, P230, DOI 10.1006/exnr.2002.7877; Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; Eikelenboom P, 2004, J NEURAL TRANSM, V111, P281, DOI 10.1007/s00702-003-0055-1; Elkon H, 2002, J MOL NEUROSCI, V18, P229, DOI 10.1385/JMN:18:3:229; Gao HM, 2003, J NEUROSCI, V23, P6181; Gao HM, 2003, J NEUROSCI, V23, P1228, DOI 10.1523/JNEUROSCI.23-04-01228.2003; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Kordower JH, 2003, ANN NEUROL, V53, pS120, DOI 10.1002/ana.10485; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee Sung Joong, 2002, Current Drug Targets - Inflammation and Allergy, V1, P181; Liu B, 2000, J PHARMACOL EXP THER, V295, P125; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu YX, 2003, J PHARMACOL EXP THER, V305, P212, DOI 10.1124/jpet.102.043166; Liu YX, 2002, J PHARMACOL EXP THER, V302, P1212, DOI 10.1124/jpet.102.035956; LOWE JS, 2002, GREENFIELDS NEUROPAT, V2, P325; McGeer PL, 2002, NEUROSCI LETT, V326, P67, DOI 10.1016/S0304-3940(02)00300-2; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; Mirza B, 2000, NEUROSCIENCE, V95, P425; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Sulzer D, 2001, NAT MED, V7, P1280, DOI 10.1038/nm1201-1280; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Wang TG, 2004, J NEUROCHEM, V88, P939, DOI 10.1046/j.1471-4159.2003.02242.x; Wilms H, 2003, FASEB J, V17, P500, DOI 10.1096/fj.02-0314fje; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; YAMADA T, 1992, ACTA NEUROPATHOL, V84, P100, DOI 10.1007/BF00427222; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	49	875	910	2	68	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					533	542		10.1096/fj.04-2751com	http://dx.doi.org/10.1096/fj.04-2751com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791003				2022-12-25	WOS:000228865300037
J	Tong, H; Bernstein, D; Murphy, E; Steenbergen, C				Tong, H; Bernstein, D; Murphy, E; Steenbergen, C			The role of beta-adrenergic receptor signaling in cardioprotection	FASEB JOURNAL			English	Article						Gs protein; PKA; ischemic preconditioning	PROTEIN-KINASE-A; BETA(2)-ADRENERGIC RECEPTOR; G(I) PROTEINS; HEART; PHOSPHORYLATION; REPERFUSION; INHIBITION; ISCHEMIA; SYSTEM; INJURY	This study examines the role of the Beta2-adrenergic receptor (Beta2-AR) in cardioprotection. The Beta2-AR couples to Gs and Gi proteins. Gs activates PKA, which phosphorylates the receptor and switches Beta2-AR coupling from Gs to Gi. Prior to 20 min of global ischemia, mouse hearts were either perfused for 30 min without treatment (control), treated with 10 nmol/L of isoproterenol (ISO) for 5 min followed by 5 min washout, or preconditioned with 4 cycles of 5 min ischemia and 5 min reflow (PC). Recovery of left ventricular developed pressure (LVDP) and infarct size were measured. Intermittent ISO treatment improved post-ischemic recovery of LVDP (58.5+/-4.8% vs. 22.0+/-6.3% in control) and reduced infarct size (31.0+/-2.4% vs. 53.0+/-4.6% in control). The Gi inhibitor pertussis toxin blocked the ISO-induced improvement in postischemic LVDP and infarct size. To test the role of Beta2-AR in PC, we studied mice lacking Beta2-AR (Beta2-AR-/-) and found that PC had no effect on postischemic LVDP or infarct size in Beta2-AR-/-. To test whether PKA is required for the PC and ISO-induced protection, hearts were treated with the PKA inhibitors PKI and H-89. We found that PKI and H-89 blocked the PC- and ISO-induced improvement in postischemic LVDP and infarct size. These data show an important role for Beta2-AR in cardioprotection and support the novel hypothesis that preconditioning involves switching of Beta2-AR coupling from Gs to Gi.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Stanford Univ, Dept Pediat, Stanford, CA USA; NIEHS, Lab Signal Transduct, Res Triangle Pk, NC USA	Duke University; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Steenbergen, C (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.	steen001@mc.duke.edu		Bernstein, Daniel/0000-0001-7761-5853	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039752, R29HL039752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010004] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-51535, R01 HL039752, HL-39752] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAXTER GF, 1994, CIRCULATION, V90, P2993, DOI 10.1161/01.CIR.90.6.2993; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Diaz RJ, 1997, J MOL CELL CARDIOL, V29, P129, DOI 10.1006/jmcc.1996.0258; Frances C, 2003, J CARDIOVASC PHARM, V41, P396, DOI 10.1097/00005344-200303000-00008; Gabel SA, 2001, AM J PHYSIOL-HEART C, V280, pH1963, DOI 10.1152/ajpheart.2001.280.5.H1963; Gauthier C, 2000, TRENDS PHARMACOL SCI, V21, P426, DOI 10.1016/S0165-6147(00)01562-5; Harris TE, 1997, BIOCHEM BIOPH RES CO, V232, P648, DOI 10.1006/bbrc.1997.6344; Lochner A, 1999, CIRCULATION, V100, P958, DOI 10.1161/01.CIR.100.9.958; Lohse MJ, 2003, CIRC RES, V93, P896, DOI 10.1161/01.RES.0000102042.83024.CA; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nomura Y, 2003, MOL CELL BIOCHEM, V248, P179, DOI 10.1023/A:1024100722413; Oldenburg O, 2002, CARDIOVASC RES, V55, P544, DOI 10.1016/S0008-6363(02)00332-2; Schultz JEJ, 1996, CIRC RES, V78, P1100, DOI 10.1161/01.RES.78.6.1100; Sichelschmidt OJ, 2003, CARDIOVASC RES, V58, P602, DOI 10.1016/S0008-6363(03)00261-X; Tong HY, 2004, CIRC RES, V94, P1133, DOI 10.1161/01.RES.0000126048.32383.6B; Xiao RP, 2000, CIRC RES, V87, P635, DOI 10.1161/01.RES.87.8.635; XIAO RP, 2001, BETA ADRENERGIC SIGN; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200	22	60	65	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					983	+		10.1096/fj.04-3067fje	http://dx.doi.org/10.1096/fj.04-3067fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15802488				2022-12-25	WOS:000227901300041
J	Kronenwett, R; Butterweck, U; Steidl, U; Kliszewski, S; Neumann, F; Bork, S; Blanco, ED; Roes, N; Graf, T; Brors, B; Eils, R; Maercker, C; Kobbe, G; Gattermann, N; Haas, R				Kronenwett, R; Butterweck, U; Steidl, U; Kliszewski, S; Neumann, F; Bork, S; Blanco, ED; Roes, N; Graf, T; Brors, B; Eils, R; Maercker, C; Kobbe, G; Gattermann, N; Haas, R			Distinct molecular phenotype of malignant CD34+hematopoietic stem and progenitor cells in chronic myelogenous leukemia	ONCOGENE			English	Article						CML; CD34+cells; gene expression; G protein-coupled receptors	CHRONIC MYELOID-LEUKEMIA; CD34(+) HEMATOPOIETIC STEM; TYROSINE KINASE-ACTIVITY; BCR-ABL; GENE-EXPRESSION; PHILADELPHIA-CHROMOSOME; BONE-MARROW; CXCR4 ANTAGONIST; IN-VITRO; TRANSFORMATION	Chronic myelogenous leukemia (CML) is a malignant disorder of the hematopoietic stem cell characterized by the BCR-ABL oncogene. We examined gene expression profiles of highly enriched CD34+ hematopoietic stem and progenitor cells from patients with CML in chronic phase using cDNA arrays covering 1.185 genes. Comparing CML CD34+ cells with normal CD34+ cells, we found 158 genes which were significantly differentially expressed. Gene expression patterns reflected BCR-ABL-induced functional alterations such as increased cell-cycle and proteasome activity. Detoxification enzymes and DNA repair proteins were downregulated in CML CD34+ cells, which might contribute to genetic instability. Decreased expression of junction plakoglobulin and CXC chemokine receptor 4 (CXCR-4) might facilitate the release of immature precursors from bone marrow in CML. GATA-2 was upregulated in CML CD34+ cells, suggesting an increased self-renewal in comparison with normal CD34+ cells. Moreover, we found upregulation of the proto-oncogene SKI and of receptors for neuromediators such as opioid mu 1 receptor, GABA B receptor, adenosine A1 receptor, orexin 1 and 2 receptors and corticotropine-releasing hormone receptor. Treatment of CML progenitor cells with the selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine ( DPCPX) resulted in a dose-dependent significant inhibition of clonogenic growth by 40% at a concentration of 10(-5) M, which could be reversed by the equimolar addition of the receptor agonist 2-chloro-N6-cyclopentyladenosine (P < 0.05). The incubation of normal progenitor cells with DPCPX resulted in an inhibition of clonogenic growth to a significantly lesser extent in comparison with CML cells (P < 0.05), suggesting that the adenosine A1 receptor is of functional relevance in CML hematopoietic progenitor cells.	Univ Dusseldorf, Dept Hematol, D-40225 Dusseldorf, Germany; Howard Hughes Med Inst, Div Hematol Oncol, Boston, MA 02115 USA; German Canc Res Ctr, D-69120 Heidelberg, Germany; German Resource Ctr Genome Res, D-69120 Heidelberg, Germany	Heinrich Heine University Dusseldorf; Howard Hughes Medical Institute; Helmholtz Association; German Cancer Research Center (DKFZ)	Kronenwett, R (corresponding author), Univ Dusseldorf, Dept Hematol, Moorenstr 5, D-40225 Dusseldorf, Germany.	kronenwett@med.uni-duesseldorf.de	Kobbe, Guido/ABG-9472-2021; Eils, Roland/B-6121-2009; Brors, Benedikt/E-5620-2013	Eils, Roland/0000-0002-0034-4036; Brors, Benedikt/0000-0001-5940-3101				BEDI A, 1994, BLOOD, V83, P2038; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Devine SM, 2004, J CLIN ONCOL, V22, P1095, DOI 10.1200/JCO.2004.07.131; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Gora-Tybor J, 1998, BRIT J HAEMATOL, V103, P716, DOI 10.1046/j.1365-2141.1998.01039.x; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; Graf L, 2001, BIOL BLOOD MARROW TR, V7, P486, DOI 10.1053/bbmt.2001.v7.pm11669215; Haase D, 2002, LEUKEMIA RES, V26, P249, DOI 10.1016/S0145-2126(01)00124-2; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Izumi T, 1996, INT J HEMATOL, V64, P73; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kronenwett R, 1998, BLOOD, V91, P852, DOI 10.1182/blood.V91.3.852.852_852_862; Kronenwett R, 2002, CANCER GENE THER, V9, P587, DOI 10.1038/sj.cgt.7700474; Liebermann DA, 1998, ONCOGENE, V17, P3319, DOI 10.1038/sj.onc.1202574; Liles WC, 2003, BLOOD, V102, P2728, DOI 10.1182/blood-2003-02-0663; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; McLean LA, 2004, CLIN CANCER RES, V10, P155, DOI 10.1158/1078-0432.CCR-0784-3; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; NAMCIU S, 1995, DEV DYNAM, V204, P291, DOI 10.1002/aja.1002040307; Neumann F, 2003, EUR J HAEMATOL, V70, P1, DOI 10.1034/j.1600-0609.2003.02811.x; Ng YY, 2004, J LEUKOCYTE BIOL, V75, P314, DOI 10.1189/jlb.0603287; Nowicki MO, 2003, ONCOGENE, V22, P3952, DOI 10.1038/sj.onc.1206620; Ohmine K, 2001, ONCOGENE, V20, P8249, DOI 10.1038/sj.onc.1205029; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Pospisil M, 2001, EXP HEMATOL, V29, P557, DOI 10.1016/S0301-472X(01)00622-1; Soligo D, 2001, BRIT J HAEMATOL, V113, P126, DOI 10.1046/j.1365-2141.2001.02683.x; Steidl U, 2003, VITAM HORM, V66, P1, DOI 10.1016/S0083-6729(03)01001-X; Steidl U, 2002, BLOOD, V99, P2037, DOI 10.1182/blood.V99.6.2037; Steidl U, 2004, BLOOD, V104, P81, DOI 10.1182/blood-2004-01-0373; Szaniszlo P, 2004, CYTOM PART A, V59A, P191, DOI 10.1002/cyto.a.20055; Tian MT, 1997, J EXP MED, V185, P1517, DOI 10.1084/jem.185.8.1517; Traycoff CM, 1998, BRIT J HAEMATOL, V102, P759, DOI 10.1046/j.1365-2141.1998.00839.x; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; Wain HM, 2002, GENOMICS, V79, P464, DOI 10.1006/geno.2002.6748; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wlodarska I, 1996, LEUKEMIA LYMPHOMA, V23, P287, DOI 10.3109/10428199609054831; Yu CR, 2003, BLOOD, V102, P3765, DOI 10.1182/blood-2003-03-0737; Zhu J, 2002, ONCOGENE, V21, P3295, DOI 10.1038/sj.onc.1205318	45	41	43	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 11	2005	24	34					5313	5324		10.1038/sj.onc.1208596	http://dx.doi.org/10.1038/sj.onc.1208596			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15806158				2022-12-25	WOS:000231158500005
J	Fladvad, M; Bellanda, M; Fernandes, AP; Mammi, S; Vlamis-Gardikas, A; Holmgren, A; Sunnerhagen, M				Fladvad, M; Bellanda, M; Fernandes, AP; Mammi, S; Vlamis-Gardikas, A; Holmgren, A; Sunnerhagen, M			Molecular mapping of functionalities in the solution structure of reduced Grx4, a monothiol glutaredoxin from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR SOLUTION STRUCTURE; MIXED DISULFIDE; 3-DIMENSIONAL STRUCTURE; COUPLING-CONSTANTS; PROTEIN STRUCTURES; HYDROGEN DONOR; THIOREDOXIN; SEQUENCE; MUTANT; GLUTATHIONE	The ubiquitous glutaredoxin protein family is present in both prokaryotes and eukaryotes, and is closely related to the thioredoxins, which reduce their substrates using a dithiol mechanism as part of the cellular defense against oxidative stress. Recently identified monothiol glutaredoxins, which must use a different functional mechanism, appear to be essential in both Escherichia coli and yeast and are well conserved in higher order genomes. We have employed high resolution NMR to determine the three-dimensional solution structure of a monothiol glutaredoxin, the reduced E. coli Grx4. The Grx4 structure comprises a glutaredoxin-like alpha-beta fold, founded on a limited set of strictly conserved and structurally critical residues. A tight hydrophobic core, together with a stringent set of secondary structure elements, is thus likely to be present in all monothiol glutaredoxins. A set of exposed and conserved residues form a surface region, implied in glutathione binding from a known structure of E. coli Grx3. The absence of glutaredoxin activity in E. coli Grx4 can be understood based on small but significant differences in the glutathione binding region, and through the lack of a conserved second GSH binding site. MALDI experiments suggest that disulfide formation on glutathionylation is accompanied by significant structural changes, in contrast with dithiol thioredoxins and glutaredoxins, where differences between oxidized and reduced forms are subtle and local. Structural and functional implications are discussed with particular emphasis on identifying common monothiol glutaredoxin properties in substrate specificity and ligand binding events, linking the thioredoxin and glutaredoxin systems.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Padua, Dept Chem Sci, I-35131 Padua, Italy; Linkoping Univ, IFM, Div Mol Biotechnol, S-58183 Linkoping, Sweden	Karolinska Institutet; University of Padua; Linkoping University	Sunnerhagen, M (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	marsu@ifm.liu.se	Vlamis, Alexios/AAF-5152-2020; Fernandes, Aristi/D-2507-2015	Vlamis, Alexios/0000-0001-5068-6459; Fernandes, Aristi/0000-0002-4145-0222				Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; Aslund F, 1996, J BIOL CHEM, V271, P6736, DOI 10.1074/jbc.271.12.6736; Babichev Y, 2001, ADV EXP MED BIOL, V495, P41; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BELLI G, 2002, J BIOL CHEM, V22, P22; BURNS JA, 1990, J AM CHEM SOC, V112, P6296, DOI 10.1021/ja00173a017; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; EKLUND H, 1992, J MOL BIOL, V228, P596, DOI 10.1016/0022-2836(92)90844-A; Fernandes AP, 2005, J BIOL CHEM, V280, P24544, DOI 10.1074/jbc.M500678200; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Gerdes SY, 2003, J BACTERIOL, V185, P5673, DOI 10.1128/JB.185.19.5673-5684.2003; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; Holm L, 1999, NUCLEIC ACIDS RES, V27, P244, DOI 10.1093/nar/27.1.244; HOLMGREN A, 1975, P NATL ACAD SCI USA, V72, P2305, DOI 10.1073/pnas.72.6.2305; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KATTI SK, 1995, PROTEIN SCI, V4, P1998, DOI 10.1002/pro.5560041005; Kern R, 2003, BIOCHEM J, V371, P965, DOI 10.1042/BJ20030093; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lillig CH, 2003, J BIOL CHEM, V278, P22325, DOI 10.1074/jbc.M302304200; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; MADEJ T, 1995, PROTEINS, V23, P356, DOI 10.1002/prot.340230309; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; Ponstingl H, 1998, J BIOMOL NMR, V12, P319, DOI 10.1023/A:1008293016073; Rahlfs S, 2001, J BIOL CHEM, V276, P37133, DOI 10.1074/jbc.M105524200; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Sierk ML, 2004, PROTEIN SCI, V13, P773, DOI 10.1110/ps.03328504; SODANO P, 1991, J MOL BIOL, V221, P1311; Sun CH, 1998, J MOL BIOL, V280, P687, DOI 10.1006/jmbi.1998.1913; SZYPERSKI T, 1992, J MAGN RESON, V99, P552, DOI 10.1016/0022-2364(92)90209-P; Tamarit J, 2003, J BIOL CHEM, V278, P25745, DOI 10.1074/jbc.M303477200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSANG MLS, 1978, J BACTERIOL, V134, P131, DOI 10.1128/JB.134.1.131-138.1978; Vlamis-Gardikas A, 2002, METHOD ENZYMOL, V347, P286; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902; Won HS, 2004, J MOL BIOL, V341, P893, DOI 10.1016/j.jmb.2004.06.046; Xia B, 2001, J MOL BIOL, V310, P907, DOI 10.1006/jmbi.2001.4721; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504	49	47	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24553	24561		10.1074/jbc.M500679200	http://dx.doi.org/10.1074/jbc.M500679200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15840565	hybrid, Green Published			2022-12-25	WOS:000230114000033
J	Li, S; Crothers, J; Haqq, CM; Blackburn, EH				Li, S; Crothers, J; Haqq, CM; Blackburn, EH			Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; LACKING TELOMERASE; HUMAN-CHROMOSOMES; MOUSE CELLS; DNA-DAMAGE; SENESCENCE; PATHWAY; PROLIFERATION; LENGTH; END	Inhibition of the up-regulated telomerase activity in cancer cells has previously been shown to slow cell growth but only after prior telomere shortening. Previously, we have reported that, unexpectedly, a hairpin short interfering RNA specifically targeting human telomerase RNA rapidly inhibits the growth of human cancer cells independently of p53 or telomere length and without bulk telomere shortening (Li, S., Rosenberg, J. E., Donjacour, A. A., Botchkina, I. L., Hom, Y. K., Cunha, G. R., and Blackburn, E. H. ( 2004) Cancer Res. 64, 4833 - 4840). Here we have demonstrated that such telomerase RNA knockdown in cancer cells does not cause telomere uncapping but rather induces changes in the global gene expression profile indicative of a novel response pathway, which includes suppression of specific genes implicated in angiogenesis and metastasis, and is distinct from the expression profile changes induced by telomere-uncapping mutant template telomerase RNAs. These cellular responses to depleting telomerase in human cancer cells together suggest that cancer cells are "telomerase-addicted" and uncover functions of telomerase in tumor growth and progression in addition to telomere maintenance.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Blackburn, EH (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	telomer@itsa.ucsf.edu	LI, SHANG/HII-4989-2022	LI, SHANG/0000-0002-6226-3362				Asai A, 2003, CANCER RES, V63, P3931; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan SWL, 2003, MOL CELL, V11, P1379, DOI 10.1016/S1097-2765(03)00174-6; Chang S, 2003, GENE DEV, V17, P88, DOI 10.1101/gad.1029903; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; Comolli LR, 2002, P NATL ACAD SCI USA, V99, P16998, DOI 10.1073/pnas.262663599; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Enomoto S, 2002, MOL BIOL CELL, V13, P2626, DOI 10.1091/mbc.02-02-0012; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Folini M, 2003, CANCER RES, V63, P3490; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; HIYAMA E, 1995, CANCER RES, V55, P3258; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Ijpma AS, 2003, MOL BIOL CELL, V14, P987, DOI 10.1091/mbc.02-04-0057; Imhof BA, 1996, CURR TOP MICROBIOL, V213, P195; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kerr JS, 2002, EXPERT OPIN INV DRUG, V11, P1765, DOI 10.1517/13543784.11.12.1765; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kishi S, 2001, J BIOL CHEM, V276, P29282, DOI 10.1074/jbc.M011534200; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Le S, 1999, GENETICS, V152, P143; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lendvay TS, 1996, GENETICS, V144, P1399; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Li S, 2004, CANCER RES, V64, P4833, DOI 10.1158/0008-5472.CAN-04-0953; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nautiyal S, 2002, P NATL ACAD SCI USA, V99, P9316, DOI 10.1073/pnas.142162499; Nemeth JA, 2003, CLIN EXP METASTAS, V20, P413, DOI 10.1023/A:1025461507027; Nosrati M, 2004, CLIN CANCER RES, V10, P4983, DOI 10.1158/1078-0432.CCR-04-0134; Rogatsky I, 2003, P NATL ACAD SCI USA, V100, P13845, DOI 10.1073/pnas.2336092100; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Strahl C, 1996, MOL CELL BIOL, V16, P53; Teng SC, 1999, MOL CELL BIOL, V19, P8083; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Wright WE, 1996, DEV GENET, V18, P173; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	68	137	153	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23709	23717		10.1074/jbc.M502782200	http://dx.doi.org/10.1074/jbc.M502782200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15831499	hybrid			2022-12-25	WOS:000229880000039
J	Moali, C; Font, B; Ruggiero, F; Eichenberger, D; Rousselle, P; Francois, V; Oldberg, A; Bruckner-Tuderman, L; Hulmes, DJS				Moali, C; Font, B; Ruggiero, F; Eichenberger, D; Rousselle, P; Francois, V; Oldberg, A; Bruckner-Tuderman, L; Hulmes, DJS			Substrate-specific modulation of a multisubstrate proteinase - C-terminal processing of fibrillar procollagens is the only BMP-1-dependent activity to be enhanced by PCPE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; I PROCOLLAGEN; LYSYL OXIDASE; MOUSE FIBROBLASTS; COLLAGEN; METALLOPROTEINASES; LAMININ-5; BINDING; EMBRYO; PURIFICATION	Members of the bone morphogenetic protein-1/tolloid (BMP-1/Tld) family of metalloproteinases, also known as procollagen C-proteinases (PCPs), control multiple biological events ( including matrix assembly, cross-linking, cell adhesion/migration and pattern formation) through enzymatic processing of several extracellular substrates. PCP activities on fibrillar procollagens can be stimulated by another family of extracellular proteins, PCP enhancers (PCPE-1, PCPE-2), which lack intrinsic enzymatic activity. While PCPs have multiple substrates, the extent to which PCPEs is involved in the processing of proteins other than fibrillar procollagens is unknown. In the experiments reported here, PCPE-1 was found to have no effect on the in vitro BMP-1 processing of procollagen VII, the procollagen V N-propeptide, the laminin 5 gamma 2 chain, osteoglycin, prolysyl oxidase, or chordin. In contrast, PCPE-1 enhanced C-terminal processing of human fibrillar procollagen III but only when this substrate was in its native, disulfide-bonded conformation. Surprisingly, processing of procollagen III continued to be enhanced when essentially all the triple-helical region was removed. These and previous results (Ricard-Blum, S., Bernocco, S., Font, B., Moali, C., Eichenberger, D., Farjanel, J., Burchardt, E. R., van der Rest, M., Kessler, E., and Hulmes, D. J. S. ( 2002) J. Biol. Chem. 277, 33864 - 33869; Bernocco, S., Steiglitz, B. M., Svergun, D. I., Petoukhov, M. V., Ruggiero, F., Ricard- Blum, S., Ebel, C., Geourjon, C., Deleage, G., Font, B., Eichenberger, D., Greenspan, D. S., and Hulmes, D. J. S. ( 2003) J. Biol. Chem. 278, 7199 - 7205) indicate that the mechanism of PCPE-1 action involves recognition sites in both the C-propeptide domain and in the C-telopeptide region of the procollagen molecule. PCPEs therefore define a new class of extracellular adaptor proteins that stimulate proteinase activity in a substrate-specific manner, thereby providing a new target for the selective regulation of PCP activity on fibrillar procollagen substrates.	UCBL1, UMR 5086, IBCP, IFR 128,CNRS, F-69367 Lyon, France; CNRS, UPR1142, Inst Genet Humaine, F-343396 Montpellier, France; Lund Univ, Dept Cell & Mol Biol, S-22100 Lund, Sweden; Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Lund University; University of Freiburg	Hulmes, DJS (corresponding author), UCBL1, UMR 5086, IBCP, IFR 128,CNRS, 7 Passage Vercors, F-69367 Lyon, France.	d.hulmes@ibcp.fr	Rousselle, Patricia/J-5290-2019; Rousselle, Patricia/CAF-3915-2022	Rousselle, Patricia/0000-0003-0275-4562; Rousselle, Patricia/0000-0003-0275-4562; Hulmes, David/0000-0002-0651-1317; RICARD-BLUM, Sylvie/0000-0001-9263-1851; MOALI, Catherine/0000-0003-2479-4290				ADAR R, 1986, COLLAGEN REL RES, V6, P267; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200; Bernocco S, 2003, J BIOL CHEM, V278, P7199, DOI 10.1074/jbc.M210857200; Bernocco S, 2001, J BIOL CHEM, V276, P48930, DOI 10.1074/jbc.M108611200; Borel A, 2001, J BIOL CHEM, V276, P48944, DOI 10.1074/jbc.M109499200; Clark TG, 1999, DEVELOPMENT, V126, P2631; Colombo M, 2003, BIOCHEMISTRY-US, V42, P11434, DOI 10.1021/bi034925d; CRONSHAW AD, 1995, BIOCHEM J, V306, P279, DOI 10.1042/bj3060279; Fichard A, 1997, J BIOL CHEM, V272, P30083, DOI 10.1074/jbc.272.48.30083; Garrigue-Antar L, 2004, J BIOL CHEM, V279, P49835, DOI 10.1074/jbc.M408134200; Ge GX, 2004, J BIOL CHEM, V279, P41626, DOI 10.1074/jbc.M406630200; Gonzalez EM, 2005, J BIOL CHEM, V280, P7080, DOI 10.1074/jbc.M409841200; Gopalakrishnan B, 2004, J BIOL CHEM, V279, P30904, DOI 10.1074/jbc.M402252200; Hintermann E, 2004, MATRIX BIOL, V23, P75, DOI 10.1016/j.matbio.2004.03.001; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Holmes DF, 1996, J MOL BIOL, V261, P93, DOI 10.1006/jmbi.1996.0443; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Kadler KE, 1996, BIOCHEM J, V316, P1; KESSLER E, 1978, ANAL BIOCHEM, V86, P463, DOI 10.1016/0003-2697(78)90770-4; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; Kessler E, 2001, J BIOL CHEM, V276, P27051, DOI 10.1074/jbc.M102921200; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297; Malone JP, 2004, BIOCHEMISTRY-US, V43, P15358, DOI 10.1021/bi048304b; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Martin R, 2000, ANAL BIOCHEM, V277, P276, DOI 10.1006/abio.1999.4395; McAlinden A, 2003, J BIOL CHEM, V278, P42200, DOI 10.1074/jbc.M302429200; Medeck RJ, 2003, BIOCHEM J, V376, P361, DOI 10.1042/BJ20030894; Moschcovich L, 2001, EUR J BIOCHEM, V268, P2991, DOI 10.1046/j.1432-1327.2001.02189.x; Palamakumbura AH, 2004, J BIOL CHEM, V279, P40593, DOI 10.1074/jbc.M406639200; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Ricard-Blum S, 2002, J BIOL CHEM, V277, P33864, DOI 10.1074/jbc.M205018200; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; Steiglitz BM, 2004, J BIOL CHEM, V279, P980, DOI 10.1074/jbc.M310179200; Steiglitz BM, 2002, J BIOL CHEM, V277, P49820, DOI 10.1074/jbc.M209891200; Suzuki N, 1996, DEVELOPMENT, V122, P3587; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Svensson L, 2001, OSTEOARTHR CARTILAGE, V9, pS23, DOI 10.1053/joca.2001.0440; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; Wolfman NM, 2003, P NATL ACAD SCI USA, V100, P15842, DOI 10.1073/pnas.2534946100; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746	55	81	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24188	24194		10.1074/jbc.M501486200	http://dx.doi.org/10.1074/jbc.M501486200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15834133	Green Published, hybrid			2022-12-25	WOS:000229880000094
J	Xiong, HB; Li, HX; Kong, HJ; Chen, YB; Zhao, J; Xiong, SD; Huang, B; Gu, H; Mayer, L; Ozato, K; Unkeless, JC				Xiong, HB; Li, HX; Kong, HJ; Chen, YB; Zhao, J; Xiong, SD; Huang, B; Gu, H; Mayer, L; Ozato, K; Unkeless, JC			Ubiquitin-dependent degradation of interferon regulatory factor-8 mediated by Cb1 down-regulates interleukin-12 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BINDING-PROTEIN; TRANSCRIPTION FACTOR; IFN-GAMMA; FACTOR FAMILY; NEGATIVE REGULATOR; PROTEASOME PATHWAY; P40 EXPRESSION; FACTOR-I; MURINE; ACTIVATION	Interferon regulatory factor (IRF)-8/interferon consensus sequence-binding protein is regulated by both transcription and degradation. IRF-8 induced in peritoneal macrophages by interferon-gamma and lipopolysaccharide was degraded rapidly, and degradation of IRF-8 was blocked by MG132, the proteasome inhibitor, but inhibitors of calpain and lysosomal enzymes had no effect. The ubiquitination of IRF-8 was shown by coimmunoprecipitation from RAW264.7 macrophages retrovirally transduced with IRF-8 and hemagglutinin-ubiquitin. The dominant negative ubiquitin mutants K48R and K29R inhibited IRF-8 degradation in 293T cells, confirming the relationship between ubiquitination of IRF-8 and its degradation. IRF-8 carboxyl-terminal truncation mutants were not ubiquitinated and were consequently stable, indicating that the carboxyl-terminal domain of IRF-8 controls ubiquitination. The ubiquitin-protein isopeptide ligase ( E3) that ubiquitinated IRF-8 was likely to be Cbl, which formed a complex with IRF-8, demonstrable by both immunoprecipitation and gel filtration. Furthermore, IRF-8 stability was increased by dominant negative Cbl, and IRF-8 ubiquitination was significantly attenuated in Cbl-/- cells. Reflecting increased stability and expression, the IRF-8 carboxyl-terminal deletion mutant induced interleukin (IL)-12 p40 promoter activity much more strongly than IRF-8 did. Furthermore, IRF-8-induced IL-12 p40 synthesis in RAW264.7 cells was enhanced by dominant negative Cbl, and peritoneal macrophages from Cbl-/- mice showed increased IL-12 p40 protein production. Taken together, these results suggest that the proteasomal degradation of IRF-8 mediated by the ubiquitin E3 ligase Cbl down-regulates IL-12 expression.	CUNY Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA; Natl Inst Child Hlth & Human Dev, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; Fudan Univ, Shanghai Med Univ, Dept Immunol, Shanghai 200025, Peoples R China; Mt Sinai Sch Med, New York, NY 10029 USA; Columbia Univ, Sch Phys & Surg, Dept Microbiol & Immunol, New York, NY 10032 USA; CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Fudan University; Icahn School of Medicine at Mount Sinai; Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Xiong, HB (corresponding author), CUNY Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA.	xionghbl@yahoo.com			NIAID NIH HHS [AI52325, AI-24322] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024322, R01AI024322, R21AI052325] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; EGWUAGU CE, 1994, DEV BIOL, V166, P557, DOI 10.1006/dbio.1994.1337; Giese NA, 1997, J EXP MED, V186, P1535, DOI 10.1084/jem.186.9.1535; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; Kantakamalakul W, 1999, J IMMUNOL, V162, P7417; Kim YM, 2000, J IMMUNOL, V165, P3198, DOI 10.4049/jimmunol.165.6.3198; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lawson TG, 1999, J BIOL CHEM, V274, P9871, DOI 10.1074/jbc.274.14.9871; Li WM, 1999, J BIOL CHEM, V274, P9686, DOI 10.1074/jbc.274.14.9686; Li WM, 1999, DEV BIOL, V210, P44, DOI 10.1006/dbio.1999.9267; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Maruyama S, 2003, J IMMUNOL, V170, P997, DOI 10.4049/jimmunol.170.2.997; Masumi A, 2002, FEBS LETT, V531, P348, DOI 10.1016/S0014-5793(02)03556-1; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Nakagawa K, 2000, EUR J BIOCHEM, V267, P1680, DOI 10.1046/j.1432-1327.2000.01163.x; Nehyba J, 2002, MOL CELL BIOL, V22, P3942, DOI 10.1128/MCB.22.11.3942-3957.2002; Nelson N, 1996, J IMMUNOL, V156, P3711; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; Neurath MF, 2002, NAT MED, V8, P567, DOI 10.1038/nm0602-567; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Pickl WF, 2001, J VIROL, V75, P7175, DOI 10.1128/JVI.75.15.7175-7183.2001; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; POLITIS AD, 1992, J IMMUNOL, V148, P801; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SchartonKersten T, 1997, J EXP MED, V186, P1523, DOI 10.1084/jem.186.9.1523; Sharf R, 1997, J BIOL CHEM, V272, P9785; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Trinchieri G, 1995, RES IMMUNOL, V146, P423, DOI 10.1016/0923-2494(96)83011-2; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; WEISZ A, 1992, J BIOL CHEM, V267, P25589; WEISZ A, 1994, INT IMMUNOL, V6, P1125; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Xiong HB, 2003, J BIOL CHEM, V278, P2271, DOI 10.1074/jbc.M209583200; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; Zhu C, 2003, J BIOL CHEM, V278, P39372, DOI 10.1074/jbc.M306441200; Zhu C, 2001, J BIOL CHEM, V276, P18519, DOI 10.1074/jbc.M100440200	52	39	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23531	23539		10.1074/jbc.M414296200	http://dx.doi.org/10.1074/jbc.M414296200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15837792	hybrid			2022-12-25	WOS:000229880000017
J	Bernal, AJ; Pan, QL; Pollack, J; Rose, L; Kozik, A; Willits, N; Luo, Y; Guittet, M; Kochetkova, E; Michelmore, RW				Bernal, AJ; Pan, QL; Pollack, J; Rose, L; Kozik, A; Willits, N; Luo, Y; Guittet, M; Kochetkova, E; Michelmore, RW			Functional analysis of the plant disease resistance gene Pto using DNA shuffling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL SPECK DISEASE; DEPENDENT HYPERSENSITIVE RESPONSE; AVIRULENCE PROTEIN AVRPTO; PSEUDOMONAS-SYRINGAE; MOLECULAR-BASIS; TOMATO; KINASE; RECOGNITION; FAMILY; DOMAIN	Pto is a serine/threonine kinase that mediates resistance in tomato to strains of Pseudomonas syringae pv. tomato expressing the (a) virulence proteins AvrPto or AvrPtoB. DNA shuffling was used as a combinatorial in vitro genetic approach to dissect the functional regions of Pto. The Pto gene was shuffled with four of its paralogs from a resistant haplotype to create a library of recombinant products that was screened for interaction with AvrPto in yeast. All interacting clones and a representative sample of noninteracting clones were sequenced, and their ability to signal downstream was tested by the elicitation of a hypersensitive response in an AvrPto-dependent or -independent manner in planta. Eight candidate regions important for binding to AvrPto or for downstream signaling were identified by statistical correlations between individual amino acid positions and phenotype. A subset of the regions had previously been identified as important for recognition, confirming the validity of the shuffling approach. Three novel regions important for Pto function were validated by site-directed mutagenesis. Several chimeras and point mutants exhibited a differential interaction with (a) virulence proteins in the AvrPto and VirPphA family, demonstrating distinct binding requirements for different ligands. Additionally, the identification of chimeras that are both constitutively active as well as capable of binding AvrPto indicates that elicitation of downstream signaling does not involve a conformational change that precludes binding of AvrPto, as previously hypothesized. The correlations between phenotypes and variation generated by DNA shuffling paralleled natural variation observed between orthologs of Pto from Lycopersicon spp.	Univ Calif Davis, Genome Ctr, Dept Plant Pathol, Dept Stat, Davis, CA 95616 USA; Univ Calif Davis, Dept Plant Sci, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Michelmore, RW (corresponding author), Univ Calif Davis, Genome Ctr, Dept Plant Pathol, Dept Stat, 1 Shields Ave, Davis, CA 95616 USA.	rwmichelmore@ucdavis.edu		Bernal, Adriana/0000-0002-3557-697X				Alexandrov N. N., 1995, Pacific Symposium on Biocomputing '96, P53; Alfano JR, 2004, ANNU REV PHYTOPATHOL, V42, P385, DOI 10.1146/annurev.phyto.42.040103.110731; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; Chang JH, 2002, MOL PLANT MICROBE IN, V15, P281, DOI 10.1094/MPMI.2002.15.3.281; Chang JH, 2001, MOL PLANT MICROBE IN, V14, P451, DOI 10.1094/MPMI.2001.14.4.451; Ellis J, 2000, CURR OPIN PLANT BIOL, V3, P278, DOI 10.1016/S1369-5266(00)00080-7; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Frederick RD, 1998, MOL CELL, V2, P241, DOI 10.1016/S1097-2765(00)80134-3; Good P, 1994, PERMUTATION TESTS PR; Hammond-Kosack KE, 2003, CURR OPIN BIOTECH, V14, P177, DOI 10.1016/S0958-1669(03)00035-1; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSMER DW, 1989, APPL LOGISTIC REGRES; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jackson RW, 1999, P NATL ACAD SCI USA, V96, P10875, DOI 10.1073/pnas.96.19.10875; Jackson RW, 2002, MOL PLANT PATHOL, V3, P205, DOI 10.1046/j.1364-3703.2002.00121.x; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KELLEY LA, 1999, RECOMB 99 P 3 ANN C; Kim YJ, 2002, CELL, V109, P589, DOI 10.1016/S0092-8674(02)00743-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leister RT, 2000, PLANT J, V22, P345, DOI 10.1046/j.1365-313x.2000.00744.x; LOH YT, 1995, PLANT PHYSIOL, V108, P1735, DOI 10.1104/pp.108.4.1735; Martin GB, 2003, ANNU REV PLANT BIOL, V54, P23, DOI 10.1146/annurev.arplant.54.031902.135035; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; Pedley KF, 2003, ANNU REV PHYTOPATHOL, V41, P215, DOI 10.1146/annurev.phyto.41.121602.143032; Rathjen JP, 1999, EMBO J, V18, P3232, DOI 10.1093/emboj/18.12.3232; ROSE L, 2002, THESIS U CALIFORNIA; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALMERON J, 1994, EUPHYTICA, V79, P195, DOI 10.1007/BF00022519; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; Scofield SR, 1996, SCIENCE, V274, P2063, DOI 10.1126/science.274.5295.2063; Sessa G, 2000, MICROBES INFECT, V2, P1591, DOI 10.1016/S1286-4579(00)01315-0; Sessa G, 2000, EMBO J, V19, P2257, DOI 10.1093/emboj/19.10.2257; Shan LB, 2000, MOL PLANT MICROBE IN, V13, P592, DOI 10.1094/MPMI.2000.13.6.592; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Stemmer WPC, 2002, J MOL CATAL B-ENZYM, V19, P3, DOI 10.1016/S1381-1177(02)00146-7; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; TANKSLEY SD, 1988, MOL MAPPING PLANT CH; Tu Z, 2003, CELL SIGNAL, V15, P65, DOI 10.1016/S0898-6568(02)00056-6; Wroblewski T, 2005, PLANT BIOTECHNOL J, V3, P259, DOI 10.1111/j.1467-7652.2005.00123.x; Wu AJ, 2004, PLANT CELL, V16, P2809, DOI 10.1105/tpc.104.024141; Wulff BBH, 2004, PLANT J, V40, P942, DOI 10.1111/j.1365-313X.2004.02268.x; Wulff BBH, 2001, PLANT CELL, V13, P255, DOI 10.1105/tpc.13.2.255; Xiang CB, 1999, PLANT MOL BIOL, V40, P711, DOI 10.1023/A:1006201910593; Xiao FM, 2003, PLANT PHYSIOL, V131, P1239, DOI 10.1104/pp.016113; Yang Z., 2000, PHYLOGENETIC ANAL MA	49	19	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23073	23083		10.1074/jbc.M500992200	http://dx.doi.org/10.1074/jbc.M500992200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15790558	hybrid			2022-12-25	WOS:000229741800064
J	Fujii, T; Onohara, N; Maruyama, Y; Tanabe, S; Kobayashi, H; Fukutomi, M; Nagamatsu, Y; Nishihara, N; Inoue, R; Sumimoto, H; Shibasaki, F; Nagao, T; Nishida, M; Kurose, H				Fujii, T; Onohara, N; Maruyama, Y; Tanabe, S; Kobayashi, H; Fukutomi, M; Nagamatsu, Y; Nishihara, N; Inoue, R; Sumimoto, H; Shibasaki, F; Nagao, T; Nishida, M; Kurose, H			G alpha(12/13)-mediated production of reactive oxygen species is critical for angiotensin receptor-induced NFAT activation in cardiac fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; G-BETA-GAMMA; GENE-EXPRESSION; NUCLEAR FACTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; P115 RHOGEF; CALCINEURIN; TRANSCRIPTION; G-ALPHA(12)	Angiotensin II (Ang II) activates multiple signaling pathways leading to hyperplasia of cardiac fibroblasts. Reactive oxygen species (ROS) produced by Ang II stimulation are assumed to play pivotal roles in this process. Here, we show that ROS mediate Ang II-induced activation of nuclear factor of activated T cells (NFAT) in rat cardiac fibroblasts. Ang II-induced NFAT activation was suppressed by diphenyleneiodonium (an NADPH oxidase inhibitor), dominant negative (DN)-Rac, DN-p47(phox), and an inhibitor of G beta(12/13) (G alpha(12/13)-specific regulator of G protein signaling domain of p115RhoGEF, p115-regulator of G protein signaling (RGS)). Stimulation of Ang II receptor increased the intracellular ROS level in a Rac- and p47(phox)-dependent manner. Because p115-RGS suppressed Ang II-induced Rac activation, Ang II receptor-coupled G alpha(12/13) mediated NFAT activation through ROS production by Rac activation. Ang II-induced nuclear translocation of the green fluorescent protein (GFP)-tagged amino-terminal region of NFAT4 (GFP-NFAT4) was suppressed by p115-RGS or BAPTA but not by diphenyleneiodonium. The expression of constitutively active (CA)-G alpha(12), CA-G alpha(13), or CA-Rac increased the nuclear translocation of GFP-NFAT4. These results suggest that NFAT activity is regulated by both Ca2+-dependent and ROS-dependent pathways. Furthermore, activation of c-Jun NH2-terminal kinase (JNK) induced by Ang II stimulation is required for NFAT activation because Ang II-induced NFAT activation was inhibited by SP600125, a selective JNK inhibitor. These results indicate that Ang II stimulates the nuclear translocation and activation of NFAT by integrated pathways including the activation of G alpha(12/13), Rac, NADPH oxidase, and JNK and that G alpha(12/13)-mediated ROS production is essential for NFAT transcriptional activation.	Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol & Toxicol, Fukuoka 8128582, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Cellular Signaling, Tokyo 1130033, Japan; Kyushu Univ, Grad Sch Med, Dept Pharmacol, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Fukuoka 8128582, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Cell Physiol, Bunkyo Ku, Tokyo 1138613, Japan; Natl Inst Hlth, Tokyo 1588501, Japan	Kyushu University; University of Tokyo; Kyushu University; Kyushu University; Tokyo Metropolitan Institute of Medical Science; National Institute of Health Sciences - Japan	Kurose, H (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol & Toxicol, Fukuoka 8128582, Japan.	kurose@phar.kyushu-u.ac.jp	Tanabe, Shihori/AAH-6584-2019; Kobayashi, Hiroyuki/F-6386-2013	Tanabe, Shihori/0000-0003-3706-0616; Kobayashi, Hiroyuki/0000-0003-4965-0883; Nishida, Motohiro/0000-0002-2587-5458				Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; Arai K, 2003, MOL PHARMACOL, V63, P478, DOI 10.1124/mol.63.3.478; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Cheng CM, 2003, MOL PHARMACOL, V63, P1002, DOI 10.1124/mol.63.5.1002; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Griendling KK, 2000, REGUL PEPTIDES, V91, P21, DOI 10.1016/S0167-0115(00)00136-1; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huang CS, 2001, J BIOL CHEM, V276, P22397, DOI 10.1074/jbc.M010828200; Huang CS, 2001, CANCER RES, V61, P8051; Ichida M, 2001, J BIOL CHEM, V276, P3524, DOI 10.1074/jbc.M004275200; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; MAISCH B, 1995, HERZ, V20, P75; Manabe I, 2002, CIRC RES, V91, P1103, DOI 10.1161/01.RES.0000046452.67724.B8; Maruyama Y, 2002, CIRC RES, V91, P961, DOI 10.1161/01.RES.0000043282.39776.7C; Matsusaka T, 1999, J CLIN INVEST, V103, P1451, DOI 10.1172/JCI5056; Minamisawa S, 2003, BIOCHEM BIOPH RES CO, V304, P1, DOI 10.1016/S0006-291X(03)00526-6; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Murasawa S, 2000, J BIOL CHEM, V275, P26856; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Nishida M, 2005, J BIOL CHEM, V280, P18434, DOI 10.1074/jbc.M409710200; Nishida M, 2002, J BIOL CHEM, V277, P9036, DOI 10.1074/jbc.M107392200; Nishida M, 2002, BIOCHEM BIOPH RES CO, V291, P995, DOI 10.1006/bbrc.2002.6553; Olofsson P, 2003, NAT GENET, V33, P25, DOI 10.1038/ng1058; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Rincon M, 1997, MOL CELL BIOL, V17, P1522, DOI 10.1128/MCB.17.3.1522; SABBAH HN, 1995, MOL CELL BIOCHEM, V147, P29, DOI 10.1007/BF00944780; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Schnee JM, 2000, CARDIOVASC RES, V46, P264, DOI 10.1016/S0008-6363(00)00044-4; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Takemoto M, 2001, J CLIN INVEST, V108, P1429, DOI 10.1172/JCI200113350; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; Xie ZL, 2004, J CELL PHYSIOL, V198, P399, DOI 10.1002/jcp.10419	47	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23041	23047		10.1074/jbc.M409397200	http://dx.doi.org/10.1074/jbc.M409397200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15826947	hybrid			2022-12-25	WOS:000229741800060
J	Lo, SS; Lo, SH; Hao, S				Lo, SS; Lo, SH; Hao, S			Cleavage of cten by caspase-3 during apoptosis	ONCOGENE			English	Article						cten; tensin; focal adhesion; apoptosis caspase	PROSTATE-CANCER; SIGNALING PATHWAY; ACTIVATION; BINDING; MATRIX; CELLS	Normal endothelial and epithelial cells undergo apoptosis when cell adhesion and spreading are disrupted, implying a critical role of focal adhesions in cell survival. Cten is a focal adhesion molecule of the tensin family. In contrast to other tensins, cten expression is limited to very few tissues, such as the prostate, and only in epithelial cells. Here, we have explored the potential roles of cten in apoptosis. We found cten was cleaved during apoptosis induced by staurosporine in normal prostate epithelial cells. By using recombinant caspases and site-directed mutagenesis, we have identified caspase-3 as the major protease to digest cten at the DSTD570 down arrow S site. The biological relevance of cten-cleaved fragments was demonstrated by cells ectopically expressing these fragments. Cten fragment ( residues 571 - 715) containing the phosphotyrosine- binding domain significantly reduced the growth rate. Detection of cleaved poly( ADP-ribose) polymerase and annexin binding in cells expressing cten ( 571 - 715) indicated that a fraction of cells underwent apoptosis. These results demonstrate that cten is a target of caspase-3 and the resultant fragments could further promote apoptosis.	Univ Calif Davis, Dept Orthopaed Surg, 4635 2nd Ave,Room 2000, Sacramento, CA 95817 USA; Natl Yang Ming Univ, Taipei Vet Gen Hosp, Div Gen Surg, Taipei 112, Taiwan; Tao Yuan Gen Hosp, Div Endocrinol & Metab, Tao Yuan, Taiwan; Univ Calif Davis, Ctr Canc, Ctr Tissue Regenerat & Repair, Sacramento, CA 95817 USA	University of California System; University of California Davis; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; University of California System; University of California Davis	Hao, S (corresponding author), Univ Calif Davis, Dept Orthopaed Surg, 4635 2nd Ave,Room 2000, Sacramento, CA 95817 USA.	shlo@ucdavis.edu		Lo, Su Hao/0000-0002-2675-9387	NCI NIH HHS [CA102537] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA102537, R01CA102537] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bowen C, 1999, CELL DEATH DIFFER, V6, P394, DOI 10.1038/sj.cdd.4400502; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Chen HY, 2003, BIOCHEM J, V370, P1039, DOI 10.1042/BJ20021308; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Guo YP, 1999, CANCER RES, V59, P1366; Henkels KM, 1999, CANCER RES, V59, P3077; Kyprianou N, 1996, HUM PATHOL, V27, P668, DOI 10.1016/S0046-8177(96)90396-2; Lo SH, 2004, INT J BIOCHEM CELL B, V36, P31, DOI 10.1016/S1357-2725(03)00171-7; Lo SH, 2002, CANCER RES, V62, P4217; Marcelli M, 1999, CANCER RES, V59, P382; Marcelli M, 1998, CANCER RES, V58, P76; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Motwani M, 1999, CLIN CANCER RES, V5, P1876; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190	17	16	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4311	4314		10.1038/sj.onc.1208571	http://dx.doi.org/10.1038/sj.onc.1208571			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806167				2022-12-25	WOS:000229815300014
J	Baldwin, J; Michnoff, CH; Malmquist, NA; White, J; Roth, MG; Rathod, PK; Phillips, MA				Baldwin, J; Michnoff, CH; Malmquist, NA; White, J; Roth, MG; Rathod, PK; Phillips, MA			High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITE; DRUG-RESISTANCE; MECHANISM; LEFLUNOMIDE; IDENTIFICATION; BIOSYNTHESIS; PURIFICATION	Plasmodium falciparum is the causative agent of the most serious and fatal malarial infections, and it has developed resistance to commonly employed chemotherapeutics. The de novo pyrimidine biosynthesis enzymes offer potential as targets for drug design, because, unlike the host, the parasite does not have pyrimidine salvage pathways. Dihydroorotate dehydrogenase (DHODH) is a flavin-dependent mitochondrial enzyme that catalyzes the fourth reaction in this essential pathway. Coenzyme Q (CoQ) is utilized as the oxidant. Potent and species-selective inhibitors of malarial DHODH were identified by high-throughput screening of a chemical library, which contained 220,000 drug-like molecules. These novel inhibitors represent a diverse range of chemical scaffolds, including a series of halogenated phenyl benzamide/naphthamides and urea-based compounds containing napthyl or quinolinyl substituents. Inhibitors in these classes with IC50 values below 600 nM were purified by high pressure liquid chromatography, characterized by mass spectroscopy, and subjected to kinetic analysis against the parasite and human enzymes. The most active compound is a competitive inhibitor of CoQ with an IC50 against malarial DHODH of 16 nM, and it is 12,500-fold less active against the human enzyme. Site-directed mutagenesis of residues in the CoQ-binding site significantly reduced inhibitor potency. The structural basis for the species selective enzyme inhibition is explained by the variable amino acid sequence in this binding site, making DHODH a particularly strong candidate for the development of new anti-malarial compounds.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75230 USA; Univ Washington, Dept Chem & Pathobiol, Seattle, WA 98195 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	margaret.phillips@UTSouthwestern.edu		Malmquist, Nicholas/0000-0003-2822-8245; Roth, Michael/0000-0002-9056-332X	NIAID NIH HHS [AI 60360, R01 AI053680, AI 26912, AI 053680] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053680, R29AI026912, R01AI026912, R21AI053680, R56AI053680, P01AI060360] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin J, 2002, J BIOL CHEM, V277, P41827, DOI 10.1074/jbc.M206854200; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Copeland RA, 2000, J BIOL CHEM, V275, P33373, DOI 10.1074/jbc.M004451200; Davis JP, 1996, BIOCHEMISTRY-US, V35, P1270, DOI 10.1021/bi952168g; Davis JP, 1997, BIOCHEM PHARMACOL, V54, P459, DOI 10.1016/S0006-2952(97)00197-4; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; Fox RI, 1999, CLIN IMMUNOL, V93, P198, DOI 10.1006/clim.1999.4777; GREENE S, 1995, BIOCHEM PHARMACOL, V50, P861, DOI 10.1016/0006-2952(95)00255-X; GUTTERIDGE WE, 1970, J PROTOZOOL, V17, P89, DOI 10.1111/j.1550-7408.1970.tb05163.x; Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; Herrmann ML, 2000, IMMUNOPHARMACOLOGY, V47, P273, DOI 10.1016/S0162-3109(00)00191-0; HINES V, 1989, BIOCHEMISTRY-US, V28, P1222, DOI 10.1021/bi00429a040; Jiang SP, 2001, ANTIMICROB AGENTS CH, V45, P2577, DOI 10.1128/AAC.45.9.2577-2584.2001; KANE HJ, 1980, MOL BIOCHEM PARASIT, V1, P347, DOI 10.1016/0166-6851(80)90052-3; KRUNGKRAI J, 1991, BIOCHEMISTRY-US, V30, P1934, DOI 10.1021/bi00221a029; KRUNGKRAI J, 1995, BBA-GEN SUBJECTS, V1243, P351, DOI 10.1016/0304-4165(94)00158-T; Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0; Loffler M, 1997, MOL CELL BIOCHEM, V174, P125, DOI 10.1023/A:1006859115450; Marcinkeviciene J, 2000, BIOCHEM PHARMACOL, V60, P339, DOI 10.1016/S0006-2952(00)00348-8; McGovern SL, 2003, J MED CHEM, V46, P4265, DOI 10.1021/jm030266r; McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y; Papageorgiou C, 2001, J MED CHEM, V44, P1986, DOI 10.1021/jm010822m; Rathod PK, 1997, P NATL ACAD SCI USA, V94, P9389, DOI 10.1073/pnas.94.17.9389; REYES P, 1982, MOL BIOCHEM PARASIT, V5, P275, DOI 10.1016/0166-6851(82)90035-4; Ryan AJ, 2003, J MED CHEM, V46, P3448, DOI 10.1021/jm0340896; Seidler J, 2003, J MED CHEM, V46, P4477, DOI 10.1021/jm030191r; SEYMOUR KK, 1994, BIOCHEMISTRY-US, V33, P5268, DOI 10.1021/bi00183a033; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; WILLIAMSON RA, 1995, J BIOL CHEM, V270, P22467, DOI 10.1074/jbc.270.38.22467; Winstanley PA, 2002, MICROBES INFECT, V4, P157, DOI 10.1016/S1286-4579(01)01523-4; Zhang K, 2002, SCIENCE, V296, P545, DOI 10.1126/science.1068274	32	157	168	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21847	21853		10.1074/jbc.M501100200	http://dx.doi.org/10.1074/jbc.M501100200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15795226	hybrid			2022-12-25	WOS:000229557900024
J	Shumskaya, MA; Paithoonrangsarid, K; Kanesaki, Y; Los, DA; Zinchenko, VV; Tanticharoen, M; Suzuki, I; Murata, N				Shumskaya, MA; Paithoonrangsarid, K; Kanesaki, Y; Los, DA; Zinchenko, VV; Tanticharoen, M; Suzuki, I; Murata, N			Identical Hik-Rre systems are involved in perception and transduction of salt signals and hyperosmotic signals but regulate the expression of individual genes to different extents in Synechocystis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSMOTIC-STRESS; SP PCC-6803; HISTIDINE KINASES; MECHANISM; PROTEINS; SENSORS; PATHWAY; SETS	In previous studies, we characterized five histidine kinases (Hiks) and the cognate response regulators (Rres) that control the expression of similar to 70% of the hyperosmotic stress-inducible genes in the cyanobacterium Synechocystis sp. PCC 6803. In the present study, we screened a gene knock-out library of Rres by RNA slot-blot hybridization and with a genome-wide DNA microarray and identified three Hik-Rre systems, namely, Hik33-Rre31, Hik10-Rre3, and Hik16-Hik41-Rre17, as well as another system that included Rre1, that were involved in perception of salt stress and transduction of the signal. We found that these Hik-Rre systems were identical to those that were involved in perception and transduction of the hyperosmotic stress signal. We compared the induction factors of the salt stress- and hyperosmotic stress- inducible genes that are located downstream of each system and found that these genes responded to the two kinds of stress to different respective extents. In addition, the Hik33-Rre31 system regulated the expression of genes that were specifically induced by hyperosmotic stress, whereas the system that included Rre1 regulated the expression of one or two genes that were specifically induced either by salt stress or by hyperosmotic stress. Our observations suggest that the perception of salt and hyperosmotic stress by the Hik-Rre systems is complex and that salt stress and hyperosmotic stress are perceived as distinct signals by the Hik-Rre systems.	Natl Inst Basic Biol, Div Cellular Regulat, Okazaki, Aichi 4448585, Japan; Russian Acad Sci, Inst Plant Physiol, Moscow 127276, Russia; Natl Ctr Genet Engn & Biotechnol, Bangkok 12120, Thailand; Moscow MV Lomonosov State Univ, Dept Genet, Moscow 119899, Russia; Grad Univ Adv Studies, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Russian Academy of Sciences; Timiryazev Institute of Plant Physiology; National Science & Technology Development Agency - Thailand; National Center Genetic Engineering & Biotechnology (BIOTEC); Lomonosov Moscow State University; Graduate University for Advanced Studies - Japan	Murata, N (corresponding author), Natl Inst Basic Biol, Div Cellular Regulat, Okazaki, Aichi 4448585, Japan.	murata@nibb.ac.jp	Murata, Norio/E-6569-2010; Murata, Norio/O-7945-2019; LOS, Dmitry A./C-6608-2013; Shumskaya, Maria/P-5972-2017; Kanesaki, Yu/J-3817-2017; Zinchenko, Vladislav V/K-3363-2017	Murata, Norio/0000-0002-6605-5800; LOS, Dmitry A./0000-0002-0142-7853; Shumskaya, Maria/0000-0001-7916-462X; Kanesaki, Yu/0000-0003-3537-9789; Zinchenko, Vladislav V/0000-0003-1931-2509; , Kalyanee/0000-0001-9121-3295				Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; COMEAU DE, 1985, J BACTERIOL, V164, P578, DOI 10.1128/JB.164.2.578-584.1985; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Figge RM, 2001, MOL MICROBIOL, V39, P455, DOI 10.1046/j.1365-2958.2001.02239.x; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Kaneko T, 2003, DNA RES, V10, P221, DOI 10.1093/dnares/10.5.221; Kaneko T, 1996, DNA Res, V3, P109; Kanesaki Y, 2002, BIOCHEM BIOPH RES CO, V290, P339, DOI 10.1006/bbrc.2001.6201; Kiseleva LL, 2000, J MOL MICROB BIOTECH, V2, P331; Marin K, 2003, P NATL ACAD SCI USA, V100, P9061, DOI 10.1073/pnas.1532302100; Mikami K, 2002, MOL MICROBIOL, V46, P905, DOI 10.1046/j.1365-2958.2002.03202.x; Paithoonrangsarid K, 2004, J BIOL CHEM, V279, P53078, DOI 10.1074/jbc.M410162200; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Sambrook J, 1989, MOL CLONING LAB MANU; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Suzuki I, 2001, MOL MICROBIOL, V40, P235, DOI 10.1046/j.1365-2958.2001.02379.x; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; van Waasbergen LG, 2002, J BACTERIOL, V184, P2481, DOI 10.1128/JB.184.9.2481-2490.2002; Van Wuytswinkel O, 2000, MOL MICROBIOL, V37, P382, DOI 10.1046/j.1365-2958.2000.02002.x; WADA H, 1989, PLANT CELL PHYSIOL, V30, P971; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999	22	123	134	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21531	21538		10.1074/jbc.m412174200	http://dx.doi.org/10.1074/jbc.m412174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15805106	Green Published, hybrid			2022-12-25	WOS:000229438800075
J	Zheng, H; Kiss, RS; Franklin, V; Wang, MD; Haidar, B; Marcel, YL				Zheng, H; Kiss, RS; Franklin, V; Wang, MD; Haidar, B; Marcel, YL			ApoA-I lipidation in primary mouse hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; CASSETTE TRANSPORTER 1; CHOLESTEROL EFFLUX; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; TANGIER-DISEASE; CHICKEN LIVER; MEDIATED CHOLESTEROL; ABCA1 TRANSPORTER	The liver is the major site of both apolipoprotein A-I (apoA-I) synthesis and ATP-binding cassette transporter A1 (ABCA1) expression. Here, we compare the lipidation with cholesterol and phospholipid of newly synthesized human apoA-I (hapoA-I) using adenoviral vector-mediated endogenous expression or exogenously added hapoA-I in wild type and ABCA1-null hepatocytes. Hepatocytes were labeled with [H-3] cholesterol (delivered with LDL or methyl-beta-cyclodextrin), [3H] mevalonate, or [3H] choline. ABCA1 deficiency decreased apoA-I phospholipidation by 80%, but acquisition of de novo synthesized and exogenous cholesterol only decreased by 40-60%. The transfer of de novo synthesized cholesterol to apoA-I was decreased at all time points, but that of exogenously delivered cholesterol was independent of ABCA1 activity at the early time points. Progesterone does not affect apoA-I synthesis or its lipidation but inhibited the early phase of apoA-I cholesterol lipidation in both wild type and ABCA1-null hepatocytes. Fast protein liquid chromatography analysis of medium lipoproteins confirmed that with ABCA1 deficiency, the proportion of secreted high density lipoprotein-associated apoA-I and cholesterol decreased by about 50%. The very low density lipoprotein (VLDL)/LDL size fraction also contained a significant level of cholesterol in ABCA1 deficiency, consistent with the result of immunoprecipitations showing the presence of lipoproteins with both apoA-I and murine apoB. ApoA-I lipidation with newly synthesized cholesterol in ABCA1-null hepatocytes was significantly decreased by brefeldin A and monensin. In conclusion, we demonstrate that: (i) whereas most hepatic phospholipidation of apoA-I is mediated by ABCA1, acquisition of cholesterol depends on active transfer from intracellular compartments by ABCA1-dependent and -independent pathways, both sensitive to progesterone and (ii) there is separate regulation of phospholipid and cholesterol lipidation of apoA-I in hepatocytes.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Biochem, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Microbiol, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Immunol, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa; University of Ottawa	Marcel, YL (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Biochem, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.	ylmarcel@ottawaheart.ca						Atger VM, 1997, J CLIN INVEST, V99, P773, DOI 10.1172/JCI119223; BANERJEE D, 1985, J CELL BIOL, V101, P1219, DOI 10.1083/jcb.101.4.1219; BANERJEE D, 1984, J CELL BIOL, V99, P1917, DOI 10.1083/jcb.99.6.1917; Banerjee D, 1997, EXP CELL RES, V235, P334, DOI 10.1006/excr.1997.3687; BANERJEE D, 1983, J CELL BIOL, V96, P651, DOI 10.1083/jcb.96.3.651; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BRESLOW JL, 1985, ANNU REV BIOCHEM, V54, P699, DOI 10.1146/annurev.biochem.54.1.699; BRESLOW JL, 1987, AM HEART J, V113, P422, DOI 10.1016/0002-8703(87)90608-9; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown AM, 1999, BBA-MOL CELL BIOL L, V1440, P253, DOI 10.1016/S1388-1981(99)00133-X; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CASTLE CK, 1991, J LIPID RES, V32, P439; Cavelier LB, 2001, J BIOL CHEM, V276, P18046, DOI 10.1074/jbc.M100565200; Chisholm JW, 2002, J LIPID RES, V43, P36; Christian AE, 1999, J LIPID RES, V40, P1475; Clay MA, 1999, BIOCHEM J, V337, P445, DOI 10.1042/0264-6021:3370445; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; Denis M, 2004, J BIOL CHEM, V279, P41529, DOI 10.1074/jbc.M406881200; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; FORTE TM, 1990, BIOCHIM BIOPHYS ACTA, V1047, P11, DOI 10.1016/0005-2760(90)90254-U; Frank PG, 2000, J LIPID RES, V41, P853; Glomset J A, 1973, Adv Lipid Res, V11, P1; Haghpassand M, 2001, J CLIN INVEST, V108, P1315, DOI 10.1172/JCI200112810; HAMILTON RL, 1991, J LIPID RES, V32, P529; HOWELL KE, 1982, J CELL BIOL, V92, P833, DOI 10.1083/jcb.92.3.833; Ishimori N, 2004, ARTERIOSCL THROM VAS, V24, P161, DOI 10.1161/01.ATV.0000104027.52895.D7; JOHNSON WJ, 1995, J BIOL CHEM, V270, P25037, DOI 10.1074/jbc.270.42.25037; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1990, J BIOL CHEM, V265, P22123; KAPLAN MR, 1985, J CELL BIOL, V101, P441, DOI 10.1083/jcb.101.2.441; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KHAN BV, 1990, BIOCHIM BIOPHYS ACTA, V1044, P297, DOI 10.1016/0005-2760(90)90073-7; Kiss RS, 2003, J BIOL CHEM, V278, P10119, DOI 10.1074/jbc.M300137200; Kojima K, 2001, BBA-MOL CELL BIOL L, V1532, P173, DOI 10.1016/S1388-1981(01)00124-X; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LANGE Y, 1989, J BIOL CHEM, V264, P3786; Langmann T, 2003, CLIN CHEM, V49, P230, DOI 10.1373/49.2.230; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lee JY, 2005, CURR OPIN LIPIDOL, V16, P19, DOI 10.1097/00041433-200502000-00005; LI QQ, 1993, BIOCHEMISTRY-US, V32, P4597, DOI 10.1021/bi00068a016; Marcel YL, 2003, CURR OPIN LIPIDOL, V14, P151, DOI 10.1097/00041433-200304000-00006; Marcil M, 2003, CIRCULATION, V107, P1366, DOI 10.1161/01.CIR.0000056764.53152.F9; MAZZONE T, 1995, J LIPID RES, V36, P544; McManus DC, 2001, J BIOL CHEM, V276, P21292, DOI 10.1074/jbc.M100463200; McManus DC, 2000, J BIOL CHEM, V275, P5043, DOI 10.1074/jbc.275.7.5043; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Neufeld EB, 2004, J BIOL CHEM, V279, P15571, DOI 10.1074/jbc.M314160200; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Olkkonen VM, 2004, CURR OPIN LIPIDOL, V15, P321, DOI 10.1097/00041433-200406000-00013; Osono Y, 1996, P NATL ACAD SCI USA, V93, P4114, DOI 10.1073/pnas.93.9.4114; Phillips MC, 1998, ATHEROSCLEROSIS, V137, pS13, DOI 10.1016/S0021-9150(97)00312-2; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; Rodrigueza WV, 1997, ARTERIOSCL THROM VAS, V17, P383, DOI 10.1161/01.ATV.17.2.383; Rothblat GH, 1999, J LIPID RES, V40, P781; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sahoo D, 2004, J LIPID RES, V45, P1122, DOI 10.1194/jlr.M300529-JLR200; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Sniderman AD, 2003, J LIPID RES, V44, P527, DOI 10.1194/jlr.M200187-JLR200; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Sparks DL, 1999, BIOCHEMISTRY-US, V38, P1727, DOI 10.1021/bi981945k; Stolowich NJ, 2002, CELL MOL LIFE SCI, V59, P193, DOI 10.1007/s00018-002-8416-8; SUBRAHMANYAN L, 1988, SCAND J IMMUNOL, V27, P251, DOI 10.1111/j.1365-3083.1988.tb02345.x; Swift LL, 2001, J LIPID RES, V42, P218; Tall AR, 2001, J CLIN INVEST, V108, P1273; Tarugi P, 1998, J LIPID RES, V39, P731; THOMAS SS, 1995, BBA-MOL BASIS DIS, V1272, P37, DOI 10.1016/0925-4439(95)00065-C; Tsujita M, 2005, J LIPID RES, V46, P154, DOI 10.1194/jlr.M400402-JLR200; URBANI L, 1990, J BIOL CHEM, V265, P1919; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Yamauchi Y, 2004, J LIPID RES, V45, P1943, DOI 10.1194/jlr.M400264-JLR200; Yamauchi Y, 2002, BBA-MOL CELL BIOL L, V1585, P1, DOI 10.1016/S1388-1981(02)00304-9; Zheng H, 2004, CIRCULATION, V110, P272	84	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21612	21621		10.1074/jbc.m502200200	http://dx.doi.org/10.1074/jbc.m502200200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797865	hybrid			2022-12-25	WOS:000229438800086
J	Liu, Y; Liu, ZG; Gao, H; Zhou, Y; Androphy, EJ; Chen, JJ				Liu, Y; Liu, ZG; Gao, H; Zhou, Y; Androphy, EJ; Chen, JJ			Opposing effects of bovine papillomavirus type 1 E6 and E7 genes on Fas-mediated apoptosis	ONCOGENE			English	Article						BPV-1; E6; E7; Fas; apoptosis; p53	TUMOR-NECROSIS-FACTOR; ALPHA-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; HUMAN KERATINOCYTES; CELL-DEATH; BINDING-PROTEIN; TRANSFORMING ACTIVITY; INHIBITS APOPTOSIS; INFECTED-CELLS; VIRUS DNA	Programmed cell death (PCD), best exemplified by apoptosis, is a genetically programmed process of cellular destruction that is indispensable for normal development and homeostasis of multicellular organisms. Tumor necrosis factor alpha (TNF) and related cytokines are employed by host defenses to eliminate virally infected cells through induction of apoptosis. Many viruses have evolved specific gene products to modulate this process. We have recently shown that the bovine papillomavirus type 1 (BPV-1) E6 and E7 genes independently sensitize mouse cells to TNF-induced apoptosis. In this report, we investigated the effect of E6 and E7 expression on Fas-mediated apoptosis. In contrast to TNF-mediated apoptosis, E6 and E7 demonstrated opposite effects: while E7 potentiated apoptosis triggered by an agonistic Fas antibody, E6 attenuated the effect. The mitochondrial pathway leading to the activation of caspases appears to be involved in Fas-mediated apoptosis in C127 cells. To further explore the mechanisms by which E6 and E7 modulate Fas-mediated apoptosis, we examined the surface expression of Fas in cells expressing E6 and E7. Significantly, levels of surface Fas expression correlated with the opposing effects of E6 and E7 on Fas-mediated apoptosis. Specifically, while E7 increased the surface expression of Fas, E6 reduced surface Fas expression. Mutational analysis demonstrated a correlation of E6's ability to downregulate surface Fas expression and apoptosis. Since the tumor suppressor p53 can be targeted for degradation by human papillomavirus and has been shown to induce apoptosis by upregulating surface Fas expression, we investigated the role of p53 in BPV-1 E6 and E7 modulation of Fas-mediated apoptosis. Our results demonstrated that the modulatory effects by E6 and E7 could occur in the absence of p53. Interestingly, the reduced Fas protein level on the cell surface is not accompanied by a decrease in total Fas levels in E6-expressing cells. Instead, considerably more Fas protein is found in the cytoplasm of cells expressing E6. These results highlight a novel activity of E6 and E7 that may be involved in viral pathogenesis.	Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Univ Nebraska, Ctr Biotechnol, Lincoln, NE 68588 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Nebraska System; University of Nebraska Lincoln	Chen, JJ (corresponding author), Univ Massachusetts, Sch Med, Dept Med, LRB Room 323,364 Plantat St, Worcester, MA 01605 USA.	jason.chen@umassmed.edu		Androphy, Elliot/0000-0002-8104-0703; liu, zhiguo/0000-0002-8485-7356	NATIONAL CANCER INSTITUTE [R01CA107394, F32CA069738] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 107394, F32 CA 69738, R01 CA107394] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar-Lemarroy A, 2002, ONCOGENE, V21, P165, DOI 10.1038/sj.onc.1204979; Alfandari J, 1999, VIROLOGY, V257, P383, DOI 10.1006/viro.1999.9675; Arnold R, 1999, J IMMUNOL, V162, P7140; Basile JR, 2001, J BIOL CHEM, V276, P22522, DOI 10.1074/jbc.M010505200; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bergqvist A, 1997, J VIROL, V71, P276, DOI 10.1128/JVI.71.1.276-283.1997; Bohl J, 2000, VIROLOGY, V271, P163, DOI 10.1006/viro.2000.0316; Boyer SN, 1996, CANCER RES, V56, P4620; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Das K, 2000, J VIROL, V74, P812, DOI 10.1128/JVI.74.2.812-816.2000; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; Elsing A, 1998, P NATL ACAD SCI USA, V95, P10072, DOI 10.1073/pnas.95.17.10072; Fan XL, 2003, J BIOL CHEM, V278, P43163, DOI 10.1074/jbc.M306008200; Finzer P, 2002, CANCER LETT, V188, P15, DOI 10.1016/S0304-3835(02)00431-7; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Howley M. P., 1996, FIELDS VIROLOGY, P2045; Iglesias M, 1998, ONCOGENE, V17, P1195, DOI 10.1038/sj.onc.1202054; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu Y, 2000, J BIOL CHEM, V275, P30894, DOI 10.1074/jbc.M000640200; Liu YM, 2000, J CELL BIOCHEM, V78, P334, DOI 10.1002/(SICI)1097-4644(20000801)78:2<334::AID-JCB15>3.3.CO;2-6; Liu ZG, 2002, VIROLOGY, V295, P230, DOI 10.1006/viro.2001.1351; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P123, DOI 10.1016/0022-1910(65)90099-5; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Magal SS, 1998, INT J CANCER, V75, P96; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; NEARY K, 1989, J VIROL, V63, P259, DOI 10.1128/JVI.63.1.259-266.1989; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; Peng SL, 1996, J EXP MED, V184, P1149, DOI 10.1084/jem.184.3.1149; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; Rapp L, 1999, ONCOGENE, V18, P607, DOI 10.1038/sj.onc.1202373; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; SAYAMA K, 1994, J INVEST DERMATOL, V103, P330, DOI 10.1111/1523-1747.ep12394858; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, CANC CELLS DNA TUMOR, V4, P571; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; Shisler J, 1997, J VIROL, V71, P8299, DOI 10.1128/JVI.71.11.8299-8306.1997; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thompson DA, 2001, ONCOGENE, V20, P3629, DOI 10.1038/sj.onc.1204483; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; Tong X, 1998, J VIROL, V72, P476, DOI 10.1128/JVI.72.1.476-482.1998; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Vanden Berghe Tom, 2004, Methods Mol Med, V98, P101; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wang XD, 2001, GENE DEV, V15, P2922; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLD WSM, 1989, MOL BIOL MED, V6, P433; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yuste VJ, 2001, J BIOL CHEM, V276, P22323, DOI 10.1074/jbc.M100072200; Zimmermann H, 2000, J GEN VIROL, V81, P2617, DOI 10.1099/0022-1317-81-11-2617; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	81	4	4	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3942	3953		10.1038/sj.onc.1208542	http://dx.doi.org/10.1038/sj.onc.1208542			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782122				2022-12-25	WOS:000229435300010
J	Nonaka, M; Horie, R; Itoh, K; Watanabe, T; Yamamoto, N; Yamaoka, S				Nonaka, M; Horie, R; Itoh, K; Watanabe, T; Yamamoto, N; Yamaoka, S			Aberrant NF-kappa B2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts	ONCOGENE			English	Article						Hodgkin/Reed-Sternberg cells; CD30; NF-kappa B2; IKK	NF-KAPPA-B; DISEASE TUMOR-CELLS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; LATENT MEMBRANE-PROTEIN-1; CONSTITUTIVE ACTIVATION; KINASE-ACTIVITY; LEUKEMIA-VIRUS; LYMPHOMA; P100	Overexpression of CD30 and constitutive nuclear factor-kappa B (NF-kappa B) activation are hallmarks of the malignant Hodgkin Reed-Sternberg (H-RS) cells. Previous investigations have demonstrated that both proliferation and survival of H-RS cells require constitutive NF-kappa B activity, which is comprised of the p50 and RekA subunits. We report here enhanced expression of NF-kappa B2/p52 and ReIB-containing NF-kappa B DNA-binding activity in Epstein-Barr virus-negative H-RS cells. Kinetic studies revealed that a proteasome inhibitor MG132 induced p100 accumulation with reduced p52 expression in H-RS cells, suggesting proteasome-dependent processing of p100. In addition, treatment with a protein synthesis inhibitor cycloheximide rapidly downregulated inhibitor of NF-kappa B (I kappa B) kinase activity in H-RS cells. We also demonstrate that overexpression of CD30 in rat fibroblasts at levels comparable to those in H-RS cells results in constitutive I kappa B kinase activation, proteasome-dependent p100 processing, and NF-kappa B-dependent cell transformation. Our results thus indicate that CD30 triggers the noncanonical NF-kappa B activation pathway, and suggest that deregulated CD30 signaling contributes to the neoplastic features of H-RS cells.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Virol, Tokyo 1138510, Japan; Kitasato Univ, Sch Med, Dept Internal Med 4, Kanagawa, Japan; Toho Univ, Sch Med, Dept Pathol 2, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Res, Div Pathol, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Kitasato University; Toho University; University of Tokyo	Yamaoka, S (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Virol, 1-5-45 Bunkyo Ku, Tokyo 1138510, Japan.	shojmmb@tmd.ac.jp						Annunziata CM, 2000, BLOOD, V96, P2841; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Ben-Neriah Y, 2004, EMBO REP, V5, P668, DOI 10.1038/sj.embor.7400187; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; CARBONE A, 1995, BLOOD, V85, P780, DOI 10.1182/blood.V85.3.780.bloodjournal853780; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chinanonwait N, 2002, FEBS LETT, V531, P553, DOI 10.1016/S0014-5793(02)03618-9; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Eliopoulos AG, 2003, ONCOGENE, V22, P7557, DOI 10.1038/sj.onc.1207120; Emmerich F, 2003, J PATHOL, V201, P413, DOI 10.1002/path.1454; Fiumara P, 2001, BLOOD, V98, P2784, DOI 10.1182/blood.V98.9.2784; Hanada K, 1996, J LEUKOCYTE BIOL, V60, P181, DOI 10.1002/jlb.60.2.181; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; Hironaka N, 2004, NEOPLASIA, V6, P266, DOI 10.1593/neo.03388; Horie R, 2004, CANCER CELL, V5, P353, DOI 10.1016/S1535-6108(04)00084-4; Horie R, 2003, INT J HEMATOL, V77, P37, DOI 10.1007/BF02982601; Horie R, 2002, ONCOGENE, V21, P2493, DOI 10.1038/sj.onc.1205337; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hubinger G, 2004, EXP HEMATOL, V32, P382, DOI 10.1016/j.exphem.2004.01.003; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Kuppers R, 2003, J CLIN INVEST, V111, P529, DOI 10.1172/JC1200316624; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; Mori N, 2000, BLOOD, V95, P3915; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; MUNOZ E, 1994, J VIROL, V68, P8035; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; Opat S, 2001, AUTOIMMUNITY, V33, P45, DOI 10.3109/08916930108994109; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Schneider C, 2002, LEUKEMIA LYMPHOMA, V43, P1355, DOI 10.1080/10428190290033288; Skinnider BF, 2002, BLOOD, V99, P4283, DOI 10.1182/blood-2002-01-0099; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Stein H, 2000, BLOOD, V96, P3681; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; Takahashi Y, 2001, J VIROL, V75, P6748, DOI 10.1128/JVI.75.15.6748-6757.2001; Thomas RK, 2004, LANCET ONCOL, V5, P11, DOI 10.1016/S1470-2045(03)01319-6; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zheng B, 2003, BLOOD, V102, P1019, DOI 10.1182/blood-2002-11-3507	56	31	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3976	3986		10.1038/sj.onc.1208564	http://dx.doi.org/10.1038/sj.onc.1208564			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782119				2022-12-25	WOS:000229435300013
J	Hartmann, TN; Burger, JA; Glodek, A; Fujii, N; Burger, M				Hartmann, TN; Burger, JA; Glodek, A; Fujii, N; Burger, M			CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells	ONCOGENE			English	Article						chemokine receptor; CXCR4; CXCR4; antagonists; integrins; lung cancer	DRUG-RESISTANCE; TYROSINE PHOSPHORYLATION; SPONTANEOUS MIGRATION; FACTOR-1-ALPHA; EXPRESSION; ACTIVATION; PROTEIN; ARREST; KINASE; TRANSDUCTION	Small cell lung cancer (SCLC) is an aggressive, rapidly metastazising neoplasm with a high propensity for marrow involvement. SCLC cells express high levels of functional CXCR4 receptors for the chemokine stromal-cell-derived factor-1 (SDF-1/CXCL12). Adhesion of SCLC cells to extracellular matrix or accessory cells within the tumor microenvironment confers resistance to chemotherapy via integrin signaling and thus may be responsible for residual disease and relapses commonly seen in SCLC. We examined the signaling mechanisms that regulate CXCL12-induced adhesion of SCLC cells to fibronectin, collagen, and stromal cells and the effects on SCLC cell chemoresistance. We found that CXCL12-induced integrin activation which resulted in an increased adhesion of SCLC cells to fibronectin and collagen. This was mediated by alpha 2, alpha 4, alpha 5, and beta 1 integrins along with CXCR4 activation, which could be inhibited by CXCR4 antagonists. Stromal cells protected SCLC cells from chemotherapy-induced apoptosis, and this protection could also be antagonized by CXCR4 inhibitors. We conclude that activation of integrins and CXCR4 chemokine receptors co-operate in mediating adhesion and survival signals from the tumor microenvironment to SCLC cells. Therefore, CXCR4 antagonists in combination with cytotoxic drugs should be explored in SCLC to overcome CXCL12-mediated adhesion and survival signals in the tumor microenvironment.	Freiburg Univ Hosp, Dept Med, Div Hematol Oncol, D-79106 Freiburg, Germany; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto, Japan	University of Freiburg; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Kyoto University	Burger, M (corresponding author), Freiburg Univ Hosp, Dept Med, Div Hematol Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	burgerm@mm11.ukl.uni-freiburg.de	Hartmann, Tanja Nicole/C-9345-2017; Hartmann, Tanja Nicole/AAA-6735-2020; Hartmann, Tanja Nicole/C-9345-2017	Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-2633-7301				Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Burger JA, 2003, BRIT J HAEMATOL, V122, P579, DOI 10.1046/j.1365-2141.2003.04466.x; Burger M, 2003, ONCOGENE, V22, P8093, DOI 10.1038/sj.onc.1207097; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N; Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910; Fujii N, 2003, EXPERT OPIN INV DRUG, V12, P185, DOI 10.1517/13543784.12.2.185; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Glodek AM, 2003, J EXP MED, V197, P461, DOI 10.1084/jem.20021477; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hidalgo A, 2001, EXP HEMATOL, V29, P345, DOI 10.1016/S0301-472X(00)00668-8; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; Kijima T, 2002, CANCER RES, V62, P6304; Kraus AC, 2002, ONCOGENE, V21, P8683, DOI 10.1038/sj.onc.1205939; LASSEN U, 1995, J CLIN ONCOL, V13, P1215, DOI 10.1200/JCO.1995.13.5.1215; LEMOINE FM, 1988, EXP HEMATOL, V16, P718; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Salgia R, 1999, ONCOGENE, V18, P67, DOI 10.1038/sj.onc.1202273; Sanz-Rodriguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Taichman RS, 2002, CANCER RES, V62, P1832; Tamamura H, 2001, BIOORG MED CHEM LETT, V11, P1897, DOI 10.1016/S0960-894X(01)00323-7; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Vicente-Manzanares M, 1998, EUR J IMMUNOL, V28, P2197, DOI 10.1002/(SICI)1521-4141(199807)28:07<2197::AID-IMMU2197>3.0.CO;2-F; Wade R, 2002, ONCOGENE, V21, P96, DOI 10.1038/sj.onc.1205013; Wright N, 2002, J IMMUNOL, V168, P5268, DOI 10.4049/jimmunol.168.10.5268; ZIPORI D, 1985, BLOOD, V66, P447	39	215	235	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4462	4471		10.1038/sj.onc.1208621	http://dx.doi.org/10.1038/sj.onc.1208621			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806155				2022-12-25	WOS:000229976900015
J	Miao, WM; Hu, LG; Scrivens, PJ; Batist, G				Miao, WM; Hu, LG; Scrivens, PJ; Batist, G			Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway - Direct cross-talk between phase I and II drug-metabolizing enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR AROMATIC-COMPOUNDS; GENE-EXPRESSION; INDUCIBLE EXPRESSION; AH RECEPTOR; NAD(P)H-QUINONE OXIDOREDUCTASE; CHEMOPREVENTIVE AGENTS; OXIDATIVE STRESS; SUBUNIT GENE; CANCER; IDENTIFICATION	The aryl hydrocarbon receptor (AHR) and NF-E2 p45-related factor (NRF2) are two distinct transcription factors involved in the regulation of drug-metabolizing enzymes. Increasing evidence from several studies implies that AHR and NRF2 have direct links, but the molecular mechanism remains unknown. In this work we demonstrate for the first time that Nrf2 gene transcription is directly modulated by AHR activation. DNA sequence analyses of the mouse Nrf2 promoter revealed one xenobiotic response element (XRE)-like element (XREL1) located at -712 and two additional XRE-like elements located at +755 (XREL2) and +850 (XREL3). Functional analysis using luciferase assay showed that XREL1, XREL2, and XREL3 are all inducible by 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment, with XREL2 being the most potent. The functionality of these XRE-like elements was further confirmed by mutagenesis and gel shift experiments. Finally, we used chromatin immuno-precipitation assay to show a direct binding of AHR to the Nrf2 promoter. Cells with silenced AHR expression using siRNA also lost NRF2 mRNA induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin. These new data position NRF2- antioxidant response element downstream in the AHR-XRE pathway. Moreover, direct regulation of NRF2 by AHR contributes to couple phase I and II enzymes into an integrated system facilitating more effective xenobiotic and carcinogen detoxification.	McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University	Batist, G (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	gbatist@onc.jgh.mcgill.ca						Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; DENISON MS, 1988, J BIOL CHEM, V263, P17221; Dyer KD, 2004, MAMM GENOME, V15, P126, DOI 10.1007/s00335-003-2304-x; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Kensler TW, 2003, NAT REV CANCER, V3, P321, DOI 10.1038/nrc1076; Klenova E, 2004, J NEUROSCI, V24, P5966, DOI 10.1523/JNEUROSCI.1150-04.2004; Koliopanos A, 2002, ONCOGENE, V21, P6059, DOI 10.1038/sj.onc.1205633; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Levi MS, 2001, CURR MED CHEM, V8, P1349, DOI 10.2174/0929867013372229; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lin CY, 2004, GENE, V334, P63, DOI 10.1016/j.gene.2004.03.016; Ma Q, 2004, BIOCHEM J, V377, P205, DOI 10.1042/BJ20031123; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Miao WM, 2004, BIOCHEM PHARMACOL, V67, P1897, DOI 10.1016/j.bcp.2004.02.009; Miao WM, 2003, MOL PHARMACOL, V64, P346, DOI 10.1124/mol.64.2.346; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Radjendirane V, 1999, BIOCHEM PHARMACOL, V58, P1649, DOI 10.1016/S0006-2952(99)00245-2; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Safe S, 2002, INT J ONCOL, V20, P1123; Sato A, 2004, J BIOCHEM, V135, P259, DOI 10.1093/jb/mvh031; Senft AP, 2002, FREE RADICAL BIO MED, V33, P1268, DOI 10.1016/S0891-5849(02)01014-6; Shen GX, 2004, J BIOL CHEM, V279, P23052, DOI 10.1074/jbc.M401368200; Sherratt PJ, 2004, METHOD ENZYMOL, V378, P286; Shertzer HG, 1998, BIOCHEM BIOPH RES CO, V253, P44, DOI 10.1006/bbrc.1998.9753; Sogawa K, 2004, BIOCHEM BIOPH RES CO, V318, P746, DOI 10.1016/j.bbrc.2004.04.090; Sudakin DL, 2003, J TOXICOL-CLIN TOXIC, V41, P195, DOI 10.1081/CLT-120019137; Vasiliou V, 1995, BIOCHEM PHARMACOL, V50, P2057, DOI 10.1016/0006-2952(95)02108-6; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang LY, 1998, J BIOL CHEM, V273, P5174, DOI 10.1074/jbc.273.9.5174; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	40	366	374	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20340	20348		10.1074/jbc.M412081200	http://dx.doi.org/10.1074/jbc.M412081200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15790560	hybrid			2022-12-25	WOS:000229242000024
J	Semov, A; Moreno, MJ; Onichtchenko, A; Abulrob, A; Ball, M; Ekiel, I; Pietrzynski, G; Stanimirovic, D; Alakhov, V				Semov, A; Moreno, MJ; Onichtchenko, A; Abulrob, A; Ball, M; Ekiel, I; Pietrzynski, G; Stanimirovic, D; Alakhov, V			Metastasis-associated protein S100A4 induces angiogenesis through interaction with annexin II and accelerated plasmin formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL SURFACE; CALCIUM-BINDING PROTEIN; MATRIX METALLOPROTEINASES; PROGNOSTIC-SIGNIFICANCE; OSTEOSARCOMA CELLS; NMR-SPECTROSCOPY; E-CADHERIN; T-PA; EXPRESSION; ACTIVATION	Many advanced tumors overexpress and secrete the S100A4 protein that is known to promote angiogenesis and metastasis development. The mechanisms of this effect and the endothelial receptor for S100A4 are both still unknown. Here we report that extracellular S100A4 interacts with annexin II, an endothelial plasminogen co-receptor. Co-localization and direct binding of S100A4 and annexin II were demonstrated, and the binding site was identified in the N-terminal region of annexin II. S100A4 alone or in a complex with annexin II accelerated tissue plasminogen activator-mediated plasminogen activation in solution and on the endothelial cell surface through interaction of the S100A4 C-terminal lysines with the lysine-binding domains of plasminogen. A synthetic peptide corresponding to the N terminus of annexin II prevented S100A4-induced plasmin formation in the endothelial cell culture. Local plasmin formation induced by circulating S100A4 could contribute to tumor-induced angiogenesis and metastasis formation that makes this protein an attractive target for new anti-cancer and anti-angiogenic therapies.	Supratek Pharma Inc, Dorval, PQ H9S 1A9, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	National Research Council Canada; National Research Council Canada	Alakhov, V (corresponding author), Supratek Pharma Inc, 215 Blvd Bouchard,Suite 1315, Dorval, PQ H9S 1A9, Canada.	Valery.Alakhov@Supratek.com						Aberg F, 2000, J COMP NEUROL, V424, P269; Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Baramova EN, 1997, FEBS LETT, V405, P157, DOI 10.1016/S0014-5793(97)00175-0; Barraclough R, 1998, BBA-MOL CELL RES, V1448, P190, DOI 10.1016/S0167-4889(98)00143-8; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; Bjornland K, 2001, J PEDIATR SURG, V36, P1040, DOI 10.1053/jpsu.2001.24735; Bjornland K, 1999, CANCER RES, V59, P4702; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; Clarkson J, 2003, BIOCHEM SOC T, V31, P1006; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; El-Mousawi M, 2003, J BIOL CHEM, V278, P46681, DOI 10.1074/jbc.M308681200; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; Felez J, 1996, THROMB HAEMOSTASIS, V76, P577; Garbuglia M, 1998, CELL CALCIUM, V24, P177, DOI 10.1016/S0143-4160(98)90127-0; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Greenway S, 2004, AM J PATHOL, V164, P253, DOI 10.1016/S0002-9440(10)63115-X; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; Hatziapostolou M, 2003, EUR J PHARMACOL, V460, P1, DOI 10.1016/S0014-2999(02)02868-6; Homans SW, 2004, ANGEW CHEM INT EDIT, V43, P290, DOI 10.1002/anie.200300581; Hsieh HL, 2003, BIOCHEM BIOPH RES CO, V307, P375, DOI 10.1016/S0006-291X(03)01190-2; Hsieh HL, 2002, J CELL SCI, V115, P3149; JOHNSSON N, 1986, FEBS LETT, V198, P361, DOI 10.1016/0014-5793(86)80437-9; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; Kimura K, 2000, INT J ONCOL, V16, P1125; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; Kriajevska M, 2000, BBA-MOL CELL RES, V1498, P252, DOI 10.1016/S0167-4889(00)00100-2; KUBE E, 1992, J BIOL CHEM, V267, P14175; Kwaan HC, 2004, J THROMB HAEMOST, V2, P306, DOI 10.1111/j.1538-7933.2004.00593.x; Kwon MJ, 2005, FRONT BIOSCI-LANDMRK, V10, P300, DOI 10.2741/1529; Li CL, 2002, J CLIN PATHOL-MOL PA, V55, P250, DOI 10.1136/mp.55.4.250; Liu Jie, 2003, BMC Biochem, V4, P10, DOI 10.1186/1471-2091-4-10; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Masuda K, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar427; Mathisen B, 2003, CLIN EXP METASTAS, V20, P701, DOI 10.1023/B:CLIN.0000006819.21361.03; Mazzucchelli L, 2002, AM J PATHOL, V160, P7, DOI 10.1016/S0002-9440(10)64342-8; Ninomiya I, 2001, INT J ONCOL, V18, P715; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; Onischenko A, 1996, INVAS METAST, V16, P160; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Robertson H, 2004, J AM SOC NEPHROL, V15, P390, DOI 10.1097/01.ASN.0000108521.39082.E1; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Rudland PS, 2000, CANCER RES, V60, P1595; Ryan DG, 2003, INVEST OPHTH VIS SCI, V44, P4255, DOI 10.1167/iovs.03-0578; Schmidt-Hansen B, 2004, ONCOGENE, V23, P5487, DOI 10.1038/sj.onc.1207720; Schmidt-Hansen B, 2004, J BIOL CHEM, V279, P24498, DOI 10.1074/jbc.M400441200; Stanimirovic D, 1996, J CELL PHYSIOL, V169, P455; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; Taylor S, 2002, BRIT J CANCER, V86, P409, DOI 10.1038/sj.bjc.6600071; WATANABE M, 1993, BIOCHEM BIOPH RES CO, V196, P1376, DOI 10.1006/bbrc.1993.2405; Yonemura Y, 2000, CLIN CANCER RES, V6, P4234; ZENG FY, 1993, INT J BIOCHEM, V25, P1019, DOI 10.1016/0020-711X(93)90116-V; Zijlstra A, 2004, J BIOL CHEM, V279, P27633, DOI 10.1074/jbc.M313617200	58	188	205	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20833	20841		10.1074/jbc.M412653200	http://dx.doi.org/10.1074/jbc.M412653200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788416	hybrid			2022-12-25	WOS:000229242000081
J	Ayash-Rashkovsky, M; Bentwich, Z; Arditti, F; Friedman, S; Reisner, Y; Borkow, G				Ayash-Rashkovsky, M; Bentwich, Z; Arditti, F; Friedman, S; Reisner, Y; Borkow, G			A novel small animal model for HIV-1 infection	FASEB JOURNAL			English	Article						Trimera; humoral and cellular responses; PBMC	PERIPHERAL-BLOOD LYMPHOCYTES; CYTOTOXIC T-LYMPHOCYTES; HUMAN IMMUNE-SYSTEM; ENGRAFTED HUMAN T; B-CELL LYMPHOMAS; TRIMERA MOUSE; RADIATION CHIMERA; PRIMATE MODELS; MICE; AIDS	Lethally irradiated normal BALB/c mice, reconstituted with murine SCID bone marrow and engrafted with human PBMC (Trimera mice), were used to establish a novel murine model for HIV-1 infection. The Trimera mice were successfully infected with different clades and primary isolates of T- and M-tropic HIV-1, with the infection persisting in the animals for 4-6 wk. Rapid loss of the human CD4+ T cells, decrease in CD4/CD8 ratio, and increased T cell activation accompanied the viral infection. All HIV-1 infected animals were able to generate both primary and secondary immune responses, including HIV specific human Immoral and cellular responses. In addition to testing the efficacy of new antiviral compounds, this new murine HIV-1 model may be used for studying host-virus interactions and, most importantly, for screening and developing potential HIV-1 protective vaccines and adjuvants (Ayash-Rashkovsky et al., http://www.fasebi.org/cgi/doi/10.1096/fj.04-3185fje; doi:10.1096/fi.04-3185fie.).	Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Weizmann Institute of Science	Bentwich, Z (corresponding author), Hebrew Univ Jerusalem, Fac Agr, IL-76701 Rehovot, Israel.	zbentwich@rosettagenomics.com; borkow@agri.huji.ac.il	Borkow, Gadi/W-4294-2019; Reisner, Yair/AAA-4772-2019	Reisner, Yair/0000-0002-3354-6945				Ayash-Rashkovsky M, 2002, VACCINE, V20, P2684, DOI 10.1016/S0264-410X(02)00202-5; Ayash-Rashkovsky M, 2001, BIOCHEM BIOPH RES CO, V282, P1169, DOI 10.1006/bbrc.2001.4698; Ben-Yedidia T, 1999, INT IMMUNOL, V11, P1043, DOI 10.1093/intimm/11.7.1043; Bocher WO, 2001, EUR J IMMUNOL, V31, P2071, DOI 10.1002/1521-4141(200107)31:7<2071::AID-IMMU2071>3.0.CO;2-D; Bonyhadi ML, 1997, MOL MED TODAY, V3, P246, DOI 10.1016/S1357-4310(97)01046-0; Browning J, 1997, P NATL ACAD SCI USA, V94, P14637, DOI 10.1073/pnas.94.26.14637; Burakova T, 1997, TRANSPLANTATION, V63, P1166, DOI 10.1097/00007890-199704270-00018; GALUN E, 1995, J INFECT DIS, V172, P25, DOI 10.1093/infdis/172.1.25; Garcia S, 1997, BLOOD, V89, P329, DOI 10.1182/blood.V89.1.329.329_329_336; Haigwood NL, 1999, J MED PRIMATOL, V28, P154, DOI 10.1111/j.1600-0684.1999.tb00264.x; Ilan E, 1999, HEPATOLOGY, V29, P553, DOI 10.1002/hep.510290228; Joag SV, 2000, MICROBES INFECT, V2, P223, DOI 10.1016/S1286-4579(00)00266-5; Jolicoeur P, 1999, LEUKEMIA, V13, pS78, DOI 10.1038/sj.leu.2401293; Kumar A, 2001, VIROLOGY, V285, P1, DOI 10.1006/viro.2001.0942; Leng QB, 2001, J ACQ IMMUN DEF SYND, V27, P389, DOI 10.1097/00126334-200108010-00010; Locher CP, 2001, IMMUNOL REV, V183, P127, DOI 10.1034/j.1600-065x.2001.1830111.x; LUBIN I, 1991, SCIENCE, V252, P427, DOI 10.1126/science.1826797; LUBIN I, 1994, BLOOD, V83, P2368; MARCUS H, 1995, BLOOD, V86, P398, DOI 10.1182/blood.V86.1.398.bloodjournal861398; Mosier D E, 1996, Semin Immunol, V8, P255, DOI 10.1006/smim.1996.0032; Mosier DE, 1996, HOSP PRACT, V31, P41, DOI 10.1080/21548331.1996.11443344; MOSIER DE, 1992, AIDS RES HUM RETROV, V8, P735; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MOSIER DE, 1991, SCIENCE, V251, P791, DOI 10.1126/science.1990441; MOSIER DE, 1990, CURR TOP MICROBIOL, V166, P317; MOSIER DE, 1996, HOSP PRACT OF ED, V31, P53; MOSIER DE, 1996, HOSP PRACT OF ED, V31, P59; Nath BM, 2000, TRENDS MICROBIOL, V8, P426, DOI 10.1016/S0966-842X(00)01816-3; NISHINO Y, 1994, VACCINE, V12, P485, DOI 10.1016/0264-410X(94)90304-2; Reid W, 2001, P NATL ACAD SCI USA, V98, P9271, DOI 10.1073/pnas.161290298; Reisner Y, 1998, TRENDS BIOTECHNOL, V16, P242, DOI 10.1016/S0167-7799(98)01203-7; Sawada S, 1998, J EXP MED, V187, P1439, DOI 10.1084/jem.187.9.1439; SAXON A, 1991, J CLIN INVEST, V87, P658, DOI 10.1172/JCI115043; Segall H, 1996, BLOOD, V88, P721, DOI 10.1182/blood.V88.2.721.bloodjournal882721; ShapiraNahor O, 1997, J VIROL, V71, P4495, DOI 10.1128/JVI.71.6.4495-4501.1997; TARYLEHMANN M, 1992, J EXP MED, V175, P503, DOI 10.1084/jem.175.2.503; TARYLEHMANN M, 1995, IMMUNOL TODAY, V16, P529, DOI 10.1016/0167-5699(95)80046-8; TARYLEHMANN M, 1994, J EXP MED, V180, P1817, DOI 10.1084/jem.180.5.1817; Zussman A, 2003, AIDS, V17, P653, DOI 10.1097/00002030-200303280-00002	39	8	8	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1149	+		10.1096/fj.04-3184fje	http://dx.doi.org/10.1096/fj.04-3184fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15833767				2022-12-25	WOS:000228865300016
J	Clayton, A; Holland, E; Pang, LH; Knox, A				Clayton, A; Holland, E; Pang, LH; Knox, A			Interleukin-1 beta differentially regulates beta(2) adrenoreceptor and prostaglandin E-2-mediated cAMP accumulation and chloride efflux from calu-3 bronchial epithelial cells - Role of receptor changes, adenylyl cyclase, cyclo-oxygenase 2, and protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; CYSTIC-FIBROSIS; DISEASE SEVERITY; AIRWAY EPITHELIA; SECRETION; EXPRESSION; ION; ACTIVATION; PRODUCTS; CULTURES	Here we tested the effect of interleukin-1 beta, a proinflammatory cytokine, on cAMP accumulation and chloride efflux in Calu-3 airway epithelial cells in response to ligands binding to adenylyl cyclase-coupled receptors such as the beta(2) adrenoreceptor and EP prostanoid receptors. Interleukin-1 beta significantly increased isoprenaline-induced cAMP accumulation by increasing beta(2) adrenoreceptor numbers via a protein kinase A-dependent mechanism. In contrast, interleukin-1 beta significantly impaired prostaglandin E-2-induced cAMP accumulation by induction of cyclo-oxygenase-2, prostaglandin E-2 production, and a resulting down-regulation of adenylyl cyclase. The cAMP changes were all mirrored by alterations in chloride efflux assessed using the fluorescent chloride probe N-(ethoxycarbonylmethyl)-6-methoxyquinolinium bromide with interleukin-1 beta increasing chloride efflux in response to isoprenaline and reducing the response to prostaglandin E2. Studies with glibenclamide confirmed that chloride efflux was via the cystic fibrosis transmembrane conductance regulator. Calu-3 expresses EP4 receptors, but not EP2, and receptor expression is reduced by interleukin-1 beta . Collectively, these results provide mechanistic insight into how interleukin-1 beta can differentially regulate cAMP generation and chloride efflux in response to different adenylyl cyclase-coupled ligands in the same cell. These findings have important implications for diseases involving inflammation and abnormal ion flux such as cystic fibrosis.	Univ Nottingham, Div Resp Med, City Hosp, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	Knox, A (corresponding author), Univ Nottingham, Div Resp Med, City Hosp, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.	alan.knox@nottingham.ac.uk		Knox, Alan/0000-0002-5906-4143				Baker JG, 2002, BRIT J PHARMACOL, V137, P400, DOI 10.1038/sj.bjp.0704855; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bronsveld I, 2001, J CLIN INVEST, V108, P1705; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Clarke DL, 2005, AM J PHYSIOL-LUNG C, V288, pL238, DOI 10.1152/ajplung.00313.2004; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Davis P B, 2001, Pediatr Rev, V22, P257, DOI 10.1542/pir.22-8-257; Freedman SD, 2004, NEW ENGL J MED, V350, P560, DOI 10.1056/NEJMoa021218; Galietta LJV, 2000, AM J PHYSIOL-LUNG C, V278, pL1186, DOI 10.1152/ajplung.2000.278.6.L1186; Gray T, 2004, MOL PHARMACOL, V66, P337, DOI 10.1124/mol.66.2.337; Hordvik NL, 2002, PEDIATR PULM, V34, P287, DOI 10.1002/ppul.10162; Kelsen SG, 1997, AM J PHYSIOL-LUNG C, V273, pL694, DOI 10.1152/ajplung.1997.273.3.L694; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KONIG P, 1995, PEDIATR PULM, V20, P205, DOI 10.1002/ppul.1950200402; KONSTAN MW, 1995, NEW ENGL J MED, V332, P848, DOI 10.1056/NEJM199503303321303; LESTER LA, 1994, PEDIATRICS, V93, P114; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; Osika E, 1999, EUR RESPIR J, V14, P339, DOI 10.1034/j.1399-3003.1999.14b17.x; Pang LH, 1998, AM J PHYSIOL-LUNG C, V275, pL322, DOI 10.1152/ajplung.1998.275.2.L322; Pang LH, 1998, BRIT J PHARMACOL, V125, P1320, DOI 10.1038/sj.bjp.0702193; PARTANEN M, 1982, HISTOCHEMISTRY, V76, P175, DOI 10.1007/BF00501920; Poschet JF, 2001, P NATL ACAD SCI USA, V98, P13972, DOI 10.1073/pnas.241182598; Quinton PM, 2001, NAT MED, V7, P292, DOI 10.1038/85429; Range SP, 2000, EUR RESPIR J, V15, P751, DOI 10.1034/j.1399-3003.2000.15d20.x; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; RIORDAN JR, 1989, SCIENCE, V245, P1066; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P2674, DOI 10.1073/pnas.95.5.2674; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Spirli C, 2001, GASTROENTEROLOGY, V121, P156, DOI 10.1053/gast.2001.25516; Thomas SR, 1999, LANCET, V353, P984, DOI 10.1016/S0140-6736(98)05447-6; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; West MR, 1996, ANAL BIOCHEM, V241, P51, DOI 10.1006/abio.1996.0377; WIDDICOMBE JH, 1989, AM J PHYSIOL, V257, pL361, DOI 10.1152/ajplung.1989.257.6.L361; WIDDICOMBE JH, 1986, AM J PHYSIOL, V251, pR818, DOI 10.1152/ajpregu.1986.251.4.R818; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Ye X, 2004, AM J PHYSIOL-LUNG C, V286, pL756, DOI 10.1152/ajplung.00214.2003; Zahm JM, 1997, AM J PHYSIOL-CELL PH, V272, pC853, DOI 10.1152/ajpcell.1997.272.3.C853	38	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23451	23463		10.1074/jbc.M502242200	http://dx.doi.org/10.1074/jbc.M502242200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15833737	hybrid			2022-12-25	WOS:000229880000008
J	Li, X; Hummer, A; Han, J; Xie, M; Melnik-Martinez, K; Moreno, RL; Buck, M; Mark, MD; Herlitze, S				Li, X; Hummer, A; Han, J; Xie, M; Melnik-Martinez, K; Moreno, RL; Buck, M; Mark, MD; Herlitze, S			G protein beta(2) subunit-derived peptides for inhibition and induction of G protein pathways - Examination of voltage-gated Ca2+ AND G Protein inwardly rectifying K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; BULLFROG SYMPATHETIC NEURONS; GREEN FLUORESCENT PROTEINS; CALCIUM-CHANNELS; N-TYPE; CRYSTAL-STRUCTURE; KINASE-C; HIPPOCAMPAL-NEURONS; INTRACELLULAR LOOP; ALPHA(1) SUBUNIT	Voltage-gated Ca2+ channels of the N-, P/Q-, and R-type and G protein inwardly rectifying K+ channels (GIRK) are modulated via direct binding of G proteins. The modulation is mediated by G protein beta gamma subunits. By using electrophysiological recordings and fluorescence resonance energy transfer, we characterized the modulatory domains of the G protein beta subunit on the recombinant P/Q- type channel and GIRK channel expressed in HEK293 cells and on native non-L-type Ca2+ currents of cultured hippocampal neurons. We found that G beta(2) subunit-derived deletion constructs and synthesized peptides can either induce or inhibit G protein modulation of the examined ion channels. In particular, the 25-amino acid peptide derived from the G beta(2) N terminus inhibits G protein modulation, whereas a 35-amino acid peptide derived from the G beta(2) C terminus induced modulation of voltage-gated Ca2+ channels and GIRK channels. Fluorescence resonance energy transfer ( FRET) analysis of the live action of these peptides revealed that the 25-amino acid peptide diminished the FRET signal between G protein beta(2)gamma(3) subunits, indicating a reorientation between G protein beta(2)gamma(3) subunits in the presence of the peptide. In contrast, the 35-amino acid peptide increased the FRET signal between GIRK1,2 channel subunits, similarly to the G beta gamma-mediated FRET increase observed for this GIRK subunit combination. Circular dichroism spectra of the synthesized peptides suggest that the 25-amino acid peptide is structured. These results indicate that individual G protein beta subunit domains can act as independent, separate modulatory domains to either induce or inhibit G protein modulation for several effector proteins.	Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Flyion GmbH, D-72076 Tubingen, Germany	Case Western Reserve University; Case Western Reserve University	Herlitze, S (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosci, Rm E604,10900 Euclid Ave, Cleveland, OH 44106 USA.	sxh106@cwru.edu	Buck, Matthias/B-2106-2017; Mark, Melanie/ABF-9102-2020	Buck, Matthias/0000-0002-2958-0403; Mark, Melanie/0000-0002-2788-6003	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042623] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS42623] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agler HL, 2003, J GEN PHYSIOL, V121, P495, DOI 10.1085/jgp.200208770; Akgoz M, 2002, J BIOL CHEM, V277, P19573, DOI 10.1074/jbc.M201546200; Arnot MI, 2000, J PHYSIOL-LONDON, V527, P203, DOI 10.1111/j.1469-7793.2000.00203.x; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BOLAND LM, 1993, J NEUROSCI, V13, P516; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Canti C, 1999, J NEUROSCI, V19, P6855, DOI 10.1523/JNEUROSCI.19-16-06855.1999; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Colecraft HM, 2001, J NEUROSCI, V21, P1137; Currie KPM, 1997, J NEUROSCI, V17, P4570; DE WM, 1997, NATURE, V385, P446; Doering CJ, 2004, J BIOL CHEM, V279, P29709, DOI 10.1074/jbc.M308693200; Dolphin AC, 1999, ANN NY ACAD SCI, V868, P160, DOI 10.1111/j.1749-6632.1999.tb11285.x; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Fathallah M, 2002, EUR J NEUROSCI, V16, P219, DOI 10.1046/j.1460-9568.2002.02074.x; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Furukawa T, 1998, J BIOL CHEM, V273, P17595, DOI 10.1074/jbc.273.28.17595; Garcia DE, 1998, J NEUROSCI, V18, P9163; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Herlitze S, 2001, P NATL ACAD SCI USA, V98, P4699, DOI 10.1073/pnas.051628998; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; Herlitze X, 1999, J PHYSIOL-LONDON, V517, P341, DOI 10.1111/j.1469-7793.1999.0341t.x; Hummer A, 2003, J BIOL CHEM, V278, P49386, DOI 10.1074/jbc.M306645200; Hynes TR, 2004, J BIOL CHEM, V279, P30279, DOI 10.1074/jbc.M401432200; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Jarvis SE, 2001, TRENDS PHARMACOL SCI, V22, P519, DOI 10.1016/S0165-6147(00)01800-9; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lee HK, 2000, J NEUROSCI, V20, P3115, DOI 10.1523/JNEUROSCI.20-09-03115.2000; Mark MD, 2000, J PHYSIOL-LONDON, V528, P65, DOI 10.1111/j.1469-7793.2000.00065.x; MARK MD, 1995, J CELL BIOL, V130, P701, DOI 10.1083/jcb.130.3.701; Mirshahi T, 2002, J BIOL CHEM, V277, P36345, DOI 10.1074/jbc.M205359200; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; Myung CS, 2000, P NATL ACAD SCI USA, V97, P9311, DOI 10.1073/pnas.97.16.9311; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Page KM, 1997, J NEUROSCI, V17, P1330; Patil PG, 1996, BIOPHYS J, V71, P2509, DOI 10.1016/S0006-3495(96)79444-4; Peng LY, 2003, J BIOL CHEM, V278, P50203, DOI 10.1074/jbc.M308299200; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Riven I, 2003, NEURON, V38, P225, DOI 10.1016/S0896-6273(03)00193-4; Rohl CA, 1997, BIOCHEMISTRY-US, V36, P8435, DOI 10.1021/bi9706677; Roth BL, 2004, NAT REV DRUG DISCOV, V3, P353, DOI 10.1038/nrd1346; Ruiz-Velasco V, 2001, J PHYSIOL-LONDON, V537, P679; Sandoz G, 2004, P NATL ACAD SCI USA, V101, P6267, DOI 10.1073/pnas.0306804101; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wittemann S, 2000, J BIOL CHEM, V275, P37807, DOI 10.1074/jbc.M004653200; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zamponi GW, 2001, CELL BIOCHEM BIOPHYS, V34, P79, DOI 10.1385/CBB:34:1:79; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	57	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23945	23959		10.1074/jbc.M414078200	http://dx.doi.org/10.1074/jbc.M414078200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15824105	hybrid			2022-12-25	WOS:000229880000069
J	Kim, DY; Ingano, LAM; Carey, BW; Pettingell, WH; Kovacs, DM				Kim, DY; Ingano, LAM; Carey, BW; Pettingell, WH; Kovacs, DM			Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta 2-subunit regulates cell adhesion and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE; INTRACELLULAR DOMAIN; BETA-SUBUNITS; INTRAMEMBRANE CLEAVAGE; NEUROBLASTOMA-CELLS; ALZHEIMERS-DISEASE; ERBB-4 RECEPTOR; MESSENGER-RNA; NOTCH	The voltage-gated sodium channel beta 2-subunit (beta 2) is a member of the IgCAM superfamily and serves as both an adhesion molecule and an auxiliary subunit of the voltage-gated sodium channel. Here we found that beta 2 undergoes ectodomain shedding followed by presenilin (PS)-dependent gamma-secretase- mediated cleavage. 12-O-Tetradecanoylphorbol13- acetate treatment or expression of an alpha-secretase enzyme, ADAM10, resulted in ectodomain cleavage of beta 2 in Chinese hamster ovary cells. Subsequent cleavage of the remaining 15-kDa C-terminal fragment (beta 2-CTF) was independently inhibited by three specific gamma-secretase inhibitors, expression of the dominant negative form of PS1, and in PS1/ PS2 knock-out cells. gamma-Secretase inhibitor treatment also increased endogenous beta 2-CTF levels in neuroblastoma cells and mouse primary neuronal cultures. In a cell-free gamma-secretase assay, we detected gamma-secretase activity-dependent generation of a 12 kDa beta 2 intracellular domain (ICD), which was loosely associated with the membrane fraction. To assess the functional role of beta 2 processing by gamma-secretase, we tested whether N-[N-(3,5- difluorophenylacetyl-L- alanyl)]-S-phenylglycine t-butylester (DAPT), a specific beta-secretase inhibitor, would alter beta 2-mediated cell adhesion and migration. We found that DAPT inhibited cell-cell aggregation and migration in a wound healing assay carried out with Chinese hamster ovary cells expressing beta 2. DAPT also reduced migration of neuroblastoma cells in a modified Boyden chamber assay. Since DAPT treatment resulted in increased beta 2-CTF levels, we also tested whether beta 2-CTFs or beta 2-ICDs would directly affect cell migration by overexpressing recombinant proteins. Interestingly, elevated levels of beta 2-CTFs, but not ICDs, also blocked cell migration by 81 to 93%. Together, our findings show for the first time that beta 2 is a PS/gamma-secretase substrate and gamma-secretase mediated cleavage of beta 2-CTF is required for cell-cell adhesion and migration of beta 2-expressing cells.	Harvard Univ, Massachusetts Gen Hosp, Sch Med,Genet & Aging Res Unit, MassGen Inst Neurodegenerat Dis,Neurobiol Dis Lab, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Kovacs, DM (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Genet & Aging Res Unit, MassGen Inst Neurodegenerat Dis,Neurobiol Dis Lab, Charlestown, MA 02129 USA.	dora_kovacs@hms.harvard.edu						Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Barker N, 2000, ADV CANCER RES, V77, P1; BENNETT V, 1992, J BIOL CHEM, V267, P8703; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Chen CL, 2002, P NATL ACAD SCI USA, V99, P17072, DOI 10.1073/pnas.212638099; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Davis TH, 2004, J BIOL CHEM, V279, P51424, DOI 10.1074/jbc.M410830200; DE SB, 1999, NATURE, V398, P518; DibHajj SD, 1996, FEBS LETT, V384, P78, DOI 10.1016/0014-5793(96)00273-6; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Flames N, 2004, NEURON, V44, P251, DOI 10.1016/j.neuron.2004.09.028; Gandy S, 2000, BBA-MOL BASIS DIS, V1502, P44, DOI 10.1016/S0925-4439(00)00031-4; Gowrishankar K, 2004, J CELL SCI, V117, P4099, DOI 10.1242/jcs.01263; Gu XQ, 1997, J NEUROPHYSIOL, V77, P236, DOI 10.1152/jn.1997.77.1.236; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Handler M, 2000, DEVELOPMENT, V127, P2593; Hussain I, 2003, J BIOL CHEM, V278, P36264, DOI 10.1074/jbc.M304186200; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Isom LL, 1996, NATURE, V383, P307, DOI 10.1038/383307b0; Isom LL, 2002, FRONT BIOSCI, V7, P12; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; Isom LL, 2001, NEUROSCIENTIST, V7, P42, DOI 10.1177/107385840100700108; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Ling Y, 2003, INT J BIOCHEM CELL B, V35, P1505, DOI 10.1016/S1357-2725(03)00133-X; Louvi A, 2004, DEVELOPMENT, V131, P3093, DOI 10.1242/dev.01191; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; McEwen DP, 2004, J BIOL CHEM, V279, P16044, DOI 10.1074/jbc.M400856200; McPhie DL, 2001, MOL BRAIN RES, V97, P103, DOI 10.1016/S0169-328X(01)00294-7; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; MIURA M, 1992, J BIOL CHEM, V267, P10752; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Parent AT, 2005, J NEUROSCI, V25, P1540, DOI 10.1523/JNEUROSCI.3850-04.2005; Pola S, 2003, J BIOL CHEM, V278, P40601, DOI 10.1074/jbc.M306510200; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Taniguchi Y, 2003, J BIOL CHEM, V278, P30425, DOI 10.1074/jbc.C300239200; Weggen S, 2003, J BIOL CHEM, V278, P30748, DOI 10.1074/jbc.M304824200; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511; Yamauchi J, 2004, P NATL ACAD SCI USA, V101, P8774, DOI 10.1073/pnas.0402795101; Yee KT, 1999, NEURON, V24, P607, DOI 10.1016/S0896-6273(00)81116-2; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200	63	124	130	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23251	23261		10.1074/jbc.M412938200	http://dx.doi.org/10.1074/jbc.M412938200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15833746	hybrid			2022-12-25	WOS:000229741800083
J	Sakagami, H; Aoki, J; Natori, Y; Nishikawa, K; Kakehi, Y; Natori, Y; Arai, H				Sakagami, H; Aoki, J; Natori, Y; Nishikawa, K; Kakehi, Y; Natori, Y; Arai, H			Biochemical and molecular characterization of a novel choline-specific glycerophosphodiester phosphodiesterase belonging to the nucleotide pyrophosphatase/phosphodiesterase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN PC-1; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPASE-D; CELL MOTILITY; AUTOTAXIN; IDENTIFICATION; EXPRESSION; PYROPHOSPHATASE; PURIFICATION; STIMULATION	Nucleotide pyrophosphatases/phosphodiesterases (NPPs) are ubiquitous membrane-associated or secreted ectoenzymes that release nucleoside 5'-monophosphate from a variety of nucleotides and nucleotide derivatives. The mammalian NPP family comprises seven members, but only three of these (NPP1-3) have been studied in some detail. Previously we showed that lysophospholipase D, which hydrolyzes lysophosphatidylcholine (LPC) to produce lysophosphatidic acid, is identical to NPP2. More recently an uncharacterized novel NPP member (NPP7) was shown to have alkaline sphingomyelinase activity. These findings raised the possibility that other members of the NPP family act on phospholipids. Here we show that the sixth member of the NPP family, NPP6, is a choline-specific glycerophosphodiester phosphodiesterase. The sequence of NPP6 encodes a transmembrane protein containing an NPP domain with significant homology to NPP4, NPP5, and NPP7/alkaline sphingomyelinase. When expressed in HeLa cells, NPP6 was detected in both the cells and the cell culture medium as judged by Western blotting and by enzymatic activity. Recombinant NPP6 efficiently hydrolyzed the classical substrate for phospholipase C, p-nitrophenyl phosphorylcholine, but not the classical nucleotide phosphodiesterase substrate, p-nitrophenyl thymidine 5'-monophosphate. In addition, NPP6 hydrolyzed LPC to form monoacylglycerol and phosphorylcholine but not lysophosphatidic acid, showing it has a lysophospholipase C activity. NPP6 showed a preference for LPC with short (12:0 and 14:0) or polyunsaturated (18:2 and 20:4) fatty acids. It also hydrolyzed glycerophosphorylcholine and sphingosylphosphorylcholine efficiently. In mice, NPP6 mRNA was predominantly detected in kidney with a lesser expression in brain and heart, and in human it was detected in kidney and brain. The present results suggest that NPP6 has a specific role through the hydrolysis of polyunsaturated LPC, glycerophosphorylcholine, or sphingosylphosphorylcholine in these organs.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Int Med Ctr Japan, Inst Res, Dept Clin Pharmacol, Shinjuku Ku, Tokyo 1628655, Japan; Kagawa Univ, Fac Med, Dept Urol, Kagawa 7610763, Japan	University of Tokyo; National Center for Global Health & Medicine - Japan; Kagawa University	Aoki, J (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	jaoki@mol.f.u-tokyo.ac.jp		Aoki, Junken/0000-0001-9435-1896				Agre P, 2000, J AM SOC NEPHROL, V11, P764, DOI 10.1681/ASN.V114764; Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Beck FX, 1998, PFLUG ARCH EUR J PHY, V436, P814, DOI 10.1007/s004240050710; Belfiore A, 1996, MOL ENDOCRINOL, V10, P1318, DOI 10.1210/me.10.11.1318; BELLI SI, 1993, EUR J BIOCHEM, V217, P421, DOI 10.1111/j.1432-1033.1993.tb18261.x; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Clair T, 2003, CANCER RES, V63, P5446; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Deterre P, 1996, J IMMUNOL, V157, P1381; Duan RD, 2003, J BIOL CHEM, V278, P38528, DOI 10.1074/jbc.M305437200; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GERLT JA, 1975, J BIOL CHEM, V250, P5053; Gijsbers R, 2003, FEBS LETT, V538, P60, DOI 10.1016/S0014-5793(03)00133-9; Goding JW, 2003, BBA-MOL BASIS DIS, V1638, P1, DOI 10.1016/S0925-4439(03)00058-9; Grobben B, 2000, BRIT J PHARMACOL, V130, P139, DOI 10.1038/sj.bjp.0703289; Grobben B, 1999, J NEUROCHEM, V72, P826, DOI 10.1046/j.1471-4159.1999.0720826.x; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; HESSION C, 1987, SCIENCE, V237, P1479, DOI 10.1126/science.3498215; HUANG R, 1994, J CLIN INVEST, V94, P560, DOI 10.1172/JCI117370; HYNIE I, 1975, CLIN CHEM, V21, P1383; Johnson K, 2001, ARTHRITIS RHEUM, V44, P1071, DOI 10.1002/1529-0131(200105)44:5<1071::AID-ANR187>3.0.CO;2-3; Johnson K, 1999, J BONE MINER RES, V14, P883, DOI 10.1359/jbmr.1999.14.6.883; KANFER JN, 1989, FEBS LETT, V257, P348, DOI 10.1016/0014-5793(89)81568-6; Kishimoto T, 2002, CLIN BIOCHEM, V35, P411, DOI 10.1016/S0009-9120(02)00327-2; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; LIAO TH, 1988, BIOCHEM J, V255, P781, DOI 10.1042/bj2550781; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohe Y, 2003, BIOCHEM BIOPH RES CO, V308, P719, DOI 10.1016/S0006-291X(03)01454-2; Okawa A, 1998, NAT GENET, V19, P271, DOI 10.1038/956; Scott LJ, 1997, HEPATOLOGY, V25, P995, DOI 10.1002/hep.510250434; SOK DE, 1990, BIOCHEM BIOPH RES CO, V172, P1317, DOI 10.1016/0006-291X(90)91593-H; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Whitehead JP, 1997, CLIN ENDOCRINOL, V47, P65, DOI 10.1046/j.1365-2265.1997.2171021.x; WIRTHENSOHN G, 1987, PFLUG ARCH EUR J PHY, V409, P411, DOI 10.1007/BF00583795; WIRTHENSOHN G, 1989, AM J PHYSIOL, V256, pF128, DOI 10.1152/ajprenal.1989.256.1.F128; Zheng B, 2003, P NATL ACAD SCI USA, V100, P1745, DOI 10.1073/pnas.0337605100; Zheng B, 2000, P NATL ACAD SCI USA, V97, P3999, DOI 10.1073/pnas.97.8.3999	43	93	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23084	23093		10.1074/jbc.M413438200	http://dx.doi.org/10.1074/jbc.M413438200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15788404	hybrid			2022-12-25	WOS:000229741800065
J	Tang, DD; Zhang, WW; Gunst, SJ				Tang, DD; Zhang, WW; Gunst, SJ			The adapter protein CrkII regulates neuronal Wiskott-Aldrich syndrome protein, actin polymerization, and tension development during contractile stimulation of smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; NBT-II CELLS; ARP2/3 COMPLEX; N-WASP; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; FORCE DEVELOPMENT; GTPASE CDC42; ACTIVATION; PAXILLIN	Actin polymerization has been shown to occur in tracheal smooth muscle tissues and cells in response to contractile stimulation, and there is evidence that the polymerization of actin is required for contraction. In tracheal smooth muscle, agonist-induced actin polymerization is mediated by activation of neuronal Wiskott-Aldrich syndrome protein (N-WASp) and the Arp (actinrelated protein) 2/3 complex, and activation of the small GTPase Cdc42 regulates the activation of N-WASp. In the present study, the role of the adapter protein CrkII in the regulation of N-WASp and Cdc42 activation, actin polymerization, and tension development in smooth muscle tissues was evaluated. Stimulation of tracheal smooth muscle tissues with acetylcholine increased the association of CrkII with N-WASp. Plasmids encoding wild type CrkII or a CrkII mutant lacking the SH3 effector-binding ability, CrkII SH3N, were introduced into tracheal smooth muscle tissues, and the tissues were incubated for 2 days to allow for protein expression. Expression of the CrkII SH3N mutant in smooth muscle tissues inhibited the association of CrkII with N-WASp and the activation of Cdc42. The CrkII SH3N mutant also inhibited the increase in the association of N-WASp with Arp2, a major component of the Arp2/3 complex, in response to contractile stimulation, indicating inhibition of N-WASp activation. Expression of the CrkII SH3N mutant also inhibited tension generation and actin polymerization in response to contractile stimulation; however, it did not inhibit myosin light chain phosphorylation. These results suggest that CrkII plays a critical role in the regulation of N-WASp activation, perhaps by regulating the activation of Cdc42, and that it thereby regulates actin polymerization and active tension generation in tracheal smooth muscle. These studies suggest a novel signaling pathway for the regulation of N-WASp activation and active contraction in smooth muscle tissues.	Indiana Univ, Sch Med, Dept Cellular& Integrat Physiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Gunst, SJ (corresponding author), Indiana Univ, Sch Med, Dept Cellular& Integrat Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	sgunst@iupui.edu		Tang, Dale/0000-0002-7339-9249; Gunst, Susan/0000-0001-9836-4782	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075388, R01HL074099, R01HL029289, R23HL029289] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL075388, HL-29289, R01 HL029289-19, HL-74099, HL-75388, R01 HL029289, R01 HL074099, R01 HL074099-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; ADLER KB, 1983, CELL MOTIL CYTOSKEL, V3, P545, DOI 10.1002/cm.970030521; Allen WE, 1997, J CELL SCI, V110, P707; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Barany M, 2001, J BIOL CHEM, V276, P48398, DOI 10.1074/jbc.M106227200; Bauerfeld CP, 2001, AM J PHYSIOL-LUNG C, V280, pL974, DOI 10.1152/ajplung.2001.280.5.L974; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Blanchoin L, 2000, CURR BIOL, V10, P1273, DOI 10.1016/S0960-9822(00)00749-1; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Gunst SJ, 2000, EUR RESPIR J, V15, P600, DOI 10.1034/j.1399-3003.2000.15.29.x; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Hirshman CA, 1998, AM J PHYSIOL-LUNG C, V275, pL911, DOI 10.1152/ajplung.1998.275.5.L911; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Jones KA, 1999, J PHYSIOL-LONDON, V519, P527, DOI 10.1111/j.1469-7793.1999.0527m.x; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Mehta D, 1999, J PHYSIOL-LONDON, V519, P829, DOI 10.1111/j.1469-7793.1999.0829n.x; Mehta D, 1996, AM J PHYSIOL-CELL PH, V270, pC243, DOI 10.1152/ajpcell.1996.270.1.C243; Miki H, 1999, J BIOL CHEM, V274, P27605, DOI 10.1074/jbc.274.39.27605; Miki H, 2003, J BIOCHEM, V134, P309, DOI 10.1093/jb/mvg146; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 1999, CURR OPIN STRUC BIOL, V9, P244; MURPHY RA, 1989, ANNU REV PHYSIOL, V51, P275, DOI 10.1146/annurev.ph.51.030189.001423; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; OBARA K, 1994, EUR J PHARMACOL, V255, P139, DOI 10.1016/0014-2999(94)90092-2; OPAZO SA, 2004, AM J PHYSIOL-CELL PH, V286, pC433; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; RAO KMK, 1985, BIOCHEM J, V230, P709, DOI 10.1042/bj2300709; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; SOMLYO AV, 1980, CARDIOVASCULAR SYSTE, P33; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tang D, 1999, AM J PHYSIOL-CELL PH, V276, pC250, DOI 10.1152/ajpcell.1999.276.1.C250; Tang DD, 2004, J BIOL CHEM, V279, P51722, DOI 10.1074/jbc.M408351200; Tang DD, 2003, HYPERTENSION, V42, P858, DOI 10.1161/01.HYP.0000085333.76141.33; Tang DD, 2003, AM J PHYSIOL-HEART C, V285, pH1528, DOI 10.1152/ajpheart.00188.2003; Tang DD, 2002, J PHYSIOL-LONDON, V542, P501, DOI 10.1113/jphysiol.2002.021006; Tang DD, 2001, J APPL PHYSIOL, V91, P1452, DOI 10.1152/jappl.2001.91.3.1452; Tang DD, 2001, AM J PHYSIOL-CELL PH, V280, pC874, DOI 10.1152/ajpcell.2001.280.4.C874; Tang DD, 2003, J PHYSIOL-LONDON, V553, P21, DOI 10.1113/jphysiol.2003.045047; Valles AM, 2004, J BIOL CHEM, V279, P44490, DOI 10.1074/jbc.M405144200; Wang ZL, 1996, AM J PHYSIOL-CELL PH, V271, pC1594, DOI 10.1152/ajpcell.1996.271.5.C1594; Yang CS, 2000, J CELL BIOL, V150, P1001, DOI 10.1083/jcb.150.5.1001; YASSIN R, 1985, J CELL BIOL, V101, P182, DOI 10.1083/jcb.101.1.182; YOUN T, 1998, AM J PHYSIOL, V274, P1601; Zhang WW, 2005, AM J PHYSIOL-CELL PH, V288, pC1145, DOI 10.1152/ajpcell.00387.2004	59	68	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23380	23389		10.1074/jbc.M413390200	http://dx.doi.org/10.1074/jbc.M413390200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15834156	hybrid			2022-12-25	WOS:000229741800098
J	Williams, GJ; Breazeale, SD; Raetz, CRH; Naismith, JH				Williams, GJ; Breazeale, SD; Raetz, CRH; Naismith, JH			Structure and function of both domains of ArnA, a dual function decarboxylase and a formyltransferase, involved in 4-amino-4-deoxy-L-arabinose biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE 4-EPIMERASE; POLYMYXIN-RESISTANT MUTANTS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; ANTIMICROBIAL PEPTIDES; CRYSTAL-STRUCTURE; ENZYME; MODEL; PHOSPHOETHANOLAMINE; AMINOTRANSFERASE	Modification of the lipid A moiety of lipopolysaccharide by the addition of the sugar 4-amino-4-deoxy-L-arabinose (L-Ara4N) is a strategy adopted by pathogenic Gram-negative bacteria to evade cationic antimicrobial peptides produced by the innate immune system. L-Ara4N biosynthesis is therefore a potential anti-infective target, because inhibiting its synthesis would render certain pathogens more sensitive to the immune system. The bifunctional enzyme ArnA, which is required for L-Ara4N biosynthesis, catalyzes the NAD(+)-dependent oxidative decarboxylation of UDP-glucuronic acid to generate a UDP-4'-keto-pentose sugar and also catalyzes transfer of a formyl group from N-10-formyltetrahydrofolate to the 4'-amine of UDP-L-Ara4N. We now report the crystal structure of the N-terminal formyltransferase domain in a complex with uridine monophosphate and N-5-formyltetrahydrofolate. Using this structure, we identify the active site of formyltransfer in ArnA, including the key catalytic residues Asn(102), His(104), and Asp(140). Additionally, we have shown that residues Ser(433) and Glu(434) of the decarboxylase domain are required for the oxidative decarboxylation of UDP- GlcUA. An E434Q mutant is inactive, suggesting that chemical rather than steric properties of this residue are crucial in the decarboxylation reaction. Our data suggest that the decarboxylase domain catalyzes both hydride abstraction (oxidation) from the C-4' position and the subsequent decarboxylation.	Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	University of St Andrews; Duke University	Naismith, JH (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.		Naismith, James Henderson/AAB-8614-2020; Naismith, James Henderson/H-3408-2012	Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051310, GM-51310] Funding Source: Medline; Wellcome Trust [081862, 067305] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Allard STM, 2002, STRUCTURE, V10, P81, DOI 10.1016/S0969-2126(01)00694-3; ALMASSY RJ, 1992, P NATL ACAD SCI USA, V89, P6114, DOI 10.1073/pnas.89.13.6114; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker SJ, 1999, MICROBIOL-SGM, V145, P367, DOI 10.1099/13500872-145-2-367; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; Beis K, 2003, J AM CHEM SOC, V125, P11872, DOI 10.1021/ja035796r; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; Breazeale SD, 2005, J BIOL CHEM, V280, P14154, DOI 10.1074/jbc.M414265200; Breazeale SD, 2003, J BIOL CHEM, V278, P24731, DOI 10.1074/jbc.M304043200; Breazeale SD, 2002, J BIOL CHEM, V277, P2886, DOI 10.1074/jbc.M109377200; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DINARELLO CA, 1991, BLOOD, V77, P1627; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans W, 1997, CHEM BRIT, V33, P22; Gatzeva-Topalova PZ, 2004, BIOCHEMISTRY-US, V43, P13370, DOI 10.1021/bi048551f; Gunn JS, 2000, INFECT IMMUN, V68, P6139, DOI 10.1128/IAI.68.11.6139-6146.2000; Gunn JS, 2001, J ENDOTOXIN RES, V7, P57, DOI 10.1177/09680519010070011001; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hegeman AD, 2002, BIOCHEMISTRY-US, V41, P2797, DOI 10.1021/bi011748c; Hegeman AD, 2001, BIOCHEMISTRY-US, V40, P6598, DOI 10.1021/bi010441a; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, NEWSLETT PROTEIN CRY, V26, P1; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Noland BW, 2002, STRUCTURE, V10, P1569, DOI 10.1016/S0969-2126(02)00879-1; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Ohl ME, 2001, ANNU REV MED, V52, P259, DOI 10.1146/annurev.med.52.1.259; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Schmitt E, 1998, EMBO J, V17, P6819, DOI 10.1093/emboj/17.23.6819; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Scott MG, 2000, CRIT REV IMMUNOL, V20, P407; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6294, DOI 10.1021/bi970025j; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	49	47	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23000	23008		10.1074/jbc.M501534200	http://dx.doi.org/10.1074/jbc.M501534200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15809294	Green Accepted, hybrid			2022-12-25	WOS:000229741800055
J	Wu, SC; Wong, SL				Wu, SC; Wong, SL			Engineering soluble monomeric streptavidin with reversible biotin binding capability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; HIGH-AFFINITY; BACILLUS-SUBTILIS; STRUCTURAL PLASTICITY; CHICKEN AVIDIN; LYSOZYME; MUTANTS; TECHNOLOGY; TRYPTOPHAN; SEQUENCE	Monomeric streptavidin with reversible biotin binding capability has many potential applications. Because a complete biotin binding site in each streptavidin subunit requires the contribution of tryptophan 120 from a neighboring subunit, monomerization of the natural tetrameric streptavidin can generate streptavidin with reduced biotin binding affinity. Three residues, valine 55, threonine 76, and valine 125, were changed to either arginine or threonine to create electrostatic repulsion and steric hindrance at the interfaces. The double mutation (T76R,V125R) was highly effective to monomerize streptavidin. Because interfacial hydrophobic residues are exposed to solvent once tetrameric streptavidin is converted to the monomeric state, a quadruple mutein (T76R,V125R,V55T,L109T) was developed. The first two mutations are for monomerization, whereas the last two mutations aim to improve hydrophilicity at the interface to minimize aggregation. Monomerization was confirmed by four different approaches including gel filtration, dynamic light scattering, sensitivity to proteinase K, and chemical cross-linking. The quadruple mutein remained in the monomeric state at a concentration greater than 2 mg/ml. Its kinetic parameters for interaction with biotin suggest excellent reversible biotin binding capability, which enables the mutein to be easily purified on the biotin-agarose matrix. Another mutein (D61A,W120K) was developed based on two mutations that have been shown to be effective in monomerizing avidin. This streptavidin mutein was oligomeric in nature. This illustrates the importance in selecting the appropriate residues and approaches for effective monomerization of streptavidin.	Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, Calgary, AB T2N 1N4, Canada	University of Calgary	Wong, SL (corresponding author), Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	slwong@ucalgary.ca						Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; Balass M, 1996, ANAL BIOCHEM, V243, P264, DOI 10.1006/abio.1996.0515; Bayer EA, 1996, ELECTROPHORESIS, V17, P1319, DOI 10.1002/elps.1150170808; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; ELLISON D, 1995, PROTEIN SCI, V4, P1337, DOI 10.1002/pro.5560040709; Freitag S, 1998, J MOL BIOL, V279, P211, DOI 10.1006/jmbi.1998.1735; Freitag S, 1997, PROTEIN SCI, V6, P1157, DOI 10.1002/pro.5560060604; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gonzalez M, 1999, BIOMOL ENG, V16, P67, DOI 10.1016/S1050-3862(99)00041-8; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HALLING SM, 1977, BIOCHEMISTRY-US, V16, P2880, DOI 10.1021/bi00632a012; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; Laitinen OH, 2003, J BIOL CHEM, V278, P4010, DOI 10.1074/jbc.M205844200; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; Laitinen OH, 2001, J BIOL CHEM, V276, P8219, DOI 10.1074/jbc.M007930200; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; Marttila AT, 1998, FEBS LETT, V441, P313, DOI 10.1016/S0014-5793(98)01570-1; Marttila AT, 2000, FEBS LETT, V467, P31, DOI 10.1016/S0014-5793(00)01119-4; Morag E, 1996, ANAL BIOCHEM, V243, P257, DOI 10.1006/abio.1996.0514; NAGARAJAN V, 1993, APPL ENVIRON MICROB, V59, P3894, DOI 10.1128/AEM.59.11.3894-3898.1993; Neshich G, 2003, NUCLEIC ACIDS RES, V31, P3386, DOI 10.1093/nar/gkg578; Qureshi MH, 2001, J BIOL CHEM, V276, P46422, DOI 10.1074/jbc.M107398200; SANO T, 1995, P NATL ACAD SCI USA, V92, P3180, DOI 10.1073/pnas.92.8.3180; SCHURR JM, 1977, CRC CR REV BIOCH MOL, V4, P371; Schwalbe H, 2001, PROTEIN SCI, V10, P677, DOI 10.1110/ps.43301; Swint-Kruse L, 2001, PROTEIN SCI, V10, P262, DOI 10.1110/ps.35801; Szarka SJ, 1999, APPL ENVIRON MICROB, V65, P506; Vetter IR, 1996, PROTEIN SCI, V5, P2399, DOI 10.1002/pro.5560051203; Waner MJ, 2004, BIOPHYS J, V87, P2701, DOI 10.1529/biophysj.104.047266; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wu SC, 1998, J BACTERIOL, V180, P2830, DOI 10.1128/JB.180.11.2830-2835.1998	34	73	88	3	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23225	23231		10.1074/jbc.M501733200	http://dx.doi.org/10.1074/jbc.M501733200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15840576	hybrid			2022-12-25	WOS:000229741800080
J	Zhu, GQ; Chen, HQ; Choi, BK; Del Piero, F; Schifferli, DM				Zhu, GQ; Chen, HQ; Choi, BK; Del Piero, F; Schifferli, DM			Histone H1 proteins act as receptors for the 987P fimbriae of enterotoxigenic Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; GASTROINTESTINAL-TRACT; ANTIMICROBIAL PEPTIDE; GLYCOLIPID RECEPTORS; COLONIZATION FACTOR; SMALL-INTESTINES; ADHESION FACTORS; OUTER-MEMBRANE; PORCINE 987P; BINDING	The tip adhesin FasG of the 987P fimbriae of enterotoxigenic Escherichia coli mediates two distinct adhesive interactions with brush border molecules of the intestinal epithelial cells of neonatal piglets. First, FasG attaches strongly to sulfatide with hydroxylated fatty acyl chains. This interaction involves lysine 117 and other lysine residues of FasG. Second, FasG recognizes specific intestinal brush border proteins that migrate on a sodium-dodecyl sulfate-polyacrylamide gel like a distinct set of 32-35-kDa proteins, as shown by ligand blotting assays. The protein sequence of high performance liquid chromatography-purified tryptic fragments of the major protein band matched sequences of human and murine histone H1 proteins. Porcine histone H1 proteins isolated from piglet intestinal epithelial cells demonstrated the same SDS-PAGE migration pattern and 987P binding properties as the 987P-specific protein receptors from porcine intestinal brush borders. Binding was dose-dependent and shown to be specific in adhesion inhibition and gel migration shift assays. Moreover, mapping of the histone H1 binding domain suggested that it is located in their lysine-rich C-terminal domains. Histone H1 molecules were visualized on the microvilli of intestinal epithelial cells by immunohistochemistry and electron microscopy. Taken together these results indicated that the intestinal protein receptors for 987P are histone H1 proteins. It is suggested that histones are released into the intestinal lumen by the high turnover of the intestinal epithelium. Their strong cationic properties can explain their association with the negatively charged brush border surfaces. There, the histone H1 molecules stabilize the sulfatide-fimbriae interaction by simultaneously binding to the membrane and to 987P.	Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Schifferli, DM (corresponding author), Univ Penn, Sch Vet Med, Dept Pathobiol, 3800 Spruce St, Philadelphia, PA 19104 USA.	dmschiff@vet.upenn.edu	Schifferli, Dieter/H-2002-2011					AGUILAR FF, 2001, REV SALUD ANIM, V23, P84; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; Blanco M, 1997, J CLIN MICROBIOL, V35, P2958, DOI 10.1128/JCM.35.11.2958-2963.1997; Brix K, 1998, J CLIN INVEST, V102, P283, DOI 10.1172/JCI1614; CAO JC, 1995, J BACTERIOL, V177, P3704, DOI 10.1128/jb.177.13.3704-3713.1995; CASEY TA, 1993, INFECT IMMUN, V61, P2249, DOI 10.1128/IAI.61.5.2249-2252.1993; CHEN C, 1984, Kitasato Archives of Experimental Medicine, V57, P211; Choi BK, 2001, INFECT IMMUN, V69, P6625, DOI 10.1128/IAI.69.11.6625-6632.2001; Choi BK, 1999, INFECT IMMUN, V67, P5755, DOI 10.1128/IAI.67.11.5755-5761.1999; DEAN EA, 1990, INFECT IMMUN, V58, P4030, DOI 10.1128/IAI.58.12.4030-4035.1990; DEAN EA, 1985, INFECT IMMUN, V47, P345, DOI 10.1128/IAI.47.2.345-348.1985; DEAN EA, 1989, INFECT IMMUN, V57, P82, DOI 10.1128/IAI.57.1.82-87.1989; DEANNYSTROM EA, 1994, INFECT IMMUN, V62, P4789, DOI 10.1128/IAI.62.11.4789-4794.1994; Dominski Z, 1999, GENE, V239, P1, DOI 10.1016/S0378-1119(99)00367-4; Edwards RA, 1997, MOL MICROBIOL, V25, P797, DOI 10.1046/j.1365-2958.1997.5161875.x; Edwards RA, 1996, J BACTERIOL, V178, P3426, DOI 10.1128/jb.178.12.3426-3433.1996; EMLEN W, 1992, J IMMUNOL, V148, P3042; Fairbrother J, 1999, DIS SWINE, P433; Fernandes JMO, 2004, DEV COMP IMMUNOL, V28, P127, DOI 10.1016/S0145-305X(03)00120-4; Flores-Abuxapqui J J, 1997, Rev Latinoam Microbiol, V39, P145; GALLAGHER SR, 1999, CURRENT PROTOCOLS MO, V2, P1; Gao Song, 1994, Weishengwu Xuebao, V34, P220; Garabal JI, 1997, VET MICROBIOL, V54, P321, DOI 10.1016/S0378-1135(96)01291-6; GARCIA D, 1987, VET MICROBIOL, V13, P47, DOI 10.1016/0378-1135(87)90097-6; HALL PA, 1994, J CELL SCI, V107, P3569; Halsted CH, 1998, J BIOL CHEM, V273, P20417, DOI 10.1074/jbc.273.32.20417; Hariton-Gazal E, 2003, J CELL SCI, V116, P4577, DOI 10.1242/jcs.00757; Henriquez JP, 2002, J CELL SCI, V115, P2041; HOLERS VM, 1985, J CLIN INVEST, V76, P991, DOI 10.1172/JCI112100; Honarvar S, 2003, MOL MICROBIOL, V48, P157, DOI 10.1046/j.1365-2958.2003.03419.x; ISAACSON RE, 1981, J BACTERIOL, V146, P784, DOI 10.1128/JB.146.2.784-789.1981; ISAACSON RE, 1977, J INFECT DIS, V135, P531, DOI 10.1093/infdis/135.4.531; Jedrusik MA, 2001, DEVELOPMENT, V128, P1069; JONES GW, 1972, INFECT IMMUN, V6, P918, DOI 10.1128/IAI.6.6.918-927.1972; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KHAI LTL, 2001, KHOA HOC KY THUAT TH, V8, P13; KHAN AS, 1994, INFECT IMMUN, V62, P4233, DOI 10.1128/IAI.62.10.4233-4243.1994; Khan AS, 1996, INFECT IMMUN, V64, P3688, DOI 10.1128/IAI.64.9.3688-3693.1996; Khochbin S, 2001, GENE, V271, P1, DOI 10.1016/S0378-1119(01)00495-4; Kim HS, 2000, J IMMUNOL, V165, P3268, DOI 10.4049/jimmunol.165.6.3268; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MECHERI S, 1993, MOL IMMUNOL, V30, P549, DOI 10.1016/0161-5890(93)90029-B; MOON HW, 1993, VACCINE, V11, P213, DOI 10.1016/0264-410X(93)90020-X; NAGY B, 1977, INFECT IMMUN, V16, P344, DOI 10.1128/IAI.16.1.344-352.1977; OFEK I, 1986, J CLIN MICROBIOL, V24, P512, DOI 10.1128/JCM.24.4.512-516.1986; OHLSSON BG, 1986, BIOL NEONATE, V49, P292; Richards RC, 2001, BIOCHEM BIOPH RES CO, V284, P549, DOI 10.1006/bbrc.2001.5020; Robinette D, 1998, CELL MOL LIFE SCI, V54, P467, DOI 10.1007/s000180050175; Rose FRAJ, 1998, INFECT IMMUN, V66, P3255, DOI 10.1128/IAI.66.7.3255-3263.1998; RUTTER JM, 1973, NATURE, V242, P531, DOI 10.1038/242531a0; SATTERWHITE TK, 1978, LANCET, V2, P181; SCHIFFERLI DM, 1991, J BACTERIOL, V173, P1230, DOI 10.1128/jb.173.3.1230-1240.1991; SCHIFFERLI DM, 1994, J BACTERIOL, V176, P1099, DOI 10.1128/JB.176.4.1099-1110.1994; SCHIFFERLI DM, 1987, INFECT IMMUN, V55, P923, DOI 10.1128/IAI.55.4.923-930.1987; SHIN SJ, 1994, VET MICROBIOL, V38, P217, DOI 10.1016/0378-1135(94)90003-5; SILHAVY TJ, 1984, EXPT GENE FUSIONS, pR12; Silver J., 1991, PCR PRACTICAL APPROA, P137; Sinclair JF, 2002, J BIOL CHEM, V277, P2876, DOI 10.1074/jbc.M110230200; SMITH HW, 1971, J MED MICROBIOL, V4, P467, DOI 10.1099/00222615-4-4-467; SMITH RM, HDB ENDOCRINE RES TE; Sullivan SA, 2000, NUCLEIC ACIDS RES, V28, P320, DOI 10.1093/nar/28.1.320; SUPAR, 1991, VET MICROBIOL, V26, P393, DOI 10.1016/0378-1135(91)90032-B; Suzuki H, 2000, GLYCOCONJUGATE J, V17, P787, DOI 10.1023/A:1010988709764; Valvatne H, 1996, INFECT IMMUN, V64, P2635, DOI 10.1128/IAI.64.7.2635-2642.1996; Viboud GI, 1996, MICROB PATHOGENESIS, V21, P139, DOI 10.1006/mpat.1996.0049; Viboud GI, 1996, INFECT IMMUN, V64, P1233, DOI 10.1128/IAI.64.4.1233-1239.1996; Watson K, 1999, J BIOL CHEM, V274, P21707, DOI 10.1074/jbc.274.31.21707; WATSON K, 1995, BIOCHEM PHARMACOL, V50, P299, DOI 10.1016/0006-2952(95)00142-M; WESTROM BR, 1982, BIOL NEONATE, V42, P185; WESTROM BR, 1987, PANCREAS, V2, P589, DOI 10.1097/00006676-198709000-00016; Wu DC, 2002, J BIOL CHEM, V277, P12001, DOI 10.1074/jbc.M109219200; Yamamoto T, 1997, J CLIN MICROBIOL, V35, P223, DOI 10.1128/JCM.35.1.223-227.1997	73	21	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23057	23065		10.1074/jbc.M503676200	http://dx.doi.org/10.1074/jbc.M503676200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15840569	hybrid			2022-12-25	WOS:000229741800062
J	Baerson, SR; Sanchez-Moreiras, A; Pedrol-Bonjoch, N; Schulz, M; Kagan, IA; Agarwal, AK; Reigosa, MJ; Duke, SO				Baerson, SR; Sanchez-Moreiras, A; Pedrol-Bonjoch, N; Schulz, M; Kagan, IA; Agarwal, AK; Reigosa, MJ; Duke, SO			Detoxification and transcriptome response in Arabidopsis seedlings exposed to the allelochemical benzoxazolin-2(3H)-one	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASES; REGULATORY ELEMENTS; GENE-EXPRESSION; PLANT DEFENSE; DNA-BINDING; MOLECULAR CHARACTERIZATION; SIGNALING PATHWAYS; ABC TRANSPORTERS; SALICYLIC-ACID; FATTY-ACIDS	Benzoxazolin-2(3H)-one (BOA) is an allelochemical most commonly associated with monocot species, formed from the O-glucoside of 2,4-dihydroxy-2H-1,4-benzoxazin-3(4H)-one by a two-step degradation process. The capacity of Arabidopsis to detoxify exogenously supplied BOA was analyzed by quantification of the major known metabolites BOA-6-OH, BOA-6-O-glucoside, and glucoside carbamate, revealing that detoxification occurs predominantly through O-glucosylation of the intermediate BOA-6-OH, most likely requiring the sequential action of as-yet-unidentified cytochrome P450 and UDP-glucosyltransferase activities. Transcriptional profiling experiments were also performed with Arabidopsis seedlings exposed to BOA concentrations, representing I-50 and I-80 levels based on root elongation inhibition assays. One of the largest functional categories observed for BOA-responsive genes corresponded to protein families known to participate in cell rescue and defense, with the majority of these genes potentially associated with chemical detoxification pathways. Further experiments using a subset of these genes revealed that many are also transcriptionally induced by a variety of structurally diverse xenobiotic compounds, suggesting they comprise components of a coordinately regulated, broad specificity xenobiotic defense response. The data significantly expand upon previous studies examining plant transcriptional responses to allelo-chemicals and other environmental toxins and provide novel insights into xenobiotic detoxification mechanisms in plants.	USDA ARS, Nat Prod Utilizat Res Unit, University, MS 38677 USA; Univ Vigo, Fac Ciencias, Lab Ecofisiol Vexetal, Vigo 36310, Spain; SERIDA, Area Nutr Pastos & Forrajes, Estacion Expt La Mata, Grado 33820, Spain; Univ Bonn, Inst Mol Physiol & Biotechnol Pflanzen, D-53115 Bonn, Germany; Univ Mississippi, Natl Ctr Nat Prod Res, University, MS 38677 USA	United States Department of Agriculture (USDA); Universidade de Vigo; Servicio Regional Investigacion Desarrollo Agroalimentario - SERIDA; University of Bonn; University of Mississippi	Baerson, SR (corresponding author), USDA ARS, Nat Prod Utilizat Res Unit, POB 8048, University, MS 38677 USA.	sbaerson@olemiss.edu	Pedrol, Nuria/I-6228-2019; Reigosa, Manuel J/K-3551-2013; Roger, Manuel Joaquín Reigosa/O-4438-2019; Agarwal, Ameeta K./H-3935-2019; Sánchez-Moreiras, Adela M/A-8222-2011	Pedrol, Nuria/0000-0001-6725-373X; Reigosa, Manuel J/0000-0003-0527-1849; Roger, Manuel Joaquín Reigosa/0000-0003-0527-1849; Sánchez-Moreiras, Adela M/0000-0002-0771-9259				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Andrade MA, 2001, PLANT MOL BIOL, V46, P603, DOI 10.1023/A:1010650809272; Bais HP, 2004, TRENDS PLANT SCI, V9, P26, DOI 10.1016/j.tplants.2003.11.008; Bais HP, 2003, SCIENCE, V301, P1377, DOI 10.1126/science.1083245; Barnes J. P., 1986, The science of allelopathy, P271; Batard Y, 1998, PLANT J, V14, P111, DOI 10.1046/j.1365-313X.1998.00099.x; Campbell EJ, 2003, PLANT PHYSIOL, V133, P1272, DOI 10.1104/pp.103.024182; Cobbett C., 2002, ARABIDOPSIS, P1; COLE DJ, 1994, PESTIC SCI, V42, P209, DOI 10.1002/ps.2780420309; COLE DJ, 2000, METABOLISM ARGROCHEM, P108; Coleman JOD, 1997, TRENDS PLANT SCI, V2, P144, DOI 10.1016/S1360-1385(97)01019-4; COLES B, 1985, DRUG METAB REV, V15, P1307, DOI 10.3109/03602538409029962; Darley CP, 2001, PLANT MOL BIOL, V47, P179, DOI 10.1023/A:1010687600670; Davies J, 1999, PESTIC SCI, V55, P1043, DOI 10.1002/(SICI)1096-9063(199911)55:11&lt;1043::AID-PS60&gt;3.0.CO;2-L; De Veylder L, 1997, PLANT CELL PHYSIOL, V38, P568, DOI 10.1093/oxfordjournals.pcp.a029206; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; DeRidder BP, 2002, PLANT PHYSIOL, V130, P1497, DOI 10.1104/pp.010066; Despres C, 2003, PLANT CELL, V15, P2181, DOI 10.1105/tpc.012849; Dixon DP, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews3004; Duke SO, 2002, J PESTIC SCI, V27, P298; Duval M, 2002, PLANT MOL BIOL, V50, P237, DOI 10.1023/A:1016028530943; ENGELS WR, 1993, TRENDS BIOCHEM SCI, V18, P448, DOI 10.1016/0968-0004(93)90148-G; Eulgem T, 1999, EMBO J, V18, P4689, DOI 10.1093/emboj/18.17.4689; Eulgem T, 2000, TRENDS PLANT SCI, V5, P199, DOI 10.1016/S1360-1385(00)01600-9; Frey M, 1997, SCIENCE, V277, P696, DOI 10.1126/science.277.5326.696; Friebe A., 2001, Journal of Crop Production, V4, P379, DOI 10.1300/J144v04n02_18; Fukuda Y, 1997, PLANT MOL BIOL, V34, P81, DOI 10.1023/A:1005737128339; Gonzalez LF, 1999, PHYTOCHEMISTRY, V50, P931, DOI 10.1016/S0031-9422(98)00635-9; Haselden JN, 1998, BIOCHEM PHARMACOL, V56, P1591, DOI 10.1016/S0006-2952(98)00195-6; Hegedus D, 2003, PLANT MOL BIOL, V53, P383, DOI 10.1023/B:PLAN.0000006944.61384.11; HERSHEY HP, 1991, PLANT MOL BIOL, V17, P679, DOI 10.1007/BF00037053; Inderjit, 2003, PLANTA, V217, P529, DOI 10.1007/s00425-003-1054-z; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; Johnson C, 2001, J BIOL CHEM, V276, P172, DOI 10.1074/jbc.M005143200; Kankainen M, 2004, NUCLEIC ACIDS RES, V32, pW222, DOI 10.1093/nar/gkh463; Klein M, 1996, J BIOL CHEM, V271, P29666, DOI 10.1074/jbc.271.47.29666; Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001-0038; KOMIVES T, 1991, Z NATURFORSCH C, V46, P798; Krawczyk S, 2002, NUCLEIC ACIDS RES, V30, P775, DOI 10.1093/nar/30.3.775; Lescot M, 2002, NUCLEIC ACIDS RES, V30, P325, DOI 10.1093/nar/30.1.325; Lim EK, 2003, GLYCOBIOLOGY, V13, P139, DOI 10.1093/glycob/cwg017; Lim EK, 2002, J BIOL CHEM, V277, P586, DOI 10.1074/jbc.M109287200; Loutre C, 2003, PLANT J, V34, P485, DOI 10.1046/j.1365-313X.2003.01742.x; Martinoia E, 2002, PLANTA, V214, P345, DOI 10.1007/s004250100661; Matvienko M, 2001, PLANT J, V25, P375, DOI 10.1046/j.1365-313x.2001.00971.x; Nebert DW, 2002, GENET MED, V4, P62, DOI 10.1097/00125817-200203000-00003; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Oppermann UCT, 2000, TOXICOLOGY, V144, P71, DOI 10.1016/S0300-483X(99)00192-4; Parkinson A, 1996, TOXICOLOGY BASIC SCI, P113; Pflugmacher S, 1998, PLANT PHYSIOL, V117, P123, DOI 10.1104/pp.117.1.123; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; RAMSEY RJL, 2001, ACS SYM SER, V777, P310; Redman JC, 2004, PLANT J, V38, P545, DOI 10.1111/j.1365-313X.2004.02061.x; Richards KD, 1995, PLANT PHYSIOL, V109, P1497; Robatzek S, 2002, GENE DEV, V16, P1139, DOI 10.1101/gad.222702; Rombauts S, 2003, PLANT PHYSIOL, V132, P1162, DOI 10.1104/pp.102.017715; Rosenfeld JM, 2003, MOL ENDOCRINOL, V17, P1268, DOI 10.1210/me.2002-0421; Roth CM, 2000, AGRON J, V92, P855, DOI 10.2134/agronj2000.925855x; Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171; Rushton PJ, 1996, EMBO J, V15, P5690, DOI 10.1002/j.1460-2075.1996.tb00953.x; Rushton PJ, 2002, PLANT CELL, V14, P749, DOI 10.1105/tpc.010412; Sanchez-Fernandez R, 1998, MOL GEN GENET, V258, P655, DOI 10.1007/s004380050779; SANDERMANN H, 1992, TRENDS BIOCHEM SCI, V17, P82, DOI 10.1016/0968-0004(92)90507-6; Sandermann H, 2004, TRENDS PLANT SCI, V9, P406, DOI 10.1016/j.tplants.2004.06.001; Sandermann H, 1999, CURR PLANT SCI BIOT, V36, P321; Schulz M, 1999, CHEMOECOLOGY, V9, P133, DOI 10.1007/s000490050044; Sicker D, 2000, INT REV CYTOL, V198, P319; Sicker D, 2001, PHYTOCHEMISTRY, V58, P819, DOI 10.1016/S0031-9422(01)00299-0; SICKER D, 2004, ALLELOPATHY CHEM MOD, P77; Singh KB, 2002, CURR OPIN PLANT BIOL, V5, P430, DOI 10.1016/S1369-5266(02)00289-3; Stiborova M, 2000, PHYTOCHEMISTRY, V54, P353, DOI 10.1016/S0031-9422(00)00123-0; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Theodoulou FL, 2003, PEST MANAG SCI, V59, P202, DOI 10.1002/ps.576; Thijs G, 2002, J COMPUT BIOL, V9, P447, DOI 10.1089/10665270252935566; Tommasini R, 1997, FEBS LETT, V411, P206, DOI 10.1016/S0014-5793(97)00702-3; Uquillas C, 2004, MOL PLANT MICROBE IN, V17, P34, DOI 10.1094/MPMI.2004.17.1.34; van den Brule S, 2002, PLANTA, V216, P95, DOI 10.1007/s00425-002-0889-z; van Helden J, 2003, NUCLEIC ACIDS RES, V31, P3593, DOI 10.1093/nar/gkg567; Vessey DA, 1999, BBA-GEN SUBJECTS, V1428, P455, DOI 10.1016/S0304-4165(99)00088-4; Wagner U, 2002, PLANT MOL BIOL, V49, P515, DOI 10.1023/A:1015557300450; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Weston LA, 2003, CRIT REV PLANT SCI, V22, P367, DOI 10.1080/713610861; WIEGAND RC, 1986, PLANT MOL BIOL, V7, P235, DOI 10.1007/BF00752897; Windsor B, 2003, NAT BIOTECHNOL, V21, P428, DOI 10.1038/nbt809; Wu HW, 2000, J AGR FOOD CHEM, V48, P5321, DOI 10.1021/jf0006473; Xu WY, 2001, GENE, V272, P61, DOI 10.1016/S0378-1119(01)00516-9; Zhang LH, 1997, P NATL ACAD SCI USA, V94, P9984, DOI 10.1073/pnas.94.18.9984	88	142	155	0	50	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21867	21881		10.1074/jbc.M500694200	http://dx.doi.org/10.1074/jbc.M500694200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824099	hybrid, Green Submitted			2022-12-25	WOS:000229557900027
J	Bergseng, E; Xia, J; Kim, CY; Khosla, C; Sollid, LM				Bergseng, E; Xia, J; Kim, CY; Khosla, C; Sollid, LM			Main chain hydrogen bond interactions in the binding of proline-rich gluten peptides to the Celiac disease-associated HLA-DQ2 molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTED T-CELLS; CLASS-II MOLECULE; CRYSTAL-STRUCTURE; TISSUE TRANSGLUTAMINASE; BETA-1-ASTERISK-0201) MOLECULE; ANTIGEN PRESENTATION; GLIADIN PEPTIDES; STRUCTURAL BASIS; PROTEIN HLA-DR1; CUTTING EDGE	Binding of peptide epitopes to major histocompatibility complex proteins involves multiple hydrogen bond interactions between the peptide main chain and major histocompatibility complex residues. The crystal structure of HLA-DQ2 complexed with the alpha I-gliadin epitope (LQPFPQPELPY) revealed four hydrogen bonds between DQ2 and peptide main chain amides. This is remarkable, given that four of the nine core residues in this peptide are proline residues that cannot engage in amide hydrogen bonding. Preserving main chain hydrogen bond interactions despite the presence of multiple proline residues in gluten peptides is a key element for the HLA-DQ2 association of celiac disease. We have investigated the relative contribution of each main chain hydrogen bond interaction by preparing a series of N-methylated alpha I epitope analogues and measuring their binding affinity and off-rate constants to DQ2. Additionally, we measured the binding of alpha I-gliadin peptide analogues in which norvaline, which contains a backbone amide hydrogen bond donor, was substituted for each proline. Our results demonstrate that hydrogen bonds at P4 and P2 positions are most important for binding, whereas the hydrogen bonds at P9 and P6 make smaller contributions to the overall binding affinity. There is no evidence for a hydrogen bond between DQ2 and the P1 amide nitrogen in peptides without proline at this position. This is a unique feature of DQ2 and is likely a key parameter for preferential binding of proline-rich gluten peptides and development of celiac disease.	Univ Hosp Oslo, Rikshosp, Inst Immunol, N-0027 Oslo, Norway; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	University of Oslo; National Hospital Norway; Stanford University; Stanford University; Stanford University	Bergseng, E (corresponding author), Univ Hosp Oslo, Rikshosp, Inst Immunol, N-0027 Oslo, Norway.	elin.bergseng@medisin.uio.no	Xia, Jiang/AAT-2366-2020; Sollid, Ludvig/N-9691-2015; Kim, Chu-Young/D-8849-2012	Sollid, Ludvig/0000-0001-8860-704X; Kim, Chu-Young/0000-0003-3744-7802; Xia, Jiang/0000-0001-8112-7625; Khosla, Chaitan/0000-0001-6529-495X	NIDDK NIH HHS [DK 63158, DK 65965] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063158, R21DK065965] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; Arentz-Hansen H, 2002, GASTROENTEROLOGY, V123, P803, DOI 10.1053/gast.2002.35381; Arneson LS, 2001, J IMMUNOL, V167, P6939, DOI 10.4049/jimmunol.167.12.6939; BRAMSON HN, 1985, J BIOL CHEM, V260, P5452; BUUS S, 1995, BBA-GEN SUBJECTS, V1243, P453, DOI 10.1016/0304-4165(94)00172-T; Cotton J, 1998, INT IMMUNOL, V10, P159, DOI 10.1093/intimm/10.2.159; Dessen A, 1997, IMMUNITY, V7, P473, DOI 10.1016/S1074-7613(00)80369-6; Falcioni F, 1999, NAT BIOTECHNOL, V17, P562, DOI 10.1038/9865; Fleckenstein B, 2002, J BIOL CHEM, V277, P34109, DOI 10.1074/jbc.M204521200; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; Fremont DH, 1998, IMMUNITY, V8, P305, DOI 10.1016/S1074-7613(00)80536-1; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; Green PHR, 2003, LANCET, V362, P383, DOI 10.1016/S0140-6736(03)14027-5; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Hausch F, 2002, AM J PHYSIOL-GASTR L, V283, pG996, DOI 10.1152/ajpgi.00136.2002; He XL, 2002, IMMUNITY, V17, P83, DOI 10.1016/S1074-7613(02)00340-0; HILL CM, 1994, J IMMUNOL, V152, P2890; JOHANSEN BH, 1994, INT IMMUNOL, V6, P453, DOI 10.1093/intimm/6.3.453; Kim CY, 2004, P NATL ACAD SCI USA, V101, P4175, DOI 10.1073/pnas.0306885101; Latek RR, 2000, IMMUNITY, V12, P699, DOI 10.1016/S1074-7613(00)80220-4; Lee KH, 2001, NAT IMMUNOL, V2, P501, DOI 10.1038/88694; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8820, DOI 10.1073/pnas.132272099; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; Maki M, 2003, NEW ENGL J MED, V348, P2517, DOI 10.1056/NEJMoa021687; McFarland BJ, 1999, J IMMUNOL, V163, P3567; McFarland BJ, 2001, P NATL ACAD SCI USA, V98, P9231, DOI 10.1073/pnas.151131498; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Nelson C A, 1999, Rev Immunogenet, V1, P47; Sant AJ, 1999, IMMUNOL REV, V172, P239, DOI 10.1111/j.1600-065X.1999.tb01369.x; Scott CA, 1998, IMMUNITY, V8, P319, DOI 10.1016/S1074-7613(00)80537-3; Siebold C, 2004, P NATL ACAD SCI USA, V101, P1999, DOI 10.1073/pnas.0308458100; Smith KJ, 1998, J EXP MED, V188, P1511, DOI 10.1084/jem.188.8.1511; Sollid LM, 2000, ANNU REV IMMUNOL, V18, P53, DOI 10.1146/annurev.immunol.18.1.53; SOLLID LM, 1993, GASTROENTEROLOGY, V105, P910, DOI 10.1016/0016-5085(93)90912-V; Sollid LM, 2002, NAT REV IMMUNOL, V2, P647, DOI 10.1038/nri885; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Stratikos E, 2004, J IMMUNOL, V172, P1109, DOI 10.4049/jimmunol.172.2.1109; VADER LW, 2002, AM J PHYSIOL-GASTR L, V195, P643; Vader W, 2003, P NATL ACAD SCI USA, V100, P12390, DOI 10.1073/pnas.2135229100; Vader W, 2002, GASTROENTEROLOGY, V122, P1729, DOI 10.1053/gast.2002.33606; van de Wal Y, 1998, J IMMUNOL, V161, P1585; vandeWal Y, 1996, IMMUNOGENETICS, V44, P246, DOI 10.1007/s002510050120; Vartdal F, 1996, EUR J IMMUNOL, V26, P2764, DOI 10.1002/eji.1830261132; Zavala-Ruiz Z, 2003, J BIOL CHEM, V278, P44904, DOI 10.1074/jbc.M307652200; Zhu YR, 2003, J MOL BIOL, V326, P1157, DOI 10.1016/S0022-2836(02)01437-7	45	29	31	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21791	21796		10.1074/jbc.M501558200	http://dx.doi.org/10.1074/jbc.M501558200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15826953	Green Published, hybrid			2022-12-25	WOS:000229557900017
J	Simonsson, M; Heldin, CH; Ericsson, J; Gronroos, E				Simonsson, M; Heldin, CH; Ericsson, J; Gronroos, E			The balance between acetylation and deacetylation controls Smad7 stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; HISTONE DEACETYLASE; NUCLEAR EXPORT; UBIQUITINATION; TRANSCRIPTION; PHOSPHORYLATION; IDENTIFICATION; DEGRADATION; ANTAGONIST; PROTEINS	Transforming growth factor beta (TGFb) regulates multiple cellular processes via activation of Smad signaling pathways. We have recently demonstrated that the inhibitory Smad7 interacts with the acetyl transferase p300 and that p300 acetylates Smad7 on two lysine residues. These lysine residues are critical for Smurf-mediated ubiquitination of Smad7, and acetylation protects Smad7 from TGFb-induced degradation. In this study we demonstrate that Smad7 interacts with specific histone deacetylases (HDACs) and that the same HDACs are able to deacetylate Smad7. The interaction with HDACs is dependent on the C-terminal MH2 domain of Smad7. In addition, HDAC1-mediated deacetylation of Smad7 decreases the stability of Smad7 by enhancing its ubiquitination. Thus, our results demonstrate that the degradation of Smad7 is regulated by the balance between acetylation, deacetylation and ubiquitination, indicating that this could be a general mechanism to regulate the stability of cellular proteins.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ericsson, J (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.	johan.ericsson@licr.uu.se	Gronroos, Eva/P-6951-2015; Gronroos, Eva/E-9351-2013; Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574; Gronroos, Eva/0000-0001-8303-5409				Bai ST, 2002, J BIOL CHEM, V277, P4176, DOI 10.1074/jbc.M105105200; Barlow AL, 2001, EXP CELL RES, V265, P90, DOI 10.1006/excr.2001.5162; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; Chawla S, 2003, J NEUROCHEM, V85, P151, DOI 10.1046/j.1471-4159.2003.01648.x; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Giandomenico V, 2003, MOL CELL BIOL, V23, P2587, DOI 10.1128/MCB.23.7.2587-2599.2003; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Pulaski L, 2001, J BIOL CHEM, V276, P14344, DOI 10.1074/jbc.M011019200; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; Takami Y, 1999, J BIOL CHEM, V274, P23977, DOI 10.1074/jbc.274.34.23977; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhao Q, 2004, J BIOL CHEM, V279, P41477, DOI 10.1074/jbc.M405129200	38	128	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21797	21803		10.1074/jbc.M503134200	http://dx.doi.org/10.1074/jbc.M503134200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15831498	hybrid			2022-12-25	WOS:000229557900018
J	Paleotti, O; Macia, E; Luton, F; Klein, S; Partisani, M; Chardin, P; Kirchhausen, T; Franco, M				Paleotti, O; Macia, E; Luton, F; Klein, S; Partisani, M; Chardin, P; Kirchhausen, T; Franco, M			The small G-protein Arf6(GTP) recruits the AP-2 adaptor complex to membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PLASMA-MEMBRANE; PHOSPHOLIPASE-D; EXCHANGE FACTOR; DOWNSTREAM EFFECTOR; CLATHRIN ADAPTERS; ARF6; BINDING; RECEPTOR; DOMAIN	The small GTP-binding protein ADP-ribosylation factor 6 (Arf6) is involved in plasma membrane/endosomes trafficking. However, precisely how the activation of Arf6 regulates vesicular transport is still unclear. Here, we show that, in vitro, recombinant Arf6GTP recruits purified clathrin-adaptor complex AP-2 (but not AP-1) onto phospholipid liposomes in the absence of phosphoinositides. We also show that phosphoinositides and Arf6 tightly cooperate to translocate AP-2 to the membrane. In vivo, Arf6GTP (but not Arf6GDP) was found associated to AP-2. The expression of the GTP-locked mutant of Arf6 leads to the plasma membrane redistribution of AP-2 in Arf6GTP-enriched areas. Finally, we demonstrated that the expression of the GTP-locked mutant of Arf6 inhibits transferrin receptor internalization without affecting its recycling. Altogether, our results demonstrated that Arf6GTP interacts specifically with AP-2 and promotes its membrane recruitment. These findings strongly suggest that Arf6 plays a major role in clathrin-mediated endocytosis by directly controlling the assembly of the AP-2/clathrin coat.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Ctr Blood Res, Biomed Res Inst, Boston, MA 02115 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)	Franco, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, 660 Route Lucioles, F-06560 Valbonne, France.	franco@ipmc.cnrs.fr	Luton, Frederic/N-7673-2017; FRANCO, michel/AAA-9735-2021; Macia, Eric/AAW-2964-2021	macia, eric/0000-0003-3686-2000; Franco, Michel/0000-0003-1853-8661				Aikawa Y, 2003, J CELL BIOL, V162, P647, DOI 10.1083/jcb.200212142; Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chavrier P, 2001, METHOD ENZYMOL, V329, P272; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; FRANCO M, 1993, J BIOL CHEM, V268, P24531; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Houndolo T, 2005, J BIOL CHEM, V280, P5598, DOI 10.1074/jbc.M411456200; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Krauss M, 2003, J CELL BIOL, V162, P113, DOI 10.1083/jcb.200301006; Macia E, 2000, BIOCHEMISTRY-US, V39, P5893, DOI 10.1021/bi992795w; Macia E, 2004, J CELL SCI, V117, P2389, DOI 10.1242/jcs.01090; Macia E, 2001, J BIOL CHEM, V276, P24925, DOI 10.1074/jbc.M103284200; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; McMahon HT, 2004, CURR OPIN CELL BIOL, V16, P379, DOI 10.1016/j.ceb.2004.06.009; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Padron D, 2003, J CELL BIOL, V162, P693, DOI 10.1083/jcb.200302051; PALACIOS F, 2002, NAT CELL BIOL, V11, P11; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Rohde G, 2002, J CELL BIOL, V158, P209, DOI 10.1083/jcb.200203103; Traub LM, 2003, J CELL BIOL, V163, P203, DOI 10.1083/jcb.200309175	35	84	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21661	21666		10.1074/jbc.m503099200	http://dx.doi.org/10.1074/jbc.m503099200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802264	hybrid			2022-12-25	WOS:000229438800092
J	Piven, I; Ajlani, G; Sokolenko, A				Piven, I; Ajlani, G; Sokolenko, A			Phycobilisome linker proteins are phosphorylated in Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN PCC-7942; PSBH GENE-PRODUCT; PHOTOSYSTEM-II; CYANOBACTERIAL PHYCOBILISOMES; MOLECULAR CHARACTERIZATION; POLYPEPTIDE COMPOSITION; LESS MUTANT; LIGHT; DEGRADATION; COMPLEX	The controversial issue of protein phosphorylation from the photosynthetic apparatus of Synechocystis sp. PCC 6803 has been reinvestigated using new detection tools that include various immunological and in vivo labeling approaches. The set of phosphoproteins detected with these methods includes ferredoxin-NADPH reductase and the linker proteins of the phycobilisome antenna. Using mutants that lack a specific set of linker proteins and are affected in phycobilisome assembly, we show that the phosphoproteins from the phycobilisomes correspond to the membrane, rod, and rod-core linkers. These proteins are in a phosphorylated state within the assembled phycobilisomes. Their dephosphorylation requires partial disassembly of the phycobilisomes and further contributes to their complete disassembly in vitro. In vivo we observed linker dephosphorylation upon long-term exposure to higher light intensities and under nitrogen limitation, two conditions that lead to remodeling and turnover of phycobilisomes. We conclude that this phosphorylation process is instrumental in the regulation of assembly/disassembly of phycobilisomes and should participate in signaling for their proteolytic cleavage and degradation.	Univ Munich, Bereich Bot, Dept Biol 1, D-80638 Munich, Germany; CEA Saclay, Dept Biol Joliot Curie, Sect Biophys Fonct Membranaires, F-91191 Gif Sur Yvette, France	University of Munich; CEA; UDICE-French Research Universities; Universite Paris Saclay	Sokolenko, A (corresponding author), Univ Munich, Bereich Bot, Dept Biol 1, Menzingerstr 67, D-80638 Munich, Germany.	Anna.Sokolenko@lrz.uni-muenchen.de						Ajlani G, 1998, PLANT MOL BIOL, V37, P577, DOI 10.1023/A:1005924730298; ALLEN JF, 1985, FEBS LETT, V193, P271, DOI 10.1016/0014-5793(85)80167-8; Anderson LK, 1998, MOL MICROBIOL, V30, P467, DOI 10.1046/j.1365-2958.1998.01081.x; [Anonymous], [No title captured]; Baier K, 2004, MICROBIOL-SGM, V150, P2739, DOI 10.1099/mic.0.27153-0; Baier K, 2001, FEMS MICROBIOL LETT, V195, P35, DOI 10.1111/j.1574-6968.2001.tb10494.x; BELKNAP WR, 1987, EMBO J, V6, P871, DOI 10.1002/j.1460-2075.1987.tb04833.x; BLOYE SA, 1992, PLANT PHYSIOL, V99, P601, DOI 10.1104/pp.99.2.601; BONAVENTURA C, 1969, BIOCHIM BIOPHYS ACTA, V189, P366, DOI 10.1016/0005-2728(69)90168-6; BRUCE D, 1989, BIOCHIM BIOPHYS ACTA, V974, P66, DOI 10.1016/S0005-2728(89)80166-5; CAPUANO V, 1991, J BIOL CHEM, V266, P7239; COLLIER JL, 1994, EMBO J, V13, P1039, DOI 10.1002/j.1460-2075.1994.tb06352.x; COLLIER JL, 1992, J BACTERIOL, V174, P4718, DOI 10.1128/JB.174.14.4718-4726.1992; DELORIMIER RM, 1992, PLANT PHYSIOL, V98, P1003, DOI 10.1104/pp.98.3.1003; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; Dolganov N, 1999, J BACTERIOL, V181, P610, DOI 10.1128/JB.181.2.610-617.1999; DUKE CS, 1989, J BACTERIOL, V171, P1960, DOI 10.1128/jb.171.4.1960-1966.1989; FORCHHAMMER K, 1994, J BACTERIOL, V176, P84, DOI 10.1128/JB.176.1.84-91.1994; GARNIER F, 1994, PLANT PHYSIOL, V106, P747, DOI 10.1104/pp.106.2.747; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GOTTSCHALK L, 1991, PHOTOCHEM PHOTOBIOL, V54, P283, DOI 10.1111/j.1751-1097.1991.tb02017.x; Grossman AR, 2001, J BIOL CHEM, V276, P11449, DOI 10.1074/jbc.R100003200; GROSSMAN AR, 1993, J BACTERIOL, V175, P575, DOI 10.1128/JB.175.3.575-582.1993; HARRISON MA, 1991, FEBS LETT, V282, P295, DOI 10.1016/0014-5793(91)80499-S; HARRISON MA, 1990, THESIS U LEEDS UK; HODGES M, 1990, BIOCHIM BIOPHYS ACTA, V1052, P446, DOI 10.1016/0167-4889(90)90154-6; JAMES CA, 1992, BIOCHEM SOC T, V21, pS3; Koivuniemi A, 1995, BIOCHEMISTRY-US, V34, P16022, DOI 10.1021/bi00049a016; Komenda J, 2002, EUR J BIOCHEM, V269, P610, DOI 10.1046/j.0014-2956.2001.02693.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li H, 2002, ARCH MICROBIOL, V178, P256, DOI 10.1007/s00203-002-0446-y; MANN NH, 1994, MICROBIOL-SGM, V140, P3207, DOI 10.1099/13500872-140-12-3207; MURATA N, 1969, BIOCHIM BIOPHYS ACTA, V172, P242, DOI 10.1016/0005-2728(69)90067-X; PAWSON T, 1994, FASEB J, V8, P1112, DOI 10.1096/fasebj.8.14.7958615; Pojidaeva E, 2004, J BACTERIOL, V186, P3991, DOI 10.1128/JB.186.12.3991-3999.2004; Pursiheimo S, 1998, FEBS LETT, V423, P178, DOI 10.1016/S0014-5793(98)00088-X; RACE HL, 1993, FEBS LETT, V323, P35, DOI 10.1016/0014-5793(93)81443-4; Reuter W, 1999, P NATL ACAD SCI USA, V96, P1363, DOI 10.1073/pnas.96.4.1363; RIPPKA R, 1988, METHOD ENZYMOL, V167, P3; RUSCKOWSKI M, 1982, PLANT PHYSIOL, V70, P1055, DOI 10.1104/pp.70.4.1055; Sanders C.E., 1987, PROGR PHOTOSYNTHESIS, V2, P761; SANDERS CE, 1989, BIOCHIM BIOPHYS ACTA, V976, P168, DOI 10.1016/S0005-2728(89)80226-9; SCHLUCHTER WM, 1992, BIOCHEMISTRY-US, V31, P3092, DOI 10.1021/bi00127a009; SCHUSTER G, 1984, BIOCHIM BIOPHYS ACTA, V767, P596, DOI 10.1016/0005-2728(84)90061-6; Schwarz R, 1998, P NATL ACAD SCI USA, V95, P11008, DOI 10.1073/pnas.95.18.11008; SHUKLA VK, 1992, MOL MICROBIOL, V6, P947, DOI 10.1111/j.1365-2958.1992.tb01544.x; Sidler W. A., 1994, MOL BIOL CYANOBACTER, P139, DOI [10.1007/978-94-011-0227-8_7, DOI 10.1007/978-94-011-0227-8_7]; Stec B, 1999, BIOPHYS J, V76, P2912, DOI 10.1016/S0006-3495(99)77446-1; van Waasbergen LG, 2002, J BACTERIOL, V184, P2481, DOI 10.1128/JB.184.9.2481-2490.2002; YAMANAKA G, 1980, ARCH MICROBIOL, V124, P39, DOI 10.1007/BF00407026; Yang DH, 1998, PLANT PHYSIOL, V118, P827, DOI 10.1104/pp.118.3.827; YU MH, 1982, J BIOL CHEM, V257, P3429	52	42	45	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21667	21672		10.1074/jbc.m412967200	http://dx.doi.org/10.1074/jbc.m412967200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15805115	hybrid			2022-12-25	WOS:000229438800093
J	Restle, A; Janz, C; Wiesmuller, L				Restle, A; Janz, C; Wiesmuller, L			Differences in the association of p53 phosphorylated on serine 15 and key enzymes of homologous recombination	ONCOGENE			English	Article						Bloom's syndrome; Mre11; Rad51; Rad52; Rad54; replication fork stalling	STRAND BREAK REPAIR; HOLLIDAY JUNCTIONS; BRANCH MIGRATION; MISMATCH REPAIR; CELL-CYCLE; DNA; COMPLEXES; PROTEINS; RAD51; BRCA1	Phosphorylation of p53 on serine 15 by ATM or ATR is a frequent modi. cation and initiates a cascade of posttranslational modi. cations. To identify possible mechanisms that modulate p53 functions in recombination surveillance, we compared the nuclear localization of p53 phosphorylated on serine 15 (p53pSer15) and the key enzymes of homologous recombination (HR) after replication fork stalling. We demonstrate an almost mutually exclusive subcompartmentalization with Rad52, while p53pSer15 was colocalizing with 40-60% of the Rad51 and Mre11 foci. Therefore, possible sites of p53pSer15-dependent regulation seem to be sites of Rad51- rather than Rad52-dependent HR processes. Remarkably, the association of p53pSer15 with repair complexes containing Rad51 or Mre11 was transient, because less than 20% of the Rad51 and Mre11 foci overlapped with p53pSer15 after 6 h. When we examined colocalization and coimmunoprecipitation of p53pSer15 and the RecQ helicase BLM with recombination surveillance and proapoptotic functions, we observed colocalization within a fraction of approximately 70% of the BLM foci and stable physical interactions until 6 h after replication arrest. Our data suggest that p53pSer15 plays a dual role in the functional interactions with early complexes of Rad51-dependent recombination within distinct nuclear subcompartments.	Univ Frauenklin, D-89075 Ulm, Germany	Ulm University	Wiesmuller, L (corresponding author), Univ Frauenklin, Prittwitzstr 43, D-89075 Ulm, Germany.	lisa.wiesmueller@medizin.uni-ulm.de						Adams MD, 2003, SCIENCE, V299, P265, DOI 10.1126/science.1077198; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Davalos AR, 2003, J CELL BIOL, V162, P1197, DOI 10.1083/jcb.200304016; Digweed M, 2002, CARCINOGENESIS, V23, P1121, DOI 10.1093/carcin/23.7.1121; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; FUCHS B, 1995, ONCOGENE, V10, P789; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Hopfner KP, 2002, CURR OPIN STRUC BIOL, V12, P115, DOI 10.1016/S0959-440X(02)00297-X; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Krejci L, 2003, PROG NUCLEIC ACID RE, V74, P159, DOI 10.1016/S0079-6603(03)01013-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 2003, CANCER RES, V63, P2596; Liu YL, 1999, CURR BIOL, V9, P975, DOI 10.1016/S0960-9822(99)80427-8; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Miyazaki T, 2004, EMBO J, V23, P939, DOI 10.1038/sj.emboj.7600091; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Pedrazzi G, 2003, BIOL CHEM, V384, P1155, DOI 10.1515/BC.2003.128; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Prabhu VP, 2002, J MOL BIOL, V316, P1023, DOI 10.1006/jmbi.2001.5408; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Subramanian D, 2002, NUCLEIC ACIDS RES, V30, P2427, DOI 10.1093/nar/30.11.2427; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Wang Y, 2000, GENE DEV, V14, P927; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Yoon D, 2004, J MOL BIOL, V336, P639, DOI 10.1016/j.jmb.2003.12.050; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	39	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4380	4387		10.1038/sj.onc.1208639	http://dx.doi.org/10.1038/sj.onc.1208639			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806145				2022-12-25	WOS:000229976900007
J	Coman, D; Russu, IM				Coman, D; Russu, IM			Base pair opening in three DNA-unwinding elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MUTATIONAL DEFECTS; REPLICATION; ENERGETICS; STABILITY; KINETICS; EXCHANGE; INITIATION; SEQUENCES; ACCOUNTS	DNA-unwinding elements are specific base sequences that are located in the origin of DNA replication where they provide the start point for strand separation and unwinding of the DNA double helix. In the present work we have obtained the first characterization of the opening of individual base pairs in DNA-unwinding elements. The three DNA molecules investigated reproduce the 13-mer DNA-unwinding elements present in the Escherichia coli chromosome. The base sequences of the three 13-mers are conserved in the origins of replication of enteric bacterial chromosomes. The exchange of imino protons with solvent protons was measured for each DNA as a function of the concentration of exchange catalyst using nuclear magnetic resonance spectroscopy. The exchange rates provided the rates and the equilibrium constants for opening of individual base pairs in each DNA at 20 degrees C. The results reveal that the kinetics and energetics of the opening reactions for AT/TA base pairs are different in the three DNA-unwinding elements due to long range effects of the base sequence. These differences encompass the AT/TA base pairs that are conserved in various bacterial genomes. Furthermore, a qualitative correlation is observed between the kinetics and energetics of opening of AT/TA base pairs and the location of the corresponding DNA-unwinding element in the origin of DNA replication.	Wesleyan Univ, Dept Chem, Hall Atwater Labs 203, Middletown, CT 06459 USA; Wesleyan Univ, Mol Biophys Program, Hall Atwater Labs 203, Middletown, CT 06459 USA	Wesleyan University; Wesleyan University	Russu, IM (corresponding author), Wesleyan Univ, Dept Chem, Hall Atwater Labs 203, Middletown, CT 06459 USA.	irussu@wesleyan.edu	Coman, Daniel/E-7856-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM065159] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65159] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENHAM CJ, 1993, P NATL ACAD SCI USA, V90, P2999, DOI 10.1073/pnas.90.7.2999; BENIGHT AS, 1988, J MOL BIOL, V200, P377, DOI 10.1016/0022-2836(88)90248-3; Boulikas T, 1996, J CELL BIOCHEM, V60, P297, DOI 10.1002/(SICI)1097-4644(19960301)60:3<297::AID-JCB2>3.0.CO;2-R; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; Coman D, 2004, NUCLEIC ACIDS RES, V32, P878, DOI 10.1093/nar/gkh228; Coman D, 2002, BIOCHEMISTRY-US, V41, P4407, DOI 10.1021/bi011832s; Davey MJ, 2002, EMBO J, V21, P3148, DOI 10.1093/emboj/cdf308; ENGLANDER SW, 1983, Q REV BIOPHYS, V16, P521, DOI 10.1017/S0033583500005217; Gueron M, 1995, METHOD ENZYMOL, V261, P383; Huang Q, 2004, BIOPHYS J, V87, P14, DOI 10.1529/biophysj.103.024562; Huang YL, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-134; Huang YL, 2003, NUCLEIC ACIDS RES, V31, P3819, DOI 10.1093/nar/gkg562; Kornberg A., 1992, DNA REPLICATION; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; KOWALSKI D, 1989, EMBO J, V8, P4335, DOI 10.1002/j.1460-2075.1989.tb08620.x; LEROY JL, 1988, BIOCHEMISTRY-US, V27, P8894, DOI 10.1021/bi00425a004; LIN S, 1994, J MOL BIOL, V235, P496, DOI 10.1006/jmbi.1994.1009; MOE JG, 1990, NUCLEIC ACIDS RES, V18, P821, DOI 10.1093/nar/18.4.821; MOE JG, 1995, NUCLEIC ACIDS RES, V23, P1984, DOI 10.1093/nar/23.11.1984; NATALE DA, 1992, P NATL ACAD SCI USA, V89, P2654, DOI 10.1073/pnas.89.7.2654; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; Russu IM, 2004, METHOD ENZYMOL, V379, P152; SantaLucia J, 2004, ANNU REV BIOPH BIOM, V33, P415, DOI 10.1146/annurev.biophys.32.110601.141800; UMEK RM, 1990, P NATL ACAD SCI USA, V87, P2486, DOI 10.1073/pnas.87.7.2486; WEAST RC, 1987, CRC HDB CHEM PHYSICS, pD163; ZYSKIND JW, 1983, P NATL ACAD SCI-BIOL, V80, P1164, DOI 10.1073/pnas.80.5.1164	28	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20216	20221		10.1074/jbc.M502773200	http://dx.doi.org/10.1074/jbc.M502773200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15784615	hybrid			2022-12-25	WOS:000229242000008
J	Obhi, RK; Creuzenet, C				Obhi, RK; Creuzenet, C			Biochemical characterization of the Campylobacter jejuni Cj1294, a novel UDP-4-keto-6-deoxy-GlcNAc aminotransferase that generates UDP-4-amino-4,6-dideoxy-GalNAc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; THYMIDINE DIPHOSPHATE 4-ACETAMIDO-4,6-DIDEOXYHEXOSES; PSEUDOMONAS-AERUGINOSA PAO1; ESCHERICHIA-COLI; PROTEIN GLYCOSYLATION; HELICOBACTER-PYLORI; FLAGELLIN GLYCOSYLATION; 4-KETO-6-DEOXY-D-GLUCOSE TRANSAMINASE; POSTTRANSLATIONAL MODIFICATION; GENETIC-CHARACTERIZATION	Campylobacter jejuni produces multiple glycoproteins whose glycans contain 4-amino 6-deoxy sugars or their derivatives, such as diacetamidobacillosamine or pseudaminic acid. Because the proteoglycans contribute to bacterial virulence and their constitutive sugars are not commonly found in humans, inhibitors developed against the enzymes that are responsible for their biosynthesis could be novel therapeutic targets to fight this important food-borne pathogen. The biosynthesis of diacetamidobacillosamine is anticipated to involve a sugar nucleotide C6 dehydratase, a C4 aminotransferase and an acetyltransferase. We have identified a set of genes (cj1293, cj1294, and cj1298) potentially encoding one of each enzymatic activity, and demonstrated earlier that Cj1293 was a UDP-GlcNAc-specific C6 dehydratase. Others have shown that Cj1293 was involved in protein glycosylation. Here, we report on our investigation of the potential activity of Cj1294 as a sugar nucleotide C4 aminotransferase. Our biochemical characterization of overexpressed and purified protein shows that Cj1294 is a pyridoxal phosphate-dependent aminotransferase specific for UDP-4-keto-6-deoxy-GlcNAc that uses preferentially glutamic acid as an amino donor. A detailed physicokinetic study of Cj1294 was performed to determine the K-m of 1.28 +/- 0.2 mM and k(cat) of 11.5 +/- 1.3 min(-1). Also, two residues essential for protein stability and activity, Arg(228) and Lys(181), respectively, were identified by site-directed mutagenesis. Finally, we demonstrated by NMR analysis of purified reaction product that Cj1294 produces UDP-4-amino-4,6-dideoxy-GalNAc. These results indicate that Cj1294 is involved in the biosynthesis of diacetamidofucosamine, a C4 epimer of diacetamidobacillosamine not yet described in C. jejuni proteoglycans, suggesting that the composition of C. jejuni proteoglycans is more variable than anticipated.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Creuzenet, C (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, DSB 3031, London, ON N6A 5C1, Canada.	ccreuzen@uwo.ca						AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; Albermann C, 2001, GLYCOBIOLOGY, V11, P655, DOI 10.1093/glycob/11.8.655; Allen AG, 1998, MOL MICROBIOL, V29, P27, DOI 10.1046/j.1365-2958.1998.00878.x; Arora SK, 2001, P NATL ACAD SCI USA, V98, P9342, DOI 10.1073/pnas.161249198; Benz I, 2002, MOL MICROBIOL, V45, P267, DOI 10.1046/j.1365-2958.2002.03030.x; Bilge SS, 1996, INFECT IMMUN, V64, P4795, DOI 10.1128/IAI.64.11.4795-4801.1996; Breazeale SD, 2003, J BIOL CHEM, V278, P24731, DOI 10.1074/jbc.M304043200; Burrows LL, 1996, MOL MICROBIOL, V22, P481, DOI 10.1046/j.1365-2958.1996.1351503.x; Castric P, 2001, J BIOL CHEM, V276, P26479, DOI 10.1074/jbc.M102685200; Creuzenet C, 2000, J BIOL CHEM, V275, P34873, DOI 10.1074/jbc.M006369200; Creuzenet C, 2000, J BIOL CHEM, V275, P19060, DOI 10.1074/jbc.M001171200; Creuzenet C, 2004, FEBS LETT, V559, P136, DOI 10.1016/S0014-5793(04)00057-2; DiGiandomenico A, 2002, MOL MICROBIOL, V46, P519, DOI 10.1046/j.1365-2958.2002.03171.x; Doig P, 1996, MOL MICROBIOL, V19, P379, DOI 10.1046/j.1365-2958.1996.370890.x; Eads JC, 1999, BIOCHEMISTRY-US, V38, P9840, DOI 10.1021/bi990018q; Goon S, 2003, MOL MICROBIOL, V50, P659, DOI 10.1046/j.1365-2958.2003.03725.x; Guerry P, 1996, MOL MICROBIOL, V19, P369, DOI 10.1046/j.1365-2958.1996.369895.x; Hayashi T, 2001, DNA RES, V8, P11, DOI 10.1093/dnares/8.1.11; Hwang BY, 2004, CHEM BIOL, V11, P915, DOI 10.1016/j.chembiol.2004.04.015; Josenhans C, 2002, FEMS MICROBIOL LETT, V210, P165, DOI 10.1016/S0378-1097(02)00638-9; Kuo CC, 1996, J CLIN INVEST, V98, P2813, DOI 10.1172/JCI119109; Lindenthal C, 2001, INFECT IMMUN, V69, P52, DOI 10.1128/IAI.69.1.52-57.2001; Linton D, 2000, MOL MICROBIOL, V35, P1120, DOI 10.1046/j.1365-2958.2000.01780.x; MATSUHASHI M, 1966, J BIOL CHEM, V241, P4738; Messner P, 2003, Fortschr Chem Org Naturst, V85, P51; Miller WL, 2004, J BIOL CHEM, V279, P37551, DOI 10.1074/jbc.M404749200; Nedal A, 2004, APPL MICROBIOL BIOT, V64, P7, DOI 10.1007/s00253-003-1535-9; Noland BW, 2002, STRUCTURE, V10, P1569, DOI 10.1016/S0969-2126(02)00879-1; OHASHI H, 1971, J BIOL CHEM, V246, P2325; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Pfoestl A, 2003, J BIOL CHEM, V278, P26410, DOI 10.1074/jbc.M300858200; Power PM, 2003, MOL MICROBIOL, V49, P833, DOI 10.1046/j.1365-2958.2003.03602.x; Power PM, 2003, FEMS MICROBIOL LETT, V218, P211, DOI 10.1111/j.1574-6968.2003.tb11520.x; Power PM, 2000, MICROBIOL-UK, V146, P967, DOI 10.1099/00221287-146-4-967; Schaffer C, 2002, J BIOL CHEM, V277, P6230, DOI 10.1074/jbc.M108873200; Schirm M, 2004, J BACTERIOL, V186, P6721, DOI 10.1128/JB.186.20.6721-6727.2004; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; Soo EC, 2004, ANAL CHEM, V76, P619, DOI 10.1021/ac034875i; STIMSON E, 1995, MOL MICROBIOL, V17, P1201, DOI 10.1111/j.1365-2958.1995.mmi_17061201.x; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Sweet CR, 2004, J BIOL CHEM, V279, P25400, DOI 10.1074/jbc.M400596200; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; Szymanski CM, 2003, TRENDS MICROBIOL, V11, P233, DOI 10.1016/S0966-842X(03)00079-9; Szymanski CM, 2002, INFECT IMMUN, V70, P2242, DOI 10.1128/IAI.70.4.2242-2244.2002; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Xu DQ, 2002, INFECT IMMUN, V70, P4414, DOI 10.1128/IAI.70.8.4414-4423.2002; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200	51	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20902	20908		10.1074/jbc.M413832200	http://dx.doi.org/10.1074/jbc.M413832200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15790564	hybrid			2022-12-25	WOS:000229242000089
J	Xie, Q; Gao, CF; Shinomiya, N; Sausville, E; Hay, R; Gustafson, M; Shen, YH; Wenkert, D; Vande Woude, GF				Xie, Q; Gao, CF; Shinomiya, N; Sausville, E; Hay, R; Gustafson, M; Shen, YH; Wenkert, D; Vande Woude, GF			Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion	ONCOGENE			English	Article						geldanamycin; HGF/SF; Met; HSP90; uPA; molecular target; urokinase-type plasminogen activator	UROKINASE PLASMINOGEN-ACTIVATOR; SHOCK-PROTEIN 90; MOLECULAR CHAPERONES; BREAST-CANCER; IN-VIVO; GROWTH; RECEPTOR; MET; DEGRADATION; EXPRESSION	Induction of the urokinase-type plasminogen activator (uPA) by hepatocyte growth factor/scatter factor (HGF/ SF) plays an important role in tumor cell invasion and metastasis that is mediated through the Met receptor tyrosine kinase. Geldanamycins (GA) are antitumor drugs that bind and inhibit HSP90 chaperone activity at nanomolarconcent rations (nM-GAi) by preventing proper folding and functioning of certain oncoproteins. Previously, we have shown that a subset of GA derivatives exhibit exquisite potency, inhibiting HGF/ SF-induced uPA-plasmin activation at femtomolarconcent rations (fM-GAi) in canine MDCK cells. Here, we report that ( 1) inhibition of HGF/ SF-induced uPA activity by fM-GAi is not uncommon, in that several human tumor glioblastoma cell lines (DBTRG, U373 and SNB19), as well as SK-LMS-1 human leiomyosarcoma cells are also sensitive to fM-GAi; ( 2) fM-GAi drugs only display inhibitory activity against HGF/SF-induced uPA activity ( rather than basal activity), and only when the observed magnitude of uPA activity induction by HGF/ SF is at least 1.5 times basal uPA activity; and ( 3) not only do fM-GAi derivatives strongly inhibit uPA activity but they also block MDCK cell scattering and in vitro invasion of human glioblastoma cells at similarly low drug concentrations. These effects of fM-GAi drugs on the Met-activated signaling pathway occur at concentrations well below those required to measurably affect Met expression or cell proliferation. We also examined the effect of Radicicol ( RA), a drug with higher affinity than GA for HSP90. RA displays uPA activity inhibition at nanomolar levels, but not at lower concentrations, indicating that HSP90 is not likely the fM-GAi molecular tar get. Thus, we show that certain GA drugs ( fM-GAi) in an HGF/ SF-dependent mannerblock uPA-plasmin activation in tumor cells at femtomolar levels. This inhibition can also be observed in scattering and in vitro invasion assays. Our findings also provide strong circumstantial evidence for a novel non-HSP90 molecular target that is involved in HGF/SF-mediated tumor cell invasion.	Van Andel Res Inst, Mol Oncol Lab, Grand Rapids, MI 49503 USA; NCI, Dev Therapeut Program, Bethesda, MD 20892 USA; Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA	Van Andel Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Michigan State University	Vande Woude, GF (corresponding author), Van Andel Res Inst, Mol Oncol Lab, 333 Bostwick NE, Grand Rapids, MI 49503 USA.	michelle.reed@vai.org	Shen, Yuehai/J-7829-2012; Shinomiya, Nariyoshi/I-9666-2014					Bhattacharya A, 2001, CLIN CANCER RES, V7, P267; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Bonvini P, 2001, CANCER RES, V61, P1671; Chavany C, 1996, J BIOL CHEM, V271, P4974; Duffy MJ, 1996, ENZYME PROTEIN, V49, P85, DOI 10.1159/000468618; Duffy MJ, 1996, CLIN CANCER RES, V2, P613; ELLIS V, 1993, METHOD ENZYMOL, V223, P223; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; GLADSON CL, 1995, AM J PATHOL, V146, P1150; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Gondi CS, 2003, ONCOGENE, V22, P5967, DOI 10.1038/sj.onc.1206535; Harbeck N, 2002, CANCER RES, V62, P4617; Hattori N, 2004, AM J PATHOL, V164, P1091, DOI 10.1016/S0002-9440(10)63196-3; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Koochekpour S, 1997, CANCER RES, V57, P5391; Lakka SS, 2003, CANCER RES, V63, P2454; LEE YB, 1995, J MED CHEM, V38, P3053, DOI 10.1021/jm00016a008; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Maulik G, 2002, CLIN CANCER RES, V8, P620; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Nimmanapalli R, 2001, CANCER RES, V61, P1799; Ochel HJ, 2001, CELL STRESS CHAPERON, V6, P105, DOI 10.1379/1466-1268(2001)006<0105:GTPOAC>2.0.CO;2; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; Schweinitz A, 2004, J BIOL CHEM, V279, P33613, DOI 10.1074/jbc.M314151200; Solit DB, 2002, CLIN CANCER RES, V8, P986; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Tacchini L, 2003, EXP CELL RES, V290, P391, DOI 10.1016/S0014-4827(03)00348-3; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Webb CP, 2000, CANCER RES, V60, P342; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; YAMAMOTO M, 1994, CANCER RES, V54, P3656; Yang J, 2001, CANCER RES, V61, P4010; Zhang X, 2000, J CLIN NEUROSCI, V7, P116, DOI 10.1054/jocn.1999.0161	41	46	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3697	3707		10.1038/sj.onc.1208499	http://dx.doi.org/10.1038/sj.onc.1208499			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782129				2022-12-25	WOS:000229346300001
J	Kropf, P; Fuentes, JM; Fahnrich, E; Arpa, L; Herath, S; Weber, V; Soler, G; Celada, A; Modolell, M; Muller, I				Kropf, P; Fuentes, JM; Fahnrich, E; Arpa, L; Herath, S; Weber, V; Soler, G; Celada, A; Modolell, M; Muller, I			Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo	FASEB JOURNAL			English	Article						L-arginine metabolism; Leishmania major; infection; macrophages	NITRIC-OXIDE SYNTHASE; HUMAN MONONUCLEAR-CELLS; L-ARGININE; MURINE MACROPHAGES; ALTERNATIVE ACTIVATION; MAJOR INFECTION; T-CELLS; EXPRESSION; AVAILABILITY; CYTOKINES	Arginase 1, an enzyme induced by Th2 cytokines, is a hallmark of alternatively activated macrophages and is responsible for the hydrolysis of L-arginine into ornithine, the building block for the production of polyamines. Upregulation of arginase 2 has been observed in a variety of diseases, but the mechanisms by which arginase contributes to pathology are not well understood. We reveal here a unique role for arginase 1 in the pathogenesis of nonhealing leishmaniasis, a prototype Th2 disease, and demonstrate that the activity of this enzyme promotes pathology and uncontrolled growth of Leishmania parasites in vivo. Inhibition of arginase activity during the course of infection has a clear therapeutic effect, as evidenced by markedly reduced pathology and efficient control of parasite replication. Despite the clear amelioration of the disease, this treatment does not alter the Th2 response. To address the underlying mechanisms, the arginase-induced L-arginine catabolism was investigated and the results demonstrate that arginase regulates parasite growth directly by affecting the polyamine synthesis in macrophages.	Univ London Imperial Coll Sci Technol & Med, Dept Immunol, Fac Med, London W2 1PG, England; Univ Extremadura, EU Enfermeria & TO, Dept Bioquim & Biol Mol, Caceres, Spain; Max Planck Inst Immunobiol, D-7800 Freiburg, Germany; Univ Barcelona, Grp Macrophage Biol, E-08007 Barcelona, Spain; Univ Extremadura, Fac Vet, Dept Bioquim & Biol Mol, Caceres, Spain	Imperial College London; Universidad de Extremadura; Max Planck Society; University of Barcelona; Universidad de Extremadura	Muller, I (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Immunol, Fac Med, Norfolk Pl, London W2 1PG, England.	i.muller@imperial.ac.uk	Celada, Antonio/I-1714-2016; Fuentes, Jose M/H-9490-2014; Fuentes, Jose M./AAV-5164-2021	Fuentes, Jose M/0000-0001-6910-2089; Fuentes, Jose M./0000-0001-6910-2089; SOLER, GERMAN/0000-0002-5859-1371; Celada, Antonio/0000-0003-3883-2171				Bansal V, 2003, CURR OPIN CLIN NUTR, V6, P223, DOI 10.1097/00075197-200303000-00012; Berkowitz DE, 2003, CIRCULATION, V108, P2000, DOI 10.1161/01.CIR.0000092948.04444.C7; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Boucher JL, 1999, CELL MOL LIFE SCI, V55, P1015, DOI 10.1007/s000180050352; Bronte V, 2003, J IMMUNOL, V170, P270, DOI 10.4049/jimmunol.170.1.270; Bruch-Gerharz D, 2003, AM J PATHOL, V162, P203, DOI 10.1016/S0002-9440(10)63811-4; CAMARGO EP, 1978, EXP PARASITOL, V46, P141, DOI 10.1016/0014-4894(78)90125-X; Cederbaum SD, 2004, MOL GENET METAB, V81, pS38, DOI 10.1016/j.ymgme.2003.10.012; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Custot J, 1997, J AM CHEM SOC, V119, P4086, DOI 10.1021/ja970285o; DIEZ A, 1994, BIOL CHEM H-S, V375, P537, DOI 10.1515/bchm3.1994.375.8.537; DING AH, 1988, J IMMUNOL, V141, P2407; Duleu S, 2004, J IMMUNOL, V172, P6298, DOI 10.4049/jimmunol.172.10.6298; El-Gayar S, 2003, J IMMUNOL, V171, P4561, DOI 10.4049/jimmunol.171.9.4561; Etges R, 1998, J MOL MED, V76, P372, DOI 10.1007/s001090050230; Fligger J, 1999, IMMUNOBIOLOGY, V200, P169, DOI 10.1016/S0171-2985(99)80068-0; Fuentes JM, 2000, ANAL BIOCHEM, V285, P276, DOI 10.1006/abio.2000.4784; Gobert AP, 2000, INFECT IMMUN, V68, P4653, DOI 10.1128/IAI.68.8.4653-4657.2000; Goerdt S, 1999, IMMUNITY, V10, P137, DOI 10.1016/S1074-7613(00)80014-X; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Hasko G, 2000, SHOCK, V14, P144, DOI 10.1097/00024382-200014020-00012; Hesse M, 2001, J IMMUNOL, V167, P6533, DOI 10.4049/jimmunol.167.11.6533; HOFMANN F, 1978, Biochemical Society Transactions, V6, P990; Iniesta V, 2002, PARASITE IMMUNOL, V24, P113, DOI 10.1046/j.1365-3024.2002.00444.x; Iniesta V, 2001, J EXP MED, V193, P777, DOI 10.1084/jem.193.6.777; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; Jost MM, 2003, FASEB J, V17, P2281, DOI 10.1096/fj.03-0071fje; Kepka-Lenhart D, 2000, AM J PHYSIOL-REG I, V279, pR2237; Kropf P, 2004, INFECT IMMUN, V72, P1920, DOI 10.1128/IAI.72.4.1920-1928.2004; Kropf P, 2004, J LEUKOCYTE BIOL, V76, P48, DOI 10.1189/jlb.1003484; Kropf P, 2003, PARASITE IMMUNOL, V25, P439, DOI 10.1111/j.1365-3024.2003.00655.x; KROPF P, 1958, METHOD MICROBIOL, P419; Kusmartsev S, 2004, J IMMUNOL, V172, P989, DOI 10.4049/jimmunol.172.2.989; Loke P, 2000, EUR J IMMUNOL, V30, P2669, DOI 10.1002/1521-4141(200009)30:9&lt;2669::AID-IMMU2669&gt;3.0.CO;2-1; Louis CA, 1999, AM J PHYSIOL-REG I, V276, pR237, DOI 10.1152/ajpregu.1999.276.1.R237; Marques L, 2004, J IMMUNOL, V173, P1103, DOI 10.4049/jimmunol.173.2.1103; MAUEL J, 1991, J LEUKOCYTE BIOL, V49, P73, DOI 10.1002/jlb.49.1.73; Meurs H, 2002, BRIT J PHARMACOL, V136, P391, DOI 10.1038/sj.bjp.0704725; Moali C, 1998, BIOCHEMISTRY-US, V37, P10453, DOI 10.1021/bi980742t; MODOLELL M, 1995, EUR J IMMUNOL, V25, P1101, DOI 10.1002/eji.1830250436; MORGAN DML, 1994, BIOCHEM SOC T, V22, P879, DOI 10.1042/bst0220879; Morris CR, 2004, AM J RESP CRIT CARE, V170, P148, DOI 10.1164/rccm.200309-1304OC; Muller S, 2001, TRENDS PARASITOL, V17, P242, DOI 10.1016/S1471-4922(01)01908-0; Munder M, 1999, J IMMUNOL, V163, P3771; Munder M, 2005, BLOOD, V105, P2549, DOI 10.1182/blood-2004-07-2521; Munder M, 1998, J IMMUNOL, V160, P5347; MUNDER PG, 1971, FEBS LETT, V15, P191, DOI 10.1016/0014-5793(71)80309-5; Noel W, 2004, TRENDS PARASITOL, V20, P126, DOI 10.1016/j.pt.2004.01.004; Ochoa JB, 2001, ANN SURG, V233, P393, DOI 10.1097/00000658-200103000-00014; Perez-Cano FJ, 2003, CELL IMMUNOL, V226, P86, DOI 10.1016/j.cellimm.2003.09.009; Rangel MD, 2002, CLIN EXP MED, V2, P53; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Roberts SC, 2004, J BIOL CHEM, V279, P23668, DOI 10.1074/jbc.M402042200; Rodriguez PC, 2002, J BIOL CHEM, V277, P21123, DOI 10.1074/jbc.M110675200; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Sacks D, 2002, NAT IMMUNOL, V3, P1041, DOI 10.1038/ni1102-1041; Stempin C, 2002, J LEUKOCYTE BIOL, V72, P727; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tenu JP, 1999, NITRIC OXIDE-BIOL CH, V3, P427, DOI 10.1006/niox.1999.0255; TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x; Vincendeau P, 2003, TRENDS PARASITOL, V19, P9, DOI 10.1016/S1471-4922(02)00010-7; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; Xu LY, 2003, IMMUNOLOGY, V110, P141, DOI 10.1046/j.1365-2567.2003.01713.x; Zea AH, 1998, INFECT IMMUN, V66, P499, DOI 10.1128/IAI.66.2.499-504.1998; Zhang MH, 1997, J EXP MED, V185, P1759, DOI 10.1084/jem.185.10.1759; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	67	220	225	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1000	+		10.1096/fj.04-3416fje	http://dx.doi.org/10.1096/fj.04-3416fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15811879				2022-12-25	WOS:000228865300028
J	Jean-Rene, B; Gardella, TJ; Dean, T; MacLean, S; Potetinova, Z; Whitfield, JF; Willick, GE				Jean-Rene, B; Gardella, TJ; Dean, T; MacLean, S; Potetinova, Z; Whitfield, JF; Willick, GE			Backbone-methylated analogues of the principle receptor binding region of human parathyroid hormone - Evidence for binding to both the N-terminal extracellular domain and extracellular loop region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PTH/PTHRP RECEPTOR; CIRCULAR-DICHROISM; SIDE-CHAIN; BIOLOGICAL-ACTIVITIES; CONSTRAINED ANALOGS; ADENYLYL-CYCLASE; BONE-GROWTH; FRAGMENTS; PEPTIDES	We have used backbone N-methylations of parathyroid hormone (PTH) to study the role of these NH groups in the C-terminal amphiphilic alpha-helix of PTH (1-31) in binding to and activating the PTH receptor (P1R). The circular dichroism ( CD) spectra indicated the structure of the C-terminal alpha-helix was locally disrupted around the methylation site. The CD spectra differences were explained by assuming a helix disruption for four residues on each side of the site of methylation and taking into account the known dependence of CD on the length of an alpha-helix. Binding and adenylyl cyclase-stimulating data showed that outside of the alpha-helix, methylation of residues Asp(30) and Val(31) had little effect on structure or activities. Within the alpha-helix, disruption of the structure was associated with increased loss of activity, but for specific residues Val(21), Leu(24), Arg(25), and Leu(28) there was a dramatic loss of activities, thus suggesting a more direct role of these NH groups in correct P1R binding and activation. Activity analyses with P1R-delNT, a mutant with its long N-terminal region deleted, gave a different pattern of effects and implicated Ser(17), Trp(23), and Lys(26) as important for its PTH activation. These two groups of residues are located on opposite sides of the helix. These results are compatible with the C-terminal helix binding to both the N-terminal segment and also to the looped-out extracellular region. These data thus provide direct evidence for important roles of the C-terminal domain of PTH in determining high affinity binding and activation of the P1R receptor.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	National Research Council Canada; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Willick, GE (corresponding author), Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.	gordon.willick@nrc.ca						Ajay, 1995, J MED CHEM, V38, P4953, DOI 10.1021/jm00026a001; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Barbier JR, 2000, BIOCHEMISTRY-US, V39, P14522, DOI 10.1021/bi001527r; Barbier JR, 1997, J MED CHEM, V40, P1373, DOI 10.1021/jm960743o; Barbier JR, 2001, BIOCHEMISTRY-US, V40, P8955, DOI 10.1021/bi010460k; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Chang CF, 1996, BIOPOLYMERS, V40, P609, DOI 10.1002/(SICI)1097-0282(1996)40:6<609::AID-BIP2>3.3.CO;2-A; Chen ZG, 2000, BIOCHEMISTRY-US, V39, P12766, DOI 10.1021/bi000882e; Chin DH, 2002, P NATL ACAD SCI USA, V99, P15416, DOI 10.1073/pnas.232591399; Chorev M, 2002, RECEPTOR CHANNEL, V8, P219, DOI 10.1080/10606820213685; Cosman F, 1998, CALCIFIED TISSUE INT, V62, P475, DOI 10.1007/s002239900464; Gardella TJ, 2001, TRENDS ENDOCRIN MET, V12, P210, DOI 10.1016/S1043-2760(01)00409-X; GARDELLA TJ, 1993, ENDOCRINOLOGY, V132, P2024, DOI 10.1210/en.132.5.2024; Gensure RC, 2003, MOL ENDOCRINOL, V17, P2647, DOI 10.1210/me.2003-0275; Gensure RC, 2001, J BIOL CHEM, V276, P28650, DOI 10.1074/jbc.M100717200; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; HERRMANNERLEE MPM, 1976, ENDOCR RES COMMUN, V3, P21, DOI 10.3109/07435807609057738; Hoare SRJ, 2000, J BONE MINER RES, V15, P605, DOI 10.1359/jbmr.2000.15.3.605; Inooka H, 2001, NAT STRUCT BIOL, V8, P161, DOI 10.1038/84159; JOUISHOMME H, 1992, ENDOCRINOLOGY, V130, P53, DOI 10.1210/en.130.1.53; JUPPER M, 1991, SCIENCE, V354, P1024; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; Lu WY, 1999, CHEM BIOL, V6, P419, DOI 10.1016/S1074-5521(99)80060-X; Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670; MANNING MC, 1991, BIOPOLYMERS, V31, P569, DOI 10.1002/bip.360310511; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; Miller SC, 1997, J AM CHEM SOC, V119, P2301, DOI 10.1021/ja9635443; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; NEUGEBAUER W, 1992, BIOCHEMISTRY-US, V31, P2056, DOI 10.1021/bi00122a023; NEUGEBAUER W, 1995, BIOCHEMISTRY-US, V34, P8835, DOI 10.1021/bi00027a035; Oldenburg KR, 1996, J BIOL CHEM, V271, P17582; Rajeswaran WG, 2001, J MED CHEM, V44, P1305, DOI 10.1021/jm0005048; RIXON RH, 1994, J BONE MINER RES, V9, P1179; Rohl CA, 1997, BIOCHEMISTRY-US, V36, P8435, DOI 10.1021/bi9706677; ROSENBLATT M, 1980, ENDOCRINOLOGY, V107, P545, DOI 10.1210/endo-107-2-545; ROSENBLATT M, 1989, ENDOCRINOLOGY, P848; Sagan S, 2004, CURR MED CHEM, V11, P2799, DOI 10.2174/0929867043364108; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; Schumann C, 2002, J PEPT RES, V60, P128, DOI 10.1034/j.1399-3011.2002.02986.x; Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199; Shimizu N, 2003, BIOCHEMISTRY-US, V42, P2282, DOI 10.1021/bi027237n; Shimizu N, 2001, J BIOL CHEM, V276, P49003, DOI 10.1074/jbc.M106827200; SIMON RJ, 1992, P NATL ACAD SCI USA, V89, P9367, DOI 10.1073/pnas.89.20.9367; SUREWICZ WK, 1993, PEPTIDES CHEM STRUCT, P556; Takasu H, 1999, J BONE MINER RES, V14, P11, DOI 10.1359/jbmr.1999.14.1.11; Tsomaia N, 2004, BIOCHEMISTRY-US, V43, P690, DOI 10.1021/bi035703i; Vogen SM, 2001, INT IMMUNOPHARMACOL, V1, P2151, DOI 10.1016/S1567-5769(01)00141-2; Whitfield J, 1998, PARATHYROID HORMONE; Whitfield JF, 2000, CALCIFIED TISSUE INT, V66, P307, DOI 10.1007/s002230010061; Whitfield JF, 2001, J BONE MINER RES, V16, P441, DOI 10.1359/jbmr.2001.16.3.441; YANG JT, 1986, METHOD ENZYMOL, V130, P208	54	16	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23771	23777		10.1074/jbc.M500817200	http://dx.doi.org/10.1074/jbc.M500817200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15826940	hybrid			2022-12-25	WOS:000229880000047
J	Ogawa, T; Verhamme, IM; Sun, MF; Bock, PE; Gailani, D				Ogawa, T; Verhamme, IM; Sun, MF; Bock, PE; Gailani, D			Exosite-mediated substrate recognition of factor IX by factor XIa - The factor XIa heavy chain is required for initial recognition of factor IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; TISSUE FACTOR PATHWAY; MACROMOLECULAR SUBSTRATE; BINDING-SITE; ACTIVE-SITE; FUNCTIONAL-CHARACTERIZATION; CRYSTAL-STRUCTURE; CHRISTMAS FACTOR; ACTIVATION; PROTHROMBINASE	Studies of the mechanisms of blood coagulation zymogen activation demonstrate that exosites ( sites on the activating complex distinct from the protease active site) play key roles in macromolecular substrate recognition. We investigated the importance of exosite interactions in recognition of factor IX by the protease factor XIa. Factor XIa cleavage of the tripeptide substrate S2366 was inhibited by the active site inhibitors p-aminobenzamidine ( Ki 28 +/- 2 mu M) and aprotinin ( K-i 1.13 +/- 0.07 mu M) in a classical competitive manner, indicating that substrate and inhibitor binding to the active site was mutually exclusive. In contrast, inhibition of factor XIa cleavage of S2366 by factor IX (Ki 224 +/- 32 nM) was characterized by hyperbolic mixed-type inhibition, indicating that factor IX binds to free and S2366-bound factor XIa at exosites. Consistent with this premise, inhibition of factor XIa activation of factor IX by aprotinin (K-i 0.89 +/- 0.52 mu M) was non-competitive, whereas inhibition by active site-inhibited factor IX alpha beta was competitive (K-i 0.33 +/- 0.05 mu M). S2366 cleavage by isolated factor XIa catalytic domain was competitively inhibited by p-aminobenzamidine (K-i 38 +/- 14 mu M) but was not inhibited by factor IX, consistent with loss of factor IX-binding exosites on the non-catalytic factor XI heavy chain. The results support a model in which factor IX binds initially to exosites on the factor XIa heavy chain, followed by interaction at the active site with subsequent bond cleavage, and support a growing body of evidence that exosite interactions are critical determinants of substrate affinity and specificity in blood coagulation reactions.	Vanderbilt Univ, Dept Pathol, Nashville, TN 37069 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37069 USA	Vanderbilt University; Vanderbilt University	Gailani, D (corresponding author), Vanderbilt Univ, Dept Pathol, Nashville, TN 37069 USA.	dave.gailani@vanderbilt.edu			NHLBI NIH HHS [R01 HL038779, R01 HL058837, HL58837, HL38779, R01 HL038779-19] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058837, R01HL038779, R29HL038779] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aktimur A, 2003, J BIOL CHEM, V278, P7981, DOI 10.1074/jbc.M212748200; ASAKAI R, 1991, NEW ENGL J MED, V325, P153, DOI 10.1056/NEJM199107183250303; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAJAJ SP, 1983, BIOCHEMISTRY-US, V22, P4047, DOI 10.1021/bi00286a009; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; Boskovic DS, 2004, J BIOL CHEM, V279, P20786, DOI 10.1074/jbc.M400469200; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; BROZE GJ, 1992, SEMIN HEMATOL, V29, P159; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DOOLITTLE RF, 1987, COLD SPRING HARB SYM, V52, P869, DOI 10.1101/SQB.1987.052.01.095; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; DUGGLEBY RG, 1977, BIOCHIM BIOPHYS ACTA, V481, P297, DOI 10.1016/0005-2744(77)90264-9; EVANS SA, 1982, J BIOL CHEM, V257, P3014; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Gale AJ, 2002, J BIOL CHEM, V277, P28836, DOI 10.1074/jbc.M204363200; Krem MM, 1999, J BIOL CHEM, V274, P28063, DOI 10.1074/jbc.274.40.28063; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANNHALTER C, 1984, BRIT J HAEMATOL, V56, P261, DOI 10.1111/j.1365-2141.1984.tb03954.x; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; Navaneetham D, 2003, BLOOD, V102, p127A; NEMERSON Y, 1992, SEMIN HEMATOL, V29, P170; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; Orcutt SJ, 2002, J BIOL CHEM, V277, P46191, DOI 10.1074/jbc.M208677200; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; OSTERUD B, 1978, J BIOL CHEM, V253, P5946; Pedicord DL, 2004, BIOCHEMISTRY-US, V43, P11883, DOI 10.1021/bi048964g; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; Schmidt AE, 2004, J BIOL CHEM, V279, P29485, DOI 10.1074/jbc.M402971200; SEGEL IH, 1993, ENZYME KINETICS BEHA, P178; SELIGSOHN U, 1993, THROMB HAEMOSTASIS, V70, P68; Shobe J, 1999, J BIOL CHEM, V274, P24171, DOI 10.1074/jbc.274.34.24171; SINHA D, 1985, J BIOL CHEM, V260, P714; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; Sun MF, 1999, J BIOL CHEM, V274, P36373, DOI 10.1074/jbc.274.51.36373; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; WALSH PN, 1992, SEMIN HEMATOL, V29, P189; Wolberg AS, 1997, BIOCHEMISTRY-US, V36, P4074, DOI 10.1021/bi962274y; Zivelin A, 2004, J THROMB HAEMOST, V2, P1782, DOI 10.1111/j.1538-7836.2004.00882.x	55	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23523	23530		10.1074/jbc.M500894200	http://dx.doi.org/10.1074/jbc.M500894200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15829482	Green Accepted, hybrid			2022-12-25	WOS:000229880000016
J	Bergstrom, AL; Cordes, H; Zsurger, N; Heegaard, PMH; Laursen, H; Chabry, J				Bergstrom, AL; Cordes, H; Zsurger, N; Heegaard, PMH; Laursen, H; Chabry, J			Amidation and structure relaxation abolish the neurotoxicity of the prion peptide PrP106-126 in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CELL-DEATH; RETINAL DEGENERATION; AMYLOID-BETA; PROTEIN PRPC; SCRAPIE; MICE; ACCUMULATION; ACTIVATION; CASPASE-3; CHRISTEN,PHILIPP	One of the major pathological hallmarks of transmissible spongiform encephalopathies (TSEs) is the accumulation of a pathogenic (scrapie) isoform (PrPSc) of the cellular prion protein (PrPC) primarily in the central nervous system. The synthetic prion peptide PrP106-126 shares many characteristics with PrPSc in that it shows PrPC-dependent neurotoxicity both in vivo and in vitro. Moreover, PrP106-126 in vitro neurotoxicity has been closely associated with the ability to form fibrils. Here, we studied the in vivo neurotoxicity of molecular variants of PrP106-126 toward retinal neurons using electroretinographic recordings in mice after intraocular injections of the peptides. We found that amidation and structure relaxation of PrP106-126 significantly reduced the neurotoxicity in vivo. This was also found in vitro in primary neuronal cultures from mouse and rat brain. Thioflavin T binding studies showed that amidation and structure relaxation significantly reduced the ability of PrP106-126 to attain fibrillar structures in physiological salt solutions. This study hence supports the assumption that the neurotoxic potential of PrP106-126 is closely related to its ability to attain secondary structure.	Danish Inst Food & Vet Res, Dept Vet Daignost & Res, DK-1790 Copenhagen, Denmark; CNRS, UMR 6097, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Rigshosp, Neuropathol Lab, DK-2100 Copenhagen, Denmark	Technical University of Denmark; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Rigshospitalet; University of Copenhagen	Bergstrom, AL (corresponding author), Danish Inst Food & Vet Res, Dept Vet Daignost & Res, Bulowsvej 27, DK-1790 Copenhagen, Denmark.	alb@dfvf.dk	Chabry, Joelle/O-2101-2016; Heegaard, Peter/E-9794-2015	Heegaard, Peter/0000-0003-4506-4932				Agostinho P, 2003, EUR J NEUROSCI, V17, P1189, DOI 10.1046/j.1460-9568.2003.02546.x; Armstrong RA, 2003, J NEURAL TRANSM, V110, P1303, DOI 10.1007/s00702-003-0039-1; Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; Brown DR, 1999, FEBS LETT, V460, P559, DOI 10.1016/S0014-5793(99)01343-5; Brown DR, 1999, J NEUROCHEM, V73, P1105, DOI 10.1046/j.1471-4159.1999.0731105.x; BRUCE ME, 1989, NEUROSCI LETT, V102, P1, DOI 10.1016/0304-3940(89)90298-X; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; BUYUKMIHCI N, 1982, J COMP NEUROL, V205, P153, DOI 10.1002/cne.902050206; BUYUKMIHCI NC, 1987, EXP NEUROL, V97, P201, DOI 10.1016/0014-4886(87)90294-9; Chabry J, 1998, J BIOL CHEM, V273, P13203, DOI 10.1074/jbc.273.21.13203; Chabry J, 2003, J NEUROSCI, V23, P462; Chishti MA, 1997, NEUROSCI LETT, V234, P11; CURTIS R, 1989, NEUROPATH APPL NEURO, V15, P75, DOI 10.1111/j.1365-2990.1989.tb01151.x; Ettaiche M, 2000, J BIOL CHEM, V275, P36487, DOI 10.1074/jbc.C000579200; Fioriti L, 2005, MOL CELL NEUROSCI, V28, P165, DOI 10.1016/j.mcn.2004.09.006; Florio T, 1998, J NEUROSCI RES, V54, P341, DOI 10.1002/(SICI)1097-4547(19981101)54:3<341::AID-JNR5>3.0.CO;2-G; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Forloni G, 2000, FEBS LETT, V466, P205, DOI 10.1016/S0014-5793(99)01781-0; Foster J, 1999, NEUROSCI LETT, V260, P1, DOI 10.1016/S0304-3940(98)00903-3; FOSTER JD, 1986, NEUROPATH APPL NEURO, V12, P185, DOI 10.1111/j.1365-2990.1986.tb00049.x; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; GIESE A, 1995, BRAIN PATHOL, V5, P213, DOI 10.1111/j.1750-3639.1995.tb00597.x; Gu YP, 2002, J BIOL CHEM, V277, P2275, DOI 10.1074/jbc.M104345200; Haik S, 2000, NEUROBIOL DIS, V7, P644, DOI 10.1006/nbdi.2000.0316; Head MW, 2003, INVEST OPHTH VIS SCI, V44, P342, DOI 10.1167/iovs.01-1273; Heegaard PMH, 2004, FEBS LETT, V577, P127, DOI 10.1016/j.febslet.2004.09.073; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; HOGAN RN, 1981, LAB INVEST, V44, P34; Horiuchi M, 2001, J BIOL CHEM, V276, P15489, DOI 10.1074/jbc.M100288200; Jamieson E, 2001, NEUROREPORT, V12, P3567, DOI 10.1097/00001756-200111160-00039; Jeffrey M, 2001, J COMP PATHOL, V124, P20, DOI 10.1053/jcpa.2000.0423; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kunz B, 1999, FEBS LETT, V458, P65, DOI 10.1016/S0014-5793(99)01123-0; Larsen BD, 1998, J PEPT RES, V52, P470; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Liberski PP, 2004, INT J BIOCHEM CELL B, V36, P2473, DOI 10.1016/j.biocel.2004.04.016; McLaughlin B, 2003, P NATL ACAD SCI USA, V100, P715, DOI 10.1073/pnas.0232966100; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; O'Donovan CN, 2001, J BIOL CHEM, V276, P43516, DOI 10.1074/jbc.M103894200; PATEL AJ, 1999, METHODS NEUROSIC, V18, P493; Peyrin JM, 1999, NEUROREPORT, V10, P723, DOI 10.1097/00001756-199903170-00012; Post K, 2000, ARCH VIROL, P265; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Prusiner SB, 1992, PRION DIS HUMANS ANI; Puig B, 2001, ACTA NEUROPATHOL, V102, P207; Raymond G. J., 2004, TECHNIQUES PRION RES, P16; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Rosenblum WI, 2002, NEUROBIOL AGING, V23, P225, DOI 10.1016/S0197-4580(01)00283-4; Rymer DL, 2000, J NEUROCHEM, V75, P2536, DOI 10.1046/j.1471-4159.2000.0752536.x; Salmona M, 1999, BIOCHEM J, V342, P207, DOI 10.1042/0264-6021:3420207; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; Turnbull S, 2003, NEUROSCI LETT, V336, P159, DOI 10.1016/S0304-3940(02)01254-5; Vaughan-Thomas A, 2000, INVEST OPHTH VIS SCI, V41, P3299; Yan XX, 2001, J COMP NEUROL, V433, P4, DOI 10.1002/cne.1121; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	58	20	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23114	23121		10.1074/jbc.M500210200	http://dx.doi.org/10.1074/jbc.M500210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824101	Green Submitted, hybrid			2022-12-25	WOS:000229741800068
J	Buzzai, M; Bauer, DE; Jones, RG; DeBerardinis, RJ; Hatzivassiliou, G; Elstrom, RL; Thompson, CB				Buzzai, M; Bauer, DE; Jones, RG; DeBerardinis, RJ; Hatzivassiliou, G; Elstrom, RL; Thompson, CB			The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation	ONCOGENE			English	Article						Akt; AMPK; fatty acid oxidation; metabolism; glucose	PROTEIN-KINASE; CANCER-CELLS; SKELETAL-MUSCLE; GLYCOLYSIS; METABOLISM; PHOSPHORYLATION; INHIBITION; DISORDERS; TOLERANCE; SURVIVAL	Activation of the oncogenic kinase Akt stimulates glucose uptake and metabolism in cancer cells and renders these cells susceptible to death in response to glucose withdrawal. Here we show that 5-aminoimidazole-4-carboxamide ribonucleoside ( AICAR) reverses the sensitivity of Akt-expressing glioblastoma cells to glucose deprivation. AICAR's protection depends on the activation of AMPK, as expression of a dominant-negative form of AMPK abolished this effect. AMPK is a cellular energy sensor whose activation can both block anabolic pathways such as protein synthesis and activate catabolic reactions such as fatty acid oxidation to maintain cellular bioenergetics. While rapamycin treatment mimicked the effect of AICAR on inhibiting markers of cap-dependent translation, it failed to protect Akt-expressing cells from death upon glucose withdrawal. Compared to control cells, Akt-expressing cells were impaired in the ability to induce fatty acid oxidation in response to glucose deprivation unless stimulated with AICAR. Stimulation of fatty acid oxidation was sufficient to maintain cell survival as activation of fatty acid oxidation with bezafibrate also protected Akt-expressing cells from glucose withdrawal-induced death. Conversely, treatment with a CPT-1 inhibitor to block fatty acid import into mitochondria prevented AICAR from stimulating fatty acid oxidation and promoting cell survival in the absence of glucose. Finally, cell survival did not require reversal of Akt's effects on either protein translation or lipid synthesis as the addition of the cell penetrant oxidizable substrate methyl-pyruvate was sufficient to maintain survival of Akt-expressing cells deprived of glucose. Together, these data suggest that activation of Akt blocks the ability of cancer cells to metabolize nonglycolytic bioenergetic substrates, leading to glucose addiction.	Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Human Genet & Mol Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Thompson, CB (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu	Jones, Russell/AAC-2861-2022; Jones, Russell Graham/ABD-5261-2021	Jones, Russell Graham/0000-0003-2250-4675	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008638] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32-GM008638-08] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; BRIVET M, 1995, ANN CLIN BIOCHEM, V32, P154, DOI 10.1177/000456329503200204; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; DISERENS AC, 1981, ACTA NEUROPATHOL, V53, P21, DOI 10.1007/BF00697180; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Halford NG, 1998, PLANT MOL BIOL, V37, P735, DOI 10.1023/A:1006024231305; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hashimoto K, 2002, BIOCHEM BIOPH RES CO, V290, P263, DOI 10.1006/bbrc.2001.6193; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jijakli H, 1996, ARCH BIOCHEM BIOPHYS, V335, P245, DOI 10.1006/abbi.1996.0505; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; LILLY K, 1992, BIOCHEM PHARMACOL, V43, P353, DOI 10.1016/0006-2952(92)90298-W; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; MOON A, 1987, J CLIN INVEST, V79, P59, DOI 10.1172/JCI112808; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; OMURA S, 1995, J ANTIBIOT, V48, P535, DOI 10.7164/antibiotics.48.535; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; VAN MEIR EG, 1994, CANCER RES, V54, P649; WARBURG O, 1956, SCIENCE, V124, P269; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047	30	289	297	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4165	4173		10.1038/sj.onc.1208622	http://dx.doi.org/10.1038/sj.onc.1208622			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806154				2022-12-25	WOS:000229815300001
J	Fialcowitz, EJ; Brewer, BY; Keenan, BP; Wilson, GM				Fialcowitz, EJ; Brewer, BY; Keenan, BP; Wilson, GM			A hairpin-like structure within an AU-rich mRNA-destabilizing element regulates trans-factor binding selectivity and mRNA decay kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RESONANCE ENERGY-TRANSFER; ZINC-FINGER PROTEINS; SECONDARY STRUCTURE; MAMMALIAN-CELLS; STABILITY; TURNOVER; HUR; TRISTETRAPROLIN; DEGRADATION	In mammals, rapid mRNA turnover directed by AU-rich elements (AREs) is mediated by selective association of cellular ARE-binding proteins. These trans-acting factors display overlapping RNA substrate specificities and may act to either stabilize or destabilize targeted transcripts; however, the mechanistic features of AREs that promote preferential binding of one trans-factor over another are not well understood. Here, we describe a hairpin-like structure adopted by the ARE from tumor necrosis factor alpha (TNF alpha) mRNA that modulates its affinity for selected ARE- binding proteins. In particular, association of the mRNA-destabilizing factor p37(AUF1) was strongly inhibited by adoption of the higher order ARE structure, whereas binding of the inducible heat shock protein Hsp70 was less severely compromised. By contrast, association of the mRNA-stabilizing protein HuR was only minimally affected by changes in ARE folding. Consistent with the inverse relationship between p37AUF1 binding affinity and the stability of ARE folding, mutations that stabilized the ARE hairpin also inhibited its ability to direct rapid mRNA turnover in transfected cells. Finally, phylogenetic analyses and structural modeling indicate that alpha(TNF alpha) mRNA sequences flanking the ARE are highly conserved and may stabilize the hairpin fold in vivo. Taken together, these data suggest that local higher order structures involving AREs may function as potent regulators of mRNA turnover in mammalian cells by modulating trans- factor binding selectivity.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Fluorescence Spect, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenbaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Wilson, GM (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	gwils001@umaryland.edu	Wilson, Gerald/AAF-3874-2019	Wilson, Gerald/0000-0002-1273-7507	NCI NIH HHS [R01 CA102428, R01 CA 102428] Funding Source: Medline; NCRR NIH HHS [P41 RR 08119, P41 RR008119] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102428] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Arao Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P228, DOI 10.1006/abbi.2000.1938; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Breslauer KJ, 1995, METHOD ENZYMOL, V259, P221; Brewer BY, 2004, J BIOL CHEM, V279, P27870, DOI 10.1074/jbc.M402551200; Briata P, 2003, MOL CELL, V12, P1201, DOI 10.1016/S1097-2765(03)00407-6; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cok SJ, 2004, J BIOL CHEM, V279, P8196, DOI 10.1074/jbc.M308475200; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Dean JLE, 2003, J BIOL CHEM, V278, P39470, DOI 10.1074/jbc.M306345200; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Draper DE, 2004, RNA, V10, P335, DOI 10.1261/rna.5205404; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fisher BM, 1998, BIOCHEMISTRY-US, V37, P12121, DOI 10.1021/bi980743l; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; Heilman-Miller SL, 2001, J MOL BIOL, V306, P1157, DOI 10.1006/jmbi.2001.4437; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Hudson BP, 2004, NAT STRUCT MOL BIOL, V11, P257, DOI 10.1038/nsmb738; Klostermeier D, 2001, METHODS, V23, P240, DOI 10.1006/meth.2000.1135; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Lapucci A, 2002, J BIOL CHEM, V277, P16139, DOI 10.1074/jbc.M201377200; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Leontis NB, 2002, NUCLEIC ACIDS RES, V30, P3497, DOI 10.1093/nar/gkf481; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Meisner NC, 2004, CHEMBIOCHEM, V5, P1432, DOI 10.1002/cbic.200400219; NELSON DL, 2005, LEHNINGER PRINCIPLES, P284; Norman DG, 2000, BIOCHEMISTRY-US, V39, P6317, DOI 10.1021/bi992944a; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Park-Lee S, 2003, J BIOL CHEM, V278, P39801, DOI 10.1074/jbc.M307105200; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021; Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang XQ, 2001, NAT STRUCT BIOL, V8, P141, DOI 10.1038/84131; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 2001, J BIOL CHEM, V276, P38400, DOI 10.1074/jbc.M106509200; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; Wilson GM, 2003, J BIOL CHEM, V278, P33039, DOI 10.1074/jbc.M305775200; Wilson GM, 1999, METHODS, V17, P74, DOI 10.1006/meth.1998.0709; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilson GM, 2001, J BIOL CHEM, V276, P44450, DOI 10.1074/jbc.M108521200; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; Winzen R, 2004, MOL CELL BIOL, V24, P4835, DOI 10.1128/MCB.24.11.4835-4847.2004; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	60	67	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22406	22417		10.1074/jbc.M500618200	http://dx.doi.org/10.1074/jbc.M500618200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15809297	Green Accepted, hybrid			2022-12-25	WOS:000229557900086
J	Miao, B; Yin, XH; Pei, DS; Zhang, QG; Zhang, GY				Miao, B; Yin, XH; Pei, DS; Zhang, QG; Zhang, GY			Neuroprotective effects of preconditioning ischemia on ischemic brain injury through down-regulating activation of JNK1/2 via N-methyl-D-aspartate receptor-mediated Akt1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-SURVIVAL; NMDA RECEPTOR; C-JUN; SIGNAL-TRANSDUCTION; KINASE ACTIVATION; CEREBRAL-ISCHEMIA; NEURONAL DAMAGE; MIXED LINEAGE; MAP KINASE; RAT	Our previous studies have demonstrated that the JNK signaling pathway plays an important role in ischemic brain injury and is mediated via glutamate receptor 6. Others studies have shown that N-methyl-D-aspartate (NMDA) receptor is involved in the neuroprotection of ischemic preconditioning. Here we examined whether ischemic preconditioning down-regulates activation of the mixed lineage kinase-JNK signaling pathway via NMDA receptor-mediated Akt1 activation. In our present results, ischemic preconditioning could not only inhibit activations of mixed lineage kinase 3, JNK1/2, and c-Jun but also enhanced activation of Akt1. In addition, both NMDA (an agonist of NMDA receptor) and preconditioning showed neuroprotective effects. In contrast, ketamine, an antagonist of NMDA receptor, prevented the above effects of preconditioning. Further studies indicated that LY294002, an inhibitor of phosphoinositide 3-kinase that is an upstream signaling protein of Akt1, could block neuroprotection of preconditioning, and KN62, an inhibitor of calmodulin-dependent protein kinase, also achieved the same effects as LY294002. Therefore, both phosphoinositide 3-kinase and calmodulin-dependent protein kinase are involved in the activation of Akt1 in ischemic tolerance. Taken together, our results indicate that preconditioning can inhibit activation of JNK signaling pathway via NMDA receptor-mediated Akt1 activation and induce neuroprotection in hippocampal CA1 region.	Xuzhou Med Coll, Res Ctr Biochem & Mol Biol, Xuzhou 221002, Jiangsu, Peoples R China	Xuzhou Medical University	Zhang, GY (corresponding author), Xuzhou Med Coll, Res Ctr Biochem & Mol Biol, 84 W Huai Hai Rd, Xuzhou 221002, Jiangsu, Peoples R China.	gyzhang@xzmc.edu.cn						Andersson O, 2001, GENOMICS, V78, P178, DOI 10.1006/geno.2001.6666; Azuma Y, 1996, NEUROCHEM INT, V29, P289, DOI 10.1016/0197-0186(95)00157-3; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bond A, 1999, EUR J PHARMACOL, V380, P91, DOI 10.1016/S0014-2999(99)00523-3; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chatterton JE, 2002, NATURE, V415, P793, DOI 10.1038/nature715; CHUANG DM, 1992, MOL PHARMACOL, V42, P210; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DEL PL, 1997, SCIENCE, V278, P687; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; Grabb MC, 1999, J NEUROSCI, V19, P1657; Gu ZL, 2001, NEUROREPORT, V12, P897, DOI 10.1097/00001756-200104170-00006; Hisatsune C, 1999, GENES CELLS, V4, P657, DOI 10.1046/j.1365-2443.1999.00287.x; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KATO H, 1992, NEUROSCI LETT, V139, P118, DOI 10.1016/0304-3940(92)90871-4; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laube B, 1998, J NEUROSCI, V18, P2954; LIU Y, 1992, BRAIN RES, V586, P121, DOI 10.1016/0006-8993(92)91380-W; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Ogita K, 2003, J NEUROCHEM, V85, P1336, DOI 10.1046/j.1471-4159.2003.01778.x; Pei DS, 2004, NEUROSCI LETT, V367, P71, DOI 10.1016/j.neulet.2004.05.082; Perkinton MS, 2002, J NEUROCHEM, V80, P239, DOI 10.1046/j.0022-3042.2001.00699.x; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; SCHRAMM M, 1990, P NATL ACAD SCI USA, V87, P1193, DOI 10.1073/pnas.87.3.1193; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SMITH ML, 1984, ACTA NEUROL SCAND, V69, P385, DOI 10.1111/j.1600-0404.1984.tb07822.x; Takagi N, 2003, J NEUROCHEM, V84, P67, DOI 10.1046/j.1471-4159.2003.01500.x; Tian H, 2003, NEUROSCI RES, V47, P47, DOI 10.1016/S0168-0102(03)00186-X; Tian H, 2003, NEUROSCI RES, V46, P191, DOI 10.1016/S0168-0102(03)00057-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Watson A, 1998, J NEUROSCI, V18, P751; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004	44	67	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21693	21699		10.1074/jbc.M500003200	http://dx.doi.org/10.1074/jbc.M500003200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15797868	hybrid			2022-12-25	WOS:000229557900003
J	Zhang, Q; Szalay, AA; Tieche, JM; Kyeyune-Nyombi, E; Sands, JF; Oberg, KC; Leonora, J				Zhang, Q; Szalay, AA; Tieche, JM; Kyeyune-Nyombi, E; Sands, JF; Oberg, KC; Leonora, J			Cloning and functional study of porcine parotid hormone, a novel proline-rich protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTINAL FLUID TRANSPORT; INTRADENTINAL DYE PENETRATION; SALIVARY PROTEINS; DENTAL-CARIES; ZINC-DEFICIENCY; RAT MOLARS; IN-VITRO; GLANDS; SECRETION; SEQUENCE	A parotid gland hormone that stimulates intradentinal fluid movement is believed to play a significant role in maintaining the vitality of dentin. This hormone has been purified from porcine parotid glands and partially sequenced in our previous study (Tieche, J. M., Leonora, J., and Steinman, R. R. (1980) Endocrinology 106, 1994-2005). We now report the cloning and functional study of porcine cDNAs that code for this hormone and its complete amino acid sequence. Three cDNA clones were isolated from a porcine parotid cDNA library. The last 30 amino acids encoded by two of the cDNAs agreed with the amino acid sequence of the isolated parotid hormone. In situ hybridization and immunohistochemical staining demonstrated that the acinar cells of the parotid glands were the primary location for both the parotid hormone-related mRNAs and the translation products. A 216-bp fragment of the cDNA that contains the coding sequence for the porcine hormone was subcloned into an expression vector, and the protein expression was detected by immunoblot analysis and quantified by enzyme-linked immunosorbent assay. In addition, the 30-amino acid parotid hormone was synthesized. Both the expressed and the synthetic proteins were biologically active in that they enhanced intradentinal fluid movement as measured by intradentinal dye penetration.	Loma Linda Univ, Sch Med, Dept Biochem, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Human Anat & Pathol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Internal Med, Loma Linda, CA 92350 USA	Loma Linda University; Loma Linda University; Loma Linda University; Loma Linda University	Leonora, J (corresponding author), Loma Linda Univ, Sch Med, Dept Biochem, Loma Linda, CA 92350 USA.	jleonora@som.llu.edu		Oberg, Kerby/0000-0002-1241-4273				ALBRECHT U, 1996, MOL CELLULAR METHODS; ALVARES O, 1981, J ORAL PATHOL MED, V10, P430, DOI 10.1111/j.1600-0714.1981.tb01294.x; AZEN E, 1984, P NATL ACAD SCI-BIOL, V81, P5561, DOI 10.1073/pnas.81.17.5561; BENNICK A, 1982, MOL CELL BIOCHEM, V45, P83; Bennick A, 2002, CRIT REV ORAL BIOL M, V13, P184, DOI 10.1177/154411130201300208; CLEMENTS S, 1985, J BIOL CHEM, V260, P3471; FANG MM, 1980, J NUTR, V110, P1032, DOI 10.1093/jn/110.5.1032; FERREIRA FD, 1992, J HISTOCHEM CYTOCHEM, V40, P1393, DOI 10.1177/40.9.1380529; GERZINA TM, 1995, J DENT RES, V74, P369, DOI 10.1177/00220345950740011301; GU M, 1995, ORAL MICROBIOL IMMUN, V10, P54, DOI 10.1111/j.1399-302X.1995.tb00118.x; HAY DI, 1973, ARCH ORAL BIOL, V18, P1517, DOI 10.1016/0003-9969(73)90127-1; Huumonen S, 1998, ACTA ODONTOL SCAND, V56, P276, DOI 10.1080/000163598428446; JAMIESON JD, 1988, CELL TISSUE BIOL TXB, P728; JOHNSON DA, 1988, J DENT RES, V67, P812, DOI 10.1177/00220345880670050301; JOHNSON DA, 1987, J DENT RES, V66, P1563, DOI 10.1177/00220345870660101001; Kagami H, 1996, HUM GENE THER, V7, P2177, DOI 10.1089/hum.1996.7.17-2177; KATCHBURIAN K, 1968, DENTIN PULP THEIR ST, P43; KAUFFMAN DL, 1991, BIOCHEMISTRY-US, V30, P3351, DOI 10.1021/bi00228a001; LEONORA J, 1987, AM J PHYSIOL, V252, pE477, DOI 10.1152/ajpendo.1987.252.4.E477; LEONORA J, 1993, ARCH ORAL BIOL, V38, P763, DOI 10.1016/0003-9969(93)90072-T; Leonora J, 2002, J DENT RES, V81, P259, DOI 10.1177/154405910208100407; LEONORA J, 1993, ARCH ORAL BIOL, V38, P911, DOI 10.1016/0003-9969(93)90101-Q; Leonora J, 2002, ARCH ORAL BIOL, V47, P147, DOI 10.1016/S0003-9969(01)00104-2; LEONORA J, 1988, DIABETES, V37, P441, DOI 10.2337/diabetes.37.4.441; LEONORA J, 1992, ARCH ORAL BIOL, V37, P733, DOI 10.1016/0003-9969(92)90080-R; LYONS KM, 1988, GENETICS, V120, P267; MAEDA N, 1985, J BIOL CHEM, V260, P1123; MAEDA N, 1985, BIOCHEM GENET, V23, P455, DOI 10.1007/BF00499086; MATTHEWS B, 1994, ARCH ORAL BIOL, V39, P87; MUENZER J, 1979, J BIOL CHEM, V254, P5629; Pashley D H, 1992, Proc Finn Dent Soc, V88 Suppl 1, P31; PASHLEY DH, 1993, ARCH ORAL BIOL, V38, P577, DOI 10.1016/0003-9969(93)90122-3; PASHLEY DH, 1994, ARCH ORAL BIOL, V39, pS73, DOI 10.1016/0003-9969(94)90191-0; Robinovitch MR, 2001, ORAL DIS, V7, P86, DOI 10.1034/j.1601-0825.2001.0070204.x; ROBINSON R, 1989, BIOCHEM J, V263, P497, DOI 10.1042/bj2630497; SCHNEIDER L C, 1975, Pharmacology and Therapeutics in Dentistry, V2, P43; Stahl LE, 1996, J CELL SCI, V109, P1637; STEINMAN RR, 1980, J DENT RES, V59, P176, DOI 10.1177/00220345800590021801; STEINMAN RR, 1975, J DENT RES, V54, P570, DOI 10.1177/00220345750540032801; TIECHE JM, 1981, BIOCHEM BIOPH RES CO, V98, P154, DOI 10.1016/0006-291X(81)91882-9; TIECHE JM, 1980, ENDOCRINOLOGY, V106, P1994, DOI 10.1210/endo-106-6-1994; TIECHE JM, 1995, ARCH ORAL BIOL, V40, P559, DOI 10.1016/0003-9969(95)00003-8; Wang C, 1997, IMMUNOPHARMACOLOGY, V36, P221, DOI 10.1016/S0162-3109(97)00025-8; WEINSTOCK M, 1974, J CELL BIOL, V60, P92, DOI 10.1083/jcb.60.1.92; YAMAMOTO T, 1986, CHEM PHARM BULL, V34, P1203; YAMAMOTO T, 1986, CHEM PHARM BULL, V34, P3803; ZIEMER MA, 1984, J BIOL CHEM, V259, P475; ZIEMER MA, 1982, J BIOL CHEM, V257, P1176	48	3	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22233	22244		10.1074/jbc.M501366200	http://dx.doi.org/10.1074/jbc.M501366200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15805110	hybrid			2022-12-25	WOS:000229557900069
J	Agassandian, M; Zhou, JM; Tephly, LA; Ryan, AJ; Carter, AB; Mallampalli, RK				Agassandian, M; Zhou, JM; Tephly, LA; Ryan, AJ; Carter, AB; Mallampalli, RK			Oxysterols inhibit phosphatidylcholine synthesis via ERK docking and phosphorylation of CTP : phosphocholine cytidylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BINDING DOMAIN; RAT-LIVER CTP; PROTEIN-KINASE; CTPPHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHOLIPID-SYNTHESIS; SPATIOTEMPORAL CONTROL; ACTIVATION; IDENTIFICATION; ALPHA; SITE	Surfactant deficiency contributes to acute lung injury and may result from the elaboration of bioactive lipids such as oxysterols. We observed that the oxysterol 22-hydroxycholesterol (22-HC) in combination with its obligate partner, 9-cis-retinoic acid (9-cis-RA), decreased surfactant phosphatidylcholine (PtdCho) synthesis by increasing phosphorylation of the regulatory enzyme CTP:phosphocholine cytidylyltransferase-alpha (CCT alpha). Phosphorylation of CCT alpha decreased its activity. 22-HC/9-cis-RA inhibition of PtdCho synthesis was blocked by PD98059 or dominant-negative ERK (p42 kinase). Overexpression of constitutively active MEK1, the kinase upstream of p42 kinase, increased CCT alpha phosphorylation. Expression of truncated CCT alpha mutants lacking proline-directed sites within the C-terminal phosphorylation domain partially blocked oxysterol-mediated inhibition of PtdCho synthesis. Mutagenesis of Ser(315) within CCT alpha was both required and sufficient to confer significant resistance to 22-HC/9-cis-RA inhibition of PtdCho synthesis. A novel putative ERK-docking domain N-terminal to this phosphoacceptor site was mapped within the CCT alpha membrane-binding domain (residues 287-300). The results are the first demonstration of a physiologically relevant phosphorylation site and docking domain within CCT alpha that serve as targets for ERKs, resulting in inhibition of surfactant synthesis.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Vet Affairs, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; University of Iowa	Mallampalli, RK (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, Div Pulm & Crit Care, C-33K,GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	rama-mallampalli@uiowa.edu	RYAN, Anderson/ACG-0319-2022	RYAN, Anderson/0000-0001-6241-7969	NHLBI NIH HHS [HL071040, HL068135, R01 HL055584, HL080229] Funding Source: Medline; BLRD VA [I01 BX001135] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068135, R01HL055584, R01HL071040, R01HL080229] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BLRD VA; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agassandian M, 2004, AM J RESP CELL MOL, V31, P227, DOI 10.1165/rcmb.2004-0038OC; Ares MPS, 2000, ATHEROSCLEROSIS, V153, P23, DOI 10.1016/S0021-9150(00)00380-4; Bakovic M, 2003, J BIOL CHEM, V278, P14753, DOI 10.1074/jbc.M300162200; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Bjorkhem I, 2002, CURR OPIN LIPIDOL, V13, P247, DOI 10.1097/00041433-200206000-00003; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonacchi A, 2001, J BIOL CHEM, V276, P9945, DOI 10.1074/jbc.M010303200; Carter KB, 2000, J BIOL CHEM, V275, P27858; CORNELL RB, 1995, BIOCHEM J, V310, P699, DOI 10.1042/bj3100699; CORNELL RB, 1983, BIOCHIM BIOPHYS ACTA, V750, P504, DOI 10.1016/0005-2760(83)90191-1; CRAIG L, 1994, J BIOL CHEM, V269, P3311; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; Edwards PA, 2002, VASC PHARMACOL, V38, P249, DOI 10.1016/S1537-1891(02)00175-1; EMMETT M, 1987, P SOC EXP BIOL MED, V184, P83; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; GILFILLAN AM, 1983, J LIPID RES, V24, P1651; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Halvorsen EM, 2002, BRAIN RES, V952, P98, DOI 10.1016/S0006-8993(02)03216-X; Heeley EL, 2000, AM J PHYSIOL-LUNG C, V278, pL305, DOI 10.1152/ajplung.2000.278.2.L305; HOUSLAY MD, BIOCH SOC T, V31, P1186; Hu XT, 2000, CELL GROWTH DIFFER, V11, P191; Ishihara K, 2003, FEBS LETT, V550, P107, DOI 10.1016/S0014-5793(03)00846-9; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Kim IS, 2003, LIFE SCI, V73, P447, DOI 10.1016/S0024-3205(03)00312-6; Kurzbauer R, 2004, P NATL ACAD SCI USA, V101, P10984, DOI 10.1073/pnas.0403435101; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; Meuillet EJ, 2004, ARCH BIOCHEM BIOPHYS, V429, P123, DOI 10.1016/j.abb.2004.04.020; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Pulfer MK, 2004, J BIOL CHEM, V279, P26331, DOI 10.1074/jbc.M403581200; Ridsdale R, 2001, J BIOL CHEM, V276, P49148, DOI 10.1074/jbc.M103566200; Rosner B., 2011, FUNDAMENTALS BIOSTAT; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Storey MK, 1997, J LIPID RES, V38, P711; Tseu I, 2002, AM J RESP CELL MOL, V26, P506, DOI 10.1165/ajrcmb.26.4.4702; Van Linden AA, 2000, J BIOL CHEM, V275, P6996, DOI 10.1074/jbc.275.10.6996; Volmat V, 2001, J CELL SCI, V114, P3433; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WANG YL, 1995, J BIOL CHEM, V270, P17843, DOI 10.1074/jbc.270.30.17843; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Wieprecht M, 1996, J BIOL CHEM, V271, P9955, DOI 10.1074/jbc.271.17.9955; WIEPRECHT M, 1994, FEBS LETT, V353, P221, DOI 10.1016/0014-5793(94)01040-4; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; Yu YM, 2003, NEUROREPORT, V14, P941, DOI 10.1097/01.wnr.0000074341.81633.b8; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023; Zhang LH, 2001, J BIOL CHEM, V276, P10476, DOI 10.1074/jbc.M008991200; Zhou JM, 2003, J BIOL CHEM, V278, P37032, DOI 10.1074/jbc.M304316200	59	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21577	21587		10.1074/jbc.M412409200	http://dx.doi.org/10.1074/jbc.M412409200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15788406	hybrid			2022-12-25	WOS:000229438800081
J	Bulut, Y; Michelsen, KS; Hayrapetian, L; Naiki, Y; Spallek, R; Singh, M; Arditi, M				Bulut, Y; Michelsen, KS; Hayrapetian, L; Naiki, Y; Spallek, R; Singh, M; Arditi, M			Mycobacterium tuberculosis heat shock proteins use diverse toll-like receptor pathways to activate pro-inflammatory signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DERMAL ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; BACTERIAL LIPOPOLYSACCHARIDE; MYD88-DEFICIENT MICE; MACROPHAGE RESPONSES; CELLULAR ACTIVATION; MURINE MACROPHAGES; ADAPTER MOLECULE; IMMUNE-RESPONSE	Although the Toll-like receptors used by Mycobacterium tuberculosis membrane and secreted factors are known, the pathways activated by M. tuberculosis heat shock proteins are not. An efficient immune response against the intracellular pathogen M. tuberculosis is critically dependent on rapid detection of the invading pathogen by the innate immune system and coordinated activation of the adaptive immune response. Macrophage phagocytosis of M. tuberculosis is accompanied by activation of the transcription factor NF-kappa B and secretion of inflammatory mediators that play an important role in granuloma formation and immune protection during M. tuberculosis infection. The interaction between M. tuberculosis and the various Toll-like receptors is complex, and it appears that distinct mycobacterial components may interact with different members of the Toll-like receptor family. Here we show that recombinant, purified, mycobacterial heat shock proteins 65 and 70 induce NF-kappa B activity in a dose-dependent manner in human endothelial cells. Furthermore, we show that whereas mycobacterial heat shock protein 65 signals exclusively through Toll-like receptor 4, heat shock protein 70 also signals through Toll-like receptor 2. Mycobacterial heat shock protein 65-induced NF-kappa B activation was MyD88-, TIRAP-, TRIF-, and TRAM-dependent and required the presence of MD-2. A better understanding of the recognition of mycobacterial heat shock proteins and their role in the host immune response to the pathogen may open the way to a better understanding of the immunological processes induced by this important human pathogen and the host-pathogen interactions and may help in the rational design of more effective vaccines or vaccine adjuvants.	Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Div Pediat Infect Dis, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Div Pediat Crit Care, Los Angeles, CA 90048 USA; Lionex Diagnost & Therapeut GmbH, D-38124 Braunschweig, Germany	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Lionex Diagnostics & Therapeutics GmbH	Arditi, M (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Div Pediat Infect Dis, 8700 Beverly Blvd,Rm 4221, Los Angeles, CA 90048 USA.	moshe.arditi@cshs.org	Bulut, Yonca/V-3290-2019		NHLBI NIH HHS [NHLB 66436] Funding Source: Medline; NIAID NIH HHS [AI 058128] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058128] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abel B, 2002, J IMMUNOL, V169, P3155, DOI 10.4049/jimmunol.169.6.3155; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Bendelac A, 2002, J EXP MED, V195, pF19, DOI 10.1084/jem.20020073; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Branger J, 2004, INT IMMUNOL, V16, P509, DOI 10.1093/intimm/dxh052; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Bulut Y, 2002, J IMMUNOL, V168, P1435, DOI 10.4049/jimmunol.168.3.1435; Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987; da Costa CP, 2002, EUR J IMMUNOL, V32, P2460, DOI 10.1002/1521-4141(200209)32:9<2460::AID-IMMU2460>3.0.CO;2-M; Drennan MB, 2004, AM J PATHOL, V164, P49, DOI 10.1016/S0002-9440(10)63095-7; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4; FRIEDLAND JS, 1993, CLIN EXP IMMUNOL, V91, P282, DOI 10.1111/j.1365-2249.1993.tb05896.x; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; Harmala LAE, 2002, J IMMUNOL, V169, P5622, DOI 10.4049/jimmunol.169.10.5622; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Kamath AB, 2003, INFECT IMMUN, V71, P4112, DOI 10.1128/IAI.71.7.4112-4118.2003; Kawasaki K, 2003, J IMMUNOL, V170, P413, DOI 10.4049/jimmunol.170.1.413; KIESSLING R, 1991, IMMUNOL REV, V121, P91, DOI 10.1111/j.1600-065X.1991.tb00824.x; Lewthwaite JC, 2001, INFECT IMMUN, V69, P7349, DOI 10.1128/IAI.69.12.7349-7355.2001; Means TK, 1999, J IMMUNOL, V163, P3920; Means TK, 2001, J IMMUNOL, V166, P4074, DOI 10.4049/jimmunol.166.6.4074; MORENO C, 1989, CLIN EXP IMMUNOL, V76, P240; Noss EH, 2001, J IMMUNOL, V167, P910, DOI 10.4049/jimmunol.167.2.910; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Reiling N, 2002, J IMMUNOL, V169, P3480, DOI 10.4049/jimmunol.169.7.3480; Sasu S, 2001, CIRC RES, V89, P244, DOI 10.1161/hh1501.094184; Scanga CA, 2004, INFECT IMMUN, V72, P2400, DOI 10.1128/IAI.72.4.2400-2404.2004; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shim TS, 2003, TUBERCULOSIS, V83, P367, DOI 10.1016/S1472-9792(03)00071-4; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; Stenger S, 2002, CURR OPIN IMMUNOL, V14, P452, DOI 10.1016/S0952-7915(02)00355-2; Sugawara I, 2003, MICROBIOL IMMUNOL, V47, P841, DOI 10.1111/j.1348-0421.2003.tb03450.x; Sugawara I, 2003, MICROBIOL IMMUNOL, V47, P327, DOI 10.1111/j.1348-0421.2003.tb03404.x; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; van Crevel R, 2002, CLIN MICROBIOL REV, V15, P294, DOI 10.1128/CMR.15.2.294-309.2002; Wang YF, 2001, IMMUNITY, V15, P971, DOI 10.1016/S1074-7613(01)00242-4; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; YOUNG DB, 1992, MOL MICROBIOL, V6, P133, DOI 10.1111/j.1365-2958.1992.tb01994.x; YOUNG DB, 1991, INFECT IMMUN, V59, P3086, DOI 10.1128/IAI.59.9.3086-3093.1991; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611; Zugel U, 1999, IMMUNOBIOLOGY, V201, P22	56	176	190	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20961	20967		10.1074/jbc.M411379200	http://dx.doi.org/10.1074/jbc.M411379200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15809303	hybrid			2022-12-25	WOS:000229438800009
J	Mere, J; Morlon-Guyot, J; Bonhoure, A; Chiche, L; Beaumelle, B				Mere, J; Morlon-Guyot, J; Bonhoure, A; Chiche, L; Beaumelle, B			Acid-triggered membrane insertion of Pseudomonas exotoxin A involves an original mechanism based on pH-regulated tryptophan exposure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-II; PROTEIN; TRANSLOCATION; AERUGINOSA; SITE; IDENTIFICATION; CYTOTOXICITY; IMMUNOTOXINS; INVOLVEMENT; SECRETION	Exposure to low endosomal pH during internalization of Pseudomonas exotoxin A (PE) triggers membrane insertion of its translocation domain. This process is a prerequisite for PE translocation to the cytosol where it inactivates protein synthesis. Although hydrophobic helices enable membrane insertion of related bacterial toxins such as diphtheria toxin, the PE translocation domain is devoid of hydrophobic stretches and the structural features triggering acid-induced membrane insertion of PE are not known. Here we have identified a molecular device that enables PE membrane insertion. This process is promoted by exposure of a key tryptophan residue. At neutral pH, this Trp is buried in a hydrophobic pocket closed by the smallest alpha-helix of the translocation domain. Upon acidification, protonation of the Asp that is the N-cap residue of the helix leads to its destabilization, enabling Trp side chain insertion into the endosome membrane. This tryptophan-based membrane insertion system is surprisingly similar to the membrane-anchoring mechanism of human annexin-V and could be used by other proteins as well.	Univ Montpellier 2, Dept Biol Sante, CNRS, UMR 5539, F-34095 Montpellier, France; Fac Pharm Montpellier, Ctr Biochim Struct, INSERM U554, CNRS UMR 5048, F-34093 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Beaumelle, B (corresponding author), Univ Montpellier 2, Dept Biol Sante, CNRS, UMR 5539, Case 107, F-34095 Montpellier, France.	beaumel@univ-montp2.fr		Beaumelle, Bruno/0000-0002-4912-9134; Bonhoure, Anne/0000-0002-4664-2848				Alami M, 1998, MOL BIOL CELL, V9, P387, DOI 10.1091/mbc.9.2.387; ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Campos B, 1998, BIOCHEMISTRY-US, V37, P8004, DOI 10.1021/bi973142n; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; Chiron MF, 1996, MOL MICROBIOL, V22, P769, DOI 10.1046/j.1365-2958.1996.d01-1721.x; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Eppens EF, 1997, EMBO J, V16, P4295, DOI 10.1093/emboj/16.14.4295; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Hessler JL, 1997, BIOCHEMISTRY-US, V36, P14577, DOI 10.1021/bi971447w; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JIANG JX, 1990, J BIOL CHEM, V265, P8636; JINNO Y, 1989, J BIOL CHEM, V264, P15953; KASTURI S, 1992, J BIOL CHEM, V267, P23427; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; Kreitman RJ, 1999, CURR OPIN IMMUNOL, V11, P570, DOI 10.1016/S0952-7915(99)00005-9; Lacy DB, 1999, J MOL BIOL, V291, P1091, DOI 10.1006/jmbi.1999.2945; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Morlon-Guyot J, 2003, J BIOL CHEM, V278, P17006, DOI 10.1074/jbc.M209516200; MUFOZ V, 1994, NAT STRUCT BIOL, V1, P399; Musse AA, 2003, J BIOL CHEM, V278, P24491, DOI 10.1074/jbc.M302371200; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; RASPER DM, 1994, BIOCHEMISTRY-US, V33, P12981, DOI 10.1021/bi00248a006; Reiter Y, 1998, TRENDS BIOTECHNOL, V16, P513, DOI 10.1016/S0167-7799(98)01226-8; Ren JH, 1999, BIOCHEMISTRY-US, V38, P976, DOI 10.1021/bi981576s; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Santos JSD, 2000, BIOCHEMISTRY-US, V39, P14065, DOI 10.1021/bi000659h; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; Taupiac MP, 1999, MOL MICROBIOL, V31, P1385, DOI 10.1046/j.1365-2958.1999.01280.x; Vendeville A, 2004, MOL BIOL CELL, V15, P2347, DOI 10.1091/mbc.E03-12-0921; Voulhoux R, 2000, J BACTERIOL, V182, P4051, DOI 10.1128/JB.182.14.4051-4058.2000; Wedekind JE, 2001, J MOL BIOL, V314, P823, DOI 10.1006/jmbi.2001.5195; YOULE RJ, 1982, J BIOL CHEM, V257, P1598; ZDANOVSKY AG, 1993, J BIOL CHEM, V268, P21791	39	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21194	21201		10.1074/jbc.M412656200	http://dx.doi.org/10.1074/jbc.M412656200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799975	Green Published, hybrid			2022-12-25	WOS:000229438800037
J	Fabre-Lafay, S; Garrido-Urbani, S; Reymond, N; Goncalves, A; Dubreuil, P; Lopez, M				Fabre-Lafay, S; Garrido-Urbani, S; Reymond, N; Goncalves, A; Dubreuil, P; Lopez, M			Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; FACTOR-RECEPTOR; TISSUE INHIBITOR; V-DOMAIN; TACE; POLIOVIRUS; CLEAVAGE; FAMILY; MEMBER; GENE	Serum markers are extensively used in diagnostic and follow-up of cancer patients. We recently described Nectin-4, a 66-kDa adhesion molecule of the Nectin family, which is a valuable new histological and serological marker for breast carcinoma. In vivo, Nectin-4 is re-expressed in breast carcinoma, and a circulating form of Nectin-4 is detected in the sera of patients with metastatic breast cancer. In vitro, a soluble form of Nectin-4 is produced in the supernatant of breast tumor cell lines (S. Fabre-Lafay, C. Ginestier, S. Garrido-Urbani, C. Berruyer, R. Sauvan, N. Reymond, J. Adelaide, J. Geneix, P. Dubreuil, J. Jacquemier, D. Birnbaum, and M. Lopez, manuscript in preparation). We have investigated the mechanisms that regulate the production of this soluble form. It was found that the soluble form of Nectin-4 detected in the sera of patients and the supernatant of breast tumor cell lines share similar biochemical and immunological features. The soluble Nectin-4 form (43 kDa) is formed by the entire Nectin-4 ectodomain. Nectin-4 shedding is constitutive, strongly enhanced by 12-O-tetradecanoylphorbol-13-acetate activation, and reduced tumor necrosis factor-alpha protease inhibitor TAPI-1 or by the tissue inhibitor of metalloproteinase-3 (TIMP-3). TAPI-1 and TIMP-3 are inhibitors of the endoprotease tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. Overexpression or small interfering RNA-mediated silencing of TACE enhanced or reduced Nectin-4 shedding, respectively. Nectin-4 is not shed when expressed in TACE-deficient fibroblasts. Interestingly, the active form of TACE is overexpressed in breast tumors and may indicate that TACE is responsible for Nectin-4 shedding not only in vitro but also in vivo.	Canc & Immunol Marseille, INSERM, Inst Canc, UMR 599, F-13009 Marseille, France; Canc & Immunol Marseille, Mol Pharmacol Lab, IFR 137, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Lopez, M (corresponding author), Canc & Immunol Marseille, INSERM, Inst Canc, UMR 599, 27 Bvd Lei Roure, F-13009 Marseille, France.	lopez@marseille.inserm.fr	dubreuil, patrice/F-5346-2011; Dubreuil, Patrice/V-4816-2019	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150				Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Bachman KE, 1999, CANCER RES, V59, P798; Balduyck M, 2000, CLIN EXP METASTAS, V18, P171, DOI 10.1023/A:1006762425323; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2003, BIOCHEM SOC SYMP, V70, P39, DOI 10.1042/bss0700039; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BYRNE JA, 1995, MOL MED, V1, P418, DOI 10.1007/BF03401579; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Contin C, 2003, J BIOL CHEM, V278, P32801, DOI 10.1074/jbc.M209993200; Cruz AC, 2004, J BIOL CHEM, V279, P5612, DOI 10.1074/jbc.M312323200; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Fabre S, 2002, J BIOL CHEM, V277, P27006, DOI 10.1074/jbc.M203228200; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Fuchs A, 2004, J IMMUNOL, V172, P3994, DOI 10.4049/jimmunol.172.7.3994; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Hinkle CL, 2004, J BIOL CHEM, V279, P24179, DOI 10.1074/jbc.M312141200; Hung CY, 2002, INFECT IMMUN, V70, P3443, DOI 10.1128/IAI.70.7.3443-3456.2002; Itai T, 2001, EUR J BIOCHEM, V268, P2074, DOI 10.1046/j.1432-1327.2001.02085.x; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Lopez M, 2001, J VIROL, V75, P5684, DOI 10.1128/JVI.75.12.5684-5691.2001; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Monvoisin A, 2002, INT J CANCER, V97, P157, DOI 10.1002/ijc.1595; Nawrocki-Raby B, 2003, INT J CANCER, V105, P790, DOI 10.1002/ijc.11168; Nuttall RK, 2003, MOL CANCER RES, V1, P333; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Reymond N, 2000, GENE, V255, P347, DOI 10.1016/S0378-1119(00)00316-4; Reymond N, 2004, J EXP MED, V199, P1331, DOI 10.1084/jem.20032206; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Schantl JA, 2004, BIOCHEM J, V377, P379, DOI 10.1042/BJ20031321; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Tanaka Y, 2002, BIOCHEM BIOPH RES CO, V299, P472, DOI 10.1016/S0006-291X(02)02681-5; Thathiah A, 2003, J BIOL CHEM, V278, P3386, DOI 10.1074/jbc.M208326200; Vincent B, 2001, J BIOL CHEM, V276, P37743; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200	45	122	133	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19543	19550		10.1074/jbc.M410943200	http://dx.doi.org/10.1074/jbc.M410943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15784625	hybrid			2022-12-25	WOS:000229113700016
J	Cuzzocrea, S; Di Paola, R; Mazzon, E; Cortes, U; Genovese, T; Muia, C; Li, WX; Xu, WZ; Li, JH; Zhang, J; Wang, ZQ				Cuzzocrea, S; Di Paola, R; Mazzon, E; Cortes, U; Genovese, T; Muia, C; Li, WX; Xu, WZ; Li, JH; Zhang, J; Wang, ZQ			PARG activity mediates intestinal injury induced by splanchnic artery occlusion and reperfusion	FASEB JOURNAL			English	Article						SAO shock; ischemia and reperfusion; PARG inhibitor; neutrophil infiltration; organ injury	ADP-RIBOSE SYNTHETASE; POLY(ADP-RIBOSE) GLYCOHYDROLASE; RAT MODEL; INHIBITOR; POLYMERASE; ISCHEMIA; INFLAMMATION; SHOCK	Poly (ADP-ribosyl)ation, an early post-translational modification in response to DNA damage, is catalyzed by poly (ADP-ribose) polymerase (PARP-1) and catabolized by poly(ADP-ribose) glycohydrolase (PARG). The aim of this study was to investigate the role of PARG on the modulation of the inflammatory response caused by splanchnic ischemia and reperfusion. SAO shock in rats and wild-type (WT) mice was associated with a significant neutrophil infiltration in the ileum and production of tumor necrosis factor-alpha (TNF-alpha). Reperfused ileum tissue sections from SAO-shocked WT mice and rats showed positive staining for P-selectin and ICAM-1 localized mainly in the vascular endothelial cells. Genetic disruption of the PARG gene in mice or pharmacological inhibition of PARG by PARG inhibitors significantly improved the histological status of the reperfused tissues associated with reduced expression of P-selectin and ICAM-1, neutrophil infiltration into the reperfused intestine, and TNF-alpha production. These results suggest that PARG activity modulates the inflammatory response in ischemia/reperfusion and participates in end (target) organ damage under these conditions.	Torre Biol Policlin Univ, Dept Clin & Expt Med & Pharmacol, Messina, Italy; Int Agcy Res Canc, F-69372 Lyon, France; Guilford Pharmaceut Inc, Baltimore, MD USA; Lilium Pharmaceut, Cockeysville, MD USA	World Health Organization; International Agency for Research on Cancer (IARC)	Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Inst Pharmacol, Torre Biol Policlin Univ, Via C Valeria Gazzi, I-98100 Messina, Italy.	salvator@unime.it	di paola, rosanna/U-4356-2019; Mazzon, Emanuela/AAL-4334-2020	di paola, rosanna/0000-0001-6725-8581; GENOVESE, Tiziana/0000-0002-3335-7327; mazzon, emanuela/0000-0002-5073-717X				ALVAREZGONZALEZ R, 1995, BIOCHIMIE, V77, P403, DOI 10.1016/0300-9084(96)88153-3; AOKI K, 1995, BIOCHEM BIOPH RES CO, V210, P329, DOI 10.1006/bbrc.1995.1665; Bernardi R, 1997, BBA-PROTEIN STRUCT M, V1338, P60, DOI 10.1016/S0167-4838(96)00188-4; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; CAPUTI AP, 1980, J PHARMACOL EXP THER, V215, P309; Cortes U, 2004, MOL CELL BIOL, V24, P7163, DOI 10.1128/MCB.24.16.7163-7178.2004; Cuzzocrea S, 1999, J LEUKOCYTE BIOL, V66, P471, DOI 10.1002/jlb.66.3.471; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Di Paola R, 2004, EUR J PHARMACOL, V492, P203, DOI 10.1016/j.ejphar.2004.03.033; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Errando C L, 1994, Rev Esp Anestesiol Reanim, V41, P237; Genovese T, 2004, CRIT CARE MED, V32, P1365, DOI 10.1097/01.CCM.0000127775.70867.0C; Granger DN, 1997, AM J PHYSIOL-GASTR L, V273, pG982, DOI 10.1152/ajpgi.1997.273.5.G982; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; LEFER AM, 1993, ANNU REV PHARMACOL, V33, P71, DOI 10.1146/annurev.pa.33.040193.000443; LI J, 2000, Patent No. 00025787; Liaudet L, 2000, SHOCK, V14, P134, DOI 10.1097/00024382-200014020-00010; Lu XCM, 2003, BRAIN RES, V978, P99, DOI 10.1016/S0006-8993(03)02774-4; Maruta H, 1997, BIOCHEM BIOPH RES CO, V236, P265, DOI 10.1006/bbrc.1997.6910; Mazzon E, 2002, SHOCK, V17, P222, DOI 10.1097/00024382-200203000-00011; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Quesada P, 1996, EXP CELL RES, V226, P183, DOI 10.1006/excr.1996.0217; SLAMA JT, 1995, J MED CHEM, V38, P389, DOI 10.1021/jm00002a021; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; TANUMA S, 1991, ARCH BIOCHEM BIOPHYS, V284, P227, DOI 10.1016/0003-9861(91)90289-U; TANUMA S, 1989, BIOCHEM INT, V19, P1395; TAVASSOLI M, 1985, BIOCHIM BIOPHYS ACTA, V827, P228, DOI 10.1016/0167-4838(85)90207-9; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; WETHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Ying WH, 2000, NEUROREPORT, V11, P1385, DOI 10.1097/00001756-200005150-00007; Zhang J, 2002, DRUG FUTURE, V27, P371, DOI 10.1358/dof.2002.027.04.669101; ZIMMERMANN BJ, 1993, PATHOPHYSIOLOGY SHOC, P322	35	46	48	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					558	566		10.1096/fj.04-3117com	http://dx.doi.org/10.1096/fj.04-3117com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791006				2022-12-25	WOS:000228865300040
J	Mayerhofer, M; Aichberger, KJ; Florian, S; Krauth, MT; Hauswirth, AW; Derdak, S; Sperr, WR; Esterbauer, H; Wagner, O; Marosi, C; Pickl, WF; Deininger, M; Weisberg, E; Druker, BJ; Griffin, JD; Sillaber, C; Valent, P				Mayerhofer, M; Aichberger, KJ; Florian, S; Krauth, MT; Hauswirth, AW; Derdak, S; Sperr, WR; Esterbauer, H; Wagner, O; Marosi, C; Pickl, WF; Deininger, M; Weisberg, E; Druker, BJ; Griffin, JD; Sillaber, C; Valent, P			Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells	FASEB JOURNAL			English	Article						CML; Bcr-Abl; imatinib; vascular endothelial growth factor	CHRONIC MYELOGENOUS LEUKEMIA; ABL TYROSINE KINASE; INDUCED G(1) ARREST; BCR-ABL; IMATINIB MESYLATE; CYTOGENETIC RESPONSES; MAMMALIAN PROTEIN; RESIDUAL DISEASE; INTERFERON-ALPHA; CANCER-THERAPY	The mammalian target of rapamycin (mTOR) has recently been described to be constitutively activated in B cr-Abl-transformed cells and to mediate rapamycin-induced inhibition of growth in respective cell lines. We have recently shown that rapamycin down-regulates expression of vascular endothelial growth factor (VEGF), a mediator of leukemia-associated angiogenesis, in primary CML cells. In the present study, we analyzed growth-inhibitory in vitro and in vivo effects of rapamycin on primary CML cells and asked whether rapamycin-induced suppression of VEGF in leukemic cells is related to growth inhibition. Rapamycin dose dependently inhibited growth of primary CML cells obtained from patients with imatinib-responsive or imatinib-resistant disease as well as growth of B cr-Abl-transformed imatinib-resistant cell lines. Moreover, we observed potent cytoreductive effects of rapamycin in a patient with imatinib-resistant Bcr-Abl+ leukemia. The growth-inhibitory effects of rapamycin on CML cells were found to be associated with G1 cell cycle arrest and with induction of apoptosis. In all cell types tested, rapamycin was found to down-regulate expression of VEGF. However, exogenously added VEGF did not counteract the rapamycin-induced decrease in proliferation. In conclusion, rapamycin inhibits growth of CML cells in vitro and in vivo and, in addition, down-regulates expression of VEGF. Both effects may contribute to the antileukernic activity of the drug in CML.	Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1097 Vienna, Austria; Med Univ Vienna, Inst Immunol, A-1097 Vienna, Austria; Med Univ Vienna, Clin Inst Med & Chem Lab Diagnost, A-1097 Vienna, Austria; Med Univ Vienna, Dept Internal Med 1, Div Oncol, A-1097 Vienna, Austria; Oregon Hlth Sci Univ, Inst Canc, Ctr hematol Malignancies, Portland, OR 97201 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Howard Hughes Med Inst, Portland, OR USA	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Oregon Health & Science University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	Mayerhofer, M (corresponding author), Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18-20, A-1097 Vienna, Austria.	matthias.mayerhofer@univie.ac.at	Test, Test/Y-7921-2019; Test, PV/U-9451-2019; Pickl, Winfried F/E-5682-2011; Sperr, Mast/V-4767-2019; Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019	Sperr, Mast/0000-0002-7778-5219; Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Druker, Brian/0000-0001-8331-8206; Pickl, Winfried F./0000-0003-0430-4952; Sperr, Wolfgang/0000-0003-3288-8027; Esterbauer, Harald/0000-0001-7343-7455				Avramis IA, 2003, CANCER CHEMOTH PHARM, V52, P307, DOI 10.1007/s00280-003-0668-y; Bellamy WT, 1999, CANCER RES, V59, P728; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Corbin AS, 2003, BLOOD, V101, P4611, DOI 10.1182/blood-2002-12-3659; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Ebos JML, 2002, MOL CANCER RES, V1, P89; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; GAMBACORTIPASSERIN, 2003, LANCET ONCOL, V4, P75; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Goldman J, 2005, CURR OPIN HEMATOL, V12, P33, DOI 10.1097/01.moh.0000148551.93303.9e; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741; Hochhaus A, 2001, SCIENCE, V293, P2163; Hoover RR, 2002, BLOOD, V100, P1068, DOI 10.1182/blood.V100.3.1068; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Hosoi H, 1999, CANCER RES, V59, P886; Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295; Huang SL, 2001, CANCER RES, V61, P3373; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513; JANOWSKAWIECZOREK, 2002, LEUKEMIA, V16, P1160; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kawamata S, 1998, BLOOD, V91, P561, DOI 10.1182/blood.V91.2.561.561_561_569; Kohmura K, 2004, J CELL PHYSIOL, V198, P370, DOI 10.1002/jcp.10426; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; Krystal GW, 2001, DRUG RESIST UPDATE, V4, P16, DOI 10.1054/drup.2000.0176; Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood-2003-01-0305; Legros L, 2004, BLOOD, V104, P495, DOI 10.1182/blood-2003-08-2695; LIVAK KJ, 1995, PCR METH APPL, V4, P357; LUKE H, 2003, BLOOD, V102, pA72; Ly C, 2003, CANCER RES, V63, P5716; Marley SB, 2002, BRIT J HAEMATOL, V116, P162, DOI 10.1046/j.1365-2141.2002.03237.x; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Metcalfe SM, 1997, ONCOGENE, V15, P1635, DOI 10.1038/sj.onc.1201341; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Nardi V, 2004, CURR OPIN HEMATOL, V11, P35, DOI 10.1097/00062752-200401000-00006; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nimmanapalli R, 2002, CURR OPIN ONCOL, V14, P616, DOI 10.1097/00001622-200211000-00005; NOWELL PC, 1960, SCIENCE, V132, P1497; O'Brien S, 2003, CANCER, V98, P888, DOI 10.1002/cncr.11620; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Seufferlein T, 1996, CANCER RES, V56, P3895; SHI YF, 1995, CANCER RES, V55, P1982; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; Verstovsek S, 2003, LEUKEMIA RES, V27, P661, DOI 10.1016/S0145-2126(02)00275-8; von Bubnoff N, 2003, LEUKEMIA, V17, P829, DOI 10.1038/sj.leu.2402889; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Yu CR, 2003, CANCER RES, V63, P2118	63	53	55	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					960	+		10.1096/fj.04-1973fje	http://dx.doi.org/10.1096/fj.04-1973fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15784722				2022-12-25	WOS:000227901300007
J	Scott, M; Hyland, PL; McGregor, G; Hillan, KJ; Russell, SEH; Hall, PA				Scott, M; Hyland, PL; McGregor, G; Hillan, KJ; Russell, SEH; Hall, PA			Multimodality expression profiling shows SEPT9 to be overexpressed in a wide range of human tumours	ONCOGENE			English	Article						septin; SEPT9; microarray; expression profile; neoplasia; RT-PCR; antibody	PUTATIVE PROTOONCOGENE; CELL-PROLIFERATION; OVARIAN-TUMORS; GENE; CANCER; MSF; GTPASES; REGION; FUSION; BREAST	Septins are an evolutionarily conserved family of GTPases with diverse functions including roles in cytokinesis that have been implicated in neoplasia. To address the potential role of SEPT9 in tumorigenesis, we assessed the expression of SEPT9 in 7287 fresh frozen human tissue samples and 292 human cell lines by microarray analysis. In addition, we used a sensitive RT-PCR strategy to de. ne the expression of SEPT9 isoforms in archival formalin-fixed and paraffin-embedded normal human tissues. The mRNA data were further concerned by immunohistological analyses of SEPT9 protein expression in normal human tissues using antisera that detect SEPT9 isoforms. Using these complementary approaches, we demonstrate that SEPT9 mRNA and protein are expressed ubiquitously, with the isoforms showing tissue-specific expression. The microarray analysis indicates that there is consistent overexpression of SEPT9 in diverse human tumours including breast, CNS, endometrium, kidney, liver, lung, lymphoid, oesophagus, ovary, pancreas, skin, soft tissue and thyroid. Since tumours are commonly associated with enhanced cell proliferation, we examined the possible correlation of Ki67 and SEPT9 express ion in normal tissues and tumours. Our data indicate that the overexpression of SEPT9 in neoplasia is not simply a proliferation-associated phenomenon, despite its role in cytokinesis.	Queens Univ Belfast, Belfast City Hosp, Ctr Canc Res & Cell Biol, Belfast BT9 7AB, Antrim, North Ireland; Genentech Inc, San Francisco, CA 94080 USA	Belfast City Hospital; Queens University Belfast; Roche Holding; Genentech	Hall, PA (corresponding author), Queens Univ Belfast, Belfast City Hosp, Ctr Canc Res & Cell Biol, Univ Floor,Tower Block, Belfast BT9 7AB, Antrim, North Ireland.	peter.hall@qub.ac.uk						Burrows JF, 2003, J PATHOL, V201, P581, DOI 10.1002/path.1484; Faty M, 2002, CURR GENET, V41, P123, DOI 10.1007/s00294-002-0304-0; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; HALL PA, 1990, J CLIN PATHOL, V43, P184, DOI 10.1136/jcp.43.3.184; HALL PA, 2004, J PATHOL, V204, P189; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Kartmann B, 2001, J CELL SCI, V114, P839; KREMER BE, 2003, MOL BIOL CELL, V14, pA447; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Martinez C, 2004, BIOCHEM J, V382, P783, DOI 10.1042/BJ20040372; MCCORMICK D, 1993, HISTOPATHOLOGY, V22, P543, DOI 10.1111/j.1365-2559.1993.tb00174.x; McIlhatton MA, 2001, ONCOGENE, V20, P5930, DOI 10.1038/sj.onc.1204752; Montagna C, 2003, CANCER RES, V63, P2179; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Peng XR, 2002, MOL CELL BIOL, V22, P378, DOI 10.1128/MCB.22.1.378-387.2002; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; Robertson C, 2004, J PATHOL, V203, P519, DOI 10.1002/path.1551; Russell SEH, 2000, CANCER RES, V60, P4729; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sorensen AB, 2000, J VIROL, V74, P2161, DOI 10.1128/JVI.74.5.2161-2168.2000; Sorensen AB, 2002, GENE, V285, P79, DOI 10.1016/S0378-1119(02)00406-7; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030	22	73	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4688	4700		10.1038/sj.onc.1208574	http://dx.doi.org/10.1038/sj.onc.1208574			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15782116				2022-12-25	WOS:000230304500007
J	David, DC; Hauptmann, S; Scherping, I; Schuessel, K; Keil, U; Rizzu, P; Ravid, R; Drose, S; Brandt, U; Muller, WE; Eckert, A; Gotz, J				David, DC; Hauptmann, S; Scherping, I; Schuessel, K; Keil, U; Rizzu, P; Ravid, R; Drose, S; Brandt, U; Muller, WE; Eckert, A; Gotz, J			Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L Tau transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; CEREBRAL GLUCOSE-METABOLISM; ANTIOXIDANT ENZYME-ACTIVITY; LIPID-PEROXIDATION PRODUCT; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; FRONTOTEMPORAL DEMENTIA; NADH-DEHYDROGENASE; OXIDATIVE STRESS; SIGNAL-TRANSDUCTION	Transgenic mice overexpressing the P301L mutant human tau protein exhibit an accumulation of hyper-phosphorylated tau and develop neurofibrillary tangles. The consequences of tau pathology were investigated here by proteomics followed by functional analysis. Mainly metabolism-related proteins including mitochondrial respiratory chain complex components, antioxidant enzymes, and synaptic proteins were identified as modified in the proteome pattern of P301L tau mice. Significantly, the reduction in mitochondrial complex V levels in the P301L tau mice revealed using proteomics was also confirmed as decreased in human P301L FTDP-17 ( frontotemporal dementia with parkinsonism linked to chromosome 17) brains. Functional analysis demonstrated a mitochondrial dysfunction in P301L tau mice together with reduced NADH-ubiquinone oxidoreductase activity and, with age, impaired mitochondrial respiration and ATP synthesis. Mitochondrial dysfunction was associated with higher levels of reactive oxygen species in aged transgenic mice. Increased tau pathology as in aged homozygous P301L tau mice revealed modified lipid peroxidation levels and the upregulation of antioxidant enzymes in response to oxidative stress. Furthermore, P301L tau mitochondria displayed increased vulnerability toward beta-amyloid (A beta) peptide insult, suggesting a synergistic action of tau and A beta pathology on the mitochondria. Taken together, we conclude that tau pathology involves a mitochondrial and oxidative stress disorder possibly distinct from that caused by A beta.	Univ Zurich, Div Psychiat Res, CH-8008 Zurich, Switzerland; Goethe Univ Frankfurt, Bioctr, Dept Pharmacol, D-60439 Frankfurt, Germany; Vrije Univ Amsterdam, Med Ctr, Dept Human Genet, Sec tMed Genom, NL-1081 BT Amsterdam, Netherlands; Free Univ Amsterdam, NL-1081 BT Amsterdam, Netherlands; Netherlands Brain Bank, NL-1105 AZ Amsterdam, Netherlands; Goethe Univ Frankfurt, Ctr Biol Chem, D-60590 Frankfurt, Germany; Psychiat Univ Clin, Neurobiol Res Lab, CH-4025 Basel, Switzerland	University of Zurich; Goethe University Frankfurt; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Goethe University Frankfurt	Gotz, J (corresponding author), Univ Sydney, Brain & Mind Res Inst, 100 Mallet St, Camperdown, NSW 2050, Australia.	jgoetz@med.usyd.edu.au	Brandt, Ulrich/GLV-1242-2022; Dröse, Stefan/E-4903-2010; Brandt, Ulrich/C-4406-2008; Götz, Jürgen/C-2448-2014	Brandt, Ulrich/0000-0003-1869-6811; Dröse, Stefan/0000-0002-9361-9034; Brandt, Ulrich/0000-0003-1869-6811; Götz, Jürgen/0000-0001-8501-7896; Muller, Werner E.G./0000-0002-8223-3689; Eckert, Anne/0000-0002-9341-3669; David, Della/0000-0001-8597-9470				Aksenov MY, 1999, NEUROCHEM RES, V24, P767, DOI 10.1023/A:1020783614031; Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Blanchard V, 2003, EXP NEUROL, V184, P247, DOI 10.1016/S0014-4886(03)00252-8; BONNESTAOUREL D, 1993, J LIPID MEDIATOR, V8, P111; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; Budd SL, 1997, FEBS LETT, V415, P21, DOI 10.1016/S0014-5793(97)01088-0; Butterfield DA, 2003, J NEUROCHEM, V86, P1313, DOI 10.1046/j.1471-4159.2003.01948.x; Casley CS, 2002, J NEUROCHEM, V80, P91, DOI 10.1046/j.0022-3042.2001.00681.x; Castegna A, 2003, J NEUROCHEM, V85, P1394, DOI 10.1046/j.1471-4159.2003.01786.x; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; COMPORTI M, 1987, CHEM PHYS LIPIDS, V45, P143, DOI 10.1016/0009-3084(87)90064-8; CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525; Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101; CROUCH SPM, 1993, J IMMUNOL METHODS, V160, P81, DOI 10.1016/0022-1759(93)90011-U; Dabir DV, 2004, AM J PATHOL, V164, P155, DOI 10.1016/S0002-9440(10)63106-9; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Davey GP, 1996, J NEUROCHEM, V66, P1617; Dei R, 2002, ACTA NEUROPATHOL, V104, P113, DOI 10.1007/s00401-002-0523-y; Diehl J, 2004, NEUROBIOL AGING, V25, P1051, DOI 10.1016/j.neurobiolaging.2003.10.007; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; Fellgiebel A, 2004, BIOL PSYCHIAT, V56, P279, DOI 10.1016/j.biopsych.2004.05.014; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Gitler D, 2004, J NEUROSCI, V24, P11368, DOI 10.1523/JNEUROSCI.3795-04.2004; Gotz J, 2004, MOL PSYCHIATR, V9, P664, DOI 10.1038/sj.mp.4001508; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gotz J, 2001, J BIOL CHEM, V276, P529, DOI 10.1074/jbc.M006531200; Grimmer T, 2004, DEMENT GERIATR COGN, V18, P32, DOI 10.1159/000077732; GUTTERIDGE JMC, 1984, FEBS LETT, V172, P245, DOI 10.1016/0014-5793(84)81134-5; GUTTERIDGE JMC, 1983, BIOCHEM BIOPH RES CO, V117, P901, DOI 10.1016/0006-291X(83)91681-9; HAJIMOHAMMADREZA I, 1990, NEUROSCI LETT, V112, P333, DOI 10.1016/0304-3940(90)90226-Y; Hartzler AW, 2002, NEUROBIOL AGING, V23, P855, DOI 10.1016/S0197-4580(02)00029-5; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; JAGUST WJ, 1991, J CEREBR BLOOD F MET, V11, P323, DOI 10.1038/jcbfm.1991.65; Jin LW, 1996, NEUROBIOL AGING, V17, P331, DOI 10.1016/0197-4580(96)00021-8; Karelson E, 2001, NEUROCHEM RES, V26, P353, DOI 10.1023/A:1010942929678; Keil U, 2004, J BIOL CHEM, V279, P50310, DOI 10.1074/jbc.M405600200; Keller JN, 1997, J NEUROCHEM, V69, P273; Kenney AM, 1998, J NEUROSCI, V18, P1318; Kim SH, 2001, LIFE SCI, V68, P2741, DOI 10.1016/S0024-3205(01)01074-8; Kinoshita A, 2000, J COMP NEUROL, V428, P223, DOI 10.1002/1096-9861(20001211)428:2<223::AID-CNE3>3.0.CO;2-M; Kinoshita A, 1998, AM J PATHOL, V153, P1551, DOI 10.1016/S0002-9440(10)65743-4; Krohn AJ, 1999, J NEUROSCI, V19, P7394, DOI 10.1523/JNEUROSCI.19-17-07394.1999; Landino LM, 2004, BIOCHEM BIOPH RES CO, V323, P112, DOI 10.1016/j.bbrc.2004.08.065; Landino LM, 2004, J BIOL CHEM, V279, P35101, DOI 10.1074/jbc.M405471200; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Li YJ, 2003, HUM MOL GENET, V12, P3259, DOI 10.1093/hmg/ddg357; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Lovell MA, 1998, NEUROLOGY, V51, P1562, DOI 10.1212/WNL.51.6.1562; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marcus DL, 1998, EXP NEUROL, V150, P40, DOI 10.1006/exnr.1997.6750; Mattson MP, 1999, ANN NY ACAD SCI, V893, P154, DOI 10.1111/j.1749-6632.1999.tb07824.x; McShea A, 1999, BRAIN RES, V815, P237, DOI 10.1016/S0006-8993(98)01135-4; Mielke R, 1996, ACTA NEUROPATHOL, V91, P174, DOI 10.1007/s004010050410; MIZUNO Y, 1986, J NEUROCHEM, V46, P1344, DOI 10.1111/j.1471-4159.1986.tb01745.x; Molloy MP, 1998, ELECTROPHORESIS, V19, P837, DOI 10.1002/elps.1150190539; Mukaetova-Ladinska EB, 2000, AM J PATHOL, V157, P623, DOI 10.1016/S0002-9440(10)64573-7; MUTISYA EM, 1994, J NEUROCHEM, V63, P2179; NEBOT C, 1993, ANAL BIOCHEM, V214, P442, DOI 10.1006/abio.1993.1521; Odetti P, 2000, J NEUROPATH EXP NEUR, V59, P393, DOI 10.1093/jnen/59.5.393; Orosz F, 2000, P NATL ACAD SCI USA, V97, P1026, DOI 10.1073/pnas.97.3.1026; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pennanen L, 2004, NEUROBIOL DIS, V15, P500, DOI 10.1016/j.nbd.2003.11.020; Perez M, 2000, FEBS LETT, V486, P270, DOI 10.1016/S0014-5793(00)02323-1; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; Rasmussen UF, 2000, MOL CELL BIOCHEM, V208, P37, DOI 10.1023/A:1007046028132; Russo C, 2002, ANN NY ACAD SCI, V973, P323, DOI 10.1111/j.1749-6632.2002.tb04660.x; Santens P, 2001, EUR NEUROL, V45, P19, DOI 10.1159/000052084; SCHAGGER H, 1995, EUR J BIOCHEM, V227, P916, DOI 10.1111/j.1432-1033.1995.tb20219.x; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schonberger SJ, 2001, PROTEOMICS, V1, P1519, DOI 10.1002/1615-9861(200111)1:12<1519::AID-PROT1519>3.0.CO;2-L; Schuessel K, 2005, NEUROBIOL DIS, V18, P89, DOI 10.1016/j.nbd.2004.09.003; Schuessel K, 2004, J NEURAL TRANSM, V111, P1167, DOI 10.1007/s00702-004-0156-5; Sergeant N, 2003, NEUROSCIENCE, V117, P293, DOI 10.1016/S0306-4522(02)00747-9; SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299; SIMS NR, 1987, BRAIN RES, V436, P30, DOI 10.1016/0006-8993(87)91553-8; Spillantini MG, 2000, NEUROGENETICS, V2, P193, DOI 10.1007/s100480050065; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; STOLL L, 1992, NEUROBIOL AGING, V13, P39, DOI 10.1016/0197-4580(92)90006-J; SUMPTER PQ, 1986, NEUROPATH APPL NEURO, V12, P305, DOI 10.1111/j.1365-2990.1986.tb00142.x; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; TIEN M, 1981, FED PROC, V40, P179; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; Yao Y, 2003, NEUROLOGY, V61, P475, DOI 10.1212/01.WNL.0000070185.02546.5D; Yoo BC, 2001, BIOCHEM BIOPH RES CO, V280, P249, DOI 10.1006/bbrc.2000.4109; Yoshida H, 1998, J BIOL CHEM, V273, P9761, DOI 10.1074/jbc.273.16.9761; YOUNES M, 1980, RES COMMUN CHEM PATH, V27, P119	95	311	320	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23802	23814		10.1074/jbc.M500356200	http://dx.doi.org/10.1074/jbc.M500356200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15831501	Green Accepted, hybrid			2022-12-25	WOS:000229880000052
J	Li, HB; Sanchez-Torres, J; del Carpio, AF; Nogales-Gonzalez, A; Molina-Ortiz, P; Moreno, MJ; Torok, K; Villalobo, A				Li, HB; Sanchez-Torres, J; del Carpio, AF; Nogales-Gonzalez, A; Molina-Ortiz, P; Moreno, MJ; Torok, K; Villalobo, A			The adaptor Grb7 is a novel calmodulin-binding protein: functional implications of the interaction of calmodulin with Grb7	ONCOGENE			English	Article						adaptor proteins; calmodulin; calmodulin-binding proteins; Grb7; Grb10; Grb14; Mig10; angiogenesis	GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; LIGHT-CHAIN KINASE; CELL-MIGRATION; ESOPHAGEAL-CARCINOMA; LIVING CELLS; ASSOCIATION; CLONING; FAMILY; DOMAIN	We demonstrate using Ca2+-dependent calmodulin (CaM)-affinity chromatography and overlay with biotinylated CaM that the adaptor proteins growth factor receptor bound (Grb) 7 and Grb7V ( a naturally occurring variant lacking the Src homology 2 (SH2) domain) are CaM-binding proteins. Deletion of an amphiphilic basic amino-acid sequence ( residues 243 - 256) predicted to form an alpha-helix located in the proximal region of its pleckstrin homology (PH) domain demonstrates the location of the CaM-binding domain. This site is identical in human and rodents Grb7, and shares great homology with similar regions of Grb10 and Grb14, and the Mig10 protein from Caenorhabditis elegans. We show that Grb7 and Grb7V are present in the cytosol and bound to membranes, while the deletion mutants (Grb7 Delta and Grb7V Delta) have less capacity to be associated to membranes. Grb7D maintains in part the capacity to bind phosphoinositides, and CaM competes for phosphoinositide binding. Activation of ErbB2 by heregulin beta 1 decreases the pool of Grb7 associated to membranes. The cell-permeable CaM antagonist W7 (N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide), but not the CaM-dependent protein kinase II inhibitor KN93, prevents this effect. Highly specific cell-permeable CaM inhibitory peptides decrease the association of Grb7 to membranes. This suggests that CaM regulates the intracellular mobilization of Grb7 in living cells. Direct interaction between enhanced yellow fluorescent protein (EYFP)- Grb7 and enhanced cyan fluorescent protein (ECFP)-CaM chimeras at the plasma membrane of living cells was demonstrated by fluorescence resonance energy transfer ( FRET). The FRET signal dramatically decreased in cells loaded with a cell-permeable Ca2+ chelator, and was significantly attenuated when enhanced yellow fluorescent protein-Grb7 chimera (EYFP-Grb7) Delta instead of EYFP-Grb7 was used. Finally, we show that conditioned media from cells transiently transfected with Grb7 Delta and Grb7V Delta lost its angiogenic activity, in contrast to those from cells transiently transfected with their wild-type counterparts.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, E-28029 Madrid, Spain; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; St George Hosp, Sch Med, Dept Basic Med Sci, Pharmacol & Clin Pharmacol Sect, London SW17 0RE, England; Shijiazhuang Med Sch, Sci & Res Ctr, Shijiazhuang 05008, Hebei, Peoples R China	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; National Research Council Canada; St Georges University London	Villalobo, A (corresponding author), CSIC, Inst Invest Biomed, C Arturo Duperier 4, E-28029 Madrid, Spain.	antonio.villalobo@iib.uam.es	NOGALES, AITOR/AAY-1590-2020; Villalobo, Antonio/O-9621-2019; Villalobo, Antonio/K-2902-2017	NOGALES, AITOR/0000-0002-2424-7900; Villalobo, Antonio/0000-0002-4200-374X; Torok, Katalin/0000-0002-3107-4534				Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cariou B, 2004, FRONT BIOSCI-LANDMRK, V9, P1626, DOI 10.2741/1228; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Feinmesser RL, 1996, ONCOGENE, V12, P2725; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; GOLDENRING JR, 1986, PROG BRAIN RES, V69, P341; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Kishi T, 1997, BIOCHEM BIOPH RES CO, V232, P5, DOI 10.1006/bbrc.1997.6218; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li HB, 2004, BIOCHEM J, V381, P257, DOI 10.1042/BJ20040515; Li HB, 2004, FEBS LETT, V559, P175, DOI 10.1016/S0014-5793(04)00067-5; Li HB, 2002, BIOCHEM J, V362, P499, DOI 10.1042/bj3620499; Lim MA, 2004, FRONT BIOSCI-LANDMRK, V9, P387, DOI 10.2741/1226; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Martin-Nieto J, 1998, BIOCHEMISTRY-US, V37, P227, DOI 10.1021/bi971765v; MEANS AR, 1982, ANN NY ACAD SCI, V383, P69, DOI 10.1111/j.1749-6632.1982.tb23162.x; Morrione A, 2003, J CELL PHYSIOL, V197, P307, DOI 10.1002/jcp.10363; NISHIKAWA M, 1980, NATURE, V287, P863, DOI 10.1038/287863a0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; OOI J, 1995, ONCOGENE, V10, P1621; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Riedel H, 2004, FRONT BIOSCI-LANDMRK, V9, P603, DOI 10.2741/1227; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; Shen TL, 2004, FRONT BIOSCI-LANDMRK, V9, P192, DOI 10.2741/1229; Shen TL, 2002, J BIOL CHEM, V277, P29069, DOI 10.1074/jbc.M203085200; Stanimirovic D, 1996, J CELL PHYSIOL, V169, P455; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Tanaka S, 1997, CANCER RES, V57, P28; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; Thorogate R, 2004, J CELL SCI, V117, P5923, DOI 10.1242/jcs.01510; Torok K, 1998, BIOCHEMISTRY-US, V37, P6188, DOI 10.1021/bi972773e; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; Torok K, 1998, CURR BIOL, V8, P692, DOI 10.1016/S0960-9822(98)70275-1; Villalobo A, 2000, CALCIUM: THE MOLECULAR BASIS OF CALCIUM ACTION IN BIOLOGY AND MEDICINE, P287; Villalobo A., 2003, CURR TOPICS BIOCH RE, V5, P105	53	27	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4206	4219		10.1038/sj.onc.1208591	http://dx.doi.org/10.1038/sj.onc.1208591			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806159				2022-12-25	WOS:000229815300005
J	Bi, XH; Slater, DM; Ohmori, H; Vaziri, C				Bi, XH; Slater, DM; Ohmori, H; Vaziri, C			DNA polymerase kappa is specifically required for recovery from the benzo[a]pyrene-dihydrodiol epoxide (BPDE)-induced S-phase checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Y-FAMILY; POL-KAPPA; REPLICATION MACHINERY; DAMAGE CHECKPOINT; MAMMALIAN-CELLS; ATR; ETA; PCNA; LOCALIZATION; CHK1	Previously we identified an intra-S-phase cell cycle checkpoint elicited by the DNA-damaging carcinogen benzo[ a] pyrene-dihydrodiol epoxide ( BPDE). Here we have investigated the roles of lesion bypass DNA polymerases pol kappa and pol eta in the BPDE- induced S-phase checkpoint. BPDE treatment induced the re-localization of an ectopically expressed green fluorescent protein-pol kappa fusion protein to nuclear foci containing sites of active DNA synthesis in human lung carcinoma H1299 cells. In contrast, a similarly expressed yellow fluorescent protein-pol eta fusion protein showed a constitutive nuclear focal distribution at replication forks ( in the same cells) that was unchanged in response to BPDE. BPDE- induced formation of green fluorescent protein-pol kappa nuclear foci was temporally coincident with checkpoint-mediated S-phase arrest. Unlike "wild-type" cells, Polk(-/-) mouse embryonic fibroblasts (MEFs) failed to recover from BPDE- induced S-phase arrest, while exhibiting normal recovery from S-phase arrest induced by ionizing radiation and hydroxyurea. XPV fibroblasts lacking pol eta showed a normal S-phase checkpoint response to BPDE ( but failed to recover from the UV light-induced S-phase checkpoint), in sharp contrast to Polk(-/-) MEFs. The persistent S-phase arrest in BPDE-treated PolK(-/-) cells was associated with increased levels of histone gamma H2AX ( a marker of DNA double- strand breaks (DSBs)) and activation of the DSB-responsive kinases ATM and Chk2. These data suggest that in the absence of pol kappa, replication forks stall at sites of damage and collapse and generate DSBs. Therefore, we conclude that the trans-lesion synthesis enzyme pol kappa is specifically required for normal recovery from the BPDE- induced S- phase checkpoint.	Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Boston University; Kyoto University	Vaziri, C (corresponding author), Boston Univ, Sch Med, Dept Genet & Genom, 80 E Concord St, Boston, MA 02118 USA.	cvaziri@bu.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES009558, R01ES012917, R01ES009558] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 12917, ES 09558] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Avkin S, 2004, J BIOL CHEM, V279, P53298, DOI 10.1074/jbc.M409155200; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Baum E, 1978, POLYCYCLIC HYDROCARB, V1, P45; Baynton K, 2000, TRENDS BIOCHEM SCI, V25, P74, DOI 10.1016/S0968-0004(99)01524-8; Bergoglio V, 2002, J CELL SCI, V115, P4413, DOI 10.1242/jcs.00162; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cleaver JE, 2003, CELL CYCLE, V2, P310, DOI 10.4161/cc.2.4.436; CORDEIROSTONE M, 1986, CARCINOGENESIS, V7, P1775, DOI 10.1093/carcin/7.10.1775; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Guo CX, 2003, EMBO J, V22, P6621, DOI 10.1093/emboj/cdg626; Guo N, 2002, CELL GROWTH DIFFER, V13, P77; Haracska L, 2002, P NATL ACAD SCI USA, V99, P16000, DOI 10.1073/pnas.252524999; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007; Hemminki K, 2000, REGUL TOXICOL PHARM, V32, P264, DOI 10.1006/rtph.2000.1431; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; Kai M, 2003, MUTAT RES-FUND MOL M, V532, P59, DOI 10.1016/j.mrfmmm.2003.08.010; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche P, 2002, EMBO J, V21, P6246, DOI 10.1093/emboj/cdf618; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kaufmann WK, 2003, MUTAT RES-FUND MOL M, V532, P85, DOI 10.1016/j.mrfmmm.2003.08.012; KAUFMANN WK, 1985, BIOCHIM BIOPHYS ACTA, V824, P146, DOI 10.1016/0167-4781(85)90091-0; Kunz BA, 2000, MUTAT RES-FUND MOL M, V451, P169, DOI 10.1016/S0027-5107(00)00048-8; Lawrence CW, 2002, DNA REPAIR, V1, P425, DOI 10.1016/S1568-7864(02)00038-1; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Liu QH, 2000, GENE DEV, V14, P1448; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Ogi T, 2005, J CELL SCI, V118, P129, DOI 10.1242/jcs.01603; Ogi T, 2002, P NATL ACAD SCI USA, V99, P15548, DOI 10.1073/pnas.222377899; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ohashi E, 2004, GENES CELLS, V9, P523, DOI 10.1111/j.1356-9597.2004.00747.x; Ohmori H, 2004, ADV PROTEIN CHEM, V69, P265; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Tissier A, 2004, DNA REPAIR, V3, P1503, DOI 10.1016/j.dnarep.2004.06.015; Ulrich HD, 2004, CELL CYCLE, V3, P15; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Velasco-Miguel S, 2003, DNA REPAIR, V2, P91, DOI 10.1016/S1568-7864(02)00189-1; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	62	116	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22343	22355		10.1074/jbc.M501562200	http://dx.doi.org/10.1074/jbc.M501562200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817457	hybrid			2022-12-25	WOS:000229557900080
J	Haguenauer, A; Raimbault, S; Masscheleyn, S; Gonzalez-Barroso, MD; Criscuolo, F; Plamondon, J; Miroux, B; Ricquier, D; Richard, D; Bouillaud, F; Pecqueur, C				Haguenauer, A; Raimbault, S; Masscheleyn, S; Gonzalez-Barroso, MD; Criscuolo, F; Plamondon, J; Miroux, B; Ricquier, D; Richard, D; Bouillaud, F; Pecqueur, C			A new renal mitochondrial carrier, KMCP1, is up-regulated during tubular cell regeneration and induction of antioxidant enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; UNCOUPLING PROTEIN; RAT-BRAIN; EXPRESSION; MEMBRANE; ISOFORMS; SYSTEM; BMCP1; GENE	The mitochondrial carrier family transports a variety of metabolites across the inner mitochondrial membrane. We identified and cloned a new member of this family, KMCP1 ( kidney mitochondrial carrier protein-1), that is highly homologous to the previously identified protein BMCP1 (brain mitochondrial carrier protein-1). Western blotting and in situ experiments showed that this carrier is expressed predominantly within the kidney cortex in the proximal and distal tubules. KMCP1 was increased during fasting and during the regenerative phase of glycerol-induced renal failure. We show that both situations are associated with transiently increased expression of superoxide-generating enzymes, followed by increased mitochondrial metabolism and antioxidant defenses. Given that KMCP1 expression occurs simultaneously with these latter events, we propose that KMCP1 is involved in situations in which mitochondrial metabolism is increased, in particular when the cellular redox balance tends toward a pro-oxidant status.	CNRS, Fac Necker Enfants Malades, F-75730 Paris, France; Univ Laval, Fac Med, Dept Anat & Physiol, Quebec City, PQ G1K 7P4, Canada	Centre National de la Recherche Scientifique (CNRS); Laval University	Pecqueur, C (corresponding author), CNRS, Fac Necker Enfants Malades, 156 Rue Vaugirard, F-75730 Paris, France.	pecqueuc@necker.fr	Miroux, Bruno/E-9267-2017; Bouillaud, Frédéric R/L-3238-2017; Pecqueur, Claire/L-3073-2015	Bouillaud, Frédéric R/0000-0002-7518-9237; Pecqueur, Claire/0000-0002-7612-1672; Miroux, Bruno/0000-0002-3066-4700; GONZALEZ BARROSO, MARIA DEL MAR/0000-0002-0278-8298; haguenauer, anne/0000-0003-2332-2929				Ali BH, 2003, FOOD CHEM TOXICOL, V41, P1447, DOI 10.1016/S0278-6915(03)00186-8; Baliga R, 1998, KIDNEY INT, V53, P394, DOI 10.1046/j.1523-1755.1998.00767.x; Brewster UC, 2004, AM J MED, V116, P263, DOI 10.1016/j.amjmed.2003.09.034; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; Chabardes-Garonne D, 2003, P NATL ACAD SCI USA, V100, P13710, DOI 10.1073/pnas.2234604100; Curthoys NP, 2001, J NUTR, V131, p2491S, DOI 10.1093/jn/131.9.2491S; FAULDS D, 1993, DRUGS, V45, P953, DOI 10.2165/00003495-199345060-00007; Gonzalez-Barroso MM, 1998, J BIOL CHEM, V273, P15528, DOI 10.1074/jbc.273.25.15528; GonzalezBarroso MM, 1996, EUR J BIOCHEM, V239, P445, DOI 10.1111/j.1432-1033.1996.0445u.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Harlow E., 1988, ANTIBODIES LAB MANUA; Kim-Han JS, 2001, J NEUROCHEM, V79, P658, DOI 10.1046/j.1471-4159.2001.00604.x; Kondou S, 2000, BBA-BIOENERGETICS, V1457, P182, DOI 10.1016/S0005-2728(00)00099-2; Lengacher S, 2004, J CEREBR BLOOD F MET, V24, P780, DOI 10.1097/01.WCB.0000122743.72175.52; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MIROUX B, 1993, EMBO J, V12, P3739, DOI 10.1002/j.1460-2075.1993.tb06051.x; Mizuno T, 2000, BIOCHEM BIOPH RES CO, V278, P691, DOI 10.1006/bbrc.2000.3859; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Sanchis D, 1998, J BIOL CHEM, V273, P34611, DOI 10.1074/jbc.273.51.34611; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; THIEL G, 1967, NEPHRON, V4, P276, DOI 10.1159/000179588; Walker PD, 1999, RENAL FAILURE, V21, P433, DOI 10.3109/08860229909085109; Yu XX, 2000, FASEB J, V14, P1611, DOI 10.1096/fj.14.11.1611	26	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22036	22043		10.1074/jbc.M412136200	http://dx.doi.org/10.1074/jbc.M412136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15809292	hybrid			2022-12-25	WOS:000229557900047
J	Li, YK; Schwabe, RF; DeVries-Seimon, T; Yao, PM; Gerbod-Giannone, MC; Tall, AR; Davis, RJ; Flavell, R; Brenner, DA; Tabas, I				Li, YK; Schwabe, RF; DeVries-Seimon, T; Yao, PM; Gerbod-Giannone, MC; Tall, AR; Davis, RJ; Flavell, R; Brenner, DA; Tabas, I			Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ENDOPLASMIC-RETICULUM STRESS; HUMAN ATHEROSCLEROTIC PLAQUES; UNFOLDED PROTEIN RESPONSE; TNF-ALPHA; TRANSLATIONAL CONTROL; INFLAMMATORY MARKERS; REDUCES ATHEROSCLEROSIS; MURINE ATHEROSCLEROSIS; TRANSCRIPTION FACTOR	Two key features of atherosclerotic plaques that precipitate acute atherothrombotic vascular occlusion ("vulnerable plaques") are abundant inflammatory mediators and macrophages with excess unesterified, or "free," cholesterol (FC). Herein we show that FC accumulation in macrophages leads to the induction and secretion of two inflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). The increases in TNF-alpha and IL-6 mRNA and protein were mediated by FC-induced activation of the I kappa B kinase/NF-kappa B pathway as well as activation of MKK3/p38, Erk1/2, and JNK1/2 mitogen-activated protein kinases (MAPK). Activation of I kappa B kinase and JNK1/2 was needed for the induction of both cytokines. However, MKK3/p38 signaling was specifically involved in TNF-alpha induction, and Erk1/2 signaling was required for IL-6. Most interestingly, activation of all of the signaling pathways and induction of both cytokines required cholesterol trafficking to the endoplasmic reticulum (ER). The CHOP branch of the unfolded protein response, an ER stress pathway, was required for Erk1/2 activation and IL-6 induction. In contrast, one or more other ER-related pathways were responsible for activation of p38, JNK1/2, and I kappa B kinase/NF-kappa B and for the induction of TNF-alpha. These data suggest a novel scenario in which cytokines are induced in macrophages by endogenous cellular events triggered by excess ER cholesterol rather than by exogenous immune cell mediators. Moreover, this model may help explain the relationship between FC accumulation and inflammation in vulnerable plaques.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06510 USA	Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Yale University; Howard Hughes Medical Institute	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	iat1@columbia.edu	Tall, Alan/AAT-8528-2021; Schwabe, Robert/AAY-6506-2021	Brenner, David/0000-0003-2573-525X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075662, P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 75662, HL 54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa M, 2004, CAN J CARDIOL, V20, P631; Azzolina A, 2003, BBA-MOL CELL RES, V1643, P75, DOI 10.1016/j.bbamcr.2003.09.003; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Boesten LSM, 2005, CARDIOVASC RES, V66, P179, DOI 10.1016/j.cardiores.2005.01.001; Branen L, 2004, ARTERIOSCL THROM VAS, V24, P2137, DOI 10.1161/01.ATV.0000143933.20616.1b; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Canault M, 2004, THROMB HAEMOSTASIS, V92, P1428, DOI 10.1160/TH04-06-0344; Cesari M, 2003, AM J CARDIOL, V92, P522, DOI 10.1016/S0002-9149(03)00718-5; Cesari M, 2003, CIRCULATION, V108, P2317, DOI 10.1161/01.CIR.0000097109.90783.FC; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Cook AD, 2003, J IMMUNOL, V171, P4816, DOI 10.4049/jimmunol.171.9.4816; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; Espel E, 1996, EUR J IMMUNOL, V26, P2417, DOI 10.1002/eji.1830261023; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Fan HZ, 2003, J BIOL CHEM, V278, P18617, DOI 10.1074/jbc.M300331200; Fan Jianglin, 2003, J Atheroscler Thromb, V10, P63; Fazio S, 2001, J CLIN INVEST, V107, P163, DOI 10.1172/JCI10310; Feng B, 2003, P NATL ACAD SCI USA, V100, P10423, DOI 10.1073/pnas.1732494100; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Ferraccioli G, 2004, AUTOIMMUN REV, V3, P261, DOI 10.1016/j.autrev.2003.09.004; Futami T, 2005, J BIOL CHEM, V280, P826, DOI 10.1074/jbc.M409948200; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hu P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200; Huber SA, 1999, ARTERIOSCL THROM VAS, V19, P2364, DOI 10.1161/01.ATV.19.10.2364; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Jiang JX, 2002, SHOCK, V18, P336, DOI 10.1097/00024382-200210000-00008; Kim SH, 2004, PHARMACOL RES, V49, P433, DOI 10.1016/j.phrs.2003.11.004; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; Kotlyarov A, 2002, BIOCHEM SOC T, V30, P959, DOI 10.1042/BST0300959; KRUTH HS, 1984, AM J PATHOL, V114, P201; Kucharczak J, 2004, ONCOGENE, V23, P8858, DOI 10.1038/sj.onc.1207744; Li YK, 2004, J BIOL CHEM, V279, P37030, DOI 10.1074/jbc.M405195200; Lind L, 2003, ATHEROSCLEROSIS, V169, P203, DOI 10.1016/S0021-9150(03)00012-1; Linton MF, 2003, INT J OBESITY, V27, pS35, DOI 10.1038/sj.ijo.0802498; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Maier W, 2004, EUR HEART J, V25, P450; Martinet W, 2001, CURR OPIN LIPIDOL, V12, P535, DOI 10.1097/00041433-200110000-00009; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Nguyen DT, 2004, MOL BIOL CELL, V15, P4248, DOI 10.1091/mbc.E03-11-0851; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Papanicolaou DA, 1998, ANN INTERN MED, V128, P127, DOI 10.7326/0003-4819-128-2-199801150-00009; Raines EW, 1996, BIOESSAYS, V18, P271, DOI 10.1002/bies.950180405; Rajavashisth TB, 1999, CIRCULATION, V99, P3103, DOI 10.1161/01.CIR.99.24.3103; RAPP JH, 1983, J LIPID RES, V24, P1329; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schieffer B, 2004, CIRCULATION, V110, P3493, DOI 10.1161/01.CIR.0000148135.08582.97; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; Schreyer SA, 2002, J BIOL CHEM, V277, P12364, DOI 10.1074/jbc.M111727200; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Schwabe RF, 2001, HEPATOLOGY, V33, P81, DOI 10.1053/jhep.2001.20799; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; Song L, 2004, ATHEROSCLEROSIS, V177, P43, DOI 10.1016/j.atherosclerosis.2004.06.018; Steffens S, 2004, HERZ, V29, P741, DOI 10.1007/s00059-004-2634-9; Steinberg D, 2002, NAT MED, V8, P1211, DOI 10.1038/nm1102-1211; Sukovich DA, 1998, ARTERIOSCL THROM VAS, V18, P1498, DOI 10.1161/01.ATV.18.9.1498; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; TIPPING PG, 1993, AM J PATHOL, V142, P1721; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Willerson JT, 2004, CIRCULATION, V109, P2, DOI 10.1161/01.CIR.0000129535.04194.38; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhou J, 1999, SCAND J CLIN LAB INV, V59, P3	70	337	351	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21763	21772		10.1074/jbc.M501759200	http://dx.doi.org/10.1074/jbc.M501759200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15826936	hybrid			2022-12-25	WOS:000229557900013
J	Kimura, H; Stephen, D; Joyner, A; Curran, T				Kimura, H; Stephen, D; Joyner, A; Curran, T			Gli1 is important for medulloblastoma formation in Ptc1+/- mice	ONCOGENE			English	Article						medulloblastoma; Patched1; Gli1	BASAL-CELL CARCINOMAS; PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; GRANULE NEURON PRECURSORS; SONIC HEDGEHOG; MOUSE CEREBELLUM; PATCHED MUTANTS; P53(-/-) MICE; HUMAN HOMOLOG; SHH PATHWAY	Germline mutations in the human homolog of the patched1 (PTCH1) are associated with basal cell nevus carcinoma syndrome (BCNS or Gorlin syndrome), which is characterized by developmental anomalies, radiation hypersensitivity and a predisposition to medulloblastomas and skin tumors. Patched1 (Ptc1) functions as a receptor for Sonic hedgehog (Shh) in a wide range of biological processes. Binding of Shh to Ptc1 results in activation of Smoothened (Smo), which in turn stimulates expression of downstream target genes including Ptc1 and Gli1. Gli1 is a member of a family of DNA-binding zinc-finger proteins, including Gli2 and Gli3, that function in transcription control. Here, we report that inactivation of both Gli1 alleles in Ptc1(+/-) mice significantly reduces spontaneous medulloblastoma formation. Therefore, Gli1 is not only a marker of pathway activation but also plays a functional role in medulloblastoma formation. Interestingly, Gli2 levels were elevated in medulloblastoma cells but not in normal granule neuron precursors during cerebellar development in mice lacking Gli1. In cultured fibroblasts, Gli1 was more potent than Gli2 at inducing cell transformation. These results demonstrate that Gli1 plays a central role in medulloblastoma formation in Ptc1(+/-) mice and that Gli2 may also contribute to oncogenesis.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA; NYU, Sch Med, Dev Genet Program,Skirball Inst Biomol Med, Dept Cell Biol, New York, NY 10016 USA	St Jude Children's Research Hospital; Howard Hughes Medical Institute; New York University; New York University	Curran, T (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	tom.curran@stjude.org	Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019; Curran, Tom/C-1164-2008; Curran, Tom/F-5234-2018	Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551	NATIONAL CANCER INSTITUTE [P01CA096832] Funding Source: NIH RePORTER; NCI NIH HHS [CA096832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai CB, 2002, DEVELOPMENT, V129, P4753; Bai CYB, 2001, DEVELOPMENT, V128, P5161; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Corrales JMD, 2004, DEVELOPMENT, V131, P5581, DOI 10.1242/dev.01438; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dong J, 2000, Hum Mutat, V16, P89, DOI 10.1002/1098-1004(200007)16:1<89::AID-HUMU18>3.3.CO;2-Z; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Grachtchouk V, 2003, EMBO J, V22, P2741, DOI 10.1093/emboj/cdg271; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Klein RS, 2001, DEVELOPMENT, V128, P1971; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Koyabu Y, 2001, J BIOL CHEM, V276, P6889, DOI 10.1074/jbc.C000773200; Lee Y, 2003, CANCER RES, V63, P5428; Lewis PM, 2004, DEV BIOL, V270, P393, DOI 10.1016/j.ydbio.2004.03.007; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mo R, 1997, DEVELOPMENT, V124, P113; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Oro AE, 2003, DEV BIOL, V255, P238, DOI 10.1016/S0012-1606(02)00042-8; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Park HL, 2000, DEVELOPMENT, V127, P1593; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Raffel C, 1997, CANCER RES, V57, P842; Reifenberger J, 1998, CANCER RES, V58, P1798; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Weiner HL, 2002, CANCER RES, V62, P6385; Wetmore C, 2000, CANCER RES, V60, P2239; Wetmore C, 2001, CANCER RES, V61, P513; Wolter M, 1997, CANCER RES, V57, P2581; Xie JW, 1997, CANCER RES, V57, P2369; Zhao Q, 2002, P NATL ACAD SCI USA, V99, P5704, DOI 10.1073/pnas.082092399; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	53	125	130	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4026	4036		10.1038/sj.onc.1208567	http://dx.doi.org/10.1038/sj.onc.1208567			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806168				2022-12-25	WOS:000229680300003
J	Gao, ZG; Chiao, P; Zhang, X; Zhang, XH; Lazar, MA; Seto, E; Young, HA; Ye, JP				Gao, ZG; Chiao, P; Zhang, X; Zhang, XH; Lazar, MA; Seto, E; Young, HA; Ye, JP			Coactivators and corepressors of NF-kappa B in I kappa Beta alpha gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; HISTONE ACETYLTRANSFERASE ACTIVITY; THYROID-HORMONE RECEPTOR; NUCLEAR RECEPTORS; TRANSCRIPTIONAL COACTIVATOR; TRANSACTIVATION DOMAIN; COR COREPRESSORS; PHOSPHORYLATION; ACTIVATION; P65	In this study, we investigated recruitment of coactivators (SRC-1, SRC-2, and SRC-3) and corepressors (HDAC1, HDAC2, HDAC3, SMRT, and NCoR) to the I kappa B alpha gene promoter after NF-kappa B activation by tumor necrosis factor-alpha. Our data from chromatin immunoprecipitation assay suggest that coactivators and corepressors are simultaneously recruited to the promoter, and their binding to the promoter DNA is oscillated in HEK293 cells. SRC-1, SRC-2, and SRC-3 all enhanced I kappa B alpha transcription. However, the interaction of each coactivator with the promoter exhibited different patterns. After tumor necrosis factor-alpha treatment, SRC-1 signal was increased gradually, but SRC-2 signal was reduced immediately, suggesting replacement of SRC-2 by SRC-1. SRC-3 signal was increased at 30 min, reduced at 60 min, and then increased again at 120 min, suggesting an oscillation of SRC-3. The corepressors were recruited to the promoter together with the coactivators. The binding pattern suggests that the corepressor proteins formed two types of corepressor complexes, SMRT-HDAC1 and NCoR- HDAC3. The two complexes exhibited a switch at 30 and 60 min. The functions of cofactors were confirmed by gene overexpression and RNA interference-mediated gene knockdown. These data suggest that gene transactivation by the transcription factor NF-kappa B is subject to the regulation of a dynamic balance between the coactivators and corepressors. This model may represent a mechanism for integration of extracellular signals into a precise control of gene transcription.	Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; NCI, Cellular & Mol Immunol Sect, Expt Immunol Lab, NIH, Ft Detrick, MD 21702 USA; Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ Penn, Div Endocrinol Diab & Metab, Philadelphia, PA 19104 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University System of Florida; University of South Florida; University of Pennsylvania	Ye, JP (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	yej@pbrc.edu	Ye, Jianping/N-1998-2017; Lazar, Mitchell A/AAF-3738-2019; Zhang, Xia/B-8152-2008; Young, Howard/A-6350-2008	Ye, Jianping/0000-0003-3875-365X; Zhang, Xia/0000-0002-9040-1486; Young, Howard/0000-0002-3118-5111	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK068036, R01DK068036] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK068036, R01 DK068036, R56 DK068036] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen SL, 2001, MOL ENDOCRINOL, V15, P783, DOI 10.1210/me.15.5.783; Espinosa L, 2003, MOL BIOL CELL, V14, P491, DOI 10.1091/mbc.E02-07-0404; Gao ZG, 2003, J BIOL CHEM, V278, P24944, DOI 10.1074/jbc.M300423200; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Glass CK, 2000, GENE DEV, V14, P121; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jonas BA, 2004, J BIOL CHEM, V279, P54676, DOI 10.1074/jbc.M410128200; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Litterst CM, 2003, J BIOL CHEM, V278, P45340, DOI 10.1074/jbc.M303644200; Mark M, 2004, P NATL ACAD SCI USA, V101, P4453, DOI 10.1073/pnas.0400234101; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; ONATE SA, 1995, SCIENCE, V270, P1354; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sengupta N, 2004, J CELL BIOCHEM, V93, P57, DOI 10.1002/jcb.20179; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yu ZT, 2002, J AM SOC NEPHROL, V13, P2009, DOI 10.1097/01.ASN.0000024253.59665.F1; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	53	104	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21091	21098		10.1074/jbc.M500754200	http://dx.doi.org/10.1074/jbc.M500754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15811852	Green Accepted, hybrid			2022-12-25	WOS:000229438800024
J	Jiang, ZY; Zhou, QL; Holik, J; Patel, S; Leszyk, J; Coleman, K; Chouinard, M; Czech, MP				Jiang, ZY; Zhou, QL; Holik, J; Patel, S; Leszyk, J; Coleman, K; Chouinard, M; Czech, MP			Identification of WNK1 as a substrate of Akt/protein kinase B and a negative regulator of insulin-stimulated mitogenesis in 3T3-L1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR SUBSTRATE-1; GLUT4 TRANSLOCATION; MEDIATED PHOSPHORYLATION; GLUCOSE-UPTAKE; AKT SUBSTRATE; PROTEIN; DEGRADATION; PATHWAY	Insulin signaling through protein kinase Akt/protein kinase B (PKB), a downstream element of the phosphatidylinositol 3-kinase (PI3K) pathway, regulates diverse cellular functions including metabolic pathways, apoptosis, mitogenesis, and membrane trafficking. To identify Akt/PKB substrates that mediate these effects, we used antibodies that recognize phosphopeptide sites containing the Akt/PKB substrate motif (RXRXX(p)S/T) to immunoprecipitate proteins from insulin-stimulated adipocytes. Tryptic peptides from a 250-kDa immuno-precipitated protein were identified as the protein kinase WNK1 (with no lysine) by matrix-assisted laser desorption ionization time-of-flight mass spectrometry, consistent with a recent report that WNK1 is phosphorylated on Thr(60) in response to insulin-like growth factor I. Insulin treatment of 3T3-L1 adipocytes stimulated WNK1 phosphorylation, as detected by immunoprecipitation with antibody against WNK1 followed by immunoblotting with the anti-phosphoAkt substrate antibody. WNK1 phosphorylation induced by insulin was unaffected by rapamycin, an inhibitor of p70 S6 kinase pathway but abolished by the PI3K inhibitor wortmannin. RNA interference-directed depletion of Akt1/PKB alpha and Akt2/PKB beta attenuated insulin- stimulated WNK1 phosphorylation, but depletion of protein kinase C lambda did not. Whereas small interfering RNA-induced loss of WNK1 protein did not significantly affect insulin-stimulated glucose transport in 3T3-L1 adipocytes, it significantly enhanced insulin- stimulated thymidine incorporation by about 2-fold. Furthermore, depletion of WNK1 promoted serum-stimulated cell proliferation of 3T3-L1 preadipocytes, as evidenced by a 36% increase in cell number after 48 h in culture. These data suggest that WNK1 is a physiologically relevant target of insulin signaling through PI3K and Akt/PKB and functions as a negative regulator of insulin-stimulated mitogenesis.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	michael.czech@umassmed.edu			NIDDK NIH HHS [DK30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kahle KT, 2003, NAT GENET, V35, P372, DOI 10.1038/ng1271; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Lee BH, 2004, MOL CELL, V15, P741, DOI 10.1016/j.molcel.2004.07.018; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; Ozes ON, 1999, NATURE, V401, P82; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vitari AC, 2004, BIOCHEM J, V378, P257, DOI 10.1042/BJ20031692; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399; Xu BE, 2002, J BIOL CHEM, V277, P48456, DOI 10.1074/jbc.M207917200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yang CL, 2003, J CLIN INVEST, V111, P1039, DOI 10.1172/JCI200317443; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou QL, 2004, BIOCHEM SOC T, V32, P817, DOI 10.1042/BST0320817	60	69	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21622	21628		10.1074/jbc.m414464200	http://dx.doi.org/10.1074/jbc.m414464200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799971	hybrid			2022-12-25	WOS:000229438800087
J	LaLonde, DP; Brown, MC; Bouverat, BP; Turner, CE				LaLonde, DP; Brown, MC; Bouverat, BP; Turner, CE			Actopaxin interacts with TESK1 to regulate cell spreading on fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; FOCAL ADHESION PROTEINS; TO-SUBSTRATE CONTACTS; COFILIN PHOSPHORYLATION; ACTIN REORGANIZATION; TESTICULAR PROTEIN-KINASE-1; SUBCELLULAR-LOCALIZATION; ARP2/3 COMPLEX; CH-ILKBP; PAXILLIN	The focal adhesion protein actopaxin contributes to integrin-actin associations and is involved in cell adhesion, spreading, and motility. Herein, we identify and characterize an association between actopaxin and the serine/threonine kinase testicular protein kinase 1 (TESK1), a ubiquitously expressed protein previously reported to regulate cellular spreading and focal adhesion formation via phosphorylation of cofilin. The interaction between actopaxin and TESK1 is direct and the binding sites were mapped to the carboxyl terminus of both proteins. The association between actopaxin and TESK1 is negatively regulated by adhesion to fibronectin, and a phosphomimetic actopaxin mutant that promotes cell spreading also exhibits impaired binding to TESK1. Binding of actopaxin to TESK1 inhibits TESK1 kinase activity in vitro. Expression of the carboxyl terminus of actopaxin has previously been reported to retard cell spreading. This effect was reversed following overexpression of TESK1 and was found to be dependent on an inability of actopaxin carboxyl terminus expressing cells to promote cofilin phosphorylation upon matrix adhesion and caused by retention of TESK1 by this actopaxin mutant. Thus, the association between actopaxin and TESK1, which is likely regulated by phosphorylation of actopaxin, regulates TESK1 activity and subsequent cellular spreading on fibronectin.	SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Turner, CE (corresponding author), SUNY Upstate Med Univ, Dept Cell & Dev Biol, 750 E Adams St, Syracuse, NY 13210 USA.	turnerce@upstate.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070244] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL070244] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bernstein BW, 2000, CELL MOTIL CYTOSKEL, V47, P319, DOI 10.1002/1097-0169(200012)47:4<319::AID-CM6>3.0.CO;2-I; Bhatt A, 2002, J CELL SCI, V115, P3415; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chan AY, 2000, J CELL BIOL, V148, P531, DOI 10.1083/jcb.148.3.531; Clarke DM, 2004, J CELL BIOL, V166, P901, DOI 10.1083/jcb.200404024; Curtis M, 2002, BIOCHEM J, V363, P233, DOI 10.1042/0264-6021:3630233; Dawe HR, 2003, CURR BIOL, V13, P252, DOI 10.1016/S0960-9822(03)00040-X; DesMarais V, 2004, J CELL SCI, V117, P3499, DOI 10.1242/jcs.01211; DesMarais V, 2005, J CELL SCI, V118, P19, DOI 10.1242/jcs.01631; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; Gupton SL, 2005, J CELL BIOL, V168, P619, DOI 10.1083/jcb.200406063; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Ichetovkin I, 2002, CURR BIOL, V12, P79, DOI 10.1016/S0960-9822(01)00629-7; IZZARD CS, 1980, J CELL SCI, V42, P81; IZZARD CS, 1976, J CELL SCI, V21, P129; Khyrul WAKM, 2004, J BIOL CHEM, V279, P54131, DOI 10.1074/jbc.M410051200; Korenbaum E, 2001, GENE, V279, P69, DOI 10.1016/S0378-1119(01)00743-0; Lin XY, 2003, CURR BIOL, V13, P922, DOI 10.1016/S0960-9822(03)00372-5; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; Mongroo PS, 2004, ONCOGENE, V23, P8959, DOI 10.1038/sj.onc.1208112; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Olski TM, 2001, J CELL SCI, V114, P525; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Ponti A, 2004, SCIENCE, V305, P1782, DOI 10.1126/science.1100533; Raymond K, 2004, J CELL SCI, V117, P2777, DOI 10.1242/jcs.01123; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Rosok O, 1999, GENOMICS, V61, P44, DOI 10.1006/geno.1999.5922; Toshima J, 1995, J BIOL CHEM, V270, P31331, DOI 10.1074/jbc.270.52.31331; Toshima J, 2001, J BIOL CHEM, V276, P31449, DOI 10.1074/jbc.M102988200; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Toshima JY, 2001, J BIOL CHEM, V276, P43471, DOI 10.1074/jbc.M104620200; TSUMURA Y, 2005, IN PRESS BIOCH J; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Zhang YJ, 2004, J BIOL CHEM, V279, P41695, DOI 10.1074/jbc.M401563200; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166	45	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21680	21688		10.1074/jbc.m500752200	http://dx.doi.org/10.1074/jbc.m500752200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15817463	hybrid			2022-12-25	WOS:000229438800095
J	Suzuki, M; Neutzner, A; Tjandra, N; Youle, RJ				Suzuki, M; Neutzner, A; Tjandra, N; Youle, RJ			Novel structure of the N terminus in yeast Fis1 correlates with a specialized function in mitochondrial fission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; DOMINANT OPTIC ATROPHY; TRIPLE-RESONANCE NMR; WD REPEAT PROTEIN; C-13-ENRICHED PROTEINS; OUTER-MEMBRANE; CHEMICAL-SHIFT; DNM1P; SPECTROSCOPY; SENSITIVITY	Mitochondrial fission is facilitated by a multiprotein complex assembled at the division site. The required components of the fission machinery in Saccharomyces cerevisiae include Dnm1, Fis1, and Mdv1. In the present study, we determined the protein structure of yeast Fis1 using NMR spectroscopy. Although the six alpha-helices, as well as their folding, in the yeast Fis1 structure are similar to those of the tetratricopeptide repeat (TPR) domains of the human Fis1 structure, the two structures differ in their N termini. The N-terminal tail of human Fis1 is flexible and unstructured, whereas a major segment of the longer N terminus of yeast Fis1 is fixed to the concave face formed by the six alpha- helices in the TPR domains. To investigate the role of the fixed N terminus, exogenous Fis1 was expressed in yeast lacking the endogenous protein. Expression of yeast Fis1 protein rescued mitochondrial fission in Delta fis1 yeast only when the N-terminal TPR binding segment was left intact. The presence of this segment is also correlated to the recruitment of Mdv1 to mitochondria. The conformation of the N- terminal segment embedded in the TPR pocket indicates an intra-molecular regulation of Fis1 bioactivity. Although the TPR-like helix bundle of Fis1 mediates the interaction with Dnm1 and Mdv1, the N terminus of Fis1 is a prerequisite to recruit Mdv1 to facilitate mitochondrial fission.	NHLBI, Biophys Chem Lab, NIH, Bethesda, MD 20892 USA; NINDS, Biochem Sect, Surg Neurol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Tjandra, N (corresponding author), NHLBI, Biophys Chem Lab, NIH, Bldg 50,Rm 3503,50 Ctr Dr,MSC 8013, Bethesda, MD 20892 USA.	nico@helix.nih.gov; youler@ninds.nih.gov	Neutzner, Albert/ABC-4368-2020	Neutzner, Albert/0000-0001-9254-5558; Suzuki, Motoshi/0000-0002-4346-7677	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002859, Z01NS002859] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Cerveny KL, 2003, MOL BIOL CELL, V14, P4126, DOI 10.1091/mbc.E03-02-0092; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Dohm JA, 2004, PROTEINS, V54, P153, DOI 10.1002/prot.10524; Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Luthy L, 2002, J BIOL CHEM, V277, P10187, DOI 10.1074/jbc.M108993200; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Santel A, 2001, J CELL SCI, V114, P867; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Suzuki M, 2003, J MOL BIOL, V334, P445, DOI 10.1016/j.jmb.2003.09.064; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; Tieu Q, 2002, J CELL BIOL, V158, P445, DOI 10.1083/jcb.200205031; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Tjandra N, 1997, J AM CHEM SOC, V119, P9576, DOI 10.1021/ja9721374; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003	49	52	59	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21444	21452		10.1074/jbc.M414092200	http://dx.doi.org/10.1074/jbc.M414092200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15809300	hybrid			2022-12-25	WOS:000229438800065
J	Mingorance, J; Tadros, M; Vicente, M; Gonzalez, JM; Rivas, G; Velez, M				Mingorance, J; Tadros, M; Vicente, M; Gonzalez, JM; Rivas, G; Velez, M			Visualization of single Escherichia coli FtsZ filament dynamics with atomic force microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVISION PROTEIN FTSZ; BACTERIAL-CELL-DIVISION; ASSEMBLY DYNAMICS; NUCLEOTIDE TURNOVER; POLYMERIZATION; TUBULIN; GTP; HYDROLYSIS; POLYMERS; HOMOLOG	FtsZ, the prokaryotic homologue of tubulin, is an essential cell division protein. In the cell, it localizes at the center, forming a ring that constricts during division. In vitro, it binds and hydrolyzes GTP and polymerizes in a GTP-dependent manner. We have used atomic force microscopy to study the structure and dynamics of FtsZ polymer assembly on a mica surface under buffer solution. The polymers were highly dynamic and flexible, and they continuously rearranged over the surface. End-to-end joining of filaments and depolymerization from internal zones were observed, suggesting that fragmentation and reannealing may contribute significantly to the dynamics of FtsZ assembly. The shape evolution of the restructured polymers manifested a strong inherent tendency to curve. Polymers formed in the presence of non-hydrolyzable nucleotide analogues or in the presence of GDP and AlF3 were structurally similar but showed a slower dynamic behavior. These results provide experimental evidence supporting the model of single-strand polymerization plus cyclization recently proposed to explain the hydrodynamic behavior of the polymers in solution.	Univ Autonoma Madrid, Fac Ciencias, Inst Nicolas Cabrera, E-28049 Madrid, Spain; Univ Autonoma Madrid, CSIC, E-28049 Madrid, Spain; Univ Autonoma Madrid, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Mingorance, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Inst Nicolas Cabrera, E-28049 Madrid, Spain.	marisela.velez@uam.es	Velez, Marisela/F-2900-2013; Rivas, German/AFL-7528-2022; Mingorance, Jesus/B-7562-2009; Rivas, German/AAG-7458-2022	Velez, Marisela/0000-0002-9424-510X; Rivas, German/0000-0003-3450-7478; Mingorance, Jesus/0000-0001-6173-5711; Rivas, German/0000-0003-3450-7478				Anderson DE, 2004, J BACTERIOL, V186, P5775, DOI 10.1128/JB.186.17.5775-5781.2004; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; CARLIER MF, 1989, BIOCHEMISTRY-US, V28, P3628, DOI 10.1021/bi00434a073; Chen YD, 2005, BIOPHYS J, V88, P505, DOI 10.1529/biophysj.104.044149; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; Gonzalez JM, 2003, J BIOL CHEM, V278, P37664, DOI 10.1074/jbc.M305230200; Gonzalez JM, 2005, P NATL ACAD SCI USA, V102, P1895, DOI 10.1073/pnas.0409517102; Huecas S, 2004, FEBS LETT, V569, P43, DOI 10.1016/j.febslet.2004.05.048; Huecas S, 2003, J BIOL CHEM, V278, P46146, DOI 10.1074/jbc.M307128200; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Mingorance J, 2001, MOL MICROBIOL, V41, P83, DOI 10.1046/j.1365-2958.2001.02498.x; Moreno-Herrero F, 2002, APPL PHYS LETT, V81, P2620, DOI 10.1063/1.1509856; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; Oliva MA, 2004, NAT STRUCT MOL BIOL, V11, P1243, DOI 10.1038/nsmb855; Oliva MA, 2003, J BIOL CHEM, V278, P33562, DOI 10.1074/jbc.M303798200; RAYCHAUDHURI D, 1994, J BIOL CHEM, V269, P22941; Rivas G, 2000, J BIOL CHEM, V275, P11740, DOI 10.1074/jbc.275.16.11740; Romberg L, 2003, ANNU REV MICROBIOL, V57, P125, DOI 10.1146/annurev.micro.57.012903.074300; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; Romberg L, 2004, BIOCHEMISTRY-US, V43, P282, DOI 10.1021/bi035465r; Rueda S, 2003, J BACTERIOL, V185, P3344, DOI 10.1128/JB.185.11.3344-3351.2003; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099	24	101	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20909	20914		10.1074/jbc.M503059200	http://dx.doi.org/10.1074/jbc.M503059200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15793307	Green Published, hybrid			2022-12-25	WOS:000229242000090
J	Yamagishi, S; Fujitani, M; Hata, K; Kitajo, K; Mimura, F; Abe, H; Yamashita, T				Yamagishi, S; Fujitani, M; Hata, K; Kitajo, K; Mimura, F; Abe, H; Yamashita, T			Wallerian degeneration involves Rho/Rho-kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD-INJURY; ENHANCES AXONAL REGENERATION; NERVOUS-SYSTEM; RHO; ACTIVATION; APOPTOSIS; NOGO	Local axon degeneration is a common pathological feature of many neurodegenerative diseases, whereas the underlying molecular mechanisms are largely unknown. In this study, we used the degeneration of transected axons, termed "Wallerian degeneration," as a model to examine the possible involvement of Rho. Nogo-66, a myelin-derived inhibitor of axon regeneration, significantly accelerated axon degeneration of the dorsal root ganglion explant in vitro, whereas inhibiting Rho-kinase activity abolished the effect. Rho activation was observed in the distal part of the injured axons after spinal cord injury. We demonstrate that degeneration of the injured cortico-spinal axons was significantly retarded by a Rho-kinase inhibitor in vivo. Our findings suggest that inhibiting the signaling pathway may retard axon degeneration in pathological conditions.	Chiba Univ, Grad Sch Med, Dept Neurobiol, Chuo Ku, Chiba 2608670, Japan	Chiba University	Yamashita, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Neurobiol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	t-yamashita@faculty.chiba-u.jp	Hata, Katsuhiko/AAA-5015-2021; Fujitani, Masashi/AAD-8874-2022	Yamashita, Toshihide/0000-0003-4559-7018; Fujitani, Masashi/0000-0002-1731-9793				Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Dergham P, 2002, J NEUROSCI, V22, P6570; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Finn JT, 2000, J NEUROSCI, V20, P1333; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896-6273(02)00621-9; Madura T, 2004, EMBO REP, V5, P412, DOI 10.1038/sj.embor.7400117; McKerracher L, 2002, NEURON, V36, P345, DOI 10.1016/S0896-6273(02)01018-8; Messler W, 1997, NATURE, V385, P151, DOI 10.1038/385151a0; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Rico B, 2004, NAT NEUROSCI, V7, P1059, DOI 10.1038/nn1317; Tanaka H, 2004, NEUROSCIENCE, V127, P155, DOI 10.1016/j.neuroscience.2004.05.010; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhai QW, 2003, NEURON, V39, P217, DOI 10.1016/S0896-6273(03)00429-X	16	36	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20384	20388		10.1074/jbc.M501945200	http://dx.doi.org/10.1074/jbc.M501945200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15799964	hybrid			2022-12-25	WOS:000229242000029
J	Yamaguchi, Y; Kuroki, T; Yasuzawa, H; Higashi, T; Jin, WC; Kawanami, A; Yamagata, Y; Arakawa, Y; Goto, M; Kurosaki, H				Yamaguchi, Y; Kuroki, T; Yasuzawa, H; Higashi, T; Jin, WC; Kawanami, A; Yamagata, Y; Arakawa, Y; Goto, M; Kurosaki, H			Probing the role of Asp-120(81) of metallo-beta-lactamase (IMP-1) by site-directed mutagenesis, kinetic studies, and X-ray crystallography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; BACTEROIDES-FRAGILIS; SERRATIA-MARCESCENS; BIOCHEMICAL-CHARACTERIZATION; CRYSTAL-STRUCTURE; CLINICAL ISOLATE; ACTIVE-SITE; INHIBITORS; GENE; MECHANISM	Metallo-beta-lactamase IMP-1 is a di-Zn(II) metalloenzyme that efficiently hydrolyzes beta-lactam antibiotics. Wild-type (WT) IMP-1 has a conserved Asp-120(81) in the active site, which plays an important role in catalysis. To probe the catalytic role of Asp-120( 81) in IMP-1, the IMP-1 mutants, D120(81)A and D120(81)E, were prepared by site-directed mutagenesis, and various kinetics studies were conducted. The IMP-1 mutants exhibited 10(2)-10(4)-fold drops in k(cat) values compared with WT despite the fact that they contained two Zn(II) ions in the active site. To evaluate the acid-base characteristics of Asp-120( 81), the pH dependence for hydrolysis was examined by stopped-flow studies. No observable pK(a) values between pH 5 and 9 were found for WT and D120( 81) A. The rapid mixing of equimolar amounts of nitrocefin and all enzymes failed to result in the detection of an anion intermediate of nitrocefin at 650 nm. These results suggest that Asp-120( 81) of IMP-1 is not a factor in decreasing the pKa for the water bridging two Zn( II) ions and is not a proton donor to the anionic intermediate. In the case of D120( 81) E, the nitrocefin hydrolysis product, which shows a maximum absorption at 460 nm, was bound to D120( 81) E in the protonated form. The three-dimensional structures of D120( 81) A and D120( 81) E were also determined at 2.0 and 3.0 angstrom resolutions, respectively. In the case of D120(81) E, the Zn-Zn distance was increased by 0.3 angstrom compared with WT, due to the change in the coordination mode of Glu-120(81)OE1 and the positional shift in the conserved His-263(197) at the active site.	Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Struct Funct Phys Chem, Kumamoto 8620973, Japan; Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Kumamoto 8620973, Japan; Natl Inst Infect Dis, Dept Bacterial Pathogenesis & Infect Control, Tokyo 2080011, Japan	Kumamoto University; Kumamoto University; National Institute of Infectious Diseases (NIID)	Yamaguchi, Y (corresponding author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Struct Funct Phys Chem, 5-1 Oe Honmachi, Kumamoto 8620973, Japan.	yyamagu@gpo.kumamoto-u.ac.jp	Yamagata, Yoshiki/T-6489-2019; jin, wanchun/B-8463-2016; Arakawa, Yoshichika/P-5997-2015					AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; ARAKAWA Y, 1995, ANTIMICROB AGENTS CH, V39, P1612, DOI 10.1128/AAC.39.7.1612; Bellais S, 2000, ANTIMICROB AGENTS CH, V44, P1878, DOI 10.1128/AAC.44.7.1878-1886.2000; BICKNELL R, 1985, BIOCHEMISTRY-US, V24, P6876, DOI 10.1021/bi00345a021; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bush K, 1998, CLIN INFECT DIS, V27, pS48, DOI 10.1086/514922; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Diaz N, 2000, J AM CHEM SOC, V122, P4197, DOI 10.1021/ja994462s; Docquier JD, 2002, ANTIMICROB AGENTS CH, V46, P1823, DOI 10.1128/AAC.46.6.1823-1830.2002; FELICI A, 1993, BIOCHEM J, V291, P151, DOI 10.1042/bj2910151; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Garrity JD, 2004, J BIOL CHEM, V279, P920, DOI 10.1074/jbc.M309852200; Goto M, 2003, BIOL PHARM BULL, V26, P589; Goto M, 1997, BIOL PHARM BULL, V20, P1136, DOI 10.1248/bpb.20.1136; Greenlee ML, 1999, BIOORG MED CHEM LETT, V9, P2549, DOI 10.1016/S0960-894X(99)00425-4; Haruta S, 2000, ANTIMICROB AGENTS CH, V44, P2304, DOI 10.1128/AAC.44.9.2304-2309.2000; HUSSAIN M, 1985, J BACTERIOL, V164, P223, DOI 10.1128/JB.164.1.223-229.1985; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaminskaia NV, 2000, J AM CHEM SOC, V122, P6411, DOI 10.1021/ja993704l; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Kurosaki H, 2003, ORG BIOMOL CHEM, V1, P17, DOI 10.1039/b209086d; Laraki N, 1999, ANTIMICROB AGENTS CH, V43, P902, DOI 10.1128/AAC.43.4.902; MASSIDDA O, 1991, J BACTERIOL, V173, P4611, DOI 10.1128/jb.173.15.4611-4617.1991; McManus-Munoz S, 1999, BIOCHEMISTRY-US, V38, P1547, DOI 10.1021/bi9826512; Mercuri PS, 2001, ANTIMICROB AGENTS CH, V45, P1254, DOI 10.1128/AAC.45.4.1254-1262.2001; Moali C, 2003, CHEM BIOL, V10, P319, DOI 10.1016/S1074-5521(03)00070-X; Mollard C, 2001, J BIOL CHEM, V276, P45015, DOI 10.1074/jbc.M107054200; Nagano R, 1999, ANTIMICROB AGENTS CH, V43, P2497, DOI 10.1128/AAC.43.10.2497; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Oelschlaeger P, 2003, PROTEIN ENG, V16, P341, DOI 10.1093/protein/gzg049; OSANO E, 1994, ANTIMICROB AGENTS CH, V38, P71, DOI 10.1128/AAC.38.1.71; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Payne DJ, 2002, ANTIMICROB AGENTS CH, V46, P1880, DOI 10.1128/AAC.46.6.1880-1886.2002; Poirel L, 2000, ANTIMICROB AGENTS CH, V44, P891, DOI 10.1128/AAC.44.4.891-897.2000; RASMUSSEN BA, 1990, ANTIMICROB AGENTS CH, V34, P1590, DOI 10.1128/AAC.34.8.1590; Rossolini GM, 1998, BIOCHEM J, V332, P145, DOI 10.1042/bj3320145; Rossolini GM, 2001, ANTIMICROB AGENTS CH, V45, P837, DOI 10.1128/AAC.45.3.837-844.2001; Siemann S, 2002, ANTIMICROB AGENTS CH, V46, P2450, DOI 10.1128/AAC.46.8.2450-2457.2002; Suarez D, 2002, BIOCHEMISTRY-US, V41, P6615, DOI 10.1021/bi0121860; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Toney JH, 1999, BIOORG MED CHEM LETT, V9, P2741, DOI 10.1016/S0960-894X(99)00458-8; Walsh TR, 1996, J ANTIMICROB CHEMOTH, V37, P423, DOI 10.1093/jac/37.3.423; Wang ZG, 1998, J AM CHEM SOC, V120, P10788, DOI 10.1021/ja982621m; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1998, J BIOL CHEM, V273, P22402, DOI 10.1074/jbc.273.35.22402; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524	47	51	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20824	20832		10.1074/jbc.M414314200	http://dx.doi.org/10.1074/jbc.M414314200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788415	hybrid			2022-12-25	WOS:000229242000080
J	Ledl, A; Schmidt, D; Muller, S				Ledl, A; Schmidt, D; Muller, S			Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor	ONCOGENE			English	Article						SUMO; pRB; viral oncoproteins; LxCxE	LARGE T-ANTIGEN; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; STRUCTURAL BASIS; GENE-EXPRESSION; CYCLE ARREST; P53 ACTIVITY; C-JUN; RB; PRB	The retinoblastoma tumor suppressor protein (pRB) is a major regulator of cell-cycle progression and cellular differentiation. Central to pRB function is the pocket domain, which serves as the main binding region for cellular regulators. In tumors pRB is frequently inactivated by mutations in the pocket domain or by binding of viral oncoproteins to this region. A characteristic feature of these viral oncoproteins and many cellular pRB-binding partners is an LxCxE sequence motif, which interacts with pRB's pocket domain. Here, we show that the ubiquitin-like modi. er SUMO is covalently attached to a distinct residue (K720) of pRB within the B-box of the pocket region that binds LxCxE-motif proteins. We provide evidence that SUMO preferentially targets the active, hypophosphorylated form of pRB and show that tumorigenic mutations of pRB in the pocket domain lead to a loss of SUMOylation. Notably, the level of pRB SUMOylation is controlled by the interaction of pRB with viral and cellular LxCxE-motif proteins. Inhibitors of pRB function, including the viral oncoproteins E1A and E7 and the cellular E1A-like inhibitor of differentiation EID-1, completely abolish SUMO modi. cation of pRB. Conversely, pRB mutants deficient in binding of LxCxE-motif proteins exhibit a drastically enhanced modification by SUMO. Finally, we provide evidence that SUMOylation can influence pRB function, as the SUMO-deficient pRB(K720R) mutant exerts a slightly higher repressive potential on an E2F-responsive reporter gene than wildtype pRB. Taken together, these data identify SUMO modification as a novel post-translational modification of pRB that may control pRB activity by modulating LxCxE - pocket interactions.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Muller, S (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	stmuelle@biochem.mpg.de		Muller, Stefan/0000-0002-8792-7700				Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brown VD, 2002, MOL CELL BIOL, V22, P1390, DOI 10.1128/MCB.22.5.1390-1401.2002; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; Dick FA, 2002, J VIROL, V76, P6224, DOI 10.1128/JVI.76.12.6224-6234.2002; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Takaki T, 2004, BIOCHEM BIOPH RES CO, V316, P252, DOI 10.1016/j.bbrc.2004.02.044; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wen H, 2001, GENE, V263, P85, DOI 10.1016/S0378-1119(00)00585-0; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	49	84	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3810	3818		10.1038/sj.onc.1208539	http://dx.doi.org/10.1038/sj.onc.1208539			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15806172				2022-12-25	WOS:000229346300011
J	Sugita, H; Fujimoto, M; Yasukawa, T; Shimizu, N; Sugita, M; Yasuhara, S; Martyn, JAJ; Kaneki, M				Sugita, H; Fujimoto, M; Yasukawa, T; Shimizu, N; Sugita, M; Yasuhara, S; Martyn, JAJ; Kaneki, M			Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; OXIDATIVE STRESS; S-NITROSYLATION; TYROSINE PHOSPHORYLATION; ENDOTHELIAL DYSFUNCTION; TARGETED DISRUPTION; MURINE MACROPHAGES; NITROSATIVE STRESS; DIABETES-MELLITUS	Chronic inflammation plays an important role in insulin resistance. Inducible nitric- oxide synthase ( iNOS), a mediator of inflammation, has been implicated in many human diseases including insulin resistance. However, the molecular mechanisms by which iNOS mediates insulin resistance remain largely unknown. Here we demonstrate that exposure to NO donor or iNOS transfection reduced insulin receptor substrate ( IRS)- 1 protein expression without altering the mRNA level in cultured skeletal muscle cells. NO donor increased IRS- 1 ubiquitination, and proteasome inhibitors blocked NO donor- induced reduction in IRS- 1 expression in cultured skeletal muscle cells. The effect of NO donor on IRS- 1 expression was cGMP- independent and accentuated by concomitant oxidative stress, suggesting an involvement of nitrosative stress. Inhibitors for phosphatidylinositol- 3 kinase, mammalian target of rapamycin, and c- Jun amino- terminal kinase failed to block NO donor- induced IRS- 1 reduction, whereas these inhibitors prevented insulin- stimulated IRS- 1 decrease. Moreover iNOS expression was increased in skeletal muscle of diabetic ( ob/ ob) mice compared with lean wild- type mice. iNOS gene disruption or treatment with iNOS inhibitor ameliorated depressed IRS- 1 expression in skeletal muscle of diabetic ( ob/ ob) mice. These findings indicate that iNOS reduces IRS- 1 expression in skeletal muscle via proteasome- mediated degradation and thereby may contribute to obesity- related insulin resistance.	Harvard Univ, Sch Med, Shriners Hosp Children, Massachusetts Gen Hosp,Dept Anesthesia & Crit Car, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Kaneki, M (corresponding author), Harvard Univ, Sch Med, Shriners Hosp Children, Massachusetts Gen Hosp,Dept Anesthesia & Crit Car, 149 13th St,Rm 6604, Charlestown, MA 02129 USA.	mkaneki@partners.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM021700, R01GM031569, R01GM061411, R01GM055082] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK058127] Funding Source: Medline; NIGMS NIH HHS [R01GM061411, R01 GM055082, R01GM055082, GM21700, R01GM031569] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bedard S, 1997, BIOCHEM J, V325, P487, DOI 10.1042/bj3250487; Beltran B, 2000, BRIT J PHARMACOL, V129, P953, DOI 10.1038/sj.bjp.0703147; Blottner D, 1998, CELL TISSUE RES, V292, P293, DOI 10.1007/s004410051060; Brozinick JT, 2003, DIABETES, V52, P935, DOI 10.2337/diabetes.52.4.935; Buren J, 2003, EUR J ENDOCRINOL, V148, P157, DOI 10.1530/eje.0.1480157; Carvalho Eugenia, 2001, FASEB Journal, V15, P1101; Catalano PM, 2002, AM J PHYSIOL-ENDOC M, V282, pE522, DOI 10.1152/ajpendo.00124.2001; Ceriello A, 2002, DIABETES, V51, P1076, DOI 10.2337/diabetes.51.4.1076; De Vriese AS, 2000, BRIT J PHARMACOL, V130, P963, DOI 10.1038/sj.bjp.0703393; Detmers PA, 2000, J IMMUNOL, V165, P3430, DOI 10.4049/jimmunol.165.6.3430; Drew B, 2002, ANN NY ACAD SCI, V959, P66, DOI 10.1111/j.1749-6632.2002.tb02084.x; Elizalde M, 2000, J LIPID RES, V41, P1244; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Evans JL, 2003, DIABETES, V52, P1, DOI 10.2337/diabetes.52.1.1; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Friedman JE, 1997, AM J PHYSIOL-ENDOC M, V273, pE1014, DOI 10.1152/ajpendo.1997.273.5.E1014; Fujimoto M, 2003, BIOCHEM BIOPH RES CO, V305, P1002, DOI 10.1016/S0006-291X(03)00885-4; Fujiwara N, 2000, CIRCULATION, V101, P856, DOI 10.1161/01.CIR.101.8.856; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Gaston Benjamin M, 2003, Mol Interv, V3, P253, DOI 10.1124/mi.3.5.253; Gath I, 1999, BIOCHEM J, V340, P723, DOI 10.1042/0264-6021:3400723; Gath I, 1996, FASEB J, V10, P1614, DOI 10.1096/fasebj.10.14.9002553; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Hamilton CA, 2001, HYPERTENSION, V37, P529, DOI 10.1161/01.HYP.37.2.529; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hirashima Y, 2003, J ENDOCRINOL, V179, P253, DOI 10.1677/joe.0.1790253; Hirose M, 2000, AM J PHYSIOL-ENDOC M, V279, pE1235, DOI 10.1152/ajpendo.2000.279.6.E1235; Honing MLH, 1998, DIABETES METAB REV, V14, P241, DOI 10.1002/(SICI)1099-0895(1998090)14:3<241::AID-DMR216>3.0.CO;2-R; Jansson PA, 2003, FASEB J, V17, P1434, DOI 10.1096/fj.02-1132com; Kaneki M, 1999, MOL CELL BIOL, V19, P461; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kido Y, 2001, J CLIN ENDOCR METAB, V86, P972, DOI 10.1210/jc.86.3.972; Kim YB, 1996, METABOLISM, V45, P1080, DOI 10.1016/S0026-0495(96)90006-2; Kisley LR, 2002, CANCER RES, V62, P6850; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Kuncewicz T, 2001, AM J PHYSIOL-RENAL, V281, pF326, DOI 10.1152/ajprenal.2001.281.2.F326; KUO PC, 1995, ANN SURG, V221, P220, DOI 10.1097/00000658-199503000-00003; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; Liberatore GT, 1999, NAT MED, V5, P1403; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Lyall F, 1998, DIABETES CARE, V21, P1753, DOI 10.2337/diacare.21.10.1753; Maccarrone M, 1997, FEBS LETT, V410, P470, DOI 10.1016/S0014-5793(97)00643-1; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Padron J, 2000, BIOCHEM BIOPH RES CO, V271, P217, DOI 10.1006/bbrc.2000.2617; Park CS, 1996, LIFE SCI, V59, P219, DOI 10.1016/0024-3205(96)00287-1; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Perreault M, 2001, NAT MED, V7, P1138, DOI 10.1038/nm1001-1138; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; Rondinone CM, 2002, BIOCHEM BIOPH RES CO, V296, P1257, DOI 10.1016/S0006-291X(02)02083-1; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sesti G, 2001, FASEB J, V15, P2099, DOI 10.1096/fj.01-0009rev; SHARMA K, 1995, BIOCHEM BIOPH RES CO, V207, P80, DOI 10.1006/bbrc.1995.1156; Shimabukuro M, 1998, J BIOL CHEM, V273, P32487, DOI 10.1074/jbc.273.49.32487; Shirakami A, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740309; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; Strand OA, 2000, CRIT CARE MED, V28, P2779, DOI 10.1097/00003246-200008000-00017; Sugita H, 2002, AM J PHYSIOL-ENDOC M, V282, pE386, DOI 10.1152/ajpendo.00087.2001; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Takata M, 2001, AM J PHYSIOL-LUNG C, V280, pL272, DOI 10.1152/ajplung.2001.280.2.L272; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tannous M, 1999, DIABETOLOGIA, V42, P539, DOI 10.1007/s001250051192; Torres SH, 2004, J ENDOCRINOL, V181, P419, DOI 10.1677/joe.0.1810419; Warnholtz A, 2002, J AM COLL CARDIOL, V40, P1356, DOI 10.1016/S0735-1097(02)02133-2; Watanabe T, 2000, CLIN CHIM ACTA, V301, P169, DOI 10.1016/S0009-8981(00)00340-5; Wink DA, 2000, SEMIN PERINATOL, V24, P20, DOI 10.1016/S0146-0005(00)80049-X; Yoon Y, 2000, CLIN CHEM, V46, P1626; Young ME, 1998, BIOCHEM J, V329, P73; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002	77	89	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14203	14211		10.1074/jbc.M411226200	http://dx.doi.org/10.1074/jbc.M411226200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15805118	hybrid			2022-12-25	WOS:000228095500123
J	Liu, RY; Loll, PJ; Eckenhoff, RG				Liu, RY; Loll, PJ; Eckenhoff, RG			Structural basis for high-affinity volatile anesthetic binding in a natural 4-helix bundle protein	FASEB JOURNAL			English	Article						anesthesia; halothane; isofurane; X-ray ctystallography; calorimetry; ferritin	POSTOPERATIVE COGNITIVE DYSFUNCTION; RESOLUTION CRYSTAL-STRUCTURES; HUMAN SERUM-ALBUMIN; GENERAL-ANESTHETICS; 4-ALPHA-HELIX BUNDLE; FIREFLY LUCIFERASE; HALOTHANE; MECHANISMS; RECEPTORS; FERRITIN	Physiologic sites for inhaled anesthetics are presumed to be cavities within transmembrane 4-alpha-helix bundles of neurotransmitter receptors, but confirmation of binding and structural detail of such sites remains elusive. To provide such detail, we screened soluble proteins containing this structural motif, and found only one that exhibited evidence of strong anesthetic binding. Ferritin is a 24-mer of 4-alpha-helix bundles; both halothane and isoflurane bind with K-A values of similar to 10(5) M-1, higher than any previously reported inhaled anesthetic-protein interaction. The crystal structures of the halothane/apoferritin and isoflurane/apoferritin complexes were determined at 1.75 angstrom resolution, revealing a common anesthetic binding pocket within an interhelical dimerization interface. The high affinity is explained by several weak polar contacts and an optimal host/guest packing relationship. Neither the acidic protons nor ether oxygen of the anesthetics contribute to the binding interaction. Compared with unliganded apoferritin, the anesthetic produced no detectable alteration of structure or B factors. The remarkably high affinity of the anesthetic/apoferritin complex implies greater selectivity of protein sites than previously thought, and suggests that direct protein actions may underlie effects at lower than surgical levels of anesthetic, including loss of awareness.	Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Drexel Univ, Coll Med, Dept Biochem, Philadelphia, PA 19104 USA	University of Pennsylvania; Drexel University	Eckenhoff, RG (corresponding author), Univ Penn, Dept Anesthesia, 305 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	roderiic.eckenhoff@uphs.upenn.edu		Eckenhoff, Roderic/0000-0002-5581-746X	PHS HHS [P-01 55876] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Chiara DC, 2003, BIOCHEMISTRY-US, V42, P13457, DOI 10.1021/bi0351561; DICKINSON R, 1993, BIOPHYS J, V64, P1264, DOI 10.1016/S0006-3495(93)81491-7; DIPAULO T, 1974, NATURE, V252, P171; Eckenhoff MF, 1998, J PHARMACOL EXP THER, V285, P371; Eckenhoff R G, 2001, Mol Interv, V1, P258; Evans G, 2002, ACTA CRYSTALLOGR D, V58, P976, DOI 10.1107/S0907444902005486; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Franks NP, 1998, BIOPHYS J, V75, P2205, DOI 10.1016/S0006-3495(98)77664-7; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hempstead PD, 1997, J MOL BIOL, V268, P424, DOI 10.1006/jmbi.1997.0970; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Johansson JS, 2000, BIOPHYS J, V78, P982, DOI 10.1016/S0006-3495(00)76656-2; Johansson JS, 2005, FEBS J, V272, P573, DOI 10.1111/j.1742-4658.2004.04500.x; Johnson T, 2002, ANESTHESIOLOGY, V96, P1351, DOI 10.1097/00000542-200206000-00014; Jurd R, 2002, FASEB J, V16, P250, DOI 10.1096/fj.02-0611fje; Ke Y, 2003, LANCET NEUROL, V2, P246, DOI 10.1016/S1474-4422(03)00353-3; KENDIG JJ, 1994, EUR J PHARMACOL, V264, P427, DOI 10.1016/0014-2999(94)00499-4; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Liu R, 2002, J BIOL CHEM, V277, P36373, DOI 10.1074/jbc.M205479200; Liu ZW, 2004, J PHYS CHEM A, V108, P781, DOI 10.1021/jp0368482; Manderson GA, 2002, BIOCHEMISTRY-US, V41, P4080, DOI 10.1021/bi0160718; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Mecozzi S, 1998, CHEM-EUR J, V4, P1016, DOI 10.1002/(SICI)1521-3765(19980615)4:6<1016::AID-CHEM1016>3.0.CO;2-B; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Moller JT, 1998, LANCET, V351, P1742; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Olsen JA, 2004, CHEMBIOCHEM, V5, P666, DOI 10.1002/cbic.200300907; PRECIGOUX G, 1994, ACTA CRYSTALLOGR D, V50, P739, DOI 10.1107/S0907444994003227; Raines DE, 1996, ANESTHESIOLOGY, V84, P663, DOI 10.1097/00000542-199603000-00022; Scharf D, 1996, CHEM PHYS LETT, V258, P276, DOI 10.1016/0009-2614(96)00652-5; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; SEDENSKY MM, 1987, SCIENCE, V236, P952, DOI 10.1126/science.3576211; Tang P, 2002, P NATL ACAD SCI USA, V99, P16035, DOI 10.1073/pnas.252522299; Tang P, 2001, J COMPUT CHEM, V22, P436, DOI 10.1002/1096-987X(200103)22:4<436::AID-JCC1014>3.0.CO;2-U; Theil E. C., 2001, HDB METALLOPROTEINS, P771; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; Trudell JR, 2002, BBA-BIOMEMBRANES, V1565, P91, DOI 10.1016/S0005-2736(02)00512-6; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xi J, 2004, J BIOL CHEM, V279, P19628, DOI 10.1074/jbc.M313864200	46	102	105	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					567	576		10.1096/fj.04-3171com	http://dx.doi.org/10.1096/fj.04-3171com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791007				2022-12-25	WOS:000228865300041
J	Pullamsetti, S; Kiss, L; Ghofrani, HA; Voswinckel, R; Haredza, P; Klepetko, W; Aigner, C; Fink, L; Muyal, JP; Weissmann, N; Grimminger, F; Seeger, W; Schermuly, RT				Pullamsetti, S; Kiss, L; Ghofrani, HA; Voswinckel, R; Haredza, P; Klepetko, W; Aigner, C; Fink, L; Muyal, JP; Weissmann, N; Grimminger, F; Seeger, W; Schermuly, RT			Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension	FASEB JOURNAL			English	Article						PAH; DDAH; SDMA	NITRIC-OXIDE SYNTHASE; L-ARGININE; ENDOTHELIAL DYSFUNCTION; PLASMA-LEVELS; EXPRESSION; IDENTIFICATION; DYSREGULATION; METABOLISM; INHIBITOR; PATHWAY	Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS) and has been implicated in endothelial dysfunction. ADMA is metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH), with DDAH2 representing the predominant endothelial DDAH isoform. Symmetric dimethylarginine (SDMA), also originating from arginine methylation by protein arginine methyltransferases, is an inhibitor of intracellular arginine uptake. In both chronic pulmonary hypertensive rats and patients suffering from idiopathic pulmonary arterial hypertension (IPAH; NYHA class III and IV), a marked increase in plasma ADMA and SDMA levels, as well as tissue levels of asymmetric and symmetric dimethylated proteins, was observed. Moreover, when comparing lung tissue from pulmonary hypertensive rats and IPAH patients to corresponding normal lung tissue, expression of DDAH2 was found to be reduced at both the mRNA and the protein level with no significant changes in DDAH1 expression. These findings were further supported by demonstrating a decrease in DDAH2 function in the experimental pulmonary hypertension model. Immunohistochemistry in human and rat control tissue demonstrated both isoforms of DDAH in the endothelial layer and in the alveolar epithelium. In contrast, in pulmonary hypertensive tissue, the immunoreactivity of DDAH2 in pulmonary endothelium was significantly decreased compared with DDAH1. Therefore, altogether we can conclude that enhanced dimethylarginine levels may contribute to vascular abnormalities in pulmonary arterial hypertension. Suppression of endothelial DDAH2 expression and function represents an important underlying mechanism.	Univ Giessen, Dept Internal Med, D-35392 Giessen, Germany; Univ Vienna, Dept Cardiothorac Surg, A-1090 Vienna, Austria; Univ Giessen, Dept Pathol, D-35392 Giessen, Germany	Justus Liebig University Giessen; University of Vienna; Justus Liebig University Giessen	Schermuly, RT (corresponding author), Med Klin, Klin Str 36, D-35392 Giessen, Germany.	ralph.schermuly@innere.med.uni-giessen.de	Ghofrani, Hossein Ardeschir/AAD-2856-2022; Ghofrani, Ardeschir/AAD-5293-2020; Aigner, Clemens/A-7284-2019	Ghofrani, Ardeschir/0000-0002-2029-4419; Aigner, Clemens/0000-0002-7787-991X; Schermuly, Ralph/0000-0002-5167-6970; Weissmann, Norbert/0000-0003-2675-3871; Pullamsetti, Soni Savai/0000-0003-0440-8831; Seeger, Werner/0000-0003-1946-0894; Grimminger, Friedrich/0000-0001-8725-6276				Abbasi F, 2001, AM J CARDIOL, V88, P1201, DOI 10.1016/S0002-9149(01)02063-X; Achan V, 2002, CIRC RES, V90, P764, DOI 10.1161/01.RES.0000014450.40853.2B; Alonso D, 2003, HEART FAIL REV, V8, P107, DOI 10.1023/A:1022155206928; Ameshima S, 2003, CIRC RES, V92, P1162, DOI 10.1161/01.RES.0000073585.50092.14; Arrigoni FI, 2003, CIRCULATION, V107, P1195, DOI 10.1161/01.CIR.0000051466.00227.13; Azuma H, 1999, Nihon Yakurigaku Zasshi, V114 Suppl 1, p33P; Boger RH, 1998, CIRCULATION, V98, P1842, DOI 10.1161/01.CIR.98.18.1842; Boger RH, 2000, CIRCULATION, V101, pE160; Boger RH, 2000, CIRC RES, V87, P99, DOI 10.1161/01.RES.87.2.99; Bowers R, 2004, AM J RESP CRIT CARE, V169, P764, DOI 10.1164/rccm.200301-147OC; Closs EI, 1997, NITRIC OXIDE-BIOL CH, V1, P65, DOI 10.1006/niox.1996.0106; Cooke JP, 2004, CIRCULATION, V109, P1813, DOI 10.1161/01.CIR.0000126823.07732.D5; Cracowski JL, 2001, AM J RESP CRIT CARE, V164, P1038, DOI 10.1164/ajrccm.164.6.2104033; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Gorenflo M, 2001, J CARDIOVASC PHARM, V37, P489, DOI 10.1097/00005344-200104000-00016; Ito A, 1999, CIRCULATION, V99, P3092, DOI 10.1161/01.CIR.99.24.3092; ITO K, 1988, BRIT J PHARMACOL, V94, P1175, DOI 10.1111/j.1476-5381.1988.tb11636.x; Ito KM, 2000, AM J PHYSIOL-HEART C, V279, pH1786, DOI 10.1152/ajpheart.2000.279.4.H1786; Jones LC, 2003, BIOCHEM BIOPH RES CO, V310, P836, DOI 10.1016/j.bbrc.2003.09.097; Knipp M, 2000, ANAL BIOCHEM, V286, P257, DOI 10.1006/abio.2000.4805; Leiper JM, 1999, BIOCHEM J, V343, P209, DOI 10.1042/0264-6021:3430209; Lin KY, 2002, CIRCULATION, V106, P987, DOI 10.1161/01.CIR.0000027109.14149.67; Lu TM, 2004, AM J CARDIOL, V94, P157, DOI 10.1016/j.amjcard.2004.03.052; Luscher TF, 2000, CIRCULATION, V102, P2434, DOI 10.1161/01.CIR.102.19.2434; MEHTA S, 1995, CIRCULATION, V92, P1539, DOI 10.1161/01.CIR.92.6.1539; Millatt LJ, 2003, CIRCULATION, V108, P1493, DOI 10.1161/01.CIR.0000089087.25930.FF; MOLTENI A, 1984, P SOC EXP BIOL MED, V176, P88; Nagaya N, 2001, AM J RESP CRIT CARE, V163, P887, DOI 10.1164/ajrccm.163.4.2007116; Nakazawa H, 1999, BRIT J PHARMACOL, V128, P1098, DOI 10.1038/sj.bjp.0702878; OGAWA T, 1987, ARCH BIOCHEM BIOPHYS, V252, P526, DOI 10.1016/0003-9861(87)90060-9; Ohnishi M, 2002, CLIN SCI, V103, p241S, DOI 10.1042/CS103S241S; Piatti PM, 2003, CIRCULATION, V107, P429, DOI 10.1161/01.CIR.0000046489.24563.79; Schermuly RT, 2004, CIRC RES, V94, P1101, DOI 10.1161/01.RES.0000126050.41296.8E; Schermuly RT, 2004, AM J RESP CRIT CARE, V169, P39, DOI 10.1164/rccm.200302-282OC; Simonneau G, 2004, J AM COLL CARDIOL, V43, p5S, DOI 10.1016/j.jacc.2004.02.037; Stuhlinger MC, 2003, CIRCULATION, V108, P933, DOI 10.1161/01.CIR.0000085067.55901.89; Stuhlinger MC, 2002, JAMA-J AM MED ASSOC, V287, P1420, DOI 10.1001/jama.287.11.1420; Sydow K, 2003, ATHEROSCLEROSIS SUPP, V4, P41, DOI 10.1016/S1567-5688(03)00033-3; Teerlink T, 2002, ANAL BIOCHEM, V303, P131, DOI 10.1006/abio.2001.5575; Weis M, 2004, CIRCULATION, V109, P500, DOI 10.1161/01.CIR.0000109692.16004.AF	44	143	150	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1175	+		10.1096/fj.04-3223fje	http://dx.doi.org/10.1096/fj.04-3223fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15827267				2022-12-25	WOS:000228865300018
J	Zhu, BM; Ramachandran, B; Gulick, T				Zhu, BM; Ramachandran, B; Gulick, T			Alternative pre-mRNA splicing governs expression of a conserved acidic transactivation domain in myocyte enhancer factor 2 factors of striated muscle and brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MEF2C; PROTEIN SECONDARY STRUCTURE; MYOSIN HEAVY-CHAIN; DNA-BINDING; MADS-BOX; GENE-EXPRESSION; HISTONE DEACETYLASES; DIFFERENT ISOFORMS; NEURONAL-ACTIVITY; MYOGENIC BHLH	Myocyte enhancer factor 2 ( MEF2) transcription factors play pivotal roles in striated muscle, neuron, and lymphocyte gene expression and are targets of stress- and calcium-mediated signaling. All MEF2 gene products have a common DNA binding and dimerization domain, but MEF2 transcripts are alternatively spliced among coding exons to produce splicing isoforms. In vertebrate MEF2A, -C, and -D, a splice versus no-splice option gives forms that include or exclude a short domain that we designate beta. We show that mRNAs containing beta are expressed predominantly in striated muscle and brain and that splicing to include beta is induced during myocyte differentiation. MEF2 beta+ isoforms are more robust than beta+ forms in activating MEF2-responsive reporters despite similar expression levels. One-hybrid transcription assays using Gal4-MEF2 fusions show similar distinctions in the transactivation produced by beta+ versus beta+ isoforms in all cell types tested, including myocytes. beta function is position-independent and exists in all MEF2 splicing variant contexts. The activity is not due to cis effects on MEF2 DNA binding or dimerization nor are established transcription factor or coactivator interactions involved. Each MEF2 beta domain contains multiple acidic residues, mutation of which abolishes function. Despite a location between the p38 MAPK docking domain and Thr phosphoacceptors of MEF2A and MEF2C, inclusion of beta does not influence responses of these factors to this signaling pathway. Thus, a conserved pattern of alternative splicing in vertebrate MEF2 genes generates an acidic activation domain in MEF2 proteins selectively in tissues where MEF2 target genes are highly expressed.	Massachusetts Gen Hosp, Diabet Res Lab, Dept Med, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Gulick, T (corresponding author), Massachusetts Gen Hosp, Diabet Res Lab, Dept Med, CNY 1498219, Charlestown, MA 02129 USA.	gulick@helix.mgh.harvard.edu			NHLBI NIH HHS [HL72713] Funding Source: Medline; NIDDK NIH HHS [DK02461, P30 DK40561, DK55875] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K02DK002461, P30DK040561, R01DK055875] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Bergstrom DA, 2002, MOL CELL, V9, P587, DOI 10.1016/S1097-2765(02)00481-1; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1997, MOL CELL BIOL, V17, P2756, DOI 10.1128/MCB.17.5.2756; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Cox DM, 2003, J BIOL CHEM, V278, P15297, DOI 10.1074/jbc.M211312200; Czubryt MP, 2004, RECENT PROG HORM RES, V59, P105, DOI 10.1210/rp.59.1.105; De Angelis L, 1998, P NATL ACAD SCI USA, V95, P12358, DOI 10.1073/pnas.95.21.12358; De Val S, 2004, DEV BIOL, V275, P424, DOI 10.1016/j.ydbio.2004.08.016; Dodou E, 2004, DEVELOPMENT, V131, P3931, DOI 10.1242/dev.01256; DODOU E, 1995, NUCLEIC ACIDS RES, V23, P4267, DOI 10.1093/nar/23.21.4267; Dodou E, 2003, MECH DEVELOP, V120, P1021, DOI 10.1016/S0925-4773(03)00178-3; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Gaudilliere B, 2002, J BIOL CHEM, V277, P46442, DOI 10.1074/jbc.M206653200; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Gillardon F, 2005, PROTEOMICS, V5, P1299, DOI 10.1002/pmic.200400992; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Grayson J, 1998, J CELL BIOCHEM, V70, P366, DOI 10.1002/(SICI)1097-4644(19980901)70:3<366::AID-JCB10>3.3.CO;2-T; Gruffat H, 2002, EMBO REP, V3, P141, DOI 10.1093/embo-reports/kvf031; Gunthorpe D, 1999, DEV BIOL, V215, P130, DOI 10.1006/dbio.1999.9449; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; Han AD, 2005, J MOL BIOL, V345, P91, DOI 10.1016/j.jmb.2004.10.033; Han AD, 2003, NATURE, V422, P730, DOI 10.1038/nature01555; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Heidenreich KA, 2004, MOL NEUROBIOL, V29, P155, DOI 10.1385/MN:29:2:155; Janson CG, 2001, MOL BRAIN RES, V97, P70, DOI 10.1016/S0169-328X(01)00187-5; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Knight JB, 2003, P NATL ACAD SCI USA, V100, P14725, DOI 10.1073/pnas.2432756100; Lazaro JB, 2002, GENE DEV, V16, P1792, DOI 10.1101/gad.U-9988R; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin Q, 1998, DEVELOPMENT, V125, P4565; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Liu D, 2004, EMBO J, V23, P1557, DOI 10.1038/sj.emboj.7600179; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Mejat A, 2005, NAT NEUROSCI, V8, P313, DOI 10.1038/nn1408; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Mora S, 2000, J BIOL CHEM, V275, P16323, DOI 10.1074/jbc.M910259199; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Ornatsky OI, 1996, J BIOL CHEM, V271, P24927, DOI 10.1074/jbc.271.40.24927; Pan F, 2004, J BIOL CHEM, V279, P14477, DOI 10.1074/jbc.C300487200; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Quinn ZA, 2001, NUCLEIC ACIDS RES, V29, P732, DOI 10.1093/nar/29.3.732; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; Subramanian SV, 1996, MECH DEVELOP, V57, P103, DOI 10.1016/0925-4773(96)00542-4; Suzuki E, 1996, CYTOGENET CELL GENET, V73, P244, DOI 10.1159/000134348; Swanson BJ, 1998, MOL IMMUNOL, V35, P445, DOI 10.1016/S0161-5890(98)00058-3; Wang DZ, 2001, DEVELOPMENT, V128, P4623; Wen F, 2004, TRENDS GENET, V20, P232, DOI 10.1016/j.tig.2004.03.005; Wilson-Rawls J, 1999, MOL CELL BIOL, V19, P2853; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Xu XD, 2005, CELL, V120, P59, DOI 10.1016/j.cell.2004.11.036; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Yu GS, 1998, J BIOL CHEM, V273, P32901, DOI 10.1074/jbc.273.49.32901; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Yu YT, 1996, J BIOL CHEM, V271, P24675; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhang CL, 2001, P NATL ACAD SCI USA, V98, P7354, DOI 10.1073/pnas.131198498; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zhu BM, 2004, MOL CELL BIOL, V24, P8264, DOI 10.1128/MCB.24.18.8264-8275.2004	95	65	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28749	28760		10.1074/jbc.M502491200	http://dx.doi.org/10.1074/jbc.M502491200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15834131	hybrid			2022-12-25	WOS:000230857300066
J	Thiefes, A; Wolter, S; Mushinski, JF; Hoffmann, E; Dittrich-Breiholz, O; Graue, N; Dorrie, A; Schneider, H; Wirth, D; Luckow, B; Resch, K; Kracht, M				Thiefes, A; Wolter, S; Mushinski, JF; Hoffmann, E; Dittrich-Breiholz, O; Graue, N; Dorrie, A; Schneider, H; Wirth, D; Luckow, B; Resch, K; Kracht, M			Simultaneous blockade of NF kappa B, JNK, and p38 MAPK by a kinase-inactive mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a distinct spectrum of tumor necrosis target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE-CHEMOATTRACTANT PROTEIN-1; INTERLEUKIN-1 RECEPTOR; SIGNAL-TRANSDUCTION; TNF-ALPHA; ACTIVATION; EXPRESSION; BINDING; IL-1; IDENTIFICATION; MECHANISMS	The inflammatory response is characterized by the induction ( or repression) of hundreds of genes. The activity of many of these genes is controlled by MAPKs and the I kappa B kinase-NF kappa B pathway. To reveal the effects of blocking these pathways simultaneously, fibroblasts were infected with retroviruses encoding TAK1K63W, an inactive mutant of the protein kinase TAK1. Expression of this protein inhibited tumor necrosis factor (TNF)-induced activation of NF kappa B, JNK, and p38 MAPK and sensitized the cells to TNF-induced apoptosis. 23 different microarray experiments were used to analyze the expression of > 7000 genes in these cells. We identified 518 genes that were regulated by TNF in both TAK1K63W-expressing cells and control cells, 37 genes induced by TNF only when TAK1K63W was present, and 48 TNF-induced genes that were suppressed by TAK1K63W. The TNF-inducible genes that were most strongly suppressed by TAK1K63W, ccl2, ccl7, ccl5, cxcl1, cxcl5, cxcl10, saa3, and slpi also had much lower basal levels of expression, indicating that TAK1 also played a role in their normal expression. Chromatin immunoprecipitation studies on four of these genes suggested that inactivation of TAK1 activity led to direct suppression of expression at the transcriptional level because of impaired recruitment of RNA polymerase II to their promoters. ccl2 induction by TNF or interleukin-1 was also suppressed in cells that expressed TAK1 antisense RNA or that were genetically deficient in JNK1/2 or p65 NF kappa B. These data suggest that regulation of the expression of a selected group of inflammation-related genes is funneled through TAK1, making it a potentially useful target for more specific anti-inflammatory drug development.	Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; NCI, Mol Genet Sect, Genet Lab, Canc Res Ctr,NIH, Bethesda, MD 20892 USA; GBF, Natl Res Inst Biotechnol, Dept Gene Regulat & Differentiat, D-38124 Braunschweig, Germany; Univ Munich, D-80336 Munich, Germany	Hannover Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Helmholtz Association; Helmholtz-Center for Infection Research; University of Munich	Kracht, M (corresponding author), Hannover Med Sch, Inst Pharmacol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Kracht.Michael@MH-Hannover.de		Kracht, Michael/0000-0002-8501-043X; Hoffmann-Lucke, Elke/0000-0002-2437-0140	NATIONAL CANCER INSTITUTE [Z01BC008727, ZIABC008727] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bandman O, 2002, ANN NY ACAD SCI, V975, P77, DOI 10.1111/j.1749-6632.2002.tb05943.x; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Boekhoudt GH, 2003, J IMMUNOL, V170, P4139, DOI 10.4049/jimmunol.170.8.4139; Bulyk ML, 2004, GENOME BIOL, V5; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; Finzer P, 2000, ONCOGENE, V19, P3235, DOI 10.1038/sj.onc.1203643; FLICK DA, 1984, J IMMUNOL METHODS, V68, P167, DOI 10.1016/0022-1759(84)90147-9; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; Goebeler M, 2001, BLOOD, V97, P46, DOI 10.1182/blood.V97.1.46; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Heyninck Karen, 2001, Molecular Cell Biology Research Communications, V4, P259, DOI 10.1006/mcbr.2001.0295; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; Holzberg D, 2003, J BIOL CHEM, V278, P40213, DOI 10.1074/jbc.M304058200; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; Lewis AJ, 1999, CURR OPIN CHEM BIOL, V3, P489, DOI 10.1016/S1367-5931(99)80071-4; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; Ninomiya-Tsuji J, 2003, J BIOL CHEM, V278, P18485, DOI 10.1074/jbc.M207453200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Nourbakhsh M, 2001, J BIOL CHEM, V276, P4501, DOI 10.1074/jbc.M007532200; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Olsen NJ, 2004, NEW ENGL J MED, V350, P2167, DOI 10.1056/NEJMra032906; Ping DS, 1999, J IMMUNOL, V162, P727; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Schwamborn J, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-46; Shi J, 2004, INFLAMM RES, V53, P377, DOI 10.1007/s00011-004-1271-3; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Taverner NV, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-210; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vincenti MP, 2001, J CLIN INVEST, V108, P181; Wagner K, 2001, GENOMICS, V78, P113, DOI 10.1006/geno.2001.6660; Wald D, 2001, EUR J IMMUNOL, V31, P3747, DOI 10.1002/1521-4141(200112)31:12<3747::AID-IMMU3747>3.0.CO;2-E; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	61	53	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27728	27741		10.1074/jbc.M411657200	http://dx.doi.org/10.1074/jbc.M411657200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15837794	hybrid			2022-12-25	WOS:000230678600032
J	Vadlamudi, RK; Manavathi, B; Singh, RR; Nguyen, D; Li, F; Kumar, R				Vadlamudi, RK; Manavathi, B; Singh, RR; Nguyen, D; Li, F; Kumar, R			An essential role of Pak1 phosphorylation of SHARP in Notch signaling	ONCOGENE			English	Article						Pak1 signaling; SHARP; Notch; repression	P21-ACTIVATED KINASES; SMRT COREPRESSOR; ACTIVATION; PATHWAY; DIFFERENTIATION; EFFECTORS; COMPLEX; CANCER; CELLS; CDC42	The p21-activated kinases (Paks), an evolutionarily conserved family of serine/threonine kinases, play an important role in cytoskeletal reorganization in mammalian cells. The Notch signaling pathway plays an important role in the determination of cell fate/differentiation in a number of organs. Notch signaling is a complex process, and the mechanism by which Notch regulates multiple cellular processes is intriguing. The expression of both Notch and Pak1 has been shown to be deregulated in several human cancers. Using yeast two-hybrid screening, we identified SHARP, one of the Notch signaling components, as a Pak1-interacting protein. We found that SHARP is a physiologic interacting substrate of Pak1, and that this interaction enhances SHARP-mediated repression of Notch target genes. Pak1 phosphorylation sites in SHARP were mapped to Ser3486 and Thr3568 within the SHARP repression domain. Mutation of Pak1 phosphorylation sites in SHARP, inhibition of Pak1 functions by a Pak1-autoinhibitory fragment ( amino acids 83-149), or expression of Pak1-specific siRNA interfered with SHARP-mediated repression of Notch target reporter gene activation. These results demonstrate that Pak1-SHARP interaction plays an essential role in enhancing the corepressor functions of SHARP, thereby modulating Notch signaling in human cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org		Manavathi, Bramanandam/0000-0002-1797-398X	PHS HHS [80066, 90970] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; Beatus P, 1998, J NEUROSCI RES, V54, P125, DOI 10.1002/(SICI)1097-4547(19981015)54:2<125::AID-JNR1>3.3.CO;2-C; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Hayashi K, 2002, MOL CELL NEUROSCI, V20, P579, DOI 10.1006/mcne.2002.1144; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Ishaq M, 2003, J BIOL CHEM, V278, P39296, DOI 10.1074/jbc.M302767200; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Zhou SF, 2001, MOL CELL BIOL, V21, P6222, DOI 10.1128/MCB.21.18.6222-6232.2001; Zhou YY, 2001, MOL CELL BIOCHEM, V220, P1, DOI 10.1023/A:1011087910699	24	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4591	4596		10.1038/sj.onc.1208672	http://dx.doi.org/10.1038/sj.onc.1208672			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15824732				2022-12-25	WOS:000230157100013
J	LaPointe, P; Wei, X; Gariepy, J				LaPointe, P; Wei, X; Gariepy, J			A role for the protease-sensitive loop region of shiga-like toxin 1 in the retrotranslocation of its A(1) domain from the endoplasmic reticulum lumen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI O157-H7; RICIN-A-CHAIN; DISULFIDE-ISOMERASE; SHIGELLA-DYSENTERIAE; PROTEOLYTIC CLEAVAGE; ANTIGEN DEGRADATION; BREFELDIN-A; C-TERMINUS; BINDING; CYTOTOXICITY	Shiga-like toxin I (Slt-I) is a ribosome-inactivating protein that undergoes retrograde transport to the endoplasmic reticulum to exert its cytotoxic effect on eukaryotic cells. Its catalytically active A(1) domain subsequently migrates from the endoplasmic reticulum ( ER) lumen to the cytoplasm. To study this final retrotrans-location event, a suicide assay was developed based on the cytoplasmic expression and ER-targeting of the cytotoxic Slt-I A1 fragment in Saccharomyces cerevisiae. Expression of the Slt-I A1 domain (residues 1-251) with and without an ER-targeting sequence was lethal to the host and demonstrated that this domain can efficiently migrate from the ER compartment to the cytosol. Deletion analyses revealed that residues 1-239 represent the minimal A1 segment displaying full enzymatic activity. This fragment, however, accumulates in the ER lumen when directed to this compartment. The addition of residues 240-251 restores the translocation property of the A1 chain in yeast. However, single mutations within this region do not significantly alter this function in the context of the 251-residue long A1 domain or affect the toxicity of the resulting Slt-I variants toward Vero cells in the context of the holotoxin. Since this mechanism of retrotranslocation is common to other protein toxins lacking a peptide motif similar in sequence to residues 240-251, the present results suggest that the ER export mechanism may involve the recognition of a more universal structural element, such as a misfolded or altered peptide domain localized at the C terminus of the A1 chain (residues 240-251) rather than a unique ER export signal sequence.	Univ Hlth Network, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Gariepy, J (corresponding author), Univ Hlth Network, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	gariepy@uhnres.utoronto.ca		LaPointe, Paul/0000-0002-5465-1795				BURGESS BJ, 1993, MOL MICROBIOL, V10, P171, DOI 10.1111/j.1365-2958.1993.tb00913.x; Day PJ, 2002, BIOCHEMISTRY-US, V41, P2836, DOI 10.1021/bi012012i; DONTA ST, 1993, INFECT IMMUN, V61, P3282, DOI 10.1128/IAI.61.8.3282-3286.1993; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; FRASER ME, 1994, NAT STRUCT BIOL, V1, P59, DOI 10.1038/nsb0194-59; GARRED O, 1995, J BIOL CHEM, V270, P10817; GARRED O, 1995, EXP CELL RES, V218, P39, DOI 10.1006/excr.1995.1128; GRANT EP, 1995, J IMMUNOL, V155, P3750; Gromme M, 2002, MOL IMMUNOL, V39, P181, DOI 10.1016/S0161-5890(02)00101-3; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hatsuzawa K, 1997, J BIOCHEM-TOKYO, V121, P270; Hazes B, 1997, BIOCHEMISTRY-US, V36, P11051, DOI 10.1021/bi971383p; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; Johannes L, 1998, TRENDS CELL BIOL, V8, P158, DOI 10.1016/S0962-8924(97)01209-9; Lea N, 1999, MICROBIOL-UK, V145, P999, DOI 10.1099/13500872-145-5-999; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; Menikh A, 1997, BIOCHEMISTRY-US, V36, P15865, DOI 10.1021/bi970944+; Pilon M, 1998, MOL BIOL CELL, V9, P3455, DOI 10.1091/mbc.9.12.3455; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Saleh MT, 1996, BIOCHEMISTRY-US, V35, P9325, DOI 10.1021/bi960177z; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SELLECK SB, 1988, P NATL ACAD SCI USA, V85, P5399, DOI 10.1073/pnas.85.15.5399; SIMPSON JC, 1995, EUR J BIOCHEM, V232, P458; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; Zheng J, 2001, J BIOL CHEM, V276, P15747, DOI 10.1074/jbc.M011444200	34	47	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23310	23318		10.1074/JBC.m414193200	http://dx.doi.org/10.1074/JBC.m414193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817449	hybrid			2022-12-25	WOS:000229741800090
J	Rey, O; Young, SH; Yuan, JZ; Slice, L; Rozengurt, E				Rey, O; Young, SH; Yuan, JZ; Slice, L; Rozengurt, E			Amino acid-stimulated Ca2+ oscillations produced by the Ca2+-sensing receptor are mediated by a phospholipase C/inositol 1,4,5-trisphosphate-independent pathway that requires G(12), Rho, Filamin-A, and the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-D; CALCIUM-SENSING RECEPTOR; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; ACTIVATION LOOP SER(744); FOCAL ADHESION KINASE; INOSITOL 1,4,5-TRISPHOSPHATE; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; ALPHA-SUBUNIT; DIACYLGLYCEROL	The G protein-coupled Ca2+- sensing receptor (CaR) is an allosteric protein that responds to two different agonists, Ca2+ and aromatic amino acids, with the production of sinusoidal or transient oscillations in intracellular Ca2+ concentration ([Ca2+](i)). Here, we examined whether these differing patterns of [Ca2+](i) oscillations produced by the CaR are mediated by separate signal transduction pathways. Using real time imaging of changes in phosphatidylinositol 4,5-biphosphate hydrolysis and generation of inositol 1,4,5-trisphosphate in single cells, we found that stimulation of CaR by an increase in the extracellular Ca2+ concentration ([Ca2+](o)) leads to periodic synthesis of inositol 1,4,5-trisphosphate, whereas L-phenylalanine stimulation of the CaR does not induce any detectable change in the level this second messenger. Furthermore, we identified a novel pathway that mediates transient [Ca2+](i) oscillations produced by the CaR in response to L-phenylalanine, which requires the organization of the actin cytoskeleton and involves the small GTPase Rho, heterotrimeric proteins of the G(12) subfamily, the C-terminal region of the CaR, and the scaffolding protein filamin-A. Our model envisages that Ca2+ or amino acids stabilize unique CaR conformations that favor coupling to different G proteins and subsequent activation of distinct downstream signaling pathways.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, CURE Digest Dis Res Ctr,Unit Signal Transduct & G, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rozengurt, E (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, CURE Digest Dis Res Ctr, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu	Centeno, Patricia Pacios/O-8368-2016	Rey, Osvaldo/0000-0003-1575-9864	NCI NIH HHS [P50 CA090388] Funding Source: Medline; NIDDK NIH HHS [DK 55003, DK 56930, 5 P30 DK41301] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, P30DK041301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIDA K, 1995, BIOCHEM BIOPH RES CO, V214, P524, DOI 10.1006/bbrc.1995.2318; Aktories K, 1997, J CLIN INVEST, V99, P827, DOI 10.1172/JCI119245; Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Breitwieser GE, 2001, AM J PHYSIOL-CELL PH, V280, pC1412, DOI 10.1152/ajpcell.2001.280.6.C1412; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Butters RR, 1997, J BONE MINER RES, V12, P568, DOI 10.1359/jbmr.1997.12.4.568; Conigrave AD, 2000, TRENDS PHARMACOL SCI, V21, P401, DOI 10.1016/S0165-6147(00)01546-7; Hebert SC, 1997, J EXP BIOL, V200, P295; Hendy GN, 2000, HUM MUTAT, V16, P281, DOI 10.1002/1098-1004(200010)16:4<281::AID-HUMU1>3.0.CO;2-A; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P188, DOI 10.1016/S0165-6147(00)89020-3; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; Lunn JA, 2000, AM J PHYSIOL-CELL PH, V279, pC2019, DOI 10.1152/ajpcell.2000.279.6.C2019; Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; Nash MS, 2001, NATURE, V413, P381, DOI 10.1038/35096643; Nash MS, 2001, BIOCHEM J, V356, P137, DOI 10.1042/0264-6021:3560137; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Pi M, 2002, ENDOCRINOLOGY, V143, P3830, DOI 10.1210/en.2002-220240; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Quarles LD, 2003, CURR OPIN NEPHROL HY, V12, P349, DOI 10.1097/00041552-200307000-00002; Rey O, 2004, J BIOL CHEM, V279, P34361, DOI 10.1074/jbc.M403265200; Rey O, 2003, J BIOL CHEM, V278, P23773, DOI 10.1074/jbc.M300226200; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Rozen S, 2000, Methods Mol Biol, V132, P365; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Sinnett-Smith J, 2001, EXP CELL RES, V266, P292, DOI 10.1006/excr.2001.5219; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Ward DT, 2002, PFLUG ARCH EUR J PHY, V445, P169, DOI 10.1007/s00424-002-0914-x; Young SH, 2002, J BIOL CHEM, V277, P46871, DOI 10.1074/jbc.M207083200; Young SH, 2002, AM J PHYSIOL-CELL PH, V282, pC1414, DOI 10.1152/ajpcell.00432.2001; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200	55	86	88	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22875	22882		10.1074/jbc.M503455200	http://dx.doi.org/10.1074/jbc.M503455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15837785	hybrid			2022-12-25	WOS:000229741800040
J	Truman, JP; Gueven, N; Lavin, M; Leibel, S; Kolesnick, R; Fuks, Z; Haimovitz-Friedman, AH				Truman, JP; Gueven, N; Lavin, M; Leibel, S; Kolesnick, R; Fuks, Z; Haimovitz-Friedman, AH			Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C ACTIVATOR; ATAXIA-TELANGIECTASIA; DNA-DAMAGE; IONIZING-RADIATION; CERAMIDE SYNTHASE; PHORBOL ESTER; LNCAP CELLS; GENE LAG1; CYCLE; DEATH	Treatment with the protein kinase C activator 12-O-tetradecanoylphorbol 12-acetate (TPA) enables radiation-resistant LNCaP human prostate cancer cells to undergo radiation-induced apoptosis, mediated via activation of the enzyme ceramide synthase ( CS) and de novo synthesis of the sphingolipid ceramide (Garzotto, M., Haimovitz-Friedman, A., Liao, W. C., White-Jones, M., Huryk, R., Heston, D. W. W., Cardon-Cardo, C., Kolesnick, R., and Fuks, Z. ( 1999) Cancer Res. 59, 5194-5201). Here, we show that TPA functions to decrease the cellular level of the ATM ( ataxia telangiectasia mutated) protein, known to repress CS activation ( Liao, W.-C., Haimovitz-Friedman, A., Persaud, R., McLoughlin, M., Ehleiter, D., Zhang, N., Gatei, M., Lavin, M., Kolesnick, R., and Fuks, Z. ( 1999) J. Biol. Chem. 274, 17908 - 17917). Gel shift analysis in LNCaP and CWR22-Rv1 cells demonstrated a significant reduction in DNA binding of the Sp1 transcription factor to the ATM promoter, and quantitative reverse transcription-PCR showed a 50% reduction of ATM mRNA between 8 and 16 h of TPA treatment, indicating that TPA inhibits ATM transcription. Furthermore, treatment of LNCaP, CWR22-Rv1, PC-3, and DU-145 human prostate cells with antisense-ATM oligonucleotides, which markedly reduced cellular ATM levels, significantly enhanced radiation-induced CS activation and apoptosis, leading to apoptosis at doses as a low as 1 gray. These data suggest that the CS pathway initiates a generic mode of radiation- induced apoptosis in human prostate cancer cells, regulated by a suppressive function of ATM, and that ATM might represent a potential target for pharmacologic inactivation with potential clinical applications in human prostate cancer.	Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Royal Brisbane Hosp, Queensland Canc Fund Res Lab, Brisbane, Qld 4029, Australia	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Royal Brisbane & Women's Hospital	Haimovitz-Friedman, AH (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave,Box 280, New York, NY 10021 USA.	haimovia@mskcc.org	Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Guven, Nuri/0000-0003-3782-767X	NCI NIH HHS [P50 CA092629, CA92629-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA092629] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; Algan O, 1996, RADIAT RES, V146, P267, DOI 10.2307/3579456; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Birbes H, 2002, ADV ENZYME REGUL, V42, P113, DOI 10.1016/S0065-2571(01)00026-7; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; CROOK JM, 1995, UROLOGY, V45, P624, DOI 10.1016/S0090-4295(99)80054-5; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Deweese TL, 1998, J UROLOGY, V159, P591, DOI 10.1016/S0022-5347(01)63990-9; FORMAN JD, 1993, PROSTATE, V23, P235, DOI 10.1002/pros.2990230306; Garzotto M, 1999, CANCER RES, V59, P5194; Garzotto M, 1998, CANCER RES, V58, P2260; GRANT S, 1992, CANCER RES, V52, P6270; Gueven N, 2003, GENE CHROMOSOME CANC, V38, P157, DOI 10.1002/gcc.10261; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Henttu P, 1998, BIOCHEM BIOPH RES CO, V244, P167, DOI 10.1006/bbrc.1998.8238; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; ISHII HH, 1993, BIOCHEM BIOPH RES CO, V192, P1415, DOI 10.1006/bbrc.1993.1574; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Keating KE, 2001, ONCOGENE, V20, P4281, DOI 10.1038/sj.onc.1204527; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KIZAKI H, 1989, J IMMUNOL, V143, P1790; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEITH JT, 1994, PROSTATE, V24, P119, DOI 10.1002/pros.2990240304; Li T, 2003, CIRC RES, V93, P1202, DOI 10.1161/01.RES.0000104085.76261.02; Li WX, 1998, RADIAT RES, V150, P190, DOI 10.2307/3579854; Li YW, 1998, ONCOGENE, V17, P2915, DOI 10.1038/sj.onc.1202218; Liao WC, 1999, J BIOL CHEM, V274, P17908, DOI 10.1074/jbc.274.25.17908; LOTEM J, 1991, BLOOD, V78, P953; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Pozarowski Piotr, 2004, Methods Mol Biol, V281, P301; Puranam KL, 1999, MOL GENET METAB, V66, P294, DOI 10.1006/mgme.1999.2834; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; Scott SL, 2004, INT J RADIAT ONCOL, V59, P219, DOI 10.1016/j.ijrobp.2004.01.027; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shiloh Y, 2001, BIOCHEM SOC T, V29, P661, DOI 10.1042/0300-5127:0290661; Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2; SINCLAIR WK, 1966, RADIAT RES, V29, P450, DOI 10.2307/3572025; Sommer SS, 2003, CANCER GENET CYTOGEN, V145, P115, DOI 10.1016/S0165-4608(03)00119-5; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P63, DOI 10.1089/oli.1.1997.7.63; Taylor MF, 1997, CYTOKINE, V9, P672, DOI 10.1006/cyto.1997.0212; TERASIMA T, 1963, BIOPHYS J, V3, P11, DOI 10.1016/S0006-3495(63)86801-0; TRUMAN J, 2004, P AM ASS CANC RES, V45; WITHERS HR, 1974, CANCER-AM CANCER SOC, V34, P39; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	65	48	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23262	23272		10.1074/jbc.M503701200	http://dx.doi.org/10.1074/jbc.M503701200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15837784	hybrid, Green Accepted			2022-12-25	WOS:000229741800084
J	Ueno, N; Takeya, R; Miyano, K; Kikuchi, H; Sumimoto, H				Ueno, N; Takeya, R; Miyano, K; Kikuchi, H; Sumimoto, H			The NADPH oxidase Nox3 constitutively produces superoxide in a p22(Phox)-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; SRC HOMOLOGY-3 DOMAINS; SH3 DOMAIN; P67(PHOX) PARTICIPATE; MOLECULAR-MECHANISM; NAD(P)H OXIDASE-1; ACTIVATION DOMAIN; P47(PHOX); PHOSPHORYLATION; PROTEINS	Nox3, a member of the superoxide-producing NADPH oxidase (Nox) family, participates in otoconia formation in mouse inner ears, which is required for perception of balance and gravity. The activity of other Nox enzymes such as gp91(phox/)Nox2 and Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) and an activator protein( p67(phox)orNoxa1); for the p47(phox)-dependent activation of these oxidases, treatment of cells with stimulants such as phorbol 12-myristate 13-acetate is also indispensable. Here we show that ectopic expression of Nox3 in various types of cells leads to phorbol 12-myristate 13-acetate-independent constitutive production of a substantial amount of superoxide under the conditions where gp91(phox) and Nox1 fail to generate superoxide, i.e. in the absence of the oxidase organizers and activators. Nox3 likely forms a functional complex with p22(phox); Nox3 physically interacts with and stabilizes p22(phox), and the Nox3-dependent superoxide production is totally dependent on p22phox. The organizers p47(phox) and Noxo1 are capable of enhancing the superoxide production by Nox3 in the absence of the activators, and the enhancement requires the interaction of the organizers with p22phox, further indicating a link between Nox3 and p22(phox). The p47(phox)-enhanced Nox3 activity is further facilitated by p67(phox) or Noxa1, whereas the activators cancel the Noxo1-induced enhancement. On the other hand, the small GTPase Rac, essential for the gp91(phox) activity, is likely dispensable to the Nox3 system. Thus Nox3 functions together with p22(phox) as an enzyme constitutively producing superoxide, which can be distinctly regulated by combinatorial use of the organizers and activators.	Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan; Hirosaki Univ, Fac Agr & Life Sci, Dept Biochem & Biotechnol, Hirosaki, Aomori 0368561, Japan	Kyushu University; Japan Science & Technology Agency (JST); Hirosaki University	Kikuchi, H (corresponding author), Kyushu Univ, Med Inst Bioregulat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	hsumi@bioreg.kyushu-u.ac.jp						Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Ago T, 2003, P NATL ACAD SCI USA, V100, P4474, DOI 10.1073/pnas.0735712100; Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Banfi B, 2004, J BIOL CHEM, V279, P46065, DOI 10.1074/jbc.M403046200; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Biberstine-Kinkade KJ, 2002, J BIOL CHEM, V277, P30368, DOI 10.1074/jbc.M203993200; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Brown GE, 2003, MOL CELL, V11, P35, DOI 10.1016/S1097-2765(03)00005-4; Cheng GJ, 2004, J BIOL CHEM, V279, P34250, DOI 10.1074/jbc.M400660200; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DINAUER MC, 1991, P NATL ACAD SCI USA, V88, P11231, DOI 10.1073/pnas.88.24.11231; DINAUER MC, 1989, J CLIN INVEST, V84, P2012, DOI 10.1172/JCI114393; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FINAN P, 1994, J BIOL CHEM, V269, P13752; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Hashida S, 2004, J BIOL CHEM, V279, P26378, DOI 10.1074/jbc.M309724200; Hata K, 1997, BIOCHEM BIOPH RES CO, V241, P226, DOI 10.1006/bbrc.1997.7807; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; HURST JK, 1991, J BIOL CHEM, V266, P1627; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kawahara T, 2005, AM J PHYSIOL-CELL PH, V288, pC450, DOI 10.1152/ajpcell.00319.2004; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Koshkin V, 1997, BBA-BIOENERGETICS, V1319, P139, DOI 10.1016/S0005-2728(96)00154-5; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lekstrom-Himes JA, 2000, NEW ENGL J MED, V343, P1703, DOI 10.1056/NEJM200012073432307; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Paffenholz R, 2004, GENE DEV, V18, P486, DOI 10.1101/gad.1172504; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Roos D, 1996, BLOOD, V87, P1663; Sarfstein R, 2004, J BIOL CHEM, V279, P16007, DOI 10.1074/jbc.M312394200; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Takeya R, 2003, MOL CELLS, V16, P271; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Yuzawa S, 2004, J BIOL CHEM, V279, P29752, DOI 10.1074/jbc.M401457200; Yuzawa S, 2004, GENES CELLS, V9, P443, DOI 10.1111/j.1356-9597.2004.00733.x	61	147	157	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23328	23339		10.1074/jbc.M414548200	http://dx.doi.org/10.1074/jbc.M414548200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824103	hybrid			2022-12-25	WOS:000229741800092
J	Wang, JB; Wu, WJ; Cerione, RA				Wang, JB; Wu, WJ; Cerione, RA			Cdc42 and Ras cooperate to mediate cellular transformation by intersectin-L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCYTIC PROTEIN INTERSECTIN; UBIQUITIN LIGASE ACTIVITY; ACTIN STRESS FIBERS; C-CBL; RHO; GROWTH; GTPASES; DBL; C-CBL/SLI-1; FILOPODIA	Cdc42, a Ras-related GTP-binding protein, has been implicated in the regulation of the actin cytoskeleton, membrane trafficking, cell-cycle progression, and malignant transformation. We have shown previously that a Cdc42 mutant (Cdc42(F28L)), capable of spontaneously exchanging GDP for GTP (referred to as "fastcycling"), transformed NIH 3T3 cells because of its ability to interfere with epidermal growth factor receptor (EGFR)-Cbl interactions and EGFR down-regulation. To further examine the link between the hyperactivation of Cdc42 and its ability to alter EGFR signaling and thereby cause cellular transformation, we examined the effects of expressing different forms of the Cdc42-specific guanine nucleotide exchange factor, intersectin-L, in fibroblasts. Full-length intersectin-L exhibited little ability to stimulate nucleotide exchange on Cdc42, whereas a truncated version that contained five Src homology 3 (SH3) domains, the Dbl and pleckstrin homology domains (DH and PH domains, respectively), and a C2 domain (designated as SH3A-C2) showed modest guanine nucleotide exchange factor activity, whereas a form containing just the DH, PH, and C2 domains (DH-C2) strongly activated Cdc42. However, DH-C2 showed little ability to stimulate growth in low serum or colony formation in soft agar, whereas SH3A-C2 gave rise to a much stronger stimulation of cell growth in low serum and was highly effective in stimulating colony formation. Moreover, although SH3A-C2 strongly transformed fibroblasts, it differed from the actions of the Cdc42(F28L) mutant, as SH3A-C2 showed little ability to alter EGFR levels or the lifetime of EGF-coupled signaling through ERK. Rather, we found that SH3A-C2 exhibited strong transforming activity through its ability to mediate cooperation between Ras and Cdc42.	Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Coll Vet Med, Dept Chem & Chem Biol, Baker Lab, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.	rac1@cornell.edu			NIGMS NIH HHS [GM47458] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 2000, J BIOL CHEM, V275, P27414; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mohney RP, 2003, J BIOL CHEM, V278, P47038, DOI 10.1074/jbc.M303895200; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; Tu SS, 2002, BIOCHEMISTRY-US, V41, P12350, DOI 10.1021/bi026167h; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; Zamanian JL, 2003, MOL BIOL CELL, V14, P1624, DOI 10.1091/mbc.E02-08-0494; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200	30	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22883	22891		10.1074/jbc.M414375200	http://dx.doi.org/10.1074/jbc.M414375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824104	hybrid			2022-12-25	WOS:000229741800041
J	Cheng, AX; McDonald, NA; Connolly, CN				Cheng, AX; McDonald, NA; Connolly, CN			Cell surface expression of 5-hydroxytryptamine type 3 receptors is promoted by RIC-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GABA(A) RECEPTORS; GLYCINE RECEPTOR; PLASMA-MEMBRANE; TRAFFICKING; GEPHYRIN; SUBUNIT; ASSOCIATION; CONDUCTANCE; REQUIREMENT	RIC-3 has been identified as a molecule essential for the recruitment of functional nicotinic acetylcholine receptors composed of a7, but it exhibits inhibitory effects on a4b2 or a3b4 receptors. In this study, we investigated the role of RIC-3 in the recruitment of 5-hydroxytryptamine type 3A (5-HT3A3A3A) receptors to the cell surface. Although RIC-3 is not essential for the surface transport of 5-HT3A receptors, we found that its presence enhances both receptor transport and function in a concentration-dependent manner. RIC-3 is localized to the endoplasmic reticulum, as evidenced by co-localization with the chaperone molecule, binding protein (BiP). RIC-3 is not detected at significant levels on the cell surface when expressed alone or in the presence of 5-HT. RIC-3 and 5-HT (show a low level interaction that is transient (< 4 h). That RIC-3 can interact with an endoplasmic reticulum-retained 5-HT)(3A) (construct, combined with the transient interaction observed and lack of significant surface-expressed RIC)(, suggests that RIC)(-3)(-3) (may play a role in 5-HT)(3A) receptor folding, assembly, or transport to the cell surface.	Univ Dundee, Ninewells Med Sch, Dept Pharmacol & Neurosci, Dundee DD1 9SY, Scotland	University of Dundee	Connolly, CN (corresponding author), Univ Dundee, Ninewells Med Sch, Dept Pharmacol & Neurosci, Dundee DD1 9SY, Scotland.	c.n.connolly@dundee.ac.uk		Connolly, Christopher/0000-0002-0445-8874				Banks GB, 2003, J NEUROCYTOL, V32, P709, DOI 10.1023/B:NEUR.0000020619.24681.2b; Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; Bollan K, 2003, BIOCHEM SOC T, V31, P875, DOI 10.1042/bst0310875; Boyd GW, 2003, J BIOL CHEM, V278, P27681, DOI 10.1074/jbc.M304938200; Boyd GW, 2002, MOL CELL NEUROSCI, V21, P38, DOI 10.1006/mcne.2002.1160; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Christianson JC, 2004, EMBO J, V23, P4156, DOI 10.1038/sj.emboj.7600436; Collingridge GL, 2004, NAT REV NEUROSCI, V5, P952, DOI 10.1038/nrn1556; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Coyle JE, 2003, NEUROSCIENTIST, V9, P205, DOI 10.1177/1073858403009003013; Ernst M, 2003, NEUROSCIENCE, V119, P933, DOI 10.1016/S0306-4522(03)00288-4; Everitt AB, 2004, J BIOL CHEM, V279, P21701, DOI 10.1074/jbc.M312806200; Fritschy JM, 2003, BIOCHEM SOC T, V31, P889, DOI 10.1042/bst0310889; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Gunthorpe MJ, 2000, J PHYSIOL-LONDON, V522, P187, DOI 10.1111/j.1469-7793.2000.00187.x; Halevi S, 2003, J BIOL CHEM, V278, P34411, DOI 10.1074/jbc.M300170200; Halevi S, 2002, EMBO J, V21, P1012, DOI 10.1093/emboj/21.5.1012; Hanus C, 2004, J NEUROSCI, V24, P1119, DOI 10.1523/JNEUROSCI.4380-03.2004; Harvey K, 2004, J NEUROSCI, V24, P5816, DOI 10.1523/JNEUROSCI.1184-04.2004; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; Helekar SA, 1997, P NATL ACAD SCI USA, V94, P5432, DOI 10.1073/pnas.94.10.5432; Ilegems E, 2004, J BIOL CHEM, V279, P53346, DOI 10.1074/jbc.M407467200; Jeanclos EM, 2001, J BIOL CHEM, V276, P28281, DOI 10.1074/jbc.M011549200; Kittler JT, 2004, P NATL ACAD SCI USA, V101, P12736, DOI 10.1073/pnas.0401860101; Kneussel M, 2002, BRAIN RES REV, V39, P74, DOI 10.1016/S0165-0173(02)00159-5; Leil TA, 2004, J NEUROSCI, V24, P11429, DOI 10.1523/JNEUROSCI.3355-04.2004; Levi S, 2004, J NEUROSCI, V24, P207, DOI 10.1523/JNEUROSCI.1661-03.2004; Marchand S, 2002, J NEUROSCI, V22, P8891; Nevin ST, 2003, J BIOL CHEM, V278, P28985, DOI 10.1074/jbc.M300097200; Ngo ST, 2004, NEUROREPORT, V15, P2501, DOI 10.1097/00001756-200411150-00014; Rakhilin S, 1999, J CELL BIOL, V146, P203; Rangwala F, 1997, J NEUROSCI, V17, P8201; Reeves DC, 2003, BIOPHYS J, V84, P2338, DOI 10.1016/S0006-3495(03)75039-5; Wanamaker CP, 2003, ANN NY ACAD SCI, V998, P66, DOI 10.1196/annals.1254.009; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; Williams ME, 2005, J BIOL CHEM, V280, P1257, DOI 10.1074/jbc.M410039200	37	55	58	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22502	22507		10.1074/jbc.M414341200	http://dx.doi.org/10.1074/jbc.M414341200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15809299	hybrid			2022-12-25	WOS:000229557900097
J	Raymond, AC; Staker, BL; Burgin, AB				Raymond, AC; Staker, BL; Burgin, AB			Substrate specificity of tyrosyl-DNA phosphodiesterase I (Tdp1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TOPOISOMERASE-I; STRAND BREAK REPAIR; COVALENT COMPLEXES; SPINOCEREBELLAR ATAXIA; CRYSTAL-STRUCTURE; PHOSPHOLIPASE D1; CAMPTOTHECIN; PROTEIN; ENZYME; MECHANISM	Tyrosyl-DNA phosphodiesterase I (Tdp1) hydrolyzes 3'-phosphotyrosyl bonds to generate 3'-phosphate DNA and tyrosine in vitro. Tdp1 is involved in the repair of DNA lesions created by topoisomerase I, although the in vivo substrate is not known. Here we study the kinetic and binding properties of human Tdp1 (hTdp1) to identify appropriate 3'-phosphotyrosyl DNA substrates. Genetic studies argue that Tdp1 is involved in double and single strand break repair pathways; however, x-ray crystal structures suggest that Tdp1 can only bind single strand DNA. Separate kinetic and binding experiments show that hTdp1 has a preference for singlestranded and blunt-ended duplex substrates over nicked and tailed duplex substrate conformations. Based on these results, we present a new model to explain Tdp1/DNA binding properties. These results suggest that Tdp1 only acts upon double strand breaks in vivo, and the roles of Tdp1 in yeast and mammalian cells are discussed.	deCODE Biostruct, Bainbridge Isl, WA 98110 USA; San Diego State Univ, Dept Biol, San Diego, CA 92164 USA	California State University System; San Diego State University	Burgin, AB (corresponding author), deCODE Biostruct, 7869 NE Day Rd, Bainbridge Isl, WA 98110 USA.	aburgin@decode.com		Staker, Bart/0000-0001-9570-5086	NCI NIH HHS [CA 92079-01A2] Funding Source: Medline; NIGMS NIH HHS [GM 58596, 1F31 GM 66372-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM066372, R01GM058596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTHELMES HU, 2004, J BIOL CHEM, V19, P19; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Caldecott KW, 2003, CELL, V112, P7, DOI 10.1016/S0092-8674(02)01247-3; Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cheng TJ, 2002, EUR J BIOCHEM, V269, P3697, DOI 10.1046/j.1432-1033.2002.03059.x; Chreneik JE, 2003, J BIOL CHEM, V278, P12461, DOI 10.1074/jbc.M212930200; Connelly JC, 2004, MOL CELL, V13, P307, DOI 10.1016/S1097-2765(04)00056-5; Davies DR, 2004, J MED CHEM, V47, P829, DOI 10.1021/jm030487x; Davies DR, 2003, CHEM BIOL, V10, P139, DOI 10.1016/S1074-5521(03)00021-8; Davies DR, 2002, J MOL BIOL, V324, P917, DOI 10.1016/S0022-2836(02)01154-3; Davies DR, 2002, STRUCTURE, V10, P237, DOI 10.1016/S0969-2126(02)00707-4; Debethune L, 2002, NUCLEIC ACIDS RES, V30, P1198, DOI 10.1093/nar/30.5.1198; Dunlop J, 2004, CURR BIOL, V14, P2039, DOI 10.1016/j.cub.2004.10.048; Henrie MS, 2003, DNA REPAIR, V2, P151, DOI 10.1016/S1568-7864(02)00199-4; Hill JJ, 1997, METHOD ENZYMOL, V278, P390; HSIANG YH, 1989, CANCER RES, V49, P5077; Hughes WE, 2004, J BIOL CHEM, V279, P27534, DOI 10.1074/jbc.M403012200; Humeau Y, 2001, P NATL ACAD SCI USA, V98, P15300, DOI 10.1073/pnas.261358698; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; Inamdar KV, 2002, J BIOL CHEM, V277, P27162, DOI 10.1074/jbc.M204688200; Interthal H, 2001, P NATL ACAD SCI USA, V98, P12009, DOI 10.1073/pnas.211429198; KROEGER PE, 1989, NUCLEIC ACIDS RES, V17, P8495, DOI 10.1093/nar/17.21.8495; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; Liu CY, 2002, P NATL ACAD SCI USA, V99, P14970, DOI 10.1073/pnas.182557199; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Meng LH, 2003, CURR TOP MED CHEM, V3, P305; Park SY, 2002, CANCER RES, V62, P459; Pizzolato JF, 2003, LANCET, V361, P2235, DOI 10.1016/S0140-6736(03)13780-4; Plo I, 2003, DNA REPAIR, V2, P1087, DOI 10.1016/S1568-7864(03)00116-2; Pommier Yves, 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P429, DOI 10.2174/1568011043352777; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Raymond AC, 2004, J MOL BIOL, V338, P895, DOI 10.1016/j.jmb.2004.03.013; Rutledge SE, 2003, J AM CHEM SOC, V125, P14336, DOI 10.1021/ja034508o; Takashima H, 2002, NAT GENET, V32, P267, DOI 10.1038/ng987; Vance JR, 2002, P NATL ACAD SCI USA, V99, P13669, DOI 10.1073/pnas.202242599; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534	41	47	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22029	22035		10.1074/jbc.M502148200	http://dx.doi.org/10.1074/jbc.M502148200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15811850	hybrid			2022-12-25	WOS:000229557900046
J	Riley, BE; Zoghbi, HY; Orr, HT				Riley, BE; Zoghbi, HY; Orr, HT			SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUMO-1 MODIFICATION; INDUCED DISEASE; PML; INTERACTS; SP100; BODY; IDENTIFICATION; ASSOCIATION; CONJUGATION; COMPLEX	SUMO (small ubiquitin-like modifier) is a member of the ubiquitin family of proteins. SUMO targets include proteins involved in numerous roles including nuclear transport and transcriptional regulation. The previous finding that mutant ataxin-1[82Q] disrupted promyelocytic leukemia (PML) oncogenic domains prompted us to determine whether ataxin-1 disrupts another component of PML oncogenic domains, Sp100 (100-kDa Speckled protein). Similar to the PML protein, mutant ataxin-1[ 82Q] redistributed Sp100 to mutant ataxin-1[82Q] nuclear inclusions. Based on the ability of PML and Sp100 to be covalently modified by SUMO, we investigated the ability of ataxin-1 to be SUMOylated. SUMO-1 was found to covalently modify the polyglutamine repeat protein ataxin-1. There was a decrease in ataxin-1 SUMOylation in the presence of the expanded polyglutamine tract, ataxin-1[82Q]. The phospho-mutant, ataxin-1[82Q]-S776A, restored SUMO levels to those of wild-type ataxin-1[30Q]. SUMOylation of ataxin-1 was dependent on a functional nuclear localization signal. Ataxin-1 SUMOylation was mapped to at least five lysine residues. Lys16, Lys194 preceding the polyglutamine tract, Lys(610)/Lys(697) in the C-terminal ataxin high mobility group domain, and Lys746 all contribute to ataxin-1 SUMOylation.	Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Biochem Mol Biol Biophys, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Baylor Coll Med, Howard Hughes Med Inst, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine; Howard Hughes Medical Institute	Orr, HT (corresponding author), Univ Minnesota, Inst Human Genet, Mayo Mail Code 206, Minneapolis, MN 55455 USA.	orrxx002@umn.edu		Zoghbi, Huda/0000-0002-0700-3349; Orr, Harry/0000-0001-6118-741X	NINDS NIH HHS [NS 45667, NS 22920] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022920, R37NS022920, R01NS045667] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Boddy MN, 1996, ONCOGENE, V13, P971; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Burright EN, 1997, HUM MOL GENET, V6, P513, DOI 10.1093/hmg/6.4.513; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Chen YW, 2004, J BIOL CHEM, V279, P3758, DOI 10.1074/jbc.M309817200; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100; Duprez E, 1999, J CELL SCI, V112, P381; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; Hong S, 2002, MOL CELL NEUROSCI, V20, P298, DOI 10.1006/mcne.2002.1103; Hong SG, 2003, BBA-MOL BASIS DIS, V1638, P35, DOI 10.1016/S0925-4439(03)00038-3; Irwin S, 2005, J CELL SCI, V118, P233, DOI 10.1242/jcs.01611; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Lieberman AP, 2004, EXP NEUROL, V185, P204, DOI 10.1016/j.expneurol.2003.10.009; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okazawa H, 2003, CELL MOL LIFE SCI, V60, P1427, DOI 10.1007/s00018-003-3013-z; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pichler A, 2002, TRAFFIC, V3, P381, DOI 10.1034/j.1600-0854.2002.30601.x; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Serra HG, 2004, HUM MOL GENET, V13, P2535, DOI 10.1093/hmg/ddh268; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Szostecki C, 1997, SEMIN LIVER DIS, V17, P71, DOI 10.1055/s-2007-1007184; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tsai CC, 2004, P NATL ACAD SCI USA, V101, P4047, DOI 10.1073/pnas.0400615101; Ueda H, 2002, BIOCHEM BIOPH RES CO, V293, P307, DOI 10.1016/S0006-291X(02)00211-5; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yue S, 2001, HUM MOL GENET, V10, P25, DOI 10.1093/hmg/10.1.25; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	51	72	74	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21942	21948		10.1074/jbc.M501677200	http://dx.doi.org/10.1074/jbc.M501677200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824120	hybrid			2022-12-25	WOS:000229557900035
J	Xie, B; Li, H; Wang, Q; Xie, SQ; Rahmeh, A; Dai, W; Lee, MYWT				Xie, B; Li, H; Wang, Q; Xie, SQ; Rahmeh, A; Dai, W; Lee, MYWT			Further characterization of human DNA polymerase delta interacting protein 38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; REPLICATION FORK; EUKARYOTIC CELLS; SIGNAL PEPTIDES; 3RD SUBUNIT; PCNA; BINDING; GENE; IDENTIFICATION; MITOCHONDRIA	Polymerase delta interacting protein 38 ( PDIP38) was identified as a human DNA polymerase (pol) delta interacting protein through a direct interaction with p50, the small subunit of human pol delta. PDIP38 was also found to interact with proliferating cell nuclear antigen, which suggested that it might play a role in vivo in the processes of DNA replication and DNA repair in the nucleus. In order to characterize further this novel protein, we have examined its subcellular localization by the use of immunochemical and cellular fractionation techniques. These studies show that PDIP38 is a novel mitochondrial protein and is localized mainly to the mitochondria. PDIP38 was shown to possess a functional mitochondrial targeting sequence that is located within the first 35 N-terminal amino acid residues. The mature PDIP38 protein is about 50 amino acid residues smaller than the full-length precursor PDIP38 protein, consistent with it being processed by cleavage of the mitochondrial targeting sequence during entry into the mitochondria. His-tagged mature PDIP38 inhibited pol delta activity in vitro and interacted with human papillomavirus 16 E7 oncoprotein, suggesting that PDIP38 might play a role in the pol delta-mediated viral DNA replication. Although the localization of PDIP38 to the mitochondria suggests that it serves functions within the mitochondria, we cannot eliminate the possibility that it may be involved in pol delta-mediated DNA replication or DNA repair under certain conditions such as viral infection.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Lee, MYWT (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	Marietta_Lee@nymc.edu		Rahmeh, Amal/0000-0003-0985-7978	NATIONAL CANCER INSTITUTE [R13CA074299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER; NCI NIH HHS [CA 74299] Funding Source: Medline; NIGMS NIH HHS [GM 31973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Bashir T, 2001, J VIROL, V75, P4394, DOI 10.1128/JVI.75.9.4394-4398.2001; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bereiter-Hahn J., 1990, International Review of Cytology, V122, P1, DOI 10.1016/S0074-7696(08)61205-X; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Christensen J, 2002, J VIROL, V76, P6518, DOI 10.1128/JVI.76.13.6518-6531.2002; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Coffey G, 2000, NUCLEIC ACIDS RES, V28, P3793, DOI 10.1093/nar/28.19.3793; Dell'Era P, 2005, ONCOGENE, V24, P1117, DOI 10.1038/sj.onc.1208359; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; Feng WY, 2001, MOL CELL BIOL, V21, P4495, DOI 10.1128/MCB.21.14.4495-4504.2001; Frouin I, 2002, EMBO J, V21, P2485, DOI 10.1093/emboj/21.10.2485; Fukui T, 2004, GENES CELLS, V9, P179, DOI 10.1111/j.1356-9597.2004.00716.x; Gakh E, 2002, BBA-MOL CELL RES, V1592, P63, DOI 10.1016/S0167-4889(02)00265-3; Garg P, 2004, GENE DEV, V18, P2764, DOI 10.1101/gad.1252304; Garner-Hamrick PA, 2004, J VIROL, V78, P9041, DOI 10.1128/JVI.78.17.9041-9050.2004; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; He H, 2001, P NATL ACAD SCI USA, V98, P11979, DOI 10.1073/pnas.221452098; Henneke G, 2003, EMBO REP, V4, P252, DOI 10.1038/sj.embor.embor774; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kasamatsu H, 1998, ANNU REV MICROBIOL, V52, P627, DOI 10.1146/annurev.micro.52.1.627; Laquel-Robert P, 2003, BIOCHEM BIOPH RES CO, V303, P713, DOI 10.1016/S0006-291X(03)00410-8; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Liao GL, 2005, J VIROL, V79, P245, DOI 10.1128/JVI.79.1.245-256.2005; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Liu L, 2003, J BIOL CHEM, V278, P10041, DOI 10.1074/jbc.M208694200; Maga G, 2001, P NATL ACAD SCI USA, V98, P14298, DOI 10.1073/pnas.251193198; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; Raj K, 2004, J VIROL, V78, P7199, DOI 10.1128/JVI.78.13.7199-7207.2004; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; TAGUCHI T, 1995, BIOCHEM BIOPH RES CO, V216, P715, DOI 10.1006/bbrc.1995.2680; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; Tsuchimoto D, 2001, NUCLEIC ACIDS RES, V29, P2349, DOI 10.1093/nar/29.11.2349; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wang Y, 2002, P NATL ACAD SCI USA, V99, P12114, DOI 10.1073/pnas.192449499; Willer M, 1999, CURR BIOL, V9, P1085, DOI 10.1016/S0960-9822(99)80477-1; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; Xie B, 2002, BIOCHEMISTRY-US, V41, P13133, DOI 10.1021/bi0262707; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; ZENG XR, 1994, J BIOL CHEM, V269, P24027; ZENG XR, 1994, J BIOL CHEM, V269, P13748; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647; ZHANG SJ, 1995, J BIOL CHEM, V270, P7988, DOI 10.1074/jbc.270.14.7988; Zhang XP, 2001, PLANT J, V27, P427, DOI 10.1046/j.1365-313X.2001.01108.x	61	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22375	22384		10.1074/jbc.M414597200	http://dx.doi.org/10.1074/jbc.M414597200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15811854	hybrid			2022-12-25	WOS:000229557900083
J	Lee, YH; Kolade, OO; Nomura, K; Arvidson, DN; He, SY				Lee, YH; Kolade, OO; Nomura, K; Arvidson, DN; He, SY			Use of dominant-negative HrpA mutants to dissect Hrp pilus assembly and type III secretion in Pseudomonas syringae pv. tomato	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUPRAMOLECULAR STRUCTURE; PROTEIN SECRETION; NEEDLE COMPLEX; AVR PROTEINS; X-RAY; SYSTEM; PILIN; AERUGINOSA; TRANSLOCATION	The Hrp pilus plays an essential role in the long-distance type III translocation of effector proteins from bacteria into plant cells. HrpA is the structural subunit of the Hrp pilus in Pseudomonas syringae pv. tomato (Pst) DC3000. Little is known about the molecular features in the HrpA protein for pilus assembly or for transporting effector proteins. From previous collections of nonfunctional HrpA derivatives that carry random pentapeptide insertions or single amino acid mutations, we identified several dominant-negative mutants that blocked the ability of wild-type Pst DC3000 to elicit host responses. The dominant-negative phenotype was correlated with the disappearance of the Hrp pilus in culture and inhibition of wild-type HrpA protein self-assembly in vitro. Dominant- negative HrpA mutants can be grouped into two functional classes: one class exerted a strong dominant- negative effect on the secretion of effector proteins AvrPto and HopPtoM in culture, and the other did not. The two classes of mutant HrpA proteins carry pentapeptide insertions in discrete regions, which are interrupted by insertions without a dominant- negative effect. These results enable prediction of possible subunit-subunit interaction sites in the assembly of the Hrp pilus and suggest the usefulness of dominant-negative mutants in dissection of the role of the wild- type HrpA protein in various stages of type III translocation: protein exit across the bacterial cell wall, the assembly and/ or stabilization of the Hrp pilus in the extracellular space, and Hrp pilus-mediated long-distance transport beyond the bacterial cell wall.	Michigan State Univ, Dept Energy Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA; Natl Inst Agr Sci & Technol, Dept Plant Biol, Rural Dev Adm, Suwon 441707, South Korea	Michigan State University; Michigan State University; Michigan State University; Rural Development Administration (RDA), Republic of Korea	He, SY (corresponding author), Michigan State Univ, Dept Energy Plant Res Lab, 206 Plant Biol Bldg, E Lansing, MI 48824 USA.	hes@msu.edu	Lee, Yong Hoon/S-8079-2016	Lee, Yong Hoon/0000-0001-9921-3871; He, Sheng Yang/0000-0003-1308-498X				Badel JL, 2003, MOL MICROBIOL, V49, P1239, DOI 10.1046/j.1365-2958.2003.03647.x; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Buttner D, 2002, EMBO J, V21, P5313, DOI 10.1093/emboj/cdf536; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Cordes FS, 2003, J BIOL CHEM, V278, P17103, DOI 10.1074/jbc.M300091200; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Craig L, 2003, MOL CELL, V11, P1139, DOI 10.1016/S1097-2765(03)00170-9; Daniell SJ, 2003, MOL MICROBIOL, V49, P301, DOI 10.1046/j.1365-2958.2003.03555.x; Ebel F, 1998, MOL MICROBIOL, V30, P147, DOI 10.1046/j.1365-2958.1998.01046.x; FLEGLER SL, 1993, SCANNING TRANSMISSIO, P43; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Guttman DS, 2001, MOL PLANT MICROBE IN, V14, P145, DOI 10.1094/MPMI.2001.14.2.145; Hazes B, 2000, J MOL BIOL, V299, P1005, DOI 10.1006/jmbi.2000.3801; He SY, 2003, CURR OPIN MICROBIOL, V6, P15, DOI 10.1016/S1369-5274(02)00007-3; He SY, 1997, TRENDS MICROBIOL, V5, P489, DOI 10.1016/S0966-842X(97)01163-3; Hoiczyk E, 2001, P NATL ACAD SCI USA, V98, P4669, DOI 10.1073/pnas.071065798; HUYNH TV, 1989, SCIENCE, V245, P1374, DOI 10.1126/science.2781284; Jin QL, 2001, SCIENCE, V294, P2556, DOI 10.1126/science.1066397; Jin QL, 2001, MOL MICROBIOL, V40, P1129, DOI 10.1046/j.1365-2958.2001.02455.x; Journet L, 2003, SCIENCE, V302, P1757, DOI 10.1126/science.1091422; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Keizer DW, 2001, J BIOL CHEM, V276, P24186, DOI 10.1074/jbc.M100659200; Kimbrough TG, 2000, P NATL ACAD SCI USA, V97, P11008, DOI 10.1073/pnas.200209497; Knutton S, 1998, EMBO J, V17, P2166, DOI 10.1093/emboj/17.8.2166; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li CM, 2002, EMBO J, V21, P1909, DOI 10.1093/emboj/21.8.1909; Marlovits TC, 2004, SCIENCE, V306, P1040, DOI 10.1126/science.1102610; Mudgett MB, 2000, P NATL ACAD SCI USA, V97, P13324, DOI 10.1073/pnas.230450797; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; Roine E, 1997, FEBS LETT, V417, P168, DOI 10.1016/S0014-5793(97)01276-3; Roine E, 1997, P NATL ACAD SCI USA, V94, P3459, DOI 10.1073/pnas.94.7.3459; Romantschuk M, 2001, EUR J PLANT PATHOL, V107, P153, DOI 10.1023/A:1011235101437; Samatey FA, 2001, NATURE, V410, P331, DOI 10.1038/35066504; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sauer FG, 2002, CELL, V111, P543, DOI 10.1016/S0092-8674(02)01050-4; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; SCHWEIZER HP, 1991, GENE, V97, P109, DOI 10.1016/0378-1119(91)90016-5; Sekiya K, 2001, P NATL ACAD SCI USA, V98, P11638, DOI 10.1073/pnas.191378598; Taira S, 1999, MOL MICROBIOL, V34, P736, DOI 10.1046/j.1365-2958.1999.01635.x; Tamano K, 2000, EMBO J, V19, P3876, DOI 10.1093/emboj/19.15.3876; Van Gijsegem F, 2000, MOL MICROBIOL, V36, P249, DOI 10.1046/j.1365-2958.2000.01851.x; Van Gijsegem F, 2002, MOL MICROBIOL, V44, P935, DOI 10.1046/j.1365-2958.2002.02936.x; Wei WS, 2000, P NATL ACAD SCI USA, V97, P2247, DOI 10.1073/pnas.040570097; Yip CK, 2005, NAT STRUCT MOL BIOL, V12, P75, DOI 10.1038/nsmb879; Yonekura K, 2003, NATURE, V424, P643, DOI 10.1038/nature01830; Zwiesler-Vollick J, 2002, MOL MICROBIOL, V45, P1207, DOI 10.1046/j.1365-2958.2002.02964.x	47	12	15	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21409	21417		10.1074/jbc.M500972200	http://dx.doi.org/10.1074/jbc.M500972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797867	hybrid			2022-12-25	WOS:000229438800061
J	Liszt, G; Ford, E; Kurtev, M; Guarente, L				Liszt, G; Ford, E; Kurtev, M; Guarente, L			Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; LIFE-SPAN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HISTONE DEACETYLATION; TRANSCRIPTION FACTORS; PROTEIN DEACETYLASES; SIR2-LIKE PROTEINS; NAD; RIBOSYLATION	Members of the Sir2 family of NAD-dependent protein deacetylases regulate diverse cellular processes including aging, gene silencing, and cellular differentiation. Here, we report that the distant mammalian Sir2 homolog SIRT6 is a broadly expressed, predominantly nuclear protein. Northern analysis of embryonic samples and multiple adult tissues revealed mouse SIRT6 (mSIRT6) mRNA peaks at day E11, persisting into adulthood in all eight tissues examined. At the protein level, mSIRT6 was readily detectable in the same eight tissue types, with the highest levels in muscle, brain, and heart. Subcellular localization studies using both C- and N- terminal green fluorescent protein fusion proteins showed mSIRT6- green fluorescent protein to be a predominantly nuclear protein. Indirect immunofluorescence using antibodies to two different mSIRT6 epitopes confirmed that endogenous mSIRT6 is also largely nuclear. Consistent with previous findings, we did not observe any NAD(+)- dependent protein deacetylase activity in preparations of mSIRT6. However, purified recombinant mSIRT6 did catalyze the robust transfer of radio-label from [P-32] NAD to mSIRT6. Two highly conserved residues within the catalytic core of the protein were required for this reaction. This reaction is most likely mono-ADP-ribosylation because only the modified form of the protein was recognized by an antibody specific to mono- ADP- ribose. Surprisingly, we observed that the catalytic mechanism of this reaction is intra-molecular, with individual molecules of mSIRT6 directing their own modification. These results provide the first characterization of a Sir2 protein from phylogenetic class IV.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave,Rm 68-280, Cambridge, MA 02139 USA.	leng@mit.edu						Armstrong CM, 2002, MOL BIOL CELL, V13, P1427, DOI 10.1091/mbc.01-10-0482; Bitterman KJ, 2003, MICROBIOL MOL BIOL R, V67, P376, DOI 10.1128/MMBR.67.3.376-399.2003; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Corda D, 2003, EMBO J, V22, P1953, DOI 10.1093/emboj/cdg209; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Itoga M, 1997, J BIOCHEM-TOKYO, V121, P1041; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KAIN SR, 1994, BIOTECHNIQUES, V17, P982; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; MEYER T, 1986, EUR J BIOCHEM, V155, P157, DOI 10.1111/j.1432-1033.1986.tb09471.x; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Riese MJ, 2002, J BIOL CHEM, V277, P12082, DOI 10.1074/jbc.M109039200; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Sauve AA, 2004, CURR MED CHEM, V11, P807, DOI 10.2174/0929867043455675; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Weng BY, 1999, J BIOL CHEM, V274, P31797, DOI 10.1074/jbc.274.45.31797; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	31	418	438	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21313	21320		10.1074/jbc.M413296200	http://dx.doi.org/10.1074/jbc.M413296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15795229	hybrid			2022-12-25	WOS:000229438800049
J	Svensson, S; Jirstrom, K; Ryden, L; Roos, G; Emdin, S; Ostrowski, MC; Landberg, G				Svensson, S; Jirstrom, K; Ryden, L; Roos, G; Emdin, S; Ostrowski, MC; Landberg, G			ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis	ONCOGENE			English	Article						breast cancer; ERK; MAPK; Ets-2; VEGF; VEGFR2; proliferation; prognosis; tamoxifen	ACTIVATED PROTEIN-KINASE; ENDOTHELIAL GROWTH-FACTOR; MAP KINASE; RETINOBLASTOMA PROTEIN; ESTROGEN-RECEPTOR; DNA-SYNTHESIS; PLC-GAMMA; G1 PHASE; CYCLIN-E; PATHWAY	Extracellular signal-regulated kinase (ERK) 1/2 signalling mediates communication between growth factor receptors and the cell nucleus and has been linked to several key events in the transformation process such as proliferation and invasion. We therefore sought to delineate the degree of phosphorylated ERK1/2 in breast cancer and potential links to upstream receptors such as VEGFR2, ErbB2, downstream targets, such as Ets-2, as well as clinicopathological parameters, clinical outcome and response to tamoxifen. ERK1/2 phosphorylation was assessed by immunohistochemistry using a phospho-specific ERK1/2 antibody in three breast cancer cohorts including a total of 886 tumours arranged in tissue arrays. Cohort I consisted of 114 patients, cohort II of 248 postmenopausal patients randomized to either 2 years of tamoxifen or no adjuvant treatment and cohort III of 524 patients. Surprisingly, ERK1/2 phosphorylation correlated inversely with tumour size. Phosphorylated ERK1/2 was further associated with the presence of VEGFR2 (cohorts II and III) and the degree of phosphorylated Ets-2, indicating in vivo, a signalling cascade from VEGFR2 via ERK1/2 to Ets-2 phosphorylation. Interestingly, ERK1/2 phosphorylation correlated with better survival in untreated patients independently of lymph- node status and tumour size indicating that ERK1/2 signalling might be associated with a less aggressive phenotype. Finally, patients with oestrogen receptor positive and ERK1/2 phosphorylated tumours also had an impaired tamoxifen response.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, SE-20502 Malmo, Sweden; Helsingborg Hosp, Dept Surg, SE-25187 Helsingborg, Sweden; Umea Univ, Dept Pathol, SE-90187 Umea, Sweden; Umea Univ, Dept Surg, SE-90187 Umea, Sweden; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	Lund University; Skane University Hospital; Helsingborgs Hospital; Umea University; Umea University; University System of Ohio; Ohio State University	Landberg, G (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, SE-20502 Malmo, Sweden.	goran.landberg@pat.mas.lu.se	Ostrowski, Michael/H-3108-2011	Ostrowski, Michael/0000-0003-2948-6297				Adeyinka A, 2002, CLIN CANCER RES, V8, P1747; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Catalano A, 2003, FASEB J, V17, P358, DOI 10.1096/fj.03-0513fje; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Clarke M, 1998, LANCET, V351, P1451; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; De Placido S, 1998, BREAST CANCER RES TR, V52, P55, DOI 10.1023/A:1006159001039; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kendall RL, 1999, J BIOL CHEM, V274, P6453, DOI 10.1074/jbc.274.10.6453; Kollermann J, 2001, AM J CLIN PATHOL, V116, P115; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; Loden M, 2003, ANTICANCER RES, V23, P2053; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Ryden L, 2003, BREAST CANCER RES TR, V82, P147, DOI 10.1023/B:BREA.0000004357.92232.cb; SAHL B, 1999, ANTICANCER RES, V19, P731; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; Stendahl M, 2004, BRIT J CANCER, V90, P1942, DOI 10.1038/sj.bjc.6601831; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Takahashi Y, 1996, CLIN CANCER RES, V2, P1679; Von Marschall Z, 2000, GASTROENTEROLOGY, V119, P1358, DOI 10.1053/gast.2000.19578; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Yang BS, 1996, MOL CELL BIOL, V16, P538	38	92	98	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4370	4379		10.1038/sj.onc.1208626	http://dx.doi.org/10.1038/sj.onc.1208626			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806151	Green Submitted			2022-12-25	WOS:000229976900006
J	Roybal, CN; Hunsaker, LA; Barbash, O; Jagt, DLV; Abcouwer, SF				Roybal, CN; Hunsaker, LA; Barbash, O; Jagt, DLV; Abcouwer, SF			The oxidative stressor arsenite activates vascular endothelial growth factor mRNA transcription by an ATF4-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; CHOROIDAL NEOVASCULAR MEMBRANES; ENDOPLASMIC-RETICULUM STRESS; FACTOR EXPRESSION; MACULAR DEGENERATION; MAMMALIAN-CELLS; SODIUM ARSENITE; HEME OXYGENASE; KINASE; ATF4	Aberrant retinal expression of vascular endothelial growth factor (VEGF) leading to neovascularization is a central feature of age-related macular degeneration and diabetic retinopathy, two leading causes of vision loss. Oxidative stress is suggested to occur in retinal tissue during age-related macular degeneration and diabetic retinopathy and is suspected in the mechanism of VEGF expression in these diseases. Arsenite, a thiol-reactive oxidative stressor, induces VEGF expression by a HIF-1 alpha-independent mechanism. Previously, we demonstrated that homocysteine, an endoplasmic reticulum stressor, increases VEGF transcription by a mechanism dependent upon activating transcription factor ATF4. Because ATF4 is expressed in response to oxidative stress, we hypothesized that ATF4 was also responsible for increased VEGF transcription in response to arsenite. We now show that arsenite increased steady state levels of VEGF mRNA and activated transcription from a VEGF promoter construct. Arsenite induced eIF2 alpha phosphorylation, resulting in increased ATF4 protein levels. Inactivation or loss of ATF4 greatly diminished the VEGF response to arsenite treatment. Overexpression of ATF4 was sufficient to activate the VEGF promoter, and arsenite cooperated with exogenous ATF4 to further activate the promoter. A complex containing ATF4 binds a DNA element at +1767 bp relative to the VEGF transcription start site, and DNA binding activity is increased by arsenite treatment. In addition, the ability of a thiol antioxidant, N-acetylcysteine, to inhibit the effect of arsenite on VEGF expression coincided with its ability to inhibit phosphorylation of eIF2 alpha and ATF4 protein expression. Thus, arsenite-induced up-regulation of VEGF gene transcription occurs by an ATF4-dependent mechanism.	Univ New Mexico, Dept Biochem & Mol Biol, Sch Med, Albuquerque, NM 87131 USA	University of New Mexico	Abcouwer, SF (corresponding author), Univ New Mexico, Dept Biochem & Mol Biol, Sch Med, MSC08-4670,1, Albuquerque, NM 87131 USA.	sabcouwer@salud.unm.edu		Abcouwer, Steven F/0000-0003-2580-1288	NATIONAL EYE INSTITUTE [R03EY013695, F31EY014535] Funding Source: NIH RePORTER; NEI NIH HHS [EY13695, EY014535] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645; Brostrom CO, 1996, J BIOL CHEM, V271, P24995, DOI 10.1074/jbc.271.40.24995; CHANG LS, 1984, VIROLOGY, V133, P341, DOI 10.1016/0042-6822(84)90400-8; DUNCAN RF, 1987, ARCH BIOCHEM BIOPHYS, V256, P651, DOI 10.1016/0003-9861(87)90622-9; Duyndam MCA, 2003, J BIOL CHEM, V278, P6885, DOI 10.1074/jbc.M206320200; Duyndam MCA, 2001, J BIOL CHEM, V276, P48066, DOI 10.1074/jbc.M106282200; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Goldstein M, 2004, EYE, V18, P460, DOI 10.1038/sj.eye.6700702; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Ji C, 2004, WORLD J GASTROENTERO, V10, P1699; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kevil CG, 1997, BIOCHEM BIOPH RES CO, V238, P277, DOI 10.1006/bbrc.1997.7284; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; Li WY, 1999, CELL MOL BIOL, V45, P59; Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466; McEwen E, 2005, J BIOL CHEM, V280, P16925, DOI 10.1074/jbc.M412882200; Obrosova IG, 2001, DIABETOLOGIA, V44, P1102, DOI 10.1007/s001250100631; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Ord D, 2003, EXP CELL RES, V286, P308, DOI 10.1016/S0014-4827(03)00070-3; Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200; SARDANA MK, 1981, PHARMACOLOGY, V23, P247, DOI 10.1159/000137557; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7	36	99	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20331	20339		10.1074/jbc.M411275200	http://dx.doi.org/10.1074/jbc.M411275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788408	hybrid			2022-12-25	WOS:000229242000023
J	Williams, TM; Hassan, GS; Li, JW; Cohen, AW; Medina, F; Frank, PG; Pestell, RG; Di Vizio, D; Loda, M; Lisanti, MP				Williams, TM; Hassan, GS; Li, JW; Cohen, AW; Medina, F; Frank, PG; Pestell, RG; Di Vizio, D; Loda, M; Lisanti, MP			Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer - Genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; ANCHORAGE-INDEPENDENT GROWTH; BREAST-CANCER; TRANSGENIC MOUSE; EXPRESSION; CARCINOMA; METASTASIS; DIFFERENTIATION; ADENOCARCINOMA; OVEREXPRESSION	Caveolin-1 (Cav-1) is the primary structural component of caveolae and is implicated in the processes of vesicular transport, cholesterol balance, transformation, and tumorigenesis. Despite an abundance of data suggesting that Cav-1 has transformation suppressor properties both in vitro and in vivo, Cav-1 is expressed at increased levels in human prostate cancer. To investigate the role of Cav-1 in prostate cancer onset and progression, we interbred Cav-1(-/-) null mice with a TRAMP (transgenic adenocarcinoma of mouse prostate) model that spontaneously develops advanced prostate cancer and metastatic disease. We found that, although the loss of Cav-1 did not affect the appearance of minimally invasive prostate cancer, its absence significantly impeded progression to highly invasive and metastatic disease. Inactivation of one (+/-) or both (-/-) alleles of Cav-1 resulted in significant reductions in prostate tumor burden, as well as decreases in regional lymph node metastases. Moreover, further examination revealed decreased metastasis to distant organs, such as the lungs, in TRAMP/Cav-1(-/-) mice. Utilizing prostate carcinoma cell lines (C1, C2, and C3) derived from TRAMP tumors, we also showed a positive correlation between Cav-1 expression and the ability of these cells to form tumors in vivo. Furthermore, down-regulation of Cav-1 expression in these cells, using a small interfering RNA approach, significantly reduced their tumorigenic and metastatic potential. Mechanistically, we showed that loss or down-regulation of Cav-1 expression results in increased apoptosis, with increased prostate apoptosis response factor-4 and PTEN levels in Cav-1(-/-) null prostate tumors. Our current findings provide the first in vivo molecular genetic evidence that Cav-1 does indeed function as a tumor promoter during prostate carcinogenesis, rather than as a tumor suppressor.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Urol, Bronx, NY 10461 USA; Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Georgetown University; Harvard University; Dana-Farber Cancer Institute	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael/B-6131-2018; Williams, Terence M/I-9614-2014; Lisanti, Michael P/C-6866-2013; Frank, Philippe G/A-3463-2011	Lisanti, Michael/0000-0003-2034-1382; Frank, Philippe G/0000-0003-4857-5279; Hassan, Ghada S./0000-0002-1391-5248	NIDDK NIH HHS [T32-DK07513] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007513] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Capozza F, 2003, AM J PATHOL, V162, P2029, DOI 10.1016/S0002-9440(10)64335-0; Chakraborty M, 2001, CANCER RES, V61, P7255; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fong A, 2003, AM J CLIN PATHOL, V120, P93, DOI 10.1309/292NHAYNWAVREJ37; Foster BA, 1997, CANCER RES, V57, P3325; Gingrich JR, 1996, CANCER RES, V56, P4096; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Gurumurthy S, 2001, CANCER METAST REV, V20, P225, DOI 10.1023/A:1015583310759; Han SE, 2004, INT J ONCOL, V24, P435; Hayashi K, 2001, CANCER RES, V61, P2361; Hu YC, 2001, CLIN CANCER RES, V7, P3519; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li LK, 2001, CANCER RES, V61, P4386; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Rajjayabun PH, 2001, UROLOGY, V58, P811, DOI 10.1016/S0090-4295(01)01337-1; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; Satoh T, 2003, CANCER-AM CANCER SOC, V97, P1225, DOI 10.1002/cncr.11198; Sloan EK, 2004, ONCOGENE, V23, P7893, DOI 10.1038/sj.onc.1208062; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Williams TM, 2004, J BIOL CHEM, V279, P24745, DOI 10.1074/jbc.M402064200; Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-214; Williams TM, 2003, MOL BIOL CELL, V14, P1027, DOI 10.1091/mbc.E02-08-0503; Williams TM, 2004, J BIOL CHEM, V279, P51630, DOI 10.1074/jbc.M409214200; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199	34	147	151	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25134	25145		10.1074/jbc.M501186200	http://dx.doi.org/10.1074/jbc.M501186200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15802273	hybrid			2022-12-25	WOS:000230114000098
J	Filipovska, A; Kelso, GF; Brown, SE; Beer, SM; Smith, RAJ; Murphy, MP				Filipovska, A; Kelso, GF; Brown, SE; Beer, SM; Smith, RAJ; Murphy, MP			Synthesis and characterization of a triphenylphosphonium-conjugated peroxidase mimetic - Insights into the interaction of ebselen with mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE ORGANOSELENIUM COMPOUND; RAT-LIVER MITOCHONDRIA; GLUTATHIONE-PEROXIDASE; THIOREDOXIN REDUCTASE; OXIDATIVE DAMAGE; PERMEABILITY TRANSITION; CEREBRAL-ISCHEMIA; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; REDOX REGULATION	Mitochondrial production of peroxides is a critical event in both pathology and redox signaling. Consequently their selective degradation within mitochondria is of considerable interest. Here we have explored the interaction of the peroxidase mimetic ebselen with mitochondria. We were particularly interested in whether ebselen was activated by mitochondrial glutathione (GSH) and thioredoxin, in determining whether an ebselen moiety could be targeted to mitochondria by conjugating it to a lipophilic cation, and in exploring the nature of ebselen binding to mitochondrial proteins. To achieve these goals we synthesized 2-[4-(4-triphenylphosphoniobutoxy) phenyl]-1,2-benzisoselenazol)-3(2H)-one iodide (MitoPeroxidase), which contains an ebselen moiety covalently linked to a triphenylphosphonium (TPP) cation. The fixed positive charge of TPP facilitated mass spectrometric analysis, which showed that the ebselen moiety was reduced by GSH to the selenol form and that subsequent reaction with a peroxide reformed the ebselen moiety. MitoPeroxidase and ebselen were effective antioxidants that degraded phospholipid hydroperoxides, prevented lipid peroxidation, and protected mitochondria from oxidative damage. Both peroxidase mimetics required activation by mitochondrial GSH or thioredoxin to be effective antioxidants. Surprisingly, conjugation to the TPP cation led to only a slight increase in the uptake of ebselen by mitochondria due to covalent binding of the ebselen moiety to proteins. Using antiserum against the TPP moiety we visualized those proteins covalently attached to the ebselen moiety. This analysis indicated that much of the ebselen present within mitochondria is bound to protein thiols through reversible selenenylsulfide bonds. Both MitoPeroxidase and ebselen decreased apoptosis induced by oxidative stress, suggesting that they can decrease mitochondrial oxidative stress. This exploration has led to new insights into the behavior of peroxidase mimetics within mitochondria and to their use in investigating mitochondrial oxidative damage.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Otago, Dept Chem, Dunedin 9001, New Zealand	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Otago	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	mpm@mrc-dunn.cam.ac.uk	Murphy, Michael P/C-2120-2009	Murphy, Michael P/0000-0003-1115-9618; Filipovska, Aleksandra/0000-0002-6998-8403				Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; ARNOLD AP, 1986, INORG CHEM, V25, P2433, DOI 10.1021/ic00234a030; Arteel GE, 1999, CHEM RES TOXICOL, V12, P264, DOI 10.1021/tx980223r; Asin-Cayuela J, 2004, FEBS LETT, V571, P9, DOI 10.1016/j.febslet.2004.06.045; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bedogni B, 2003, J BIOL CHEM, V278, P16510, DOI 10.1074/jbc.M301089200; Beer SM, 2004, J BIOL CHEM, V279, P47939, DOI 10.1074/jbc.M408011200; Boireau A, 2000, NEUROSCI LETT, V289, P95, DOI 10.1016/S0304-3940(00)01267-2; Brand M. D., 1995, BIOENERGETICS, V154, P62; BROWN GC, 1985, BIOCHEM J, V225, P399, DOI 10.1042/bj2250399; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; COTGREAVE IA, 1992, CHEM-BIOL INTERACT, V84, P69, DOI 10.1016/0009-2797(92)90121-Z; Daiber A, 2000, BIOCHEM PHARMACOL, V59, P153, DOI 10.1016/S0006-2952(99)00309-3; DAVEY GP, 1992, BIOCHEM J, V288, P439, DOI 10.1042/bj2880439; Dhanasekaran A, 2004, J BIOL CHEM, V279, P37575, DOI 10.1074/jbc.M404003200; ENGMAN L, 1989, J ORG CHEM, V54, P2964, DOI 10.1021/jo00273a035; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FISCHER H, 1987, B SOC CHIM BELG, V96, P757; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAENEN GRMM, 1990, MOL PHARMACOL, V37, P412; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Huang JK, 1998, ORGANOMETALLICS, V17, P3516, DOI 10.1021/om980253p; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Imai H, 2003, FREE RADICAL BIO MED, V34, P56, DOI 10.1016/S0891-5849(02)01180-2; Jacob C, 2003, ANGEW CHEM INT EDIT, V42, P4742, DOI 10.1002/anie.200300573; James AM, 2003, EUR J BIOCHEM, V270, P2827, DOI 10.1046/j.1432-1033.2003.03660.x; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; Lesser R, 1924, BER DTSCH CHEM GES, V57, P1077, DOI 10.1002/cber.19240570703; LIBERMAN EA, 1969, NATURE, V222, P1076, DOI 10.1038/2221076a0; Lin TK, 2002, J BIOL CHEM, V277, P17048, DOI 10.1074/jbc.M110797200; Masumoto H, 1996, CHEM RES TOXICOL, V9, P262, DOI 10.1021/tx950115u; Masumoto K, 1996, FEBS LETT, V398, P179, DOI 10.1016/S0014-5793(96)01237-9; MORGENSTERN R, 1992, CHEM-BIOL INTERACT, V84, P77, DOI 10.1016/0009-2797(92)90122-2; Morin D, 2003, BIOCHEM PHARMACOL, V65, P1643, DOI 10.1016/S0006-2952(03)00114-X; Mugesh G, 2001, CHEM REV, V101, P2125, DOI 10.1021/cr000426w; MULLER A, 1984, BIOCHEM PHARMACOL, V33, P3235, DOI 10.1016/0006-2952(84)90083-2; Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8; Murphy MP, 2001, EXPERT OPIN BIOL TH, V1, P753, DOI 10.1517/14712598.1.5.753; Nakamura Y, 2002, J BIOL CHEM, V277, P2687, DOI 10.1074/jbc.M109641200; NARAYANASWAMI V, 1990, BIOCHEM PHARMACOL, V40, P1623, DOI 10.1016/0006-2952(90)90464-V; NIKAWA T, 1994, BIOCHEM PHARMACOL, V47, P1007, DOI 10.1016/0006-2952(94)90411-1; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Parnham M, 2000, EXPERT OPIN INV DRUG, V9, P607, DOI 10.1517/13543784.9.3.607; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Ross MF, 2005, BIOCHEMISTRY-MOSCOW+, V70, P222, DOI 10.1007/s10541-005-0104-5; Saito I, 1998, NEUROSURGERY, V42, P269, DOI 10.1097/00006123-199802000-00038; Saretzki G, 2003, AGING CELL, V2, P141, DOI 10.1046/j.1474-9728.2003.00040.x; Scarlett JL, 1996, BIOCHEM PHARMACOL, V52, P1047, DOI 10.1016/0006-2952(96)99426-5; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHEWE T, 1995, GEN PHARMACOL-VASC S, V26, P1153, DOI 10.1016/0306-3623(95)00003-J; SCOTT ID, 1980, BIOCHEM J, V186, P21, DOI 10.1042/bj1860021; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100; Ullrich V, 1996, BIOCHEM PHARMACOL, V52, P15, DOI 10.1016/0006-2952(96)00109-8; WAGNER G, 1994, BIOCHEM PHARMACOL, V48, P1137, DOI 10.1016/0006-2952(94)90150-3; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WENDEL A, 1984, BIOCHEM PHARMACOL, V33, P3241, DOI 10.1016/0006-2952(84)90084-4; Yamaguchi T, 1998, STROKE, V29, P12, DOI 10.1161/01.STR.29.1.12; Zhao R, 2002, J BIOL CHEM, V277, P39456, DOI 10.1074/jbc.M206452200; Zhao R, 2002, P NATL ACAD SCI USA, V99, P8579, DOI 10.1073/pnas.122061399	70	110	120	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24113	24126		10.1074/jbc.M501148200	http://dx.doi.org/10.1074/jbc.M501148200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15831495	hybrid			2022-12-25	WOS:000229880000085
J	Bhide, VM; Laschinger, CA; Arora, PD; Lee, W; Hakkinen, L; Larjava, H; Sodek, J; McCulloch, CA				Bhide, VM; Laschinger, CA; Arora, PD; Lee, W; Hakkinen, L; Larjava, H; Sodek, J; McCulloch, CA			Collagen phagocytosis by fibroblasts is regulated by decorin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; GROWTH-FACTOR-BETA; I COLLAGEN; CORE PROTEIN; PERIODONTAL-LIGAMENT; PROTEOGLYCAN DECORIN; BINDING-SITES; FIBRILLOGENESIS; MATRIX; DEGRADATION	Decorin is a small, leucine-rich proteoglycan that binds to collagen and regulates fibrillogenesis. We hypothesized that decorin binding to collagen inhibits phagocytosis of collagen fibrils. To determine the effects of decorin on collagen degradation, we analyzed phagocytosis of collagen and collagen/decorin-coated fluorescent beads by Rat-2 and gingival fibroblasts. Collagen beads bound to gingival cells by alpha 2 beta 1 integrins. Binding and internalization of decorin/collagen-coated beads decreased dose-dependently with increasing decorin concentration (p < 0.001). Inhibition of binding was sustained over 5 h (p < 0.001) and was attributed to interactions between decorin and collagen and not to decorin-collagen receptor interactions. Both the nonglycosylated decorin core protein and the thermally denatured decorin significantly inhibited collagen bead binding (similar to 50 and 89%, respectively; p < 0.05). Mimetic peptides corresponding to leucine-rich repeats 1-3, encompassed by a collagen-binding similar to 11-kDa cyanogen bromide fragment of decorin and leucine-rich repeats 4 and 5, previously shown to bind to collagen, were tested for their ability to inhibit collagen bead binding. Although the synthetic peptide 3 alone exhibited saturable binding to collagen, neither peptides 3 nor 1 and 2 markedly inhibited phagocytosis. Leucine-rich repeat 3 bound to a triple helical peptide containing the alpha 2 integrin-binding site of collagen. When collagen beads were co-incubated with peptides 3 and 4, inhibition of collagen phagocytosis (55%) was equivalent to intact native/recombinant core protein. Thus a novel collagen binding domain in decorin acts cooperatively with leucine-rich repeat 4 to mask the alpha 2 beta 1 integrin-binding site on collagen, an important sequence for the phagocytosis of collagen fibrils.	Univ Toronto, Canadian Inst Hlth, Res Grp Matrix Dynam, Fac Dent, Toronto, ON M5S 3E2, Canada; Univ British Columbia, Fac Dent, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada	University of Toronto; University of British Columbia	McCulloch, CA (corresponding author), Univ Toronto, Canadian Inst Hlth, Res Grp Matrix Dynam, Fac Dent, Rm 239,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	christopher.mcculloch@utoronto.ca	Larjava, Hannu/GRO-4325-2022; Hakkinen, Lari/B-2228-2016					Arora PD, 2001, J BIOL CHEM, V276, P14100, DOI 10.1074/jbc.M010298200; Arora PD, 2000, J BIOL CHEM, V275, P35432, DOI 10.1074/jbc.M003221200; Baronas-Lowell D, 2004, J BIOL CHEM, V279, P952, DOI 10.1074/jbc.M305989200; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; Bittner K, 1996, BIOCHEM J, V314, P159, DOI 10.1042/bj3140159; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DINGEMANS KP, 1994, ULTRASTRUCT PATHOL, V18, P539, DOI 10.3109/01913129409021896; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Everts V, 1996, HISTOCHEM J, V28, P229, DOI 10.1007/BF02409011; Hakkinen L, 2000, LAB INVEST, V80, P1869, DOI 10.1038/labinvest.3780197; HAKKINEN L, 1993, J HISTOCHEM CYTOCHEM, V41, P1689, DOI 10.1177/41.11.8409375; Hausser H, 1998, ARCH BIOCHEM BIOPHYS, V349, P363, DOI 10.1006/abbi.1997.0471; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; KLEOVITCH O, 1998, J BIOL CHEM, V273, P23856; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; Lauer-Fields JL, 2000, J CHROMATOGR A, V890, P117, DOI 10.1016/S0021-9673(00)00396-4; Lee W, 1996, J CELL PHYSIOL, V168, P695, DOI 10.1002/(SICI)1097-4652(199609)168:3<695::AID-JCP22>3.0.CO;2-X; MCCULLOCH CAG, 1993, J CELL PHYSIOL, V155, P461, DOI 10.1002/jcp.1041550305; MCKEOWN M, 1990, CELL TISSUE RES, V262, P523, DOI 10.1007/BF00305249; MELCHER AH, 1981, J ULTRA MOL STRUCT R, V77, P1, DOI 10.1016/S0022-5320(81)80064-0; Neame PJ, 2000, CELL MOL LIFE SCI, V57, P859, DOI 10.1007/s000180050048; POGANY G, 1992, BIOCHEM BIOPH RES CO, V189, P165, DOI 10.1016/0006-291X(92)91539-3; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Schaefer L, 2002, AM J PATHOL, V160, P1181, DOI 10.1016/S0002-9440(10)64937-1; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; Scott PG, 2003, J BIOL CHEM, V278, P18353, DOI 10.1074/jbc.M211936200; Segal G, 2001, J CELL SCI, V114, P119; Sini P, 1997, GLYCOCONJUGATE J, V14, P871, DOI 10.1023/A:1018550307649; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; SVOBODA ELA, 1981, ANAT REC, V199, P473, DOI 10.1002/ar.1091990404; TENCATE AR, 1974, ARCH ORAL BIOL, V19, P339; Tenni R, 2002, EUR J BIOCHEM, V269, P1428, DOI 10.1046/j.1432-1033.2002.02784.x; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	46	38	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23103	23113		10.1074/jbc.M410060200	http://dx.doi.org/10.1074/jbc.M410060200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15811857	hybrid			2022-12-25	WOS:000229741800067
J	De Cristofaro, R; Peyvandi, F; Palla, R; Lavoretano, S; Lombardi, R; Merati, G; Romitelli, F; Di Stasio, E; Mannucci, PM				De Cristofaro, R; Peyvandi, F; Palla, R; Lavoretano, S; Lombardi, R; Merati, G; Romitelli, F; Di Stasio, E; Mannucci, PM			Role of chloride ions in modulation of the interaction between von Willebrand factor and ADAMTS-13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; FACTOR-CLEAVING PROTEASE; PLATELET GLYCOPROTEIN IB; FACTOR A1 DOMAIN; HEMOLYTIC-UREMIC SYNDROME; HOFMEISTER SERIES; BINDING; DISEASE; ALPHA; WATER	The degradation of von Willebrand factor (VWF) depends on the activity of a zinc protease ( referred to as ADAMTS-13), which cleaves VWF at the Tyr(1605)-Met(1606) peptide bond. Little information is available on the physiological mechanisms involved in regulation of ADAMTS-13 activity. In this study, the role of ions on the ADAMTS-13/VWF interaction was investigated. In the presence of 1.5 M urea, the protease cleaved multimeric VWF in the absence of NaCl at pH 8.00 and 37 degrees C, with an apparent k(cat)/K-m congruent to 3.4 x 10(4) m(-1) s-(1,) but this value decreased by similar to 10-fold in the presence of 0.15 M NaCl. Using several monovalent salts, the inhibitory effect was attributed mostly to anions, whose potency was inversely related to the corresponding Jones-Dole viscosity B coefficients (ClO4- > Cl- > F-). The specific inhibitory effect of anions was due to their binding to VWF, which caused a conformational change responsible for quenching the intrinsic fluorescence of the protein and reducing tyrosine exposition to bulk solvent. Ristocetin binding to VWF could reduce the apparent affinity and reverse the inhibitory effect of chloride. We hypothesize that, after secretion into the extracellular compartment, VWF is bound by chloride ions abundantly present in this milieu, becoming unavailable to proteolysis by ADAMTS-13. Shear forces, which facilitate GpIb alpha binding ( this effect being artificially obtained by ristocetin), can reverse the inhibitory effect of chloride, whose concentration gradient across the cell membrane may represent a simple but efficient strategy to regulate the enzymatic activity of ADAMTS-13.	Univ Sacred Heart, Sch Med, Hemostasis Res Ctr, Inst Internal Med & Geriatr, I-00168 Rome, Italy; Univ Sacred Heart, Sch Med, Inst Biochem & Clin Biochem, I-00168 Rome, Italy; Regina Elena & Univ Milan, IRCCS, Fdn Maggiore Hosp, Angelo Bianchi Bonomi Hemphilia & Thrombosis Ctr, I-20121 Milan, Italy; Regina Elena & Univ Milan, IRCCS, Fdn Maggiore Hosp, Fdn Luigi Villa, I-20121 Milan, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Milan; University of Milan	De Cristofaro, R (corresponding author), Univ Sacred Heart, Sch Med, Hemostasis Res Ctr, Inst Internal Med & Geriatr, Largo F Vito 1, I-00168 Rome, Italy.	rdecristofaro@rm.unicatt.it	Merati, Giuliana/B-4706-2009; Peyvandi, Flora/AAK-7437-2020; De Cristofaro, Raimondo/K-3942-2018; di stasio, enrico/AAL-3082-2020; Merati, Giampiero/J-9713-2018	Merati, Giuliana/0000-0002-6185-5294; Peyvandi, Flora/0000-0001-7423-9864; De Cristofaro, Raimondo/0000-0002-8066-8849; Merati, Giampiero/0000-0002-1389-7596; Palla, Roberta/0000-0001-8837-2367				Baerga-Ortiz A, 2000, J MOL BIOL, V296, P651, DOI 10.1006/jmbi.1999.3447; Cacace MG, 1997, Q REV BIOPHYS, V30, P241, DOI 10.1017/S0033583597003363; Celikel R, 2000, NAT STRUCT BIOL, V7, P881; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; Chung DW, 2002, BIOCHEMISTRY-US, V41, P11065, DOI 10.1021/bi0204692; Collins KD, 2004, METHODS, V34, P300, DOI 10.1016/j.ymeth.2004.03.021; COLLINS KD, 1985, Q REV BIOPHYS, V18, P323, DOI 10.1017/S0033583500005369; COLLINS KD, 1995, P NATL ACAD SCI USA, V92, P5553, DOI 10.1073/pnas.92.12.5553; Di Stasio E, 2004, BIOPHYS CHEM, V107, P197, DOI 10.1016/j.bpc.2003.09.005; Dumas JJ, 2004, J BIOL CHEM, V279, P23327, DOI 10.1074/jbc.M401659200; Favaloro EJ, 2000, AM J CLIN PATHOL, V114, P608, DOI 10.1309/2PMF-3HK9-V8TT-VFUN; Fersht A, 1985, ENZYME STRUCTURE MEC, P105; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Galla JH, 2002, ACID BASE ELECTROLYT, P109; Gerritsen HE, 1999, THROMB HAEMOSTASIS, V82, P1386; Griffon N, 2001, BIOPHYS CHEM, V90, P89, DOI 10.1016/S0301-4622(01)00129-6; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Jenkins PV, 1998, BLOOD, V91, P2032, DOI 10.1182/blood.V91.6.2032.2032_2032_2044; Ledvina PS, 1996, P NATL ACAD SCI USA, V93, P6786, DOI 10.1073/pnas.93.13.6786; Lo Nostro P, 2002, BIOMACROMOLECULES, V3, P1217, DOI 10.1021/bm0255692; Matsushita T, 2000, J BIOL CHEM, V275, P11044, DOI 10.1074/jbc.275.15.11044; Miyata S, 1999, J BIOL CHEM, V274, P6586, DOI 10.1074/jbc.274.10.6586; Nishio K, 2004, P NATL ACAD SCI USA, V101, P10578, DOI 10.1073/pnas.0402041101; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; RAINES G, 1990, THROMB RES, V60, P201, DOI 10.1016/0049-3848(90)90181-B; Rastegar-Lari G, 2002, BIOCHEMISTRY-US, V41, P6668, DOI 10.1021/bi020044f; Remuzzi G, 2002, BLOOD, V100, P778, DOI 10.1182/blood-2001-12-0166; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Schneppenheim R, 2004, THROMB HAEMOSTASIS, V92, P36, DOI 10.1160/th04-02-0084; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; Tsai HM, 2004, SEMIN THROMB HEMOST, V30, P549, DOI 10.1055/s-2004-835675; Tsai HM, 2003, SEMIN THROMB HEMOST, V29, P479; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Uchida T, 2004, BLOOD, V104, P2081, DOI 10.1182/blood-2004-02-0715; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; WYMAN J, 1990, BINDING LINKAGE FUNC, P33; Zavitsas AA, 2001, J PHYS CHEM B, V105, P7805, DOI 10.1021/jp011053l	39	40	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23295	23302		10.1074/jbc.M501143200	http://dx.doi.org/10.1074/jbc.M501143200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15809291	hybrid			2022-12-25	WOS:000229741800088
J	McCarthy, TC; Li, XF; Sinal, CJ				McCarthy, TC; Li, XF; Sinal, CJ			Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE ANDROSTANE RECEPTOR; PREGNANE-X-RECEPTOR; NUCLEAR RECEPTOR; LITHOCHOLIC ACID; COLORECTAL-CANCER; TRANSPORTING POLYPEPTIDE; OBSTRUCTIVE CHOLESTASIS; TRANSCRIPTIONAL CONTROL; ABC TRANSPORTERS; RAT HEPATOCYTES	The multidrug resistance-associated protein 3 (MRP3) is a multispecific anion transporter that is capable of transporting a number of conjugated and unconjugated bile acids. Expression of the MRP3 gene is increased during pathological states associated with elevated bile acid concentrations indicating a role for this transporter in adaptive and homeostatic bile acid metabolism. Analysis of Mrp3 mRNA levels in various mouse tissues with known relevance and/or exposure to bile acids revealed the highest levels of basal expression in the colon followed in order by the liver, duodenum, jejunum, ileum, and kidney. Functional analysis of a murine Mrp3 promoter reporter construct revealed vitamin D receptor (VDR)-dependent activation by 1,25-dihydroxyvitamin D-3 (VD3), 9-cis-retinoic acid (RA), and the cholestatic secondary bile acid, lithocholic acid (LCA). Using a series of deletion constructs combined with sequence analysis, a candidate VDR response element (VDRE) was identified between -1028 and -1014 bp of the Mrp3 promoter. Activation of the Mrp3 promoter in response to VD3, RA, or LCA, as well as binding of VDR/RXR heterodimers, was attenuated substantially by mutation of this VDRE. Treatment of mice with VD3 or LCA demonstrated in vivo modulation of the Mrp3 gene in colon but not in the liver. Reduction of endogenous VDR expression in colon adenocarcinoma MCA-38 cells by siRNA transfection was associated with reduced constitutive and inducible expression of the Mrp3 gene. These data support a regulatory role for the VDR in the protection of colon cells from bile acid toxicity through regulation of the Mrp3 expression.	Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 1X5, Canada	Dalhousie University	Sinal, CJ (corresponding author), Dalhousie Univ, Dept Pharmacol, 5850 Coll St, Halifax, NS B3H 1X5, Canada.	csinal@dal.ca		Sinal, Christopher/0000-0001-8301-3349				Adorini L, 2002, INT IMMUNOPHARMACOL, V2, P1017, DOI 10.1016/S1567-5769(02)00049-8; Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; Baijal PK, 1998, NUTR CANCER, V31, P81, DOI 10.1080/01635589809514685; Batta AK, 1999, J LIPID RES, V40, P1148; Benedetti A, 1997, HEPATOLOGY, V26, P9; Bohan A, 2003, J BIOL CHEM, V278, P36688, DOI 10.1074/jbc.M304011200; Bradley BA, 1997, SURG ONCOL, V6, P143, DOI 10.1016/S0960-7404(97)00020-0; Brousseau ME, 2003, CURR OPIN LIPIDOL, V14, P35, DOI 10.1097/00041433-200302000-00007; Chang G, 2003, FEBS LETT, V555, P102, DOI 10.1016/S0014-5793(03)01085-8; Drocourt L, 2002, J BIOL CHEM, V277, P25125, DOI 10.1074/jbc.M201323200; Echchgadda I, 2004, MOL PHARMACOL, V65, P720, DOI 10.1124/mol.65.3.720; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; Guo GL, 2003, J BIOL CHEM, V278, P45062, DOI 10.1074/jbc.M307145200; Hirohashi T, 2000, J BIOL CHEM, V275, P2905, DOI 10.1074/jbc.275.4.2905; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Hofmann AF, 1999, ARCH INTERN MED, V159, P2647, DOI 10.1001/archinte.159.22.2647; Inokuchi A, 2001, J BIOL CHEM, V276, P46822, DOI 10.1074/jbc.M104612200; Kishida T, 1997, J GASTROENTEROL, V32, P306, DOI 10.1007/BF02934485; Kitada H, 2003, J BIOL CHEM, V278, P17838, DOI 10.1074/jbc.M210634200; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kouzuki H, 2000, J PHARMACOL EXP THER, V292, P505; Kouzuki H, 1998, J PHARMACOL EXP THER, V286, P1043; Kozoni V, 2000, CARCINOGENESIS, V21, P999, DOI 10.1093/carcin/21.5.999; Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953; Lamprecht SA, 2003, NAT REV CANCER, V3, P601, DOI 10.1038/nrc1144; Lang T, 2004, PHARMACOGENETICS, V14, P155, DOI 10.1097/00008571-200403000-00003; LATTA RK, 1993, CANCER LETT, V70, P167, DOI 10.1016/0304-3835(93)90227-Z; Lin R, 2004, BIOESSAYS, V26, P21, DOI 10.1002/bies.10368; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; NAGENGAST FM, 1995, EUR J CANCER, V31A, P1067, DOI 10.1016/0959-8049(95)00216-6; O'Kelly J, 2002, J CLIN INVEST, V109, P1091, DOI 10.1172/JCI200212392; Oram JF, 2002, TRENDS MOL MED, V8, P168, DOI 10.1016/S1471-4914(02)02289-X; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; REDDY BS, 1979, CANCER RES, V39, P1521; Ros JE, 2003, J PATHOL, V200, P553, DOI 10.1002/path.1379; Rost D, 2002, AM J PHYSIOL-GASTR L, V282, pG720, DOI 10.1152/ajpgi.00318.2001; Saini SPS, 2004, MOL PHARMACOL, V65, P292, DOI 10.1124/mol.65.2.292; Scheffer GL, 2002, LAB INVEST, V82, P193, DOI 10.1038/labinvest.3780411; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; Sinal CJ, 2001, J BIOL CHEM, V276, P47154, DOI 10.1074/jbc.M107000200; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Slattery ML, 2004, INT J CANCER, V111, P750, DOI 10.1002/ijc.20330; Slattery ML, 2004, CANCER EPIDEM BIOMAR, V13, P538; Soroka CJ, 2001, HEPATOLOGY, V33, P783, DOI 10.1053/jhep.2001.23501; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; TAKIKAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1091, P173, DOI 10.1016/0167-4889(91)90058-6; Thummel KE, 2001, MOL PHARMACOL, V60, P1399, DOI 10.1124/mol.60.6.1399; Tomer G, 2003, GASTROENTEROL CLIN N, V32, P839, DOI 10.1016/S0889-8553(03)00044-X; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang RX, 2001, P NATL ACAD SCI USA, V98, P2011, DOI 10.1073/pnas.031465498; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Zhang J, 2004, J BIOL CHEM, V279, P49517, DOI 10.1074/jbc.M409041200	55	68	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23232	23242		10.1074/jbc.M411520200	http://dx.doi.org/10.1074/jbc.M411520200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824121	hybrid			2022-12-25	WOS:000229741800081
J	Chaudhary, K; Donald, RGK; Nishi, M; Carter, D; Ullman, B; Roos, DS				Chaudhary, K; Donald, RGK; Nishi, M; Carter, D; Ullman, B; Roos, DS			Differential localization of alternatively spliced hypoxanthine-xanthine-guanine phosphoribosyltransferase isoforms in Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTABLE MARKER; CRYSTAL-STRUCTURES; ADENOSINE KINASE; APICOMPLEXAN PARASITES; PROTEIN PALMITOYLATION; EXPRESSION; GENE; TRANSFORMATION; CYTOSKELETON; INHIBITION	A unique feature of the Toxoplasma gondii purine salvage pathway is the expression of two isoforms of the hypoxanthine-xanthine-guanine phosophoribosyltransferase (HXGPRT) of the parasite encoded by a single genetic locus. These isoforms differ in the presence or absence of a 49-amino acid insertion (which is specified by a single differentially spliced exon) but exhibit similar substrate specificity, kinetic characteristics, and temporal expression patterns. To examine possible functional differences between the two HXGPRT isoforms, fluorescent protein fusions were expressed in parasites lacking the endogenous hxgprt gene. Immunoblot analysis of fractionated cell extracts and fluorescence microscopy indicated that HXGPRT-I (which lacks the 49-amino acid insertion) is found in the cytosol, whereas HXGPRT-II (which contains the insertion) localizes to the inner membrane complex (IMC) of the parasite. Simultaneous expression of both isoforms resulted in the formation of hetero-oligomers, which distributed between the cytosol and IMC. Chimeric constructs expressing N-terminal peptides from either isoform I (11 amino acids) or isoform II (60 amino acids) fused to a chloramphenicol acetyl transferase ( CAT) reporter demonstrated that the N-terminal domain of isoform II is both necessary and sufficient for membrane association. Metabolic labeling experiments with transgenic parasites showed that isoform II or an isoform II-CAT fusion protein (but not isoform I or isoform I-CAT) incorporate [H-3] palmitate. Mutation of three adjacent cysteine residues within the isoform II-targeting domain to serines blocked both palmitate incorporation and IMC attachment without affecting enzyme activity, demonstrating that acylation of N-terminal isoform II cysteine residues is responsible for the association of HXGPRT-II with the IMC.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	University of Pennsylvania; Oregon Health & Science University	Roos, DS (corresponding author), Univ Penn, Dept Biol, 415 S Univ Ave, Philadelphia, PA 19104 USA.	droos@sas.upenn.edu	Donald, Robert George Konrad/GNP-4958-2022; Carter, Darrick/N-3304-2016	Roos, David Siker/0000-0001-6725-4089; Carter, Darrick/0000-0001-5901-3402				Berens R. I., 1995, BIOCH MOL BIOL PARAS, P323; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Bohne W, 1997, MOL BIOCHEM PARASIT, V88, P115, DOI 10.1016/S0166-6851(97)00087-X; CARTER NS, 2003, MOL MED PARASITOLOGY, P197; Chaudhary K, 2004, J BIOL CHEM, V279, P31221, DOI 10.1074/jbc.M404232200; Darling JA, 1999, MOL BIOCHEM PARASIT, V103, P15, DOI 10.1016/S0166-6851(99)00109-7; Donald RGK, 1998, MOL BIOCHEM PARASIT, V91, P295, DOI 10.1016/S0166-6851(97)00210-7; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; DONALD RGK, 1993, P NATL ACAD SCI USA, V90, P11703, DOI 10.1073/pnas.90.24.11703; Gaskins E, 2004, J CELL BIOL, V165, P383, DOI 10.1083/jcb.200311137; Heroux A, 1999, BIOCHEMISTRY-US, V38, P14485, DOI 10.1021/bi990507q; HOWE DK, 1995, J INFECT DIS, V172, P1561, DOI 10.1093/infdis/172.6.1561; Hu K, 2002, MOL BIOL CELL, V13, P593, DOI 10.1091/mbc.01-06-0309; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; Knoll LJ, 1998, MOL CELL BIOL, V18, P807, DOI 10.1128/MCB.18.2.807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; Mann T, 2001, MOL BIOCHEM PARASIT, V115, P257, DOI 10.1016/S0166-6851(01)00289-4; Morrissette NS, 2002, MICROBIOL MOL BIOL R, V66, P21, DOI 10.1128/MMBR.66.1.21-38.2002; Morrissette NS, 1997, J CELL SCI, V110, P35; Opitz C, 2002, MOL MICROBIOL, V45, P597, DOI 10.1046/j.1365-2958.2002.03056.x; PFEFFERKORN ER, 1994, EXP PARASITOL, V79, P374, DOI 10.1006/expr.1994.1099; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; Schumacher MA, 2000, J MOL BIOL, V296, P549, DOI 10.1006/jmbi.1999.3474; Schumacher MA, 1996, NAT STRUCT BIOL, V3, P881, DOI 10.1038/nsb1096-881; SHAHABUDDIN M, 1992, EXP PARASITOL, V74, P11, DOI 10.1016/0014-4894(92)90134-V; Stokkermans TJW, 1996, EXP PARASITOL, V84, P355, DOI 10.1006/expr.1996.0124; Sullivan WJ, 1999, MOL BIOCHEM PARASIT, V103, P1, DOI 10.1016/S0166-6851(99)00114-0; Tomavo S, 2001, INT J PARASITOL, V31, P1023, DOI 10.1016/S0020-7519(01)00193-X; ULLMAN B, 1995, INFECT AGENT DIS, V4, P29; White EL, 2000, J BIOL CHEM, V275, P19218, DOI 10.1074/jbc.M908879199; WILSON CB, 1980, AM J OBSTET GYNECOL, V138, P357, DOI 10.1016/0002-9378(80)90129-5	34	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22053	22059		10.1074/jbc.M503178200	http://dx.doi.org/10.1074/jbc.M503178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15814612	hybrid			2022-12-25	WOS:000229557900049
J	Rangone, H; Pardo, R; Colin, E; Girault, JA; Saudou, F; Humbert, S				Rangone, H; Pardo, R; Colin, E; Girault, JA; Saudou, F; Humbert, S			Phosphorylation of arfaptin 2 at Ser(260) by Akt inhibits poly-Q-huntingtin-induced toxicity by rescuing proteasome impairment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT HUNTINGTIN; RAC1-INTERACTING PROTEIN; AGGREGATE FORMATION; REDUCES TOXICITY; WILD-TYPE; DEGRADATION; CLEAVAGE; DISEASE; DEATH; STABILIZATION	Huntington disease (HD) is caused by an abnormal expanded polyglutamine repeat in the huntingtin protein. Insulin-like growth factor-1 is of particular interest in HD because it strongly inhibits polyQ-huntingtin-induced neurotoxicity. This neuroprotective effect involves the phosphorylation of huntingtin at Ser(421) by the prosurvival kinase Akt (Humbert, S., Bryson, E. A., Cordelieres, F. P., Connors, N. C., Datta, S. R., Finkbeiner, S., Greenberg, M. E., and Saudou, F. ( 2002) Dev. Cell 2, 831 - 837). Here, we report that Akt inhibits polyQ-huntingtin-induced toxicity in the absence of phosphorylation of huntingtin at Ser421, suggesting that Akt also acts on other downstream effector(s) to prevent neuronal death in HD. We show that this survival effect involves the ADP-ribosylation factorinteracting protein arfaptin 2, the levels of which are increased in HD patients. Akt phosphorylated arfaptin 2 at Ser260. Lack of phosphorylation of arfaptin 2 at this site substantially modified its subcellular distribution and increased neuronal death and intranuclear inclusions caused by polyQ-huntingtin. In contrast, arfaptin 2 had a neuroprotective effect on striatal neurons when phosphorylated by Akt. This effect is mediated through the proteasome, as phosphorylated arfaptin 2 inhibited the blockade of the proteasome induced by polyQ-huntingtin. This study points out a new mechanism by which Akt promotes neuroprotection in HD, emphasizing the potential therapeutic interest of this pathway in the disease.	Ctr Univ Orsay, CNRS, UMR 146, Inst Curie, F-91405 Orsay, France; Univ Paris 06, INSERM, U536, Inst Fer Moulin, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Saudou, F (corresponding author), Ctr Univ Orsay, CNRS, UMR 146, Inst Curie, Bldg 110, F-91405 Orsay, France.	frederic.saudou@curie.u-psud.fr	Girault, Jean-Antoine/F-7518-2013; SAUDOU, Frédéric/L-3454-2014; Humbert, Sandrine/S-2981-2016	Girault, Jean-Antoine/0000-0002-7900-1705; SAUDOU, Frédéric/0000-0001-6107-1046; Humbert, Sandrine/0000-0002-9501-2658	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH031862] Funding Source: NIH RePORTER; NIMH NIH HHS [MH.NS 31862] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Berke SJS, 2003, CURR OPIN GENET DEV, V13, P253, DOI 10.1016/S0959-437X(03)00053-4; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; Goffredo D, 2002, J BIOL CHEM, V277, P39594, DOI 10.1074/jbc.C200353200; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; Martin-Aparicio E, 2001, J NEUROSCI, V21, P8772, DOI 10.1523/JNEUROSCI.21-22-08772.2001; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Peters PJ, 2002, NAT CELL BIOL, V4, P240, DOI 10.1038/ncb761; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Rangone H, 2004, EUR J NEUROSCI, V19, P273, DOI 10.1111/j.0953-816X.2003.03131.x; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Shin OH, 2001, BIOCHEM BIOPH RES CO, V285, P1267, DOI 10.1006/bbrc.2001.5330; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Verhoef LGGC, 2002, HUM MOL GENET, V11, P2689, DOI 10.1093/hmg/11.22.2689; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Young AB, 2003, J CLIN INVEST, V111, P299, DOI 10.1172/JCI200317742; Zhou H, 2003, J CELL BIOL, V163, P109, DOI 10.1083/jcb.200306038	34	38	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22021	22028		10.1074/jbc.M407528200	http://dx.doi.org/10.1074/jbc.M407528200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15809304	hybrid			2022-12-25	WOS:000229557900045
J	Chen, HB; Rud, JG; Lin, K; Xu, L				Chen, HB; Rud, JG; Lin, K; Xu, L			Nuclear targeting of transforming growth factor-b-activated smad complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; NUCLEOCYTOPLASMIC TRANSPORT; LOCALIZATION SIGNAL; CRYSTAL-STRUCTURE; TUMOR-SUPPRESSOR; PORE COMPLEX; CANCER-CELLS; IMPORT; EXPORT; PHOSPHORYLATION	Upon stimulation by the transforming growth factor b (TGF-b), Smad2 and Smad3 are phosphorylated at their C termini and assemble into stable heteromeric complexes with Smad4. These complexes are the functional entities that translocate into the nucleus and regulate the expression of TGF-b target genes. Here we report that the TGF-b- activated phospho-Smad3/ Smad4 complex utilizes an importin-independent mechanism for nuclear import and engages different nucleoporins for nuclear import compared with the monomeric Smad4. Within the heteromeric complex, phospho-Smad3 appears to dominate over Smad4 in the nuclear import process and guides the complex to its nuclear destination. We also demonstrate that the binding of phospho-Smad3 to Smad4 prevents Smad4 from interacting with the nuclear export receptor chromosome region maintenance 1. In this way, TGF-b signaling suppresses nuclear export of Smad4 by chromosome region maintenance 1 and thereby targets Smad4 into the nucleus. Indeed tumorigenic mutations in Smad4 that affect its interaction with Smad2 or Smad3 impair nuclear accumulation of Smad4 in response to TGF-b.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Xu, L (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St,Rm 308, Worcester, MA 01605 USA.	lan.xu@umassmed.edu		Rud, Jonathan/0000-0003-0295-7714	NATIONAL CANCER INSTITUTE [R01CA108509] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA108509] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Dai JL, 1998, CANCER RES, V58, P4592; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Iacobuzio-Donahue CA, 2004, CLIN CANCER RES, V10, P1597, DOI 10.1158/1078-0432.CCR-1121-3; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nicolas FJ, 2004, J CELL SCI, V117, P4113, DOI 10.1242/jcs.01289; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Souchelnytskyi S, 2002, TRENDS CELL BIOL, V12, P304, DOI 10.1016/S0962-8924(02)02300-0; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Watanabe M, 2000, EMBO REP, V1, P176, DOI 10.1093/embo-reports/kvd029; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xiao Z, 2003, ONCOGENE, V22, P1057, DOI 10.1038/sj.onc.1206212; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Xu L, 2003, J BIOL CHEM, V278, P42569, DOI 10.1074/jbc.M307601200; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	44	51	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21329	21336		10.1074/jbc.M500362200	http://dx.doi.org/10.1074/jbc.M500362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799969	hybrid			2022-12-25	WOS:000229438800051
J	Holmen, SL; Zylstra, CR; Mukherjee, A; Sigler, RE; Faugere, MC; Bouxsein, ML; Deng, LF; Clemens, TL; Williams, BO				Holmen, SL; Zylstra, CR; Mukherjee, A; Sigler, RE; Faugere, MC; Bouxsein, ML; Deng, LF; Clemens, TL; Williams, BO			Essential role of beta-catenin in postnatal bone acquisition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN-5; OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME; OSTEOBLAST PROLIFERATION; PROGRESSIVE DEVELOPMENT; MOUSE DEVELOPMENT; LRP5 GENE; APC GENE; MICE; GASTRULATION; MUTATION	Mutations in the Wnt co-receptor LRP5 alter bone mass in humans, but the mechanisms responsible for Wnts actions in bone are unclear. To investigate the role of the classical Wnt signaling pathway in osteogenesis, we generated mice lacking the beta-catenin or adenomatous polyposis coli (Apc) genes in osteoblasts. Loss of beta-catenin produced severe osteopenia with striking increases in osteoclasts, whereas constitutive activation of beta-catenin in the conditional Apc mutants resulted in dramatically increased bone deposition and a disappearance of osteoclasts. In vitro, osteoblasts lacking the beta-catenin gene exhibited impaired maturation and mineralization with elevated expression of the osteoclast differentiation factor, receptor activated by nuclear factor-kappa B ligand (RANKL), and diminished expression of the RANKL decoy receptor, osteoprotegerin. By contrast, Apc-deficient osteoblasts matured normally but demonstrated decreased expression of RANKL and increased osteoprotegerin. These findings suggest that Wnt/beta-catenin signaling in osteoblasts coordinates postnatal bone acquisition by controlling the differentiation and activity of both osteoblasts and osteoclasts.	Van Andel Res Inst, Lab Cell Signaling & Carcinnogenesis, Grand Rapids, MI 49503 USA; Van Andel Res Inst, Lab Analyt Cellular & Mol Microscopy, Grand Rapids, MI 49503 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Kentucky, Dept Med, Lexington, KY 40536 USA; Beth Israel Deaconess Med Ctr, Orthoped Biomech Lab, Boston, MA 02215 USA	Van Andel Institute; Van Andel Institute; University of Alabama System; University of Alabama Birmingham; University of Kentucky; Harvard University; Beth Israel Deaconess Medical Center	Williams, BO (corresponding author), Van Andel Res Inst, Lab Cell Signaling & Carcinnogenesis, Grand Rapids, MI 49503 USA.	bart.williams@vai.org	Williams, Bart/A-3539-2013	Williams, Bart/0000-0002-5261-5301; Diegel, Cassandra/0000-0002-6526-9372	NIAMS NIH HHS [AR44410] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brault V, 2001, DEVELOPMENT, V128, P1253; DEPAEPE A, 1993, AM J MED GENET, V45, P30, DOI 10.1002/ajmg.1320450110; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gong YQ, 1996, AM J HUM GENET, V59, P146; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hofbauer LC, 2004, JAMA-J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490; Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Jackson A, 2005, BONE, V36, P585, DOI 10.1016/j.bone.2005.01.007; Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kelly OG, 2004, DEVELOPMENT, V131, P2803, DOI 10.1242/dev.01137; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200	28	477	519	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21162	21168		10.1074/jbc.M501900200	http://dx.doi.org/10.1074/jbc.M501900200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802266	hybrid			2022-12-25	WOS:000229438800033
J	Zhuang, SG; Yan, Y; Han, JH; Schnellmann, RG				Zhuang, SG; Yan, Y; Han, JH; Schnellmann, RG			P38 kinase-mediated transactivation of the epidermal growth factor receptor is required for dedifferentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ACUTE-RENAL-FAILURE; MUSCLE-CELL-MIGRATION; BETA-CATENIN; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; CANCER-CELLS; E-CADHERIN; IN-VITRO; GENE-EXPRESSION	Renal proximal tubular cell (RPTC) dedifferentiation is thought to be a prerequisite for regenerative proliferation and migration after renal injury. However, the specific mediators and the mechanisms that regulate RPTC dedifferentiation have not been elucidated. Because epidermal growth factor (EGF) receptor activity is required for recovery from acute renal failure, we examined the role of the EGF receptor in dedifferentiation and the mechanisms of EGF receptor transactivation in primary cultures of RPTCs after oxidant injury. Exposure of confluent RPTCs to H2O2 resulted in 40 % cell death, and surviving RPTCs acquired a dedifferentiated phenotype ( e. g. elongated morphology and vimetin expression). The EGF receptor, p38, Src, and MKK3 were activated after oxidant injury and inhibition of the EGF receptor or p38 with specific inhibitors (AG1478 and SB203580, respectively) blocked RPTC dedifferentiation. Treatment with SB203580 or adenoviral overexpression of dominant negative p38 alpha or its upstream activator, MKK3, inhibited EGF receptor phosphorylation induced by oxidant injury, whereas AG1478 had no effect on p38 phosphorylation. Inhibition of Src with 4amino-5-( 4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP1) blocked MKK3 and p38 activation, and inhibition of MKK3 blocked p38 activation. In addition, inactivation of Src, MKK3, p38, or the EGF receptor blocked tyrosine phosphorylation of beta-catenin, a key signaling intermediate that is involved in the epithelial-mesenchymal transition and vimentin expression. These results reveal that p38 mediates EGF receptor activation after oxidant injury; that Src activates MMK3, which, in turn, activates p38; and that the EGF receptor signaling pathway plays a critical role in RPTC dedifferentiation.	Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Medical University of South Carolina; Medical University of South Carolina; Scripps Research Institute	Schnellmann, RG (corresponding author), Med Univ S Carolina, Dept Pharmaceut Sci, 280 Calhoun St,POB 250140, Charleston, SC 29425 USA.	schnell@musc.edu	Han, J/G-4671-2010					ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Awazu M, 2002, NEPHROL DIAL TRANSPL, V17, P5, DOI 10.1093/ndt/17.suppl_9.5; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; Bakin AV, 2002, J CELL SCI, V115, P3193; Bonventre JV, 2003, J AM SOC NEPHROL, V14, pS55, DOI 10.1097/01.ASN.0000067652.51441.21; Cheng H, 2002, J CELL PHYSIOL, V192, P234, DOI 10.1002/jcp.10134; COFFER PJ, 1995, ONCOGENE, V11, P561; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; COUNTS RS, 1995, AM J PHYSIOL-RENAL, V269, pF274, DOI 10.1152/ajprenal.1995.269.2.F274; Cummings BS, 2000, TOXICOLOGY, V150, P83, DOI 10.1016/S0300-483X(00)00252-3; CYBULSKY AV, 1994, AM J PHYSIOL, V267, pF428, DOI 10.1152/ajprenal.1994.267.3.F428; Devarajan P, 2003, MOL GENET METAB, V80, P365, DOI 10.1016/j.ymgme.2003.09.012; Eckert RL, 2003, J INVEST DERMATOL, V120, P823, DOI 10.1046/j.1523-1747.2003.12120.x; Eguchi S, 2003, BIOCHEM SOC T, V31, P1198; FINI ME, 1992, ACTA OPHTHALMOL, V70, P26; Fischer OM, 2004, MOL CELL BIOL, V24, P5172, DOI 10.1128/MCB.24.12.5172-5183.2004; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Frank GD, 2003, MOL CELL BIOL, V23, P1581, DOI 10.1128/MCB.23.5.1581-1589.2003; Gilles C, 2003, CANCER RES, V63, P2658; GOODYER PR, 1991, MOL CELL ENDOCRINOL, V77, P199, DOI 10.1016/0303-7207(91)90075-4; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Hay ED, 1995, ACTA ANAT, V154, P8; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Iijima K, 2002, CIRCULATION, V105, P2404, DOI 10.1161/01.CIR.0000016349.36385.FB; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; KAYS SE, 1995, TOXICOL APPL PHARM, V132, P273, DOI 10.1006/taap.1995.1108; Kim K, 2002, CELL BIOL INT, V26, P463, DOI 10.1006/cbir.2002.0901; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Li XJ, 2004, J BIOL CHEM, V279, P27365, DOI 10.1074/jbc.M401690200; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Lui VWY, 2003, ONCOGENE, V22, P6183, DOI 10.1038/sj.onc.1206720; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nony PA, 2003, J PHARMACOL EXP THER, V304, P905, DOI 10.1124/jpet.102.035022; NOWAK G, 1996, AM J PHYSIOL, V271, pC2080; Omori S, 2000, KIDNEY INT, V58, P27, DOI 10.1046/j.1523-1755.2000.00137.x; Pargellis Christopher, 2003, Curr Opin Investig Drugs, V4, P566; Partik G, 1999, J CANCER RES CLIN, V125, P379, DOI 10.1007/s004320050290; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Price VR, 2002, J AM SOC NEPHROL, V13, P1152, DOI 10.1097/01.ASN.0000012609.22035.44; PUGH JL, 1995, KIDNEY INT, V47, P774, DOI 10.1038/ki.1995.118; Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SAFIRSTEIN R, 1990, KIDNEY INT, V37, P1515, DOI 10.1038/ki.1990.143; Sato K, 2003, GENES CELLS, V8, P995, DOI 10.1046/j.1356-9597.2003.00691.x; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schramek H, 2003, AM J PHYSIOL-CELL PH, V285, pC652, DOI 10.1152/ajpcell.00463.2002; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Simon C, 1998, CANCER RES, V58, P1135; Strniskova M, 2002, GEN PHYSIOL BIOPHYS, V21, P231; Taira T, 1996, VIRCHOWS ARCH, V427, P583; Takahashi K, 1997, ONCOGENE, V15, P71, DOI 10.1038/sj.onc.1201160; Takahashi M, 2003, CIRCULATION, V108, P2524, DOI 10.1161/01.CIR.0000096482.02567.8C; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214; Yano T, 1999, NEPHRON, V81, P230, DOI 10.1159/000045281; Zhougang SG, 2004, AM J PHYSIOL-RENAL, V286, pF858, DOI 10.1152/ajprenal.00282.2003; Zhuang SG, 2004, AM J PHYSIOL-RENAL, V287, pF365, DOI 10.1152/ajprenal.00035.2004	62	58	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21036	21042		10.1074/jbc.M413300200	http://dx.doi.org/10.1074/jbc.M413300200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797859	hybrid			2022-12-25	WOS:000229438800018
J	Ghosh, AK; Steele, R; Ray, RB				Ghosh, AK; Steele, R; Ray, RB			c-myc promoter-binding protein 1 (MBP-1) regulates prostate cancer cell growth by inhibiting MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; CARCINOMA-CELLS; CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION; FUNCTIONAL DOMAINS; ALPHA-ENOLASE; NUDE-MICE; CYCLIN D1; EXPRESSION	Prostate cancer is the most common and invasive type of cancer among American men, and the second leading cause of cancer-elated deaths in the United States. Unfortunately, an effective therapeutic regimen is still lacking for advance stages of the disease. Recently, MEK5 has been shown to overexpress in prostate cancer and is associated with poor survival outcome. MEK5 exists as alpha- and beta-isoforms. MEK5 alpha induces cell proliferation by activating its downstream molecules, whereas MEK5 beta expression is associated with inhibition of cell growth. We have recently shown that exogenous expression of c-myc promoter-binding protein 1 (MBP-1) induces prostate cancer cell death (Ghosh, A. K., Steele, R., and Ray, R. B. (2005) Cancer Res. 65, 718-721). In this study, we have investigated whether inhibition of MEK5 signaling pathway can modulate prostate cancer cell growth. MBP-1 is a general transcriptional repressor and modulates a number of cellular genes. Therefore, we examined the endogenous expression status of MEK5 in androgen-independent prostate cancer cells upon recombinant adenovirus-mediated introduction of MBP-1. Our results demonstrated that MBP-1 expression reduced the endogenous MEK5 alpha protein level; on the other hand, MEK5 beta expression was enhanced significantly. Transduction of MBP-1 modulates the downstream signaling molecules of MEK5, such as activation of the cyclin D1 promoter and MEF2C transcriptional activities in androgen-independent prostate cancer cells. MBP-1 expression also modulates MEK5-mediated activation of NF-kappa B. Further analysis suggested that MBP-1 physically associates with MEK5 and induces proteasome-mediated degradation of the MEK5 protein, which appears to occur independently of ubiquitination. Together, our results suggested a novel role of MBP-1 for suppression of prostate cancer cell growth by regulating the MEK5-mediated signaling pathway.	St Louis Univ, Dept Pathol, St Louis, MO 63104 USA	Saint Louis University	Ray, RB (corresponding author), St Louis Univ, Dept Pathol, 1402 S Grand Blvd,4th Floor, St Louis, MO 63104 USA.	rayrb@slu.edu			NATIONAL CANCER INSTITUTE [R01CA052799, R29CA052799] Funding Source: NIH RePORTER; NCI NIH HHS [CA52799] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; American Cancer Society, 2002, SURV RES CANC FACTS; Cameron SJ, 2004, J BIOL CHEM, V279, P1506, DOI 10.1074/jbc.M308755200; CHAUDHARY D, 1995, BIOCHEMISTRY-US, V34, P3438, DOI 10.1021/bi00010a036; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Feo S, 2000, FEBS LETT, V473, P47, DOI 10.1016/S0014-5793(00)01494-0; Gasparian AV, 2002, J CELL SCI, V115, P141; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Ghosh AK, 2005, CANCER RES, V65, P718; Ghosh AK, 1999, MOL CELL BIOL, V19, P2880; Ghosh AK, 2002, ONCOGENE, V21, P2775, DOI 10.1038/sj.onc.1205384; GIALLONGO A, 1986, P NATL ACAD SCI USA, V83, P6741, DOI 10.1073/pnas.83.18.6741; Isaacs WB, 1995, CANCER SURV, V25, P357; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; Mulloy R, 2003, ONCOGENE, V22, P5387, DOI 10.1038/sj.onc.1206839; Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; RAY RB, 1995, CELL GROWTH DIFFER, V6, P1089; RAY RB, 1995, CANCER RES, V55, P3747; RAY RB, 1994, INT J ONCOL, V5, P1433; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Song H, 2004, ONCOGENE, V23, P8301, DOI 10.1038/sj.onc.1208026; Subramanian A, 2000, J BIOL CHEM, V275, P5958, DOI 10.1074/jbc.275.8.5958; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; White RA, 1997, GENOMICS, V39, P406, DOI 10.1006/geno.1996.4499; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	40	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14325	14330		10.1074/jbc.M413313200	http://dx.doi.org/10.1074/jbc.M413313200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15805119	hybrid			2022-12-25	WOS:000228095500137
J	Lesne, S; Gabriel, C; Nelson, DA; White, E; MacKenzie, ET; Vivien, D; Buisson, A				Lesne, S; Gabriel, C; Nelson, DA; White, E; MacKenzie, ET; Vivien, D; Buisson, A			Akt-dependent expression of NAIP-1 protects neurons against amyloid-beta toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NEUROTROPHIN SIGNAL-TRANSDUCTION; APOPTOSIS-INHIBITORY PROTEIN; NERVE GROWTH-FACTOR; FACTOR GENE-THERAPY; ALZHEIMERS-DISEASE; CELL-DEATH; DIFFERENTIAL REGULATION; ENDOTHELIAL-CELLS; CORTICAL-NEURONS	Neurotrophins are a family of growth factors that attenuate several forms of pathological neuronal cell death and may represent a putative therapeutic approach to neurodegenerative diseases. In Alzheimer disease, amyloid-beta (A beta) is thought to play a central role in the neuronal death occurring in brains of patients. In the present study, we evaluate the ability of neurotrophin-3 (NT-3) to protect neurons against the toxicity induced by aggregated A beta. We showed that in primary cultures of cortical neurons, NT-3 reduces A beta-induced apoptosis by limiting caspase-8, caspase-9, and caspase-3 cleavage. This neuroprotective effect of NT-3 was concomitant to an increased level of Akt phosphorylation and was abolished by an inhibitor of the phosphatidylinositol-3 kinase (PI-3K), LY294002. In parallel, NT-3 treatment reduced A beta induced caspase-3 processing to control levels. In an attempt to link PI-3K/Akt to caspase inhibition, we evaluated the influence of the PI-3K/Akt axis on the expression of a member of the inhibitors of apoptosis proteins (IAPs), the neuronal apoptosis inhibitory protein-1. We demonstrated that NT-3 induces an up-regulation of neuronal apoptosis inhibitory protein-1 expression in neurons that promotes the inhibition of A beta-induced neuronal apoptosis. Together, these findings demonstrate that NT-3 signaling counters A beta-dependent neuronal cell death and may represent an innovative therapeutic intervention to limit neuronal death in Alzheimer disease.	Univ Caen, UMR CNRS 6185, F-14074 Caen, France; Rutgers State Univ, Howard Hughes Med Inst, Piscataway, NJ 08854 USA	Universite de Caen Normandie; Howard Hughes Medical Institute; Rutgers State University New Brunswick	Buisson, A (corresponding author), Univ Caen, UMR CNRS 6185, Bd H Becquerel,BP5229, F-14074 Caen, France.	a.buisson@neuro.unicaen.fr	Mackenzie, Eric Thomson/L-1938-2015; White, Eileen/ABD-6745-2021; buisson, alain/AAI-8218-2020	White, Eileen/0000-0003-2961-3065; buisson, alain/0000-0002-4281-7911; MacKenzie, Eric T/0000-0003-1057-7033; Lesne, Sylvain/0000-0001-9411-1868; Nelson, Deirdre/0000-0001-5527-2570; VIVIEN, DENIS/0000-0002-7636-2185				Berhow MT, 1996, J NEUROSCI, V16, P4707; BRION JP, 1985, J SUBMICR CYTOL PATH, V17, P89; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; Chao MV, 2002, NEURON, V33, P9, DOI 10.1016/S0896-6273(01)00573-6; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Das KP, 2001, NEUROSCIENCE, V103, P739, DOI 10.1016/S0306-4522(01)00011-2; Davoodi J, 2004, J BIOL CHEM, V279, P40622, DOI 10.1074/jbc.M405963200; Durany N, 2000, INT J DEV NEUROSCI, V18, P807, DOI 10.1016/S0736-5748(00)00046-0; FRIEDMAN WJ, 1991, J NEUROSCI, V11, P1577; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Harada J, 1999, BRAIN RES, V842, P311, DOI 10.1016/S0006-8993(99)01808-9; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hock C, 2000, ARCH NEUROL-CHICAGO, V57, P846, DOI 10.1001/archneur.57.6.846; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Hu YQ, 1998, J NEUROCHEM, V71, P213; Hugon J, 2000, J NEURAL TRANSM-SUPP, P125; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; Martin D, 2001, J NEUROCHEM, V78, P1000, DOI 10.1046/j.1471-4159.2001.00472.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; NarisawaSaito M, 1996, J NEUROCHEM, V67, P1124; Rose Kamala, 1993, P46; Roth KA, 2001, J NEUROPATH EXP NEUR, V60, P829, DOI 10.1093/jnen/60.9.829; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Smith DE, 1999, P NATL ACAD SCI USA, V96, P10893, DOI 10.1073/pnas.96.19.10893; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Troy CM, 2000, J NEUROSCI, V20, P1386; Tuszynski MH, 2002, LANCET NEUROL, V1, P51, DOI 10.1016/S1474-4422(02)00006-6; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Wei WL, 2002, J BIOL CHEM, V277, P17649, DOI 10.1074/jbc.M111704200; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Wiese S, 1999, NAT NEUROSCI, V2, P978, DOI 10.1038/14777; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang Y, 2003, J NEUROSCI, V23, P7385	57	55	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24941	24947		10.1074/jbc.M413495200	http://dx.doi.org/10.1074/jbc.M413495200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15797869	hybrid			2022-12-25	WOS:000230114000078
J	Kobayashi, Y; Take, I; Yamashita, T; Mizoguchi, T; Ninomiya, T; Hattori, T; Kurihara, S; Ozawa, H; Udagawa, N; Takahashi, N				Kobayashi, Y; Take, I; Yamashita, T; Mizoguchi, T; Ninomiya, T; Hattori, T; Kurihara, S; Ozawa, H; Udagawa, N; Takahashi, N			Prostaglandin E-2 receptors EP2 and EP4 are down-regulated during differentiation of mouse osteoclasts from their precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPAIRED BONE-RESORPTION; CYTOSOLIC-FREE CALCIUM; PROTEIN-KINASE-A; KAPPA-B LIGAND; ISOLATED RAT; IN-VIVO; HEMATOPOIETIC PRECURSORS; PARATHYROID-HORMONE; CYTOKINE PRODUCTION; CALCITONIN	Prostaglandin E-2 (PGE(2)) has been proposed to be a potent stimulator of bone resorption. However, PGE2 itself has been shown to directly inhibit bone-resorbing activity of osteoclasts. We examined the role of PGE2 in the function of mouse osteoclasts formed in vitro. Bone marrow macrophage osteoclast precursors expressed PGE2 receptors EP1, EP2, EP3 beta, and EP4, and the expression of EP2 and EP4 was down-regulated during osteoclastic differentiation induced by receptor activator of NF-kappa B ligand and macrophage colony-stimulating factor. In contrast, functional EP1 was continuously expressed in mature osteoclasts. PGE2 as well as calcitonin caused intracellular Ca2+ influx in osteoclasts. However, PGE(2) and 17-phenyltrinol-PGE(2) (an EP1 agonist) failed to inhibit actin- ring formation and pit formation by osteoclasts cultured on dentine slices. When EP4 was expressed in osteoclasts using an adenovirus carrying EP4 cDNA, both actin-ring and pit-forming activities of osteoclasts were inhibited in an infectious unit-dependent manner. Treatment of EP4-expressing osteoclasts with PGE2 further inhibited their actin- ring and pit-forming activities. Such inhibitory effects of EP4-mediated signals on osteoclast function are similar to those that are calcitonin receptor-mediated. Thus, osteoclast precursors down-regulate their own EP2 and EP4 levels during their differentiation into osteoclasts to escape inhibitory effects of PGE(2) on bone resorption.	Matsumoto Dent Univ, Inst Oral Sci, Nagano 3990781, Japan; Matsumoto Dent Univ, Dept Orthodont, Nagano 3990781, Japan; Matsumoto Dent Univ, Dept Biochem, Nagano 3990781, Japan; Matsumoto Dent Univ, Dept Pharmacol, Nagano 3990781, Japan	Matsumoto Dental University; Matsumoto Dental University; Matsumoto Dental University; Matsumoto Dental University	Takahashi, N (corresponding author), Matsumoto Dent Univ, Inst Oral Sci, 1780 Hiro Oka, Nagano 3990781, Japan.	takahashinao@po.mdu.ac.jp	KOBAYASHI, YASUHIRO/AAU-4931-2021	Kobayashi, Yasuhiro/0000-0002-0903-3226				AKATSU T, 1991, J BONE MINER RES, V6, P183; BARON R, 1986, AM J PATHOL, V122, P363; CHAMBERS TJ, 1984, J ENDOCRINOL, V102, P281, DOI 10.1677/joe.0.1020281; Chambers TJ, 2000, J PATHOL, V192, P4; DEVERNEJOUL MC, 1988, J BONE MINER RES, V3, P69; FULLER K, 1989, J BONE MINER RES, V4, P209; IBBOTSON KJ, 1984, J CELL BIOL, V99, P471, DOI 10.1083/jcb.99.2.471; Ikegami R, 2001, J IMMUNOL, V166, P4689, DOI 10.4049/jimmunol.166.7.4689; Itoh K, 2003, J IMMUNOL, V170, P3688, DOI 10.4049/jimmunol.170.7.3688; Jee WSS, 1997, BONE, V21, P297, DOI 10.1016/S8756-3282(97)00147-6; Kanaoka K, 2000, ENDOCRINOLOGY, V141, P2995, DOI 10.1210/en.141.8.2995; KATZ JM, 1981, PROSTAGLANDINS, V22, P537, DOI 10.1016/0090-6980(81)90064-2; Keila S, 2001, J ENDOCRINOL, V168, P131, DOI 10.1677/joe.0.1680131; Kobayashi Y, 2005, J BIOL CHEM, V280, P11395, DOI 10.1074/jbc.M411189200; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kuroda H, 1996, BONE, V19, P115, DOI 10.1016/8756-3282(96)00172-X; LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817; LERNER UH, 1987, CALCIFIED TISSUE INT, V40, P323, DOI 10.1007/BF02556694; Li XT, 2003, ENDOCRINOLOGY, V144, P4999, DOI 10.1210/en.2003-0166; MALGAROLI A, 1989, J BIOL CHEM, V264, P14342; Mano M, 2000, CALCIFIED TISSUE INT, V67, P85, DOI 10.1007/s00223001102; MILLER SC, 1993, BONE, V14, P587, DOI 10.1016/8756-3282(93)90198-J; Miyaura C, 2003, J EXP MED, V197, P1303, DOI 10.1084/jem.20030015; Miyaura C, 2000, J BIOL CHEM, V275, P19819, DOI 10.1074/jbc.M002079200; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; Mo A, 2002, BONE, V31, P402, DOI 10.1016/S8756-3282(02)00835-9; MOONGA BS, 1992, J ENDOCRINOL, V132, P241, DOI 10.1677/joe.0.1320241; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; NICHOLSON GC, 1988, J BONE MINER RES, V3, P181; Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195; Okamoto F, 2004, AM J PHYSIOL-CELL PH, V287, pC114, DOI 10.1152/ajpcell.00551.2003; OSDOBY P, 1982, J EXP ZOOL, V224, P331, DOI 10.1002/jez.1402240306; Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100; Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681; RAISZ LG, 2001, AM J MED, V110, P43; Sakuma Y, 2000, INFECT IMMUN, V68, P6819, DOI 10.1128/IAI.68.12.6819-6825.2000; Samura A, 2000, ENDOCRINOLOGY, V141, P3774, DOI 10.1210/en.141.10.3774; Selander KS, 1996, MOL CELL ENDOCRINOL, V122, P119, DOI 10.1016/0303-7207(96)03870-1; Sibonga JD, 2000, J GERONTOL A-BIOL, V55, pB71; Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Suzuki H, 1996, ENDOCRINOLOGY, V137, P4685, DOI 10.1210/en.137.11.4685; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Tintut Y, 2002, J BIOL CHEM, V277, P14221, DOI 10.1074/jbc.M111551200; Tomita M, 2002, BONE, V30, P159, DOI 10.1016/S8756-3282(01)00688-3; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Vaananen HK, 2000, J CELL SCI, V113, P377; Vrotsos Y, 2003, CRIT REV EUKAR GENE, V13, P255; Wani MR, 1999, ENDOCRINOLOGY, V140, P1927, DOI 10.1210/en.140.4.1927; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399; ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V163, P1461, DOI 10.1016/0006-291X(89)91143-1; Zhang Z, 2002, BONE, V31, P359, DOI 10.1016/S8756-3282(02)00834-7	56	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24035	24042		10.1074/jbc.M500926200	http://dx.doi.org/10.1074/jbc.M500926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15834134	hybrid			2022-12-25	WOS:000229880000077
J	Ghiladi, RA; Knudsen, GM; Medzihradszky, KF; de Montellano, PRO				Ghiladi, RA; Knudsen, GM; Medzihradszky, KF; de Montellano, PRO			The Met-Tyr-Trp cross-link in Mycobacterium tuberculosis catalase-peroxidase (KatG) - Autocatalytic formation and effect on enzyme catalysis and spectroscopic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; DISTAL SIDE TRYPTOPHAN; CRYSTAL-STRUCTURE; BURKHOLDERIA-PSEUDOMALLEI; SYNECHOCYSTIS CATALASE; ISONIAZID RESISTANCE; ELECTRON-TRANSFER; RADICAL FORMATION; ESCHERICHIA-COLI; ACTIVE-SITE	Catalase-peroxidases ( KatG) are bifunctional enzymes possessing both catalase and peroxidase activities. Three crystal structures of different KatGs revealed the presence of a novel Met-Tyr-Trp cross-link that has been suggested to impart catalatic activity to the KatGs. High-performance liquid chromatographic separation of the peptide fragments resulting from tryptic digestion of recombinant Mycobacterium tuberculosis WT KatG identified a peptide with unusual UV-visible spectroscopic features attributable to the Met(255)-Tyr(229)-Trp(107) cross-link, whose structure was confirmed by mass spectrometry. WT KatG lacking the Met-Tyr-Trp cross-link was prepared, making possible studies of its formation under oxidizing conditions that generate either compound I ( peroxyacetic acid, PAA) or compound II (2-methyl-1-phenyl-2-propyl hydroperoxide, MPPH). Incubation of this "cross-link-free" WT KatG with PAA revealed complete formation of the Met-Tyr-Trp structure after six equivalents of peracid were added, whereas MPPH was unable to promote cross-link formation. A mechanism for Met-Tyr-Trp autocatalytic formation by KatG compound I is proposed from these studies. Optical stopped-flow studies of WT KatG and KatG(Y229F), a mutant in which the cross-link cannot be formed, were performed with MPPH and revealed an unusual compound II spectrum for WT KatG, best described as (P-.) Fe-III, where P-. represents a protein-based radical. This contrasts with the oxoferryl compound II spectrum observed for KatG( Y229F) under identical conditions. The structure-function-spectroscopy relationship in KatG is discussed with relevance to the role that the Met-Tyr-Trp cross-link plays in the catalase-peroxidase mechanism.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu	Ghiladi, Reza/J-8492-2017	Ghiladi, Reza/0000-0002-6450-9311	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614, S10RR012961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI058524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103481, P01GM056531, R01GM032488] Funding Source: NIH RePORTER; NCRR NIH HHS [RR001614, RR012961] Funding Source: Medline; NIAID NIH HHS [F32 AI58524] Funding Source: Medline; NIGMS NIH HHS [GM56531, GM32488, P41 GM103481] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEERS RF, 1952, J BIOL CHEM, V195, P133; Bertrand T, 2004, J BIOL CHEM, V279, P38991, DOI 10.1074/jbc.M402382200; Bhaskar B, 2003, J MOL BIOL, V328, P157, DOI 10.1016/S0022-2836(03)00179-7; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Bravo J, 1997, PROTEIN SCI, V6, P1016, DOI 10.1002/pro.5560060507; Buse G, 1999, PROTEIN SCI, V8, P985, DOI 10.1110/ps.8.5.985; Cappuccio JA, 2002, J AM CHEM SOC, V124, P1750, DOI 10.1021/ja011852h; Carpena X, 2003, J MOL BIOL, V327, P475, DOI 10.1016/S0022-2836(03)00122-0; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; Chouchane S, 2003, J BIOL CHEM, V278, P8154, DOI 10.1074/jbc.M208256200; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; Colas C, 2003, CHEM REV, V103, P2305, DOI 10.1021/cr0204303; COULSON AFW, 1971, J BIOL CHEM, V246, P917; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P14; CRICHTON R, 2001, INORGANIC BIOCH IRON, P64; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; Diaz A, 2004, J MOL BIOL, V342, P971, DOI 10.1016/j.jmb.2004.07.027; Donald LJ, 2003, J BIOL CHEM, V278, P35687, DOI 10.1074/jbc.M304053200; DUNFORD HB, 1999, HEME PEROXIDASES, P226; Engleder M, 2000, BIOCHIMIE, V82, P211, DOI 10.1016/S0300-9084(00)00204-2; Falk J.E, 1964, PORPHYRINS METALLOPO, P181, DOI [10.1002/jobm.19640040512, DOI 10.1002/JOBM.19640040512]; FIESER LF, 1948, J ORG CHEM, V13, P800, DOI 10.1021/jo01164a003; Foster TL, 2003, J AM CHEM SOC, V125, P3678, DOI 10.1021/ja0286268; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; Ghiladi RA, 2004, J AM CHEM SOC, V126, P4772, DOI 10.1021/ja031728t; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; Gray HB, 2003, Q REV BIOPHYS, V36, P341, DOI 10.1017/S0033583503003913; HIATT RR, 1963, J ORG CHEM, V28, P1893, DOI 10.1021/jo01042a041; HO PS, 1984, BIOCHEMISTRY-US, V23, P4122, DOI 10.1021/bi00313a017; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; Ivancich A, 2003, J AM CHEM SOC, V125, P14093, DOI 10.1021/ja035582+; Jakopitsch C, 2003, FEBS LETT, V552, P135, DOI 10.1016/S0014-5793(03)00901-3; Jakopitsch C, 2004, J BIOL CHEM, V279, P46082, DOI 10.1074/jbc.M408399200; Jakopitsch C, 2003, J BIOL CHEM, V278, P20185, DOI 10.1074/jbc.M211625200; Lei BF, 2000, J BIOL CHEM, V275, P2520, DOI 10.1074/jbc.275.4.2520; Lukat-Rodgers GS, 2001, BIOCHEMISTRY-US, V40, P7149, DOI 10.1021/bi010369g; Magliozzo RS, 1996, J AM CHEM SOC, V118, P11303, DOI 10.1021/ja962047j; Magliozzo RS, 1997, J BIOL CHEM, V272, P8867; Mate M. J., 2001, HDB METALLOPROTEINS, V1, P486; Mate MJ, 1999, J BIOL CHEM, V274, P27717, DOI 10.1074/jbc.274.39.27717; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; Nam W, 2000, J AM CHEM SOC, V122, P8677, DOI 10.1021/ja994403e; Nam W, 1999, CHEM COMMUN, P387, DOI 10.1039/a809876j; Nguyen M, 2002, ANTIMICROB AGENTS CH, V46, P2137, DOI 10.1128/AAC.46.7.2137-2144.2002; Nicholls P, 2001, ADV INORG CHEM, V51, P51; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; Pierattelli R, 2004, J BIOL CHEM, V279, P39000, DOI 10.1074/jbc.M402384200; Proshlyakov DA, 2000, SCIENCE, V290, P1588, DOI 10.1126/science.290.5496.1588; Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002; Regelsberger G, 1999, BIOCHEMISTRY-US, V38, P10480, DOI 10.1021/bi990886n; RILEY LW, 1996, TUBERCULOSIS; Rogers MS, 2003, CURR OPIN CHEM BIOL, V7, P189, DOI 10.1016/S1367-5931(03)00024-3; Rouse DA, 1996, MOL MICROBIOL, V22, P583, DOI 10.1046/j.1365-2958.1996.00133.x; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Santoni E, 2004, BIOPOLYMERS, V74, P46, DOI 10.1002/bip.20041; Santoni E, 2004, BIOCHEMISTRY-US, V43, P5792, DOI 10.1021/bi035835b; SCIOR T, 2002, ARCH PHARM PHARM MED, V11, P511; Silverstein R. M., 1991, SPECTROMETRIC IDENTI, P289; Slayden RA, 2000, MICROBES INFECT, V2, P659, DOI 10.1016/S1286-4579(00)00359-2; Wei CJ, 2003, ANTIMICROB AGENTS CH, V47, P670, DOI 10.1128/AAC.47.2.670-675.2003; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]; Wengenack NL, 1997, J INFECT DIS, V176, P722, DOI 10.1086/514096; Wengenack NL, 2000, BIOCHEMISTRY-US, V39, P11508, DOI 10.1021/bi001239v; Wengenack NL, 1999, BIOCHEM BIOPH RES CO, V256, P485, DOI 10.1006/bbrc.1999.0358; Whittaker JW, 2005, ARCH BIOCHEM BIOPHYS, V433, P227, DOI 10.1016/j.abb.2004.08.034; Woodward R. B., 1941, J AM CHEM SOC, V63, P1123; Woodward RB, 1942, J AM CHEM SOC, V64, P72, DOI 10.1021/ja01253a018; Woodward RB, 1942, J AM CHEM SOC, V64, P76, DOI 10.1021/ja01253a019; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; Yu SW, 2002, PROTEIN SCI, V11, P58, DOI 10.1110/ps.ps.09902; Yu SW, 2003, J BIOL CHEM, V278, P44121, DOI 10.1074/jbc.M304757200; Zabinski RF, 1997, J AM CHEM SOC, V119, P2331, DOI 10.1021/ja9639731; Zamocky M, 2001, FEBS LETT, V492, P177, DOI 10.1016/S0014-5793(01)02237-2; Zhao XB, 2004, J BIOL CHEM, V279, P7606, DOI 10.1074/jbc.M311884200	81	74	77	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22651	22663		10.1074/jbc.M502486200	http://dx.doi.org/10.1074/jbc.M502486200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15840564	hybrid			2022-12-25	WOS:000229741800014
J	Hsu, WC; Chang, HC; Chou, CY; Tsai, PJ; Lin, PI; Chang, GG				Hsu, WC; Chang, HC; Chou, CY; Tsai, PJ; Lin, PI; Chang, GG			Critical assessment of important regions in the subunit association and catalytic action of the severe acute respiratory syndrome coronavirus main protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTRA; SIZE-DISTRIBUTION ANALYSIS; SECONDARY STRUCTURE; SARS CORONAVIRUS; ANALYTICAL ULTRACENTRIFUGATION; 3C-LIKE PROTEINASE; SUBSTRATE; DESIGN; DIMERIZATION; INHIBITORS	The severe acute respiratory syndrome (SARS) coronavirus ( CoV) main protease represents an attractive target for the development of novel anti-SARS agents. The tertiary structure of the protease consists of two distinct folds. One is the N-terminal chymotrypsin-like fold that consists of two structural domains and constitutes the catalytic machinery; the other is the C-terminal helical domain, which has an unclear function and is not found in other RNA virus main proteases. To understand the functional roles of the two structural parts of the SARS-CoV main protease, we generated the full-length of this enzyme as well as several terminally truncated forms, different from each other only by the number of amino acid residues at the C- or N-terminal regions. The quaternary structure and K-d value of the protease were analyzed by analytical ultracentrifugation. The results showed that the N-terminal 1-3 amino acid-truncated protease maintains 76% of enzyme activity and that the major form is a dimer, as in the wild type. However, the amino acids 1-4-truncated protease showed the major form to be a monomer and had little enzyme activity. As a result, the fourth amino acid seemed to have a powerful effect on the quaternary structure and activity of this protease. The last C- terminal helically truncated protease also exhibited a greater tendency to form monomer and showed little activity. We concluded that both the C- and the N-terminal regions influence the dimerization and enzyme activity of the SARS-CoV main protease.	Natl Yang Ming Univ, Fac Life Sci, Inst Biochem, Taipei 112, Taiwan; Natl Yang Ming Univ, Struct Biol Program, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Chang, GG (corresponding author), Natl Yang Ming Univ, Fac Life Sci, Inst Biochem, 155 Li Nong St,Sect 2, Taipei 112, Taiwan.	ggchang@ym.edu.tw		Chou, Chi-Yuan/0000-0002-3400-171X				Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766; Chan HLY, 2003, TRENDS MOL MED, V9, P323, DOI 10.1016/S1471-4914(03)00135-7; Chen S, 2005, J BIOL CHEM, V280, P164, DOI 10.1074/jbc.M408211200; Chou CY, 2004, BIOCHEMISTRY-US, V43, P14958, DOI 10.1021/bi0490237; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; delPino MMS, 1997, BIOCHEMISTRY-US, V36, P5560, DOI 10.1021/bi963133z; Eickmann M, 2003, SCIENCE, V302, P1504; Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200; Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595; Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI18819, 10.1172/JCI200318819]; Kesel AJ, 2003, BIOORGAN MED CHEM, V11, P4599, DOI 10.1016/S0968-0896(03)00500-5; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; Kuo CJ, 2004, BIOCHEM BIOPH RES CO, V318, P862, DOI 10.1016/j.bbrc.2004.04.098; Lamm O., 1929, ARK MAT ASTR FYS, V21B, P1; Laue T.M., 1992, ANAL ULTRACENTRIFUGA; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Leng QB, 2003, NEW ENGL J MED, V349, P709, DOI 10.1056/NEJMc031427; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MAO D, 1982, BIOCHEMISTRY-US, V21, P4960, DOI 10.1021/bi00263a020; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stavrinides J, 2004, J VIROL, V78, P76, DOI 10.1128/JVI.78.1.76-82.2004; Tanner JA, 2003, J BIOL CHEM, V278, P39578, DOI 10.1074/jbc.C300328200; Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0; Tong L, 2002, CHEM REV, V102, P4609, DOI 10.1021/cr010184f; VANSTOKKUM IHM, 1990, ANAL BIOCHEM, V191, P110, DOI 10.1016/0003-2697(90)90396-Q; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100	41	83	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22741	22748		10.1074/jbc.M502556200	http://dx.doi.org/10.1074/jbc.M502556200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15831489	Green Published, hybrid			2022-12-25	WOS:000229741800024
J	Lancaster, GI; Febbraio, MA				Lancaster, GI; Febbraio, MA			Exosome-dependent trafficking of HSP70 - A novel secretory pathway for cellular stress proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR HSP72; MONONUCLEAR-CELLS; IMMUNE-RESPONSE; TUMOR-CELLS; K562 CELLS; RECEPTOR; RELEASE; SIGNAL; EXPRESSION; CHAPERONE	The heat shock proteins (HSPs) are a family of intracellular proteins found in all eukaryotes and prokaryotes. Their functions are well characterized and are central to maintaining cellular homeostasis and in promoting cell survival in response to stressful cellular conditions. However, several studies provide evidence that specific members of the HSP family might be secreted via an unidentified exocytotic pathway. Here we show that exosomes, small membrane vesicles that are secreted by numerous cell types, contribute to the release of HSP70 from human peripheral blood mononuclear cells (PBMCs) in both basal and stress-induced (heat shock at 40 or 43 C for 1 h) states. HSP70 release from PBMCs is independent of the common secretory pathway because Brefeldin A, an inhibitor of the classical protein transport pathway, did not block HSP70 release. Furthermore, we show that HSP70 release from PBMCs does not occur via a lipid raft- dependent pathway, because treatment with methyl-beta-cyclodextrin, a raft-disrupting drug, had no affect on HSP70 release. To examine whether exosomes contributed to HSP70 release from PBMCs, exosomes were purified from PBMC cultures, and exosomal number and HSP70 content were determined. We demonstrate that although heat shock does not influence the exosomal secretory rate, the HSP70 content of exosomes isolated from heat shocked PBMCs is significantly higher than control. These data identify a novel secretory pathway by which HSP70 can be actively released from cells in both the basal and stress-induced state.	Royal Melbourne Inst Technol, Sch Med Sci, Cellular & Mol Metab Lab, Bundoora, Vic 3083, Australia	Royal Melbourne Institute of Technology (RMIT)	Lancaster, GI (corresponding author), Royal Melbourne Inst Technol, Sch Med Sci, Cellular & Mol Metab Lab, Bundoora, Vic 3083, Australia.	Graeme.Lancaster@rmit.edu.au	Febbraio, Mark/AAE-9632-2019	Febbraio, Mark/0000-0002-9296-4418				Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Broquet AH, 2003, J BIOL CHEM, V278, P21601, DOI 10.1074/jbc.M302326200; Campisi J, 2003, CELL STRESS CHAPERON, V8, P272, DOI 10.1379/1466-1268(2003)008<0272:SEHIAF>2.0.CO;2; Denzer K, 2000, J CELL SCI, V113, P3365; Febbraio MA, 2002, J PHYSIOL-LONDON, V544, P957, DOI 10.1113/jphysiol.2002.025148; Feng HP, 2003, BLOOD, V101, P245, DOI 10.1182/blood-2002-05-1580; Fevrier B, 2004, CURR OPIN CELL BIOL, V16, P415, DOI 10.1016/j.ceb.2004.06.003; Fleshner M, 2004, PSYCHONEUROENDOCRINO, V29, P1142, DOI 10.1016/j.psyneuen.2004.01.007; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gross C, 2003, J BIOL CHEM, V278, P41173, DOI 10.1074/jbc.M302644200; Guzhova I, 2001, BRAIN RES, V914, P66, DOI 10.1016/S0006-8993(01)02774-3; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Hegmans JPJJ, 2004, AM J PATHOL, V164, P1807, DOI 10.1016/S0002-9440(10)63739-X; HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206; Hunter-Lavin C, 2004, BIOCHEM BIOPH RES CO, V324, P511, DOI 10.1016/j.bbrc.2004.09.075; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Multhoff G, 1996, CELL STRESS CHAPERON, V1, P167, DOI 10.1379/1466-1268(1996)001<0167:CSEOHS>2.3.CO;2; Multhoff G, 1997, J IMMUNOL, V158, P4341; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Savina A, 2003, J BIOL CHEM, V278, P20083, DOI 10.1074/jbc.M301642200; Savina A, 2002, J CELL SCI, V115, P2505; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	27	420	443	2	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23349	23355		10.1074/jbc.M502017200	http://dx.doi.org/10.1074/jbc.M502017200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15826944	hybrid			2022-12-25	WOS:000229741800094
J	Wang, DQ; Guo, M; Liang, Z; Fan, J; Zhu, ZQ; Zang, JY; Zhu, ZG; Li, XW; Teng, MK; Niu, LW; Dong, YH; Liu, P				Wang, DQ; Guo, M; Liang, Z; Fan, J; Zhu, ZQ; Zang, JY; Zhu, ZG; Li, XW; Teng, MK; Niu, LW; Dong, YH; Liu, P			Crystal structure of human vacuolar protein sorting protein 29 reveals a phosphodiesterase/nuclease-like fold and two protein-protein interaction sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI RETROGRADE TRANSPORT; MEMBRANE-PROTEINS; YEAST; ENDOSOME; ASSOCIATION; RETRIEVAL; RETROMER; RECEPTOR; MUTANTS; NEXIN-1	Vacuolar protein sorting protein 29 (Vps29p), which is involved in retrograde trafficking from prevacuolar endosomes to the trans-Golgi network, performs its biological functions by participating in the formation of a "retromer complex." In human cells, this complex comprises four conserved proteins: hVps35p, hVps29p, hVps26p, and sorting nexin 1 protein (SNX1). Here, we report the crystal structure of hVps29p at 2.1 angstrom resolution, the first three-dimensional structure of the retromer subunits. This novel structure adopts a four-layered alpha-beta-beta-alpha sandwich fold. hVps29p contains a metal-binding site that is very similar to the active sites of some proteins of the phosphodiesterase/nuclease protein family, indicating that hVps29p may carry out chemically similar functions. Structure and sequence conservation analysis suggests that hVps29p contains two protein-protein interaction sites. One site, which potentially serves as the interface between hVps29p and hVps35p, comprises 5 conserved hydrophobic and 8 hydrophilic residues. The other site is relatively more hydrophilic and may serve as a binding interface with hVps26p, SNX1, or other target proteins.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China; Univ Sci & Technol China, Chinese Acad Sci, Key Lab Struct Biol, Hefei 230026, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Dept Mol & Cell Biol, Hefei 230026, Anhui, Peoples R China; Chinese Acad Sci, Inst High Energy Phys, Beijing Synchrotron Radiat Facil, Beijing 100039, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; Institute of High Energy Physics, CAS	Teng, MK (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, 96 Jinzhai Rd, Hefei 230026, Anhui, Peoples R China.	mkteng@ustc.edu.cn; lwniu@ustc.edu.cn	Zang, Jianye/E-5228-2013; Zhu, Zhiqiang/J-6210-2016	Dong, Yuhui/0000-0002-4422-4685				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Bryant NJ, 1997, J CELL BIOL, V136, P287, DOI 10.1083/jcb.136.2.287; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Burda P, 2002, J CELL SCI, V115, P3889, DOI 10.1242/jcs.00090; Chen SF, 2004, J BIOL CHEM, V279, P31854, DOI 10.1074/jbc.M401059200; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Cozier GE, 2002, J BIOL CHEM, V277, P48730, DOI 10.1074/jbc.M206986200; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Edgar AJ, 2000, BIOCHEM BIOPH RES CO, V277, P622, DOI 10.1006/bbrc.2000.3727; Glaser F, 2001, PROTEINS, V43, P89, DOI 10.1002/1097-0134(20010501)43:2<89::AID-PROT1021>3.3.CO;2-8; GOTO K, 1995, BIOCHEM BIOPH RES CO, V206, P497, DOI 10.1006/bbrc.1995.1071; Guddat LW, 1999, STRUCT FOLD DES, V7, P757, DOI 10.1016/S0969-2126(99)80100-2; Gullapalli A, 2004, MOL BIOL CELL, V15, P2143, DOI 10.1091/mbc.E03-09-0711; Haft CR, 2000, MOL BIOL CELL, V11, P4105, DOI 10.1091/mbc.11.12.4105; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; HORTON N, 1992, PROTEIN SCI, V1, P169; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klabunde T, 1996, J MOL BIOL, V259, P737, DOI 10.1006/jmbi.1996.0354; Knofel T, 1999, NAT STRUCT BIOL, V6, P448; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nothwehr SF, 2000, J CELL BIOL, V151, P297, DOI 10.1083/jcb.151.2.297; Nothwehr SF, 1997, J CELL SCI, V110, P1063; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pfeffer SR, 2001, CURR BIOL, V11, pR109, DOI 10.1016/S0960-9822(01)00042-2; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reddy JV, 2001, MOL BIOL CELL, V12, P3242, DOI 10.1091/mbc.12.10.3242; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Seaman MNJ, 2004, J CELL BIOL, V165, P111, DOI 10.1083/jcb.200312034; Seaman MNJ, 2002, MOL BIOL CELL, V13, P2826, DOI 10.1091/mbc.02-05-0064; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; van Vliet C, 2003, PROG BIOPHYS MOL BIO, V83, P1, DOI 10.1016/S0079-6107(03)00019-1; Verges M, 2004, NAT CELL BIOL, V6, P763, DOI 10.1038/ncb1153; Voegtli WC, 2000, BIOCHEMISTRY-US, V39, P15365, DOI 10.1021/bi0021030; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699	52	53	54	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22962	22967		10.1074/jbc.M500464200	http://dx.doi.org/10.1074/jbc.M500464200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15788412	hybrid			2022-12-25	WOS:000229741800050
J	Weber, ANR; Moncrieffe, MC; Gangloff, M; Imler, JL; Gay, NJ				Weber, ANR; Moncrieffe, MC; Gangloff, M; Imler, JL; Gay, NJ			Ligand-receptor and receptor-receptor interactions act in concert to activate signaling in the Drosophila toll pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DORSAL-VENTRAL POLARITY; CRYSTAL-STRUCTURE; PROTEIN; LIPOPOLYSACCHARIDE; RECOGNITION; COMPLEX; SPATZLE; MD-2; OLIGOMERIZATION	In Drosophila, the signaling pathway mediated by the Toll receptor is critical for the establishment of embryonic dorso-ventral pattern and for innate immune responses to bacterial and fungal pathogens. Toll is activated by high affinity binding of the cytokine Spatzle, a dimeric ligand of the cystine knot family. In vertebrates, a related family of Toll-like receptors play a critical role in innate immune responses. Despite the importance of this family of receptors, little is known about the biochemical events that lead to receptor activation and signaling. Here, we show that Spatzle binds to the N-terminal region of Toll and, using biophysical methods, that the binding is complex. The two binding events that cause formation of the cross-linked complex are non-equivalent: the first Toll ectodomain binds Spatzle with an affinity 3-fold higher than the second molecule suggesting that pathway activation involves negative cooperativity. We further show that the Toll ectodomains are able to form low affinity dimers in solution and that juxtamembrane sequences of Toll are critical for the activation or derepression of the pathway. These results, taken together, suggest a mechanism of signal transduction that requires both ligand-receptor and receptor-receptor interactions.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; CNRS, Inst Biol Mol & Cellulaire, UPR 9022, F-67084 Strasbourg, France	University of Cambridge; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gay, NJ (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	njg11@mole.bio.cam.ac.uk	Imler, Jean-Luc/GXH-4323-2022	Gangloff, Monique/0000-0001-6131-0115; Weber, Alexander/0000-0002-8627-7056				Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bischoff V, 2004, NAT IMMUNOL, V5, P1175, DOI 10.1038/ni1123; DeLotto Y, 1998, MECH DEVELOP, V72, P141, DOI 10.1016/S0925-4773(98)00024-0; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Harmer NJ, 2003, BIOPHYS CHEM, V100, P545, DOI 10.1016/S0301-4622(02)00305-8; He XL, 2004, SCIENCE, V304, P870, DOI 10.1126/science.1095190; He XLL, 2003, NEURON, V38, P177, DOI 10.1016/S0896-6273(03)00232-0; Hu XD, 2004, P NATL ACAD SCI USA, V101, P9369, DOI 10.1073/pnas.0307062101; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kennedy MN, 2004, J BIOL CHEM, V279, P34698, DOI 10.1074/jbc.M405444200; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Miyake K, 2004, TRENDS MICROBIOL, V12, P186, DOI 10.1016/j.tim.2004.02.009; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; Mizuguchi K, 1998, TRENDS BIOCHEM SCI, V23, P239, DOI 10.1016/S0968-0004(98)01216-X; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; Tauszig S, 2000, P NATL ACAD SCI USA, V97, P10520, DOI 10.1073/pnas.180130797; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; Weber ANR, 2004, J BIOL CHEM, V279, P34589, DOI 10.1074/jbc.M403830200; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; WINANS KA, 1995, MOL BIOL CELL, V6, P587, DOI 10.1091/mbc.6.5.587	35	52	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22793	22799		10.1074/jbc.M502074200	http://dx.doi.org/10.1074/jbc.M502074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15795223	hybrid			2022-12-25	WOS:000229741800030
J	Swaminath, G; Deupi, X; Lee, TW; Zhu, W; Thian, FS; Kobilka, TS; Kobilka, B				Swaminath, G; Deupi, X; Lee, TW; Zhu, W; Thian, FS; Kobilka, TS; Kobilka, B			Probing the beta(2) adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTORS; CONFORMATIONAL STATES; SERINE; DOMAIN	The beta(2) adrenergic receptor (beta(2)AR) is a prototypical family A G protein-coupled receptor (GPCR) and an excellent model system for studying the mechanism of GPCR activation. The beta(2)AR agonist binding site is well characterized, and there is a wealth of structurally related ligands with functionally diverse properties. In the present study, we use catechol (1,2-benzenediol, a structural component of catecholamine agonists) as a molecular probe to identify mechanistic differences between beta(2)AR activation by catecholamine agonists, such as isoproterenol, and by the structurally related non-catechol partial agonist salbutamol. Using biophysical and pharmacologic approaches, we show that the aromatic ring of salbutamol binds to a different site on the beta(2)AR than the aromatic ring of catecholamines. This difference is important in receptor activation as it has been hypothesized that the aromatic ring of catecholamines plays a role in triggering receptor activation through interactions with a conserved cluster of aromatic residues in the sixth transmembrane segment by a rotamer toggle switch mechanism. Our experiments indicate that the aromatic ring of salbutamol does not activate this mechanism either directly or indirectly. Moreover, the non-catechol ring of partial agonists does not interact optimally with serine residues in the fifth transmembrane helix that have been shown to play an important role in activation by catecholamines. These results demonstrate unexpected differences in binding and activation by structurally similar agonists and partial agonists. Moreover, they provide evidence that activation of a GPCR is a multistep process that can be dissected into its component parts using agonist fragments.	Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Palo Alto, CA 94305 USA	Stanford University	Kobilka, B (corresponding author), Stanford Univ, Sch Med, 157 Beckman Ctr,279 Campus Dr, Stanford, CA 94305 USA.	kobilka@cmgm.stanford.edu	Centeno, Patricia Pacios/O-8368-2016; Deupi, Xavier/B-2424-2009	Deupi, Xavier/0000-0003-4572-9316; Kobilka, Brian/0000-0001-5958-3990	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028471] Funding Source: NIH RePORTER; NINDS NIH HHS [5R01 NS 28471] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; CASE DA, 2004, AMBER 8; Chen SH, 2002, BIOCHEMISTRY-US, V41, P6045, DOI 10.1021/bi012189c; Del Carmine R, 2004, MOL PHARMACOL, V66, P356, DOI 10.1124/mol.66.2.356; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Kobilka B, 2004, MOL PHARMACOL, V65, P1060, DOI 10.1124/mol.65.5.1060; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee TW, 1999, BIOCHEMISTRY-US, V38, P13801, DOI 10.1021/bi9908282; Liapakis G, 2000, J BIOL CHEM, V275, P37779, DOI 10.1074/jbc.M002092200; Liapakis G, 2004, MOL PHARMACOL, V65, P1181, DOI 10.1124/mol.65.5.1181; Luttrell LM, 2002, J CELL SCI, V115, P455; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Palanche T, 2001, J BIOL CHEM, V276, P34853, DOI 10.1074/jbc.M104363200; Rees DC, 2004, NAT REV DRUG DISCOV, V3, P660, DOI 10.1038/nrd1467; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1989, TRENDS PHARM SCI S, V10, P26; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Wieland K, 1996, P NATL ACAD SCI USA, V93, P9276, DOI 10.1073/pnas.93.17.9276; Wu ZR, 2001, BIOCHEM J, V354, P485, DOI 10.1042/0264-6021:3540485	30	227	234	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22165	22171		10.1074/jbc.M502352200	http://dx.doi.org/10.1074/jbc.M502352200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817484	hybrid			2022-12-25	WOS:000229557900061
J	Wendt, J; von Haefen, C; Hemmati, P; Belka, C; Dorken, B; Daniel, PT				Wendt, J; von Haefen, C; Hemmati, P; Belka, C; Dorken, B; Daniel, PT			TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway	ONCOGENE			English	Article						TRAIL; ionizing irradiation; Bax; apoptosis; mitochondrial pathway; synergy	NEGATIVE PROGNOSTIC-FACTOR; DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; HUMAN-MELANOMA CELLS; MEDIATED APOPTOSIS; BREAST-CANCER; CHEMOTHERAPEUTIC DRUGS; PROTEIN EXPRESSION; ANTITUMOR-ACTIVITY; CD95/FAS RECEPTOR	The death ligand TRAIL has been suggested as a suitable biological agent for the selective induction of cell death in cancer cells. Moreover, TRAIL synergizes with DNA-damaging therapies such as chemotherapeutic drugs or ionizing irradiation (IR). Here, we show that synergy of TRAIL and IR, that is, crosssensitization between TRAIL and IR for induction of apoptosis, entirely depends on Bax proficiency in human DU145 and HCT116 carcinoma cells. DU145 prostate carcinoma cells that have lost Bax protein expression due to mutation fail to activate caspase-3 and - 9 when exposed to TRAIL and IR. In contrast, TRAIL sensitized for IR-induced apoptosis and vice versa upon reconstitution of Bax expression. Notably, both DU145 and HCT116 still express significant levels of the multidomain proapoptotic Bcl-2 homolog Bak. This indicates that Bak is not sufficient to mediate cross-sensitization and synergism between IR and TRAIL. These data clearly establish distinct roles for Bax and Bak in linking the TRAIL death receptor pathway to the mitochondrial apoptosis signaling cascade upon DNA damage by IR.	Humboldt Univ, Charite, Univ Med Ctr, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Tubingen, Fac Med, Dept Radiat Oncol, Tubingen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Daniel, PT (corresponding author), Humboldt Univ, Charite, Univ Med Ctr, Dept Hematol Oncol & Tumor Immunol, Campus Berlin,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de						Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ballestrero A, 2004, CLIN CANCER RES, V10, P1463, DOI 10.1158/1078-0432.CCR-1365-02; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bonavida B, 1999, INT J ONCOL, V15, P793; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CONEY LR, 1994, INT J CANCER, V58, P562, DOI 10.1002/ijc.2910580419; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; DHEIN J, 1992, J IMMUNOL, V149, P3166; Eberle J, 2003, ONCOGENE, V22, P9131, DOI 10.1038/sj.onc.1207228; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gliniak B, 1999, CANCER RES, V59, P6153; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Klopfer A, 2004, ONCOGENE, V23, P9408, DOI 10.1038/sj.onc.1207975; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LUCKINGFAMIRA KM, 1994, LEUKEMIA, V8, P1825; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marini P, 2003, RADIOTHER ONCOL, V68, P189, DOI 10.1016/S0167-8140(03)00186-5; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Prokop A, 2003, ONCOGENE, V22, P9107, DOI 10.1038/sj.onc.1207196; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380; Schmelz K, 2004, ONCOGENE, V23, P6743, DOI 10.1038/sj.onc.1207848; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Sturm I, 2003, CELL DEATH DIFFER, V10, P477, DOI 10.1038/sj.cdd.4401194; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	62	52	60	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4052	4064		10.1038/sj.onc.1208580	http://dx.doi.org/10.1038/sj.onc.1208580			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806163				2022-12-25	WOS:000229680300005
J	Benn, M; Nordestgaard, BG; Jensen, JS; Nilausen, K; Meinertz, H; Tybjaerg-Hansen, A				Benn, M; Nordestgaard, BG; Jensen, JS; Nilausen, K; Meinertz, H; Tybjaerg-Hansen, A			Mutation in apolipoprotein B associated with hypobetalipoproteinemia despite decreased binding to the low density lipoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRUNCATED APOLIPOPROTEIN; PLASMA; IDENTIFICATION; GENE; CODON-3500; SEQUENCE; B-100	Mutations in apolipoprotein B (APOB) may reduce binding of low density lipoprotein (LDL) to the LDL receptor and cause hypercholesterolemia. We showed that heterozygotes for a new mutation in APOB have hypobetalipoproteinemia, despite a reduced binding of LDL to the LDL receptor. APOB R3480P heterozygotes were identified among 9,255 individuals from the general population and had reduced levels of apoB-containing lipoproteins. Most surprisingly, R3480P LDL bound with lower affinity to the LDL receptor than non- carrier LDL in vitro, and these results were confirmed by turnover studies of LDL in vivo. In very low density lipoprotein (VLDL) turnover studies, the amount of VLDL converted to LDL in R3480P heterozygotes was substantially reduced, suggesting that this was the explanation for the hypobetalipoproteinemia observed in these individuals. Our findings emphasized the importance of combining in vitro studies with both human in vivo and population- based studies, as in vitro studies often have focused on very limited aspects of complex mechanisms taken out of their natural context.	Univ Copenhagen Hosp, Rigshosp, Dept Clin Biochem, Sect Mol Genet, DK-2100 Copenhagen, Denmark; Herlev Univ Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark; Bispebjerg Hosp, Copenhagen City Heart Study, DK-2400 Copenhagen, Denmark; Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark; Univ Copenhagen Hosp, Rigshosp, Dept Med B, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg Hospital; Rigshospitalet; University of Copenhagen	Tybjaerg-Hansen, A (corresponding author), Univ Copenhagen Hosp, Rigshosp, Dept Clin Biochem, Sect Mol Genet, KB3011,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	at-h@rh.dk	Benn, Marianne/O-4164-2019; Nordestgaard, Borge Gronne/ABF-1310-2020	Benn, Marianne/0000-0002-1701-595X; Nordestgaard, Borge/0000-0002-1954-7220				APPLEYARD M, 1989, SCAND J SOC MED S, V41, P1; ARMITAGE P, 2002, STAT METHODS MED RES, P1; ARNOLD KS, 1992, LIPOPROTEIN ANAL PRA, P145; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; Boren J, 2001, J BIOL CHEM, V276, P9214, DOI 10.1074/jbc.M008890200; CHATTERTON JE, 1995, J LIPID RES, V36, P2027; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; EGUSA G, 1983, J LIPID RES, V24, P1261; Frikke-Schmidt R, 2000, J LIPID RES, V41, P1812; Gabelli C, 1996, ARTERIOSCL THROM VAS, V16, P1189, DOI 10.1161/01.ATV.16.9.1189; GAFFNEY D, 1995, ARTERIOSCL THROM VAS, V15, P1025, DOI 10.1161/01.ATV.15.8.1025; Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863; HAVEL RJ, 2001, METABOLIC MOL BASES, P2717; Kornerup K, 2002, ARTERIOSCL THROM VAS, V22, P1168, DOI 10.1161/01.ATV.0000022849.26083.FA; KRAUSS RM, 1982, J LIPID RES, V23, P97; LINTON MF, 1993, J LIPID RES, V34, P521; LUDWIG EH, 1987, DNA-J MOLEC CELL BIO, V6, P363, DOI 10.1089/dna.1987.6.363; MATTHEWS CME, 1957, PHYS MED BIOL, V2, P36, DOI 10.1088/0031-9155/2/1/305; *MIN INC, 1995, MIN WIND MIN REL 10; NISSEN H, 1995, CLIN CHEM, V41, P419; NORDESTGAARD BG, 1992, ARTERIOSCLER THROMB, V12, P6, DOI 10.1161/01.ATV.12.1.6; PARHOFER KG, 1992, J CLIN INVEST, V89, P1931, DOI 10.1172/JCI115799; PULLINGER CR, 1995, J CLIN INVEST, V95, P1225, DOI 10.1172/JCI117772; *SAAM I, 2002, SAAM 2 VERS 1 2; Schnohr P, 2001, EUR HEART J SUPPL, V3, pH1; SORIA LF, 1989, P NATL ACAD SCI USA, V86, P587, DOI 10.1073/pnas.86.2.587; Sparks JD, 1996, METHOD ENZYMOL, V263, P104; *SPSS INC, 1999, SPSS WIND REL 11 5 0; Tybjaerg-Hansen A, 1998, NEW ENGL J MED, V338, P1577, DOI 10.1056/NEJM199805283382203	29	16	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21052	21060		10.1074/jbc.M413877200	http://dx.doi.org/10.1074/jbc.M413877200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797858	hybrid			2022-12-25	WOS:000229438800020
J	Norris, EH; Giasson, BI; Hodara, R; Xu, SH; Trojanowski, JQ; Ischiropoulos, H; Lee, VMY				Norris, EH; Giasson, BI; Hodara, R; Xu, SH; Trojanowski, JQ; Ischiropoulos, H; Lee, VMY			Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; LEWY BODY DISEASE; PARKINSONS-DISEASE; IN-VITRO; ALZHEIMERS-DISEASE; SUBSTANTIA-NIGRA; NEURODEGENERATIVE DISEASES; FIBRIL FORMATION; HUMAN BRAIN; BODIES	Previous studies demonstrated that alpha-synuclein (alpha-syn) fibrillization is inhibited by dopamine, and studies to understand the molecular basis of this process were conducted (Conway, K. A., Rochet, J. C., Bieganski, R. M., and Lansbury, P. T., Jr. ( 2001) Science 294, 1346-1349). Dopamine inhibition of alpha-syn fibrillization generated exclusively spherical oligomers that depended on dopamine autoxidation but not alpha-syn oxidation, because mutagenesis of Met, His, and Tyr residues in alpha-syn did not abrogate this inhibition. However, truncation of alpha-syn at residue 125 restored the ability of alpha-syn to fibrillize in the presence of dopamine. Mutagenesis and competition studies with specific synthetic peptides identified alpha-syn residues 125-129 (i.e. YEMPS) as an important region in the dopamine-induced inhibition of alpha-syn fibrillization. Significantly, the dopamine oxidation product dopaminochrome was identified as a specific inhibitor of alpha-syn fibrillization. Dopaminochrome promotes the formation of spherical oligomers by inducing conformational changes, as these oligomers regained the ability to fibrillize by simple denaturation/ renaturation. Taken together, these data indicate that dopamine inhibits alpha-syn fibrillization by inducing structural changes in alpha-syn that can occur through the interaction of dopaminochrome with the (YEMPS129)-Y-125 motif of alpha-syn. These results suggest that the dopamine autoxidation can prevent alpha-syn fibrillization in dopaminergic neurons through a novel mechanism. Thus, decreased dopamine levels in substantia nigra neurons might promote alpha-syn aggregation in Parkinson's disease.	Univ Penn, Inst Aging, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Stokes Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Lee, VMY (corresponding author), Univ Penn, Inst Aging, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.	vmylee@mail.med.upenn.edu		Norris, Erin/0000-0002-4522-3537	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS044233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009215] Funding Source: NIH RePORTER; NIA NIH HHS [AG09215] Funding Source: Medline; NINDS NIH HHS [NS044233] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Cabin DE, 2002, J NEUROSCI, V22, P8797; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Crowther RA, 2000, NEUROSCI LETT, V292, P128, DOI 10.1016/S0304-3940(00)01440-3; Crystal AS, 2003, J NEUROCHEM, V86, P1359, DOI 10.1046/j.1471-4159.2003.01949.x; Damier P, 1999, BRAIN, V122, P1437, DOI 10.1093/brain/122.8.1437; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; Duda JE, 2002, ANN NEUROL, V52, P205, DOI 10.1002/ana.10279; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Kosaka K, 1996, CURR OPIN NEUROL, V9, P271, DOI 10.1097/00019052-199608000-00005; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Li J, 2004, FASEB J, V18, P962, DOI 10.1096/fj.03-0770fje; Louis ED, 1996, ADV NEUROL, V69, P311; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Murray IVJ, 2003, BIOCHEMISTRY-US, V42, P8530, DOI 10.1021/bi027363r; Norris EH, 2003, J BIOL CHEM, V278, P27230, DOI 10.1074/jbc.M212436200; PAKKENBERG B, 1991, J NEUROL NEUROSUR PS, V54, P30, DOI 10.1136/jnnp.54.1.30; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Takeda A, 1998, AM J PATHOL, V152, P367; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wersinger C, 2003, NEUROSCI LETT, V340, P189, DOI 10.1016/S0304-3940(03)00097-1; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600	48	216	221	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21212	21219		10.1074/jbc.M412621200	http://dx.doi.org/10.1074/jbc.M412621200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15817478	hybrid			2022-12-25	WOS:000229438800039
J	Torres, VJ; Ivie, SE; McClain, MS; Cover, TL				Torres, VJ; Ivie, SE; McClain, MS; Cover, TL			Functional properties of the p33 and p55 domains of the Helicobacter pylori vacuolating cytotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN VACA; CELLULAR VACUOLATION; ACID ACTIVATION; PLASMA-MEMBRANE; BINDING; RECEPTOR; INDUCTION; REVEALS; INTERNALIZATION; IDENTIFICATION	Helicobacter pylori secretes an 88-kDa vacuolating cytotoxin (VacA) that may contribute to the pathogenesis of peptic ulcer disease and gastric cancer. VacA cytotoxic activity requires assembly of VacA monomers into oligomeric structures, formation of anion-selective membrane channels, and entry of VacA into host cells. In this study, we analyzed the functional properties of recombinant VacA fragments corresponding to two putative VacA domains ( designated p33 and p55). Immunoprecipitation experiments indicated that these two domains can interact with each other to form protein complexes. In comparison to the individual VacA domains, a mixture of the p33 and p55 proteins exhibited markedly enhanced binding to the plasma membrane of mammalian cells. Furthermore, internalization of the VacA domains was detected when cells were incubated with the p33/ p55 mixture but not when the p33 and p55 proteins were tested individually. Incubation of cells with the p33/ p55 mixture resulted in cell vacuolation, whereas the individual domains lacked detectable cytotoxic activity. Interestingly, sequential addition of p55 followed by p33 resulted in VacA internalization and cell vacuolation, whereas sequential addition in the reverse order was ineffective. These results indicate that both the p33 and p55 domains contribute to the binding and internalization of VacA and that both domains are required for vacuolating cytotoxic activity. Reconstitution of toxin activity from two separate domains, as described here for VacA, has rarely been described for pore-forming bacterial toxins, which suggests that VacA is a pore-forming toxin with unique structural properties.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Div Infect Dis, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Torres, VJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Div Infect Dis, A2200 MCN, Nashville, TN 37232 USA.	timothy.L.cover@vanderbilt.edu	Cover, Timothy/I-3814-2015; McClain, Mark S/A-6942-2009	Cover, Timothy/0000-0001-8503-002X; McClain, Mark S/0000-0002-9857-4883; Torres, Victor/0000-0002-7126-0489	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053623] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM070061] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39657] Funding Source: Medline; NIDDK NIH HHS [DK53623] Funding Source: Medline; NIGMS NIH HHS [GM070061-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adrian M, 2002, J MOL BIOL, V318, P121, DOI 10.1016/S0022-2836(02)00047-5; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; Boncristiano M, 2003, J EXP MED, V198, P1887, DOI 10.1084/jem.20030621; Cover TL, 2005, NAT REV MICROBIOL, V3, P320, DOI 10.1038/nrmicro1095; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; Cover TL, 2003, CANCER RES, V63, P951; COVER TL, 1992, J BIOL CHEM, V267, P10570; COVER TL, 1994, J BIOL CHEM, V269, P10566; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; Diep DB, 1998, MOL MICROBIOL, V30, P341, DOI 10.1046/j.1365-2958.1998.01068.x; Dubail I, 2001, MICROBIOL-SGM, V147, P2679, DOI 10.1099/00221287-147-10-2679; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; Figueiredo C, 2002, J NATL CANCER I, V94, P1680, DOI 10.1093/jnci/94.22.1680; Fujikawa A, 2003, NAT GENET, V33, P375, DOI 10.1038/ng1112; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; Gebert B, 2005, REV PHYSIOL BIOCH P, V152, P205, DOI 10.1007/s10254-004-0027-3; Gebert B, 2003, SCIENCE, V301, P1099, DOI 10.1126/science.1086871; Geisse NA, 2004, BIOCHEM J, V381, P911, DOI 10.1042/BJ20031719; HAWRYLIK SJ, 1994, J CLIN MICROBIOL, V32, P790, DOI 10.1128/JCM.32.3.790-792.1994; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Li Y, 2004, MOL BIOL CELL, V15, P1946, DOI 10.1091/mbc.e03-08-0618; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; MARSHALL BJ, 1984, LANCET, V1, P1311; McClain MS, 2000, MOL MICROBIOL, V37, P433, DOI 10.1046/j.1365-2958.2000.02013.x; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; McClain MS, 2003, INFECT IMMUN, V71, P2266, DOI 10.1128/IAI.71.4.2266-2271.2003; McClain MS, 2001, J BACTERIOL, V183, P6499, DOI 10.1128/JB.183.22.6499-6508.2001; McClain MS, 2001, INFECT IMMUN, V69, P1181, DOI 10.1128/IAI.69.2.1181-1184.2001; Molinari M, 1998, BIOCHEM BIOPH RES CO, V248, P334, DOI 10.1006/bbrc.1998.8808; Molinari M, 1998, J EXP MED, V187, P135, DOI 10.1084/jem.187.1.135; Moll G, 1995, EUR J BIOCHEM, V234, P947, DOI 10.1111/j.1432-1033.1995.947_a.x; Montecucco C, 2003, J EXP MED, V198, P1767, DOI 10.1084/jem.20031839; Nakayama M, 2004, J BIOL CHEM, V279, P7024, DOI 10.1074/jbc.M308898200; Nguyen VQ, 2001, INFECT IMMUN, V69, P543, DOI 10.1128/IAI.69.1.543-546.2001; Padilla PI, 2000, J BIOL CHEM, V275, P15200, DOI 10.1074/jbc.275.20.15200; Patel HK, 2002, INFECT IMMUN, V70, P4112, DOI 10.1128/IAI.70.8.4112-4123.2002; Reyrat JM, 1999, J MOL BIOL, V290, P459, DOI 10.1006/jmbi.1999.2877; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Schraw W, 2002, J BIOL CHEM, V277, P34642, DOI 10.1074/jbc.M203466200; Seto K, 1998, FEBS LETT, V431, P347, DOI 10.1016/S0014-5793(98)00788-1; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Sundrud MS, 2004, P NATL ACAD SCI USA, V101, P7727, DOI 10.1073/pnas.0401528101; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Torres VJ, 2004, J BIOL CHEM, V279, P2324, DOI 10.1074/jbc.M310159200; Utt M, 2001, FEMS IMMUNOL MED MIC, V30, P109, DOI 10.1111/j.1574-695X.2001.tb01557.x; Vinion-Dubiel AD, 1999, J BIOL CHEM, V274, P37736, DOI 10.1074/jbc.274.53.37736; Wang HJ, 2000, BIOCHEM BIOPH RES CO, V278, P449, DOI 10.1006/bbrc.2000.3820; Wang WC, 2001, BIOCHEMISTRY-US, V40, P11887, DOI 10.1021/bi010065u; Willhite DC, 2004, CELL MICROBIOL, V6, P143, DOI 10.1046/j.1462-5822.2003.00347.x; Willhite DC, 2003, J BIOL CHEM, V278, P48204, DOI 10.1074/jbc.M304131200; Willhite DC, 2002, INFECT IMMUN, V70, P3824, DOI 10.1128/IAI.70.7.3824-3832.2002; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693; Yahiro K, 2003, J BIOL CHEM, V278, P19183, DOI 10.1074/jbc.M300117200; Ye D, 2000, INFECT IMMUN, V68, P4354, DOI 10.1128/IAI.68.7.4354-4357.2000; Ye D, 2002, MOL MICROBIOL, V43, P1243, DOI 10.1046/j.1365-2958.2002.02818.x; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277	59	59	64	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21107	21114		10.1074/jbc.M501042200	http://dx.doi.org/10.1074/jbc.M501042200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15817461	hybrid			2022-12-25	WOS:000229438800026
J	Li, L; Forman, SJ; Bhatia, R				Li, L; Forman, SJ; Bhatia, R			Expression of DLK1 in hematopoietic cells results in inhibition of differentiation and proliferation	ONCOGENE			English	Article						Delta-like; myelodysplastic syndrome; hematopoietic progenitor cell; cell differentiation; cell proliferation	HOMEOTIC PROTEIN DLK; DELTA-LIKE DLK; ADIPOCYTE DIFFERENTIATION; MYELODYSPLASTIC SYNDROMES; BONE-MARROW; PREF-1; GROWTH; PROGENITORS; ANTIGEN-1; IDENTIFICATION	The Delta-like (DLK1) gene is overexpressed in CD34+ cells from myelodysplastic syndrome (MDS) patients. DLK1 encodes an EGF-like homeotic transmembrane protein homologous to the notch/delta/serrate family. Although exogenous DLK1 promotes maintenance of murine hematopoietic stem cells, the functional effects of DLK1 overexpression in hematopoietic cells are unknown. We show that ectopically expressed DLK1 significantly inhibits differentiation and proliferation of human promyelocytic HL-60 cells. Unlike preadipocytes, where proteolytic processing of membrane-bound protein and release of a soluble form mediates differentiation inhibition, proteolytic release of the extracellular domain was not required for inhibition of hematopoietic cell differentiation. However, intracellular domain interactions were critical to this DLK1 function. We conclude that DLK1 overexpression in hematopoietic cells has important functional consequences. Our studies identify novel molecular mechanisms and indicate that DLK1 has activity both as a soluble and a transmembrane expressed protein. Our results support further investigation of the role of DLK1 in abnormal hematopoiesis in MDS.	City Hope Natl Med Ctr, Div Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA	City of Hope	Bhatia, R (corresponding author), City Hope Natl Med Ctr, Div Hematol & Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA.	rbhatia@coh.org						Abdallah BM, 2004, J BONE MINER RES, V19, P841, DOI 10.1359/JBMR.040118; Allampallam K, 1999, ANTICANCER RES, V19, P5323; Bachmann E, 1996, J REPROD FERTIL, V107, P279; Baladron V, 2002, BIOCHEM BIOPH RES CO, V291, P193, DOI 10.1006/bbrc.2002.6431; Bauer SR, 1998, MOL CELL BIOL, V18, P5247, DOI 10.1128/MCB.18.9.5247; Bhatia R, 2000, EXP HEMATOL, V28, P1401, DOI 10.1016/S0301-472X(00)00545-2; Costaglioli P, 2001, FEBS LETT, V509, P413, DOI 10.1016/S0014-5793(01)03205-7; Friedrichsen BN, 2003, J ENDOCRINOL, V176, P257, DOI 10.1677/joe.0.1760257; Garces C, 1999, DIFFERENTIATION, V64, P103, DOI 10.1007/s002580050265; Greenberg Peter L, 2002, Hematology Am Soc Hematol Educ Program, P136; Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553; JENSEN CH, 1994, EUR J BIOCHEM, V225, P83, DOI 10.1111/j.1432-1033.1994.00083.x; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; LABORDA J, 1993, J BIOL CHEM, V268, P3817; Langer F, 2004, LEUKEMIA RES, V28, P1081, DOI 10.1016/j.leukres.2004.01.020; LEE YL, 1995, BBA-GENE STRUCT EXPR, V1261, P223; Mei BS, 2002, BIOCHEM J, V364, P137, DOI 10.1042/bj3640137; Miyazato A, 2001, BLOOD, V98, P422, DOI 10.1182/blood.V98.2.422; Moore KA, 1997, P NATL ACAD SCI USA, V94, P4011, DOI 10.1073/pnas.94.8.4011; Ramaraj P, 2004, CANCER RES, V64, P5322, DOI 10.1158/0008-5472.CAN-03-3656; Raza A, 1997, LEUKEMIA LYMPHOMA, V27, P111, DOI 10.3109/10428199709068277; Silver RT, 2004, LEUKEMIA RES, V28, P979, DOI 10.1016/j.leukres.2004.01.012; Smas CM, 1997, MOL CELL BIOL, V17, P977, DOI 10.1128/MCB.17.2.977; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Sul HS, 2000, INT J OBESITY, V24, pS15, DOI 10.1038/sj.ijo.0801494; van Limpt VAE, 2003, INT J CANCER, V105, P61, DOI 10.1002/ijc.11047; Walker L, 1999, STEM CELLS, V17, P162, DOI 10.1002/stem.170162; Ye Q, 2004, LEUKEMIA, V18, P777, DOI 10.1038/sj.leu.2403291	28	64	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4472	4476		10.1038/sj.onc.1208637	http://dx.doi.org/10.1038/sj.onc.1208637			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806146				2022-12-25	WOS:000229976900016
J	Marcelain, K; Hayman, MJ				Marcelain, K; Hayman, MJ			The Ski oncoprotein is upregulated and localized at the centrosomes and mitotic spindle during mitosis	ONCOGENE			English	Article						ski oncoprotein; cell cycle regulation; mitosis	ANAPHASE-PROMOTING COMPLEX; ONCOGENIC PROTEIN SKI; C-SKI; CELL-CYCLE; IN-VIVO; REPRESSION; SNON; DEGRADATION; PROTEOLYSIS; EXPRESSION	Ski is an oncoprotein that represses transforming growth factor-beta and nuclear receptor signaling. Despite evidence that relates increased Ski protein levels directly with tumor progression in human cells, the signaling pathways that regulate Ski expression are mostly unidentified. Here we show that the Ski protein levels vary throughout the cell cycle, being lowest at G0/G1. This reduction in Ski protein levels results from proteosomal degradation as suggested by in vivo ubiquitination of Ski and the effects of proteosomal inhibitors. In contrast, an upregulation of the Ski protein was observed in cells going through mitosis. At this stage, we also found that Ski is phosphorylated. In vitro and in vivo data suggest that the phosphorylation of Ski in mitosis is carried out by the main kinase controlling the progression of mitosis, namely cdc2/cyclinB. Interestingly, immunofluorescence experiments, supported by biochemical data, show not only an increase in the Ski protein levels, but also a dramatic redistribution of Ski to the centrosomes and mitotic spindle throughout mitosis. Studies to date on Ski have focused on its role as a transcriptional regulator. However, Ski's increased level and specific relocalization during mitosis suggest that Ski might play a distinct role during this particular phase of the cell cycle.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	mhayman@ms.cc.sunysb.edu	Marcelain, Katherine/I-2791-2013	Marcelain, Katherine/0000-0003-4018-6623	NCI NIH HHS [CA42573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Blomberg-Wirschell M, 1998, METHOD ENZYMOL, V298, P228, DOI 10.1016/S0076-6879(98)98022-3; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Buess M, 2004, NEOPLASIA, V6, P207, DOI 10.1593/neo.03442; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; De Lucia F, 2001, BIOCHEM J, V358, P447, DOI 10.1042/0264-6021:3580447; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Faust M, 2002, CELL MOL LIFE SCI, V59, P2155, DOI 10.1007/s000180200022; Fukuchi M, 2004, INT J CANCER, V108, P818, DOI 10.1002/ijc.11651; FUMAGALLI S, 1993, MELANOMA RES, V3, P23, DOI 10.1097/00008390-199304000-00004; GRIMES HL, 1993, ONCOGENE, V8, P2863; Hasskarl J, 2004, ONCOGENE, V23, P1930, DOI 10.1038/sj.onc.1207310; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Li G, 2002, P NATL ACAD SCI USA, V99, P832, DOI 10.1073/pnas.022649699; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Macdonald M, 2004, ONCOGENE, V23, P5643, DOI 10.1038/sj.onc.1207733; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Medrano EE, 2003, ONCOGENE, V22, P3123, DOI 10.1038/sj.onc.1206452; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; NAGASE T, 1993, J BIOL CHEM, V268, P13710; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Reed JA, 2001, CANCER RES, V61, P8074; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; Stroschein SL, 2001, GENE DEV, V15, P2822; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; Ueki N, 2003, J BIOL CHEM, V278, P24858, DOI 10.1074/jbc.M303447200; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yang R, 1999, MOL CELL BIOL, V19, P2400	40	27	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4321	4329		10.1038/sj.onc.1208631	http://dx.doi.org/10.1038/sj.onc.1208631			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806149				2022-12-25	WOS:000229976900001
J	Varroto, A; Leydier, S; Pell, G; Macdonald, JM; Stick, RV; Henrissat, B; Gilbert, HJ; Davies, GJ				Varroto, A; Leydier, S; Pell, G; Macdonald, JM; Stick, RV; Henrissat, B; Gilbert, HJ; Davies, GJ			Mycobacterium tuberculosis strains possess functional cellulases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; CELLOBIOHYDROLASE; ISOFAGOMINE; REFINEMENT; DOMAIN	The genomes of various Mycobacterium tuberculosis strains encode proteins that do not appear to play a role in the growth or survival of the bacterium in its mammalian host, including some implicated in plant cell wall breakdown. Here we show that M. tuberculosis H37Rv does indeed possess a functional cellulase. The x-ray crystal structure of this enzyme, in ligand complex forms, from 1.9 to 1.1 angstrom resolution, reveals a highly conserved substrate-binding cleft, which affords similar, and unusual, distortion of the substrate at the catalytic center. The endoglucanase activity, together with the existence of a putative membrane-associated crystalline polysaccharide-binding protein, may reflect the ancestral soil origin of the Mycobacterium or hint at a previously unconsidered environmental niche.	European Mol Biol Lab, F-38042 Grenoble, France; Univ York, Dept Chem, York Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Newcastle Univ, Sch Med, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Western Australia, Sch Biomed & Chem Sci M313, Crawley, WA 6009, Australia; Univ Aix Marseille 1, F-13402 Marseille, France; Univ Aix Marseille 2, F-13402 Marseille, France; CNRS, UMR6098, F-13402 Marseille, France	European Molecular Biology Laboratory (EMBL); University of York - UK; Newcastle University - UK; University of Western Australia; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS)	Davies, GJ (corresponding author), European Mol Biol Lab, 6 Rue Jules Horowitz,BP181, F-38042 Grenoble, France.	davies@ysbl.york.ac.uk	Davies, Gideon J/A-9042-2011; Henrissat, Bernard/J-2475-2012; Macdonald, James M/H-4209-2013	Davies, Gideon J/0000-0002-7343-776X; Henrissat, Bernard/0000-0002-3434-8588; Varrot, Annabelle/0000-0001-6667-8162				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Coutinho PM, 1999, ROY SOC CH, P3; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Davies GJ, 2000, BIOCHEM J, V348, P201, DOI 10.1042/0264-6021:3480201; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Goodman AL, 2004, DEV CELL, V7, P745, DOI 10.1016/j.devcel.2004.08.020; HALL J, 1995, BIOCHEM J, V309, P749, DOI 10.1042/bj3090749; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Macdonald JM, 2002, AUST J CHEM, V55, P747, DOI 10.1071/CH02165; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SCHOU C, 1993, J CARBOHYD CHEM, V12, P743, DOI 10.1080/07328309308019004; SPEZIO M, 1993, BIOCHEMISTRY-US, V32, P9906, DOI 10.1021/bi00089a006; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Varrot A, 1999, BIOCHEMISTRY-US, V38, P8884, DOI 10.1021/bi9903998; Varrot A, 2003, CHEM COMMUN, P946, DOI 10.1039/b301592k	26	56	59	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20181	20184		10.1074/jbc.C500142200	http://dx.doi.org/10.1074/jbc.C500142200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15824123	hybrid			2022-12-25	WOS:000229242000003
J	Yuan, ZQ; Gaba, AG; Kent, TS; Bennett, A; Miller, A; Weber, TK				Yuan, ZQ; Gaba, AG; Kent, TS; Bennett, A; Miller, A; Weber, TK			Modulation of CDK2-AP1 (p12(DOC-1)) expression in human colorectal cancer	ONCOGENE			English	Article						colorectal cancer; microsatellite instability; CDK2-AP1; siRNA	DNA-REPLICATION ERRORS; MICROSATELLITE INSTABILITY; FUNCTIONAL-ANALYSIS; APOPTOSIS; MUTATIONS; GENE; CARCINOMAS; HMSH2; RNA; IMBALANCE	We have previously demon strated an association between microsatellite instability and decreased CDK2-AP1 (p12(DOC-1)) expression in human colorectal cancer (CRC) cell lines. In those same studies, induction of CDK2-AP1 expression promoted both cell cycle arrest and apoptosis. The goals of our present study were to better understand the mechanisms leading to reduced CDK2-AP1 expression in microsatellite unstable (MSI) CRC and to study further the effect of CDK2-AP1 modulation on cell proliferation and apoptosis utilizing RNA interference (RNAi) techniques. We used direct sequencing to screen for mutations of the poly(T) 8 microsatellite-like region in the 3' end of the CDK2-AP1 gene in 24 CRC cell lines. We then utilized an in vitro human mismatch repair (MMR) recombinant system to assess for correction of the mutation and changes in CDK2-AP1 expression secondary to hMLH1 transfection. We also investigated the effect of CDK2-AP1 modulation in four settings: (1) native CDK2-AP1 absence, (2) endogenous CDK2-AP1 expression, (3) RNAi-induced CDK2-AP1 inhibition and (4) induced CDK2-AP1 over expression. The mutation-del T poly (T)8-at the 3' end of the CDK2-AP1 gene was found in 3/12 (25%) of MSI CRC cell lines, but in none of the microsatellite stable samples (0/12). Interestingly, when wild-type MMR protein-MLH1-was induced in an in vitro human recombinant system, the del T poly (T) 8 mutation was reversed and CDK2-AP1 expression increased. RNAi-mediated CDK2-AP1 inhibition was associated with decreased apoptosis and increased cell proliferation in CDK2-AP1-non deficient CRC cell lines. We conclude that mutations in the microsatellite-like sequence of the CDK2-AP1 gene in MSI CRC are associated with decreased CDK2-AP1 expression. In addition, modulation of CDK2-AP1 expression in human CRC alters cell proliferation and apoptosis.	Albert Einstein Coll Med, Dept Mol Genet, New York, NY 10461 USA; Albert Einstein Coll Med, Dept Med Oncol, New York, NY 10461 USA; Albert Einstein Coll Med, Dept Surg, New York, NY 10461 USA	Yeshiva University; Yeshiva University; Yeshiva University	Weber, TK (corresponding author), Albert Einstein Coll Med, Dept Mol Genet & Surg, 1300 Morris Pk Ave,Ullmann Bldg 1219 Bronx, New York, NY 10461 USA.	tweber@aecom.yu.edu						BEDI A, 1995, CANCER RES, V55, P1811; Boland CR, 1998, CANCER RES, V58, P5248; Brieger A, 2002, GUT, V51, P677, DOI 10.1136/gut.51.5.677; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bubb VJ, 1996, ONCOGENE, V12, P2641; DIEBOLD J, 1992, VIRCHOWS ARCH B, V62, P283, DOI 10.1007/BF02899694; Dolcetti R, 1999, AM J PATHOL, V154, P1805, DOI 10.1016/S0002-9440(10)65436-3; Farrington SM, 2002, INT J CANCER, V98, P844, DOI 10.1002/ijc.10264; Fujiwara T, 1998, AM J PATHOL, V153, P1063, DOI 10.1016/S0002-9440(10)65651-9; Halling KC, 1999, JNCI-J NATL CANCER I, V91, P1295, DOI 10.1093/jnci/91.15.1295; Hao XP, 1998, VIRCHOWS ARCH, V433, P523, DOI 10.1007/s004280050284; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Irmer H, 2001, NUCLEIC ACIDS RES, V29, P4707, DOI 10.1093/nar/29.22.4707; Johannsdottir JT, 2000, INT J ONCOL, V16, P133; JOHNSTON PG, 1989, HUM PATHOL, V20, P696, DOI 10.1016/0046-8177(89)90158-5; KEE F, 1991, GUT, V32, P509, DOI 10.1136/gut.32.5.509; Kent TS, 2004, ANN SURG ONCOL, V11, P192, DOI 10.1245/ASO.2004.03.056; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KIM HG, 1994, AM J PATHOL, V145, P148; Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X; LOTHE RA, 1993, CANCER RES, V53, P5849; Lukish JR, 1998, ANN SURG, V227, P51, DOI 10.1097/00000658-199801000-00008; Manjeshwar S, 2003, CANCER RES, V63, P5251; Matsuo K, 2000, FASEB J, V14, P1318, DOI 10.1096/fj.14.10.1318; Shintani S, 2001, CLIN CANCER RES, V7, P2776; Shintani S, 2000, MOL CELL BIOL, V20, P6300, DOI 10.1128/MCB.20.17.6300-6307.2000; SLATTERY ML, 1995, DIS COLON RECTUM, V38, P1053, DOI 10.1007/BF02133978; TODD R, 1995, FASEB J, V9, P1362, DOI 10.1096/fasebj.9.13.7557027; Trojan J, 2002, GASTROENTEROLOGY, V122, P211, DOI 10.1053/gast.2002.30296; Tsuji T, 1998, J BIOL CHEM, V273, P6704, DOI 10.1074/jbc.273.12.6704; Williams NS, 2003, CLIN CANCER RES, V9, P931; Yasuda M, 2003, AM J HUM GENET, V73, P162, DOI 10.1086/376608; Yuan ZQ, 2003, ONCOGENE, V22, P6304, DOI 10.1038/sj.onc.1206609; Zhang H, 1999, CANCER RES, V59, P3021	35	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3657	3668		10.1038/sj.onc.1208378	http://dx.doi.org/10.1038/sj.onc.1208378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15806176				2022-12-25	WOS:000229221800013
J	Gerber, D; Quintana, FJ; Bloch, I; Cohen, IR; Shai, Y				Gerber, D; Quintana, FJ; Bloch, I; Cohen, IR; Shai, Y			D-enantiomer peptide of the TCR alpha transmembrane domain inhibits T-cell activation in vitro and in vivo	FASEB JOURNAL			English	Article						transmembrane domain assembly; peptide inhibitor; immunosuppression; protein-protein interaction	HELIX-HELIX INTERACTIONS; ADJUVANT ARTHRITIS; POLAR; DIMERIZATION; LYMPHOCYTES; RECOGNITION; SPECIFICITY; INTERFACE; VACCINATE; MEMBRANES	T cell activation requires the cross-talk between the CD3-signaling complex and the T cell receptor (TCR). A synthetic peptide coding for the TCR alpha. transmembrane domain (CP) binds CD3 molecules, interferes with the CD3/TCR cross-talk, and inhibits T cell activation. Intermolecular interactions are sterically constrained; accordingly no sequence-specific interactions are thought to occur between D- and L-stereoisomers. This argument was recently challenged when applied to intra-membrane protein assembly. In this paper we studied the ability of a D-stereoisomer of CP (D-CP) to inhibit T cell activation. L-CP and D-CP co-localized with the TCR in the membrane and inhibited T cell activation in a sequence-specific manner. In vivo, both L-CP and D-CP inhibited adjuvant arthritis. In molecular terms, these results suggest the occurrence of structural reorientation that facilitates native-like interactions between D-CP and CD3 within the membrane. In clinical terms, our results demonstrate that D-stereoisomers retain the therapeutic properties of their L-stereoisomers, while they benefit from an increased resistance to degradation.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il	Quintana, Francisco Javier/AAB-6915-2020; Cohen, Irun R/B-3542-2009					ANDERTON SM, 1994, J IMMUNOL, V152, P3656; Arkin IT, 2002, BBA-BIOMEMBRANES, V1565, P347, DOI 10.1016/S0005-2736(02)00580-1; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Chin CN, 2000, J MOL BIOL, V303, P1, DOI 10.1006/jmbi.2000.4122; Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7; Fleming KG, 2001, P NATL ACAD SCI USA, V98, P14340, DOI 10.1073/pnas.251367498; Fruton J. S., 1972, MOL LIFE HIST ESSAYS; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; Gerber D, 2002, J MOL BIOL, V322, P491, DOI 10.1016/S0022-2836(02)00807-0; Hermansson M, 2003, J MOL BIOL, V334, P803, DOI 10.1016/j.jmb.2003.10.019; HOLOSHITZ J, 1983, SCIENCE, V219, P56, DOI 10.1126/science.6336851; HOLOSHITZ J, 1984, J CLIN INVEST, V73, P211, DOI 10.1172/JCI111193; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; Li RH, 2004, J BIOL CHEM, V279, P26666, DOI 10.1074/jbc.M314168200; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Manolios N, 1997, NAT MED, V3, P84, DOI 10.1038/nm0197-84; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; Melnyk RA, 2004, J BIOL CHEM, V279, P16591, DOI 10.1074/jbc.M313936200; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; Quintana FJ, 2003, J IMMUNOL, V171, P3533, DOI 10.4049/jimmunol.171.7.3533; Quintana FJ, 2002, J IMMUNOL, V169, P3422, DOI 10.4049/jimmunol.169.6.3422; Ruan WM, 2004, J BIOL CHEM, V279, P3273, DOI 10.1074/jbc.M309311200; Ruan WM, 2004, PROTEIN SCI, V13, P555, DOI 10.1110/ps.03357404; Sal-Man N, 2004, J MOL BIOL, V344, P855, DOI 10.1016/j.jmb.2004.09.066; Sal-Man N, 2004, BIOCHEMISTRY-US, V43, P2309, DOI 10.1021/bi0356294; Senes A, 2004, CURR OPIN STRUC BIOL, V14, P465, DOI 10.1016/j.sbi.2004.07.007; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; Wang XM, 2002, CLIN IMMUNOL, V105, P199, DOI 10.1006/clim.2002.5270; Wang XM, 2002, CELL IMMUNOL, V215, P12, DOI 10.1016/S0008-8749(02)00002-3; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	36	31	37	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1190	+		10.1096/fj.04-3498fje	http://dx.doi.org/10.1096/fj.04-3498fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15837719				2022-12-25	WOS:000228865300012
J	Lu, XF; Jiang, XG; Lu, YB; Bai, JH; Mao, ZB				Lu, XF; Jiang, XG; Lu, YB; Bai, JH; Mao, ZB			Characterization of a novel positive transcription regulatory element that differentially regulates the insulin-like growth factor binding protein-3 (IGFBP-3) gene in senescent cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; I IGF-I; HUMAN FIBROBLASTS; APOPTOSIS; P53; INHIBITION; EXPRESSION; RECEPTOR; DEATH; OVEREXPRESSION	Insulin-like growth factor binding protein-3 (IGFBP-3) is a well documented growth inhibitor and proapoptotic factor. IGFBP-3 mRNA and its protein are overexpressed by senescent human diploid fibroblasts. However, the mechanism responsible for the up-regulation of its expression is still unclear. This report describes a novel transcriptional regulatory element, IGFBP-3 enhancer element (IEE), identified in the 5' untranslated region of the IGFBP-3 gene. This element differentially activates IGFBP-3 expression in senescent versus young fibroblasts. Electrophoretic mobility shift assays revealed abundant complexes in senescent cell nuclear extracts compared with young cell nuclear extracts. Similar to young proliferative cells, young quiescent cells showed reduced binding activity; enhancement of this activity was specific to senescent cells and not an effect of cell cycle arrest. The DNase I footprint revealed the protein-binding core sequence within the IEE through which the protein binds the IEE. Site-directed mutagenesis within IEE abolished binding activity and selectively decreased IGFBP-3 promoter activity in senescent ( but not young) cells. Furthermore, introduction of an IEE decoy suppressed the endogenous IGFBP-3 gene expression specifically in senescent cells. These results point to the IEE as being a positive transcription regulatory element that contributes to the up-regulation of IGFBP-3 during cellular senescence.	Peking Univ, Ctr Hlth Sci, Dept Biochem & Mol Biol, Beijing 100871, Peoples R China; Xi An Jiao Tong Univ, Dept Biochem & Mol Biol, Sch Med, Xian 710061, Peoples R China	Peking University; Xi'an Jiaotong University	Mao, ZB (corresponding author), Peking Univ, Ctr Hlth Sci, Dept Biochem & Mol Biol, 38 Xueyuan Rd, Beijing 100871, Peoples R China.	zbmao@bjmu.edu.cn						ARANY E, 1994, J CLIN ENDOCR METAB, V79, P1871, DOI 10.1210/jc.79.6.1871; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BALLARD FJ, 1991, J ENDOCRINOL, V128, P197, DOI 10.1677/joe.0.1280197; Barreca A, 1996, J ENDOCRINOL INVEST, V19, P35, DOI 10.1007/BF03347856; Baxter RC, 1997, ADV MOL CELL ENDOCRI, V1, P123, DOI [10.1016/S1569-2566(97)80036-1, DOI 10.1016/S1569-2566(97)80036-1]; Berardi P, 2003, J BIOL CHEM, V278, P7510, DOI 10.1074/jbc.M210864200; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; CHIN E, 1994, ENDOCRINOLOGY, V134, P2498, DOI 10.1210/en.134.6.2498; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; COHEN P, 1993, GROWTH REGULAT, V3, P23; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DIMRI GP, 1994, EXP CELL RES, V212, P132, DOI 10.1006/excr.1994.1127; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Firth SM, 1998, BIOCHEM BIOPH RES CO, V246, P325, DOI 10.1006/bbrc.1998.8615; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; GOLDSTEIN S, 1993, J CELL PHYSIOL, V156, P294, DOI 10.1002/jcp.1041560211; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; GRIGORIEV VG, 1995, EXP CELL RES, V219, P315, DOI 10.1006/excr.1995.1234; GROSSMANN ME, 1994, MOL ENDOCRINOL, V8, P448, DOI 10.1210/me.8.4.448; Gucev ZS, 1996, CANCER RES, V56, P1545; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; Karas M, 1997, J BIOL CHEM, V272, P16514, DOI 10.1074/jbc.272.26.16514; Li YM, 1997, ENDOCRINOLOGY, V138, P362, DOI 10.1210/en.138.1.362; Mao ZB, 2003, ONCOGENE, V22, P4434, DOI 10.1038/sj.onc.1206508; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MIYASHITA T, 1994, CANCER RES, V54, P3131; MOERMAN EJ, 1993, EXP GERONTOL, V28, P361, DOI 10.1016/0531-5565(93)90063-J; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; Nickerson T, 1998, ENDOCRINOLOGY, V139, P807, DOI 10.1210/en.139.2.807; Nickerson T, 1997, BIOCHEM BIOPH RES CO, V237, P690, DOI 10.1006/bbrc.1997.7089; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Rozen F, 1998, INT J ONCOL, V13, P865; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Shen L, 1998, BIOCHEM PHARMACOL, V55, P1711, DOI 10.1016/S0006-2952(98)00045-8; TANG ZQ, 1994, MECH AGEING DEV, V73, P57, DOI 10.1016/0047-6374(94)90038-8; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Wang W, 2001, J BIOL CHEM, V276, P48655, DOI 10.1074/jbc.M108278200; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; YATEMAN ME, 1993, J ENDOCRINOL, V137, P151, DOI 10.1677/joe.0.1370151; Yeo EJ, 2000, MOL CELLS, V10, P415	42	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22606	22615		10.1074/jbc.M412073200	http://dx.doi.org/10.1074/jbc.M412073200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817480	hybrid			2022-12-25	WOS:000229741800009
J	Gaigg, B; Timischl, B; Corbino, L; Schneiter, R				Gaigg, B; Timischl, B; Corbino, L; Schneiter, R			Synthesis of sphingolipids with very long chain fatty acids but not ergosterol is required for routing of newly synthesized plasma membrane ATPase to the cell surface of yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; INOSITOL PHOSPHORYLCERAMIDE SYNTHASE; SACCHAROMYCES-CEREVISIAE; CERAMIDE SYNTHESIS; GOLGI-APPARATUS; ENDOPLASMIC-RETICULUM; H+-ATPASE; MUTANT; GENE; TRANSPORT	The proton pumping H+- ATPase, Pma1p, is an abundant and very long-lived polytopic protein of the Saccharomyces cerevisiae plasma membrane. Pma1p constitutes a major cargo of the secretory pathway and thus serves as an excellent model to study plasma membrane biogenesis. We have previously shown that newly synthesized Pma1p is mistargeted to the vacuole in an elo3 Delta mutant that affects the synthesis of the ceramide-bound C26 very long chain fatty acid (Eisenkolb, M., Zenzmaier, C., Leitner, E., and Schneiter, R. ( 2002) Mol. Biol. Cell 13, 4414-4428) and now describe a more detailed analysis of the role of lipids in Pma1p biogenesis. Remarkably, a block at various steps of sterol biosynthesis, a complete block in sterol synthesis, or the substitution of internally synthesized ergosterol by externally supplied ergosterol or even by cholesterol does not affect Pma1p biogenesis or its association with detergent-resistant membrane domains (lipid "rafts"). However, a block in sphingolipid synthesis or any perturbation in the synthesis of the ceramide-bound C26 very long chain fatty acid results in mistargeting of newly synthesized Pma1p to the vacuole. Mistargeting correlates with a lack of newly synthesized Pma1p to acquire detergent resistance, suggesting that sphingolipids with very long acyl chains affect sorting of Pma1p to the cell surface.	Univ Fribourg, Dept Med, Div Biochem, CH-1700 Fribourg, Switzerland	University of Fribourg	Schneiter, R (corresponding author), Univ Fribourg, Dept Med, Div Biochem, Chemin Musee 5, CH-1700 Fribourg, Switzerland.	roger.schneiter@unifr.ch		Schneiter, Roger/0000-0002-9102-8396				Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Balguerie A, 2002, EUKARYOT CELL, V1, P1021, DOI 10.1128/EC.1.6.1021-1031.2002; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chung JH, 2003, J BIOL CHEM, V278, P28872, DOI 10.1074/jbc.M300943200; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Chung NJ, 2001, J BIOL CHEM, V276, P35614, DOI 10.1074/jbc.M105653200; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Eisenkolb M, 2002, MOL BIOL CELL, V13, P4414, DOI 10.1091/mbc.E02-02-0116; Ferreira T, 2001, J BIOL CHEM, V276, P29613, DOI 10.1074/jbc.R100022200; Funato K, 2002, BIOCHEMISTRY-US, V41, P15105, DOI 10.1021/bi026616d; Funato K, 2001, J CELL BIOL, V155, P949, DOI 10.1083/jcb.200105033; Gaigg B, 2001, MOL BIOL CELL, V12, P1147, DOI 10.1091/mbc.12.4.1147; GOLLUB EG, 1977, J BIOL CHEM, V252, P2846; Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998; Guillas I, 2003, J BIOL CHEM, V278, P37083, DOI 10.1074/jbc.M307554200; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Gurunathan S, 2002, EMBO J, V21, P602, DOI 10.1093/emboj/21.4.602; Han GS, 2002, J BIOL CHEM, V277, P35440, DOI 10.1074/jbc.M205620200; Harsay E, 2002, J CELL BIOL, V156, P271, DOI 10.1083/jcb.200109077; Hettema EH, 2004, EMBO J, V23, P1279, DOI 10.1038/sj.emboj.7600137; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; JANDROSITZ A, 1991, GENE, V107, P155, DOI 10.1016/0378-1119(91)90310-8; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Kobayashi SD, 2003, EUKARYOT CELL, V2, P284, DOI 10.1128/EC.2.2.284-294.2003; Koffel R, 2005, MOL CELL BIOL, V25, P1655, DOI 10.1128/MCB.25.5.1655-1668.2005; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; Lee MCS, 2002, J BIOL CHEM, V277, P22395, DOI 10.1074/jbc.M200450200; Lees ND, 1999, CRIT REV BIOCHEM MOL, V34, P33; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Lisman Q, 2004, J BIOL CHEM, V279, P1020, DOI 10.1074/jbc.M306119200; LORENZ RT, 1991, LIPIDS, V26, P598, DOI 10.1007/BF02536423; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; Luo WJ, 2000, MOL BIOL CELL, V11, P579, DOI 10.1091/mbc.11.2.579; Malinska K, 2003, MOL BIOL CELL, V14, P4427, DOI 10.1091/mbc.E03-04-0221; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; Morsomme P, 2000, BBA-REV BIOMEMBRANES, V1469, P133, DOI 10.1016/S0304-4157(00)00015-0; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Obeid LA, 2002, BBA-MOL CELL BIOL L, V1585, P163, DOI 10.1016/S1388-1981(02)00337-2; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Opekarova M, 2002, BBA-BIOMEMBRANES, V1564, P9, DOI 10.1016/S0005-2736(02)00455-8; Pizzirusso M, 2004, MOL BIOL CELL, V15, P2401, DOI 10.1091/mbc.E03-10-0727; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; Schneiter R, 2000, J BACTERIOL, V182, P3655, DOI 10.1128/JB.182.13.3655-3660.2000; Schneiter R, 1996, MOL CELL BIOL, V16, P7161; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Skrzypek MS, 1998, J BIOL CHEM, V273, P2829, DOI 10.1074/jbc.273.5.2829; Sutterlin C, 1997, J CELL SCI, V110, P2703; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Umebayashi K, 2003, J CELL BIOL, V161, P1117, DOI 10.1083/jcb.200303088; Vallee B, 2005, EMBO J, V24, P730, DOI 10.1038/sj.emboj.7600562; Wang QQ, 2002, P NATL ACAD SCI USA, V99, P12853, DOI 10.1073/pnas.202115499; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353	56	79	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22515	22522		10.1074/jbc.M413472200	http://dx.doi.org/10.1074/jbc.M413472200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817474	Green Submitted, hybrid			2022-12-25	WOS:000229557900099
J	Lolkema, MP; Gervais, ML; Snijckers, CM; Hill, RP; Giles, RH; Voest, EE; Ohh, M				Lolkema, MP; Gervais, ML; Snijckers, CM; Hill, RP; Giles, RH; Voest, EE; Ohh, M			Tumor suppression by the von hippel-lindau protein requires phosphorylation of the acidic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR; BIOLOGICALLY-ACTIVE PRODUCT; KINASE CK2; FIBRONECTIN MATRIX; CELL-SURFACE; REGULATE HIF; GENE-PRODUCT; VHL; BINDING; EXPRESSION	The tumor suppressor function of the von Hippel-Lindau protein (pVHL) has previously been linked to its role in regulating hypoxia-inducible factor levels. However, VHL gene mutations suggest a hypoxia-inducible factor-independent function for the N-terminal acidic domain in tumor suppression. Here, we report that phosphorylation of the N-terminal acidic domain of pVHL by casein kinase-2 is essential for its tumor suppressor function. This post-translational modification did not affect the levels of hypoxia-inducible factor; however, it did change the binding of pVHL to another known binding partner, fibronectin. Cells expressing phospho-defective mutants caused improper fibronectin matrix deposition and demonstrated retarded tumor formation in mice. We propose that phosphorylation of the acidic domain plays a role in the regulation of proper fibronectin matrix deposition and that this may be relevant for the development of VHL-associated malignancies.	Univ Utrecht, Med Ctr, Dept Med Oncol, NL-3584 CX Utrecht, Netherlands; Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	Utrecht University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Voest, EE (corresponding author), Univ Utrecht, Med Ctr, Dept Med Oncol, F02-126,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	michael.ohh@utoronto.ca	Lolkema, M.P./AAE-2906-2019	Lolkema, M.P./0000-0003-0466-2928; Giles, Rachel/0000-0001-9133-2008; Hill, Richard Peter/0000-0001-5331-8045				AVILA J, 1994, CELL MOL BIOL RES, V40, P573; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Bluyssen HAR, 2004, FEBS LETT, V556, P137, DOI 10.1016/S0014-5793(03)01392-9; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; KONDO K, 2003, PLOS BIOL; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Lim ACB, 2004, J BIOL CHEM, V279, P4433, DOI 10.1074/jbc.M310563200; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Marsden M, 2001, DEVELOPMENT, V128, P3635; Maynard MA, 2004, AM J NEPHROL, V24, P1, DOI 10.1159/000075346; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Moreno FJ, 1999, MOL CELL BIOCHEM, V191, P201, DOI 10.1023/A:1006836211318; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pasqualini R, 1996, NAT MED, V2, P1197, DOI 10.1038/nm1196-1197; Patel SK, 2003, MOL CARCINOGEN, V38, P141, DOI 10.1002/mc.10153; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Zimmer M, 2004, MOL CANCER RES, V2, P89	34	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22205	22211		10.1074/jbc.M503220200	http://dx.doi.org/10.1074/jbc.M503220200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824109	hybrid			2022-12-25	WOS:000229557900066
J	Vijayan, KV; Liu, Y; Sun, WS; Ito, M; Bray, PF				Vijayan, KV; Liu, Y; Sun, WS; Ito, M; Bray, PF			The Pro(33) isoform of integrin beta(3) enhances outside-in signaling in human platelets by regulating the activation of serine/threonine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LIGHT-CHAIN KINASE; MAP KINASE; MYOSIN PHOSPHATASE; SHAPE CHANGE; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; ARACHIDONIC-ACID; IIB-IIIA; ALPHA(IIB)BETA(3)	Integrin beta(3) is polymorphic at residue 33 (Leu(33) or Pro(33)), and the Pro(33)-positive platelets display enhanced aggregation, P-selectin secretion, and shorter bleeding times. Because outside-in signaling is critical for platelet function, we hypothesized that the Pro(33) variant provides a more efficient signaling than the Leu(33) isoform. When compared with Pro(33)-negative platelets, Pro(33)-positive platelets demonstrated significantly greater serine/threonine phosphorylation of extracellular signal-regulated kinase (ERK2) and myosin light chain (MLC) but not cytoplasmic phospholipase A2 upon thrombin-induced aggregation. Tyrosine phosphorylation of integrin beta(3) and the adaptor protein Shc was no different in the fibrinogen-engaged platelets from both genotypes. The addition of Integrilin (alpha(IIb)beta(3)-fibrinogen blocker) or okadaic acid (serine/threonine phosphatase inhibitor) dramatically enhanced ERK2 and MLC phosphorylation in the Pro(33)-negative platelets when compared with Pro(33)-positive platelets, suggesting that integrin engagement during platelet aggregation activates serine/threonine phosphatases. The phosphatase activity of myosin phosphatase (MP) that dephosphorylates MLC is inactivated by phosphorylation of the myosin binding subunit of MP at Thr(696), and aggregating Pro(33)-positive platelets exhibited an increased Thr(696) phosphorylation of MP. These studies highlight a role for the dephosphorylation events via the serine/threonine phosphatases during the integrin outside-in signaling mechanism, and the Leu(33) -> Pro polymorphism regulates this process. Furthermore, these findings support a mechanism whereby the reported enhanced alpha granule secretion in the Pro(33)-positive platelets could be mediated by an increased phosphorylation of MLC, which in turn is caused by an increased phosphorylation and subsequent inactivation of myosin phosphatase.	Baylor Coll Med, Thrombosis Res Sect, Dept Med, Houston, TX 77030 USA; Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 5148507, Japan	Baylor College of Medicine; Mie University	Bray, PF (corresponding author), Baylor Coll Med, Thrombosis Res Sect, Dept Med, 1 Baylor Pl,BCM 286 N1319, Houston, TX 77030 USA.	pbray@bcm.tmc.edu			NHLBI NIH HHS [HL 65967, HL 57488] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL065967, R01HL057488] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Buensuceso CS, 2005, J BIOL CHEM, V280, P644, DOI 10.1074/jbc.M410229200; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CHEN YP, 1994, BLOOD, V84, P1857; Chung HY, 1999, CELL SIGNAL, V11, P575, DOI 10.1016/S0898-6568(99)00033-9; Cowan KJ, 2000, J BIOL CHEM, V275, P36423, DOI 10.1074/jbc.M004068200; DANIEL JL, 1984, J BIOL CHEM, V259, P9826; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; Feng DL, 1999, ARTERIOSCL THROM VAS, V19, P1142, DOI 10.1161/01.ATV.19.4.1142; GONG MC, 1992, J BIOL CHEM, V267, P21492; Haimovich B, 1999, THROMB HAEMOSTASIS, V81, P618; Hartshorne DJ, 1998, ACTA PHYSIOL SCAND, V164, P483; HASHIMOTO Y, 1994, BBA-MOL CELL RES, V1223, P163, DOI 10.1016/0167-4889(94)90222-4; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; Jiang F, 2002, BLOOD, V99, P3579, DOI 10.1182/blood.V99.10.3579; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; McCluskey A, 2002, J MED CHEM, V45, P1151, DOI 10.1021/jm010066k; McNicol A, 1998, BIOCHEM PHARMACOL, V55, P1759, DOI 10.1016/S0006-2952(97)00632-1; Michelson AD, 2000, CIRCULATION, V101, P1013, DOI 10.1161/01.CIR.101.9.1013; Nadal F, 1997, J BIOL CHEM, V272, P22381, DOI 10.1074/jbc.272.36.22381; Nadal-Wollbold F, 2002, FEBS LETT, V531, P475, DOI 10.1016/S0014-5793(02)03587-1; Naik UP, 2003, BLOOD, V102, P1355, DOI 10.1182/blood-2003-02-0591; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Pawlowski M, 2002, FEBS LETT, V521, P145, DOI 10.1016/S0014-5793(02)02862-4; Phillips DR, 2001, THROMB HAEMOSTASIS, V86, P246; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; Sajid M, 2002, ARTERIOSCL THROM VAS, V22, P1984, DOI 10.1161/01.ATV.0000043664.48689.7F; Schoenwaelder SM, 2002, J BIOL CHEM, V277, P14738, DOI 10.1074/jbc.M200661200; Tulasne D, 2002, EUR J BIOCHEM, V269, P1511, DOI 10.1046/j.1432-1033.2002.02798.x; Vijayan KV, 2004, J BIOL CHEM, V279, P33039, DOI 10.1074/jbc.C400239200; Vijayan KV, 2000, J CLIN INVEST, V105, P793, DOI 10.1172/JCI6982; Vijayan KV, 2003, FEBS LETT, V540, P41, DOI 10.1016/S0014-5793(03)00170-4; Vijayan KV, 2003, J BIOL CHEM, V278, P3860, DOI 10.1074/jbc.M208680200; Wang RG, 1997, J CLIN INVEST, V100, P2393, DOI 10.1172/JCI119780; Watanabe Y, 2001, BLOOD, V97, P3798, DOI 10.1182/blood.V97.12.3798; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Wilde JI, 2000, PLATELETS, V11, P286; Williams MS, 2001, EXP BIOL MED, V226, P409, DOI 10.1177/153537020122600504; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	44	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21756	21762		10.1074/jbc.M500872200	http://dx.doi.org/10.1074/jbc.M500872200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15826939	hybrid			2022-12-25	WOS:000229557900012
J	James, AM; Cocheme, HM; Smith, RAJ; Murphy, MP				James, AM; Cocheme, HM; Smith, RAJ; Murphy, MP			Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species - Implications for the use of exogenous ubiquinones as therapies and experimental tools	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MANGANOUS SUPEROXIDE-DISMUTASE; BOVINE HEART-MITOCHONDRIA; COENZYME-Q; FRIEDREICHS-ATAXIA; OXIDATIVE STRESS; NITRIC-OXIDE; SACCHAROMYCES-CEREVISIAE; BC(1) COMPLEX; CYTOCHROME-C	Antioxidants, such as ubiquinones, are widely used in mitochondrial studies as both potential therapies and useful research tools. However, the effects of exogenous ubiquinones can be difficult to interpret because they can also be pro-oxidants or electron carriers that facilitate respiration. Recently we developed a mitochondria-targeted ubiquinone (MitoQ(10)(10)() that accumulates within mitochondria. MitoQ) (has been used to prevent mitochondrial oxidative damage and to infer the involvement of mitochondrial reactive oxygen species in signaling pathways. However, uncertainties remain about the mitochondrial reduction of MitoQ)(, its oxidation by the respiratory chain, and its pro-oxidant potential. Therefore, we compared MitoQ analogs of varying alkyl chain lengths (MitoQ)(, n = 3-15) with untargeted exogenous ubiquinones. We found that MitoQ)(10)(n)(10) (could not restore respiration in ubiquinone-deficient mitochondria because oxidation of MitoQ analogs by complex III was minimal. Complex II and glycerol 3-phosphate dehydrogenase reduced MitoQ analogs, and the rate depended on chain length. Because of its rapid reduction and negligible oxidation, MitoQ)(10) (is a more effective antioxidant against lipid peroxidation, peroxynitrite and superoxide. Paradoxically, exogenous ubiquinols also autoxidize to generate superoxide, but this requires their deprotonation in the aqueous phase. Consequently, in the presence of phospholipid bilayers, the rate of autoxidation is proportional to ubiquinol hydrophilicity. Superoxide production by MitoQ)(10) was insufficient to damage aconitase but did lead to hydrogen peroxide production and nitric oxide consumption, both of which may affect cell signaling pathways. Our results comprehensively describe the interaction of exogenous ubiquinones with mitochondria and have implications for their rational design and use as therapies and as research tools to probe mitochondrial function.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Otago, Dept Chem, Dunedin, New Zealand	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Otago	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	mpm@mrc-dunn.cam.ac.uk	James, Andrew M/A-2639-2015; Murphy, Michael P/C-2120-2009	James, Andrew M/0000-0002-0515-9649; Murphy, Michael P/0000-0003-1115-9618; Cocheme, Helena/0000-0001-8637-0042				Abe K, 1999, J NEUROL SCI, V162, P65, DOI 10.1016/S0022-510X(98)00296-2; Asin-Cayuela J, 2004, FEBS LETT, V571, P9, DOI 10.1016/j.febslet.2004.06.045; Aure K, 2004, NEUROLOGY, V63, P727, DOI 10.1212/01.WNL.0000134607.76780.B2; AZZI A, 1975, BIOCHEM BIOPH RES CO, V65, P597, DOI 10.1016/S0006-291X(75)80188-4; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bedogni B, 2003, J BIOL CHEM, V278, P16510, DOI 10.1074/jbc.M301089200; Borrello S, 1997, ARCH BIOCHEM BIOPHYS, V348, P289, DOI 10.1006/abbi.1997.0355; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Buyse G, 2003, NEUROLOGY, V60, P1679, DOI 10.1212/01.WNL.0000068549.52812.0F; Calabrese EJ, 2004, EMBO REP, V5, pS37, DOI 10.1038/sj.embor.7400222; Carreras Maria C., 2004, Molecular Aspects of Medicine, V25, P125, DOI 10.1016/j.mam.2004.02.014; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; Chen K, 2004, J BIOL CHEM, V279, P35079, DOI 10.1074/jbc.M404859200; CRANE F. L., 1971, Methods in Enzymology, V18C, P137, DOI 10.1016/S0076-6879(71)18022-6; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Dallner G, 2000, FREE RADICAL BIO MED, V29, P285, DOI 10.1016/S0891-5849(00)00307-5; Dhanasekaran A, 2004, J BIOL CHEM, V279, P37575, DOI 10.1074/jbc.M404003200; Di Giovanni S, 2001, NEUROLOGY, V57, P515, DOI 10.1212/WNL.57.3.515; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Duchen Michael R., 2004, Molecular Aspects of Medicine, V25, P365, DOI 10.1016/j.mam.2004.03.001; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; FLEWELLING RF, 1986, BIOPHYS J, V49, P531, DOI 10.1016/S0006-3495(86)83663-3; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; GARRIB A, 1986, J BIOL CHEM, V261, P8042; Genova MW, 2003, EXP BIOL MED, V228, P506, DOI 10.1177/15353702-0322805-14; GILLIS JC, 1994, DRUG AGING, V5, P133, DOI 10.2165/00002512-199405020-00007; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; Hausse AO, 2002, HEART, V87, P346, DOI 10.1136/heart.87.4.346; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; James AM, 2004, ARCH BIOCHEM BIOPHYS, V423, P47, DOI 10.1016/j.abb.2003.12.025; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Kaiser J, 2003, SCIENCE, V302, P376, DOI 10.1126/science.302.5644.376; Kamzalov S, 2003, J NUTR, V133, P3175, DOI 10.1093/jn/133.10.3175; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; KETTERER B, 1971, J MEMBRANE BIOL, V5, P225, DOI 10.1007/BF01870551; Kwong LK, 2002, FREE RADICAL BIO MED, V33, P627, DOI 10.1016/S0891-5849(02)00916-4; Lambert AJ, 2004, BIOCHEM J, V382, P511, DOI 10.1042/BJ20040485; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Mariotti C, 2003, NEUROLOGY, V60, P1676, DOI 10.1212/01.WNL.0000055872.50364.FC; Marriage BJ, 2004, MOL GENET METAB, V81, P263, DOI 10.1016/j.ymgme.2003.12.008; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Muller T, 2003, NEUROSCI LETT, V341, P201, DOI 10.1016/S0304-3940(03)00185-X; Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Murphy MP, 2001, EXPERT OPIN BIOL TH, V1, P753, DOI 10.1517/14712598.1.5.753; Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101; Nohl H, 1998, FREE RADICAL BIO MED, V25, P666, DOI 10.1016/S0891-5849(98)00105-1; Okada K, 1998, FEBS LETT, V431, P241, DOI 10.1016/S0014-5793(98)00753-4; ONO A, 1994, BIOCHEMISTRY-US, V33, P4312, DOI 10.1021/bi00180a027; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; Poderoso JJ, 1999, FREE RADICAL BIO MED, V26, P925, DOI 10.1016/S0891-5849(98)00277-9; Quiles JL, 2004, EXP GERONTOL, V39, P189, DOI 10.1016/j.exger.2003.10.002; RICH PR, 1980, BIOCHIM BIOPHYS ACTA, V592, P506, DOI 10.1016/0005-2728(80)90095-X; RICH PR, 1979, FEBS LETT, V105, P189, DOI 10.1016/0014-5793(79)80608-0; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; ROSE IA, 1967, J BIOL CHEM, V242, P1870; Rustin P, 1999, LANCET, V354, P477, DOI 10.1016/S0140-6736(99)01341-0; Rustin P, 2002, FREE RADICAL RES, V36, P467, DOI 10.1080/10715760290021333; Santos-Ocana C, 2002, J BIOL CHEM, V277, P10973, DOI 10.1074/jbc.M112222200; Saretzki G, 2003, AGING CELL, V2, P141, DOI 10.1046/j.1474-9728.2003.00040.x; Schafer M, 2003, CIRC RES, V92, P1010, DOI 10.1161/01.RES.0000070882.81508.FC; Schopfer F, 2000, BIOCHEM J, V349, P35, DOI 10.1042/0264-6021:3490035; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smith RAJ, 2003, BIOCHEM SOC T, V31, P1295; Smith RAJ, 2004, METHOD ENZYMOL, V382, P45; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; SUNO M, 1984, JPN J PHARMACOL, V35, P196, DOI 10.1254/jjp.35.196; Svensson M, 1999, INT J SPORT NUTR, V9, P166, DOI 10.1123/ijsn.9.2.166; TAKADA M, 1984, METHOD ENZYMOL, V105, P147; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012; TYLER DD, 1992, MITOCHONDRION HLTH D, P41; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WINTERBOURN CC, 1981, ARCH BIOCHEM BIOPHYS, V209, P159, DOI 10.1016/0003-9861(81)90268-X; Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yokoo S, 2004, J CELL BIOCHEM, V93, P588, DOI 10.1002/jcb.20208; Zhang YY, 1996, J NUTR, V126, P2089, DOI 10.1093/jn/126.9.2089	95	287	314	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21295	21312		10.1074/jbc.M501527200	http://dx.doi.org/10.1074/jbc.M501527200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15788391	hybrid			2022-12-25	WOS:000229438800048
J	Sciamanna, E; Landriscina, M; Pittoggi, C; Quirino, M; Mearelli, C; Beraldi, R; Mattei, E; Serafino, A; Cassano, A; Sinibaldi-Vallebona, P; Garaci, E; Barone, C; Spadafora, C				Sciamanna, E; Landriscina, M; Pittoggi, C; Quirino, M; Mearelli, C; Beraldi, R; Mattei, E; Serafino, A; Cassano, A; Sinibaldi-Vallebona, P; Garaci, E; Barone, C; Spadafora, C			Inhibition of endogenous reverse transcriptase antagonizes human tumor growth	ONCOGENE			English	Article						endogenous reverse transcriptase; proliferation; differentiation; tumor growth; RNAi; anticancer therapy	EMBRYONAL CARCINOMA-CELLS; CUTANEOUS MELANOMA; LINE-1 RNA; MOUSE; EXPRESSION; CANCER; RETROTRANSPOSITION; DIFFERENTIATION; PROLIFERATION; EPIGENETICS	Undifferentiated cells and embryos express high levels of endogenous non-telomerase reverse transcriptase (RT) of retroposon/retroviral origin. We previously found that RT inhibitors modulate cell growth and differentiation in several cell lines. We have now sought to establish whether high levels of RT activity are directly linked to cell transformation. To address this possibility, we have employed two different approaches to inhibit RT activity in melanoma and prostate carcinoma cell fines: pharmacological inhibition by two characterized RT inhibitors, nevirapine and efavirenz, and downregulation of expression of RT-encoding LINE-1 elements by RNA interference (RNAi). Both treatments reduced proliferation, induced morphological differentiation and reprogrammed gene expression. These features are reversible upon discontinuation of the anti-RT treatment, suggesting that RT contributes to an epigenetic level of control. Most importantly, inhibition of RT activity in vivo antagonized tumor growth in animal experiments. Moreover, pretreatment with RT inhibitors attenuated the tumorigenic phenotype of prostate carcinoma cells inoculated in nude mice. Based on these data, the endogenous RT can be regarded as an epigenetic regulator of cell differentiation and proliferation and may represent a novel target in cancer therapy.	Ist Super Sanita, I-00161 Rome, Italy; Univ Sacred Heart, Med Oncol Unit, I-00168 Rome, Italy; Univ Siena, Dept Pediat Obstet & Reprod Med, I-53100 Siena, Italy; CNR, Inst Mol Biol & Pathol, Rome, Italy; CNR, Inst Neurobiol & Mol Med, Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00173 Rome, Italy	Istituto Superiore di Sanita (ISS); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Siena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata	Spadafora, C (corresponding author), Ist Super Sanita, Viale Regina Elena 299,Via Castro Laurenziano 25, I-00161 Rome, Italy.	cspadaf@tin.it	Landriscina, Matteo/K-1092-2016; Serafino, Annalucia/AAC-1719-2019	Serafino, Annalucia/0000-0002-1142-4752; Sciamanna, Ilaria/0000-0002-5629-6184; Landriscina, Matteo/0000-0003-0591-9799; SINIBALDI VALLEBONA, PAOLA/0000-0002-8186-9861; Spadafora, Corrado/0000-0001-9647-1410; Spadafora, Corrado/0000-0002-5743-3224				Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Crone TM, 1999, HEPATOLOGY, V29, P1114, DOI 10.1002/hep.510290449; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Deininger PL, 2003, CURR OPIN GENET DEV, V13, P651, DOI 10.1016/j.gde.2003.10.013; DERAGON JM, 1990, EMBO J, V9, P3363, DOI 10.1002/j.1460-2075.1990.tb07537.x; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ergun S, 2004, J BIOL CHEM, V279, P27753, DOI 10.1074/jbc.M312985200; Friedlander A, 1999, CRIT REV ONCOGENESIS, V10, P129; Giordano R, 2000, J CELL BIOL, V148, P1107, DOI 10.1083/jcb.148.6.1107; Hagan Christy R, 2002, Am J Pharmacogenomics, V2, P25, DOI 10.2165/00129785-200202010-00003; Hagan CR, 2003, NAT GENET, V35, P219, DOI 10.1038/ng1259; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Khan AS, 2001, VIRUS RES, V79, P39, DOI 10.1016/S0168-1702(01)00280-5; KIESSLING AA, 1989, P NATL ACAD SCI USA, V86, P5109, DOI 10.1073/pnas.86.13.5109; Kuo KW, 1998, BIOCHEM BIOPH RES CO, V253, P566, DOI 10.1006/bbrc.1998.9811; Li L, 2003, CANCER RES, V63, P2733; Li TH, 2001, GENE, V276, P135, DOI 10.1016/S0378-1119(01)00637-0; Lilja H, 2003, UROLOGY, V62, P27, DOI 10.1016/S0090-4295(03)00775-1; Linja MJ, 2001, CANCER RES, V61, P3550; Lotem J, 2002, SEMIN CANCER BIOL, V12, P339, DOI 10.1016/S1044-579X(02)00054-8; Mangiacasale R, 2003, ONCOGENE, V22, P2750, DOI 10.1038/sj.onc.1206354; MARTIN SL, 1993, MOL CELL BIOL, V13, P5383, DOI 10.1128/MCB.13.9.5383; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; Melino G, 1993, CLIN CHEM ENZYM COMM, V6, P105; MWENDA JM, 1993, CELL MOL BIOL, V39, P317; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; PACKER AI, 1993, DEV BIOL, V157, P281, DOI 10.1006/dbio.1993.1133; Pittoggi C, 2003, MOL REPROD DEV, V66, P225, DOI 10.1002/mrd.10349; Portsmouth S, 2003, AIDS, V17, pF17, DOI 10.1097/00002030-200307250-00001; POZNANSKI AA, 1991, DEV BIOL, V143, P271, DOI 10.1016/0012-1606(91)90077-G; PYRA H, 1994, P NATL ACAD SCI USA, V91, P1544, DOI 10.1073/pnas.91.4.1544; Ren J, 2001, J MOL BIOL, V312, P795, DOI 10.1006/jmbi.2001.4988; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Sauter ER, 2002, CANCER RES, V62, P3200; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Tirelli U, 2001, EUR J CANCER, V37, P1320, DOI 10.1016/S0959-8049(01)00106-X; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802; Utikal J, 2002, CANCER INVEST, V20, P914, DOI 10.1081/CNV-120005904; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504	40	146	162	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3923	3931		10.1038/sj.onc.1208562	http://dx.doi.org/10.1038/sj.onc.1208562			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15806170				2022-12-25	WOS:000229435300008
J	Luwor, RB; Lu, Y; Li, XQ; Mendelsohn, J; Fan, Z				Luwor, RB; Lu, Y; Li, XQ; Mendelsohn, J; Fan, Z			The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression	ONCOGENE			English	Article						HIF-1 alpha; VEGF; EGF receptor; Akt; Ras; PTEN	CELL LUNG-CANCER; FACTOR 1-ALPHA HIF-1-ALPHA; TYROSINE KINASE INHIBITOR; SMOOTH-MUSCLE-CELLS; TUMOR-CELLS; FACTOR (HIF)-1-ALPHA; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; NITRIC-OXIDE; SOLID TUMORS	We have previously shown that the antiepidermal growth factor receptor monoclonal antibody cetuximab (C225; Erbitux), which was recently approved for the treatment of metastatic colorectal cancer, has antiangiogenic properties, inhibiting vascular endothelial growth factor (VEGF) secretion in culture and in animal models. Here, we have furthered the study by demonstrating that cetuximab reduces cellular levels of hypoxia-inducible factor-1 alpha (HIF-1 alpha), a transcriptional regulator of VEGF expression, in A431 epidermoid carcinoma cells under both normoxic and hypoxic culture conditions. Expression of a constitutively active Ras in A431 cells rendered cellular resistance to the cetuximab-mediated reduction of the HIF-1 alpha level. Cell lines with naturally occurring phosphatase and tensin homologue deleted on chromosome 10 mutations or deletions were also resistant to cetuximab-mediated reduction of the HIF-1 alpha level. Pharmacologic inhibition of phosphatidylinositol 3-kinase with LY294002 reduced the HIF-1 alpha level in both normoxic and hypoxic A431 cells, whereas inhibition of the mitogen- activated protein kinase kinase by PD98059 reduced the level of HIF-1 alpha only in normoxic A431 cells. In addition, cetuximab reduced the cellular level of HIF-1 alpha in the presence of a proteasome inhibitor, lactacystin, indicating that cetuximab acts mainly at the level of protein synthesis. The reduction of HIF-1 alpha in response to cetuximab treatment was accompanied by transcriptional inhibition of VEGF expression, measured by a luciferase assay in A431 cells transfected with a vector containing the VEGF hypoxia response element. Taken together, our results indicate that the previously demonstrated inhibition of VEGF by cetuximab occurs at the level of transcription in response to a reduced level of HIF-1 alpha and justify further testing of therapeutic strategies that combine cetuximab with approaches inhibiting the function of VEGF or the VEGF receptor.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 036, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 036, 1515 Holcombe Blvd, Houston, TX 77030 USA.	zfan@mdanderson.org		Luwor, Rodney/0000-0002-3020-4245				Albanell J, 2001, CANCER RES, V61, P6500; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; Beitner-Johnson D, 2001, CELL SIGNAL, V13, P23, DOI 10.1016/S0898-6568(00)00128-5; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; Blancher C, 2001, CANCER RES, V61, P7349; Blancher C, 2000, CANCER RES, V60, P7106; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Ciardiello F, 2000, CLIN CANCER RES, V6, P3739; Clarke K, 2001, BRIT J CANCER, V84, P1322, DOI 10.1054/bjoc.2001.1805; Cohen MH, 2004, CLIN CANCER RES, V10, P1212, DOI 10.1158/1078-0432.CCR-03-0564; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1993, CANCER RES, V53, P4637; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; Feldser D, 1999, CANCER RES, V59, P3915; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harper ME, 2002, PROSTATE, V52, P59, DOI 10.1002/pros.10069; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Herbst RS, 2004, J CLIN ONCOL, V22, P785, DOI 10.1200/JCO.2004.07.215; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Huang SM, 2002, CANCER RES, V62, P4300; Huang SM, 2002, MOL CANCER THER, V1, P507; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1997, CANCER RES, V57, P5328; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Jung YD, 2002, EUR J CANCER, V38, P1133, DOI 10.1016/S0959-8049(02)00013-8; Karashima T, 2002, CLIN CANCER RES, V8, P1253; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Liang K, 2003, INT J RADIAT ONCOL, V57, P246, DOI 10.1016/S0360-3016(03)00511-X; Liu BL, 2001, ONCOGENE, V20, P1913, DOI 10.1038/sj.onc.1204277; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Milas L, 2000, CLIN CANCER RES, V6, P701; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Perrotte P, 1999, CLIN CANCER RES, V5, P257; Petit AMV, 1997, AM J PATHOL, V151, P1523; Post DE, 2001, GENE THER, V8, P1801, DOI 10.1038/sj.gt.3301605; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ruas JL, 2005, J CELL SCI, V118, P301, DOI 10.1242/jcs.01617; Sandau KB, 2000, BIOCHEM BIOPH RES CO, V278, P263, DOI 10.1006/bbrc.2000.3789; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Shaheen RM, 2001, BRIT J CANCER, V85, P584, DOI 10.1054/bjoc.2001.1936; She QB, 2003, CLIN CANCER RES, V9, P4340; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Shimada K, 2004, MOL CARCINOGEN, V39, P1, DOI 10.1002/mc.10158; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Sweeney P, 2002, CLIN CANCER RES, V8, P2714; Tacchini L, 2001, CARCINOGENESIS, V22, P1363, DOI 10.1093/carcin/22.9.1363; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Traxler P, 2004, CANCER RES, V64, P4931, DOI 10.1158/0008-5472.CAN-03-3681; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vlietstra RJ, 1998, CANCER RES, V58, P2720; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang SXL, 2003, FASEB J, V17, P1709, DOI 10.1096/fj.02-1111fje; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	78	107	111	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4433	4441		10.1038/sj.onc.1208625	http://dx.doi.org/10.1038/sj.onc.1208625			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806152				2022-12-25	WOS:000229976900012
J	Gao, N; Rahmani, M; Dent, P; Grant, S				Gao, N; Rahmani, M; Dent, P; Grant, S			2-methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process	ONCOGENE			English	Article						2ME; apoptosis; leukemia; Akt; ROS	PROSTATE-CANCER CELLS; PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY; HISTONE DEACETYLASE INHIBITORS; FORKHEAD TRANSCRIPTION FACTOR; ACTIVATED PROTEIN-KINASE; OXIDATIVE STRESS; GROWTH-FACTOR; SUPEROXIDE-DISMUTASE; MEDIATED APOPTOSIS; IN-VITRO	The effects of 2-Methoxyestradiol (2ME)-induced apoptosis was examined in human leukemia cells (U937 and Jurkat) in relation to mitochondrial injury, oxidative damage, and perturbations in signaling pathways. 2ME induced apoptosis in these cells in a dose-dependent manner associated with release of mitochondrial proteins ( cytochrome c, AIF), generation of reactive oxygen species (ROS), downregulation of Mcl-1 and XIAP, and inactivation ( dephosphorylation) of Akt accompanied by activation of JNK. In these cells, enforced activation of Akt by a constitutively active myristolated Akt construct prevented 2ME-mediated mitochondrial injury, XIAP and Mcl-1 downregulation, JNK activation, and apoptosis, but not ROS generation. Conversely, 2ME lethality was potentiated by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. Furthermore, in U937 cells, the hydrogen peroxide scavenger catalase and a superoxide dismutase ( SOD) mimetic, TBAP, blocked these events, as well as Akt inactivation. Interruption of the JNK pathway by pharmacologic or genetic ( e. g. siRNA) means attenuated 2ME-induced mitochondrial injury, XIAP and Mcl-1 downregulation, and apoptosis. Collectively, these findings suggest a hierarchical model of 2ME-related apoptosis induction in human leukemia cells in which 2ME-induced oxidative injury represents a primary event resulting in Akt inactivation, leading, in turn, to JNK activation, and culminating in XIAP and Mcl-1 downregulation, mitochondrial injury, and apoptosis. They also suggest that in human leukemia cells, the Akt pathway plays a critical role in mediating the response to oxidative stress induced by 2ME.	Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.	stgrant@hsc.vcu.edu		Rahmani, Mohamed/0000-0002-3992-8039	NATIONAL CANCER INSTITUTE [R01CA093738, R01CA063753, R01CA100866] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63753, R01 CA093738, R01 CA063753, CA 93738, CA 100866, R01 CA100866] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Bae JY, 2003, J BIOL CHEM, V278, P5195, DOI 10.1074/jbc.M201988200; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bu SZ, 2002, FEBS LETT, V531, P141, DOI 10.1016/S0014-5793(02)03478-6; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Curnock AP, 1998, CELL IMMUNOL, V187, P77, DOI 10.1006/cimm.1998.1335; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Djavaheri-Mergny M, 2003, ONCOGENE, V22, P2558, DOI 10.1038/sj.onc.1206356; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Fridovich I, 1999, ANN NY ACAD SCI, V893, P13, DOI 10.1111/j.1749-6632.1999.tb07814.x; Fuino L, 2003, MOL CANCER THER, V2, P971; Gao N, 2002, J BIOL CHEM, V277, P31963, DOI 10.1074/jbc.M200082200; Harris TK, 2003, IUBMB LIFE, V55, P117, DOI 10.1080/1521654031000115951; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; Holgado-Madruga M, 2003, MOL CELL BIOL, V23, P4471, DOI 10.1128/MCB.23.13.4471-4484.2003; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Hughes RA, 2002, MOL PHARMACOL, V61, P1053, DOI 10.1124/mol.61.5.1053; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kausalya S, 2001, J IMMUNOL, V166, P4721, DOI 10.4049/jimmunol.166.7.4721; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim YS, 2004, EXP MOL MED, V36, P157, DOI 10.1038/emm.2004.22; Kobayashi S, 2002, J BIOL CHEM, V277, P33968, DOI 10.1074/jbc.M203350200; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; LaVallee TM, 2002, CANCER RES, V62, P3691; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Li SY, 2004, J BIOL CHEM, V279, P11244, DOI 10.1074/jbc.M308011200; Lin HL, 2001, CANCER, V92, P500, DOI 10.1002/1097-0142(20010801)92:3<500::AID-CNCR1348>3.0.CO;2-4; MANNING BD, 2003, BIOCHEM SOC T, V31, P3; Mansat-De Mas V, 1999, MOL PHARMACOL, V56, P867, DOI 10.1124/mol.56.5.867; Mao JH, 2004, GENE DEV, V18, P1800, DOI 10.1101/gad.1213804; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; MARTUCCI CP, 1993, PHARMACOL THERAPEUT, V57, P237, DOI 10.1016/0163-7258(93)90057-K; Mildner M, 2002, J BIOL CHEM, V277, P14146, DOI 10.1074/jbc.M110687200; Minutoli L, 2004, LIFE SCI, V75, P2853, DOI 10.1016/j.lfs.2004.03.040; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Mockridge JW, 2000, BIOCHEM BIOPH RES CO, V273, P322, DOI 10.1006/bbrc.2000.2934; Mooberry SL, 2003, DRUG RESIST UPDATE, V6, P355, DOI 10.1016/j.drup.2003.10.001; Ozaki M, 2003, CELL DEATH DIFFER, V10, P508, DOI 10.1038/sj.cdd.4401172; Paez Juan, 2003, Cancer Treat Res, V115, P145; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Rahmani M, 2003, ONCOGENE, V22, P6231, DOI 10.1038/sj.onc.1206646; Rahmani M, 2005, CANCER RES, V65, P2422, DOI 10.1158/0008-5472.CAN-04-2440; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Rego AC, 2003, NEUROCHEM RES, V28, P1563, DOI 10.1023/A:1025682611389; Rosato RR, 2003, CANCER RES, V63, P3637; Sawada M, 2001, ONCOGENE, V20, P1368, DOI 10.1038/sj.onc.1204207; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shimada K, 2004, MOL CARCINOGEN, V39, P1, DOI 10.1002/mc.10158; Tinley TL, 2003, CANCER RES, V63, P1538; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yu CR, 2004, ONCOGENE, V23, P1364, DOI 10.1038/sj.onc.1207248; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220; Zhou DC, 2002, BLOOD, V99, P1356, DOI 10.1182/blood.V99.4.1356; Zoubine MN, 1999, INT J ONCOL, V15, P639	67	92	97	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3797	3809		10.1038/sj.onc.1208530	http://dx.doi.org/10.1038/sj.onc.1208530			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782127	Green Accepted			2022-12-25	WOS:000229346300010
J	Edwards, LA; Thiessen, B; Dragowska, WH; Daynard, T; Bally, MB; Dedhar, S				Edwards, LA; Thiessen, B; Dragowska, WH; Daynard, T; Bally, MB; Dedhar, S			Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth	ONCOGENE			English	Article						glioblastomas; integrin-linked kinase; brain cancer	INTEGRIN-LINKED KINASE; GLYCOGEN-SYNTHASE KINASE; PROTEIN-KINASE; GERMLINE MUTATIONS; SIGNALING PATHWAYS; COWDEN-DISEASE; CELL-ADHESION; BREAST-CANCER; IN-VITRO; EXPRESSION	The tumor suppressor gene phosphatase and tensin homologue ( PTEN) regulates the phosphatidylinositol-3'- kinase ( PI3K) signaling pathway and has been shown to correlate with poor prognosis in high- grade astrocytomas when mutational inactivation or loss of the PTEN gene occurs. PTEN mutation leads to constitutive activation of protein kinase B ( PKB)/ Akt with phosphorylation at the PKB/ Akt sites Thr- 308 and Ser- 473. Integrin- linked kinase ( ILK) has been shown to regulate PKB/ Akt activity with the loss of PTEN in prostate cancer. We now demonstrate that ILK activity regulates PKB/ Akt activity in glioblastoma cells. The activity of ILK is constitutively elevated in a serum- independent manner in PTEN mutant cells, and transfection of wild- type PTEN under the control of an inducible promoter into mutant PTEN cells inhibits ILK activity. Transfection of ILK antisense ( ILKAS) or exposure to a small- molecule ILK inhibitor suppresses the constitutive phosphorylation of PKB/ Akt on Ser- 473 in PTEN- mutant glioblastoma cell lines. In addition, the delivery of ILKAS to PTEN-negative glioblastoma cells resulted in apoptosis. Rag- 2M mice bearing established ( similar to 100 mg) human U87MG glioblastoma tumors, treated QD x 5 for 3 consecutive weeks with ILKAS ( i. p. 5 mg/ kg), exhibited stable disease with <= 7% increase in tumor volume over the 3- week course of treatment. In contrast, animals treated with an oligonucleotide control or saline exhibited a > 100% increase in tumor volume over the same time period. Our initial results indicate that therapeutic strategies targeting ILK maybe beneficial in the treatment of glioblastomas.	British Columbia Canc Agcy, British Columbia Canc Res Ctr, Dept Adv Therapeut, Vancouver, BC V5Z 4E6, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada; QLT Inc, Dept Med Chem, Vancouver, BC, Canada; Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC, Canada; British Columbia Canc Agcy, Dept Canc Genet, Vancouver, BC V5Z 4E6, Canada	British Columbia Cancer Agency; University of British Columbia; British Columbia Cancer Agency; University of British Columbia; University of British Columbia; British Columbia Cancer Agency	Edwards, LA (corresponding author), British Columbia Canc Agcy, British Columbia Canc Res Ctr, Dept Adv Therapeut, 601 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	ledwards@bccrc.ca		Dedhar, Shoukat/0000-0003-4355-1657				Cheyney IW, 1999, CANCER RES, V59, P2318; Choe G, 2003, CANCER RES, V63, P2742; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; EDWARDS L, 2003, NEURO-ONCOLOGY, V5, P300; EDWARDS LA, 2004, INTEGRIN LINKED KINA; Ermoian RP, 2002, CLIN CANCER RES, V8, P1100; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Ishii T, 2003, J BIOL CHEM, V278, P26970, DOI 10.1074/jbc.M304113200; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Knobbe CB, 2002, NEURO-ONCOLOGY, V4, P196; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Marsh DJ, 1997, CANCER RES, V57, P5017; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Obara S, 2004, CANCER LETT, V208, P115, DOI 10.1016/j.canlet.2003.11.020; Park MJ, 2002, CANCER RES, V62, P6318; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pore N, 2003, CANCER RES, V63, P236; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stolarov J, 2001, P NATL ACAD SCI USA, V98, P13043, DOI 10.1073/pnas.221450598; Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Tsou HC, 1997, AM J HUM GENET, V61, P1036, DOI 10.1086/301607; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; Wang SI, 1997, CANCER RES, V57, P4183; Waterhouse DN, 2004, CANCER BIOL THER, V3, P197, DOI 10.4161/cbt.3.2.622; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910	39	92	105	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3596	3605		10.1038/sj.onc.1208427	http://dx.doi.org/10.1038/sj.onc.1208427			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782140				2022-12-25	WOS:000229221800007
J	Tirado, OM; Mateo-Lozano, S; Notario, V				Tirado, OM; Mateo-Lozano, S; Notario, V			Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity	ONCOGENE			English	Article						apoptosis; DSRCT; EWS/WT1; proteasome; rapamycin	ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; TRANSLATION INITIATION; MAMMALIAN TARGET; WILMS-TUMOR; TRANSCRIPTIONAL ACTIVATOR; CHROMOSOME-TRANSLOCATION; BINDING PROTEIN; SKELETAL-MUSCLE; T-LYMPHOCYTES	Rapamycin, a complex macrolide and potent fungicide, immunosuppressant and anticancer agent, is a highly specific inhibitor of mammalian target of rapamycin ( mTOR). Rapamycin has been shown to induce G1-phase cell cycle arrest in diverse tumor cell types, and its derivatives RAD001 and CCI-779 are currently in phase I and phase II clinical trials, respectively, as anticancer agents. In this study, we show that rapamycin induced the apoptotic death of JN-DSRCT-1 cells, the only available in vitro model for Desmoplastic Small Round Cell Tumors (DSRCT), while having only minor effects on their cell cycle. Rapamycin induced apoptosis by increasing the Bax : Bcl-xL ratio as a consequence of the concomitant downregulation of Bcl-xL and upregulation of Bax, both at the post-transcriptional level. Rapamycin also downregulated the levels of EWS/WT1, the fusion protein characteristic of DSRCT. Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap-dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity. Moreover, rapamycin treatment downregulated the mRNA and protein levels of the 26S p44.5 proteasome subunit, suggesting the involvement of the proteasome complex in the mechanisms of rapamycin-induced apoptosis. Treatment of JN-DSRCT-1 cells with MG-132, a proteasome specific inhibitor, also resulted in the induction of apoptosis through a similar increase in the Bax : Bcl-xL ratio specifically caused by inhibiting Bax degradation and turnover. These results suggested that rapamycin induces apoptosis by preventing the degradation of the Bax protein by the proteasome, and that this process is independent of mTOR inhibition. Furthermore, these results strongly support the introduction of the use of rapamycin as a cytotoxic agent for the treatment of DSRCT.	Georgetown Univ, Med Ctr, Dept Radiat Med, Expt Carcinogenesis Lab, Washington, DC 20057 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Expt Carcinogenesis Lab, Res Bldg,Room E215,3970 Reservoir Rd NW, Washington, DC 20057 USA.	notariov@georgetown.edu	/AFP-0764-2022; Tirado, Oscar Martínez/R-9604-2019; /AAB-6461-2022	Tirado, Oscar Martínez/0000-0002-4666-2822; Mateo, Silvia/0000-0002-2365-1573	NATIONAL CANCER INSTITUTE [P30CA051008, P01CA074175] Funding Source: NIH RePORTER; NCI NIH HHS [2P30-CA51008, P01-CA74175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aranha O, 2003, INT J ONCOL, V22, P787; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BIEGEL JA, 1993, GENE CHROMOSOME CANC, V7, P119, DOI 10.1002/gcc.2870070210; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Davis DL, 2000, BIOCHEM BIOPH RES CO, V277, P325, DOI 10.1006/bbrc.2000.3684; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Erbay E, 2003, J CELL BIOL, V163, P931, DOI 10.1083/jcb.200307158; Frost P, 2004, BLOOD, V104, P4181, DOI 10.1182/blood-2004-03-1153; Geoerger B, 2001, CANCER RES, V61, P1527; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hleb M, 2004, J BIOL CHEM, V279, P31948, DOI 10.1074/jbc.M400638200; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2001, DRUG RESIST UPDATE, V4, P378, DOI 10.1054/drup.2002.0227; Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295; Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Ito E, 2003, AM J PATHOL, V163, P2165, DOI 10.1016/S0002-9440(10)63573-0; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; Kim J, 1998, ONCOGENE, V16, P1973, DOI 10.1038/sj.onc.1201716; LADANYI M, 1994, CANCER RES, V54, P2837; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Liu FT, 2004, APOPTOSIS, V9, P377, DOI 10.1023/B:APPT.0000025815.78761.5c; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mateo-Lozano S, 2003, ONCOGENE, V22, P9282, DOI 10.1038/sj.onc.1207081; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Mohiuddin M, 2001, CANCER GENE THER, V8, P547, DOI 10.1038/sj.cgt.7700332; Nishio J, 2002, LAB INVEST, V82, P1175, DOI 10.1097/01.LAB.0000028059.92642.03; OHNO T, 1994, ONCOGENE, V9, P3087; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAWYER JR, 1992, AM J SURG PATHOL, V16, P411, DOI 10.1097/00000478-199204000-00010; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Schimke JMC, 1999, GROWTH HORM IGF RES, V9, P179, DOI 10.1054/ghir.1999.0104; Schoffstall B, 2005, J PHARMACOL EXP THER, V312, P12, DOI 10.1124/jpet.104.073445; Sekulic A, 2000, CANCER RES, V60, P3504; SHEN WPV, 1992, CANCER GENET CYTOGEN, V64, P189; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang X, 1997, EUR J IMMUNOL, V27, P2781, DOI 10.1002/eji.1830271106; Zhou CX, 2003, MOL CANCER THER, V2, P789	56	60	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3348	3357		10.1038/sj.onc.1208471	http://dx.doi.org/10.1038/sj.onc.1208471			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15782132				2022-12-25	WOS:000228881800013
J	Ameln, H; Gustafsson, T; Sundberg, CJ; Okamoto, K; Jansson, E; Poellinger, L; Makino, Y				Ameln, H; Gustafsson, T; Sundberg, CJ; Okamoto, K; Jansson, E; Poellinger, L; Makino, Y			Physiological activation of hypoxia inducible factor-1 in human skeletal muscle	FASEB JOURNAL			English	Article						exercise; gene expression; gene regulation; ischemia; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; GENE-EXPRESSION; FACTOR 1-ALPHA; EXERCISE; ERYTHROPOIETIN; ANGIOGENESIS; ISCHEMIA; TRANSCRIPTION; DESATURATION; RESTRICTION	The human hypoxia inducible factor 1 (HIF-1) system is activated under various pathological conditions, yet less is known about its physiological regulation in healthy human tissue. We have studied the effect of exercise on the activation of HIF-1 in human skeletal muscle. Employing a model where oxygen consumption increases and oxygen tension can be manipulated, nine healthy male subjects performed 45 min of one-legged knee-extension exercise. Biopsies were taken before, directly after, and 30, 120, and 360 min after exercise. Exercise led to elevated HIF-1 alpha protein levels and a more prevalent nuclear staining of HIF-1 alpha. Interestingly, a concurrent decrease in von Hippel-Lindau tumor suppressor protein (VHL) levels was detected in some subjects. Moreover, exercise induced an increase in the DNA binding activity of HIF-1 alpha. Characterization of gene expression by real-time PCR demonstrated that the HIF-1 target genes VEGF and EPO were activated. VEGF mRNA was further increased when blood flow to the exercising leg was restricted. In conclusion, these data clearly demonstrate that physical activity induces the HIF-1-mediated signaling pathway in human skeletal muscle, providing the first evidence that human HIF-1 alpha can be activated during physiologically relevant conditions.	Karolinska Inst, Dept Physiol & Pharmacol, Sect Mol Exercise Physiol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Lab Med, S-17177 Stockholm, Sweden; Univ Tokyo, Inst Med Sci, Div Clin Immunol, Tokyo, Japan	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Tokyo	Ameln, H (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Sect Mol Exercise Physiol, S-17177 Stockholm, Sweden.	Helene.Ameln@fyfa.ki.se; Thomas.Gustafson@fyfa.ki.se	Sundberg, Carl Johan/B-9356-2013; Gustafsson, Thomas/AAH-1056-2019	Sundberg, Carl Johan/0000-0002-7000-466X; Rundqvist, Helene/0000-0002-5617-9076; Gustafsson, Thomas/0000-0002-1559-4206				BERGSTROM J, 1962, SCAND J CLIN LAB INV, V14, P1; BLOMQVIST CG, 1983, ANNU REV PHYSIOL, V45, P169, DOI 10.1146/annurev.ph.45.030183.001125; BORG G, 1982, INT J SPORTS MED, V3, P153, DOI 10.1055/s-2008-1026080; Brieger J, 1999, J MOL MED-JMM, V77, P505, DOI 10.1007/s001099900022; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESPLANCHES D, 1993, PFLUG ARCH EUR J PHY, V425, P263, DOI 10.1007/BF00374176; EIKEN O, 1985, EUR J APPL PHYSIOL O, V54, P451, DOI 10.1007/BF00422950; EIKEN O, 1987, ACTA PHYSIOL SCAND, V131, P339, DOI 10.1111/j.1748-1716.1987.tb08248.x; Gustafsson T, 1999, AM J PHYSIOL-HEART C, V276, pH679, DOI 10.1152/ajpheart.1999.276.2.H679; Gustafsson T, 2001, FRONT BIOSCI-LANDMRK, V6, pD75, DOI 10.2741/gustafss; HOGAN MC, 1983, J APPL PHYSIOL, V55, P1134, DOI 10.1152/jappl.1983.55.4.1134; HOHORST HJ, 1962, L PLUS LACTATBESTIMM, P266; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; HUDLICKA O, 1992, PHYSIOL REV, V72, P369, DOI 10.1152/physrev.1992.72.2.369; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; RICHARDSON RS, 1995, J CLIN INVEST, V96, P1916, DOI 10.1172/JCI118237; Richardson RS, 2001, J APPL PHYSIOL, V91, P2679, DOI 10.1152/jappl.2001.91.6.2679; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Sundberg C J, 1994, Acta Physiol Scand Suppl, V615, P1; SUNDBERG CJ, 1992, ACTA PHYSIOL SCAND, V146, P1, DOI 10.1111/j.1748-1716.1992.tb09386.x; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; TERRADOS N, 1990, J APPL PHYSIOL, V68, P2369, DOI 10.1152/jappl.1990.68.6.2369; Vogt M, 2001, J APPL PHYSIOL, V91, P173, DOI 10.1152/jappl.2001.91.1.173; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Williams RS, 1996, HDB PHYSL EXERCISE R, P1124; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; Yokomizo R, 2002, MOL HUM REPROD, V8, P441, DOI 10.1093/molehr/8.5.441; Zhong H, 1999, CANCER RES, V59, P5830	40	182	185	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1009	+		10.1096/fj.04-2304fje	http://dx.doi.org/10.1096/fj.04-2304fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15811877				2022-12-25	WOS:000228865300029
J	Russell, AP; Hesselink, MKC; Lo, SK; Schrauwen, P				Russell, AP; Hesselink, MKC; Lo, SK; Schrauwen, P			Regulation of metabolic transcriptional co-activators and transcription factors with acute exercise	FASEB JOURNAL			English	Article						PGC-1; PPAR-1 alpha; REBP-1c; FKHR; MCIP1	HUMAN SKELETAL-MUSCLE; CONTROLLING MITOCHONDRIAL BIOGENESIS; MESSENGER-RNA EXPRESSION; ACTIVATED RECEPTOR-ALPHA; LIPOPROTEIN-LIPASE GENE; FATTY-ACID OXIDATION; PPAR-GAMMA; NUCLEAR RECEPTORS; LIPID-METABOLISM; FACTOR FKHR	Endurance exercise improves insulin sensitivity and increases fat oxidation, which are partly facilitated by the induction of metabolic transcription factors. Next to exercise, increased levels of FFA's also increase the gene expression of transcription factors, hence making it difficult to discern the effects from contractile signals produced during exercise, from those produced by increased circulatory FFA's. We aimed to investigate, in human skeletal muscle, whether acute exercise affects gene expression of metabolic transcriptional co-activators and transcription factors, including PGC-1 alpha, PRC, PPAR alpha, beta/delta, and gamma and RXR, SREBP-1c and FKHR, and to discern the effect of exercise per se from those of elevated levels of FFA. Two hours of endurance exercise was performed either in the fasted state, or following carbohydrate ingestion prior to and during exercise, thereby blunting the fasting-induced increase in FA availability and oxidation. Of the genes measured, PGC-1 alpha and PRC mRNA increased immediately after, while PPAR beta/delta and FKHR mRNA increased 1-4 h after exercise, irrespective of the increases in FFA's. Our results suggest that the induction in vivo of metabolic transcription factors implicated in mitochondrial biogenesis are under the control of inherent signals, (PGC-1 alpha, PRC), while those implicated in substrate selection are under the control of associated signals (PPAR beta/delta, FKHR) stimulated from the contracting skeletal muscle that are independent of circulating FFA levels.	Clin Romande Readaptat SUVA Care, Sion, Switzerland; Maastricht Univ, Dept Movement Sci, Maastricht, Netherlands; Univ Sydney, Inst Int Hlth, Sydney, NSW 2006, Australia; Maastricht Univ, Dept Human Biol, Maastricht, Netherlands	Maastricht University; University of Sydney; Maastricht University	Russell, AP (corresponding author), Clin Romande Readaptat, Case Postale 352,Av Gd Champsec 90, CH-1951 Sion, Switzerland.	aaron.russell@crr-suva.ch		Russell, Aaron/0000-0002-7323-9501; schrauwen, patrick/0000-0002-0973-847X; LO, Sing Kai/0000-0001-8401-1759				Andersson U, 2001, MOL CELL BIOL, V21, P3738, DOI 10.1128/MCB.21.11.3738-3749.2001; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Barthel A, 2002, ENDOCRINOLOGY, V143, P3183, DOI 10.1210/endo.143.8.8792; BERGSTROM J, 1975, SCAND J CLIN LAB INV, V35, P606, DOI 10.3109/00365517509095787; Bey L, 1998, GENE, V209, P31, DOI 10.1016/S0378-1119(98)00003-1; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coyle EF, 1997, AM J PHYSIOL-ENDOC M, V273, pE268, DOI 10.1152/ajpendo.1997.273.2.E268; DELA F, 1994, DIABETES, V43, P862, DOI 10.2337/diabetes.43.7.862; DELA F, 1992, AM J PHYSIOL, V263, pE1134; Delerive P, 2002, J BIOL CHEM, V277, P3913, DOI 10.1074/jbc.M109409200; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; Herzig S, 2003, NATURE, V426, P190, DOI 10.1038/nature02110; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; Horowitz JF, 2000, AM J PHYSIOL-ENDOC M, V279, pE348, DOI 10.1152/ajpendo.2000.279.2.E348; Ikeda S, 2002, BIOCHEM BIOPH RES CO, V296, P395, DOI 10.1016/S0006-291X(02)00883-5; Jeukendrup AE, 1999, J PHYSIOL-LONDON, V515, P579, DOI 10.1111/j.1469-7793.1999.579ac.x; Kaestner KH, 2000, GENE DEV, V14, P142; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kliewer SA, 1998, CURR OPIN GENET DEV, V8, P576, DOI 10.1016/S0959-437X(98)80014-2; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Matsuzaka T, 2002, J LIPID RES, V43, P107; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Norrbom J, 2004, J APPL PHYSIOL, V96, P189, DOI 10.1152/japplphysiol.00765.2003; Ojuka EO, 2003, FASEB J, V17, P675, DOI 10.1096/fj.02-0951com; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Russell AP, 2003, DIABETES, V52, P2874, DOI 10.2337/diabetes.52.12.2874; Russell AP, 2003, PFLUG ARCH EUR J PHY, V445, P563, DOI 10.1007/s00424-002-0943-5; Scarpulla RC, 2002, GENE, V286, P81, DOI 10.1016/S0378-1119(01)00809-5; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schrauwen P, 2002, DIABETES, V51, P2220, DOI 10.2337/diabetes.51.7.2220; Schrauwen P, 2002, AM J PHYSIOL-ENDOC M, V282, pE11, DOI 10.1152/ajpendo.2002.282.1.E11; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Short KR, 2003, DIABETES, V52, P1888, DOI 10.2337/diabetes.52.8.1888; Simoneau JA, 1999, FASEB J, V13, P2051, DOI 10.1096/fasebj.13.14.2051; Terada S, 2002, BIOCHEM BIOPH RES CO, V296, P350, DOI 10.1016/S0006-291X(02)00881-1; THARP GD, 1975, MED SCI SPORT EXER, V7, P6; Tunstall RJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE66, DOI 10.1152/ajpendo.00475.2001; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61	61	124	129	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					986	+		10.1096/fj.04-3168fje	http://dx.doi.org/10.1096/fj.04-3168fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15814608	Green Published			2022-12-25	WOS:000228865300024
J	Cho, YG; Kim, CJ; Park, CH; Yang, YM; Kim, SY; Nam, SW; Lee, SH; Yoo, NJ; Lee, JY; Park, WS				Cho, YG; Kim, CJ; Park, CH; Yang, YM; Kim, SY; Nam, SW; Lee, SH; Yoo, NJ; Lee, JY; Park, WS			Genetic alterations of the KLF6 gene in gastric cancer	ONCOGENE			English	Article						mutation; tumor suppressor gene; loss of heterozygosity	TUMOR-SUPPRESSOR GENE; KRUPPEL-LIKE FACTOR-6; DIFFERENTIATED ADENOCARCINOMA; CHROMOSOME 10P15; HETEROZYGOSITY; ALLELOTYPE; MUTATION; PROTEIN	The KLF6 is a zinc-finger tumor suppressor that is frequently mutated in several human cancers and broadly involved in differentiation and development, growth-related signal transduction, cell proliferation, apoptosis, and angiogenesis. To determine whether genetic alterations of KLF6 gene are involved in the development and/or progression of gastric cancer, we have screened a set of 80 sporadic gastric cancers for mutations and allele loss of the KLF6 gene. Four missense mutations, S155R, P172 T, S180L, and R198 K, were detected in transactivation domain of the KLF6 gene and one of them had biallelic mutations with somatic mutation of one allele and loss of the remaining allele. All of the cases with mutation were of advanced intestinal-type gastric cancer with lymph node metastasis. In addition, 16 (43.2%) of 37 informative cases showed allelic loss at KLF6 locus. Interestingly, allelic loss was also frequent in intestinal-type gastric cancer. Therefore, our data suggest that genetic alterations of KLF6 gene might play an important role in the development or progression of sporadic gastric cancers.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Surg Pathol, Seoul 137701, South Korea; Konkuk Univ Coll Med, Genet Lab Premed Course, Chungju 380701, South Korea	Catholic University of Korea; Catholic University of Korea; Konkuk University	Park, WS (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea.	wonsang@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Clements WM, 2002, CANCER RES, V62, P3503; Fodde R, 2002, SCIENCE, V298, P761, DOI 10.1126/science.1077707; Hiyama T, 2003, ONCOL REP, V10, P1297; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Nishizuka S, 1998, J PATHOL, V185, P38, DOI 10.1002/(SICI)1096-9896(199805)185:1<38::AID-PATH58>3.0.CO;2-T; Onyango P, 1998, GENOMICS, V48, P143, DOI 10.1006/geno.1997.5124; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SUH CI, 2000, J KOREAN CANC ASS, V32, P827; Tamura G, 1996, J PATHOL, V180, P371, DOI 10.1002/(SICI)1096-9896(199612)180:4<371::AID-PATH704>3.0.CO;2-2; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yustein AS, 1999, CANCER RES, V59, P1437	21	55	58	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4588	4590		10.1038/sj.onc.1208670	http://dx.doi.org/10.1038/sj.onc.1208670			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15824733				2022-12-25	WOS:000230157100012
J	Gould, PS; Easton, AJ				Gould, PS; Easton, AJ			Coupled translation of the respiratory syncytial virus M2 open reading frames requires upstream sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT REINITIATION MECHANISM; RIBOSOME ENTRY SITES; MESSENGER-RNA; INITIATION; PROTEIN; TRANSCRIPTION; ELONGATION; EXPRESSION; COMPLEXES; GENE	We have investigated the mechanism of the translation of the second open reading frame (ORF) of the respiratory syncytial virus M2 transcript that uses a novel coupled translation process requiring prior translation of the upstream ORF. The second M2-2 ORF sequences play no role in the coupling process and can be replaced with other gene sequences. Surprisingly, the overlap region of the two ORFs alone was not sufficient for coupled translation to occur. An analysis of the sequences required for the coupling process showed that portions of the transcript located along the length of the first ORF M2-1, upstream of the ORF overlap region, were essential for coupled translation to occur. A critically important region for this process was centered similar to 150 nucleotides upstream of the ORF2 initiation codons. This region was shown to contain a significant degree of secondary structure, and mutation of this sequence to remove predicted areas of base pairing significantly reduced coupled translation, confirming that the secondary structure was important for the coupling process. Additional sequences further upstream increased the efficiency of the coupled translation process. These data indicate that upstream sequences act in conjunction with the M2-1/M2-2 overlap region to promote coupled translation.	Univ Warwick, Dept Biol Sci, Warwick CV4 7AL, W Midlands, England	University of Warwick	Easton, AJ (corresponding author), Univ Warwick, Dept Biol Sci, Gibbet Hill Rd, Warwick CV4 7AL, W Midlands, England.	a.j.easton@warwick.ac.uk		Gould, Phillip/0000-0003-1230-6771				Ahmadian G, 1999, J GEN VIROL, V80, P2011, DOI 10.1099/0022-1317-80-8-2011; Ahmadian G, 2000, EMBO J, V19, P2681, DOI 10.1093/emboj/19.11.2681; ANTHONY DD, 1992, J BIOL CHEM, V267, P1554; BALTIMORE D, 1971, BACTERIOL REV, V35, P235, DOI 10.1128/MMBR.35.3.235-241.1971; Bermingham A, 1999, P NATL ACAD SCI USA, V96, P11259, DOI 10.1073/pnas.96.20.11259; Collins PL, 1996, P NATL ACAD SCI USA, V93, P81, DOI 10.1073/pnas.93.1.81; GARDNER PS, 1973, POSTGRAD MED J, V49, P788, DOI 10.1136/pgmj.49.577.788; Gould PS, 2005, BIOTECHNIQUES, V38, P397, DOI 10.2144/05383ST02; Green KY, 2000, J INFECT DIS, V181, pS322, DOI 10.1086/315591; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135, DOI 10.1093/oxfordjournals.aje.a115826; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Jin H, 2000, VIROLOGY, V273, P210, DOI 10.1006/viro.2000.0393; Kozak M, 1998, NUCLEIC ACIDS RES, V26, P4853, DOI 10.1093/nar/26.21.4853; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; Meyers G, 2003, J BIOL CHEM, V278, P34051, DOI 10.1074/jbc.M304874200; PARROTT RH, 1973, AM J EPIDEMIOL, V98, P289, DOI 10.1093/oxfordjournals.aje.a121558; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pestova TV, 2003, GENE DEV, V17, P181, DOI 10.1101/gad.1040803; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Pisarev AV, 2004, J VIROL, V78, P4487, DOI 10.1128/JVI.78.9.4487-4497.2004; Plant EP, 2003, RNA, V9, P168, DOI 10.1261/rna.2132503; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	24	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21972	21980		10.1074/jbc.M502276200	http://dx.doi.org/10.1074/jbc.M502276200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15784616	hybrid			2022-12-25	WOS:000229557900039
J	Nagano, S; Cupp-Vickery, JR; Poulos, TL				Nagano, S; Cupp-Vickery, JR; Poulos, TL			Crystal structures of the ferrous dioxygen complex of wild-type cytochrome P450eryF and its mutants, A245S and A245T - Investigation of the proton transfer system in P450eryF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-DEOXYERYTHRONOLIDE-B HYDROXYLASE; ERYTHROMYCIN BIOSYNTHESIS; OXYGEN ACTIVATION; AMINO-ACID; P450CAM; DYNAMICS; MUTATION; PATHWAY	Cytochrome P450eryF (CYP107A) from Saccaropolyspora ertherea catalyzes the hydroxylation of 6-deoxyerythronolide B, one of the early steps in the biosynthesis of erythromycin. P450eryF has an alanine rather than the conserved threonine that participates in the activation of dioxygen (O-2) in most other P450s. The initial structure of P450eryF (Cupp-Vickery, J. R., Han, O., Hutchinson, C. R., and Poulos, T. L. (1996) Nat. Struct. Biol. 3, 632-637) suggests that the substrate 5-OH replaces the missing threonine OH group and holds a key active site water molecule in position to donate protons to the iron-linked dioxygen, a critical step for the monooxygenase reaction. To probe the proton delivery system in P450eryF, we have solved crystal structures of ferrous wild-type and mutant (Fe2+) dioxygen-bound complexes. The catalytic water molecule that was postulated to provide protons to dioxygen is absent, although the substrate 5-OH group donates a hydrogen bond to the iron-linked dioxygen. The hydrogen bond network observed in the wild-type ferrous dioxygen complex, water 63-Glu(360)-Ser(246)-water 53-Ala(241) carbonyl in the I-helix cleft, is proposed as the proton transfer pathway. Consistent with this view, the hydrogen bond network in the O-2 center dot A245S and O-2 center dot A245T mutants, which have decreased or no enzyme activity, was perturbed or disrupted, respectively. The mutant Thr(245) side chain also perturbs the hydrogen bond between the substrate 5-OH and dioxygen ligand. Contrary to the previously proposed mechanism, these results support the direct involvement of the substrate in O-2 activation but raise questions on the role water plays as a direct proton donor to the iron-linked dioxygen.	Univ Calif Irvine, Dept Mol Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Phys & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Program Chem & Struct Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Poulos, TL (corresponding author), RIKEN, Harima Inst, SPring-8,1-1-1 Koto, Sayo, Hyogo 6795148, Japan.	poulos@uci.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033688] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33688] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JF, 1992, J BACTERIOL, V174, P725, DOI 10.1128/jb.174.3.725-735.1992; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CuppVickery JR, 1996, NAT STRUCT BIOL, V3, P632, DOI 10.1038/nsb0796-632; CUPPVICKERY JR, 1994, PROTEINS, V20, P197, DOI 10.1002/prot.340200210; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; DAWSON JH, 1986, J AM CHEM SOC, V108, P8114, DOI 10.1021/ja00285a052; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; Guallar V, 2002, J AM CHEM SOC, V124, P1430, DOI 10.1021/ja016474v; Harris DL, 2002, J INORG BIOCHEM, V91, P568, DOI 10.1016/S0162-0134(02)00477-4; Harris DL, 1996, J AM CHEM SOC, V118, P6377, DOI 10.1021/ja954101m; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; KIMATA Y, 1995, BIOCHEM BIOPH RES CO, V208, P96, DOI 10.1006/bbrc.1995.1310; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; Nagano S, 2004, J BIOL CHEM, V279, P42844, DOI 10.1074/jbc.M404217200; OMURA T, 1962, J BIOL CHEM, V237, P1375; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; SHAFIEE A, 1987, BIOCHEMISTRY-US, V26, P6204, DOI 10.1021/bi00393a037; Taraphder S, 2003, J AM CHEM SOC, V125, P3931, DOI 10.1021/ja016860c; Xiang H, 2000, J BIOL CHEM, V275, P35999, DOI 10.1074/jbc.M005811200	26	78	79	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22102	22107		10.1074/jbc.M501732200	http://dx.doi.org/10.1074/jbc.M501732200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824115	hybrid			2022-12-25	WOS:000229557900054
J	Sauer, SW; Okun, JG; Schwab, MA; Crnic, LR; Hoffmann, GF; Goodman, SI; Koeller, DM; Kolker, S				Sauer, SW; Okun, JG; Schwab, MA; Crnic, LR; Hoffmann, GF; Goodman, SI; Koeller, DM; Kolker, S			Bioenergetics in glutaryl-coenzyme A dehydrogenase deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-KETOGLUTARATE DEHYDROGENASE; PRIMARY NEURONAL CULTURES; ACIDURIA TYPE-I; 3-HYDROXYGLUTARATE NEUROTOXICITY; PYRUVATE-DEHYDROGENASE; OXIDATIVE STRESS; CEREBRAL-CORTEX; COMPLEX; COA; INHIBITION	Inherited deficiency of glutaryl-CoA dehydrogenase results in an accumulation of glutaryl-CoA, glutaric, and 3-hydroxyglutaric acids. If untreated, most patients suffer an acute encephalopathic crisis and, subsequently, acute striatal damage being precipitated by febrile infectious diseases during a vulnerable period of brain development (age 3 and 36 months). It has been suggested before that some of these organic acids may induce excitotoxic cell damage, however, the relevance of bioenergetic impairment is not yet understood. The major aim of our study was to investigate respiratory chain, tricarboxylic acid cycle, and fatty acid oxidation in this disease using purified single enzymes and tissue homogenates from Gcdh-deficient and wild-type mice. In purified enzymes, glutaryl-CoA but not glutaric or 3-hydroxyglutaric induced an uncompetitive inhibition of alpha-ketoglutarate dehydrogenase complex activity. Notably, reduced activity of alpha-ketoglutarate dehydrogenase activity has recently been demonstrated in other neurodegenerative diseases, such as Alzheimer, Parkinson, and Huntington diseases. In contrast to alpha-ketoglutarate dehydrogenase complex, no direct inhibition of glutaryl-CoA, glutaric acid, and 3-hydroxyglutaric acid was found in other enzymes tested. In Gcdh-deficient mice, respiratory chain and tricarboxylic acid activities remained widely unaffected, virtually excluding regulatory changes in these enzymes. However, hepatic activity of very long-chain acyl-CoA dehydrogenase was decreased and concentrations of long-chain acylcarnitines increased in the bile of these mice, which suggested disturbed oxidation of long-chain fatty acids. In conclusion, our results demonstrate that bioenergetic impairment may play an important role in the patho-mechanisms underlying neurodegenerative changes in glutaryl-CoA dehydrogenase deficiency.	Univ Childrens Hosp Heidelberg, Div Inborn Metab Dis, Dept Gen Pediat, D-69120 Heidelberg, Germany; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Ruprecht Karls University Heidelberg; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Oregon Health & Science University; Oregon Health & Science University	Kolker, S (corresponding author), Dept Gen Pediat, Div Inborn Metab Dis, Neuenheimer Feld 50, D-69120 Heidelberg, Germany.	Stefan_Koelker@med.uni-heidelberg.de	Sauer, Sven/E-5424-2013					BENNETT MJ, 1986, EUR J PEDIATR, V145, P403, DOI 10.1007/BF00439248; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bjugstad KB, 2001, J INHERIT METAB DIS, V24, P631, DOI 10.1023/A:1012706908779; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; Buerstatte CR, 2000, DEV BRAIN RES, V125, P139, DOI 10.1016/S0165-3806(00)00134-6; Bunik V, 1997, BIOL CHEM, V378, P1125, DOI 10.1515/bchm.1997.378.10.1125; Busquets C, 2000, PEDIATR RES, V48, P315, DOI 10.1203/00006450-200009000-00009; BUTTERWORTH PJ, 1975, J BIOL CHEM, V250, P1921; Chen Y, 2002, J BIOL CHEM, V277, P33242, DOI 10.1074/jbc.M202026200; Chow SL, 2003, J INHERIT METAB DIS, V26, P711, DOI 10.1023/B:BOLI.0000005635.89043.8a; CHRISTENSEN E, 1993, CLIN CHIM ACTA, V220, P71, DOI 10.1016/0009-8981(93)90007-Q; Das AM, 2003, MOL GENET METAB, V78, P108, DOI 10.1016/S1096-7192(02)00227-5; de Mello CF, 2001, BRAIN RES, V916, P70, DOI 10.1016/S0006-8993(01)02865-7; Fern R, 2003, J NEUROSCI RES, V71, P759, DOI 10.1002/jnr.10553; Freudenberg F, 2004, NEUROBIOL DIS, V16, P581, DOI 10.1016/j.nbd.2004.05.001; GIBSON GE, 1988, ARCH NEUROL-CHICAGO, V45, P836, DOI 10.1001/archneur.1988.00520320022009; Goodman SI, 1998, HUM MUTAT, V12, P141, DOI 10.1002/(SICI)1098-1004(1998)12:3<141::AID-HUMU1>3.0.CO;2-K; GOODMAN SI, 1977, J PEDIATR-US, V90, P746, DOI 10.1016/S0022-3476(77)81240-7; GREENBERG CR, 1995, HUM MOL GENET, V4, P493, DOI 10.1093/hmg/4.3.493; Greenberg CR, 2002, MOL GENET METAB, V75, P70, DOI 10.1006/mgme.2001.3270; HELENIUS A, 1972, J BIOL CHEM, V247, P3656; Hoffmann GF, 1996, NEUROPEDIATRICS, V27, P115, DOI 10.1055/s-2007-973761; Huang HM, 2003, J NEUROSCI RES, V74, P309, DOI 10.1002/jnr.10756; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Jeitner TM, 2005, J NEUROCHEM, V92, P302, DOI 10.1111/j.1471-4159.2004.02868.x; Klivenyi P, 2004, J NEUROCHEM, V88, P1352, DOI 10.1046/j.1471-4159.2003.02263.x; Kobayashi T, 1998, ANN NEUROL, V43, P120, DOI 10.1002/ana.410430121; Koeller DM, 2002, HUM MOL GENET, V11, P347, DOI 10.1093/hmg/11.4.347; Kolker S, 2004, ANN NEUROL, V55, P7, DOI 10.1002/ana.10784; Kolker S, 2003, J BIOL CHEM, V278, P47388, DOI 10.1074/jbc.M308861200; Kolker S, 2002, PEDIATR RES, V52, DOI 10.1203/01.PDR.0000023176.89966.45; Kolker S, 2001, EUR J NEUROSCI, V13, P2115, DOI 10.1046/j.0953-816x.2001.01595.x; Kolker S, 2001, PEDIATR RES, V50, P76; Kumar MJ, 2003, J BIOL CHEM, V278, P46432, DOI 10.1074/jbc.M306378200; Kyllerman M, 2004, EUR J PAEDIATR NEURO, V8, P121, DOI 10.1016/j.ejpn.2003.12.007; Latini A, 2002, BRAIN RES, V956, P367, DOI 10.1016/S0006-8993(02)03573-4; LENARTOWICZ E, 1978, J BIOL CHEM, V253, P5990; Lindner M, 2004, J INHERIT METAB DIS, V27, P851, DOI 10.1023/B:BOLI.0000045769.96657.af; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lund TM, 2004, J NEUROSCI RES, V77, P143, DOI 10.1002/jnr.20136; Marques FD, 2003, BRAIN RES, V964, P153, DOI 10.1016/S0006-8993(02)04118-5; MATSUMOTO M, 1990, Acta Paediatrica Japonica, V32, P76; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; MIZUNO Y, 1994, ANN NEUROL, V35, P204, DOI 10.1002/ana.410350212; MORRISON JF, 1954, BIOCHEM J, V58, P685, DOI 10.1042/bj0580685; Naughten ER, 2004, J INHERIT METAB DIS, V27, P917, DOI 10.1023/B:BOLI.0000045777.82784.74; Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625; Okun JG, 2004, J INHERIT METAB DIS, V27, P783, DOI 10.1023/B:BOLI.0000045838.65498.ff; Okun JG, 2002, BBA-MOL CELL BIOL L, V1584, P91, DOI 10.1016/S1388-1981(02)00296-2; Okun JG, 2002, J BIOL CHEM, V277, P14674, DOI 10.1074/jbc.M200997200; Park LCH, 1999, J NEUROCHEM, V72, P1948, DOI 10.1046/j.1471-4159.1999.0721948.x; Porciuncula LO, 2000, J NEUROL SCI, V173, P93, DOI 10.1016/S0022-510X(99)00307-X; Rosa RB, 2004, NEUROCHEM INT, V45, P1087, DOI 10.1016/j.neuint.2004.05.001; Schwab MA, 2005, CLIN CHEM, V51, P151, DOI 10.1373/clinchem.2004.033852; SHEU KF, 1999, ANN NEUROL, V35, P312; Shi QL, 2005, J BIOL CHEM, V280, P10888, DOI 10.1074/jbc.M409064200; STOKKE O, 1976, CLIN CHIM ACTA, V66, P411, DOI 10.1016/0009-8981(76)90241-2; Strauss KA, 2003, AM J MED GENET C, V121C, P38, DOI 10.1002/ajmg.c.20007; Strauss KA, 2003, AM J MED GENET C, V121C, P53, DOI 10.1002/ajmg.c.20008; Tanaka T, 2002, EMBO J, V21, P1695, DOI 10.1093/emboj/21.7.1695; Ullrich K, 1999, J INHERIT METAB DIS, V22, P392, DOI 10.1023/A:1005595921323; Ventura FV, 1996, J INHERIT METAB DIS, V19, P161, DOI 10.1007/BF01799419; Wilson CJ, 1999, J INHERIT METAB DIS, V22, P663, DOI 10.1023/A:1005542400135; Zschocke J, 2000, J MED GENET, V37, P177, DOI 10.1136/jmg.37.3.177	64	94	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21830	21836		10.1074/jbc.M502845200	http://dx.doi.org/10.1074/jbc.M502845200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15840571	hybrid			2022-12-25	WOS:000229557900022
J	Weber, GF; Menko, AS				Weber, GF; Menko, AS			The canonical intrinsic mitochondrial death pathway has a non-apoptotic role in signaling lens cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-X-L; CYTOCHROME-C; CASPASE ACTIVATION; FIBER CELLS; TERMINAL DIFFERENTIATION; NUCLEAR DEGENERATION; MEMBRANE SKELETON; GOLGI-APPARATUS; PROTEIN; BAX	The mitochondrial cell death pathway is known for its role in signaling apoptosis. Here, we describe a novel function for the mitochondrial cell death pathway in signaling initiation of differentiation in the developing lens. Most remarkably, we induced lens cell differentiation by short-term exposure of lens epithelial cells to the apoptogen staurosporine. Activation of apoptosis-related pathways induced lens epithelial cells to express differentiation-specific markers and to undergo morphogenetic changes that led to formation of the lens-like structures known as lentoids. The fact that multiple stages of differentiation are expressed at a single stage of development in the embryonic lens made it possible to precisely determine the timing of expression of proteins associated with the apoptotic pathway. We discovered that there was high expression in the lens equatorial epithelium ( the region of the lens in which differentiation is initiated) of pro-apoptotic molecules such as Bax and Bcl-x(S) and release of cytochrome c from mitochondria. Furthermore, we found significant caspase-3-like activity in the equatorial epithelium, yet this activity was far lower than that associated with lens cell apoptosis. These apoptotic pathways are likely regulated by the concurrent expression of prosurvival molecules, including Bcl-2 and Bcl-x(L); phosphorylation of Bad; and high expression of inhibitor of apoptosis proteins chicken IAP1, IAP3, and survivin. This finding suggests that prosurvival pathways allow pro-apoptotic molecules to function as molecular switches in the differentiation process without tipping the balance toward apoptosis. We call this process apoptosis-related Bcl-2- and caspase-dependent (ABC) differentiation.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Menko, AS (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, 57 Jefferson Alumni Hall,Locust St, Philadelphia, PA 19107 USA.	sue.menko@jefferson.edu		Menko, A. Sue/0000-0002-7514-4696	NATIONAL EYE INSTITUTE [R01EY010577, R24EY014798, R01EY014258] Funding Source: NIH RePORTER; NEI NIH HHS [EY 10577, EY 014798, EY 014258] Funding Source: Medline; NIEHS NIH HHS [ES 007282] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bassnett S, 1997, J CELL BIOL, V137, P37, DOI 10.1083/jcb.137.1.37; BASSNETT S, 1995, INVEST OPHTH VIS SCI, V36, P1793; BASSNETT S, 1992, DEV DYNAM, V194, P85, DOI 10.1002/aja.1001940202; BASSNETT S, 1992, CURR EYE RES, V11, P1227, DOI 10.3109/02713689208999548; BEEBE DC, 1987, P NATL ACAD SCI USA, V84, P2327, DOI 10.1073/pnas.84.8.2327; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Carlile GW, 2004, BLOOD, V103, P4310, DOI 10.1182/blood-2003-09-3362; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chen Q, 2000, INVEST OPHTH VIS SCI, V41, P4223; Chiu R, 2002, J CELL BIOL, V159, P637, DOI 10.1083/jcb.200208013; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; DAWSON CW, 1995, ONCOGENE, V10, P69; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Ferreira-Cornwell MC, 2000, EXP CELL RES, V256, P237, DOI 10.1006/excr.2000.4819; Foley JD, 2004, J BIOL CHEM, V279, P32142, DOI 10.1074/jbc.M313683200; Fromm L, 1997, DEV GENET, V20, P276, DOI 10.1002/(SICI)1520-6408(1997)20:3<276::AID-DVG10>3.0.CO;2-6; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Goldstein JC, 2000, ANN NY ACAD SCI, V926, P132; Hafid-Medheb K, 2003, BLOOD, V101, P2575, DOI 10.1182/blood-2002-02-0478; Harada H, 1998, J ORAL PATHOL MED, V27, P11; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Johnson AL, 2002, ENDOCRINOLOGY, V143, P3405, DOI 10.1210/en.2002-220107; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KUWABARA T, 1975, EXP EYE RES, V20, P427, DOI 10.1016/0014-4835(75)90085-8; KUWABARA T, 1974, INVEST OPHTH VISUAL, V13, P973; Lane JD, 2002, J CELL BIOL, V156, P495, DOI 10.1083/jcb.200110007; Le ACN, 2001, DEV BIOL, V233, P394, DOI 10.1006/dbio.2001.0194; Lee A, 2000, DEV DYNAM, V217, P257, DOI 10.1002/(SICI)1097-0177(200003)217:3<257::AID-DVDY4>3.0.CO;2-5; Lee A, 2001, J BIOL CHEM, V276, P20735, DOI 10.1074/jbc.M009723200; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindenboim L, 2000, ONCOGENE, V19, P1783, DOI 10.1038/sj.onc.1203495; Lovicu FJ, 2001, DEVELOPMENT, V128, P5075; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; McNulty R, 2004, J PHYSIOL-LONDON, V559, P883, DOI 10.1113/jphysiol.2004.068619; MENKO AS, 1984, DEV BIOL, V103, P129, DOI 10.1016/0012-1606(84)90014-9; Menko AS, 2002, EXP EYE RES, V75, P485, DOI 10.1006/exer.2002.2057; Mercatante DR, 2002, J BIOL CHEM, V277, P49374, DOI 10.1074/jbc.M209236200; MERIO GR, 1997, CELL GROWTH DIFFER, V8, P251; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MODAK SP, 1970, EXP CELL RES, V59, P43, DOI 10.1016/0014-4827(70)90622-1; Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PERSONS BJ, 1970, EXP EYE RES, V9, P144, DOI 10.1016/S0014-4835(70)80069-0; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sanders EJ, 2003, DIFFERENTIATION, V71, P425, DOI 10.1046/j.1432-0436.2003.7107005.x; Sanders EJ, 2002, J ANAT, V201, P121, DOI 10.1046/j.1469-7580.2002.00081.x; SELL C, 1995, CANCER RES, V55, P303; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Tamm I, 1998, CANCER RES, V58, P5315; Walker JL, 1999, DEV BIOL, V210, P497, DOI 10.1006/dbio.1999.9277; Weil M, 1999, CURR BIOL, V9, P361, DOI 10.1016/S0960-9822(99)80162-6; Wistow G, 2002, MOL VIS, V8, P171; Wride MA, 1998, EXP EYE RES, V66, P371, DOI 10.1006/exer.1997.0440; Wride MA, 1999, DEV BIOL, V213, P142, DOI 10.1006/dbio.1999.9375; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou J, 2002, INVEST OPHTH VIS SCI, V43, P2293	68	87	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22135	22145		10.1074/jbc.M414270200	http://dx.doi.org/10.1074/jbc.M414270200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15826955	hybrid			2022-12-25	WOS:000229557900058
J	Liu, XB; Bandyopadhyay, BC; Singh, BB; Groschner, K; Ambudkar, IS				Liu, XB; Bandyopadhyay, BC; Singh, BB; Groschner, K; Ambudkar, IS			Molecular analysis of a store-operated and 2-acetyl-sn-glycerol-sensitive non-selective cation channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR POTENTIAL CHANNELS; CA2+ INFLUX; CALCIUM-ENTRY; TRP; PROTEINS; DIACYLGLYCEROL; DEPLETION; COMPLEX; CELLS; HSG	We have reported that internal Ca2+ store depletion in HSY cells stimulates a nonselective cation current which is distinct from I-CRAC in RBL cells and TRPC1-dependent I-SOC in HSG cells (Liu, X., Groschner, K., and Ambudkar, I. S. ( 2004) J. Membr. Biol. 200, 93 - 104). Here we have analyzed the molecular composition of this channel. Both thapsigargin (Tg) and 2-acetyl-sn-glycerol (OAG) stimulated similar non-selective cation currents and Ca2+ entry in HSY cells. The effects of Tg and OAG were not additive. HSY cells endogenously expressed TRPC1, TRPC3, and TRPC4 but not TRPC5 or TRPC6. Immunoprecipitation of TRPC1 pulled down TRPC3 but not TRPC4. Conversely, TRPC1 co-immunoprecipitated with TRPC3. Expression of antisense TRPC1 decreased (i) Tg- and OAG-stimulated currents and Ca2+ entry and (ii) the level of endogenous TRPC1 but not TRPC4. Antisense TRPC3 similarly reduced Ca2+ entry and endogenous TRPC3. Yeast two-hybrid analysis revealed an interaction between NTRPC1 and NTRPC3 (CTRPC1-CTRPC3, CTRPC3-CTRPC1, or CTRPC1-NTRPC3 did not interact), which was confirmed by glutathione S-transferase (GST) pull-down assays (GST-NTRPC3 pulled down TRPC1 and vice versa). Expression of NTRPC1 or NTRPC3 induced similar dominant suppression of Tg- and OAG-stimulated Ca2+ entry. NTRPC3 did not alter surface expression of TRPC1 or TRPC3 but disrupted TRPC1-TRPC3 association. In aggregate, our data demonstrate that TRPC1 and TRPC3 co-assemble, via N-terminal interactions, to form a heteromeric storeoperated non-selective cation channel in HSY cells. Thus selective association between TRPCs generate distinct store-operated channels. Diversity of store-operated channels might be related to the physiology of the different cell types.	NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH,DHHS, Bethesda, MD 20892 USA; Univ N Dakota, Sch Med, Dept Biochem & Mol Biol, Grand Forks, ND 58203 USA; Graz Univ, Dept Pharmacol & Toxikol, A-8010 Graz, Austria	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of North Dakota Grand Forks; University of Graz	Ambudkar, IS (corresponding author), NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH,DHHS, Bldg 10,Rm 1N-113, Bethesda, MD 20892 USA.	indu.ambudkar@nih.gov	Bandyopadhyay, Bidhan/AAC-6828-2022; Groschner, Klaus/A-2550-2010	Bandyopadhyay, Bidhan/0000-0003-2364-8945; Groschner, Klaus/0000-0002-8659-377X; Singh, Brij/0000-0003-0535-5997	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Beech DJ, 2003, CELL CALCIUM, V33, P433, DOI 10.1016/S0143-4160(03)00054-X; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu X, 2004, J MEMBRANE BIOL, V200, P93, DOI 10.1007/s00232-004-0698-3; Liu X, 2001, J MEMBRANE BIOL, V181, P185, DOI 10.1007/s00232-001-0020-6; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Prakriya M, 2003, CELL CALCIUM, V33, P311, DOI 10.1016/S0143-4160(03)00045-9; Schilling William P, 2004, Novartis Found Symp, V258, P18; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Sydorenko V, 2003, J PHYSIOL-LONDON, V548, P823, DOI 10.1113/jphysiol.2002.036772; Trebak M, 2003, CELL CALCIUM, V33, P451, DOI 10.1016/S0143-4160(03)00056-3; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5	30	134	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21600	21606		10.1074/jbc.c400492200	http://dx.doi.org/10.1074/jbc.c400492200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15834157	hybrid			2022-12-25	WOS:000229438800084
J	Maza, J; Das Sarma, J; Koval, M				Maza, J; Das Sarma, J; Koval, M			Defining a minimal motif required to prevent connexin oligomerization in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; VASCULAR SMOOTH-MUSCLE; AMINO-ACID-RESIDUES; INTRACELLULAR-TRANSPORT; MEMBRANE CHANNEL; CELL-LINES; PROTEINS; TRAFFICKING; DISEASE; EXPRESSION	In contrast to most multimeric transmembrane complexes that oligomerize in the endoplasmic reticulum (ER), the gap junction protein connexin43 (Cx43) oligomerizes in an aspect of the Golgi apparatus. The mechanisms that prevent oligomerization of Cx43 and related connexins in the ER are not well understood. Also, some studies suggest that connexins can oligomerize in the ER. We used connexin constructs containing a C-terminal dilysine-based ER retention/ retrieval signal (HKKSL) transfected into HeLa cells to study early events in connexin oligomerization. Using this approach, Cx43- HKKSL was retained in the ER and prevented from oligomerization. However, another ER-retained HKKSL-tagged connexin, Cx32-HKKSL, had the capacity to oligomerize. Because this suggested that Cx43 contains a motif that prevented oligomerization in the ER, a series of HKKSL-tagged and untagged Cx32/ Cx43 chimeras was screened to define this motif. The minimal motif, which prevented ER oligomerization, consisted of the complete third transmembrane domain and the second extracellular loop from Cx43 on a Cx32 backbone. We propose that charged residues present in Cx43 and related connexins help prevent ER oligomerization by stabilizing the third transmembrane domain in the membrane bilayer.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Koval, M (corresponding author), Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Whitehead Biomed Res Bldg,615 Micheale St,Suite 2, Atlanta, GA 30322 USA.		Sarma, Jayasri Das/AAS-3837-2020; Koval, Michael/C-6366-2015	Koval, Michael/0000-0002-5422-5614	NHLBI NIH HHS [P01 HL019737, P01 HL019737-300018, P01-HL019737-26] Funding Source: Medline; NIGMS NIH HHS [R01 GM061012-06, GM61012, R01 GM061012] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061012] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad S, 2001, EUR J BIOCHEM, V268, P4544, DOI 10.1046/j.1432-1327.2001.02380.x; Bennett MVL, 2004, NEURON, V41, P495, DOI 10.1016/S0896-6273(04)00043-1; Berthoud VM, 2003, EUR J CELL BIOL, V82, P209, DOI 10.1078/0171-9335-00316; Beyer EC, 2001, CELL COMMUN ADHES, V8, P199, DOI 10.3109/15419060109080723; Brink PR, 1998, ACTA PHYSIOL SCAND, V164, P349; BRUZZONE R, 1994, J CELL SCI, V107, P955; CIVITELLI R, 1993, J CLIN INVEST, V91, P1888, DOI 10.1172/JCI116406; Cottrell GT, 2002, AM J PHYSIOL-CELL PH, V282, pC1469, DOI 10.1152/ajpcell.00484.2001; Das Sarma J, 2002, J BIOL CHEM, V277, P20911, DOI 10.1074/jbc.M111498200; Das Sarma J, 2001, J CELL SCI, V114, P4013; Delmar M, 2004, CARDIOVASC RES, V62, P268, DOI 10.1016/j.cardiores.2003.12.030; Deschenes SM, 1997, J NEUROSCI, V17, P9077; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Figueroa XF, 2004, PHYSIOLOGY, V19, P277, DOI 10.1152/physiol.00008.2004; Fleishman SJ, 2004, MOL CELL, V15, P879, DOI 10.1016/j.molcel.2004.08.016; Gemel J, 2004, J CELL SCI, V117, P2469, DOI 10.1242/jcs.01084; George CH, 1999, J BIOL CHEM, V274, P8678, DOI 10.1074/jbc.274.13.8678; Govindarajan R, 2002, J BIOL CHEM, V277, P50087, DOI 10.1074/jbc.M202652200; He DS, 1999, P NATL ACAD SCI USA, V96, P6495, DOI 10.1073/pnas.96.11.6495; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kelsell DP, 2001, TRENDS CELL BIOL, V11, P2, DOI 10.1016/S0962-8924(00)01866-3; KOVAL M, 1995, J CELL BIOL, V130, P987, DOI 10.1083/jcb.130.4.987; Koval M, 1997, J CELL BIOL, V137, P847, DOI 10.1083/jcb.137.4.847; KUMAR NM, 1995, J CELL SCI, V108, P3725; Lagree V, 2003, J CELL SCI, V116, P3189, DOI 10.1242/jcs.00604; Larson D. M., 2000, Molecular Cell Biology Research Communications, V3, P115, DOI 10.1006/mcbr.2000.0200; Lauf U, 2001, FEBS LETT, V498, P11, DOI 10.1016/S0014-5793(01)02462-0; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Martin PEM, 2000, BIOCHEM J, V349, P281, DOI 10.1042/0264-6021:3490281; Martin PEM, 2004, CARDIOVASC RES, V62, P378, DOI 10.1016/j.cardiores.2004.01.016; Martin PEM, 2000, J NEUROCHEM, V74, P711, DOI 10.1046/j.1471-4159.2000.740711.x; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; Rouan F, 2001, J CELL SCI, V114, P2105; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Segretain D, 2004, BBA-BIOMEMBRANES, V1662, P3, DOI 10.1016/j.bbamem.2004.01.007; Simon AM, 2003, J CELL SCI, V116, P2223, DOI 10.1242/jcs.00429; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Simon AM, 2002, DEV BIOL, V251, P206, DOI 10.1006/dbio.2002.0826; Skerrett IM, 2002, J CELL BIOL, V159, P349, DOI 10.1083/jcb.200207060; Stergiopoulos K, 1999, CIRC RES, V84, P1144, DOI 10.1161/01.RES.84.10.1144; Thomas T, 2004, J BIOL CHEM, V279, P19157, DOI 10.1074/jbc.M314117200; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; Valiunas V, 2001, AM J PHYSIOL-HEART C, V281, pH1675, DOI 10.1152/ajpheart.2001.281.4.H1675; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; Wang HL, 2004, NEUROBIOL DIS, V15, P361, DOI 10.1016/j.nbd.2003.11.005; WILLECKE K, 1991, EUR J CELL BIOL, V56, P1; Yum SW, 2002, NEUROBIOL DIS, V11, P43, DOI 10.1006/nbdi.2002.0545	50	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21115	21121		10.1074/jbc.M412612200	http://dx.doi.org/10.1074/jbc.M412612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15817491	hybrid			2022-12-25	WOS:000229438800027
J	Kasus-Jacobi, A; Ou, JF; Birch, DG; Locke, KG; Shelton, JM; Richardson, JA; Murphy, AJ; Valenzuela, DM; Yancopoulos, GD; Edwards, AO				Kasus-Jacobi, A; Ou, JF; Birch, DG; Locke, KG; Shelton, JM; Richardson, JA; Murphy, AJ; Valenzuela, DM; Yancopoulos, GD; Edwards, AO			Functional characterization of mouse RDH11 as a retinol dehydrogenase involved in dark adaptation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-CHAIN DEHYDROGENASE/REDUCTASE; ALL-TRANS-RETINOL; SUBSTRATE-SPECIFICITY; RETINITIS-PIGMENTOSA; OUTER SEGMENTS; A-WAVE; MUTATIONS; FAMILY; ENZYME; GENE	We previously cloned mouse RDH11 ( mRDH11) as a gene regulated by the transcription factor sterol regulatory element-binding proteins and showed that it is a retinol dehydrogenase expressed in non-ocular tissues such as the liver and testis and in the retina (Kasus-Jacobi, A., Ou, J., Bashmakov, Y. K., Shelton, J. M., Richardson, J. A., Goldstein, J. L., and Brown, M. S. ( 2003) J. Biol. Chem. 278, 32380-32389). It was proposed to function in the recycling of the visual chromophore 11-cis-retinal after photoisomerization by a bleaching light, a pathway referred to as the visual cycle. In this work, we describe our studies on the ocular function of mRDH11. We created a knockout mouse by replacing the mrdh11 coding sequence with the lacZ reporter gene for expression profiling. 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal) staining demonstrated active transcription of this gene in photoreceptor cells. We show by immunoblot analysis that mRDH11 is associated with retinal membranes purified from a non-outer segment fraction of the retina. No obvious retinal defect was found during development and aging of RDH11-deficient mice. The functional consequences of mRDH11 disruption were investigated by electroretinography. Dark adaptation was delayed by a factor of 2.5-3 compared with wild-type mice. However, the kinetics of 11-cis-retinal recycling during dark adaptation was not affected, suggesting that mRDH11 is not involved in the visual cycle. We propose that mRDH11 disruption affects retinoid metabolism in photoreceptor inner segments and delays the kinetics of dark adaptation through modulation of calcium homeostasis.	Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Ophthalmol, Dallas, TX 75390 USA; Retina Fdn SW, Dallas, TX 75231 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Retina Foundation of the Southwest; Regeneron	Kasus-Jacobi, A (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Dean A McGee Eye Inst,608 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	anne-kasus-jacobi@ouhsc.edu	KASUS-JACOBI, Anne/V-7799-2019	KASUS-JACOBI, Anne/0000-0003-3844-0450; Birch, David/0000-0002-6594-2897; Murphy, Andrew/0000-0003-4152-4081	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belyaeva OV, 2003, BIOCHEMISTRY-US, V42, P14838, DOI 10.1021/bi035288u; BIRCH DG, 1995, INVEST OPHTH VIS SCI, V36, P1603; BRETON ME, 1994, INVEST OPHTH VIS SCI, V35, P295; Dean DM, 2002, P NATL ACAD SCI USA, V99, P8372, DOI 10.1073/pnas.122681899; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; HOOD DC, 1993, VISION RES, V33, P1605, DOI 10.1016/0042-6989(93)90027-T; HOOD DC, 1994, INVEST OPHTH VIS SCI, V35, P2948; Janecke AR, 2004, NAT GENET, V36, P850, DOI 10.1038/ng1394; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; Kasus-Jacobi A, 2003, J BIOL CHEM, V278, P32380, DOI 10.1074/jbc.M304969200; Kedishvili NY, 2002, J BIOL CHEM, V277, P28909, DOI 10.1074/jbc.M202588200; Kim TS, 2005, J BIOL CHEM, V280, P8694, DOI 10.1074/jbc.M413172200; Krizaj D, 2002, FRONT BIOSCI-LANDMRK, V7, pD2023, DOI 10.2741/krizaj; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; Lin BY, 2001, CANCER RES, V61, P1611; Martin RE, 2004, MOL VIS, V10, P199; McCabe SL, 2004, J GEN PHYSIOL, V123, P521, DOI 10.1085/jgp.200409011; Oppermann UCT, 2001, CHEM-BIOL INTERACT, V130, P699, DOI 10.1016/S0009-2797(00)00301-X; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; Perrault I, 2004, AM J HUM GENET, V75, P639, DOI 10.1086/424889; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; Shang EY, 2002, J LIPID RES, V43, P590; Sheehan D.C., 1980, THEORY PRACTICE HIST; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Vellani V, 2000, J PHYSIOL-LONDON, V529, P333, DOI 10.1111/j.1469-7793.2000.00333.x; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; Woods A, 1994, LAB HISTOPATHOLOGY C; Wu BX, 2004, INVEST OPHTH VIS SCI, V45, P3857, DOI 10.1167/iovs.03-1302; Wu BX, 2002, INVEST OPHTH VIS SCI, V43, P3365; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707; Zhao XY, 1998, J BIOL CHEM, V273, P5124, DOI 10.1074/jbc.273.9.5124	39	33	34	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20413	20420		10.1074/jbc.M413789200	http://dx.doi.org/10.1074/jbc.M413789200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15790565	hybrid			2022-12-25	WOS:000229242000033
J	Bergamaschi, D; Samuels, Y; Zhong, S; Lu, X				Bergamaschi, D; Samuels, Y; Zhong, S; Lu, X			Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation	ONCOGENE			English	Article						ASPP; p53; mdm2; mdmX; apoptosis; transactivation	EMBRYONIC LETHALITY; TRANSCRIPTIONAL ACTIVATION; MDM2-DEFICIENT MICE; APOPTOSIS; RESCUE; ONCOPROTEIN; PATHWAYS; PROTEINS; P300/CBP; BINDING	Using various mutants of p53 and mdm2, we demonstrate here that both the DNA binding and transactivation function of p53 are required for ASPP1 and ASPP2 to stimulate the apoptotic functions of p53. Mdm2 and mdmx prevent ASPP1 and ASPP2 from stimulating the apoptotic function of p53 by binding and inhibiting the transcriptional activity of p53. Importantly, mdm2 and mdmx can prevent the stimulatory effects of ASPP1 and ASPP2 without targeting p53 for degradation. These data provide a novel mechanism by which mdm2 and mdmx act as potent inhibitors of p53.	UCL, Ludwig Inst Canc Res, London W1W 7BS, England	Ludwig Institute for Cancer Research; University of London; University College London	Lu, X (corresponding author), UCL, Ludwig Inst Canc Res, Courtauld Bldg,91 Riding House St, London W1W 7BS, England.	x.lu@ludwig.ucl.ac.uk		Lu, Xin/0000-0002-6587-1152; Bergamaschi, Daniele/0000-0002-3955-1091; Samuels, Yardena/0000-0002-3349-7266				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; CORDONCARDO C, 1994, CANCER RES, V54, P794; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Ramos YFM, 2001, CANCER RES, V61, P1839; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Tang HJ, 2004, BRIT J CANCER, V90, P1285, DOI 10.1038/sj.bjc.6601653; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	26	9	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3836	3841		10.1038/sj.onc.1208535	http://dx.doi.org/10.1038/sj.onc.1208535			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782125				2022-12-25	WOS:000229346300014
J	Lee, YJ; Lee, DH; Cho, CK; Chung, HY; Bae, S; Jhon, GJ; Soh, JW; Jeoung, DI; Lee, SJ; Lee, YS				Lee, YJ; Lee, DH; Cho, CK; Chung, HY; Bae, S; Jhon, GJ; Soh, JW; Jeoung, DI; Lee, SJ; Lee, YS			HSP25 inhibits radiation-induced apoptosis through reduction of PKC delta-mediated ROS production	ONCOGENE			English	Article						HSP25; radiation-induced apoptosis; reactive oxygen species; PKC delta; p38 MAP kinase	PROTEIN-KINASE-C; HEAT-SHOCK-PROTEIN; MANGANESE SUPEROXIDE-DISMUTASE; STRESS-INDUCED APOPTOSIS; INDUCED CELL-DEATH; OXIDATIVE STRESS; CYTOCHROME-C; PROTEOLYTIC ACTIVATION; PROTECTIVE ACTIVITY; CANCER-CELLS	Since radiation-induced caspase-dependent apoptosis and ROS generation were partially prevented by HSP25 overexpression, similar to the treatment of control cells with antioxidant agents such as DPI and tiron, questions arise whether radiation-mediated ROS generation contributes to the apoptotic cell death, and also whether HSP25 overexpression can reduce ROS mediated apoptotic cell death. In the present study, radiation-induced cytochrome c release from mitochondria and activation of caspases accompanied by a decrease of mitochondrial membrane potential in Jurkat T cells were shown to be inhibited by mitochondrial complex I inhibitor rotenone, suggesting that mitochondrial ROS might be important in radiation-induced caspase-dependent apoptosis. When HSP25 was overexpressed, effects similar to the treatment of cells with the antioxidants were obtained, indicating that HSP25 suppressed radiation-induced mitochondrial alteration that resulted in apoptosis. Furthermore, activation of p38 MAP kinase by radiation was associated with radiation-induced cell death and ROS production and PKC delta was an upstream molecule for p38 MAP kinase activation, ROS generation and subsequent caspase-dependent apoptotic events. However, in the HSP25 overexpressed cells, the above-described effects were blocked. In fact, radiation-induced membrane translocation of PKC delta and tyrosine phosphorylation were inhibited by HSP25. Based on the above data, we suggest that HSP25 downregulates PKC delta, which is a key molecule for radiation-induced ROS generation and mitochondrial-mediated caspase-dependent apoptotic events.	Korea Inst Radiol & Med Sci, Div Radiat Biol, Lab Radiat Effect, Seoul 139706, South Korea; Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Inha Univ, Dept Chem, Lab Signal Transduct, Inchon 402751, South Korea; Kangweon Natl Univ, Coll Nat Sci, Div Life Sci, Chunchon 200701, South Korea	Korea Institute of Radiological & Medical Sciences; Hanyang University; Ewha Womans University; Inha University; Kangwon National University	Lee, YS (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Biol, Lab Radiat Effect, 215-4 Gongneung Dong, Seoul 139706, South Korea.	yslee@kcch.re.kr	Lee, Yun-Sil/AAP-1378-2020	Lee, Yun-Sil/0000-0002-7538-8850; Chung, Hee Yong/0000-0001-7580-0537				Brown GE, 2003, MOL CELL, V11, P35, DOI 10.1016/S1097-2765(03)00005-4; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Charette SJ, 2000, ANN NY ACAD SCI, V926, P126; Cho HN, 2002, CELL DEATH DIFFER, V9, P448, DOI 10.1038/sj.cdd.4400979; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Garrido C, 1996, EUR J BIOCHEM, V237, P653, DOI 10.1111/j.1432-1033.1996.0653p.x; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; HUOT J, 1991, CANCER RES, V51, P5245; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; Kim YS, 2003, EUR J BIOCHEM, V270, P4089, DOI 10.1046/j.1432-1033.2003.03800.x; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Lee YJ, 2004, FREE RADICAL BIO MED, V36, P429, DOI 10.1016/j.freeradbiomed.2003.11.009; Lee YJ, 2003, EXP CELL RES, V291, P251, DOI 10.1016/S0014-4827(03)00391-4; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martelli AM, 1999, J CELL BIOCHEM, V74, P499, DOI 10.1002/(SICI)1097-4644(19990915)74:4<499::AID-JCB1>3.0.CO;2-X; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Musashi M, 2000, INT J HEMATOL, V72, P12; OESTERREICH S, 1993, CANCER RES, V53, P4443; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Park MT, 2003, J BIOL CHEM, V278, P50624, DOI 10.1074/jbc.M309011200; Park SH, 2000, RADIAT RES, V154, P421, DOI 10.1667/0033-7587(2000)154[0421:HIRIAW]2.0.CO;2; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Yi MJ, 2002, RADIAT RES, V158, P641, DOI 10.1667/0033-7587(2002)158[0641:HSPHRM]2.0.CO;2; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	40	44	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3715	3725		10.1038/sj.onc.1208440	http://dx.doi.org/10.1038/sj.onc.1208440			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15806174				2022-12-25	WOS:000229346300003
J	Wang, JY; Ho, T; Trojanek, J; Chintapalli, J; Grabacka, M; Stoklosa, T; Garcia, FU; Skorski, T; Reiss, K				Wang, JY; Ho, T; Trojanek, J; Chintapalli, J; Grabacka, M; Stoklosa, T; Garcia, FU; Skorski, T; Reiss, K			Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence	ONCOGENE			English	Article						prostate cancer; anchorage-independence; Rad51; homologous recombination; DNA repair	HUMAN RAD51 PROTEIN; FACTOR-I RECEPTOR; STRAND BREAK REPAIR; MAMMALIAN-CELLS; BIOCHEMICAL-CHARACTERIZATION; GENOMIC INSTABILITY; MISMATCH REPAIR; DOWN-REGULATION; TUMOR-GROWTH; APOPTOSIS	During metastases, cancer cells are temporarily exposed to the condition in which interactions with extracellular environment can be restricted (anchorage-independence). We demonstrate that the sensitivity of prostate cancer cell lines, DU145 and PC-3, to genotoxic treatment ( cisplatin and gamma-irradiation) increased several folds when cells were forced to grow in anchorage-independence. This enhanced drug sensitivity was associated with a severe impairment of homologous recombination-directed DNA repair (HRR). The mechanism involves Rad51, which is the major enzymatic component of HRR. The protein level of Rad51 and its recruitment to DNA double-strand breaks (DSBs) were both attenuated. Rad51 deficiency in anchorage-independence was not associated with Rad51 promoter activity, and was not compensated by a constitutive overexpression of Rad51 cDNA. Instead, Rad51 protein level and its ability to colocalize with DSBs were restored in the presence of proteosome inhibitors, or when cells from the suspension cultures were allowed reattachment. Presented results indicate that anchorage-independence sensitizes prostate cancer cells to genotoxic agents; however, it also attenuates faithful component of DNA repair by targeting stability of Rad51. This temporal attenuation of HRR may contribute to the accumulation mutations after DNA damage, and possibly the selection of new adaptations in cells, which survived genotoxic treatment.	Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Drexel Univ, Coll Med, Dept Pathol & Lab Med, Philadelphia, PA 19146 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Drexel University	Reiss, K (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Biol Life Sci Bldg,Room 230,1900 N 12th St, Philadelphia, PA 19122 USA.	kreiss@temple.edu	Grabacka, Maja/ABE-5286-2021; Stoklosa, Tomasz A/I-8825-2017	Grabacka, Maja/0000-0003-4407-8814; Trojanek, Joanna/0000-0002-3200-735X; Stoklosa, Tomasz/0000-0001-6918-5056				Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bindra RS, 2004, MOL CELL BIOL, V24, P8504, DOI 10.1128/MCB.24.19.8504-8518.2004; Bondar VM, 2002, PROSTATE, V51, P42, DOI 10.1002/pros.10070; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Chen Y, 2003, INT J ONCOL, V22, P1033; Chen Y, 2001, CANCER RES, V61, P4112; Chendil D, 2004, ONCOGENE, V23, P1599, DOI 10.1038/sj.onc.1207284; Collis SJ, 2001, NUCLEIC ACIDS RES, V29, P1534, DOI 10.1093/nar/29.7.1534; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Del Valle L, 2002, CLIN CANCER RES, V8, P1822; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Flygare J, 2001, EXP CELL RES, V268, P61, DOI 10.1006/excr.2001.5265; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Karan D, 2003, INT J CANCER, V103, P285, DOI 10.1002/ijc.10813; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Labhart P, 1999, EUR J BIOCHEM, V265, P849, DOI 10.1046/j.1432-1327.1999.00805.x; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pierce AJ, 2001, MOL CELL, V8, P1160, DOI 10.1016/S1097-2765(01)00424-5; Raderschall E, 2002, CANCER RES, V62, P219; Reiss K, 1999, J CELL PHYSIOL, V181, P124, DOI 10.1002/(SICI)1097-4652(199910)181:1<124::AID-JCP13>3.0.CO;2-0; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Rodgers KJ, 2003, INT J BIOCHEM CELL B, V35, P716, DOI 10.1016/S1357-2725(02)00391-6; Schindewolf C, 2000, MAMM GENOME, V11, P552, DOI 10.1007/s003350010106; Schmutte C, 1999, CANCER RES, V59, P4564; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Sigurdsson S, 2002, J BIOL CHEM, V277, P42790, DOI 10.1074/jbc.M208004200; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Tombline G, 2002, J BIOL CHEM, V277, P14426, DOI 10.1074/jbc.M109916200; Tombline G, 2002, J BIOL CHEM, V277, P14417, DOI 10.1074/jbc.M109915200; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; Wozniak K, 2002, ACTA BIOCHIM POL, V49, P583; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Yeh CC, 2001, BIOCHEM BIOPH RES CO, V285, P409, DOI 10.1006/bbrc.2001.5187; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	52	16	16	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3748	3758		10.1038/sj.onc.1208537	http://dx.doi.org/10.1038/sj.onc.1208537			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782124				2022-12-25	WOS:000229346300006
J	Martin, ST; Matsubayashi, H; Rogers, CD; Philips, J; Couch, FJ; Brune, K; Yeo, CJ; Kern, SE; Hruban, RH; Goggins, M				Martin, ST; Matsubayashi, H; Rogers, CD; Philips, J; Couch, FJ; Brune, K; Yeo, CJ; Kern, SE; Hruban, RH; Goggins, M			Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer	ONCOGENE			English	Article						K3326X; BRCA2; familial pancreatic cancer	GERMLINE MUTATIONS; GENE-MUTATIONS; RISK	Germline BRCA2 mutations predispose to the development of pancreatic cancer. A polymorphic stop codon in the coding region of BRCA2 (K3326X) has been described, and although an initial epidemiological study suggested it was not disease causing, subsequent studies have been inconclusive. To investigate the biological significance of the K3326X polymorphism, we determined its prevalence in patients with sporadic and familial pancreatic cancer. Using a case-control design, we studied 250 patients with resected sporadic pancreatic adenocarcinomas, 144 patients with familial pancreatic adenocarcinoma, 115 spouses of patients with pancreatic cancer, and a disease control group of 135 patients without a personal history of cancer who had undergone cholecystectomy for non-neoplastic disease. The K3326X polymorphism was detected using heteroduplex analysis and DNA sequencing. The BRCA2 K3326X polymorphism was significantly more prevalent in individuals with familial pancreatic cancer: 8/144 (5.6%) vs 3/250 controls (1.2%)(odds ratio, 4.84; 95% CI, 1.27-18.55, P<0.01). One K3326X carrier with familial pancreatic cancer carried an alteration (IVS 16-2A>G) suspected to be deleterious. Excluding this case did not alter the significance of the association (OR:4.24, P<0.01). In contrast, there was no difference in prevalence among individuals with sporadic pancreatic cancer -7/250 (OR:2.37, 95% CI: 0.61-9.27). The increased prevalence of the BRCA2 K3326X polymorphism in patients with familial pancreatic cancer suggests that this polymorphism is deleterious and contributes to pancreatic cancer risk.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Mayo Clinic; Mayo Clinic; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu						Bartsch DK, 2002, ANN SURG, V236, P730, DOI 10.1097/00000658-200212000-00005; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Claes K, 2003, GENE CHROMOSOME CANC, V37, P314, DOI 10.1002/gcc.10221; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; Figer A, 2001, BRIT J CANCER, V84, P478, DOI 10.1054/bjoc.2000.1605; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; Goggins M, 1996, CANCER RES, V56, P5360; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; Hahn SA, 2003, JNCI-J NATL CANCER I, V95, P214, DOI 10.1093/jnci/95.3.214; Haraldsson K, 1998, CANCER RES, V58, P1367; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Klein AP, 2001, CANCER J, V7, P266; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Lim W, 2004, GASTROENTEROLOGY, V126, P1788, DOI 10.1053/j.gastro.2004.03.014; Lowenfels AB, 1997, J NATL CANCER I, V89, P442, DOI 10.1093/jnci/89.6.442; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; Lynch HT, 2000, GASTROENTEROLOGY, V119, P1756, DOI 10.1053/gast.2000.20335; Matsubayashi H, 2003, CANCER BIOL THER, V2, P652; Mazoyer S, 1996, NAT GENET, V14, P253, DOI 10.1038/ng1196-253; Morimatsu M, 1998, CANCER RES, V58, P3441; Murphy KM, 2002, CANCER RES, V62, P3789; NIEDERHUBER JE, 1995, CANCER, V76, P1671, DOI 10.1002/1097-0142(19951101)76:9<1671::AID-CNCR2820760926>3.0.CO;2-R; Ozcelik H, 1997, NAT GENET, V16, P17, DOI 10.1038/ng0597-17; Petersen GM, 2003, JNCI-J NATL CANCER I, V95, P180, DOI 10.1093/jnci/95.3.180; Rogers CD, 2004, CANCER BIOL THER, V3, P167, DOI 10.4161/cbt.3.2.609; van der Heijden MS, 2003, CANCER RES, V63, P2585; Vasen HFA, 2000, INT J CANCER, V87, P809, DOI 10.1002/1097-0215(20000915)87:6<809::AID-IJC8>3.3.CO;2-L; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; Yamamoto H, 2001, CANCER RES, V61, P3139; Yeo CJ, 1998, ANN SURG, V227, P821, DOI 10.1097/00000658-199806000-00005	30	61	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3652	3656		10.1038/sj.onc.1208411	http://dx.doi.org/10.1038/sj.onc.1208411			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15806175				2022-12-25	WOS:000229221800012
J	De Servi, B; Hermani, A; Medunjanin, S; Mayer, D				De Servi, B; Hermani, A; Medunjanin, S; Mayer, D			Impact of PKC delta on estrogen receptor localization and activity in breast cancer cells	ONCOGENE			English	Article						PKC delta; phorbol ester; estrogen receptor; GSK3; breast cancer	PROTEIN-KINASE-C; PHORBOL ESTER; CARCINOMA-CELLS; DOWN-REGULATION; MESSENGER-RNA; ESTRADIOL; MCF-7; ACTIVATION; PHOSPHORYLATION; ALPHA	Regulation of estrogen receptor (ER) function in breast cancer cells is a complex process involving different signalling mechanisms. One signal transduction component that appears to influence ER signalling is protein kinase C (PKC). PKC delta is a particular isoenzyme of the novel PKC subfamily that plays a role in growth control, differentiation and apoptosis. The aim of the present study was to investigate the impact of PKC delta on the regulation of the transcriptional activity of the human ER alpha. By using 12-O-tetradecanoylphorbol- 13-acetate (TPA), Bryostatin1 and Rottlerin, we show that active PKC delta is a proproliferative factor in estrogen-dependent breast cancer cells. Furthermore, activation of PKC delta by TPA resulted in activation and nuclear translocation of ER alpha and in an increase of ER-dependent reporter gene expression. Transfection and expression of the regulatory domain RD delta of PKC delta, which is inhibitory to PKC delta, inhibited the TPA-induced ER alpha activation and translocation. ER alpha was not phosphorylated by PKC delta; however, glycogen synthase kinase-3 (GSK3) was identified as a substrate of PKC delta. The expression of RD delta resulted in a decrease of TPA-induced GSK3 phosphorylation and translocation into the nucleus. We suggest that GSK3 plays a role in the PKC delta-related nuclear translocation of ER alpha.	Deutsch Krebsforschungszentrum, Hormones & Signal Transduct, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Mayer, D (corresponding author), Deutsch Krebsforschungszentrum, Hormones & Signal Transduct, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	d.mayer@dkfz-heidelberg.de						BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahooti H, 1998, J MOL ENDOCRINOL, V20, P245, DOI 10.1677/jme.0.0200245; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Le Bail JC, 1998, STEROIDS, V63, P678, DOI 10.1016/S0039-128X(98)00078-6; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Longo M, 2004, BONE, V34, P100, DOI 10.1016/j.bone.2003.09.007; Lorenzo PS, 1999, CANCER RES, V59, P6137; Maizels ET, 1996, MOL CELL ENDOCRINOL, V122, P213, DOI 10.1016/0303-7207(96)03885-3; Marino M, 2001, J CELL PHYSIOL, V188, P170, DOI 10.1002/jcp.1105; MARTIN MB, 1995, J BIOL CHEM, V270, P25244, DOI 10.1074/jbc.270.42.25244; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; McCracken MA, 2003, MOL CANCER THER, V2, P273; MIGLIACCIO A, 1993, ONCOGENE, V8, P2183; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; PARKER MG, 1993, ANN NY ACAD SCI, V684, P119, DOI 10.1111/j.1749-6632.1993.tb32276.x; REE AH, 1991, ENDOCRINOLOGY, V129, P339, DOI 10.1210/endo-129-1-339; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; SACEDA M, 1991, J BIOL CHEM, V266, P17809; Shanmugam M, 1999, MOL CELL ENDOCRINOL, V148, P109, DOI 10.1016/S0303-7207(98)00229-9; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; Tonetti DA, 2000, BRIT J CANCER, V83, P782, DOI 10.1054/bjoc.2000.1326; Tsujio I, 2000, FEBS LETT, V469, P111, DOI 10.1016/S0014-5793(00)01234-5; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; VALETTE A, 1987, CANCER RES, V47, P1615	47	34	34	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4946	4955		10.1038/sj.onc.1208676	http://dx.doi.org/10.1038/sj.onc.1208676			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15824731				2022-12-25	WOS:000230646500007
J	Das, S; Cho, J; Lambertz, I; Kelliher, MA; Eliopoulos, AG; Du, KY; Tsichlis, PN				Das, S; Cho, J; Lambertz, I; Kelliher, MA; Eliopoulos, AG; Du, KY; Tsichlis, PN			Tpl2/Cot signals activate ERK, JNK, and NF-kappa B in a cell-type and stimulus-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN KINASE RIP; TRANSCRIPTIONAL ACTIVITY; ESSENTIAL COMPONENT; INDUCED ARTHRITIS; DISTINCT ROLES; NUCLEAR-FACTOR; P65 SUBUNIT; MAP KINASE; ALPHA; TPL-2	Macrophages and B-cells from Tpl2 knock-out mice exhibit a restricted defect in lipopolysaccharide and death receptor signaling that is limited to the activation of ERK. Here we show that Tpl2(-/-) MEFs exhibit defects in ERK, JNK, and NF-kappa B activation, or ERK activation only when stimulated with tumor necrosis factor-alpha (TNF-alpha) or interleukin-1 beta, respectively. In addition, we show that the activation of Tpl2 by TNF-alpha depends on signals transduced by both TRAF2 and RIP1. Activated Tpl2 phosphorylates MKK4/SEK1 upstream of JNK and stimulates NF-kappa B DNA binding and transcriptional activity by mechanisms that are independent of the nuclear translocation of p50 and p65. Tpl2-transduced TNF-alpha signals instead promote the phosphorylation of p65 at Ser(276) and modulate the spectrum of proteins associated with p65. Phosphorylation stimulates the transcriptional activity of NF-kappa B but does not affect its ability to bind DNA, which may be affected by the composition of the nuclear NF-kappa B complexes. These data confirm that defects caused by a single mutation may be cell-type and signal-specific and delineate the role of Tpl2 in the transduction of TNF-alpha signals that activate JNK and NF-kappa B in MEFs.	Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Interdisciplinary Grad Program, Worcester, MA 01655 USA; Univ Birmingham, Sch Med, Canc Res Inst UK Canc Studies, Birmingham B15 2TA, W Midlands, England; Univ Birmingham, Sch Med, MRC, Ctr Immune Regulat, Birmingham B15 2TA, W Midlands, England	Tufts Medical Center; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Birmingham; University of Birmingham	Tsichlis, PN (corresponding author), Tufts Univ New England Med Ctr, Mol Oncol Res Inst, 750 WAshington St,Box 5609, Boston, MA 02111 USA.	ptsichlis@tufts-nemc.org	ELIOPOULOS, ARISTIDES/R-9449-2018; ELIOPOULOS, ARISTIDES/ABI-6632-2020	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761	NCI NIH HHS [R01 CA38047] Funding Source: Medline; NIGMS NIH HHS [R01 GM061298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Chung JY, 2002, J CELL SCI, V115, P679; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eliopoulos AG, 2003, EMBO J, V22, P3855, DOI 10.1093/emboj/cdg386; Eliopoulos AG, 2002, J VIROL, V76, P4567, DOI 10.1128/JVI.76.9.4567-4579.2002; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kontoyiannis D, 2002, J EXP MED, V196, P1563, DOI 10.1084/jem.20020281; Kontoyiannis D, 2000, ARTHRITIS RES, V2, P342, DOI 10.1186/ar109; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Molestina RE, 2003, J CELL SCI, V116, P4359, DOI 10.1242/jcs.00683; Mori L, 1996, J IMMUNOL, V157, P3178; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Palladino MA, 2003, NAT REV DRUG DISCOV, V2, P736, DOI 10.1038/nrd1175; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Plows D, 1999, J IMMUNOL, V162, P1018; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yamaguchi N, 2003, J RHEUMATOL, V30, P22; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	46	116	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23748	23757		10.1074/jbc.M412837200	http://dx.doi.org/10.1074/jbc.M412837200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15833743	hybrid			2022-12-25	WOS:000229880000044
J	Kiyokawa, E; Baba, T; Otsuka, N; Makino, A; Ohno, S; Kobayashi, T				Kiyokawa, E; Baba, T; Otsuka, N; Makino, A; Ohno, S; Kobayashi, T			Spatial and functional heterogeneity of sphingolipid-rich membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-KINASE-C; GPI-ANCHORED PROTEINS; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; BINDING-PROTEIN; LIPID RAFTS; PHOSPHOLIPASE C-GAMMA-1; LYSOPHOSPHATIDIC ACID; FLUORESCENT PROTEIN	Little is known about the organization of lipids in biomembranes. Lipid rafts are defined as sphingolipid- and cholesterol-rich clusters in the membrane. Details of the lipid distribution of lipid rafts are not well characterized mainly because of a lack of appropriate probes. Ganglioside GM1-specific protein, cholera toxin, has long been the only lipid probe of lipid rafts. Recently it was shown that earthworm toxin, lysenin, specifically recognizes sphingomyelin-rich membrane domains. Binding of lysenin to sphingomyelin is accompanied by the oligomerization of the toxin that leads to pore formation in the target membrane. In this study, we generated a truncated lysenin mutant that does not oligomerize and thus is non-toxic. Using this mutant lysenin, we showed that plasma membrane sphingomyelin-rich domains are spatially distinct from ganglioside GM1-rich membrane domains in Jurkat T cells. Like T cell receptor activation and cross-linking of GM1, cross-linking of sphingomyelin induced calcium influx and ERK phosphorylation in the cell. However, unlike CD3 or GM1, cross-linking of sphingomyelin did not induce significant protein tyrosine phosphorylation. Combination of lysenin and sphingomyelinase treatment suggested the involvement of G-protein-coupled receptor in sphingomyelin-mediated signal transduction. These results thus suggest that the sphingomyelin-rich domain provides a functional signal cascade platform that is distinct from those provided by T cell receptor or GM1. Our study therefore elucidates the spatial and functional heterogeneity of lipid rafts.	RIKEN, Wako, Saitama 3510198, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO, Kawaguchi, Saitama 3320012, Japan; Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Anat, Yamanashi 4093898, Japan; Inst Natl Sci Appl, INSERM, U585, F-69621 Villeurbanne, France	RIKEN; Japan Science & Technology Agency (JST); University of Yamanashi; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon	Kobayashi, T (corresponding author), Osaka Univ, Inst Res, Dept Tumor Virol, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	kobayasi@riken.jp	Kobayashi, Toshihide/B-6298-2015	Kobayashi, Toshihide/0000-0002-4811-7270				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Baba T, 1999, J HISTOCHEM CYTOCHEM, V47, P637, DOI 10.1177/002215549904700506; Balasubramanian K, 2003, ANNU REV PHYSIOL, V65, P701, DOI 10.1146/annurev.physiol.65.092101.142459; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CARMICHAEL J, 1987, CANCER RES, V47, P936; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Franklin RA, 2000, MOL IMMUNOL, V37, P675, DOI 10.1016/S0161-5890(00)00087-0; Gaus K, 2003, P NATL ACAD SCI USA, V100, P15554, DOI 10.1073/pnas.2534386100; Glebov OO, 2004, NAT CELL BIOL, V6, P238, DOI 10.1038/ncb1103; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; GOUY H, 1994, J IMMUNOL, V152, P3271; HAHNER L, 1991, FASEB J, V5, P2466, DOI 10.1096/fasebj.5.10.1648524; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Ishitsuka R, 2004, BIOPHYS J, V86, P296, DOI 10.1016/S0006-3495(04)74105-3; Ishitsuka Reiko, 2004, Anatomical Science International, V79, P184, DOI 10.1111/j.1447-073x.2004.00086.x; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kiyokawa E, 2004, BIOCHEMISTRY-US, V43, P9766, DOI 10.1021/bi049561j; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kobayashi T, 2000, MOL BIOL CELL, V11, P1829, DOI 10.1091/mbc.11.5.1829; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; KOBAYASHI T, 1992, NATURE, V359, P647, DOI 10.1038/359647a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Makino A, 2003, J BIOL CHEM, V278, P3204, DOI 10.1074/jbc.M210347200; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nakada C, 2003, NAT CELL BIOL, V5, P626, DOI 10.1038/ncb1009; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Parton RG, 2001, METHOD ENZYMOL, V333, P172; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; Sekizawa Y, 1997, GENE, V191, P97, DOI 10.1016/S0378-1119(97)00047-4; Shakor ABA, 2003, FEBS LETT, V542, P1, DOI 10.1016/S0014-5793(03)00330-2; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Subczynski WK, 2003, BBA-BIOMEMBRANES, V1610, P231, DOI 10.1016/S0005-2736(03)00021-X; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; VAN MEER G, 1982, EMBO J, V1, P847, DOI 10.1002/j.1460-2075.1982.tb01258.x; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wilson BS, 2004, MOL BIOL CELL, V15, P2580, DOI 10.1091/mbc.E03-08-0574; Winslow MM, 2003, CURR OPIN IMMUNOL, V15, P299, DOI 10.1016/S0952-7915(03)00050-5; Woodside DG, 2002, J BIOL CHEM, V277, P39401, DOI 10.1074/jbc.M207657200; Yamaji A, 1998, J BIOL CHEM, V273, P5300, DOI 10.1074/jbc.273.9.5300; Yamaji-Hasegawa A, 2003, J BIOL CHEM, V278, P22762, DOI 10.1074/jbc.M213209200; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	67	136	139	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24072	24084		10.1074/jbc.M502244200	http://dx.doi.org/10.1074/jbc.M502244200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15840575	hybrid			2022-12-25	WOS:000229880000081
J	Burstein, E; Hoberg, JE; Wilkinson, AS; Rumble, JM; Csomos, RA; Komarck, CM; Maine, GN; Wilkinson, JC; Mayo, MW; Duckett, CS				Burstein, E; Hoberg, JE; Wilkinson, AS; Rumble, JM; Csomos, RA; Komarck, CM; Maine, GN; Wilkinson, JC; Mayo, MW; Duckett, CS			COMMD proteins, a novel family of structural and functional homologs of MURR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; T-CELLS; GENE; TRANSCRIPTION; ALPHA; ACTIVATION; APOPTOSIS; BINDING; HIV; DNA	MURR1 is a multifunctional protein that inhibits nuclear factor kB (NF-kB), a transcription factor with pleiotropic functions affecting innate and adaptive immunity, apoptosis, cell cycle regulation, and oncogenesis. Here we report the discovery of a new family of proteins with homology to MURR1. These proteins form multimeric complexes and were identified in a biochemical screen for MURR1-associated factors. The family is defined by the presence of a conserved and unique motif termed the COMM ( copper metabolism gene MURR1) domain, which functions as an interface for protein-protein interactions. Like MURR1, several of these factors also associate with and inhibit NF-kB. The proteins designated as COMMD or COMM domain containing 1-10 are extensively conserved in multicellular eukaryotic organisms and define a novel family of structural and functional homologs of MURR1. The prototype of this family, MURR1/COMMD1, suppresses NF-kB not by affecting nuclear translocation or binding of NF-kB to cognate motifs; rather, it functions in the nucleus by affecting the association of NF-kB with chromatin.	Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Virginia, Dept Mol Genet & Biochem, Charlottesville, VA 22908 USA; Ann Arbor Vet Affairs MEd Ctr, Gastroenterol Sect, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Virginia; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Duckett, CS (corresponding author), Med Sci 1,Rm 5315,1301 Catherine, Ann Arbor, MI 48109 USA.	colind@umich.edu	Burstein, Ezra/B-7247-2016; Martinez, Octavio/B-7375-2009	Burstein, Ezra/0000-0003-4341-6367; Duckett, Colin/0000-0001-9413-2263	NCI NIH HHS [T32 CA 09676, R01 CA 104397, R01 CA 095644, K01 CA 78595] Funding Source: Medline; NIGMS NIH HHS [GM 067287] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676, R01CA095644, R01CA104397, K01CA078595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Burstein E, 2004, EMBO J, V23, P244, DOI 10.1038/sj.emboj.7600031; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Ganesh L, 2003, NATURE, V426, P853, DOI 10.1038/nature02171; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Greene WC, 2004, NAT IMMUNOL, V5, P18, DOI 10.1038/ni0104-18; HAUPT Y, 1992, MOL BIOL REP, V17, P17, DOI 10.1007/BF01006395; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Mir SS, 2000, BLOOD, V96, P4307; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nabetani A, 1997, MOL CELL BIOL, V17, P789, DOI 10.1128/MCB.17.2.789; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Richter BWM, 2001, MOL CELL BIOL, V21, P4292, DOI 10.1128/MCB.21.13.4292-4301.2001; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Schmid JA, 2000, J BIOL CHEM, V275, P17035, DOI 10.1074/jbc.M000291200; Semenova E, 2003, HUM MOL GENET, V12, P1301, DOI 10.1093/hmg/ddg140; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Solban N, 2000, J BIOL CHEM, V275, P32234, DOI 10.1074/jbc.M001352200; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tao TY, 2003, J BIOL CHEM, V278, P41593, DOI 10.1074/jbc.C300391200; van de Sluis B, 2002, HUM MOL GENET, V11, P165, DOI 10.1093/hmg/11.2.165; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	40	198	225	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22222	22232		10.1074/jbc.M501928200	http://dx.doi.org/10.1074/jbc.M501928200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15799966	hybrid			2022-12-25	WOS:000229557900068
J	Kane, LP; Watkins, SC				Kane, LP; Watkins, SC			Dynamic regulation of tec kinase localization in membraneproximal vesicles of a T cell clone revealed by total internal reflection fluorescence and confocal microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY TYROSINE KINASES; PLECKSTRIN HOMOLOGY DOMAIN; IMMUNE-SYSTEM; IMMUNOLOGICAL SYNAPSE; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION; ITK; ACTIVATION; PATHWAYS; 3-KINASE	Tec family tyrosine kinases are key regulators of lymphocyte activation and effector function. Several Tec family kinases ( Tec, Itk, Rlk/Txk) are expressed in T cells, but it is still not clear to what degree these are redundant or have unique functions. We recently demonstrated that Tec alone, among the Tec kinase family members examined, can induce nuclear factor of activated T cell-dependent transcription. This unique functional characteristic correlated with a unique pattern of subcellular localization, as Tec ( but not other family members) was found in small vesicles, the appearance of which requires signaling through the T cell receptor for antigen. Here we report on our studies of these Tec-containing structures in live T cells, using total internal reflection fluorescence microscopy. With this technique, we showed that, in live T cells, the Tec vesicles are located at the plasma membrane, the vesicles are unique to Tec ( and not the related kinase Itk), and their formation and maintenance require T cell receptor signaling through Src family kinases and PI 3-kinase. Finally, we have imaged isolated T cell membranes by confocal microscopy, confirming the membrane-proximal location of Tec vesicles, as well as demonstrating overlap of these vesicles with the tyrosine kinase Lck, the Tec substrate PLC-gamma 1, and the early endosomal antigen 1 marker EEA1.	Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kane, LP (corresponding author), Univ Pittsburgh, Dept Immunol, BST E-1056, Pittsburgh, PA 15261 USA.	lkane@pitt.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552; Kane, Lawrence/0000-0001-5198-516X	NATIONAL CANCER INSTITUTE [P01CA073743] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 73743] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcover A, 2000, CRIT REV IMMUNOL, V20, P325; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Astoul E, 2001, TRENDS IMMUNOL, V22, P490, DOI 10.1016/S1471-4906(01)01973-1; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Das V, 2004, IMMUNITY, V20, P577, DOI 10.1016/S1074-7613(04)00106-2; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; Garcon F, 2004, EUR J IMMUNOL, V34, P1972, DOI 10.1002/eji.200324777; Garcon F, 2004, J IMMUNOL, V173, P770, DOI 10.4049/jimmunol.173.2.770; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kane LP, 2004, J IMMUNOL, V172, P5441, DOI 10.4049/jimmunol.172.9.5441; Kashiwakura J, 1999, J EXP MED, V190, P1147, DOI 10.1084/jem.190.8.1147; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Keyel PA, 2004, J BIOL CHEM, V279, P13190, DOI 10.1074/jbc.M312717200; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lewis CM, 2001, CURR OPIN IMMUNOL, V13, P317, DOI 10.1016/S0952-7915(00)00221-1; Lucas JA, 2003, IMMUNOL REV, V191, P119, DOI 10.1034/j.1600-065X.2003.00029.x; Miller AT, 2002, CURR OPIN IMMUNOL, V14, P331, DOI 10.1016/S0952-7915(02)00345-X; Miller AT, 2004, IMMUNITY, V21, P67, DOI 10.1016/j.immuni.2004.06.009; Schwartzberg PL, 2003, IMMUNOL RES, V27, P481, DOI 10.1385/IR:27:2-3:481; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Stefanova I, 2003, NAT IMMUNOL, V4, P248, DOI 10.1038/ni895; Takeno M, 2004, CLIN EXP ALLERGY, V34, P965, DOI 10.1111/j.1365-2222.2004.01981.x; Takesono A, 2002, J CELL SCI, V115, P3039; Tomlinson MG, 2004, J BIOL CHEM, V279, P55089, DOI 10.1074/jbc.M408141200; Tomlinson MG, 2004, MOL CELL BIOL, V24, P2455, DOI 10.1128/MCB.24.6.2455-2466.2004; Tomlinson MG, 1999, J BIOL CHEM, V274, P13577, DOI 10.1074/jbc.274.19.13577; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Yang WC, 2000, INT IMMUNOL, V12, P1547, DOI 10.1093/intimm/12.11.1547; Yang WC, 2001, J IMMUNOL, V166, P387, DOI 10.4049/jimmunol.166.1.387; Yang WC, 1999, EUR J IMMUNOL, V29, P1842, DOI 10.1002/(SICI)1521-4141(199906)29:06<1842::AID-IMMU1842>3.0.CO;2-D; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223	37	7	9	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21949	21954		10.1074/jbc.M412913200	http://dx.doi.org/10.1074/jbc.M412913200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817477	hybrid			2022-12-25	WOS:000229557900036
J	Majerus, EM; Anderson, PJ; Sadler, JE				Majerus, EM; Anderson, PJ; Sadler, JE			Binding of ADAMTS13 to von Willebrand factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; FACTOR-CLEAVING PROTEASE; FACTOR MULTIMERS; SPACER DOMAIN; CLEAVAGE; PROTEOLYSIS; SURFACE; PLASMA; FAMILY; AGGRECANASE-1	ADAMTS13, a metalloprotease, cleaves von Willebrand factor (VWF) in plasma to generate smaller, less thrombogenic fragments. The interaction of von Willebrand factor with specific ADAMTS13 domains was characterized with a binding assay employing von Willebrand factor immobilized on a plastic surface. ADAMTS13 binding was saturable and reversible. Equilibrium binding occurred within 2 h and the half-time for dissociation was similar to 4 h. Binding to von Willebrand factor was similar with either recombinant ADAMTS13 or normal plasma ADAMTS13; plasma from a patient who lacked ADAMTS13 activity showed no binding. The stoichiometry of binding was one ADAMTS13 per two von Willebrand factor monomers, and the K-d was 14 nM. The ADAMTS13 metalloprotease and disintegrin domains did not bind VWF detectably. ADAMTS13 truncated after the first thrombospondin type 1 repeat bound VWF with a K-d of 206 nM, whereas ADAMTS13 truncated after the spacer domain had a K-d of 23 nM, which is comparable with that of full-length ADAMTS13. Truncation after the eighth thrombospondin type 1 repeat reduced the binding affinity by similar to 3-fold and truncation after the seventh thrombospondin type 1 repeat in addition to the CUB domains increased the affinity for von Willebrand factor by similar to 2-fold. Therefore, the spacer domain is required for ADAMTS13 binding to von Willebrand factor. The first thrombospondin repeat also affects binding, and the C-terminal thrombospondin type 1 and CUB domains of ADAMTS13 may modulate this interaction.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Sadler, JE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.	esadler@im.wustl	Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X	NHLBI NIH HHS [HL 72917] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072917] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Dong JF, 2003, J BIOL CHEM, V278, P29633, DOI 10.1074/jbc.M301385200; Dong JF, 2002, BLOOD, V100, P4033, DOI 10.1182/blood-2002-05-1401; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Furian M, 1999, THROMB HAEMOSTASIS, V82, P592; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; Hartigan N, 2003, J BIOL CHEM, V278, P18045, DOI 10.1074/jbc.M211448200; Klaus C, 2004, BLOOD, V103, P4514, DOI 10.1182/blood-2003-12-4165; Kokame K, 2004, BLOOD, V103, P607, DOI 10.1182/blood-2003-08-2861; Kristiansen M, 1999, J BIOL CHEM, V274, P20540, DOI 10.1074/jbc.274.29.20540; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Luken BM, 2005, THROMB HAEMOSTASIS, V93, P267, DOI 10.1160/TH04-05-0301; Moake JL, 2002, NEW ENGL J MED, V347, P589, DOI 10.1056/NEJMra020528; Nishio K, 2004, P NATL ACAD SCI USA, V101, P10578, DOI 10.1073/pnas.0402041101; Padilla A, 2004, BLOOD, V103, P2150, DOI 10.1182/blood-2003-08-2956; Raghavachari M, 2000, COLLOID SURFACE B, V19, P315, DOI 10.1016/S0927-7765(00)00140-5; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Sadler JE, 2002, P NATL ACAD SCI USA, V99, P11552, DOI 10.1073/pnas.192448999; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Soejima K, 2001, J BIOCHEM-TOKYO, V130, P475, DOI 10.1093/oxfordjournals.jbchem.a003009; Soejima K, 2003, BLOOD, V102, P3232, DOI 10.1182/blood-2003-03-0908; STECK TL, 1965, BIOCHIM BIOPHYS ACTA, V97, P510; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TSAI HM, 1994, BLOOD, V83, P2171; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; Vankemmelbeke MN, 2001, EUR J BIOCHEM, V268, P1259, DOI 10.1046/j.1432-1327.2001.01990.x; Zhang WR, 2004, BLOOD, V104, p39A; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200	36	95	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21773	21778		10.1074/jbc.M502529200	http://dx.doi.org/10.1074/jbc.M502529200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824096	hybrid			2022-12-25	WOS:000229557900014
J	Parakati, R; DiMario, JX				Parakati, R; DiMario, JX			Dynamic transcriptional regulatory complexes, including E2F4, p107, p130, and Sp1, control fibroblast growth factor receptor 1 gene expression during myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CELLS; HISTONE DEACETYLASE; CHROMATIN IMMUNOPRECIPITATION; NEURONAL DIFFERENTIATION; REPRESS TRANSCRIPTION; IN-VIVO; CYCLE; PROTEIN; FAMILY; PRB	Developmentally controlled transcriptional regulation of myogenic cell proliferation and differentiation via expression of the fibroblast growth factor receptor 1 (FGFR1) gene is positively regulated by Sp1 and negatively regulated by E2F4-based transcriptional complexes. We report that p107 and p130 formed transcriptional complexes with E2F4 on the FGFR1 promoter and repressed FGFR1 gene transcription in myogenic cells. However, in Drosophila melanogaster SL2 cells, only p107 was able to repress Sp1-mediated transactivation of the FGFR1 promoter. Gel shift assays using transfected myoblast nuclear extracts showed that ectopic p107 reduced Sp1 occupancy of the proximal Sp binding site of the FGFR1 promoter, and coimmunoprecipitation studies indicated that Sp1 interacts with p107 but not with p130. Gel shift assays also demonstrated that Sp1 interacted with p107 in E2F4-p107 transcriptional complexes in myoblasts. The nature of the repressor transcriptional complex was altered in differentiated muscle fibers by the relative loss of the E2F4-p107-Sp1 transcription complex and replacement by the repressor E2F4-p130 complex. These findings demonstrate that activation and repression of FGFR1 gene transcription is governed by interplay between Sp1, p107, p130, and E2F4 in distinct transcriptional complexes during skeletal muscle development.	Univ Chicago, Sch Med, Dept Cell Biol & Anat, N Chicago, IL 60064 USA	University of Chicago	DiMario, JX (corresponding author), Univ Chicago, Sch Med, Dept Cell Biol & Anat, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	joseph.dimario@rosalindfranklin.edu						Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; Chang YC, 2001, MOL CELL BIOL, V21, P1121, DOI 10.1128/MCB.21.4.1121-1131.2001; CORBEIL HB, 1995, ONCOGENE, V11, P909; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIMARIO JX, 1995, EXP CELL RES, V216, P431, DOI 10.1006/excr.1995.1054; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Flanagan-Steet H, 2000, DEV BIOL, V218, P21, DOI 10.1006/dbio.1999.9535; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Huet X, 1996, MOL CELL BIOL, V16, P3789; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Itoh N, 1996, DEVELOPMENT, V122, P291; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lavrrar JL, 2004, J BIOL CHEM, V279, P46343, DOI 10.1074/jbc.M402692200; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; ONEILL MC, 1972, J CELL BIOL, V52, P52, DOI 10.1083/jcb.52.1.52; Parakati R, 2005, DEV DYNAM, V232, P119, DOI 10.1002/dvdy.20214; Parakati R, 2002, J BIOL CHEM, V277, P9278, DOI 10.1074/jbc.M108411200; Patel SG, 2001, GENE, V270, P171, DOI 10.1016/S0378-1119(01)00478-4; Patel SG, 1999, GENE, V237, P265, DOI 10.1016/S0378-1119(99)00278-4; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Sambrook J., 2002, MOL CLONING LAB MANU; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001	46	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21284	21294		10.1074/jbc.M410744200	http://dx.doi.org/10.1074/jbc.M410744200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15811856	hybrid			2022-12-25	WOS:000229438800047
J	Xiao, RY; Lundstrom-Ljung, J; Holmgren, A; Gilbert, HF				Xiao, RY; Lundstrom-Ljung, J; Holmgren, A; Gilbert, HF			Catalysis of thiol/disulfide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; THIOREDOXIN-LIKE DOMAINS; ESCHERICHIA-COLI; ACTIVE-SITE; RIBONUCLEASE-A; MIXED DISULFIDE; BOND FORMATION; GLUTAREDOXIN; ISOMERIZATION; GLUTATHIONE	Glutaredoxin (Grx) and protein-disulfide isomerase (PDI) are members of the thioredoxin superfamily of thiol/disulfide exchange catalysts. Thermodynamically, rat PDI is a 600-fold better oxidizing agent than Grx1 from Escherichia coli. Despite that, Grx1 is a surprisingly good protein oxidase. It catalyzes protein disulfide formation in a redox buffer with an initial velocity that is 30-fold faster than PDI. Catalysis of protein and peptide oxidation by the individual catalytic domains of PDI and by a Grx1-PDI chimera show that differences in active site chemistry are fundamental to their oxidase activity. Mutations in the active site cysteines reveal that Grx1 needs only one cysteine to catalyze rapid substrate oxidation, whereas PDI requires both cysteines. Grx1 is a good oxidase because of the high reactivity of a Grx1-glutathione mixed disulfide, and PDI is a good oxidase because of the high reactivity of the disulfide between the two active site cysteines. As a protein disulfide reductase, Grx1 is also superior to PDI. It catalyzes the reduction of nonnative disulfides in scrambled ribonuclease and protein-glutathione mixed disulfides 30-180 times faster than PDI. A multidomain structure is necessary for PDI to catalyze effective protein reduction; however, placing Grx1 into the PDI multidomain structure does not enhance its already high reductase activity. Grx1 and PDI have both found mechanisms to enhance active site reactivity toward proteins, particularly in the kinetically difficult direction: Grx1 by providing a reactive glutathione mixed disulfide to supplement its oxidase activity and PDI by utilizing its multidomain structure to supplement its reductase activity.	Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, Stockholm, Sweden	Baylor College of Medicine; Karolinska Institutet	Gilbert, HF (corresponding author), Baylor Coll Med, Dept Biochem, 1 Baylor Pl, Houston, TX 77030 USA.	hgilbert@bcm.tmc.edu			NIGMS NIH HHS [GM-40379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; ASLUND F, 1996, GLUTAREDOXINS STRUCT; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; Foloppe N, 2004, STRUCTURE, V12, P289, DOI 10.1016/j.str.2004.01.009; Foloppe N, 2001, J MOL BIOL, V310, P449, DOI 10.1006/jmbi.2001.4767; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; JENG MF, 1995, BIOCHEMISTRY-US, V34, P10101, DOI 10.1021/bi00032a001; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kortemme T, 1996, BIOCHEMISTRY-US, V35, P14503, DOI 10.1021/bi9617724; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; Lundstrom-Ljung J, 1999, FEBS LETT, V443, P85, DOI 10.1016/S0014-5793(98)01698-6; LUNDSTROMLJUNG J, 1995, J BIOL CHEM, V270, P7822, DOI 10.1074/jbc.270.14.7822; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; Marino G, 2000, METH MOL B, V160, P227; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P8883, DOI 10.1021/bi00100a023; Nordstrand K, 1999, FEBS LETT, V449, P196, DOI 10.1016/S0014-5793(99)00401-9; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Ruoppolo M, 1997, BIOCHEMISTRY-US, V36, P12259, DOI 10.1021/bi970851s; Sahlin L, 2000, MOL HUM REPROD, V6, P1147, DOI 10.1093/molehr/6.12.1147; Schwaller M, 2003, J BIOL CHEM, V278, P7154, DOI 10.1074/jbc.M211036200; Solovyov A, 2004, J BIOL CHEM, V279, P34095, DOI 10.1074/jbc.M405640200; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; WILSON JM, 1977, J AM CHEM SOC, V99, P7922, DOI 10.1021/ja00466a027; Xiao R, 2001, J BIOL CHEM, V276, P27975, DOI 10.1074/jbc.M104203200; YANG YF, 1991, J BIOL CHEM, V266, P12759	43	49	56	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21099	21106		10.1074/jbc.M411476200	http://dx.doi.org/10.1074/jbc.M411476200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15814611	hybrid			2022-12-25	WOS:000229438800025
J	Jiang, H; Luo, SQ; Li, HL				Jiang, H; Luo, SQ; Li, HL			Cdk5 activator-binding protein C53 regulates apoptosis induced by genotoxic stress via modulating the G(2)/M DNA damage checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; NUCLEAR-LOCALIZATION; P34(CDC2) KINASE; CELL-CYCLE; B1; PHOSPHORYLATION; MECHANISMS; PATHWAY; CDC25C; EXPORT	In response to DNA damage, the cellular decision of life versus death involves an intricate network of multiple factors that play critical roles in regulation of DNA repair, cell cycle, and cell death. DNA damage checkpoint proteins are crucial for maintaining DNA integrity and normal cellular functions, but they may also reduce the effectiveness of cancer treatment. Here we report the involvement of Cdk5 activator p35-binding protein C53 in regulation of apoptosis induced by genotoxic stress through modulating Cdk1-cyclin B1 function. C53 was originally identified as a Cdk5 activator p35-binding protein and a caspase substrate. Importantly, our results demonstrated that C53 deficiency conferred partial resistance to genotoxic agents such as etoposide and x-ray irradiation, whereas ectopic expression of C53 rendered cells susceptible to multiple genotoxins that usually trigger G(2)/M arrest. Furthermore, we found that Cdk1 activity was required for etoposide-induced apoptosis of HeLa cells. Overexpression of C53 promoted Cdk1 activity and nuclear accumulation of cyclin B1, whereas C53 deficiency led to more cytoplasmic retention of cyclin B1, suggesting that C53 acts as a pivotal player in modulating the G(2)/M DNA damage checkpoint. Finally, C53 and cyclin B1 co-localize and associate in vivo, indicating a direct role of C53 in regulating the Cdk1-cyclin B1 complex. Taken together, our results strongly indicate that in response to genotoxic stress, C53 serves as an important regulatory component of the G(2)/M DNA damage checkpoint. By overriding the G(2)/M checkpoint-mediated inhibition of Cdk1-cyclin B1 function, ectopic expression of C53 may represent a novel approach for chemo- and radio-sensitization of cancer cells.	Northwestern Univ, Childrens Mem Res Ctr, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60614 USA; Northwestern Univ, IGP Grad Program, Chicago, IL 60614 USA; Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge CB2 2XY, England	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Cambridge	Li, HL (corresponding author), Northwestern Univ, Childrens Mem Res Ctr, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, 2430 N Halsted St, Chicago, IL 60614 USA.	h-li2@northwestern.edu		jiang, hai/0000-0002-2508-5413				Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Ching YP, 2000, GENE, V242, P285, DOI 10.1016/S0378-1119(99)00499-0; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Erenpreisa Jekaterina, 2001, Cancer Cell Int, V1, P1, DOI 10.1186/1475-2867-1-1; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Okada S., 1970, RAD BIOCH, VI; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Porter LA, 2003, BLOOD, V101, P1928, DOI 10.1182/blood-2002-04-1103; Porter LA, 2000, BLOOD, V95, P2645; Porter Lisa A, 2003, Prog Cell Cycle Res, V5, P335; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	28	61	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20651	20659		10.1074/jbc.M413431200	http://dx.doi.org/10.1074/jbc.M413431200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15790566	hybrid			2022-12-25	WOS:000229242000062
J	Zhou, YG; Kanner, BI				Zhou, YG; Kanner, BI			Transporter-associated currents in the gamma-aminobutyric acid transporter GAT-1 are conditionally impaired by mutations of a conserved glycine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CL-COTRANSPORT FUNCTION; OOCYTE-MEMBRANE-PATCHES; TRANSMEMBRANE DOMAIN-I; CONFORMATIONAL-CHANGES; SCANNING MUTAGENESIS; XENOPUS OOCYTES; NEUROTRANSMITTER; SODIUM; EXPRESSION; STATES	To determine whether glycine residues play a role in the conformational changes during neurotransmitter transport, we have analyzed site-directed mutants of the gamma-aminobutyric acid ( GABA) transporter GAT-1 in a domain containing three consecutive glycines conserved throughout the sodium- and chloride-dependent neurotransmitter transporter family. Only cysteine replacement of glycine 80 resulted in the complete loss of [H-3] GABA uptake, but oocytes expressing this mutant exhibited the sodium- dependent transient currents thought to reflect a charge-moving conformational change. When sodium was removed and subsequently added back, the transients by G80C did not recover, as opposed to wild type, where recovery was almost complete. Remarkably, the transients by G80C could be restored after exposure of the oocytes to either GABA or a depolarizing pre-pulse. These treatments also resulted in a full recovery of the transients by the wild type. Whereas in wild type lithium leak currents are observed after prior sodium depletion, this was not the case for the glycine 80 mutants unless GABA was added or the oocytes were subjected to a depolarizing pre-pulse. Thus, glycine 80 appears essential for conformational transitions in GAT-1. When this residue is mutated, removal of sodium results in "freezing" the transporter in one conformation from which it can only exit by compensatory changes induced by GABA or depolarization. Our results can be explained by a model invoking two outward-facing states of the empty transporter and a defective transition between these states in the glycine 80 mutants.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.	kannerb@cc.huji.ac.il						Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Kanner BI, 2003, J BIOL CHEM, V278, P3705, DOI 10.1074/jbc.M210525200; KANNER BI, 1994, J EXP BIOL, V196, P237; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Larsson HP, 2004, P NATL ACAD SCI USA, V101, P3951, DOI 10.1073/pnas.0306737101; Loo DDF, 2000, J BIOL CHEM, V275, P37414, DOI 10.1074/jbc.M007241200; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; Lu CC, 1999, J GEN PHYSIOL, V114, P445, DOI 10.1085/jgp.114.3.445; MABJEESH NJ, 1993, BIOCHEMISTRY-US, V32, P8540, DOI 10.1021/bi00084a021; MacAulay N, 2002, J PHYSIOL-LONDON, V544, P447, DOI 10.1113/jphysiol.2002.022897; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Nelson N, 1998, J NEUROCHEM, V71, P1785; Weinglass AB, 2001, BIOCHEMISTRY-US, V40, P769, DOI 10.1021/bi002171m; Zhou YG, 2004, J BIOL CHEM, V279, P13800, DOI 10.1074/jbc.M311579200; Zomot E, 2003, J BIOL CHEM, V278, P42950, DOI 10.1074/jbc.M209307200	25	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20316	20324		10.1074/jbc.M412937200	http://dx.doi.org/10.1074/jbc.M412937200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15784623	hybrid			2022-12-25	WOS:000229242000021
J	Follows, GA; Tagoh, H; Richards, SJ; Melnik, S; Dickinson, H; de Wynter, E; Lefevre, P; Morgan, GJ; Bonifer, C				Follows, GA; Tagoh, H; Richards, SJ; Melnik, S; Dickinson, H; de Wynter, E; Lefevre, P; Morgan, GJ; Bonifer, C			c-FMS chromatin structure and expression in normal and leukaemic myelopoiesis	ONCOGENE			English	Article						c-FMS; AML; myelopoiesis; AML1-ETO	ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR; RECEPTOR; GENE; LOCUS; ONCOGENE; BINDING; CSF1R	The macrophage colony-stimulating factor receptor is encoded by the c-FMS gene, and it has been suggested that altered regulation of c-FMS expression may contribute to leukaemic transformation. c-FMS is expressed in pluripotent haemopoietic precursor cells and is subsequently upregulated during monocytic differentiation, but downregulated during granulopoiesis. We have examined transcription factor occupancy and aspects of chromatin structure of the critical c-FMS regulatory element located within the second intron (FIRE-fms intonic regulatory element) during normal and leukaemic myelopoiesis. Granulocytic differentiation from normal and leukaemic precursors is accompanied by loss of transcription factors at FIRE and downregulated c-FMS expression. The presence of AML1-ETO in leukaemic cells does not prevent this disassembly. In nonleukaemic cells, granulocytic differentiation is accompanied by reversal to a chromatin. ne structure characteristic of c-FMS-nonexpressing cells. In addition, we show that low-level expression of the gene in leukaemic blast cells and granulocytes does not associate with increased CpG methylation across the c-FMS locus.	St James Univ Hosp, Mol Med Unit, Leeds, W Yorkshire, England; Leeds Gen Infirm, Acad Unit Haematol & Oncol, Leeds, W Yorkshire, England; St James Univ Hosp, Dept Cytogenet, Leeds, W Yorkshire, England	Saint James's University Hospital; University of Leeds; Leeds General Infirmary; University of Leeds; Saint James's University Hospital	Follows, GA (corresponding author), Cambridge Inst Med Res, Dept Haematol, Hills Rd, Cambridge, England.	gf246@cam.ac.uk	Bonifer, Constanze/B-3000-2009; Tagoh, Hiromi/B-2954-2009	Tagoh, Hiromi/0000-0001-9905-6992; morgan, gareth/0000-0002-4271-6360; Richards, Stephen/0000-0002-8421-5353; Melnik, Svitlana/0000-0001-7227-3321; Bonifer, Constanze/0000-0002-4267-0825	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; BOULTWOOD J, 1991, P NATL ACAD SCI USA, V88, P6176, DOI 10.1073/pnas.88.14.6176; Casas S, 2003, LEUKEMIA LYMPHOMA, V44, P1935, DOI 10.1080/1042819031000119299; CHEN HH, 2001, SCI STKE, pPL1; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Debernardi S, 2003, GENE CHROMOSOME CANC, V37, P149, DOI 10.1002/gcc.10198; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Follows GA, 2003, NUCLEIC ACIDS RES, V31, P5805, DOI 10.1093/nar/gkg804; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Himes SR, 2001, J LEUKOCYTE BIOL, V70, P812; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Kontaraki J, 2000, GENE DEV, V14, P2106; Lichtenberger C, 1999, J IMMUNOL METHODS, V227, P75, DOI 10.1016/S0022-1759(99)00076-9; McGlynn H, 1997, LEUKEMIA RES, V21, P919, DOI 10.1016/S0145-2126(97)00024-6; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPRINGALL F, 1993, LEUKEMIA, V7, P978; Tagoh H, 2004, EMBO J, V23, P4275, DOI 10.1038/sj.emboj.7600421; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002	27	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3643	3651		10.1038/sj.onc.1208655	http://dx.doi.org/10.1038/sj.onc.1208655			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15806141				2022-12-25	WOS:000229221800011
J	Fujimoto, E; Sato, H; Shirai, S; Nagashima, Y; Fukumoto, K; Hagiwara, H; Negishi, E; Ueno, K; Omori, Y; Yamasaki, H; Hagiwara, K; Yano, T				Fujimoto, E; Sato, H; Shirai, S; Nagashima, Y; Fukumoto, K; Hagiwara, H; Negishi, E; Ueno, K; Omori, Y; Yamasaki, H; Hagiwara, K; Yano, T			Connexin32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line	ONCOGENE			English	Article						connexin32; tumor suppressor gene; Src; VEGF; metastatic renal cell carcinoma	JUNCTIONAL INTERCELLULAR COMMUNICATION; ENDOTHELIAL GROWTH-FACTOR; MOLECULAR TARGETS; KINASE-ACTIVITY; HEPG2 CELL; EXPRESSION; GAP; PHENOTYPE; CANCER; MOUSE	Connexin genes expressing gap junction proteins have tumor-suppressive effects on primary cancers with certain cell specificity, but the suppressive effects on metastatic cancers are still conflicting. In this study, we show that connexin32 (Cx32) has a strong tumor-suppressive effect on a human metastatic renal cell carcinoma cell line (Caki-1 cell). Cx32 expression in Caki-1 cells reduced in vitro malignant phenotypes of the cells such as anchorage independency and invasion capacity. Furthermore, the Cx32 expression drastically reduced the development of Caki-1 cells in nude mice. We also determined that Cx32 reduced the malignant phenotypes in Caki-1 cells mainly through the inactivation of Src signaling. Especially, Cx32-dependent inactivation of Src decreased the production of vascular epithelial growth factor (VEGF) via the suppression of signal transducers and activators of transcription 3 (Stat3) activation, and we confirmed this result using short interfering RNA. In nude mice, Cx32-transfected Caki-1 cells showed lower serum level of VEGF comparing mock transfectant, and the development of the cells in nude mice positively related to the VEGF level. These data suggest that Cx32 acts as a tumor suppressor gene in Caki-1 cells and that the tumor suppressive effect partly depends on the inhibition of Src-Stat3-VEGF signal pathway.	Natl Inst Hlth & Nutr, Dept Food Sci Res Hlth, Shinjuku Ku, Tokyo 1628636, Japan; Chiba Univ, Fac Pharmaceut Sci, Chiba 2608675, Japan; Yokohama City Univ, Sch Med, Dept Pathol, Kanagawa 2360004, Japan; Japan Human Sci Fdn, Chuo Ku, Tokyo 1030001, Japan; Akita Univ, Sch Med, Dept Pathol, Akita 0108543, Japan; Kwansei Gakuin Univ, Fac Sci & Technol, Sanda, Hyogo 6691337, Japan	National Institute of Health & Nutrition - Japan; Chiba University; Yokohama City University; Akita University; Kwansei Gakuin University	Yano, T (corresponding author), Natl Inst Hlth & Nutr, Dept Food Sci Res Hlth, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628636, Japan.	yano@nih.go.jp	Nagashima, Yoji/AAA-2591-2021; Yano, Tomohiro/J-2166-2016	Yano, Tomohiro/0000-0002-9490-3424; Sato, Hiromi/0000-0001-8815-4829				BOND SL, 1994, CELL GROWTH DIFFER, V5, P179; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; FITZGERALD DJ, 1990, TERATOGEN CARCIN MUT, V10, P89; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Fujimoto E, 2004, MOL CARCINOGEN, V40, P135, DOI 10.1002/mc.20025; Genda T, 2000, LAB INVEST, V80, P387, DOI 10.1038/labinvest.3780043; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; Grunstein J, 1999, CANCER RES, V59, P1592; Hirai A, 2003, AM J NEPHROL, V23, P172, DOI 10.1159/000070653; HOLDER JW, 1993, CANCER RES, V53, P3475; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; KORHONEN M, 1994, CANCER RES, V54, P4532; Laird AD, 2003, MOL CANCER THER, V2, P461; Mareel MM, 1997, ENCY CANC, V2, P1072; Martyn KD, 1997, CELL GROWTH DIFFER, V8, P1015; Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4; Motzer RJ, 2000, J UROLOGY, V163, P408, DOI 10.1016/S0022-5347(05)67889-5; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; NICOLSON GL, 1988, P NATL ACAD SCI USA, V85, P473, DOI 10.1073/pnas.85.2.473; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Omori Y, 1999, CARCINOGENESIS, V20, P1913, DOI 10.1093/carcin/20.10.1913; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; Rae RS, 1998, MOL CARCINOGEN, V22, P120, DOI 10.1002/(SICI)1098-2744(199806)22:2<120::AID-MC7>3.0.CO;2-Q; Ren ZY, 2002, J BIOL CHEM, V277, P38486, DOI 10.1074/jbc.M112438200; SIMPSON I, 1977, SCIENCE, V195, P294, DOI 10.1126/science.831276; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; TROSKO JE, 1993, LIFE SCI, V53, P1, DOI 10.1016/0024-3205(93)90606-4; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Yano T, 2003, KIDNEY INT, V63, P381, DOI 10.1046/j.1523-1755.2003.00745.x; Yano T, 2001, MOL CARCINOGEN, V31, P101, DOI 10.1002/mc.1045; Yano T, 2001, CARCINOGENESIS, V22, P1593, DOI 10.1093/carcin/22.10.1593; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	41	47	54	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3684	3690		10.1038/sj.onc.1208430	http://dx.doi.org/10.1038/sj.onc.1208430			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782139	Bronze			2022-12-25	WOS:000229221800016
J	Aziz, MH; Reagan-Shaw, S; Wu, JQ; Longley, BJ; Ahmad, N				Aziz, MH; Reagan-Shaw, S; Wu, JQ; Longley, BJ; Ahmad, N			Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease?	FASEB JOURNAL			English	Article						ultraviolet; photocarcinogenesis; Survivin	CELL-CYCLE; APOPTOSIS INHIBITOR; HUMAN KERATINOCYTES; ACTINIC KERATOSIS; GREEN TEA; RED WINE; IN-VIVO; SURVIVIN; EXPRESSION; PHOTOCARCINOGENESIS	According to the World Cancer Report, skin cancer constitutes similar to 30% of all newly diagnosed cancers in the world, and solar ultraviolet (UV) radiation (particularly, its UVB component; 290-320 nm) is an established cause of similar to 90% of skin cancers. The available options have proven to be inadequate for the management of skin cancers. Therefore, there is an urgent need to develop mechanism-based novel approaches for prevention/therapy of skin cancer. In this study, we evaluated the chemopreventive effects of resveratrol against UVB radiation-mediated skin tumorigenesis in the SKH-1 hairless mouse model. For our studies, we used a UVB initiation-promotion protocol in which the control mice were subjected to chronic UVB exposure (180 mJ/cm(2), twice weekly, for 28 weeks). The experimental animals received either a pretreatment (30 min before each UVB) or post-treatment (5 min after UVB) of resveratrol (25 or 50 micro mole/0.2 ml acetone/mouse). The mice were followed for skin tumorigenesis and were killed at 24 h after the last UVB exposure, for further studies. The topical application of skin with resveratrol (both pre- and post- treatment) resulted in a highly significant 1) inhibition in tumor incidence, and 2) delay in the onset of tumorigenesis. Interestingly, the post-treatment of resveratrol was found to impart equal protection than the pretreatment; suggesting that resveratrol-mediated responses may not be sunscreen effects. Because Survivin is a critical regulator of survival/death of cells, and its overexpression has been implicated in several cancers, we evaluated its involvement in chemoprevention of UVB-mediated skin carcinogenesis by resveratrol. Our data demonstrated a significant 1) up-regulation of Survivin (both at protein- and mRNA- levels), 2) up-regulation of phospho-Survivin protein, and 3) down-regulation of proapoptotic Smac/DIABLO protein in skin tumors; whereas treatment with resveratrol resulted in the attenuation of these responses. Our study also suggests that resveratrol enhanced apoptosis in UVB-exposure-mediated skin tumors. Our study, for the first time, demonstrated that 1) resveratrol imparts strong chemopreventive effects against UVB exposure-mediated skin carcinogenesis (relevant to human skin cancers), and 2) the chemopreventive effects of resveratrol may, at least in part, be mediated via modulations in Survivin and other associated events. On the basis of our work, it is conceivable to design resveratrol-containing emollient or patch, as well as sunscreen and skin-care products for prevention of skin cancer and other conditions, which are believed to be caused by UV radiation.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Ctr Comprehens Canc, Madison, WI 53706 USA; Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ahmad, N (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Ctr Comprehens Canc, 1300 Univ Ave, Madison, WI 53706 USA.	nahmad@wisc.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887	NCI NIH HHS [CA-098368] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA098368] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhami VM, 2003, NEOPLASIA, V5, P74, DOI 10.1016/S1476-5586(03)80019-2; Adhami VM, 2001, BIOCHEM BIOPH RES CO, V288, P579, DOI 10.1006/bbrc.2001.5819; Afaq F, 2003, TOXICOL APPL PHARM, V186, P28, DOI 10.1016/S0041-008X(02)00014-5; Afaq F, 2002, SKIN PHARMACOL APPL, V15, P297, DOI 10.1159/000064533; Afaq F, 2002, FRONT BIOSCI-LANDMRK, V7, pD784, DOI 10.2741/afaq; Ahmad N, 2001, AM J PATHOL, V159, P885, DOI 10.1016/S0002-9440(10)61764-6; Ahmad N, 2001, CLIN CANCER RES, V7, P1466; Ahmad N, 2001, SKIN PHARMACOL APPL, V14, P69, DOI 10.1159/000056336; Allen SM, 2003, CANCER RES, V63, P567; Altieri Dario C, 2003, Methods Mol Biol, V223, P533; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Altieri DC, 1999, LAB INVEST, V79, P1327; Ananthaswamy H N, 1998, J Investig Dermatol Symp Proc, V3, P52; Aziz MH, 2004, PHOTOCHEM PHOTOBIOL, V80, P602; Aziz MH, 2003, INT J ONCOL, V23, P17; Balasubramanian S, 1999, ONCOGENE, V18, P1297, DOI 10.1038/sj.onc.1202417; Black HS, 1997, J PHOTOCH PHOTOBIO B, V40, P29, DOI 10.1016/S1011-1344(97)00021-3; Blanc-Brude OP, 2003, CLIN CANCER RES, V9, P2683; Bode A M, 2000, Lancet Oncol, V1, P181, DOI 10.1016/S1470-2045(00)00029-2; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Chiodino C, 1999, J INVEST DERMATOL, V113, P415, DOI 10.1046/j.1523-1747.1999.00711.x; Conney AH, 1999, P SOC EXP BIOL MED, V220, P229, DOI 10.1046/j.1525-1373.1999.d01-39.x; Conney AH, 2004, J CELL BIOCHEM, V91, P277, DOI 10.1002/jcb.20001; DING Z, 2002, SLEEP, V25, P7; Einspahr JG, 2003, RECENT RESULTS CANC, V163, P151; Elmets CA, 2001, J AM ACAD DERMATOL, V44, P425, DOI 10.1067/mjd.2001.112919; Gauthier Y, 2003, BRIT J DERMATOL, V148, P95, DOI 10.1046/j.1365-2133.2003.05024.x; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 1999, LAB INVEST, V79, P1121; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Hou Z, 2004, MUTAT RES-FUND MOL M, V555, P3, DOI 10.1016/j.mrfmmm.2004.06.040; Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kapadia GJ, 2002, PHARMACOL RES, V45, P499, DOI 10.1006/phrs.2002.0992; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; KLIGMAN LH, 1981, JNCI-J NATL CANCER I, V67, P1289; Kopp P, 1998, EUR J ENDOCRINOL, V138, P619, DOI 10.1530/eje.0.1380619; KUFLIK AS, 1994, AM FAM PHYSICIAN, V49, P817; Lo Muzio L, 2001, EXP MOL PATHOL, V70, P249, DOI 10.1006/exmp.2001.2367; Matsumura Y, 2004, TOXICOL APPL PHARM, V195, P298, DOI 10.1016/j.taap.2003.08.019; Matsumura Y, 2002, FRONT BIOSCI-LANDMRK, V7, pD765, DOI 10.2741/matsumur; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Mittal A, 2003, CARCINOGENESIS, V24, P1379, DOI 10.1093/carcin/bgg095; Nahm Walter K, 2004, J Drugs Dermatol, V3, P209; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Ortonne JP, 2002, BRIT J DERMATOL, V146, P20, DOI 10.1046/j.1365-2133.146.s61.6.x; Reagan-Shaw S, 2004, ONCOGENE, V23, P5151, DOI 10.1038/sj.onc.1207666; SOEHNGE H, 1997, FRONT BIOSCI, V2, P538; Soleas GJ, 2002, CLIN BIOCHEM, V35, P119, DOI 10.1016/S0009-9120(02)00275-8; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; STEWARD BW, 2004, REDUCTION EXPOSURE U, P141; Sun AY, 2002, FREE RADICAL BIO MED, V32, P314, DOI 10.1016/S0891-5849(01)00803-6; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Tsao AS, 2004, CA-CANCER J CLIN, V54, P150, DOI 10.3322/canjclin.54.3.150; VONBREUCKMANN F, 2002, ARCH DERMATOL RES, V294, P303; Wall NR, 2003, CANCER RES, V63, P230	59	165	174	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1193	+		10.1096/fj.04-3582fje	http://dx.doi.org/10.1096/fj.04-3582fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15837718				2022-12-25	WOS:000228865300011
J	Bezaire, V; Spriet, LL; Campbell, S; Sabet, N; Gerrits, M; Bonen, A; Harper, ME				Bezaire, V; Spriet, LL; Campbell, S; Sabet, N; Gerrits, M; Bonen, A; Harper, ME			Constitutive UCP3 overexpression at physiological levels increases mouse skeletal muscle capacity for fatty acid transport and oxidation	FASEB JOURNAL			English	Article						metabolic efficiency; fat oxidation; thermogenesis	HUMAN UNCOUPLING PROTEIN-3; CARNITINE PALMITOYLTRANSFERASE-I; HORMONE-SENSITIVE LIPASE; HIGH-ENERGY PHOSPHATES; BROWN ADIPOSE-TISSUE; THYROID-HORMONE; INCREASED EXPRESSION; MESSENGER-RNA; UP-REGULATION; MALONYL-COA	Uncoupling protein 3 (UCP3) expression is directly correlated to fatty acid oxidation in skeletal muscle. UCP3 has been hypothesized to facilitate high rates of fatty acid oxidation, but evidence thus far is lacking. Our aim was to investigate the effects of UCP3 overexpression and ablation on fatty acid uptake and metabolism in muscle of mice having congenic backgrounds. In mice constitutively expressing the UCP3 protein (human form) at levels just over twofold higher than normal (230% of wild-type levels), indirect calorimetry demonstrated no differences in total energy expenditure (VO2), but a shift toward increased fat oxidation compared with wild-type (WT) mice. Metabolic efficiency (gram weight gain/kcal ingested) was similar between Ucp3 overexpressors, WT and Ucp3 (-/-) mice. In muscle of Ucp3-tg mice, plasma membrane fatty acid binding protein (FABPpm) content was increased compared with WT mice. Although hormone-sensitive lipase activity was unchanged across the genotypes, there were increases in carnitine palmitoyltransferase I, beta-hydroxyacylCoA dehydrogenase, and citrate synthase activities and decreases in intramuscular triacylglycerol in muscle of Ucp3-tg mice. There were no differences in muscle mitochondrial content. High-energy phosphates and total muscle carnitine and CoA were also greater in Ucp3-tg compared with WT mice. Taken together, the findings demonstrate an increased capacity for fat oxidation in the absence of significant increases in thermogenesis in Ucp3-tg mice. Findings from Ucp3 (-/-) mice revealed few differences compared with WT mice, consistent with the possibility of compensatory mechanisms. In conjunction with our observed increases in CoA and carnitine in muscle of Ucp3 overexpressors, the findings support the hypothesized role for Ucp3 in facilitating fatty acid oxidation in muscle.	Univ Ottawa, Fac Med, Ottawa, ON, Canada; Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada	University of Ottawa; University of Guelph	Harper, ME (corresponding author), Univ Ottawa, Fac Med, Ottawa, ON, Canada.	MaryEllen.Harper@uottawa.ca		Harper, Mary-Ellen/0000-0003-3864-5886				ALEXSON SEH, 1988, J BIOL CHEM, V263, P13564; Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; BERGMEYER HU, 1974, METHODS ENZYMATIC AN; Berthon PM, 1998, J APPL PHYSIOL, V85, P148, DOI 10.1152/jappl.1998.85.1.148; Bezaire V, 2001, AM J PHYSIOL-ENDOC M, V281, pE975, DOI 10.1152/ajpendo.2001.281.5.E975; Bonen A, 2003, ACTA PHYSIOL SCAND, V178, P347, DOI 10.1046/j.1365-201X.2003.01157.x; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CEDERBLAD G, 1990, ANAL BIOCHEM, V185, P274, DOI 10.1016/0003-2697(90)90292-H; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; CONTE A, 1991, INT J TISSUE REACT, V13, P33; Cortright RN, 1999, AM J PHYSIOL-ENDOC M, V276, pE217, DOI 10.1152/ajpendo.1999.276.1.E217; Eaton S, 2001, BIOCHEM SOC T, V29, P245, DOI 10.1042/BST0290245; EATON S, 1999, CURRENT VIEWS FATTY; EDSTROM L, 1982, J PHYSIOL-LONDON, V332, P47, DOI 10.1113/jphysiol.1982.sp014399; FRAYN KN, 1980, J LIPID RES, V21, P139; Garcia-Martinez C, 2001, FASEB J, V15, P2033, DOI 10.1096/fj.00-0828fje; Gong DW, 1999, BIOCHEM BIOPH RES CO, V256, P27, DOI 10.1006/bbrc.1999.0239; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Harper JA, 2002, BIOCHEM J, V361, P49, DOI 10.1042/0264-6021:3610049; Harper ME, 2002, DIABETES, V51, P2459, DOI 10.2337/diabetes.51.8.2459; HARRIS RC, 1974, SCAND J CLIN LAB INV, V33, P109; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Hinz W, 1999, FEBS LETT, V462, P411, DOI 10.1016/S0014-5793(99)01568-9; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; HORIE S, 1986, J BIOCHEM, V99, P1345, DOI 10.1093/oxfordjournals.jbchem.a135602; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; Langfort J, 1998, ADV EXP MED BIOL, V441, P219; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Moore GBT, 2001, BIOCHEM BIOPH RES CO, V283, P785, DOI 10.1006/bbrc.2001.4848; Moreno M, 2003, FASEB J, V17, P1112, DOI 10.1096/fj.02-0839fje; Nagase I, 1999, FEBS LETT, V461, P319, DOI 10.1016/S0014-5793(99)01477-5; Ruderman NB, 2003, ENDOCRINOLOGY, V144, P5166, DOI 10.1210/en.2003-0849; Russell AP, 2003, PFLUG ARCH EUR J PHY, V445, P563, DOI 10.1007/s00424-002-0943-5; Samec S, 2002, PFLUG ARCH EUR J PHY, V445, P80, DOI 10.1007/s00424-002-0879-9; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Schrauwen P, 2004, INT J OBESITY, V28, P824, DOI 10.1038/sj.ijo.0802629; Schrauwen P, 2003, FASEB J, V17, P2272, DOI 10.1096/fj.03-0515fje; Schrauwen P, 2001, FASEB J, V15, P2497, DOI 10.1096/fj.01-0400hyp; Short KR, 2001, AM J PHYSIOL-ENDOC M, V280, pE761, DOI 10.1152/ajpendo.2001.280.5.E761; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Son C, 2004, DIABETOLOGIA, V47, P47, DOI 10.1007/s00125-003-1272-8; SRERE PA, 1969, ARCH BIOCHEM BIOPHYS, V129, P708, DOI 10.1016/0003-9861(69)90231-8; STAVINOHA MA, 2004, IN PRESS AM J PHYSL; Stuart JA, 2001, BIOCHEM J, V356, P779, DOI 10.1042/0264-6021:3560779; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Wang S, 2003, DIABETES OBES METAB, V5, P295, DOI 10.1046/j.1463-1326.2003.00273.x; Watt MJ, 2003, J PHYSIOL-LONDON, V547, P301, DOI 10.1113/jphysiol.2002.034595; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	52	108	117	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					977	+		10.1096/fj.04-2765fje	http://dx.doi.org/10.1096/fj.04-2765fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15814607				2022-12-25	WOS:000228865300026
J	Hudry-Clergeon, H; Stengel, D; Ninio, E; Vilgrain, I				Hudry-Clergeon, H; Stengel, D; Ninio, E; Vilgrain, I			Platelet-activating factor increases VIE-cadherin tyrosine phosphorylation in mouse endothelial cells and its association with the PtdIns3 '-kinase	FASEB JOURNAL			English	Article						adherens junction; VE cadherin; Akt; angiogenesis	FOCAL ADHESION KINASE; FACTOR RECEPTOR; VE-CADHERIN; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; MAP-KINASE; FACTOR PAF; EXPRESSION; PERMEABILITY; PATHWAYS	Platelet-activating factor (PAF), a potent inflammatory mediator, is involved in endothelial permeability. This study was designed to characterize PAF receptor (PAF-R) expression and its specific contribution to the modifications of adherens junctions in mouse endothelial cells. We demonstrated that PAF-R was expressed in mouse endothelial cells and was functionally active in stimulating p42/p44 MAPK and phosphatidylinositol 3-kinase (PtdIns3'-kinase)/Akt activities. Treatment of cells with PAF induced a rapid time- and dose-dependent (10(-7) to 10(-10) M) increase in tyrosine phosphorylation of a subset of proteins ranging from 90 to 220 kDa, including the VE-cadherin, the latter effect being prevented by the tyrosine kinase inhibitors herbimycin A and bis-tyrphostin. We demonstrated that PAF promoted formation of multimeric aggregates of VE-cadherin with PtdIns3'-kinase, which was also inhibited by herbimycin and bis-tyrphostin. Finally, we show by immunostaining of endothelial cells VE-cadherin that PAF dissociated adherens junctions. The present data provide the first evidence that treatment of endothelial cells with PAF promoted activation of tyrosine kinases and the VE-cadherin tyrosine phosphorylation and PtdIns3'-kinase association, which ultimately lead to the dissociation of adherens junctions. Physical association between PtdIns3'-kinase, serving as a docking protein, and VE-cadherin may thus provide an efficient mechanism for amplification and perpetuation of PAF-induced cellular activation.	CEA Grenoble, INSERM,EMI 0219, Dept Response & Dynam Cellulaire, Lab Dev & Vieillissement Endothelium, F-38054 Grenoble, France; Univ Paris 06, Fac Med Pitie Salpetriere, INSERM,U525, Paris 13, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Vilgrain, I (corresponding author), CEA Grenoble, INSERM,EMI 0219, Dept Response & Dynam Cellulaire, Lab Dev & Vieillissement Endothelium, 17 Rue Martyrs, F-38054 Grenoble, France.	ivilgrain@cea.fr		VILGRAIN, Isabelle/0000-0002-5511-5871				Alexander JS, 2000, INFLAMMATION, V24, P99, DOI 10.1023/A:1007025325451; Axelrad TW, 2004, FASEB J, V18, P568, DOI 10.1096/fj.03-0479fje; Bazan HEP, 1997, CURR EYE RES, V16, P372, DOI 10.1076/ceyr.16.4.372.10699; Biancone L, 1999, AM J PATHOL, V155, P1731, DOI 10.1016/S0002-9440(10)65488-0; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Brocheriou I, 2000, CIRCULATION, V102, P2569; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; Calcerrada MC, 1999, BRAIN RES, V835, P275, DOI 10.1016/S0006-8993(99)01612-1; Calcerrada MC, 2002, NEUROCHEM RES, V27, P313, DOI 10.1023/A:1014911329489; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Cascone I, 2003, J BIOL CHEM, V278, P50702, DOI 10.1074/jbc.M307234200; CHABRE O, 1995, ENDOCRINOLOGY, V136, P956, DOI 10.1210/en.136.3.956; CHAO W, 1992, J BIOL CHEM, V267, P6725; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Deo DD, 2004, J BIOL CHEM, V279, P3497, DOI 10.1074/jbc.M304497200; DHAR A, 1994, J BIOL CHEM, V269, P9123; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Ishii S, 2002, PROSTAG OTH LIPID M, V68-9, P599, DOI 10.1016/S0090-6980(02)00058-8; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257; Kouklis P, 2003, J BIOL CHEM, V278, P16230, DOI 10.1074/jbc.M212591200; KURUVILLA A, 1994, J IMMUNOL, V153, P5433; LIU B, 1995, BIOCHEM BIOPH RES CO, V214, P418, DOI 10.1006/bbrc.1995.2303; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Lukashova V, 2001, J BIOL CHEM, V276, P24113, DOI 10.1074/jbc.M100720200; McManus LM, 2000, CRIT REV ORAL BIOL M, V11, P240, DOI 10.1177/10454411000110020701; Montrucchio G, 2000, PHYSIOL REV, V80, P1669, DOI 10.1152/physrev.2000.80.4.1669; MUTOH H, 1993, FEBS LETT, V322, P129, DOI 10.1016/0014-5793(93)81552-B; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; PITTON C, 1989, J NATL CANCER I, V81, P1298, DOI 10.1093/jnci/81.17.1298; Pouyssegur J, 2000, SCIENCE, V290, P1515, DOI 10.1126/science.290.5496.1515; Prescott SM, 2002, ARTERIOSCL THROM VAS, V22, P727, DOI 10.1161/01.ATV.0000016153.47693.B2; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; Rezaul K, 1997, BIOCHEM BIOPH RES CO, V239, P23, DOI 10.1006/bbrc.1997.7419; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Soldi R, 1996, ONCOGENE, V13, P515; Venkiteswaran K, 2002, AM J PHYSIOL-CELL PH, V283, pC811, DOI 10.1152/ajpcell.00417.2001; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Yuan SY, 2002, VASC PHARMACOL, V39, P213, DOI 10.1016/S1537-1891(03)00010-7; Zhang YP, 2003, J SOC GYNECOL INVEST, V10, P5, DOI 10.1016/S1071-5576(02)00185-5	45	51	55	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					512	520		10.1096/fj.04-2202com	http://dx.doi.org/10.1096/fj.04-2202com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791001	Green Accepted, Green Published			2022-12-25	WOS:000228865300035
J	Wang, HW; Babic, AM; Mitchell, HA; Liu, K; Wagner, DD				Wang, HW; Babic, AM; Mitchell, HA; Liu, K; Wagner, DD			Elevated soluble ICAM-1 levels induce immune deficiency and increase adiposity in mice	FASEB JOURNAL			English	Article						adhesion molecule; inflammation; contact hypersensitivity; obesity	INTERCELLULAR-ADHESION MOLECULE-1; ISCHEMIA-REPERFUSION INJURY; TUMOR-NECROSIS-FACTOR; LEUKOCYTE ADHESION; INSULIN-RESISTANCE; LANGERHANS CELLS; OBESITY; ANTIBODIES; ANTI-ICAM-1; EXPRESSION	Elevated soluble intercellular adhesion molecule-1 (sICAM-1) levels have been found in many pathological conditions, including obesity. To determine the effects of elevated sICAM-1 on immune responses and metabolism, we generated a transgenic mouse model overexpressing the extracellular domain of mouse ICAM-1 in the liver. The mice, showing 10-fold higher sICAM-1 levels than wild-type mice, presented elevated neutrophil count. Despite this, after intraperitoneal injection of thioglycollate, neutrophil recruitment into the peritoneal cavity was reduced, and the delayed macrophage recruitment was also affected in the transgenic mice compared with wildtype mice. Inhibition of contact hypersensitivity response in the sICAM-1 transgenic mice was comparable to ICAM-1-deficient mice and characterized by significantly less ear swelling and inflammatory cell infiltration than in wild-type mice. sICAM-1transgenic mice were more susceptible to weight gain on a Western-type diet than wild-type mice, and older animals showed excessive fat accumulation, again reminiscent of ICAM-1-deficient mice. Together, these data indicate that sICAM-1 interferes with ICAM-1-mediated cell-cell interactions, which could produce immune-suppressant effects and alteration of metabolism in persons with high levels of this soluble adhesion receptor.	CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School	Wagner, DD (corresponding author), CBR Inst Biomed Res, 800 Huntington Ave, Boston, MA 02115 USA.	Wagner@cbr.med.harvard.edu			NHLBI NIH HHS [R37 HL041002, R01 HL53756, R01 HL053756, R37 HL41002] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053756, R37HL041002] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABIC AM, 2004, IN PRESS MOL MED; Bertry-Coussot L, 2002, J IMMUNOL, V168, P3641, DOI 10.4049/jimmunol.168.7.3641; Biancone L, 1996, J EXP MED, V183, P581, DOI 10.1084/jem.183.2.581; Capra F, 2000, J INFECT DIS, V181, P425, DOI 10.1086/315265; Dong ZM, 1997, P NATL ACAD SCI USA, V94, P7526, DOI 10.1073/pnas.94.14.7526; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; Gadek TR, 2002, SCIENCE, V295, P1086, DOI 10.1126/science.295.5557.1086; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; Ito H, 2002, CLIN EXP PHARMACOL P, V29, P399, DOI 10.1046/j.1440-1681.2002.03672.x; KING PD, 1995, J IMMUNOL, V154, P6080; Kumasaka T, 1996, J CLIN INVEST, V97, P2362, DOI 10.1172/JCI118679; Kusterer K, 1998, AM J PHYSIOL-GASTR L, V275, pG377, DOI 10.1152/ajpgi.1998.275.2.G377; Lamas O, 2002, EUR J CLIN NUTR, V56, pS42, DOI 10.1038/sj.ejcn.1601484; Leinonen E, 2003, ATHEROSCLEROSIS, V166, P387, DOI 10.1016/S0021-9150(02)00371-4; Liao F, 1999, J IMMUNOL, V163, P5640; MA J, 1994, CELL IMMUNOL, V158, P389, DOI 10.1006/cimm.1994.1285; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; Matarese G, 2004, TRENDS IMMUNOL, V25, P193, DOI 10.1016/j.it.2004.02.009; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; Moore SI, 2003, INFECT IMMUN, V71, P4182, DOI 10.1128/IAI.71.7.4182-4185.2003; Nieman DC, 1999, J AM DIET ASSOC, V99, P294, DOI 10.1016/S0002-8223(99)00077-2; POBER JS, 1987, J IMMUNOL, V138, P3319; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; Shahi CN, 1997, AM J CARDIOL, V79, P980, DOI 10.1016/S0002-9149(97)00027-1; Shapiro S, 2003, J NEUROL SCI, V206, P43, DOI 10.1016/S0022-510X(02)00317-9; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Straczkowski M, 2002, METABOLISM, V51, P75, DOI 10.1053/meta.2002.28095; Tedla N, 1998, J IMMUNOL, V161, P5663; UCHIKOSHI F, 1995, TRANSPLANT P, V27, P1527; van den Engel NK, 2000, BLOOD, V95, P1350, DOI 10.1182/blood.V95.4.1350.004k07_1350_1355; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; VOLLMAR B, 1995, SURGERY, V117, P195, DOI 10.1016/S0039-6060(05)80085-6; Wang HW, 2002, J IMMUNOL, V169, P5145, DOI 10.4049/jimmunol.169.9.5145; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514; Weyer C, 2002, ATHEROSCLEROSIS, V161, P233, DOI 10.1016/S0021-9150(01)00626-8; Wu KK, 2003, CIRCULATION, V107, P1729, DOI 10.1161/01.CIR.0000064894.97094.4F; Xu H, 2001, EUR J IMMUNOL, V31, P3085, DOI 10.1002/1521-4141(2001010)31:10<3085::AID-IMMU3085>3.0.CO;2-B; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95	43	34	35	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1018	+		10.1096/fj.04-3094fje	http://dx.doi.org/10.1096/fj.04-3094fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15817637				2022-12-25	WOS:000228865300020
J	Azran, I; Jeang, KT; Aboud, M				Azran, I; Jeang, KT; Aboud, M			High levels of cytoplasmic HTLV-1 Tax mutant proteins retain a Tax-NF-kappa B-CBP ternary complex in the cytoplasm	ONCOGENE			English	Article						HTLV-1; Tax; cytoplasmic Tax mutants; NF-kappa B; CBP; PKAc	T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; CREB BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATION; TYPE-1 TAX; TRANSACTIVATOR TAX; COACTIVATOR CBP; IKK-ALPHA; NUCLEAR TRANSLOCATION	The oncogenic potential of HTLV- 1 Tax protein is partially ascribed to its capacity to activate NF-kappa B. The current view is that Tax acts first in the cytoplasm to dissociate NF-kappa B factors from the I kappa B proteins and enable their nuclear translocation, then Tax links p65( RelA), within the nucleus, to CBP/p300 and P/ CAF, which are essential for its optimal transcriptional activity. Our present study challenges the paradigm that Tax-p65( RelA)-CBP/p300 assembly occurs in the nucleus. Using Tax mutants defective for nuclear localization we show that at low levels these mutants induce the nuclear translocation of NF-kappa B factors but not their transcriptional activity, whereas at high levels they trap CBP and free p65( RelA) in the cytoplasm and block, thereby, their transcriptional function. In contrast, wildtype (w.t.) Tax strongly stimulated NF-kappa B-dependent gene expression in all tested experimental settings. These data suggest that the Tax-p65( RelA)-CBP ternary complex is established in the cytoplasm rather than in the nucleus. When this complex is formed with w.t. Tax, the entire moiety translocates into the nucleus and exerts high transcriptional activity. However, if the complex is formed with the cytoplasmic Tax mutants, the resulting moiety is retained in the cytoplasm and is, therefore, devoid of transcriptional activity.	Ben Gurion Univ Negev, Fac Hlth Sci, Canc Res Ctr, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	Ben Gurion University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Aboud, M (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Canc Res Ctr, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel.	aboud@bgu.ac.il	Jeang, Kuan-Teh/A-2424-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Azran Inbal, 2004, Retrovirology, V1, P20; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Catley MC, 2004, J BIOL CHEM, V279, P18457, DOI 10.1074/jbc.M400765200; Chan HM, 2001, J CELL SCI, V114, P2363; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; Iha H, 2003, ONCOGENE, V22, P8912, DOI 10.1038/sj.onc.1207058; Inoue M, 1998, JPN J CANCER RES, V89, P53, DOI 10.1111/j.1349-7006.1998.tb00479.x; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; MorVaknin N, 1997, VIROLOGY, V232, P337, DOI 10.1006/viro.1997.8566; MURAKAMI T, 1995, VIROLOGY, V206, P1066, DOI 10.1006/viro.1995.1029; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Neuveut C, 2002, FRONT BIOSCI-LANDMRK, V7, pD157, DOI 10.2741/neuveut; Nicot C, 2000, ONCOGENE, V19, P2155, DOI 10.1038/sj.onc.1203536; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Petropoulos L, 1996, VIROLOGY, V225, P52, DOI 10.1006/viro.1996.0574; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI T, 1994, ONCOGENE, V9, P3099; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; SUZUKI T, 1995, ONCOGENE, V10, P1199; SUZUKI T, 1993, ONCOGENE, V8, P2391; Tabakin-Fix Y, 2004, BIOCHEM BIOPH RES CO, V318, P1052, DOI 10.1016/j.bbrc.2004.04.137; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Torgeman A, 2001, EXP CELL RES, V271, P169, DOI 10.1006/excr.2001.5363; Turgeman H, 1998, FEBS LETT, V428, P183, DOI 10.1016/S0014-5793(98)00513-4; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Van Orden K, 2000, GENE EXPRESSION, V9, P29; Van Orden K, 1999, ONCOGENE, V18, P3766, DOI 10.1038/sj.onc.1202703; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang TL, 2002, INT IMMUNOPHARMACOL, V2, P1509, DOI 10.1016/S1567-5769(02)00058-9; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yasunaga JI, 2003, INT J HEMATOL, V78, P312, DOI 10.1007/BF02983555; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Yoshida M, 1997, LEUKEMIA, V11, P14, DOI 10.1038/sj.leu.2400545; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; YOSHIZAWA H, 1994, J ADHES SCI TECHNOL, V8, P1; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	78	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4521	4530		10.1038/sj.onc.1208645	http://dx.doi.org/10.1038/sj.onc.1208645			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15806143				2022-12-25	WOS:000230157100005
J	Bayrhuber, M; Vijayan, V; Ferber, M; Graf, R; Korukottu, J; Imperial, J; Garrett, JE; Olivera, BM; Terlau, H; Zweckstetter, M; Becker, S				Bayrhuber, M; Vijayan, V; Ferber, M; Graf, R; Korukottu, J; Imperial, J; Garrett, JE; Olivera, BM; Terlau, H; Zweckstetter, M; Becker, S			Conkunitzin-S1 is the first member of a new Kunitz-type neurotoxin family - Structural and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; NUCLEAR-MAGNETIC-RESONANCE; POTASSIUM CHANNEL; DENDROTOXIN-K; CONUS VENOMS; PROTEIN; NMR; ASSIGNMENT; COUPLINGS; ALIGNMENT	Conkunitzin-S1 (Conk-S1) is a 60-residue neurotoxin from the venom of the cone snail Conus striatus that interacts with voltage-gated potassium channels. Conk-S1 shares sequence homology with Kunitz-type proteins but contains only two out of the three highly conserved cysteine bridges, which are typically found in these small, basic protein modules. In this study the three-dimensional structure of Conk-S1 has been solved by multidimensional NMR spectroscopy. The solution structure of recombinant Conk-S1 shows that a Kunitz fold is present, even though one of the highly conserved disulfide cross-links is missing. Introduction of a third, homologous disulfide bond into Conk-S1 results in a functional toxin with similar affinity for Shaker potassium channels. The affinity of Conk-S1 can be enhanced by a pore mutation within the Shaker channel pore indicating an interaction of Conk-S1 with the vestibule of potassium channels.	Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany; Max Planck Inst Expt Med, Mol & Cellular Neuropharmacol Grp, D-37075 Gottingen, Germany; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Cognetix Inc, Salt Lake City, UT 84108 USA	Max Planck Society; Max Planck Society; Utah System of Higher Education; University of Utah	Becker, S (corresponding author), Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, Am Fassberg 11, D-37077 Gottingen, Germany.	sabe@nmr.mpibpc.mpg.de		vijayan, vinesh/0000-0001-5483-1860				BAX A, 1993, ACCOUNTS CHEM RES, V26, P542; BERNDT KD, 1993, J MOL BIOL, V234, P735, DOI 10.1006/jmbi.1993.1623; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Craig AG, 1999, EUR J BIOCHEM, V264, P271, DOI 10.1046/j.1432-1327.1999.00624.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DREYER F, 1990, REV PHYSIOL BIOCH P, V115, P93; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; HOLLECKER M, 1993, BRIT J PHARMACOL, V110, P790, DOI 10.1111/j.1476-5381.1993.tb13881.x; Hu JS, 1997, J BIOMOL NMR, V9, P323, DOI 10.1023/A:1018691228238; Imredy JP, 2000, J MOL BIOL, V296, P1283, DOI 10.1006/jmbi.2000.3522; Jacobsen RB, 2000, J BIOL CHEM, V275, P24639, DOI 10.1074/jbc.C900990199; Jung YS, 2004, J BIOMOL NMR, V30, P11, DOI 10.1023/B:JNMR.0000042954.99056.ad; Jung YS, 2004, ANGEW CHEM INT EDIT, V43, P3479, DOI 10.1002/anie.200353588; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kortemme T, 1996, J MOL BIOL, V257, P188, DOI 10.1006/jmbi.1996.0155; KRESS LF, 1967, J BIOL CHEM, V242, P4925; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; MacLean JA, 2004, BIOL REPROD, V71, P455, DOI 10.1095/biolreprod.103.025908; MARKS CB, 1987, SCIENCE, V235, P1370, DOI 10.1126/science.2435002; Mathys S, 1999, GENE, V231, P1, DOI 10.1016/S0378-1119(99)00103-1; PARDI A, 1983, EUR J BIOCHEM, V137, P445, DOI 10.1111/j.1432-1033.1983.tb07848.x; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Simons KT, 1997, J MOL BIOL, V268, P209, DOI 10.1006/jmbi.1997.0959; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; VANMIERLO CPM, 1994, J MOL BIOL, V235, P1044, DOI 10.1006/jmbi.1994.1056; VINCENT JP, 1972, BIOCHEMISTRY-US, V11, P2967, DOI 10.1021/bi00766a007; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	30	82	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23766	23770		10.1074/jbc.C500064200	http://dx.doi.org/10.1074/jbc.C500064200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15833744	hybrid			2022-12-25	WOS:000229880000046
J	Flint, J; Bolam, DN; Nurizzo, D; Taylor, EJ; Williamson, MP; Walters, C; Davies, GJ; Gilbert, HJ				Flint, J; Bolam, DN; Nurizzo, D; Taylor, EJ; Williamson, MP; Walters, C; Davies, GJ; Gilbert, HJ			Probing the mechanism of ligand recognition in family 29 carbohydrate-binding modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOMONAS-FIMI; XYLANASE 10A; PSEUDOMONAS XYLANASE; TRICHODERMA-REESEI; CRYSTAL-STRUCTURES; ENDOGLUCANASE Z; PEANUT LECTIN; AMINO-ACIDS; DOMAIN; COMPLEX	The recycling of photosynthetically fixed carbon, by the action of microbial plant cell wall hydrolases, is integral to one of the major geochemical cycles and is of considerable industrial importance. Non-catalytic carbohydrate-binding modules (CBMs) play a key role in this degradative process by targeting hydrolytic enzymes to their cognate substrate within the complex milieu of polysaccharides that comprise the plant cell wall. Family 29 CBMs have, thus far, only been found in an extracellular multienzyme plant cell wall-degrading complex from the anaerobic fungus Piromyces equi, where they exist as a CBM29-1:CBM29-2 tandem. Here we present both the structure of the CBM29-1 partner, at 1.5 angstrom resolution, and examine the importance of hydrophobic stacking interactions as well as direct and solvent-mediated hydrogen bonds in the binding of CBM29-2 to different polysaccharides. CBM29 domains display unusual binding properties, exhibiting specificity for both beta-manno- and beta-gluco-configured ligands such as mannan, cellulose, and glucomannan. Mutagenesis reveals that "stacking" of tryptophan residues in the n and n + 2 subsites plays a critical role in ligand binding, whereas the loss of tyrosine-mediated stacking in the n + 4 subsite reduces, but does not abrogate, polysaccharide recognition. Direct hydrogen bonds to ligand, such as those provided by Arg-112 and Glu-78, play a pivotal role in the interaction with both mannan and cellulose, whereas removal of water-mediated interactions has comparatively little effect on carbohydrate binding. The interactions of CBM29-2 with the O2 of glucose or mannose contribute little to binding affinity, explaining why this CBM displays dual gluco/manno specificity.	Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2UH, S Yorkshire, England	Newcastle University - UK; University of York - UK; University of Sheffield	Gilbert, HJ (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	H.J.Gilbert@ncl.ac.uk	Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X; Williamson, Mike/0000-0001-5572-1903; Flint, James/0000-0003-2923-7813; Taylor, Edward/0000-0003-4024-0976; Bolam, David/0000-0003-0314-3122				Abou Hachem M, 2000, BIOCHEM J, V345, P53, DOI 10.1042/0264-6021:3450053; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2003, STRUCTURE, V11, P665, DOI 10.1016/S0969-2126(03)00100-X; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Boraston AB, 1999, ROY SOC CH, P202; Bray MR, 1996, PROTEIN SCI, V5, P2311, DOI 10.1002/pro.5560051117; Brett CT, 1996, PHYSL BIOCH PLANT CE, P4; Brun E, 1997, BIOCHEMISTRY-US, V36, P16074, DOI 10.1021/bi9718494; Brzozowski AM, 2001, J APPL CRYSTALLOGR, V34, P97, DOI 10.1107/S0021889800017362; Carvalho AL, 2004, J BIOL CHEM, V279, P34785, DOI 10.1074/jbc.M405867200; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P14077, DOI 10.1073/pnas.212516199; Coutinho PM, 1999, ROY SOC CH, P3; Creagh AL, 1996, P NATL ACAD SCI USA, V93, P12229, DOI 10.1073/pnas.93.22.12229; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Elgavish S, 1998, J MOL BIOL, V277, P917, DOI 10.1006/jmbi.1998.1664; Flint J, 2004, J MOL BIOL, V337, P417, DOI 10.1016/j.jmb.2003.12.081; Freelove ACJ, 2001, J BIOL CHEM, V276, P43010, DOI 10.1074/jbc.M107143200; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Henshaw JL, 2004, J BIOL CHEM, V279, P21552, DOI 10.1074/jbc.M401620200; Hogg D, 2003, BIOCHEM J, V371, P1027, DOI 10.1042/BJ20021860; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LINDER M, 1995, PROTEIN SCI, V4, P1056, DOI 10.1002/pro.5560040604; LINDER M, 1995, FEBS LETT, V372, P96, DOI 10.1016/0014-5793(95)00961-8; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; McLean BW, 2000, PROTEIN ENG, V13, P801, DOI 10.1093/protein/13.11.801; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Notenboom V, 2001, J MOL BIOL, V314, P797, DOI 10.1006/jmbi.2001.5153; Notenboom V, 2002, BIOCHEMISTRY-US, V41, P4246, DOI 10.1021/bi015865j; Notenboom V, 2001, BIOCHEMISTRY-US, V40, P6248, DOI 10.1021/bi0101704; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pell G, 2003, BIOCHEMISTRY-US, V42, P9316, DOI 10.1021/bi0347510; Ponyi T, 2000, BIOCHEMISTRY-US, V39, P985, DOI 10.1021/bi9921642; Raghothama S, 2000, BIOCHEMISTRY-US, V39, P978, DOI 10.1021/bi992163+; Ravishankar R, 1999, ACTA CRYSTALLOGR D, V55, P1375, DOI 10.1107/S0907444999006587; Ravishankar R, 1997, CURR SCI INDIA, V72, P855; Simpson HD, 1999, J BACTERIOL, V181, P4611, DOI 10.1128/JB.181.15.4611-4616.1999; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; TAKEO K, 1984, ELECTROPHORESIS, V5, P187, DOI 10.1002/elps.1150050402; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z; Xie HF, 2001, BIOCHEMISTRY-US, V40, P9167, DOI 10.1021/bi0106742; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	48	33	33	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23718	23726		10.1074/jbc.M501551200	http://dx.doi.org/10.1074/jbc.M501551200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15784618	hybrid			2022-12-25	WOS:000229880000040
J	Saslowsky, DE; Warek, U; Winkel, BSJ				Saslowsky, DE; Warek, U; Winkel, BSJ			Nuclear localization of flavonoid enzymes in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOKINASE REGULATORY PROTEIN; TRANSPARENT TESTA MUTANTS; DNA-POLYMERASE-ALPHA; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; TISSUE LOCALIZATION; PHENOLIC-COMPOUNDS; CHALCONE SYNTHASE; AUXIN TRANSPORT; BINDING; EXPRESSION	Flavonoids represent one of the oldest, largest, and most diverse families of plant secondary metabolites. These compounds serve a wide range of functions in plants, from pigmentation and UV protection to the regulation of hormone transport. Flavonoids also have interesting pharmacological activities in animals that are increasingly being characterized in terms of effects on specific proteins or other macromolecules. Although flavonoids are found in many different locations both inside and outside the cell, biosynthesis has long been believed to take place exclusively in the cytoplasm. Recent reports from a number of different plant species have documented the presence of flavonoids in nuclei, raising the possibility of novel mechanisms of action for these compounds. Here we present evidence that not only flavonoids, but also at least two of the biosynthetic enzymes, are located in the nucleus in several cell types in Arabidopsis. This is the first indication that differential targeting of the biosynthetic machinery may be used to regulate the deposition of plant secondary products at diverse sites of action within the cell.	Virginia Tech, Dept Biol, W Campus Dr, VA 24061 USA; Virginia Tech, Franklin Ctr Biotechnol, W Campus Dr, VA 24061 USA	Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University	Winkel, BSJ (corresponding author), Virginia Tech, Dept Biol, W Campus Dr, VA 24061 USA.	winkel@vt.edu	Winkel, Brenda S.J./A-6602-2008	Winkel, Brenda S.J./0000-0003-3481-024X				Agius L, 1997, BIOCHEM SOC T, V25, P145, DOI 10.1042/bst0250145; Anderson LE, 2004, PROTOPLASMA, V223, P103, DOI 10.1007/s00709-004-0041-y; ANDERSON LE, 1995, PLANT PHYSIOL, V108, P659, DOI 10.1104/pp.108.2.659; Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; BECKER D, 1990, NUCLEIC ACIDS RES, V18, P203, DOI 10.1093/nar/18.1.203; Ben-Efraim I, 2004, BIOCHEMISTRY-US, V43, P3518, DOI 10.1021/bi0356911; Bosco D, 2000, BIOCHEM J, V348, P215, DOI 10.1042/0264-6021:3480215; Bovy A, 2002, PLANT CELL, V14, P2509, DOI 10.1105/tpc.004218; Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753-4887.1998.tb01670.x; Bryant JA, 2000, J EXP BOT, V51, P1945, DOI 10.1093/jexbot/51.352.1945; Buer CS, 2004, PLANT CELL, V16, P1191, DOI 10.1105/tpc.020313; Burbulis IE, 1999, P NATL ACAD SCI USA, V96, P12929, DOI 10.1073/pnas.96.22.12929; CHEN H, 1994, BIOTECHNIQUES, V16, P664; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Cuadra P, 1996, Z NATURFORSCH C, V51, P671; DANA CD, 2005, IN PRESS J MOL MODEL; Debeaujon I, 2001, PLANT CELL, V13, P853, DOI 10.1105/tpc.13.4.853; DeLong A, 2002, PLANT MOL BIOL, V49, P285, DOI 10.1023/A:1015246828230; Dixon RA, 1999, TRENDS PLANT SCI, V4, P394, DOI 10.1016/S1360-1385(99)01471-5; Endt DV, 2002, PHYTOCHEMISTRY, V61, P107, DOI 10.1016/S0031-9422(02)00185-1; Farrelly D, 1999, P NATL ACAD SCI USA, V96, P14511, DOI 10.1073/pnas.96.25.14511; Feucht W, 2004, PLANT CELL REP, V22, P430, DOI 10.1007/s00299-003-0705-7; Goodman CD, 2004, PLANT CELL, V16, P1812, DOI 10.1105/tpc.022574; Grandmaison J, 1996, J PLANT PHYSIOL, V147, P653, DOI 10.1016/S0176-1617(11)81474-4; Grotewold E, 1998, PLANT CELL, V10, P721, DOI 10.1105/tpc.10.5.721; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gutzeit HO, 2004, BIOCHEM BIOPH RES CO, V318, P490, DOI 10.1016/j.bbrc.2004.04.078; Hanaka H, 2002, BIOCHEM J, V361, P505, DOI 10.1042/0264-6021:3610505; Harborne JB, 2000, PHYTOCHEMISTRY, V55, P481, DOI 10.1016/S0031-9422(00)00235-1; Havsteen BH, 2002, PHARMACOL THERAPEUT, V96, P67, DOI 10.1016/S0163-7258(02)00298-X; Herrero P, 1998, FEBS LETT, V434, P71, DOI 10.1016/S0014-5793(98)00872-2; Hodek P, 2002, CHEM-BIOL INTERACT, V139, P1, DOI 10.1016/S0009-2797(01)00285-X; HRAZDINA G, 1992, ANNU REV PLANT PHYS, V43, P241, DOI 10.1146/annurev.pp.43.060192.001325; HRAZDINA G, 1985, ANN P PHYTOCHEM SOC, V25, P120; Hutzler P, 1998, J EXP BOT, V49, P953, DOI 10.1093/jexbot/49.323.953; Keminer O, 1999, BIOPHYS J, V77, P217, DOI 10.1016/S0006-3495(99)76883-9; Kuras M, 1999, ANN BOT-LONDON, V84, P135, DOI 10.1006/anbo.1999.0884; Lin Yakang, 2003, BMC Plant Biology, V3, P10, DOI 10.1186/1471-2229-3-10; Mamczur P, 2004, HISTOL HISTOPATHOL, V19, P753, DOI 10.14670/HH-19.753; MARCHAND L, 1987, J PLANT PHYSIOL, V131, P339, DOI 10.1016/S0176-1617(87)80173-6; Markham KR, 2001, PHYTOCHEMISTRY, V58, P403, DOI 10.1016/S0031-9422(01)00276-X; Mathews H, 2003, PLANT CELL, V15, P1689, DOI 10.1105/tpc.012963; Mazzola JL, 2003, BBA-GEN SUBJECTS, V1622, P50, DOI 10.1016/S0304-4165(03)00117-X; Mizushina Y, 2003, BIOCHEM BIOPH RES CO, V301, P480, DOI 10.1016/S0006-291X(02)03083-8; MOSKALEWSKI S, 1980, CELL TISSUE RES, V210, P403; Murphy A, 2000, PLANTA, V211, P315, DOI 10.1007/s004250000300; Nijveldt RJ, 2001, AM J CLIN NUTR, V74, P418; Peer WA, 2001, PLANT PHYSIOL, V126, P536, DOI 10.1104/pp.126.2.536; Pelletier MK, 1996, PLANT PHYSIOL, V111, P339, DOI 10.1104/pp.111.1.339; Popanda O, 1998, BBA-GENE STRUCT EXPR, V1397, P102, DOI 10.1016/S0167-4781(97)00229-7; Ramadass P, 2003, TOXICOL SCI, V76, P212, DOI 10.1093/toxsci/kfg227; Rice-Evans C, 2001, CURR MED CHEM, V8, P797, DOI 10.2174/0929867013373011; Sarma AD, 1999, PHYTOCHEMISTRY, V52, P1313, DOI 10.1016/S0031-9422(99)00427-6; Saslowsky D, 2001, PLANT J, V27, P37, DOI 10.1046/j.1365-313x.2001.01073.x; Schnitzler JP, 1996, NEW PHYTOL, V132, P247, DOI 10.1111/j.1469-8137.1996.tb01844.x; SHEAHAN JJ, 1993, ANAL CHEM, V65, P961, DOI 10.1021/ac00055a022; SHIRLEY BW, 1992, PLANT CELL, V4, P333, DOI 10.1105/tpc.4.3.333; SNYDER BA, 1990, SCIENCE, V248, P1637, DOI 10.1126/science.248.4963.1637; STAFFORD HA, 1974, RECENT ADV PHYTOCHEM, V8, P53, DOI DOI 10.1016/B978-0-12-612408-8.50009-3; Stevens JF, 2004, PHYTOCHEMISTRY, V65, P1317, DOI 10.1016/j.phytochem.2004.04.025; Suetsugu S, 2003, J BIOL CHEM, V278, P42515, DOI 10.1074/jbc.M302177200; Verhoeyen ME, 2002, J EXP BOT, V53, P2099, DOI 10.1093/jxb/erf044; von Arnim AG, 1998, GENE, V221, P35, DOI 10.1016/S0378-1119(98)00433-8; Walle T, 2003, BIOCHEM PHARMACOL, V65, P1603, DOI 10.1016/S0006-2952(03)00151-5; Wang XW, 1999, ARCH BIOCHEM BIOPHYS, V367, P348, DOI 10.1006/abbi.1999.1261; Wietzke JA, 2003, J STEROID BIOCHEM, V84, P149, DOI 10.1016/S0960-0760(03)00024-4; Winkel BSJ, 2004, ANNU REV PLANT BIOL, V55, P85, DOI 10.1146/annurev.arplant.55.031903.141714; Winkel-Shirley B, 1999, PHYSIOL PLANTARUM, V107, P142, DOI 10.1034/j.1399-3054.1999.100119.x; Winkel-Shirley B, 2001, PLANT PHYSIOL, V126, P485, DOI 10.1104/pp.126.2.485; WOLLENWEBER E, 1981, PHYTOCHEMISTRY, V20, P869, DOI 10.1016/0031-9422(81)83001-4; Yoshizumi M, 2002, BIOCHEM BIOPH RES CO, V293, P1458, DOI 10.1016/S0006-291X(02)00407-2; Yu O, 2003, PHYTOCHEMISTRY, V63, P753, DOI 10.1016/S0031-9422(03)00345-5	72	165	178	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23735	23740		10.1074/jbc.M413506200	http://dx.doi.org/10.1074/jbc.M413506200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15817473	hybrid			2022-12-25	WOS:000229880000042
J	Gokhale, KC; Newnam, GP; Sherman, MY; Chernoff, YO				Gokhale, KC; Newnam, GP; Sherman, MY; Chernoff, YO			Modulation of prion-dependent polyglutamine aggregation and toxicity by chaperone proteins in the yeast model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTAGONISTIC INTERACTIONS; SACCHAROMYCES-CEREVISIAE; CYTOSOLIC HSP70; PSI+ PRION; HUNTINGTIN; HSP104; PROPAGATION; SUPPRESSION; EXPRESSION; DOMAIN	In yeast, aggregation and toxicity of the expanded polyglutamine fragment of human huntingtin strictly depend on the presence of the endogenous self-perpetuating aggregated proteins (prions), which contain glutamine/asparagine-rich domains. Some chaperones of the Hsp100/70/40 complex, modulating propagation of yeast prions, were also reported to influence polyglutamine aggregation in yeast, but it was not clear whether they do it directly or via affecting prions. Our data show that although some chaperone alterations indeed act on polyglutamines via curing endogenous prions, other alterations decrease size and ameliorate toxicity of polyglutamine aggregates without affecting prion propagation. Therefore, the role of yeast chaperones in polyglutamine aggregation and toxicity is not restricted only to their effects on the endogenous prions. Moreover, chaperone interactions with prion and polyglutamine aggregates appear to be of a highly specific nature. One and the same chaperone alteration, substitution A503V in the middle region of the chaperone Hsp104, exhibited opposite effects on one of the endogenous prions ([PSI+], the prion form of Sup35) and on polyglutamines, increasing aggregate size and toxicity in the former case and decreasing them in the latter case. On the other hand, different members of a single chaperone family exhibited opposite effects on one and the same type of aggregates: excess of the Hsp40 chaperone Ydj1 increased polyglutamine aggregate size and toxicity, whereas excess of the other Hsp40 chaperone, Sis1, decreased them. As many stress-defense proteins are conserved between yeast and mammals, these data shed light on possible mechanisms modulating polyglutamine aggregation and toxicity in mammalian cells.	Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Georgia Inst Technol, Inst Bioengn & Biosci, Atlanta, GA 30332 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; Boston University	Chernoff, YO (corresponding author), Georgia Inst Technol, Sch Biol, 310 Ferst Dr, Atlanta, GA 30332 USA.	yury.chernoff@biology.gatech.edu	Chernoff, Yury O/J-2833-2014	Chernoff, Yury/0000-0002-8934-9051; Sherman, Michael/0000-0003-3345-073X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058763] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM58763] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen KD, 2005, GENETICS, V169, P1227, DOI 10.1534/genetics.104.037168; Bailleul PA, 1999, GENETICS, V153, P81; Bailleul-Winslett PA, 2000, GENE EXPRESSION, V9, P145; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cao F, 2001, BBA-MOL BASIS DIS, V1537, P158, DOI 10.1016/S0925-4439(01)00068-0; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Chacinska A, 2001, CURR GENET, V39, P62, DOI 10.1007/s002940000180; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Chernoff YO, 2004, TRENDS BIOTECHNOL, V22, P549, DOI 10.1016/j.tibtech.2004.09.001; CHERNOFF YO, 1992, YEAST, V8, P489, DOI 10.1002/yea.320080702; Chernoff YO, 1999, MOL CELL BIOL, V19, P8103; Chernoff YO, 2002, METHOD ENZYMOL, V351, P499; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Chernoff YO, 2001, MUTAT RES-REV MUTAT, V488, P39, DOI 10.1016/S1383-5742(00)00060-0; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Derkatch IL, 1997, GENETICS, V147, P507; Derkatch IL, 1996, GENETICS, V144, P1375; Faber PW, 1999, P NATL ACAD SCI USA, V96, P179, DOI 10.1073/pnas.96.1.179; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Jung G, 2000, GENETICS, V156, P559; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kimura Y, 2001, GENES CELLS, V6, P887, DOI 10.1046/j.1365-2443.2001.00472.x; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; LIU HP, 1992, GENETICS, V132, P665; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Meriin AB, 2003, MOL CELL BIOL, V23, P7554, DOI 10.1128/MCB.23.21.7554-7565.2003; Meriin AB, 2002, J CELL BIOL, V157, P997, DOI 10.1083/jcb.200112104; Michelitsch MD, 2000, P NATL ACAD SCI USA, V97, P11910, DOI 10.1073/pnas.97.22.11910; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Newnam GP, 1999, MOL CELL BIOL, V19, P1325; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Osherovich LZ, 2004, PLOS BIOL, V2, P442, DOI 10.1371/journal.pbio.0020086; Osherovich LZ, 2001, CELL, V106, P183, DOI 10.1016/S0092-8674(01)00440-8; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Roberts BT, 2004, YEAST, V21, P107, DOI 10.1002/yea.1062; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Schirmer EC, 2004, MOL BIOL CELL, V15, P2061, DOI 10.1091/mbc.E02-08-0502; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schwimmer C, 2002, MOL CELL BIOL, V22, P3590, DOI 10.1128/MCB.22.11.3590-3598.2002; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; Sondheimer N, 2001, EMBO J, V20, P2435, DOI 10.1093/emboj/20.10.2435; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wegrzyn RD, 2001, MOL CELL BIOL, V21, P4656, DOI 10.1128/MCB.21.14.4656-4669.2001; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898	58	110	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22809	22818		10.1074/jbc.M500390200	http://dx.doi.org/10.1074/jbc.M500390200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824100	hybrid			2022-12-25	WOS:000229741800032
J	Hannah, MJ; Skehel, P; Erent, M; Knipe, L; Ogden, D; Carter, T				Hannah, MJ; Skehel, P; Erent, M; Knipe, L; Ogden, D; Carter, T			Differential kinetics of cell surface loss of von Willebrand factor and its propolypeptide after secretion from Weibel-Palade bodies in living human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND ANTIGEN-II; EXOCYTOSIS; PLATELETS; BIOGENESIS; MULTIMERS; COMPONENT; PROTEINS; INTEGRIN; STORAGE	The time course for cell surface loss of von Willebrand factor (VWF) and the propolypeptide of VWF (proregion) following exocytosis of individual Weibel-Palade bodies (WPBs) from single human endothelial cells was analyzed. Chimeras of enhanced green fluorescent protein (EGFP) and full-length pre-pro-VWF (VWF-EGFP) or the VWF propolypeptide (proregion-EGFP) were made and expressed in human umbilical vein endothelial cells. Expression of VWF-EGFP or proregion-EGFP resulted in fluorescent rod-shaped organelles that recruited the WPB membrane markers P-selectin and CD63. The WPB secretagogue histamine evoked exocytosis of these fluorescent WPBs and extracellular release of VWF-EGFP or proregion-EGFP. Secreted VWF-EGFP formed distinctive extracellular patches of fluorescence that were labeled with an extracellular antibody to VWF. The half-time for dispersal of VWF-EGFP from extracellular patches was 323.5 +/- 146.2 s (+/- S. D., n = 20 WPBs). In contrast, secreted proregion-EGFP did not form extracellular patches but dispersed rapidly from its site of release. The half-time for dispersal of proregion-EGFP following WPB exocytosis was 2.98 +/- 1.88 s (+/- S. D., n = 32 WPBs). The slow rate of loss of VWF-EGFP is consistent with the adhesive nature of this protein for the endothelial membrane. The much faster rate of loss of proregion-EGFP indicates that this protein does not interact strongly with extracellular VWF or the endothelial membrane and consequently may not play an adhesive role at the endothelial cell surface.	Natl Inst Med Res, London NW7 1AA, England; Univ Edinburgh, Dept Neurosci, Edinburgh EH8 9JZ, Midlothian, Scotland	MRC National Institute for Medical Research; University of Edinburgh	Carter, T (corresponding author), Natl Inst Med Res, Mill Hill, London NW7 1AA, England.	tcarter@nimr.mrc.ac.uk	Carter, Tom/E-5035-2016	Carter, Tom/0000-0002-6248-7278	MRC [MC_U117570589, MC_U117573808] Funding Source: UKRI; Medical Research Council [MC_U117570589, MC_U117573808] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andre P, 2000, BLOOD, V96, P3322, DOI 10.1182/blood.V96.10.3322.h8003322_3322_3328; Arribas M, 2000, TRAFFIC, V1, P783, DOI 10.1034/j.1600-0854.2000.011005.x; Blagoveshchenskaya AD, 2002, MOL BIOL CELL, V13, P1582, DOI 10.1091/mbc.01-09-0462; BONFANTI R, 1989, BLOOD, V73, P1109; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; de Wit TR, 2003, ARTERIOSCL THROM VAS, V23, P755, DOI 10.1161/01.ATV.0000069847.72001.E8; de Wit TR, 2001, BEST PRACT RES CL HA, V14, P241; ERENT M, 2004, BIOPHYS J S1, V86; FAY PJ, 1986, SCIENCE, V232, P995, DOI 10.1126/science.3486471; Haberichter SL, 2000, BLOOD, V96, P1808, DOI 10.1182/blood.V96.5.1808.h8001808_1808_1815; Hannah MJ, 2002, SEMIN CELL DEV BIOL, V13, P313, DOI 10.1016/S1084-9521(02)00061-7; Isobe T, 1997, J BIOL CHEM, V272, P8447, DOI 10.1074/jbc.272.13.8447; Kobayashi T, 2000, MOL BIOL CELL, V11, P1829, DOI 10.1091/mbc.11.5.1829; Royo T, 1998, THROMB HAEMOSTASIS, V80, P677; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Shih PT, 1999, CIRC RES, V84, P345, DOI 10.1161/01.RES.84.3.345; SPORN LA, 1989, J CELL BIOL, V108, P1283, DOI 10.1083/jcb.108.4.1283; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; TAKAGI J, 1989, J BIOL CHEM, V264, P10425; van Mourik JA, 2002, HISTOCHEM CELL BIOL, V117, P113, DOI 10.1007/s00418-001-0368-9; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VISCHER UM, 1993, BLOOD, V82, P1184, DOI 10.1182/blood.V82.4.1184.1184; WAGNER DD, 1987, P NATL ACAD SCI USA, V84, P1955, DOI 10.1073/pnas.84.7.1955; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WEIBEL ER, 1964, J CELL BIOL, V23, P101, DOI 10.1083/jcb.23.1.101; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9; Zupancic G, 2002, J PHYSIOL-LONDON, V544, P741, DOI 10.1113/jphysiol.2002.027490	30	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22827	22830		10.1074/jbc.M412547200	http://dx.doi.org/10.1074/jbc.M412547200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15831502	hybrid			2022-12-25	WOS:000229741800034
J	Sutherland, BW; Kucab, J; Wu, J; Lee, C; Cheang, MCU; Yorida, E; Turbin, D; Dedhar, S; Nelson, C; Pollak, M; Grimes, HL; Miller, K; Badve, S; Huntsman, D; Blake-Gilks, C; Chen, M; Pallen, CJ; Dunn, SE				Sutherland, BW; Kucab, J; Wu, J; Lee, C; Cheang, MCU; Yorida, E; Turbin, D; Dedhar, S; Nelson, C; Pollak, M; Grimes, HL; Miller, K; Badve, S; Huntsman, D; Blake-Gilks, C; Chen, M; Pallen, CJ; Dunn, SE			Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells	ONCOGENE			English	Article						breast cancer; Akt; YB-1; phosphorylation; cold shock domain; signal transduction	PROTEIN-KINASE B/AKT; TRANSCRIPTION FACTOR YB-1; DOMINANT-NEGATIVE MUTANT; GLYCOGEN-SYNTHASE KINASE; INTEGRIN-LINKED KINASE; BINDING-PROTEIN; NUCLEAR EXPRESSION; P-GLYCOPROTEIN; GENE; PROGRESSION	Akt/PKBis a serine/threonine kinase that promotes tumor cell growth by phosphorylating transcription factors and cell cycle proteins. There is particular interest in finding tumor-specific substrates for Akt to understand how this protein functions in cancer and to provide new avenues for therapeutic targeting. Our laboratory sought to identify novel Akt substrates that are expressed in breast cancer. In this study, we determined that activated Akt is positively correlated with the protein expression of the transcription/translation factor Y-box binding protein-1 (YB-1) in primary breast cancer by screening tumor tissue microarrays. We therefore questioned whether Akt and YB-1 might be functionally linked. Herein, we illustrate that activated Akt binds to and phosphorylates the YB-1 cold shock domain at Ser102. We then addressed the functional significance of disrupting Ser102 by mutating it to Ala102. Following the stable expression of Flag: YB-1 and Flag: YB-1 ( Ala102) in MCF-7 cells, we observed that disruption of the Akt phosphorylation site on YB-1 suppressed tumor cell growth in soft agar and in monolayer. This correlated with an inhibition of nuclear translocation by the YB-1( Ala102) mutant. In conclusion, YB-1 is a new Akt substrate and disruption of this specific site inhibits tumor cell growth.	Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Dept Pediat, Lab Oncogenom Res, Vancouver, BC V5Z 4H4, Canada; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; Vancouver Hosp & Hlth Sci Ctr, Genet Pathol Evaluat Ctr, Vancouver, BC V5Z 1M9, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Vancouver Gen Hosp, Jack Bell Res Labs, Prostate Ctr, Vancouver, BC, Canada; McGill Univ, Dept Med, Div Expt Med, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; Inst Cellular Therapeut, Louisville, KY USA; Indiana Univ, Dept Med, Bloomington, IN USA; Indiana Univ, Dept Pathol, Bloomington, IN USA; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Dept Pediat, Cell Phosphosignaling Lab, Vancouver, BC V5Z 4H4, Canada	University of British Columbia; Fred Hutchinson Cancer Center; University of British Columbia; British Columbia Cancer Agency; University of British Columbia; McGill University; McGill University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of British Columbia	Dunn, SE (corresponding author), Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Dept Pediat, Lab Oncogenom Res, 950 W 28th Ave,Room 3083, Vancouver, BC V5Z 4H4, Canada.	sedunn@interchange.ubc.ca	Pollak, Michael/G-9094-2011; Huntsman, David/ABE-6082-2020	Pollak, Michael/0000-0003-3047-0604; Cheang, Maggie Chon U/0000-0001-5718-2501; Dedhar, Shoukat/0000-0003-4355-1657; Pallen, Catherine/0000-0002-3576-5295; Badve, Sunil/0000-0001-8861-9980; Grimes, H. Leighton/0000-0001-8162-6758				Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Bader AG, 2003, P NATL ACAD SCI USA, V100, P12384, DOI 10.1073/pnas.2135336100; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dunn SE, 1998, CANCER RES, V58, P3353; Dunn SE, 2001, CANCER RES, V61, P1367; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Gimenez-Bonafe P, 2004, PROSTATE, V59, P337, DOI 10.1002/pros.20023; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Higashi K, 2003, J BIOL CHEM, V278, P43470, DOI 10.1074/jbc.M302339200; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kloks CPAM, 2002, J MOL BIOL, V316, P317, DOI 10.1006/jmbi.2001.5334; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Makretsov NA, 2004, CLIN CANCER RES, V10, P6143, DOI 10.1158/1078-0432.CCR-04-0429; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Oda Y, 2003, J PATHOL, V199, P251, DOI 10.1002/path.1282; Oh JS, 2002, NEOPLASIA, V4, P204, DOI 10.1038/sj.neo.7900229; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Rubinstein DB, 2002, CANCER RES, V62, P4985; Shibao K, 1999, INT J CANCER, V83, P732; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Swamynathan SK, 2002, BIOCHEM BIOPH RES CO, V296, P451, DOI 10.1016/S0006-291X(02)00875-6; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Yahata H, 2002, J CANCER RES CLIN, V128, P621, DOI 10.1007/s00432-002-0386-6; Zhou BP, 2001, NAT CELL BIOL, V3, P438	39	220	230	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4281	4292		10.1038/sj.onc.1208590	http://dx.doi.org/10.1038/sj.onc.1208590			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806160				2022-12-25	WOS:000229815300011
J	Brown, ST; Scragg, JL; Boyle, JP; Hudasek, K; Peers, C; Fearon, IM				Brown, ST; Scragg, JL; Boyle, JP; Hudasek, K; Peers, C; Fearon, IM			Hypoxic augmentation of Ca2+channel currents requires a functional electron transport chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MITOCHONDRIAL DYSFUNCTION; CALCIUM HOMEOSTASIS; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; BETA; CELLS; MODEL; SUPEROXIDE; ASTROCYTES	The incidence of Alzheimer disease is increased following ischemic episodes, and we previously demonstrated that following chronic hypoxia (CH), amyloid b (Ab) peptide-mediated increases in voltage-gated L-type Ca-2(2+ channel activity contribute to the Ca2+ dyshomeostasis seen in Alzheimer disease. Because in certain cell types mitochondria are responsible for detecting altered O) (levels we examined the role of mitochondrial oxidant production in the regulation of recombinant Ca2+ channel a)(1C) (subunits during CH and exposure to Ab-(1-40). In wild-type (r+) HEK 293 cells expressing recombinant L-type a)(1C) (subunits, Ca2+ currents were enhanced by prolonged (24 h) exposure to either CH (6% O)() or Ab-(1-40) (50 nM). By contrast the response to CH was absent in r0 cells in which the mitochondrial electron transport chain (ETC) was depleted following long term treatment with ethidium bromide or in r+ cells cultured in the presence of 1 mM rotenone. CH was mimicked in r0 cells by the exogenous production of O)(2)(2). by xanthine/xanthine oxidase. Furthermore Ab-(1-40) enhanced currents in r0 cells to a degree similar to that seen in cells with an intact ETC. The antioxidants ascorbate (200 mM) and Trolox (500 mM) ablated the effect of CH in r+ cells but were without effect on Ab-(1-40)-mediated augmentation of Ca2+ current in r0 cells. Thus oxidant production in the mitochondrial ETC is a critical factor, acting upstream of amyloid b peptide production in the up-regulation of Ca2+ channels in response to CH.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; Univ Leeds, Sch Med, Leeds LS2 9JT, W Yorkshire, England; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	University of Manchester; University of Leeds; McMaster University	Fearon, IM (corresponding author), Univ Manchester, Fac Life Sci, G38 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	ian.fearon@manchester.ac.uk	Boyle, John/N-4868-2016	Peers, Chris/0000-0002-8354-346X				Abramov AY, 2004, J NEUROSCI, V24, P565, DOI 10.1523/JNEUROSCI.4042-03.2004; Fearon IM, 1997, J PHYSIOL-LONDON, V500, P551, DOI 10.1113/jphysiol.1997.sp022041; Green KN, 2002, J NEUROCHEM, V81, P1043, DOI 10.1046/j.1471-4159.2002.00907.x; Green KN, 2002, J PHYSIOL-LONDON, V541, P1013, DOI 10.1113/jphysiol.2002.017582; Green KN, 2001, J NEUROCHEM, V77, P953, DOI 10.1046/j.1471-4159.2001.00338.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hartness ME, 2003, J BIOL CHEM, V278, P51422, DOI 10.1074/jbc.M309463200; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kim SH, 2001, LIFE SCI, V68, P2741, DOI 10.1016/S0024-3205(01)01074-8; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Lambert AJ, 2004, J BIOL CHEM, V279, P39414, DOI 10.1074/jbc.M406576200; Li F, 2004, J NEUROCHEM, V89, P1308, DOI 10.1111/j.1471-4159.2004.02455.x; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; Mattson MP, 2002, J NEUROVIROL, V8, P539, DOI 10.1080/13550280290100978; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mattson MP, 2001, J MOL NEUROSCI, V17, P205, DOI 10.1385/JMN:17:2:205; Moroney JT, 1996, STROKE, V27, P1283, DOI 10.1161/01.STR.27.8.1283; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Schroedl C, 2002, AM J PHYSIOL-LUNG C, V283, pL922, DOI 10.1152/ajplung.00014.2002; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; Scragg JL, 2004, FASEB J, V18, P150, DOI 10.1096/fj.04-2659fje; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sharp FR, 2004, NAT REV NEUROSCI, V5, P437, DOI 10.1038/nrn1408; Smith IF, 2004, J NEUROCHEM, V88, P869, DOI 10.1016/j.1471-4159.2003.02212.x; Smith MA, 2002, NEUROCHEM INT, V40, P527, DOI 10.1016/S0197-0186(01)00123-1; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Valencia A, 2004, FREE RADICAL BIO MED, V36, P1112, DOI 10.1016/j.freeradbiomed.2004.02.013; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Walter J, 2001, CURR OPIN NEUROBIOL, V11, P585, DOI 10.1016/S0959-4388(00)00253-1; Waypa GB, 2001, CIRC RES, V88, P1259, DOI 10.1161/hh1201.091960; Wen Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/j.brainres.2003.09.086; Wolfe MS, 2003, CURR TOP DEV BIOL, V54, P233, DOI 10.1016/S0070-2153(03)54011-X; Wyatt CN, 2004, J PHYSIOL-LONDON, V556, P175, DOI 10.1113/jphysiol.2003.058131	35	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21706	21712		10.1074/jbc.M503144200	http://dx.doi.org/10.1074/jbc.M503144200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824110	hybrid			2022-12-25	WOS:000229557900005
J	Fujimori, T; Hihara, Y; Sonoike, K				Fujimori, T; Hihara, Y; Sonoike, K			PsaK2 subunit in photosystem I is involved in state transition under high light condition in the cyanobacterium Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCITATION-ENERGY TRANSFER; PSI-K SUBUNIT; PCC 6803; TARGETED INACTIVATION; THYLAKOID MEMBRANES; GENE; PHOTOSYNTHESIS; PHYCOBILISOMES; COMPLEX; FLUORESCENCE	To avoid the photodamage, cyanobacteria regulate the distribution of light energy absorbed by phycobilisome antenna either to photosystem II or to photosystem I ( PSI) upon high light acclimation by the process so-called state transition. We found that an alternative PSI subunit, PsaK2 (sll0629 gene product), is involved in this process in the cyanobacterium Synechocystis sp. PCC 6803. An examination of the subunit composition of the purified PSI reaction center complexes revealed that PsaK2 subunit was absent in the PSI complexes under low light condition, but was incorporated into the complexes during acclimation to high light. The growth of the psaK2 mutant on solid medium was inhibited under high light condition. We determined the photosynthetic characteristics of the wild type strain and the two mutants, the psaK1 ( ssr0390) mutant and the psaK2 mutant, using pulse amplitude modulation fluorometer. Non-photochemical quenching, which reflects the energy transfer from phycobilisome to PSI in cyanobacteria, was higher in high light grown cells than in low light grown cells, both in the wild type and the psaK1 mutant. However, this change of non-photochemical quenching during acclimation to high light was not observed in the psaK2 mutant. Thus, PsaK2 subunit is involved in the energy transfer from phycobilisome to PSI under high light condition. The role of PsaK2 in state transition under high light condition was also confirmed by chlorophyll fluorescence emission spectra determined at 77 K. The results suggest that PsaK2-dependent state transition is essential for the growth of this cyanobacterium under high light condition.	Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Kashiwa, Chiba 2778562, Japan; Saitama Univ, Fac Sci, Dept Biochem & Mol Biol, Urawa, Saitama 3388570, Japan	University of Tokyo; Saitama University	Sonoike, K (corresponding author), Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Box 101,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	sonoike@k.u-tokyo.ac.jp	Hihara, Yukako/E-3461-2010; Hihara, Yukako/AAX-2065-2020; Sonoike, Kintake/E-3699-2010; Hihara, Yukako/AAO-6742-2020	Sonoike, Kintake/0000-0002-5327-473X; Hihara, Yukako/0000-0003-1916-2053				ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; Ashby MK, 1999, PHOTOSYNTH RES, V61, P169, DOI 10.1023/A:1006217201666; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; BONAVENTURA C, 1969, BIOCHIM BIOPHYS ACTA, V189, P366, DOI 10.1016/0005-2728(69)90168-6; Campbell D, 1998, MICROBIOL MOL BIOL R, V62, P667, DOI 10.1128/MMBR.62.3.667-683.1998; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; CLARKE AK, 1995, PLANTA, V197, P553; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Emlyn-Jones D, 1999, MOL MICROBIOL, V33, P1050, DOI 10.1046/j.1365-2958.1999.01547.x; GLAZER AN, 1984, BIOCHIM BIOPHYS ACTA, V768, P29, DOI 10.1016/0304-4173(84)90006-5; GRIMME LH, 1972, BIOCHEM BIOPH RES CO, V49, P1617, DOI 10.1016/0006-291X(72)90527-X; Hihara Y, 2001, PLANT CELL, V13, P793, DOI 10.1105/tpc.13.4.793; Hihara Y, 1998, PLANT PHYSIOL, V117, P1205, DOI 10.1104/pp.117.4.1205; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; Jensen PE, 2004, J BIOL CHEM, V279, P24212, DOI 10.1074/jbc.M403147200; Jensen PE, 2002, J BIOL CHEM, V277, P2798, DOI 10.1074/jbc.M110448200; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KJAERULFF S, 1993, J BIOL CHEM, V268, P18912; KRUPA Z, 1991, PHYSIOL PLANTARUM, V82, P1; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; Mao HB, 2002, FEBS LETT, V519, P82, DOI 10.1016/S0014-5793(02)02715-1; MULLINEAUX CW, 1992, BIOCHIM BIOPHYS ACTA, V1100, P285, DOI 10.1016/0167-4838(92)90483-T; MULLINEAUX CW, 1994, BBA-BIOENERGETICS, V1184, P71, DOI 10.1016/0005-2728(94)90155-4; Mullineaux CW, 1997, NATURE, V390, P421, DOI 10.1038/37157; MURATA N, 1969, BIOCHIM BIOPHYS ACTA, V172, P242, DOI 10.1016/0005-2728(69)90067-X; Naithani S, 2000, PHOTOSYNTH RES, V63, P225, DOI 10.1023/A:1006463932538; Nakamoto H, 1999, PLANT CELL PHYSIOL, V40, P9, DOI 10.1093/oxfordjournals.pcp.a029479; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; ROGNER M, 1990, J BIOL CHEM, V265, P6189; Sarcina M, 2001, J BIOL CHEM, V276, P46830, DOI 10.1074/jbc.M107111200; SONOIKE K, 1994, PLANTA, V194, P287, DOI 10.1007/BF01101690; Sonoike K, 2001, PLANT CELL PHYSIOL, V42, P379, DOI 10.1093/pcp/pce046; Sun J, 1998, METHOD ENZYMOL, V297, P124; van Thor JJ, 1998, BOT ACTA, V111, P430, DOI 10.1111/j.1438-8677.1998.tb00731.x; Zhang SP, 2004, J BIOL CHEM, V279, P3180, DOI 10.1074/jbc.M311640200; ZILINSKAS BA, 1986, PHOTOSYNTH RES, V10, P7, DOI 10.1007/BF00024183	37	40	42	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22191	22197		10.1074/jbc.M500369200	http://dx.doi.org/10.1074/jbc.M500369200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824118	hybrid			2022-12-25	WOS:000229557900064
J	Phillips, RJ; Mestas, J; Gharee-Kermani, M; Burdick, MD; Sica, A; Belperio, JA; Keane, MP; Strieter, RM				Phillips, RJ; Mestas, J; Gharee-Kermani, M; Burdick, MD; Sica, A; Belperio, JA; Keane, MP; Strieter, RM			Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; HIF-ALPHA; PTEN; HIF-1-ALPHA; ANGIOGENESIS; METASTASIS; PROMOTER; BIOLOGY; KINASE	Non-small cell lung cancer (NSCLC) expresses a particularly aggressive metastatic phenotype, and patients with this disease have a poor prognosis. CXC chemokine receptor 4 (CXCR4) is a cell surface receptor that has been shown to mediate the metastasis of many solid tumors including lung, breast, kidney, and prostate. In addition, overexpression of the epidermal growth factor receptor ( EGFR) is associated with the majority of NSCLC and has been implicated in the process of malignant transformation by promoting cell proliferation, cell survival, and motility. Here we show for the first time that activation of the EGFR by EGF increases CXCR4 expression and the migratory capacity of NSCLC cells. Furthermore, many solid tumors are associated with low oxygen tension, and when NSCLC cells were cultured with EGF under hypoxic conditions, CXCR4 expression was dramatically enhanced. A molecular analysis of these events indicated that augmented CXCR4 expression was regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/ mammalian target of rapamycin signal transduction pathway, activation of hypoxia inducible factor (HIF) 1 alpha, and ultimately HIF-1-dependent transcription of the CXCR4 gene. Thus, a combination of low oxygen tension and overexpression of EGFR within the primary tumor of NSCLC may provide the microenvironmental signals necessary to upregulate CXCR4 expression and promote metastasis.	Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; Ist Ric Farmacol Mario Negri, I-20157 Milan, Italy	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Strieter, RM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, 900 Vet Ave,14-154 Warren Hall, Los Angeles, CA 90095 USA.	rstrieter@mednet.ucla.edu	Sica, Antonio/AAB-9546-2020		NCI NIH HHS [P50 CA 90388, CA 87879] Funding Source: Medline; NHLBI NIH HHS [HL 66027] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087879, P50CA090388] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066027] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belperio JA, 2004, CHEST, V125, p156S, DOI 10.1378/chest.125.5_suppl.156S; Belperio JA, 2002, AM J RESP CELL MOL, V27, P419, DOI 10.1165/rcmb.2002-0009OC; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Brognard J, 2001, CANCER RES, V61, P3986; Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014-5793(98)00359-7; DEVESA SS, 1995, JNCI-J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; FIDLER IJ, 1990, CANCER RES, V50, P6130; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Goberdhan DCI, 2003, HUM MOL GENET, V12, pR239, DOI 10.1093/hmg/ddg288; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HENDLER FJ, 1984, J CLIN INVEST, V74, P647, DOI 10.1172/JCI111463; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Jung YJ, 2003, BIOCHEM J, V370, P1011, DOI 10.1042/BJ20021279; Krishnamachary B, 2003, CANCER RES, V63, P1138; KUZMIN I, 1995, ONCOGENE, V10, P2185; Leung Sherri K., 2002, Journal of Biomedicine & Biotechnology, V2, P131, DOI 10.1155/S1110724302205057; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Scotton CJ, 2001, CANCER RES, V61, P4961; Semenza G L, 2000, Respir Res, V1, P159, DOI 10.1186/rr27; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Smith W, 2004, SEMIN ONCOL, V31, P11, DOI 10.1053/j.seminoncol.2004.02.012; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Strieter RM, 2004, SEMIN CANCER BIOL, V14, P195, DOI 10.1016/j.semcancer.2003.10.006; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Taichman RS, 2002, CANCER RES, V62, P1832; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Zatyka M, 2002, J MED GENET, V39, P463, DOI 10.1136/jmg.39.7.463; Zhong H, 2000, CANCER RES, V60, P1541; Zlotnik A, 2004, SEMIN CANCER BIOL, V14, P181, DOI 10.1016/j.semcancer.2003.10.004; Zundel W, 2000, GENE DEV, V14, P391	45	271	294	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22473	22481		10.1074/jbc.M500963200	http://dx.doi.org/10.1074/jbc.M500963200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15802268	hybrid			2022-12-25	WOS:000229557900093
J	Sidhu, RS; Clough, RR; Bhullar, RP				Sidhu, RS; Clough, RR; Bhullar, RP			Regulation of phospholipase C-delta 1 through direct interactions with the small GTPase Ral and calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEINS; C-DELTA; CA2+ OSCILLATIONS; HUMAN PLATELETS; ACTIVATION; EFFECTOR; IDENTIFICATION; PATHWAY; COMPLEX; MEMBRANE	Second messengers generated from membrane lipids play a critical role in signaling and control diverse cellular processes. Despite being one of the most evolutionarily conserved of all the phosphoinositide-specific phospholipase C (PLC) isoforms, a family of enzymes responsible for hydrolysis of the membrane lipid phosphatidylinositol bisphosphate, the mechanism of PLC-delta 1 activation is still poorly understood. Here we report a novel regulatory mechanism for PLC-delta 1 activation that involves direct interaction of the small GTPase Ral and the universal calcium-signaling molecule calmodulin (CaM) with PLC-delta 1. In addition, we have identified a novel IQ type CaM binding motif within the catalytic region of PLC-delta 1 that is not found in other PLC isoforms. Binding of CaM at the IQ motif inhibits PLC-delta 1 activity, while addition of Ral reverses the inhibition. The overexpression of various Ral mutants in cells potentiates PLC-delta 1 activity. Thus, the Ral-CaM complex defines a multifaceted regulatory mechanism for PLC-delta 1 activation.	Univ Manitoba, Fac Dent, Dept Oral Biol, Winnipeg, MB R3E 0W2, Canada; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0W2, Canada	University of Manitoba; University of Manitoba	Bhullar, RP (corresponding author), Univ Manitoba, Fac Dent, Dept Oral Biol, Winnipeg, MB R3E 0W2, Canada.	bhullar@MS.Umanitoba.CA						Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Bauer B, 1999, J BIOL CHEM, V274, P17763, DOI 10.1074/jbc.274.25.17763; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Clough RR, 2002, J BIOL CHEM, V277, P28972, DOI 10.1074/jbc.M201504200; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; ELLIS MV, 1993, EUR J BIOCHEM, V213, P339, DOI 10.1111/j.1432-1033.1993.tb17767.x; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Gildea JJ, 2002, CANCER RES, V62, P982; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; HWANG JI, 2005, UNPUB BIOCH J; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Jilkina O, 1996, BBA-MOL CELL RES, V1314, P157, DOI 10.1016/S0167-4889(96)00073-0; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Katan M, 1999, FEBS LETT, V452, P36, DOI 10.1016/S0014-5793(99)00531-1; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Kouchi Z, 2004, J BIOL CHEM, V279, P10408, DOI 10.1074/jbc.M313801200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; McCullar JS, 2003, J BIOL CHEM, V278, P33708, DOI 10.1074/jbc.M301940200; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Nakamura Y, 2003, EMBO J, V22, P2981, DOI 10.1093/emboj/cdg302; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; PARK DG, 1993, J BIOL CHEM, V268, P4573; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Richard EA, 1997, P NATL ACAD SCI USA, V94, P14095, DOI 10.1073/pnas.94.25.14095; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Stewart AJ, 2005, INT J MOL MED, V15, P117; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; WAHL MI, 1992, J BIOL CHEM, V267, P10447; Wang KL, 1997, J BIOL CHEM, V272, P16002, DOI 10.1074/jbc.272.25.16002; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Wing MR, 2003, J BIOL CHEM, V278, P41253, DOI 10.1074/jbc.M306904200; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; WU DQ, 1993, J BIOL CHEM, V268, P3704; Xu LZ, 2003, MOL CELL BIOL, V23, P645, DOI 10.1128/MCB.23.2.645-654.2003; Yamniuk AP, 2004, MOL BIOTECHNOL, V27, P33, DOI 10.1385/MB:27:1:33; Ziegelhoffer A, 2001, CARDIOVASC RES, V49, P118, DOI 10.1016/S0008-6363(00)00209-1	55	51	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21933	21941		10.1074/jbc.M412966200	http://dx.doi.org/10.1074/jbc.M412966200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817490	hybrid			2022-12-25	WOS:000229557900034
J	Tang, XQ; Powelka, AM; Soriano, NA; Czech, MP; Guilherme, A				Tang, XQ; Powelka, AM; Soriano, NA; Czech, MP; Guilherme, A			PTEN, but not SHIP2, suppresses insulin signaling through the phosphatidylinositol 3-kinase/Akt pathway in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; TUMOR-SUPPRESSOR; CAENORHABDITIS-ELEGANS; PHOSPHOINOSITIDE 3-KINASE; GLUT4 TRANSLOCATION; GLUCOSE-TRANSPORT; AKT; PHOSPHATASE; HOMOLOG; ACTIVATION	Glucose homeostasis is controlled by insulin in part through the stimulation of glucose transport in muscle and fat cells. This insulin signaling pathway requires phosphatidylinositol ( PI) 3-kinase- mediated 3'-polyphosphoinositide generation and activation of Akt/ protein kinase B. Previous experiments using dominant negative constructs and gene ablation in mice suggested that two phosphoinositide phosphatases, SH2 domain- containing inositol 5'- phosphatase 2 (SHIP2) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) negatively regulate this insulin signaling pathway. Here we directly tested this hypothesis by selectively inhibiting the expression of SHIP2 or PTEN in intact cultured 3T3-L1 adipocytes through the use of short interfering RNA ( siRNA). Attenuation of PTEN expression by RNAi markedly enhanced insulin-stimulated Akt and glycogen synthase kinase 3 alpha (GSK-3 alpha) phosphorylation, as well as deoxyglucose transport in 3T3-L1 adipocytes. In contrast, depletion of SHIP2 protein by about 90% surprisingly failed to modulate these insulin-regulated events under identical assay conditions. In control studies, no diminution of insulin signaling to the mitogen- activated protein kinases Erk1 and Erk2 was observed when either PTEN or SHIP2 were depleted. Taken together, these results demonstrate that endogenous PTEN functions as a suppressor of insulin signaling to glucose transport through the PI3-kinase pathway in cultured 3T3-L1 adipocytes.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Guilherme, A (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	Adilson.Guilherme@umassmed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030898, R37DK030898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 30898] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Butler M, 2002, DIABETES, V51, P1028, DOI 10.2337/diabetes.51.4.1028; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carricaburu V, 2003, P NATL ACAD SCI USA, V100, P9867, DOI 10.1073/pnas.1734038100; Chaussade C, 2003, MOL ENDOCRINOL, V17, P2448, DOI 10.1210/me.2003-0261; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Choi Y, 2002, ONCOGENE, V21, P5289, DOI 10.1038/sj.onc.1205650; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gil EB, 1999, P NATL ACAD SCI USA, V96, P2925, DOI 10.1073/pnas.96.6.2925; Guilherme A, 2004, J BIOL CHEM, V279, P10593, DOI 10.1074/jbc.M307702200; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Ijuin T, 2000, J BIOL CHEM, V275, P10870, DOI 10.1074/jbc.275.15.10870; Ijuin T, 2003, MOL CELL BIOL, V23, P1209, DOI 10.1128/MCB.23.4.1209-1220.2003; Ishihara H, 1999, BIOCHEM BIOPH RES CO, V260, P265, DOI 10.1006/bbrc.1999.0888; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lawe DC, 2003, MOL BIOL CELL, V14, P2935, DOI 10.1091/mbc.E02-09-0591; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mihaylova VT, 1999, P NATL ACAD SCI USA, V96, P7427, DOI 10.1073/pnas.96.13.7427; Mosser VA, 2001, BIOCHEM BIOPH RES CO, V288, P1011, DOI 10.1006/bbrc.2001.5876; Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Ono H, 2001, MOL ENDOCRINOL, V15, P1411, DOI 10.1210/me.15.8.1411; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; Sasaoka T, 2004, J BIOL CHEM, V279, P14835, DOI 10.1074/jbc.M311534200; Sasaoka T, 2001, DIABETOLOGIA, V44, P1258, DOI 10.1007/s001250100645; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shisheva A, 2003, FRONT BIOSCI-LANDMRK, V8, pS945, DOI 10.2741/1101; Sleeman MW, 2005, NAT MED, V11, P199, DOI 10.1038/nm1178; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wada T, 2001, MOL CELL BIOL, V21, P1633, DOI 10.1128/MCB.21.5.1633-1646.2001; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3	59	85	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22523	22529		10.1074/jbc.M501949200	http://dx.doi.org/10.1074/jbc.M501949200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824124	hybrid			2022-12-25	WOS:000229557900100
J	Wijayanti, N; Kietzmann, T; Immenschuh, S				Wijayanti, N; Kietzmann, T; Immenschuh, S			Heme oxygenase-1 gene activation by the NAD(P)H oxidase inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride via a protein kinase B, p38-dependent signaling pathway in monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P38 MAP KINASE; NF-KAPPA-B; TRANSCRIPTION FACTOR; NADPH OXIDASE; DEPENDENT ACTIVATION; OXIDATIVE STRESS; EXPRESSION; ANTIOXIDANT; INDUCTION; TARGET	Heme oxygenase (HO)-1 is the inducible isoform of the rate-limiting enzyme of heme degradation and modulates the inflammatory immune response. Because HO-1 is up-regulated by NAD(P)H oxidase activators such as lipopolysaccharide and 12-O-tetradecanoylphorbol-13-acetate in monocytic cells, we investigated the gene regulation of HO-1 by the chemical NAD(P) H oxidase inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF). Unexpectedly, AEBSF induced endogenous gene expression and promoter activity of HO-1 in cell cultures of human and mouse monocytes. Inhibition of the phosphatidylinositol 3-kinase/protein kinase B (PKB) pathway by pharmacological inhibitors and cotransfection of an expression vector for a dominant negative mutant of PKB reduced the AEBSF-dependent induction of HO-1 gene transcription. Accordingly, overexpressed constitutively active PKB markedly up-regulated HO-1 promoter activity. AEBSF activated the mitogen-activated protein kinases (MAPK) JNK and p38. Inhibition of p38 alpha and p38 beta, but not that of JNK or p38 gamma and p38 delta, prevented the induction of HO-1 gene expression by AEBSF. p38 was stimulated by AEBSF in a PKB-dependent manner as demonstrated by a luciferase assay with a Gal4-CHOP fusion protein. Finally, AEBSF- and PKB-dependent induction of HO-1 promoter activity was reduced by simultaneous mutation of an E-box motif (-47/-42) and a cAMP response element/AP-1 element (-664/-657) of the proximal HO-1 gene promoter. Over-expression of the basic helix-loop-helix transcription factor USF2 and coactivator p300 enhanced the AEBSF- dependent response of the HO-1 promoter. The data suggest that the transcriptional induction of HO-1 gene expression by AEBSF is mediated via activation of a PKB, p38 MAPK signaling pathway.	Univ Giessen Klinikum, Inst Klin Immunol & Transfusionsmed, D-35392 Giessen, Germany; Univ Kaiserslautern, Fachbereich Chem Biochem, D-67663 Kaiserslautern, Germany	University Hospital of Giessen & Marburg; University of Kaiserslautern	Wijayanti, N (corresponding author), Univ Giessen Klinikum, Inst Klin Immunol & Transfusionsmed, Langhansstr 7, D-35392 Giessen, Germany.	Stephan.Immenschuh@immunologie.med.uni-giessen.de	Immenschuh, Stephan/AAM-9181-2020	Immenschuh, Stephan/0000-0003-3722-5791; Wijayanti, Nastiti/0000-0001-6483-2816; Kietzmann, Thomas/0000-0003-0242-8636				ABRAHAM NG, 1988, INT J BIOCHEM, V20, P543, DOI 10.1016/0020-711X(88)90093-6; Alam J, 2004, ANTIOXID REDOX SIGN, V6, P924, DOI 10.1089/1523086041798114; Avogaro A, 2003, J CLIN ENDOCR METAB, V88, P1753, DOI 10.1210/jc.2002-021025; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bestilny LJ, 2000, EXP CELL RES, V256, P264, DOI 10.1006/excr.2000.4821; Blobel GA, 2002, J LEUKOCYTE BIOL, V71, P545; CHOI SY, 1996, J PARODONTOL IMPLANT, V15, P19; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; GALANG CK, 1994, ONCOGENE, V9, P2913; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; Goueli BS, 2003, ONCOGENE, V22, P8042, DOI 10.1038/sj.onc.1206847; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Hartsfield CL, 1998, FASEB J, V12, P1675, DOI 10.1096/fasebj.12.15.1675; Hess A, 2003, J BIOL CHEM, V278, P45419, DOI 10.1074/jbc.M307871200; Hock TD, 2004, BIOCHEM J, V383, P209, DOI 10.1042/BJ20040794; Immenschuh S, 2000, MOL PHARMACOL, V57, P610, DOI 10.1124/mol.57.3.610; Immenschuh S, 2000, BIOCHEM PHARMACOL, V60, P1121, DOI 10.1016/S0006-2952(00)00443-3; Kapturczak MH, 2004, AM J PATHOL, V165, P1045, DOI 10.1016/S0002-9440(10)63365-2; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; Lee HM, 2003, FEBS LETT, V549, P110, DOI 10.1016/S0014-5793(03)00800-7; Lee TS, 2004, CIRCULATION, V110, P1296, DOI 10.1161/01.CIR.0000140694.67251.9C; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; MURAOSA Y, 1993, MOL CELL BIOL, V13, P7881, DOI 10.1128/MCB.13.12.7881; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Roth U, 2004, J BIOL CHEM, V279, P2623, DOI 10.1074/jbc.M308391200; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Scapagnini G, 2002, MOL PHARMACOL, V61, P554, DOI 10.1124/mol.61.3.554; Singh VP, 2001, GASTROENTEROLOGY, V120, P1818, DOI 10.1053/gast.2001.24883; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Taniyama Y, 2004, AM J PHYSIOL-CELL PH, V287, pC494, DOI 10.1152/ajpcell.00439.2003; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; Wagener FADTG, 2001, BLOOD, V98, P1802, DOI 10.1182/blood.V98.6.1802; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wijayanti N, 2004, ANTIOXID REDOX SIGN, V6, P802, DOI 10.1089/1523086041798132; Wijayanti N, 2004, CURR MED CHEM, V11, P981, DOI 10.2174/0929867043455521; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165	47	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21820	21829		10.1074/jbc.M502943200	http://dx.doi.org/10.1074/jbc.M502943200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15833736	hybrid			2022-12-25	WOS:000229557900021
J	Hanson, AJ; Nahreini, P; Andreatta, C; Yan, XD; Prasad, KN				Hanson, AJ; Nahreini, P; Andreatta, C; Yan, XD; Prasad, KN			Role of the adenosine 3 ',5 '-cyclic monophosphate (cAMP) in enhancing the efficacy of siRNA-mediated gene silencing in neuroblastoma cells	ONCOGENE			English	Article						cAMP; siRNA; neuroblastoma; phosphatidylinositol 3-kinase	INDUCED DIFFERENTIATION; RNA INTERFERENCE; MAMMALIAN-CELLS; EXPRESSION; GROWTH; APOPTOSIS; NEURONS; CULTURE; CANCER	Gene-silencing activity mediated by siRNA has been demonstrated in mammalian cells; however, the mechanism of its regulation is not well understood. Since downregulation of a number of genes occurs during adenosine 3',5'-cyclic monophosphate (cAMP)-induced differentiation of neuroblastoma ( NB) cells, it is possible that cAMP may play a role in regulating siRNA activity during differentiation. To study this, we utilized an NB cell line (NBP2-PN25) that expresses a short-lived green fluorescent protein (d2EGFP) under the CMV promoter. These cells were transfected with a retroviral plasmid that expresses U6 promoter-driven expression of siRNA targeted to d2EGFP and then were treated with cAMP-elevating agents ( 200 mu g/ml RO20- 1724, an inhibitor of cyclic nucleotide phosphodiesterase, and 1 mu g/ml prostaglandin A(1), a stimulator of adenylate cyclase) for 2 or 24 h. The siRNA activity was measured by determining the level of intensity of d2EGFP protein by flow cytometry, and the level of d2EGFP mRNA by real-time PCR. The results showed that cAMP-elevating agents enhanced U6-driven siRNA activity directed towards d2EGFP in NB cells 24 h after treatment. One of the mechanisms of action of cAMP is mediated via phosphatidylinositol 3-kinase (PI3K) inhibition; therefore, we have investigated the effect of a PI3K inhibitor on siRNA activity. This study showed that inhibition of PI3K also enhanced U6-driven siRNA activity towards d2EGFP. cAMP-stimulating agents increased U6 transcript levels, perhaps suggesting that increased siRNA activity may in part be due to an increase in transcriptional activity. When NB cells were transfected with a synthetic siRNA directed to d2EGFP, both cAMP elevation and PI3K inhibition similarly enhanced siRNA activity. Sodium butyrate, which inhibits the growth of NB cells similar to the effect produced by cAMP, did not affect U6-driven siRNA activity towards d2EGFP. Protein kinase C (PKC) activation or inhibition also failed to affect siRNA activity in NB cells. This study also showed that cAMP elevation and PI3K inhibition increases U6-driven siRNA activity directed towards an endogenous gene, p53. Our data suggest a role for the cAMP pathway in affecting the efficacy of siRNA system during differentiation of NB cells.	Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Radiol,Ctr Vitamins & Canc Res, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Prasad, KN (corresponding author), Premier Mironutr Corp, 14 Galli Dr,Suite 200, Navato, CA 94949 USA.	kedar@knprasad.com			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018285] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG18285] Funding Source: Medline; NINDS NIH HHS [R01 NS38647] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Castell X, 2003, NEUROCHEM RES, V28, P557, DOI 10.1023/A:1022829608540; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hanson AJ, 2003, J NEUROSCI RES, V74, P148, DOI 10.1002/jnr.10726; KHALED M, 2003, PIGM CELL RES, V16, P573; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; Lee HT, 2003, INVEST OPHTH VIS SCI, V44, P3816, DOI 10.1167/iovs.03-0147; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Nahreini P, 2001, CELL MOL NEUROBIOL, V21, P509, DOI 10.1023/A:1013819423394; Nahreini P, 2001, CELL MOL NEUROBIOL, V21, P65, DOI 10.1023/A:1007173329237; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pickford AS, 2003, CELL MOL LIFE SCI, V60, P871, DOI 10.1007/s00018-003-2245-2; Poser S, 2003, J NEUROSCI, V23, P4420; PRASAD KN, 1980, LIFE SCI, V27, P1351, DOI 10.1016/0024-3205(80)90397-5; PRASAD KN, 1991, BIOL REV, V66, P431, DOI 10.1111/j.1469-185X.1991.tb01148.x; PRASAD KN, 1976, IN VITRO CELL DEV B, V12, P125; Takei Y, 2004, CANCER RES, V64, P3365, DOI 10.1158/0008-5472.CAN-03-2682; Tijsterman M, 2002, ANNU REV GENET, V36, P489, DOI 10.1146/annurev.genet.36.043002.091619; Yan XD, 2002, IN VITRO CELL DEV-AN, V38, P529	21	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4149	4154		10.1038/sj.onc.1208577	http://dx.doi.org/10.1038/sj.onc.1208577			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806165				2022-12-25	WOS:000229680300013
J	Kamalakaran, S; Radhakrishnan, SK; Beck, WT				Kamalakaran, S; Radhakrishnan, SK; Beck, WT			Identification of estrogen-responsive genes using a genome-wide analysis of promoter elements for transcription factor binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							START SITES; DATABASE; DNA; SEQUENCE; TRANSFAC; SYSTEM; DBTSS; TOOL	We developed a pipeline to identify novel genes regulated by the steroid hormone-dependent transcription factor, estrogen receptor, through a systematic analysis of upstream regions of all human and mouse genes. We built a data base of putative promoter regions for 23,077 human and 19,984 mouse transcripts from National Center for Biotechnology Information annotation and 8793 human and 6785 mouse promoters from the Data Base of Transcriptional Start Sites. We used this data base of putative promoters to identify potential targets of estrogen receptor by identifying estrogen response elements ( EREs) in their promoters. Our program correctly identified EREs in genes known to be regulated by estrogen in addition to several new genes whose putative promoters contained EREs. We validated six genes (KIAA1243, NRIP1, MADH9, NME3, TPD52L, and ABCG2) to be estrogen-responsive in MCF7 cells using reverse transcription PCR. To allow for extensibility of our program in identifying targets of other transcription factors, we have built a Web interface to access our data base and programs. Our Web-based program for Promoter Analysis of Genome, PAGen@UIC, allows a user to identify putative target genes for vertebrate transcription factors through the analysis of their upstream sequences. The interface allows the user to search the human and mouse promoter data bases for potential target genes containing one or more listed transcription factor binding sites (TFBSs) in their upstream elements, using either regular expression-based consensus or position weight matrices. The data base can also be searched for promoters harboring user-defined TFBSs given as a consensus or a position weight matrix. Furthermore, the user can retrieve putative promoter sequences for any given gene together with identified TFBSs located on its promoter. Orthologous promoters are also analyzed to determine conserved elements.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60612 USA; Univ Illinois, Dept Med Microbiol & Immunol, Chicago, IL 60612 USA; Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA; Univ Illinois, Ctr Canc, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Beck, WT (corresponding author), Univ Illinois, Dept Biopharmaceut Sci MC 865, 833 S Wood St, Chicago, IL 60612 USA.	wtbeck@uic.edu		Radhakrishnan, Senthil/0000-0002-5211-9498	NATIONAL CANCER INSTITUTE [R01CA030103, R01CA040570] Funding Source: NIH RePORTER; NCI NIH HHS [CA30103, CA40570] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bajic VB, 2003, NUCLEIC ACIDS RES, V31, P3605, DOI 10.1093/nar/gkg517; Benos PV, 2002, NUCLEIC ACIDS RES, V30, P4442, DOI 10.1093/nar/gkf578; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; Bulyk ML, 2004, GENOME BIOL, V5; Ee PLR, 2004, CANCER RES, V64, P1247, DOI 10.1158/0008-5472.CAN-03-3583; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Friedl JEF, 2002, MASTERING REGULAR EX; Halees AS, 2003, NUCLEIC ACIDS RES, V31, P3554, DOI 10.1093/nar/gkg549; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Kasprzyk A, 2004, GENOME RES, V14, P160, DOI 10.1101/gr.1645104; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Perier RC, 2000, NUCLEIC ACIDS RES, V28, P302, DOI 10.1093/nar/28.1.302; Perier RC, 1998, NUCLEIC ACIDS RES, V26, P353, DOI 10.1093/nar/26.1.353; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Rosenfeld CS, 2001, REPRODUCTION, V122, P215, DOI 10.1530/rep.0.1220215; Sanchez R, 2002, BIOESSAYS, V24, P244, DOI 10.1002/bies.10066; Schmid CD, 2004, NUCLEIC ACIDS RES, V32, pD82, DOI 10.1093/nar/gkh122; Schuldiner O, 2002, GENE, V292, P91, DOI 10.1016/S0378-1119(02)00668-6; SCHWABE JW, 2004, SCI STKE, pPE4; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stormo GD, 2000, BIOINFORMATICS, V16, P16, DOI 10.1093/bioinformatics/16.1.16; Sun H, 2004, BIOINFORMATICS, V20, P727, DOI 10.1093/bioinformatics/btg476; Suzuki Y, 2004, NUCLEIC ACIDS RES, V32, pD78, DOI 10.1093/nar/gkh076; Suzuki Y, 2002, NUCLEIC ACIDS RES, V30, P328, DOI 10.1093/nar/30.1.328; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281	33	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21491	21497		10.1074/jbc.M409176200	http://dx.doi.org/10.1074/jbc.M409176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15790569	hybrid			2022-12-25	WOS:000229438800070
J	Klamt, F; Shacter, E				Klamt, F; Shacter, E			Taurine chloramine, an oxidant derived from neutrophils, induces apoptosis in human B lymphoma cells through mitochondrial damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; HYPOCHLOROUS ACID; OXIDATIVE STRESS; AMINO-ACID; LEUKEMIA-CELLS; CYCLOSPORINE-A; DEATH; RECEPTOR; PHOSPHATIDYLSERINE	Taurine chloramine (TN-Cl) is one of the most abundant compounds generated by activated neutrophils. In contrast to HOCl, which causes necrosis, TN-Cl is a potent inducer of apoptosis in tumor cells. Here we show that the apoptosis induced by TN-Cl in human B lymphoma cells is dependent upon oxidant-mediated mitochondrial damage, a decrease in mitochondrial membrane potential, and caspase-9 activation. Further, we show that TN-Cl is taken up into the cells and is concentrated in the mitochondria, where it induces opening of the permeability transition pore and mitochondrial swelling. Identical activity is seen upon treatment of isolated mitochondria with TN-Cl and is blocked by the permeability transition pore inhibitors bongkrekic acid and cyclosporin A, as well as by the sulfhydryl-reducing agent tris(2-carboxyethyl)-phosphine. The data suggest that TN-Cl causes apoptosis through direct damage to the mitochondria.	US FDA, Biochem Lab, Div Therapeut Prot, CDER, Bethesda, MD 20892 USA; Lutheran Univ Brazil ULBRA, Dept Biol, BR-92450900 Canoas, RS, Brazil	US Food & Drug Administration (FDA); Universidade Luterana do Brasil	Shacter, E (corresponding author), US FDA, Biochem Lab, Div Therapeut Prot, CDER, 29 Lincoln Dr,Bldg 29A,Rm 2A-11, Bethesda, MD 20892 USA.	emily.shacter@fda.gov						Anderson HA, 2002, CELL DEATH DIFFER, V9, P616, DOI 10.1038/sj.cdd.4401013; Anderson HA, 2003, NAT IMMUNOL, V4, P87, DOI 10.1038/ni871; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; de Graaf AO, 2004, EXP CELL RES, V299, P533, DOI 10.1016/j.yexcr.2004.06.024; Elamiri A, 2003, PHARMACOL RES, V48, P467, DOI 10.1016/S1043-6618(03)00187-7; Emerson DK, 2005, J BIOL CHEM, V280, P3233, DOI 10.1074/jbc.M411672200; Englert RP, 2002, J BIOL CHEM, V277, P20518, DOI 10.1074/jbc.M200212200; Fadok VA, 2003, CURR BIOL, V13, pR655, DOI 10.1016/S0960-9822(03)00575-X; FUKUDA K, 1982, CLIN CHEM, V28, P1758; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Garg Tarun K., 2004, BMC Pharmacology, V4, P6, DOI 10.1186/1471-2210-4-6; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Illmer T, 2004, LEUKEMIA, V18, P401, DOI 10.1038/sj.leu.2403257; Kanayama A, 2002, J BIOL CHEM, V277, P24049, DOI 10.1074/jbc.M110832200; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Kontny E, 2003, ADV EXP MED BIOL, V526, P329; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Lee Y, 1999, J BIOL CHEM, V274, P19792, DOI 10.1074/jbc.274.28.19792; Lee YJ, 1997, BLOOD, V89, P4480, DOI 10.1182/blood.V89.12.4480; Midwinter RG, 2004, J BIOL CHEM, V279, P32205, DOI 10.1074/jbc.M402070200; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Ogino T, 1997, FREE RADICAL BIO MED, V23, P445, DOI 10.1016/S0891-5849(97)00115-9; PARK E, 1993, J LEUKOCYTE BIOL, V54, P119, DOI 10.1002/jlb.54.2.119; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Peskin AV, 2004, FREE RADICAL BIO MED, V37, P1622, DOI 10.1016/j.freeradbiomed.2004.08.010; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Pullar JM, 2000, IUBMB LIFE, V50, P259, DOI 10.1080/15216540051080958; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Schuller-Levis GB, 2004, NEUROCHEM RES, V29, P117, DOI 10.1023/B:NERE.0000010440.37629.17; Schuller-Levis GB, 2003, FEMS MICROBIOL LETT, V226, P195, DOI 10.1016/S0378-1097(03)00611-6; Shacter E, 2000, BLOOD, V96, P307, DOI 10.1182/blood.V96.1.307.013k47_307_313; Shacter E, 2002, ONCOLOGY-NY, V16, P217; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1985, J BIOL CHEM, V260, P3321; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wagner BA, 2002, ARCH BIOCHEM BIOPHYS, V401, P223, DOI 10.1016/S0003-9861(02)00053-X; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652	48	57	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21346	21352		10.1074/jbc.M501170200	http://dx.doi.org/10.1074/jbc.M501170200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799967	hybrid			2022-12-25	WOS:000229438800053
J	Kreiling, JL; Byrd, JC; MacDonald, RG				Kreiling, JL; Byrd, JC; MacDonald, RG			Domain interactions of the mannose 6-phosphate/insulin-like growth factor II receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II/MANNOSE 6-PHOSPHATE RECEPTOR; LIGAND-BINDING; CARBOHYDRATE-RECOGNITION; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACYTOPLASMIC REGION; UROKINASE RECEPTOR; FULL-LENGTH; SITE; LOCALIZATION; IDENTIFICATION	The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) forms oligomeric structures important for optimal function in binding and internalization of Man-6-P-bearing extracellular ligands as well as lysosomal biogenesis and growth regulation. However, neither the mechanism of inter-receptor interaction nor the dimerization domain has yet been identified. We hypothesized that areas near the ligand binding domains of the receptor would contribute preferentially to oligomerization. Two panels of minireceptors were constructed that involved truncations of either the N- or C-terminal regions of the M6P/IGF2R encompassing deletions of various ligand binding domains. alpha-FLAG or alpha-Myc-based immunoprecipitation assays showed that all of the minireceptors tested were able to associate with a full-length, Myc-tagged M6P/IGF2R (WT-M). In the alpha-FLAG but not alpha-Myc immunoprecipitation assays, the degree of association of a series of C- terminally truncated minireceptors with WT-M showed a positive trend with length of the minireceptor. In contrast, length did not seem to affect the association of the N- terminally truncated minireceptors with WT-M, except that the 12th extracytoplasmic repeat appeared exceptionally important in dimerization in the alpha-FLAG assays. The presence of mutations in the ligand-binding sites of the minireceptors had no effect on their ability to associate with WT-M. Thus, association within the heterodimers was not dependent on the presence of functional ligand binding domains. Heterodimers formed between WT-M and the minireceptors demonstrated high affinity IGF-II and Man-6-P-ligand binding, suggesting a functional association. We conclude that there is no finite M6P/IGF2R dimerization domain, but rather that interactions between dimer partners occur all along the extracytoplasmic region of the receptor.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	MacDonald, RG (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	rgmacdon@unmc.edu			NATIONAL CANCER INSTITUTE [R01CA091885] Funding Source: NIH RePORTER; NCI NIH HHS [5R01CA91885] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Braulke T, 1999, HORM METAB RES, V31, P242, DOI 10.1055/s-2007-978725; Brown J, 2002, EMBO J, V21, P1054, DOI 10.1093/emboj/21.5.1054; Byrd JC, 2000, J BIOL CHEM, V275, P18638, DOI 10.1074/jbc.M000010200; Byrd JC, 1999, J BIOL CHEM, V274, P24408, DOI 10.1074/jbc.274.34.24408; Byrd JC, 2000, J BIOL CHEM, V275, P18647, DOI 10.1074/jbc.M001273200; Dahms NM, 1996, BIOCHEM SOC T, V24, P136, DOI 10.1042/bst0240136; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; Dahms NM, 2002, BBA-GEN SUBJECTS, V1572, P317, DOI 10.1016/S0304-4165(02)00317-3; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; Devi GR, 1998, MOL ENDOCRINOL, V12, P1661, DOI 10.1210/me.12.11.1661; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; GARMROUDI F, 1994, J BIOL CHEM, V269, P26944; Ghahary A, 1999, J CELL PHYSIOL, V180, P61, DOI 10.1002/(SICI)1097-4652(199907)180:1<61::AID-JCP7>3.0.CO;2-R; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; Hancock MK, 2002, J BIOL CHEM, V277, P47205, DOI 10.1074/jbc.M208534200; Hancock MK, 2002, J BIOL CHEM, V277, P11255, DOI 10.1074/jbc.M109855200; Hassan AB, 2003, AM J PATHOL, V162, P3, DOI 10.1016/S0002-9440(10)63791-1; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Kreiling JL, 2003, J BIOL CHEM, V278, P20628, DOI 10.1074/jbc.M302249200; Leksa V, 2002, J BIOL CHEM, V277, P40575, DOI 10.1074/jbc.M207979200; Linnell J, 2001, J BIOL CHEM, V276, P23986, DOI 10.1074/jbc.M100700200; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; Marron-Terada PG, 2000, BIOCHEMISTRY-US, V39, P2243, DOI 10.1021/bi992226o; Marron-Terada PG, 1998, J BIOL CHEM, V273, P22358, DOI 10.1074/jbc.273.35.22358; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; Olson LJ, 1999, J BIOL CHEM, V274, P29889, DOI 10.1074/jbc.274.42.29889; Olson LJ, 2004, J BIOL CHEM, V279, P34000, DOI 10.1074/jbc.M404588200; Olson LJ, 2004, EMBO J, V23, P2019, DOI 10.1038/sj.emboj.7600215; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERDUE JF, 1983, J BIOL CHEM, V258, P7800; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; Reddy ST, 2004, J BIOL CHEM, V279, P38658, DOI 10.1074/jbc.M407474200; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; TONG PY, 1989, J BIOL CHEM, V264, P7962; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; York SJ, 1999, J BIOL CHEM, V274, P1164, DOI 10.1074/jbc.274.2.1164	48	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21067	21077		10.1074/jbc.M412971200	http://dx.doi.org/10.1074/jbc.M412971200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799974	hybrid			2022-12-25	WOS:000229438800022
J	Frescas, D; Valenti, L; Accili, D				Frescas, D; Valenti, L; Accili, D			Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN ACTION; CELL-SURVIVAL; FAMILY-MEMBER; FACTOR AFX; LIFE-SPAN; PHOSPHORYLATION; KINASE; FKHR; P53; RESTRICTION	Activation of NAD-dependent deacetylases, or Sirtuins, prolongs life span and mimics the effects of caloric restriction in yeast. The FoxO subfamily of forkhead transcription factors has been shown to mediate some of the effects of Sirtuins. Here we have shown that Sirtuin activation or hydrogen peroxide treatment overrides the phosphorylation-dependent nuclear exclusion of FoxO1 caused by growth factors and causes nuclear translocation of FoxO1 in hepatocytes. Kinetic measurements of nuclear fluorescence recovery after photo-bleaching show that FoxO1 is readily diffusible within the nucleus under normal conditions but becomes restricted within a nuclear subdomain following treatment with the prototypical Sirtuin agonist resveratrol or oxidative stress. Expression of FoxO1 target genes is accordingly increased, leading to activation of gluconeogenesis and increased glucose release from hepatocytes. Selective modulation of the FoxO/Sirtuin interaction represents a promising therapeutic modality for metabolic disorders.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University	Accili, D (corresponding author), 1150 St Nicholas Ave, New York, NY 10032 USA.	da230@columbia.edu	Valenti, Luca/B-3695-2009	Valenti, Luca/0000-0001-8909-0345	NIDDK NIH HHS [DK57539, DK63608] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK063608, R01DK057539] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Fukuoka M, 2003, INT J MOL MED, V12, P503; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lippincott-Schwartz J, 2003, NAT CELL BIOL, pS7, DOI 10.1038/ncb1032; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789	38	423	446	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20589	20595		10.1074/jbc.M412357200	http://dx.doi.org/10.1074/jbc.M412357200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788402	hybrid			2022-12-25	WOS:000229242000054
J	Schumacher, M; Mizuno, K; Bachinger, HP				Schumacher, M; Mizuno, K; Bachinger, HP			The crystal structure of the collagen-like polypeptide (Glycyl-4(R)-hydroxyprolyl-4(R)-hydroxyprolyl)(9) at 1.55 angstrom resolution shows up-puckering of the proline ring in the Xaa position	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYLATION-INDUCED STABILIZATION; TRIPLE-HELIX; MODEL PEPTIDES; MOLECULAR-STRUCTURE; REPEATING SEQUENCE; X-RAY; STABILITY; NMR; 4-HYDROXYPROLINE; HYDROXYPROLINE	The collagen triple helix is characterized by the repeating sequence motif Gly-Xaa-Yaa, where Xaa and Yaa are typically proline and (2S, 4R)-4-hydroxyproline (4(R)Hyp), respectively. Previous analyses have revealed that H-(Pro-4(R)Hyp-Gly)(10)-OH forms a stable triple helix, whereas H-(4(R)Hyp-Pro-Gly)(10)-OH does not. Several theories have been put forth to explain the importance of proline puckering and conformation in triple helix formation; however, the details of how they affect triple helix stability are unknown. Underscoring this, we recently demonstrated that the polypeptide Ac(Gly-4(R)Hyp-4(R)Hyp)(10)-NH2 forms a triple helix that is more stable than Ac-(Gly-Pro-4(R)Hyp)(10)-NH2. Here we report the crystal structure of the H-(Gly-4(R)Hyp4(R)Hyp)(9)-OH peptide at 1.55 angstrom resolution. The puckering of the Yaa position 4(R)Hyp in this structure is up (C gamma exo), as has been found in other collagen peptide structures. Notably, however, the 4(R)Hyp in the Xaa position also takes the up pucker, which is distinct from all other collagen structures. Regardless of the notable difference in the Xaa proline puckering, our structure still adopts a 7/2 superhelical symmetry similar to that observed in other collagen structures. Thus, the basis for the observed differences in the thermodynamic data of the triple helix <-> coil transition between our peptide and other triple helical peptides likely results from contributions from the unfolded state. Indeed, the unfolded state of the H-(Gly-4(R)Hyp-4(R)Hyp)(9)-OH peptide seems to be stabilized by a preformed polyproline II helix in each strand, which could be explained by the presence of a unique repeating intra-strand water-mediated bridge observed in the H-(Gly-4(R)Hyp-4(R)Hyp)(9)-OH structure, as well as a higher amount of trans peptide bonds.	Shriners Hosp Children, Res Dept, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Bachinger, HP (corresponding author), Shriners Hosp Children, Res Dept, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	hpb@shcc.org	Mizuno, Kazunori/AAY-7613-2021	Mizuno, Kazunori/0000-0003-3354-6264				Bann JG, 2000, J BIOL CHEM, V275, P24466, DOI 10.1074/jbc.M003336200; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Berisio R, 2002, PROTEIN SCI, V11, P262, DOI 10.1110/ps.32602; BRAHMACHARI SK, 1979, MACROMOLECULES, V12, P23, DOI 10.1021/ma60067a006; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; DeRider ML, 2002, J AM CHEM SOC, V124, P2497, DOI 10.1021/ja0166904; Engel J, 1998, MATRIX BIOL, V17, P679, DOI 10.1016/S0945-053X(98)90119-6; Fields GB, 1996, BIOPOLYMERS, V40, P345, DOI 10.1002/(SICI)1097-0282(1996)40:4<345::AID-BIP1>3.0.CO;2-W; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; GAILL F, 1995, J MOL BIOL, V246, P284, DOI 10.1006/jmbi.1994.0084; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; Holmgren SK, 1998, NATURE, V392, P666, DOI 10.1038/33573; Hongo C, 2001, POLYM J, V33, P812; Improta R, 2002, J AM CHEM SOC, V124, P7857, DOI 10.1021/ja020187p; Improta R, 2001, J AM CHEM SOC, V123, P12568, DOI 10.1021/ja010599i; INOUYE K, 1976, BIOCHIM BIOPHYS ACTA, V420, P133, DOI 10.1016/0005-2795(76)90352-4; INOUYE K, 1982, ARCH BIOCHEM BIOPHYS, V219, P198, DOI 10.1016/0003-9861(82)90149-7; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kivirikko KI, 1998, MATRIX BIOL, V16, P355, DOI 10.1016/S0945-053X(98)90008-7; Kramer RZ, 2000, J MOL BIOL, V301, P1191, DOI 10.1006/jmbi.2000.4017; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kramer RZ, 1998, J MOL BIOL, V280, P623, DOI 10.1006/jmbi.1998.1881; Kramer RZ, 2001, J MOL BIOL, V311, P131, DOI 10.1006/jmbi.2001.4849; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; LESLI AGW, 1992, JOINT CCP4 ESF EAMCB; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; Mann K, 1996, J MOL BIOL, V261, P255, DOI 10.1006/jmbi.1996.0457; Mayo KH, 1996, BIOPOLYMERS, V40, P359, DOI 10.1002/(SICI)1097-0282(1996)40:4<359::AID-BIP2>3.0.CO;2-V; Mizuno K, 2004, J BIOL CHEM, V279, P38072, DOI 10.1074/jbc.M402953200; Mizuno K, 2004, J BIOL CHEM, V279, P282, DOI 10.1074/jbc.M308181200; Mizuno K, 2003, J BIOL CHEM, V278, P32373, DOI 10.1074/jbc.M304741200; Mogilner IG, 2002, J MOL GRAPH MODEL, V21, P209, DOI 10.1016/S1093-3263(02)00145-6; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nagarajan V, 1998, J BIOCHEM-TOKYO, V124, P1117, DOI 10.1093/oxfordjournals.jbchem.a022229; Nagarajan V, 1999, J BIOCHEM-TOKYO, V125, P310, DOI 10.1093/oxfordjournals.jbchem.a022288; Okuyama K, 2004, BIOPOLYMERS, V76, P367, DOI 10.1002/bip.20107; OKUYAMA K, 1981, J MOL BIOL, V152, P427, DOI 10.1016/0022-2836(81)90252-7; PANASIK N, 1994, INT J PEPT PROT RES, V44, P262; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Vitagliano L, 2001, BIOPOLYMERS, V58, P459, DOI 10.1002/1097-0282(20010415)58:5<459::AID-BIP1021>3.0.CO;2-V	46	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20397	20403		10.1074/jbc.M501453200	http://dx.doi.org/10.1074/jbc.M501453200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15784619	hybrid			2022-12-25	WOS:000229242000031
J	Feki, A; Jefford, CE; Berardi, P; Wu, JY; Cartier, L; Krause, KH; Irminger-Finger, I				Feki, A; Jefford, CE; Berardi, P; Wu, JY; Cartier, L; Krause, KH; Irminger-Finger, I			BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinase	ONCOGENE			English	Article						apoptosis; BARD1; DNA-PK; Ku-70; p53; phosphorylation	DEPENDENT PROTEIN-KINASE; BREAST-CANCER; IN-VIVO; TUMOR-SUPPRESSOR; P53-DEPENDENT APOPTOSIS; LATENT POPULATION; BRCA1; GENE; MUTATION; DOMAIN	The BRCA1-associated RING domain protein BARD1 acts with BRCA1 in double-strand break repair and ubiquitination. BARD1 plays a role as mediator of apoptosis by binding to and stabilizing p53, and BARD1-repressed cells are resistant to apoptosis. We therefore investigated the mechanism by which BARD1 induces p53 stability and apoptosis. The apoptotic activity of p53 is regulated by phosphorylation. We demonstrate that BARD1 binds to unphosphorylated and serine-15 phosphorylated forms of p53 in several cell types and that the region required for binding comprises the region sufficient for apoptosis induction. In addition, BARD1 binds to Ku-70, the regulatory subunit of DNA-PK, suggesting that the mechanism of p53-induced apoptosis requires BARD1 for the phosphorylation of p53. Upregulation of BARD1 alone is sufficient for stabilization of p53 and phosphorylation on serine-15, as shown in nonmalignant epithelial cells and ovarian cancer cells, NuTu-19, which are defective in apoptosis induction and express aberrant splice variants of BARD1. Stabilization and phosphorylation of p53 in NuTu-19 cells, as well as apoptosis, can be induced by the exogenous expression of wild-type BARD1, suggesting that BARD1, by binding to the kinase and its substrate, catalyses p53 phosphorylation.	Univ Geneva, Dept Geriatr, Biol Aging Lab, CH-1225 Geneva, Switzerland; Univ Hosp Geneva, Dept Obstet & Gynecol, Geneva, Switzerland; Univ Calgary, Calgary, AB, Canada	University of Geneva; University of Geneva; University of Calgary	Irminger-Finger, I (corresponding author), Univ Geneva, Dept Geriatr, Biol Aging Lab, Chemin Petit Bel Air 2, CH-1225 Geneva, Switzerland.	irmgard.irminger@medecine.unige.ch	Krause, Karl-Heinz/E-8030-2011	Krause, Karl-Heinz/0000-0002-9033-6768; Feki, Anis/0000-0002-9817-9445; Berardi, Philip/0000-0002-2302-6145				Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Fathalla M F, 1972, Obstet Gynecol Surv, V27, P751, DOI 10.1097/00006254-197211000-00001; Feki A, 2004, BIOL REPROD, V71, P1614, DOI 10.1095/biolreprod.104.029678; Gautier F, 2000, CANCER RES, V60, P6895; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda T, 2002, CANCER BIOL THER, V1, P163, DOI 10.4161/cbt.63; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Irminger-Finger I, 2002, INT J BIOCHEM CELL B, V34, P582, DOI 10.1016/S1357-2725(01)00161-3; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Ishitobi M, 2003, CANCER LETT, V200, P1, DOI 10.1016/S0304-3835(03)00387-2; Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737; Jack MT, 2004, J BIOL CHEM, V279, P15269, DOI 10.1074/jbc.M309917200; Jefford CE, 2004, ONCOGENE, V23, P3509, DOI 10.1038/sj.onc.1207427; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Karppinen SM, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.020669; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum M, 1996, ONCOGENE, V13, P2527; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Rose GS, 1996, AM J OBSTET GYNECOL, V175, P593; Schafer R, 2003, ADV ENZYME REGUL, V43, P379, DOI 10.1016/S0065-2571(02)00040-7; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shangary S, 2000, J BIOL CHEM, V275, P30163, DOI 10.1074/jbc.M004302200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Stark JM, 2004, MOL CELL BIOL, V24, P9305, DOI 10.1128/MCB.24.21.9305-9316.2004; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zuco V, 2003, BIOCHEM PHARMACOL, V65, P1281, DOI 10.1016/S0006-2952(03)00079-0; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	57	63	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3726	3736		10.1038/sj.onc.1208491	http://dx.doi.org/10.1038/sj.onc.1208491			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782130				2022-12-25	WOS:000229346300004
J	Zhu, Z; Mukhina, S; Zhu, T; Mertani, HC; Lee, KO; Lobie, PE				Zhu, Z; Mukhina, S; Zhu, T; Mertani, HC; Lee, KO; Lobie, PE			p44/42 MAP kinase-dependent regulation of catalase by autocrine human growth hormone protects human mammary carcinoma cells from oxidative stress-induced apoptosis	ONCOGENE			English	Article						growth hormone; autocrine; mammary carcinoma; oxidative stress; catalase	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; MN-SUPEROXIDE DISMUTASE; GENE-EXPRESSION; ANTIOXIDANT ENZYMES; GLUTATHIONE-PEROXIDASE; HYDROGEN-PEROXIDE; EPITHELIAL-CELLS; ACTIVATION; CANCER; OVEREXPRESSION	Previous microarray expression analyses have indicated autocrine human growth hormone (hGH) regulation of genes involved in the oxidative stress response. Expression analysis of antioxidant enzymes revealed that autocrine hGH increased both the mRNA and protein levels of catalase, superoxide dismutase 1 (SOD1), glutathione peroxidase and glutamylcysteine synthetase but not that of SOD2. As a consequence, autocrine hGH increased the antioxidant capacity of mammary carcinoma cells and protected against oxidative stress-induced apoptosis. Catalase activity was increased by autocrine production of hGH in mammary carcinoma cells and a catalase inhibitor abrogated protection from oxidative stress afforded by autocrine hGH. Autocrine hGH transcriptionally regulated catalase gene expression in a p44/42 MAP kinase-dependent manner and inhibition of MEK concordantly abrogated the protective effect of autocrine hGH against oxidative stress-induced apoptosis. Given that increased cellular oxidative stress is a key effector mechanism of specific chemotherapeutic agents, we propose that antagonism of autocrine hGH will improve the efficacy of chemotherapeutic regimes utilized for human mammary carcinoma.	Univ Auckland, Liggins Inst, Auckland 1, New Zealand; Natl Univ Singapore, Dept Med, Singapore 117609, Singapore; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; Univ Lyon 1, CNRS, UMR 5578, F-69365 Lyon, France; Univ Auckland, Natl Res Ctr Growth & Dev, Auckland 1, New Zealand	University of Auckland; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Johns Hopkins University; Johns Hopkins Medicine; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Auckland	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave, Auckland 1, New Zealand.	p.lobie@auckland.ac.nz	MERTANI, Hichem-Claude/AAR-6415-2020; Lee, Kok-Onn/E-9874-2011	Lee, Kok-Onn/0000-0002-3040-1185				AKMAN SA, 1990, CANCER RES, V50, P1397; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Brown-Borg HM, 2000, EXP GERONTOL, V35, P199, DOI 10.1016/S0531-5565(00)00079-6; Brown-Borg HM, 2003, MECH AGEING DEV, V124, P1013, DOI 10.1016/j.mad.2003.07.001; Brown-Borg HM, 1999, ENDOCRINE, V11, P41, DOI 10.1385/ENDO:11:1:41; BRYANT RW, 1982, J BIOL CHEM, V257, P4937; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Chelikani P, 2004, CELL MOL LIFE SCI, V61, P192, DOI 10.1007/s00018-003-3206-5; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; DIILIO C, 1985, CANCER LETT, V29, P37, DOI 10.1016/0304-3835(85)90120-X; DOROSHOW JH, 1986, J BIOL CHEM, V261, P3068; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; El Mouatassim S, 2000, EUR J OBSTET GYN R B, V89, P1, DOI 10.1016/S0301-2115(99)00169-4; FRIDOVICH I, 1978, PHOTOCHEM PHOTOBIOL, V28, P733, DOI 10.1111/j.1751-1097.1978.tb07009.x; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Graichen R, 2002, J BIOL CHEM, V277, P26662, DOI 10.1074/jbc.M109931200; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hauck SJ, 2002, HORM METAB RES, V34, P481, DOI 10.1055/s-2002-34787; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; Iscan M, 2002, BREAST CANCER RES TR, V72, P173, DOI 10.1023/A:1014828705281; Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492; Kaulsay KK, 2001, ENDOCRINOLOGY, V142, P767, DOI 10.1210/en.142.2.767; Kaulsay KK, 2000, ENDOCRINOLOGY, V141, P1571, DOI 10.1210/en.141.4.1571; Kennedy MA, 2003, EXP GERONTOL, V38, P997, DOI 10.1016/S0531-5565(03)00164-5; Kumaraguruparan R, 2002, CLIN CHIM ACTA, V325, P165, DOI 10.1016/S0009-8981(02)00292-9; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Li JJ, 1998, CARCINOGENESIS, V19, P833, DOI 10.1093/carcin/19.5.833; Mates JM, 1999, CLIN BIOCHEM, V32, P595, DOI 10.1016/S0009-9120(99)00075-2; Mertani HC, 1998, INT J CANCER, V79, P202; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; Mize AL, 2003, ENDOCRINOLOGY, V144, P306, DOI 10.1210/en.2002-220698; Mukhina S, 2004, P NATL ACAD SCI USA, V101, P15166, DOI 10.1073/pnas.0405881101; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Nenoi M, 2001, CANCER RES, V61, P5885; Raccurt M, 2002, J ENDOCRINOL, V175, P307, DOI 10.1677/joe.0.1750307; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; Santanam N, 1999, ARTERIOSCL THROM VAS, V19, P1912, DOI 10.1161/01.ATV.19.8.1912; SHINGU M, 1985, INFLAMMATION, V9, P309, DOI 10.1007/BF00916279; Siitonen T, 1999, ANN ONCOL, V10, P1361, DOI 10.1023/A:1008382912096; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; Takahashi Miho, 2002, Frontiers of Medical and Biological Engineering, V11, P279; TEICHER BA, 1990, CANCER RES, V50, P3339; TERAO K, 1986, Journal of Free Radicals in Biology and Medicine, V2, P193; Thomas Patricia A, 1997, Pathol Oncol Res, V3, P278; Tipnis SR, 1999, BIOCHEM J, V337, P559, DOI 10.1042/0264-6021:3370559; Tome ME, 2003, BBA-MOL CELL RES, V1642, P149, DOI 10.1016/j.bbamcr.2003.08.002; VanRemmen H, 1998, J CELL PHYSIOL, V174, P18, DOI 10.1002/(SICI)1097-4652(199801)174:1<18::AID-JCP3>3.0.CO;2-J; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wen J, 2002, J BIOL CHEM, V277, P38954, DOI 10.1074/jbc.M203842200; WISPE JR, 1992, J BIOL CHEM, V267, P23937; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; XU XQ, 2005, IN PRESS J BIOL CHEM; Yang CR, 1997, CANCER LETT, V119, P157, DOI 10.1016/S0304-3835(97)00274-7; YAO KS, 1995, CANCER RES, V55, P4367; YOKOMIZO A, 1995, CANCER RES, V55, P4293; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZACHARA AM, 1993, ELENIUM GLUTATHIONE; Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103; Zhu T, 2005, CANCER RES, V65, P317; Zhu T, 2002, J BIOL CHEM, V277, P45592, DOI 10.1074/jbc.M201385200; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3; ZYAD A, 1994, CANCER RES, V54, P825	68	36	36	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3774	3785		10.1038/sj.onc.1208541	http://dx.doi.org/10.1038/sj.onc.1208541			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782123				2022-12-25	WOS:000229346300008
J	Narizhneva, NV; Razorenova, OV; Podrez, EA; Chen, JH; Chandrasekharan, UM; DiCorleto, PE; Plow, EF; Topol, EJ; Byzova, TV				Narizhneva, NV; Razorenova, OV; Podrez, EA; Chen, JH; Chandrasekharan, UM; DiCorleto, PE; Plow, EF; Topol, EJ; Byzova, TV			Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium	FASEB JOURNAL			English	Article						integrin-associated protein; cardiovascular disease; TNF-alpha	INTEGRIN-ASSOCIATED PROTEIN; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; DIFFERENTIAL EXPRESSION; RECEPTOR; INHIBITION; ATHEROSCLEROSIS; IDENTIFICATION; ACTIVATION; DOMAIN	Expression of cell adhesion molecules (CAM) responsible for leukocyte-endothelium interactions plays a crucial role in inflammation and atherogenesis. Up-regulation of vascular CAM-1 (VCAM-1), intracellular CAM-1 (ICAM-1), and E-selectin expression promotes monocyte recruitment to sites of injury and is considered to be a critical step in atherosclerotic plaque development. Factors that trigger this initial response are not well understood. As platelet activation not only promotes thrombosis but also early stages of atherogenesis, we considered the role of thrombospondin-1 (TSP-1), a matricellular protein released in abundance from activated platelets and accumulated in sites of vascular injury, as a regulator of CAM expression. TSP-1 induced expression of VCAM-1 and ICAM-1 on endothelium of various origins, which in turn, resulted in a significant increase of monocyte attachment. This effect could be mimicked by a peptide derived from the C-terminal domain of TSP-1 and known to interact with CD47 on the cell surface. The essential role of CD47 in the cellular responses to TSP-1 was demonstrated further using inhibitory antibodies and knockdown of CD47 with small interfering RNA. Furthermore, we demonstrated that secretion of endogenous TSP-1 and its interaction with CD47 on the cell surface mediates endothelial response to the major proinflammatory agent, tumor necrosis factor alpha (TNF-alpha). Taken together, this study identifies a novel mechanism regulating CAM expression and subsequent monocyte binding to endothelium, which might influence the development of anti-atherosclerosis therapeutic strategies.	Cleveland Clin Fdn, Dept Mol Cardiol, Cardiol & Taussig Canc Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Byzova, TV (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Cardiol & Taussig Canc Ctr, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.	byzovat@ccf.org	Razorenova, Olga V/A-6400-2014	Topol, Eric/0000-0002-1478-4729; Byzova, Tatiana/0000-0002-2615-875X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071625, P50HL077107] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000080, RR-00080] Funding Source: Medline; NHLBI NIH HHS [P50 HL77107, R01 HL071625, P50 HL077107, HL071625.] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Agah A, 2002, AM J PATHOL, V161, P831, DOI 10.1016/S0002-9440(10)64243-5; AIKEN ML, 1986, J CLIN INVEST, V78, P1713, DOI 10.1172/JCI112767; BAENZIGE.NL, 1971, P NATL ACAD SCI USA, V68, P240, DOI 10.1073/pnas.68.1.240; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Brittain JE, 2001, BLOOD, V97, P2159, DOI 10.1182/blood.V97.7.2159; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Byzova TV, 2002, BLOOD, V99, P4434, DOI 10.1182/blood.V99.12.4434; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chen DH, 1999, CIRCULATION, V100, P849, DOI 10.1161/01.CIR.100.8.849; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chiu JJ, 2004, ARTERIOSCL THROM VAS, V24, P73, DOI 10.1161/01.ATV.0000106321.63667.24; Chung J, 1999, BLOOD, V94, P642, DOI 10.1182/blood.V94.2.642.414k35_642_648; Collard CD, 1999, ARTERIOSCL THROM VAS, V19, P2623, DOI 10.1161/01.ATV.19.11.2623; Collins RG, 2000, J EXP MED, V191, P189, DOI 10.1084/jem.191.1.189; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; Doyen V, 2003, J EXP MED, V198, P1277, DOI 10.1084/jem.20030705; FAVALORO EJ, 1993, IMMUNOL CELL BIOL, V71, P571, DOI 10.1038/icb.1993.63; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Freyberg MA, 2001, BIOCHEM BIOPH RES CO, V286, P141, DOI 10.1006/bbrc.2001.5314; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; GAO JF, 1996, ALGEBRA C, V3, P135; Gonzalez-Amaro R, 1998, DRUGS, V56, P977, DOI 10.2165/00003495-199856060-00003; Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kootstra NA, 2003, MOL THER, V7, P623, DOI 10.1016/S1525-0016(03)00073-X; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; Krieglstein CF, 2001, AM J HYPERTENS, V14, p44S, DOI 10.1016/S0895-7061(01)02069-6; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI WX, 1993, J BIOL CHEM, V268, P16179; Lin TN, 2003, STROKE, V34, P177, DOI 10.1161/01.STR.0000047100.84604.BA; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; Maile LA, 2003, CIRC RES, V93, P925, DOI 10.1161/01.RES.0000101754.33652.B7; MORANDI V, 1994, J CELL PHYSIOL, V160, P367, DOI 10.1002/jcp.1041600218; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Peyvandi F, 2003, BLOOD, V102, p314A; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; Riessen R, 1998, AM HEART J, V135, P357, DOI 10.1016/S0002-8703(98)70105-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Sajid M, 2001, J INVEST MED, V49, P398, DOI 10.2310/6650.2001.33784; Schellings MWM, 2004, CARDIOVASC RES, V64, P24, DOI 10.1016/j.cardiores.2004.06.006; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; Sengupta K, 2004, MOL CANCER RES, V2, P150; Shi WB, 2000, CIRCULATION, V102, P75, DOI 10.1161/01.CIR.102.1.75; Stenina OI, 2003, CIRCULATION, V107, P3209, DOI 10.1161/01.CIR.0000074223.56882.97; SWERLICK RA, 1991, J INVEST DERMATOL, V97, P190, DOI 10.1111/1523-1747.ep12479643; SWERLICK RA, 1992, J IMMUNOL, V149, P698; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; Unger RE, 2002, MICROVASC RES, V64, P384, DOI 10.1006/mvre.2002.2434; VANZANTEN GH, 1994, J CLIN INVEST, V93, P615, DOI 10.1172/JCI117014; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; WOOD KM, 1993, HISTOPATHOLOGY, V22, P437, DOI 10.1111/j.1365-2559.1993.tb00157.x; Yamauchi Y, 2002, MATRIX BIOL, V21, P441, DOI 10.1016/S0945-053X(02)00036-7; Zapolska-Downar D, 2004, LIFE SCI, V75, P1287, DOI 10.1016/j.lfs.2004.03.005	64	90	94	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1158	+		10.1096/fj.04-3310fje	http://dx.doi.org/10.1096/fj.04-3310fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15833768	Green Accepted			2022-12-25	WOS:000228865300014
J	Beer, HD; Bittner, M; Niklaus, G; Munding, C; Max, N; Goppelt, A; Werner, S				Beer, HD; Bittner, M; Niklaus, G; Munding, C; Max, N; Goppelt, A; Werner, S			The fibroblast growth factor binding protein is a novel interaction partner of FGF-7, FGF-10 and FGF-22 and regulates FGF activity: implications for epithelial repair	ONCOGENE			English	Article						epidermis; heparin; KGF; skin; wound	FACTOR EXPRESSION; FACTOR RECEPTOR-2; PROLIFERATION; INDUCTION; REVEALS; BP; MORPHOGENESIS; SPECIFICITY; PROTECTION; CLONING	The fibroblast growth factor-binding protein (FGF-BP) binds and activates FGF-1 and FGF-2, thereby contributing to tumor angiogenesis. In this study, we identified novel binding partners of FGF-BP, and we provide evidence for a role of this protein in epithelial repair processes. We show that expression of FGF-BP increases after injury to murine and human skin, in particular in keratinocytes. This upregulation is most likely achieved by major keratinocyte mitogens present at the wound site. Most importantly, we demonstrate that FGF-BP interacts with FGF-7, FGF-10, and with the recently identified FGF-22, and enhances the activity of low concentrations of ligand. Due to the important functions of FGF-7 and FGF-10 for repair of injured epithelia, our findings suggest that upregulation of FGF-BP expression after injury stimulates FGF activity at the wound site, thus enhancing the process of epithelial repair.	ETH Honggerberg, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland; Switch Biotech AG, D-82061 Neuried, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich	Werner, S (corresponding author), ETH Honggerberg, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland.	sabine.werner@cell.biol.ethz.ch		Werner, Sabine/0000-0001-7397-8710; Beer, Hans-Dietmar/0000-0002-8085-713X; Goppelt, Andreas/0000-0002-0780-1332				Aigner A, 2000, GROWTH FACTORS, V18, P51, DOI 10.3109/08977190009003233; Aigner A, 2002, ONCOGENE, V21, P5733, DOI 10.1038/sj.onc.1205560; Aigner A, 2002, HISTOCHEM CELL BIOL, V117, P1, DOI 10.1007/s00418-001-0360-4; Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H; Beer HD, 1997, ONCOGENE, V15, P2211, DOI 10.1038/sj.onc.1201383; Beyer TA, 2003, EXP CELL RES, V287, P228, DOI 10.1016/S0014-4827(03)00139-3; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRAUCHLE M, 1994, ONCOGENE, V9, P3199; Chen YP, 2002, P NATL ACAD SCI USA, V99, P14338, DOI 10.1073/pnas.212290499; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; DELL KR, 1992, J BIOL CHEM, V267, P21225; Finch PW, 2004, ADV CANCER RES, V91, P69, DOI 10.1016/S0065-230X(04)91003-2; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Kurtz A, 2004, NEOPLASIA, V6, P595, DOI 10.1593/neo.04214; Liu XH, 2001, KIDNEY INT, V59, P1717, DOI 10.1046/j.1523-1755.2001.0590051717.x; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Nakatake Y, 2001, BBA-GENE STRUCT EXPR, V1517, P460, DOI 10.1016/S0167-4781(00)00302-X; Okamoto T, 1996, IN VITRO CELL DEV-AN, V32, P69; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sauter ER, 2001, INT J CANCER, V92, P374, DOI 10.1002/ijc.1207; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Steiling H, 2003, CURR OPIN BIOTECH, V14, P533, DOI 10.1016/j.copbio.2003.08.003; Steiling H, 2003, ONCOGENE, V22, P4380, DOI 10.1038/sj.onc.1206499; Tagashira S, 1997, GENE, V197, P399, DOI 10.1016/S0378-1119(97)00187-X; Tassi E, 2001, J BIOL CHEM, V276, P40247, DOI 10.1074/jbc.M104933200; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WU DQ, 1991, J BIOL CHEM, V266, P16778	43	72	81	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5269	5277		10.1038/sj.onc.1208560	http://dx.doi.org/10.1038/sj.onc.1208560			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15806171				2022-12-25	WOS:000231158500001
J	Chavan, M; Yan, AX; Lennarz, WJ				Chavan, M; Yan, AX; Lennarz, WJ			Subunits of the translocon interact with components of the oligosaccharyl transferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST 2-HYBRID SYSTEM; SACCHAROMYCES-CEREVISIAE OLIGOSACCHARYLTRANSFERASE; ENDOPLASMIC-RETICULUM MEMBRANE; AMINO-ACID-SEQUENCE; SPLIT-UBIQUITIN; PROTEIN-TRANSPORT; ER MEMBRANE; N-GLYCOSYLATION; RIBOPHORIN-I; 50-KDA SUBUNIT	Following initiation of translocation across the membrane of the endoplasmic reticulum via the translocon, polypeptide chains are N-glycosylated by the oligosaccharyl transferase (OT) enzyme complex. Translocation and N-glycosylation are concurrent events and would be expected to require juxtaposition of the translocon and the OT complex. To determine whether any of the sub-units of the OT complex and translocon mediate interactions between the two complexes, we initiated a systematic study in budding yeast using the split-ubiquitin approach. Interestingly, the OT subunit Stt3p was found to interact only with Sec61p, whereas another OT subunit, Ost4p, was found to interact with all three components of the translocon, Sec61p, Sbh1p, and Sss1p. The OT subunit Wbp1p was found to interact very strongly with Sec61p and Sbh1p and weakly with Sss1p. Other OT subunits, Ost1p, Ost2p, and Swp1p were found to interact with Sec61p and either Sbh1p or Sss1p. Ost3p exhibited a weak interaction with Sec61p and Sbh1p, whereas Ost5p and Ost6p interacted very weakly with Sec61p and failed to interact with Sbh1p or Sss1p. We were able to confirm these split-ubiquitin findings by a chemical cross-linking technique. Based on our findings using these two techniques, we conclude that the association of these two complexes is stabilized via multiple protein-protein contacts. Based on extrapolation of the structural parameters of the crystal structure of the prokaryotic Sec complex to the eukaryotic complex, we propose a working model to understand the organization of the translocon-OT supercomplex.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lennarz, WJ (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	wlennarz@notes.cc.sunysb.edu	/A-2734-2010	/0000-0003-0310-5492	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033185, R37GM033185] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREUER W, 1995, EUR J BIOCHEM, V228, P689, DOI 10.1111/j.1432-1033.1995.0689m.x; Chavan M, 2003, J BIOL CHEM, V278, P51441, DOI 10.1074/jbc.M310456200; Chi JH, 1996, J BIOL CHEM, V271, P3132, DOI 10.1074/jbc.271.6.3132; Dempski RE, 2004, ARCH BIOCHEM BIOPHYS, V431, P63, DOI 10.1016/j.abb.2004.07.017; Eckert JH, 2003, J CELL SCI, V116, P3623, DOI 10.1242/jcs.00678; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; Fetchko M, 2004, METHODS, V32, P349, DOI 10.1016/j.ymeth.2003.10.010; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Goo JH, 2004, DNA CELL BIOL, V23, P59, DOI 10.1089/104454904322745934; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; Hegde RS, 1998, CELL, V92, P621, DOI 10.1016/S0092-8674(00)81130-7; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; Karaoglu D, 1997, J BIOL CHEM, V272, P32513, DOI 10.1074/jbc.272.51.32513; Kelleher DJ, 2003, MOL CELL, V12, P101, DOI 10.1016/S1097-2765(03)00243-0; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; Kerkmann K, 2001, CURR GENET, V39, P284, DOI 10.1007/s002940100229; Kim H, 2003, P NATL ACAD SCI USA, V100, P7460, DOI 10.1073/pnas.1332735100; Kim H, 2000, P NATL ACAD SCI USA, V97, P1516, DOI 10.1073/pnas.040556797; Knauer R, 1999, J BIOL CHEM, V274, P17249, DOI 10.1074/jbc.274.24.17249; KREIBICH G, 1978, J CELL BIOL, V77, P488, DOI 10.1083/jcb.77.2.488; KUMAR V, 1994, J BIOL CHEM, V269, P13451; KUMAR V, 1995, ARCH BIOCHEM BIOPHYS, V320, P217, DOI 10.1016/0003-9861(95)90003-9; Maniatis T., 1989, MOL CLONING LAB MAN; Mo CQ, 2004, BBA-MOL CELL BIOL L, V1686, P30, DOI 10.1016/j.bbalip.2004.08.001; Nilsson I, 2003, J CELL BIOL, V161, P715, DOI 10.1083/jcb.200301043; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Reiss G, 1997, EMBO J, V16, P1164, DOI 10.1093/emboj/16.6.1164; Scheper W, 2003, J BIOL CHEM, V278, P37998, DOI 10.1074/jbc.M300176200; SILBERSTEIN S, 1995, J CELL BIOL, V131, P371, DOI 10.1083/jcb.131.2.371; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; Snapp EL, 2004, J CELL BIOL, V164, P997, DOI 10.1083/jcb.200312079; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; Thaminy S, 2003, GENOME RES, V13, P1744, DOI 10.1101/gr.1276503; Thaminy Safia, 2004, Methods Mol Biol, V261, P297; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; Wang B, 2004, MOL CELL BIOL, V24, P2767, DOI 10.1128/MCB.24.7.2767-2778.2004; Wang L, 1999, FEBS LETT, V457, P316, DOI 10.1016/S0014-5793(99)01075-3; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Wilkinson BM, 2001, DEV CELL, V1, P401, DOI 10.1016/S1534-5807(01)00043-0; Wilson CM, 2005, J BIOL CHEM, V280, P4195, DOI 10.1074/jbc.M410329200; Wittke S, 2002, MOL BIOL CELL, V13, P2223, DOI 10.1091/mbc.01-10-0518; YAN A, 2005, IN PRESS P NATL ACAD; Yan AX, 2005, J BIOL CHEM, V280, P3121, DOI 10.1074/jbc.R400036200; Yan AX, 2003, J BIOL CHEM, V278, P33078, DOI 10.1074/jbc.M305337200; Yan G, 2002, J BIOL CHEM, V277, P47692, DOI 10.1074/jbc.M208136200; Yan Q, 2002, P NATL ACAD SCI USA, V99, P15994, DOI 10.1073/pnas.212637999; Yan Q, 1999, J BIOL CHEM, V274, P5021, DOI 10.1074/jbc.274.8.5021; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335; Zubkov S, 2004, P NATL ACAD SCI USA, V101, P3821, DOI 10.1073/pnas.0400512101	61	53	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22917	22924		10.1074/jbc.M502858200	http://dx.doi.org/10.1074/jbc.M502858200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15831493	hybrid			2022-12-25	WOS:000229741800045
J	Chen, YH; Wang, CC; Greenwell, L; Rix, U; Hoffmeister, D; Vining, LC; Rohr, JR; Yang, KQ				Chen, YH; Wang, CC; Greenwell, L; Rix, U; Hoffmeister, D; Vining, LC; Rohr, JR; Yang, KQ			Functional analyses of oxygenases in jadomycin biosynthesis and identification of JadH as a bifunctional oxygenase/dehydrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-VENEZUELAE ISP5230; ANTITUMOR DRUG MITHRAMYCIN; GENE-CLUSTER; RATIONAL DESIGN; GILVOCARCIN-V; CLONING; MONOOXYGENASE; POLYKETIDES; PURIFICATION; MANIPULATION	A novel angucycline metabolite, 2,3-dehydro-UWM6, was identified in a jadH mutant of Streptomyces venezuelae ISP5230. Both UWM6 and 2,3-dehydro- UWM6 could be converted to jadomycin A or B by a ketosynthase alpha (jadA) mutant of S. venezuelae. These angucycline intermediates were also converted to jadomycin A by trans-formant of the heterologous host Streptomyces lividans expressing the jadFGH oxygenases in vivo and by its cell-free extracts in vitro; thus the three gene products JadFGH are implicated in catalysis of the post-polyketide synthase biosynthetic reactions converting UWM6 to jadomycin aglycone. Genetic and biochemical analyses indicate that JadH possesses dehydrase activity, not previously associated with polyketide-modifying oxygenase. Since the formation of aromatic polyketides often requires multiple dehydration steps, bifunctionality of oxygenases modifying aromatic polyketides may be a general phenomenon.	Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA; Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resources, Beijing 100080, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing 100080, Peoples R China; Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada	University of Kentucky; Chinese Academy of Sciences; Institute of Microbiology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Dalhousie University	Rohr, JR (corresponding author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 725 Rose St, Lexington, KY 40536 USA.	jrohr2@uky.edu; yangkq@im.ac.cn	Rohr, Jason R./AAJ-5856-2021; Wang, Chenchen/F-1061-2011		NCI NIH HHS [R01 CA102102, R01 CA091901, CA 91901, R01 CA102102-01A2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091901, R01CA102102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYER SW, 1991, TETRAHEDRON LETT, V32, P6301, DOI 10.1016/0040-4039(91)80152-V; Bak S, 1998, PLANT MOL BIOL, V36, P393, DOI 10.1023/A:1005915507497; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DOULL JL, 1994, J IND MICROBIOL, V13, P120, DOI 10.1007/BF01584109; Doumith M, 2000, MOL GEN GENET, V264, P477, DOI 10.1007/s004380000329; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; Eppink MHM, 1997, PROTEIN SCI, V6, P2454; Fischer C, 2003, J AM CHEM SOC, V125, P7818, DOI 10.1021/ja034781q; Gould SJ, 1997, CHEM REV, V97, P2499, DOI 10.1021/cr9600215; Gould SJ, 1998, J ANTIBIOT, V51, P50, DOI 10.7164/antibiotics.51.50; HAN L, 1994, MICROBIOL-SGM, V140, P3379, DOI 10.1099/13500872-140-12-3379; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; Kendrew SG, 1997, J BACTERIOL, V179, P4305, DOI 10.1128/jb.179.13.4305-4310.1997; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Kulowski K, 1999, J AM CHEM SOC, V121, P1786, DOI 10.1021/ja982707f; Li AY, 2002, CHEM BIOL, V9, P1017, DOI 10.1016/S1074-5521(02)00223-5; Liu T, 2004, J AM CHEM SOC, V126, P12262, DOI 10.1021/ja0467521; MACNEIL DJ, 1992, GENE, V111, P61, DOI 10.1016/0378-1119(92)90603-M; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; MCVEY J, 1998, THESIS DALHOUSIE U C; Menendez N, 2004, CHEM BIOL, V11, P21, DOI 10.1016/j.chembiol.2003.12.011; Ostash B, 2004, CHEM BIOL, V11, P547, DOI 10.1016/j.chembiol.2004.03.011; Prado L, 1999, CHEM BIOL, V6, P19, DOI 10.1016/S1074-5521(99)80017-9; Rawlings BJ, 1999, NAT PROD REP, V16, P425, DOI 10.1039/a900566h; Rix U, 2005, CHEMBIOCHEM, V6, P838, DOI 10.1002/cbic.200400395; Rix U, 2004, J AM CHEM SOC, V126, P4496, DOI 10.1021/ja031724o; Rix U, 2002, NAT PROD REP, V19, P542, DOI 10.1039/b103920m; Rodriguez D, 2003, J BACTERIOL, V185, P3962, DOI 10.1128/JB.185.13.3962-3965.2003; Sambrook J, 2001, MOL CLONING LAB MANU; Sciara G, 2003, EMBO J, V22, P205, DOI 10.1093/emboj/cdg031; SEATON PJ, 1987, J AM CHEM SOC, V109, P5282, DOI 10.1021/ja00251a045; Shen B, 2000, TOP CURR CHEM, V209, P1; SHEN B, 1993, BIOCHEMISTRY-US, V32, P6656, DOI 10.1021/bi00077a019; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vallon O, 2000, PROTEINS, V38, P95, DOI 10.1002/(SICI)1097-0134(20000101)38:1<95::AID-PROT10>3.0.CO;2-A; WEBER S, 1994, J ORG CHEM, V59, P4211, DOI 10.1021/jo00094a037; Westrich L, 1999, FEMS MICROBIOL LETT, V170, P381, DOI 10.1111/j.1574-6968.1999.tb13398.x; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YANG KQ, 1995, J BACTERIOL, V177, P6111, DOI 10.1128/jb.177.21.6111-6117.1995; Yang KQ, 1996, MICROBIOL-UK, V142, P123, DOI 10.1099/13500872-142-1-123	43	60	63	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22508	22514		10.1074/jbc.M414229200	http://dx.doi.org/10.1074/jbc.M414229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817470	Green Accepted, hybrid			2022-12-25	WOS:000229557900098
J	Kimura, T; Ohno, N; Terada, N; Rokuhara, A; Matsumoto, A; Yagi, S; Tanaka, E; Kiyosawa, K; Ohno, S; Maki, N				Kimura, T; Ohno, N; Terada, N; Rokuhara, A; Matsumoto, A; Yagi, S; Tanaka, E; Kiyosawa, K; Ohno, S; Maki, N			Hepatitis B virus DNA-negative Dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-ANTIGEN; SIGNAL PEPTIDE; ENZYME-IMMUNOASSAY; ELECTRON CRYOMICROSCOPY; AUSTRALIA-ANTIGEN; ESCHERICHIA-COLI; XENOPUS OOCYTES; GENE; EXPRESSION; STABILITY	DNA-negative Dane particles have been observed in hepatitis B virus (HBV)-infected sera. The capsids of the empty particles are thought to be composed of core protein but have not been studied in detail. In the present study, the protein composition of the particles was examined using new enzyme immunoassays for the HBV core antigen (HBcAg) and for the HBV precore/core proteins (core-related antigens, HBcrAg). HBcrAg were abundant in fractions slightly less dense than HBcAg and HBV DNA. Three times more Dane-like particles were observed in the HBcrAg-rich fraction than in the HBV DNA-rich fraction by electron microscopy. Western blots and mass spectrometry identified the HBcrAg as a 22-kDa precore protein (p22cr) containing the un-cleaved signal peptide and lacking the arginine-rich domain that is involved in binding the RNA pregenome or the DNA genome. In sera from 30 HBV-infected patients, HBcAg represented only a median 10.5% of the precore/core proteins in enveloped particles. These data suggest that most of the Dane particles lack viral DNA and core capsid but contain p22cr. This study provides a model for the formation of the DNA-negative Dane particles. The precore proteins, which lack the arginine-rich nucleotide-binding domain, form viral RNA/DNA-negative capsid-like particles and are enveloped and released as empty particles.	Adv Life Sci Inst Inc, Div Res & Dev, Wako, Saitama 3510112, Japan; Univ Yamanashi, Dept Anat, Interdisciplinary Grad Sch Med & Engn, Yamanashi 4093898, Japan; Shinshu Univ, Sch Med, Dept Internal Med, Matsumoto, Nagano 3908621, Japan	University of Yamanashi; Shinshu University	Kimura, T (corresponding author), Adv Life Sci Inst Inc, Div Res & Dev, 2-10-23 Maruyamadai, Wako, Saitama 3510112, Japan.	tkimura@alsi-i.co.jp						ALBERTI A, 1978, GASTROENTEROLOGY, V75, P869; BEAMES B, 1993, VIROLOGY, V194, P597, DOI 10.1006/viro.1993.1299; BIRNBAUM F, 1990, J VIROL, V64, P3319, DOI 10.1128/JVI.64.7.3319-3330.1990; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; Conway JF, 1997, NATURE, V386, P91, DOI 10.1038/386091a0; CROWTHER RA, 1994, CELL, V77, P943, DOI 10.1016/0092-8674(94)90142-2; DANE DS, 1970, LANCET, V1, P695; GALLINA A, 1989, J VIROL, V63, P4645, DOI 10.1128/JVI.63.11.4645-4652.1989; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GERIN JL, 1975, AM J PATHOL, V81, P651; Guidotti LG, 1996, J VIROL, V70, P7056, DOI 10.1128/JVI.70.10.7056-7061.1996; Kimura T, 2003, J CLIN MICROBIOL, V41, P1901, DOI 10.1128/JCM.41.5.1901-1906.2003; Kimura T, 2002, J CLIN MICROBIOL, V40, P439, DOI 10.1128/JCM.40.2.439-445.2002; LOK ASF, 1994, P NATL ACAD SCI USA, V91, P4077, DOI 10.1073/pnas.91.9.4077; MAASSEN A, 1994, ARCH VIROL, V135, P131, DOI 10.1007/BF01309770; Messageot F, 2003, J BIOL CHEM, V278, P891, DOI 10.1074/jbc.M207634200; MIYANOHARA A, 1986, J VIROL, V59, P176, DOI 10.1128/JVI.59.1.176-180.1986; Mukaide M, 2003, J GASTROEN HEPATOL, V18, P1264, DOI 10.1046/j.1440-1746.2003.03204.x; NASSAL M, 1993, J VIROL, V67, P4307, DOI 10.1128/JVI.67.7.4307-4315.1993; Newman M, 2003, J VIROL, V77, P12950, DOI 10.1128/JVI.77.24.12950-12960.2003; OU JH, 1990, VIROLOGY, V174, P185, DOI 10.1016/0042-6822(90)90067-2; OU JH, 1986, P NATL ACAD SCI USA, V83, P1578, DOI 10.1073/pnas.83.6.1578; OU JH, 1989, J VIROL, V63, P5238, DOI 10.1128/JVI.63.12.5238-5243.1989; Rokuhara A, 2003, J VIRAL HEPATITIS, V10, P324, DOI 10.1046/j.1365-2893.2003.00437.x; SAKAMOTO Y, 1983, LAB INVEST, V48, P678; Scaglioni PP, 1997, J VIROL, V71, P345, DOI 10.1128/JVI.71.1.345-353.1997; SCHLICHT HJ, 1991, J VIROL, V65, P3489, DOI 10.1128/JVI.65.7.3489-3495.1991; SCHLICHT HJ, 1991, J VIROL, V65, P6817, DOI 10.1128/JVI.65.12.6817-6825.1991; SCHODEL F, 1993, J BIOL CHEM, V268, P1332; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; STANDRING DN, 1988, P NATL ACAD SCI USA, V85, P8405, DOI 10.1073/pnas.85.22.8405; TAKAHASHI K, 1991, J IMMUNOL, V147, P3156; TAKAHASHI K, 1983, J IMMUNOL, V130, P2903; TAKAHASHI T, 1980, J MED MICROBIOL, V13, P163, DOI 10.1099/00222615-13-1-163; WASENAUER G, 1992, J VIROL, V66, P5338, DOI 10.1128/JVI.66.9.5338-5346.1992; WEIMER T, 1987, J VIROL, V61, P3109, DOI 10.1128/JVI.61.10.3109-3113.1987; WINGFIELD PT, 1995, BIOCHEMISTRY-US, V34, P4919, DOI 10.1021/bi00015a003; YANG SQ, 1992, J VIROL, V66, P37, DOI 10.1128/JVI.66.1.37-45.1992; ZHOU SL, 1992, J VIROL, V66, P5393, DOI 10.1128/JVI.66.9.5393-5398.1992	39	105	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21713	21719		10.1074/jbc.M501564200	http://dx.doi.org/10.1074/jbc.M501564200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15814524	hybrid			2022-12-25	WOS:000229557900006
J	McLaughlin, JN; Mazzoni, MR; Cleator, JH; Earls, L; Perdigoto, AL; Brooks, JD; Muldowney, JAS; Vaughan, DE; Hamm, HE				McLaughlin, JN; Mazzoni, MR; Cleator, JH; Earls, L; Perdigoto, AL; Brooks, JD; Muldowney, JAS; Vaughan, DE; Hamm, HE			Thrombin modulates the expression of a set of genes including thrombospondin-1 in human microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; PROTEASE-ACTIVATED RECEPTOR-1; COLONY-STIMULATING FACTOR; TERNARY COMPLEX FACTORS; SERUM RESPONSE ELEMENT; DIFFERENTIAL EXPRESSION; MOLECULAR-CLONING; G-PROTEINS; REAL-TIME; KINASE-C	Thrombospondin-1 (THBS1) is a large extracellular matrix glycoprotein that affects vasculature systems such as platelet activation, angiogenesis, and wound healing. Increases in THBS1 expression have been liked to disease states including tumor progression, atherosclerosis, and arthritis. The present study focuses on the effects of thrombin activation of the G-protein-coupled, protease-activated receptor-1 (PAR-1) on THBS1 gene expression in the microvascular endothelium. Thrombin-induced changes in gene expression were characterized by microarray analysis of similar to 11,000 different human genes in human microvascular endothelial cells (HMEC-1). Thrombin induced the expression of a set of at least 65 genes including THBS1. Changes in THBS1 mRNA correlated with an increase in the extracellular THBS1 protein concentration. The PAR-1-specific agonist peptide (TFLLRNK-PDK) mimicked thrombin stimulation of THBS1 expression, suggesting that thrombin signaling is through PAR-1. Further studies showed THBS1 expression was sensitive to pertussis toxin and protein kinase C inhibition indicating G(i/o)- and G(q)-mediated pathways. THBS1 up-regulation was also confirmed in human umbilical vein endothelial cells stimulated with thrombin. Analysis of the promoter region of THBS1 and other genes of similar expression profile identified from the microarray predicted an EBOX/EGRF transcription model. Expression of members of each family, MYC and EGR1, respectively, correlated with THBS1 expression. These results suggest thrombin formed at sites of vascular injury increases THBS1 expression into the extracellular matrix via activation of a PAR-1, G(i/o), G(q), EBOX/EGRF-signaling cascade, elucidating regulatory points that may play a role in increased THBS1 expression in disease states.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Div Cardiovasc Med, Nashville, TN 37232 USA; Univ Pisa, Dept Psychiat Neurobiol Pharmacol & Biotechnol, I-56126 Pisa, Italy	Vanderbilt University; Vanderbilt University; University of Pisa	McLaughlin, JN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 444 Robinson Res Bldg,23rd Ave S Pierce, Nashville, TN 37232 USA.	mclaughlin@vanderbilt.edu	Hamm, Heidi E/G-2374-2014; Mazzoni, Maria Rosa/AAA-2366-2022	Mazzoni, Maria Rosa/0000-0003-2612-432X	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060906, T32HL007751, T32HL007411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK058404] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 68485] Funding Source: Medline; NHLBI NIH HHS [5R01 HL 60906-04, 5T32 HL 07411-23, 5T32 HL 07751-11, P01 HL 6744-01] Funding Source: Medline; NIDDK NIH HHS [P30 DK 58404, P60 DK 20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anrather D, 1997, J IMMUNOL, V159, P5620; BAENZIGE.NL, 1971, P NATL ACAD SCI USA, V68, P240, DOI 10.1073/pnas.68.1.240; Bartoli M, 2003, FASEB J, V17, P1562, DOI 10.1096/fj.02-1084fje; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; Bochkov VN, 2002, BLOOD, V99, P199, DOI 10.1182/blood.V99.1.199; Bogatcheva NV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P75, DOI 10.1023/A:1013904231324; Bonnefoy A, 2001, THROMB HAEMOSTASIS, V85, P552, DOI 10.1055/s-0037-1615620; Bonnefoy A, 2001, J BIOL CHEM, V276, P5605, DOI 10.1074/jbc.M010091200; BOTNEY MD, 1992, AM J PATHOL, V140, P357; Cesari F, 2004, GENESIS, V38, P87, DOI 10.1002/gene.20003; Chandrasekharan UM, 2004, J BIOL CHEM, V279, P46678, DOI 10.1074/jbc.M406441200; Chapman NR, 2002, BIOCHEM J, V366, P459, DOI 10.1042/BJ20020444; CHEN J, 1994, J BIOL CHEM, V269, P16041; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Coughlin SR, 2003, J CLIN INVEST, V111, P25, DOI 10.1172/JCI200317564; DaSilva L, 2003, TOXICON, V41, P813, DOI 10.1016/S0041-0101(03)00035-7; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; DORN GW, 1992, J PHARMACOL EXP THER, V262, P1242; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Esemuede N, 2004, J SURG RES, V122, P135, DOI 10.1016/j.jss.2004.05.015; Feoktistov I, 2002, CIRC RES, V90, P531, DOI 10.1161/01.RES.0000012203.21416.14; Fishman P, 2003, ANTICANCER RES, V23, P2077; Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Hanlon M, 1999, J BIOL CHEM, V274, P14224, DOI 10.1074/jbc.274.20.14224; Hirota Y, 2003, J CLIN ENDOCR METAB, V88, P3952, DOI 10.1210/jc.2002-021785; Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203; Hoshi S, 2000, J BIOL CHEM, V275, P883, DOI 10.1074/jbc.275.2.883; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; Jurk K, 2003, FASEB J, V17, P1490, DOI 10.1096/fj.02-0830fje; Kim JA, 2001, J CELL BIOCHEM, V81, P93, DOI 10.1002/1097-4644(20010401)81:1<93::AID-JCB1026>3.0.CO;2-I; Kuhn I, 2001, PHYSIOL GENOMICS, V7, P105, DOI 10.1152/physiolgenomics.00052.2001; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Lidington EA, 2000, BLOOD, V96, P2784; Lidington EA, 1999, TRANSPL IMMUNOL, V7, P239, DOI 10.1016/S0966-3274(99)80008-2; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; MALIK AB, 1992, SEMIN THROMB HEMOST, V18, P193, DOI 10.1055/s-2007-1002425; Martin TA, 2002, J CELL PHYSIOL, V192, P268, DOI 10.1002/jcp.10133; Maruyama I, 1998, LUPUS, V7, pS41, DOI 10.1177/096120339800700210; MCCARTHY SA, 1992, J BIOL CHEM, V267, P21617; MCCREATH G, 1994, BRIT J PHARMACOL, V113, P823, DOI 10.1111/j.1476-5381.1994.tb17067.x; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Mora-Garcia P, 2000, J BIOL CHEM, V275, P22418, DOI 10.1074/jbc.M001731200; MORANDI V, 1993, IN VITRO CELL DEV-AN, V29A, P585; Nasi S, 2001, FEBS LETT, V490, P153, DOI 10.1016/S0014-5793(01)02118-4; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Park JK, 2002, MOL PHARMACOL, V62, P1400, DOI 10.1124/mol.62.6.1400; Park SW, 2003, J BIOL CHEM, V278, P29776, DOI 10.1074/jbc.M303306200; Rahman A, 1999, J IMMUNOL, V162, P5466; RajagopalanGupta RM, 1997, MOL ENDOCRINOL, V11, P538, DOI 10.1210/me.11.5.538; RAUGI GJ, 1990, AM J PATHOL, V137, P179; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Ryu J, 2000, J BIOL CHEM, V275, P29955, DOI 10.1074/jbc.M001220200; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Schmidt VA, 1998, J BIOL CHEM, V273, P15061, DOI 10.1074/jbc.273.24.15061; Shimizu T, 2004, J BIOL CHEM, V279, P13729, DOI 10.1074/jbc.M400150200; Shin H, 1999, ANN RHEUM DIS, V58, P55, DOI 10.1136/ard.58.1.55; SHINGU T, 1994, J BIOL CHEM, V269, P32551; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Stenina OI, 2003, CIRCULATION, V107, P3209, DOI 10.1161/01.CIR.0000074223.56882.97; Stenina OI, 2001, P NATL ACAD SCI USA, V98, P7277, DOI 10.1073/pnas.121592298; Stepien O, 1998, J CARDIOVASC PHARM, V31, P786, DOI 10.1097/00005344-199805000-00019; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Tolsma SS, 1997, MICROVASC RES, V54, P13, DOI 10.1006/mvre.1997.2015; Trumel C, 2003, J THROMB HAEMOST, V1, P320, DOI 10.1046/j.1538-7836.2003.00068.x; TUSZYNSKI GP, 1992, THROMB HAEMOSTASIS, V67, P607; Unger RE, 2002, MICROVASC RES, V64, P384, DOI 10.1006/mvre.2002.2434; Vallejo AN, 2000, J IMMUNOL, V164, P2947, DOI 10.4049/jimmunol.164.6.2947; Vanhauwe JF, 2002, J BIOL CHEM, V277, P34143, DOI 10.1074/jbc.M204477200; VARANI J, 1989, CLIN EXP METASTAS, V7, P265, DOI 10.1007/BF01753679; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; WIGHT TN, 1985, J HISTOCHEM CYTOCHEM, V33, P295, DOI 10.1177/33.4.3884704; Wu SQ, 2002, BLOOD, V100, P4454, DOI 10.1182/blood-2002-02-0415; Yang GF, 2004, WORLD J GASTROENTERO, V10, P491, DOI 10.3748/wjg.v10.i4.491	92	50	57	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22172	22180		10.1074/jbc.M500721200	http://dx.doi.org/10.1074/jbc.M500721200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817447	hybrid			2022-12-25	WOS:000229557900062
J	Pan, XQ; Ohnedal, O; Ohneda, K; Lindeboom, F; Iwata, F; Shimizu, R; Nagano, M; Suwabe, N; Philipsen, S; Lim, KC; Engel, JD; Yamamoto, M				Pan, XQ; Ohnedal, O; Ohneda, K; Lindeboom, F; Iwata, F; Shimizu, R; Nagano, M; Suwabe, N; Philipsen, S; Lim, KC; Engel, JD; Yamamoto, M			Graded levels of GATA-1 expression modulate survival, proliferation, and differentiation of erythroid progenitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; TRANSIENT MYELOPROLIFERATIVE DISORDER; EMBRYONIC STEM-CELLS; DOWN-SYNDROME; MEGAKARYOBLASTIC LEUKEMIA; DEFINITIVE ERYTHROCYTES; IN-VIVO; MICE; LEUKEMOGENESIS; PRECURSORS	Transcription factor GATA-1 plays an important role in gene regulation during the development of erythroid cells. Several reports suggest that GATA-1 plays multiple roles in survival, proliferation, and differentiation of erythroid cells. However, little is known about the relationship between the level of GATA-1 expression and its nature of multifunction to affect erythroid cell fate. To address this issue, we developed in vitro embryonic stem (ES) culture system by using OP9 stromal cells (OP9/ ES cell co-culture system), and cultured the mutant (GATA-1.05 and GATA-1-null) and wild type (WT) ES cells, respectively. By using this OP9/ ES cell co-culture system, primitive and definitive erythroid cells were developed individually, and we examined how expression level of GATA-1 affects the development of erythroid cells. GATA-1.05 ES-derived definitive erythroid cells were immature with the appearance of proerythroblasts, and highly proliferated, compared with WT and GATA-1-null ES- derived erythroid cells. Extensive studies of cell cycle kinetics revealed that the GATA-1.05 proerythroblasts accumulated in S phase and expressed lower levels of p16(INK4A) than WT ES cell-derived proerythroblasts. We concluded that GATA-1 must achieve a critical threshold activity to achieve selective activation of specific target genes, thereby influencing the developmental decision of an erythroid progenitor cell to undergo apoptosis, proliferation, or terminal differentiation.	Univ Tsukuba, Dept Regenerat Med & Stem Cell Biol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr TARA, ERATO, Environm Res Project,Dept Mol & Dev Biol, Tsukuba, Ibaraki 3058577, Japan; Erasmus MC, Med Genet Cluster, Dept Cell Biol, NL-3000 DR Rotterdam, Netherlands; Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Tsukuba; Japan Science & Technology Agency (JST); University of Tsukuba; Erasmus University Rotterdam; Erasmus MC; University of Michigan System; University of Michigan	Pan, XQ (corresponding author), Univ Tsukuba, Dept Regenerat Med & Stem Cell Biol, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.	oohneda@md.tsukuba.ac.jp; masi@tara.tsukuba.ac.jp	Yamamoto, Masayuki/A-4873-2010; Shimizu, Ritsuko/A-4877-2010; Ohneda, Kinuko/AAC-8822-2019	Yamamoto, Masayuki/0000-0002-9073-9436; Shimizu, Ritsuko/0000-0001-6672-7606; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028896] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28896] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Briegel K, 1996, DEVELOPMENT, V122, P3839; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Cullen ME, 1997, J BIOL CHEM, V272, P2464; Dubart A, 1996, BLOOD, V87, P3711, DOI 10.1182/blood.V87.9.3711.bloodjournal8793711; Ferreira R, 2005, MOL CELL BIOL, V25, P1215, DOI 10.1128/MCB.25.4.1215-1227.2005; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Gurbuxani S, 2004, BLOOD, V103, P399, DOI 10.1182/blood-2003-05-1556; Ikonomi P, 2000, EXP HEMATOL, V28, P1423, DOI 10.1016/S0301-472X(00)00553-1; Lacronique V, 1997, BLOOD, V90, P3050, DOI 10.1182/blood.V90.8.3050; LEONARD M, 1993, BLOOD, V82, P1071; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Mundschau G, 2003, BLOOD, V101, P4298, DOI 10.1182/blood-2002-12-3904; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722; Ohneda K, 2002, ACTA HAEMATOL-BASEL, V108, P237, DOI 10.1159/000065660; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Rainis L, 2003, BLOOD, V102, P981, DOI 10.1182/blood-2002-11-3599; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimada A, 2004, BLOOD, V103, P366, DOI 10.1182/blood-2003-09-3219; Shimizu R, 2004, MOL CELL BIOL, V24, P10814, DOI 10.1128/MCB.24.24.10814-10825.2004; Shimizu R, 2001, EMBO J, V20, P5250, DOI 10.1093/emboj/20.18.5250; Suwabe N, 1998, BLOOD, V92, P4108, DOI 10.1182/blood.V92.11.4108.423k29_4108_4118; Suzuki N, 2003, BLOOD, V102, P3575, DOI 10.1182/blood-2003-04-1154; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Whyatt David J., 1997, Genes and Function, V1, P11; Xu G, 2003, BLOOD, V102, P2960, DOI 10.1182/blood-2003-02-0390; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	40	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22385	22394		10.1074/jbc.M500081200	http://dx.doi.org/10.1074/jbc.M500081200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817467	hybrid			2022-12-25	WOS:000229557900084
J	Zang, Y; Wang, WH; Wu, SW; Ealick, SE; Wang, CC				Zang, Y; Wang, WH; Wu, SW; Ealick, SE; Wang, CC			Identification of a subversive substrate of Trichomonas vaginalis purine nucleoside phosphorylase and the crystal structure of the enzyme-substrate complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEXUALLY-TRANSMITTED DISEASES; ELECTRON-DENSITY MAPS; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE; GUANINE PHOSPHORIBOSYLTRANSFERASE; 3-DIMENSIONAL STRUCTURE; URIDINE PHOSPHORYLASE; REVEALS SIMILARITY; RATIONAL DESIGN	Trichomonas vaginalis is an anaerobic protozoan parasite that causes trichomoniasis, a common sexually transmitted disease with worldwide impact. One of the pivotal enzymes in its purine salvage pathway, purine nucleoside phosphorylase (PNP), shows physical properties and substrate specificities similar to those of the high molecular mass bacterial PNPs but differing from those of human PNP. While carrying out studies to identify inhibitors of T. vaginalis PNP (TvPNP), we discovered that the nontoxic nucleoside analogue 2-fluoro-2'-deoxyadenosine (F-dAdo) is a "subversive substrate." Phosphorolysis by TvPNP of F-dAdo, which is not a substrate for human PNP, releases highly cytotoxic 2-fluoroadenine (F-Ade). In vitro studies showed that both F-dAdo and F-Ade exert strong inhibition of T. vaginalis growth with estimated IC50 values of 106 and 84 nM, respectively, suggesting that F-dAdo might be useful as a potential chemotherapeutic agent against T. vaginalis. To understand the basis of TvPNP specificity, the structures of TvPNP complexed with F-dAdo, 2-fluoroadenosine, formycin A, adenosine, inosine, or 2'-deoxyinosine were determined by x-ray crystallography with resolutions ranging from 2.4 to 2.9 . These studies showed that the quaternary structure, monomer fold, and active site are similar to those of Escherichia coli PNP. The principal active site difference is at Thr-156, which is alanine in E. coli PNP. In the complex of TvPNP with F-dAdo, Thr-156 causes the purine base to tilt and shift by 0.5 as compared with the binding scheme of F-dAdo in E. coli PNP. The structures of the TvPNP complexes suggest opportunities for further improved subversive substrates beyond F-dAdo.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	University of California System; University of California San Francisco; Cornell University	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu			NATIONAL CANCER INSTITUTE [U19CA067763] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060660] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67763] Funding Source: Medline; NCRR NIH HHS [RR 15301] Funding Source: Medline; NIAID NIH HHS [AI 60660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Appleby TC, 2001, J BIOL CHEM, V276, P39232, DOI 10.1074/jbc.M105694200; Appleby TC, 1999, STRUCTURE, V7, P629, DOI 10.1016/S0969-2126(99)80084-7; Aronov A.M., 2001, Patent No. [6221877, US 6221877 B1]; Aronov AM, 2001, ANTIMICROB AGENTS CH, V45, P2571, DOI 10.1128/AAC.45.9.2571-2576.2001; Aronov AM, 2000, BIOCHEMISTRY-US, V39, P4684, DOI 10.1021/bi992555g; Bennett EM, 2003, J BIOL CHEM, V278, P47110, DOI 10.1074/jbc.M304622200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BZOWSKA A, 1992, BIOCHIM BIOPHYS ACTA, V1120, P239, DOI 10.1016/0167-4838(92)90243-7; BZOWSKA A, 1990, Z NATURFORSCH C, V45, P59; BZOWSKA A, 1995, FEBS LETT, V367, P214, DOI 10.1016/0014-5793(95)00540-P; CAMERON D W, 1990, AIDS (London), V4, pS99; Craig SP, 2000, J BIOL CHEM, V275, P20231, DOI 10.1074/jbc.R000002200; EALICK SE, 1990, J BIOL CHEM, V265, P1812; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11725, DOI 10.1021/bi961969w; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11735, DOI 10.1021/bi961970v; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HARRIS DI, 1988, MOL BIOCHEM PARASIT, V29, P105, DOI 10.1016/0166-6851(88)90065-5; HEYWORTH PG, 1982, FEBS LETT, V141, P106, DOI 10.1016/0014-5793(82)80026-4; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; JENSEN KF, 1975, EUR J BIOCHEM, V51, P253, DOI 10.1111/j.1432-1033.1975.tb03925.x; JOHNSON PJ, 1993, PARASITOL TODAY, V9, P183, DOI 10.1016/0169-4758(93)90143-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koellner G, 1998, J MOL BIOL, V280, P153, DOI 10.1006/jmbi.1998.1799; Koellner G, 1997, J MOL BIOL, V265, P202, DOI 10.1006/jmbi.1996.0730; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; Lee JE, 2001, STRUCTURE, V9, P941, DOI 10.1016/S0969-2126(01)00656-6; Mao C, 1997, STRUCTURE, V5, P1373, DOI 10.1016/S0969-2126(97)00287-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miller R L, 1986, Adv Exp Med Biol, V195 Pt B, P573; MILLER RL, 1983, MOL BIOCHEM PARASIT, V7, P41, DOI 10.1016/0166-6851(83)90115-9; MORGUNOVA EY, 1995, FEBS LETT, V367, P183, DOI 10.1016/0014-5793(95)00489-V; Munagala N, 2002, BIOCHEMISTRY-US, V41, P10382, DOI 10.1021/bi026025n; Munagala N, 2002, MOL MICROBIOL, V44, P1073, DOI 10.1046/j.1365-2958.2002.02942.x; Munagala NR, 2003, MOL BIOCHEM PARASIT, V127, P143, DOI 10.1016/S0166-6851(02)00330-4; NELSON DJ, 1979, J BIOL CHEM, V254, P1544; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parker WB, 1998, BIOCHEM PHARMACOL, V55, P1673, DOI 10.1016/S0006-2952(98)00034-3; Parker WB, 2003, CANCER GENE THER, V10, P23, DOI 10.1038/sj.cgt.7700520; Parker WB, 1997, HUM GENE THER, V8, P1637, DOI 10.1089/hum.1997.8.14-1637; Petrin D, 1998, CLIN MICROBIOL REV, V11, P300, DOI 10.1128/CMR.11.2.300; Pugmire MJ, 2002, BIOCHEM J, V361, P1, DOI 10.1042/0264-6021:3610001; Secrist JA, 1999, NUCLEOS NUCLEOT, V18, P745, DOI 10.1080/15257779908041562; Shi WX, 2004, J BIOL CHEM, V279, P18103, DOI 10.1074/jbc.C400068200; Somoza JR, 1998, BIOCHEMISTRY-US, V37, P5344, DOI 10.1021/bi973095z; TAKEHARA M, 1995, BIOSCI BIOTECH BIOCH, V59, P1987, DOI 10.1271/bbb.59.1987; Upcroft P, 2001, CLIN MICROBIOL REV, V14, P150, DOI 10.1128/CMR.14.1.150-164.2001; Wang C.C., 2000, Heterocyclic derivatives as inhibitors of purine salvage phosphoribosyltransferases, Patent No. [US006075044A, 006075044, 6075044]; WANG CC, 1984, J MED CHEM, V27, P1, DOI 10.1021/jm00367a001; WANG CC, 1984, EXP PARASITOL, V57, P68, DOI 10.1016/0014-4894(84)90064-X; Zhang Y, 2004, STRUCTURE, V12, P1383, DOI 10.1016/j.str.2004.05.015	53	17	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22318	22325		10.1074/jbc.M501843200	http://dx.doi.org/10.1074/jbc.M501843200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817485	hybrid			2022-12-25	WOS:000229557900077
J	Druzhyna, NM; Musiyenko, SI; Wilson, GL; LeDoux, SP				Druzhyna, NM; Musiyenko, SI; Wilson, GL; LeDoux, SP			Cytokines induce nitric oxide-mediated mtDNA damage and apoptosis in oligodendrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-DNA DAMAGE; MULTIPLE-SCLEROSIS; CELL-DEATH; OXIDATIVE STRESS; SYNTHASE; REPAIR; EXPRESSION; GAMMA; 8-OXOGUANINE; DYSFUNCTION	Nitric oxide (NO) that is produced by inducible NO synthase (iNOS) in glial cells is thought to contribute significantly to the pathogenesis of multiple sclerosis. Oligodendrocytes can be stimulated to express iNOS by inflammatory cytokines, which are known to accumulate in the multiple sclerotic brain. The potentially pathological levels of NO produced under these circumstances can target a wide spectrum of intracellular components. We hypothesized that one of the critical targets for damage that leads to disease is mtDNA. In this study, we found that cytokines, in particular a combination of tumor necrosis factor-alpha (50 ng/ml) and IFN gamma (25 ng/ml), cause elevated NO production in primary cultures of rat oligodendrocytes. Western blot analysis revealed a strong enhancement of iNOS expression 48 h after cytokine treatment. Within the same time period, NO-mediated mtDNA damage was shown by Southern blot analysis and by ligation-mediated PCR. Targeting the DNA repair enzyme human 8-oxoguanine DNA glycosylase (hOGG1) to the mitochondria of oligodendrocytes had a protective effect against this cytokine-mediated mtDNA damage. Moreover, it was shown that mitochondrial transport sequence hOGG1-transfected oligodendrocytes had fewer apoptotic cells compared with cells containing vector only following treatment with the cytokines. Subsequent experiments revealed that targeting hOGG1 to mitochondria reduces the activation of caspase-9, showing that this recombinant protein works to reduce apoptosis that is occurring through a mitochondria-based pathway.	Univ S Alabama, Dept Cell Biol & Neurosci, Coll Med, Mobile, AL 36688 USA	University of South Alabama	LeDoux, SP (corresponding author), Univ S Alabama, Dept Cell Biol & Neurosci, Coll Med, MSB 1200, Mobile, AL 36688 USA.	sledoux@usouthal.edu						Andrews T, 1998, J NEUROSCI RES, V54, P574, DOI 10.1002/(SICI)1097-4547(19981201)54:5<574::AID-JNR2>3.3.CO;2-S; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Begolka WS, 1998, J IMMUNOL, V161, P4437; Bhat NR, 1999, J NEUROCHEM, V72, P472, DOI 10.1046/j.1471-4159.1999.0720472.x; Blasi F, 1999, BIOL CHEM, V380, P259, DOI 10.1515/BC.1999.034; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; Boullerne AI, 1999, J NEUROCHEM, V72, P1050, DOI 10.1046/j.1471-4159.1999.0721050.x; Brosnan CF, 1997, BIOCHEM SOC T, V25, P679, DOI 10.1042/bst0250679; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; Dobson AW, 2002, AM J PHYSIOL-LUNG C, V283, pL205, DOI 10.1152/ajplung.00443.2001; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; Druzhyna NM, 2003, GLIA, V42, P370, DOI 10.1002/glia.10230; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Grishko VI, 1999, NUCLEIC ACIDS RES, V27, P4510, DOI 10.1093/nar/27.22.4510; Hewett JA, 1999, J NEUROSCI RES, V56, P189, DOI 10.1002/(SICI)1097-4547(19990415)56:2<189::AID-JNR8>3.3.CO;2-2; Horwitz MS, 1997, NAT MED, V3, P1037, DOI 10.1038/nm0997-1037; Jurewicz A, 2003, BRAIN, V126, P1358, DOI 10.1093/brain/awg146; Kennedy LJ, 1997, CHEM RES TOXICOL, V10, P386, DOI 10.1021/tx960102w; LeDoux SP, 1998, GLIA, V24, P304, DOI 10.1002/(SICI)1098-1136(199811)24:3<304::AID-GLIA4>3.3.CO;2-J; Lucchinetti CF, 1997, MAYO CLIN PROC, V72, P665; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Merrill JE, 1997, J NEUROSCI RES, V48, P372, DOI 10.1002/(SICI)1097-4547(19970515)48:4<372::AID-JNR9>3.0.CO;2-8; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MITROVIC B, 1995, J NEUROSCI, V61, P575; Molina-Holgado E, 2001, EUR J NEUROSCI, V13, P493, DOI 10.1046/j.0953-816x.2000.01412.x; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; PFEIFER GP, 1993, MUTAT RES, V288, P39, DOI 10.1016/0027-5107(93)90206-U; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; Phoa N, 2002, CARCINOGENESIS, V23, P469, DOI 10.1093/carcin/23.3.469; PIKO L, 1992, ANN NY ACAD SCI, V663, P450, DOI 10.1111/j.1749-6632.1992.tb38698.x; Popko B, 1997, MOL NEUROBIOL, V14, P19, DOI 10.1007/BF02740619; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; Rachek LI, 2002, J BIOL CHEM, V277, P44932, DOI 10.1074/jbc.M208770200; Rachek LI, 2004, NUCLEIC ACIDS RES, V32, P3240, DOI 10.1093/nar/gkh648; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; RAINE CS, 1994, ANN NEUROL, V36, pS61, DOI 10.1002/ana.410360716; RAINE CS, 1995, NAT MED, V1, P211, DOI 10.1038/nm0395-211; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Suematsu N, 2003, CIRCULATION, V107, P1418, DOI 10.1161/01.CIR.0000055318.09997.1F; Tamir S, 1996, CHEM RES TOXICOL, V9, P821, DOI 10.1021/tx9600311; Wilson GL, 1997, DIABETES, V46, P1291, DOI 10.2337/diabetes.46.8.1291; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Zhao WG, 1996, J NEUROIMMUNOL, V64, P123, DOI 10.1016/0165-5728(95)00158-1	51	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21673	21679		10.1074/jbc.m411531200	http://dx.doi.org/10.1074/jbc.m411531200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15811855	hybrid			2022-12-25	WOS:000229438800094
J	Mancl, ME; Hu, GD; Sangster-Guity, N; Olshalsky, SL; Hoops, K; Fitzgerald-Bocarsly, P; Pitha, PM; Pinder, K; Barnes, BJ				Mancl, ME; Hu, GD; Sangster-Guity, N; Olshalsky, SL; Hoops, K; Fitzgerald-Bocarsly, P; Pitha, PM; Pinder, K; Barnes, BJ			Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMACYTOID DENDRITIC CELLS; IFN-ALPHA PRODUCTION; FUNCTIONAL-ANALYSIS; VIRUS; IRF-5; GENE; TRANSCRIPTION; EXPRESSION; ACTIVATION; INDUCTION	Interferon regulatory factor-5 (IRF-5) is a mediator of virus-induced immune activation and type I interferon (IFN) gene regulation. In human primary plasmacytoid dendritic cells (PDC), IRF-5 is transcribed into four distinct alternatively spliced isoforms (V1, V2, V3, and V4), whereas in human primary peripheral blood mononuclear cells two additional new isoforms (V5 and V6) were identified. The IRF-5 V1, V2, and V3 transcripts have different noncoding first exons and distinct insertion/ deletion patterns in exon 6. Here we showed that V1 and V3 have distinct transcription start sites and are regulated by two discrete promoters. The V1 promoter (P- V1) is constitutively active, contains an IRF-E consensus-binding site, and is further stimulated in virus-infected cells by IRF family members. In contrast, endogenous V3 transcripts were up-regulated by type I IFNs, and the V3 promoter ( P- V3) contains an IFN-stimulated responsive element-binding site that confers responsiveness to IFN through binding of the ISGF3 complex. In addition to V5 and V6, we have identified three more alternatively spliced IRF-5 isoforms (V7, V8, and V9); V5 and V6 were expressed in peripheral blood mononuclear cells from healthy donors and in immortalized B and T cell malignancies, whereas expression of V7, V8, and V9 transcripts were detected only in human cancers. The results of this study demonstrated the existence of multiple IRF-5 spliced isoforms with distinct cell type-specific expression, cellular localization, differential regulation, and dissimilar functions in virus-mediated type I IFN gene induction.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Div Viral Oncol, Baltimore, MD 21231 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Univ Med & Dent New Jersey Grad Sch Biomed Sci, Newark, NJ 07103 USA	Johns Hopkins University; Johns Hopkins Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Barnes, BJ (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Div Viral Oncol, 1650 Orleans St, Baltimore, MD 21231 USA.	barnebe@jhmi.edu	hu, guodong/B-4794-2010	Pinder, Karen/0000-0003-4173-4759	NATIONAL CANCER INSTITUTE [P50CA096888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI019737, R01AI026806, R01AI019737] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA96888] Funding Source: Medline; NIAID NIH HHS [R01 AI26806, R01 AI19737-21] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AU WC, 1993, J BIOL CHEM, V268, P24032; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Barnes BJ, 2004, J BIOL CHEM, V279, P45194, DOI 10.1074/jbc.M400726200; Barnes BJ, 2003, CANCER RES, V63, P6424; Barnes BJ, 2003, J BIOL CHEM, V278, P16630, DOI 10.1074/jbc.M212609200; Barnes BJ, 2002, MOL CELL BIOL, V22, P5721, DOI 10.1128/MCB.22.16.5721-5740.2002; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; CHENG F, 2004, JOINT M ICS ISICR SA, P27; CHEUNG SC, 1991, J IMMUNOL, V146, P121; Coccia EM, 2004, EUR J IMMUNOL, V34, P796, DOI 10.1002/eji.200324610; Dai JH, 2004, J IMMUNOL, V173, P1535, DOI 10.4049/jimmunol.173.3.1535; Dent CL, 1996, J INTERF CYTOK RES, V16, P99, DOI 10.1089/jir.1996.16.99; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; INCE TA, 1995, GENE, V156, P287, DOI 10.1016/0378-1119(94)00907-A; Izaguirre A, 2003, J LEUKOCYTE BIOL, V74, P1125, DOI 10.1189/jlb.0603255; Karpova AY, 2001, MOL CELL BIOL, V21, P4169, DOI 10.1128/MCB.21.13.4169-4176.2001; Karpova AY, 2000, GENE DEV, V14, P2813, DOI 10.1101/gad.813800; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Lin RT, 2005, J BIOL CHEM, V280, P3088, DOI 10.1074/jbc.M408452200; Lowther WJ, 1999, DNA CELL BIOL, V18, P685, DOI 10.1089/104454999314962; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Megjugorac NJ, 2004, J LEUKOCYTE BIOL, V75, P504, DOI 10.1189/jlb.0603291; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Rothenfusser S, 2002, HUM IMMUNOL, V63, P1111, DOI 10.1016/S0198-8859(02)00749-8; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; Schoenemeyer A, 2005, J BIOL CHEM, V280, P17005, DOI 10.1074/jbc.M412584200; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Takauji R, 2002, J LEUKOCYTE BIOL, V72, P1011; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Tanaka N, 2000, SEMIN CANCER BIOL, V10, P73, DOI 10.1006/scbi.2000.0310; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; Zhang LW, 2001, SEMIN CANCER BIOL, V11, P445, DOI 10.1006/scbi.2001.0411	45	127	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21078	21090		10.1074/jbc.M500543200	http://dx.doi.org/10.1074/jbc.M500543200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15805103	hybrid			2022-12-25	WOS:000229438800023
J	Marsh, VL; Peak-Chew, SY; Bell, SD				Marsh, VL; Peak-Chew, SY; Bell, SD			Sir2 and the acetyltransferase, Pat, regulate the archaeal chromatin protein, Alba	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA SYNTHETASE; DNA-BINDING PROTEINS; SULFOLOBUS-SOLFATARICUS; IDENTIFICATION; REPLICATION; GENE; DEACETYLATION; COMPLEXES; MECHANISM; SSH10B	The DNA binding affinity of Alba, a chromatin protein of the archaeon Sulfolobus solfataricus P2, is regulated by acetylation of lysine 16. Here we identify an acetyltransferase that specifically acetylates Alba on this residue. The effect of acetylation is to lower the affinity of Alba for DNA. Remarkably, the acetyltransferase is conserved not only in archaea but also in bacteria where it appears to play a role in metabolic regulation. Therefore, our data suggest that S. solfataricus has co-opted this bacterial regulatory system to generate a rudimentary form of chromatin regulation.	Hutchison Med Res Council MRC, Res Ctr, Canc Cell Unit, Cambridge CB2 2XZ, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bell, SD (corresponding author), Hutchison Med Res Council MRC, Res Ctr, Canc Cell Unit, Hills Rd, Cambridge CB2 2XZ, England.	sb419@hutchison-mrc.cam.ac.uk		Bell, Stephen/0000-0002-8474-6592				Adhya S, 1998, COLD SPRING HARB SYM, V63, P1, DOI 10.1101/sqb.1998.63.1; Alsford S, 2004, MOL MICROBIOL, V53, P365, DOI 10.1111/j.1365-2958.2004.04151.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bell SD, 2002, SCIENCE, V296, P148, DOI 10.1126/science.1070506; Bell SD, 2001, CURR OPIN MICROBIOL, V4, P208, DOI 10.1016/S1369-5274(00)00190-9; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Cui Q, 2003, J BIOL CHEM, V278, P51015, DOI 10.1074/jbc.M308510200; Edmondson SP, 2001, METHOD ENZYMOL, V334, P129; Fiorentino G, 2003, J BACTERIOL, V185, P3926, DOI 10.1128/JB.185.13.3926-3934.2003; Forbes AJ, 2004, P NATL ACAD SCI USA, V101, P2678, DOI 10.1073/pnas.0306575101; Forterre P, 1999, MOL MICROBIOL, V32, P669, DOI 10.1046/j.1365-2958.1999.01366.x; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Guo R, 2003, MOL MICROBIOL, V50, P1605, DOI 10.1046/j.1365-2958.2003.03793.x; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Kelman LM, 2003, MOL MICROBIOL, V48, P605, DOI 10.1046/j.1365-2958.2003.03369.x; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LURZ R, 1986, EMBO J, V5, P3715, DOI 10.1002/j.1460-2075.1986.tb04705.x; Matsunaga F, 2001, P NATL ACAD SCI USA, V98, P11152, DOI 10.1073/pnas.191387498; Napoli A, 2004, J BIOL CHEM, V279, P33192, DOI 10.1074/jbc.M402619200; Reeve JN, 2004, BIOCHEM SOC T, V32, P227, DOI 10.1042/BST0320227; Robinson NP, 2004, CELL, V116, P25, DOI 10.1016/S0092-8674(03)01034-1; SANDMAN K, 1990, P NATL ACAD SCI USA, V87, P5788, DOI 10.1073/pnas.87.15.5788; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Starai VJ, 2004, J MOL BIOL, V340, P1005, DOI 10.1016/j.jmb.2004.05.010; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wardleworth BN, 2002, EMBO J, V21, P4654, DOI 10.1093/emboj/cdf465; White MF, 2002, TRENDS GENET, V18, P621, DOI 10.1016/S0168-9525(02)02808-1; Xue H, 2000, J BACTERIOL, V182, P3929, DOI 10.1128/JB.182.14.3929-3933.2000; Zhao KH, 2003, J BIOL CHEM, V278, P26071, DOI 10.1074/jbc.M303666200	33	80	86	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21122	21128		10.1074/jbc.M501280200	http://dx.doi.org/10.1074/jbc.M501280200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15824122	hybrid			2022-12-25	WOS:000229438800028
J	Uchida, T; Sato, E; Sato, A; Sagami, I; Shimizu, T; Kitagawa, T				Uchida, T; Sato, E; Sato, A; Sagami, I; Shimizu, T; Kitagawa, T			CO-dependent activity-controlling mechanism of heme-containing CO-sensor protein, neuronal PAS domain protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; SOLUBLE GUANYLATE-CYCLASE; TRANSCRIPTIONAL ACTIVATOR COOA; DIRECT OXYGEN SENSOR; CIRCADIAN CLOCK GENE; ESCHERICHIA-COLI; NITRIC-OXIDE; CARBON-MONOXIDE; RHODOSPIRILLUM-RUBRUM; SIGNAL-TRANSDUCTION	Neuronal PAS domain protein 2, which was recently established to be a heme protein, acts as a CO-dependent transcription factor. The protein consists of the basic helix-loop-helix domain and two heme- containing PAS domains (PAS-A and PAS-B). In this study, we prepared wild type and mutants of the isolated PAS-A domain and measured resonance Raman spectra of these proteins. Upon excitation of the Raman spectrum at 363.8 nm, a band assignable to Fe3+-S stretching was observed at 334 cm(-1) for the ferric wild type protein; in contrast, this band was drastically weaker in the spectrum of C170A, suggesting that Cys(170) is an axial ligand of the ferric heme. The Raman spectrum of the reduced form of wild type was mainly of six-coordinate low spin, and the v(11) band, which is sensitive to the donor strength of the axial ligand, was lower than that of reduced cytochrome c(3), suggesting coordination of a strong ligand and thus a deprotonated His. In the reduced forms of H119A and H171A, the five-coordinate species became more prevalent, whereas no such changes were observed for C170A, indicating that His(119) and His(171), but not Cys(170), are axial ligands in the ferrous heme. This means that ligand replacement from Cys to His occurs upon heme reduction. The v(Fe-CO) versus v(C-O) correlation indicates that a neutral His is a trans ligand of CO. Our results support a mechanism in which CO binding disrupts the hydrogen bonding of His(171) with surrounding amino acids, which induces conformational changes in the His(171)- Cys(170) moiety, leading to physiological signaling.	Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Tohoku University	Kitagawa, T (corresponding author), Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan.	teizo@ims.ac.jp	Uchida, Takeshi/A-6455-2017	Uchida, Takeshi/0000-0001-9270-8329				ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; ANDERSSON LA, 1992, NEW J CHEM, V16, P569; ANDERSSON LA, 1989, J BIOL CHEM, V264, P19099; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 2002, J BIOL CHEM, V277, P13528, DOI 10.1074/jbc.M112256200; ASHER SA, 1979, BIOCHEMISTRY-US, V18, P5377, DOI 10.1021/bi00591a019; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Cerda-Colon JF, 1998, J AM CHEM SOC, V120, P9312, DOI 10.1021/ja972654m; CHAMPION PM, 1982, J AM CHEM SOC, V104, P5469, DOI 10.1021/ja00384a037; Chan MK, 2001, CURR OPIN CHEM BIOL, V5, P216, DOI 10.1016/S1367-5931(00)00193-9; Chang AL, 2001, BIOCHEMISTRY-US, V40, P3420, DOI 10.1021/bi0100236; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; DESBOIS A, 1979, BIOCHEMISTRY-US, V18, P1510, DOI 10.1021/bi00575a019; DESBOIS A, 1992, EUR BIOPHYS J BIOPHY, V20, P321, DOI 10.1007/BF00196591; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; Fan BC, 1998, BIOCHEMISTRY-US, V37, P1178, DOI 10.1021/bi971934b; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; Gao F, 1998, BIOCHEMISTRY-US, V37, P9751, DOI 10.1021/bi9800653; Gao F, 1999, BBA-PROTEIN STRUCT M, V1430, P203, DOI 10.1016/S0167-4838(98)00284-2; Garcia JA, 2000, SCIENCE, V288, P2226, DOI 10.1126/science.288.5474.2226; Gilles-Gonzalez MA, 2004, J APPL PHYSIOL, V96, P774, DOI 10.1152/japplphysiol.00941.2003; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Gong WM, 2000, BIOCHEMISTRY-US, V39, P3955, DOI 10.1021/bi992346w; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HASHIMOTO S, 1986, J BIOL CHEM, V261, P1110; HOBBS JD, 1990, BIOCHEMISTRY-US, V29, P4166, DOI 10.1021/bi00469a020; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; HU SZ, 1993, J AM CHEM SOC, V115, P12446, DOI 10.1021/ja00079a028; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Igarashi J, 2004, J BIOL CHEM, V279, P15752, DOI 10.1074/jbc.M310273200; Kim Sunyoung, 1998, Biochimica et Biophysica Acta, V1366, P331, DOI 10.1016/S0005-2728(98)00133-9; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Kurokawa H, 2004, J BIOL CHEM, V279, P20186, DOI 10.1074/jbc.M314199200; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Liu Y, 1999, BIOCHEMISTRY-US, V38, P3733, DOI 10.1021/bi982707s; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Mukai M, 2000, BIOCHEMISTRY-US, V39, P13810, DOI 10.1021/bi001184x; Nakajima H, 2001, J BIOL CHEM, V276, P37895; Othman S, 1996, BIOCHEMISTRY-US, V35, P9224, DOI 10.1021/bi952818g; Pal B, 2005, J INORG BIOCHEM, V99, P267, DOI 10.1016/j.jinorgbio.2004.09.027; Park HJ, 2004, BIOCHEMISTRY-US, V43, P2738, DOI 10.1021/bi035980p; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P12301, DOI 10.1021/bi980752u; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Rodgers KR, 1996, BIOCHEMISTRY-US, V35, P9539, DOI 10.1021/bi9530853; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Sasakura Y, 2002, J BIOL CHEM, V277, P23821, DOI 10.1074/jbc.M202738200; Sato A, 2002, J BIOL CHEM, V277, P32650, DOI 10.1074/jbc.M204559200; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SMULEVICH G, 1988, BIOCHEMISTRY-US, V27, P5477, DOI 10.1021/bi00415a014; SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027; SPIRO TG, 1990, BIOCHEMISTRY-US, V29, P4497, DOI 10.1021/bi00471a001; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; Taylor BL, 1999, ANNU REV MICROBIOL, V53, P103, DOI 10.1146/annurev.micro.53.1.103; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; VERMA AL, 1988, J AM CHEM SOC, V110, P6617, DOI 10.1021/ja00228a004; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; WELLS AV, 1992, BIOCHEMISTRY-US, V31, P4384, DOI 10.1021/bi00133a002; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; YU AE, 1994, J AM CHEM SOC, V116, P4117, DOI 10.1021/ja00088a073; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	76	66	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21358	21368		10.1074/jbc.M412350200	http://dx.doi.org/10.1074/jbc.M412350200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797872	hybrid			2022-12-25	WOS:000229438800055
J	Verdier, L; Al-Sabi, A; Rivier, JEF; Olivera, BM; Terlau, H; Carlomagno, T				Verdier, L; Al-Sabi, A; Rivier, JEF; Olivera, BM; Terlau, H; Carlomagno, T			Identification of a novel pharmacophore for peptide toxins interacting with K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-CONOTOXIN-GIIIA; AMINO-ACID SUBSTITUTIONS; POTASSIUM CHANNEL; MOLECULAR-BASIS; SCORPION TOXIN; MUTANT CYCLES; BLOCKER; CHARYBDOTOXIN; SELECTIVITY; SIMULATION	kappa M-conotoxin RIIIK blocks TSha1 K+ channels from trout with high affinity by interacting with the ion channel pore. As opposed to many other peptides targeting K+ channels, kappa M-RIIIK does not possess a functional dyad. In this study we combine thermodynamic mutant cycle analysis and docking calculations to derive the binding mode of kappa M-conotoxin RIIIK to the TSha1 channel. The final model reveals a novel pharmacophore, where no positively charged side chain occludes the channel pore. Instead the positive-charged residues of the toxin form a basic ring; kappa M-RIIIK is anchored to the K+ channel via electrostatic interactions of this basic ring with the loop and pore helix residues of the channel. The channel amino acid Glu-354 is likely to be a fundamental determinant of the selectivity of kappa M-RIIIK for the TSha1 channel. The C gamma-OH of Hyp-15 is in contact with the carbonyls of the selectivity filter, disturbing the charge distribution pattern necessary for the coordination of K+ ions. This novel, experimentally based pharmacophore model proves the existence of diverse binding modes of peptidic toxins to K+ channels and underlines the role of intermolecular electrostatic interactions involving channel loop side chains in determining the selectivity of toxins for specific K+ channel types.	Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany; Max Planck Inst Expt Med, Grp Mol & Cellular Neuropharmacol, D-37075 Gottingen, Germany; Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Max Planck Society; Max Planck Society; Salk Institute; Utah System of Higher Education; University of Utah	Terlau, H (corresponding author), Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, Fassberg 11, D-37077 Gottingen, Germany.	hterlau@gwdg.de	Al-Sabi, Ahmed/H-3438-2015; Al-Sabi, AHMED/AAF-9211-2020	Al-Sabi, Ahmed/0000-0002-1957-7569; Carlomagno, Teresa/0000-0002-2437-2760				Al-Sabi A, 2004, BIOCHEMISTRY-US, V43, P8625, DOI 10.1021/bi0495681; BECKER S, 1992, BIOCHEMISTRY-US, V31, P8229, DOI 10.1021/bi00150a016; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.3.CO;2-D; de la Vega RCR, 2003, TRENDS PHARMACOL SCI, V24, P222, DOI 10.1016/S0165-6147(02)00080-4; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Eriksson MAL, 2002, BIOPHYS J, V83, P2595, DOI 10.1016/S0006-3495(02)75270-3; Ferber M, 2004, TOXICON, V43, P915, DOI 10.1016/j.toxicon.2003.12.010; Ferber M, 2003, J BIOL CHEM, V278, P2177, DOI 10.1074/jbc.M205953200; Gao YD, 2003, PROTEINS, V52, P146, DOI 10.1002/prot.10341; Gilquin B, 2002, J BIOL CHEM, V277, P37406, DOI 10.1074/jbc.M206205200; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Huys I, 2004, BIOCHEM J, V378, P745, DOI 10.1042/BJ20031324; Ishii TM, 1998, METHOD ENZYMOL, V293, P53; Jacobsen RB, 2000, J BIOL CHEM, V275, P24639, DOI 10.1074/jbc.C900990199; LANCELIN JM, 1991, BIOCHEMISTRY-US, V30, P6908, DOI 10.1021/bi00242a014; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Mouhat S, 2004, BIOCHEM J, V377, P25, DOI 10.1042/BJ20030115; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J, 2001, MOL CLONING LAB MANU; SATO K, 1991, J BIOL CHEM, V266, P16989; Savarin P, 1998, BIOCHEMISTRY-US, V37, P5407, DOI 10.1021/bi9730341; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Srinivasan KN, 2002, J BIOL CHEM, V277, P30040, DOI 10.1074/jbc.M111258200; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P12577, DOI 10.1021/bi00165a006; Xu CQ, 2003, TRENDS PHARMACOL SCI, V24, P446, DOI 10.1016/S0165-6147(03)00223-2	33	27	31	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21246	21255		10.1074/jbc.M502376200	http://dx.doi.org/10.1074/jbc.M502376200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799976	hybrid			2022-12-25	WOS:000229438800043
J	Lei, M; Zaug, AJ; Podell, ER; Cech, TR				Lei, M; Zaug, AJ; Podell, ER; Cech, TR			Switching human telomerase on and off with hPOT1 protein in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POT1; LENGTH REGULATOR; BINDING PROTEIN; DNA; END; PROTECTION; YEAST; CDC13; STN1; TRF1	POT1 ( protection of telomeres 1) protein binds the G-rich single-stranded telomeric DNA at the ends of chromosomes. In human cells hPOT1 is involved in telomere length regulation, but the mechanism of this regulation remains unknown. Examination of the high-resolution crystal structure of the hPOT1-TTAGGGTTAG complex suggested that it would not be extended by telomerase, a hypothesis that we confirm by in vitro assays with recombinant telomerase. On the other hand, when hPOT1 is bound at a position one telomeric repeat before the 3'-end, leaving an 8-nucleotide 3'-tail, the complex is extended with improved activity and processivity. Thus, depending on its location relative to the DNA 3'-end, hPOT1 can either inhibit telomerase action or form a preferred substrate for telomerase. We propose that another factor catalyzes the interconversion of these states in vivo.	Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Cech, TR (corresponding author), Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA.	Thomas.Cech@colorado.edu						Armbruster BN, 2004, MOL CELL BIOL, V24, P3552, DOI 10.1128/MCB.24.8.3552-3561.2004; Baumann P, 2002, MOL CELL BIOL, V22, P8079, DOI 10.1128/MCB.22.22.8079-8087.2002; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bryan TM, 2000, J BIOL CHEM, V275, P24199, DOI 10.1074/jbc.M003246200; Chandra A, 2001, GENE DEV, V15, P404, DOI 10.1101/gad.861001; Chen JL, 2003, EMBO J, V22, P304, DOI 10.1093/emboj/cdg024; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Evans SK, 2002, GENETICS, V162, P1101; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Froelich-Ammon SJ, 1998, GENE DEV, V12, P1504, DOI 10.1101/gad.12.10.1504; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; Grandin N, 2000, MOL CELL BIOL, V20, P8397, DOI 10.1128/MCB.20.22.8397-8408.2000; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Grandin N, 2001, EMBO J, V20, P1173, DOI 10.1093/emboj/20.5.1173; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Houghtaling BR, 2004, CURR BIOL, V14, P1621, DOI 10.1016/j.cub.2004.08.052; Kelleher C, 2005, MOL CELL BIOL, V25, P808, DOI 10.1128/MCB.25.2.808-818.2005; Kim S, 2004, J BIOL CHEM, V279, P43799, DOI 10.1074/jbc.M408650200; Lei M, 2004, NAT STRUCT MOL BIOL, V11, P1223, DOI 10.1038/nsmb867; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Lei M, 2002, BIOCHEMISTRY-US, V41, P14560, DOI 10.1021/bi026674z; Liu D, 2004, J BIOL CHEM, V279, P51338, DOI 10.1074/jbc.M409293200; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; Loayza D, 2004, J BIOL CHEM, V279, P13241, DOI 10.1074/jbc.M312309200; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Lundblad V, 2003, CURR BIOL, V13, pR439, DOI 10.1016/S0960-9822(03)00365-8; Maine IP, 1999, BIOCHEMISTRY-US, V38, P15325, DOI 10.1021/bi991596+; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nikitina T, 2004, J CELL BIOL, V166, P161, DOI 10.1083/jcb.200403118; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; Reichenbach P, 2003, CURR BIOL, V13, P568, DOI 10.1016/S0960-9822(03)00173-8; Rivera MA, 2004, J BIOL CHEM, V279, P53770, DOI 10.1074/jbc.M407768200; SHIPPEN DE, 1994, P NATL ACAD SCI USA, V91, P405, DOI 10.1073/pnas.91.1.405; Snow BE, 2003, CURR BIOL, V13, P698, DOI 10.1016/S0960-9822(03)00210-0; Sun D, 1999, BIOCHEMISTRY-US, V38, P4037, DOI 10.1021/bi982249n; Taggart AKP, 2002, SCIENCE, V297, P1023, DOI 10.1126/science.1074968; Wei C, 2004, MOL CELL BIOL, V24, P2091, DOI 10.1128/MCB.24.5.2091-2102.2004; Ye JZS, 2004, J BIOL CHEM, V279, P47264, DOI 10.1074/jbc.M409047200; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404	44	130	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20449	20456		10.1074/jbc.M502212200	http://dx.doi.org/10.1074/jbc.M502212200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15792951	hybrid			2022-12-25	WOS:000229242000037
J	Morosinotto, T; Mozzo, M; Bassi, R; Croce, R				Morosinotto, T; Mozzo, M; Bassi, R; Croce, R			Pigment-pigment interactions in Lhca4 antenna complex of higher plants photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; FLUORESCENCE EMISSION; CRYSTAL-STRUCTURE; MUTATION ANALYSIS; BINDING; PROTEINS; RECONSTITUTION; ORGANIZATION; FORMS	The red-most fluorescence emission of photosystem I (733 nm at 4 K) is associated with the Lhca4 subunit of the antenna complex. It has been proposed that this unique spectral feature originates from the low energy absorption band of an excitonic interaction involving chlorophyll A5 and a second chlorophyll a molecule, probably B5 (Morosinotto, T., Breton, J., Bassi, R., and Croce, R. (2003) J. Biol. Chem. 278, 49223-49229). Because of the short distances between chromophores in Lhc proteins, the possibility that other pigments are involved in the red-shifted spectral forms could not be ruled out. In this study, we have analyzed the pigment-pigment interactions between nearest neighboring chromophores in Lhca4. This was done by deleting individual chlorophyll binding sites by mutagenesis, and analyzing the changes in the spectroscopic properties of recombinant proteins refolded in vitro. The red-shifted ( 733 nm) fluorescence peak, the major target of this analysis, was lost upon mutations affecting sites A4, A5, and B5 and was modified by mutating site B6. In agreement with the shorter distance between chlorophylls A5 and B5 ( 7.9 A) versus A4 and A5 ( 12.2 A) in Lhca4 (Ben-Shem, A., Frolow, F., and Nelson, N. ( 2003) Nature 426, 630 - 635), we conclude that the low energy spectral form originates from an interaction involving pigments in sites A5 and B5. Mutation at site B6, although inducing a 15-nm blue-shift of the emission peak, maintains the red- shifted emission. This implies that chromophores responsible for the interaction are conserved and suggests a modification in the pigment organization. Besides the A5 - B5 pair, evidence for additional pigment-pigment interactions between chlorophylls in sites B3-A3 and B6-A6 was obtained. However, these features do not affect the red- most spectral form responsible for the 733-nm fluorescence emission band.	ITC, CNR, Ist Biofis, I-38100 Trento, Italy; Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy; Univ Aix Marseille 2, Fac Sci Luminy, LGBP, Dept Biol, F-13288 Marseille, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Istituto per le Tecnologie della Costruzione (ITC-CNR); University of Verona; UDICE-French Research Universities; Aix-Marseille Universite	Croce, R (corresponding author), ITC, CNR, Ist Biofis, Via Sommarive 18, I-38100 Trento, Italy.	croce@itc.it	Croce, Roberta/ABG-3595-2021; Croce, Roberta/F-1174-2014; Croce, Roberta/N-4067-2014; Croce, Roberta/HGU-9554-2022; Morosinotto, Tomas/AAC-3188-2019	Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Morosinotto, Tomas/0000-0002-0803-7591; bassi, roberto/0000-0002-4140-8446				Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Castelletti S, 2003, BIOCHEMISTRY-US, V42, P4226, DOI 10.1021/bi027398r; Croce R, 1996, BIOCHEMISTRY-US, V35, P8572, DOI 10.1021/bi960214m; Croce R, 2004, J BIOL CHEM, V279, P48543, DOI 10.1074/jbc.M408908200; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; Croce R, 2002, BIOCHEMISTRY-US, V41, P7334, DOI 10.1021/bi0257437; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; GILMORE AM, 1991, PLANT PHYSIOL, V96, P635, DOI 10.1104/pp.96.2.635; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; Gobets B, 2001, BBA-BIOENERGETICS, V1507, P80, DOI 10.1016/S0005-2728(01)00203-1; HAWORTH P, 1983, BIOCHIM BIOPHYS ACTA, V724, P151, DOI 10.1016/0005-2728(83)90036-1; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JENNINGS RC, 1992, RES PHOTOSYNTH, V1, P291; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Morosinotto T, 2003, J BIOL CHEM, V278, P49223, DOI 10.1074/jbc.M309203200; Morosinotto T, 2002, J BIOL CHEM, V277, P36253, DOI 10.1074/jbc.M205062200; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; Remelli R, 1999, J BIOL CHEM, V274, P33510, DOI 10.1074/jbc.274.47.33510; Rivadossi A, 1999, PHOTOSYNTH RES, V60, P209, DOI 10.1023/A:1006236829711; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; Schmid VHR, 2002, J BIOL CHEM, V277, P37307, DOI 10.1074/jbc.M205889200; VANAMERONGEN H, 2000, PHOTOSYNTHETIC EXCIT, P52	25	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20612	20619		10.1074/jbc.M500705200	http://dx.doi.org/10.1074/jbc.M500705200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788395	hybrid			2022-12-25	WOS:000229242000057
J	Yanagi, K; Mizuno, T; Tsuyama, T; Tada, S; Iida, Y; Sugimoto, A; Eki, T; Enomoto, T; Hanaoka, F				Yanagi, K; Mizuno, T; Tsuyama, T; Tada, S; Iida, Y; Sugimoto, A; Eki, T; Enomoto, T; Hanaoka, F			Caenorhabditis elegans geminin homologue participates in cell cycle regulation and germ line development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LICENSING FACTOR CDT1; EUKARYOTIC DNA-REPLICATION; XENOPUS EGG EXTRACTS; DOWN-REGULATION; S-PHASE; INHIBITION; REREPLICATION; RNAI; PROTEOLYSIS; COMPLEX	Cdt1 is an essential component for the assembly of a pre-replicative complex. Cdt1 activity is inhibited by geminin, which also participates in neural development and embryonic differentiation in many eukaryotes. Although Cdt1 homologues have been identified in organisms ranging from yeast to human, geminin homologues had not been described for Caenorhabditis elegans and fungi. Here, we identify the C. elegans geminin, GMN-1. Biochemical analysis reveals that GMN-1 associates with C. elegans CDT-1, the Hox protein NOB-1, and the Six protein CEH-32. GMN-1 inhibits not only the interaction between mouse Cdt1 and Mcm6 but also licensing activity in Xenopus egg extracts. RNA interference-mediated reduction of GMN-1 is associated with enlarged germ nuclei with aberrant nucleolar morphology, severely impaired gametogenesis, and chromosome bridging in intestinal cells. We conclude that the Cdt1-geminin system is conserved throughout metazoans and that geminin has evolved in these taxa to regulate proliferation and differentiation by directly interacting with Cdt1 and homeobox proteins.	Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; RIKEN, Discovery Res Inst, Cellular Physiol Lab, Wako, Saitama 3510198, Japan; CREST, Japan Sci & Technol Corp, Wako, Saitama 3510198, Japan; Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 9808578, Japan; RIKEN, Ctr Dev Biol, Lab Dev Genet, Kobe, Hyogo 6500047, Japan; Toyohashi Univ Technol, Dept Ecol Engn, Toyohashi, Aichi 4418580, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	Osaka University; RIKEN; Japan Science & Technology Agency (JST); Tohoku University; RIKEN; Toyohashi University of Technology; Osaka University	Hanaoka, F (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.	fhanaoka@fbs.osaka-u.ac.jp	Sugimoto, Asako/U-3707-2019; Sugimoto, Asako/I-7239-2015	Sugimoto, Asako/0000-0001-6001-4293; Sugimoto, Asako/0000-0001-6001-4293				Aboobaker A, 2003, CURR OPIN GENET DEV, V13, P593, DOI 10.1016/j.gde.2003.10.009; Arias EE, 2005, GENE DEV, V19, P114, DOI 10.1101/gad.1255805; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Del Bene F, 2004, NATURE, V427, P745, DOI 10.1038/nature02292; Devault A, 2002, CURR BIOL, V12, P689, DOI 10.1016/S0960-9822(02)00768-6; Dozier C, 2001, DEV BIOL, V236, P289, DOI 10.1006/dbio.2001.0325; Ferenbach A, 2005, NUCLEIC ACIDS RES, V33, P316, DOI 10.1093/nar/gki176; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; HEDGECOCK EM, 1985, DEV BIOL, V107, P128, DOI 10.1016/0012-1606(85)90381-1; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Lee C, 2004, NATURE, V430, P913, DOI 10.1038/nature02813; Li A, 2005, EMBO J, V24, P395, DOI 10.1038/sj.emboj.7600520; Luo LF, 2004, NATURE, V427, P749, DOI 10.1038/nature02305; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Maiorano D, 2005, CURR BIOL, V15, P146, DOI 10.1016/j.cub.2004.12.002; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Mizuno T, 1998, MOL CELL BIOL, V18, P3552, DOI 10.1128/MCB.18.6.3552; Nishitani H, 2004, J BIOL CHEM, V279, P30807, DOI 10.1074/jbc.M312644200; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Saxena S, 2004, MOL CELL, V15, P245, DOI 10.1016/j.molcel.2004.06.045; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Whittaker AJ, 2000, GENE DEV, V14, P1765; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yoshida K, 2005, GENES CELLS, V10, P63, DOI 10.1111/j.1365-2443.2005.00815.x; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	40	31	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19689	19694		10.1074/jbc.C500070200	http://dx.doi.org/10.1074/jbc.C500070200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15811859	hybrid			2022-12-25	WOS:000229113700034
J	Covian, R; Trumpower, BL				Covian, R; Trumpower, BL			Rapid electron transfer between monomers when the cytochrome bc(1) complex dimer is reduced through center N	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; UBIQUINOL OXIDATION; CRYSTAL-STRUCTURE; SITES MECHANISM; TIGHT-BINDING; OXIDOREDUCTASE; INHIBITOR; STATE; UBISEMIQUINONE; MITOCHONDRIAL	We have obtained evidence for electron transfer between cytochrome b subunits of the yeast bc(1) complex dimer by analyzing pre-steady state reduction of cytochrome b in the presence of center P inhibitors. The kinetics and extent of cytochrome b reduced by quinol in the presence of variable concentrations of antimycin decreased non-linearly and could only be fitted to a model in which electrons entering through one center N can equilibrate between the two cytochrome b subunits of the bc(1) complex dimer. The b(H) heme absorbance in a bc(1) complex inhibited at center P and preincubated with substoichiometric concentrations of antimycin showed a red shift upon the addition of substrate, which indicates that electrons from the uninhibited center N in one monomer are able to reach the b(H) heme at the antimycin-blocked site in the other. The extent of cytochrome b reduction by variable concentrations of menaquinol could only be fitted to a kinetic model that assumes electron equilibration between center N sites in the dimer. Kinetic simulations showed that non-rate-limiting electron equilibration between the two b(H) hemes in the dimer through the two b(L) hemes is possible upon reduction through one center N despite the thermodynamically unfavorable b(H) to b(L) electron transfer step. We propose that electron transfer between cytochrome b subunits minimizes the formation of semiquinone-ferrocytochrome b(H) complexes at center N and favors ubiquinol oxidation at center P by increasing the amount of oxidized cytochrome b.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Trumpower, BL (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	Trumpower@Dartmouth.edu			NIGMS NIH HHS [GM 20379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECHMANN G, 1992, EUR J BIOCHEM, V208, P315, DOI 10.1111/j.1432-1033.1992.tb17189.x; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; Covian R, 2004, J BIOL CHEM, V279, P15040, DOI 10.1074/jbc.M400193200; Covian R, 2002, J BIOL CHEM, V277, P48449, DOI 10.1074/jbc.M208060200; de Vries S., 1982, FUNCTION QUINONES EN, P235; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DEKOK J, 1975, BIOCHIM BIOPHYS ACTA, V376, P27, DOI 10.1016/0005-2728(75)90202-9; DEVRIES S, 1982, BIOCHIM BIOPHYS ACTA, V681, P41, DOI 10.1016/0005-2728(82)90276-6; Gong X, 2005, J BIOL CHEM, V280, P9251, DOI 10.1074/jbc.M409994200; Gutierrez-Cirlos EB, 2004, J BIOL CHEM, V279, P8708, DOI 10.1074/jbc.M311805200; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P50703, DOI 10.1074/jbc.M208556200; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; KLINGENBERG M, 1967, BIOCH MITOCHONDRIA, P11; Kroger A, 1978, Methods Enzymol, V53, P579; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MARRES CAM, 1991, BIOCHIM BIOPHYS ACTA, V1057, P51, DOI 10.1016/S0005-2728(05)80083-0; MEINHARDT SW, 1987, J BIOL CHEM, V262, P8702; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Muller FL, 2003, BIOCHEMISTRY-US, V42, P6493, DOI 10.1021/bi0342160; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; Osyczka A, 2004, NATURE, V427, P607, DOI 10.1038/nature02242; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; RICH PR, 1990, BIOCHIM BIOPHYS ACTA, V1018, P29, DOI 10.1016/0005-2728(90)90106-E; Rich PR, 2004, BBA-BIOENERGETICS, V1658, P165, DOI 10.1016/j.bbabio.2004.04.021; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; Shinkarev VP, 2001, BIOCHEMISTRY-US, V40, P12584, DOI 10.1021/bi011334j; SIEDOW JN, 1978, J BIOL CHEM, V253, P2392; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; Sun H, 2003, ARCH BIOCHEM BIOPHYS, V419, P198, DOI 10.1016/j.abb.2003.08.028; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; Trumpower BL, 2002, BBA-BIOENERGETICS, V1555, P166, DOI 10.1016/S0005-2728(02)00273-6; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSAI AL, 1983, BIOCHIM BIOPHYS ACTA, V722, P349, DOI 10.1016/0005-2728(83)90083-X; VANDENBERG WH, 1979, J BIOL CHEM, V254, P8594; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YU CA, 1972, J BIOL CHEM, V247, P1012; Zhang L, 1999, FEBS LETT, V460, P349, DOI 10.1016/S0014-5793(99)01340-X; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	44	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22732	22740		10.1074/jbc.M413592200	http://dx.doi.org/10.1074/jbc.M413592200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15833742	hybrid			2022-12-25	WOS:000229741800023
J	Jaskolski, F; Normand, E; Mulle, C; Coussen, F				Jaskolski, F; Normand, E; Mulle, C; Coussen, F			Differential trafficking of GluR7 kainate receptor subunit splice variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; ER RETENTION SIGNAL; ENDOPLASMIC-RETICULUM; GLUTAMATE-RECEPTOR; AMPA RECEPTOR; HIPPOCAMPAL INTERNEURONS; SYNAPTIC-TRANSMISSION; EXCITATORY SYNAPSES; LOCALIZATION; DOMAIN	Kainate receptors (KARs) are heteromeric ionotropic glutamate receptors that play a variety of roles in the regulation of synaptic network activity. The function of glutamate receptors (GluRs) is highly dependent on their surface density in specific neuronal domains. Alternative splicing is known to regulate surface expression of GluR5 and GluR6 subunits. The KAR subunit GluR7 exists under different splice variant isoforms in the C-terminal domain (GluR7a and GluR7b). Here we have studied the trafficking of GluR7 splice variants in cultured hippocampal neurons from wild-type and KAR mutant mice. We have found that alternative splicing regulates surface expression of GluR7-containing KARs. GluR7a and GluR7b differentially traffic from the ER to the plasma membrane. GluR7a is highly expressed at the plasma membrane, and its trafficking is dependent on a stretch of positively charged amino acids also found in GluR6a. In contrast, GluR7b is detected at the plasma membrane at a low level and retained mostly in the endoplasmic reticulum (ER). The RXR motif of GluR7b does not act as an ER retention motif, at variance with other receptors and ion channels, but might be involved during the assembly process. Like GluR6a, GluR7a promotes surface expression of ER-retained subunit splice variants when assembled in heteromeric KARs. However, our results also suggest that this positive regulation of KAR trafficking is limited by the ability of different combinations of subunits to form heteromeric receptor assemblies. These data further define the complex rules that govern membrane delivery and subcellular distribution of KARs.	Univ Bordeaux 2, UMR 5091, Lab Phys Cellulaire Synapse, CNRS,Inst Magendie, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Mulle, C (corresponding author), Univ Bordeaux 2, UMR 5091, Lab Phys Cellulaire Synapse, CNRS,Inst Magendie, Rue C St Saens, F-33077 Bordeaux, France.	mulle@u-bordeaux2.fr		Mulle, Christophe/0000-0003-2709-6615				Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; Barry MF, 2002, CURR OPIN NEUROBIOL, V12, P279, DOI 10.1016/S0959-4388(02)00329-X; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; BETTLER B, 1992, NEURON, V8, P257, DOI 10.1016/0896-6273(92)90292-L; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Bureau I, 2000, P NATL ACAD SCI USA, V97, P6838, DOI 10.1073/pnas.97.12.6838; Bureau I, 1999, J NEUROSCI, V19, P653; Carroll RC, 2002, TRENDS NEUROSCI, V25, P571, DOI 10.1016/S0166-2236(02)02272-5; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; Chittajallu R, 1999, TRENDS PHARMACOL SCI, V20, P26, DOI 10.1016/S0165-6147(98)01286-3; Christensen JK, 2004, J NEUROSCI, V24, P8986, DOI 10.1523/JNEUROSCI.2156-04.2004; Coleman SK, 2003, J NEUROSCI, V23, P798; Coussen F, 2002, J NEUROSCI, V22, P6426, DOI 10.1523/jneurosci.22-15-06426.2002; Cui CH, 1999, J NEUROSCI, V19, P8281; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Gallyas F, 2003, J NEUROCHEM, V86, P1414, DOI 10.1046/j.1471-4159.2003.01945.x; Herzog E, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-22-j0001.2001; Huettner JE, 2003, PROG NEUROBIOL, V70, P387, DOI 10.1016/S0301-0082(03)00122-9; Janssens N, 2001, J NEUROCHEM, V77, P1457, DOI 10.1046/j.1471-4159.2001.00369.x; Jaskolski F, 2005, TRENDS PHARMACOL SCI, V26, P20, DOI 10.1016/j.tips.2004.11.008; Jaskolski F, 2004, J NEUROSCI, V24, P2506, DOI 10.1523/JNEUROSCI.5116-03.2004; JASKOLSKI F, 2005, IN PRESS J NEUROSCI; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Lerma J, 2001, PHYSIOL REV, V81, P971, DOI 10.1152/physrev.2001.81.3.971; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Mulle C, 2000, NEURON, V28, P475, DOI 10.1016/S0896-6273(00)00126-4; Pagano A, 2001, J NEUROSCI, V21, P1189; Pickering DS, 1995, P NATL ACAD SCI USA, V92, P12090, DOI 10.1073/pnas.92.26.12090; Ren Z, 2003, J BIOL CHEM, V278, P52700, DOI 10.1074/jbc.M309585200; Ren Z, 2003, J NEUROSCI, V23, P6608; RUANO D, 1995, NEURON, V14, P1009, DOI 10.1016/0896-6273(95)90339-9; Schiffer HH, 1997, NEURON, V19, P1141, DOI 10.1016/S0896-6273(00)80404-3; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Shen L, 2000, J NEUROSCI, V20, P7932; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Strutz N, 2001, J NEUROSCI, V21, P401, DOI 10.1523/JNEUROSCI.21-02-00401.2001; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; WISDEN W, 1993, J NEUROSCI, V13, P3582; Xia HH, 2002, J BIOL CHEM, V277, P47765, DOI 10.1074/jbc.M207122200; Yan S, 2004, J NEUROSCI, V24, P679, DOI 10.1523/JNEUROSCI.4985-03.2004; Yuan HB, 2003, CURR BIOL, V13, P638, DOI 10.1016/S0960-9822(03)00208-2; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198	45	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22968	22976		10.1074/jbc.M413166200	http://dx.doi.org/10.1074/jbc.M413166200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15805114	hybrid			2022-12-25	WOS:000229741800051
J	Chao, W; Shen, Y; Zhu, XS; Zhao, HL; Novikov, M; Schmidt, U; Rosenzweig, A				Chao, W; Shen, Y; Zhu, XS; Zhao, HL; Novikov, M; Schmidt, U; Rosenzweig, A			Lipopolysaccharide improves cardiomyocyte survival and function after serum deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ISCHEMIA-REPERFUSION INJURY; RECEPTOR-ASSOCIATED KINASE; NF-KAPPA-B; APOPTOTIC CELL-DEATH; HEAT-SHOCK PROTEINS; BACTERIAL LIPOPOLYSACCHARIDE; INFARCT SIZE; NITRIC-OXIDE; CARDIAC MYOCYTES	Toll-like receptor-4 ( TLR4) and its signaling molecule interleukin-1 receptor-associated kinase (IRAK-1) play an important role in host defense and tissue inflammation. Intriguingly, systemic administration of lipopolysaccharide (LPS), the agonist for TLR4, confers a cardio-protective effect against ischemic injury. However, the mechanisms leading to the cardiac protection remain largely unknown. The present study was designed to investigate the role of TLR4 activation by LPS in protecting cardiomyocytes (CM) against apoptosis in an in vitro model of ischemia and to explore the downstream mechanisms leading to the protective effect. Incubation with LPS led to activation of IRAK-1 and protected CMs against serum deprivation (SD)induced apoptosis as demonstrated by DNA laddering, histone-DNA fragment enzyme-linked immunosorbent assay, and activation of caspase-3. Phosphatidylinositol 3-kinase/Akt, extracellular signal-regulated kinase 1/2, and I kappa B kinase beta appear to contribute to the antiapoptotic effect of LPS since the specific inhibitors, wortmannin, PD98059, and dominant negative IKK beta transgene expression reversed the LPS effect. To assess whether LPS improves CM function, we examined intracellular Ca2+ transients and cell shortening in single adult rat CMs. SD for 6 h dramatically inhibited Ca2+ transients and CM contractility. LPS at 500 ng/ml significantly improved the [Ca2+](i) transients and enhanced contractility in control CMs as well as in CMs subjected to SD. Importantly, transient ischemia led to rapid activation of IRAK-1 in cultured CMs and in adult rat myocardium. Adenovirus-mediated transgene expression of IRAK-1 but not its kinase-deficient mutant IRAK-1( K239S) protected CMs against SD-induced apoptosis. Taken together, these data suggest an important role of TLR4 signaling via IRAK-1 in protecting against SD-induced apoptosis.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Program Cardiovasc Gene Therapy, Charlestown, MA 02139 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Chao, W (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Jackson 4,Rm 462,55 Fruit St, Boston, MA 02114 USA.	wchao@partners.org		Chao, Wei/0000-0002-2505-1360	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004336, R01HL061557] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 04336, HL 61557] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Bannerman DD, 2002, J BIOL CHEM, V277, P8048, DOI 10.1074/jbc.M111249200; Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200; Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371; Baumgarten G, 2001, J INFECT DIS, V183, P1617, DOI 10.1086/320712; Belosjorow S, 1999, AM J PHYSIOL-HEART C, V277, pH2470, DOI 10.1152/ajpheart.1999.277.6.H2470; BROWN JM, 1989, P NATL ACAD SCI USA, V86, P2516, DOI 10.1073/pnas.86.7.2516; Cain BS, 1999, CRIT CARE MED, V27, P1309, DOI 10.1097/00003246-199907000-00018; Chao W, 2003, J GENE MED, V5, P277, DOI 10.1002/jgm.347; Chao W, 2002, J BIOL CHEM, V277, P31639, DOI 10.1074/jbc.M204104200; Cowan DB, 2000, AM J PHYSIOL-HEART C, V279, pH619, DOI 10.1152/ajpheart.2000.279.2.H619; Demidov ON, 1999, EUR J CARDIO-THORAC, V16, P444, DOI 10.1016/S1010-7940(99)00291-2; Dybdahl B, 2002, CIRCULATION, V105, P685, DOI 10.1161/hc0602.103617; Eising GP, 1996, CARDIOVASC RES, V31, P73, DOI 10.1016/0008-6363(95)00173-5; Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709; Frantz S, 2001, J BIOL CHEM, V276, P5197, DOI 10.1074/jbc.M009160200; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEARD SO, 1992, CRIT CARE MED, V20, P523, DOI 10.1097/00003246-199204000-00015; Hotchkiss RS, 2000, CRIT CARE MED, V28, P3207, DOI 10.1097/00003246-200009000-00016; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 1997, CRIT CARE MED, V25, P1298, DOI 10.1097/00003246-199708000-00015; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Hull C, 2002, J IMMUNOL, V169, P2611, DOI 10.4049/jimmunol.169.5.2611; ITOH G, 1995, AM J PATHOL, V146, P1325; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Kajstura J, 1996, LAB INVEST, V74, P86; KAPADIA S, 1995, J CLIN INVEST, V96, P1042, DOI 10.1172/JCI118090; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Knuefermann P, 2002, CIRCULATION, V106, P2608, DOI 10.1161/01.CIR.0000038110.69369.4C; Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949; Li HL, 2002, AM J PHYSIOL-HEART C, V283, pH461, DOI 10.1152/ajpheart.00701.2001; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Martinez-Cordova L. R., 1998, Journal of Applied Aquaculture, V8, P17, DOI 10.1300/J028v08n03_02; Matsui T, 2001, CIRCULATION, V104, P330; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Meiler SE, 2002, J MOL CELL CARDIOL, V34, P349, DOI 10.1006/jmcc.2001.1519; Meng XZ, 1997, AM J PHYSIOL-HEART C, V273, pH1894, DOI 10.1152/ajpheart.1997.273.4.H1894; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P2005, DOI 10.1006/jmcc.1996.0193; Oyama J, 2004, CIRCULATION, V109, P784, DOI 10.1161/01.CIR.0000112575.66565.84; Ozes ON, 1999, NATURE, V401, P82; PAGANI FD, 1992, SURGERY, V111, P683; Sam F, 2000, AM J PHYSIOL-HEART C, V279, pH422, DOI 10.1152/ajpheart.2000.279.1.H422; Saraste A, 1997, CIRCULATION, V95, P320; Song W, 1996, BRIT J PHARMACOL, V118, P2157, DOI 10.1111/j.1476-5381.1996.tb15657.x; Song W, 1998, EUR J PHARMACOL, V345, P285, DOI 10.1016/S0014-2999(98)00126-5; Stein B, 1996, J MOL CELL CARDIOL, V28, P1631, DOI 10.1006/jmcc.1996.0153; Tavener SA, 2004, CIRC RES, V95, P700, DOI 10.1161/01.RES.0000144175.70140.8c; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Valen G, 2000, CARDIOVASC RES, V47, P49, DOI 10.1016/S0008-6363(00)00071-7; Venkataraman C, 1999, IMMUNOL LETT, V69, P233, DOI 10.1016/S0165-2478(99)00068-1; Vivarelli MS, 2004, J EXP MED, V200, P399, DOI 10.1084/jem.20040446; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Watters JJ, 2002, J BIOL CHEM, V277, P9077, DOI 10.1074/jbc.M104385200; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664; Wong F, 2004, BLOOD, V103, P4520, DOI 10.1182/blood-2003-06-2118; Yamashita N, 1999, BRIT J PHARMACOL, V128, P412, DOI 10.1038/sj.bjp.0702809; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yasuda S, 1997, CIRC RES, V81, P1011; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692	68	52	53	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21997	22005		10.1074/jbc.M413676200	http://dx.doi.org/10.1074/jbc.M413676200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15793310	hybrid			2022-12-25	WOS:000229557900042
J	Estall, JL; Koehler, JA; Yusta, B; Drucker, DJ				Estall, JL; Koehler, JA; Yusta, B; Drucker, DJ			The glucagon-like peptide-2 receptor C terminus modulates beta-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE-1; BETA-ARRESTIN; COUPLED RECEPTOR; HORMONE RECEPTOR; PHOSPHORYLATION; INTERNALIZATION; EXPRESSION; DOMAIN; PROLIFERATION; TRAFFICKING	Classic models of receptor desensitization and internalization have been largely based on the behavior of Family A G-protein-coupled receptors (GPCRs). The glucagon-like peptide-2 receptor (GLP-2R) is a member of the Family B glucagon-secretin GPCR family, which exhibit significant sequence and structural differences from the Family A receptors in their intracellular and extracellular domains. To identify structural motifs that regulate GLP-2R signaling and cell surface receptor expression, we analyzed the functional properties of a series of mutant GLP-2Rs. The majority of the C-terminal receptor tail was dispensable for GLP-2-induced cAMP accumulation, ERK1/2 activation, and endocytosis in transfected cells. However, progressive truncation of the C terminus reduced cell surface receptor expression, altered agonist-induced GLP-2R trafficking, and abrogated protein kinase A-mediated heterologous receptor desensitization. Elimination of the distal 21 amino acids of the receptor was sufficient to promote constitutive receptor internalization and prevent agonist-induced recruitment of beta-arrestin-2. Site-directed mutagenesis identified specific amino acid residues within the distal GLP-2R C terminus that mediate the stable association with beta-arrestin-2. Surprisingly, although the truncated mutant receptors failed to interact with beta-arrestin-2, they underwent homologous desensitization and subsequent resensitization with kinetics similar to that observed with the wild-type GLP-2R. Our data suggest that, although the GLP-2R C terminus is not required for coupling to cellular machinery regulating signaling or desensitization, it may serve as a sorting signal for intracellular trafficking. Taken together with the previously demonstrated clathrin and dynamin-independent, lipid-raft-dependent pathways for internalization, our data suggest that GLP-2 receptor signaling has evolved unique structural and functional mechanisms for control of receptor trafficking, desensitization, and resensitization.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2C4, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Drucker, DJ (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, 100 Coll St, Toronto, ON M5G 2C4, Canada.	d.drucker@utoronto.ca	Drucker, Daniel J/A-4092-2010	Estall, Jennifer/0000-0002-9838-1440				Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Bjerknes M, 2001, P NATL ACAD SCI USA, V98, P12497, DOI 10.1073/pnas.211278098; Blomenrohr M, 1999, MOL PHARMACOL, V56, P1229, DOI 10.1124/mol.56.6.1229; Buggy JJ, 1997, DIABETES, V46, P1400, DOI 10.2337/diabetes.46.9.1400; Chauvin S, 2002, MOL ENDOCRINOL, V16, P2720, DOI 10.1210/me.2002-0049; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dhami GK, 2004, J BIOL CHEM, V279, P16614, DOI 10.1074/jbc.M314090200; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Drucker DJ, 2001, ENDOCRINOLOGY, V142, P521, DOI 10.1210/en.142.2.521; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911; Estall JL, 2004, MOL BIOL CELL, V15, P3673, DOI 10.1091/mbc.E03-11-0825; Estall JL, 2003, J NUTR, V133, P3708, DOI 10.1093/jn/133.11.3708; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; Koehler JA, 2005, MOL ENDOCRINOL, V19, P459, DOI 10.1210/me.2004-0196; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lin XW, 1998, MOL ENDOCRINOL, V12, P161, DOI 10.1210/me.12.2.161; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mayo KE, 2003, PHARMACOL REV, V55, P167, DOI 10.1124/pr.55.1.6; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Munroe DG, 1999, P NATL ACAD SCI USA, V96, P1569, DOI 10.1073/pnas.96.4.1569; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Orskov C, 2005, REGUL PEPTIDES, V124, P105, DOI 10.1016/j.regpep.2004.07.009; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qian HW, 2001, MOL ENDOCRINOL, V15, P1706, DOI 10.1210/me.15.10.1706; Rasmussen TN, 2004, EUR J BIOCHEM, V271, P4366, DOI 10.1111/j.1432-1033.2004.04371.x; Schwartkop CP, 1999, J NEUROCHEM, V72, P1275, DOI 10.1046/j.1471-4159.1999.0721275.x; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Tsai CH, 1997, AM J PHYSIOL-ENDOC M, V273, pE77, DOI 10.1152/ajpendo.1997.273.1.E77; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Wei HJ, 2004, J BIOL CHEM, V279, P48255, DOI 10.1074/jbc.M406205200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Wheeler MB, 1999, J BIOL CHEM, V274, P24593, DOI 10.1074/jbc.274.35.24593; Yusta B, 2000, J BIOL CHEM, V275, P35345, DOI 10.1074/jbc.M005510200; Yusta B, 1999, J BIOL CHEM, V274, P30459, DOI 10.1074/jbc.274.43.30459; Yusta B, 2002, J BIOL CHEM, V277, P24896, DOI 10.1074/jbc.M201358200; Yusta B, 2000, GASTROENTEROLOGY, V119, P744, DOI 10.1053/gast.2000.16489; Zhong HL, 2001, J PHARMACOL EXP THER, V297, P837	48	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22124	22134		10.1074/jbc.M500078200	http://dx.doi.org/10.1074/jbc.M500078200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817468	hybrid			2022-12-25	WOS:000229557900057
J	Ferreira, ME; Hermann, S; Prochasson, P; Workman, JL; Berndt, KD; Wright, APH				Ferreira, ME; Hermann, S; Prochasson, P; Workman, JL; Berndt, KD; Wright, APH			Mechanism of transcription factor recruitment by acidic activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC AMINO-ACIDS; HERPES-SIMPLEX-VIRUS; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID-RECEPTOR; GENE-EXPRESSION; VP16; DOMAIN; GAL4; COMPLEX	Many transcriptional activators are intrinsically unstructured yet display unique, defined conformations when bound to target proteins. Target-induced folding provides a mechanism by which activators could form specific interactions with an array of structurally unrelated target proteins. Evidence for such a binding mechanism has been reported previously in the context of the interaction between the cancer-related c-Myc protein and the TATA-binding protein, which can be modeled as a two-step process in which a rapidly forming, low affinity complex slowly converts to a more stable form, consistent with a coupled binding and folding reaction. To test the generality of the target-induced folding model, we investigated the binding of two widely studied acidic activators, Gal4 and VP16, to a set of target proteins, including TATA-binding protein and the Swi1 and Snf5 subunits of the Swi/Snf chromatin remodeling complex. Using surface plasmon resonance, we show that these activator-target combinations also display bi-phasic kinetics suggesting two distinct steps. A fast initial binding phase that is inhibited by high ionic strength is followed by a slow phase that is favored by increased temperature. In all cases, overall affinity increases with temperature and, in most cases, with increased ionic strength. These results are consistent with a general mechanism for recruitment of transcriptional components to promoters by naturally occurring acidic activators, by which the initial contact is mediated predominantly through electrostatic interactions, whereas subsequent target-induced folding of the activator results in a stable complex.	Sodertorns Hogskola, Dept Life Sci, S-14189 Huddinge, Sweden; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Stowers Inst Med Res, Kansas City, MO 64110 USA	Sodertorn University; Karolinska Institutet; Stowers Institute for Medical Research	Ferreira, ME (corresponding author), Sodertorns Hogskola, Dept Life Sci, S-14189 Huddinge, Sweden.	monica.ferreira@sh.se	Berndt, Kurt/J-8574-2015; Wright, Anthony/J-8187-2015	Berndt, Kurt/0000-0002-3049-967X; Wright, Anthony/0000-0003-1029-9969				ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; Ansari AZ, 1998, P NATL ACAD SCI USA, V95, P13543, DOI 10.1073/pnas.95.23.13543; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; Carrozza MJ, 2002, J BIOL CHEM, V277, P24648, DOI 10.1074/jbc.M201965200; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Flinn EM, 2002, J BIOL CHEM, V277, P23399, DOI 10.1074/jbc.M201704200; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; Grossmann JG, 2001, BIOCHEMISTRY-US, V40, P6267, DOI 10.1021/bi0028946; Hermann S, 2001, J BIOL CHEM, V276, P40127, DOI 10.1074/jbc.M103793200; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JOHNSTON M, 1994, MOL CELL BIOL, V14, P3834, DOI 10.1128/MCB.14.6.3834; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; Nedialkov YA, 2004, ARCH BIOCHEM BIOPHYS, V425, P77, DOI 10.1016/j.abb.2004.03.002; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Neely KE, 2002, MOL CELL BIOL, V22, P1615, DOI 10.1128/MCB.22.6.1615-1625.2002; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; Prochasson P, 2003, MOL CELL, V12, P983, DOI 10.1016/S1097-2765(03)00366-6; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Rohde JR, 2000, MOL CELL BIOL, V20, P3880, DOI 10.1128/MCB.20.11.3880-3886.2000; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Sullivan SM, 1998, NUCLEIC ACIDS RES, V26, P4487, DOI 10.1093/nar/26.19.4487; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4	38	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21779	21784		10.1074/jbc.M502627200	http://dx.doi.org/10.1074/jbc.M502627200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15826952	hybrid			2022-12-25	WOS:000229557900015
J	Kumar, MS; Kapoor, M; Sinha, S; Reddy, GB				Kumar, MS; Kapoor, M; Sinha, S; Reddy, GB			Insights into hydrophobicity and the chaperone-like function of alpha A- and alpha B-crystallins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS EPITHELIAL-CELLS; 1,1'-BI(4-ANILINO)NAPHTHALENE-5,5'-DISULFONIC ACID; KNOCKOUT MICE; TEMPERATURE; BINDING; HYPERPROLIFERATION; AGGREGATION; PROTEINS/; STABILITY; CATARACT	Crystallin, composed of two subunits, alpha A and alpha B, has been shown to function as a molecular chaperone that prevents aggregation of other proteins under stress conditions. The exposed hydrophobic surfaces of alpha-crystallins have been implicated in this process, but their exact role has not been elucidated. In this study, we quantify the hydrophobic surfaces of alpha A- and alpha B-crystallins by isothermal titration calorimetry using 8-anilino-1-napthalenesulfonic acid (ANS) as a hydrophobic probe and analyze its correlation to the chaperone potential of alpha A- and alpha B-crystallins under various conditions. Two ANS binding sites, one with low and another with high affinity, were clearly detected, with alpha B showing a higher number of sites than alpha A at 30 degrees C. In agreement with the higher number of hydrophobic sites, alpha B-crystallin demonstrated higher chaperone activity than alpha A at this temperature. Thermodynamic analysis of ANS binding to alpha A- and alpha B-crystallins indicates that high affinity binding is driven by both enthalpy and entropy changes, with entropy dominating the low affinity binding. Interestingly, although the number of ANS binding sites was similar for alpha A and alpha B at 15 degrees C, alpha A was more potent than alpha B in preventing aggregation of the insulin B-chain. Although there was no change in the number of high affinity binding sites of alpha A and alpha B for ANS upon preheating, there was an increase in the number of low affinity sites of alpha A and alpha B. Preheated alpha A, in contrast to alpha B, exhibited remarkably enhanced chaperone activity. Our results indicate that although hydrophobicity appears to be a factor in determining the chaperone-like activity of alpha-crystallins, it does not quantitatively correlate with the chaperone function of alpha-crystallins.	Natl Inst Nutr, Div Biochem, Hyderabad 500007, Andhra Pradesh, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Nutrition (NIN); Indian Institute of Science (IISC) - Bangalore	Reddy, GB (corresponding author), Natl Inst Nutr, Div Biochem, Hyderabad 500007, Andhra Pradesh, India.	geereddy@yahoo.com	Reddy, G Bhanuprakash/AAJ-3494-2020	Reddy, G Bhanuprakash/0000-0003-4787-3944; Sinha, Sharmistha/0000-0003-2459-650X				Andley UP, 2001, FASEB J, V15, P221, DOI 10.1096/fj.00-0296com; Andley UP, 2000, J BIOL CHEM, V275, P36823, DOI 10.1074/jbc.M004233200; Bai F, 2003, J BIOL CHEM, V278, P36876, DOI 10.1074/jbc.M304010200; Bhat SP, 2003, PROG DRUG RES, V60, P205; Bhattacharyya J, 2002, J PROTEIN CHEM, V21, P65, DOI 10.1023/A:1014187300930; Bloemendal H, 2004, PROG BIOPHYS MOL BIO, V86, P407, DOI 10.1016/j.pbiomolbio.2003.11.012; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Burgio MR, 2000, BIOCHEM BIOPH RES CO, V268, P426, DOI 10.1006/bbrc.1999.2036; Burgio MR, 2001, MOL VIS, V7, P228; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Fujita Y, 2004, J CELL SCI, V117, P1719, DOI 10.1242/jcs.01021; Ganea E, 2001, CURR PROTEIN PEPT SC, V2, P205, DOI 10.2174/1389203013381107; Gomez-Puertas P, 2004, J MOL RECOGNIT, V17, P85, DOI 10.1002/jmr.654; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; Kumar LVS, 2000, J BIOL CHEM, V275, P22009, DOI 10.1074/jbc.M003307200; Kumar MS, 2004, BIOCHEM J, V379, P273, DOI 10.1042/BJ20031633; LIANG JN, 1991, EXP EYE RES, V53, P61, DOI 10.1016/0014-4835(91)90145-5; Liao JH, 2002, BIOCHEM BIOPH RES CO, V295, P854, DOI 10.1016/S0006-291X(02)00784-2; Mao Q, 2001, BIOCHEMISTRY-MOSCOW+, V66, P904, DOI 10.1023/A:1011960904542; Mchaourab HS, 2002, J BIOL CHEM, V277, P40557, DOI 10.1074/jbc.M206250200; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; Santhoshkumar P, 2001, J BIOL CHEM, V276, P47094, DOI 10.1074/jbc.M107737200; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; Smulders RHPH, 1997, FEBS LETT, V409, P101, DOI 10.1016/S0014-5793(97)00498-5; Stevens A, 1997, EUR J BIOCHEM, V243, P792, DOI 10.1111/j.1432-1033.1997.00792.x; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	35	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21726	21730		10.1074/jbc.M500405200	http://dx.doi.org/10.1074/jbc.M500405200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817465	hybrid			2022-12-25	WOS:000229557900008
J	Moren, A; Imamura, T; Miyazono, K; Heldin, CH; Moustakas, A				Moren, A; Imamura, T; Miyazono, K; Heldin, CH; Moustakas, A			Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; BONE MORPHOGENETIC PROTEIN; TGF-BETA; TRANSCRIPTIONAL ACTIVITY; FUNCTIONAL CONSEQUENCES; DEPENDENT DEGRADATION; SUMO-1 MODIFICATION; MISSENSE MUTATIONS; STRUCTURAL BASIS; I RECEPTOR	Smad4 mediates signaling by the transforming growth factor-beta (TGF-beta) superfamily of cytokines. Smad signaling is negatively regulated by inhibitory (I) Smads and ubiquitin-mediated processes. Known mechanisms of proteasomal degradation of Smads depend on the direct interaction of specific E3 ligases with Smads. Alternatively, I-Smads elicit degradation of the TGF-beta receptor by recruiting the WW and HECT domain E3 ligases, Smurfs, WWP1, or NEDD4-2. We describe an equivalent mechanism of degradation of Smad4 by the above E3 ligases, via formation of ternary complexes between Smad4 and Smurfs, mediated by R-Smads (Smad2) or I-Smads (Smad6/7), acting as adaptors. Smurfs, which otherwise cannot directly bind to Smad4, mediated polyubiquitination of Smad4 in the presence of Smad6 or Smad7. Smad4 co-localized with Smad7 and Smurf1 primarily in the cytoplasm and in peripheral cell protrusions. Smad2 or Smad7 mutants defective in Smad4 interaction failed to induce Smurf1-mediated down-regulation of Smad4. A Smad4 mutant defective in Smad2 or Smad7 interaction could not be effectively down-regulated by Smurf1. We propose that Smad4 is targeted for degradation by multiple ubiquitin ligases that can simultaneously act on R-Smads and signaling receptors. Such mechanisms of down-regulation of TGF-beta signaling may be critical for proper physiological response to this pathway.	Uppsala Univ, Biomed Ctr, Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Univ Tokyo, Grad Sch Med, Dept Med Pathol, Bunkyo Ku, Tokyo 1130033, Japan	Ludwig Institute for Cancer Research; Uppsala University; Japanese Foundation for Cancer Research; University of Tokyo	Moustakas, A (corresponding author), Uppsala Univ, Biomed Ctr, Ludwig Inst Canc Res, Box 595, SE-75124 Uppsala, Sweden.	aris.moustakas@licr.uu.se						Bai YL, 2004, MOL CELL, V15, P825, DOI 10.1016/j.molcel.2004.07.021; Brodin G, 1999, CANCER RES, V59, P2731; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; De Bosscher K, 2004, BIOCHEM J, V379, P209, DOI 10.1042/BJ20031886; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim BC, 2004, MOL CELL BIOL, V24, P2251, DOI 10.1128/MCB.24.6.2251-2262.2004; Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Kuratomi G, 2005, BIOCHEM J, V386, P461, DOI 10.1042/BJ20040738; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Li LY, 2004, MOL CELL BIOL, V24, P856, DOI 10.1128/MCB.24.2.856-864.2004; Liang M, 2004, MOL CELL BIOL, V24, P7524, DOI 10.1128/MCB.24.17.7524-7537.2004; Liang M, 2004, J BIOL CHEM, V279, P22857, DOI 10.1074/jbc.M401554200; Liang YY, 2003, J BIOL CHEM, V278, P26307, DOI 10.1074/jbc.C300028200; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Long JY, 2004, BIOCHEM J, V379, P23, DOI 10.1042/BJ20031867; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; McCabe BD, 2004, NEURON, V41, P891, DOI 10.1016/S0896-6273(04)00073-X; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; Moren A, 2003, J BIOL CHEM, V278, P33571, DOI 10.1074/jbc.M300159200; Moustakas A, 2001, J CELL SCI, V114, P4359; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; Reguly T, 2003, TRENDS CELL BIOL, V13, P216, DOI 10.1016/S0962-8924(03)00075-8; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; Shi W, 2004, AM J PHYSIOL-LUNG C, V286, pL293, DOI 10.1152/ajplung.00228.2003; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Wan M, 2004, J BIOL CHEM, V279, P14484, DOI 10.1074/jbc.C400005200; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Ying SX, 2003, J BIOL CHEM, V278, P39029, DOI 10.1074/jbc.M301193200; Zhang LX, 2004, SCIENCE, V306, P114, DOI 10.1126/science.1100569; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	58	148	165	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22115	22123		10.1074/jbc.M414027200	http://dx.doi.org/10.1074/jbc.M414027200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817471	hybrid			2022-12-25	WOS:000229557900056
J	Shibata, HS; Takaku, H; Takagi, M; Nashimoto, M				Shibata, HS; Takaku, H; Takagi, M; Nashimoto, M			The T loop structure is dispensable for substrate recognition by tRNase ZL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' PROCESSING ENDORIBONUCLEASE; CANCER SUSCEPTIBILITY GENE; RNA 3'-PROCESSING ENDORIBONUCLEASE; CLEAVAGE; CCA; NUCLEOTIDES; MOLECULES; MECHANISM; HEPTAMERS; 3'-TRNASE	tRNA 3'-processing endoribonucleases ( tRNase Z, or 3'-tRNase; EC 3.1.26.11) are enzymes that remove 3'-trailers from pre-tRNAs. An about 12-base-pair stem, a T loop-like structure, and a 3'-trailer were considered to be the minimum requirements for recognition by the long form (tRNase ZL) of tRNase Z; tRNase ZL can recognize and cleave a micro-pre-tRNA or a hooker/target RNA complex that resembles a micro-pre-tRNA. We examined four hook RNAs containing systematically weakened T stems for directing target RNA cleavage by tRNase ZL. As expected, the cleavage efficiency decreased with the decrease in T stem stability, and to our surprise, even the hook RNA that forms no T stem-loop-directed slight cleavage of the target RNA, suggesting that the T stem-loop structure is important but dispensable for substrate recognition by tRNase ZL. To analyze the effect of the T loop on substrate recognition, we compared the cleavage reaction for a micro-pre-tRNA with that for a 12-base-pair double-stranded RNA, which is the same as the micro-pre-tRNA except for the lack of the T loop structure. The observed rate constant value for the double-stranded RNA was comparable with that for the micro-pre-tRNA, whereas the K-d value for the complex with the double-stranded RNA was much higher than that for the complex with the micro-pretRNA. These results suggest that the T loop structure is not indispensable for the recognition, although the interaction between the T loop and the enzyme exists. Cleavage assays for such double-stranded RNA substrates of various lengths suggested that tRNase ZL can recognize and cleave double-stranded RNA substrates that are longer than 5 base pairs and shorter than 20 base pairs. We also showed that double-stranded RNA is not a substrate for the short form of tRNase Z.	Niigata Univ Pharm & Appl Life Sci, Dept Appl Life Sci, Niigata 9568603, Japan	Niigata University	Nashimoto, M (corresponding author), Niigata Univ Pharm & Appl Life Sci, Dept Appl Life Sci, Niigata 9568603, Japan.	mnashimoto@niigatayakudai.jp						Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; CASTANO JG, 1985, J BIOL CHEM, V260, P9002; Dubrovsky EB, 2004, NUCLEIC ACIDS RES, V32, P255, DOI 10.1093/nar/gkh182; Korver W, 2003, INT J CANCER, V104, P283, DOI 10.1002/ijc.10945; Levinger L, 1998, J BIOL CHEM, V273, P1015, DOI 10.1074/jbc.273.2.1015; Minagawa A, 2004, J BIOL CHEM, V279, P15688, DOI 10.1074/jbc.M313951200; MINAGAWA A, 2005, IN PRESS CANC LETT; Mohan A, 1999, RNA, V5, P245, DOI 10.1017/S1355838299981256; NASHIMOTO M, 1995, NUCLEIC ACIDS RES, V23, P3642, DOI 10.1093/nar/23.18.3642; NASHIMOTO M, 1993, NUCLEIC ACIDS RES, V21, P4696, DOI 10.1093/nar/21.20.4696; Nashimoto M, 1996, RNA, V2, P523; Nashimoto M, 1999, J MOL BIOL, V287, P727, DOI 10.1006/jmbi.1999.2639; Nashimoto M, 1999, BIOCHEMISTRY-US, V38, P12089, DOI 10.1021/bi9911942; Nashimoto M, 1997, NUCLEIC ACIDS RES, V25, P1148, DOI 10.1093/nar/25.6.1148; Nashimoto M, 1998, NUCLEIC ACIDS RES, V26, P2565, DOI 10.1093/nar/26.11.2565; Nashimoto M, 1999, NUCLEIC ACIDS RES, V27, P2770, DOI 10.1093/nar/27.13.2770; Nashimoto M, 2001, J MOL BIOL, V312, P975, DOI 10.1006/jmbi.2001.5026; OOMMEN A, 1992, MOL CELL BIOL, V12, P865, DOI 10.1128/MCB.12.2.865; Pellegrini O, 2003, EMBO J, V22, P4534, DOI 10.1093/emboj/cdg435; Schiffer S, 2003, BIOL CHEM, V384, P333, DOI 10.1515/BC.2003.039; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; Takaku H, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh092; Takaku H, 2004, NUCLEIC ACIDS RES, V32, P4429, DOI 10.1093/nar/gkh774; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; Tamura M, 2003, NUCLEIC ACIDS RES, V31, P4354, DOI 10.1093/nar/gkg641; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808	26	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22326	22334		10.1074/jbc.M502048200	http://dx.doi.org/10.1074/jbc.M502048200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824113	hybrid			2022-12-25	WOS:000229557900078
J	Yu, XS; Yin, XY; Lafer, EM; Jiang, JX				Yu, XS; Yin, XY; Lafer, EM; Jiang, JX			Development regulation of the direct interaction between the intracellular loop of connexin 45.6 and the C terminus of major intrinsic protein (aquaporin-0)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC CHICK LENS; PLASMON RESONANCE; GAP-JUNCTIONS; DYE TRANSFER; EXPRESSION; MEMBRANE; WATER; MIP; COMMUNICATION; PERMEABILITY	The eye lens is dependent upon a network of gap junction-mediated intercellular communication to facilitate its homeostasis and development. Three gap junction-forming proteins are expressed in the lens of which two are in lens fibers, namely connexin (Cx) 45.6 and 56. Major intrinsic protein (MIP), also known as aquaporin-0 (AQP0), is the most abundant membrane protein in lens fibers. However, its role in the lens is not clear. Our previous studies show that MIP( AQP0) associates with gap junction plaques formed by Cx45.6 and Cx56 during the early stages of embryonic chick lens development but not in late embryonic and adult lenses. We report here that MIP( AQP0) directly interacts with Cx45.6 but not with Cx56. We further identified the intracellular loop of Cx45.6 as the interacting domain for the MIP(AQP0) C terminus. Surface plasmon resonance experiments indicated that the C-terminal domain of MIP(AQP0) interacts with two binding sites within the intracellular loop region of Cx45.6 with a K-D(app) of 7.5 and 10.3 mu M, respectively. The K-D(app) for the full-length loop region is 7.7 mu M. The cleavage at the intracellular loop of Cx45.6 was observed during lens development, and the C terminus of MIP( AQP0) did not interact with the loop-cleaved form of Cx45.6. Thus, the dissociation between these two proteins that occurs in the mature fibers of late lens development is likely caused by this cleavage. Finally this interaction had no impact on Cx45.6-mediated intercellular communication, suggesting that the Cx45.6-MIP(AQP0) interaction plays a novel unidentified role in lens fibers.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Jiang, JX (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, MSC 7760,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	jiangj@uthscsa.edu		Lafer, Eileen/0000-0002-0493-6522; Jiang, Jean/0000-0002-2185-5716	NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012085, R29EY012085] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA054174] Funding Source: Medline; NEI NIH HHS [EY 12085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Al-Ghoul KJ, 2003, ANAT REC PART A, V273A, P714, DOI 10.1002/ar.a.10080; BEEBE DC, 1981, DEV BIOL, V84, P96, DOI 10.1016/0012-1606(81)90374-2; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; DONALDSON PJ, 1995, AM J PHYSIOL-CELL PH, V269, pC590, DOI 10.1152/ajpcell.1995.269.3.C590; Duchesne L, 2002, J BIOL CHEM, V277, P20598, DOI 10.1074/jbc.M201179200; Dunia I, 1998, J CELL SCI, V111, P2109; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; FISCHBARG J, 1995, INVEST OPHTH VIS SCI, V36, P758; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; Gong XH, 1997, CELL, V91, P833, DOI 10.1016/S0092-8674(00)80471-7; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; HARLOW E, 1999, USING ANTIBODIES LAB, P245; Jiang JX, 1998, INVEST OPHTH VIS SCI, V39, P537; JIANG JX, 1994, MOL BIOL CELL, V5, P363, DOI 10.1091/mbc.5.3.363; Jiang JX, 2001, METH MOL B, V154, P159; Jiang JX, 1996, P NATL ACAD SCI USA, V93, P1287, DOI 10.1073/pnas.93.3.1287; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUSHMERICK C, 1995, EXP EYE RES, V61, P351, DOI 10.1016/S0014-4835(05)80129-0; McDonnell JM, 2001, CURR OPIN CHEM BIOL, V5, P572, DOI 10.1016/S1367-5931(00)00251-9; MILLER AG, 1992, J MEMBRANE BIOL, V128, P91; MILLER TM, 1986, J CELL BIOL, V102, P194, DOI 10.1083/jcb.102.1.194; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nemeth-Cahalan KL, 2000, J BIOL CHEM, V275, P6777, DOI 10.1074/jbc.275.10.6777; Nielsen PA, 2003, MOL BIOL CELL, V14, P2470, DOI 10.1091/mbc.E02-10-0637; OSTRER H, 1981, DEV BIOL, V86, P403, DOI 10.1016/0012-1606(81)90198-6; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; Salamon Z, 1999, TRENDS BIOCHEM SCI, V24, P213, DOI 10.1016/S0968-0004(99)01394-8; SAS DF, 1985, CURR EYE RES, V4, P1171, DOI 10.3109/02713688509003363; SCHUETZE SM, 1982, J CELL BIOL, V92, P694, DOI 10.1083/jcb.92.3.694; Tan FG, 2004, INVEST OPHTH VIS SCI, V45, P863, DOI 10.1167/iovs.03-0708; TANAKA M, 1980, INVEST OPHTH VIS SCI, V19, P619; Thomas MA, 2002, BIOL CELL, V94, P445, DOI 10.1016/S0248-4900(02)00015-1; Virkki LV, 2001, AM J PHYSIOL-REG I, V281, pR1994, DOI 10.1152/ajpregu.2001.281.6.R1994; White TW, 1998, J CELL BIOL, V143, P815, DOI 10.1083/jcb.143.3.815; WHITE TW, 1992, MOL BIOL CELL, V3, P711, DOI 10.1091/mbc.3.7.711; YANCEY SB, 1988, J CELL BIOL, V106, P705, DOI 10.1083/jcb.106.3.705; Yin XY, 2001, J BIOL CHEM, V276, P34567, DOI 10.1074/jbc.M106073200; Yu XS, 2004, J CELL SCI, V117, P871, DOI 10.1242/jcs.00945	40	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22081	22090		10.1074/jbc.M414377200	http://dx.doi.org/10.1074/jbc.M414377200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15802270	hybrid			2022-12-25	WOS:000229557900052
J	Godley, BF; Shamsi, FA; Liang, FQ; Jarrett, SG; Davies, S; Boulton, M				Godley, BF; Shamsi, FA; Liang, FQ; Jarrett, SG; Davies, S; Boulton, M			Blue light induces mitochondrial DNA damage and free radical production in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; BLOOD-RETINAL BARRIER; BASE EXCISION-REPAIR; OXIDATIVE STRESS; PIGMENT-EPITHELIUM; AGE PIGMENT; NUCLEAR-DNA; IN-VITRO; OXYGEN; ULTRAVIOLET	Exposure of biological chromophores to ultraviolet radiation can lead to photochemical damage. However, the role of visible light, particularly in the blue region of the spectrum, has been largely ignored. To test the hypothesis that blue light is toxic to non-pigmented epithelial cells, confluent cultures of human primary retinal epithelial cells were exposed to visible light (390 - 550 nm at 2.8 milliwatts/cm(2)) for up to 6 h. A small loss of mitochondrial respiratory activity was observed at 6 h compared with dark-maintained cells, and this loss became greater with increasing time. To investigate the mechanism of cell loss, the damage to mitochondrial and nuclear genes was assessed using the quantitative PCR. Light exposure significantly damaged mitochondrial DNA at 3 h (0.7 lesion/10 kb DNA) compared with dark-maintained controls. However, by 6 h of light exposure, the number of lesions was decreased in the surviving cells, indicating DNA repair. Isolated mitochondria exposed to light generated singlet oxygen, superoxide anion, and the hydroxyl radical. Antioxidants confirmed the superoxide anion to be the primary species responsible for the mitochondrial DNA lesions. The effect of lipofuscin, a photoinducible intracellular generator of reactive oxygen intermediates, was investigated for comparison. Exposure of lipofuscin-containing cells to visible light caused an increase in both mitochondrial and nuclear DNA lesions compared with non-pigmented cells. We conclude that visible light can cause cell dysfunction through the action of reactive oxygen species on DNA and that this may contribute to cellular aging, age-related pathologies, and tumorigenesis.	Retina Fdn SW, Dallas, TX 75231 USA; Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF10 3NB, Wales; King Khalid Eye Specialist Hosp, Dept Res, Riyadh 11462, Saudi Arabia	Retina Foundation of the Southwest; Cardiff University; King Khaled Eye Specialist Hospital	Godley, BF (corresponding author), Retina Fdn SW, 9900 N Cent Expressway,Suite 400, Dallas, TX 75231 USA.	bgodley@retinafoundation.org			NEI NIH HHS [R01 EY12850] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012850] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661; BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Bunik VI, 2002, EUR J BIOCHEM, V269, P5004, DOI 10.1046/j.1432-1033.2002.03204.x; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; CHEN EP, 1992, CURR EYE RES, V11, P825, DOI 10.3109/02713689209033480; CRAWFORD DR, 1994, ENVIRON HEALTH PERSP, V102, P25, DOI 10.2307/3432208; Croteau DL, 1999, MUTAT RES-DNA REPAIR, V434, P137, DOI 10.1016/S0921-8777(99)00025-7; CUNNINGHAM M L, 1985, Journal of Free Radicals in Biology and Medicine, V1, P381, DOI 10.1016/0748-5514(85)90150-3; Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; Genova ML, 2004, ANN NY ACAD SCI, V1011, P86, DOI 10.1196/annals.1293.010; Goyns MH, 2002, MECH AGEING DEV, V123, P791, DOI 10.1016/S0047-6374(01)00424-9; HENDERSON LM, 1993, EUR J BIOCHEM, V217, P973, DOI 10.1111/j.1432-1033.1993.tb18328.x; Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255; Hoffmann S, 2004, FREE RADICAL BIO MED, V36, P765, DOI 10.1016/j.freeradbiomed.2003.12.019; JARRETT SG, 2005, IN PRESS FREE RADIC; Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517; JONES CA, 1987, RADIAT RES, V110, P244, DOI 10.2307/3576902; Jou MJ, 2004, J PINEAL RES, V37, P55, DOI 10.1111/j.1600-079X.2004.00140.x; Jou MJ, 2002, J BIOMED SCI, V9, P507; Kagan VE, 2002, ANN NY ACAD SCI, V959, P188, DOI 10.1111/j.1749-6632.2002.tb02093.x; Kang D, 2003, CLIN CHEM LAB MED, V41, P1281, DOI 10.1515/CCLM.2003.195; King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1; KRALJIC I, 1978, PHOTOCHEM PHOTOBIOL, V28, P577, DOI 10.1111/j.1751-1097.1978.tb06972.x; Kravchenko LV, 2003, B EXP BIOL MED+, V136, P572, DOI 10.1023/B:BEBM.0000020207.67705.59; LeDoux SP, 2001, PROG NUCLEIC ACID RE, V68, P273; Lee HC, 2001, BIOGERONTOLOGY, V2, P231, DOI 10.1023/A:1013270512172; LUBART R, 1992, J PHOTOCH PHOTOBIO B, V12, P305, DOI 10.1016/1011-1344(92)85032-P; Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Pang JJ, 1998, GRAEF ARCH CLIN EXP, V236, P696, DOI 10.1007/s004170050143; Pang JJ, 1999, JPN J OPHTHALMOL, V43, P103, DOI 10.1016/S0021-5155(98)00073-2; PEAK JG, 1985, PHOTOCHEM PHOTOBIOL, V41, P295, DOI 10.1111/j.1751-1097.1985.tb03488.x; PEAK JG, 1995, PHOTOCHEM PHOTOBIOL, V61, P484, DOI 10.1111/j.1751-1097.1995.tb02349.x; PEAK MJ, 1990, PHOTOCHEM PHOTOBIOL, V51, P649, DOI 10.1111/php.1990.51.6.649; PEAK MJ, 1989, PHOTODERMATOLOGY, V6, P1; Peng TI, 2004, ANN NY ACAD SCI, V1011, P112, DOI 10.1196/annals.1293.012; Pflaum M, 1998, MUTAT RES-DNA REPAIR, V408, P137, DOI 10.1016/S0921-8777(98)00029-9; PUTTING BJ, 1993, GRAEF ARCH CLIN EXP, V231, P600, DOI 10.1007/BF00936526; PUTTING BJ, 1994, EXP EYE RES, V58, P31, DOI 10.1006/exer.1994.1192; Rabilloud T, 2001, PROTEOMICS, V1, P1105, DOI 10.1002/1615-9861(200109)1:9<1105::AID-PROT1105>3.0.CO;2-M; RICHMOND R, 1981, ANAL BIOCHEM, V118, P328, DOI 10.1016/0003-2697(81)90590-X; ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825; RYAN TC, 1990, J IMMUNOL METHODS, V130, P223, DOI 10.1016/0022-1759(90)90052-W; Sasaki N, 2003, CHEM-BIOL INTERACT, V145, P101, DOI 10.1016/S0009-2797(02)00248-X; Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303; SETLOW RB, 1994, MUTAT RES, V307, P365, DOI 10.1016/0027-5107(94)90310-7; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041; Suematsu N, 2003, CIRCULATION, V107, P1418, DOI 10.1161/01.CIR.0000055318.09997.1F; Takahashi A, 2004, BRAIN RES BULL, V62, P497, DOI 10.1016/j.brainresbull.2003.07.009; TYRRELL RM, 1984, PHOTOCHEM PHOTOBIOL, V39, P183, DOI 10.1111/j.1751-1097.1984.tb03426.x; Vamecq J, 1989, Essays Biochem, V24, P115; Van Remmen H, 2001, EXP GERONTOL, V36, P957; Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901; Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972	60	287	298	2	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21061	21066		10.1074/jbc.M502194200	http://dx.doi.org/10.1074/jbc.M502194200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797866	hybrid			2022-12-25	WOS:000229438800021
J	Thomas, JL; Boswell, EL; Scaccia, LA; Pletnev, V; Umland, TC				Thomas, JL; Boswell, EL; Scaccia, LA; Pletnev, V; Umland, TC			Identification of key amino acids responsible for the substantially higher affinities of human type 1 3 beta-hydroxysteroid dehydrogenase/isomerase (3 beta-HSD1) for substrates, coenzymes, and inhibitors relative to human 3 beta-HSD2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL 3-BETA-HYDROXY-5-ENE-STEROID DEHYDROGENASE; STEROID 5->4-ENE-ISOMERASE; EPITHELIAL-CELLS; BREAST-CANCER; PURIFICATION; EXPRESSION; INTERLEUKIN-4; INDUCTION; THERAPY	The human type 1 ( placenta, breast tumors, and prostate tumors) and type 2 ( adrenals and gonads) isoforms of 3 beta-hydroxysteroid dehydrogenase/ isomerase (3 beta-HSD1 and 3 beta-HSD2) are encoded by two distinct genes that are expressed in a tissue-specific pattern. Our recent studies have shown that His(156) contributes to the 14-fold higher affinity that 3 beta-HSD1 exhibits for substrate and inhibitor steroids compared with human 3 beta-HSD2 containing Tyr(156) in the otherwise identical catalytic domain. Our structural model of human 3 beta-HSD localizes His(156) or Tyr(156) in the subunit interface of the enzyme homodimer. The model predicts that Gln(105) on one enzyme subunit has a higher probability of interacting with His(156) on the other subunit in 3 beta-HSD1 than with Tyr(156) in 3 beta-HSD2. The Q105M mutant of 3 beta-HSD1 (Q105M1) shifts the Michaelis-Menten constant (K-m) for 3 beta-HSD substrate and inhibition constants (K-i) for epostane and trilostane to the much lower affinity profiles measured for wild-type 3 beta-HSD2 and H156Y1. However, the Q105M2 mutant retains substrate and inhibitor kinetic profiles similar to those of 3 beta-HSD2. Our model also predicts that Gln(240) in 3 beta-HSD1 and Arg(240) in 3 beta-HSD2 may be responsible for the 3-fold higher affinity of the type 1 isomerase activity for substrate steroid and cofactors. The Q240R1 mutation increases the isomerase substrate K-m by 2.2- fold to a value similar to that of 3 beta-HSD2 isomerase and abolishes the allosteric activation of isomerase by NADH. The R240Q2 mutation converts the isomerase substrate, cofactor, and inhibitor kinetic profiles to the 4-14-fold higher affinity profiles of 3 beta-HSD1. Thus, key structural reasons for the substantially higher affinities of 3 beta-HSD1 for substrates, coenzymes, and inhibitors have been identified. These structure and function relationships can be used in future docking studies to design better inhibitors of the 3 beta-HSD1 that may be useful in the treatment of hormone-sensitive cancers and preterm labor.	Mercer Univ, Sch Med, Div Basic Med Sci, Macon, GA 31207 USA; Mercer Univ, Sch Med, Dept Obstet Gynecol, Macon, GA 31207 USA; Hauptman Woodward Med Res Inst, Buffalo, NY 14203 USA; Russian Acad Sci, Inst Bioorgan Chem, Moscow 142290, Russia; SUNY Buffalo, Dept Biol Struct, Buffalo, NY 14203 USA	Mercer University; Mercer University; Hauptman Woodward Medical Research Institute; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Thomas, JL (corresponding author), Mercer Univ, Sch Med, Div Basic Med Sci, 1550 Coll St, Macon, GA 31207 USA.	Thomas_J@Mercer.edu	Pletnev, Vladimir/Q-6151-2016	Umland, Timothy/0000-0002-0772-9510	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020055] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA114717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026546, R37DK026546] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA114717, CA114717] Funding Source: Medline; NICHD NIH HHS [HD20055, R01 HD020055] Funding Source: Medline; NIDDK NIH HHS [R01 DK026546, DK26546, R37 DK026546] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Dowsett M, 2003, SEMIN ONCOL, V30, P58, DOI 10.1016/S0093-7754(03)00300-2; GELDOF AA, 1995, ANTICANCER RES, V15, P1349; Ghosh D, 2001, J BIOL CHEM, V276, P18457, DOI 10.1074/jbc.M100538200; Gingras S, 1999, MOL ENDOCRINOL, V13, P66, DOI 10.1210/me.13.1.66; Gingras S, 1999, ENDOCRINOLOGY, V140, P4573, DOI 10.1210/en.140.10.4573; KACSOH B, 2000, ENDOCRINE PHYSL, P566; Kasperk CH, 1997, J BONE MINER RES, V12, P464, DOI 10.1359/jbmr.1997.12.3.464; McLeod DG, 2003, UROLOGY, V61, P3, DOI 10.1016/S0090-4295(02)02393-2; NAWATA H, 1995, J STEROID BIOCHEM, V53, P165, DOI 10.1016/0960-0760(95)00031-T; Pasqualini JR, 2004, BBA-REV CANCER, V1654, P123, DOI 10.1016/j.bbcan.2004.03.001; Penning TM, 2004, MOL CELL ENDOCRINOL, V215, P63, DOI 10.1016/j.mce.2003.11.006; Rainey WE, 2002, TRENDS ENDOCRIN MET, V13, P234, DOI 10.1016/S1043-2760(02)00609-4; Reddy G Kesava, 2004, Clin Prostate Cancer, V2, P206; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; Richter ON, 2004, MOL HUM REPROD, V10, P339, DOI 10.1093/molehr/gah039; SEGEL IH, 1975, ENZYME KINETICS, P109; Simpson ER, 2002, FERTIL STERIL, V77, pS6; SINGH J, 1992, ATLAS PROTEIN SIDE C, V1, P244; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thomas JL, 2004, ENDOCR RES, V30, P935, DOI 10.1081/ERC-200044164; THOMAS JL, 1988, J STEROID BIOCHEM, V31, P785, DOI 10.1016/0022-4731(88)90287-7; Thomas JL, 1998, J STEROID BIOCHEM, V66, P327, DOI 10.1016/S0960-0760(98)00058-2; Thomas JL, 2003, J BIOL CHEM, V278, P35483, DOI 10.1074/jbc.M304752200; THOMAS JL, 1989, J STEROID BIOCHEM, V33, P209, DOI 10.1016/0022-4731(89)90296-3; Thomas JL, 2002, J BIOL CHEM, V277, P42795, DOI 10.1074/jbc.M208537200; THOMAS JL, 1995, J BIOL CHEM, V270, P21003, DOI 10.1074/jbc.270.36.21003; Thomas JL, 2001, J MOL ENDOCRINOL, V27, P77, DOI 10.1677/jme.0.0270077; Xu D, 1997, PROTEIN ENG, V10, P999, DOI 10.1093/protein/10.9.999	32	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21321	21328		10.1074/jbc.M501269200	http://dx.doi.org/10.1074/jbc.M501269200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797861	Green Accepted, hybrid			2022-12-25	WOS:000229438800050
J	Shang, F; Deng, GJ; Liu, Q; Guo, WM; Haas, AL; Crosas, B; Finley, D; Taylor, A				Shang, F; Deng, GJ; Liu, Q; Guo, WM; Haas, AL; Crosas, B; Finley, D; Taylor, A			Lys(6)-modified ubiquitin inhibits ubiquitin-dependent protein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS EPITHELIAL-CELLS; MULTIUBIQUITIN CHAIN; ACTIVATING ENZYME; OXIDATIVE STRESS; POLYUBIQUITIN CHAINS; CALORIE RESTRICTION; RETICULOCYTE LYSATE; 20S PROTEASOME; KAPPA-B; PROTEOLYSIS	Ubiquitin plays essential roles in various cellular processes; therefore, it is of keen interest to study the structure-function relationship of ubiquitin itself. We investigated the modification of Lys(6) of ubiquitin and its physiological consequences. Mass spectrometry-based peptide mapping and N-terminal sequencing demonstrated that, of the 7 Lys residues in ubiquitin, Lys6 was the most readily labeled with sulfosuccinimidobiotin. Lys(6)-biotinylated ubiquitin was incorporated into high molecular mass ubiquitin conjugates as efficiently as unmodified ubiquitin. However, Lys(6)-biotinylated ubiquitin inhibited ubiquitin-dependent proteolysis, as conjugates formed with Lys(6)-biotinylated ubiquitin were resistant to proteasomal degradation. Ubiquitins with a mutation of Lys(6) had similar phenotypes as Lys(6)-biotinylated ubiquitin. Lys(6) mutant ubiquitins (K6A, K6R, and K6W) also inhibited ATP-dependent proteolysis and caused accumulation of ubiquitin conjugates. Conjugates formed with K6W mutant ubiquitin were also resistant to proteasomal degradation. The dominant-negative effect of Lys(6)-modified ubiquitin was further demonstrated in intact cells. Overexpression of K6W mutant ubiquitin resulted in accumulation of intracellular ubiquitin conjugates, stabilization of typical substrates for ubiquitin-dependent proteolysis, and enhanced susceptibility to oxidative stress. Taken together, these results show that Lys(6)-modified ubiquitin is a potent and specific inhibitor of ubiquitin-mediated protein degradation.	Tufts Univ, Jean Mayer USDA, HNRCA, Lab Nutr & Vis Res, Boston, MA 02111 USA; Louisiana State Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Harvard Univ, Sch Med, Dept Cell Biol, Cambridge, MA 02138 USA	Tufts University; United States Department of Agriculture (USDA); Louisiana State University System; Harvard University	Shang, F (corresponding author), Tufts Univ, Jean Mayer USDA, HNRCA, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.	fu.shang@tufts.edu	Guo, Weimin/B-3155-2009	Guo, Weimin/0000-0003-4318-7154	NATIONAL EYE INSTITUTE [R01EY011717, R29EY011717, R01EY013250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER; NEI NIH HHS [EY13250, R01 EY011717-07, R29 EY011717, EY11717, R01 EY013250, R01 EY011717, R01 EY011717-06A1] Funding Source: Medline; NIGMS NIH HHS [GM34009, R01 GM034009] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; Ciechanover A, 2000, J CELL BIOCHEM, P40; CORSI D, 1995, J BIOL CHEM, V270, P8928, DOI 10.1074/jbc.270.15.8928; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dudek EJ, 2001, FREE RADICAL BIO MED, V31, P651, DOI 10.1016/S0891-5849(01)00634-7; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; FINCH JS, 1990, NUCLEIC ACIDS RES, V18, P1907, DOI 10.1093/nar/18.7.1907; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; GREGORI L, 1990, J BIOL CHEM, V265, P8354; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; HAAS A, 1990, J BIOL CHEM, V265, P21664; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; HUANG LL, 1993, BIOCHIM BIOPHYS ACTA, V1175, P181, DOI 10.1016/0167-4889(93)90021-G; IVY GO, 1989, BRAIN RES, V498, P360, DOI 10.1016/0006-8993(89)91117-7; JABUSCH JR, 1985, ARCH BIOCHEM BIOPHYS, V238, P170, DOI 10.1016/0003-9861(85)90153-5; JAHNGEN JH, 1990, ARCH BIOCHEM BIOPHYS, V276, P32, DOI 10.1016/0003-9861(90)90006-K; JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L; KUDO T, 1994, BRAIN RES, V639, P1, DOI 10.1016/0006-8993(94)91757-4; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Layfield R, 2001, PROTEOMICS, V1, P773, DOI 10.1002/1615-9861(200106)1:6<773::AID-PROT773>3.0.CO;2-0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Macdonald JM, 1999, BIOCHEM PHARMACOL, V57, P1233, DOI 10.1016/S0006-2952(99)00039-8; Macdonald JM, 2000, J BIOL CHEM, V275, P31908, DOI 10.1074/jbc.M000684200; Morris JR, 2004, HUM MOL GENET, V13, P807, DOI 10.1093/hmg/ddh095; OBIN M, 1995, CURR EYE RES, V14, P751, DOI 10.3109/02713689508995796; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Scrofano MM, 1998, MECH AGEING DEV, V105, P273, DOI 10.1016/S0047-6374(98)00097-9; Scrofano MM, 1998, MECH AGEING DEV, V101, P277, DOI 10.1016/S0047-6374(97)00178-4; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176; Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; SHANG F, 1994, CURR EYE RES, V13, P423, DOI 10.3109/02713689408999870; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; VIJAYKUMAR S, 1987, J BIOL CHEM, V262, P6396; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wee KE, 2000, J PROTEIN CHEM, V19, P489, DOI 10.1023/A:1026501515450; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	60	67	71	5	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20365	20374		10.1074/jbc.M414356200	http://dx.doi.org/10.1074/jbc.M414356200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15790562	Green Accepted, hybrid			2022-12-25	WOS:000229242000027
J	Duffy, SM; Cruse, G; Lawley, WJ; Bradding, P				Duffy, SM; Cruse, G; Lawley, WJ; Bradding, P			beta(2)-Adrenoceptor regulation of the K+ channel iK(Ca)1 in human mast cells	FASEB JOURNAL			English	Article						salbutamol; ICI 118551; K(Ca)3.1; lung; G protein	HUMAN LUNG; INTERMEDIATE-CONDUCTANCE; DEPENDENT REGULATION; POTASSIUM CHANNELS; ION CHANNELS; ACTIVATION; RELEASE; INHIBITION; SALMETEROL; RESPONSES	Human mast cells express the intermediate conductance Ca2+-activated K+ channel iK(Ca)1, which opens following IgE-dependent activation. This results in cell membrane hyperpolarization and potentiation of both Ca2+ influx and degranulation. Mast cell activation is attenuated following exposure to beta(2)-adrenoceptor agonists such as salbutamol, an effect postulated to operate via intracellular cyclic AMP. In this study, we show that salbutamol closes iK(Ca)1 in mast cells derived from human lung and peripheral blood. Salbutamol (1-10 mu M) inhibited iK(Ca)1 currents following activation with both anti-IgE and the iK(Ca)1 opener I-EBIO, and was reversed by removing salbutamol or by the addition of the selective beta(2)-adrenoceptor antagonist and inverse agonist ICI 118551. Interestingly, ICI 118551 consistently opened iK(Ca)1 in quiescent cells, suggesting that constitutive beta(2)-receptor signaling suppresses channel activity. Manipulation of intracellular cAMP, G alpha i, and G alpha s demonstrates that the beta(2)-adrenergic effects are consistent with a membrane-delimited mechanism involving G alpha s. This is the first demonstration that gating of the iK(Ca)1 channel is regulated by a G protein-coupled receptor and provides a clearly defined mechanism for the mast cell "stabilizing" effect Of beta(2)-agonists. Furthermore, the degree of constitutive beta(2)-receptor "tone" may control the threshold for human mast cell activation through the regulation of iK(Ca)1.	Univ Leicester, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England	University of Leicester	Bradding, P (corresponding author), Glenfield Gen Hosp, Dept Resp Med, Groby Rd, Leicester LE3 9QP, Leics, England.	pbradding@hotmail.com	Cruse, Glenn/B-4597-2012; Cruse, Glenn/AAZ-1093-2021	Cruse, Glenn/0000-0002-7511-0082; Bradding, Peter/0000-0001-8403-0319				Benovic Jeffrey L., 2002, Journal of Allergy and Clinical Immunology, V110, pS229, DOI 10.1067/mai.2002.129370; Bradding P, 2003, J LEUKOCYTE BIOL, V73, P614, DOI 10.1189/jlb.1202602; Bradding P, 2002, CLIN EXP ALLERGY, V32, P979, DOI 10.1046/j.1365-2222.2002.01419.x; BRADDING P, 2000, ASTHMA RHINITIS, P319; Bradding P, 2003, CURR OPIN ALLERGY CL, V3, P45, DOI 10.1097/01.all.0000053267.39029.fd; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; Drury DEJ, 1998, BRIT J PHARMACOL, V124, P711, DOI 10.1038/sj.bjp.0701897; Duffy SM, 2004, J ALLERGY CLIN IMMUN, V114, P66, DOI 10.1016/j.jaci.2004.04.005; Duffy SM, 2003, J ALLERGY CLIN IMMUN, V112, P965, DOI 10.1016/j.jaci.2003.07.004; Duffy SM, 2001, J IMMUNOL, V167, P4261, DOI 10.4049/jimmunol.167.8.4261; Duffy SM, 2001, J LEUKOCYTE BIOL, V70, P233; Gerlach AC, 2000, J BIOL CHEM, V275, P585, DOI 10.1074/jbc.275.1.585; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Giannini D, 1996, CHEST, V110, P1452, DOI 10.1378/chest.110.6.1452; Gong HB, 2002, CIRCULATION, V105, P2497, DOI 10.1161/01.CIR.0000017187.61348.95; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hayashi M, 2004, AM J PHYSIOL-CELL PH, V286, pC635, DOI 10.1152/ajpcell.00283.2003; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Jensen BS, 1999, P NATL ACAD SCI USA, V96, P10917, DOI 10.1073/pnas.96.19.10917; KUME H, 1992, P NATL ACAD SCI USA, V89, P11051, DOI 10.1073/pnas.89.22.11051; KUME H, 1994, J CLIN INVEST, V93, P371, DOI 10.1172/JCI116969; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Liggett Stephen B., 2002, Journal of Allergy and Clinical Immunology, V110, pS223, DOI 10.1067/mai.2002.129945; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; PEACHELL PT, 1988, J IMMUNOL, V140, P571; Pedersen KA, 1999, BBA-BIOMEMBRANES, V1420, P231, DOI 10.1016/S0005-2736(99)00110-8; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; PELLEGRINO M, 2004, PFLUG ARCH EUR J PHY, V436, P749; Roberts JA, 1999, EUR RESPIR J, V14, P275, DOI 10.1034/j.1399-3003.1999.14b07.x; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; Sanmugalingam D, 2000, J LEUKOCYTE BIOL, V68, P38; Swystun VA, 2000, J ALLERGY CLIN IMMUN, V106, P57; Tsuji T, 2004, BIOL PHARM BULL, V27, P1549, DOI 10.1248/bpb.27.1549; von Hahn T, 2001, CELL PHYSIOL BIOCHEM, V11, P219, DOI 10.1159/000051936	36	49	50	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1006	+		10.1096/fj.04-3439fje	http://dx.doi.org/10.1096/fj.04-3439fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15817638				2022-12-25	WOS:000228865300021
J	Zhu, HB; Zhang, LD; Dong, FQ; Guo, W; Wu, SH; Teraishi, F; Davis, JJ; Chiao, P; Fang, BL				Zhu, HB; Zhang, LD; Dong, FQ; Guo, W; Wu, SH; Teraishi, F; Davis, JJ; Chiao, P; Fang, BL			Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors	ONCOGENE			English	Article						proteasome inhibitor; apoptosis; Bik; PS341; bortezomib	NF-KAPPA-B; CYTOCHROME-C; PROTEIN; RELEASE; PATHWAY; PROTEOLYSIS; ACTIVATION; SURVIVAL; DEATH; BIK	Proteasome inhibitors have emerged as promising anticancer therapeutic agents. Bortezomib (PS-341), a specific proteasome inhibitor, exhibits antitumor activity against a wide range of malignancies and has been approved by the US Food and Drug Administration for the treatment of relapsed or refractory multiple myeloma. However, the molecular mechanisms of bortezomib-mediated apoptosis remain unclear. To characterize the mechanisms of apoptosis induction by proteasome inhibitors, we examined levels of Bcl-2 protein family members (Bik/NBK, Bax, Bak, Bcl-2, and Bcl-XL), release of cytochrome c, and activation of caspase-9 and -3 in human colon cancer cell lines DLD1, LOVO, SW620, and HCT116; human lung cancer cell line H1299; and human ovarian cancer cell line SKOV3 after they were treated with bortezomib. The result showed that bortezomib induced rapid accumulation of Bik/NBK but not other Bcl-2 family members in all six cell lines. Bortezomib-mediated Bik/NBK accumulation and apoptosis were also observed in human embryonic kidney cells 293 and normal human bronchial epithelial cells. Moreover, dramatic Bik/NBK accumulation and apoptosis induction were observed when cells were treated with proteasome inhibitor MG132 and calpain inhibitor I (ALLN). Furthermore, no detectable changes in I kappa B alpha levels or in NF kappa B functionality were found after treatment with bortezomib. Finally, Bik/NBK accumulation was caused by stabilization of the protein from degradation and was associated with bortezomib cytotoxicity and apoptosis induction. Pretreatment of DLD1 cells with Bik/NBK siRNA reduced bortezomib-mediated Bik/NBK accumulation and cell death. Our results suggested that Bik/NBK is one of the mediators of proteasome inhibitor-induced apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, Houston, TX 77030 USA; Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Surg Oncol, Hangzhou, Peoples R China; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Gene Therapy & Virol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Zhejiang University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Fang, BL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, 1515 Holcombe Blvd, Houston, TX 77030 USA.	Bfang@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA098582, P30CA016672, R01CA092487] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 092487-01A1, R01 CA092487, CA-16672, R01 CA 098582-01A1, R01 CA098582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2002, ONCOLOGIST, V7, P9, DOI 10.1634/theoncologist.7-1-9; Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; BOYD JM, 1995, ONCOGENE, V11, P1921; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Kagawa S, 2001, CANCER RES, V61, P3330; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Lara PN, 2004, SEMIN ONCOL, V31, P40, DOI 10.1053/j.seminoncol.2003.12.013; Lenz HJ, 2003, CANCER TREAT REV, V29, P41, DOI 10.1016/S0305-7372(03)00082-3; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pei XY, 2003, LEUKEMIA, V17, P2036, DOI 10.1038/sj.leu.2403109; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Wu SH, 2004, CANCER RES, V64, P1110, DOI 10.1158/0008-5472.CAN-03-2790; Yu J, 2003, CANCER BIOL THER, V2, P694	21	105	110	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4993	4999		10.1038/sj.onc.1208683	http://dx.doi.org/10.1038/sj.onc.1208683			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15824729	Green Accepted			2022-12-25	WOS:000230646500012
J	Maina, EN; Morris, MR; Zatyka, M; Raval, RR; Banks, RE; Richards, FM; Johnson, CM; Maher, ER				Maina, EN; Morris, MR; Zatyka, M; Raval, RR; Banks, RE; Richards, FM; Johnson, CM; Maher, ER			Identification of novel VHL target genes and relationship to hypoxic response pathways	ONCOGENE			English	Article						VHL; HIF gene expression; microarray hypoxia; renal cell carcinoma	LINDAU TUMOR-SUPPRESSOR; RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; BECKWITH-WIEDEMANN-SYNDROME; FACTOR MESSENGER-RNA; OVARIAN-CANCER CELLS; INDUCIBLE FACTOR; TISSUE FACTOR; PROSTATE-CANCER; CLINICAL-FEATURES	Upregulation of hypoxia-inducible factors HIF-1 and HIF-2 is frequent in human cancers and may result from tissue hypoxia or genetic mechanisms, in particular the inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene (TSG). Tumours with VHL inactivation are highly vascular, but it is unclear to what extent HIF-dependent and HIF-independent mechanisms account for pVHL tumour suppressor activity. As the identification of novel pVHL targets might provide insights into pVHL tumour suppressor activity, we performed gene expression microarray analysis in VHL-wild-type and VHL-null renal cell carcinoma (RCC) cell lines. We identified 30 differentially regulated pVHL targets ( 26 of which were 'novel') and the results of microarray analysis were confirmed in all 11 novel targets further analysed by real-time RT-PCR or Western blotting. Furthermore, nine of 11 targets were dysregulated in the majority of a series of primary clear cell RCC with VHL inactivation. Three of the nine targets had been identified previously as candidate TSGs (DOC-2/DAB2, CDKN1C and SPARC) and all were upregulated by wild-type pVHL. The significance for pVHL function of two further genes upregulated by wild-type pVHL was initially unclear, but re-expression of GNG4 ( G protein gamma-4 subunit/ guanine nucleotide-binding protein-4) and MLC2 ( myosin light chain) in a RCC cell line suppressed tumour cell growth. pVHL regulation of CDKN1C, SPARC and GNG4 was not mimicked by hypoxia, whereas for six of 11 novel targets analysed ( including DOC-2/DAB2 and MLC2) the effects of pVHL inactivation and hypoxia were similar. For GPR56 there was evidence of a tissue-specific hypoxia response. Such a phenomenon might, in part, explain organ-specific tumorigenesis in VHL disease. These provide insights into mechanisms of pVHL tumour suppressor function and identify novel hypoxia-responsive targets that might be implicated in tumorigenesis both VHL disease and in other cancers with HIF upregulation.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Sch Med, Canc Res UK Res Grp, Birmingham B15 2TT, W Midlands, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England; Pfizer Global R&D, Discovery Biol, Sandwich CT13 9NJ, Kent, England	University of Birmingham; University of Birmingham; University of Oxford; Wellcome Centre for Human Genetics; Cancer Research UK; Saint James's University Hospital; University of Leeds; Pfizer	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	e.r.maher@bham.ac.uk	Morris, Mark/C-6413-2008; MAHER, EAMONN R/A-9507-2008; Zatyka, Malgorzata/D-9340-2017	MAHER, EAMONN R/0000-0002-6226-6918; Zatyka, Malgorzata/0000-0003-3427-1653; Morris, Mark/0000-0002-0700-355X; Johnson, Claire/0000-0003-4428-3594; Banks, Rosamonde/0000-0002-0042-8715				Agathanggelou A, 2003, CANCER RES, V63, P5344; Baba M, 2003, ONCOGENE, V22, P2728, DOI 10.1038/sj.onc.1206373; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Chlenski A, 2002, CANCER RES, V62, P7357; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FOSTER K, 1994, BRIT J CANCER, V69, P230, DOI 10.1038/bjc.1994.44; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Guan M, 2002, MOL BIOTECHNOL, V20, P123, DOI 10.1385/MB:20:2:123; HASSELAAR P, 1992, J CELL BIOCHEM, V49, P272, DOI 10.1002/jcb.240490310; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Horiuchi A, 2002, ANTICANCER RES, V22, P2697; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivanov S, 2001, AM J PATHOL, V158, P905, DOI 10.1016/S0002-9440(10)64038-2; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jiang YD, 2003, MOL CANCER RES, V1, P453; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kalyanaraman S, 1998, GENOMICS, V49, P147, DOI 10.1006/geno.1998.5223; Kikuchi T, 2002, ONCOGENE, V21, P2741, DOI 10.1038/sj.onc.1205376; Kleeff J, 2002, DIS COLON RECTUM, V45, P1242, DOI 10.1007/s10350-004-6399-2; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Knebelmann B, 1998, CANCER RES, V58, P226; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kumar J, 2003, J HIGH ENERGY PHYS; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Kuroda N, 2003, HISTOL HISTOPATHOL, V18, P487, DOI 10.14670/HH-18.487; Lam WWK, 1999, J MED GENET, V36, P518; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Li YH, 2002, BLOOD, V100, P2572, DOI 10.1182/blood-2001-11-0026; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Michl P, 2001, GASTROENTEROLOGY, V121, P678, DOI 10.1053/gast.2001.27124; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Morrissey C, 2001, CANCER RES, V61, P7277; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Ohta S, 2002, ANTICANCER RES, V22, P2991; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; Schwahn DJ, 1998, ONCOGENE, V17, P1173, DOI 10.1038/sj.onc.1202038; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Turner A, 2003, BIOCHEM J, V370, P403, DOI 10.1042/BJ20021360; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; Zatyka M, 2002, CANCER RES, V62, P3803; Zimmer M, 2004, MOL CANCER RES, V2, P89	68	38	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4549	4558		10.1038/sj.onc.1208649	http://dx.doi.org/10.1038/sj.onc.1208649			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15824735				2022-12-25	WOS:000230157100008
J	Caldinelli, L; Iametti, S; Barbiroli, A; Bonomi, F; Fessas, D; Molla, G; Pilone, MS; Pollegioni, L				Caldinelli, L; Iametti, S; Barbiroli, A; Bonomi, F; Fessas, D; Molla, G; Pilone, MS; Pollegioni, L			Dissecting the structural determinants of the stability of cholesterol oxidase containing covalently bound flavin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-HYGROSCOPICUS; BREVIBACTERIUM-STEROLICUM; FAD; FLAVINYLATION; DENATURATION; BINDING; STATE	Cholesterol oxidase from Brevibacterium sterolicum is a monomeric flavoenzyme catalyzing the oxidation and isomerization of cholesterol to cholest-4-en-3-one. This protein is a class II cholesterol oxidases, with the FAD cofactor covalently linked to the enzyme through the His(69) residue. In this work, unfolding of wild-type cholesterol oxidase was compared with that of a H69A mutant, which does not covalently bind the flavin cofactor. The two protein forms do not show significant differences in their overall topology, but the urea-induced unfolding of the H69A mutant occurred at significant lower urea concentrations than wild-type (similar to 3 versus similar to 5 M, respectively), and the mutant protein had a melting temperature similar to 10 - 15 degrees C lower than wild-type in thermal denaturation experiments. The different sensitivity of the various spectroscopic features used to monitor protein unfolding indicated that in both proteins a two-step (three-state) process occurs. The presence of an intermediate was more evident for the H69A mutant at 2 M urea, where catalytic activity and tertiary structure were lost, and new hydrophobic patches were exposed on the protein surface, resulting in protein aggregation. Comparative analysis of the changes occurring upon urea and thermal treatment of the wild-type and H69A protein showed a good correlation between protein instability and the elimination of the covalent link between the flavin and the protein. This covalent bond represents a structural device to modify the flavin redox potentials and stabilize the tertiary structure of cholesterol oxidase, thus pointing to a specific meaning of the flavin binding mode in enzymes that carry out the same reaction in pathogenic versus non-pathogenic bacteria.	Univ Insubria, Dept Biotechnol & Mol Sci, I-21100 Varese, Italy; Univ Milan, DISMA, I-20133 Milan, Italy; Univ Milan, DISTAM, I-20133 Milan, Italy	University of Insubria; University of Milan; University of Milan	Pollegioni, L (corresponding author), Univ Insubria, Dept Biotechnol & Mol Sci, Via JH Dunant 3, I-21100 Varese, Italy.	loredano.pollegioni@uninsubria.it	Iametti, Stefania/AGY-9694-2022	Bonomi, Francesco/0000-0003-4556-2640; Iametti, Stefania/0000-0002-4159-3768; POLLEGIONI, LOREDANO/0000-0003-1733-7243; Molla, Gianluca/0000-0003-3688-3397; BARBIROLI, ALBERTO GIUSEPPE/0000-0003-1678-5431				BARONE G, 1992, J THERM ANAL, V38, P2779, DOI 10.1007/BF01979752; BARONE G, 1994, CHEM PROPERTIES BIOM, P67; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CAIROLI S, 1994, J PROTEIN CHEM, V13, P347, DOI 10.1007/BF01901568; Caldinelli L, 2004, J BIOL CHEM, V279, P28426, DOI 10.1074/jbc.M403489200; Corbin DR, 2001, PLANT PHYSIOL, V126, P1116, DOI 10.1104/pp.126.3.1116; Coulombe R, 2001, J BIOL CHEM, V276, P30435, DOI 10.1074/jbc.M104103200; DAuria S, 1997, BIOCHEM J, V323, P833, DOI 10.1042/bj3230833; DEFRANCESCO R, 1988, ARCH BIOCHEM BIOPHYS, V264, P281, DOI 10.1016/0003-9861(88)90595-4; Edmondson DE, 2001, ANTIOXID REDOX SIGN, V3, P789, DOI 10.1089/15230860152664984; Fessas D, 2001, EUR J BIOCHEM, V268, P5439, DOI 10.1046/j.0014-2956.2001.02484.x; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; Gadda G, 1997, EUR J BIOCHEM, V250, P369, DOI 10.1111/j.1432-1033.1997.0369a.x; Iametti S, 1998, J AGR FOOD CHEM, V46, P2159, DOI 10.1021/jf980004b; Iametti S, 1996, EUR J BIOCHEM, V237, P106, DOI 10.1111/j.1432-1033.1996.0106n.x; KEARNEY EB, 1960, J BIOL CHEM, V235, P865; MacLachlan J, 2000, J STEROID BIOCHEM, V72, P169, DOI 10.1016/S0960-0760(00)00044-3; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; Motteran L, 2001, J BIOL CHEM, V276, P18024, DOI 10.1074/jbc.M010953200; Nandigama RK, 2000, J BIOL CHEM, V275, P20527, DOI 10.1074/jbc.M002132200; Navas J, 2001, J BACTERIOL, V183, P4796, DOI 10.1128/JB.183.16.4796-4805.2001; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; Pollegioni L, 2003, PROTEIN SCI, V12, P1018, DOI 10.1110/ps.0234603; Pollegioni L, 1999, EUR J BIOCHEM, V264, P140, DOI 10.1046/j.1432-1327.1999.00586.x; Prakash K, 2002, PROTEIN SCI, V11, P46, DOI 10.1110/ps.ps.20102; PRESS WH, 1989, NUMERICAL RECIPLES; PTISTYN OB, 1992, PROTEIN FOLDING, P243; Sampson NS, 2003, ACCOUNTS CHEM RES, V36, P713, DOI 10.1021/ar9800587; TANFORD C, 1968, ADV PROTEIN CHEM, V23, P69; VRIELINK A, 1991, J MOL BIOL, V219, P533, DOI 10.1016/0022-2836(91)90192-9; Yue QK, 1999, BIOCHEMISTRY-US, V38, P4277, DOI 10.1021/bi982497j	32	55	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22572	22581		10.1074/jbc.M500549200	http://dx.doi.org/10.1074/jbc.M500549200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817448	hybrid			2022-12-25	WOS:000229741800005
J	Gerin, I; Dolinsky, VW; Shackman, JG; Kennedy, RT; Chiang, SH; Burant, CF; Steffensen, KR; Gustafsson, JA; MacDougald, OA				Gerin, I; Dolinsky, VW; Shackman, JG; Kennedy, RT; Chiang, SH; Burant, CF; Steffensen, KR; Gustafsson, JA; MacDougald, OA			LXR beta is required for adipocyte growth, glucose homeostasis, and beta cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-X-RECEPTOR; FATTY-ACID SYNTHESIS; ADIPOSE-TISSUE; GENE-EXPRESSION; NUCLEAR RECEPTOR; CHOLESTEROL-METABOLISM; LIPID-METABOLISM; DEFICIENT MICE; ALPHA; ACTIVATION	Liver X receptors (LXR) alpha and beta are nuclear oxysterol receptors with established roles in cholesterol, lipid, and carbohydrate metabolism. Although LXRs have been extensively studied in liver and macrophages, the importance for development and metabolism of other tissues and cell types is not as well characterized. We demonstrate here that although LXR alpha and LXR beta are not required for adipocyte development per se, LXR beta is required for the increase in adipocyte size that normally occurs with aging and diet-induced obesity. Similar food intake and oxygen consumption in LXR beta-/- mice suggests that reduced storage of lipid in adipose tissue is not due to altered energy balance. Despite reduced amounts of adipose tissue, LXR beta-/- mice on a chow diet have insulin sensitivity and levels of adipocyte hormones similar to wild type mice. However, these mice are glucose-intolerant due to impaired glucose-induced insulin secretion. Lipid droplets in pancreatic islets may result from accumulation of cholesterol esters as analysis of islet gene expression reveals that LXR beta is required for expression of the cholesterol transporters, ABCA1 and ABCG1. Our data establish novel roles for LXR beta in adipocyte growth, glucose homeostasis, and beta cell function.	Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Catholique Louvain, Chim Physiol Lab, B-1200 Brussels, Belgium; Karolinska Inst, Dept Med Nutr & Biosci, S-14157 Huddinge, Sweden	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Universite Catholique Louvain; Karolinska Institutet	MacDougald, OA (corresponding author), Univ Michigan, Dept Mol & Integrat Physiol, 7620 Med Sci 2,1301 E Cathrine Dr, Ann Arbor, MI 48109 USA.	macdouga@umich.edu	Kennedy, Robert/G-9095-2016; Burant, Charles/GPC-5690-2022	Kennedy, Robert/0000-0003-2447-7471; Burant, Charles/0000-0001-9189-5003; Steffensen, Knut/0000-0001-6093-2801; MacDougald, Ormond/0000-0001-6907-7960	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062876, R01DK051563, P60DK020572, R01DK062876, R37DK046960, R01DK046960] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60 DK20572, DK046960, DK62876, DK51563] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; Andersson S, 2005, P NATL ACAD SCI USA, V102, P3857, DOI 10.1073/pnas.0500634102; Brendel C, 2002, MOL ENDOCRINOL, V16, P2065, DOI 10.1210/me.2001-0194; Cao GQ, 2003, J BIOL CHEM, V278, P1131, DOI 10.1074/jbc.M210208200; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Costet P, 2000, J BIOL CHEM, V275, P28240; Dalen KT, 2003, J BIOL CHEM, V278, P48283, DOI 10.1074/jbc.M302287200; Efanov AM, 2004, DIABETES, V53, pS75, DOI 10.2337/diabetes.53.suppl_3.S75; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hu X, 2003, MOL ENDOCRINOL, V17, P1019, DOI 10.1210/me.2002-0399; Hummasti S, 2004, J LIPID RES, V45, P616, DOI 10.1194/jlr.M300312-JLR200; Huuskonen J, 2004, ARTERIOSCL THROM VAS, V24, P703, DOI 10.1161/01.ATV.0000121202.72593.da; Juvet LK, 2003, MOL ENDOCRINOL, V17, P172, DOI 10.1210/me.2001-0210; KRAUSE BR, 1984, J LIPID RES, V25, P97; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Li AC, 2004, J LIPID RES, V45, P2161, DOI 10.1194/jlr.R400010-JLR200; Margareto J, 2001, BIOCHEM PHARMACOL, V61, P1471, DOI 10.1016/S0006-2952(01)00562-7; Millatt LJ, 2003, BBA-MOL CELL BIOL L, V1631, P107, DOI 10.1016/S1388-1981(02)00366-9; Mo JY, 2002, J BIOL CHEM, V277, P50788, DOI 10.1074/jbc.M210376200; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Schuster GU, 2002, CIRCULATION, V106, P1147, DOI 10.1161/01.CIR.0000026802.79202.96; Seo JB, 2004, MOL CELL BIOL, V24, P3430, DOI 10.1128/MCB.24.8.3430-3444.2004; Shackman JG, 2005, LAB CHIP, V5, P56, DOI 10.1039/b404974h; Steffensen KR, 2004, J MOL ENDOCRINOL, V33, P609, DOI 10.1677/jme.1.01508; Steffensen KR, 2004, DIABETES, V53, pS36, DOI 10.2337/diabetes.53.2007.S36; Steffensen KR, 2003, BIOCHEM BIOPH RES CO, V310, P589, DOI 10.1016/j.bbrc.2003.08.139; Stulnig TM, 2002, MOL PHARMACOL, V62, P1299, DOI 10.1124/mol.62.6.1299; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; Tobin KAR, 2002, J BIOL CHEM, V277, P10691, DOI 10.1074/jbc.M109771200; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Ulven SM, 2004, J LIPID RES, V45, P2052, DOI 10.1194/jlr.M400119-JLR200; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wagner BL, 2003, MOL CELL BIOL, V23, P5780, DOI 10.1128/MCB.23.16.5780-5789.2003; Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	40	134	140	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23024	23031		10.1074/jbc.M412564200	http://dx.doi.org/10.1074/jbc.M412564200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15831500	hybrid			2022-12-25	WOS:000229741800058
J	Patel, RT; Soulages, JL; Hariharasundaram, B; Arrese, EL				Patel, RT; Soulages, JL; Hariharasundaram, B; Arrese, EL			Activation of the lipid droplet controls the rate of lipolysis of triglycerides in the insect fat body	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; DEPENDENT PROTEIN-KINASE; A-MEDIATED LIPOLYSIS; ADULT MANDUCA-SEXTA; ADIPOKINETIC HORMONE; CARBOHYDRATE-METABOLISM; LOCUSTA-MIGRATORIA; 3T3-L1 ADIPOCYTES; FUTURE-DIRECTIONS; STORAGE DROPLETS	hydrolysis of triglyceride (TG) stored in the lipid droplets of the insect fat body is under hormonal regulation by the adipokinetic hormone (AKH), which triggers a rapid activation cAMP-dependent kinase cascade (protein kinase A (PKA)). The role of phosphorylation on two components of the lipolytic process, the TG-lipase and the lipid droplet, was investigated in fat body adipocytes. The activity of purified TG-lipase determined using in vivo TG-radiolabeled lipid droplets was unaffected by the phosphorylation of the lipase. However, the activity of purified lipase was 2.4-fold higher against lipid droplets isolated from hormone-stimulated fat bodies than against lipid droplets isolated from unstimulated tissue. In vivo stimulation of lipolysis promotes a rapid phosphorylation of a lipid droplet protein with an apparent mass of 42-44 kDa. This protein was identified as "Lipid Storage Droplet Protein 1" (Lsdp1). In vivo phosphorylation of this protein reached a peak similar to 10 min after the injection of AKH. Supporting a role of Lsdp1 in lipolysis, maximum TG-lipase activity was also observed with lipid droplets isolated 10 min after hormonal stimulation. The activation of lipolysis was reconstituted in vitro using purified insect PKA and TG-lipase and lipid droplets. In vitro phosphorylation of lipid droplets catalyzed by PKA enhanced the phosphorylation of Lsdp1 and the lipolytic rate of the lipase, demonstrating a prominent role PKA and protein phosphorylation on the activation of the lipid droplets. AKH-induced changes in the properties of the substrate do not promote a tight association of the lipase with the lipid droplets. It is concluded that the lipolysis in fat body adipocytes is controlled by the activation of the lipid droplet. This activation is achieved by PKA-mediated phosphorylation of the lipid droplet. Lsdp1 is the main target of PKA, suggesting that this protein is a major player in the activation of lipolysis in insects.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Arrese, EL (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, 246 Noble Res Ctr, Stillwater, OK 74078 USA.	estela@biochem.okstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064677] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM064677, GM 64677] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrese EL, 1997, J LIPID RES, V38, P68; Arrese EL, 1996, INSECT BIOCHEM MOLEC, V26, P775, DOI 10.1016/S0965-1748(96)00024-0; Arrese EL, 1999, J LIPID RES, V40, P556; Arrese EL, 1996, ARCH INSECT BIOCHEM, V31, P325, DOI 10.1002/(SICI)1520-6327(1996)31:3&lt;325::AID-ARCH7&gt;3.0.CO;2-W; ARRESE EL, 1994, J LIPID RES, V35, P1652; Arrese EL, 2001, J LIPID RES, V42, P225; Arrese EL, 2001, INSECT BIOCHEM MOLEC, V31, P7, DOI 10.1016/S0965-1748(00)00102-8; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; Canavoso LE, 2001, ANNU REV NUTR, V21, P23, DOI 10.1146/annurev.nutr.21.1.23; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; EGAN JJ, 1990, J BIOL CHEM, V265, P18769; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; FERNANDOWARNAKULASURIYA GJP, 1988, INSECT BIOCHEM, V18, P211, DOI 10.1016/0020-1790(88)90025-X; Gade G, 2003, GEN COMP ENDOCR, V132, P10, DOI 10.1016/S0016-6480(03)00159-X; Gade G, 1997, PHYSIOL REV, V77, P963, DOI 10.1152/physrev.1997.77.4.963; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; Gronke S, 2003, CURR BIOL, V13, P603, DOI 10.1016/S0960-9822(03)00175-1; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; Holm C, 2003, BIOCHEM SOC T, V31, P1120, DOI 10.1042/BST0311120; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; LAW JH, 1989, J BIOL CHEM, V264, P16335; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; LONDOS C, 1995, BIOCHEM SOC T, V23, P611, DOI 10.1042/bst0230611; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; LUM PY, 1990, J LIPID RES, V31, P2039; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; OLSSON H, 1984, BIOCHIM BIOPHYS ACTA, V794, P488, DOI 10.1016/0005-2760(84)90017-1; Patel R, 2004, INSECT BIOCHEM MOLEC, V34, P1269, DOI 10.1016/j.ibmb.2004.08.008; Schoofs L, 1997, PEPTIDES, V18, P145, DOI 10.1016/S0196-9781(96)00236-7; SOULAGES JL, 1994, ADV PROTEIN CHEM, V45, P371; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Staubli F, 2002, P NATL ACAD SCI USA, V99, P3446, DOI 10.1073/pnas.052556499; STRALFORS P, 1983, J BIOL CHEM, V258, P5146; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; WANG ZW, 1990, INSECT BIOCHEM, V20, P325; WILLOTT E, 1988, TISSUE CELL, V20, P635, DOI 10.1016/0040-8166(88)90065-1; Xue BZ, 2001, FASEB J, V15, P2527, DOI 10.1096/fj.01-0278fje; ZIEGLER R, 1990, PEPTIDES, V11, P1037, DOI 10.1016/0196-9781(90)90030-9; ZIEGLER R, 1991, J COMP PHYSIOL B, V161, P125, DOI 10.1007/BF00262874; ZIEGLER R, 1986, J INSECT PHYSIOL, V32, P997, DOI 10.1016/0022-1910(86)90118-6; ZIEGLER R, 1986, J INSECT PHYSIOL, V32, P903, DOI 10.1016/0022-1910(86)90106-X	49	76	76	4	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22624	22631		10.1074/jbc.M413128200	http://dx.doi.org/10.1074/jbc.M413128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15829485	hybrid			2022-12-25	WOS:000229741800011
J	Tang, CH; Yang, RS; Fu, WM				Tang, CH; Yang, RS; Fu, WM			Prostaglandin E-2 stimulates fibronectin expression through EP1 receptor, phospholipase C, protein kinase C alpha, and c-Src pathway in primary cultured rat osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; BONE-RESORPTION; GROWTH-FACTOR; E-2 PGE(2); TGF-BETA; CLONING; FIBRILLOGENESIS; MECHANISM; SUBTYPES; CAMP	Fibronectin (Fn) is involved in the early stages of bone formation, and prostaglandin E (PGE) is an important factor regulating osteogenesis. Here we found that PGE(2) enhanced extracellular Fn assembly in rat primary osteoblasts, as shown by immunofluorescence staining and enzyme-linked immunosorbent assay. PGE(2) also increased the protein levels of Fn by using Western blotting analysis. By using pharmacological inhibitors or activators or genetic inhibition by the EP receptor, antisense oligonucleotides revealed that the EP1 receptor but not other PGE receptors is involved in PGE(2)-mediated up-regulation of Fn. At the mechanistic level, Ca2+ chelator (1,2-bis(2-aminophenoxy) ethane-N,N,N ',N '-tetraacetic acid tetrakis(acetoxymethyl ester)), phosphatidylinositol-phospholipase C inhibitor (U73122), or Src inhibitor (PP2) attenuated the PGE2-induced Fn expression. Protein kinaseC(PKC) inhibitor (GF109203X) also inhibited the potentiating action of PGE(2). Furthermore, treatment with antisense oligonucleotides of various PKC isoforms, including alpha, beta, epsilon, and delta, demonstrated that alpha isozyme plays an important role in the enhancement action of PGE(2) on Fn assembly. Flow cytometry and reverse transcription-PCR showed that PGE(2) and 17-phenyl trinor PGE(2) (EP1/EP3 agonist) increased the surface expression and mRNA level of alpha 5 or beta 1 integrins. Fn promoter activity was enhanced by PGE(2) and 17-phenyl trinor PGE2 in cells transfected with pGL2F1900-Luc. Cotransfection with dominant negative mutants of PKC alpha or c-Src inhibited the potentiating action of PGE(2) on Fn promoter activity. Local administration of PGE(2) or 17-phenyl trinor PGE2 into the metaphysis of the tibia via the implantation of a needle cannula significantly increased the Fn and alpha 5 beta 1 integrin immunostaining and bone volume of secondary spongiosa in tibia. Taken together, our results provided evidence that PGE(2) increased Fn and promoted bone formation in rat osteoblasts via the EP1/phospholipase C/PKC alpha/c-Src signaling pathway.	Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Dept Orthopaed, Taipei, Taiwan	National Taiwan University; National Taiwan University	Yang, RS (corresponding author), Natl Taiwan Univ, Coll Med, Dept Pharmacol, 1,Sect 1,Jen Ai Rd, Taipei, Taiwan.	yang@ha.mc.ntu.edu.tw		Yang, Rong-Sen/0000-0002-0553-4779; FU, WEN-MEI/0000-0003-4157-8987				AKATSU T, 1989, J BONE MINER RES, V4, P29; Boie Y, 1997, EUR J PHARMACOL, V340, P227, DOI 10.1016/S0014-2999(97)01383-6; Burke A, 2002, PROSTAG LEUKOTR ESS, V67, P229, DOI 10.1054/plef.2002.0424; Canalis Ernesto, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P155; CLOVER J, 1992, J CELL SCI, V103, P267; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Globus RK, 1998, J CELL SCI, V111, P1385; GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408; HEINO J, 1993, ANN MED, V25, P335, DOI 10.3109/07853899309147294; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; Kaiser E, 2001, J CELL BIOCHEM, V83, P617, DOI 10.1002/jcb.1256; Kaneki H, 1999, J CELL BIOCHEM, V73, P36, DOI 10.1002/(SICI)1097-4644(19990401)73:1<36::AID-JCB5>3.3.CO;2-6; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Mo A, 2002, BONE, V31, P402, DOI 10.1016/S8756-3282(02)00835-9; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; Moursi AM, 1997, J CELL SCI, V110, P2187; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Park YG, 2004, INT J BIOCHEM CELL B, V36, P2270, DOI 10.1016/j.biocel.2004.04.019; Ping PP, 1999, CIRC RES, V85, P542, DOI 10.1161/01.RES.85.6.542; POTTS JR, 1994, CURR OPIN CELL BIOL, V6, P648, DOI 10.1016/0955-0674(94)90090-6; Samoto H, 2003, J BIOL CHEM, V278, P28659, DOI 10.1074/jbc.M300671200; Southall MD, 2001, J BIOL CHEM, V276, P16083, DOI 10.1074/jbc.M011408200; Su JL, 2004, CANCER RES, V64, P554, DOI 10.1158/0008-5472.CAN-03-1301; Suda M, 1996, ENDOCRINOLOGY, V137, P1698, DOI 10.1210/en.137.5.1698; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Tang CH, 2004, MOL PHARMACOL, V66, P440; Tang CH, 2003, J BONE MINER RES, V18, P502, DOI 10.1359/jbmr.2003.18.3.502; WATABE A, 1993, J BIOL CHEM, V268, P20175; Weinreb M, 2001, BONE, V28, P275, DOI 10.1016/S8756-3282(00)00447-6; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; WU CY, 1993, J BIOL CHEM, V268, P21883; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi T, 2004, J NEUROCHEM, V88, P148, DOI 10.1046/j.1471-4159.2003.02151.x; Yang RS, 2002, MOL PHARMACOL, V61, P1163, DOI 10.1124/mol.61.5.1163; Zent R, 2001, DEV BIOL, V238, P289, DOI 10.1006/dbio.2001.0391	41	87	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22907	22916		10.1074/jbc.M500130200	http://dx.doi.org/10.1074/jbc.M500130200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15833739	hybrid			2022-12-25	WOS:000229741800044
J	Adiseshaiah, P; Peddakama, S; Zhang, Q; Kalvakolanu, DV; Reddy, SP				Adiseshaiah, P; Peddakama, S; Zhang, Q; Kalvakolanu, DV; Reddy, SP			Mitogen regulated induction of FRA-1 proto-oncogene is controlled by the transcription factors binding to both serum and TPA response elements	ONCOGENE			English	Article						AP1; proto-oncogene; SRF; Elk1; transcription; ATF/CREB	C-FOS TRANSCRIPTION; BRONCHIAL EPITHELIAL-CELLS; FAMILY-MEMBERS; CANCER CELLS; UV-LIGHT; ERK; EXPRESSION; TRANSFORMATION; ACTIVATION; GENE	FRA-1, a member of the FOS family of transcription factors, is overexpressed in a variety of human tumors, and contributes to tumor progression. In addition to mitogens, various toxicants and carcinogens persistently induce FRA-1 expression in vitro and in vivo. Although the mitogen induced expression of c-FOS is relatively well understood, it is poorly defined in the case of FRA-1. Our recent analysis of the FRA-1 promoter has shown a critical role for a TRE located at - 318 in mediating the TPA-induced expression. The - 379 to - 283 bp promoter segment containing a critical TRE ( - 318), however, is insufficient for the induction of FRA-1 promoter. Here, we show that a 40-bp (- 276/- 237) segment, comprising a TCF binding site and the CArG box ( collectively known as serum response element, SRE), and an ATF site, is also necessary for the FRA-1 induction by TPA and EGF. Interestingly, the - 283 to +32 bp FRA-1 promoter fragment containing an SRE and an ATF site alone was also insufficient to confer TPA sensitivity to a reporter gene. However, in association with the - 318 TRE, the SRE and ATF sites imparted a strong TPA-inducibility to the reporter. Similarly, EGF also required these motifs for the full induction of this gene. Using ChIP assays we show that, in contrast to c-Jun, SRF, Elk1, ATF1 and CREB proteins bind to SRE and ATF sites of the FRA-1 promoter, constitutively. RNAi-mediated knockdown of endogenous SRF, ELK1 and c-JUN protein expression significantly reduced TPA-stimulated FRA-1 promoter activity. Thus, a bipartite enhancer formed by an upstream TRE and the downstream SRE and ATF sites and the cognate factors is necessary and sufficient for the regulation of FRA-1 in response to mitogens.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Div Physiol, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine	Reddy, SP (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Div Physiol, Dept Environm Hlth Sci, Rm W7006,615 N Wolfe St, Baltimore, MD 21205 USA.	sreddy@jhsph.edu	Adiseshaiah, Pavan/R-3917-2018		NCI NIH HHS [CA78282, CA105005] Funding Source: Medline; NHLBI NIH HHS [HL58122, HL66109] Funding Source: Medline; NIEHS NIH HHS [ES011863, ES30819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA105005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058122, R01HL066109, R01HL058122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011863] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adiseshaiah P, 2003, J BIOL CHEM, V278, P47423, DOI 10.1074/jbc.M303505200; Andersen H, 2002, ONCOGENE, V21, P4843, DOI 10.1038/sj.onc.1205590; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gupta P, 2002, J BIOL CHEM, V277, P50550, DOI 10.1074/jbc.M209799200; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Hurd TW, 2002, BIOCHEM J, V368, P573, DOI 10.1042/BJ20020579; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; MATSUI M, 1990, ONCOGENE, V5, P249; Papaiahgari S, 2004, J BIOL CHEM, V279, P42302, DOI 10.1074/jbc.M408275200; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Patterson T, 2001, ONCOGENE, V20, P634, DOI 10.1038/sj.onc.1204134; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Ramos-Nino ME, 2002, CANCER RES, V62, P6065; REDDY SP, 2002, AM J RESP CRIT CARE, V165, pA828; Reddy SPM, 2002, AM J PHYSIOL-LUNG C, V283, pL1161, DOI 10.1152/ajplung.00140.2002; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; Schreiber M, 1997, ONCOGENE, V15, P1171, DOI 10.1038/sj.onc.1201460; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; Soh JW, 1999, MOL CELL BIOL, V19, P1313; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; van Riggelen J, 2005, J BIOL CHEM, V280, P3286, DOI 10.1074/jbc.M409915200; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WISDOM R, 1993, MOL CELL BIOL, V13, P2635, DOI 10.1128/MCB.13.5.2635; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zajchowski DA, 2001, CANCER RES, V61, P5168	41	44	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4193	4205		10.1038/sj.onc.1208583	http://dx.doi.org/10.1038/sj.onc.1208583			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806162				2022-12-25	WOS:000229815300004
J	Helmrich, A; Lee, S; O'Brien, P; Dorken, B; Lowe, SW; Schrock, E; Schmitt, CA				Helmrich, A; Lee, S; O'Brien, P; Dorken, B; Lowe, SW; Schrock, E; Schmitt, CA			Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo	ONCOGENE			English	Article						cytogenetic analysis; chemoresistance; INK4a/ARF; lymphoma; mouse model	ACUTE LYMPHOBLASTIC-LEUKEMIA; GENOMIC ABERRATIONS; C-MYC; P16(INK4A); APOPTOSIS; CANCER; SENESCENCE; RELAPSE; P53	Predicting responsiveness to anticancer therapy based on molecular findings at diagnosis is important to optimize treatment decisions. Although clinical outcome correlates with distinct mutations in some cancer entities, treatment responses within these lesion-stratified subgroups still remain heterogeneous, underscoring the need for additional prognosticators. We previously demonstrated that defined genetic defects at the INK4a/ARF locus, which encodes the tumor suppressors p16(INK4a) and ARF, not only accelerated lymphomagenesis in the E mu-myc transgenic mouse but also interfered with treatment sensitivity. In this study, we take a nonbiased genome-wide approach to examine whether the responsiveness of these lymphomas can be further stratified based on cytogenetic information at diagnosis. Indeed, using spectral karyotyping, comparative genomic hybridization, and fluorescence in situ hybridization in 38 primary lymphomas, we find recurrent cytogenetic alterations that re. ne the predictive value of INK4a/ARF lesions on drug responses in vivo: gain of chromosome 14, which was never detected in INK4a/ ARFnull lymphomas, defined an ARFnull subgroup with superior treatment outcome. Gain of chromosome 6 was identified as a recurrent chromosomal aberration that predisposed ARFnull tumors to their subsequent INK4a loss during therapy. These data illustrate how cytogenetic information from cancer specimens might complement established prognostic markers and may improve anticancer treatment strategies.	Max Delbruck Ctr Mol Med, D-13353 Berlin, Germany; Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Clin Genet, D-01307 Dresden, Germany; Charite Univ Med Berlin, D-13353 Berlin, Germany; Univ Cambridge, Dept Clin Vet Med, Cambridge CB3 0ES, England; Watson Sch Biol Sci, Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Cambridge; Cold Spring Harbor Laboratory	Schmitt, CA (corresponding author), Max Delbruck Ctr Mol Med, Campus Virchow,Augustenburger Pl 1, D-13353 Berlin, Germany.	clemens.schmitt@charite.de	Schmitt, Clemens A/S-9479-2017; Lee, Soyoung/T-6669-2019; Lee, Soyoung/AHC-5032-2022	Schmitt, Clemens A/0000-0002-4731-2226; Lee, Soyoung/0000-0002-4614-2931	NATIONAL CANCER INSTITUTE [P30CA008748, P01CA087497] Funding Source: NIH RePORTER; NCI NIH HHS [CA87497, P30 CA008748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Carter TL, 2001, BRIT J HAEMATOL, V113, P323, DOI 10.1046/j.1365-2141.2001.02729.x; Carter TL, 2001, BLOOD, V97, P572, DOI 10.1182/blood.V97.2.572; DAVISSON MT, 1996, COMMITTEE STANDARDIZ; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Haslinger C, 2004, J CLIN ONCOL, V22, P3937, DOI 10.1200/JCO.2004.12.133; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Maloney KW, 1999, BLOOD, V93, P2380, DOI 10.1182/blood.V93.7.2380.407k27_2380_2385; Moorman AV, 2003, BLOOD, V102, P2756, DOI 10.1182/blood-2003-04-1128; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt CA, 2000, COLD SPRING HARB SYM, V65, P499, DOI 10.1101/sqb.2000.65.499; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; SCHROCK E, 1999, SPECTRAL KARYOTYPING; SCHROCK E, 2001, COMP GENOMIC HYBRIDI; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; Wei G, 1999, INT J CANCER, V80, P199, DOI 10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	29	8	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4174	4182		10.1038/sj.onc.1208600	http://dx.doi.org/10.1038/sj.onc.1208600			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15824738				2022-12-25	WOS:000229815300002
J	Thompson, ME; Robinson-Benion, CL; Holt, JT				Thompson, ME; Robinson-Benion, CL; Holt, JT			An amino-terminal motif functions as a second nuclear export sequence in BRCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN-CANCER; DNA-REPAIR; PROTEIN; SIGNAL; LOCALIZATION; BREAST; TRANSCRIPTION; ASSOCIATION; EXPRESSION; RECEPTOR	Mutations in the breast cancer susceptibility gene 1 (BRCA1) account for a substantial percentage of familial breast and ovarian cancers. Although BRCA1 is thought to function within the nucleus, it has also been located in the cytoplasm. In addition, BRCA1 accumulates in the nucleus of cells treated with leptomycin B, an inhibitor of chromosome region maintenance 1-mediated nuclear export, indicative of its active nuclear export via this pathway. The nuclear export signal in BRCA1 has been described as consisting of amino acid residues 81-99. However, a number of other tumor suppressors have multiple nuclear export sequences, and we sought to determine whether BRCA1 did also. Here, we report that BRCA1 contains a second nuclear export sequence that comprises amino acid residues 22-30. By use of the human immunodeficiency virus-1 Rev complementation assay, this sequence was shown to confer export capability to an export-defective Rev fusion protein. The level of export activity was comparable with that of residues 81-99 comprising the previously reported nuclear export sequence in BRCA1. Mutation of leucine 28 to an alanine reduced nuclear export by similar to 75%. In MCF-7 cells stably transfected with a BRCA1 cDNA containing mutations in this novel sequence or the previously reported export sequence, BRCA1 accumulated in the nucleus. These data imply that BRCA1 contains at least two leucine-dependent nuclear export sequences.	Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA; Vanderbilt Univ, Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA	Meharry Medical College; Vanderbilt University; Vanderbilt University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Thompson, ME (corresponding author), Meharry Med Coll, Dept Biochem, 1005 DB Todd Blvd, Nashville, TN 37208 USA.	methompson@mmc.edu			NATIONAL CANCER INSTITUTE [P30CA068485, R01CA085269, K01CA089494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK058404] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 85269, K01 CA 89494, CA 68485] Funding Source: Medline; NCRR NIH HHS [2G12 RR 03032] Funding Source: Medline; NIDDK NIH HHS [DK 58404, DK 20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; BEGERD HP, 1996, MOL CELL BIOL, V16, P4207; Bienstock RJ, 1996, CANCER RES, V56, P2539; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; EASTON DF, 1993, AM J HUM GENET, V52, P678; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; KAMATA N, 1991, MOL CELL BIOL, V11, P765, DOI 10.1128/MCB.11.2.765; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Ossareh-Nazari B, 2001, TRAFFIC, V2, P684, DOI 10.1034/j.1600-0854.2001.21002.x; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tickenbrock L, 2002, J BIOL CHEM, V277, P32332, DOI 10.1074/jbc.M203990200; Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	28	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21854	21857		10.1074/jbc.M502676200	http://dx.doi.org/10.1074/jbc.M502676200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15811849	hybrid			2022-12-25	WOS:000229557900025
J	Dhanalakshmi, S; Agarwal, C; Singh, RP; Agarwal, R				Dhanalakshmi, S; Agarwal, C; Singh, RP; Agarwal, R			Silibinin up-regulates DNA-protein kinase-dependent p53 activation to enhance UVB-induced apoptosis in mouse epithelial JB6 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVONOID ANTIOXIDANT SILYMARIN; ULTRAVIOLET-B RADIATION; NEOPLASTIC TRANSFORMATION; P53-DEPENDENT APOPTOSIS; CANCER CHEMOPREVENTION; SIGNAL-TRANSDUCTION; CATALYTIC SUBUNIT; LATENT POPULATION; REPAIR PATHWAYS; TUMOR PROMOTION	In the present study, we employed a well established JB6 mouse epithelial cell model to define the molecular mechanism of efficacy of a naturally occurring flavonoid silibinin against ultraviolet B (UVB)-induced skin tumorigenesis. UVB exposure of cells caused a moderate phosphorylation of ERK1/2 and Akt and a stronger phosphorylation of p53 at Ser(15), which was enhanced markedly by silibinin pretreatment. Kinase activity of ERK1/2 for Elk-1 and Akt for glycogen synthase kinase-3 beta was also potently enhanced by silibinin pretreatment. Furthermore, silibinin increased the UVB-induced level of cleaved caspase 3 as well as apoptotic cells. Based on these observations, next we investigated the role of upstream kinases, ATM/ATR and DNA-PK, which act as sensors for UVB-induced DNA damage and transduce signals leading to DNA repair or apoptosis. Whereas UVB strongly activated ATM as observed by Ser(1981) phosphorylation, it was not affected by silibinin pretreatment. However, pretreatment of cells with the DNA-protein kinase (PK) inhibitor LY294002 strongly reversed silibinin-enhanced Akt-Ser(473) and p53-Ser(15) as well as ERK1/2 phosphorylation together with a dose-dependent decrease in cleaved caspase 3 and apoptosis (p < 0.05). In addition, silibinin pretreatment strongly enhanced H2A.X-Ser(139) phosphorylation and DNA-PK-associated kinase activity as well as the physical interaction of p53 with DNA-PK; pretreatment of cells with LY294002 but not caffeine abolished the silibinin-caused increase in both DNA-PK activation and p53-Ser(15) phosphorylations. Together, these findings suggest that silibinin preferentially activates the DNA-PK-p53 pathway for apoptosis in response to UVB-induced DNA damage, and that this could be a predominant mechanism of silibinin efficacy against UVB-induced skin cancer.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	Rajesh.Agarwal@UCHSC.edu		Singh, Rana Pratap/0000-0003-4261-7044	NATIONAL CANCER INSTITUTE [R29CA064514, R01CA064514] Funding Source: NIH RePORTER; NCI NIH HHS [CA64514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Achanta G, 2001, CANCER RES, V61, P8723; Bachelor MA, 2004, SEMIN CANCER BIOL, V14, P131, DOI 10.1016/j.semcancer.2003.09.017; Bai L, 2004, CELL DEATH DIFFER, V11, P663, DOI 10.1038/sj.cdd.4401393; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Brash DE, 1996, J INVEST DERMATOL S, V1, P136; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Chang KL, 2004, BIOCHEM PHARMACOL, V67, P717, DOI 10.1016/j.bcp.2003.10.003; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Dhanalakshmi S, 2004, CARCINOGENESIS, V25, P99, DOI 10.1093/carcin/bgg188; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gines S, 2003, J BIOL CHEM, V278, P50514, DOI 10.1074/jbc.M309348200; He ZW, 2003, CANCER RES, V63, P4396; Heck DE, 2004, TOXICOL APPL PHARM, V195, P288, DOI 10.1016/j.taap.2003.09.028; Hofmann CS, 2003, FASEB J, V17, P702, DOI 10.1096/fj.02-0665fje; Holmes WF, 2004, J CELL PHYSIOL, V199, P317, DOI 10.1002/jcp.10338; Huang CS, 2002, CANCER RES, V62, P6857; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; Jack MT, 2004, J BIOL CHEM, V279, P15269, DOI 10.1074/jbc.M309917200; Kaji A, 2003, MOL CARCINOGEN, V37, P138, DOI 10.1002/mc.10130; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; Kim KY, 2004, J BIOL CHEM, V279, P29478, DOI 10.1074/jbc.M313947200; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee JK, 2003, J DERMATOL SCI, V32, P171, DOI 10.1016/S0923-1811(03)00094-X; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Li JJ, 1997, CANCER RES, V57, P3569; Ma CL, 2003, J BIOL CHEM, V278, P44265, DOI 10.1074/jbc.M309023200; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P1302, DOI 10.1210/en.2003-0709; Mallikarjuna G, 2004, CANCER RES, V64, P6349, DOI 10.1158/0008-5472.CAN-04-1632; Manson MM, 2000, TOXICOL LETT, V112, P499, DOI 10.1016/S0378-4274(99)00211-8; Mohan S, 2004, BIOCHEM BIOPH RES CO, V320, P183, DOI 10.1016/j.bbrc.2004.05.153; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; Rul W, 2002, ANN NY ACAD SCI, V973, P145, DOI 10.1111/j.1749-6632.2002.tb04624.x; Sarkaria JN, 1999, CANCER RES, V59, P4375; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2001, CANCER RES, V61, P1604; Singh RP, 2002, CARCINOGENESIS, V23, P499, DOI 10.1093/carcin/23.3.499; Singh RP, 2002, ANTIOXID REDOX SIGN, V4, P655, DOI 10.1089/15230860260220166; Sinha R, 2004, CURR CANCER DRUG TAR, V4, P13, DOI 10.2174/1568009043481614; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sodhi A, 2003, IMMUNOL LETT, V90, P123, DOI 10.1016/j.imlet.2003.08.008; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Suzukawa K, 2002, ENVIRON HEALTH PERSP, V110, P865, DOI 10.1289/ehp.02110865; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Whittaker S, 1996, BRIT J HOSP MED, V56, P515; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Xiao D, 2002, CANCER RES, V62, P3615; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Zhang Z, 2002, CHEM RES TOXICOL, V15, P950, DOI 10.1021/tx0255018; Zhao JF, 1999, MOL CARCINOGEN, V26, P321, DOI 10.1002/(SICI)1098-2744(199912)26:4<321::AID-MC11>3.3.CO;2-0; Zhao JF, 1999, CARCINOGENESIS, V20, P2101, DOI 10.1093/carcin/20.11.2101	57	59	60	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20375	20383		10.1074/jbc.M414640200	http://dx.doi.org/10.1074/jbc.M414640200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15792956	hybrid			2022-12-25	WOS:000229242000028
J	Timchenko, NA; Wang, GL; Timchenko, LT				Timchenko, NA; Wang, GL; Timchenko, LT			RNA CUG-binding protein 1 increases translation of 20-kDa isoform of CCAAT/enhancer-binding protein beta by interacting with the alpha and beta subunits of eukaryotic initiation translation factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL INHIBITORY PROTEIN; C/EBP-ALPHA; MESSENGER-RNA; CALRETICULIN; LIVER; ACTIVATION; EXPRESSION; PROLIFERATION; REGION; MICE	Expression of a dominant negative 20-kDa isoform of CCAAT/enhancer-binding protein (C/EBP beta), LIP, is increased in proliferating livers and in tumor cells. Two RNA-binding proteins, CUGBP1 and calreticulin, have been implicated in the translational regulation of C/EBP beta. In this paper, we present evidence showing several critical steps by which liver increases translation of LIP after partial hepatectomy. At early stages after partial hepatectomy, liver activates CUGBP1 by a hyperphosphorylation. The activated CUGBP1 binds to the 5' region of C/EBP beta mRNA and replaces calreticulin, which partially represses translation of C/EBP beta in quiescent livers. The hyperphosphorylated CUGBP1 also interacts with the alpha and beta subunits of initiation factor eIF2. Our data demonstrate that the interaction of CUGBP1 with the eIF2 alpha enhances the association of CUGBP1 with ribosomes and correlates with increased translation of LIP in the liver after partial hepatectomy. Our data support the hypothesis that CUGBP1 increases translation of LIP by the interaction with the eIF2 alpha subunit. This facilitates subsequent recruitment of larger numbers of ribosomes to initiate translation of LIP.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Timchenko, LT (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	lubovt@bcm.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA100070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049222, R01AR044387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG020752] Funding Source: NIH RePORTER; NCI NIH HHS [CA100070, R01 CA100070] Funding Source: Medline; NIAMS NIH HHS [AR49222, AR44387] Funding Source: Medline; NIA NIH HHS [AG20752] Funding Source: Medline; NIGMS NIH HHS [GM55188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An MR, 1996, MOL CELL BIOL, V16, P2295; ATREYA CD, 1995, J VIROL, V69, P3848, DOI 10.1128/JVI.69.6.3848-3851.1995; CALKHOVEN CF, 1994, NUCLEIC ACIDS RES, V22, P5540, DOI 10.1093/nar/22.25.5540; Calkhoven CF, 2000, GENE DEV, V14, P1920; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Helbling D, 2004, P NATL ACAD SCI USA, V101, P13312, DOI 10.1073/pnas.0404731101; Iakova P, 2004, EMBO J, V23, P406, DOI 10.1038/sj.emboj.7600052; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; Kimball SR, 1999, INT J BIOCHEM CELL B, V31, P25, DOI 10.1016/S1357-2725(98)00128-9; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Luedde T, 2004, HEPATOLOGY, V40, P356, DOI 10.1002/hep.20333; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Pugachev KV, 1998, J VIROL, V72, P641, DOI 10.1128/JVI.72.1.641-650.1998; Raught B, 1996, CANCER RES, V56, P4382; Shi YG, 2003, ENDOCR REV, V24, P91, DOI 10.1210/er.2002-0018; Shim M, 2003, J BIOL CHEM, V278, P19674, DOI 10.1074/jbc.M301356200; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770; Timchenko LT, 2002, MOL CELL BIOL, V22, P7242, DOI 10.1128/MCB.22.20.7242-7257.2002; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 2004, J BIOL CHEM, V279, P13129, DOI 10.1074/jbc.M312923200; Timchenko NA, 2001, J BIOL CHEM, V276, P7820, DOI 10.1074/jbc.M005960200; Timchenko NA, 2001, MOL CELL BIOL, V21, P6927, DOI 10.1128/MCB.21.20.6927-6938.2001; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; Welm AL, 1999, MOL CELL BIOL, V19, P1695; Welm AL, 2000, J BIOL CHEM, V275, P27406; Zahnow CA, 2001, CANCER RES, V61, P261	35	69	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20549	20557		10.1074/jbc.M409563200	http://dx.doi.org/10.1074/jbc.M409563200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788409	hybrid			2022-12-25	WOS:000229242000049
J	Daboussi, F; Thacker, J; Lopez, BS				Daboussi, F; Thacker, J; Lopez, BS			Genetic interactions between RAD51 and its paralogues for centrosome fragmentation and ploidy control, independently of the sensitivity to genotoxic stresses	ONCOGENE			English	Article						RAD51; paralogues; centrosome; genotoxic stress; homologous recombination	HOMOLOGY-DIRECTED REPAIR; DOUBLE-STRAND BREAKS; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; REPLICATION INHIBITION; RADIOSENSITIZING AGENT; RECOMBINATION; XRCC3; CAFFEINE; COMPLEXES	We evaluate here whether RAD51 and its paralogues XRCC2 and XRCC3 act via a common pathway for sensitivity to genotoxic stress, centrosome fragmentation and chromosome stability. We expressed the RAD51 dominant-negative SMRAD51 in irs1 and irs1SF cells, defective for XRCC2 and XRCC3, respectively, and in their corresponding wild-type cells (V79 and AA8, respectively). V79-SMRAD51 cells are sensitive to mitomycin C(MMC), but SMRAD51 did not further sensitize irs1 cells to MMC, showing that SMRAD51 and XRCC2 act on the same pathway for resistance to MMC. However, in contrast to irs1 and irs1SF cells, SMRAD51-V79 and SMRAD51-AA8 cells are not sensitive to c-rays or UV-C. Despite these differences in sensitivity, SMRAD51-expressing cells and xrcc2- or xrcc3-defective cells show similar increased levels of centrosome fragmentation. This spontaneous centrosome fragmentation is resistant to caffeine, suggesting that ATM and ATR are not involved. Consistent with centrosome fragmentation, increased aneuploidy was measured in irs1 and SMRAD51-expressing cells. Expression of SMRAD51 in irs1 or irs1SF cells did not increase further the frequency of multipolar cells. Thus, RAD51, XRCC2 and XRCC3 act in the same pathway for centrosome fragmentation, independently of the sensitivity to exogenous genotoxic stresses and of the ATM/ATR pathway.	CEA, CNRS, UMR 217, Direct Sci Vivant,Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France; MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, CNRS, UMR 217, Direct Sci Vivant,Dept Radiobiol & Radiopathol, 18 Route Panorama,POB 06,Bat 05, F-92265 Fontenay Aux Roses, France.	bernard.lopez@cea.fr	Lopez, Bernard S/O-7308-2017	Lopez, Bernard S/0000-0001-5088-0155; Daboussi, Fayza/0000-0001-7689-7975				Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; Ausubel F., 1999, CURRENT PROTOCOLS MO; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Bertrand P, 2003, ONCOGENE, V22, P7587, DOI 10.1038/sj.onc.1206998; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Block WD, 2004, NUCLEIC ACIDS RES, V32, P1967, DOI 10.1093/nar/gkh508; Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Henry-Mowatt J, 2003, MOL CELL, V11, P1109, DOI 10.1016/S1097-2765(03)00132-1; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lambert S, 2002, ONCOGENE, V21, P4065, DOI 10.1038/sj.onc.1205535; Lambert S, 2001, ONCOGENE, V20, P6627, DOI 10.1038/sj.onc.1204813; Linke SP, 2003, CANCER RES, V63, P2596; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Liu YL, 2004, SCIENCE, V303, P243, DOI 10.1126/science.1093037; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; Wang HC, 2004, ONCOGENE, V23, P824, DOI 10.1038/sj.onc.1207168	36	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3691	3696		10.1038/sj.onc.1208438	http://dx.doi.org/10.1038/sj.onc.1208438			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782136				2022-12-25	WOS:000229221800017
J	Wang, HQ; Altomare, DA; Skele, KL; Poulikakos, PI; Kuhajda, FP; Di Cristofano, A; Testa, JR				Wang, HQ; Altomare, DA; Skele, KL; Poulikakos, PI; Kuhajda, FP; Di Cristofano, A; Testa, JR			Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells	ONCOGENE			English	Article						apoptosis; AKT/protein kinase B; fatty acid synthase; ovarian cancer	BREAST-CANCER CELLS; CHEMOTHERAPY-INDUCED APOPTOSIS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; THERAPEUTIC TARGET; CELLULAR-SURVIVAL; INHIBITION; RESISTANCE; PROSTATE; PATHWAY	Activation of AKT and overexpression of fatty acid synthase (FAS) are frequently observed in human ovarian cancer. To explore a possible connection between AKT and FAS, immunohistochemical analyses were conducted on an ovarian cancer tissue microarray, which revealed a significant correlation between phosphorylated AKT (phospho-AKT) and expression of FAS. To investigate the relationship between phospho-AKT and FAS in vitro, a variety of experiments employing a specific phosphatidylinositol 3-OH kinase (PI3K) inhibitor (LY294002), inducible PTEN expression in PTEN-null cells, or AKT1 siRNA demonstrated that phosphatidylinositol-3 kinase (PI3K)/AKT signaling modulates FAS expression. In contrast, inhibition of FAS activity by the drug C75 resulted in downregulation of phospho-AKT and increased cell death. To explore the functional relationship between phospho-AKT and FAS, we used SKOV3, C200, and OVCAR10 ovarian carcinoma cells, which have constitutively active AKT, and OVCAR5 cells, which have very low basal phospho-AKT levels. Treatment with LY294002 abolished AKT activity and potentiated apoptosis induced by FAS inhibitors cerulenin or C75 only in cells with constitutively active AKT, suggesting that constitutive activation of AKT protects against FAS inhibitor-induced cell death. Furthermore, inhibition of FAS activity by cerulenin or C75 resulted in downregulation of phospho-AKT, which preceded the induction of apoptosis. To investigate the relationship between phospho-AKT and FAS in vivo, severe combined immunodeficient mice injected intraperitoneally with SKOV3 cells were treated with C75. Growth of SKOV3 xenografts was markedly inhibited by C75. Analysis of the levels of phospho-AKT and FAS in C75-treated tumors revealed concordant downregulation of phospho-AKT and FAS. Collectively, our findings are consistent with a working model in which AKT activation regulates FAS expression, at least in part, whereas FAS activity modulates AKT activation.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21224 USA	Fox Chase Cancer Center; Johns Hopkins University	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	joseph.testa@fccc.edu	Di Cristofano, Antonio/B-4148-2016; di cristofano, antonio/AAJ-3796-2020	di cristofano, antonio/0000-0003-2537-3228	NATIONAL CANCER INSTITUTE [P50CA083638, R01CA077429, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA083638, CA-09035-28, CA77429, R01 CA077429, CA83638, P30 CA006927, CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Alo PL, 2000, ONCOL REP, V7, P1383; Aunoble B, 2000, INT J ONCOL, V16, P567; Brognard J, 2001, CANCER RES, V61, P3986; Camassei FD, 2003, INVEST OPHTH VIS SCI, V44, P2399, DOI 10.1167/iovs.02-0934; Camassei FD, 2003, MED PEDIATR ONCOL, V40, P302, DOI 10.1002/mpo.10274; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Clark AS, 2002, MOL CANCER THER, V1, P707; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Schrijver E, 2003, CANCER RES, V63, P3799; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Gabrielson EW, 2001, CLIN CANCER RES, V7, P153; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hu LM, 2002, CANCER RES, V62, P1087; Jackowski S, 2000, BBA-MOL CELL BIOL L, V1483, P301, DOI 10.1016/S1388-1981(99)00203-6; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kusakabe T, 2002, HISTOPATHOLOGY, V40, P71, DOI 10.1046/j.1365-2559.2002.01289.x; Ng SSW, 2000, CANCER RES, V60, P5451; Page C, 2000, ANTICANCER RES, V20, P407; Philp AJ, 2001, CANCER RES, V61, P7426; Piyathilake CJ, 2000, HUM PATHOL, V31, P1068, DOI 10.1053/hupa.2000.9842; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 2000, CANCER RES, V60, P213; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schmidt M, 2002, BRIT J CANCER, V87, P924, DOI 10.1038/sj.bjc.6600566; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Swinnen JV, 2003, BIOCHEM BIOPH RES CO, V302, P898, DOI 10.1016/S0006-291X(03)00265-1; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Van de Sande T, 2002, CANCER RES, V62, P642; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wang HQ, 1999, J CELL SCI, V112, P3497; Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Zhou WB, 2003, CANCER RES, V63, P7330; Zhuang LY, 2002, CANCER RES, V62, P2227	46	155	166	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3574	3582		10.1038/sj.onc.1208463	http://dx.doi.org/10.1038/sj.onc.1208463			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15806173				2022-12-25	WOS:000229221800005
J	Klinger, MB; Guilbault, B; Goulding, RE; Kay, RJ				Klinger, MB; Guilbault, B; Goulding, RE; Kay, RJ			Deregulated expression of RasGRP1 initiates thymic lymphomagenesis independently of T-cell receptors	ONCOGENE			English	Article						T lymphocytes; T-cell receptors; leukemia; lymphoma	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACTIVATED RAS; TCR SIGNALS; THYMOCYTE DIFFERENTIATION; PRE-TCR; GENES; SELECTION; MATURATION; MICE; P53	RasGRP1 is a Ras-specific exchange factor, which is activated by T-cell receptor (TCR) and promotes TCR-dependent positive selection of thymocytes. RasGRP1 is highly expressed on most T lymphocytic leukemias and is a common site of proviral insertion in retrovirus-induced murine T-cell lymphomas. We used RasGRP1 transgenic mice to determine if deregulated expression of RasGRP1 has a causative role in the development of T-cell malignancies. Thymic lymphomas occurred in three different RasGRP1 transgenic mouse lines. Thymocyte transformation correlated with high transgene expression in early stage lymphomas, indicating that deregulated RasGRP1 expression contributed to the initiation of lymphomagenesis. Expression of the positively selectable H-Y TCR accelerated lymphomagenesis in RasGRP1 transgenic mice. However, the transformed thymocytes lacked markers of positive selection and lymphomas occurred when positive selection was precluded by negative selection of the H-Y TCR. Therefore, initiation of lymphomagenesis via RasGRP1 was not associated with TCR-dependent positive selection of thymocytes. Thymic lymphomas occurred in RasGRP1 transgenic/ Rag2(-/-) mice, demonstrating that neither TCR nor pre-TCR were required for RasGRP1-driven lymphomagenesis. The RasGRP1 transgene conferred pre-TCR-independent survival and proliferation of immature thymocytes, suggesting that deregulated expression of RasGRP1 promotes lymphomagenesis by expanding the pool of thymocytes which are susceptible to transformation.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; University of British Columbia	Kay, RJ (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	rkay@bccrc.ca						Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; AHUJA HG, 1990, BLOOD, V75, P1684; Anderson G, 1999, IMMUNOL TODAY, V20, P463, DOI 10.1016/S0167-5699(99)01524-8; Asnafi V, 2003, BLOOD, V101, P2693, DOI 10.1182/blood-2002-08-2438; Azzam HS, 1998, J EXP MED, V188, P2301, DOI 10.1084/jem.188.12.2301; BIVONA TG, 2003, NATURE, V29, P29; Bruno L, 1996, IMMUNITY, V5, P343, DOI 10.1016/S1074-7613(00)80260-5; Cleverley SC, 2000, ONCOGENE, V19, P13, DOI 10.1038/sj.onc.1203259; Curtis DJ, 1997, ONCOGENE, V15, P2975, DOI 10.1038/sj.onc.1201467; Dailey MO, 1998, CRIT REV IMMUNOL, V18, P153, DOI 10.1615/CritRevImmunol.v18.i3.10; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; DUNBAR CE, 1991, ONCOGENE RES, V6, P39; Ebinu JO, 2000, BLOOD, V95, P3199; EGERTON M, 1990, INT IMMUNOL, V2, P501, DOI 10.1093/intimm/2.6.501; Erman B, 2002, NAT IMMUNOL, V3, P564, DOI 10.1038/ni800; HAWLEY RG, 1995, ONCOGENE, V11, P1113; Hogquist KA, 2001, CURR OPIN IMMUNOL, V13, P225, DOI 10.1016/S0952-7915(00)00208-9; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Iritani BM, 1999, IMMUNITY, V10, P713, DOI 10.1016/S1074-7613(00)80070-9; Kawamura M, 1999, LEUKEMIA RES, V23, P115, DOI 10.1016/S0145-2126(98)00146-5; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Kruisbeek AM, 2000, IMMUNOL TODAY, V21, P637, DOI 10.1016/S0167-5699(00)01744-8; Layer K, 2003, IMMUNITY, V19, P243, DOI 10.1016/S1074-7613(03)00209-7; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Michie AM, 2002, SEMIN IMMUNOL, V14, P311, DOI 10.1016/S1044-5323(02)00064-7; Norment AM, 2003, J IMMUNOL, V170, P1141, DOI 10.4049/jimmunol.170.3.1141; Ong ST, 2003, CELL IMMUNOL, V221, P64, DOI 10.1016/S0008-8749(03)00065-0; Priatel JJ, 2002, IMMUNITY, V17, P617, DOI 10.1016/S1074-7613(02)00451-X; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683; Terrence K, 2000, J EXP MED, V192, P537, DOI 10.1084/jem.192.4.537; von Boehmer H, 2003, IMMUNOL REV, V191, P62, DOI 10.1034/j.1600-065X.2003.00010.x; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yokota S, 1998, INT J HEMATOL, V67, P379	37	27	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2695	2704		10.1038/sj.onc.1208334	http://dx.doi.org/10.1038/sj.onc.1208334			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829980				2022-12-25	WOS:000228356700011
J	Ayash-Rashkovsky, M; Borkow, G; Davis, HL; Moss, RB; Bartholomew, R; Bentwich, Z				Ayash-Rashkovsky, M; Borkow, G; Davis, HL; Moss, RB; Bartholomew, R; Bentwich, Z			Enhanced HIV-1 specific immune response by CpG ODN and HIV-1 immunogen-pulsed dendritic cells confers protection in the Trimera murine model of HIV-1 infection	FASEB JOURNAL			English	Article						vaccines; cytosine-phosphate-guanosine oligonucleotides; small animal model	TOLL-LIKE RECEPTORS; T-HELPER-CELL; GP120-DEPLETED HIV-1; IN-VITRO; IMMUNOSTIMULATORY SEQUENCES; RADIATION CHIMERA; DNA; MOUSE; VACCINATION; VACCINES	We have recently developed a novel small animal model for HIV-1 infection (Ayash-Rashkovsky et al., http://www.fasebi.org/cgi/doi/10.1096/fj.04-3184fje; doi:10.1096/fj.043184fie). The mice were successfully infected with HIV-1 for 4-6 wk with different clades of either T- or M-tropic isolates. HIV-1 infection was accompanied by rapid loss of human CD4+ T cells, decrease in CD4/CD8 ratio, and increased T cell activation. HIV specific human Immoral and cellular immune responses were observed in all HIV-1 infected animals. In the present study, HIV specific human immune responses, both Immoral and cellular, were generated in noninfected Trimera mice, after their immunization with gp120-depleted HIV-1 antigen, presented by autologous human dendritic cells. Addition of CpG ODN to the antigen-pulsed DCs significantly enhanced (by 2- to 30-fold) the Immoral and cellular HIV-1 specific immune responses. Only mice immunized with the HIV-1 immunogen and CpG were completely protected from infection with HIV-1 after challenge with high infection titers of the virus. This novel small animal model for HIV-1 infection may thus serve as an attractive platform for rapid testing of candidate HIV-1 vaccines and of adjuvants and may shorten the time needed for the development and final assessment of protective HIV-1 vaccines in human trials.	Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel; Coley Pharmaceut Grp, Ottawa, ON K2K 3A2, Canada; Immune Response Corp, San Diego, CA USA	Hebrew University of Jerusalem; Coley Pharmaceutical Group	Borkow, G (corresponding author), Rosetta Genom, 10 Plaut St,Sci Pk, IL-76701 Rehovot, Israel.	borkow@agri.huji.ac.il; zbentwich@rosettagenomics.com	Borkow, Gadi/W-4294-2019; Moss, Richard B./S-9218-2019	Moss, Richard B./0000-0003-3611-4221				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Ayash-Rashkovsky M, 2002, VACCINE, V20, P2684, DOI 10.1016/S0264-410X(02)00202-5; Ayash-Rashkovsky M, 2001, BIOCHEM BIOPH RES CO, V282, P1169, DOI 10.1006/bbrc.2001.4698; Ben-Yedidia T, 1999, INT IMMUNOL, V11, P1043, DOI 10.1093/intimm/11.7.1043; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; Bentwich Z, 1996, CLIN EXP IMMUNOL, V103, P239, DOI 10.1046/j.1365-2249.1996.d01-612.x; Blackwell SE, 2003, J IMMUNOL, V170, P4061, DOI 10.4049/jimmunol.170.8.4061; Bocher WO, 2001, EUR J IMMUNOL, V31, P2071, DOI 10.1002/1521-4141(200107)31:7<2071::AID-IMMU2071>3.0.CO;2-D; Borkow G, 2000, B WORLD HEALTH ORGAN, V78, P1368; Borkow G, 2002, CLIN DIAGN LAB IMMUN, V9, P505, DOI 10.1128/CDLI.9.3.505-507.2002; Borkow G, 2000, J CLIN INVEST, V106, P1053, DOI 10.1172/JCI10182; Burakova T, 1997, TRANSPLANTATION, V63, P1166, DOI 10.1097/00007890-199704270-00018; Dalpke A, 2002, BIOL CHEM, V383, P1491, DOI 10.1515/BC.2002.171; Deml L, 1999, CLIN CHEM LAB MED, V37, P199, DOI 10.1515/CCLM.1999.037; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Dzionek A, 2001, J EXP MED, V194, P1823, DOI 10.1084/jem.194.12.1823; GALUN E, 1995, J INFECT DIS, V172, P25, DOI 10.1093/infdis/172.1.25; Gursel M, 2002, EUR J IMMUNOL, V32, P2617, DOI 10.1002/1521-4141(200209)32:9<2617::AID-IMMU2617>3.0.CO;2-F; Gurunathan S, 2000, CURR OPIN IMMUNOL, V12, P442, DOI 10.1016/S0952-7915(00)00118-7; Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617; Heckelsmiller K, 2002, EUR J IMMUNOL, V32, P3235, DOI 10.1002/1521-4141(200211)32:11<3235::AID-IMMU3235>3.0.CO;2-J; Heckelsmiller K, 2002, J IMMUNOL, V169, P3892, DOI 10.4049/jimmunol.169.7.3892; Heeg K, 2000, INT ARCH ALLERGY IMM, V121, P87, DOI 10.1159/000024303; Heeney JL, 1999, IMMUNOL TODAY, V20, P247, DOI 10.1016/S0167-5699(98)01437-6; Ilan E, 1999, HEPATOLOGY, V29, P553, DOI 10.1002/hep.510290228; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kerkmann M, 2003, J IMMUNOL, V170, P4465, DOI 10.4049/jimmunol.170.9.4465; Kojima Y, 2002, VACCINE, V20, P2857, DOI 10.1016/S0264-410X(02)00238-4; Krieg AM, 2000, IMMUNOL TODAY, V21, P521, DOI 10.1016/S0167-5699(00)01719-9; Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703-831; Krieg AM, 2001, CURR OPIN MOL THER, V3, P15; Krug A, 2003, J IMMUNOL, V170, P3468, DOI 10.4049/jimmunol.170.7.3468; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; Lapenta C, 2003, J EXP MED, V198, P361, DOI 10.1084/jem.20021924; LUBIN I, 1991, SCIENCE, V252, P427, DOI 10.1126/science.1826797; LUBIN I, 1994, BLOOD, V83, P2368; Maino VC, 2000, AIDS RES HUM RETROV, V16, P2065, DOI 10.1089/088922200750054819; MARCUS H, 1995, BLOOD, V86, P398, DOI 10.1182/blood.V86.1.398.bloodjournal861398; Mascola Jr, 1999, METH MOLEC MED, V17, P317, DOI 10.1385/0-89603-369-4:317; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Medzhitov R, 2001, NAT IMMUNOL, V2, P15, DOI 10.1038/83121; Moss RB, 2000, VACCINE, V18, P1081, DOI 10.1016/S0264-410X(99)00368-0; Moss RB, 1997, VIRAL IMMUNOL, V10, P221, DOI 10.1089/vim.1997.10.221; Moss RB, 2000, J INTERF CYTOK RES, V20, P1131, DOI 10.1089/107999000750053807; Moss RB, 2001, J HUMAN VIROL, V4, P39; Moss RB, 2000, J ACQ IMMUN DEF SYND, V24, P264; Olbrich ARM, 2002, J VIROL, V76, P11397, DOI 10.1128/JVI.76.22.11397-11404.2002; Reisner Y, 1998, TRENDS BIOTECHNOL, V16, P242, DOI 10.1016/S0167-7799(98)01203-7; Robbins GK, 2003, AIDS, V17, P1121, DOI 10.1097/00002030-200305230-00002; Robinson SP, 1999, EUR J IMMUNOL, V29, P2769, DOI 10.1002/(SICI)1521-4141(199909)29:09<2769::AID-IMMU2769>3.0.CO;2-2; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Santini SM, 2000, J EXP MED, V191, P1777, DOI 10.1084/jem.191.10.1777; Segall H, 1996, BLOOD, V88, P721, DOI 10.1182/blood.V88.2.721.bloodjournal882721; Steinman RM, 2002, J CLIN INVEST, V109, P1519, DOI 10.1172/JCI200215962	54	10	10	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1152	+		10.1096/fj.04-3185fje	http://dx.doi.org/10.1096/fj.04-3185fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15833766				2022-12-25	WOS:000228865300015
J	Huang, KT; Keszler, A; Patel, N; Patel, RP; Patel, RP; Gladwin, MT; Kim-Shapiro, DB; Hogg, N				Huang, KT; Keszler, A; Patel, N; Patel, RP; Patel, RP; Gladwin, MT; Kim-Shapiro, DB; Hogg, N			The reaction between nitrite and deoxyhemoglobin - Reassessment of reaction kinetics and stoichiometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-NITROSOGLUTATHIONE; HEMOGLOBIN HYBRIDS; OXIDE; NO; REDUCTION; OXIDATION; OXYGEN; CYCLE	Recent evidence suggests that the reaction between nitrite and deoxygenated hemoglobin provides a mechanism by which nitric oxide is synthesized in vivo. This reaction has been previously defined to follow second order kinetics, although variable product stoichiometry has been reported. In this study we have re-examined this reaction and found that under fully deoxygenated conditions the product stoichiometry is 1: 1 ( methemoglobin: nitrosylhemoglobin), and unexpectedly, the kinetics deviate substantially from a simple second order reaction and exhibit a sigmoidal profile. The kinetics of this reaction are consistent with an increase in reaction rate elicited by heme oxidation and iron-nitrosylation. In addition, conditions that favor the "R" conformation show an increased rate over conditions that favor the "T" conformation. The reactivity of nitrite with heme is clearly more complex than has been previously realized and is dependent upon the conformational state of the hemoglobin tetramer, suggesting that the nitrite reductase activity of hemoglobin is under allosteric control.	Wake Forest Univ, Sch Med, Dept Biomed Engn, Winston Salem, NC USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; NHLBI, Cardiovasc Branch, Vasc Therapeut Sect, NIH, Bethesda, MD 20892 USA; Ctr Clin, Dept Crit Care Med, NIH, Bethesda, MD 20892 USA; Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA	Wake Forest University; University of Alabama System; University of Alabama Birmingham; Medical College of Wisconsin; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Wake Forest University	Kim-Shapiro, DB (corresponding author), Wake Forest Univ, Sch Med, Dept Biomed Engn, Winston Salem, NC USA.	shapiro@wfu.edu	Kim-Shapiro, Daniel/HGA-2682-2022	Patel, Rakesh/0000-0002-1526-4303	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070146, R01HL058091, R29HL058091, R37HL058091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055792, R29GM055792, T32GM008361] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL70146, R01 HL058091, HL58091] Funding Source: Medline; NIBIB NIH HHS [EB001980] Funding Source: Medline; NIGMS NIH HHS [T32GM08361, GM55792] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P1; Brooks J, 1937, PROC R SOC SER B-BIO, V123, P368, DOI 10.1098/rspb.1937.0057; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; Einsle O, 2004, BIOL CHEM, V385, P875, DOI 10.1515/BC.2004.115; FAULKNER KM, 1995, J BIOL CHEM, V270, P13604, DOI 10.1074/jbc.270.23.13604; Gladwin MT, 2003, NAT MED, V9, P496, DOI 10.1038/nm0503-496; Kiger L, 1999, J MOL BIOL, V291, P227, DOI 10.1006/jmbi.1999.2970; Kim-Shapiro DB, 2005, J INORG BIOCHEM, V99, P237, DOI 10.1016/j.jinorgbio.2004.10.034; Marden MC, 1996, J MOL BIOL, V263, P90, DOI 10.1006/jmbi.1996.0558; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; Nagababu E, 2003, J BIOL CHEM, V278, P46349, DOI 10.1074/jbc.M307572200; Olson JS, 2004, FREE RADICAL BIO MED, V36, P685, DOI 10.1016/j.freeradbiomed.2003.11.030; Reutov VP, 1998, BIOCHEMISTRY-MOSCOW+, V63, P874; ROBINSON J, 2001, FREE RADIC BIOL ME S, V37, P88; ROSS JM, 1962, AM J PHYSIOL, V202, P21, DOI 10.1152/ajplegacy.1962.202.1.21; Spencer NY, 2000, J BIOL CHEM, V275, P36562, DOI 10.1074/jbc.M005347200; Spencer NY, 2003, FREE RADICAL BIO MED, V35, P1515, DOI 10.1016/j.freeradbiomed.2003.08.021; Turner B W, 1981, Methods Enzymol, V76, P596; Vandegriff KD, 2004, BIOCHEM J, V382, P183, DOI 10.1042/BJ20040156; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Xu XL, 2003, P NATL ACAD SCI USA, V100, P11303, DOI 10.1073/pnas.2033883100; Zhang Y, 2002, FREE RADICAL BIO MED, V32, P1212, DOI 10.1016/S0891-5849(02)00829-8	23	226	233	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31126	31131		10.1074/jbc.M501496200	http://dx.doi.org/10.1074/jbc.M501496200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15837788	hybrid			2022-12-25	WOS:000231487800058
J	Bernasconi, D; Amici, C; La Frazia, S; Ianaro, A; Santoro, MG				Bernasconi, D; Amici, C; La Frazia, S; Ianaro, A; Santoro, MG			The I kappa B kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSCRIPTION FACTOR; CYCLOPENTENONE PROSTAGLANDINS; ANTIVIRAL ACTIVITY; HIV-1 REPLICATION; GENE-EXPRESSION; ACTIVATION; INFECTION; INHIBITION; INDUCTION	Influenza A viruses continue to represent a severe threat worldwide, causing large epidemics and pandemics responsible for thousands of deaths every year. Excessive inflammation due to overabundant production of proinflammatory cytokines by airway epithelial cells is considered an important factor in disease pathogenesis. Here we report that influenza A virus induced I kappa B kinase (IKK) activity in human airway epithelial A549 cells, resulting in persistent activation of nuclear factor-kappa B (NF-kappa B), a critical regulator of the inflammatory response. Although lung epithelial cells are highly sensitive to stimulation of the IKK/NF-kappa B pathway by influenza virus infection, NF-kappa B was not activated in several non-pulmonary cells permissive to the virus, indicating a cell-specific response. Moreover, NF-kappa B was not essential for virus replication but triggered the expression of proinflammatory cytokines in infected lung cells and was directly responsible for production of high levels of interleukin-8, a chemokine associated with influenza-induced inflammation and airway pathology. We also report that 9-deoxy-Delta(9), Delta(12)-13,14-dihydro-prostaglandin D-2, a cyclopentenone prostanoid with therapeutic efficacy against influenza in preclinical studies, was a powerful inhibitor of influenza virus-induced IKK activity and interleukin-8 production by human pulmonary cells. The results identify IKK as an important factor in triggering influenza virus-induced inflammatory reactions in pulmonary epithelium, suggesting novel therapeutic approaches in the treatment of influenza.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Naples Federico II, Dept Expt Pharmacol, I-80131 Naples, Italy	University of Rome Tor Vergata; University of Naples Federico II	Santoro, MG (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	santoro@bio.uniroma2.it	ianaro, angela/ABC-2713-2020	Santoro, Maria Gabriella/0000-0003-1432-4949; La Frazia, Simone/0000-0002-6987-5409				Amici C, 2004, AIDS, V18, P1271, DOI 10.1097/00002030-200406180-00005; Amici C, 2001, J BIOL CHEM, V276, P28759, DOI 10.1074/jbc.M103408200; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bridges Carolyn B, 2003, MMWR Recomm Rep, V52, P1; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; CHOI AMK, 1992, FEBS LETT, V309, P327, DOI 10.1016/0014-5793(92)80799-M; Cooper JAD, 2000, BIOCHEM PHARMACOL, V59, P605, DOI 10.1016/S0006-2952(99)00375-5; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Flory E, 2000, J BIOL CHEM, V275, P8307, DOI 10.1074/jbc.275.12.8307; Geiss GK, 2002, P NATL ACAD SCI USA, V99, P10736, DOI 10.1073/pnas.112338099; Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355; Humphreys IR, 2003, J EXP MED, V198, P1237, DOI 10.1084/jem.20030351; Julkunen I, 2000, VACCINE, V19, pS32, DOI 10.1016/S0264-410X(00)00275-9; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Ludwig S, 2003, TRENDS MOL MED, V9, P46, DOI 10.1016/S1471-4914(02)00010-2; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Mukaida N, 2003, AM J PHYSIOL-LUNG C, V284, pL566, DOI 10.1152/ajplung.00233.2002; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nimmerjahn F, 2004, J GEN VIROL, V85, P2347, DOI 10.1099/vir.0.79958-0; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Patel A, 1998, VIROLOGY, V247, P212, DOI 10.1006/viro.1998.9243; Pica F, 2000, ANTIMICROB AGENTS CH, V44, P200, DOI 10.1128/AAC.44.1.200-204.2000; Reid AH, 2004, NAT REV MICROBIOL, V2, P909, DOI 10.1038/nrmicro1027; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Rozera C, 1996, J CLIN INVEST, V97, P1795, DOI 10.1172/JCI118609; Santoro MG, 2000, BIOCHEM PHARMACOL, V59, P55, DOI 10.1016/S0006-2952(99)00299-3; SANTORO MG, 1988, ARCH VIROL, V99, P89, DOI 10.1007/BF01311026; Santoro MG, 2003, EMBO J, V22, P2552, DOI 10.1093/emboj/cdg267; Santoro MG, 1997, TRENDS MICROBIOL, V5, P276, DOI 10.1016/S0966-842X(97)01066-4; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Superti F, 1998, J INFECT DIS, V178, P564, DOI 10.1086/517475; Surabhi RM, 2002, J VIROL, V76, P12963, DOI 10.1128/JVI.76.24.12963-12973.2002; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; Wurzer WJ, 2004, J BIOL CHEM, V279, P30931, DOI 10.1074/jbc.M403258200; Zhang X, 2001, J IMMUNOL, V166, P7104, DOI 10.4049/jimmunol.166.12.7104	43	47	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24127	24134		10.1074/jbc.M413726200	http://dx.doi.org/10.1074/jbc.M413726200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15837793	hybrid			2022-12-25	WOS:000229880000086
J	Kristiansen, PE; Fimland, G; Mantzilas, D; Nissen-Meyer, J				Kristiansen, PE; Fimland, G; Mantzilas, D; Nissen-Meyer, J			Structure and mode of action of the membrane-permeabilizing antimicrobial peptide pheromone plantaricin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTRA; TORSION ANGLE DYNAMICS; LACTOBACILLUS-PLANTARUM; 3-DIMENSIONAL STRUCTURE; PROTEIN; BACTERIOCIN; MICELLES; SEQUENCE; C-11; SPECTROSCOPY	The three-dimensional structure in dodecyl phosphocholine micelles of the 26-mer membrane-permeabilizing bacteriocin-like pheromone plantaricin A (PlnA) has been determined by use of nuclear magnetic resonance spectroscopy. The peptide was unstructured in water but became partly structured upon exposure to micelles. An amphiphilic alpha-helix stretching from residue 12 to 21 (possibly also including residues 22 and 23) was then formed in the C-terminal part of the peptide, whereas the N-terminal part remained largely unstructured. PlnA exerted its membrane-permeabilizing antimicrobial activity through a nonchiral interaction with the target cell membrane because the D-enantiomeric form had the same activity as the natural L-form. This nonchiral interaction involved the amphiphilic alpha-helical region in the C-terminal half of PlnA because a 17-mer fragment that contains the amphiphilic alpha-helical part of the peptide had antimicrobial potency that was similar to that of the L- and D-enantiomeric forms of PlnA. Also the pheromone activity of PlnA depended on this nonchiral interaction because both the L- and D-enantiomeric forms of the 17-mer fragment inhibited the pheromone activity. The pheromone activity also involved, however, a chiral interaction between the N-terminal part of PlnA and its receptor because high concentrations of the L-form (but not the D-form) of a 5-mer fragment derived from the N-terminal part of PlnA had pheromone activity. The results thus reveal a novel mechanism whereby peptide pheromones such as PlnA may function. An initial nonchiral interaction with membrane lipids induces alpha-helical structuring in a segment of the peptide pheromone. The peptide becomes thereby sufficiently structured and properly positioned in the membrane interface, thus enabling it to engage in a chiral interaction with its receptor in or near the membrane water interface. This membrane-interacting mode of action explains why some peptide pheromones/hormones such as PlnA sometimes display antimicrobial activity in addition to their pheromone activity.	Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway	University of Oslo	Kristiansen, PE (corresponding author), Univ Oslo, Dept Mol Biosci, POB 1041, N-0316 Oslo, Norway.	eugen@kjemi.uio.no	Nissen-Meyer, Jon/Y-8727-2019; Kristiansen, Per Eugen/L-5798-2019; Nissen-Meyer, Jon/A-5581-2008					Anderssen EL, 1998, APPL ENVIRON MICROB, V64, P2269; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DIEP DB, 1994, APPL ENVIRON MICROB, V60, P160, DOI 10.1128/AEM.60.1.160-166.1994; Diep DB, 1995, MOL MICROBIOL, V18, P631, DOI 10.1111/j.1365-2958.1995.mmi_18040631.x; Gallagher NLF, 1997, BIOCHEMISTRY-US, V36, P15062, DOI 10.1021/bi971263h; Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hauge HH, 1998, BIOCHEMISTRY-US, V37, P16026, DOI 10.1021/bi981532j; HAVARSTEIN LS, 2002, HISTIDINE KINASES SI, P341; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Johnsborg O, 2004, ARCH MICROBIOL, V182, P450, DOI 10.1007/s00203-004-0728-7; Johnsborg O, 2003, J BACTERIOL, V185, P6913, DOI 10.1128/JB.185.23.6913-6920.2003; Kleerebezem M, 2001, PEPTIDES, V22, P1579, DOI 10.1016/S0196-9781(01)00493-4; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nes IF, 1999, CELL-CELL SIGNALING IN BACTERIA, P175; NissenMeyer J, 1997, ARCH MICROBIOL, V167, P67, DOI 10.1007/s002030050418; Risoen PA, 2001, MOL GENET GENOMICS, V265, P198, DOI 10.1007/s004380000397; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; Shenkarev ZO, 2002, BIOPHYS J, V82, P762, DOI 10.1016/S0006-3495(02)75438-6; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SLETTEN K, 1974, EUR J BIOCHEM, V41, P117, DOI 10.1111/j.1432-1033.1974.tb03251.x; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 2004, PROTEIN SCI, V13, P100, DOI 10.1110/ps.03258404; Uteng M, 2003, BIOCHEMISTRY-US, V42, P11417, DOI 10.1021/bi034572i; Wuthrich K, 1986, NMR PROTEINS NUCL AC	31	63	69	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22945	22950		10.1074/jbc.M501620200	http://dx.doi.org/10.1074/jbc.M501620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15805109	hybrid			2022-12-25	WOS:000229741800048
J	Solomaha, E; Szeto, FL; Yousef, MA; Palfrey, C				Solomaha, E; Szeto, FL; Yousef, MA; Palfrey, C			Kinetics of Src homology 3 domain association with the proline-rich domain of dynamins - Specificity, occlusion, and the effects of phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; HIGH-AFFINITY; MEDIATED ENDOCYTOSIS; RAPID ENDOCYTOSIS; ADAPTER PROTEIN; BINDING; AMPHIPHYSIN; RECEPTOR; SYNAPTOJANIN; FAMILY	Dynamin function is mediated in part through association of its proline-rich domain (PRD) with the Src homology 3 (SH3) domains of several putative binding proteins. To assess the specificity and kinetics of this process, we undertook surface plasmon resonance studies of the interaction between isolated PRDs of dynamin-1 and -2 and several purified SH3 domains. Glutathione S-transferase-linked SH3 domains bound with high affinity (K-D similar to 10 nM to 1 mu M) to both dynamin-1 and -2. The simplest interaction appeared to take place with the amphiphysin-SH3 domain; this bound to a single high affinity site (K-D similar to 10 nM) in the C terminus of dynamin-1 PRD, as predicted by previous studies. Binding to the dynamin-2 PRD was also monophasic but with a slightly lower affinity (K-D similar to 25 nM). Endophilin-SH3 binding to both dynamin-1 and -2 PRDs was biphasic, with one high affinity site (K-D similar to 14 nM) in the N terminus of the PRD and another lower affinity site (K-D similar to 60 nM) in the C terminus of dynamin-1. The N-terminal site in dynamin-2 PRD had a 10-fold lower affinity for endophilin-SH3. Preloading of dynamin-1 PRD with the amphiphysin-SH3 domain partially occluded binding of the endophilin-SH3 domain, indicating overlap between the binding sites in the C terminus, but endophilin was still able to interact with the high affinity N-terminal site. This shows that more than one SH3 domain can simultaneously bind to the PRD and suggests that competition probably occurs in vivo between different SH3-containing proteins for the limited number of PXXP motifs. Endophilin-SH3 binding to the high affinity site was disrupted when dynamin-1 PRD was phosphorylated with Cdk5, indicating that this site overlaps the phosphorylation sites, but amphiphysin-SH3 binding was unaffected. Other SH3 domains showed similarly complex binding characteristics, and substantial differences were noted between the PRDs from dynamin-1 and -2. For example, SH3 domains from c-Src, Grb2, and intersectin bound only to the C-terminal half of dynamin-2 PRD but to both the N- and C-terminal portions of dynamin-1 PRD. Thus, differential binding of SH3 domain-containing proteins to dynamin-1 and -2 may contribute to the distinct functions performed by these isoforms.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Biophys Core Facil, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Palfrey, C (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA.	hpalfrey@midway.uchicago.edu						Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Artalejo CR, 2002, P NATL ACAD SCI USA, V99, P6358, DOI 10.1073/pnas.082658499; Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; De Crescenzo G, 2003, J MOL BIOL, V328, P1173, DOI 10.1016/S0022-2836(03)00360-7; Di Paolo G, 2002, NEURON, V33, P789, DOI 10.1016/S0896-6273(02)00601-3; Dong JX, 2000, PROTEIN EXPRES PURIF, V20, P314, DOI 10.1006/prep.2000.1305; Dutta K, 2004, BIOCHEMISTRY-US, V43, P8094, DOI 10.1021/bi030268d; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Ghose R, 2001, NAT STRUCT BIOL, V8, P998, DOI 10.1038/nsb1101-998; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Hauck CR, 2001, J BIOL CHEM, V276, P17653, DOI 10.1074/jbc.M009329200; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; Marles JA, 2004, MOL CELL, V14, P813, DOI 10.1016/j.molcel.2004.05.024; Mattes MJ, 1997, J IMMUNOL METHODS, V202, P97, DOI 10.1016/S0022-1759(96)00228-1; Mayer BJ, 2001, J CELL SCI, V114, P1253; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Musacchio A, 2003, ADV PROTEIN CHEM, V61, P211; Myszka DG, 2000, METHOD ENZYMOL, V323, P325; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nieba L, 1997, ANAL BIOCHEM, V252, P217, DOI 10.1006/abio.1997.2326; NIMNUAL A, 2002, SCI STK 2002 PE36; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Razzaq A, 2001, GENE DEV, V15, P2967, DOI 10.1101/gad.207801; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 2001, J BIOL CHEM, V276, P40424, DOI 10.1074/jbc.M106338200; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; ROBINSON PJ, 1994, TRENDS NEUROSCI, V17, P348, DOI 10.1016/0166-2236(94)90179-1; Sharma P, 1999, P NATL ACAD SCI USA, V96, P11156, DOI 10.1073/pnas.96.20.11156; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Vidal M, 1998, J BIOL CHEM, V273, P5343, DOI 10.1074/jbc.273.9.5343; Vidal M, 1999, J MOL BIOL, V290, P717, DOI 10.1006/jmbi.1999.2899; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; ZARRINPAR A, 2003, SCI STKE 2003 RE8; Zelhof AC, 2001, DEVELOPMENT, V128, P5005	60	47	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23147	23156		10.1074/jbc.M501745200	http://dx.doi.org/10.1074/jbc.M501745200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15834155	hybrid			2022-12-25	WOS:000229741800072
J	Wong, HK; Sakurai, T; Oyama, F; Kaneko, K; Wada, K; Miyazaki, H; Kurosawa, M; De Strooper, B; Saftig, P; Nukina, N				Wong, HK; Sakurai, T; Oyama, F; Kaneko, K; Wada, K; Miyazaki, H; Kurosawa, M; De Strooper, B; Saftig, P; Nukina, N			beta subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; ASPARTYL PROTEASE; KNOCKOUT MICE; STEM-CELLS; CLEAVAGE; PRESENILIN; MEMBRANE; FAMILY; ALPHA-2,6-SIALYLTRANSFERASE; IDENTIFICATION	Sequential processing of amyloid precursor protein (APP) by membrane-bound proteases, BACE1 and gamma-secretase, plays a crucial role in the pathogenesis of Alzheimer disease. Much has been discovered on the properties of these proteases; however, regulatory mechanisms of enzyme-substrate interaction in neurons and their involvement in pathological changes are still not fully understood. It is mainly because of the membrane-associated cleavage of these proteases and the lack of information on new substrates processed in a similar way to APP. Here, using RNA interference-mediated BACE1 knockdown, mouse embryonic fibroblasts that are deficient in either BACE1 or presenilins, and BACE1-deficient mouse brain, we show clear evidence that beta subunits of voltage-gated sodium channels are sequentially processed by BACE1 and gamma-secretase. These results may provide new insights into the underlying pathology of Alzheimer disease.	RIKEN, Brain Sci Inst, Lab Struct Neuropathol, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Lab Neurodegenerat Signal, Wako, Saitama 3510198, Japan; Katholieke Univ Leuven, CME, Neuronal Cell Biol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; Univ Kiel, Inst Biochem, D-24018 Kiel, Germany	RIKEN; RIKEN; KU Leuven; University of Kiel	Nukina, N (corresponding author), RIKEN, Brain Sci Inst, Lab Struct Neuropathol, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	nukina@brain.riken.jp	Nukina, Nobuyuki/GPP-6265-2022; Wong, Hon-Kit/G-3944-2014; Oyama, Fumitaka/P-6186-2016	Wong, Hon-Kit/0000-0003-0049-8454; Oyama, Fumitaka/0000-0002-1095-8306				De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Eggert S, 2004, J BIOL CHEM, V279, P18146, DOI 10.1074/jbc.M311601200; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Feng RB, 2004, P NATL ACAD SCI USA, V101, P8162, DOI 10.1073/pnas.0402733101; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Hanlon MR, 2002, BIOCHEMISTRY-US, V41, P2886, DOI 10.1021/bi0119565; Harrison SM, 2003, MOL CELL NEUROSCI, V24, P646, DOI 10.1016/S1044-7431(03)00227-6; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; KIKUCHI H, 1995, BBA-MOL CELL RES, V1269, P253, DOI 10.1016/0167-4889(95)00127-3; Kitazume S, 2005, J BIOL CHEM, V280, P8589, DOI 10.1074/jbc.M409417200; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walsh DM, 2003, BIOCHEMISTRY-US, V42, P6664, DOI 10.1021/bi027375c; Wolfe MS, 2003, CURR TOP DEV BIOL, V54, P233, DOI 10.1016/S0070-2153(03)54011-X; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207; Yu FH, 2003, J NEUROSCI, V23, P7577	35	250	253	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23009	23017		10.1074/jbc.M414648200	http://dx.doi.org/10.1074/jbc.M414648200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824102	hybrid			2022-12-25	WOS:000229741800056
J	Briknarova, K; Nasertorabi, F; Havert, ML; Eggleston, E; Hoyt, DW; Li, CL; Olson, AJ; Vuori, K; Ely, KR				Briknarova, K; Nasertorabi, F; Havert, ML; Eggleston, E; Hoyt, DW; Li, CL; Olson, AJ; Vuori, K; Ely, KR			The serine-rich domain from Crk-associated substrate (p130(cas)) is a four-helix bundle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; BREAST-CANCER CELLS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; ADAPTER PROTEIN; VINCULIN ACTIVATION; TARGETING DOMAIN; DOCKING PROTEIN	p130(cas) (Crk-associated substrate) is a docking protein that is involved in assembly of focal adhesions and concomitant cellular signaling. It plays a role in physiological regulation of cell adhesion, migration, survival, and proliferation, as well as in oncogenic transformation. The molecule consists of multiple protein-protein interaction motifs, including a serine-rich region that is positioned between Crk and Src-binding sites. This study reports the first structure of a functional domain of Cas. The solution structure of the serine-rich region has been determined by NMR spectroscopy, demonstrating that this is a stable domain that folds as a four-helix bundle, a protein-interaction motif. The serine-rich region bears strong structural similarity to four-helix bundles found in other adhesion components like focal adhesion kinase, alpha-catenin, or vinculin. Potential sites for phosphorylation and interaction with the 14-3-3 family of cellular regulators are identified in the domain and characterized by site-directed mutagenesis and binding assays. Mapping the degree of amino acid conservation onto the molecular surface reveals a patch of invariant residues near the C terminus of the bundle, which may represent a previously unidentified site for protein interaction.	Burnham Inst, La Jolla, CA 92037 USA; Pacific NW Natl Lab, Environm Mol Sci Lab, Richland, WA 99352 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; United States Department of Energy (DOE); Pacific Northwest National Laboratory; Scripps Research Institute	Ely, KR (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ely@burnham.org	Hoyt, David/H-6295-2013; Li, Chenglong/E-7182-2010	Hoyt, David/0000-0002-2857-719X; Li, Chenglong/0000-0003-3174-8719	NATIONAL CANCER INSTITUTE [R01CA071560] Funding Source: NIH RePORTER; NCI NIH HHS [CA 71560] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Arold ST, 2002, STRUCTURE, V10, P319, DOI 10.1016/S0969-2126(02)00717-7; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; Bakolitsa C, 2004, NATURE, V430, P583, DOI 10.1038/nature02610; Borgon RA, 2004, STRUCTURE, V12, P1189, DOI 10.1016/j.str.2004.05.009; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Bridges D, 2004, SCI STKE, pre10; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Burnham MR, 1996, ONCOGENE, V12, P2467; Cai DP, 1999, J IMMUNOL, V163, P2104; Clore GM, 2002, J AM CHEM SOC, V124, P2866, DOI 10.1021/ja017712p; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; GRZESIEK S, 1995, J AM CHEM SOC, V117, P9594, DOI 10.1021/ja00142a040; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hayashi I, 2002, NAT STRUCT BIOL, V9, P101, DOI 10.1038/nsb755; Hoellerer MK, 2003, STRUCTURE, V11, P1207, DOI 10.1016/j.str.2003.08.010; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ishino M, 1995, ONCOGENE, V11, P2331; Izard T, 2004, J BIOL CHEM, V279, P27667, DOI 10.1074/jbc.M403076200; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuszewski J, 1997, J MAGN RESON, V125, P171, DOI 10.1006/jmre.1997.1116; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; Kuszewski J, 1999, J AM CHEM SOC, V121, P2337, DOI 10.1021/ja9843730; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Law SF, 1996, MOL CELL BIOL, V16, P3327; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nasertorabi F, 2004, BIOCHEM BIOPH RES CO, V324, P993, DOI 10.1016/j.bbrc.2004.09.148; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Prutzman KC, 2004, STRUCTURE, V12, P881, DOI 10.1016/S0969-2126(04)00097-8; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakakibara A, 2000, J BIOL CHEM, V275, P6404, DOI 10.1074/jbc.275.9.6404; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tjandra N, 1996, J AM CHEM SOC, V118, P6264, DOI 10.1021/ja960106n; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wurtele M, 2003, EMBO J, V22, P987, DOI 10.1093/emboj/cdg104; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang J, 2001, EMBO J, V20, P3645, DOI 10.1093/emboj/20.14.3645; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	71	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21908	21914		10.1074/jbc.M501258200	http://dx.doi.org/10.1074/jbc.M501258200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15795225	hybrid			2022-12-25	WOS:000229557900031
J	Litjens, SHM; Wilhelmsen, K; de Pereda, JM; Perrakis, A; Sonnenberg, A				Litjens, SHM; Wilhelmsen, K; de Pereda, JM; Perrakis, A; Sonnenberg, A			Modeling and experimental validation of the binary complex of the plectin actin-binding domain and the first pair of fibronectin type III (FNIII) domains of the beta 4 integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; INTEGRIN BETA-4 SUBUNIT; PYLORIC ATRESIA; MUSCULAR-DYSTROPHY; CRYSTAL-STRUCTURE; ALPHA-6-BETA-4 INTEGRIN; CSF-1 RECEPTOR; F-ACTIN; HEMIDESMOSOMES; PROTEIN	The binding of plectin to the beta 4 subunit of the alpha 6 beta 4 integrin is a critical step in the formation of hemidesmosomes. An important interaction between these two proteins occurs between the actin-binding domain (ABD) of plectin and the first pair of fibronectin type III (FNIII) domains and a small part of the connecting segment of beta 4. Previously, a few amino acids, critical for this interaction, were identified in both plectin and beta 4 and mapped on the crystal structures of the ABD of plectin and the first pair of FNIII domains of beta 4. In the present study, we used this biochemical information and protein-protein docking calculations to construct a model of the binary complex between these two protein domains. The top scoring computational model predicts that the calponin-homology 1 (CH1) domain of the ABD associates with the first and the second FNIII domains of beta 4. Our mutational analysis of the residues at the proposed interface of both the FNIII and the CH1 domains is in agreement with the suggested interaction model. Computational simulations to predict protein motions suggest that the exact model of FNIII and plectin CH1 interaction might well differ in detail from the suggested model due to the conformational plasticity of the FNIII domains, which might lead to a closely related but different mode of interaction with the plectin-ABD. Furthermore, we show that Ser-1325 in the connecting segment of beta 4 appears to be essential for the recruitment of plectin into hemidesmosomes in vivo. This is consistent with the proposed model and previously published mutational data. In conclusion, our data support a model in which the CH1 domain of the plectin-ABD associates with the groove between the two FNIII domains of beta 4.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain	Netherlands Cancer Institute; Netherlands Cancer Institute; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Sonnenberg, A (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.sonnenberg@nki.nl	Perrakis, Anastassis/E-8704-2013; de Pereda, Jose M/AAE-5226-2022; de Pereda, Jose M/F-1733-2010	Perrakis, Anastassis/0000-0002-1151-6227; de Pereda, Jose M/0000-0002-8912-6739; de Pereda, Jose M/0000-0002-8912-6739				Altroff H, 2004, J BIOL CHEM, V279, P55995, DOI 10.1074/jbc.M406976200; Andra K, 2003, J INVEST DERMATOL, V120, P189, DOI 10.1046/j.1523-1747.2003.12027.x; Andra K, 1997, GENE DEV, V11, P3143, DOI 10.1101/gad.11.23.3143; Barrett CP, 2004, ACTA CRYSTALLOGR D, V60, P2280, DOI 10.1107/S0907444904019171; de Pereda JM, 1999, EMBO J, V18, P4087, DOI 10.1093/emboj/18.15.4087; deGroot BL, 1997, PROTEINS, V29, P240, DOI 10.1002/(SICI)1097-0134(199710)29:2<240::AID-PROT11>3.0.CO;2-O; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Fontao L, 2001, J CELL SCI, V114, P2065; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Gache Y, 1996, J CLIN INVEST, V97, P2289, DOI 10.1172/JCI118671; Garcia-Alvarez B, 2003, STRUCTURE, V11, P615, DOI 10.1016/S0969-2126(03)00090-X; Geerts D, 1999, J CELL BIOL, V147, P417, DOI 10.1083/jcb.147.2.417; Geuijen CAW, 2002, MOL BIOL CELL, V13, P3845, DOI 10.1091/mbc.02-01-0601; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; HIEDA Y, 1992, J CELL BIOL, V116, P1497, DOI 10.1083/jcb.116.6.1497; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; James P, 1996, GENETICS, V144, P1425; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; Koster J, 2004, HANDB EXP PHARM, V165, P243, DOI 10.1007/978-3-540-68170-0_9; Koster J, 2004, MOL BIOL CELL, V15, P1211, DOI 10.1091/mbc.E03-09-0697; Koster J, 2003, J CELL SCI, V116, P387, DOI 10.1242/jcs.00241; Koster J, 2001, J INVEST DERMATOL, V117, P1405, DOI 10.1046/j.0022-202x.2001.01567.x; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Litjens SHM, 2003, MOL BIOL CELL, V14, P4039, DOI 10.1091/mbc.E03-05-0268; McLean WHI, 1996, GENE DEV, V10, P1724, DOI 10.1101/gad.10.14.1724; Nakano A, 2001, PEDIATR RES, V49, P618, DOI 10.1203/00006450-200105000-00003; Nievers MG, 1998, J CELL SCI, V111, P1659; Pulkkinen L, 1998, AM J HUM GENET, V63, P1376, DOI 10.1086/302116; Resjo S, 1999, BIOCHEM J, V341, P839, DOI 10.1042/0264-6021:3410839; Ruzzi L, 1997, J CLIN INVEST, V99, P2826, DOI 10.1172/JCI119474; Schaapveld RQJ, 1998, J CELL BIOL, V142, P271, DOI 10.1083/jcb.142.1.271; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Sevcik J, 2004, EUR J BIOCHEM, V271, P1873, DOI 10.1111/j.1432-1033.2004.04095.x; SKALLI O, 1994, J CELL BIOL, V125, P159, DOI 10.1083/jcb.125.1.159; Smith FJD, 1996, NAT GENET, V13, P450, DOI 10.1038/ng0896-450; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; Sterk LMT, 2000, J CELL BIOL, V149, P969, DOI 10.1083/jcb.149.4.969; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166	42	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22270	22277		10.1074/jbc.M411818200	http://dx.doi.org/10.1074/jbc.M411818200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817481	hybrid			2022-12-25	WOS:000229557900072
J	Polykratis, A; Katsoris, P; Courty, J; Papadimitriou, E				Polykratis, A; Katsoris, P; Courty, J; Papadimitriou, E			Characterization of heparin affin regulatory peptide signaling in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; FOCAL ADHESION KINASE; MOLECULE HB-GAM; ACTIVATION LOOP PHOSPHORYLATION; ANAPLASTIC LYMPHOMA KINASE; GROWTH-FACTOR PLEIOTROPHIN; ZETA/RPTP-BETA; N-SYNDECAN; IN-VITRO; RECEPTOR	Heparin affin regulatory peptide (HARP) is an 18-kDa secreted growth factor that has a high affinity for heparin and a potent role on tumor growth and angiogenesis. We have previously reported that HARP is mitogenic for different types of endothelial cells and also affects cell migration and differentiation (12). In this study we examined the signaling pathways involved in the migration and tube formation on matrigel of human umbilical vein endothelial cells (HUVEC) induced by HARP. We report for the first time that receptor-type protein- tyrosine phosphatase beta/zeta (RPTP beta/zeta), which is a receptor for HARP in neuronal cell types, is also expressed in HUVEC. We also document that HARP signaling through RPTP beta/zeta leads to activation of Src kinase, focal adhesion kinase, phosphatidylinositol 3-kinase, and Erk1/2. Sodium orthovanadate, chondroitin sulfate-C, PP1, wortmannin, LY294002, and U0126 inhibit HARP-mediated signaling and HUVEC migration and tube formation. In addition, RPTP beta/zeta suppression using small interfering RNA technology interrupts intracellular signals and HUVEC migration and tube formation induced by HARP. These results establish the role of RPTP beta/zeta as a receptor of HARP in HUVEC and elucidate the HARP signaling pathway in endothelial cells.	Univ Patras, Dept Pharm, Mol Pharmacol Lab, Patras 26504, Greece; Univ Patras, Dept Biol, Div Genet, Patras 26504, Greece; Univ Paris 12, CNRS, UMR 7149, Lab Rech Croissance Cellulaire, F-94010 Creteil, France	University of Patras; University of Patras; Centre National de la Recherche Scientifique (CNRS); Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Papadimitriou, E (corresponding author), Univ Patras, Dept Pharm, Mol Pharmacol Lab, Patras 26504, Greece.	epapad@upatras.gr	Papadimitriou, Evangelia/ABG-1356-2020; Papadimitriou, Evangelia/F-3396-2010; Courty, Jose/Q-3702-2018	Papadimitriou, Evangelia/0000-0001-6429-4325; Polykratis, Apostolos/0000-0001-6720-3302				Chattopadhyay N, 2003, J CELL BIOL, V163, P1351, DOI 10.1083/jcb.200306067; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Ensslen-Craig SE, 2004, DEV BIOL, V275, P12, DOI 10.1016/j.ydbio.2004.08.009; FANG WJ, 1992, J BIOL CHEM, V267, P25889; GIEFFERS C, 1993, EUR J CELL BIOL, V62, P352; GRUMET M, 1994, J BIOL CHEM, V269, P12142; KATCHALSKI HT, 1999, ONCOGENE, V18, P5024; Kinnunen A, 1998, EUR J NEUROSCI, V10, P635, DOI 10.1046/j.1460-9568.1998.00082.x; Kronenwett R, 2002, CANCER GENE THER, V9, P587, DOI 10.1038/sj.cgt.7700474; Lin MT, 2003, MOL PHARMACOL, V64, P1029, DOI 10.1124/mol.64.5.1029; Maa MC, 1998, BIOCHEM BIOPH RES CO, V251, P344, DOI 10.1006/bbrc.1998.9464; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; Muller S, 2003, ONCOGENE, V22, P6661, DOI 10.1038/sj.onc.1206763; Muramatsu H, 2004, J CELL SCI, V117, P5405, DOI 10.1242/jcs.01423; NEAME PJ, 1993, J ORTHOP RES, V11, P479, DOI 10.1002/jor.1100110403; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Papadimitriou E, 2004, CURR CANCER DRUG TAR, V4, P471, DOI 10.2174/1568009043332835; Papadimitriou E, 2000, BIOCHEM BIOPH RES CO, V274, P242, DOI 10.1006/bbrc.2000.3126; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Petrone A, 2000, J CELL SCI, V113, P2345; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Sakurai T, 1996, J NEUROSCI RES, V43, P694, DOI 10.1002/(SICI)1097-4547(19960315)43:6<694::AID-JNR6>3.3.CO;2-9; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Souttou B, 2001, J CELL PHYSIOL, V187, P59, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1051>3.0.CO;2-F; Souttou B, 1998, J NATL CANCER I, V90, P1468, DOI 10.1093/jnci/90.19.1468; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Zhang N, 1997, J BIOL CHEM, V272, P16733, DOI 10.1074/jbc.272.27.16733; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964	41	73	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22454	22461		10.1074/jbc.M414407200	http://dx.doi.org/10.1074/jbc.M414407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15797857	hybrid			2022-12-25	WOS:000229557900091
J	Huang, SX; Gilfillan, S; Cella, M; Miley, MJ; Lantz, O; Lybarger, L; Fremont, DH; Hansen, TH				Huang, SX; Gilfillan, S; Cella, M; Miley, MJ; Lantz, O; Lybarger, L; Fremont, DH; Hansen, TH			Evidence for MR1 antigen presentation to mucosal-associated invariant T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDE-LOADING COMPLEX; CRYSTAL-STRUCTURE; NKT CELLS; STRUCTURAL BASIS; ALPHA-BETA; RECEPTOR RECOGNITION; POLYMORPHIC RESIDUE; SURFACE EXPRESSION	The novel class Ib molecule MR1 is highly conserved in mammals, particularly in its alpha 1/alpha 2 domains. Recent studies demonstrated that MR1 expression is required for development and expansion of a small population of T cells expressing an invariant T cell receptor (TCR) alpha chain called mucosal-associated invariant T (MAIT) cells. Despite these intriguing properties it has been difficult to determine whether MR1 expression and MAIT cell recognition is ligand-dependent. To address these outstanding questions, monoclonal antibodies were produced in MR1 knock-out mice immunized with recombinant MR1 protein, and a series of MR1 mutations were generated at sites previously shown to disrupt the ability of class Ia molecules to bind peptide or TCR. Here we show that 1) MR1 molecules are detected by monoclonal antibodies in either an open or folded conformation that correlates precisely with peptide-induced conformational changes in class Ia molecules, 2) only the folded MR1 conformer activated 2/2 MAIT hybridoma cells tested, 3) the pattern of MAIT cell activation by the MR1 mutants implies the MR1/TCR orientation is strikingly similar to published major histocompatibility complex/alpha beta TCR engagements, 4) all the MR1 mutations tested and found to severely reduce surface expression of folded molecules were located in the putative ligand binding groove, and 5) certain groove mutants of MR1 that are highly expressed on the cell surface disrupt MAIT cell activation. These combined data strongly support the conclusion that MR1 has an antigen presentation function.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; XCInst Curie, Immunol Lab, Paris, France; XCInst Curie, INSERM, U520, Paris, France; Univ Arizona, Arizona Hlth Sci Ctr, Dept Cell Biol & Anat, Tucson, AZ 85724 USA	Washington University (WUSTL); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Arizona; University of Arizona Health Sciences	Hansen, TH (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 4566 Scott Ave, St Louis, MO 63110 USA.	hansen@pathology.wustl.edu	Lantz, Olivier J/J-4960-2012; Cella, Marina/ABA-8564-2020	Lantz, Olivier J/0000-0003-3161-7719; Cella, Marina/0000-0003-1230-1313; Huang, Shouxiong/0000-0001-7797-3626; Fremont, Daved/0000-0002-8544-2689	NIAID NIH HHS [AI46553, AI19687] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019687, R01AI046553] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABASTADO JP, 1993, J IMMUNOL, V151, P3569; Allison TJ, 2002, MOL IMMUNOL, V38, P1051, DOI 10.1016/S0161-5890(02)00034-2; Bai A, 2000, J IMMUNOL, V165, P7025, DOI 10.4049/jimmunol.165.12.7025; Bai A, 1998, IMMUNITY, V9, P413, DOI 10.1016/S1074-7613(00)80624-X; Bendelac A, 2001, NAT REV IMMUNOL, V1, P177, DOI 10.1038/35105052; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; Bennett MJ, 2000, NATURE, V403, P46, DOI 10.1038/47417; BLUESTONE JA, 1992, J EXP MED, V176, P1757, DOI 10.1084/jem.176.6.1757; Braud VM, 1999, CURR OPIN IMMUNOL, V11, P100, DOI 10.1016/S0952-7915(99)80018-1; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; Buslepp J, 2003, IMMUNITY, V19, P595, DOI 10.1016/S1074-7613(03)00269-3; Carayannopoulos LN, 2002, EUR J IMMUNOL, V32, P597, DOI 10.1002/1521-4141(200203)32:3<597::AID-IMMU597>3.3.CO;2-5; CARRENO BM, 1993, INT IMMUNOL, V5, P353, DOI 10.1093/intimm/5.4.353; CATIPOVIC B, 1992, J EXP MED, V176, P1611, DOI 10.1084/jem.176.6.1611; Chiu NM, 1999, J EXP MED, V190, P423, DOI 10.1084/jem.190.3.423; Crowley MP, 1997, J EXP MED, V185, P1223, DOI 10.1084/jem.185.7.1223; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203; Garboczi DN, 1999, IMMUNITY, V10, P1, DOI 10.1016/S1074-7613(00)80001-1; Garboczi DN, 1996, J IMMUNOL, V157, P5403; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; GIGLIA JS, 1985, CANCER RES, V45, P5027; Hansen T, 2000, IMMUNOL TODAY, V21, P83, DOI 10.1016/S0167-5699(98)01426-1; HASHIMOTO K, 1995, SCIENCE, V269, P693, DOI 10.1126/science.7624800; He XL, 2001, STRUCTURE, V9, P1213, DOI 10.1016/S0969-2126(01)00689-X; HEMMI S, 1988, J EXP MED, V168, P2319, DOI 10.1084/jem.168.6.2319; Hennecke J, 2001, CELL, V104, P1, DOI 10.1016/S0092-8674(01)00185-4; Hornell TMC, 1999, J IMMUNOL, V163, P3217; Kjer-Nielsen L, 2003, IMMUNITY, V18, P53, DOI 10.1016/S1074-7613(02)00513-7; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; Lee N, 1998, J IMMUNOL, V160, P4951; Li PW, 2002, IMMUNITY, V16, P77, DOI 10.1016/S1074-7613(02)00258-3; Lybarger L, 2003, IMMUNITY, V18, P121, DOI 10.1016/S1074-7613(02)00509-5; Lybarger L, 2001, J IMMUNOL, V167, P2097, DOI 10.4049/jimmunol.167.4.2097; Marguet D, 1999, IMMUNITY, V11, P231, DOI 10.1016/S1074-7613(00)80098-9; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; Miley MJ, 2003, J IMMUNOL, V170, P6090, DOI 10.4049/jimmunol.170.12.6090; MORIWAKI S, 1993, P NATL ACAD SCI USA, V90, P11396, DOI 10.1073/pnas.90.23.11396; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; Myers NB, 2000, J IMMUNOL, V165, P5656, DOI 10.4049/jimmunol.165.10.5656; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Park B, 2003, J IMMUNOL, V170, P961, DOI 10.4049/jimmunol.170.2.961; Park SH, 2000, EUR J IMMUNOL, V30, P620, DOI 10.1002/1521-4141(200002)30:2<620::AID-IMMU620>3.0.CO;2-4; PRETELL J, 1979, VIROLOGY, V97, P32, DOI 10.1016/0042-6822(79)90370-2; PULLEN JK, 1991, J IMMUNOL, V146, P2145; Reinherz EL, 1999, SCIENCE, V286, P1913, DOI 10.1126/science.286.5446.1913; Reiser JB, 2000, NAT IMMUNOL, V1, P291, DOI 10.1038/79728; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; RIBAUDO RK, 1995, J IMMUNOL, V155, P3481; Riegert P, 1998, J IMMUNOL, V161, P4066; Sanchez LM, 1999, SCIENCE, V283, P1914, DOI 10.1126/science.283.5409.1914; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; SMITH JD, 1993, J EXP MED, V178, P2035, DOI 10.1084/jem.178.6.2035; SMITH JD, 1992, J EXP MED, V175, P191, DOI 10.1084/jem.175.1.191; Smith KD, 1996, IMMUNOGENETICS, V43, P27; Smith RA, 2002, J IMMUNOL, V169, P3105, DOI 10.4049/jimmunol.169.6.3105; Smyth MJ, 2002, CURR OPIN IMMUNOL, V14, P165, DOI 10.1016/S0952-7915(02)00316-3; SOLHEIM JC, 1993, J IMMUNOL, V151, P5387; Stanic AK, 2003, P NATL ACAD SCI USA, V100, P1849, DOI 10.1073/pnas.0430327100; Stein-Streilein J, 2003, J EXP MED, V198, P1779, DOI 10.1084/jem.20031946; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325; Stewart-Jones GBE, 2003, NAT IMMUNOL, V4, P657, DOI 10.1038/ni942; TALKEN BL, 1994, MOL IMMUNOL, V31, P1169, DOI 10.1016/0161-5890(94)90031-0; Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.immunol.21.120601.141057; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5; Tilloy F, 1999, J EXP MED, V189, P1907, DOI 10.1084/jem.189.12.1907; Treiner E, 2003, NATURE, V422, P164, DOI 10.1038/nature01433; TREINER E, 2005, IN PRESS MICROBES IN; Wang CR, 1996, RES IMMUNOL, V147, P313, DOI 10.1016/0923-2494(96)89644-1; Wang XL, 2004, J VIROL, V78, P8673, DOI 10.1128/JVI.78.16.8673-8686.2004; Wingren C, 2000, SCIENCE, V287, P310, DOI 10.1126/science.287.5451.310; Yamaguchi H, 1997, BIOCHEM BIOPH RES CO, V238, P697, DOI 10.1006/bbrc.1997.7379; Yu YYL, 1999, INT IMMUNOL, V11, P1897, DOI 10.1093/intimm/11.12.1897; Yu YYL, 2002, J VIROL, V76, P2796, DOI 10.1128/JVI.76.6.2796-2803.2002; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	81	118	121	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21183	21193		10.1074/jbc.M501087200	http://dx.doi.org/10.1074/jbc.M501087200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802267	hybrid			2022-12-25	WOS:000229438800036
J	Morita, YS; Velasquez, R; Taig, E; Waller, RF; Patterson, JH; Tull, D; Williams, SJ; Billman-Jacobe, H; McConville, MJ				Morita, YS; Velasquez, R; Taig, E; Waller, RF; Patterson, JH; Tull, D; Williams, SJ; Billman-Jacobe, H; McConville, MJ			Compartmentalization of lipid biosynthesis in mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; CELL-WALL; IN-VITRO; PHOSPHATIDYLINOSITOL; LIPOARABINOMANNAN; TUBERCULOSIS; IDENTIFICATION; BIOGENESIS; METABOLISM; SYNTHASE	The plasma membrane of Mycobacterium sp. is the site of synthesis of several distinct classes of lipids that are either retained in the membrane or exported to the overlying cell envelope. Here, we provide evidence that enzymes involved in the biosynthesis of two major lipid classes, the phosphatidylinositol mannosides (PIMs) and aminophospholipids, are compartmentalized within the plasma membrane. Enzymes involved in the synthesis of early PIM intermediates were localized to a membrane subdomain termed PMf, that was clearly resolved from the cell wall by isopyknic density centrifugation and amplified in rapidly dividing Mycobacterium smegmatis. In contrast, the major pool of apolar PIMs and enzymes involved in polar PIM biosynthesis were localized to a denser fraction that contained both plasma membrane and cell wall markers (PM-CW). Based on the resistance of the PIMs to solvent extraction in live but not lysed cells, we propose that polar PIM biosynthesis occurs in the plasma membrane rather than the cell wall component of the PM-CW. Enzymes involved in phosphatidylethanolamine biosynthesis also displayed a highly polarized distribution between the PMf and PM-CW fractions. The PMf was greatly reduced in non-dividing cells, concomitant with a reduction in the synthesis and steady-state levels of PIMs and amino-phospholipids and the redistribution of PMf marker enzymes to non-PM-CW fractions. The formation of the PMf and recruitment of enzymes to this domain may thus play a role in regulating growth-specific changes in the biosynthesis of membrane and cell wall lipids.	Univ Melbourne, Mol Sci & Biotechnol Inst B1021, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; Univ Melbourne, Mol Sci & Biotechnol Inst B1021, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; Univ Melbourne, Mol Sci & Biotechnol Inst B1021, Sch Chem, Parkville, Vic 3010, Australia	University of Melbourne; University of Melbourne; University of Melbourne	McConville, MJ (corresponding author), Univ Melbourne, Mol Sci & Biotechnol Inst B1021, Dept Biochem & Mol Biol, 30 Flemington Rd, Parkville, Vic 3010, Australia.	malcolmm@unimelb.edu.au	Waller, Ross F/D-5761-2016; Williams, Spencer/C-3545-2009	Waller, Ross F/0000-0001-6961-9344; Williams, Spencer/0000-0001-6341-4364; Billman-Jacobe, Helen/0000-0001-5713-4657; Morita, Yasu/0000-0002-4514-9242; Tull, Dedreia/0000-0003-2546-6707				Baulard AR, 2003, J BIOL CHEM, V278, P2242, DOI 10.1074/jbc.M207922200; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6; Briken V, 2004, MOL MICROBIOL, V53, P391, DOI 10.1111/j.1365-2958.2004.04183.x; Brown JR, 2001, BIOORGAN MED CHEM, V9, P815, DOI 10.1016/S0968-0896(00)00300-X; Campo N, 2004, MOL MICROBIOL, V53, P1583, DOI 10.1111/j.1365-2958.2004.04278.x; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; Christensen H, 1999, MOL MICROBIOL, V31, P1561, DOI 10.1046/j.1365-2958.1999.01304.x; Crick DC, 2001, GLYCOBIOLOGY, V11, p107R, DOI 10.1093/glycob/11.9.107R; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; DAVIS WB, 1975, J BIOL CHEM, V250, P1648; Garton NJ, 2002, MICROBIOL-SGM, V148, P2951, DOI 10.1099/00221287-148-10-2951; Gurcha SS, 2002, BIOCHEM J, V365, P441, DOI 10.1042/BJ20020107; Haites RE, 2005, J BIOL CHEM, V280, P10981, DOI 10.1074/jbc.M413443200; Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; Kawai F, 2004, J BACTERIOL, V186, P1475, DOI 10.1128/JB.186.5.1475-1483.2004; Koppelman CM, 2001, J BACTERIOL, V183, P6144, DOI 10.1128/JB.183.20.6144-6147.2001; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Mawuenyega KG, 2005, MOL BIOL CELL, V16, P396, DOI 10.1091/mbc.e04-04-0329; Mileykovskaya E, 2003, J BIOL CHEM, V278, P22193, DOI 10.1074/jbc.M302603200; Morita YS, 2004, BIOCHEM J, V378, P589, DOI 10.1042/BJ20031372; Mullin KA, 2001, MOL BIOL CELL, V12, P2364, DOI 10.1091/mbc.12.8.2364; Onyebujoh P, 2004, NAT REV MICROBIOL, V2, P930, DOI 10.1038/nrmicro1050; OrtaloMagne A, 1996, J BACTERIOL, V178, P456, DOI 10.1128/jb.178.2.456-461.1996; Patterson JH, 2000, J BIOL CHEM, V275, P24900, DOI 10.1074/jbc.M000147200; Patterson JH, 2003, BIOCHEM J, V372, P77, DOI 10.1042/BJ20021700; Pinho MG, 2003, MOL MICROBIOL, V50, P871, DOI 10.1046/j.1365-2958.2003.03719.x; Pugsley AP, 2004, MOL MICROBIOL, V53, P1559, DOI 10.1111/j.1365-2958.2004.04273.x; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAMAKRISHNAN T, 1972, BACTERIOL REV, V36, P65, DOI 10.1128/MMBR.36.1.65-108.1972; Rosch J, 2004, SCIENCE, V304, P1513, DOI 10.1126/science.1097404; Russell DG, 2002, J CELL BIOL, V158, P421, DOI 10.1083/jcb.200205034; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Triccas JA, 1998, FEMS MICROBIOL LETT, V167, P151, DOI 10.1111/j.1574-6968.1998.tb13221.x; Vidugiriene J, 1999, J BIOL CHEM, V274, P15203, DOI 10.1074/jbc.274.21.15203; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200	39	59	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21645	21652		10.1074/jbc.m414181200	http://dx.doi.org/10.1074/jbc.m414181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15805104	hybrid			2022-12-25	WOS:000229438800090
J	Deponte, M; Urig, S; Arscott, LD; Wolf, KF; Reau, R; Herold-Mende, C; Koncarevic, S; Meyer, M; Davioud-Charvet, E; Ballou, DP; Williams, CH; Becker, K				Deponte, M; Urig, S; Arscott, LD; Wolf, KF; Reau, R; Herold-Mende, C; Koncarevic, S; Meyer, M; Davioud-Charvet, E; Ballou, DP; Williams, CH; Becker, K			Mechanistic studies on a novel, highly potent gold-phosphole inhibitor of human glutathione reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITE PLASMODIUM-FALCIPARUM; THIOREDOXIN REDUCTASE; CRYSTAL-STRUCTURE; CATALYSIS; ENZYME; 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA; SUBSTRATE; BINDING; SYSTEMS; DRUGS	The homodimeric flavoprotein glutathione reductase (GR) is a central player of cellular redox metabolism, connecting NADPH to the large pool of redox-active thiols. In this work, the inhibition of human GR by a novel gold-phosphole inhibitor (GoPI) has been studied in vitro. Two modes of inhibition are observed, reversible inhibition that is competitive with GSSG followed by irreversible inhibition. When similar to 1 nM GoPI is incubated with NADPH-reduced GR (1.4 nM) the enzyme becomes 50% inhibited. This appears to be the most potent stable inhibitor of human GR to date. Analyzing the monophasic oxidative half-reaction of reduced GR with GSSG at pH 6.9 revealed a K-d( app) for GSSG of 63 mu M, and a k((obs)max) of 106 s(-1) at 4 degrees C. The reversible inhibition by the gold-phosphole complex [{1-phenyl-2,5-di(2pyridyl) phosphole} AuCI] involves formation of a complex at the GSSG-binding site of GR ( K-d = 0.46 mu M) followed by nucleophilic attack of an active site cysteine residue that leads to covalent modification and complete inactivation of the enzyme. Data from titration spectra, molecular modeling, stopped-flow, and steady-state kinetics support this theory. In addition, covalent binding of the inhibitor to human GR was demonstrated by mass spectrometry. The extraordinary properties of the compound and its derivatives might be exploited for cell biological studies or medical applications, e. g. as an anti-tumor or antiparasitic drug. Preliminary experiments with glioblastoma cells cultured in vitro indicate an anti-proliferative effect of the inhibitor in the lower micromolar range.	Univ Giessen, Interdisciplinary Res Ctr, D-35392 Giessen, Germany; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Max Planck Inst Med Res, Dept Biophys, D-69120 Heidelberg, Germany; Univ Rennes 1, CNRS, UMR 6509, Inst Chim, F-35042 Rennes, France; Univ Heidelberg, Zentrum Biochem, Dept Head & Neck Surg, D-69120 Heidelberg, Germany; Ciphergen Biosyst GmbH, D-37085 Gottingen, Germany	Justus Liebig University Giessen; University of Michigan System; University of Michigan; Max Planck Society; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Ruprecht Karls University Heidelberg	Becker, K (corresponding author), Univ Giessen, Interdisciplinary Res Ctr, Heinrich Buff Ring 26-32, D-35392 Giessen, Germany.	becker.katja@gmx.de	dballou@umich.edu, David P/A-1298-2007; Davioud-Charvet, Elisabeth/I-3805-2013	Davioud-Charvet, Elisabeth/0000-0001-7026-4034; Deponte, Marcel/0000-0003-2141-917X	NIGMS NIH HHS [GM11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS MJ, 1993, SCIENCE, V261, P725, DOI 10.1126/science.8102010; BECKER K, 1995, EUR J BIOCHEM, V234, P472, DOI 10.1111/j.1432-1033.1995.472_b.x; BECKER K, 1995, METHOD ENZYMOL, V251, P173, DOI 10.1016/0076-6879(95)51120-2; Becker K, 2003, BIOL CHEM, V384, P551, DOI 10.1515/BC.2003.063; Becker K, 2001, J MED CHEM, V44, P2784, DOI 10.1021/jm001014i; Bisswanger H, 2000, ENZYMKINETIK; Bohme CC, 2000, J BIOL CHEM, V275, P37317, DOI 10.1074/jbc.M007695200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Davioud-Charvet E, 2003, BIOCHEMISTRY-US, V42, P13319, DOI 10.1021/bi0353629; Davioud-Charvet E, 2001, J MED CHEM, V44, P4268, DOI 10.1021/jm010268g; DAVIS RE, 1960, J AM CHEM SOC, V82, P5949, DOI 10.1021/ja01507a039; Fave C, 2004, J AM CHEM SOC, V126, P6058, DOI 10.1021/ja0317067; Fave C, 2003, J AM CHEM SOC, V125, P9254, DOI 10.1021/ja035155w; Hay C, 2001, CHEM-EUR J, V7, P4222, DOI 10.1002/1521-3765(20011001)7:19<4222::AID-CHEM4222>3.0.CO;2-3; Hay C, 1999, CHEM COMMUN, P345, DOI 10.1039/a808408d; Herold-Mende C, 1999, LAB INVEST, V79, P1573; Irmler A, 2002, FLAVINS FLAVOPROTEIN, P803; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KARPLUS PA, 1988, EUR J BIOCHEM, V171, P193, DOI 10.1111/j.1432-1033.1988.tb13775.x; KITZ R, 1962, J BIOL CHEM, V237, P3245; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krauth-Siegel RL, 1998, BIOCHEMISTRY-US, V37, P13968, DOI 10.1021/bi980637j; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NORDHOFF A, 1993, BIOCHEMISTRY-US, V32, P4060, DOI 10.1021/bi00066a029; PAI EF, 1983, J BIOL CHEM, V258, P1752; RIETVELD P, 1994, BIOCHEMISTRY-US, V33, P13888, DOI 10.1021/bi00250a043; Sarma GN, 2003, J MOL BIOL, V328, P893, DOI 10.1016/S0022-2836(03)00347-4; Shaw CF, 1999, CHEM REV, V99, P2589, DOI 10.1021/cr980431o; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; Zou J, 2000, ANGEW CHEM INT EDIT, V39, P2931, DOI 10.1002/1521-3773(20000818)39:16<2931::AID-ANIE2931>3.0.CO;2-W	31	73	76	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20628	20637		10.1074/jbc.M412519200	http://dx.doi.org/10.1074/jbc.M412519200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15792952	hybrid			2022-12-25	WOS:000229242000059
J	Ren, SY; Nguyen, L; Wu, SX; Encinas, C; Adams, JS; Hewison, M				Ren, SY; Nguyen, L; Wu, SX; Encinas, C; Adams, JS; Hewison, M			Alternative splicing of vitamin D-24-hydroxylase - A novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D METABOLISM; CULTURED ALVEOLAR MACROPHAGES; D-RESPONSIVE ELEMENTS; 25-HYDROXYVITAMIN D-3-1-ALPHA-HYDROXYLASE; ELEVATED 1,25-DIHYDROXYVITAMIN-D; 24-HYDROXYLASE CYP24; PROSTATE-CANCER; CALCITROIC ACID; CELL-LINE; D-3	Synthesis of the active form of vitamin D, 1,25-dihydroxyvitamin D ( 1,25-(OH)(2)D), by renal epithelial cells is tightly controlled during normal calcium homeostasis. By contrast, macrophage production of 1,25-( OH) 2D is often dysregulated with potential hypercalcemic complications. We have postulated that this is due to abnormal catabolism of 1,25-(OH) 2D by the feedback control enzyme, vitamin D-24-hydroxylase (CYP24). Using chick HD-11 and human THP-1 myelomonocytic cell lines, we have shown that macrophage-like cells express a splice variant of the CYP24 gene (CYP24-SV), which encodes a truncated protein. Compared with the holo-CYP24 gene product in chick and human cells (508 and 513 amino acids, respectively), the truncated CYP24-SV versions consisted of 351 and 372 amino acids. These CYP24-SV proteins retained intact substrate- binding domains but lacked mitochondrial targeting sequences and were therefore catalytically inactive. In common with CYP24, expression of the CYP24 variants was induced by 1,25( OH) 2D but without a concomitant rise in 24-hydroxylase activity. However, overexpression of CYP24-SV in HD-11 and THP-1 cells reduced synthesis of 1,25-(OH) 2D (40-50%), whereas antisense CYP24-SV expression increased 1,25-(OH) 2D production by 2-7-fold. These data suggest that alternative splicing of CYP24 leads to the generation of a dominant negative-acting protein that is catalytically dysfunctional. We theorize that expression of the CYP24-SV may contribute to the extracellular accumulation of 1,25(OH) 2D in human health and disease.	Univ Birmingham, Biomed Res Inst, Div Med Sci, Birmingham B15 2TT, W Midlands, England; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Div Endocrinol, Dept Med, Los Angeles, CA 90048 USA	University of Birmingham; Cedars Sinai Medical Center	Hewison, M (corresponding author), Univ Birmingham, Biomed Res Inst, Div Med Sci, Birmingham B15 2TT, W Midlands, England.	M.Hewison@bham.ac.uk	Adams, John S/I-3365-2013	Adams, John S/0000-0001-9607-5020	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050626] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00425] Funding Source: Medline; NIAID NIH HHS [AI40403] Funding Source: Medline; NIAMS NIH HHS [AR50626] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abreu MT, 2004, GUT, V53, P1129, DOI 10.1136/gut.2003.036657; ADAMS JS, 1985, J EXP MED, V161, P755, DOI 10.1084/jem.161.4.755; ADAMS JS, 1983, J CLIN INVEST, V72, P1856, DOI 10.1172/JCI111147; ADAMS JS, 1994, ENDOCRINOLOGY, V134, P2567, DOI 10.1210/en.134.6.2567; Akker SA, 2001, J MOL ENDOCRINOL, V27, P123, DOI 10.1677/jme.0.0270123; Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Armbrecht HJ, 1998, ENDOCRINOLOGY, V139, P3375, DOI 10.1210/en.139.8.3375; Bland R, 1999, ENDOCRINOLOGY, V140, P2027, DOI 10.1210/en.140.5.2027; Bland R, 2000, CURR OPIN NEPHROL HY, V9, P17, DOI 10.1097/00041552-200001000-00004; Chen TC, 2003, J CELL BIOCHEM, V88, P315, DOI 10.1002/jcb.10342; Christakos S, 2003, J CELL BIOCHEM, V88, P695, DOI 10.1002/jcb.10423; Christmas P, 1999, J BIOL CHEM, V274, P21191, DOI 10.1074/jbc.274.30.21191; Christmas P, 2001, J BIOL CHEM, V276, P38166; DING SH, 1995, BIOCHEM J, V306, P161, DOI 10.1042/bj3060161; Dusso AS, 1997, J CLIN ENDOCR METAB, V82, P2222, DOI 10.1210/jc.82.7.2222; Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961; Henry HL, 2001, STEROIDS, V66, P391, DOI 10.1016/S0039-128X(00)00158-6; Hewison M, 2003, J IMMUNOL, V170, P5382, DOI 10.4049/jimmunol.170.11.5382; Hewison M, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P1379; Huang ZQ, 1997, ARCH BIOCHEM BIOPHYS, V343, P101, DOI 10.1006/abbi.1997.0153; Kerry DM, 1996, J BIOL CHEM, V271, P29715, DOI 10.1074/jbc.271.47.29715; Kong XF, 1999, P NATL ACAD SCI USA, V96, P6988, DOI 10.1073/pnas.96.12.6988; KUMAMOTO T, 1989, J BIOCHEM-TOKYO, V105, P72, DOI 10.1093/oxfordjournals.jbchem.a122622; Lou YR, 2003, FASEB J, V17, P332, DOI 10.1096/fj.03-0140fje; Ly LH, 1999, ENDOCRINOLOGY, V140, P2071, DOI 10.1210/en.140.5.2071; Maas RM, 2001, CLIN CANCER RES, V7, P868; MAKIN G, 1989, BIOCHEM J, V262, P173, DOI 10.1042/bj2620173; Masuda S, 2005, ENDOCRINOLOGY, V146, P825, DOI 10.1210/en.2004-1116; Miller WL, 2000, TRENDS ENDOCRIN MET, V11, P315, DOI 10.1016/S1043-2760(00)00287-3; Monkawa T, 2000, KIDNEY INT, V58, P559, DOI 10.1046/j.1523-1755.2000.00202.x; Neve EPA, 2001, J BIOL CHEM, V276, P11317, DOI 10.1074/jbc.M008640200; Ohyama Y, 1996, J BIOL CHEM, V271, P30381, DOI 10.1074/jbc.271.48.30381; Ohyama Y, 2004, FRONT BIOSCI-LANDMRK, V9, P3007, DOI 10.2741/1455; Omdahl JL, 2002, ANNU REV NUTR, V22, P139, DOI 10.1146/annurev.nutr.22.120501.150216; OMURA T, 1991, METHOD ENZYMOL, V206, P75; OU W, 1986, J BIOCHEM-TOKYO, V100, P1287, DOI 10.1093/oxfordjournals.jbchem.a121835; OU WJ, 1994, J BIOL CHEM, V269, P24673; Panda DK, 2001, P NATL ACAD SCI USA, V98, P7498, DOI 10.1073/pnas.131029498; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; REDDY GS, 1989, BIOCHEMISTRY-US, V28, P1763, DOI 10.1021/bi00430a051; REICHEL H, 1987, J CLIN ENDOCR METAB, V65, P1201, DOI 10.1210/jcem-65-6-1201; SHANY S, 1993, J BONE MINER RES, V8, P269; Smith SJ, 1999, J BONE MINER RES, V14, P730, DOI 10.1359/jbmr.1999.14.5.730; St-Arnaud R, 2000, ENDOCRINOLOGY, V141, P2658, DOI 10.1210/en.141.7.2658; Xie ZJ, 2002, J BIOL CHEM, V277, P36987, DOI 10.1074/jbc.M201404200; Zehnder D, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133621; Zehnder D, 2002, AM J PATHOL, V161, P105, DOI 10.1016/S0002-9440(10)64162-4; Zehnder D, 1999, MOL CELL ENDOCRINOL, V151, P213, DOI 10.1016/S0303-7207(99)00039-8; Zehnder D, 2001, J CLIN ENDOCR METAB, V86, P888, DOI 10.1210/jc.86.2.888	49	88	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20604	20611		10.1074/jbc.M414522200	http://dx.doi.org/10.1074/jbc.M414522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788398	hybrid			2022-12-25	WOS:000229242000056
J	Kaur, B; Brat, DJ; Devi, NS; Van Meir, EG				Kaur, B; Brat, DJ; Devi, NS; Van Meir, EG			Vasculostatin, a proteolytic fragment of Brain Angiogenesis Inhibitor 1, is an antiangiogenic and antitumorigenic factor	ONCOGENE			English	Article						brain angiogenesis inhibitor; central nervous system; cancer; glioma; proteolytic cleavage; thrombospondin	TUMOR-GROWTH; ENDOTHELIAL-CELLS; REGULATES ANGIOGENESIS; THROMBOSPONDIN-1; PROTEIN; RECEPTOR; BAI1; OVEREXPRESSION; SUPPRESSION; CARCINOMA	Brain angiogenesis inhibitor 1 (BAI1) is a transmembrane protein with unknown function expressed primarily in normal but not tumoral brain. The finding of thrombospondin type 1 repeats in its extracellular domain suggested an antiangiogenic function, but the mechanisms by which a transmembrane receptor could inhibit angiogenesis remained unexplained. Here we demonstrate that BAI1 is proteolytically cleaved at a conserved G-protein-coupled receptor proteolytic cleavage site (GPS), releasing its 120 kDa extracellular domain. We named this secreted fragment Vasculostatin as it inhibited migration of endothelial cells in vitro and dramatically reduced in vivo angiogenesis. Both constitutive and doxycycline-induced expression of Vasculostatin elicited dose-dependent suppression of tumor growth and vascular density in mice, implicating Vasculostatin in the regulation of vascular homeostasis and tumor prevention. Generation of a soluble antiangiogenic factor by cleavage of a pre-existing transmembrane protein represents a novel mechanism for regulating vascular homeostasis and preventing tumorigenesis. Modulation of this cleavage or delivery of Vasculostatin may constitute novel treatment modalities for cancer and other diseases of aberrant angiogenesis, especially in the brain.	Emory Univ, Winship Canc Inst, Dept Neurosurg, Mol Neurooncol Lab, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Inst, Dept Hematol Oncol, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Inst, Sch Med, Dept Pathol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Winship Canc Inst, Dept Neurosurg, Mol Neurooncol Lab, 1365C Clifotn Rd NE,Room C5078, Atlanta, GA 30322 USA.	evanmei@emory.edu	kaur, Balveen/E-3355-2011	Van Meir, Erwin G./0000-0003-2444-7707	NCI NIH HHS [CA86335] Funding Source: Medline; NINDS NIH HHS [NS41403] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS041403] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carpizo D, 2000, CANCER METAST REV, V19, P159, DOI 10.1023/A:1026570331022; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; de Fraipont F, 2001, TRENDS MOL MED, V7, P401, DOI 10.1016/S1471-4914(01)02102-5; Detmar M, 2000, J DERMATOL SCI, V24, pS78, DOI 10.1016/S0923-1811(00)00145-6; Duda DG, 2002, BRIT J CANCER, V86, P490, DOI 10.1038/sj.bjc.6600067; FERRARA N, 1991, ENDOCRINOLOGY, V129, P896, DOI 10.1210/endo-129-2-896; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Gray JX, 1996, J IMMUNOL, V157, P5438; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; Hatanaka H, 2000, INT J MOL MED, V5, P181; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Huwiler KG, 2002, BIOCHEMISTRY-US, V41, P14329, DOI 10.1021/bi026463u; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kaur B, 2003, AM J PATHOL, V162, P19, DOI 10.1016/S0002-9440(10)63794-7; Krasnoperov V, 2002, J BIOL CHEM, V277, P46518, DOI 10.1074/jbc.M206415200; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; Lee JH, 2001, INT J ONCOL, V18, P355; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Mengerink KJ, 2002, J BIOL CHEM, V277, P943, DOI 10.1074/jbc.M109673200; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mori K, 2002, NEUROSCI RES, V43, P69, DOI 10.1016/S0168-0102(02)00018-4; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; Simantov R, 2003, FRONT BIOSCI-LANDMRK, V8, pS874, DOI 10.2741/1168; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Van Meir EG, 1997, INT J CANCER, V71, P310; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Volpert OV, 2000, CANCER METAST REV, V19, P87, DOI 10.1023/A:1026560618302; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	50	132	136	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3632	3642		10.1038/sj.onc.1208317	http://dx.doi.org/10.1038/sj.onc.1208317			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782143				2022-12-25	WOS:000229221800010
J	Liang, H; Samanta, S; Nagarajan, L				Liang, H; Samanta, S; Nagarajan, L			SSBP2, a candidate tumor suppressor gene, induces growth arrest and differentiation of myeloid leukemia cells	ONCOGENE			English	Article						AML; leukemia; suppressor; SSBP2	BINDING PROTEIN LDB1; EXPRESSION; LINES; OVEREXPRESSION; REPRESSION; MUTATIONS; REVEALS; CLONING; TARGET; TAL1	Acute myelogenous leukemia (AML) is the most common leukemia in adults with clonal proliferation of myeloid stem cells. Two or more cooperating mechanisms, namely block in differentiation, enhanced proliferation and resistance to programmed cell death, underlie this neoplastic transformation. Nonrandom, complete and partial deletions of chromosome 5 are common anomalies in AML. Using positional cloning strategies, we characterized an evolutionarily conserved candidate myeloid leukemia suppressor gene encoding sequence-specific single-stranded DNA binding protein 2 ( SSBP2) from chromosome 5q13.3, a locus that is frequently deleted in AML. Recent studies in Drosophila and Xenopus demonstrate a pivotal role for SSBPs in embryonic differentiation. In mammals, SSBP2 is one of three highly related and ubiquitously expressed genes. Here, we identify frequent loss of SSBP2 protein expression in human AML cell lines using highly specific antibodies. Furthermore, inducible expression of SSBP2 in the AML cell line U937 leads to loss of clonogenicity, G1 arrest and partial differentiation. Remarkably, inducible expression of SSBP2 is accompanied by downregulation of C-MYC expression. Our findings are consistent with human SSBP2 being a novel regulator of hematopoietic growth and differentiation, whose loss confers a block in differentiation advantage to myeloid leukemic cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Nagarajan, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holocombe Blvd,Box 45, Houston, TX 77030 USA.	lnagaraj@mdanderson.org			NCI NIH HHS [CA16672] Funding Source: Medline; NHLBI NIH HHS [HL074449] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074449] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bayarsaihan D, 1998, BIOCHEM J, V331, P447, DOI 10.1042/bj3310447; BI SC, 1992, LEUKEMIA, V6, P839; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Castro P, 2002, GENOMICS, V80, P78, DOI 10.1006/geno.2002.6805; Castro PD, 2000, BLOOD, V95, P2138, DOI 10.1182/blood.V95.6.2138; Chen L, 2002, P NATL ACAD SCI USA, V99, P14320, DOI 10.1073/pnas.212532399; Dong WF, 1997, DNA CELL BIOL, V16, P671, DOI 10.1089/dna.1997.16.671; Emes RD, 2001, HUM MOL GENET, V10, P2813, DOI 10.1093/hmg/10.24.2813; Fleckenstein DS, 2002, LEUKEMIA RES, V26, P207, DOI 10.1016/S0145-2126(01)00107-2; Grand CL, 2004, P NATL ACAD SCI USA, V101, P6140, DOI 10.1073/pnas.0400460101; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Qian ZJ, 2002, P NATL ACAD SCI USA, V99, P14925, DOI 10.1073/pnas.222491799; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Suzuki H, 2001, GENOME RES, V11, P1758, DOI 10.1101/gr.180101; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; van Meyel DJ, 2003, DEVELOPMENT, V130, P1915, DOI 10.1242/dev.00389; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Xu ZX, 2003, MOL CELL BIOL, V23, P7585, DOI 10.1128/MCB.23.21.7585-7599.2003	23	38	39	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2625	2634		10.1038/sj.onc.1208167	http://dx.doi.org/10.1038/sj.onc.1208167			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15782145				2022-12-25	WOS:000228356700004
J	Liu, MT; Chang, YT; Chen, SC; Chuang, YC; Chen, YR; Lin, CS; Chen, JY				Liu, MT; Chang, YT; Chen, SC; Chuang, YC; Chen, YR; Lin, CS; Chen, JY			Epstein-Barr virus latent membrane protein 1 represses p53-mediated DNA repair and transcriptional activity	ONCOGENE			English	Article						p53; Epstein-Barr virus LMP1; DNA repair	NF-KAPPA-B; NUCLEOTIDE EXCISION-REPAIR; PROGRAMMED CELL-DEATH; TYPE-1 TAX PROTEIN; HTLV-I TAX; MEMBRANE PROTEIN-1; GENOMIC INTEGRITY; SIGNALING PATHWAY; DAMAGING AGENTS; P53 GENE	The latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV), a viral oncogene, is essential for transformation of resting B cells by the virus. We previously demonstrated that LMP1 could repress DNA repair in p53-wild-type and p53-deficient human epithelial cells. In this study, using a host cell reactivation (HCR) assay, we demonstrated that p53-enhanced DNA repair was repressed by LMP1 in p53-deficient cells. Moreover, we found that LMP1 was able to repress p53-dependent transcriptional activity. Regarding the mechanisms of p53 repression by LMP1, we found that LMP1 did not inhibit p53 function through direct interaction, by promoting protein degradation or reducing its DNA-binding ability. Using chimeric proteins in the reporter assay, we demonstrated that LMP1 inhibited p53 transactivation by influencing the N-terminal transactivation domain of p53. Subsequent experiments using various LMP1 deletion mutants indicated that a C-terminus-activating region of LMP1, CTAR1 or CTAR2, is responsible for the repression of p53-mediated DNA repair and p53-dependent transcription, which is correlated with the region responsible for NF-kappa B activation. Furthermore, blockage of NF-kappa B signalling by I kappa B-Delta N was shown to abolish the repression of p53 by LMP1, suggesting that LMP1 likely repressed p53 function through the NF-kappa B pathway. Based on these results, we propose that inhibition of p53-dependent transcriptional activity and DNA repair by LMP1 results in the loss of p53 activity for maintaining genomic stability, which may contribute to the oncogenesis of LMP1 in human epithelial cells.	Natl Hlth Res Inst, Taipei 114, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 100, Taiwan	National Health Research Institutes - Taiwan; National Taiwan University	Chen, JY (corresponding author), Natl Hlth Res Inst, 3F 109,Sect 6,Min Chuan E Rd, Taipei 114, Taiwan.	cjy@nhri.org.tw	Lin, Chang-Shen/D-5140-2009; Chen, Jen-Yang/D-2085-2010; Lin, Chang-Shen/X-2189-2019	Lin, Chang-Shen/0000-0001-7415-2187; Chuang, Yu-Chia/0000-0002-5069-9468				AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Adimoolam S, 2003, DNA REPAIR, V2, P947, DOI 10.1016/S1568-7864(03)00087-9; Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Burt EC, 2000, BRIT J CANCER, V83, P467, DOI 10.1054/bjoc.2000.1292; Capovilla A, 1997, BIOCHEM BIOPH RES CO, V232, P255, DOI 10.1006/bbrc.1997.6269; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 2003, ONCOGENE, V22, P7557, DOI 10.1038/sj.onc.1207120; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Fujioka S, 2004, J BIOL CHEM, V279, P27549, DOI 10.1074/jbc.M313435200; Groisman IJ, 1999, CARCINOGENESIS, V20, P479, DOI 10.1093/carcin/20.3.479; HARVEY M, 1993, ONCOGENE, V8, P2457; He ZM, 2000, CANCER RES, V60, P1845; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Honma M, 2000, MOL CARCINOGEN, V28, P203, DOI 10.1002/1098-2744(200008)28:4<203::AID-MC3>3.0.CO;2-1; HUEN DS, 1995, ONCOGENE, V10, P549; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li HP, 2003, J BIOMED SCI, V10, P490, DOI 10.1159/000072376; Lin CS, 2000, J MOL BIOL, V303, P7, DOI 10.1006/jmbi.2000.4121; Liu MT, 2004, ONCOGENE, V23, P2531, DOI 10.1038/sj.onc.1207375; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; OKAN I, 1995, ONCOGENE, V11, P1027; Overholtzer M, 2003, P NATL ACAD SCI USA, V100, P11547, DOI 10.1073/pnas.1934852100; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Ravi R, 1998, CANCER RES, V58, P4531; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2002, MUTAGENESIS, V17, P149, DOI 10.1093/mutage/17.2.149; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yang XH, 2000, ONCOGENE, V19, P2002, DOI 10.1038/sj.onc.1203515; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; Zhou MX, 2003, ONCOGENE, V22, P8137, DOI 10.1038/sj.onc.1206911; Zurer I, 2004, CARCINOGENESIS, V25, P11, DOI 10.1093/carcin/bgg186	66	43	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2635	2646		10.1038/sj.onc.1208319	http://dx.doi.org/10.1038/sj.onc.1208319			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829976				2022-12-25	WOS:000228356700005
J	Hafizi, S; Ibraimi, F; Dahlback, B				Hafizi, S; Ibraimi, F; Dahlback, B			C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration	FASEB JOURNAL			English	Article						Ax1; phosphatase; receptor tyrosine kinase; tensin	PROTEIN-TYROSINE PHOSPHATASES; LIPID 2ND-MESSENGER; TUMOR-SUPPRESSOR; C1 DOMAIN; KINASE; PTEN; TENSIN; DEPHOSPHORYLATES; GROWTH; JNK	We have previously identified C1 domain-containing phosphatase and TENsin homologue (C1-TEN) as being an intracellular binding partner for Axl receptor tyrosine kinase (RTK). C1-TEN is a tensin-related protein that houses an N-terminal region with predicted structural similarity to PTEN. Here, we report our observations on the effects of ectopic expression of C1-TEN in HEK293 cells, which resulted in profound molecular and phenotypic changes. Stable expression of C1-TEN altered cellular morphology, with less cell spreading and weaker filamentous actin staining. Cells overexpressing C1-TEN were inhibited greatly in their proliferation and migration rates as compared with mock-transfected cells. Furthermore, serum starvation-induced apoptosis caused a twofold increase in caspase 3 activity in C1-TEN-overexpressing cells vs. mock cells. In addition, C1-TEN-overexpressing cells showed a markedly reduced phosphorylation of Akt/PKB kinase and its substrate GSK3, as well as reduced Akt enzymatic activity. No such effects on JNK were observed. Also, serum-stimulated activation of Akt was delayed in C1-TEN-overexpressing cells, while no difference in profile of ERK activation was observed. Furthermore, cells expressing a C1-TEN mutant where the putative phosphatase active site cysteine at position 231 was substituted for a serine displayed full restoration of both cell proliferation and Akt activation. In conclusion, C1-TEN appears to be a novel intracellular phosphatase that negatively regulates the Akt/PKB signaling cascade, and is similar to its relative PTEN in this respect. However, the particular domain organization of C1-TEN may enable it to regulate RTK and other signaling complexes that are linked to Akt/PKB signaling in a unique manner.	Lund Univ, Malmo Univ Hosp, Wallenberg Lab, Sect Clin Chem,Dept Lab Med, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Hafizi, S (corresponding author), Lund Univ, Malmo Univ Hosp, Wallenberg Lab, Sect Clin Chem,Dept Lab Med, SE-20502 Malmo, Sweden.	sassan.hafizi@med.lu.se	Hafizi, Sassan/W-4424-2019	Hafizi, Sassan/0000-0002-4539-0888; Dahlback, Bjorn/0000-0003-1546-0328				Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Chen HY, 2000, BIOCHEM J, V351, P403, DOI 10.1042/0264-6021:3510403; Chen HY, 2002, P NATL ACAD SCI USA, V99, P733, DOI 10.1073/pnas.022518699; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Goruppi S, 1999, ONCOGENE, V18, P4224, DOI 10.1038/sj.onc.1202788; Hafizi S, 2002, BIOCHEM BIOPH RES CO, V299, P793, DOI 10.1016/S0006-291X(02)02718-3; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Katz BZ, 2000, BIOCHEM BIOPH RES CO, V272, P717, DOI 10.1006/bbrc.2000.2853; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Stenhoff J, 2004, BIOCHEM BIOPH RES CO, V319, P871, DOI 10.1016/j.bbrc.2004.05.070; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4	23	75	78	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					971	+		10.1096/fj.04-2532fje	http://dx.doi.org/10.1096/fj.04-2532fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15817639				2022-12-25	WOS:000228865300022
J	Hoshino, M; Yoshimori, T; Nakamura, S				Hoshino, M; Yoshimori, T; Nakamura, S			Small GTPase proteins Rin and Rit bind to PAR6 GTP-dependently and regulate cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; EPITHELIAL TIGHT; KINASE-C; POLARITY; RAS; COMPLEX; CALMODULIN; JUNCTIONS; EFFECTOR; CDC42	The novel small GTPases Rin and Rit are close relatives of Ras, and recent studies show that they play a role in mediating neuronal differentiation. However, the direct effectors of Rin and Rit have yet to be fully characterized. Here we showed that Rin and Rit directly bind to the PDZ domain of PAR6, a cell polarity-regulating protein, in a GTP-dependent manner both in vivo and in vitro. Moreover, Rin and Rit can form a ternary complex consisting of PAR6 and Rac/Cdc42, members of the Rho family of small GTPases modulating cell growth and polarity. This ternary complex synergistically potentiates cell transformation in NIH3T3 cells, and the interaction between Rin/Rit and the PDZ domain of PAR6 is important for this effect. These results suggest that the Rin/Rit-PAR6-Rac/Cdc42 ternary complex may work physiologically in the cells, such as in tumorigenesis.	Natl Inst Neurosci, Dept Biochem & Cellular Biol, Natl Ctr Neurol & Psychiat, Tokyo 1878502, Japan; Natl Inst Genet, Dept Cell Genet, Shizuoka, Japan	National Center for Neurology & Psychiatry - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Hoshino, M (corresponding author), Natl Inst Neurosci, Dept Biochem & Cellular Biol, Natl Ctr Neurol & Psychiat, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.	hoshinom@ncnp.go.jp						Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Ehrhardt GRA, 2001, ONCOGENE, V20, P188, DOI 10.1038/sj.onc.1204053; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Gotta M, 2001, CURR BIOL, V11, P482, DOI 10.1016/S0960-9822(01)00142-7; Henrique D, 2003, CURR OPIN GENET DEV, V13, P341, DOI 10.1016/S0959-437X(03)00077-7; Hirose T, 2002, J CELL SCI, V115, P2485; Hoshino M, 2003, J CELL BIOL, V163, P1067, DOI 10.1083/jcb.200308070; Hoshino M, 2002, BIOCHEM BIOPH RES CO, V295, P651, DOI 10.1016/S0006-291X(02)00731-3; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kay AJ, 2001, CURR BIOL, V11, P474, DOI 10.1016/S0960-9822(01)00141-5; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Shao HP, 2000, J BIOL CHEM, V275, P26914; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Spencer ML, 2002, J BIOL CHEM, V277, P20160, DOI 10.1074/jbc.M201092200; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x	26	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22868	22874		10.1074/jbc.M411592200	http://dx.doi.org/10.1074/jbc.M411592200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15831491	hybrid			2022-12-25	WOS:000229741800039
J	Benetti, R; Copetti, T; Dell'Orso, S; Melloni, E; Brancolini, C; Monte, M; Schneider, C				Benetti, R; Copetti, T; Dell'Orso, S; Melloni, E; Brancolini, C; Monte, M; Schneider, C			The calpain system is involved in the constitutive regulation of beta-catenin signaling functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; E-CADHERIN; TRANSCRIPTIONAL ACTIVATION; TUMOR PROGRESSION; EPITHELIAL-CELLS; PROTEIN; DROSOPHILA; GROWTH; DEGRADATION; PROSTATE	beta-Catenin is a multifunctional protein serving both as a structural element in cell adhesion and as a signaling component in the Wnt pathway, regulating embryogenesis and tumorigenesis. The signaling fraction of beta-catenin is tightly controlled by the adenomatous polyposis coli-axin-glycogen synthase kinase 3 beta complex, which targets it for proteasomal degradation. It has been recently shown that Ca2(+) release from internal stores results in nuclear export and calpain-mediated degradation of beta-catenin in the cytoplasm. Here we have highlighted the critical relevance of constitutive calpain pathway in the control of beta-catenin levels and functions, showing that small interference RNA knock down of endogenous calpain per se (i.e. in the absence of external stimuli) induces an increase in the free transcriptional competent pool of endogenous beta-catenin. We further characterized the role of the known calpain inhibitors, Gas2 and Calpastatin, demonstrating that they can also control levels, function, and localization of beta-catenin through endogenous calpain regulation. Finally we present Gas2 dominant negative (Gas2DN) as a new tool for regulating calpain activity, providing evidence that it counteracts the described effects of both Gas2 and Calpastatin on beta-catenin and that it works via calpain independently of the classical glycogen synthase kinase 3 beta and proteasome pathway. Moreover, we provide in vitro biochemical evidence showing that Gas2DN can increase the activity of calpain and that in vivo it can induce degradation of stabilized/mutated beta-catenin. In fact, in a context where the classical proteasome pathway is impaired, as in colon cancer cells, Gas2DN biological effects accounted for a significant reduction in proliferation and anchorage-independent growth of colon cancer.	Lab Nazl Consorzio Interuniv Biotecnol, I-34012 Trieste, Italy; Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	University of Genoa; University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Schneider, C (corresponding author), Lab Nazl Consorzio Interuniv Biotecnol, Area Sci Pk,Padriciano 99, I-34012 Trieste, Italy.	schneide@lncib.it		Monte, Martin/0000-0002-5068-563X; Dell'Orso, Stefania/0000-0002-1634-5631; BRANCOLINI, Claudio/0000-0002-6597-5373; BENETTI, Roberta/0000-0001-8863-0821				Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Franco S, 2004, EXP CELL RES, V299, P179, DOI 10.1016/j.yexcr.2004.05.021; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gonzalez-Reyes A, 2003, J CELL SCI, V116, P949, DOI 10.1242/jcs.00310; Goriounov D, 2003, J CELL SCI, V116, P1045, DOI 10.1242/jcs.00272; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hegde P, 2001, CANCER RES, V61, P7792; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li G, 2002, P NATL ACAD SCI USA, V99, P13254, DOI 10.1073/pnas.202355799; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Melloni E, 2000, J BIOL CHEM, V275, P82, DOI 10.1074/jbc.275.1.82; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Oving IM, 2002, EUR J CLIN INVEST, V32, P448, DOI 10.1046/j.1365-2362.2002.01004.x; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Polakis P, 2000, GENE DEV, V14, P1837; Rios-Doria J, 2005, PROSTATE, V63, P259, DOI 10.1002/pros.20179; Rios-Doria J, 2004, CANCER RES, V64, P7237, DOI 10.1158/0008-5472.CAN-04-1048; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Santella L, 1998, CELL CALCIUM, V23, P123, DOI 10.1016/S0143-4160(98)90110-5; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	42	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22070	22080		10.1074/jbc.M501810200	http://dx.doi.org/10.1074/jbc.M501810200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817486	hybrid			2022-12-25	WOS:000229557900051
J	Felice, MR; De Domenico, I; Li, LT; Ward, DM; Bartok, B; Musci, G; Kaplan, J				Felice, MR; De Domenico, I; Li, LT; Ward, DM; Bartok, B; Musci, G; Kaplan, J			Post-transcriptional regulation of the yeast high affinity iron transport system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICOPPER OXIDASE FET3P; FLUID-PHASE ENDOCYTOSIS; ZRT1 ZINC TRANSPORTER; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; GENE ENCODES; PERMEASE; UBIQUITIN; PROTEIN; EXPRESSION	Saccharomyces cerevisiae transcriptionally regulates the expression of the plasma membrane high affinity iron transport system in response to iron need. This transport system is comprised of the products of the FET3 and FTR1 genes. We show that Fet3p and Ftr1p are post-translationally regulated by iron. Incubation of cells in high iron leads to the internalization and degradation of both Fet3p and Ftr1p. Yeast strains defective in endocytosis (Delta end4) show a reduced iron-induced loss of Fet3p-Ftr1p. In cells with a deletion in the vacuolar protease PEP4, high iron medium leads to the accumulation of Fet3p and Ftr1p in the vacuole. Iron-induced degradation of Fet3p-Ftr1p is significantly reduced in strains containing a deletion of a gene, VTA1, which is involved in multivesicular body ( MVB) sorting in yeast. Sorting through the MVB can involve ubiquitination. We demonstrate that Ftr1p is ubiquitinated, whereas Fet3p is not ubiquitinated. Iron-induced internalization and degradation of Fet3p-Ftr1p occurs in a mutant strain of the E3 ubiquitin ligase RSP5 (rsp5-1), suggesting that Rsp5p is not required. Internalization of Fet3p-Ftr1p is specific for iron and requires both an active Fet3p and Ftr1p, indicating that it is the transport of iron through the iron permease Ftr1p that is responsible for the internalization and degradation of the Fet3p-Ftr1p complex.	Univ Utah, Sch Med, Dept Pathol, Div Immunol & Cell Biol, Salt Lake City, UT 84132 USA; Univ Messina, Dipartimento Sci Microbiol Genet & Mol, I-98166 Messina, Italy	Utah System of Higher Education; University of Utah; University of Messina	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Div Immunol & Cell Biol, 50 N Med Dr, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu	Musci, Giovanni/H-2862-2012	Musci, Giovanni/0000-0002-5196-709X; felice, maria rosa/0000-0002-4224-2345	NCI NIH HHS [CA 43014] Funding Source: Medline; NIDDK NIH HHS [DK 30534] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030534, R01DK030534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Askwith CC, 1998, J BIOL CHEM, V273, P22415, DOI 10.1074/jbc.273.35.22415; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; Chen OS, 2002, P NATL ACAD SCI USA, V99, P16922, DOI 10.1073/pnas.232392299; Davis-Kaplan SR, 2004, J BIOL CHEM, V279, P4322, DOI 10.1074/jbc.M310680200; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; Dunn R, 2001, MOL BIOL CELL, V12, P421, DOI 10.1091/mbc.12.2.421; EIDE D, 1992, J BIOL CHEM, V267, P20774; Gaxiola RA, 1998, P NATL ACAD SCI USA, V95, P4046, DOI 10.1073/pnas.95.7.4046; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; Harris ZL, 2004, BLOOD, V103, P4672, DOI 10.1182/blood-2003-11-4060; Hassett RF, 1998, J BIOL CHEM, V273, P23274, DOI 10.1074/jbc.273.36.23274; Hettema EH, 2004, EMBO J, V23, P1279, DOI 10.1038/sj.emboj.7600137; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kosman DJ, 2003, MOL MICROBIOL, V47, P1185, DOI 10.1046/j.1365-2958.2003.03368.x; LESUISSE E, 1991, BIOCHEM J, V280, P545, DOI 10.1042/bj2800545; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Liu XF, 1999, J BIOL CHEM, V274, P4863, DOI 10.1074/jbc.274.8.4863; Mason PB, 2003, MOL CELL BIOL, V23, P8323, DOI 10.1128/MCB.23.22.8323-8333.2003; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Severance S, 2004, BIOCHEM J, V380, P487, DOI 10.1042/BJ20031921; Shiflett SL, 2004, J BIOL CHEM, V279, P10982, DOI 10.1074/jbc.M312669200; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Spizzo T, 1997, MOL GEN GENET, V256, P547; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yeo SCL, 2003, J CELL SCI, V116, P3957, DOI 10.1242/jcs.00751; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709	38	84	85	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22181	22190		10.1074/jbc.M414663200	http://dx.doi.org/10.1074/jbc.M414663200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817488	hybrid			2022-12-25	WOS:000229557900063
J	Kim, SJ; Winter, K; Nian, C; Tsuneoka, M; Koda, Y; McIntosh, CHS				Kim, SJ; Winter, K; Nian, C; Tsuneoka, M; Koda, Y; McIntosh, CHS			Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; APOPTOSIS; PHOSPHORYLATION; ACTIVATION; MECHANISMS; CASPASE-9; AKTION; FAMILY; GROWTH	The hormone glucose-dependent insulinotropic polypeptide ( GIP) potently stimulates insulin secretion and promotes beta-cell proliferation and cell survival. In the present study we identified Forkhead (Foxo1)-mediated suppression of the bax gene as a critical component of the effects of GIP on cell survival. Treatment of INS-1( 832/13) beta-cells with GIP resulted in concentration-dependent activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB)/Foxo1 signaling module. In parallel studies, GIP decreased bax promoter activity. Serial deletion analysis of the bax promoter demonstrated that the region -682 to -320, containing FHRE-II (5AAAACAAACA), was responsible for GIP-mediated effects. Foxo1 bound to FHRE-II in gel mobility shift assays, and Foxo1-FHRE-II interactions conferred GIP responsiveness to the bax promoter. INS-1 cells incubated under proapoptotic and glucolipotoxic conditions demonstrated increased nuclear localization of Foxo1 and bax promoter activity and decreased cytoplasmic phospho-PKB/Foxo1. GIP partially restored expression PKB/Foxo1 and bax promoter activity. Similar protective effects were found with dispersed islet cells from C57BL/6 mice, but not with those from GIP receptor knock-out (GIPR(-/-)) mice. GIP treatment reduced glucolipotoxicity-induced cell death in C57 BL/6 and Bax(-/-) islets, but not GIPR(-/-) mouse islets. Chronic treatment of Vancouver diabetic fatty Zucker rats with GIP resulted in down-regulation of Bax and up-regulation of Bcl-2 in pancreatic beta-cells. The results show that PI3K/PKB/Foxo1 signaling mediates GIP suppression of bax gene expression and that this module is a key pathway by which GIP regulates beta-cell apoptosis in vivo.	Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada; Kurume Univ, Sch Med, Dept Forens Med, Div Human Genet, Kurume, Fukuoka 8300011, Japan	University of British Columbia; Kurume University	McIntosh, CHS (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintoch@interchange.ubc.ca	Koda, Yoshiro/AAY-6902-2020	Koda, Yoshiro/0000-0003-1368-0116				Accili D, 2004, DIABETES, V53, P1633, DOI 10.2337/diabetes.53.7.1633; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Arden KC, 2002, ARCH BIOCHEM BIOPHYS, V403, P292, DOI 10.1016/S0003-9861(02)00207-2; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheung PY, 2004, J BIOL CHEM, V279, P45308, DOI 10.1074/jbc.C400333200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dockray JH., 1994, GUT PEPTIDES BIOCH P, P217; Drucker DJ, 2003, MOL ENDOCRINOL, V17, P161, DOI 10.1210/me.2002-0306; Ehses JA, 2003, ENDOCRINOLOGY, V144, P4433, DOI 10.1210/en.2002-0068; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Farilla L, 2002, ENDOCRINOLOGY, V143, P4397, DOI 10.1210/en.2002-220405; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Hui HX, 2004, J CELL PHYSIOL, V200, P177, DOI 10.1002/jcp.20021; Kaestner KH, 2000, GENE DEV, V14, P142; Kharroubi I, 2004, ENDOCRINOLOGY, V145, P5087, DOI 10.1210/en.2004-0478; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; Kilic M, 2002, CELL DEATH DIFFER, V9, P125, DOI 10.1038/sj/cdd/4400968; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; Maestre I, 2003, ENDOCRINOLOGY, V144, P335, DOI 10.1210/en.2001-211282; Miyawaki K, 1999, P NATL ACAD SCI USA, V96, P14843, DOI 10.1073/pnas.96.26.14843; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Prentki M, 2002, DIABETES, V51, pS405, DOI 10.2337/diabetes.51.2007.S405; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Schamberger CJ, 2005, EXP CELL RES, V302, P115, DOI 10.1016/j.yexcr.2004.08.026; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Trumper A, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740233; Trumper A, 2001, MOL ENDOCRINOL, V15, P1559, DOI 10.1210/me.15.9.1559; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; Unger RH, 2001, DIABETES, V50, pS118, DOI 10.2337/diabetes.50.2007.S118; Webster KA, 2004, CIRC RES, V94, P856, DOI 10.1161/01.RES.0000126699.49835.5D; Winter KD, 2004, DIABETES, V53, pA447; Yamauchi J, 2001, J BIOL CHEM, V276, P23362, DOI 10.1074/jbc.M011752200	41	188	201	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22297	22307		10.1074/jbc.M500540200	http://dx.doi.org/10.1074/jbc.M500540200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817464	hybrid			2022-12-25	WOS:000229557900075
J	Langer, I; Tikhonova, IG; Travers, MA; Archer-Lahlou, E; Escrieut, C; Maigret, B; Fourmy, D				Langer, I; Tikhonova, IG; Travers, MA; Archer-Lahlou, E; Escrieut, C; Maigret, B; Fourmy, D			Evidence that interspecies polymorphism in the human and rat cholecystokinin receptor-2 affects structure of the binding site for the endogenous agonist cholecystokinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B GASTRIN RECEPTOR; PENULTIMATE ASPARTIC-ACID; SINGLE AMINO-ACID; C-TERMINAL AMIDE; A RECEPTOR; DIRECTED MUTAGENESIS; FUNCTIONAL EXPRESSION; TRANSMEMBRANE DOMAINS; NONPEPTIDE AGONISTS; EXTRACELLULAR LOOP	The cholecystokinin (CCK) receptor-2 exerts very important central and peripheral functions by binding the neuropeptides cholecystokinin or gastrin. Because this receptor is a potential therapeutic target, great interest has been devoted to the identification of efficient antagonists. However, interspecies genetic polymorphism that does not alter cholecystokinin-induced signaling was shown to markedly affect activity of synthetic ligands. In this context, precise structural study of the agonist binding site on the human cholecystokinin receptor-2 is a prerequisite to elucidating the molecular basis for its activation and to optimizing properties of synthetic ligands. In this study, using site-directed mutagenesis and molecular modeling, we delineated the binding site for CCK on the human cholecystokinin receptor-2 by mutating amino acids corresponding to that of the rat homolog. By doing so, we demonstrated that, although resembling that of rat homolog, the human cholecystokinin receptor-2 binding site also displays important distinct structural features that were demonstrated by susceptibility to several point mutations (F120A, Y189A, H207A). Furthermore, docking of CCK in the human and rat cholecystokinin receptor-2, followed by dynamic simulations, allowed us to propose a plausible structural explanation of the experimentally observed difference between rat and human cholecystokinin-2 receptors.	CHU Rangueil, Inst Louis Bugnard, INSERM, F-31432 Toulouse, France; Univ Nancy, Chim Theor Lab, F-54506 Vandoeuvre Les Nancy, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Fourmy, D (corresponding author), Univ Libre Bruxelles, Fac Med, Chim Biol Lab, 808 Route Lennik, F-31432 Toulouse, France.	fourmyd@toulouse.inserm.fr	Fourmy, Daniel/AAE-3703-2019	Fourmy, Daniel/0000-0001-9910-4827; Travers, Marie-Agnes/0000-0001-5340-7435				Anders J, 1999, BIOCHEMISTRY-US, V38, P6043, DOI 10.1021/bi990269z; Archer-Lahlou E, 2005, J BIOL CHEM, V280, P10664, DOI 10.1074/jbc.M409451200; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; Blaker M, 1998, MOL PHARMACOL, V54, P857, DOI 10.1124/mol.54.5.857; CASCIERI MA, 1992, MOL PHARMACOL, V41, P1096; DEWEERTH A, 1993, BIOCHEM BIOPH RES CO, V194, P811, DOI 10.1006/bbrc.1993.1894; Escrieut C, 2002, J BIOL CHEM, V277, P7546, DOI 10.1074/jbc.M108563200; FONG TM, 1992, J BIOL CHEM, V267, P25668; FOURMY D, 1989, EUR J BIOCHEM, V185, P397, DOI 10.1111/j.1432-1033.1989.tb15128.x; Gales C, 2003, MOL PHARMACOL, V63, P973, DOI 10.1124/mol.63.5.973; Gigoux V, 1999, PROTEIN SCI, V8, P2347; Gigoux V, 1998, J BIOL CHEM, V273, P14380, DOI 10.1074/jbc.273.23.14380; Gigoux V, 1999, J BIOL CHEM, V274, P20457, DOI 10.1074/jbc.274.29.20457; Giragossian C, 2002, BIOCHEMISTRY-US, V41, P4560, DOI 10.1021/bi0160009; Herranz R, 2003, MED RES REV, V23, P559, DOI 10.1002/med.10042; Jagerschmidt A, 1996, EUR J PHARMACOL, V296, P97, DOI 10.1016/0014-2999(95)00676-1; Jagerschmidt A, 1998, MOL PHARMACOL, V53, P878; Kopin AS, 2000, TRENDS PHARMACOL SCI, V21, P346, DOI 10.1016/S0165-6147(00)01526-1; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; Kopin AS, 2003, P NATL ACAD SCI USA, V100, P5525, DOI 10.1073/pnas.0831223100; Kopin AS, 1997, P NATL ACAD SCI USA, V94, P11043, DOI 10.1073/pnas.94.20.11043; LEE YM, 1993, J BIOL CHEM, V268, P8164; MORODER L, 1981, H-S Z PHYSIOL CHEM, V362, P929, DOI 10.1515/bchm2.1981.362.2.929; Noble F, 1999, PHARMACOL REV, V51, P745; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; Pommier B, 2003, J NEUROCHEM, V85, P454, DOI 10.1046/j.1471-4159.2003.01690.x; Silvente-Poirot S, 1999, J BIOL CHEM, V274, P23191, DOI 10.1074/jbc.274.33.23191; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V215, P513, DOI 10.1111/j.1432-1033.1993.tb18061.x; VIGUERA AR, 1995, BIOCHEMISTRY-US, V34, P8771, DOI 10.1021/bi00027a028; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691	31	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22198	22204		10.1074/jbc.M501786200	http://dx.doi.org/10.1074/jbc.M501786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817487	Green Published, hybrid			2022-12-25	WOS:000229557900065
J	Baris, O; Mirebeau-Prunier, D; Savagner, F; Rodien, P; Ballester, B; Loriod, B; Granjeaud, S; Guyetant, S; Franc, B; Houlgatte, R; Reynier, P; Malthiery, Y				Baris, O; Mirebeau-Prunier, D; Savagner, F; Rodien, P; Ballester, B; Loriod, B; Granjeaud, S; Guyetant, S; Franc, B; Houlgatte, R; Reynier, P; Malthiery, Y			Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma	ONCOGENE			English	Article						carcinoma; thyroid; mitochondria	CYTOCHROME-C-OXIDASE; NITRIC-OXIDE; EXPRESSION; CANCER; CELL; PATHOGENESIS; TUMOR	The oncogenic pathways in mitochondrial-rich thyroid carcinomas are not clearly understood. To investigate the possible implication of mitochondrial abundance in the genesis of thyroid tumors, we have explored the gene expression profile of six oncocytic carcinomas and six mitochondrial-rich papillary carcinomas using cDNA-microarray technology. A supervised approach allowed us to identify 83 genes differentially expressed in the two types of carcinoma. These genes were classified according to their ontologic profiles. Three genes, NOS3, alphaactinin-2 and alpha-catenin, suspected of playing a role in tumor genesis, were explored by quantitative RT - PCR analysis and immunohistochemistry. Of the 59 genes overexpressed in papillary carcinomas, 51% were involved in cell communication. Of the 24 genes overexpressed in oncocytic carcinomas, 84% were involved in mitochondrial and cellular metabolism. Our results suggest that mitochondrial respiratory chain complexes III and IV play a significant role in the regulation of reactive oxygen species production by oncocytic tumors.	CHU Angers, Lab Biochim & Biol Mol, INSERM EMI U 0018, F-49033 Angers, France; CHU Angers, Serv Endocrinol Nutr & Med Interne, F-49033 Angers, France; INSERM ERM 206, Lab TAGC, F-13009 Marseille, France; CHRU, Anat Pathol Lab, F-37044 Tours, France; Hop Ambroise Pare, Anat Pathol Lab, F-92104 Boulogne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; CHU Tours; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Baris, O (corresponding author), CHU Angers, Lab Biochim & Biol Mol, INSERM EMI U 0018, 4 Rue Larrey, F-49033 Angers, France.	olivier.baris@med.univ-angers.fr	Rodien, Patrice/AAT-7909-2021; loriod, beatrice bl/L-2948-2016; Prunier, Delphine/K-3301-2015; Houlgatte, Remi/P-3020-2017; Granjeaud, Samuel/AAE-6488-2022; Baris, Olivier R/L-3463-2016; Reynier, Pascal/K-3677-2015; Ballester, Benoit/N-6127-2016	loriod, beatrice bl/0000-0001-5801-2264; Granjeaud, Samuel/0000-0001-9245-1535; Baris, Olivier R/0000-0003-0974-6856; Ballester, Benoit/0000-0002-0834-7135; Reynier, Pascal/0000-0003-0802-4608				Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Augenlicht LH, 1999, ANN NY ACAD SCI, V889, P20, DOI 10.1111/j.1749-6632.1999.tb08720.x; Baris O, 2004, J CLIN ENDOCR METAB, V89, P994, DOI 10.1210/jc.2003-031238; CAMIEL MR, 1968, NEW ENGL J MED, V279, P326; Cheung CC, 2000, AM J SURG PATHOL, V24, P1622, DOI 10.1097/00000478-200012000-00005; Chua EL, 2000, GENOMICS, V69, P342, DOI 10.1006/geno.2000.6348; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; EBNER D, 1991, VIRCHOWS ARCH B, V60, P139, DOI 10.1007/BF02899539; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Haugen DRF, 2003, THYROID, V13, P613; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Ishigaki K, 2002, J CLIN ENDOCR METAB, V87, P3433, DOI 10.1210/jc.87.7.3433; Kim JY, 2002, ACTA CYTOL, V46, P679, DOI 10.1159/000326975; Kimura ET, 2003, CANCER RES, V63, P1454; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Maeta H, 2001, VIRCHOWS ARCH, V438, P121, DOI 10.1007/s004280000286; Magrangeas F, 2003, BLOOD, V101, P4998, DOI 10.1182/blood-2002-11-3385; Moretti F, 2000, BEST PRACT RES CL EN, V14, P517, DOI 10.1053/beem.2000.0101; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Papa S, 1997, BIOSCIENCE REP, V17, P23, DOI 10.1023/A:1027331116866; Savagner F, 2001, J CLIN ENDOCR METAB, V86, P4920, DOI 10.1210/jc.86.10.4920; Savagner F, 2001, THYROID, V11, P327, DOI 10.1089/10507250152039055; Savagner F, 2003, BIOCHEM BIOPH RES CO, V310, P779, DOI 10.1016/j.bbrc.2003.09.076; Thieblemont C, 2004, BLOOD, V103, P2727, DOI 10.1182/blood-2003-06-2160	29	36	39	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 9	2005	24	25					4155	4161		10.1038/sj.onc.1208578	http://dx.doi.org/10.1038/sj.onc.1208578			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806164				2022-12-25	WOS:000229680300014
J	Chen, LN; Cagniard, B; Mathews, T; Jones, S; Koh, HC; Ding, YM; Carvey, PM; Ling, ZD; Kang, UJ; Zhuang, XX				Chen, LN; Cagniard, B; Mathews, T; Jones, S; Koh, HC; Ding, YM; Carvey, PM; Ling, ZD; Kang, UJ; Zhuang, XX			Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL PARKINSONS-DISEASE; CRYSTAL-STRUCTURE; ANTIOXIDATIVE STRESS; ANDROGEN RECEPTOR; ALPHA-SYNUCLEIN; PROTEIN; ONSET; MUTATIONS; TRANSPORTER; EXPRESSION	Mutations in the DJ-1 gene were recently identified in an autosomal recessive form of early-onset familial Parkinson disease. Structural biology, biochemistry, and cell biology studies have suggested potential functions of DJ-1 in oxidative stress, protein folding, and degradation pathways. However, animal models are needed to determine whether and how loss of DJ-1 function leads to Parkinson disease. We have generated DJ-1 null mice with a mutation that resembles the large deletion mutation reported in patients. Our behavioral analyses indicated that DJ-1 deficiency led to age-dependent and task-dependent motoric behavioral deficits that are detectable by 5 months of age. Unbiased stereological studies did not find obvious dopamine neuron loss in 6-month-and 11-month-old mice. Neurochemical examination revealed significant changes in striatal dopaminergic function consisting of increased dopamine reuptake rates and elevated tissue dopamine content. These data represent the in vivo evidence that loss of DJ-1 function alters nigrostriatal dopaminergic function and produces motor deficits.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; Rush Univ, Ctr Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Chicago; Wake Forest University; University of Chicago; Rush University	Zhuang, XX (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 924 E 57th St, Chicago, IL 60637 USA.	xzhuang@bsd.uchicago.edu	Jones, Sara R/K-4816-2014; Kang, Un/AAV-2858-2020	Jones, Sara R/0000-0002-3424-7576; Kang, Un/0000-0002-5970-6839; Chen, Lie/0000-0001-9764-4299; Macdonald, Stephen/0000-0001-6306-8035	NIAAA NIH HHS [AA014091] Funding Source: Medline; NINDS NIH HHS [NS32080] Funding Source: Medline; PHS HHS [MS43286] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032080, R01NS032080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [U01AA014091] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abou-Sleiman PM, 2003, ANN NEUROL, V54, P283, DOI 10.1002/ana.10675; Bandopadhyay R, 2004, BRAIN, V127, P420, DOI 10.1093/brain/awh054; BARNEOUD P, 1995, NEUROSCIENCE, V67, P837, DOI 10.1016/0306-4522(95)00112-V; Barzilai A, 2000, ADV RES NEURODEGENER, V8, P59; Ben-Shachar D, 2004, BIOCHEM PHARMACOL, V67, P1965, DOI 10.1016/j.bcp.2004.02.015; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Braak H, 2000, J NEUROL, V247, P3; Budygin EA, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0002.2002; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Carneiro AM, 2002, J NEUROSCI, V22, P7045; Carter RJ, 1999, J NEUROSCI, V19, P3248; Chang JW, 1999, NEUROSCIENCE, V88, P617, DOI 10.1016/S0306-4522(98)00217-6; Dekker MCJ, 2004, J NEURAL TRANSM, V111, P1575, DOI 10.1007/s00702-004-0165-4; Fleming SM, 2004, J NEUROSCI, V24, P9434, DOI 10.1523/JNEUROSCI.3080-04.2004; Gainetdinov RR, 1997, J NEUROCHEM, V69, P1322; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Gorner K, 2004, J BIOL CHEM, V279, P6943, DOI 10.1074/jbc.M309204200; Hague S, 2003, ANN NEUROL, V54, P271, DOI 10.1002/ana.10663; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; Hedrich K, 2004, NEUROLOGY, V62, P389, DOI 10.1212/01.WNL.0000113022.51739.88; Hering R, 2004, HUM MUTAT, V24, P321, DOI 10.1002/humu.20089; Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8; Honbou K, 2003, J BIOL CHEM, V278, P31380, DOI 10.1074/jbc.M305878200; Huai Q, 2003, FEBS LETT, V549, P171, DOI 10.1016/S0014-5793(03)00764-6; Jankovic J, 2000, ARCH NEUROL-CHICAGO, V57, P369, DOI 10.1001/archneur.57.3.369; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Lee SJ, 2003, J BIOL CHEM, V278, P44552, DOI 10.1074/jbc.M304517200; Lotharius J, 2000, J BIOL CHEM, V275, P38581, DOI 10.1074/jbc.M005385200; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; MANETTO V, 1988, P NATL ACAD SCI USA, V85, P4501, DOI 10.1073/pnas.85.12.4501; Martinat C, 2004, PLOS BIOL, V2, P1754, DOI 10.1371/journal.pbio.0020327; Mazzola JL, 2002, NEUROTOXICOLOGY, V23, P603, DOI 10.1016/S0161-813X(02)00062-1; McLaughlin BA, 1998, J NEUROCHEM, V70, P2406; Miller DW, 2003, J BIOL CHEM, V278, P36588, DOI 10.1074/jbc.M304272200; Mitsumoto A, 2001, FREE RADICAL RES, V35, P885, DOI 10.1080/10715760100301381; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Moore DJ, 2003, J NEUROCHEM, V87, P1558, DOI 10.1111/j.1471-4159.2003.02265.x; Mouton P.R., 2001, PRINCIPLES PRACTICES; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Niki T, 2003, MOL CANCER RES, V1, P247; Nolan MF, 2003, CELL, V115, P551, DOI 10.1016/S0092-8674(03)00884-5; Okada M, 2002, BIOL PHARM BULL, V25, P853, DOI 10.1248/bpb.25.853; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Phillips PEM, 2003, BRAIN RES, V961, P63, DOI 10.1016/S0006-8993(02)03840-4; Sasaki S, 2004, NEUROLOGY, V63, P678, DOI 10.1212/01.WNL.0000134657.25904.0B; Shang H, 2004, NEUROSCI LETT, V367, P273, DOI 10.1016/j.neulet.2004.06.002; Shendelman S, 2004, PLOS BIOL, V2, P1764, DOI 10.1371/journal.pbio.0020362; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Stokes AH, 2000, BRAIN RES, V858, P1, DOI 10.1016/S0006-8993(99)02329-X; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Takahashi-Niki K, 2004, BIOCHEM BIOPH RES CO, V320, P389, DOI 10.1016/j.bbrc.2004.05.187; Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200; Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; Wagenfeld A, 2000, J ANDROL, V21, P954; Weydt P, 2003, NEUROREPORT, V14, P1051, DOI 10.1097/01.wnr.0000073685.00308.89; Whishaw IQ, 2002, BEHAV BRAIN RES, V133, P165, DOI 10.1016/S0166-4328(01)00479-X; Wilson MA, 2003, P NATL ACAD SCI USA, V100, P9256, DOI 10.1073/pnas.1133288100; Zhuang XX, 2001, P NATL ACAD SCI USA, V98, P1982, DOI 10.1073/pnas.98.4.1982	66	285	294	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21418	21426		10.1074/jbc.M413955200	http://dx.doi.org/10.1074/jbc.M413955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799973	hybrid			2022-12-25	WOS:000229438800062
J	Nemeria, N; Tittmann, K; Joseph, E; Zhou, L; Vazquez-Coll, MB; Arjunan, P; Hubner, G; Furey, W; Jordan, F				Nemeria, N; Tittmann, K; Joseph, E; Zhou, L; Vazquez-Coll, MB; Arjunan, P; Hubner, G; Furey, W; Jordan, F			Glutamate 636 of the Escherichia coli pyruvate dehydrogenase-E1 participates in active center communication and behaves as an engineered acetolactate synthase with unusual stereoselectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX E1 SUBUNIT; REDUCTIVE ACETYLATION; MULTIENZYME COMPLEX; BENZOYLFORMATE DECARBOXYLASE; ACETOHYDROXYACID SYNTHASE; ANGSTROM RESOLUTION; ACID-BASE; DIPHOSPHATE; ENZYMES; BINDING	The residue Glu(636) is located near the thiamine diphosphate ( ThDP) binding site of the Escherichia coli pyruvate dehydrogenase complex E1 subunit (PDHc-E1), and to probe its function two variants, E636A and E636Q were created with specific activities of 2.5 and 26% compared with parental PDHc-E1. According to both fluorescence binding and kinetic assays, the E636A variant behaved according to half-of-the-sites mechanism with respect to ThDP. In contrast, with the E636Q variant a K-d,K-ThDP = 4.34 mu M and K-m,K- ThDP = 11 mu M were obtained with behavior more reminiscent of the parental enzyme. The CD spectra of both variants gave evidence for formation of the 1', 4'- iminopyrimidine tautomer on binding of phosphonolactylthiamine diphosphate, a stable analog of the substrate-ThDP covalent complex. Rapid formation of optically active (R)- acetolactate by both variants, but not by the parental enzyme, was observed by CD and NMR spectroscopy. The acetolactate configuration produced by the Glu636 variants is opposite that produced by the enzyme acetolactate synthase and the Asp(28)-substituted variants of yeast pyruvate decarboxylase, suggesting that the active centers of the two sets of enzymes exhibit different facial selectivity ( re or si) vis a vis pyruvate. The tryptic peptide map ( mass spectral analysis) revealed that the Glu636 substitution changed the mobility of a loop comprising amino acid residues from the ThDP binding fold. Apparently, the residue Glu636 has important functions both in active center communication and in protecting the active center from undesirable "carboligase" side reactions.	Rutgers State Univ, Dept Chem, Newark, NJ 07102 USA; Univ Halle Wittenberg, D-06099 Halle An Der Saale, Germany; Univ Puerto Rico, Mayaguez, PR 00681 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Vet Affairs Med Ctr, Pittsburgh, PA 15240 USA	Rutgers State University Newark; Rutgers State University New Brunswick; Martin Luther University Halle Wittenberg; University of Puerto Rico; University of Puerto Rico Mayaguez; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Nemeria, N (corresponding author), Rutgers State Univ, Dept Chem, 73 Warren St, Newark, NJ 07102 USA.	nemeria@andromeda.rutgers.edu; frjordan@newark.rutgers.edu			NIGMS NIH HHS [GM-61791, GM-62330] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061791, R01GM062330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI ST, 1990, BIOCHEM J, V271, P39; Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; Arjunan P, 2004, BIOCHEMISTRY-US, V43, P2405, DOI 10.1021/bi030200y; BAGGETTO LG, 1987, J BIOL CHEM, V262, P9535; BERNASCONI CF, 1976, RELAXATION KINETICS, P24; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chipman D, 1998, BBA-PROTEIN STRUCT M, V1385, P401, DOI 10.1016/S0167-4838(98)00083-1; Engel S, 2004, J BIOL CHEM, V279, P24803, DOI 10.1074/jbc.M401667200; Frank RAW, 2004, SCIENCE, V306, P872, DOI 10.1126/science.1101030; Hasson MS, 1998, BIOCHEMISTRY-US, V37, P9918, DOI 10.1021/bi973047e; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; Jordan F, 2003, J AM CHEM SOC, V125, P12732, DOI 10.1021/ja0346126; JORDAN F, 2004, PERSPECT SCI, V306, P818; JUNI E, 1956, J BIOL CHEM, V218, P365; KHAILOVA LS, 1983, BIOCHEM INT, V7, P423; KOIKE M, 1960, J BIOL CHEM, V235, P1924; Nakai T, 2004, J MOL BIOL, V337, P1011, DOI 10.1016/j.jmb.2004.02.011; NEET KE, 1983, CONT ENZYME KINETICS, P267; Nemeria N, 2004, BIOCHEMISTRY-US, V43, P6565, DOI 10.1021/bi049549r; Nemeria N, 2002, BIOCHEMISTRY-US, V41, P15459, DOI 10.1021/bi0205909; Nemeria N, 1998, BIOCHEMISTRY-US, V37, P911, DOI 10.1021/bi9722251; Nemeria N, 2001, J BIOL CHEM, V276, P45969, DOI 10.1074/jbc.M104116200; Park YH, 2004, BIOCHEMISTRY-US, V43, P14037, DOI 10.1021/bi049027b; Polovnikova ES, 2003, BIOCHEMISTRY-US, V42, P1820, DOI 10.1021/bi026490k; Sergienko EA, 2001, BIOCHEMISTRY-US, V40, P7369, DOI 10.1021/bi002856m; SUNDSTROM M, 1992, FEBS LETT, V313, P229, DOI 10.1016/0014-5793(92)81197-T; Tittmann K, 2005, P NATL ACAD SCI USA, V102, P553, DOI 10.1073/pnas.0408210101; Tittmann K, 2003, BIOCHEMISTRY-US, V42, P7885, DOI 10.1021/bi034465o; Tittmann K, 2004, BIOCHEMISTRY-US, V43, P8652, DOI 10.1021/bi049897t; Wei W, 2003, PROTEIN EXPRES PURIF, V28, P140, DOI 10.1016/S1046-5928(02)00674-5; Wu YG, 2000, EUR J BIOCHEM, V267, P6493, DOI 10.1046/j.1432-1327.2000.01744.x; Yi JZ, 1996, J BIOL CHEM, V271, P33192, DOI 10.1074/jbc.271.52.33192	32	29	31	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21473	21482		10.1074/jbc.M502691200	http://dx.doi.org/10.1074/jbc.M502691200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802265	hybrid			2022-12-25	WOS:000229438800068
J	Rose, C; Kresse, W; Kettenmann, H				Rose, C; Kresse, W; Kettenmann, H			Acute insult of ammonia leads to calcium-dependent glutamate release from cultured astrocytes, an effect of pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LIVER-FAILURE; EXTRACELLULAR BRAIN GLUTAMATE; RAT CORTICAL ASTROCYTES; NEUROACTIVE AMINO-ACIDS; INTRACELLULAR PH; SENSORY NEURONS; FRONTAL-CORTEX; GLIAL-CELLS; MICRODIALYSIS; EXOCYTOSIS	Hyperammonemia is a key factor in the pathogenesis of hepatic encephalopathy (HE) as well as other metabolic encephalopathies, such as those associated with inherited disorders of urea cycle enzymes and in Reye's syndrome. Acute HE results in increased brain ammonia (up to 5 mM), astrocytic swelling, and altered glutamatergic function. In the present study, using fluorescence imaging techniques, acute exposure (10 min) of ammonia (NH4+/NH3) to cultured astrocytes resulted in a concentration-dependent, transient increase in [Ca2+](i). This calcium transient was due to release from intracellular calcium stores, since the response was thapsigargin-sensitive and was still observed in calcium-free buffer. Using an enzyme-linked fluorescence assay, glutamate release was measured indirectly via the production of NADH ( a naturally fluorescent product when excited with UV light). NH4+/NH3 (5 mM) stimulated a calcium- dependent glutamate release from cultured astrocytes, which was inhibited after preincubation with 1,2-bis(2-aminophenoxy) ethane- N, N, N', N'-tetraacetic acid acetoxymethyl ester but unaffected after preincubation with glutamate transport inhibitors dihydrokainate and DL-threo-beta-benzyloxyaspartate. NH4+/NH3 (5 mM) also induced a transient intracellular alkaline shift. To investigate whether the effects of NH4+/ NH3 were mediated by an increase in pH(i), we applied trimethylamine (TMA(+)/TMA) as another weak base. TMA(+)/TMA ( 5 mM) induced a similar transient increase in both pHi and [Ca2+](i) ( mobilization from intracellular calcium stores) and resulted in calcium-dependent release of glutamate. These results indicate that an acute exposure to ammonia, resulting in cytosolic alkalinization, leads to calcium- dependent glutamate release from astrocytes. A deregulation of glutamate release from astrocytes by ammonia could contribute to glutamate dysfunction consistently observed in acute HE.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kettenmann, H (corresponding author), Max Delbruck Ctr Mol Med, 10 Robert Rossle Str, D-13092 Berlin, Germany.	kettenmann@mdc-berlin.de	Rose, Christopher F/F-1105-2010; Kettenmann, Helmut/AAJ-5142-2021	Rose, Christopher F/0000-0001-9854-6834; Kettenmann, Helmut/0000-0001-8208-0291				ALBRECHT J, 1994, BRAIN RES, V660, P228; Allert N, 1998, BRAIN RES, V782, P261, DOI 10.1016/S0006-8993(97)01288-2; Anderson CM, 2001, J NEUROCHEM, V79, P1207; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; AYOUB GS, 1991, J NEUROSCI METH, V37, P7, DOI 10.1016/0165-0270(91)90016-S; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; BOSMAN DK, 1992, J NEUROCHEM, V59, P591, DOI 10.1111/j.1471-4159.1992.tb09410.x; BOYARSKY G, 1993, GLIA, V8, P241, DOI 10.1002/glia.440080404; Chan H, 2000, NEUROCHEM INT, V37, P243, DOI 10.1016/S0197-0186(00)00026-7; DANTHULURI NR, 1990, J BIOL CHEM, V265, P19071; DEKNEGT RJ, 1994, J HEPATOL, V20, P19, DOI 10.1016/S0168-8278(05)80462-3; FAFFMICHALAK L, 1994, GLIA, V10, P114, DOI 10.1002/glia.440100205; Felipo V, 2002, PROG NEUROBIOL, V67, P259, DOI 10.1016/S0301-0082(02)00019-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hermenegildo C, 2000, HEPATOLOGY, V31, P709, DOI 10.1002/hep.510310322; Hilgier W, 1999, J NEUROSCI RES, V56, P76, DOI 10.1002/(SICI)1097-4547(19990401)56:1<76::AID-JNR10>3.0.CO;2-Y; Innocenti B, 2000, J NEUROSCI, V20, P1800; Jeremic A, 2001, J NEUROCHEM, V77, P664, DOI 10.1046/j.1471-4159.2001.00272.x; Kaila K., 1998, PH BRAIN FUNCTION; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Knecht K, 1997, NEUROSCI LETT, V229, P201, DOI 10.1016/S0304-3940(97)00444-8; Kreft M, 2004, GLIA, V46, P437, DOI 10.1002/glia.20018; Longuemare MC, 1999, NEUROSCIENCE, V93, P285, DOI 10.1016/S0306-4522(99)00152-9; Lyons SA, 1998, J CEREBR BLOOD F MET, V18, P521, DOI 10.1097/00004647-199805000-00007; Marcaggi P, 2001, PROG NEUROBIOL, V64, P157, DOI 10.1016/S0301-0082(00)00043-5; Michalak A, 1996, HEPATOLOGY, V24, P908, DOI 10.1002/hep.510240425; Minelli A, 2000, PFLUG ARCH EUR J PHY, V439, P370, DOI 10.1007/s004240050952; MIRONOV SL, 1993, NEUROREPORT, V4, P1055, DOI 10.1097/00001756-199308000-00016; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; Nicholson C, 1998, TRENDS NEUROSCI, V21, P207, DOI 10.1016/S0166-2236(98)01261-2; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Rose C, 2000, HEPATOLOGY, V31, P872, DOI 10.1053/he.2000.5923; Rose C, 2002, METAB BRAIN DIS, V17, P251, DOI 10.1023/A:1021945515514; Rose Christine R., 1998, P253; SALTER MW, 1994, J NEUROSCI, V14, P1563, DOI 10.1523/JNEUROSCI.14-03-01563.1994; SHORTE SL, 1991, CELL CALCIUM, V12, P301, DOI 10.1016/0143-4160(91)90004-X; Speake T, 1998, J PHYSIOL-LONDON, V506, P415, DOI 10.1111/j.1469-7793.1998.415bw.x; SWAIN M, 1992, HEPATOLOGY, V15, P449, DOI 10.1002/hep.1840150316; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; USACHEV Y, 1993, NEUROSCIENCE, V57, P845, DOI 10.1016/0306-4522(93)90029-F; Zhang Q, 2004, J BIOL CHEM, V279, P12724, DOI 10.1074/jbc.M312845200; Zwingmann C, 2003, HEPATOLOGY, V37, P420, DOI 10.1053/jhep.2003.50052	45	87	90	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20937	20944		10.1074/jbc.M412448200	http://dx.doi.org/10.1074/jbc.M412448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802262	Green Submitted, hybrid			2022-12-25	WOS:000229438800006
J	Seidle, HF; Bieganowski, P; Brenner, C				Seidle, HF; Bieganowski, P; Brenner, C			Disease-associated mutations inactivate AMP-lysine hydrolase activity of aprataxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCULAR MOTOR APRAXIA; EARLY-ONSET ATAXIA; GENE-MUTATIONS; CEREBELLAR-ATAXIA; HISTIDINE TRIAD; HINT; FHIT; SPECIFICITY; PROTEIN; HYPOALBUMINEMIA	Ataxia-oculomotor apraxia syndrome 1 is an early onset cerebellar ataxia that results from loss of function mutations in the APTX gene, encoding Aprataxin, which contains three conserved domains. The forkhead-associated domain of Aprataxin mediates protein-protein interactions with molecules that respond to DNA damage, but the cellular phenotype of the disease does not appear to be consistent with a major loss in DNA damage responses. Disease-associated mutations in Aprataxin target a histidine triad domain that is similar to Hint, a universally conserved AMP-lysine hydrolase, or truncate the protein NH2-terminal to a zinc finger. With novel fluorigenic substrates, we demonstrate that Aprataxin possesses an active-site-dependent AMP-lysine and GMP-lysine hydrolase activity that depends additionally on the zinc finger for protein stability and on the forkhead associated domain for enzymatic activity. Alleles carrying any of eight recessive mutations associated with ataxia and oculomotor apraxia encode proteins with huge losses in protein stability and enzymatic activity, consistent with a null phenotype. The mild presentation allele, APTX-K197Q, associated with ataxia but not oculomotor apraxia, encodes a protein with a mild defect in stability and activity, while enzyme encoded by the atypical presentation allele, APTX-R199H, retained substantial function, consistent with altered and not loss of activity. The data suggest that the essential function of Aprataxin is reversal of nucleoti-dylylated protein modifications, that all three domains contribute to formation of a stable enzyme, and that the in vitro behavior of cloned APTX alleles can score disease-associated mutations.	Dartmouth Coll Sch Med, Sch Med, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Sch Med, Dept Genet, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Sch Med, Dept Biochem, Lebanon, NH 03756 USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Dartmouth College	Brenner, C (corresponding author), Dartmouth Coll Sch Med, Sch Med, Norris Cotton Canc Ctr, Rubin 733-HB7937, Lebanon, NH 03756 USA.	charles.brenner@dartmouth.edu	Bieganowski, Pawel/ABC-8554-2021; Brenner, Charles/D-6339-2014	Bieganowski, Pawel/0000-0002-1169-4517; Brenner, Charles/0000-0002-4955-3226	NCI NIH HHS [R01 CA075954-08, CA75954, R01 CA075954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AICARDI J, 1988, ANN NEUROL, V24, P497, DOI 10.1002/ana.410240404; Amouri R, 2004, NEUROLOGY, V63, P928, DOI 10.1212/01.WNL.0000137044.06573.46; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Chen YZ, 2004, AM J HUM GENET, V74, P1128, DOI 10.1086/421054; Chou TF, 2005, J BIOL CHEM, V280, P15356, DOI 10.1074/jbc.M500434200; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Clements PM, 2004, DNA REPAIR, V3, P1493, DOI 10.1016/j.dnarep.2004.06.017; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Draganescu A, 2000, J BIOL CHEM, V275, P4555, DOI 10.1074/jbc.275.7.4555; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Gueven N, 2004, HUM MOL GENET, V13, P1081, DOI 10.1093/hmg/ddh122; Habeck M, 2004, J NEUROL, V251, P591, DOI 10.1007/s00415-004-0374-7; Hirano M, 2004, BIOCHEM BIOPH RES CO, V322, P380, DOI 10.1016/j.bbrc.2004.07.135; Huang K, 2004, BIOCHEMISTRY-US, V43, P7637, DOI 10.1021/bi049762n; Kaytor MD, 2002, CURR OPIN NEUROBIOL, V12, P275, DOI 10.1016/S0959-4388(02)00320-3; Krakowiak A, 2004, J BIOL CHEM, V279, P18711, DOI 10.1074/jbc.M314271200; Kwasnicka DA, 2003, J BIOL CHEM, V278, P39051, DOI 10.1074/jbc.M306355200; Le Ber I, 2003, BRAIN, V126, P2761, DOI 10.1093/brain/awg283; Luo H, 2004, MOL CELL BIOL, V24, P8356, DOI 10.1128/MCB.24.19.8356-8365.2004; Moreira MC, 2004, NAT GENET, V36, P225, DOI 10.1038/ng1303; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; Pace HC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r18; Parks KP, 2004, PHYSIOL GENOMICS, V20, P12, DOI 10.1152/physiolgenomics.00204.2004; Quinzii CM, 2005, NEUROLOGY, V64, P539, DOI 10.1212/01.WNL.0000150588.75281.58; Sano Y, 2004, ANN NEUROL, V55, P241, DOI 10.1002/ana.10808; Shimazaki H, 2002, NEUROLOGY, V59, P590, DOI 10.1212/WNL.59.4.590; Shults CW, 2003, CURR MED CHEM, V10, P1917, DOI 10.2174/0929867033456882; Tranchant C, 2003, NEUROLOGY, V60, P868, DOI 10.1212/01.WNL.0000048562.88536.A4	31	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20927	20931		10.1074/jbc.M502889200	http://dx.doi.org/10.1074/jbc.M502889200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15790557	hybrid, Green Accepted			2022-12-25	WOS:000229438800004
J	Wei, AD; Butler, A; Salkoff, L				Wei, AD; Butler, A; Salkoff, L			KCNQ-like potassium channels in Caenorhabditis elegans - Conserved properties and modulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; FUNCTIONAL EXPRESSION; SIGNALING COMPLEX; C-ELEGANS; INHIBITION; GENE; MUTATION; SUBUNIT; PIP2; MECHANISM	The human KCNQ gene family encodes potassium channels linked to several genetic syndromes including neonatal epilepsy, cardiac arrhythmia, and progressive deafness. KCNQ channels form M-type potassium channels, which are critical regulators of neuronal excitability that mediate autonomic responses, pain, and higher brain function. Fundamental mechanisms of the normal and abnormal cellular roles for these channels may be gained from their study in simple model organisms. Here we report that a multigene family of KCNQ-like channels is present in the nematode, Caenorhabditis elegans. We show that many aspects of the functional properties, tissue expression pattern, and modulation of these C. elegans channels are conserved, including suppression by the M1 muscarinic receptor. We also describe a conserved mechanism of modulation by diacylglycerol for a subset of C. elegans and vertebrate KCNQ/ KQT channels, which is dependent upon the carboxyl-terminal domains of channel subunits and activated protein kinase C.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Salkoff, L (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	salkoffl@wustl.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR017342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067154] Funding Source: NIH RePORTER; NCRR NIH HHS [R24RR017342-02] Funding Source: Medline; NIGMS NIH HHS [R01GM067154-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVERY L, 1997, C ELEGANS, V2, P679, DOI [10.1101/087969532.33.679, DOI 10.1101/087969532.33.679]; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bianchi L, 2003, J BIOL CHEM, V278, P12415, DOI 10.1074/jbc.M212788200; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; BROWN DA, 1989, J PHYSIOL-LONDON, V413, P469, DOI 10.1113/jphysiol.1989.sp017664; CAULFIELD MP, 1994, J PHYSIOL-LONDON, V477, P415, DOI 10.1113/jphysiol.1994.sp020203; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; Crary JI, 2000, J GEN PHYSIOL, V116, P769, DOI 10.1085/jgp.116.6.769; Crary JI, 2000, J GEN PHYSIOL, V116, P755, DOI 10.1085/jgp.116.6.755; Gamper N, 2003, J GEN PHYSIOL, V122, P17, DOI 10.1085/jgp.200208783; Gamper N, 2003, J NEUROSCI, V23, P84; GORDON SE, 1995, BIOPHYS J, V69, P409, DOI 10.1016/S0006-3495(95)79913-1; Hadley JK, 2003, J NEUROSCI, V23, P5012; Haley JE, 2000, J NEUROSCI, V20, P3973; Hardie RC, 2003, ANNU REV PHYSIOL, V65, P735, DOI 10.1146/annurev.physiol.65.092101.142505; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HIGASHIDA H, 1995, J PHYSIOL-LONDON, V482, P317, DOI 10.1113/jphysiol.1995.sp020520; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hoshi N, 2003, NAT NEUROSCI, V6, P564, DOI 10.1038/nn1062; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Lerche C, 2000, J BIOL CHEM, V275, P22395, DOI 10.1074/jbc.M002378200; Loussouarn G, 2003, EMBO J, V22, P5412, DOI 10.1093/emboj/cdg526; Maljevic S, 2003, J PHYSIOL-LONDON, V548, P353, DOI 10.1113/jphysiol.2003.040980; Marrion NV, 1996, NEURON, V16, P163, DOI 10.1016/S0896-6273(00)80033-1; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Montell C, 2005, SCI STKE; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Santi CM, 2003, P NATL ACAD SCI USA, V100, P14391, DOI 10.1073/pnas.1935976100; Schroeder BC, 2000, J BIOL CHEM, V275, P24089, DOI 10.1074/jbc.M003245200; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Schwake M, 2003, EMBO REP, V4, P76, DOI 10.1038/sj.embor.embor715; Selyanko AA, 2000, J PHYSIOL-LONDON, V522, P349, DOI 10.1111/j.1469-7793.2000.t01-2-00349.x; Selyanko AA, 1996, NEURON, V16, P151, DOI 10.1016/S0896-6273(00)80032-X; SIMS SM, 1988, SCIENCE, V239, P190, DOI 10.1126/science.2827305; Singh NA, 2003, BRAIN, V126, P2726, DOI 10.1093/brain/awg286; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Stemkowski PL, 2002, J NEUROPHYSIOL, V88, P277, DOI 10.1152/jn.2002.88.1.277; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Wei AG, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf109; Yang WP, 1998, J BIOL CHEM, V273, P19419, DOI 10.1074/jbc.273.31.19419; Yuan A, 2000, NAT NEUROSCI, V3, P771, DOI 10.1038/77670; Zhang HL, 2003, NEURON, V37, P963, DOI 10.1016/S0896-6273(03)00125-9	56	30	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21337	21345		10.1074/jbc.M502734200	http://dx.doi.org/10.1074/jbc.M502734200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797864	hybrid			2022-12-25	WOS:000229438800052
J	Marbois, B; Gin, P; Faull, KF; Poon, WW; Lee, PT; Strahan, J; Shepherd, JN; Clarke, CF				Marbois, B; Gin, P; Faull, KF; Poon, WW; Lee, PT; Strahan, J; Shepherd, JN; Clarke, CF			Coq3 and Coq4 define a polypeptide complex in yeast mitochondria for the biosynthesis of coenzyme Q	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-METHYLTRANSFERASE STEPS; SACCHAROMYCES-CEREVISIAE; UBIQUINONE BIOSYNTHESIS; QH2-CYTOCHROME-C REDUCTASE; CAENORHABDITIS-ELEGANS; CYTOCHROME-OXIDASE; MEMBRANE SYSTEM; STRUCTURAL GENE; LIFE-SPAN; PROTEIN	Coenzyme Q (Q) is a redox active lipid essential for aerobic respiration in eukaryotes. In Saccharomyces cerevisiae at least eight mitochondrial polypeptides, designated Coq1-Coq8, are required for Q biosynthesis. Here we present physical evidence for a coenzyme Q-biosynthetic polypeptide complex in isolated mitochondria. Separation of digitonin-solubilized mitochondrial extracts in one- and two-dimensional Blue Native PAGE analyses shows that Coq3 and Coq4 polypeptides co-migrate as high molecular mass complexes. Similarly, gel filtration chromatography shows that Coq1p, Coq3p, Coq4p, Coq5p, and Coq6p elute in fractions higher than expected for their respective subunit molecular masses. Coq3p, Coq4p, and Coq6p coelute with an apparent molecular mass exceeding 700 kDa. Coq3 O-methyltransferase activity, a surrogate for Q biosynthesis and complex activity, also elutes at this high molecular mass. We have determined the quinone content in lipid extracts of gel filtration fractions by liquid chromatography-tandem mass spectrometry and find that demethoxy-Q(6) is enriched in fractions with Coq3p. Co-precipitation of biotinylated-Coq3 and Coq4 polypeptide from digitonin-solubilized mitochondrial extracts shows their physical association. This study identifies Coq3p and Coq4p as defining members of a Q-biosynthetic Coq polypeptide complex.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; Gonzaga Univ, Dept Chem, Spokane, WA 99258 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Gonzaga University	Clarke, CF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E,Box 951569, Los Angeles, CA 90095 USA.	cathy@chem.ucla.edu		Poon, Wayne/0000-0003-0625-3968	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45952] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY MN, 1992, J BIOL CHEM, V267, P4128; Baba SW, 2004, J BIOL CHEM, V279, P10052, DOI 10.1074/jbc.M313712200; Baker W, 1941, J CHEM SOC, P670, DOI 10.1039/jr9410000670; Beal F, 2004, METHOD ENZYMOL, V382, P473; BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; Belogrudov GI, 2001, ARCH BIOCHEM BIOPHYS, V392, P48, DOI 10.1006/abbi.2001.2448; Burke D., 2000, METHODS YEAST GENETI, P171; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; CRANE FL, 1965, BIOCH QUINONES, V1, P183; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; Dutton P.L., 2001, COENZYME Q OXIDATION, P65; Geromel V, 2002, MOL GENET METAB, V77, P21, DOI 10.1016/S1096-7192(02)00145-2; GIBSON F, 1973, Biochemical Society Transactions, V1, P317; Gille L, 2000, ARCH BIOCHEM BIOPHYS, V375, P347, DOI 10.1006/abbi.1999.1649; Gin P, 2003, J BIOL CHEM, V278, P25308, DOI 10.1074/jbc.M303234200; GIN P, 1980, J BIOL CHEM, P2676; Glerum DM, 1998, ANAL BIOCHEM, V260, P38, DOI 10.1006/abio.1998.2683; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Hsieh EJ, 2004, BIOCHEM BIOPH RES CO, V317, P648, DOI 10.1016/j.bbrc.2004.03.096; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Ishii N, 2004, MECH AGEING DEV, V125, P41, DOI 10.1016/j.mad.2003.10.002; Jonassen T, 2002, J BIOL CHEM, V277, P45020, DOI 10.1074/jbc.M204758200; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; JONASSEN T, 2001, EOENZYME Q MOL MECH, P185; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; Kainou T, 2001, J BIOL CHEM, V276, P7876, DOI 10.1074/jbc.M007472200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; Lass A, 1997, J BIOL CHEM, V272, P19199, DOI 10.1074/jbc.272.31.19199; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; MATARASSOTCHIROUKHINE E, 1976, J ORGANOMET CHEM, V121, P155, DOI 10.1016/S0022-328X(00)80763-9; McAlisterHenn L, 1997, PROG NUCLEIC ACID RE, V57, P317, DOI 10.1016/S0079-6603(08)60285-8; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; Meganathan R, 2001, FEMS MICROBIOL LETT, V203, P131, DOI 10.1016/S0378-1097(01)00330-5; MURACA RF, 1967, J AM CHEM SOC, V89, P1505, DOI 10.1021/ja00982a038; Nakai D, 2004, AGING CELL, V3, P273, DOI 10.1111/j.1474-9728.2004.00116.x; NARUTA Y, 1980, J ORG CHEM, V45, P4097, DOI 10.1021/jo01309a006; Padilla S, 2004, J BIOL CHEM, V279, P25995, DOI 10.1074/jbc.M400001200; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; POON WW, 1995, ARCH BIOCHEM BIOPHYS, V320, P305, DOI 10.1016/0003-9861(95)90014-4; POON WW, 1997, MOL ASPECTS MED, V18, P121; Radin N S, 1981, Methods Enzymol, V72, P5; Saiki R, 2003, EUR J BIOCHEM, V270, P4113, DOI 10.1046/j.1432-1033.2003.03804.x; Santos-Ocana C, 1998, J BIOL CHEM, V273, P8099, DOI 10.1074/jbc.273.14.8099; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Shepherd JA, 1996, TETRAHEDRON LETT, V37, P2395, DOI 10.1016/0040-4039(96)00324-3; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; SIKORSKI RS, 1989, GENETICS, V122, P19; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; WAITE JH, 1990, COMP BIOCHEM PHYS B, V97, P19, DOI 10.1016/0305-0491(90)90172-P	59	69	73	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20231	20238		10.1074/jbc.M501315200	http://dx.doi.org/10.1074/jbc.M501315200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15792955	hybrid			2022-12-25	WOS:000229242000010
J	Wang, W; Jia, LY; Wang, TK; Sun, WT; Wu, S; Wang, X				Wang, W; Jia, LY; Wang, TK; Sun, WT; Wu, S; Wang, X			Endogenous calcitonin gene-related peptide protects human alveolar epithelial cells through protein kinase C epsilon and heat shock protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; REPERFUSION; MODULATION; INJURY; PKC; ACTIVATION; PHYSIOLOGY; RECEPTORS; CHANNELS	The intracellular mechanisms of ischemic preconditioning (PC) in preventing lung dysfunction following transplantation, shock, and trauma remain poorly understood. Previously, we have shown that alveolar epithelial cells secrete calcitonin gene-related peptide (CGRP) under inflammatory stress. Using a hypoxia/reoxygenation (H/R) and PC model, we found that CGRP was also secreted from human type II alveolar epithelial cells (A549) after PC. The locally released CGRP interacted with its receptor on the membrane of A549 cells and elicited downstream signals mediating the PC effect, because hCGRP(8-37), a specific CGRP receptor antagonist, attenuated the protective effect of PC. Preinhibition of CGRP protein synthesis by small interfering RNA exacerbated (but overexpression of the CGRP gene ameliorated) H/R-induced cell death, which supports the autocrine effect of CGRP on A549 cells. Exogenous bioactive CGRP mimicked the beneficial effect of PC and up-regulated the expression of heat shock protein 70 (HSP70), which might act as the end effector to maintain cell viability. These effects were sensitive to hCGRP(8-37), calphostin C (a protein kinase C (PKC) inhibitor), and 5-hydroxydecanoic acid ( a mitochondrial K-ATP(+) channel blocker) but were insensitive to protein kinase A blockers. Moreover, CGRP induced the membrane translocation of PKC is an element of. PKCV1-2 (a cell-permeable inhibitory peptide of PKC is an element of) effectively abolished CGRP-induced HSP70 expression and cell protection. Therefore, PC induces CGRP secretion from human alveolar epithelial cells, and the locally released CGRP acts back on these cells, protecting them from H/R injury. The post-receptor signaling of CGRP is through PKC is an element of-dependent expression of HSP70.	Peking Univ, Hosp 3, Inst Vasc Med, Beijing 100083, Peoples R China; Peking Univ, Dept Physiol, Key Lab Mol Cardiovasc Sci, Minist Educ,Hlth Sci Ctr, Beijing 100083, Peoples R China	Peking University; Peking University	Wang, X (corresponding author), Peking Univ, Hosp 3, Inst Vasc Med, 38,Xue Yuan Rd, Beijing 100083, Peoples R China.	xwang@bjmu.edu.cn	wang, wang/GWQ-7272-2022	Wang, Wang/0000-0001-9093-412X				Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; Bell D, 1996, PHARMACOL REV, V48, P253; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Dakhama A, 2004, CURR OPIN PHARMACOL, V4, P215, DOI 10.1016/j.coph.2004.01.006; de Perrot M, 2003, AM J RESP CRIT CARE, V167, P490, DOI 10.1164/rccm.200207-670SO; Ding XZ, 1997, J CLIN INVEST, V99, P136, DOI 10.1172/JCI119124; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Drissi H, 1998, J BIOL CHEM, V273, P20168, DOI 10.1074/jbc.273.32.20168; Drissi H, 1999, CYTOKINE, V11, P200, DOI 10.1006/cyto.1998.0415; Fehrenbach H, 2001, RESP RES, V2, P33, DOI 10.1186/rr36; Ferdinandy P, 2003, BRIT J PHARMACOL, V138, P532, DOI 10.1038/sj.bjp.0705080; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Gross GJ, 2003, AM J PHYSIOL-HEART C, V285, pH921, DOI 10.1152/ajpheart.00421.2003; Inagaki K, 2003, CIRCULATION, V108, P869, DOI 10.1161/01.CIR.0000081943.93653.73; Kallner G, 1998, J CARDIOVASC PHARM, V32, P500, DOI 10.1097/00005344-199809000-00023; Latchman DS, 2001, CARDIOVASC RES, V51, P637, DOI 10.1016/S0008-6363(01)00354-6; LECHLEITNER P, 1992, AM HEART J, V124, P1433, DOI 10.1016/0002-8703(92)90054-Y; Li WJ, 2004, FASEB J, V18, P1603, DOI 10.1096/fj.04-1737fje; Li Y, 1997, NEUROPEPTIDES, V31, P503, DOI 10.1016/S0143-4179(97)90046-9; Mubagwa K, 2001, CARDIOVASC RES, V52, P25, DOI 10.1016/S0008-6363(01)00358-3; Napoli C, 2000, PHARMACOL THERAPEUT, V88, P311, DOI 10.1016/S0163-7258(00)00093-0; Ohnuma Y, 2002, AM J PHYSIOL-HEART C, V283, pH440, DOI 10.1152/ajpheart.00434.2001; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; Sato T, 1998, CIRC RES, V83, P110, DOI 10.1161/01.RES.83.1.110; Schulz R, 2001, CARDIOVASC RES, V52, P181, DOI 10.1016/S0008-6363(01)00384-4; Schulz R, 2004, CARDIOVASC RES, V61, P402, DOI 10.1016/j.cardiores.2003.09.019; Simkhovich BZ, 1998, CARDIOVASC RES, V40, P9, DOI 10.1016/S0008-6363(98)00142-4; Sun W, 2003, EUR J IMMUNOL, V33, P233, DOI 10.1002/immu.200390026; Villa I, 2003, AM J PHYSIOL-ENDOC M, V284, pE627, DOI 10.1152/ajpendo.00307.2002; Wang W, 2004, AM J PHYSIOL-HEART C, V287, pH1582, DOI 10.1152/ajpheart.00168.2004; WANG X, 1991, CIRC SHOCK, V34, P217; Wang YG, 1999, CIRC RES, V84, P1156, DOI 10.1161/01.RES.84.10.1156; Wimalawansa SJ, 1996, ENDOCR REV, V17, P533, DOI 10.1210/er.17.5.533; Wong HR, 1998, AM J PHYSIOL-LUNG C, V275, pL836, DOI 10.1152/ajplung.1998.275.4.L836; Xiao L, 2001, EUR J PHARMACOL, V427, P131, DOI 10.1016/S0014-2999(01)01231-6; Yellon DM, 2003, PHYSIOL REV, V83, P1113, DOI 10.1152/physrev.00009.2003	38	29	38	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20325	20330		10.1074/jbc.M413864200	http://dx.doi.org/10.1074/jbc.M413864200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15784626	hybrid			2022-12-25	WOS:000229242000022
J	Maertens, G; Vercammen, J; Debyser, Z; Engelborghs, Y				Maertens, G; Vercammen, J; Debyser, Z; Engelborghs, Y			Measuring protein-protein interactions inside living cells using single color fluorescence correlation spectroscopy. Application to human immunodeficiency virus type I integrase and LEDGF/p75	FASEB JOURNAL			English	Article						HIV-1 integrase; microscopy; intracellular diffusion; GFP; FCS	AMINO-ACID-RESIDUES; HIV-1 INTEGRASE; 2-PHOTON EXCITATION; NONDIVIDING CELLS; DNA INTEGRATION; PREINTEGRATION COMPLEXES; TRANSLATIONAL DIFFUSION; CORRELATION MICROSCOPY; NUCLEAR-LOCALIZATION; CROSS-CORRELATION	Recently we described the interaction of human immunodeficiency virus type 1 (HIV-1)(1) integrase (IN) with a cellular protein, lens epithelium-derived growth factor/transcription coactivator p75 (LEDGF/p75). We now present the study of the diffusion behavior of the three independent domains of IN and LEDGF/p75 using fluorescence correlation microscopy (FCM). We show that diffusion in the cell of the different enhanced green fluorescent protein (EGFP) fusion proteins is described by two components with different fractions and that the average parameters in the nucleus are comparable with those in the cytoplasm. In addition, we demonstrate that specific interaction between EGFP-fused HIV-1 IN and LEDGF/p75 results in a shift in diffusion coefficient (D). The opposite shift was observed in an IN-deletion mutant that does not exhibit LEDGF/p75 binding or in a LEDGF/p75 knock-down experiment using siRNA. We thus demonstrate that protein-protein interactions can be studied in living cells, using single-color FCM (scFCM).	Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Louvain, Belgium; Katholieke Univ Leuven, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Engelborghs, Y (corresponding author), Katholieke Univ Leuven, Lab Biomol Dynam, Celestijnenlaan 200D, B-3001 Louvain, Belgium.	Yves.Engelborghs@fys.kuleuven.ac.be	Maertens, Goedele/D-8628-2015	Maertens, Goedele/0000-0002-1963-8026				Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; Bacia K, 2002, BIOPHYS J, V83, P1184, DOI 10.1016/S0006-3495(02)75242-9; Billinton N, 2001, ANAL BIOCHEM, V291, P175, DOI 10.1006/abio.2000.5006; Brock R, 1999, P NATL ACAD SCI USA, V96, P10123, DOI 10.1073/pnas.96.18.10123; Brock R, 1998, BIOPHYS J, V75, P2547, DOI 10.1016/S0006-3495(98)77699-4; Brown P. O., 1997, P161; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Chen Y, 2002, BIOPHYS J, V82, P133, DOI 10.1016/S0006-3495(02)75380-0; Cherepanov P, 2000, FASEB J, V14, P1389, DOI 10.1096/fj.14.10.1389; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; CHEREPANOV P, 2004, J BIOL CHEM, V14, P14; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; Depienne C, 2000, EXP CELL RES, V260, P387, DOI 10.1006/excr.2000.5016; Eijkelenboom APAM, 1997, CURR BIOL, V7, P739, DOI 10.1016/S0960-9822(06)00332-0; ELSON EL, 1974, BIOPOLYMERS, V13, P1, DOI 10.1002/bip.1974.360130102; Engelman A, 2003, CURR TOP MICROBIOL, V281, P209; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Gallop MA, 1997, CURR OPIN CHEM BIOL, V1, P94, DOI 10.1016/S1367-5931(97)80114-7; Hess ST, 2003, BIOPHYS J, V85, P2566, DOI 10.1016/S0006-3495(03)74679-7; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Kim SA, 2004, P NATL ACAD SCI USA, V101, P105, DOI 10.1073/pnas.2436461100; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Llano M, 2004, J VIROL, V78, P9524, DOI 10.1128/JVI.78.17.9524-9537.2004; LLANO M, 2004, J BIOL CHEM, V8, P8; LUTZKE RAP, 1994, NUCLEIC ACIDS RES, V22, P4125, DOI 10.1093/nar/22.20.4125; Maertens G, 2004, J BIOL CHEM, V279, P33421, DOI 10.1074/jbc.M404700200; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; Meseth U, 1999, BIOPHYS J, V76, P1619, DOI 10.1016/S0006-3495(99)77321-2; Moreau K, 2004, VIROLOGY, V318, P566, DOI 10.1016/j.virol.2003.09.037; Moreau K, 2003, EUR J BIOCHEM, V270, P4426, DOI 10.1046/j.1432-1033.2003.03833.x; Pluymers W, 1999, VIROLOGY, V258, P327, DOI 10.1006/viro.1999.9727; Politz JC, 1998, P NATL ACAD SCI USA, V95, P6043, DOI 10.1073/pnas.95.11.6043; QIAN H, 1991, APPL OPTICS, V30, P1185, DOI 10.1364/AO.30.001185; Rauer B, 1996, BIOPHYS CHEM, V58, P3, DOI 10.1016/0301-4622(95)00080-1; RIGLER R, 1993, EUR BIOPHYS J BIOPHY, V22, P169, DOI 10.1007/BF00185777; Ruan QQ, 2002, BIOPHYS J, V83, P3177, DOI 10.1016/S0006-3495(02)75320-4; Schmiedeberg L, 2004, MOL BIOL CELL, V15, P2819, DOI 10.1091/mbc.E03-11-0827; Schwille P, 1999, BIOPHYS J, V77, P2251, DOI 10.1016/S0006-3495(99)77065-7; Schwille P, 2001, CELL BIOCHEM BIOPHYS, V34, P383, DOI 10.1385/CBB:34:3:383; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Sherman MP, 2002, MICROBES INFECT, V4, P67, DOI 10.1016/S1286-4579(01)01511-8; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Tsurutani N, 2000, J VIROL, V74, P4795, DOI 10.1128/JVI.74.10.4795-4806.2000; Turlure F, 2004, FRONT BIOSCI-LANDMRK, V9, P3187, DOI 10.2741/1472; Van Craenenbroeck  E, 2000, J MOL RECOGNIT, V13, P93, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<93::AID-JMR492>3.0.CO;2-6; Vodicka Marie A., 2001, Somatic Cell and Molecular Genetics, V26, P35, DOI 10.1023/A:1021022629126; Wachsmuth M, 2000, J MOL BIOL, V298, P677, DOI 10.1006/jmbi.2000.3692; Wang ZF, 2004, J BIOMED OPT, V9, P395, DOI 10.1117/1.1646416; Woodward CL, 2003, J VIROL, V77, P4516, DOI 10.1128/JVI.77.8.4516-4527.2003	58	36	39	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					1039	+		10.1096/fj.04-3373fje	http://dx.doi.org/10.1096/fj.04-3373fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15788449				2022-12-25	WOS:000227901300003
J	Hsu, MF; Kuo, CJ; Chang, KT; Chang, HC; Chou, CC; Ko, TP; Shr, HL; Chang, GG; Wang, AHJ; Liang, PH				Hsu, MF; Kuo, CJ; Chang, KT; Chang, HC; Chou, CC; Ko, TP; Shr, HL; Chang, GG; Wang, AHJ; Liang, PH			Mechanism of the maturation process of SARS-CoV 3CL protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAIN PROTEASE; GENOME SEQUENCE; CORONAVIRUS; INHIBITORS; DESIGN; IDENTIFICATION; REVEALS	Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a novel human coronavirus. Viral maturation requires a main protease (3CL(pro)) to cleave the virus-encoded polyproteins. We report here that the 3CLpro containing additional N- and/or C-terminal segments of the polyprotein sequences undergoes autoprocessing and yields the mature protease in vitro. The dimeric three-dimensional structure of the C145A mutant protease shows that the active site of one protomer binds with the C-terminal six amino acids of the protomer from another asymmetric unit, mimicking the product-bound form and suggesting a possible mechanism for maturation. The P1 pocket of the active site binds the Gln side chain specifically, and the P2 and P4 sites are clustered together to accommodate large hydrophobic side chains. The tagged C145A mutant protein served as a substrate for the wild-type protease, and the N terminus was first digested (55-fold faster) at the Gln(-1)-Ser(1) site followed by the C-terminal cleavage at the Gln(306)-Gly(307) site. Analytical ultracentrifuge of the quaternary structures of the tagged and mature proteases reveals the remarkably tighter dimer formation for the mature enzyme (K-d = 0.35 nM) than for the mutant (C145A) containing 10 extra N- terminal (K-d = 17.2 nM) or C-terminal amino acids (K-d = 5.6 nM). The data indicate that immature 3CLpro can form dimer enabling it to undergo autoprocessing to yield the mature enzyme, which further serves as a seed for facilitated maturation. Taken together, this study provides insights into the maturation process of the SARS 3CLpro from the polyprotein and design of new structure-based inhibitors.	Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan; Acad Sinica, Core Facil Prot Xray Crystallog, Taipei 115, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Yang Ming Univ, Fac Life Sci, Taipei 112, Taiwan	National Taiwan University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Wang, AHJ (corresponding author), Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan.	ahjwang@gate.sinica.edu.tw; phliang@gate.sinica.edu.tw	Liang, Po-Huang/H-6610-2015	Liang, Po-Huang/0000-0003-1207-5256; Kuo, Chih-Jung/0000-0002-4988-5124				Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327; Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang HC, 2003, J BIOL CHEM, V278, P23996, DOI 10.1074/jbc.M213242200; Chou CY, 2004, BIOCHEMISTRY-US, V43, P14958, DOI 10.1021/bi0490237; De Clercq E, 2002, NAT REV DRUG DISCOV, V1, P13, DOI 10.1038/nrd703; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595; Hsu JTA, 2004, FEBS LETT, V574, P116, DOI 10.1016/j.febslet.2004.08.015; Jain RP, 2004, J MED CHEM, V47, P6113, DOI 10.1021/jm0494873; Kao RY, 2004, CHEM BIOL, V11, P1293, DOI 10.1016/j.chembiol.2004.07.013; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Kuo CJ, 2004, BIOCHEM BIOPH RES CO, V318, P862, DOI 10.1016/j.bbrc.2004.04.098; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000; McQueney MS, 1997, J BIOL CHEM, V272, P13955, DOI 10.1074/jbc.272.21.13955; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9; Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200; Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101; Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100	31	169	177	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31257	31266		10.1074/jbc.M502577200	http://dx.doi.org/10.1074/jbc.M502577200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15788388	Green Published, hybrid			2022-12-25	WOS:000231487800073
J	Vatamaniuk, OK; Bucher, EA; Sundaram, MV; Rea, PA				Vatamaniuk, OK; Bucher, EA; Sundaram, MV; Rea, PA			CeHMT-1, a putative phytochelatin transporter, is required for cadmium tolerance in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-METAL DETOXIFICATION; ARABIDOPSIS-THALIANA; SCHIZOSACCHAROMYCES-POMBE; MULTIDRUG-RESISTANCE; HIGHER-PLANTS; GENE FAMILY; SYNTHASE; PROTEIN; YEAST; PEPTIDES	Phytochelatins (PCs), (gamma-Glu-Cys) nGly polymers that were formerly considered to be restricted to plants and some fungal systems, are now known to play a critical role in heavy metal (notably Cd2+) detoxification in Caenorhabditis elegans. In view of the functional equivalence of the gene encoding C. elegans PC synthase 1, ce-pcs-1, to its homologs from plant and fungal sources, we have gone on to explore processes downstream of PC fabrication in this organism. Here we describe the identification of a half-molecule ATP-binding cassette transporter, CeHMT-1, from C. elegans with an equivalent topology to that of the putative PC transporter SpHMT-1 from Schizosaccharomyces pombe. At one level, CeHMT-1 satisfies the requirements of a Cd2+ tolerance factor involved in the sequestration and/or elimination of (CdPC)-P-. complexes. Heterologous expression of cehmt-1 in S. pombe alleviates the Cd2+-hypersensitivity of hmt(-) mutants concomitant with the localization of Ce-HMT-1 to the vacuolar membrane. Suppression of the expression of ce-hmt-1 in intact worms by RNA interference (RNAi) confers a Cd2+-hypersensitive phenotype similar to but more pronounced than that exhibited by ce-pcs-1 RNAi worms. At another level, it is evident from comparisons of the cell morphology of ce-hmt-1 and ce-pcs-1 single and double RNAi mutants that CeHMT-1 also contributes to Cd2+ tolerance in other ways. Whereas the intestinal epithelial cells of ce-pcs-1 RNAi worms undergo necrosis upon exposure to toxic levels of Cd2+, the corresponding cells of ce-hmt-1 RNAi worms instead elaborate punctate refractive inclusions within the vicinity of the nucleus. Moreover, a deficiency in Ce-HMT-1 does not interfere with the phenotype associated with CePCS-1 deficiency and vice versa. Double ce-hmt-1; ce-pcs-1 RNAi mutants exhibit both cell morphologies when exposed to Cd2+. These results and those from our previous investigations of the requirement for PC synthase for heavy metal tolerance in C. elegans demonstrate PC-dependent, HMT-1-mediated heavy metal detoxification not only in S. pombe but also in some invertebrates while at the same time indicating that the action of Ce-HMT-1 does not depend exclusively on PC synthesis.	Univ Penn, Inst Plant Sci, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Rea, PA (corresponding author), Univ Penn, Inst Plant Sci, Dept Biol, 3800 Hamilton Walk, Philadelphia, PA 19104 USA.	parea@sas.upenn.edu		Sundaram, Meera/0000-0002-2940-8750	NATIONAL CANCER INSTITUTE [R01CA087512] Funding Source: NIH RePORTER; NCI NIH HHS [CA87512] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], [No title captured]; Broeks A, 1996, EMBO J, V15, P6132, DOI 10.1002/j.1460-2075.1996.tb01001.x; Clemens S, 2001, EUR J BIOCHEM, V268, P3640, DOI 10.1046/j.1432-1327.2001.02293.x; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cobbett CS, 2000, CURR OPIN PLANT BIOL, V3, P211, DOI 10.1016/S1369-5266(00)00066-2; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GRILL E, 1985, SCIENCE, V230, P674, DOI 10.1126/science.230.4726.674; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hope IA., 1999, C ELEGANS PRACTICAL; HOWDEN R, 1995, PLANT PHYSIOL, V107, P1059, DOI 10.1104/pp.107.4.1059; Hyman MH, 2004, ALTERN THER HEALTH M, V10, P70; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; LENZ A, 1991, J BIOL CHEM, V266, P7661; Liao VHC, 2002, J BIOL CHEM, V277, P42049, DOI 10.1074/jbc.M206740200; Mills RF, 2003, PLANT J, V35, P164, DOI 10.1046/j.1365-313X.2003.01790.x; Mitsuhashi N, 2000, J BIOL CHEM, V275, P17536, DOI 10.1074/jbc.275.23.17536; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; ORTIZ DF, 1995, J BIOL CHEM, V270, P4721, DOI 10.1074/jbc.270.9.4721; Rea PA, 2004, PLANT PHYSIOL, V136, P2463, DOI 10.1104/pp.104.048579; SALT DE, 1995, PLANT PHYSIOL, V107, P1293, DOI 10.1104/pp.107.4.1293; Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200; Sheps JA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r15; Vatamaniuk OK, 2001, J BIOL CHEM, V276, P20817, DOI 10.1074/jbc.C100152200; Vatamaniuk OK, 1999, P NATL ACAD SCI USA, V96, P7110, DOI 10.1073/pnas.96.12.7110; Vatamaniuk OK, 2004, J BIOL CHEM, V279, P22449, DOI 10.1074/jbc.M313142200; Vatamaniuk OK, 2002, TRENDS BIOTECHNOL, V20, P61, DOI 10.1016/S0167-7799(01)01873-X; Waalkes MP, 2000, J INORG BIOCHEM, V79, P241, DOI 10.1016/S0162-0134(00)00009-X; Zenk MH, 1996, GENE, V179, P21, DOI 10.1016/S0378-1119(96)00422-2	31	69	78	3	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23684	23690		10.1074/jbc.M503362200	http://dx.doi.org/10.1074/jbc.M503362200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15840570	hybrid			2022-12-25	WOS:000229880000036
J	Prats, C; Cadefau, JA; Cusso, R; Qvortrup, K; Nielsen, JN; Wojtaszewki, JFP; Hardie, DG; Stewart, G; Hansen, BF; Ploug, T				Prats, C; Cadefau, JA; Cusso, R; Qvortrup, K; Nielsen, JN; Wojtaszewki, JFP; Hardie, DG; Stewart, G; Hansen, BF; Ploug, T			Phosphorylation-dependent translocation of glycogen synthase to a novel structure during glycogen resynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE GLYCOGEN; LOW-FREQUENCY STIMULATION; VIRUS-LIKE PARTICLES; SARCOPLASMIC-RETICULUM; CELL-NUCLEUS; TROPOMYOSIN; IDENTIFICATION; LOCALIZATION; GLUCOSE-6-PHOSPHATE; POTENTIATION	Glycogen metabolism has been the subject of extensive research, but the mechanisms by which it is regulated are still not fully understood. It is well accepted that the rate-limiting enzymes in glycogenesis and glycogenolysis are glycogen synthase (GS) and glycogen phosphorylase (GPh), respectively. Both enzymes are regulated by reversible phosphorylation and by allosteric effectors. However, evidence in the literature indicates that changes in muscle GS and GPh intracellular distribution may constitute a new regulatory mechanism of glycogen metabolism. Already in the 1960s, it was proposed that glycogen was present in dynamic cellular organelles that were termed glycosomas but no such cellular entities have ever been demonstrated. The aim of this study was to characterize muscle GS and GPh intracellular distribution and to identify possible translocation processes of both enzymes. Using in situ stimulation of rabbit tibialis anterior muscle, we show GS and GPh intracellular redistribution at the beginning of glycogen resynthesis after contraction-induced glycogen depletion. We identify a new "player," a new intracellular compartment involved in skeletal muscle glycogen metabolism. They are spherical structures that were not present in basal muscle, and we present evidence that indicate that they are products of actin cytoskeleton remodeling. Furthermore, for the first time, we show a phosphorylation-dependent intracellular distribution of GS. Here, we present evidence of a new regulatory mechanism of skeletal muscle glycogen metabolism based on glycogen enzyme intracellular compartmentalization.	Univ Copenhagen, Panum Inst, Dept Med Physiol, Copenhagen Muscle Res Ctr, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Inst Exercise & Sport Sci, DK-2200 Copenhagen, Denmark; Univ Barcelona, Fac Med, Unitat Bioquim, Inst Invest Biomed August Pi I Sunyer, E-08036 Barcelona, Spain; Univ Dundee, Welcome Trust Bioctr, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland; Novo Nordisk AS, Diabet Biol, DK-2880 Bagsvaerd, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Dundee; Novo Nordisk	Prats, C (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Physiol, Copenhagen Muscle Res Ctr, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.	cprats@mfi.ku.dk	Cadefau, Joan AurelI/M-7934-2018; Prats, Clara/F-5993-2014; Hardie, David/Z-1979-2019; Cadefau, Joan Aureli/G-2906-2016; Wojtaszewski, Jørgen FP/P-6583-2014	Cadefau, Joan AurelI/0000-0001-6020-189X; Prats, Clara/0000-0001-6465-3068; Cadefau, Joan Aureli/0000-0001-6020-189X; Wojtaszewski, Jørgen FP/0000-0001-9785-6830; Qvortrup, Klaus/0000-0001-8811-0260; Ploug, Thorkil/0000-0002-5375-6595; Hardie, Grahame/0000-0002-8373-7379				Baque S, 1997, FEBS LETT, V417, P355, DOI 10.1016/S0014-5793(97)01299-4; Beck-Nielsen Henning, 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P255; BERGAMINI C, 1977, FEBS LETT, V81, P166, DOI 10.1016/0014-5793(77)80952-6; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; BURCH GE, 1968, ARCH ENVIRON HEALTH, V17, P984, DOI 10.1080/00039896.1968.10665356; Burgstaller G, 2004, J CELL SCI, V117, P223, DOI 10.1242/jcs.00839; CALDER PC, 1991, INT J BIOCHEM, V23, P1335, DOI 10.1016/0020-711X(91)90274-Q; CHACKO S, 1990, J BIOL CHEM, V265, P2105; Chowrashi P, 2002, CELL MOTIL CYTOSKEL, V53, P125, DOI 10.1002/cm.10059; CIUDAD CJ, 1980, MOL CELL BIOCHEM, V30, P33, DOI 10.1007/BF00215303; Cohen P, 1978, Curr Top Cell Regul, V14, P117; Cohen P., 1986, ENZYMES, VXVII, P461; Cohen PTW, 2002, J CELL SCI, V115, P241; DAMSBO P, 1991, DIABETOLOGIA, V34, P239, DOI 10.1007/BF00405082; ENTMAN ML, 1980, J BIOL CHEM, V255, P6245; ENTMAN ML, 1976, LIFE SCI, V19, P1623, DOI 10.1016/0024-3205(76)90066-7; FernandezNovell JM, 1997, BIOCHEM J, V321, P227, DOI 10.1042/bj3210227; Ferrer JC, 1997, FEBS LETT, V415, P249, DOI 10.1016/S0014-5793(97)01136-8; FLETTERICK RJ, 1980, ANNU REV BIOCHEM, V49, P31, DOI 10.1146/annurev.bi.49.070180.000335; Flood G, 1997, EUR BIOPHYS J BIOPHY, V25, P431, DOI 10.1007/s002490050057; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FRIDEN J, 1989, ACTA PHYSIOL SCAND, V135, P381, DOI 10.1111/j.1748-1716.1989.tb08591.x; Garcia-Rocha M, 2001, BIOCHEM J, V357, P17, DOI 10.1042/0264-6021:3570017; GIOMETTI CS, 1984, J BIOL CHEM, V259, P4113; GREEN HJ, 1992, PFLUG ARCH EUR J PHY, V420, P359, DOI 10.1007/BF00374471; Hicks A, 1997, AM J PHYSIOL-CELL PH, V273, pC297, DOI 10.1152/ajpcell.1997.273.1.C297; HIMES MM, 1962, J HISTOCHEM CYTOCHEM, V10, P175, DOI 10.1177/10.2.175; Hirata Y, 2003, BIOCHEM J, V371, P81, DOI 10.1042/BJ20021844; HO KL, 1987, ACTA NEUROPATHOL, V74, P22, DOI 10.1007/BF00688334; Hojlund K, 2003, DIABETES, V52, P1393, DOI 10.2337/diabetes.52.6.1393; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; KATZ J, 1979, BIOCHEM J, V180, P389, DOI 10.1042/bj1800389; Khaitlina SY, 2001, INT REV CYTOL, V202, P35, DOI 10.1016/S0074-7696(01)02003-4; LANE RD, 1989, BIOCHEM INT, V18, P961; LOMAKO J, 1990, FEBS LETT, V268, P8, DOI 10.1016/0014-5793(90)80959-M; MacArthur DG, 2004, BIOESSAYS, V26, P786, DOI 10.1002/bies.20061; MASTERS C, 1984, J CELL BIOL, V99, pS222, DOI 10.1083/jcb.99.1.222s; MCHUGH KM, 1991, DEV BIOL, V148, P442, DOI 10.1016/0012-1606(91)90263-3; Nielsen JN, 2001, J PHYSIOL-LONDON, V531, P757, DOI 10.1111/j.1469-7793.2001.0757h.x; NORRIS FH, 1969, ARCH NEUROL-CHICAGO, V21, P25, DOI 10.1001/archneur.1969.00480130039004; Ou HS, 2005, ENDOCRINOLOGY, V146, P494, DOI 10.1210/en.2004-1022; Perry SV, 2001, J MUSCLE RES CELL M, V22, P5, DOI 10.1023/A:1010303732441; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; Prats C, 2002, BBA-GEN SUBJECTS, V1573, P68, DOI 10.1016/S0304-4165(02)00332-X; Rakus D, 2003, BIOCHEM BIOPH RES CO, V311, P294, DOI 10.1016/j.bbrc.2003.09.209; Roach P. J., 1986, ENZYMES, VXVII, P499; Roach Peter J., 2002, Current Molecular Medicine (Hilversum), V2, P101, DOI 10.2174/1566524024605761; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROSTGAARD J, 1993, J MICROSC-OXFORD, V172, P137, DOI 10.1111/j.1365-2818.1993.tb03405.x; ROTHMANDENES LB, 1971, BIOCHEMISTRY-US, V10, P1236; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; Sugden C, 1999, PLANT J, V19, P433, DOI 10.1046/j.1365-313X.1999.00532.x; VILLARPALASI C, 1991, BIOCHIM BIOPHYS ACTA, V1095, P261, DOI 10.1016/0167-4889(91)90109-B; WANSON JC, 1968, J CELL BIOL, V38, P130, DOI 10.1083/jcb.38.1.130; WARREN KS, 1995, J CELL BIOL, V129, P697, DOI 10.1083/jcb.129.3.697; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0	59	51	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23165	23172		10.1074/jbc.M502713200	http://dx.doi.org/10.1074/jbc.M502713200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15840572	hybrid			2022-12-25	WOS:000229741800074
J	Urbaniak, MD; Crossman, A; Chang, TH; Smith, TK; van Aalten, DMF; Ferguson, MAJ				Urbaniak, MD; Crossman, A; Chang, TH; Smith, TK; van Aalten, DMF; Ferguson, MAJ			The N-acetyl-d-glucosaminylphosphatidylinositol De-N-acetylase of glycosylphosphatidylinositol biosynthesis is a zinc metalloenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ANCHOR BIOSYNTHESIS; GPI BIOSYNTHESIS; MEMBRANE ANCHOR; MYCOBACTERIUM-TUBERCULOSIS; SUBSTRATE-SPECIFICITY; AFRICAN TRYPANOSOMES; INOSITOL-ACYLATION; PATHWAY; ENZYMES	The de-N-acetylation of N-acetyl-D-glucosaminylphosphatidylinositol (GlcNAc-PI) is the second step of mammalian and trypanosomal glycosylphosphatidylinositol biosynthesis. Glycosylphosphatidylinositol biosynthesis is essential for Trypanosoma brucei, the causative agent of African sleeping sickness, and GlcNAc-PI de-N-acetylase has previously been validated as a drug target. Inhibition of the trypanosome cell-free system and recombinant rat GlcNAc-PI de-N-acetylase by divalent metal cation chelators demonstrates that a tightly bound divalent metal cation is essential for activity. Reconstitution of metal-free GlcNAc-PI de-N-acetylase with divalent metal cations restores activity in the order Zn2+ > Cu2+ > Ni2+ > Co2+ > Mg2+. Site-directed mutagenesis and homology modeling were used to identify active site residues and postulate a mechanism of action. The characterization of GlcNAc-PI de-N-acetylase as a zinc metalloenzyme will facilitate the rational design of anti-protozoan parasite drugs.	Univ Dundee, Div Biol Chem & Mol Microbiol, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of Dundee	Ferguson, MAJ (corresponding author), Univ Dundee, Div Biol Chem & Mol Microbiol, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	m.a.j.ferguson@dundee.ac.uk	Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714; van Aalten, Daan/0000-0002-1499-6908; Urbaniak, Michael/0000-0003-2745-9420	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AULD DS, 1995, METHOD ENZYMOL, V248, P228; Chang TH, 2002, J BIOL CHEM, V277, P50176, DOI 10.1074/jbc.M208374200; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; Crossman A, 2002, CARBOHYD RES, V337, P2049, DOI 10.1016/S0008-6215(02)00187-8; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DOERING TL, 1989, J BIOL CHEM, V264, P11168; Eisenhaber B, 2003, BIOESSAYS, V25, P367, DOI 10.1002/bies.10254; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; FERGUSON MAJ, 1994, GLYCOBIOLOGY PRACTIC, P349; GUTHER MLS, 1994, J BIOL CHEM, V269, P18694; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; Handa N, 2003, PROTEIN SCI, V12, P1621, DOI 10.1110/gad.03104003; Jackman JE, 1999, BIOCHEMISTRY-US, V38, P1902, DOI 10.1021/bi982339s; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; LARSEN KS, 1989, BIOCHEMISTRY-US, V28, P9620, DOI 10.1021/bi00451a012; Lillico S, 2003, MOL BIOL CELL, V14, P1182, DOI 10.1091/mbc.E02-03-0167; MACEDO CSD, 2003, BIOCHIMIE, V85, P465; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; Maynes JT, 2003, J BIOL CHEM, V278, P47166, DOI 10.1074/jbc.M308914200; McCarthy AA, 2004, J MOL BIOL, V335, P1131, DOI 10.1016/j.jmb.2003.11.034; Mehlert A, 1998, MOL BIOCHEM PARASIT, V91, P145, DOI 10.1016/S0166-6851(97)00187-4; MILNE KG, 1994, J BIOL CHEM, V269, P16403; Morita Y. S., 2000, OLIGOSACCHARIDES CHE, P417; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Sharma DK, 1999, GLYCOBIOLOGY, V9, P415, DOI 10.1093/glycob/9.4.415; Sharma DK, 1997, BIOCHEM J, V328, P171; Smith TK, 2000, BIOCHEMISTRY-US, V39, P11801, DOI 10.1021/bi000854w; Smith TK, 2004, EMBO J, V23, P4701, DOI 10.1038/sj.emboj.7600456; Smith TK, 1996, J BIOL CHEM, V271, P6476, DOI 10.1074/jbc.271.11.6476; Smith TK, 2002, J BIOL CHEM, V277, P37147, DOI 10.1074/jbc.M203371200; Smith TK, 2001, EMBO J, V20, P3322, DOI 10.1093/emboj/20.13.3322; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Watanabe R, 1999, BIOCHEM J, V339, P185, DOI 10.1042/0264-6021:3390185; White RJ, 2003, CURR OPIN PHARMACOL, V3, P502, DOI 10.1016/S1471-4892(03)00115-2; Whittington DA, 2003, P NATL ACAD SCI USA, V100, P8146, DOI 10.1073/pnas.1432990100	40	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22831	22838		10.1074/jbc.M502402200	http://dx.doi.org/10.1074/jbc.M502402200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817455	hybrid			2022-12-25	WOS:000229741800035
J	Zhang, XM; Podsypanina, K; Huang, SX; Mohsin, SK; Chamness, GC; Hatsell, S; Cowin, P; Schiff, R; Li, Y				Zhang, XM; Podsypanina, K; Huang, SX; Mohsin, SK; Chamness, GC; Hatsell, S; Cowin, P; Schiff, R; Li, Y			Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations	ONCOGENE			English	Article						estrogen receptor; breast cancer; Wnt; mouse model	HUMAN-BREAST-CANCER; HUMAN ENDOTHELIAL-CELLS; IN-VIVO; PATHWAY ACTIVATION; HORMONE DEPENDENCE; NEU PROTOONCOGENE; GLAND HYPERPLASIA; PROGENITOR CELLS; BETA-CATENIN; STEM-CELLS	The majority (75%) of human breast cancers express estrogen receptor (ER). Although ER-positive tumors usually respond to antiestrogen therapies, 30% of them do not. It is not known what controls the ER status of breast cancers or their responsiveness to antihormone interventions. In this report, we document that transgenic (TG) expression of Wnt-1 in mice induces ER-positive tumors. Loss of Pten or gain of Ras mutations during the evolution of tumors in Wnt-1 TG mice has no effect on the expression of ER, but overexpression of Neu or loss of p53 leads to ER-negative tumors. Thus, our results provide compelling evidence that expression of ER in breast cancer may be influenced by specific genetic changes that promote cancer progression. These findings constitute a first step to explore the molecular mechanisms leading to ER-positive or ER-negative mammary tumors. In addition, we find that ER-positive tumors arising in Wnt-1 TG mice are refractory to both ovariectomy and the ER antagonist tamoxifen, but lose ER expression with tamoxifen, suggesting that antiestrogen selects for ER-negative tumor cells and that the ER-positive cell fraction is dispensable for growth of these tumors. This is a first report of a mouse model of antiestrogen-resistant ER-positive breast cancers, and could provide a powerful tool to study the molecular mechanisms that control antiestrogen resistance.	Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Mem Sloan Kettering Canc Ctr, Cell Biol & Genet Program, Varmus Lab, New York, NY 10021 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Memorial Sloan Kettering Cancer Center; New York University; New York University; Baylor College of Medicine	Li, Y (corresponding author), Baylor Coll Med, Breast Ctr, 1 Baylor Plaza,N1210-03, Houston, TX 77030 USA.	liyi@breastcenter.tmc.edu	Li, Yi/A-7635-2009	Li, Yi/0000-0002-9976-518X; Hatsell, Sarah/0000-0003-1103-6087; Cowin, Pamela/0000-0002-1827-1154; li, yi/0000-0002-3875-3513	NATIONAL CANCER INSTITUTE [P01CA094060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047429] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA94060-02] Funding Source: Medline; NIGMS NIH HHS [GM47429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allred DC, 2004, BREAST CANCER RES, V6, P240, DOI 10.1186/bcr938; Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Barbareschi M, 1996, HUM PATHOL, V27, P1149, DOI 10.1016/S0046-8177(96)90307-X; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; Brennan KR, 2004, J MAMMARY GLAND BIOL, V9, P119, DOI 10.1023/B:JOMG.0000037157.94207.33; Cheng GJ, 2004, P NATL ACAD SCI USA, V101, P3739, DOI 10.1073/pnas.0307864100; Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Clarke RB, 1997, CANCER RES, V57, P4987; Cui XS, 2000, ONCOGENE, V19, P5988, DOI 10.1038/sj.onc.1203993; Cunha GR, 1996, J MAMMARY GLAND BIOL, V1, P21, DOI 10.1007/BF02096300; Dai C, 2003, CANCER J, V9, P72, DOI 10.1097/00130404-200303000-00002; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011; Faridi J, 2003, CLIN CANCER RES, V9, P2933; Figtree GA, 2003, CIRCULATION, V107, P120, DOI 10.1161/01.CIR.0000043805.11780.F5; Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976; Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426; Gattelli A, 2004, CANCER RES, V64, P5193, DOI 10.1158/0008-5472.CAN-03-3992; Giamarchi C, 2002, BBA-GENE STRUCT EXPR, V1578, P12, DOI 10.1016/S0167-4781(02)00480-3; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; Klopocki E, 2004, INT J ONCOL, V25, P641; Konecny G, 2003, J NATL CANCER I, V95, P142, DOI 10.1093/jnci/95.2.142; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; LE GP, 1994, J BIOL CHEM, V269, P4458; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Lin SCJ, 2004, CANCER RES, V64, P3525, DOI 10.1158/0008-5472.CAN-03-3524; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; MATSUZAWA A, 1986, INT REV CYTOL, V103, P303, DOI 10.1016/S0074-7696(08)60839-6; MCGUIRE WL, 1991, MOL ENDOCRINOL, V5, P1571, DOI 10.1210/mend-5-11-1571; Medina D, 2003, CANCER RES, V63, P1067; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; MEDINA D, 1980, CANCER RES, V40, P368; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016; Milovanovic T, 2004, INT J ONCOL, V25, P1337; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Podsypanina K, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-24; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shi W, 2003, INT J CANCER, V104, P195, DOI 10.1002/ijc.10909; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307; Swope DL, 2002, GENE, V294, P239, DOI 10.1016/S0378-1119(02)00796-5; Tilli MT, 2003, AM J PATHOL, V163, P1713, DOI 10.1016/S0002-9440(10)63529-8; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Wu KD, 2002, CANCER RES, V62, P6376; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	77	38	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4220	4231		10.1038/sj.onc.1208597	http://dx.doi.org/10.1038/sj.onc.1208597			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15824740				2022-12-25	WOS:000229815300006
J	Argmann, CA; Edwards, JY; Sawyez, CG; O'Neil, CH; Hegele, RA; Pickering, JG; Huff, MW				Argmann, CA; Edwards, JY; Sawyez, CG; O'Neil, CH; Hegele, RA; Pickering, JG; Huff, MW			Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; HIGH-DENSITY-LIPOPROTEINS; CASSETTE TRANSPORTER A1; PPAR-GAMMA; X-RECEPTOR; HYPERTRIGLYCERIDEMIC VLDL; CARDIOVASCULAR-DISEASE; ESTER ACCUMULATION; SCAVENGER RECEPTOR; FOAM CELL	The cholesterol biosynthetic pathway produces numerous signaling molecules. Oxysterols through liver X receptor (LXR) activation regulate cholesterol efflux, whereas the non-sterol mevalonate metabolite, geranylgeranyl pyrophosphate (GGPP), was recently demonstrated to inhibit ABCA1 expression directly, through antagonism of LXR and indirectly through enhanced RhoA geranylgeranylation. We used HMG-CoA reductase inhibitors (statins) to test the hypothesis that reduced synthesis of mevalonate metabolites would enhance cholesterol efflux and attenuate foam cell formation. Preincubation of THP-1 macrophages with atorvastatin, dose dependently (1-10 mu M) stimulated cholesterol efflux to apolipoprotein AI (apoAI, 10-60%, p < 0.05) and high density lipoprotein (HDL3) (2-50%, p < 0.05), despite a significant decrease in cholesterol synthesis (2-90%). Atorvastatin also increased ABCA1 and ABCG1 mRNA abundance ( 30 and 35%, p < 0.05). Addition of mevalonate, GGPP or farnesyl pyrophosphate completely blocked the statin-induced increase in ABCA1 expression and apoAI-mediated cholesterol efflux. A role for RhoA was established, because two inhibitors of Rho protein activity, a geranylgeranyl transferase inhibitor and C3 exoenzyme, increased cholesterol efflux to apoAI (20-35%, p < 0.05), and macrophage expression of dominant-negative RhoA enhanced cholesterol efflux to apoAI (20%, p < 0.05). In addition, atorvastatin increased the RhoA levels in the cytosol fraction and decreased the membrane localization of RhoA. Atorvastatin treatment activated peroxisome proliferator activated receptor gamma and increased LXR-mediated gene expression suggesting that atorvastatin induces cholesterol efflux through a molecular cascade involving inhibition of RhoA signaling, leading to increased peroxisome proliferator activated receptor gamma activity, enhanced LXR activation, increased ABCA1 expression, and cholesterol efflux. Finally, statin treatment inhibited cholesteryl ester accumulation in macrophages challenged with atherogenic hypertriglyceridemic very low density lipoproteins indicating that statins can regulate foam cell formation.	Univ Western Ontario, Vasc Biol Grp, Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Med, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Huff, MW (corresponding author), Univ Western Ontario, Vasc Biol Grp, Robarts Res Inst, Rm 4-16,100 Perth Dr, London, ON N6A 5K8, Canada.	mhuff@uwo.ca	Huff, Murray/G-3307-2011; Hegele, Robert/AAF-6482-2020; Hegele, Robert/G-3301-2011; Pickering, J. Geoffrey/G-3341-2011	Hegele, Robert/0000-0003-2861-5325; Pickering, J. Geoffrey/0000-0001-6474-3274				Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Argmann CA, 2001, ARTERIOSCL THROM VAS, V21, P2011, DOI 10.1161/hq1201.099426; Argmann CA, 2003, ARTERIOSCL THROM VAS, V23, P475, DOI 10.1161/01.ATV.0000058860.62870.6E; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bocher V, 2002, ANN NY ACAD SCI, V967, P7; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J LIPID RES, V21, P505; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Costet P, 2000, J BIOL CHEM, V275, P28240; Dussault I, 2000, PROSTAG OTH LIPID M, V62, P1, DOI 10.1016/S0090-6980(00)00071-X; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; EVANS AJ, 1993, J LIPID RES, V34, P703; EVANS AJ, 1992, J BIOL CHEM, V267, P10743; Fitzgerald ML, 2002, J MOL MED, V80, P271, DOI 10.1007/s00109-001-0318-y; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Grip O, 2002, INFLAMM RES, V51, P58, DOI 10.1007/BF02684000; Han JH, 2004, CIRCULATION, V110, P3472, DOI 10.1161/01.CIR.0000148368.79202.F1; Han JH, 2000, J BIOL CHEM, V275, P1241, DOI 10.1074/jbc.275.2.1241; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hillyard DZ, 2004, ATHEROSCLEROSIS, V175, P305, DOI 10.1016/j.atherosclerosis.2004.03.018; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Inoue I, 2002, BIOCHEM BIOPH RES CO, V290, P131, DOI 10.1006/bbrc.2001.6141; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344; Keller RK, 1996, ARCH BIOCHEM BIOPHYS, V328, P324, DOI 10.1006/abbi.1996.0180; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Laufs U, 2000, CIRC RES, V87, P526, DOI 10.1161/01.RES.87.7.526; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; Li AC, 2002, NAT MED, V8, P1235, DOI 10.1038/nm1102-1235; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Maejima T, 2004, BIOCHEM BIOPH RES CO, V324, P835, DOI 10.1016/j.bbrc.2004.09.122; Martin G, 2001, J CLIN INVEST, V107, P1423, DOI 10.1172/JCI10852; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; Meiner V, 1997, J LIPID RES, V38, P1928; Oram JF, 2002, CURR OPIN LIPIDOL, V13, P373, DOI 10.1097/00041433-200208000-00004; Ory DS, 2004, CIRC RES, V95, P660, DOI 10.1161/01.RES.0000143422.83209.be; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rowe AH, 2003, CIRC RES, V93, P717, DOI 10.1161/01.RES.0000097606.43659.F4; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shimokawa H, 2002, J CARDIOVASC PHARM, V39, P319, DOI 10.1097/00005344-200203000-00001; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1529, P203, DOI 10.1016/S1388-1981(00)00149-9; Sone H, 2004, BIOCHEM BIOPH RES CO, V316, P790, DOI 10.1016/j.bbrc.2004.02.121; Song C, 2001, STEROIDS, V66, P473, DOI 10.1016/S0039-128X(00)00239-7; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Tall AR, 2002, J CLIN INVEST, V110, P899, DOI 10.1172/JCI200216391; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Whitman SC, 1997, ARTERIOSCL THROM VAS, V17, P1707, DOI 10.1161/01.ATV.17.9.1707; Whitman SC, 1998, J LIPID RES, V39, P1008; Wilcox LJ, 2001, J LIPID RES, V42, P725; Wilcox LJ, 1999, CARDIOVASC DRUG REV, V17, P160, DOI 10.1111/j.1527-3466.1999.tb00011.x; Wong J, 2004, ARTERIOSCL THROM VAS, V24, P2365, DOI 10.1161/01.ATV.0000148707.93054.7d; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873	57	112	122	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22212	22221		10.1074/jbc.M502761200	http://dx.doi.org/10.1074/jbc.M502761200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817453	hybrid			2022-12-25	WOS:000229557900067
J	Arnold, NB; Korc, M				Arnold, NB; Korc, M			Smad7 abrogates transforming growth factor-beta 1-mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA-RECEPTOR; PANCREATIC-CANCER CELLS; TUMOR-SUPPRESSOR GENE; CYCLIN D1 EXPRESSION; MESENCHYMAL TRANSDIFFERENTIATION; NEGATIVE REGULATION; UP-REGULATION; KINASE; ROLES; APOPTOSIS	Smad7 is overexpressed in 50% of human pancreatic cancers. COLO-357 pancreatic cancer cells engineered to overexpress Smad7 are resistant to the actions of transforming growth factor-beta 1 (TGF-beta 1) with respect to growth inhibition and cisplatin-induced apoptosis but not with respect to modulation of gene expression. To delineate the mechanisms underlying these divergent consequences of Smad7 overexpression, we studied the effects of Smad7 on TGF-beta 1-dependent signaling pathways and cell cycle regulating proteins. TGF-beta 1 induced the phosphorylation of MAPK, p38 MAPK, and AKT2 irrespective of the levels of Smad7, and inhibitors of these pathways did not alter TGF-beta 1 actions on cell growth. By contrast, Smad7 overexpression interfered with TGF-beta 1-mediated attenuation of cyclin A and B levels, inhibition of cdc2 dephosphorylation and CDK2 inactivation, up-regulation of p27, and the maintenance of the retinoblastoma protein (RB) in a hypophosphorylated state. Smad7 also suppressed TGF-beta 1-mediated inhibition of E2F activity but did not alter TGF-beta 1-mediated phosphorylation of Smad2, the nuclear translocation of Smad2/3/4, or DNA binding of the Smad2/3/4 complex. Although Smad7 did not associate with the type I TGF-beta receptor (T beta RI), SB-431542, an inhibitor of the kinase activity of this receptor, blocked TGF-beta 1-mediated effects on Smad-2 phosphorylation. These findings point toward a novel paradigm whereby Smad7 acts to functionally inactivate RB and de-repress E2F without blocking the activation of T beta RI and the nuclear translocation of Smad2/3, thereby allowing for TGF-beta 1 to exert effects in a cancer cell that is resistant to TGF-beta 1-mediated growth inhibition.	Dartmouth Coll, Hitchcock Med Ctr, Dept Med, Lebanon, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College; Dartmouth College	Korc, M (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dept Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Murray.Korc@Dartmouth.edu			NCI NIH HHS [CA 75059] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA075059, R01CA075059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnold NB, 2004, CANCER RES, V64, P3599, DOI 10.1158/0008-5472.CAN-03-2999; Asano Y, 2004, J CLIN INVEST, V113, P253, DOI 10.1172/JCI200416269; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; BARTON CM, 1995, MOL CARCINOGEN, V13, P61, DOI 10.1002/mc.2940130202; Berg DT, 2005, J BIOL CHEM, V280, P14943, DOI 10.1074/jbc.C400579200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chung DC, 1997, CLIN ENDOCRINOL, V47, P523, DOI 10.1046/j.1365-2265.1997.2861110.x; Claudio P, 2002, GENOME BIOL, V3; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Cowgill SM, 2003, AM J SURG, V186, P279, DOI 10.1016/S0002-9610(03)00226-5; Dahler AL, 2001, J INVEST DERMATOL, V116, P266, DOI 10.1046/j.1523-1747.2001.01243.x; Davoodpour P, 2005, J BIOL CHEM, V280, P14773, DOI 10.1074/jbc.M414470200; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ellenrieder V, 2001, CANCER RES, V61, P4222; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Ferrigno O, 2002, ONCOGENE, V21, P4879, DOI 10.1038/sj.onc.1205623; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FRIESS H, 1993, CANCER RES, V53, P2704; Goggins M, 1998, AM J PATHOL, V152, P1501; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; JEOUNG DI, 1995, BIOCHEM BIOPH RES CO, V216, P964, DOI 10.1006/bbrc.1995.2714; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; KO TC, 1995, ONCOGENE, V10, P177; KORC M, 2003, GASTROINTESTINAL CAN, V1, P519; Kornmann M, 1997, ONCOGENE, V15, P1417, DOI 10.1038/sj.onc.1201307; Kornmann M, 1999, INT J CANCER, V83, P247, DOI 10.1002/(SICI)1097-0215(19991008)83:2<247::AID-IJC17>3.0.CO;2-0; MANAGHIJAULIN J, 1998, NATURE, V391, P601; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Munger K, 2002, FRONT BIOSCI-LANDMRK, V7, pD641, DOI 10.2741/munger; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Pulaski L, 2001, J BIOL CHEM, V276, P14344, DOI 10.1074/jbc.M011019200; RAITANO AB, 1990, J BIOL CHEM, V265, P10466; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; ROBERTS AB, 1983, FED PROC, V42, P2621; ROBERTS AB, 1988, BRIT J CANCER, V57, P594, DOI 10.1038/bjc.1988.135; Robson CN, 1999, J ENDOCRINOL, V160, P257, DOI 10.1677/joe.0.1600257; Shi WB, 2004, J CELL BIOL, V164, P291, DOI 10.1083/jcb.200307151; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Zhu HJ, 1999, J BIOL CHEM, V274, P32258, DOI 10.1074/jbc.274.45.32258	66	27	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21858	21866		10.1074/jbc.M500583200	http://dx.doi.org/10.1074/jbc.M500583200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15811853	hybrid			2022-12-25	WOS:000229557900026
J	Bartlett, PJ; Young, KW; Nahorski, SR; Challiss, RAJ				Bartlett, PJ; Young, KW; Nahorski, SR; Challiss, RAJ			Single cell analysis and temporal profiling of agonist-mediated inositol 1,4,5-trisphosphate, Ca2+, diacylglycerol, and protein kinase C signaling using fluorescent biosensors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D; RECEPTOR; CALCIUM; PHOSPHORYLATION; ACTIVATION; OSCILLATIONS; DYNAMICS; PHOSPHATIDATE; VISUALIZATION; TRANSLOCATION	The magnitude and temporal nature of intracellular signaling cascades can now be visualized directly in single cells by the use of protein domains tagged with enhanced green fluorescent protein (eGFP). In this study, signaling downstream of G protein-coupled receptor-mediated phospholipase C (PLC) activation has been investigated in a cell line coexpressing recombinant M-3 muscarinic acetylcholine and alpha(1B)-adrenergic receptors. Confocal measurements of changes in inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3), using the pleckstrin homology domain of PLC delta 1 tagged to eGFP (eGFP-PHPLC delta), and 1,2-diacylglycerol (DAG), using the C1 domain of protein kinase C gamma (PKC gamma) (eGFP-C1(2)-PKC gamma), demonstrated clear translocation responses to methacholine and noradrenaline. Single cell EC50 values calculated for each agonist indicated that responses to downstream signaling targets (Ca2+ mobilization and PKC activation) were approximately 10-fold lower compared with respective Ins(1,4,5)P-3 and DAG EC50 values. Examining the temporal profile of second messenger responses to sub-EC50 concentrations of noradrenaline revealed oscillatory Ins(1,4,5)P-3, DAG, and Ca2+ responses. Oscillatory recruitments of conventional (PKC beta II) and novel (PKC epsilon) PKC isoenzymes were also observed which were synchronous with the Ca2+ response measured simultaneously in the same cell. However, oscillatory PKC activity (as determined by translocation of eGFP-tagged myristoylated alanine-rich C kinase substrate protein) required oscillatory DAG production. We suggest a model that uses regenerative Ca2+ release via Ins(1,4,5)P-3 receptors to initiate oscillatory second messenger production through a positive feedback effect on PLC. By acting on various components of the PLC signaling pathway the frequency-encoded Ca2+ response is able to maintain signal specificity at a level downstream of PKC activation.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Bartlett, PJ (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Maurice Shock Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.	pb70@le.ac.uk	Challiss, R.A. John/A-9412-2008	Challiss, John/0000-0001-5506-2848	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Babwah AV, 2003, J BIOL CHEM, V278, P5419, DOI 10.1074/jbc.M211053200; BATTY IH, 1997, NEUROCHEMISTRY PRACT, P229; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHALLISS RAJ, 1988, BIOCHEM BIOPH RES CO, V157, P684, DOI 10.1016/S0006-291X(88)80304-8; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; Dale LB, 2001, J BIOL CHEM, V276, P35900, DOI 10.1074/jbc.M103847200; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898-6568(02)00074-8; Lee TW, 1997, BIOCHEM J, V325, P733, DOI 10.1042/bj3250733; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Meyer T, 2003, TRENDS CELL BIOL, V13, P101, DOI 10.1016/S0962-8924(02)00040-5; Miyawaki A, 2003, CURR OPIN NEUROBIOL, V13, P591, DOI 10.1016/j.conb.2003.09.005; Mogami H, 2003, J BIOL CHEM, V278, P9896, DOI 10.1074/jbc.M210653200; Nahorski SR, 2003, TRENDS NEUROSCI, V26, P444, DOI 10.1016/S0166-2236(03)00178-4; Nash MS, 2002, J BIOL CHEM, V277, P35947, DOI 10.1074/jbc.M205622200; Nash MS, 2001, BIOCHEM J, V356, P137, DOI 10.1042/0264-6021:3560137; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; Okubo Y, 2001, NEURON, V32, P113, DOI 10.1016/S0896-6273(01)00464-0; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; PURKISS JR, 1992, BIOCHEM J, V287, P31, DOI 10.1042/bj2870031; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; SCHMIDT M, 1995, J BIOL CHEM, V270, P19949, DOI 10.1074/jbc.270.34.19949; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TOBIN AB, 1995, BRIT J PHARMACOL, V116, P1723, DOI 10.1111/j.1476-5381.1995.tb16654.x; Uchino M, 2004, J BIOL CHEM, V279, P2254, DOI 10.1074/jbc.M309894200; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; WILLARS GB, 1995, BRIT J PHARMACOL, V114, P1133, DOI 10.1111/j.1476-5381.1995.tb13325.x; Xu C, 2003, J CELL BIOL, V161, P779, DOI 10.1083/jcb.200301070; Young KW, 2003, J BIOL CHEM, V278, P20753, DOI 10.1074/jbc.M211555200; Young KW, 2004, J NEUROCHEM, V89, P1537, DOI 10.1111/j.1471-4159.2004.02458.x	40	46	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21837	21846		10.1074/jbc.M411843200	http://dx.doi.org/10.1074/jbc.M411843200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15788407	hybrid			2022-12-25	WOS:000229557900023
J	Humphrey, D; Rajfur, Z; Vazquez, ME; Scheswohl, D; Schaller, MD; Jacobson, K; Imperiali, B				Humphrey, D; Rajfur, Z; Vazquez, ME; Scheswohl, D; Schaller, MD; Jacobson, K; Imperiali, B			In Situ photoactivation of a caged phosphotyrosine peptide derived from focal adhesion kinase temporarily halts lamellar extension of single migrating tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC SH2 DOMAIN; TYROSINE PHOSPHORYLATION; C-SRC; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; NULL CELLS; INTEGRIN; BINDING; ASSOCIATION	Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, mediates integrin-based cell signaling by transferring signals regulating cell migration, adhesion, and survival from the extracellular matrix to the cytoplasm. Following autophosphorylation at tyrosine 397, FAK binds the Src homology 2 domains of Src and phosphoinositide 3-kinase, among several other possible binding partners. To further investigate the role of phosphorylated FAK in cell migration in situ, peptides comprising residues 391-406 of human FAK with caged phosphotyrosine 397 were synthesized. Although the caged phosphopeptides were stable to phosphatase activity, the free phosphopeptides showed a half-life of beta 10-15 min in cell lysates. Migrating NBT-II cells (a rat bladder tumor cell line) were microinjected with the caged FAK peptide and locally photoactivated using a focused laser beam. The photoactivation of caged FAK peptide in 8-mu m diameter spots over the cell body led to the temporary arrest of the leading edge migration within similar to 1 min of irradiation. In contrast, cell body migration was not inhibited. Microinjection of a noncaged phosphorylated tyrosine 397 FAK peptide into migrating NBT-II cells also led to lamellar arrest; however, this approach lacks the temporal control afforded by the caged phosphopeptides. Photoactivation of related phosphotyrosine peptides with altered sequences did not result in transient lamellar arrest. We hypothesize that the phosphorylated FAK peptide competes with the endogenous FAK for binding to FAK effectors including, but not limited to, Src and phosphoinositide 3-kinase, causing spatiotemporal misregulation and subsequent lamellar arrest.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Jacobson, K (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.	frap@med.unc.edu	Jacobson, Kenneth Alan/A-1530-2009; Rajfur, Zenon/H-2506-2013; Vazquez, M. Eugenio/D-4083-2012	Jacobson, Kenneth Alan/0000-0001-8104-1493; Vazquez, M. Eugenio/0000-0001-7500-985X; Imperiali, Barbara/0000-0002-5749-7869; Rajfur, Zenon/0000-0003-1265-6480	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM064346] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 64346] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; Chen BH, 2002, J BIOL CHEM, V277, P33857, DOI 10.1074/jbc.M204429200; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Corrie J. E. T., 1993, BIOORGANIC PHOTOCHEM, P243; de Beus E, 1998, CELL MOTIL CYTOSKEL, V41, P126, DOI 10.1002/(SICI)1097-0169(1998)41:2<126::AID-CM4>3.0.CO;2-C; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; Ghosh M, 2002, J AM CHEM SOC, V124, P2440, DOI 10.1021/ja017592l; GILMER T, 1994, J BIOL CHEM, V269, P31711; Goicoechea SM, 2002, INT J BIOCHEM CELL B, V34, P791, DOI 10.1016/S1357-2725(02)00002-X; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; HANCOCK WS, 1976, ANAL BIOCHEM, V71, P260, DOI 10.1016/0003-2697(76)90034-8; HUMPHREY D, 2005, LIVE CELL IMAGING LA, P159; ILLC D, 1995, NATURE, V377, P539; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU XQ, 1993, ONCOGENE, V8, P1119; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Park CH, 1997, J AM CHEM SOC, V119, P2453, DOI 10.1021/ja9635589; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Ren XD, 2000, J CELL SCI, V113, P3673; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rothman DM, 2005, J AM CHEM SOC, V127, P846, DOI 10.1021/ja043875c; Rothman DM, 2003, J ORG CHEM, V68, P6795, DOI 10.1021/jo0344891; Rothman DM, 2002, ORG LETT, V4, P2865, DOI 10.1021/ol0262587; Roy P, 2001, J CELL BIOL, V153, P1035, DOI 10.1083/jcb.153.5.1035; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Shen TL, 2002, J BIOL CHEM, V277, P29069, DOI 10.1074/jbc.M203085200; Sieg DJ, 1999, J CELL SCI, V112, P2677; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Walker JW, 1998, P NATL ACAD SCI USA, V95, P1568, DOI 10.1073/pnas.95.4.1568; Wells A, 1999, CELL MOTIL CYTOSKEL, V44, P227, DOI 10.1002/(SICI)1097-0169(199912)44:4<227::AID-CM1>3.0.CO;2-B; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yeh RH, 2002, J BIOL CHEM, V277, P11527, DOI 10.1074/jbc.M111300200; Zamir E, 2001, J CELL SCI, V114, P3583; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22091	22101		10.1074/jbc.M502726200	http://dx.doi.org/10.1074/jbc.M502726200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817454	hybrid, Green Published			2022-12-25	WOS:000229557900053
J	Schulmann, K; Sterian, A; Berki, A; Yin, J; Sato, F; Xu, Y; Olaru, A; Wang, S; Mori, Y; Deacu, E; Hamilton, J; Kan, T; Krasna, MJ; Beer, DG; Pepe, MS; Abraham, JM; Feng, ZD; Schmiegel, W; Greenwald, BD; Meltzer, SJ				Schulmann, K; Sterian, A; Berki, A; Yin, J; Sato, F; Xu, Y; Olaru, A; Wang, S; Mori, Y; Deacu, E; Hamilton, J; Kan, T; Krasna, MJ; Beer, DG; Pepe, MS; Abraham, JM; Feng, ZD; Schmiegel, W; Greenwald, BD; Meltzer, SJ			Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk	ONCOGENE			English	Article						esophageal cancer; Barrett's esophagus; hypermethylation; early cancer detection; neoplastic progression; cancer biomarkers	HIGH-GRADE DYSPLASIA; CPG ISLAND HYPERMETHYLATION; TUMOR-SUPPRESSOR GENE; PROMOTER HYPERMETHYLATION; FOLLOW-UP; ENDOSCOPIC SURVEILLANCE; ESOPHAGEAL CANCER; CLONAL EXPANSION; DNA METHYLATION; ALLELIC LOSS	Patients with Barrett's esophagus ( BE) are at increased risk of developing esophageal adenocarcinoma (EAC). Clinical neoplastic progression risk factors, such as age and the length of the esophageal BE segment, have been identified. However, improved molecular biomarkers predicting increased progression risk are needed for improved risk assessment and strati. cation. Using real-time quantitative methylation-specific PCR, we screened 10 genes (HPP1, RUNX3, RIZ1, CRBP1, 3-OST-2, APC, TIMP3, p16, MGMT, p14) for promoter hypermethylation in 77 EAC, 93 BE, and 64 normal esophagus ( NE) specimens. A subset of genes manifesting significant differences in methylation frequencies between BE and EAC was then analysed in 20 dysplastic specimens. All 10 genes except p14 were frequently methylated in EACs, with RUNX3, HPP1, CRBP1, RIZ1, and OST-2 representing novel methylation targets in EAC and/or BE. p16, RUNX3, and HPP1 displayed increasing methylation frequencies in BE vs EAC. Furthermore, these increases in methylation occurred early, at the interface between BE and low-grade dysplasia (LGD). To demonstrate the silencing effect of hypermethylation, we selected the EAC cells BIC1, in which the HPP1 promoter is natively methylated, and subjected them to 5-aza-2'-deoxycytidine (Aza-C) treatment. Real-time RT-PCR indicated increased HPP1 mRNA levels after 3 days of Aza-C treatment, as well as decreased levels of methylated HPP1 DNA. Hypermethylation of a subset of six genes ( APC, TIMP3, CRBP1, p16, RUNX3, and HPP1) was then tested in a retrospective longitudinal study of 99 BE and nine LGD specimens obtained from 53 BE patients undergoing surveillance endoscopy. Only high-grade dysplasia (HGD) or EACwere defined as progression end points. Two patient groups were compared: eight progressors ( P) and 45 nonprogressors (NP), using Cox proportional hazards models to determine the relative progression risks of age, BE segment length, and methylation events. Multivariate analyses revealed that only hypermethylation of p16 ( odds ratio ( OR) 1.74, 95% confidence interval (CI) 1.33 - 2.20), RUNX3 ( OR 1.80, 95% CI 1.08 - 2.81), and HPP1 ( OR 1.77, 95% CI 1.06 - 2.81) were independently associated with an increased risk of progression, whereas age, BE segment length, and hypermethylation of TIMP3, APC, or CRBP1 were not independent risk factors. In combined analyses, risk was detectable up to, but not earlier than, 2 years preceding neoplastic progression. Hypermethylation of p16, RUNX3, and HPP1 in BE or LGD may represent independent risk factors for the progression of BE to HGD or EAC. These findings have implications regarding risk strati. cation, early EAC detection, and the appropriate endoscopic surveillance interval for patients with BE.	Univ Maryland, Sch Med, Div Gastroenterol, Baltimore, MD 21201 USA; Ruhr Univ Bochum, Knappschaftskrankenhaus, Dept Med, D-4630 Bochum, Germany; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Fred Hutchinson Canc Res Ctr, Data Management & Coordinating Ctr, Seattle, WA 98104 USA; Baltimore VA Hosp, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Ruhr University Bochum; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Michigan System; University of Michigan; Fred Hutchinson Cancer Center	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Div Gastroenterol, 22 S Greene St,Room N3W62, Baltimore, MD 21201 USA.	smeltzer@medicine.umaryland.edu	Schulmann, Karsten/N-2230-2016	Berki, Agnes/0000-0003-1515-016X	NATIONAL CANCER INSTITUTE [R01CA095323, R01CA001808, R21CA098450, U01CA085069, R01CA077057] Funding Source: NIH RePORTER; NCI NIH HHS [CA95323, CA77057, CA01808, CA85069, CA098450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alikhan M, 1999, GASTROINTEST ENDOSC, V50, P23, DOI 10.1016/S0016-5107(99)70339-1; Arber N, 1996, CANCER EPIDEM BIOMAR, V5, P457; Avidan B, 2002, AM J GASTROENTEROL, V97, P1930, DOI 10.1111/j.1572-0241.2002.05902.x; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Bani-Hani K, 2000, J NATL CANCER I, V92, P1316, DOI 10.1093/jnci/92.16.1316; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; Barrett MT, 1996, ONCOGENE, V13, P1867; Bender CM, 1999, MOL CELL BIOL, V19, P6690; Bian YS, 2002, GASTROENTEROLOGY, V122, P1113, DOI 10.1053/gast.2002.32370; Blot WJ, 1999, SEMIN ONCOL, V26, P2; BROWN LM, 2002, CANC UPPER GASTROINT, P1; CAMERON AJ, 1995, GASTROENTEROLOGY, V109, P1541, DOI 10.1016/0016-5085(95)90642-8; Carling T, 2003, SURGERY, V134, P932, DOI 10.1016/S0039-6060(03)00422-7; Chang HW, 2003, CLIN CANCER RES, V9, P1033; Conio M, 2003, AM J GASTROENTEROL, V98, P1931, DOI 10.1016/S0002-9270(03)00629-4; Corley DA, 2002, GASTROENTEROLOGY, V122, P633, DOI 10.1053/gast.2002.31879; Corn PG, 2001, CLIN CANCER RES, V7, P2765; Cox D. R., 1984, ANAL SURVIVAL DATA; COX DR, 1972, J R STAT SOC B, V34, P187; Drewitz DJ, 1997, AM J GASTROENTEROL, V92, P212; Du Y, 2001, CANCER RES, V61, P8094; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 2000, CANCER RES, V60, P5021; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Esteller M, 2002, CANCER RES, V62, P5902; Galipeau PC, 1999, J NATL CANCER I, V91, P2087, DOI 10.1093/jnci/91.24.2087; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Geddert H, 2004, INT J CANCER, V110, P208, DOI 10.1002/ijc.20058; Gopal DV, 2003, DIGEST DIS SCI, V48, P1537, DOI 10.1023/A:1024715824149; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Heath EI, 2003, DIS ESOPHAGUS, V16, P177, DOI 10.1046/j.1442-2050.2003.00325.x; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; IFTIKHAR SY, 1992, GUT, V33, P1155, DOI 10.1136/gut.33.9.1155; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Issa JPJ, 2001, CANCER RES, V61, P3573; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Jankowski J, 2004, ALIMENT PHARM THER, V19, P54, DOI 10.1111/j.0953-0673.2004.01839.x; Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x; Kang GH, 2004, J PATHOL, V202, P233, DOI 10.1002/path.1503; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060; Klump B, 1998, GASTROENTEROLOGY, V115, P1381, DOI 10.1016/S0016-5085(98)70016-2; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li QL, 2004, BIOCHEM BIOPH RES CO, V314, P223, DOI 10.1016/j.bbrc.2003.12.079; Maley CC, 2004, CANCER RES, V64, P3414, DOI 10.1158/0008-5472.CAN-03-3249; McManus DT, 2004, CANCER RES, V64, P1561, DOI 10.1158/0008-5472.CAN-03-2438; MELTZER SJ, 1990, CANCER RES, V50, P3627; MENKEPLUYMERS MBE, 1993, CANCER, V72, P1155, DOI 10.1002/1097-0142(19930815)72:4<1155::AID-CNCR2820720404>3.0.CO;2-C; MIROS M, 1991, GUT, V32, P1441, DOI 10.1136/gut.32.12.1441; Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146; Montgomery E, 2001, HUM PATHOL, V32, P379, DOI 10.1053/hupa.2001.23511; Montgomery E, 2001, HUM PATHOL, V32, P368, DOI 10.1053/hupa.2001.23510; Mori Y, 2004, CANCER RES, V64, P2434, DOI 10.1158/0008-5472.CAN-03-3508; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; O'Connor JB, 1999, AM J GASTROENTEROL, V94, P2037; Oshimo Y, 2004, INT J CANCER, V110, P212, DOI 10.1002/ijc.20090; Oshimo Y, 2004, PATHOBIOLOGY, V71, P137, DOI 10.1159/000076468; Pepe MS, 2001, J NATL CANCER I, V93, P1054, DOI 10.1093/jnci/93.14.1054; PETERS JH, 1994, J THORAC CARDIOV SUR, V108, P813, DOI 10.1016/S0022-5223(94)70178-4; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; Rabinovitch PS, 2001, AM J GASTROENTEROL, V96, P3071, DOI 10.1111/j.1572-0241.2001.05261.x; Reid BJ, 2001, AM J GASTROENTEROL, V96, P2839; Sampliner RE, 2002, AM J GASTROENTEROL, V97, P1888; Sarbia M, 2004, INT J CANCER, V111, P224, DOI 10.1002/ijc.20212; Sato F, 2002, CANCER RES, V62, P1148; Sato F, 2002, CANCER RES, V62, P6820; Schnell TG, 2001, GASTROENTEROLOGY, V120, P1607, DOI 10.1053/gast.2001.25065; SCHNELL TG, 1992, DIGEST DIS SCI, V37, P137, DOI 10.1007/BF01308357; Shaheen N, 2002, JAMA-J AM MED ASSOC, V287, P1972, DOI 10.1001/jama.287.15.1972; Sharma P, 2000, GUT, V46, P9, DOI 10.1136/gut.46.1.9; Sharma P, 2001, GASTROENTEROLOGY, V120, pA16, DOI 10.1016/S0016-5085(01)80081-0; Shibata DM, 2002, CANCER RES, V62, P5637; Skacel M, 2000, AM J GASTROENTEROL, V95, P3383; Soldes OS, 1999, BRIT J CANCER, V79, P595, DOI 10.1038/sj.bjc.6690094; Spechler SJ, 2002, NEW ENGL J MED, V346, P836, DOI 10.1056/NEJMcp012118; STREITZ JM, 1993, J THORAC CARDIOV SUR, V105, P383; SUZUKI H, 1995, HUM MOL GENET, V4, P1883, DOI 10.1093/hmg/4.10.1883; Teodori L, 1998, CYTOMETRY, V34, P257, DOI 10.1002/(SICI)1097-0320(19981215)34:6<257::AID-CYTO3>3.0.CO;2-S; Tokumaru Y, 2003, ONCOGENE, V22, P6954, DOI 10.1038/sj.onc.1206403; Tseng EE, 2003, J GASTROINTEST SURG, V7, P164, DOI 10.1016/S1091-255X(02)00153-1; vanderBurgh A, 1996, GUT, V39, P5, DOI 10.1136/gut.39.1.5; Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x; Weston AP, 2001, AM J GASTROENTEROL, V96, P1355, DOI 10.1111/j.1572-0241.2001.03851.x; Weston AP, 1997, AM J GASTROENTEROL, V92, P407; Weston AP, 1999, AM J GASTROENTEROL, V94, P3413, DOI 10.1111/j.1572-0241.1999.01602.x; WILLIAMSON WA, 1991, ARCH INTERN MED, V151, P2212, DOI 10.1001/archinte.151.11.2212; Wong DJ, 1997, CANCER RES, V57, P2619; Wong DJ, 2001, CANCER RES, V61, P8284; Xiao WH, 2004, WORLD J GASTROENTERO, V10, P376	92	195	205	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4138	4148		10.1038/sj.onc.1208598	http://dx.doi.org/10.1038/sj.onc.1208598			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15824739				2022-12-25	WOS:000229680300012
J	Choi, CY; Kim, YH; Kim, YO; Park, SJ; Kim, EA; Riemenschneider, W; Gajewski, K; Schulz, RA; Kim, Y				Choi, CY; Kim, YH; Kim, YO; Park, SJ; Kim, EA; Riemenschneider, W; Gajewski, K; Schulz, RA; Kim, Y			Phosphorylation by the DHIPK2 protein kinase modulates the corepressor activity of groucho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TCF; EYE-SPECIFIC ENHANCER; EYELESS GENE; VISCERAL MESODERM; DROSOPHILA EMBRYO; CO-REPRESSORS; EXPRESSION; INTERACTS; HIPK2; DIFFERENTIATION	Groucho function is essential for Drosophila development, acting as a corepressor for specific transcription factors that are downstream targets of various signaling pathways. Here we provide evidence that Groucho is phosphorylated by the DHIPK2 protein kinase. Phosphorylation modulates Groucho corepressor activity by attenuating its protein-protein interaction with a DNA-bound transcription factor. During eye development, DHIPK2 modifies Groucho activity, and eye phenotypes generated by overexpression of Groucho differ depending on its phosphorylation state. Moreover, analysis of nuclear extracts fractionated by column chromatography further shows that phospho- Groucho associates poorly with the corepressor complex, whereas the unphosphorylated form binds tightly. We propose that Groucho phosphorylation by DHIPK2 and its subsequent dissociation from the corepressor complex play a key role in relieving the transcriptional repression of target genes regulated by Groucho, thereby controlling cell fate determination during development.	NHLBI, Lab Res Program, NIH, Bethesda, MD 20892 USA; Sungkyunkwan Univ, Dept Sci Biol, Suwon 440746, South Korea; Digital Biotech, Ansan 425839, South Korea; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Sungkyunkwan University (SKKU); University of Texas System; UTMD Anderson Cancer Center	Choi, CY (corresponding author), NHLBI, Lab Res Program, NIH, Bldg 10, Bethesda, MD 20892 USA.	choicy@skku.ac.kr; yongsok@helix.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Barolo S, 1997, EMBO J, V16, P2883, DOI 10.1093/emboj/16.10.2883; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Choi CY, 1999, J BIOL CHEM, V274, P31543, DOI 10.1074/jbc.274.44.31543; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Courey AJ, 2001, GENE DEV, V15, P2786; Czerny T, 1999, MOL CELL, V3, P297, DOI 10.1016/S1097-2765(00)80457-8; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Flores GV, 2000, CELL, V103, P75, DOI 10.1016/S0092-8674(00)00106-9; Gajewski K, 2001, DEV BIOL, V233, P425, DOI 10.1006/dbio.2001.0220; Goldstein RE, 1999, DEVELOPMENT, V126, P3747; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Hasson P, 2005, NAT GENET, V37, P101, DOI 10.1038/ng1486; Hasson P, 2001, EMBO J, V20, P5725, DOI 10.1093/emboj/20.20.5725; Hauck B, 1999, P NATL ACAD SCI USA, V96, P564, DOI 10.1073/pnas.96.2.564; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Jimenez G, 2000, GENE DEV, V14, P224; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Kanei-Ishii C, 2004, GENE DEV, V18, P816, DOI 10.1101/gad.1170604; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kim YO, 2004, P NATL ACAD SCI USA, V101, P159, DOI 10.1073/pnas.0307205101; Kosman D, 1998, DEV GENES EVOL, V208, P290, DOI 10.1007/s004270050184; Kurata S, 2000, P NATL ACAD SCI USA, V97, P2117, DOI 10.1073/pnas.040556497; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lawrence N, 2001, CURR BIOL, V11, P375, DOI 10.1016/S0960-9822(01)00120-8; Lee YM, 1997, J BIOL CHEM, V272, P17531, DOI 10.1074/jbc.272.28.17531; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; MARDON G, 1994, DEVELOPMENT, V120, P3473; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Niimi T, 1999, DEVELOPMENT, V126, P2253; Nuthall HN, 2004, MOL CELL BIOL, V24, P8395, DOI 10.1128/MCB.24.19.8395-8407.2004; Paroush Z, 1997, DEVELOPMENT, V124, P3827; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Song HY, 2004, MOL CELL BIOL, V24, P4341, DOI 10.1128/MCB.24.10.4341-4350.2004; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; Valentine SA, 1998, MOL CELL BIOL, V18, P6584, DOI 10.1128/MCB.18.11.6584; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wiggins AK, 2004, J CELL BIOL, V167, P257, DOI 10.1083/jcb.200406131; WOLFF T, 2000, DROSOPHILA PROTOCOLS, P201; Zhang HL, 2001, GENE DEV, V15, P261, DOI 10.1101/gad.861201; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	62	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21427	21436		10.1074/jbc.M500496200	http://dx.doi.org/10.1074/jbc.M500496200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802274	hybrid			2022-12-25	WOS:000229438800063
J	Pamplona, R; Dalfo, E; Ayala, VR; Bellmunt, MJ; Prat, J; Ferrer, I; Portero-Otin, M				Pamplona, R; Dalfo, E; Ayala, VR; Bellmunt, MJ; Prat, J; Ferrer, I; Portero-Otin, M			Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation - Effects of Alzheimer disease and identification of lipoxidation targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; LIPID-PEROXIDATION; GLUTAMINE-SYNTHETASE; CREATINE-KINASE; ALPHA-CHAIN; RAT-BRAIN; RECEPTOR; BETA; ASTROCYTES; EXPRESSION	Diverse oxidative pathways, such as direct oxidation of amino acids, glycoxidation, and lipoxidation could contribute to Alzheimer disease pathogenesis. A global survey for the amount of structurally characterized probes for these reactions is lacking and could overcome the lack of specificity derived from measurement of 2,4-dinitrophenylhydrazine reactive carbonyls. Consequently we analyzed (i) the presence and concentrations of glutamic and aminoadipic semialdehydes, N-is an element of(carboxymethyl)-lysine, N-is an element of-(carboxyethyl)-lysine, and N-is an element of-(malondialdehyde)-lysine by means of gas chromatography/mass spectrometry, (ii) the biological response through expression of the receptor for advanced glycation end products, (iii) the fatty acid composition in brain samples from Alzheimer disease patients and age-matched controls, and (iv) the targets of N-is an element of-(malondialdehyde)lysine formation in brain cortex by proteomic techniques. Alzheimer disease was associated with significant, although heterogeneous, increases in the concentrations of all evaluated markers. Alzheimer disease samples presented increases in expression of the receptor for advanced glycation end products with high molecular heterogeneity. Samples from Alzheimer disease patients also showed content of docosahexaenoic acid, which increased lipid peroxidizability. In accordance, N-is an element of-(malondialdehyde)-lysine formation targeted important proteins for both glial and neuronal homeostasis such as neurofilament L, alpha-tubulin, glial fibrillary acidic protein, ubiquinol-cytochrome c reductase complex protein I, and the beta chain of ATP synthase. These data support an important role for lipid peroxidation-derived protein modifications in Alzheimer disease pathogenesis.	Univ Lleida, Fac Med & Ciencies Salut, Dept Ciencies Med Basiques, Metab Pathophysiol Res Grp, E-25008 Lleida, Spain; Univ Barcelona, Bellvitge Hosp, Hosp Llobregat, Inst Neuropatol,Serv Anat Patol, E-08907 Barcelona, Spain; Univ Barcelona, Hosp Llobregat, Fac Med, Dept Biol Cellular & Anat Patol, E-08907 Barcelona, Spain	Universitat de Lleida; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; University of Barcelona	Portero-Otin, M (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, C Montserrat Roig 2, E-25008 Lleida, Spain.	manuel.portero@cmb.udl.es	Dalfo, Esther/AAW-5581-2020; Pamplona, Reinald/A-7359-2010; Prat Sala, Joan/HCI-3331-2022; Portero-Otin, Manuel/B-7122-2009; Ayala, Maria Victoria/A-7391-2010; Curcó, Maria Josep Bellmunt/C-3784-2011	Dalfo, Esther/0000-0003-4677-8515; Pamplona, Reinald/0000-0003-4337-6107; Portero-Otin, Manuel/0000-0002-1823-0299; Ayala, Maria Victoria/0000-0002-1496-966X; Curcó, Maria Josep Bellmunt/0000-0002-3187-1576				Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Aksenov MY, 2001, NEUROSCIENCE, V103, P373, DOI 10.1016/S0306-4522(00)00580-7; AMICI A, 1988, J BIOL CHEM, V365, P3341; Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; Balcz B, 2001, J NEURAL TRANSM-SUPP, P193; Barcelo-Coblijn G, 2003, P NATL ACAD SCI USA, V100, P11321, DOI 10.1073/pnas.1734008100; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bogdanovic N, 2001, DEMENT GERIATR COGN, V12, P364, DOI 10.1159/000051282; BRAAK H, 1999, CEREBRAL CORTEX NEUR, V14; BRETT J, 1993, AM J PATHOL, V143, P1699; Butterfield DA, 2002, NEUROBIOL AGING, V23, P655; CAO GH, 1995, ARCH BIOCHEM BIOPHYS, V320, P106, DOI 10.1006/abbi.1995.1347; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; Chen F, 2004, P NATL ACAD SCI USA, V101, P7687, DOI 10.1073/pnas.0402338101; COSGROVE JP, 1987, LIPIDS, V22, P299, DOI 10.1007/BF02533996; David S, 1998, MOL BRAIN RES, V54, P276, DOI 10.1016/S0169-328X(97)00343-4; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Forne I, 2003, J BIOL CHEM, V278, P50641, DOI 10.1074/jbc.M308531200; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; HAGA S, 1993, BRAIN RES, V601, P88, DOI 10.1016/0006-8993(93)91698-R; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; Kikuchi S, 2003, BRAIN RES REV, V41, P306, DOI 10.1016/S0165-0173(02)00273-4; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Lyras L, 1997, J NEUROCHEM, V68, P2061; Mark RJ, 1997, J NEUROSCI, V17, P1046; Montine TJ, 1999, AM J PATHOL, V155, P863, DOI 10.1016/S0002-9440(10)65185-1; Munch G, 2002, NEUROREPORT, V13, P601; Oyama R, 2000, BBA-PROTEIN STRUCT M, V1479, P91, DOI 10.1016/S0167-4838(00)00057-1; Palmer AM, 1999, J NEURAL TRANSM, V106, P317, DOI 10.1007/s007020050161; Pamplona R, 2002, MECH AGEING DEV, V123, P1437, DOI 10.1016/S0047-6374(02)00076-3; Park IH, 2004, MOL IMMUNOL, V40, P1203, DOI 10.1016/j.molimm.2003.11.027; Poon HF, 2004, NEUROSCIENCE, V126, P915, DOI 10.1016/j.neuroscience.2004.04.046; Porchet R, 2003, PROTEOMICS, V3, P1476, DOI 10.1002/pmic.200300456; Portero-Otin M, 1999, DIABETES, V48, P2215, DOI 10.2337/diabetes.48.11.2215; Rapoport SI, 2001, J LIPID RES, V42, P678; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; Requena JR, 2001, P NATL ACAD SCI USA, V98, P69, DOI 10.1073/pnas.011526698; Robinson SR, 2000, NEUROCHEM INT, V36, P471, DOI 10.1016/S0197-0186(99)00150-3; Sasaki N, 2001, BRAIN RES, V888, P256, DOI 10.1016/S0006-8993(00)03075-4; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; Schmidt AM, 1999, CIRC RES, V84, P489, DOI 10.1161/01.RES.84.5.489; Sergeant N, 2003, NEUROSCIENCE, V117, P293, DOI 10.1016/S0306-4522(02)00747-9; Shoffner JM, 1997, NEUROGENETICS, V1, P13, DOI 10.1007/s100480050002; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Sorensen BK, 2002, ANAL BIOCHEM, V304, P33, DOI 10.1006/abio.2001.5604; Thornalley PJ, 1999, BIOCHEM J, V344, P109, DOI 10.1042/0264-6021:3440109; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yatin SM, 1999, NEUROCHEM RES, V24, P427, DOI 10.1023/A:1020997903147; Yonekura H, 2003, BIOCHEM J, V370, P1097, DOI 10.1042/BJ20021371	50	221	226	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21522	21530		10.1074/jbc.M502255200	http://dx.doi.org/10.1074/jbc.M502255200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799962	Green Published, hybrid			2022-12-25	WOS:000229438800074
J	Vellon, L; Menendez, JA; Lupu, R				Vellon, L; Menendez, JA; Lupu, R			alpha(v)beta(3) integrin regulates Heregulin (HRG)-induced cell proliferation and survival in breast cancer	ONCOGENE			English	Article						Heregulin; alpha(v)beta(3); integrins; S-247; breast cancer	ANGIOGENIC FACTOR; CYR61; METASTASIS; ANTAGONIST; ACTIVATION; EXPRESSION; GROWTH; TUMORIGENICITY; APOPTOSIS; MIGRATION	alpha(v)beta(3) integrin-overexpression in tumor associated vasculature is a marker of poor prognosis in breast cancer. A positive correlation between alpha(v)beta(3) integrin and overexpression of Heregulin (HRG), a growth factor associated with breast cancer aggressiveness was recently demonstrated. Here, we addressed the role of alpha(v)beta(3) in the proliferation and survival of HRG-overexpressing breast cancer models. Expression of the RGD-binding integrins alpha(v)beta(3), alpha(v)beta(5) and alpha(v)beta(6) was assessed in the HRG-overexpressing breast cancer cells MDA-MB-231, Hs578T (231/WT and Hs578T/WT, respectively) and derived cells transfected with the antisense orientation of the HRG-beta 2 full-length cDNA (231/ASPOOL, 231/AS31 and Hs578T/AS15). Interestingly, only alpha(v)beta(3) expression was noticeably decreased by blockade of HRG expression in the 231/ ASPOOL, 231/AS31 and Hs578T/AS15 cells. Small RGD-based peptidomimetic alpha(v)beta(3) antagonists significantly decreased cell viability and anchorage-dependent cell growth of HRG- overexpressing cells, while the low-HRG-expressing 231/AS31 cells did not show a significant response. Mechanistically, functional blockade of alpha(v)beta(3) impaired HRG- promoted hyperactivation of ERK1/ ERK2 MAPK without altering the activation of AKT. Flow cytometric analysis of the cell cycle demonstrated that alpha(v)beta(3) antagonists significantly decreased S- and G2/ M-phase subpopulations of 231/WT and control 231/ VEC cells. Comparable, this effect was linked to an increase in the levels and nuclear translocation of the CDKs inhibitor p27(Kip1). Besides downregulating alpha(v)beta(3) and its driven signaling, HRG blockade led to decreased levels of CYR61 in 231/ASPOOL and 231/AS31 cells. Considering that CYR61 is sufficient to upregulate the expression of alpha(v)beta(3), we then assessed alpha(v)beta(3) levels in MDA-MB-231 cell derivatives expressing the antisense orientation of the CYR61 cDNA (231/CYR61AS-5 and 231/CYR61AS-8). Remarkably, downregulation of CYR61 drastically decreased the levels of alpha(v)beta(3) in the 231/ CYR61-5 and 231/CYR61-8 cells, providing further evidence of a key role for CYR61 in HRG- dependent alpha(v)beta(3) overexpression. Moreover, blockade of CYR61 expression impaired the HRG- induced hyperactivation of ERK1/ ERK2 MAPK without altering the activation status of AKT in MDA-MB-231 cells, thus resembling the effects exerted by the downregulation of HRG expression as well as by functional blockade of alpha(v)beta(3). These results indicate that HRG is regulating alpha(v)beta(3) levels as well as alpha(v)beta(3)-triggered signaling through its downstream effector, CYR61, in highly invasive breast cancer cells. Altogether, the data presented here provide evidence of a CYR61-regulatory role on alpha(v)beta(3) integrin expression in the modulation of uncontrolled growth of HRG-overexpressing breast carcinomas. This work supports additional studies concerning the use of integrin antagonists as dual therapeutic agents in breast cancer, targeting both, endothelial and tumor cells.	Evanston Northwestern Healthcare Res Inst, Dept Med, Breast Canc Translat Res Lab, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Lupu, R (corresponding author), Evanston Northwestern Healthcare Res Inst, Dept Med, Breast Canc Translat Res Lab, 1001 Univ Pl, Evanston, IL 60201 USA.	r-lupu@northwestern.edu	MENENDEZ, JAVIER A/C-6148-2016	MENENDEZ, JAVIER A/0000-0001-8733-4561	PHS HHS [R01-0490490] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Atlas E, 2003, MOL CANCER RES, V1, P165; Buerkle MA, 2002, BRIT J CANCER, V86, P788, DOI 10.1038/sj.bjc.6600141; Butler B, 2003, J BIOL CHEM, V278, P5264, DOI 10.1074/jbc.M206997200; Carron CP, 1998, CANCER RES, V58, P1930; CRAIG WS, 1995, BIOPOLYMERS, V37, P157, DOI 10.1002/bip.360370209; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Griggs David William, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P263; Harms JF, 2004, CLIN EXP METASTAS, V21, P119, DOI 10.1023/B:CLIN.0000024763.69809.64; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Janssen ML, 2002, CANCER RES, V62, P6146; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Leu SJ, 2004, J BIOL CHEM, V279, P44177, DOI 10.1074/jbc.M407850200; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Levkau B, 2002, CELL DEATH DIFFER, V9, P1360, DOI 10.1038/sj.cdd.4401106; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Martin KH, 2002, SCIENCE, V296, P1652, DOI 10.1126/science.296.5573.1652; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; MENENDEZ JA, 2004, ONCOGENE        1213; Meyer Debra Mary, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P825; PERCHEUR I, 2002, FASEB J, V16, P1266; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Reinmuth N, 2003, CANCER RES, V63, P2079; Roberts MS, 2003, J BIOL CHEM, V278, P1975, DOI 10.1074/jbc.M208607200; Rolli M, 2003, P NATL ACAD SCI USA, V100, P9482, DOI 10.1073/pnas.1633689100; Ruegg C, 2004, BBA-REV CANCER, V1654, P51, DOI 10.1016/j.bbcan.2003.09.003; Schaffner P, 2003, CELL MOL LIFE SCI, V60, P119, DOI 10.1007/s000180300008; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Shannon KE, 2004, CLIN EXP METASTAS, V21, P129, DOI 10.1023/B:CLIN.0000024764.93092.5f; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Stupack DG, 2003, ONCOGENE, V22, P9022, DOI 10.1038/sj.onc.1207110; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Tang CK, 1996, CANCER RES, V56, P3350; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2000, CANCER RES, V60, P5603	38	84	88	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3759	3773		10.1038/sj.onc.1208452	http://dx.doi.org/10.1038/sj.onc.1208452			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782133				2022-12-25	WOS:000229346300007
J	Ali, SM; Sabatini, DM				Ali, SM; Sabatini, DM			Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPAMYCIN-INDUCED INHIBITION; MAMMALIAN TARGET; BINDING PARTNER; TOR; ACTIVATION; CYTOSKELETON; PATHWAY; COMPLEX; 4E-BP1; CELLS	The mTOR protein kinase is the target of the immunosuppressive and anti-cancer drug rapamycin and is increasingly recognized as a key regulator of cell growth in mammals. S6 kinase 1 (S6K1) is the best characterized effector of mTOR, and its regulation serves as a model for mTOR signaling. Nutrients and growth factors activate S6K1 by inducing the phosphorylation of threonine 389 in the hydrophobic motif of S6K1. As phosphorylation of Thr(389) is rapamycin sensitive and mTOR can phosphorylate the same site in vitro, it has been suggested that mTOR is the physiological Thr389 kinase. This proposal is not supported, however, by the existence of mutants of S6K1 that are phosphorylated in vivo on Thr389 in a rapamycin-resistant fashion. Here, we demonstrate that the raptor-mTOR complex phosphorylates the rapamycin-sensitive forms of S6K1, while the distinct rictor-mTOR complex phosphorylates the rapamycin-resistant mutants of S6K1. Phosphorylation of Thr389 by rictor-mTOR is independent of the TOR signaling motif and depends on removal of the carboxyl terminal domain of S6K1. Because many members of the AGC family of kinases lack an analogous domain, rictor-mTOR may phosphorylate the hydrophobic motifs of other kinases.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Sabatini, DM (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	sabatini@wi.mit.edu	Ali, Siraj/AAE-2958-2019	/0000-0002-1446-7256	NATIONAL CANCER INSTITUTE [R01CA103866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI047389, R01AI047389] Funding Source: NIH RePORTER; NCI NIH HHS [CA103866] Funding Source: Medline; NIAID NIH HHS [AI47389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; GREZ M, 1990, P NATL ACAD SCI USA, V87, P9202, DOI 10.1073/pnas.87.23.9202; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Oshiro N, 2004, GENES CELLS, V9, P359, DOI 10.1111/j.1356-9597.2004.00727.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; WENG QP, 1995, MOL CELL BIOL, V15, P2333	21	115	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19445	19448		10.1074/jbc.C500125200	http://dx.doi.org/10.1074/jbc.C500125200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15809305	hybrid			2022-12-25	WOS:000229113700004
J	Besnault-Mascard, L; Leprince, C; Auffredou, MT; Meunier, B; Bourgeade, MF; Camonis, J; Lorenzo, HK; Vazquez, A				Besnault-Mascard, L; Leprince, C; Auffredou, MT; Meunier, B; Bourgeade, MF; Camonis, J; Lorenzo, HK; Vazquez, A			Caspase-8 sumoylation is associated with nuclear localization	ONCOGENE			English	Article						caspase; SUMO; nuclear localization; apoptosis; human	DEATH DOMAIN PROTEIN; SUMO-1 MODIFICATION; INDUCED APOPTOSIS; EFFECTOR DOMAIN; P53 ACTIVITY; C-JUN; ACTIVATION; CELLS; RECEPTORS; UBIQUITIN	The cysteine protease caspase-8 plays a pivotal role in the initiation of different apoptotic pathways and controls the maturation and differentiation of various cell types including neurons, fibroblasts and lymphocytes. Specific substrates of caspase-8 are present in both the cytoplasm and the nucleus, which may determine the ultimate biological effect of caspase-8. However, the mechanisms regulating the cellular localization of caspase-8 are still unknown. We show here that, in contrast to other caspases such as caspase-9 and -3, caspase-8 can be sumoylated at lysine 156. This sumoylation (i) is associated with the nuclear localization of caspase-8 and (ii) did not impair caspase-8 activation.	Hop Paul Brousse, INSERM, U542, F-94807 Villejuif, France; Inst Curie, INSERM 528, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Vazquez, A (corresponding author), Hop Paul Brousse, INSERM, U542, Batiment Lavoisier,14 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	vazquez@vjf.inserm.fr	Leprince, Corinne/M-7109-2018; Lorenzo, Hans-Kristian/GLR-5785-2022	Leprince, Corinne/0000-0002-4462-5737; Lorenzo, Hans Kristian/0000-0002-7921-177X				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Benchoua A, 2002, J BIOL CHEM, V277, P34217, DOI 10.1074/jbc.M203941200; Besnault L, 2001, J IMMUNOL, V167, P733, DOI 10.4049/jimmunol.167.2.733; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chatfield K, 2004, BIOCHEM BIOPH RES CO, V323, P1313, DOI 10.1016/j.bbrc.2004.09.003; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Gomez-Angelats M, 2003, CELL DEATH DIFFER, V10, P791, DOI 10.1038/sj.cdd.4401237; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Pichler A, 2002, TRAFFIC, V3, P381, DOI 10.1034/j.1600-0854.2002.30601.x; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sheikh MS, 2003, CELL CYCLE, V2, P346, DOI 10.4161/cc.2.4.421; Shevchenko A, 2000, METH MOL B, V146, P1, DOI 10.1385/1-59259-045-4:1; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265	42	57	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3268	3273		10.1038/sj.onc.1208448	http://dx.doi.org/10.1038/sj.onc.1208448			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15782135				2022-12-25	WOS:000228881800005
J	Piec I; Listrat, A; Alliot, J; Chambon, C; Taylor, RG; Bechet, D				Piec, I; Listrat, A; Alliot, J; Chambon, C; Taylor, RG; Bechet, D			Differential proteome analysis of aging in rat skeletal muscle	FASEB JOURNAL			English	Article						sarcopenia; old; proteomics; stress; cytoskeleton	2-DIMENSIONAL GEL-ELECTROPHORESIS; GENE-EXPRESSION PROFILE; CALORIC RESTRICTION; ENDOPLASMIC-RETICULUM; MASS-SPECTROMETRY; STRIATED-MUSCLE; RHESUS-MONKEYS; FIBER TYPES; OLD RATS; MYBP-C	To identify the mechanisms underlying muscle aging, we have undertaken a high-resolution differential proteomic analysis of gastrocnemius muscle in young adults, mature adults, and old LOU/c/jall rats. Two-dimensional gel electrophoresis and subsequent MALDI-ToF mass spectrometry analyses led to the identification of 40 differentially expressed proteins. Strikingly, most differences characterized old (30-month) animals, whereas young (7-month) and mature (18-month) adults exhibited similar patterns of expression. Important modifications in contractile (actin, myosin light-chains, troponins-T) and cytoskeletal (desmin, tubulin) proteins, and in essential regulatory proteins (gelsolin, myosin binding proteins, CapZ-beta, P23), likely account for dysfunctions in old muscle force generation and speed of contraction. Other features support decreases in cytosolic (triose-phosphate isomerase, enolase, glycerol-3-P dehydrogenase, creatine kinase) and mitochondrial (isocitrate dehydrogenase, cytochrome-c oxidase) energy metabolisms. Muscle aging is often associated with increased oxidative stress. Accordingly, we observed differential regulation of molecular chaperones (hsp20, hsp27, reticuloplasmin ER60) and of proteins implicated in reactive aldehyde detoxification (aldehyde dehydrogenase, glutathione transferase, glyoxalase). We further noticed up-regulation of proteins involved in transcriptional elongation (RNA capping protein) and RNA-editing (Apobec2). Most of these proteins were previously unrecognized as differentially expressed in old muscles, and they represent novel starting points for elucidating the mechanisms of muscle aging.	INRA, Nutr & Prot Metab Lab, Human Nutr Res Ctr, F-63122 Ceyrat, France; Growth & Muscle Metab Lab, Ceyrat, France; Univ Clermont Ferrand, Lab Neuroendocrinol Aging, Aubiere, France; Meat Res Stn, Ceyrat, France	INRAE	Bechet, D (corresponding author), INRA, Nutr & Prot Metab Lab, Human Nutr Res Ctr, UR 551, F-63122 Ceyrat, France.	daniel.bechet@clermont.inra.fr	chambon, christophe/A-1788-2017; Bechet, Daniel/AAU-2874-2020; , Listrat/J-1501-2019; Piec, Isabelle Danielle/GQA-9932-2022	chambon, christophe/0000-0003-0357-9807; Bechet, Daniel/0000-0002-3812-8099; Piec, Isabelle Danielle/0000-0002-0648-1330; Listrat, Anne/0000-0002-6182-1764				Alliot J, 2002, J GERONTOL A-BIOL, V57, pB312, DOI 10.1093/gerona/57.8.B312; BALAGOPAL P, 1997, AM J PHYSIOL, V273, P790; Bejma J, 1999, J APPL PHYSIOL, V87, P465, DOI 10.1152/jappl.1999.87.1.465; Berthier C, 1997, BIOL CELL, V89, P413, DOI 10.1016/S0248-4900(97)89313-6; Bouley J, 2004, PROTEOMICS, V4, P1811, DOI 10.1002/pmic.200300688; Cai D, 2000, ELECTROPHORESIS, V21, P465, DOI 10.1002/(SICI)1522-2683(20000101)21:2<465::AID-ELPS465>3.3.CO;2-X; Carmeli E, 2002, EXP GERONTOL, V37, P477, DOI 10.1016/S0531-5565(01)00220-0; Chang JS, 2003, MECH AGEING DEV, V124, P33, DOI 10.1016/S0047-6374(02)00167-7; Chen JJ, 1996, AGING CLIN EXP RES, V8, P334, DOI 10.1007/BF03339590; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Dalle-Donne I, 2001, FREE RADICAL BIO MED, V31, P1624, DOI 10.1016/S0891-5849(01)00749-3; Davydov VV, 2004, EXP GERONTOL, V39, P11, DOI 10.1016/j.exger.2003.08.009; Ek P, 2002, EUR J BIOCHEM, V269, P5016, DOI 10.1046/j.1432-1033.2002.03206.x; Filatov VL, 1999, BIOCHEMISTRY-MOSCOW+, V64, P969; Gilbert R, 1996, J CELL SCI, V109, P101; Gilbert R, 1999, J CELL SCI, V112, P69; Goldring K, 2002, J CELL SCI, V115, P355; Greenlund LJS, 2003, MECH AGEING DEV, V124, P287, DOI 10.1016/S0047-6374(02)00196-3; Hart MC, 1999, J CELL BIOL, V147, P1287, DOI 10.1083/jcb.147.6.1287; HOLLOSZY JO, 1991, MECH AGEING DEV, V60, P199, DOI 10.1016/0047-6374(91)90131-I; Hughes RC, 2001, BIOCHIMIE, V83, P667; Isfort RJ, 2000, ELECTROPHORESIS, V21, P2228, DOI 10.1002/1522-2683(20000601)21:11<2228::AID-ELPS2228>3.0.CO;2-V; Jideama NM, 1996, J BIOL CHEM, V271, P23277, DOI 10.1074/jbc.271.38.23277; Jubrias SA, 1997, PFLUG ARCH EUR J PHY, V434, P246, DOI 10.1007/s004240050392; Kamel HK, 2003, NUTR REV, V61, P157, DOI 10.1301/nr.2003.may.157-167; Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898; Kim YJ, 2004, BIOCHEM BIOPH RES CO, V318, P579, DOI 10.1016/j.bbrc.2004.04.068; KLITGAARD H, 1990, ACTA PHYSIOL SCAND, V140, P41, DOI 10.1111/j.1748-1716.1990.tb08974.x; Klumpp S, 2003, BIOCHEM BIOPH RES CO, V306, P110, DOI 10.1016/S0006-291X(03)00920-3; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; LARSSON L, 1994, J PHYSIOL-LONDON, V481, P149, DOI 10.1113/jphysiol.1994.sp020426; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; Liao W, 1999, BIOCHEM BIOPH RES CO, V260, P398, DOI 10.1006/bbrc.1999.0925; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; Pastoris O, 2000, EXP GERONTOL, V35, P95, DOI 10.1016/S0531-5565(99)00077-7; Payne AM, 2003, J APPL PHYSIOL, V95, P2554, DOI 10.1152/japplphysiol.00758.2003; Renault V, 2002, AGING CELL, V1, P132, DOI 10.1046/j.1474-9728.2002.00017.x; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Sanchez JC, 2001, PROTEOMICS, V1, P136; Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9; Su T, 2003, P NATL ACAD SCI USA, V100, P7824, DOI 10.1073/pnas.1332160100; Veyrat-Durebex C, 1997, PHYSIOL BEHAV, V62, P1273, DOI 10.1016/S0031-9384(97)00304-1; Vyakarnam A, 1997, MOL CELL BIOL, V17, P4730, DOI 10.1128/MCB.17.8.4730; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Watt Diana J., 2004, Glycoconjugate Journal, V19, P615; Welle S, 2003, PHYSIOL GENOMICS, V14, P149, DOI 10.1152/physiolgenomics.00049.2003; Yan JX, 2001, PROTEOMICS, V1, P424, DOI 10.1002/1615-9861(200103)1:3<424::AID-PROT424>3.3.CO;2-P; Zainal TA, 2000, FASEB J, V14, P1825, DOI 10.1096/fj.99-0881com	50	142	146	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					1143	+		10.1096/fj.04-3084fje	http://dx.doi.org/10.1096/fj.04-3084fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15831715				2022-12-25	WOS:000228865300017
J	Urbich, C; Knau, A; Fichtlscherer, S; Walter, DH; Bruhl, T; Potente, M; Hofmann, WK; de Vos, S; Zeiher, AM; Dimmeler, S				Urbich, C; Knau, A; Fichtlscherer, S; Walter, DH; Bruhl, T; Potente, M; Hofmann, WK; de Vos, S; Zeiher, AM; Dimmeler, S			FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells	FASEB JOURNAL			English	Article						forkhead transcription factors; cell death; PI3K/Akt signaling; statins	FORKHEAD TRANSCRIPTION FACTORS; FAMILY-MEMBER BIM; BCL-2 FAMILY; STATIN THERAPY; AKT; PHOSPHORYLATION; GENE; SURVIVAL; ANGIOGENESIS; BINDING	Endothelial progenitor cells (EPCs) contribute to postnatal neovascularization. Risk factors for coronary artery disease reduce the number of EPCs in humans. Since EPC apoptosis might be a potential mechanism to regulate the number of EPCs, we investigated the effects of oxidative stress and HMG-CoA-reductase inhibitors (statins) on EPC apoptosis. Atorvastatin, mevastatin, or VEGF prevented EPC apoptosis induced by H2O2. The antiapoptotic effect was reversed by inhibition of the PI3K/Akt pathway. Forkhead transcription factors (FOXO1, FOXO3a, FOXO4) exert proapoptotic effects and are phosphorylated and, thereby, inactivated by Akt. Therefore, we elucidated the involvement of forkhead transcription factors. Atorvastatin induced the phosphorylation of the predominant forkhead factor FOXO4 in EPCs. In addition, atorvastatin reduced the expression of the proapoptotic forkhead-regulated protein Bim in a PI3K-dependent manner. Consistently, overexpression of FOXO4 activated the Bim promoter as determined by reporter gene expression and stimulated the expression of Bim, resulting in an increased EPC apoptosis. Statins failed to prevent EPC apoptosis induced by overexpression of Bim or noriphosphorylatable FOXO4, suggesting that the protective effects of statins depend on this pathway. In summary, our results show that FOXO-dependent expression of Bim plays a pivotal role for EPC apoptosis. Statins reduce oxidative stress-induced EPC apoptosis, inactivate FOXO4, and down-regulate Bim.	Goethe Univ Frankfurt, Dept Internal Med 3, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Dept Hematol & Oncol, D-60590 Frankfurt, Germany; Univ Calif Los Angeles, Sch Med, Dept Hematol & Oncol, Los Angeles, CA USA	Goethe University Frankfurt; Goethe University Frankfurt; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Dimmeler, S (corresponding author), Goethe Univ Frankfurt, Dept Internal Med 3, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Dimmeler@em.uni-frankfurt.de		Dimmeler, Stefanie/0000-0002-1045-2436; Potente, Michael/0000-0002-5689-0036				Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; ASSMUS B, 2003, CIRC RES, V3, P3; Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Bhattacharya V, 2000, BLOOD, V95, P581, DOI 10.1182/blood.V95.2.581; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; BRUHL T, 2004, CIRC RES, V5, P5; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen D, 2004, P NATL ACAD SCI USA, V101, P1235, DOI 10.1073/pnas.0308050100; Chen JZ, 2004, INT J BIOCHEM CELL B, V36, P1554, DOI 10.1016/j.biocel.2003.12.015; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; DERNBACH E, 2004, BLOOD, V25, P25; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI200113152; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gehling UM, 2000, BLOOD, V95, P3106; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; He TR, 2004, ARTERIOSCL THROM VAS, V24, P2021, DOI 10.1161/01.ATV.0000142810.27849.8f; Hofmann WK, 2001, BLOOD, V98, P787, DOI 10.1182/blood.V98.3.787; Ito H, 1999, CANCER RES, V59, P5875; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lefer AM, 1999, CIRCULATION, V100, P178, DOI 10.1161/01.CIR.100.2.178; Liu JW, 2002, CANCER RES, V62, P2976; Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI200113131; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Schatteman GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Sorescu D, 2001, TRENDS CARDIOVAS MED, V11, P124, DOI 10.1016/S1050-1738(01)00097-4; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93; Urbich C, 2000, CIRC RES, V87, P683, DOI 10.1161/01.RES.87.8.683; Urbich C, 2002, CIRC RES, V90, P737, DOI 10.1161/01.RES.0000014081.30867.F8; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Vasa M, 2001, CIRCULATION, V103, P2885, DOI 10.1161/hc2401.092816; VILLUNGER A, 2002, BLOOD, V14, P14; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	61	165	186	2	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					974	+		10.1096/fj.04-2727fje	http://dx.doi.org/10.1096/fj.04-2727fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15824087				2022-12-25	WOS:000228865300019
J	Harmancey, R; Senard, JM; Pathak, A; Desmoulin, F; Claparols, C; Rouet, P; Smih, F				Harmancey, R; Senard, JM; Pathak, A; Desmoulin, F; Claparols, C; Rouet, P; Smih, F			The vasoactive peptide adrenomedullin is secreted by adipocytes and inhibits lipolysis through NO-mediated adrenergic agonist oxidation	FASEB JOURNAL			English	Article						3T3-F442A; human adipocytes; isoprenochrome; NEFA	NITRIC-OXIDE; ADIPOSE-TISSUE; NATRIURETIC PEPTIDES; S-NITROSYLATION; PLASMA-LEVELS; REAL-TIME; EXPRESSION; HYPERTENSION; HYPERTROPHY; MECHANISM	Adipocytes are known to secrete a number of adipokines, but many adipocyte secretions and their functional importance remain to be characterized. This work shows that human white adipocytes and 3T3-F442A-derived adipocytes produce adrenomedullin (AM) and that AM acts in an autocrine/paracrine way on lipid metabolism by extracellular inactivation of isoproterenol, a beta-adrenergic agonist. AM is described as a counter-regulatory factor involved in the control of cardiovascular homeostasis. This peptide is believed to protect the heart from several complications implicated in obesity-linked cardiomorbidity, such as arterial hypertension, cardiac fibrosis, and decreased sinusal variability. The exact source of circulating AM remains a matter of debate, although endothelial and vascular smooth muscle cells seem to be important sites of production. We show that human adipose cells and 3T3-F442A-derived adipocytes express AM receptors and secrete AM. The function of this feature was investigated in 3T3-F442A cell line at the level of lipolysis regulation. AM inhibited beta-adrenergic-stimulated lipolysis by a nitric oxide (NO)-dependent mechanism, inducing a significant decrease in pD2 value for isoproterenol (8.6 +/- 0.2 vs. 9.8 +/- 0.1, P<0.001). This effect is cGMP-independent since it occurred in the presence of the NO-sensitive guanylate cyclase inhibitor ODQ. It is apparently mediated by a novel extracellular mechanism. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) demonstrated that AM-produced NO oxidized isoproterenol to generate its aminochrome, namely isoprenochrome. Isoprenochrome amounts were increased 3.62 +/- 1.13-fold in cell culture media (P<0.05). We describe for the first time that AM downregulates lipolysis in adipocytes through the chemical modification of a beta-agonist.	Univ Toulouse 3, CHU Rangueil, Inst Louis Bugnard, INSERM,U586, F-31059 Toulouse, France; Univ Toulouse 3, CNRS, UMR 5068, F-31062 Toulouse, France; Univ Toulouse 3, Serv Spectrometrie Masse FR 2599, F-31062 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Smih, F (corresponding author), Fac Med Toulouse, Pharmacol Lab, 37 Allees Jules Guesde, F-31073 Toulouse, France.	fatima.smih@toulouse.inserm.fr	desmoulin, franck/AAU-4544-2020; Pathak, Atul/E-7532-2010; Pathak, Atul/ABC-5223-2020; DESMOULIN, Franck/O-1895-2018	desmoulin, franck/0000-0003-0560-6266; Pathak, Atul/0000-0001-6151-0096; DESMOULIN, Franck/0000-0003-0560-6266; Senard, Jean-Michel/0000-0001-7679-1281; Rouet, Philippe/0000-0001-6204-2079				Adam L, 1999, J BIOL CHEM, V274, P26337, DOI 10.1074/jbc.274.37.26337; Aerts JL, 2004, BIOTECHNIQUES, V36, P84, DOI 10.2144/04361ST04; Andersson K, 1999, BRIT J PHARMACOL, V126, P1639, DOI 10.1038/sj.bjp.0702430; Autelitano DJ, 2001, CARDIOVASC RES, V51, P255, DOI 10.1016/S0008-6363(01)00318-2; Buys S, 2003, BRIT J PHARMACOL, V139, P1219, DOI 10.1038/sj.bjp.0705350; Daveu C, 1997, NITRIC OXIDE-BIOL CH, V1, P234, DOI 10.1006/niox.1997.0123; Elizalde M, 2000, J LIPID RES, V41, P1244; Engeli S, 2004, J LIPID RES, V45, P1640, DOI 10.1194/jlr.M300322-JLR200; Estrada C, 1997, BIOCHEM J, V326, P369, DOI 10.1042/bj3260369; Eto T, 2003, REGUL PEPTIDES, V112, P61, DOI 10.1016/S0167-0115(03)00023-5; Fruhbeck G., 2004, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V2, P197, DOI 10.2174/1568016043356255; Fukai N, 2005, AM J PHYSIOL-ENDOC M, V288, pE56, DOI 10.1152/ajpendo.00586.2003; Gaudiot N, 1998, J BIOL CHEM, V273, P13475, DOI 10.1074/jbc.273.22.13475; Gaudiot N, 2000, AM J PHYSIOL-CELL PH, V279, pC1603, DOI 10.1152/ajpcell.2000.279.5.C1603; Hanafy K A, 2001, Med Sci Monit, V7, P801; Hayakawa H, 1999, HYPERTENSION, V33, P689, DOI 10.1161/01.HYP.33.2.689; Heo JY, 2004, BIOCHEMISTRY-US, V43, P2314, DOI 10.1021/bi035275g; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Ishihara T, 1999, CLIN NEPHROL, V52, P119; ISHIZAKA Y, 1994, BIOCHEM BIOPH RES CO, V200, P642, DOI 10.1006/bbrc.1994.1496; Kato J, 1999, HYPERTENS RES-CLIN E, V22, P61, DOI 10.1291/hypres.22.61; Kato J, 2002, HYPERTENS RES, V25, P887; Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Klatt P, 2000, BIOCHEM J, V351, P485, DOI 10.1042/0264-6021:3510485; Kleinhenz DJ, 2003, FREE RADICAL BIO MED, V34, P856, DOI 10.1016/S0891-5849(02)01438-7; Lemos-Amado F, 2001, RAPID COMMUN MASS SP, V15, P2466, DOI 10.1002/rcm.498; Letizia C, 2001, Ital Heart J Suppl, V2, P1011; Li S, 2003, ARCH BIOCHEM BIOPHYS, V410, P269, DOI 10.1016/S0003-9861(02)00696-3; Li Y, 2003, EUR J ENDOCRINOL, V149, P231, DOI 10.1530/eje.0.1490231; Lukas A, 2003, EUR J CLIN INVEST, V33, P223, DOI 10.1046/j.1365-2362.2003.01139.x; Luodonpaa M, 2001, PEPTIDES, V22, P1859, DOI 10.1016/S0196-9781(01)00505-8; Martinez A, 1999, PEPTIDES, V20, P1471, DOI 10.1016/S0196-9781(99)00158-8; MESSERLI FH, 1981, ARCH INTERN MED, V141, P81, DOI 10.1001/archinte.141.1.81; Minami J, 2000, J CARDIOVASC PHARM, V36, pS83, DOI 10.1097/00005344-200000006-00018; Minamino N, 2002, MICROSC RES TECHNIQ, V57, P28, DOI 10.1002/jemt.10048; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; Remiao F, 2003, BIOMED CHROMATOGR, V17, P6, DOI 10.1002/bmc.203; RODBELL M, 1964, J BIOL CHEM, V239, P375; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Sharma AM, 2002, INT J OBESITY, V26, pS5, DOI 10.1038/sj.ijo.0802210; Shimosawa T, 2002, CIRCULATION, V105, P106, DOI 10.1161/hc0102.101399; Shindo T, 2000, CIRCULATION, V101, P2309, DOI 10.1161/01.CIR.101.19.2309; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Tomoda Y, 2001, PEPTIDES, V22, P1783, DOI 10.1016/S0196-9781(01)00519-8; Zhang JJ, 2000, HUM GENE THER, V11, P1817, DOI 10.1089/10430340050129440	47	31	31	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					1045	+		10.1096/fj.04-2868fje	http://dx.doi.org/10.1096/fj.04-2868fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15788445				2022-12-25	WOS:000227901300004
J	Kalajzic, I; Staal, A; Yang, WP; Wu, YL; Johnson, SE; Feyen, JHM; Krueger, W; Maye, P; Yu, F; Zhao, YF; Kuo, L; Gupta, RR; Achenie, LEK; Wang, HW; Shin, DG; Rowe, DW				Kalajzic, I; Staal, A; Yang, WP; Wu, YL; Johnson, SE; Feyen, JHM; Krueger, W; Maye, P; Yu, F; Zhao, YF; Kuo, L; Gupta, RR; Achenie, LEK; Wang, HW; Shin, DG; Rowe, DW			Expression profile of osteoblast lineage at defined stages of differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; GENE-EXPRESSION; IN-VITRO; MESSENGER-RNA; MOUSE; RECEPTOR; IDENTIFICATION; TRANSCRIPTION; ANTAGONISTS; TRANSGENES	The inherent heterogeneity of bone cells complicates the interpretation of microarray studies designed to identify genes highly associated with osteoblast differentiation. To overcome this problem, we have utilized Col1a1 promoter-green fluorescent protein transgenic mouse lines to isolate bone cells at distinct stages of osteoprogenitor maturation. Comparison of gene expression patterns from unsorted or isolated sorted bone cell populations at days 7 and 17 of calvarial cultures revealed an increased specificity regarding which genes are selectively expressed in a subset of bone cell types during differentiation. Furthermore, distinctly different patterns of gene expression associated with major signaling pathways (Igf1, Bmp, and Wnt) were observed at different levels of maturation. Some of our data differ from current models of osteoprogenitor cell differentiation and emphasize components of the pathways that were not revealed in studies based on a total cell population. Thus, applying methods to generate more homogeneous populations of cells at a defined level of cellular differentiation from a primary osteogenic culture is feasible and leads to a novel interpretation of the gene expression associated with increasing levels of osteoprogenitor maturation.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06053 USA; Bristol Myers Squibb Co, Dept Metab & Cardiovasc Drug Discovery, Princeton, NJ 08534 USA; Bristol Myers Squibb Co, Dept Appl Genom, Princeton, NJ 08534 USA; Univ Connecticut, Dept Stat, Storrs, CT 06269 USA; Univ Connecticut, Dept Chem Engn, Storrs, CT 06269 USA; Univ Connecticut, Dept Comp Sci, Storrs, CT 06269 USA	University of Connecticut; Bristol-Myers Squibb; Bristol-Myers Squibb; University of Connecticut; University of Connecticut; University of Connecticut	Rowe, DW (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave,MC 3301, Farmington, CT 06053 USA.	rowe@neuron.uchc.edu	Yu, Fang/B-9874-2013; Kuo, Lynn/AAQ-6409-2021	Kuo, Lynn/0000-0002-1903-4425; Maye, Peter/0000-0003-0098-4399	NIDDK NIH HHS [U01-DK63478] Funding Source: Medline; NIGMS NIH HHS [P20 GM65764, P30 GM46026] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK063478] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM065764] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe Y, 2004, J BONE MINER RES, V19, P1302, DOI 10.1359/JBMR.040408; Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb-76-6-899; Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P7873, DOI 10.1093/nar/14.20.7873; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; Garrett IR, 2001, CURR PHARM DESIGN, V7, P715, DOI 10.2174/1381612013397762; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; Harris SE, 2003, FRONT BIOSCI, V8, pS1249, DOI 10.2741/1170; Kaifu T, 2003, J CLIN INVEST, V111, P323, DOI 10.1172/JCI200316923; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Korchynskyi O, 2003, J BONE MINER RES, V18, P1177, DOI 10.1359/jbmr.2003.18.7.1177; Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl; MacDougall M, 1998, J BONE MINER RES, V13, P422, DOI 10.1359/jbmr.1998.13.3.422; Malaval L, 1999, J CELL BIOCHEM, V74, P616; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Newton MA, 2004, BIOSTATISTICS, V5, P155, DOI 10.1093/biostatistics/5.2.155; Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744; Roman-Roman S, 2003, BONE, V32, P474, DOI 10.1016/S8756-3282(03)00052-8; Sambrook J., 1989, MOL CLONING, pA1; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Yoshino K, 2001, MECH DEVELOP, V102, P45, DOI 10.1016/S0925-4773(01)00282-9; YOUNG MF, 1994, MAMM GENOME, V5, P108, DOI 10.1007/BF00292337	28	138	143	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24618	24626		10.1074/jbc.M413834200	http://dx.doi.org/10.1074/jbc.M413834200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15834136	hybrid			2022-12-25	WOS:000230114000041
J	Chan, W; Calderon, G; Swift, AL; Moseley, J; Li, SH; Hosoya, H; Arias, IM; Ortiz, DF				Chan, W; Calderon, G; Swift, AL; Moseley, J; Li, SH; Hosoya, H; Arias, IM; Ortiz, DF			Myosin II regulatory light chain is required for trafficking of bile salt export protein to the apical membrane in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL INTRAHEPATIC CHOLESTASIS; ACTIN-BINDING PROTEINS; GOLGI-DERIVED VESICLES; RAT-LIVER; BLEBBISTATIN INHIBITION; CANALICULAR MEMBRANE; ABC TRANSPORTERS; P-GLYCOPROTEIN; CLAM OOCYTES; IN-VITRO	BSEP, MDR1, and MDR2 ATP binding cassette transporters are targeted to the apical ( canalicular) membrane of hepatocytes, where they mediate ATP-dependent secretion of bile acids, drugs, and phospholipids, respectively. Sorting to the apical membrane is essential for transporter function; however, little is known regarding cellular proteins that bind ATP binding cassette proteins and regulate their trafficking. A yeast two-hybrid screen of a rat liver cDNA library identified the myosin II regulatory light chain, MLC2, as a binding partner for BSEP, MDR1, and MDR2. The interactions were confirmed by glutathione S-transferase pulldown and co-immunoprecipitation assays. BSEP and MLC2 were overrepresented in a rat liver subcellular fraction enriched in canalicular membrane vesicles, and MLC2 colocalized with BSEP in the apical domain of hepatocytes and polarized WifB, HepG2, and Madin-Darby canine kidney cells. Expression of a dominant negative, non-phosphorylatable MLC2 mutant reduced steady state BSEP levels in the apical domain of polarized Madin-Darby canine kidney cells. Pulse-chase studies revealed that Blebbistatin, a specific myosin II inhibitor, severely impaired delivery of newly synthesized BSEP to the apical surface. These findings indicate that myosin II is required for BSEP trafficking to the apical membrane.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Hiroshima Univ, Grad Sch Sci, Dept Sci Biol, Higashihiroshima 7398526, Japan; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	Tufts University; Hiroshima University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Ortiz, DF (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.	daniel.ortiz@tufts.edu			NIDDK NIH HHS [R01DK35652, R01DK060719, T32DK07542, P30 DK34928] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060719, T32DK007542, R01DK035652, P30DK034928] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANIENTO F, 1993, J BIOL CHEM, V268, P10463; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Childs S, 1998, CANCER RES, V58, P4160; CHIU JH, 1990, HEPATOLOGY, V11, P834, DOI 10.1002/hep.1840110519; Dixon PH, 2000, HUM MOL GENET, V9, P1209, DOI 10.1093/hmg/9.8.1209; Dombrowski F, 2000, BIOCHEM J, V348, P183, DOI 10.1042/0264-6021:3480183; Fucini RV, 2002, MOL BIOL CELL, V13, P621, DOI 10.1091/mbc.01-11-0547; Fumoto K, 2003, BIOCHEM J, V370, P551, DOI 10.1042/BJ20021559; Gatmaitan ZC, 1997, AM J PHYSIOL-GASTR L, V272, pG1041, DOI 10.1152/ajpgi.1997.272.5.G1041; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; Heerssen HM, 2004, NAT NEUROSCI, V7, P596, DOI 10.1038/nn1242; Heimann K, 1999, J BIOL CHEM, V274, P10743, DOI 10.1074/jbc.274.16.10743; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; Iida Y, 1997, AM J PHYSIOL-ENDOC M, V273, pE782, DOI 10.1152/ajpendo.1997.273.4.E782; Ikonen E, 1997, J CELL SCI, V110, P2155; Kipp H, 2000, J BIOL CHEM, V275, P15917, DOI 10.1074/jbc.M909875199; Kovacs M, 2004, J BIOL CHEM, V279, P35557, DOI 10.1074/jbc.M405319200; Kullak-Ublick GA, 2000, J HEPATOL, V32, P3, DOI 10.1016/S0168-8278(00)80411-0; Limouze J, 2004, J MUSCLE RES CELL M, V25, P337, DOI 10.1007/s10974-004-6060-7; LOTSCHER HR, 1980, J BIOL CHEM, V255, P9325; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; MOCHIDA S, 1994, NEURON, V13, P1131, DOI 10.1016/0896-6273(94)90051-5; Musch A, 1997, J CELL BIOL, V138, P291, DOI 10.1083/jcb.138.2.291; Neco P, 2004, J BIOL CHEM, V279, P27450, DOI 10.1074/jbc.M311462200; Nies AT, 1996, J LIPID RES, V37, P1125; Novikoff PM, 1996, J CELL SCI, V109, P21; Ortiz DF, 2004, J BIOL CHEM, V279, P32761, DOI 10.1074/jbc.M404337200; Ortiz DF, 1999, AM J PHYSIOL-GASTR L, V276, pG1493, DOI 10.1152/ajpgi.1999.276.6.G1493; Ramamurthy B, 2004, BIOCHEMISTRY-US, V43, P14832, DOI 10.1021/bi0490284; RUETZ S, 1994, J BIOL CHEM, V269, P12277; Ryan TA, 1999, J NEUROSCI, V19, P1317; Sandberg L, 2000, BIOL BULL, V199, P202, DOI 10.2307/1542898; Sellers J. R., 1999, MYOSINS; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; Simerly C, 1998, MOL BIOL CELL, V9, P2509, DOI 10.1091/mbc.9.9.2509; SORMUNEN R, 1993, LAB INVEST, V68, P652; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Suzuki S, 1996, SCAND J GASTROENTERO, V31, P391, DOI 10.3109/00365529609006416; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; TSUKADA N, 1995, HEPATOLOGY, V21, P1106, DOI 10.1002/hep.1840210433; TSUKADA N, 1994, P NATL ACAD SCI USA, V91, P6919, DOI 10.1073/pnas.91.15.6919; VREE JMD, 1998, P NATL ACAD SCI USA, V95, P282; Wakabayashi Y, 2004, MOL BIOL CELL, V15, P3485, DOI 10.1091/mbc.E03-10-0737; Wang L, 2002, J CLIN INVEST, V110, P965, DOI 10.1172/JCI200215968; Wollert T, 2003, BIOL BULL-US, V205, P195, DOI 10.2307/1543249	52	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23741	23747		10.1074/jbc.M502767200	http://dx.doi.org/10.1074/jbc.M502767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15826951	hybrid			2022-12-25	WOS:000229880000043
J	Rybakova, IN; Ervasti, JM				Rybakova, IN; Ervasti, JM			Identification of spectrin-like repeats required for high affinity utrophin-actin interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-RELATED PROTEIN; BINDS F-ACTIN; MUSCULAR-DYSTROPHY; CRYSTAL-STRUCTURE; COSTAMERIC ACTIN; MDX MICE; DOMAIN; MUSCLE; ASSOCIATION; EXPRESSION	Most studies aimed at characterizing the utrophin-actin interaction have focused on the amino-terminal tandem calponin homology domain. However, we recently reported evidence suggesting that spectrin-like repeats of utrophin also participate in binding to actin. Here we expressed several recombinant fragments encoding the utrophin amino-terminal domain alone or in combination with various numbers of spectrin-like repeats. We further quantitatively characterized the actin binding properties of each recombinant utrophin fragment using a high-speed sedimentation assay. To evaluate the capacity of each protein to stabilize actin filaments, we compared the effect of utrophin recombinant fragments and full-length utrophin on 6-propionyl-2-(N,N-dimethylamino) naphthalene actin depolymerization. Our results suggest that, whereas the amino-terminal domain is essential for primary interaction between utrophin and actin, spectrin-like repeats have additive effects on the affinity and stoichiometry of binding. Our data indicate that the amino-terminal domain and first 10 consecutive spectrin-like repeats recapitulate the actin binding activity of full-length utrophin more faithfully than the amino-terminal domain alone. These findings support the model for lateral association of utrophin along the actin filament and provide the molecular basis for designing the most effective utrophin "mini-genes" for treatment of dystrophinopathies.	Univ Wisconsin, Dept Physiol, Serv Mem Inst 127, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ervasti, JM (corresponding author), Univ Wisconsin, Dept Physiol, Serv Mem Inst 127, Sch Med, 1300 Univ Ave, Madison, WI 53706 USA.	ervasti@physiology.wisc.edu	Ervasti, James/AAZ-4786-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042423] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR042423] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; Amann KJ, 1998, J BIOL CHEM, V273, P28419, DOI 10.1074/jbc.273.43.28419; Amann KJ, 1999, J BIOL CHEM, V274, P35375, DOI 10.1074/jbc.274.50.35375; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; Deconinck N, 1997, NAT MED, V3, P1216, DOI 10.1038/nm1197-1216; Djinovic-Carugo K, 2002, FEBS LETT, V513, P119, DOI 10.1016/S0014-5793(01)03304-X; Ervasti JM, 1993, CURR OPIN CELL BIOL, V5, P82, DOI 10.1016/S0955-0674(05)80012-2; Galkin VE, 2003, J MOL BIOL, V331, P967, DOI 10.1016/S0022-2836(03)00842-8; Galkin VE, 2002, J CELL BIOL, V157, P243, DOI 10.1083/jcb.200111097; Garcia-Alvarez B, 2003, STRUCTURE, V11, P615, DOI 10.1016/S0969-2126(03)00090-X; Goldsmith SC, 1997, NAT STRUCT BIOL, V4, P708, DOI 10.1038/nsb0997-708; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Guo WXA, 1996, FEBS LETT, V398, P259; Harper SQ, 2002, HUM MOL GENET, V11, P1807, DOI 10.1093/hmg/11.16.1807; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; Karakesisoglou I, 2000, J CELL BIOL, V149, P195, DOI 10.1083/jcb.149.1.195; Keep NH, 1999, STRUCTURE, V7, P1539, DOI 10.1016/S0969-2126(00)88344-6; Klein MG, 2004, STRUCTURE, V12, P999, DOI 10.1016/j.str.2004.04.010; Leung CL, 2001, J CELL SCI, V114, P3409; Li XL, 1996, J BIOL CHEM, V271, P15695, DOI 10.1074/jbc.271.26.15695; Liu J, 2004, J MOL BIOL, V338, P115, DOI 10.1016/j.jmb.2004.02.034; MAN NT, 1992, FEBS LETT, V313, P19; MARRIOTT G, 1988, BIOCHEMISTRY-US, V27, P6214, DOI 10.1021/bi00417a004; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Moores CA, 2000, CELL MOTIL CYTOSKEL, V46, P116, DOI 10.1002/1097-0169(200006)46:2<116::AID-CM4>3.0.CO;2-L; Norwood FLM, 2000, STRUCTURE, V8, P481, DOI 10.1016/S0969-2126(00)00132-5; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; Rybakova IN, 2002, MOL BIOL CELL, V13, P1512, DOI 10.1091/mbc.01-09-0446; Rybakova IN, 1997, J BIOL CHEM, V272, P28771, DOI 10.1074/jbc.272.45.28771; Rybakova IN, 2000, J CELL BIOL, V150, P1209, DOI 10.1083/jcb.150.5.1209; STRAUB V, 1992, J CELL BIOL, V119, P1183, DOI 10.1083/jcb.119.5.1183; Sutherland-Smith AJ, 2003, J MOL BIOL, V329, P15, DOI 10.1016/S0022-2836(03)00422-4; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; WINDER SJ, 1995, J CELL SCI, V108, P63; WINDER SJ, 1995, FEBS LETT, V369, P27, DOI 10.1016/0014-5793(95)00398-S; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; Zuellig RA, 2000, J CELL BIOCHEM, V77, P418, DOI 10.1002/(SICI)1097-4644(20000601)77:3<418::AID-JCB7>3.0.CO;2-Z	40	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23018	23023		10.1074/jbc.M502530200	http://dx.doi.org/10.1074/jbc.M502530200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15826935	hybrid			2022-12-25	WOS:000229741800057
J	Vanoevelen, J; Dode, L; Van Baelen, K; Fairclough, RJ; Missiaen, L; Raeymaekers, L; Wuytack, F				Vanoevelen, J; Dode, L; Van Baelen, K; Fairclough, RJ; Missiaen, L; Raeymaekers, L; Wuytack, F			The secretory pathway Ca2+/Mn2+-ATPase 2 is a Golgi-localized pump with high affinity for Ca2+ ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAILEY-HAILEY-DISEASE; ENDOPLASMIC-RETICULUM; CALCIUM-PUMP; PROPERTIES DISTINCT; MESSENGER-RNAS; DARIER-DISEASE; CA2+-ATPASE; YEAST; MUTATIONS; PMR1	Accumulation of Ca2+ into the Golgi apparatus is mediated by sarco(endo) plasmic reticulum Ca2+-ATPases (SERCAs) and by secretory pathway Ca2+-ATPases (SPCAs). Mammals and birds express in addition to the housekeeping SPCA1 (human gene name ATP2C1, cytogenetic position 3q22.1) a homologous SPCA2 isoform (human gene name ATP2C2, cytogenetic position 16q24.1). We show here that both genes present an identical exon/intron layout. We confirmed that hSPCA2 has the ability to transport Ca2+, demonstrated its Mn2+-transporting activity, showed its Ca2+- and Mn2+-dependent phosphoprotein intermediate formation, and documented the insensitivity of these functional activities to thapsigargin inhibition. The mRNA encoding hSPCA2 showed a limited tissue expression pattern mainly confined to the gastrointestinal and respiratory tract, prostate, thyroid, salivary, and mammary glands. Immunocytochemical localization in human colon sections presented a typical apical juxtanuclear Golgi-like staining. The expression in COS-1 cells allowed the direct demonstration of Ca-45(2+) (K-0.5 = 0.27 mu M) or Mn-54(2+) transport into an A23187-releasable compartment.	Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium	KU Leuven	Wuytack, F (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gathuisberg O-N,Herestr 49, B-3000 Louvain, Belgium.	Frank.Wuytack@med.kuleuven.be	Vanoevelen, Jo M/F-2686-2013	Vanoevelen, Jo M/0000-0003-1830-8858				ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Behne MJ, 2003, J INVEST DERMATOL, V121, P688, DOI 10.1046/j.1523-1747.2003.12528.x; Callewaert G, 2003, CELL CALCIUM, V34, P157, DOI 10.1016/S0143-4160(03)00070-8; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Dode L, 2003, J BIOL CHEM, V278, P47877, DOI 10.1074/jbc.M306784200; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fairclough RJ, 2003, J BIOL CHEM, V278, P24721, DOI 10.1074/jbc.M300509200; Foggia L, 2004, AM J MED GENET C, V131C, P20, DOI 10.1002/ajmg.c.30031; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; Hu ZL, 2000, NAT GENET, V24, P61, DOI 10.1038/71701; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kraev A, 2002, ANN NY ACAD SCI, V976, P53; Martell A. E., 1974, CRIT STABILITY CONST, V1, P270; Missiaen L, 2001, J BIOL CHEM, V276, P39161, DOI 10.1074/jbc.M104044200; Mitchell KJ, 2004, DIABETES, V53, P393, DOI 10.2337/diabetes.53.2.393; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Reinhardt TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1595, DOI 10.1152/ajpcell.2000.279.5.C1595; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Sorin A, 1997, J BIOL CHEM, V272, P9895; Sudbrak R, 2000, HUM MOL GENET, V9, P1131, DOI 10.1093/hmg/9.7.1131; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Ton VK, 2002, J BIOL CHEM, V277, P6422, DOI 10.1074/jbc.M110612200; Van Baelen K, 2003, BIOCHEM BIOPH RES CO, V306, P430, DOI 10.1016/S0006-291X(03)00977-X; Van Baelen K, 2001, J BIOL CHEM, V276, P10683, DOI 10.1074/jbc.M010553200; Vanoevelen J, 2004, CELL CALCIUM, V35, P115, DOI 10.1016/j.ceca.2003.08.003; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; Verstuyf A, 1998, J BONE MINER RES, V13, P549, DOI 10.1359/jbmr.1998.13.4.549; Wuytack F, 2002, CELL CALCIUM, V32, P279, DOI 10.1016/S0143416002001847; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; Xiang MH, 2005, J BIOL CHEM, V280, P11608, DOI 10.1074/jbc.M413116200	35	105	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22800	22808		10.1074/jbc.M501026200	http://dx.doi.org/10.1074/jbc.M501026200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15831496	hybrid			2022-12-25	WOS:000229741800031
J	Fraysse, AS; Moller, ALB; Poulsen, LR; Wollenweber, B; Bush-Pedersen, MJ; Palmgren, MG				Fraysse, AS; Moller, ALB; Poulsen, LR; Wollenweber, B; Bush-Pedersen, MJ; Palmgren, MG			A systematic mutagenesis study of Ile-282 in transmembrane segment M4 of the plasma membrane H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; CALCIUM-PUMP; TRANSPORT; MECHANISM; YEAST; RESIDUES; COMPLEX; PROTONS; AHA2	Homology models of plasma membrane H+-ATPase (Bukrinsky, J. T., Buch-Pedersen, M. J., Larsen, S., and Palmgren, M. G. (2001) FEBS Lett. 494, 6-10) has pointed to residues in transmembrane segment M4 as being important for proton translocation by P-type proton pumps. To test this model, alanine-scanning mutagenesis was carried out through 12 residues in the M4 of the plant plasma membrane H+-ATPase AHA2. An I282A mutation showed apparent reduced H+ affinity, and this residue was subsequently substituted with all other naturally occurring amino acids by saturation mutagenesis. The ability of mutant enzymes to substitute for the yeast proton pump PMA1 was found to correlate with the size of the side chain rather than its chemical nature. Thus, smaller side chains (Gly, Ala, and Ser) at this position resulted in lower H+ affinity and lowered levels of H+ transport in vivo, whereas substitution with side chains of similar and larger size resulted in only minor effects. Substitutions of Ile-282 had only minor effects on ATP affinity and sensitivity toward vanadate, ruling out an indirect effect through changes in the enzyme conformational equilibrium. These results are consistent with a model in which the backbone carbonyl oxygen of Ile-282 contributes directly to proton translocation.	Royal Vet & Agr Univ, Dept Plant Biol, DK-1871 Frederiksberg, Denmark; Danish Inst Agr Sci, DK-4200 Slagelse, Denmark	University of Copenhagen; Aarhus University	Palmgren, MG (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Thorvaldsensvej 40, DK-1871 Frederiksberg, Denmark.	palmgren@kvl.dk	Poulsen, Lisbeth R/I-1843-2014; Wollenweber, Bernd/D-1922-2009; Poulsen, Lisbeth Rosager/AAP-1301-2020; Palmgren, Michael/A-9808-2013	Poulsen, Lisbeth R/0000-0002-9133-3358; Palmgren, Michael/0000-0002-9982-6114				Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; Axelsen KB, 1999, BIOCHEMISTRY-US, V38, P7227, DOI 10.1021/bi982482l; Baunsgaard L, 1996, PLANT J, V10, P451, DOI 10.1046/j.1365-313X.1996.10030451.x; BEHR JP, 1982, J AM CHEM SOC, V104, P4540, DOI 10.1021/ja00381a007; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISKIN DP, 1992, J EXP BOT, V43, P269, DOI 10.1093/jxb/43.3.269; Buch-Pedersen MJ, 2003, J BIOL CHEM, V278, P17845, DOI 10.1074/jbc.M212729200; Buch-Pedersen MJ, 2000, J BIOL CHEM, V275, P39167, DOI 10.1074/jbc.M007537200; Buhl M, 2002, J AM CHEM SOC, V124, P4473, DOI 10.1021/ja012428j; Bukrinsky JT, 2001, FEBS LETT, V494, P6, DOI 10.1016/S0014-5793(01)02301-8; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; Fillingame RH, 2000, J EXP BIOL, V203, P9; Guerini D, 1996, BIOCHEMISTRY-US, V35, P3290, DOI 10.1021/bi952572f; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horisberger JD, 2004, J BIOL CHEM, V279, P29542, DOI 10.1074/jbc.M400585200; Kuhlbrandt W, 2002, SCIENCE, V297, P1692, DOI 10.1126/science.1072574; Lanyi JK, 1997, J BIOL CHEM, V272, P31209, DOI 10.1074/jbc.272.50.31209; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Palmgren MG, 2001, ANNU REV PLANT PHYS, V52, P817, DOI 10.1146/annurev.arplant.52.1.817; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VENEMA K, 1995, J BIOL CHEM, V270, P19659, DOI 10.1074/jbc.270.33.19659; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Wollenweber B, 1997, PLANT CELL ENVIRON, V20, P400, DOI 10.1046/j.1365-3040.1997.d01-79.x; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9	27	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21785	21790		10.1074/jbc.M413091200	http://dx.doi.org/10.1074/jbc.M413091200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15829483	hybrid			2022-12-25	WOS:000229557900016
J	Vetting, MW; de Carvalho, LPS; Roderick, SL; Blanchard, JS				Vetting, MW; de Carvalho, LPS; Roderick, SL; Blanchard, JS			A novel dimeric structure of the RimL N-alpha-acetyltransferase from Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN MODIFICATION; 1.8 ANGSTROM RESOLUTION; ESCHERICHIA-COLI; TERMINAL ACETYLATION; CRYSTAL-STRUCTURE; HISTONE ACETYLTRANSFERASE; GNAT SUPERFAMILY; MUTANT LACKING; L12; ENZYME	RimL is responsible for converting the prokaryotic ribosomal protein from L12 to L7 by acetylation of its N-terminal amino group. We demonstrate that purified RimL is capable of posttranslationally acetylating L12, exhibiting a V-max of 21 min(-1). We have also determined the apostructure of RimL from Salmonella typhimurium and its complex with coenzyme A, revealing a homodimeric oligomer with structural similarity to other Gcn5-related N-acetyltransferase superfamily members. A large central trough located at the dimer interface provides sufficient room to bind both L12 N-terminal helices. Structural and biochemical analysis indicates that RimL proceeds by single-step transfer rather than a covalent-enzyme intermediate. This is the first structure of a Gen5-related N-acetyltransferase family member with demonstrated activity toward a protein N(alpha)amino group and is a first step toward understanding the molecular basis for N(alpha)acetylation and its function in cellular regulation.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Blanchard, JS (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	blanchar@aecom.yu.edu		Sorio de Carvalho, Luiz Pedro/0000-0003-2875-4552	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060899, R01AI033696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 33696, AI 60899] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABSHIRE KZ, 1993, J BACTERIOL, V175, P3744, DOI 10.1128/JB.175.12.3744-3748.1993; Angus-Hill ML, 1999, J MOL BIOL, V294, P1311, DOI 10.1006/jmbi.1999.3338; Bhatnagar RS, 1998, NAT STRUCT BIOL, V5, P1091, DOI 10.1038/4202; Bocharov EV, 2004, J BIOL CHEM, V279, P17697, DOI 10.1074/jbc.M313384200; BROT N, 1973, J BIOL CHEM, V248, P6952; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brunzelle JS, 2004, PROTEINS, V57, P850, DOI 10.1002/prot.10601; Burk DL, 2003, PROTEIN SCI, V12, P426, DOI 10.1110/ps.0233503; CUMBERLIDGE AG, 1979, J MOL BIOL, V131, P169, DOI 10.1016/0022-2836(79)90072-X; Griaznova O, 2000, BIOCHEMISTRY-US, V39, P4075, DOI 10.1021/bi992621e; GUDKOV AT, 1989, BIOCHIMIE, V71, P779, DOI 10.1016/0300-9084(89)90040-0; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; ISONO K, 1980, MOL GEN GENET, V177, P645; ISONO S, 1981, MOL GEN GENET, V183, P473, DOI 10.1007/BF00268767; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kalpaxis DL, 1995, BIOCHIMIE, V77, P963, DOI 10.1016/0300-9084(95)80009-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; KUNG HF, 1973, J BIOL CHEM, V248, P5012; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; LILJAS A, 1982, PROG BIOPHYS MOL BIO, V40, P161, DOI 10.1016/0079-6107(82)90013-X; LOCKWOOD AH, 1974, J BIOL CHEM, V249, P1213; Mohr D, 2002, BIOCHEMISTRY-US, V41, P12520, DOI 10.1021/bi026301y; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Okkels LM, 2004, PROTEOMICS, V4, P2954, DOI 10.1002/pmic.200400906; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PETTERSSON I, 1976, FEBS LETT, V64, P135, DOI 10.1016/0014-5793(76)80267-0; PETTERSSON I, 1980, P NATL ACAD SCI-BIOL, V77, P4007, DOI 10.1073/pnas.77.7.4007; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; RAMAGOPA.S, 1974, P NATL ACAD SCI USA, V71, P2136, DOI 10.1073/pnas.71.5.2136; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; Sun PD, 2002, ACTA CRYSTALLOGR D, V58, P1092, DOI 10.1107/S0907444902006510; TANAKA S, 1989, MOL GEN GENET, V217, P289, DOI 10.1007/BF02464895; TERHORST C, 1972, EUR J BIOCHEM, V25, P13, DOI 10.1111/j.1432-1033.1972.tb01661.x; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Vetting MW, 2005, ARCH BIOCHEM BIOPHYS, V433, P212, DOI 10.1016/j.abb.2004.09.003; Vetting MW, 2004, CHEM BIOL, V11, P565, DOI 10.1016/j.chembiol.2004.03.017; Wahl MC, 2000, EMBO J, V19, P174, DOI 10.1093/emboj/19.2.174; Wybenga-Groot LE, 1999, STRUCTURE, V7, P497, DOI 10.1016/S0969-2126(99)80066-5; Yan Y, 2002, NAT STRUCT BIOL, V9, P862, DOI 10.1038/nsb849; YOSHIKAWA A, 1987, MOL GEN GENET, V209, P481, DOI 10.1007/BF00331153	41	49	50	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22108	22114		10.1074/jbc.M502401200	http://dx.doi.org/10.1074/jbc.M502401200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817456	hybrid			2022-12-25	WOS:000229557900055
J	Brunati, AM; Deana, R; Folda, A; Massimino, ML; Marin, O; Ledro, S; Pinna, LA; Donella-Deana, AD				Brunati, AM; Deana, R; Folda, A; Massimino, ML; Marin, O; Ledro, S; Pinna, LA; Donella-Deana, AD			Thrombin-induced tyrosine phosphorylation of HS1 in human platelets is sequentially catalyzed by Syk and Lyn tyrosine kinases and associated with the cellular migration of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY; HEMATOPOIETIC LINEAGE; SIGNAL-TRANSDUCTION; INTEGRIN ALPHA(IIB)BETA(3); MEDIATED APOPTOSIS; BINDING-PROTEIN; SH3 DOMAINS; C-SRC; ACTIVATION; CELLS	Thrombin stimulation of platelets triggers Tyr phosphorylation of several signaling proteins, most of which remain unidentified. In this study, we demonstrate for the first time that hematopoietic lineage cell-specific protein 1 (HS1) undergoes a transient Tyr phosphorylation in human platelets stimulated with thrombin. The protein is synergistically phosphorylated by Syk and Lyn tyrosine kinases according to a sequential phosphorylation mechanism. By means of specific inhibitors (PP2, SU6656, and piceatannol) and phosphopeptide-specific antibodies, as well as by coimmunoprecipitation and binding competition experiments, we show that Syk acts as the primary kinase that phosphorylates HS1 at Tyr(397) and that Syk phosphorylation is required for HS1 interaction with the Lyn SH2 domain. Upon docking to Syk-phosphorylated HS1, Lyn catalyzes the secondary phosphorylation of the protein at Tyr(222). Once the secondary Tyr phosphorylation of HS1 is accomplished the protein dissociates from Lyn and undergoes a dephosphorylation process. HS1 Tyr phosphorylation does not occur when thrombin-induced actin assembly is inhibited by cytochalasin D even under conditions in which Syk and Lyn are still active. Immunofluorescence microscopic analysis shows that the agonist promotes HS1 migration to the plasma membrane and that the inhibition of Lyn-mediated secondary phosphorylation of HS1 abrogates the subcellular translocation of the protein. All together these results indicate that HS1 Tyr phosphorylation catalyzed by Syk and Lyn plays a crucial role in the translocation of the protein to the membrane and is involved in the cytoskeleton rearrangement triggered by thrombin in human platelets.	Univ Padua, Dept Biochem, I-35121 Padua, Italy	University of Padua	Donella-Deana, AD (corresponding author), Univ Padua, Dipartimento Chim Biol, Viale G Colombo 3, I-35121 Padua, Italy.	arianna.donella@unipd.it	Brunati, Anna Maria/I-8136-2018; Massimino, Maria Lina/AAX-8773-2020	Brunati, Anna Maria/0000-0002-3481-9503; massimino, maria lina/0000-0002-1839-1404				Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bauer M, 2001, THROMB HAEMOSTASIS, V85, P331, DOI 10.1055/s-0037-1615689; Bertagnolli ME, 1999, BIOCHEM BIOPH RES CO, V260, P790, DOI 10.1006/bbrc.1999.0985; Brunati AM, 2000, BLOOD, V96, P1550, DOI 10.1182/blood.V96.4.1550.h8001550_1550_1557; Brunati AM, 1999, J BIOL CHEM, V274, P7557, DOI 10.1074/jbc.274.11.7557; Brunati AM, 1996, EUR J BIOCHEM, V240, P400, DOI 10.1111/j.1432-1033.1996.0400h.x; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; BRUNATI AM, 1993, EUR J BIOCHEM, V216, P323, DOI 10.1111/j.1432-1033.1993.tb18149.x; Chen YR, 2001, BIOCHEM BIOPH RES CO, V288, P981, DOI 10.1006/bbrc.2001.5862; Cho MJ, 2002, BLOOD, V99, P2442, DOI 10.1182/blood.V99.7.2442; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1994, J BIOL CHEM, V269, P28859; Deana R, 2003, THROMB HAEMOSTASIS, V89, P866, DOI 10.1055/s-0037-1613474; Donella-Deana A, 1998, BIOCHEMISTRY-US, V37, P1438, DOI 10.1021/bi971332s; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hao JJ, 2004, J BIOL CHEM, V279, P33413, DOI 10.1074/jbc.M313564200; HATA D, 1993, IMMUNOL LETT, V40, P65; He H, 1998, MOL CELL BIOL, V18, P3829, DOI 10.1128/MCB.18.7.3829; Hutchcroft JE, 1998, J IMMUNOL, V161, P4506; Ingley E, 2000, J BIOL CHEM, V275, P7887, DOI 10.1074/jbc.275.11.7887; Jackson SP, 1996, THROMB HAEMOSTASIS, V76, P640; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; Kurosaki T, 1998, INT J MOL MED, V1, P515; LevyToledano S, 1997, THROMB HAEMOSTASIS, V78, P226; Maguire PB, 2002, PROTEOMICS, V2, P642, DOI 10.1002/1615-9861(200206)2:6<642::AID-PROT642>3.0.CO;2-I; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Rosado JA, 2000, BIOCHEM J, V351, P429, DOI 10.1042/0264-6021:3510429; Ruzzene M, 1996, BIOCHEMISTRY-US, V35, P5327, DOI 10.1021/bi9528614; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Suzuki H, 1997, J IMMUNOL, V159, P5881; Takemoto Y, 1996, INT IMMUNOL, V8, P1699, DOI 10.1093/intimm/8.11.1699; TANIUCHI I, 1995, EMBO J, V14, P3664, DOI 10.1002/j.1460-2075.1995.tb00036.x; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; Uruno T, 2003, BIOCHEM J, V371, P485, DOI 10.1042/BJ20021791; WONG S, 1992, ONCOGENE, V7, P2407; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; Yamanashi Y, 1997, J EXP MED, V185, P1387, DOI 10.1084/jem.185.7.1387	46	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21029	21035		10.1074/jbc.M412634200	http://dx.doi.org/10.1074/jbc.M412634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15795233	hybrid			2022-12-25	WOS:000229438800017
J	Oh, JE; Kook, JK; Min, BM				Oh, JE; Kook, JK; Min, BM			beta ig-h3 induces keratinocyte differentiation via modulation of involucrin and transglutaminase expression through the integrin alpha 3 beta 1 and the phosphatidylinositol 3-kinase/Akt signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HUMAN ORAL KERATINOCYTES; MATRIX PROTEIN BETA-IG-H3; TERMINAL DIFFERENTIATION; REPLICATIVE SENESCENCE; EXTRACELLULAR-MATRIX; CELL-ADHESION; IN-VITRO; TGF-BETA; GENE	beta ig-h3 is an extracellular matrix protein whose expression is highly induced by transforming growth factor (TGF)-beta 1. Whereas beta ig-h3 is known to mediate keratinocyte adhesion and migration, its effects on keratinocyte differentiation remain unclear. In the present study, it was demonstrated that expression of both beta ig-h3 and TGF-beta 1 was enhanced during keratinocyte differentiation and that expression of the former was strongly induced by that of the latter. This study also asked whether changes in beta ig-h3 expression would affect keratinocyte differentiation. Indeed, down-regulation of beta ig-h3 by transfection with antisense beta ig-h3 cDNA constructs effectively inhibited keratinocyte differentiation by decreasing the promoter activities and thus expression of involucrin and transglutaminase. The result was a similar to 2-fold increase in mitotic capacity of the cells. Conversely, overexpression of beta ig-h3, either by transfection with beta ig-h3 expression plasmids or by exposure to recombinant beta ig-h3, enhanced keratinocyte differentiation by inhibiting cell proliferation and concomitantly increasing involucrin and transglutaminase expression. Recombinant beta ig-h3 also promoted keratinocyte adhesion through interaction with integrin alpha 3 beta 1. Changes in beta ig-h3 expression did not affect intracellular calcium levels. Subsequent analysis revealed not only induction of Akt phosphorylation by recombinant beta ig-h3 but also blockage of Akt phosphorylation by LY294002, an inhibitor of phosphatidylinositol 3-kinase. Taken together, these findings indicate that enhanced beta ig-h3, induced by enhanced TGF-beta during keratinocyte differentiation, provoked cell differentiation by enhancing involucrin and transglutaminase expression through the integrin alpha 3 beta 1 and phosphatidylinositol 3-kinase/Akt signaling pathway. Lastly, it was observed that beta ig-h3-mediated keratinocyte differentiation was caused by promotion of cell adhesion and not by calcium regulation.	Seoul Natl Univ, Coll Dent, Dept Oral Biochem & Craniomaxillofacial Reconstru, Dent Res Inst, Seoul 110749, South Korea; Seoul Natl Univ, Coll Dent, BK21 HLS, Seoul 110749, South Korea; Chosun Univ, Coll Dent, Dept Oral Biochem, Kwangju 501759, South Korea	Seoul National University (SNU); Seoul National University (SNU); Chosun University	Min, BM (corresponding author), Seoul Natl Univ, Coll Dent, Dept Oral Biochem & Craniomaxillofacial Reconstru, Dent Res Inst, 28 Yeonkun Dong, Seoul 110749, South Korea.	bmmin@snu.ac.kr	Min, Byung-Moo/F-2854-2012	Kook, Joong-Ki/0000-0003-2628-2870				Bae JS, 2002, BIOCHEM BIOPH RES CO, V294, P940, DOI 10.1016/S0006-291X(02)00576-4; Billings PC, 2002, J BIOL CHEM, V277, P28003, DOI 10.1074/jbc.M106837200; Billings PC, 2000, J CELL BIOCHEM, V79, P261, DOI 10.1002/1097-4644(20001101)79:2<261::AID-JCB90>3.0.CO;2-#; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dieudonne SC, 2000, J CELL BIOCHEM, V76, P231, DOI 10.1002/(SICI)1097-4644(20000201)76:2<231::AID-JCB7>3.0.CO;2-X; Fuchs E, 1990, CURR OPIN CELL BIOL, V2, P1028, DOI 10.1016/0955-0674(90)90152-5; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gibson MA, 1997, J HISTOCHEM CYTOCHEM, V45, P1683, DOI 10.1177/002215549704501212; Gilbert RE, 1998, KIDNEY INT, V54, P1052, DOI 10.1046/j.1523-1755.1998.00081.x; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; HENNINGS H, 1989, CARCINOGENESIS, V10, P777, DOI 10.1093/carcin/10.4.777; Jeong HW, 2004, J CELL BIOCHEM, V92, P770, DOI 10.1002/jcb.20110; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; KANE CJM, 1991, J CELL PHYSIOL, V148, P157, DOI 10.1002/jcp.1041480119; Kang MK, 1998, CELL GROWTH DIFFER, V9, P85; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Kim JE, 2002, J BIOL CHEM, V277, P46159, DOI 10.1074/jbc.M207055200; Kim JE, 2002, INVEST OPHTH VIS SCI, V43, P656; Kook JK, 1998, INT J ONCOL, V13, P765; LARJAVA H, 1991, AM J MED SCI, V301, P63, DOI 10.1097/00000441-199101000-00012; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Lee G, 2000, ARCH ORAL BIOL, V45, P809, DOI 10.1016/S0003-9969(00)00061-3; LEVINE JH, 1993, AM J PATHOL, V143, P368; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; Maruoka Y, 1997, BIOCHEM BIOPH RES CO, V238, P886, DOI 10.1006/bbrc.1997.7405; Min BM, 1999, EXP CELL RES, V249, P377, DOI 10.1006/excr.1999.4489; Nam JO, 2003, J BIOL CHEM, V278, P25902, DOI 10.1074/jbc.M300358200; OBrien ER, 1996, ARTERIOSCL THROM VAS, V16, P576, DOI 10.1161/01.ATV.16.4.576; Oh JE, 2003, INT J MOL MED, V11, P491; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; Ohno S, 2002, J DENT RES, V81, P822, DOI 10.1177/154405910208101205; Okazaki I, 2002, J BIOL CHEM, V277, P37070, DOI 10.1074/jbc.M201672200; Rawe IM, 1997, INVEST OPHTH VIS SCI, V38, P893; Rodeck U, 1997, J CELL SCI, V110, P113; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858	38	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21629	21637		10.1074/jbc.m412293200	http://dx.doi.org/10.1074/jbc.m412293200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15805105	hybrid			2022-12-25	WOS:000229438800088
J	Venkataraman, P; Lamb, RA; Pinto, LH				Venkataraman, P; Lamb, RA; Pinto, LH			Chemical rescue of histidine selectivity filter mutants of the M2 ion channel of influenza A virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC-ANHYDRASE-II; BACTERIAL REACTION CENTERS; INTEGRAL MEMBRANE-PROTEIN; PLANAR LIPID-BILAYERS; SITE-SPECIFIC MUTANT; M-2 PROTON CHANNEL; TRANSMEMBRANE DOMAIN; CATALYTIC BASE; M(2) PROTEIN; ACTIVATION	The influenza virus M2 proton- selective ion channel activity facilitates virus uncoating, a process that occurs in the acidic environment of the endosome. The M2 channel causes acidification of the interior of the virus particle, which results in viral protein-protein dissociation. The M2 protein is a homotetramer that contains in its aqueous pore a histidine residue (His-37) that acts as a selectivity filter and a tryptophan residue (Trp-41) that acts as a channel gate. Substitution of His-37 modifies M2 ion channel properties drastically. However, the results of such experiments are difficult to interpret because substitution of His-37 could cause gross structural changes to the channel pore. We described here experiments in which partial or, in some cases, full rescue of specific M2 ion channel properties of His-37 substitution mutants was achieved by addition of imidazole to the bathing medium. Chemical rescue was demonstrated for three histidine substitution mutant ion channels (M2-H37G, M2-H37S, and M2-H37T) and for two double mutants in which the Trp-41 channel gate was also mutated (H37G/W41Y and H37G/W41A). Currents of the M2-H37G mutant ion channel were inhibited by Cu(II), which has been shown to coordinate with His- 37 in the wild- type channel. Chemical rescue was very specific for imidazole. Buffer molecules that were neutral when protonated (4-morpholineethanesulfonic acid and 3- morpholino-2- hydroxypropanesulfonic acid) did not rescue ion channel activity of the M2-H37G mutant ion channel, but 1-methylimidazole did provide partial rescue of function. These results were consistent with a model for proton transport through the pore of the wildtype channel in which the imidazole side chain of His-37 acted as an intermediate proton acceptor/ donor group.	Northwestern Univ, Howard Hughes Med Inst, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Northwestern Univ, Howard Hughes Med Inst, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Howard Hughes Medical Institute; Northwestern University; Howard Hughes Medical Institute; Northwestern University	Pinto, LH (corresponding author), Northwestern Univ, Howard Hughes Med Inst, Dept Neurobiol & Physiol, Hogan Hall,2205 Tech Dr, Evanston, IL 60208 USA.	larry-pinto@northwestern.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020201, R01AI031882] Funding Source: NIH RePORTER; NIAID NIH HHS [R37AI-20201, R01AI-31882] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adelroth P, 2001, BIOCHEMISTRY-US, V40, P14538, DOI 10.1021/bi011585s; Admiraal SJ, 1999, BIOCHEMISTRY-US, V38, P4701, DOI 10.1021/bi9827565; An HQ, 2002, BIOCHEMISTRY-US, V41, P3235, DOI 10.1021/bi0120695; Chizhmakov IV, 1996, J PHYSIOL-LONDON, V494, P329, DOI 10.1113/jphysiol.1996.sp021495; Duda D, 2001, BIOCHEMISTRY-US, V40, P1741, DOI 10.1021/bi002295z; Duda D, 2003, ACTA CRYSTALLOGR D, V59, P93, DOI 10.1107/S0907444902019455; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; Gandhi CS, 1999, J BIOL CHEM, V274, P5474, DOI 10.1074/jbc.274.9.5474; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; Hopkins CE, 2002, PROTEIN SCI, V11, P1591, DOI 10.1110/ps.3900102; Huang SQ, 1997, BIOCHEMISTRY-US, V36, P14609, DOI 10.1021/bi9722554; KURTZ S, 1995, ANTIMICROB AGENTS CH, V39, P2204, DOI 10.1128/AAC.39.10.2204; Lamb R. A., 1994, RECEPTOR MEDIATED VI, P303; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LAMB RA, 2005, IN PRESS CONT TOPICS; Lehoux IE, 1999, BIOCHEMISTRY-US, V38, P9948, DOI 10.1021/bi9907532; Lin TI, 2001, J VIROL, V75, P3647, DOI 10.1128/JVI.75.8.3647-3656.2001; Matsunami H, 2004, BIOCHEMISTRY-US, V43, P2178, DOI 10.1021/bi0361923; Mould JA, 2000, J BIOL CHEM, V275, P31038, DOI 10.1074/jbc.M003663200; Mould JA, 2000, J BIOL CHEM, V275, P8592, DOI 10.1074/jbc.275.12.8592; Okada A, 2001, BIOCHEMISTRY-US, V40, P6053, DOI 10.1021/bi0028441; Paddock ML, 2002, BIOCHEMISTRY-US, V41, P14716, DOI 10.1021/bi020419x; PANAYOTOV PP, 1992, VIROLOGY, V186, P352, DOI 10.1016/0042-6822(92)90096-8; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Sakaguchi T, 1997, P NATL ACAD SCI USA, V94, P5000, DOI 10.1073/pnas.94.10.5000; SHIMBO K, 1996, BIOPHYS J, V70, P1336; Shuck K, 2000, J VIROL, V74, P7755, DOI 10.1128/JVI.74.17.7755-7761.2000; Smondyrev AM, 2002, BIOPHYS J, V83, P1987, DOI 10.1016/S0006-3495(02)73960-X; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; Tang YJ, 2002, J BIOL CHEM, V277, P39880, DOI 10.1074/jbc.M206582200; TOSTESON MT, 1994, J MEMBRANE BIOL, V142, P117; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; Tu CK, 2002, BIOCHEMISTRY-US, V41, P15429, DOI 10.1021/bi026831u; Tu Q, 1996, J VIROL, V70, P4246, DOI 10.1128/JVI.70.7.4246-4252.1996; Vijayvergiya V, 2004, BIOPHYS J, V87, P1697, DOI 10.1529/biophysj.104.043018; WANG C, 1995, BIOPHYS J, V69, P1363, DOI 10.1016/S0006-3495(95)80003-2; WANG C, 1993, J VIROL, V67, P5585, DOI 10.1128/JVI.67.9.5585-5594.1993; WANG C, 1994, VIROLOGY, V205, P133, DOI 10.1006/viro.1994.1628; ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988	42	85	93	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21463	21472		10.1074/jbc.M412406200	http://dx.doi.org/10.1074/jbc.M412406200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15784624	hybrid			2022-12-25	WOS:000229438800067
J	Perez-Gomez, E; Eleno, N; Lopez, JM; Ramirez, JR; Velasco, B; Letarte, M; Bernabeu, C; Quintanilla, M				Perez-Gomez, E; Eleno, N; Lopez, JM; Ramirez, JR; Velasco, B; Letarte, M; Bernabeu, C; Quintanilla, M			Characterization of murine S-endoglin isoform and its effects on tumor development	ONCOGENE			English	Article						endoglin; TGF-beta; endothelial cells; angiogenesis; carcinogenesis	GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; BINDING PROTEIN ENDOGLIN; HUMAN ENDOTHELIAL-CELLS; TGF-BETA; PROSTATE-CANCER; MOUSE SKIN; TRANSFORMING GROWTH-FACTOR-BETA-1; MONOCLONAL-ANTIBODIES; CELLULAR-RESPONSES	Endoglin is a transmembrane glycoprotein that acts as an auxiliary receptor for transforming growth factor-beta (TGF-beta) and modulates cellular responses to this pleiotropic cytokine. Endoglin is strongly expressed in endothelial cells, where it appears to exert a crucial role in vascular development and angiogenesis. Two endoglin isoforms (L and S), differing in their cytoplasmic domains, have been previously characterized in human tissues. We now demonstrate the existence of similar L- and S-endoglin variants in murine tissues with 47 and 35 amino acids, respectively, in their cytoplasmic tail. RT-PCR analysis showed that L is the predominant endoglin isoform expressed in mouse tissues, although S-endoglin mRNA is significantly expressed in liver and lung, as well as in endothelial cell lines. Furthermore, a protein of size equivalent to recombinant S-endoglin expressed in mammalian cells was detected in mouse endothelial cells by Western blot analysis. L- and S-endoglin isoforms can form disulfide-linked heterodimers, as demonstrated by cotransfection of L- and S-endoglin constructs. To address the role of S-endoglin in vivo, an S-Eng(+) transgenic mouse model that targets S-endoglin expression to the endothelium was generated. The lethal phenotype of endoglin-null (Eng(-/-)) mice was not rescued by breeding S-Eng(+) transgenic mice into the endoglin-null background. S-Eng(+) mice exhibited reduced tumor growth and neovascularization after transplantation of Lewis lung carcinoma cells. In addition, S-Eng(+) mice showed a drastic inhibition of benign papilloma formation when subjected to two-stage chemical skin carcinogenesis. These results point to S-endoglin as an antiangiogenic molecule, in contrast to L-endoglin which is proangiogenic.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Univ Salamanca, Dept Fisiol & Farmacol, Edificio Dept, Salamanca 37007, Spain; Hosp Gomez Ulla, Dept Anat Patol, Madrid, Spain; CSIC, Ctr Invest Biol, Madrid 28040, Spain; Univ Toronto, Hosp Sick Children, Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 1X8, Canada	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Quintanilla, M (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	mquintanilla@iib.uam.es	Eleno, Nélida/A-5281-2016; Quintanilla, Miguel/K-9293-2017; Bernabeu, Carmelo/P-4662-2019; Bernabeu, Carmelo/L-3226-2014; Perez-gomez, Eduardo/F-5906-2015; Pérez-Gómez, Eduardo/GYA-5856-2022	Eleno, Nélida/0000-0002-9906-2118; Bernabeu, Carmelo/0000-0002-1563-6162; Bernabeu, Carmelo/0000-0002-1563-6162; Perez-gomez, Eduardo/0000-0003-0160-5565; Pérez-Gómez, Eduardo/0000-0003-0160-5565; Quintanilla, Miguel/0000-0002-2124-7657; Lopez-Novoa, Jose M./0000-0002-6211-7269				Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; Altomonte M, 1996, BRIT J CANCER, V74, P1586, DOI 10.1038/bjc.1996.593; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Bolontrade MF, 1998, CARCINOGENESIS, V19, P2107, DOI 10.1093/carcin/19.12.2107; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Diez-Marques L, 2002, BBA-MOL BASIS DIS, V1587, P36, DOI 10.1016/S0925-4439(02)00051-0; Duff SE, 2003, FASEB J, V17, P984, DOI 10.1096/fj.02-0634rev; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Fonsatti E, 2001, J CELL PHYSIOL, V188, P1, DOI 10.1002/jcp.1095; Fonsatti Ester, 2004, J Transl Med, V2, P18, DOI 10.1186/1479-5876-2-18; Frontelo P, 1998, EXP CELL RES, V244, P420, DOI 10.1006/excr.1998.4219; GE AZ, 1994, GENE, V138, P201, DOI 10.1016/0378-1119(94)90808-7; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARUTA Y, 1986, P NATL ACAD SCI USA, V83, P7898, DOI 10.1073/pnas.83.20.7898; Hasegawa Y, 2001, CANCER-AM CANCER SOC, V91, P964, DOI 10.1002/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O; Huss WJ, 2001, CANCER RES, V61, P2736; Jerkic M, 2004, FASEB J, V18, P609, DOI 10.1096/fj.03-0197fje; JINDAL SK, 1995, BIOL REPROD, V52, P1027, DOI 10.1095/biolreprod52.5.1027; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, INT J CANCER, V76, P541, DOI 10.1002/(SICI)1097-0215(19980518)76:4<541::AID-IJC16>3.0.CO;2-A; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li C, 2003, BRIT J CANCER, V88, P1424, DOI 10.1038/sj.bjc.6600874; Li CG, 2001, MICROSC RES TECHNIQ, V52, P437, DOI 10.1002/1097-0029(20010215)52:4<437::AID-JEMT1029>3.0.CO;2-G; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; OBESO J, 1990, LAB INVEST, V63, P259; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Pichuantes S, 1997, TISSUE ANTIGENS, V50, P265, DOI 10.1111/j.1399-0039.1997.tb02870.x; Portella G, 2003, FASEB J, V17, P1771, DOI 10.1096/fj.02-1129fje; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; QUACKENBUSH EJ, 1985, J IMMUNOL, V134, P1276; Quintanilla M, 2003, ONCOGENE, V22, P5976, DOI 10.1038/sj.onc.1206841; Raab U, 1999, BIOCHEM J, V339, P579, DOI 10.1042/0264-6021:3390579; Rodriguez-Pena A, 2002, HYPERTENSION, V40, P713, DOI 10.1161/01.HYP.0000037429.73954.27; Sanz-Rodriguez F, 2004, J BIOL CHEM, V279, P32858, DOI 10.1074/jbc.M400843200; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Takahashi N, 2001, CANCER RES, V61, P7846; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tuxhorn JA, 2002, CANCER RES, V62, P6021; Velasco B, 2001, GENE THER, V8, P897, DOI 10.1038/sj.gt.3301468; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; YUSPA SH, 1994, CANCER RES, V54, P1178; Zhang HW, 1996, J IMMUNOL, V156, P565	69	77	81	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4450	4461		10.1038/sj.onc.1208644	http://dx.doi.org/10.1038/sj.onc.1208644			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806144				2022-12-25	WOS:000229976900014
J	Woischwill, C; Karczewski, P; Bartsch, H; Luther, HP; Kott, M; Haase, H; Morano, I				Woischwill, C; Karczewski, P; Bartsch, H; Luther, HP; Kott, M; Haase, H; Morano, I			Regulation of the human atrial myosin light chain 1 promoter by Ca2+-calmodulin-dependent signaling pathways	FASEB JOURNAL			English	Article						atrial myosin light chain; H9c2; promoter regulation; Ca2+ signaling	CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; MEF2 TRANSCRIPTION FACTOR; CARDIAC-HYPERTROPHY; DEPENDENT ACTIVATION; HUMAN MYOCARDIUM; TRANSGENIC MICE; LIGHT-CHAINS; HEART; EXPRESSION; ISOFORMS	e investigated expression regulation of the human atrial myosin light chain 1 (hALC-1) gene using a cardiomyocyte H9c2 cell line stably transfected with a construct consisting of the human ALC-1 promoter cloned in front of the luciferase gene (H9c2T1). H9c2T1 cells were stimulated with vasopressin, which is known to induce cardiomyocyte hypertrophy and to activate a panel of signaling pathways. Those pathways involved in hALC-1 promoter activity regulation were dissected by using pharmacological inhibitor substances. Stimulation with vasopressin was associated with nuclear NFAT translocation and significantly increased human ALC-1 promoter activity. Inhibition of calcineurin by cyclosporin A blocked the effects of vasopressin on ALC-1 promoter activity to similar to 50%. This suggests that the Ca2+-calmodulin-calcineurin-NFAT pathway is involved in human ALC-1 promoter activation. However, inhibition of multifunctional Ca2+-calmodulin-dependent protein kinases (CaMK) by KN-93 decreased human ALC-1 promoter activity to almost basal levels. CaMK regulation of ALC-1 promoter activity effect could well be mediated by CaMKIV, which accumulated in the nucleus upon vasopressin stimulation. Inhibition of protein kinase C (PKC) isoforms by bisindolylmaleimide had no significant influence on human ALC-1 promoter activity. Thus, our results demonstrate a dominant role of Ca2+-calmodulin-dependent signaling pathways in the regulation of human ALC-1 expression.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Med Berlin Charite, Johannes Muller Inst Physiol, Berlin, Germany; Univ Med Berlin Charite, Med Clin 1, Dept Cardiol, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Morano, I (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.	imorano@mdc-berlin.de						ADELAZIZ AI, 2004, J MOL MED; Brostrom MA, 2000, INT J BIOCHEM CELL B, V32, P993, DOI 10.1016/S1357-2725(00)00037-6; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Chen WC, 1999, ENDOCRINOLOGY, V140, P1639, DOI 10.1210/en.140.4.1639; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Fewell JG, 1998, J CLIN INVEST, V101, P2630, DOI 10.1172/JCI2825; Hagemann D, 2001, MOL CELL BIOCHEM, V220, P69, DOI 10.1023/A:1010899724222; Hoch B, 1998, J CELL BIOCHEM, V68, P259, DOI 10.1002/(SICI)1097-4644(19980201)68:2<259::AID-JCB12>3.0.CO;2-A; Hoch B, 1999, CIRC RES, V84, P713, DOI 10.1161/01.RES.84.6.713; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; LOWEY S, 1971, NATURE, V234, P81, DOI 10.1038/234081a0; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; MERCADIER JJ, 1983, CIRC RES, V53, P52, DOI 10.1161/01.RES.53.1.52; MIYANO O, 1992, J BIOL CHEM, V267, P1198; Molkentin JD, 1997, CIRCULATION, V96, P3833; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morano I, 1999, J MOL MED-JMM, V77, P544, DOI 10.1007/s001099900031; Morano M, 1996, J CLIN INVEST, V98, P467, DOI 10.1172/JCI118813; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; PRICE KM, 1980, BIOCHEM J, V191, P571, DOI 10.1042/bj1910571; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Ritter O, 1999, J CELL BIOCHEM, V74, P551, DOI 10.1002/(SICI)1097-4644(19990915)74:4<551::AID-JCB5>3.3.CO;2-0; Ritter O, 2002, CIRCULATION, V105, P2265, DOI 10.1161/01.CIR.0000016044.19527.96; ROTTER M, 1991, NUCLEIC ACIDS RES, V19, P1497, DOI 10.1093/nar/19.7.1497; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; SUTSCH G, 1992, CIRC RES, V70, P1035, DOI 10.1161/01.RES.70.5.1035; Tahara A, 1998, CARDIOVASC RES, V38, P198, DOI 10.1016/S0008-6363(97)00324-6; THIBONNIER M, 1992, REGUL PEPTIDES, V38, P1, DOI 10.1016/0167-0115(92)90067-5; Zhang T, 2003, CIRC RES, V92, P912, DOI 10.1161/01.RES.0000069686.31472.C5	33	11	13	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					503	511		10.1096/fj.04-2201com	http://dx.doi.org/10.1096/fj.04-2201com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791000				2022-12-25	WOS:000228865300034
J	Andreassi, MG; Cioppa, A; Botto, N; Joksic, G; Manfredi, S; Federici, C; Ostojic, M; Rubino, P; Picano, E				Andreassi, MG; Cioppa, A; Botto, N; Joksic, G; Manfredi, S; Federici, C; Ostojic, M; Rubino, P; Picano, E			Somatic DNA damage in interventional cardiologists: a case control study	FASEB JOURNAL			English	Article						MN assay; professional radiation exposure; low-dose radiation; human lymphocytes	SISTER-CHROMATID EXCHANGES; CHROMOSOMAL-ABERRATIONS; CYTOGENETIC ANALYSIS; IONIZING-RADIATION; LYMPHOCYTES; CANCER; RISK; MICRONUCLEI; BIOMARKERS; PERSONNEL	Interventional cardiologists who work in cardiac catheterization laboratories are exposed to low doses of ionizing radiation that could pose a health hazard. DNA damage is considered to be the main initiating event by which radiation damage to cells results in development of cancer and hereditary disease. The aim of the present study was to assess the effects of chronic low-dose X-ray radiation exposure on somatic DNA damage of interventional cardiologists working in high-volume cardiac catheterization laboratories. For this analysis, we used peripheral lymphocytes and the assay for micronuclei (MNs), which is considered to be a reliable biological dosimeter for radiation exposure. We obtained peripheral blood from 62 physicians (mean age+/-se = 40.6+/-1.5 years): 31 interventional cardiologists (group I, exposed) and 31 age- and sex-matched clinical cardiologists (group II, nonexposed). Interventional cardiologists showed higher MN values (group I=20.5+/-1.6 vs. group II=12.8+/-1.3, P=0.001), although some overlap was apparent in the individual subject analysis. A correlation between years of professional activity and MN frequency value was detectable for interventional cardiologists (r=0.428, P=0.02) but not for clinical cardiologists (r=0.253, P=0.17). The results indicated that, overall, interventional cardiologists working in a high-volume catheterization laboratory have higher levels of somatic DNA damage when compared with clinical cardiologists working outside the catheterization laboratory. The amount of this damage varies and is only weakly related to the duration of professional exposure, which suggests that a dominant modulation of the underlying genetic substrate by environmental factors has a role in determining the harm in individual physicians.	CNR, Inst Clin Physiol, I-54100 Massa, Italy; Vinca Inst Nucl Sci, Belgrade, Serbia Monteneg, Serbia Monteneg	Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Belgrade	Andreassi, MG (corresponding author), CNR, Inst Clin Physiol, Via Aurelia Sud, I-54100 Massa, Italy.	andreas@ifc.cnr.it	Picano, E/G-2261-2014; Botto, Nicoletta/AHD-4957-2022	Joksic, Gordana/0000-0002-7186-301X; Botto, Nicoletta/0000-0002-8336-3610; Andreassi, Maria Grazia/0000-0002-2163-0816; CIOPPA, ANGELO/0000-0003-4324-4227				Andreassi MG, 2003, TRENDS CARDIOVAS MED, V13, P270, DOI 10.1016/S1050-1738(03)00109-9; Andreassi MG, 2002, J AM COLL CARDIOL, V40, P862, DOI 10.1016/S0735-1097(02)02042-9; ANDREASSI MG, 2004, ULTRASOUND, V2, P25; BARQUINERO JF, 1993, MUTAT RES, V286, P275, DOI 10.1016/0027-5107(93)90192-I; Berrington de Gonzalez A, 2004, LANCET, V363, P345, DOI 10.1016/S0140-6736(04)15433-0; BIGATTI P, 1988, MUTAT RES, V204, P343, DOI 10.1016/0165-1218(88)90109-7; Bonassi S, 2004, CYTOGENET GENOME RES, V104, P376, DOI 10.1159/000077519; Bonassi S, 1997, AM J IND MED, V31, P353, DOI 10.1002/(SICI)1097-0274(199703)31:3<353::AID-AJIM12>3.0.CO;2-#; Bozkurt G, 2003, MUTAT RES-GEN TOX EN, V535, P205, DOI 10.1016/S1383-5718(02)00321-2; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; Cardoso RS, 2001, TERATOGEN CARCIN MUT, V21, P431, DOI 10.1002/tcm.1030; *COMM BIOL EFF ION, 1990, HEALTH EFF EXP LOW L; CORREJA MJ, 2005, IN PRESS INT J CARDI; Fenech M, 2002, TOXICOLOGY, V181, P411, DOI 10.1016/S0300-483X(02)00480-8; FENECH M, 1981, NEW HORIZONS BIOL DO, P373; Finestone A, 2003, ARCH ENVIRON HEALTH, V58, P59, DOI 10.3200/AEOH.58.1.59-62; Garaj-Vrhovac V, 2003, MUTAGENESIS, V18, P265, DOI 10.1093/mutage/18.3.265; Hagmar L, 1998, CANCER RES, V58, P4117; *IAEA, 2001, IAEA TECH REP S, V405; *INT COMM RAD PROT, 1989, 57 ICRP; Jacob K, 2004, CLIN RADIOL, V59, P928, DOI 10.1016/j.crad.2004.04.020; JHA AN, 1991, MUTAT RES, V260, P343, DOI 10.1016/0165-1218(91)90020-M; Kuon E, 2003, BRIT J RADIOL, V76, P406, DOI 10.1259/bjr/82051842; Lee CI, 2004, RADIOLOGY, V231, P393, DOI 10.1148/radiol.2312030767; Limacher MC, 1998, J AM COLL CARDIOL, V31, P892; Maffei F, 2004, MUTAT RES-FUND MOL M, V547, P91, DOI 10.1016/j.mrfmmm.2003.12.003; Maffei F, 2002, MUTAGENESIS, V17, P405, DOI 10.1093/mutage/17.5.405; Maluf SW, 2001, ENVIRON MOL MUTAGEN, V38, P311, DOI 10.1002/em.10029; Markowitz SD, 1997, J CLIN INVEST, V100, P2143, DOI 10.1172/JCI119749; McKetty MH, 1996, HEALTH PHYS, V70, P563, DOI 10.1097/00004032-199604000-00016; Migliore L, 2002, NEUROLOGY, V58, P1809, DOI 10.1212/WNL.58.12.1809; Milacic S, 2004, ENVIRON RES, V95, P2, DOI 10.1016/j.envres.2003.12.006; Miller MC, 2001, TOXICOL LETT, V120, P269, DOI 10.1016/S0378-4274(01)00279-X; NCRP 116. National Council on Radiation Protection and Measurements, 1993, 116 NCRP; PAZYMINO C, 1995, MUTAT RES-ENVIR MUTA, V335, P245, DOI 10.1016/0165-1161(95)00027-5; Picano E, 2004, LANCET, V363, P1909, DOI 10.1016/S0140-6736(04)16373-3; Picano E, 2004, BMJ-BRIT MED J, V328, P578, DOI 10.1136/bmj.328.7439.578; PICANO E, 2004, BRIT MED J, V329, P610; Preston DL, 2003, RADIAT RES, V160, P381, DOI 10.1667/RR3049; Rozgaj R, 1999, OCCUP MED-OXFORD, V49, P353, DOI 10.1093/occmed/49.6.353; Sari-Minodier I, 2002, MUTAT RES-GEN TOX EN, V521, P37, DOI 10.1016/S1383-5718(02)00213-9; SCIOCCHETTI G, 1983, HEALTH PHYS, V45, P385, DOI 10.1097/00004032-198308000-00011; Shiralkar S, 2003, BRIT MED J, V327, P371, DOI 10.1136/bmj.327.7411.371; Smerhovsky Z, 2001, ENVIRON HEALTH PERSP, V109, P41, DOI 10.2307/3434919; Zakeri F, 2004, MUTAT RES-GEN TOX EN, V562, P1, DOI 10.1016/j.mrgentox.2004.04.005; 2001, RADIATION PROTECT, V118	46	78	83	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					998	+		10.1096/fj.04-3287fje	http://dx.doi.org/10.1096/fj.04-3287fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15802491				2022-12-25	WOS:000227901300042
J	Macauley, MS; Whitworth, GE; Debowski, AW; Chin, D; Vocadlo, DJ				Macauley, MS; Whitworth, GE; Debowski, AW; Chin, D; Vocadlo, DJ			O-GlcNAcase uses substrate-assisted catalysis - Kinetic analysis and development of highly selective mechanism-inspired inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; BETA-D-GLUCOSAMINIDASE; TAY-SACHS-DISEASE; INSULIN-RESISTANCE; CRYSTAL-STRUCTURE; NUCLEOCYTOPLASMIC PROTEINS; GLYCOSYL HYDROLASES; DIABETOGENIC ACTION; ALZHEIMERS-DISEASE; CYTOSOLIC PROTEINS	The post-translational modification of serine and threonine residues of nucleocytoplasmic proteins with 2-acetamido-2-deoxy-D-glucopyranose ( GlcNAc) is a reversible process implicated in multiple cellular processes. The enzyme O-GlcNAcase catalyzes the cleavage of beta-O-linked GlcNAc (O-GlcNAc) from modified proteins and is a member of the family 84 glycoside hydrolases. The family 20 beta-hexosaminidases bear no apparent sequence similarity yet are functionally related to O-GlcNAcase because both enzymes cleave terminal GlcNAc residues from glycoconjugates. Lysosomal beta-hexosaminidase is known to use substrate-assisted catalysis involving the 2-acetamido group of the substrate; however, the catalytic mechanism of human O-GlcNAcase is unknown. By using a series of 4-methylumbelliferyl 2-deoxy-2-N-fluoroacetyl-beta-D-glucopyranoside substrates, Taft-like linear free energy analyses of these enzymes indicates that O-GlcNAcase uses a catalytic mechanism involving anchimeric assistance. Consistent with this proposal, 1,2-dideoxy-2'-methyl-alpha-D-glucopyranoso-[2,1-d]-Delta 2'-thiazoline, an inhibitor that mimics the oxazoline intermediate proposed in the catalytic mechanism of family 20 glycoside hydrolases, is shown to act as a potent competitive inhibitor of both O-GlcNAcase (K-I = 0.070 mu M) and beta-hexosaminidase (KI = 0.070 mu M). A series of 1,2-dideoxy-2'-methyl-alpha-D-glucopyranoso[2,1-d]-Delta 2'-thiazoline analogues were prepared, and one inhibitor demonstrated a remarkable 1500-fold selectivity for O-GlcNAcase (K-I = 0.230 mu M) over beta-hexosaminidase (K-I = 340 mu M). These inhibitors are cell permeable and modulate the activity of O-GlcNAcase in tissue culture. Because both enzymes have vital roles in organismal health, these potent and selective inhibitors of O-GlcNAcase should prove useful in studying the role of this enzyme at the organismal level without generating a complex chemical phenotype stemming from concomitant inhibition of beta-hexosaminidase.	Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada	Simon Fraser University	Vocadlo, DJ (corresponding author), Simon Fraser Univ, Dept Chem, 8888 Univ Blvd, Burnaby, BC V5A 1S6, Canada.	dvocadlo@sfu.ca	Vocadlo, David J/E-5508-2014	Vocadlo, David J/0000-0001-6897-5558; Macauley, Matthew/0000-0003-4579-1048				Arias EB, 2004, DIABETES, V53, P921, DOI 10.2337/diabetes.53.4.921; BENNETT RA, 1981, CANCER RES, V41, P2786; Bergmann M, 1931, BER DTSCH CHEM GES, V64, P975, DOI 10.1002/cber.19310640506; BRAIDMAN I, 1974, BIOCHEM J, V143, P295, DOI 10.1042/bj1430295; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Chou TY, 2001, ADV EXP MED BIOL, V491, P413; Cole RN, 1999, J NEUROCHEM, V73, P418, DOI 10.1046/j.1471-4159.1999.0730418.x; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Gao Y, 2000, ARCH BIOCHEM BIOPHYS, V383, P296, DOI 10.1006/abbi.2000.2094; GRIFFITH LS, 1995, BIOCHEM BIOPH RES CO, V213, P424, DOI 10.1006/bbrc.1995.2149; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hanover JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P38, DOI 10.1006/abbi.1998.1016; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Hansch C, 1979, SUBSTITUENT CONSTANT, P1; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HORSCH M, 1991, EUR J BIOCHEM, V197, P815, DOI 10.1111/j.1432-1033.1991.tb15976.x; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JONES CS, 1980, J BIOL CHEM, V255, P1861; JUNOD A, 1967, P SOC EXP BIOL MED, V126, P201; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Knapp S, 1996, J AM CHEM SOC, V118, P6804, DOI 10.1021/ja960826u; Konrad RJ, 2001, BIOCHEM J, V356, P31, DOI 10.1042/0264-6021:3560031; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P179, DOI 10.1515/bchm3.1995.376.3.179; Kuroki R, 1999, P NATL ACAD SCI USA, V96, P8949, DOI 10.1073/pnas.96.16.8949; Lamarre-Vincent N, 2003, J AM CHEM SOC, V125, P6612, DOI 10.1021/ja028200t; LEGLER G, 1991, BIOCHIM BIOPHYS ACTA, V1080, P89, DOI 10.1016/0167-4838(91)90133-K; Lillelund VH, 2002, CHEM REV, V102, P515, DOI 10.1021/cr000433k; Liu F, 2004, P NATL ACAD SCI USA, V101, P10804, DOI 10.1073/pnas.0400348101; Liu JJ, 2001, CHEM BIOL, V8, P701, DOI 10.1016/S1074-5521(01)00045-X; Liu K, 2004, J NEUROCHEM, V89, P1044, DOI 10.1111/j.1471-4159.2004.02389.x; Liu K, 2002, MOL CELL ENDOCRINOL, V194, P135, DOI 10.1016/S0303-7207(02)00155-7; LUBAS WA, 1995, BIOCHEMISTRY-US, V34, P1686, DOI 10.1021/bi00005a025; Maier T, 2003, J MOL BIOL, V328, P669, DOI 10.1016/S0022-2836(03)00311-5; Mark BL, 2003, J MOL BIOL, V327, P1093, DOI 10.1016/S0022-2836(03)00216-X; Mark BL, 2002, CAN J CHEM, V80, P1064, DOI 10.1139/V02-130; Mark BL, 2001, J BIOL CHEM, V276, P10330, DOI 10.1074/jbc.M011067200; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; MILLER DJ, 1993, DEVELOPMENT, V118, P1279; Okuyama R, 2001, BIOCHEM BIOPH RES CO, V287, P366, DOI 10.1006/bbrc.2001.5607; Parker G, 2004, J BIOL CHEM, V279, P20636, DOI 10.1074/jbc.M312139200; ROESER KR, 1981, BIOCHIM BIOPHYS ACTA, V657, P321, DOI 10.1016/0005-2744(81)90318-1; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Roos MD, 1998, P ASSOC AM PHYSICIAN, V110, P422; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Toleman C, 2004, J BIOL CHEM, V279, P53665, DOI 10.1074/jbc.M410406200; TORRES CR, 1984, J BIOL CHEM, V259, P3308; Triggs-Raine B, 2001, ADV GENET, V44, P199; Tropak MB, 2004, J BIOL CHEM, V279, P13478, DOI 10.1074/jbc.M308523200; UENO R, 1991, BIOCHIM BIOPHYS ACTA, V1074, P79, DOI 10.1016/0304-4165(91)90043-G; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; Vocadlo DJ, 2000, BIOCHEMISTRY-US, V39, P117, DOI 10.1021/bi991958d; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Wells L, 2002, J BIOL CHEM, V277, P1755, DOI 10.1074/jbc.M109656200; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; YAMADA K, 1982, DIABETES, V31, P749, DOI 10.2337/diabetes.31.9.749; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0; Yao PJ, 1998, J NEUROSCI, V18, P2399; Zachara NE, 2004, J BIOL CHEM, V279, P30133, DOI 10.1074/jbc.M403773200; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	66	304	326	2	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25313	25322		10.1074/jbc.M413819200	http://dx.doi.org/10.1074/jbc.M413819200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15795231	hybrid			2022-12-25	WOS:000230207900003
J	Saji, S; Kawakami, M; Hayashi, S; Yoshida, N; Hirose, M; Horiguchi, SI; Itoh, A; Funata, N; Schreiber, SL; Yoshida, M; Toi, M				Saji, S; Kawakami, M; Hayashi, S; Yoshida, N; Hirose, M; Horiguchi, SI; Itoh, A; Funata, N; Schreiber, SL; Yoshida, M; Toi, M			Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer	ONCOGENE			English	Article						breast cancer; estrogen receptor; HDAC6; tamoxifen	PROGESTERONE-RECEPTOR; HISTONE DEACETYLASES; ENDOCRINE THERAPY; EXPRESSION; TAMOXIFEN; PROTEIN; PREDICTION; CHROMATIN; GENES; BETA	Histone deacetylase ( HDAC) 6 is a subtype of the HDAC family; it deacetylates alpha-tubulin and increases cell motility. Here, we investigate the impact of an alteration of HDAC6 expression in estrogen receptor a ( ER)positive breast cancer MCF-7 cells, as we identified that HDAC6 is a novel estrogen-regulated gene. MCF-7 treated with estradiol showed increased expression of HDAC6 mRNA and protein and a four-fold increase in cell motility in a migration assay. Cell motility was increased to the same degree by stably transfecting the HDAC6 expression vector into MCF-7 cells. In both cases, the cells changed in appearance from their original round shape to an axon-extended shape, like a neuronal cell. This HDAC6 accumulation caused the deacetylation of alpha-tubulin. Either the selective estrogen receptor modulator tamoxifen (TAM) or the pure antiestrogen ICI 182,780 prevented estradiol-induced HDAC6 accumulation and deacetylation of alpha-tubulin, leading to reduced cell motility. Tubacin, an inhibitory molecule that binds to the tubulin deacetylation domain of HDAC6, also prevented estradiol-stimulated cell migration. Finally, we evaluated HDAC6 protein expression in 139 consecutively archived human breast cancer tissues by immunohistochemical staining. The prognostic analyses for these patients revealed no significant differences based on HDAC6 expression. However, subset analysis of ER-positive patients who received adjuvant treatment with TAM (n = 67) showed a statistically significant difference in relapse-free survival and overall survival in favor of the HDAC6-positive group (P < 0.02 and P < 0.05, respectively). HDAC 6 expression was an independent prognostic indicator by multivariate analysis ( odds ratio = 2.82, P = 0.047). These results indicate the biological significance of HDAC6 regulation via estrogen signaling.	Tokyo Metropolitan Komagome Hosp, Dept Clin Trials & Res, Bunkyo Ku, Tokyo 1138677, Japan; Tohoku Univ, Fac Med, Dept Mol Med Technol, Sendai, Miyagi 980, Japan; Saitama Canc Ctr, Inst Res, Div Endocrinol, Ina, Saitama, Japan; Tokyo Metropolitan Komagome Hosp, Dept Pathol, Tokyo, Japan; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tohoku University; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Harvard University	Saji, S (corresponding author), Tokyo Metropolitan Komagome Hosp, Dept Clin Trials & Res, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.	ss-saji@wa2.so-net.ne.jp	Ito, Akihiro/A-6100-2015; Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				Bardou VJ, 2003, J CLIN ONCOL, V21, P1973, DOI 10.1200/JCO.2003.09.099; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Ciocca DR, 2000, ENDOCRINE, V13, P1, DOI 10.1385/ENDO:13:1:1; CLARK GM, 1983, NEW ENGL J MED, V309, P1343, DOI 10.1056/NEJM198312013092240; Clarke M, 1998, LANCET, V351, P1451; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511; Omoto Y, 2001, BIOCHEM BIOPH RES CO, V285, P340, DOI 10.1006/bbrc.2001.5158; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Palazzo A, 2003, NATURE, V421, P230, DOI 10.1038/421230a; RAVDIN PM, 1992, J CLIN ONCOL, V10, P1284, DOI 10.1200/JCO.1992.10.8.1284; Saji S, 2002, CANCER RES, V62, P4849; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Yoshida N, 2004, CANCER SCI, V95, P496, DOI 10.1111/j.1349-7006.2004.tb03239.x; Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455	23	193	206	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 30	2005	24	28					4531	4539		10.1038/sj.onc.1208646	http://dx.doi.org/10.1038/sj.onc.1208646			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15806142				2022-12-25	WOS:000230157100006
J	Sobhany, M; Dong, J; Negishi, M				Sobhany, M; Dong, J; Negishi, M			Two step mechanism that determines the donor binding specificity of human UDP-N-acetylhexosaminyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; CRYSTAL-STRUCTURE; ENZYME; EXTL2; GLYCOSYLTRANSFERASES; BIOSYNTHESIS; CATALYSIS; AFFINITY; COMPLEX; WATER	In its x-ray crystal structures, alpha-1,4-N-acteylhexosaminyltransferase (exostosin-like protein 2 (EXTL2)) forms no direct interaction with the N-acetyl group of the UDP-N-acetylhexosamine. Mutation of the residues that interact with the hydroxyl groups of the donor not only failed to abrogate donor binding but in fact increased binding affinity. Isothermal titration calorimetry is now used to examine the binding nature of various UDP-sugars in H2O and D2O solutions. UDP-N-acetylhexosamines bind to EXTL2 with a high affinity in both solutions, resulting in a relatively large increase of entropy, whereas the weak binding of UDP-galactose and -glucose, which occurred only in D2O solution, only slightly increased entropy. Thus, specific donor binding appears to undergo two distinct steps, beginning with the N-acetyl group expelling water from the donor enzyme complex into the bulk solvent followed by positioning of the donor into the binding site for the subsequent interactions with the enzyme.	NIEHS, Lab Reprod & Dev Toxicol, Pharmacogenet Sect, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Negishi, M (corresponding author), NIEHS, Lab Reprod & Dev Toxicol, Pharmacogenet Sect, NIH, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov	Negishi, Masahiko/F-7805-2019	Negishi, Masahiko/0000-0002-2076-8928	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071005] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boix E, 2002, J BIOL CHEM, V277, P28310, DOI 10.1074/jbc.M202631200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Hu YN, 2002, CHEM BIOL, V9, P1287, DOI 10.1016/S1074-5521(02)00295-8; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; KOSHLAND DE, 1960, ADV ENZYMOL REL S BI, V22, P45; Kushner DJ, 1999, CAN J PHYSIOL PHARM, V77, P79, DOI 10.1139/cjpp-77-2-79; Negishi M, 2003, BIOCHEM BIOPH RES CO, V303, P393, DOI 10.1016/S0006-291X(03)00356-5; Pedersen LC, 2003, J BIOL CHEM, V278, P14420, DOI 10.1074/jbc.M210532200; Pedersen LC, 2002, J BIOL CHEM, V277, P21869, DOI 10.1074/jbc.M112343200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; PRESS WH, 1989, NUMERICAL RECIPES FO; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; Segel IH, 1976, BIOCH CALCULATIONS; Sievers A, 2004, P NATL ACAD SCI USA, V101, P7897, DOI 10.1073/pnas.0402488101; Snider MJ, 2002, BIOCHEMISTRY-US, V41, P3925, DOI 10.1021/bi011696r; Tarbouriech N, 2001, J MOL BIOL, V314, P655, DOI 10.1006/jmbi.2001.5159; UNGLIGI UM, 2000, CURR OPIN STRUCT BIL, V10, P510; Velazquez-Campoy A, 2000, BIOCHEMISTRY-US, V39, P2201, DOI 10.1021/bi992399d; WESTHEIMER FH, 1962, ADV ENZYMOL REL S BI, V24, P441	21	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23441	23445		10.1074/jbc.M413379200	http://dx.doi.org/10.1074/jbc.M413379200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15831490	hybrid			2022-12-25	WOS:000229880000006
J	Higashi, H; Yokoyama, K; Fujii, Y; Ren, S; Yuasa, H; Saadat, I; Kamiya, NM; Azuma, T; Hatakeyama, M				Higashi, H; Yokoyama, K; Fujii, Y; Ren, S; Yuasa, H; Saadat, I; Kamiya, NM; Azuma, T; Hatakeyama, M			EPIYA motif is a membrane-targeting signal of Helicobacter pylori virulence factor CagA in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC EPITHELIAL-CELLS; TYROSINE PHOSPHORYLATION; IN-VIVO; PATHOGENICITY ISLAND; MONGOLIAN GERBILS; IV SECRETION; PROTEIN; CANCER; INFECTION; TRANSLOCATION	Helicobacter pylori contributes to the development of peptic ulcers and atrophic gastritis. Furthermore, H. pylori strains carrying the cagA gene are more virulent than cagA-negative strains and are associated with the development of gastric adenocarcinoma. The cagA gene product, CagA, is translocated into gastric epithelial cells and localizes to the inner surface of the plasma membrane, in which it undergoes tyrosine phosphorylation at the Glu-Pro-Ile-Tyr-Ala (EPIYA) motif. Tyrosine-phosphorylated CagA specifically binds to and activates Src homology 2-containing protein-tyrosine phosphatase-2 (SHP-2) at the membrane, thereby inducing an elongated cell shape termed the hummingbird phenotype. Accordingly, membrane tethering of CagA is an essential prerequisite for the pathogenic activity of CagA. We show here that membrane association of CagA requires the EPIYA-containing region but is independent of EPIYA tyrosine phosphorylation. We further show that specific deletion of the EPIYA motif abolishes the ability of CagA to associate with the membrane. Conversely, reintroduction of an EPIYA sequence into a CagA mutant that lacks the EPIYA-containing region restores membrane association of CagA. Thus, the presence of a single EPIYA motif is necessary for the membrane localization of CagA. Our results indicate that the EPIYA motif has a dual function in membrane association and tyrosine phosphorylation, both of which are critically involved in the activity of CagA to deregulate intracellular signaling, and suggest that the EPIYA motif is a crucial therapeutic target of cagA-positive H. pylori infection.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Kobe Univ, Grad Sch Med, Int Ctr Med Res & Treatment, Kobe, Hyogo 6500017, Japan	Hokkaido University; Kobe University	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp	Higashi, Hideaki/F-6872-2012	Saadat, Iraj/0000-0002-8169-4707				Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Asahi M, 2003, HELICOBACTER, V8, P1, DOI 10.1046/j.1523-5378.2003.00118.x; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Azuma T, 2004, J INFECT DIS, V189, P820, DOI 10.1086/381782; Azuma T, 2004, J GASTROENTEROL, V39, P97, DOI 10.1007/s00535-003-1279-4; Backert S, 2001, MOL MICROBIOL, V42, P631, DOI 10.1046/j.1365-2958.2001.02649.x; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; BLASER MJ, 1995, CANCER RES, V55, P2111; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Churin Y, 2003, J CELL BIOL, V161, P249, DOI 10.1083/jcb.200208039; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Danesh J, 1999, ALIMENT PHARM THERAP, V13, P851; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Honda S, 1998, CANCER RES, V58, P4255; Huang JQ, 1998, GASTROENTEROLOGY, V114, P1169, DOI 10.1016/S0016-5085(98)70422-6; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Peek RM, 1995, LAB INVEST, V73, P760; Rugge M, 1999, CANCER-AM CANCER SOC, V85, P2506, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2506::AID-CNCR3>3.3.CO;2-9; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; Tsutsumi R, 2003, J BIOL CHEM, V278, P3664, DOI 10.1074/jbc.M208155200; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Umehara S, 2003, ONCOGENE, V22, P8337, DOI 10.1038/sj.onc.1207028; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Yamaoka Y, 2000, EPIDEMIOL INFECT, V124, P91, DOI 10.1017/S0950268899003209; Yamazaki S, 2003, J INFECT DIS, V187, P334, DOI 10.1086/367807	35	108	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23130	23137		10.1074/jbc.M503583200	http://dx.doi.org/10.1074/jbc.M503583200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15831497	hybrid			2022-12-25	WOS:000229741800070
J	Petropoulou, V; Garrigue-Antar, L; Kadler, KE				Petropoulou, V; Garrigue-Antar, L; Kadler, KE			Identification of the minimal domain structure of bone morphogenetic protein-1 (BMP-1) for chordinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN C-PROTEINASE; EPIDERMAL-GROWTH-FACTOR; MAMMALIAN TOLLOID-LIKE; POSTTRANSLATIONAL MODIFICATION; DROSOPHILA EMBRYO; LYSYL OXIDASE; COLLAGEN; METALLOPROTEINASES; ENHANCER; GENE	Bone morphogenetic protein 1 (BMP-1), which is a tolloid member of the astacin-like family of zinc metalloproteinases, is a highly effective procollagen C-proteinase (PCP) and chordinase. On the other hand, mammalian tolloid like-2 (mTLL-2) does not cleave chordin or procollagen; procollagen is cleaved by mTLL-2 in the presence of high levels of procollagen C-proteinase enhancer-1 (PCPE-1), for reasons that are unknown. We used these differences in activity between BMP-1 and mTLL-2 to narrow in on the domains in BMP-1 that specify PCP and chordinase activity. Using a domain swap approach, we showed that: 1) the metalloproteinase and CUB2 domains of BMP-1 are absolutely required for PCP activity; swaps with either of the corresponding domains in BMP-1 and mTLL-2 did not result in procollagen cleavage and 2) the proteinase domain of mTLL-2 can cleave chordin if coupled to the CUB1 domain of BMP-1. Therefore, the minimal structure for chordinase activity comprises a metalloproteinase domain (either from BMP-1 or from mTLL-2) and the CUB1 domain of BMP-1 (the CUB1 domain of mTLL-2 cannot substitute for the CUB1 domain of BMP-1). We showed that the minimal procollagen C-proteinase (BMP-1 lacking the EGF and CUB3 domain) was enhanced by PCPE-1 but not as well as BMP-1 retaining the CUB3 domain. Further studies showed that PCPE-1 had no effect on the ability of BMP-1 to cleave chordin. The data support a previously suggested mechanism of PCPE-1 whereby PCPE-1 interacts with procollagen, but in addition, the CUB3 domain of BMP-1 appears to augment the interaction.	Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Kadler, KE (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	karl.kadler@manchester.ac.uk	KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Garrigue-Antar, Laure/0000-0001-6331-8882	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAR R, 1986, COLLAGEN REL RES, V6, P267; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Garrigue-Antar L, 2004, J BIOL CHEM, V279, P49835, DOI 10.1074/jbc.M408134200; Garrigue-Antar L, 2002, J BIOL CHEM, V277, P43327, DOI 10.1074/jbc.M207342200; Garrigue-Antar L, 2001, J BIOL CHEM, V276, P26237, DOI 10.1074/jbc.M010814200; Ge GX, 2004, J BIOL CHEM, V279, P41626, DOI 10.1074/jbc.M406630200; Gopalakrishnan B, 2004, J BIOL CHEM, V279, P30904, DOI 10.1074/jbc.M402252200; Hartigan N, 2003, J BIOL CHEM, V278, P18045, DOI 10.1074/jbc.M211448200; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; HULMES D, 2004, ABSTR AM SOC MATRIX; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; Larrain J, 2000, DEVELOPMENT, V127, P821; Leighton M, 2003, J BIOL CHEM, V278, P18478, DOI 10.1074/jbc.M213021200; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Medeck RJ, 2003, BIOCHEM J, V376, P361, DOI 10.1042/BJ20030894; Millet C, 2001, MECH DEVELOP, V106, P85, DOI 10.1016/S0925-4773(01)00423-3; Moschcovich L, 2001, EUR J BIOCHEM, V268, P2991, DOI 10.1046/j.1432-1327.2001.02189.x; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Ricard-Blum S, 2002, J BIOL CHEM, V277, P33864, DOI 10.1074/jbc.M205018200; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Steiglitz BM, 2004, J BIOL CHEM, V279, P980, DOI 10.1074/jbc.M310179200; Steiglitz BM, 2002, J BIOL CHEM, V277, P49820, DOI 10.1074/jbc.M209891200; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Van de Putte K A, 1965, Clin Orthop Relat Res, V43, P257; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; Wolfman NM, 2003, P NATL ACAD SCI USA, V100, P15842, DOI 10.1073/pnas.2534946100; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	48	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22616	22623		10.1074/jbc.M413468200	http://dx.doi.org/10.1074/jbc.M413468200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817489	hybrid			2022-12-25	WOS:000229741800010
J	Chen, YD; Erickson, HP				Chen, YD; Erickson, HP			Rapid in vitro assembly dynamics and subunit turnover of FtsZ demonstrated by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-CELL DIVISION; ESCHERICHIA-COLI; COMPUTER-SIMULATION; NUCLEOTIDE TURNOVER; FITTING PROGRAMS; GTPASE ACTIVITY; INHIBITOR SULA; PROTEIN FTSZ; TUBULIN; HOMOLOG	We have developed an assay for the assembly of FtsZ based on fluorescence resonance energy transfer ( FRET). We mutated an innocuous surface residue to cysteine and labeled separate pools with fluorescein ( donor) and tetramethylrhodamine ( acceptor). When the pools were mixed and GTP was added, assembly produced a FRET signal that was linearly proportional to FtsZ concentration from 0.7 mM ( the critical concentration (C-c(c)c()) to 3 mM. At concentrations greater than 3 mM, an enhanced FRET signal was observed with both GTP and GDP, indicating additional assembly above this second C). This second C (varied with Mg2+ concentration, whereas the 0.7 mM C)(c) did not. We used the FRET assay to measure the kinetics of initial assembly by stopped flow. The data were fit by the simple kinetic model used previously: monomer activation, a weak dimer nucleus, and elongation, although with some differences in kinetic parameters from the L68W mutant. We then studied the rate of turnover at steady state by pre-assembling separate pools of donor and acceptor protofilaments. When the pools were mixed, a FRET signal developed with a half-time of 7 s, demonstrating a rapid and continuous disassembly and reassembly of protofilaments at steady state. This is comparable with the 9-s half- time for FtsZ turnover in vivo and the 8-s turnover time of GTP hydrolysis in vitro. Finally, we found that an excess of GDP caused disassembly of protofilaments with a half- time of 5 s. Our new data suggest that GDP does not exchange into intact protofilaments. Rather, our interpretation is that subunits are released following GTP hydrolysis, and then they exchange GDP for GTP and reassemble into new protofilaments, all on a time scale of 7 s. The mechanism may be related to the dynamic instability of microtubules.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Erickson, HP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	h.erickson@cellbio.duke.edu	Chen, Yaodong/C-6138-2011; Chen, Yaodong/X-8923-2019	Chen, Yaodong/0000-0002-3751-0923	NIGMS NIH HHS [GM 66014, R01 GM066014-05, R01 GM066014] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066014] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DE, 2004, J BACTERIOL, V186, P5775, DOI 10.1128/JB.186.17.5775-5781.2004; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BI E, 1990, J BACTERIOL, V172, P5602, DOI 10.1128/jb.172.10.5602-5609.1990; Chen YD, 2005, BIOPHYS J, V88, P505, DOI 10.1529/biophysj.104.044149; CORBALANGARCIA S, 1993, EUR J BIOCHEM, V217, P737, DOI 10.1111/j.1432-1033.1993.tb18300.x; Cordell SC, 2003, P NATL ACAD SCI USA, V100, P7889, DOI 10.1073/pnas.1330742100; CORREIA JJ, 1987, J BIOL CHEM, V262, P17278; Dang Q, 1997, TRENDS BIOCHEM SCI, V22, P317, DOI 10.1016/S0968-0004(97)01062-1; Erickson HP, 1996, J CELL BIOL, V135, P5, DOI 10.1083/jcb.135.1.5; FRIEDEN C, 1994, METHOD ENZYMOL, V240, P311; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Lu C, 2001, BMC Microbiol, V1, P7, DOI 10.1186/1471-2180-1-7; Lu CL, 1998, METHOD ENZYMOL, V298, P305, DOI 10.1016/S0076-6879(98)98027-2; Mingorance J, 2001, MOL MICROBIOL, V41, P83, DOI 10.1046/j.1365-2958.2001.02498.x; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; Mukherjee A, 2001, J BACTERIOL, V183, P7190, DOI 10.1128/JB.183.24.7190-7197.2001; Oliva MA, 2004, NAT STRUCT MOL BIOL, V11, P1243, DOI 10.1038/nsmb855; Redick SD, 2005, J BACTERIOL, V187, P2727, DOI 10.1128/JB.187.8.2727-2736.2005; Rivas G, 2000, J BIOL CHEM, V275, P11740, DOI 10.1074/jbc.275.16.11740; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; Romberg L, 2004, BIOCHEMISTRY-US, V43, P282, DOI 10.1021/bi035465r; Scheffers DJ, 2000, MOL MICROBIOL, V35, P1211, DOI 10.1046/j.1365-2958.2000.01791.x; Sossong TM, 1999, BIOCHEMISTRY-US, V38, P14843, DOI 10.1021/bi990917e; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099; Yu XC, 1997, EMBO J, V16, P5455, DOI 10.1093/emboj/16.17.5455; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	26	139	142	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22549	22554		10.1074/jbc.M500895200	http://dx.doi.org/10.1074/jbc.M500895200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15826938	Green Accepted, hybrid			2022-12-25	WOS:000229557900103
J	Lupu, C; Hu, XH; Lupu, F				Lupu, C; Hu, XH; Lupu, F			Caveolin-1 enhances tissue factor pathway inhibitor exposure and function on the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; COAGULATION INHIBITOR; LIPID RAFTS; FACTOR VIIA; IN-VITRO; EXPRESSION; RELEASE; COMPLEX; LOCALIZATION; LYMPHOCYTES	Tissue factor pathway inhibitor ( TFPI) blocks tissue factor-factor VIIa (TF-FVIIa) activation of factors X and IX through the formation of the TF-FVIIa-FXa-TFPI complex. Most TFPI in vivo associates with caveolae in endothelial cells (EC). The mechanism of this association and the anticoagulant role of caveolar TFPI are not yet known. Here we show that expression of caveolin-1 (Cav-1) in 293 cells keeps TFPI exposed on the plasmalemma surface, decreases the membrane lateral mobility of TFPI, and increases the TFPI-dependent inhibition of TF-FVIIa. Caveolae-associated TFPI supports the co-localization of the quaternary complex with caveolae. To investigate the significance of these observations for EC we used RNA interference to deplete the cells of Cav-1. Functional assays and fluorescence microscopy revealed that the inhibitory properties of TFPI were diminished in EC lacking Cav-1, apparently through deficient assembly of the quaternary complex. These findings demonstrate that caveolae regulate the inhibition by cell-bound TFPI of the active protease production by the extrinsic pathway of coagulation.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Lupu, C (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	cristina-lupu@omrf.ouhsc.edu	Lupu, Florea/AAV-3257-2021; Lupu, Florea/C-3162-2009	Lupu, Florea/0000-0003-1249-9278; Lupu, Florea/0000-0003-1249-9278	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018758] Funding Source: NIH RePORTER; NCRR NIH HHS [5P20 RR 018758-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAJAJ MS, 1990, P NATL ACAD SCI USA, V87, P8869, DOI 10.1073/pnas.87.22.8869; BROZE GJ, 1988, BLOOD, V71, P335; Caplice NM, 1998, CIRC RES, V83, P1264, DOI 10.1161/01.RES.83.12.1264; CONTRINO J, 1994, AM J PATHOL, V145, P1315; Crawley J, 2000, ARTERIOSCL THROM VAS, V20, P1362, DOI 10.1161/01.ATV.20.5.1362; Dietzen DJ, 2003, THROMB HAEMOSTASIS, V89, P65; DRAKE TA, 1993, AM J PATHOL, V142, P1458; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1994, J BIOL CHEM, V269, P30745; Hansen JB, 2000, THROMB RES, V100, P413, DOI 10.1016/S0049-3848(00)00351-0; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Krajewska WM, 2004, CELL MOL BIOL LETT, V9, P195; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Lupu C, 1997, ARTERIOSCL THROM VAS, V17, P2964, DOI 10.1161/01.ATV.17.11.2964; Lupu C, 1999, ARTERIOSCL THROM VAS, V19, P2251, DOI 10.1161/01.ATV.19.9.2251; Lupu C, 1999, THROMB HAEMOSTASIS, V82, P1652; Mast AE, 2002, ARTERIOSCL THROM VAS, V22, P2099, DOI 10.1161/01.ATV.0000042456.84190.F0; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; NORDFANG O, 1991, BIOCHEMISTRY-US, V30, P10371, DOI 10.1021/bi00107a002; Ott I, 2000, ARTERIOSCL THROM VAS, V20, P874, DOI 10.1161/01.ATV.20.3.874; Ott I, 2001, BLOOD, V97, P3721, DOI 10.1182/blood.V97.12.3721; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Roque M, 2000, J AM COLL CARDIOL, V36, P2303, DOI 10.1016/S0735-1097(00)01018-4; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Ruf W, 1996, Curr Opin Hematol, V3, P379; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; SIMIONESCU N, 1983, J CELL BIOL, V97, P1592, DOI 10.1083/jcb.97.5.1592; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; Vogel U, 1998, J CELL SCI, V111, P825; Westmuckett AD, 2000, ARTERIOSCL THROM VAS, V20, P2474, DOI 10.1161/01.ATV.20.11.2474; Westmuckett AD, 2001, THROMB HAEMOSTASIS, V86, P1547, DOI 10.1055/s-0037-1616761; Xu J, 2000, J BIOL CHEM, V275, P6038, DOI 10.1074/jbc.275.8.6038; Zhang J, 2003, CIRCULATION, V108, P623, DOI 10.1161/01.CIR.0000078642.45127.7B	37	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22308	22317		10.1074/jbc.M503333200	http://dx.doi.org/10.1074/jbc.M503333200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817451	hybrid			2022-12-25	WOS:000229557900076
J	Wang, CC; Tsai, MF; Hong, TM; Chang, GC; Chen, CY; Yang, WM; Chen, JJW; Yang, PC				Wang, CC; Tsai, MF; Hong, TM; Chang, GC; Chen, CY; Yang, WM; Chen, JJW; Yang, PC			The transcriptional factor YY1 upregulates the novel invasion suppressor HLJ1 expression and inhibits cancer cell invasion	ONCOGENE			English	Article						DnaJ-like HSP40; invasion suppressor; promoter; YY1; E-cadherin	CORE PROMOTER ELEMENT; HEAT-SHOCK PROTEINS; ZINC-FINGER PROTEIN; C-FOS PROMOTER; E-CADHERIN; LUNG-CANCER; MOLECULAR CHAPERONES; BINDING PROTEIN; ADENOVIRUS E1A; GENE	By using microarray and an invasion/ metastasis lung cell line model, we identified the DnaJ-like heat shock protein 40, HLJ1, and found that the expression of HLJ1 correlates negatively with cancer cell invasion ability. Overexpression of HLJ1 can suppress cancer cell invasion in vitro. We further characterize the putative promoter region and investigate the transcriptional regulations of human HLJ1. A serial deletion of the 1.2 kb at the 5'-flanking region of the human HLJ1 gene was subcloned into a vector containing reporter gene and transfected into human lung adenocarcinoma cell line CL1-0, followed by luciferase activity assay. The results indicated that the region from - 232 to +176 could drive the basal transcriptional activity of the HLJ1 gene. Sequence analysis of the HLJ1 gene promoter region showed absence of a TATA box, but identified an inverted CCAAT box and four YY1 transcriptional factor-binding sites, which may be important in the regulation of HLJ1 expression. Co-transfection of the YY1 and HLJ1 basal promoter regions, site-directed mutagenesis, and electrophoretic mobility shift assay confirmed that YY1 could upregulate HLJ1 basal promoter activity. Furthermore, we also demonstrated that overexpression of YY1 in CL1-0 cells can increase HLJ1 expression and reduce cell invasive capability. The reduction of cancer cell invasive ability is, at least in part, through upregulation of E-cadherin expression. The increase in HLJ1 and E-cadherin expression, as well as the suppression of invasion ability, can be reversed specifically by HLJ1 siRNA.	Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, NTU Ctr Genom Med, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan; Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan; Chung Shan Med Univ, Inst Toxicol, Taichung, Taiwan; Taichung Vet Gen Hosp, Dept Surg, Div Thorac Surg, Taichung, Taiwan; Natl Chung Hsing Univ, Inst Mol Biol, Taichung 40227, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	National Chung Hsing University; National Defense Medical Center; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; Taichung Veterans General Hospital; Chung Shan Medical University; Taichung Veterans General Hospital; National Chung Hsing University; Academia Sinica - Taiwan	Chen, JJW (corresponding author), Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan.	jwchen@dragon.nchu.edu.tw	Yang, Pan-Chyr/B-8808-2009	Chen, Jeremy J.W./0000-0003-1049-3825; Yang, Wen-Ming/0000-0002-5871-5979; YANG, PAN-CHYR/0000-0001-6330-6048				Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; BIRCH M, 1991, CANCER RES, V51, P6660; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bremnes RM, 2002, LUNG CANCER, V36, P115, DOI 10.1016/S0169-5002(01)00471-8; Bukholm IK, 1998, J PATHOL, V185, P262, DOI 10.1002/(SICI)1096-9896(199807)185:3<262::AID-PATH97>3.0.CO;2-Y; CAROLINE J, 2000, JNCI-J NATL CANCER I, V92, P1564; Chen HW, 2002, BRIT J PHARMACOL, V137, P771, DOI 10.1038/sj.bjp.0704908; Chen JJW, 2003, CLIN CANCER RES, V9, P729; Chen JJW, 2001, CANCER RES, V61, P5223; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; Ficzycz A, 2002, J BIOL CHEM, V277, P8382, DOI 10.1074/jbc.M110304200; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; Hajra KM, 2002, CANCER RES, V62, P1613; Hamajima F, 2002, J CELL BIOCHEM, V84, P401, DOI 10.1002/jcb.10029; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HATTORI H, 1992, CELL STRUCT FUNCT, V17, P77, DOI 10.1247/csf.17.77; HEHLGANS T, 1995, J IMMUNOL, V154, P5181; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hoe KL, 1998, BBA-PROTEIN STRUCT M, V1383, P4, DOI 10.1016/S0167-4838(97)00207-0; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Matz M, 1999, NUCLEIC ACIDS RES, V27, P1558, DOI 10.1093/nar/27.6.1558; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Ohtsuka K, 2000, CELL STRESS CHAPERON, V5, P98, DOI 10.1379/1466-1268(2000)005<0098:MHDHCO>2.0.CO;2; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Shih JY, 2001, JNCI-J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; SREENATH T, 1992, CANCER RES, V52, P4942; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; ULEMINCKX K, 1991, CELL, V66, P107; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; ZHOU QJ, 1995, J VIROL, V69, P7402, DOI 10.1128/JVI.69.12.7402-7409.1995	54	69	82	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4081	4093		10.1038/sj.onc.1208573	http://dx.doi.org/10.1038/sj.onc.1208573			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15782117				2022-12-25	WOS:000229680300007
J	Kopp, J; Preis, E; Said, H; Hafemann, B; Wickert, L; Gressner, AM; Pallua, N; Dooley, S				Kopp, J; Preis, E; Said, H; Hafemann, B; Wickert, L; Gressner, AM; Pallua, N; Dooley, S			Abrogation of transforming growth factor-beta signaling by SMAD7 inhibits collagen gel contraction of human dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; TGF-BETA; GENE-TRANSFER; IN-VIVO; FIBROSIS; RECEPTOR; ANTAGONIST; ACTIVATION; EXPRESSION; TRANSDIFFERENTIATION	Human fibroproliferative disorders like hypertrophic scarring of the skin are characterized by increased contractility and excess extracellular matrix synthesis. A beneficial role of transforming growth factor (TGF)-beta in wound healing was proposed; however, chronic stimulation by this cytokine leads to fibrosis. In the present report, the intracellular TGF-beta signaling in fibroblasts derived from hypertrophic scars and normal skin was examined. In an attempt to intervene in profibrogenic TGF-beta functions, ectopic expression of Smad7 or dominant negative Smads3/4 completely inhibited contractility of scar-derived and normal fibroblasts after suspension in collagen gels. Both cell types displayed constitutive Smad2/3 phosphorylation and (CAGA)(9)MLP-Luc activity with expression and phosphorylation of Smad3 being predominant in hypertrophic scar-derived fibroblasts. Down-regulation of intrinsic signaling with various TGF-beta antagonists, e. g. soluble TGF-beta receptor, latency-associated peptide, and anti-TGF-beta(1) antibodies, confirms autocrine TGF-beta stimulation of both cell populations. Further, Smad7 expression inhibited alpha 1 (I) collagen and alpha-smooth muscle actin expression. In summary, our data indicate that autocrine TGF-beta/Smad signaling is involved in contractility and matrix gene expression of fibroblasts from normal and hypertrophic scars. Smad7 inhibits these processes and may exert beneficial effects on excessive scar formation.	Univ Erlangen Nurnberg, Chirurg Klin, D-91054 Erlangen, Germany; Rhein Westfal TH Aachen, Univ Klinikum, Klin Plast Chirurg, D-52074 Aachen, Germany; Rhein Westfal TH Aachen, Univ Klinikum, Inst Clin Chem & Pathobiochem, D-52074 Aachen, Germany; Heidelberg Univ, Univ Klinikum Mannheim, Med Klin 2, D-68167 Mannheim, Germany	University of Erlangen Nuremberg; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Dooley, S (corresponding author), Heidelberg Univ, Univ Hosp Mannheim, Med Clin, Bergheimer Str 58, Heidelberg, Germany.	dooley@med.ma.uni-heidelberg.de	Said, Harun Muayad/AAZ-7299-2021; Dooley, Steven/T-6491-2018	Dooley, Steven/0000-0002-4840-6240; Said, Harun M./0000-0002-7032-2668				Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Ashcroft GS, 2000, CYTOKINE GROWTH F R, V11, P125, DOI 10.1016/S1359-6101(99)00036-2; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BERG F, 2002, SIGNAL TRANSDUCT, V2, P11; Berry DP, 1998, PLAST RECONSTR SURG, V102, P124, DOI 10.1097/00006534-199807000-00019; Brissett A E, 2001, Facial Plast Surg, V17, P263, DOI 10.1055/s-2001-18827; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CLARK RAF, 1993, AM J MED SCI, V306, P42, DOI 10.1097/00000441-199307000-00011; Cowin AJ, 2001, EUR J DERMATOL, V11, P424; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dooley S, 2000, HEPATOLOGY, V31, P1094, DOI 10.1053/he.2000.6126; Dooley S, 2003, GASTROENTEROLOGY, V125, P178, DOI 10.1016/S0016-5085(03)00666-8; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; ENGEL K, 1993, FEBS LETT, V336, P143, DOI 10.1016/0014-5793(93)81628-D; Flanders KC, 2003, AM J PATHOL, V163, P2247, DOI 10.1016/S0002-9440(10)63582-1; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; George J, 1999, P NATL ACAD SCI USA, V96, P12719, DOI 10.1073/pnas.96.22.12719; Gressner AM, 2003, J HEPATOL, V39, P856, DOI 10.1016/S0168-8278(03)00432-X; Hasegawa T, 2003, J DERMATOL SCI, V32, P19, DOI 10.1016/S0923-1811(03)00044-6; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Herrmann J, 2004, ARCH VIROL, V149, P1611, DOI 10.1007/s00705-004-0300-4; Huang JS, 2002, FASEB J, V16, P1269, DOI 10.1096/fj.02-0103fje; Isaka Y, 1999, KIDNEY INT, V55, P465, DOI 10.1046/j.1523-1755.1999.00275.x; Lan HY, 2003, J AM SOC NEPHROL, V14, P1535, DOI 10.1097/01.ASN.0000067632.04658.B8; Liu XD, 2003, CELL MOTIL CYTOSKEL, V54, P248, DOI 10.1002/cm.10098; MARTIN P, 1992, Progress in Growth Factor Research, V4, P25, DOI 10.1016/0955-2235(92)90003-Z; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Schmid P, 1998, AM J PATHOL, V152, P485; Schnabl B, 2001, HEPATOLOGY, V34, P89, DOI 10.1053/jhep.2001.25349; SHAH M, 1995, J CELL SCI, V108, P985; SHAH M, 1994, J CELL SCI, V107, P1137; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; TERADA Y, 2002, KIDNEY INT S1, V61, P94, DOI DOI 10.1046/J.1523-1755.2002.0610S1094.X; Tredget EE, 1998, PLAST RECONSTR SURG, V102, P1317, DOI 10.1097/00006534-199810000-00001; Ueno H, 2000, HUM GENE THER, V11, P33, DOI 10.1089/10430340050016139; WEBER L, 1986, J INVEST DERMATOL, V87, P217, DOI 10.1111/1523-1747.ep12696545; Zhang Y, 2003, J INVEST DERMATOL, V121, P713, DOI 10.1046/j.1523-1747.2003.12517.x; Zhao JS, 2002, AM J PHYSIOL-LUNG C, V282, pL585, DOI 10.1152/ajplung.00151.2001	44	77	110	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21570	21576		10.1074/jbc.m502071200	http://dx.doi.org/10.1074/jbc.m502071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15788410	hybrid			2022-12-25	WOS:000229438800080
J	Reynolds, CM; Kalb, SR; Cotter, RJ; Raetz, CRH				Reynolds, CM; Kalb, SR; Cotter, RJ; Raetz, CRH			A phosphoethanolamine transferase specific for the outer 3-deoxy-D-manno-octulosonic acid residue of Escherichia coli lipopolysaccharide - Identification of the EptB gene and Ca2+ hypersensitivity of an EptB deletion mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-A; SALMONELLA-TYPHIMURIUM; RESISTANT MUTANTS; MEMBRANE-LIPIDS; INNER MEMBRANE; ACYL CHAINS; BIOSYNTHESIS; 4-AMINO-4-DEOXY-L-ARABINOSE; PURIFICATION; LACKING	Addition of a phosphoethanolamine (pEtN) moiety to the outer 3-deoxy-D-manno-octulosonic acid (Kdo) residue of lipopolysaccharide (LPS) in WBB06, a heptose-deficient Escherichia coli mutant, occurs when cells are grown in 5-50 mM CaCl2 (Kanipes, M. I., Lin, S., Cotter, R. J., and Raetz, C. R. H. ( 2001) J. Biol. Chem. 276, 1156-1163). A Ca2+-induced, membrane-bound enzyme was responsible for the transfer of the pEtN unit to the Kdo domain. We now report the identification of the gene encoding the pEtN transferase. E. coli yhjW was cloned and overexpressed, because it is homologous to a putative pEtN transferase implicated in the modification of the beta-chain heptose residue of Neisseria meningitidis lipo-oligosaccharide (Mackinnon, F. G., Cox, A. D., Plested, J. S., Tang, C. M., Makepeace, K., Coull, P. A., Wright, J. C., Chalmers, R., Hood, D. W., Richards, J. C., and Moxon, E. R. (2002) Mol. Microbiol. 43, 931-943). In vitro assays with Kdo(2)-4'-[P-32] lipid A as the acceptor showed that YhjW ( renamed EptB) utilizes phosphatidylethanolamine in the presence of Ca2+ to transfer the pEtN group. Stoichiometric amounts of diacylglycerol were generated during the EptB-catalyzed transfer of pEtN to Kdo(2)-lipid A. EptB is an inner membrane protein of 574 amino acid residues with five predicted trans-membrane segments within its N-terminal region. An in-frame replacement of eptB with a kanamycin resistance cassette rendered E. coli WBB06 ( but not wild-type WBB06) hypersensitive to CaCl2 at 5mM or higher. Ca2+ hypersensitivity was suppressed by excess Mg2+ in the medium or by restoring the LPS core of WBB06. The latter was achieved by reintroducing the waaC and waaF genes, which encode LPS heptosyl transferases I and II, respectively. Our data demonstrate that pEtN modification of the outer Kdo protected cells containing heptose-deficient LPS from damage by high concentrations of Ca2+. Based on its sequence similarity to EptA(PmrC), we propose that the active site of EptB faces the periplasmic surface of the inner membrane.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectrometry Lab, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Kalb, Suzanne/0000-0002-8067-136X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310, R01GM064402] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-64402, GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; Brade H, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P927; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; CRONAN JE, 1975, BACTERIOL REV, V39, P232, DOI 10.1128/MMBR.39.3.232-256.1975; Cronan JE, 2003, ANNU REV MICROBIOL, V57, P203, DOI 10.1146/annurev.micro.57.030502.090851; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Fahy E, 2005, J LIPID RES, V46, P839, DOI 10.1194/jlr.E400004-JLR200; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; GANGOLA P, 1987, J BIOL CHEM, V262, P12570; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GOLDMAN RC, 1985, J BACTERIOL, V163, P256, DOI 10.1128/JB.163.1.256-261.1985; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Kadrmas JL, 1998, J BIOL CHEM, V273, P2799, DOI 10.1074/jbc.273.5.2799; Kanipes MI, 2001, J BIOL CHEM, V276, P1156, DOI 10.1074/jbc.M009019200; KENNEDY EP, 1987, ESCHERICHIA COLI SAL, V1, P672; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lazar K, 2002, CURR OPIN CHEM BIOL, V6, P786, DOI 10.1016/S1367-5931(02)00355-1; Lee H, 2004, J BACTERIOL, V186, P4124, DOI 10.1128/JB.186.13.4124-4133.2004; Mackinnon FG, 2002, MOL MICROBIOL, V43, P931, DOI 10.1046/j.1365-2958.2002.02754.x; MILLER KJ, 1987, J BACTERIOL, V169, P682, DOI 10.1128/jb.169.2.682-686.1987; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Osborn M J, 1974, Methods Enzymol, V31, P642; RADIKA K, 1988, J BIOL CHEM, V263, P14859; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P498; RAY BL, 1984, J BIOL CHEM, V259, P4852; ROTERING H, 1983, J BIOL CHEM, V258, P8068; Sambrook J, 2001, MOL CLONING LAB MANU; SIRISENA DM, 1992, J BIOL CHEM, V267, P18874; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snijder HJ, 1999, NATURE, V401, P717, DOI 10.1038/44890; Tran AX, 2004, J BIOL CHEM, V279, P55780, DOI 10.1074/jbc.M406480200; Trent M. Stephen, 2002, Journal of Endotoxin Research, V8, P158; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14194, DOI 10.1074/jbc.M200409200; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14186, DOI 10.1074/jbc.M200408200; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466; Zwaal R F, 1974, Methods Enzymol, V32, P154	57	113	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21202	21211		10.1074/jbc.M500964200	http://dx.doi.org/10.1074/jbc.M500964200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15795227	hybrid			2022-12-25	WOS:000229438800038
J	Park, S; Yeung, ML; Beach, S; Shields, JM; Yeung, KC				Park, S; Yeung, ML; Beach, S; Shields, JM; Yeung, KC			RKIP downregulates B-Raf kinase activity in melanoma cancer cells	ONCOGENE			English	Article						B-Raf; melanomas; RKIP	RNA INTERFERENCE; TRANSFORMATION; SUPPRESSION; ACTIVATION; MUTATIONS; ONCOGENE; PATHWAY; BRAF; APOPTOSIS; MECHANISM	The Raf-MEK-ERK protein kinase cascade is a highly conserved signaling pathway that is pivotal in relaying environmental cues from the cell surface to the nucleus. Three Raf isoforms, which share great sequence and structure similarities, have been identified in mammalian cells. We have previously identified Raf kinase inhibitor protein (RKIP) as a negative regulator of the Raf-MEK-ERK signaling pathway by specifically binding to the Raf-1 isoform. We show here that RKIP also antagonizes kinase activity of the B-Raf isoform. Yeast two-hybrid and coimmunoprecipitation experiments indicated that RKIP specifically interacted with B-Raf. Ectopic expression of RKIP antagonized the kinase activity of B-Raf. We showed that the effects of RKIP on B-Raf functions were independent of its known inhibitory action on Raf-1. The expression levels of RKIP in melanoma cancer cell lines are low relative to primary melanocytes. Forced expression of RKIP partially reverted the oncogenic B-Raf kinase-transformed melanoma cancer cell line SK-Mel-28. The low expression of RKIP and its antagonistic action on B-Raf suggests that RKIP may play an important role in melanoma turmorgenesis.	Med Coll Ohio, Dept Biochem & Canc Biol, Toledo, OH 43614 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Yeung, KC (corresponding author), Med Coll Ohio, Dept Biochem & Canc Biol, BHSB Rm 469,3035 Arlington Ave, Toledo, OH 43614 USA.	kyeung@mco.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064767] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM64767] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARR J, 1994, BRIT J DERMATOL, V131, P72, DOI 10.1111/j.1365-2133.1994.tb08460.x; Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hingorani SR, 2003, CANCER RES, V63, P5198; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Mercer K, 2002, ONCOGENE, V21, P347, DOI 10.1038/sj.onc.1205101; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	20	95	111	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3535	3540		10.1038/sj.onc.1208435	http://dx.doi.org/10.1038/sj.onc.1208435			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15782137				2022-12-25	WOS:000229038800015
J	Kunzelmann, K; Sun, J; Markovich, D; Konig, J; Murle, B; Mall, M; Schreiber, R				Kunzelmann, K; Sun, J; Markovich, D; Konig, J; Murle, B; Mall, M; Schreiber, R			Control of ion transport in mammalian airways by protease activated receptors type 2 (PAR-2)	FASEB JOURNAL			English	Article						airway epithelium; trypsin; tryptase	CYSTIC-FIBROSIS MOUSE; CL-SECRETION; INFLAMMATION; INHIBITION; MODULATION; EXPRESSION; EPITHELIUM; CHANNELS	Protease-activated receptors (PARs) are widely distributed in human airways. They couple to G-proteins and are activated after proteolytic cleavage of the N terminus of the receptor. Evidence is growing that PAR subtype 2 plays a pivotal role in inflammatory airway diseases, such as allergic asthma or bronchitis. However, nothing is known about the effects of PAR-2 on electrolyte transport in the native airways. PAR-2 is expressed in airway epithelial cells, where they are activated by mast cell tryptase, neutrophil proteinase 3, or trypsin. Recent studies produced conflicting results about the functional consequence of PAR-2 stimulation. Here we report that stimulation of PAR-2 receptors in mouse and human airways leads to a change in electrolyte transport and a shift from absorption to secretion. Although PAR-2 appears to be expressed on both sides of the epithelium, only basolateral stimulation results in inhibition of amiloride sensitive Na+ conductance and stimulation of both luminal Cl- channels and basolateral K+ channels. The present data indicate that these changes occur through activation of phospholipase C and increase in intracellular Ca2+, which activates basolateral SK4 K+ channels and luminal Ca2+-dependent Cl- channels. In addition, the present data suggest a PAR-2 mediated release of prostaglandin E2, which may contribute to the secretory response. In conclusion, these results provide further evidence for a role of PAR-2 in inflammatory airway disease: stimulation of these receptors may cause accumulation of airway surface liquid, which, however, may help to flush noxious stimuli away from the affected airways.	Univ Regensburg, Inst Physiol, D-93053 Regensburg, Germany; Univ Queensland, Sch Biomed Sci, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Heidelberg Univ, Kinderklin 3, Mukoviszidose Zentrum, Heidelberg, Germany	University of Regensburg; University of Queensland; Ruprecht Karls University Heidelberg	Kunzelmann, K (corresponding author), Univ Regensburg, Inst Physiol, Univ Str 31, D-93053 Regensburg, Germany.	uqkkunze@mailbox.uq.edu.au	Markovich, Daniel/F-7884-2012; Mall, Marcus A./AAA-1498-2022; Schreiber, Robert/Q-7550-2019	Mall, Marcus A./0000-0002-4057-2199; Kunzelmann, Karl/0000-0002-4583-7037				Cenac N, 2003, J IMMUNOL, V170, P4296, DOI 10.4049/jimmunol.170.8.4296; Cenac N, 2002, AM J PATHOL, V161, P1903, DOI 10.1016/S0002-9440(10)64466-5; Chambers LS, 2001, AM J PHYSIOL-LUNG C, V281, pL1369, DOI 10.1152/ajplung.2001.281.6.L1369; Cicala C, 2001, BRIT J PHARMACOL, V132, P1229, DOI 10.1038/sj.bjp.0703934; Cocks TM, 2001, PULM PHARMACOL THER, V14, P183, DOI 10.1006/pupt.2001.0285; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Cottrell GS, 2004, J BIOL CHEM, V279, P13532, DOI 10.1074/jbc.M312090200; Cuffe JE, 2002, J PHYSIOL-LONDON, V539, P209, DOI 10.1113/jphysiol.2001.013159; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Danahay H, 2001, AM J PHYSIOL-CELL PH, V280, pC1455, DOI 10.1152/ajpcell.2001.280.6.C1455; Ellis CA, 1999, AM J PHYSIOL-CELL PH, V276, pC38, DOI 10.1152/ajpcell.1999.276.1.C38; Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P13936, DOI 10.1073/pnas.241377298; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; KAWABATA A, 2004, IN PRESS J PHARM EXP; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; KOSLOWSKY T, 1994, PFLUG ARCH EUR J PHY, V428, P597, DOI 10.1007/BF00374583; Kunzelmann K, 2004, FASEB J, V18, P142, DOI 10.1096/fj.04-2314fje; Lan RS, 2004, AM J PHYSIOL-LUNG C, V286, pL388, DOI 10.1152/ajplung.00286.2003; Lan RS, 2001, BRIT J PHARMACOL, V132, P93, DOI 10.1038/sj.bjp.0703776; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Mall M, 2003, PEDIATR RES, V53, P608, DOI 10.1203/01.PDR.0000057204.51420.DC; Mall M, 2000, AM J RESP CELL MOL, V23, P283, DOI 10.1165/ajrcmb.23.3.4060; MALL M, 2002, AM J PHYSIOL, V282, P200; Nguyen C, 2003, CAN J PHYSIOL PHARM, V81, P920, DOI 10.1139/Y03-080; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; Oceandy D, 2003, J MEMBRANE BIOL, V192, P159, DOI 10.1007/s00232-002-1072-y; Oceandy D, 2002, HUM MOL GENET, V11, P1059, DOI 10.1093/hmg/11.9.1059; Reed DE, 2003, J PHYSIOL-LONDON, V547, P531, DOI 10.1113/jphysiol.2002.032011; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672, DOI 10.1164/ajrccm.161.5.9907133; Risse PA, 2004, LIFE SCI, V75, P991, DOI 10.1016/j.lfs.2004.02.008; Rochelle LG, 2000, AM J PHYSIOL-LUNG C, V279, pL14, DOI 10.1152/ajplung.2000.279.1.L14; Schmidlin F, 2001, AM J RESP CRIT CARE, V164, P1276, DOI 10.1164/ajrccm.164.7.2101157; Vergnolle N, 2004, BRIT J PHARMACOL, V141, P1264, DOI 10.1038/sj.bjp.0705750; Vergnolle N, 1998, P NATL ACAD SCI USA, V95, P7766, DOI 10.1073/pnas.95.13.7766; Witko-Sarsat V, 1999, AM J RESP CELL MOL, V20, P729, DOI 10.1165/ajrcmb.20.4.3371; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200	38	89	90	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					969	+		10.1096/fj.04-2469fje	http://dx.doi.org/10.1096/fj.04-2469fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15809358				2022-12-25	WOS:000228865300031
